0000078003-25-000054.txt : 20250227 0000078003-25-000054.hdr.sgml : 20250227 20250227162718 ACCESSION NUMBER: 0000078003-25-000054 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 175 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250227 DATE AS OF CHANGE: 20250227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25679434 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 10-K 1 pfe-20241231.htm 10-K pfe-20241231
00000780032024FYfalseP4YConsolidated Statements of OperationsConsolidated Statements of OperationsConsolidated Statements of Operationshttp://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrent010104045805350%101020457015350595100P5YP7YP3YP3YP5YP1YP3YP1YP5YP7YP3YP5YP7YP3Y333333P3YP3YP5YP3Yhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpenseiso4217:USDxbrli:sharesiso4217:USDxbrli:sharespfe:segmentxbrli:purepfe:medicineiso4217:EURiso4217:GBPpfe:employeeStockOwnershipPlanpfe:tradingDaypfe:measurepfe:periodpfe:companypfe:patentpfe:Patentpfe:complaintpfe:operatingSegmentpfe:facilitypfe:countrypfe:treatmentCourse00000780032024-01-012024-12-310000078003us-gaap:CommonStockMember2024-01-012024-12-310000078003pfe:NotesDue20271.000Member2024-01-012024-12-3100000780032024-06-3000000780032025-02-200000078003us-gaap:ProductMember2024-01-012024-12-310000078003us-gaap:ProductMember2023-01-012023-12-310000078003us-gaap:ProductMember2022-01-012022-12-3100000780032023-01-012023-12-3100000780032022-01-012022-12-310000078003us-gaap:RoyaltyMember2024-01-012024-12-310000078003us-gaap:RoyaltyMember2023-01-012023-12-310000078003us-gaap:RoyaltyMember2022-01-012022-12-3100000780032024-12-3100000780032023-12-310000078003us-gaap:CommonStockMember2021-12-310000078003us-gaap:AdditionalPaidInCapitalMember2021-12-310000078003us-gaap:TreasuryStockCommonMember2021-12-310000078003us-gaap:RetainedEarningsMember2021-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000078003us-gaap:ParentMember2021-12-310000078003us-gaap:NoncontrollingInterestMember2021-12-3100000780032021-12-310000078003us-gaap:RetainedEarningsMember2022-01-012022-12-310000078003us-gaap:ParentMember2022-01-012022-12-310000078003us-gaap:NoncontrollingInterestMember2022-01-012022-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000078003us-gaap:CommonStockMember2022-01-012022-12-310000078003us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000078003us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000078003us-gaap:CommonStockMember2022-12-310000078003us-gaap:AdditionalPaidInCapitalMember2022-12-310000078003us-gaap:TreasuryStockCommonMember2022-12-310000078003us-gaap:RetainedEarningsMember2022-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000078003us-gaap:ParentMember2022-12-310000078003us-gaap:NoncontrollingInterestMember2022-12-3100000780032022-12-310000078003us-gaap:RetainedEarningsMember2023-01-012023-12-310000078003us-gaap:ParentMember2023-01-012023-12-310000078003us-gaap:NoncontrollingInterestMember2023-01-012023-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000078003us-gaap:CommonStockMember2023-01-012023-12-310000078003us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000078003us-gaap:TreasuryStockCommonMember2023-01-012023-12-310000078003us-gaap:CommonStockMember2023-12-310000078003us-gaap:AdditionalPaidInCapitalMember2023-12-310000078003us-gaap:TreasuryStockCommonMember2023-12-310000078003us-gaap:RetainedEarningsMember2023-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000078003us-gaap:ParentMember2023-12-310000078003us-gaap:NoncontrollingInterestMember2023-12-310000078003us-gaap:RetainedEarningsMember2024-01-012024-12-310000078003us-gaap:ParentMember2024-01-012024-12-310000078003us-gaap:NoncontrollingInterestMember2024-01-012024-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000078003us-gaap:CommonStockMember2024-01-012024-12-310000078003us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310000078003us-gaap:TreasuryStockCommonMember2024-01-012024-12-310000078003us-gaap:CommonStockMember2024-12-310000078003us-gaap:AdditionalPaidInCapitalMember2024-12-310000078003us-gaap:TreasuryStockCommonMember2024-12-310000078003us-gaap:RetainedEarningsMember2024-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000078003us-gaap:ParentMember2024-12-310000078003us-gaap:NoncontrollingInterestMember2024-12-310000078003us-gaap:ProductConcentrationRiskMemberpfe:TopElevenProductsMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-12-310000078003us-gaap:ProductConcentrationRiskMemberpfe:TopTenProductsMemberus-gaap:SalesRevenueProductLineMember2022-01-012022-12-310000078003us-gaap:ProductConcentrationRiskMemberpfe:TopNineProductsMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-12-310000078003us-gaap:AccountsReceivableMember2024-12-310000078003us-gaap:AccountsReceivableMember2023-12-310000078003us-gaap:OtherCurrentLiabilitiesMember2024-12-310000078003us-gaap:OtherCurrentLiabilitiesMember2023-12-310000078003us-gaap:OtherNoncurrentLiabilitiesMember2024-12-310000078003us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000078003pfe:SeagenMember2023-12-140000078003pfe:SeagenMember2023-12-142023-12-140000078003pfe:SeagenMember2023-10-022023-12-310000078003pfe:SeagenMember2024-01-012024-12-310000078003pfe:SeagenMember2024-12-310000078003pfe:SeagenMemberpfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember2023-12-140000078003pfe:SeagenMemberpfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember2024-01-012024-12-310000078003pfe:SeagenMemberpfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember2024-12-310000078003pfe:SeagenMemberus-gaap:InProcessResearchAndDevelopmentMember2023-12-140000078003pfe:SeagenMemberus-gaap:InProcessResearchAndDevelopmentMember2024-01-012024-12-310000078003pfe:SeagenMemberus-gaap:InProcessResearchAndDevelopmentMember2024-12-310000078003pfe:SeagenMemberus-gaap:DevelopedTechnologyRightsMember2023-12-140000078003pfe:SeagenMemberus-gaap:DevelopedTechnologyRightsMember2023-12-142023-12-140000078003pfe:SeagenMember2023-12-142023-12-310000078003pfe:SeagenMemberpfe:RestructuringIntegrationAndAcquisitionRelatedCostsMember2023-12-142023-12-310000078003pfe:SeagenMemberus-gaap:FairValueAdjustmentToInventoryMember2023-12-142023-12-310000078003pfe:SeagenMemberpfe:AmortizationExpenseMember2023-12-142023-12-310000078003pfe:SeagenMemberpfe:DepreciationExpenseMember2023-12-142023-12-310000078003pfe:SeagenMember2023-01-012023-12-310000078003pfe:SeagenMember2022-01-012022-12-310000078003pfe:SeagenMemberpfe:AmortizationExpenseMember2023-01-012023-12-310000078003pfe:SeagenMemberpfe:AmortizationExpenseMember2022-01-012022-12-310000078003pfe:SeagenMemberus-gaap:FairValueAdjustmentToInventoryMember2023-01-012023-12-310000078003pfe:SeagenMemberus-gaap:FairValueAdjustmentToInventoryMember2022-01-012022-12-310000078003pfe:SeagenMemberus-gaap:InterestExpenseMember2023-01-012023-12-310000078003pfe:SeagenMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000078003pfe:SeagenMemberus-gaap:InterestIncomeMember2023-01-012023-12-310000078003pfe:SeagenMemberus-gaap:InterestIncomeMember2022-01-012022-12-310000078003pfe:GBTMember2022-10-050000078003pfe:GBTMember2022-10-052022-10-050000078003pfe:GBTMemberpfe:RestructuringChargesAndAcquisitionRelatedCostsMember2022-10-052022-10-050000078003pfe:GBTMemberus-gaap:InProcessResearchAndDevelopmentMember2022-10-050000078003pfe:GBTMemberus-gaap:DevelopedTechnologyRightsMember2022-10-050000078003pfe:GBTMemberus-gaap:DevelopedTechnologyRightsMember2022-10-052022-10-050000078003pfe:BiohavenMember2022-10-310000078003pfe:BiohavenMember2022-10-012022-10-310000078003pfe:BiohavenMember2022-10-032022-10-030000078003pfe:BiohavenMember2022-10-030000078003pfe:BiohavenMemberus-gaap:DevelopedTechnologyRightsMember2022-10-030000078003pfe:BiohavenMemberus-gaap:DevelopedTechnologyRightsMember2022-10-032022-10-030000078003pfe:BiohavenMemberus-gaap:InProcessResearchAndDevelopmentMember2022-10-030000078003pfe:ArenaMember2022-03-110000078003pfe:ArenaMember2022-03-112022-03-110000078003pfe:ArenaMemberus-gaap:InProcessResearchAndDevelopmentMember2022-03-110000078003pfe:ArenaMemberus-gaap:LicensingAgreementsMember2022-03-110000078003pfe:ReViralAssetAcquisitionMember2022-06-092022-06-0900000780032023-09-1900000780032023-09-192023-09-190000078003pfe:ManufacturingAndSupplyAgreementMemberpfe:ViatrisMembersrt:MinimumMember2020-01-012020-12-310000078003pfe:ManufacturingAndSupplyAgreementMemberpfe:ViatrisMembersrt:MaximumMember2020-01-012020-12-310000078003pfe:ViatrisMember2024-12-310000078003pfe:ViatrisMember2023-12-310000078003pfe:HaleonMember2023-12-310000078003pfe:HaleonMember2024-03-012024-03-310000078003pfe:HaleonMemberpfe:SaleOfEquityMethodInvestmentInPublicStockOfferingMember2024-03-012024-03-310000078003pfe:HaleonMemberpfe:SaleOfEquityMethodInvestmentInPrivatePlacementMember2024-03-012024-03-310000078003pfe:HaleonMember2024-10-012024-10-310000078003pfe:HaleonMemberpfe:SaleOfEquityMethodInvestmentInPublicStockOfferingMember2024-10-012024-10-310000078003pfe:HaleonMemberpfe:SaleOfEquityMethodInvestmentInPrivatePlacementMember2024-10-012024-10-310000078003pfe:HaleonMember2024-01-012024-12-310000078003pfe:HaleonMember2024-10-310000078003pfe:HaleonMember2022-12-310000078003pfe:HaleonMember2023-01-012023-12-310000078003pfe:HaleonMember2024-12-310000078003pfe:HaleonMember2024-04-012024-06-300000078003pfe:HaleonMember2024-07-012024-09-290000078003pfe:HaleonMember2024-09-300000078003pfe:HaleonMember2023-09-300000078003pfe:HaleonMember2023-10-022024-09-290000078003pfe:HaleonMember2022-10-012023-09-300000078003pfe:ConsumerHealthcareJVHaleonMember2021-10-012022-09-300000078003pfe:ConsumerHealthcareJVHaleonMemberpfe:GSKMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-03-310000078003pfe:ConsumerHealthcareJVHaleonMemberpfe:GSKMember2019-07-310000078003pfe:ConsumerHealthcareJVSeniorNotesUSDDenominatedMemberpfe:ConsumerHealthcareJVHaleonMemberus-gaap:SeniorNotesMember2022-03-310000078003pfe:ConsumerHealthcareJVSeniorNotesEURDenominatedMemberpfe:ConsumerHealthcareJVHaleonMemberus-gaap:SeniorNotesMember2022-03-310000078003pfe:ConsumerHealthcareJVSeniorNotesGBPDenominatedMemberpfe:ConsumerHealthcareJVHaleonMemberus-gaap:SeniorNotesMember2022-03-310000078003pfe:ConsumerHealthcareJVHaleonMember2022-03-310000078003pfe:A1365ConsumerHealthcareJVLoanMemberus-gaap:LoansPayableMember2023-07-020000078003pfe:ConsumerHealthcareJVHaleonMember2022-07-012022-07-310000078003pfe:A1365ConsumerHealthcareJVLoanMemberus-gaap:LoansPayableMember2022-07-310000078003pfe:ViivHealthcareLimitedMember2024-12-310000078003pfe:ViivHealthcareLimitedMember2016-12-310000078003pfe:ViivHealthcareLimitedMember2024-01-012024-12-310000078003pfe:ViivHealthcareLimitedMember2023-01-012023-12-310000078003pfe:ViivHealthcareLimitedMember2022-01-012022-12-310000078003pfe:ViivHealthcareLimitedMember2024-12-310000078003pfe:ViivHealthcareLimitedMember2023-12-310000078003pfe:ViivHealthcareLimitedMember2024-01-012024-12-310000078003pfe:ViivHealthcareLimitedMember2023-01-012023-12-310000078003pfe:ViivHealthcareLimitedMember2022-01-012022-12-310000078003pfe:BiohavenMemberus-gaap:CollaborativeArrangementMember2022-01-042022-01-040000078003pfe:BiohavenMemberus-gaap:CollaborativeArrangementMember2022-01-040000078003us-gaap:ProductMemberus-gaap:CollaborativeArrangementMember2024-01-012024-12-310000078003us-gaap:ProductMemberus-gaap:CollaborativeArrangementMember2023-01-012023-12-310000078003us-gaap:ProductMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000078003us-gaap:CollaborativeArrangementMember2024-01-012024-12-310000078003us-gaap:CollaborativeArrangementMember2023-01-012023-12-310000078003us-gaap:CollaborativeArrangementMember2022-01-012022-12-310000078003us-gaap:RoyaltyMemberus-gaap:CollaborativeArrangementMember2024-01-012024-12-310000078003us-gaap:RoyaltyMemberus-gaap:CollaborativeArrangementMember2023-01-012023-12-310000078003us-gaap:RoyaltyMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000078003pfe:BlackstoneMember2023-04-012023-04-300000078003pfe:BlackstoneMember2024-01-012024-12-310000078003pfe:BlackstoneMember2023-01-012023-12-310000078003pfe:ClinicalTrialAgreementTermsMemberpfe:BlackstoneMember2023-04-300000078003pfe:NetSalesAndRoyaltyAgreementTermsMemberpfe:BlackstoneMember2023-04-300000078003pfe:RealigningOurCostBaseProgramMember2024-12-310000078003pfe:RealigningOurCostBaseProgramMemberpfe:BiopharmaSegmentMember2024-12-310000078003pfe:RealigningOurCostBaseProgramMemberpfe:BiopharmaSegmentMember2023-10-022024-12-310000078003pfe:ManufacturingOptimizationProgramPhaseOneMemberpfe:BiopharmaSegmentMember2024-12-310000078003pfe:ManufacturingOptimizationProgramMemberpfe:BiopharmaSegmentMember2024-12-310000078003us-gaap:OtherNonoperatingIncomeExpenseMember2024-01-012024-12-310000078003us-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-12-310000078003us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310000078003us-gaap:CostOfSalesMember2024-01-012024-12-310000078003us-gaap:CostOfSalesMember2023-01-012023-12-310000078003us-gaap:CostOfSalesMember2022-01-012022-12-310000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000078003us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-310000078003us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310000078003us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000078003pfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:ManufacturingOptimizationProgramMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:RealigningOurCostBaseProgramMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003us-gaap:OneTimeTerminationBenefitsMemberpfe:RealigningOurCostBaseProgramMemberpfe:BiopharmaSegmentMember2023-10-022024-12-310000078003pfe:RealigningOurCostBaseProgramMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:TransformingToAMoreFocusedCompanyPlanMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:TransformingToAMoreFocusedCompanyPlanMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SeagenMemberpfe:RestructuringChargesAndAcquisitionRelatedCostsMember2023-10-022023-12-310000078003pfe:ArenaMemberpfe:RestructuringChargesAndAcquisitionRelatedCostsMember2022-01-012022-04-030000078003pfe:GBTMemberpfe:RestructuringChargesAndAcquisitionRelatedCostsMember2022-10-032022-12-310000078003us-gaap:EmployeeSeveranceMember2022-12-310000078003pfe:AssetImpairmentsMember2022-12-310000078003us-gaap:OtherRestructuringMember2022-12-310000078003us-gaap:EmployeeSeveranceMember2023-01-012023-12-310000078003pfe:AssetImpairmentsMember2023-01-012023-12-310000078003us-gaap:OtherRestructuringMember2023-01-012023-12-310000078003us-gaap:EmployeeSeveranceMember2023-12-310000078003pfe:AssetImpairmentsMember2023-12-310000078003us-gaap:OtherRestructuringMember2023-12-310000078003us-gaap:EmployeeSeveranceMember2024-01-012024-12-310000078003pfe:AssetImpairmentsMember2024-01-012024-12-310000078003us-gaap:OtherRestructuringMember2024-01-012024-12-310000078003us-gaap:EmployeeSeveranceMember2024-12-310000078003pfe:AssetImpairmentsMember2024-12-310000078003us-gaap:OtherRestructuringMember2024-12-310000078003us-gaap:UnsecuredDebtMember2023-05-310000078003pfe:SeagenMember2023-12-310000078003pfe:TelavantHoldingsIncMember2023-01-012023-12-310000078003pfe:CerevelTherapeuticsHoldingsIncMember2023-01-012023-12-310000078003pfe:BioNTechMember2023-01-012023-12-310000078003pfe:BioNTechAndCerevelTherapeuticsLLCMember2022-01-012022-12-310000078003pfe:BiopharmaSegmentMember2024-09-302024-12-310000078003pfe:B7H4VFelmetatugVedotinMemberus-gaap:InProcessResearchAndDevelopmentMemberpfe:BiopharmaSegmentMember2024-09-302024-12-310000078003pfe:BrandMemberpfe:MedrolMemberpfe:BiopharmaSegmentMember2024-09-302024-12-310000078003us-gaap:DevelopedTechnologyRightsMemberpfe:ZavzpretMemberpfe:BiopharmaSegmentMember2024-09-302024-12-310000078003pfe:TukysaMemberus-gaap:InProcessResearchAndDevelopmentMemberpfe:BiopharmaSegmentMember2024-09-302024-12-310000078003pfe:DisitamabVedotinMemberus-gaap:InProcessResearchAndDevelopmentMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OtherDevelopedTechnologyRightsInProcessResearchAndDevelopmentAndFiniteLivedLicensingAgreementMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003us-gaap:InProcessResearchAndDevelopmentMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:BiopharmaSegmentMember2023-10-022023-12-310000078003pfe:EtrasimodVelsipityMemberus-gaap:InProcessResearchAndDevelopmentMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003us-gaap:DevelopedTechnologyRightsMemberpfe:Prevnar13Memberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OtherInProcessResearchAndDevelopmentAndDevelopedTechnologyRightsMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003us-gaap:InProcessResearchAndDevelopmentMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003us-gaap:InProcessResearchAndDevelopmentMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003us-gaap:DevelopedTechnologyRightsMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:HospiraMemberpfe:LicensingAgreementsAndOtherMemberpfe:GenericSterileInjectableProductMember2022-01-012022-12-3100000780032024-07-012024-09-290000078003pfe:NimbusMember2023-01-012023-12-310000078003pfe:TransitionServiceAgreementMember2022-01-012022-12-310000078003pfe:ViiVMember2022-01-012022-12-310000078003us-gaap:InProcessResearchAndDevelopmentMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InProcessResearchAndDevelopmentMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InProcessResearchAndDevelopmentMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:InProcessResearchAndDevelopmentMember2024-12-310000078003us-gaap:InProcessResearchAndDevelopmentMember2024-01-012024-12-310000078003us-gaap:DevelopedTechnologyRightsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:DevelopedTechnologyRightsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:DevelopedTechnologyRightsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:DevelopedTechnologyRightsMember2024-12-310000078003us-gaap:DevelopedTechnologyRightsMember2024-01-012024-12-310000078003pfe:BrandMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberpfe:BrandMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:BrandMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberpfe:BrandMember2024-12-310000078003pfe:BrandMember2024-01-012024-12-310000078003pfe:LicensingAgreementsAndOtherMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberpfe:LicensingAgreementsAndOtherMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LicensingAgreementsAndOtherMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberpfe:LicensingAgreementsAndOtherMember2024-12-310000078003pfe:LicensingAgreementsAndOtherMember2024-01-012024-12-310000078003us-gaap:FairValueInputsLevel1Member2024-12-310000078003us-gaap:FairValueInputsLevel2Member2024-12-310000078003us-gaap:FairValueInputsLevel3Member2024-12-310000078003pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember2024-12-310000078003pfe:NoncurrentDeferredTaxLiabilitiesMember2024-12-310000078003pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember2023-12-310000078003pfe:NoncurrentDeferredTaxLiabilitiesMember2023-12-310000078003pfe:IncomeTaxesPayableMember2024-12-310000078003pfe:CurrentTaxAssetsMember2024-12-310000078003pfe:OtherTaxesPayableMember2024-12-310000078003pfe:IncomeTaxesPayableMember2023-12-310000078003pfe:CurrentTaxAssetsMember2023-12-310000078003pfe:OtherTaxesPayableMember2023-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2021-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2022-01-012022-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2022-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-01-012023-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-01-012024-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000078003us-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:BankTimeDepositsMember2024-12-310000078003us-gaap:BankTimeDepositsMember2023-12-310000078003us-gaap:CommercialPaperMember2024-12-310000078003us-gaap:CommercialPaperMember2023-12-310000078003us-gaap:RevolvingCreditFacilityMember2024-12-310000078003pfe:CreditFacilityMaturingOctober2025Memberus-gaap:RevolvingCreditFacilityMember2024-12-310000078003pfe:CreditFacilityMaturingOctober2029Memberus-gaap:RevolvingCreditFacilityMember2024-12-310000078003us-gaap:LineOfCreditMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue2025Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue2025Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue2026Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue2026Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue2027Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue2027Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue2028Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue2028Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue2029Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue2029Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue2030Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue2030Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue20312035Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue20312035Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue20362040Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue20362040Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue20412045Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue20412045Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue20462050Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue20462050Memberus-gaap:UnsecuredDebtMember2024-12-310000078003pfe:SeniorUnsecuredDebtDue20512063Memberus-gaap:UnsecuredDebtMember2023-12-310000078003pfe:SeniorUnsecuredDebtDue20512063Memberus-gaap:UnsecuredDebtMember2024-12-310000078003us-gaap:UnsecuredDebtMember2024-12-310000078003us-gaap:UnsecuredDebtMember2023-12-3100000780032023-05-310000078003us-gaap:ForeignExchangeContractMember2024-01-012024-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000078003us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000078003us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SalesMember2024-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SalesMember2023-12-310000078003us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000078003us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000078003us-gaap:InterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000078003us-gaap:InterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000078003pfe:ForeignCurrencyShortTermBorrowingsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000078003pfe:ForeignCurrencyShortTermBorrowingsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-01-012024-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-01-012023-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2024-01-012024-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2023-01-012023-12-310000078003pfe:ForeignCurrencyDebtMember2024-12-310000078003pfe:ForeignCurrencyDebtMember2023-12-310000078003pfe:BioNTechMemberpfe:ComirnatyMemberus-gaap:CollaborativeArrangementMember2024-12-310000078003pfe:BioNTechMemberpfe:ComirnatyMemberus-gaap:CollaborativeArrangementMember2023-12-310000078003srt:MinimumMember2024-12-310000078003srt:MaximumMember2024-12-310000078003us-gaap:LandMember2024-12-310000078003us-gaap:LandMember2023-12-310000078003srt:MinimumMemberus-gaap:BuildingMember2024-12-310000078003srt:MaximumMemberus-gaap:BuildingMember2024-12-310000078003us-gaap:BuildingMember2024-12-310000078003us-gaap:BuildingMember2023-12-310000078003srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000078003srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000078003us-gaap:MachineryAndEquipmentMember2024-12-310000078003us-gaap:MachineryAndEquipmentMember2023-12-310000078003srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2024-12-310000078003srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2024-12-310000078003us-gaap:FurnitureAndFixturesMember2024-12-310000078003us-gaap:FurnitureAndFixturesMember2023-12-310000078003us-gaap:ConstructionInProgressMember2024-12-310000078003us-gaap:ConstructionInProgressMember2023-12-310000078003country:US2024-12-310000078003country:US2023-12-310000078003pfe:DevelopedMarketsMember2024-12-310000078003pfe:DevelopedMarketsMember2023-12-310000078003pfe:InternationalEmergingMarketsMember2024-12-310000078003pfe:InternationalEmergingMarketsMember2023-12-310000078003us-gaap:DevelopedTechnologyRightsMember2023-12-310000078003us-gaap:TradeNamesMember2024-12-310000078003us-gaap:TradeNamesMember2023-12-310000078003pfe:LicensingAgreementsAndOtherMember2023-12-310000078003us-gaap:TradeNamesMember2024-12-310000078003us-gaap:TradeNamesMember2023-12-310000078003us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000078003pfe:LicensingAgreementsAndOtherMember2024-12-310000078003pfe:LicensingAgreementsAndOtherMember2023-12-310000078003us-gaap:DevelopedTechnologyRightsMemberpfe:TalazoparibTalzennaMember2024-01-012024-12-310000078003pfe:TalazoparibTalzennaMemberus-gaap:InProcessResearchAndDevelopmentMember2024-01-012024-12-310000078003pfe:DepoMedrolMemberus-gaap:TradeNamesMember2024-01-012024-12-310000078003us-gaap:TradeNamesMember2024-01-012024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberpfe:OtherCommingledFundsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:OtherCommingledFundsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:OtherCommingledFundsMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:OtherCommingledFundsMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMemberpfe:OtherCommingledFundsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:OtherCommingledFundsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:OtherCommingledFundsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberpfe:OtherCommingledFundsMember2023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasurySecuritiesMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:PartnershipInterestMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAggregatedInvestmentsMember2023-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberpfe:InsuranceContractsMember2024-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberpfe:InsuranceContractsMember2023-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembersrt:MinimumMember2024-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000078003us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMemberpfe:DefinedBenefitPlanOtherInvestmentsMember2024-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMemberpfe:DefinedBenefitPlanOtherInvestmentsMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MinimumMemberpfe:DefinedBenefitPlanOtherInvestmentsMember2024-12-310000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMemberpfe:DefinedBenefitPlanOtherInvestmentsMember2024-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembersrt:MinimumMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembersrt:MaximumMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembersrt:MinimumMemberpfe:InsuranceContractsMember2024-12-310000078003country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembersrt:MaximumMemberpfe:InsuranceContractsMember2024-12-3100000780032018-12-3100000780032022-01-012022-04-030000078003pfe:CommonESOPPlanMember2024-01-012024-12-310000078003pfe:CommonESOPPlanMember2023-01-012023-12-310000078003pfe:CommonESOPPlanMember2022-01-012022-12-310000078003pfe:BreakthroughPerformanceAwardsMember2024-01-012024-12-310000078003pfe:BreakthroughPerformanceAwardsMember2024-12-310000078003pfe:A2019StockPlanMember2024-01-012024-12-310000078003us-gaap:RestrictedStockUnitsRSUMemberpfe:A2019StockPlanMember2024-01-012024-12-310000078003us-gaap:PerformanceSharesMemberpfe:A2019StockPlanMember2024-01-012024-12-310000078003pfe:PortfolioPerformanceSharesMemberpfe:A2019StockPlanMember2024-01-012024-12-310000078003pfe:BreakthroughPerformanceAwardsMemberpfe:A2019StockPlanMember2024-01-012024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMemberpfe:A2019StockPlanMember2024-01-012024-12-310000078003us-gaap:EmployeeStockOptionMemberpfe:A2019StockPlanMember2024-01-012024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMembersrt:MinimumMember2024-01-012024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMembersrt:MaximumMember2024-01-012024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMember2024-01-012024-12-310000078003us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310000078003pfe:PortfolioPerformanceSharesMembersrt:MinimumMember2024-01-012024-12-310000078003pfe:PortfolioPerformanceSharesMembersrt:MaximumMember2024-01-012024-12-310000078003us-gaap:PerformanceSharesMember2024-01-012024-12-310000078003us-gaap:PerformanceSharesMembersrt:MinimumMember2024-01-012024-12-310000078003us-gaap:PerformanceSharesMembersrt:MaximumMember2024-01-012024-12-310000078003pfe:BreakthroughPerformanceAwardsMembersrt:MinimumMember2024-01-012024-12-310000078003pfe:BreakthroughPerformanceAwardsMembersrt:MaximumMember2024-01-012024-12-310000078003srt:ManagementMember2024-01-012024-12-310000078003us-gaap:EmployeeStockOptionMember2024-01-012024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMember2023-01-012023-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMember2022-01-012022-12-310000078003us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310000078003us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000078003pfe:PortfolioPerformanceSharesMember2024-01-012024-12-310000078003pfe:PortfolioPerformanceSharesMember2023-01-012023-12-310000078003pfe:PortfolioPerformanceSharesMember2022-01-012022-12-310000078003us-gaap:PerformanceSharesMember2023-01-012023-12-310000078003us-gaap:PerformanceSharesMember2022-01-012022-12-310000078003us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000078003us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMember2024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMember2023-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMember2022-12-310000078003us-gaap:RestrictedStockUnitsRSUMember2024-12-310000078003us-gaap:RestrictedStockUnitsRSUMember2023-12-310000078003us-gaap:RestrictedStockUnitsRSUMember2022-12-310000078003pfe:PortfolioPerformanceSharesMember2024-12-310000078003pfe:PortfolioPerformanceSharesMember2023-12-310000078003pfe:PortfolioPerformanceSharesMember2022-12-310000078003us-gaap:PerformanceSharesMember2024-12-310000078003us-gaap:PerformanceSharesMember2023-12-310000078003us-gaap:PerformanceSharesMember2022-12-310000078003us-gaap:EmployeeStockOptionMember2024-12-310000078003us-gaap:EmployeeStockOptionMember2023-12-310000078003us-gaap:EmployeeStockOptionMember2022-12-310000078003pfe:ProfitUnitsMember2024-12-310000078003pfe:ProfitUnitsMember2024-01-012024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMemberpfe:TotalShareholderReturnUnitsVestingPeriodOneMember2024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMemberpfe:TotalShareholderReturnUnitsVestingPeriodTwoMember2024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMemberpfe:CertainTSRUsGrantedIn2022And2023Member2024-01-012024-12-310000078003pfe:TotalShareholderReturnUnitsTSRUsMemberpfe:CertainTSRUsGrantedIn2022And2023Member2024-12-310000078003us-gaap:RestrictedStockUnitsRSUMemberpfe:RestrictedStockUnitsGrantedBefore2022Member2024-01-012024-12-310000078003us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-12-310000078003us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-12-310000078003us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-12-310000078003us-gaap:PerformanceSharesMemberpfe:PSAsGrantedIn2022And2023Member2024-01-012024-12-310000078003srt:MinimumMember2024-01-012024-12-310000078003srt:MaximumMember2024-01-012024-12-310000078003us-gaap:PendingLitigationMemberpfe:PfizerAndVersusSeveralGenericManufacturersMemberpfe:MektoviMemberpfe:PatentInfringementMember2022-08-012022-08-310000078003us-gaap:PendingLitigationMemberpfe:MektoviMemberpfe:PatentInfringementMemberpfe:Expiring2030Memberpfe:PfizerAndVersusSeveralGenericManufacturersMember2022-08-012022-08-310000078003us-gaap:PendingLitigationMemberpfe:MektoviMemberpfe:PatentInfringementMemberpfe:Expiring2033Memberpfe:PfizerAndVersusSeveralGenericManufacturersMember2022-08-012022-08-310000078003us-gaap:PendingLitigationMemberpfe:PfizerAndVersusSeveralGenericManufacturersMemberpfe:MektoviMemberpfe:PatentInfringementMember2022-09-012022-09-300000078003us-gaap:SettledLitigationMemberus-gaap:SubsequentEventMemberpfe:MektoviMemberpfe:PatentInfringementMemberpfe:PfizerAndVersusSeveralGenericManufacturersMember2025-01-012025-01-310000078003pfe:TevaPharmaceuticalsIncMemberus-gaap:PendingLitigationMemberpfe:MektoviMemberpfe:PatentInvalidityAndNonInfringementMemberpfe:PfizerVersusTevaPharmaceuticalsIncMember2022-08-012022-08-310000078003us-gaap:PendingLitigationMemberpfe:PfizerVersusTevaPharmaceuticalsIncMemberpfe:MektoviMemberpfe:PatentInvalidityAndNonInfringementMember2023-06-012023-06-300000078003pfe:AlnylamPatentInfringementCaseMemberpfe:ComirnatyMember2023-05-012023-05-310000078003pfe:ModernaTXUSPatentInfringementCaseMemberpfe:ComirnatyMember2022-08-012022-08-310000078003pfe:ModernaTXUSPatentInfringementCaseMemberpfe:ComirnatyMember2024-03-012024-03-310000078003pfe:ModernaTXEuropeanPatentInfringementCaseMemberpfe:ComirnatyMember2022-08-012022-08-310000078003pfe:ModernaTXEuropeanPatentInfringementCaseMemberpfe:ComirnatyMember2022-09-012022-09-3000000780032023-11-012023-11-300000078003pfe:ModernaTXEuropeanPatentInfringementCaseMemberpfe:ComirnatyMember2024-07-012024-07-310000078003pfe:ArbutusAndGenevantUSPatentInfringementCaseMemberpfe:ComirnatyMember2023-04-012023-04-300000078003pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMemberpfe:ComirnatyMember2024-04-012024-04-300000078003pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMemberpfe:ComirnatyMember2024-08-012024-08-310000078003pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMemberpfe:AbrysvoMember2023-08-012023-08-310000078003pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMemberpfe:AbrysvoMember2023-11-012023-11-300000078003pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMemberpfe:AbrysvoMember2024-11-012024-11-300000078003pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMemberpfe:AbrysvoMember2024-10-012024-10-310000078003pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMemberpfe:ComirnatyMember2022-07-012022-07-310000078003pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMemberpfe:ComirnatyMember2023-05-012023-05-310000078003pfe:GreenstoneAntitrustLitigationMemberus-gaap:PendingLitigationMember2020-12-310000078003us-gaap:SettledLitigationMemberpfe:GovernmentInquiresRelatingToBiohavenMemberus-gaap:SubsequentEventMemberpfe:U.S.AndParticipatingStatesMember2025-01-012025-01-310000078003us-gaap:SettledLitigationMemberpfe:GovernmentInquiresRelatingToBiohavenMemberus-gaap:SubsequentEventMemberpfe:CaliforniaDepartmentOfInsuranceMember2025-01-012025-01-310000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003us-gaap:CorporateNonSegmentMember2024-01-012024-12-310000078003us-gaap:CorporateNonSegmentMember2023-01-012023-12-310000078003us-gaap:CorporateNonSegmentMember2022-01-012022-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember2024-01-012024-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember2023-01-012023-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember2022-01-012022-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAcquisitionRelatedCostsMember2024-01-012024-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAcquisitionRelatedCostsMember2023-01-012023-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAcquisitionRelatedCostsMember2022-01-012022-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsOtherMember2024-01-012024-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsOtherMember2023-01-012023-12-310000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsOtherMember2022-01-012022-12-310000078003us-gaap:CorporateNonSegmentMemberus-gaap:ReclassificationOtherMember2023-01-012023-12-310000078003us-gaap:CorporateNonSegmentMemberus-gaap:ReclassificationOtherMember2022-01-012022-12-310000078003pfe:PaxlovidEUALabeledMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PaxlovidEUALabeledMemberpfe:BiopharmaSegmentMember2024-01-012024-03-310000078003pfe:PaxlovidEUALabeledMemberpfe:BiopharmaSegmentMember2023-12-310000078003us-gaap:CorporateNonSegmentMemberpfe:PaxlovidMember2022-01-012022-12-310000078003pfe:ViivHealthcareLimitedMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:ViivHealthcareLimitedMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:ViivHealthcareLimitedMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:HaleonMember2024-09-302024-12-310000078003pfe:PrimaryCareMemberpfe:ComirnatyMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:ComirnatyMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:ComirnatyMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:PaxlovidMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:PaxlovidMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:PaxlovidMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:ExcludingComirnatyAndPaxlovidMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:ExcludingComirnatyAndPaxlovidMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:ExcludingComirnatyAndPaxlovidMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003country:US2024-01-012024-12-310000078003country:US2023-01-012023-12-310000078003country:US2022-01-012022-12-310000078003pfe:InternationalDevelopedMarketsMember2024-01-012024-12-310000078003pfe:InternationalDevelopedMarketsMember2023-01-012023-12-310000078003pfe:InternationalDevelopedMarketsMember2022-01-012022-12-310000078003pfe:InternationalEmergingMarketsMember2024-01-012024-12-310000078003pfe:InternationalEmergingMarketsMember2023-01-012023-12-310000078003pfe:InternationalEmergingMarketsMember2022-01-012022-12-310000078003pfe:NonUnitedStatesMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-12-310000078003pfe:NonUnitedStatesMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-12-310000078003pfe:NonUnitedStatesMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-12-310000078003country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000078003country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000078003country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000078003country:CNus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000078003country:JPus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000078003country:JPus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000078003pfe:PaxlovidEUALabeledMember2023-12-310000078003pfe:PaxlovidEUALabeledMember2024-01-012024-03-310000078003pfe:PaxlovidEUALabeledMember2024-01-012024-02-290000078003pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember2024-09-290000078003pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember2024-07-012024-09-290000078003pfe:McKessonInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000078003pfe:McKessonInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000078003pfe:McKessonInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000078003pfe:CencoraInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000078003pfe:CencoraInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000078003pfe:CencoraInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000078003pfe:CardinalHealthInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000078003pfe:CardinalHealthInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000078003pfe:CardinalHealthInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000078003pfe:USGovernmentMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-310000078003pfe:USGovernmentMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310000078003pfe:USGovernmentMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310000078003pfe:ThreeLargestUSWholesaleCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310000078003pfe:ThreeLargestUSWholesaleCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:EliquisMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:EliquisMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:EliquisMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:PrevnarPrevenarFamilyMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:PrevnarPrevenarFamilyMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:PrevnarPrevenarFamilyMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:NurtecODTVyduraMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:NurtecODTVyduraMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:NurtecODTVyduraMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:AbrysvoMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:AbrysvoMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:AbrysvoMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:PremarinFamilyMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:PremarinFamilyMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:PremarinFamilyMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:BMP2Memberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:BMP2Memberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:BMP2Memberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:FSMEIMMUNTicoVacMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:FSMEIMMUNTicoVacMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:FSMEIMMUNTicoVacMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:OtherPrimaryCareProductsMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:PrimaryCareMemberpfe:OtherPrimaryCareProductsMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:PrimaryCareMemberpfe:OtherPrimaryCareProductsMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:VyndaqelMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:VyndaqelMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:VyndaqelMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:XeljanzMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:XeljanzMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:XeljanzMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:EnbrelMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:EnbrelMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:EnbrelMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:SulperazonMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:SulperazonMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:SulperazonMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:ZaviceftaMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:ZaviceftaMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:ZaviceftaMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:OctagamMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:OctagamMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:OctagamMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:InflectraRemsimaMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:InflectraRemsimaMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:InflectraRemsimaMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:ZithromaxZmaxMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:ZithromaxZmaxMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:ZithromaxZmaxMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:GenotropinMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:GenotropinMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:GenotropinMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:BeneFIXMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:BeneFIXMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:BeneFIXMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:CibinqoMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:CibinqoMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:CibinqoMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:OxbrytaMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:OxbrytaMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:OxbrytaMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:OtherHospitalMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:OtherHospitalMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:OtherHospitalMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:SpecialtyCareMemberpfe:OtherSpecialtyCareMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:OtherSpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:SpecialtyCareMemberpfe:OtherSpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:XtandiMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:XtandiMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:XtandiMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:PadcevMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:PadcevMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:PadcevMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:AdcetrisMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:AdcetrisMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:AdcetrisMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:OncologyBiosimilarsMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:OncologyBiosimilarsMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:OncologyBiosimilarsMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:InlytaMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:InlytaMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:InlytaMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:LorbrenaMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:LorbrenaMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:LorbrenaMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:BosulifMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:BosulifMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:BosulifMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:BraftoviMektoviMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:BraftoviMektoviMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:BraftoviMektoviMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:TukysaMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:TukysaMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:TukysaMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:ElrexfioMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:ElrexfioMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:ElrexfioMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:TivdakMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:TivdakMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:TivdakMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:TalzennaMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:TalzennaMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:TalzennaMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:OncologyMemberpfe:OtherOncologyProductsMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:OncologyMemberpfe:OtherOncologyProductsMemberpfe:BiopharmaSegmentMember2023-01-012023-12-310000078003pfe:OncologyMemberpfe:OtherOncologyProductsMemberpfe:BiopharmaSegmentMember2022-01-012022-12-310000078003pfe:PfizerCentreOneMember2024-01-012024-12-310000078003pfe:PfizerCentreOneMember2023-01-012023-12-310000078003pfe:PfizerCentreOneMember2022-01-012022-12-310000078003pfe:PfizerIgniteMember2024-01-012024-12-310000078003pfe:PfizerIgniteMember2023-01-012023-12-310000078003pfe:PfizerIgniteMember2022-01-012022-12-310000078003pfe:BiopharmaSegmentMemberpfe:U.S.CommercialDivisionMember2024-01-012024-12-310000078003pfe:BiopharmaSegmentMemberpfe:U.S.CommercialDivisionMember2023-01-012023-12-310000078003pfe:BiopharmaSegmentMemberpfe:U.S.CommercialDivisionMember2022-01-012022-12-310000078003pfe:BiopharmaSegmentMemberpfe:OncologyDivisionMember2024-01-012024-12-310000078003pfe:BiopharmaSegmentMemberpfe:OncologyDivisionMember2023-01-012023-12-310000078003pfe:BiopharmaSegmentMemberpfe:OncologyDivisionMember2022-01-012022-12-310000078003pfe:BiopharmaSegmentMemberpfe:InternationalCommercialDivisionMember2024-01-012024-12-310000078003pfe:BiopharmaSegmentMemberpfe:InternationalCommercialDivisionMember2023-01-012023-12-310000078003pfe:BiopharmaSegmentMemberpfe:InternationalCommercialDivisionMember2022-01-012022-12-310000078003pfe:TotalAllianceBiopharmaceuticalsMember2024-01-012024-12-310000078003pfe:TotalAllianceBiopharmaceuticalsMember2023-01-012023-12-310000078003pfe:TotalAllianceBiopharmaceuticalsMember2022-01-012022-12-310000078003pfe:PaxlovidEUALabeledMember2024-01-012024-12-310000078003pfe:SpecialtyCareMemberpfe:CommercializationPartnerMemberpfe:OctagamMemberpfe:BiopharmaSegmentMember2024-01-012024-12-310000078003pfe:ComirnatyMember2024-12-310000078003pfe:PaxlovidMember2024-12-310000078003pfe:GovernmentAndGovernmentSponsoredMemberpfe:PaxlovidAndComirnatyMember2024-12-310000078003pfe:GovernmentAndGovernmentSponsoredMemberpfe:PaxlovidAndComirnatyMember2023-12-310000078003pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember2024-01-012024-12-310000078003pfe:GovernmentAndGovernmentSponsoredMemberpfe:PaxlovidAndComirnatyMember2024-01-012024-12-3100000780032024-09-302024-12-31


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2024
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 1-3619
Pfizer Logo.jpg
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
66 Hudson Boulevard East, New York, New York 10001-2192
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes      No  
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes    No  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes    No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)     Yes     No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated filer               Accelerated filer                 Non-accelerated filer           Smaller reporting company   Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  
The aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $158 billion. This excludes shares of common stock held by directors and executive officers. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. The registrant has no non-voting common stock.
The number of shares outstanding of the registrant’s common stock as of February 20, 2025 was 5,667,340,414 shares of common stock, all of one class.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Proxy Statement for the 2025 Annual Meeting of ShareholdersPart III



TABLE OF CONTENTS
  Page
ITEM 1B. UNRESOLVED STAFF COMMENTSN/A
ITEM 4. MINE SAFETY DISCLOSURESN/A
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONSN/A
N/A = Not Applicable



DEFINED TERMS
Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Form 10-K (defined below) refer to Pfizer Inc. and its subsidiaries. For each year presented, Pfizer’s fiscal year-end for subsidiaries operating outside the U.S. is as of and for the year ended November 30 and for U.S. subsidiaries is as of and for the year ended December 31. References to “Notes” in this Form 10-K are to the Notes to the consolidated financial statements in Item 8. Financial Statements and Supplementary Data in this Form 10-K. We also have used several other terms in this Form 10-K, most of which are explained or defined below:
*
Indicates calculation not meaningful or results are greater than 100%
Form 10-K
This Annual Report on Form 10-K for the fiscal year ended December 31, 2024
2023 Form 10-K
Our Annual Report on Form 10-K for the fiscal year ended December 31, 2023
340B Program
340B Drug Pricing Program
Proxy Statement
Proxy Statement for the 2025 Annual Meeting of Shareholders, which will be filed no later than 120 days after December 31, 2024
ABOAccumulated benefit obligation; represents the present value of the benefit obligation earned through the end of the year but does not factor in future compensation increases
ACIPAdvisory Committee on Immunization Practices
ADC
Antibody-Drug Conjugate
Alexion
Alexion Pharma International Operations Limited, a subsidiary of AstraZeneca PLC
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Arena
Arena Pharmaceuticals, Inc.
AI
artificial intelligence
ArvinasArvinas, Inc.
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
Biohaven
Biohaven Pharmaceutical Holding Company Limited
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
Blackstone
Blackstone Life Sciences
BLABiologics License Application
BMSBristol-Myers Squibb Company
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
cGMP
current Good Manufacturing Practices
CGRPcalcitonin gene-related peptide
CMS
Centers for Medicare & Medicaid Services
CODM
Chief Operating Decision Maker
Comirnaty(a)
Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; Comirnaty JN.1 and Comirnaty KP.2.
Consumer Healthcare JVGSK Consumer Healthcare JV
COVID-19novel coronavirus disease of 2019
DEAU.S. Drug Enforcement Agency
Developed Markets
Includes, but is not limited to, the following markets: Western Europe, Japan, Canada, Central Europe, Australia, Scandinavian countries, South Korea, the Balkans, New Zealand and Finland
DMD
Duchenne muscular dystrophy
ECEuropean Commission
EMAEuropean Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, the Middle East, Eastern Europe (excluding the Balkans) and Turkey
EPSearnings per share
ESOPemployee stock ownership plan
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FCPAU.S. Foreign Corrupt Practices Act
FDAU.S. Food and Drug Administration

Pfizer Inc.
2024 Form 10-K
i


FFDCAU.S. Federal Food, Drug and Cosmetic Act
GAAP
U.S. Generally Accepted Accounting Principles
GBTGlobal Blood Therapeutics, Inc.
GDFVgrant-date fair value
Genmab
Genmab A/S
GSKGSK plc
HaleonHaleon plc
HHSU.S. Department of Health and Human Services
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRCInternal Revenue Code
IRSU.S. Internal Revenue Service
ITinformation technology
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
mCC
metastatic cervical cancer
MCOmanaged care organization
mCRCmetastatic colorectal cancer
mCRPCmetastatic castration-resistant prostate cancer
mCSPCmetastatic castration-sensitive prostate cancer
MD&AManagement’s Discussion and Analysis of Financial Condition and Results of Operations
MDLMulti-District Litigation
MDPNP
Medicare Drug Price Negotiation Program
MDRP
Medicaid Drug Rebate Program
Medicare Part B
a medical insurance plan that helps cover medically necessary services, outpatient care, and preventative services for people with Medicare
Medicare Part D
a prescription drug coverage program for people with Medicare
MeridianMeridian Medical Technologies, Inc.
Moody’sMoody’s Ratings (formerly Moody’s Investors Service)
mRNAmessenger ribonucleic acid
MSAManufacturing Supply Agreement
MylanMylan N.V.
NAVnet asset value
NDA
New Drug Application
Nimbus
Nimbus Therapeutics, LLC
nmCRPCnon-metastatic castration-resistant prostate cancer
nmCSPC
non-metastatic castration-sensitive prostate cancer
NSCLCnon-small cell lung cancer
NYSENew York Stock Exchange
ODT
oral disintegrating tablet
Ono
Ono Pharmaceutical Co., Ltd.
ORD
Oncology Research and Development
OTCover-the-counter
Paxlovid(a)
an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)
PBMpharmacy benefit manager
PBOProjected benefit obligation; represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases
PC1Pfizer CentreOne
PGSPfizer Global Supply
Pharmacia
Pharmacia LLC (formerly Pharmacia Corporation)
PIE
Pfizer Investment Enterprises Pte. Ltd. (a wholly-owned finance subsidiary of Pfizer)
PP&E
Property, plant and equipment
Pierre Fabre
Pierre Fabre Medicament SAS
PRAC
Pharmacovigilance Risk Assessment Committee
PRD
Pfizer Research and Development
Prevnar family
Includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)
PsApsoriatic arthritis

Pfizer Inc.
2024 Form 10-K
ii


QCEquality consistency evaluation
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
ReViralReViral Ltd.
ROUright of use
RSV
respiratory syncytial virus
S&P
S&P Global (formerly Standard & Poor’s)
Seagen
Seagen Inc. and its subsidiaries
SECU.S. Securities and Exchange Commission
SNS
Strategic National Stockpile
SMPS
Sumitomo Pharma Switzerland GMBH
Takeda
Takeda Pharmaceutical Company Limited
Tax Cuts and Jobs Act or TCJALegislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
TSAstransition service arrangements
UCulcerative colitis
U.K.United Kingdom
Upjohn BusinessPfizer’s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris
U.S.United States
VBPvolume-based procurement
ViatrisViatris Inc.
ViiVViiV Healthcare Limited
Vyndaqel family
Includes Vyndaqel, Vyndamax and Vynmac
WHO
World Health Organization
WTOWorld Trade Organization
Wyeth
Wyeth LLC (formerly Wyeth)
(a)Certain uses of Paxlovid and COVID-19 vaccines from BioNTech and Pfizer have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of COVID-19 vaccines from Pfizer and BioNTech, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.
This Form 10-K includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-K may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
Our website is www.pfizer.com. This Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and our proxy statements, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are, or will be, available (free of charge) on our website, in text format and, where applicable, in interactive data file format, as soon as reasonably practicable after we electronically file this material with, or furnish it to, the SEC.
Throughout this Form 10-K, we “incorporate by reference” certain information from other documents filed or to be filed with the SEC, including our Proxy Statement. Please refer to this information. This Form 10-K will be available on our website on or about February 27, 2025. Our Proxy Statement will be available on our website on or about March 13, 2025.
Our annual Impact Report, which provides disclosures regarding our responsible business practices, is made available on our website. We also have a Pfizer Investor Insights website, which includes articles on the company, its products and its pipeline, located at insights.pfizer.com. Information in our Impact Report and on the Pfizer Investor Insights website are not incorporated by reference into this Form 10-K.
We may use our website as a means of disclosing material information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures are included on our website in the “About—Investors” or “Newsroom” sections. Accordingly, investors should monitor these portions of our website, in addition to following our press releases, SEC filings, public conference calls and webcasts, as well as our social media channels (our Facebook page, Instagram account (@Pfizerinc), YouTube page, LinkedIn page, and X (formerly known as Twitter) accounts (@Pfizer and @Pfizer_News)). The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-K.

Pfizer Inc.
2024 Form 10-K
iii


Information relating to corporate governance at Pfizer, including our Corporate Governance Principles; Director Qualification Standards; Pfizer Policies on Business Conduct (for all of our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer); Code of Business Conduct and Ethics for Members of the Board of Directors; information concerning our Directors; ways to communicate by e-mail with our Directors; information concerning our Board Committees; Committee Charters; Charter of the Lead Independent Director; and transactions in Pfizer securities by Directors and Officers are available on our website. We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001-2192. We will disclose any future amendments to, or waivers from, provisions of the Pfizer Policies on Business Conduct affecting our Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and executive officers on our website as promptly as practicable, as may be required under applicable SEC and NYSE rules. Information relating to shareholder services, including the Computershare Investment Program, book-entry share ownership and direct deposit of dividends, is also available on our website.

Pfizer Inc.
2024 Form 10-K
iv


FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS
This Form 10-K contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions.
These statements may be identified by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning or by using future dates.
We include forward-looking information in our discussion of the following, among other topics:
our anticipated operating and financial performance, including financial guidance and projections;
reorganizations, business plans, strategy, goals and prospects;
expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data; revenue contribution and projections; potential pricing and reimbursement; potential market dynamics, including demand, market size and utilization rates; and growth, performance, timing of exclusivity and potential benefits;
strategic reviews, capital allocation objectives, dividends and share repurchases;
plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on growth opportunities and prospects;
sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;
expectations regarding the impact of or changes to existing or new government regulations or laws;
our ability to anticipate and respond to and our expectations regarding the impact of macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises; and
manufacturing and product supply.
In particular, forward-looking information in this Form 10-K includes statements relating to specific future actions, performance and effects, including, among others, the expected benefits of the organizational changes to our operations; our anticipated operating and financial performance; our ongoing efforts to respond to COVID-19; our expectations regarding the impact of COVID-19 on our business; the expected revenue, seasonality of demand and phasing for certain of our products; expected patent terms; the expected impact of patent expiries and generic and biosimilar competition; the expected pricing pressures on our products and the anticipated impact to our business; the benefits expected from our business development transactions, including our December 2023 acquisition of Seagen; the availability of raw materials; our efforts to develop plans to help mitigate the potential impact of tariffs on our business and operations; our anticipated cash flows and liquidity position; the anticipated costs, savings and potential benefits from certain of our initiatives, including our enterprise-wide Realigning our Cost Base Program, which we launched in October 2023, and our Manufacturing Optimization Program to reduce our cost of goods sold, which we announced in May 2024; our greenhouse gas emission reduction goals; our planned capital spending; and our capital allocation framework.
Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from past results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or incomplete, or by known or unknown risks and uncertainties, including those described in this section, in the Item 1A. Risk Factors section or in MD&A.
Therefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form 10-K. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. You are advised, however, to consult any further disclosures we make on related subjects.
Some of the factors that could cause actual results to differ are identified below, as well as those discussed in the Item 1A. Risk Factors section and within MD&A. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below, in the Item 1A. Risk Factors section, or within MD&A, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties:
Risks Related to Our Business, Industry and Operations, and Business Development:
the outcome of R&D activities, including the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from our pipeline programs will be published in scientific journal publications, and if so, when and with what modifications and interpretations; and uncertainties regarding the future development of our product candidates, including whether or when our product candidates will advance to future studies or phases of development or whether or when regulatory applications may be filed for any of our product candidates;
our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all;
regulatory decisions impacting labeling, approval or authorization, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; uncertainties regarding the ability to obtain or maintain, and the scope of, recommendations by technical or advisory committees, and the timing of, and ability to obtain, pricing approvals and product launches, all of which could impact the availability or commercial potential of our products and product candidates;
claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the conduct or outcome of post-approval clinical trials, pharmacovigilance or Risk Evaluation and Mitigation Strategies, which could impact marketing approval, product labeling, and/or availability or commercial potential;

Pfizer Inc.
2024 Form 10-K
1


the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which has in the past and could in the future result in increased leverage and/or a downgrade of our credit ratings and could limit our ability to obtain future financing; challenges integrating the businesses and operations; disruption to business or operations relationships; risks related to growing revenues for certain acquired or partnered products; significant transaction costs; and unknown liabilities;
competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;
the ability to successfully market both new and existing products, including biosimilars;
difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions;
the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&D and clinical trials;
risks and uncertainties related to Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, including, among others, the risk that as the market for COVID-19 products remains endemic and seasonal, demand for our COVID-19 products has and may continue to be reduced or not meet expectations, which has in the past and may continue to lead to reduced revenues, excess inventory or other unanticipated charges; risks related to our ability to develop and commercialize variant adapted vaccines, combinations and/or treatments; uncertainties related to recommendations and coverage for, and the public’s adherence to, vaccines, boosters, treatments or combinations; and potential third-party royalties or other claims related to Comirnaty and Paxlovid;
trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;
interest rate and foreign currency exchange rate fluctuations, including the impact of currency devaluations and monetary policy actions in countries experiencing high inflation or deflation rates;
any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;
the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain;
any significant issues related to the outsourcing of certain operational and staff functions to third parties;
any significant issues related to our JVs and other third-party business arrangements, including modifications or disputes related to supply agreements or other contracts with customers including governments or other payors;
uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation or interest rate fluctuations, and recent and possible future changes in global financial markets;
the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation, sanctions, tariffs and/or other restrictive government actions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes;
the impact of disruptions related to climate change and natural disasters;
any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the resulting economic or other consequences;
the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, such as our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines, and our voluntary withdrawal of all lots of Oxbryta in all markets where it is approved and any regulatory or other impact on Oxbryta and other sickle cell disease assets;
trade buying patterns;
the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;
the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, including any potential future phases, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption, adverse effects on employee morale, retention issues or other unintended consequences;
the ability to successfully achieve our climate-related goals and progress our environmental sustainability and other priorities;
Risks Related to Government Regulation and Legal Proceedings:
the impact of any U.S. healthcare reform or legislation or any significant spending reduction or cost control efforts affecting Medicare, Medicaid, the 340B Program or other publicly funded or subsidized health programs, including the IRA, or changes in the tax treatment of employer-sponsored health insurance that may be implemented;
U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access to or recommendations for our medicines and vaccines, taxes or other restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive biopharmaceutical markets;
legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, medical regulation, environmental protections, reimbursement or access,

Pfizer Inc.
2024 Form 10-K
2


including, in particular, continued government-mandated reductions in prices and access restrictions for certain products to control costs in those markets;
legal defense costs, insurance expenses, settlement costs and contingencies, including without limitation, those related to legal proceedings and actual or alleged environmental contamination;
the risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings;
the risk and impact of tax related litigation and investigations;
governmental laws, regulations and policies affecting our operations, including, without limitation, the IRA, as well as changes in such laws, regulations or policies, or their interpretation, including, among others, changes in tariffs, tax laws and regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024 and potential changes to existing tax laws, tariffs, or changes to other laws, regulations or policies in the U.S., including by the U.S. Presidential administration and Congress, as well as in other countries;
Risks Related to Intellectual Property, Technology and Cybersecurity:
the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all;
risks to our products, patents and other intellectual property, such as: (i) claims of invalidity that could result in loss of patent coverage; (ii) claims of patent infringement, including asserted and/or unasserted intellectual property claims; (iii) claims we may assert against intellectual property rights held by third parties; (iv) challenges faced by our collaboration or licensing partners to the validity of their patent rights; or (v) any pressure from, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products, including Comirnaty and Paxlovid;
any significant breakdown or interruption of our IT systems and infrastructure (including cloud services);
any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack, which may include those using adversarial AI techniques, or other malfeasance by, but not limited to, nation states, employees, business partners or others; and
risks and challenges related to the use of software and services that include AI-based functionality and other emerging technologies.
PART I
ITEM 1.BUSINESS
Pfizer Logo.jpg
ABOUT PFIZER
Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The Company was incorporated under the laws of the State of Delaware on June 2, 1942.
Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients through improved treatment of diseases and improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room visits or hospitalizations. We seek to enhance the value of our medicines and vaccines and actively engage in dialogues about how we can best work with patients, physicians and payors to prevent and treat disease and improve outcomes. We seek to maximize patient access and evaluate our pricing arrangements and contracting methods with payors to minimize adverse impact on our revenues within the current legal and pricing structures.
We are committed to fulfilling our purpose: Breakthroughs that change patients’ lives. Our purpose fuels everything we do and reflects both our passion for science and our commitment to patients. Our core business principles are:
1.Trust is Everything
2.Science Will Win
3.Disruption Calls for Innovation
4.Time is Life
5.Execution Makes the Difference.
Our 2025 key priorities are:
1.Improve R&D productivity with sharpened focus
2.Expand margins and maximize operational efficiency
3.Achieve commercial excellence in our key categories
4.Optimize capital allocation.
We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our

Pfizer Inc.
2024 Form 10-K
3


capabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our business strategy.
For a discussion of our strategy and our business development initiatives, see the Overview of Our Performance, Operating Environment, Strategy and Outlook section within MD&A and Note 2.
COMMERCIAL OPERATIONS
We manage our commercial operations through a global structure consisting of three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma, our innovative science-based biopharmaceutical business, is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Pfizer Ignite is an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with our R&D focus areas. Biopharma is the only reportable segment. Our commercial divisions market, sell and distribute our products, and global operating functions are responsible for the research, development, manufacturing and supply of our products. The commercial structure within our Biopharma reportable segment in 2024 was comprised of the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division:
Pfizer Oncology Division combined the U.S. Oncology commercial organizations, global Oncology marketing organizations and global and U.S. Oncology medical affairs from both Pfizer and Seagen (which we acquired in December 2023).
Pfizer U.S. Commercial Division included the U.S. Primary Care and U.S. Specialty Care customer groups, the Chief Marketing Office, the Global Chief Medical Affairs Office and Global Access & Value.
Pfizer International Commercial Division included the ex-U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio in all international markets.
As part of our continued focus on commercial execution, at the beginning of 2025, we made changes in our commercial structure, which included the transition of all activities within the Pfizer Oncology Division to other parts of Biopharma, among other changes. Specifically, within our Biopharma reportable segment, the U.S. Oncology commercial organization and the global Oncology marketing organization, which were part of the former Pfizer Oncology Division, are now part of the Pfizer U.S. Commercial Division. In 2025, the commercial structure within our Biopharma reportable segment is as follows:
Division
Description
Pfizer U.S. Commercial Division

Includes the U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio (excluding Oncology medical affairs which is part of global R&D), as well as the Global Access & Value and Global Chief Marketing Office organizations.
Primary Care includes:
Internal medicine product portfolio of brands in cardiovascular metabolic, as well as brands that have experienced patent-based expirations or loss of regulatory exclusivity.
Migraine product portfolio.
Vaccines product portfolio across all ages with a pipeline focus on infectious diseases with significant unmet medical need, including COVID-19.
Treatment for COVID-19.

Specialty Care includes:
Inflammation & immunology product portfolio of brands and biosimilars for chronic immune and inflammatory diseases.
Rare disease product portfolio of brands for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia and endocrine diseases.
Hospital product portfolio of sterile injectable and immunoglobulin medicines.
Oncology includes:
Innovative oncology product portfolio of ADCs, small molecules, bispecifics and other immunotherapies that treat a wide range of cancers including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer.
Oncology biosimilars.
Pfizer International Commercial Division
Includes the ex-U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio in all international markets.
Select Primary Care, Specialty Care and Oncology products include:
Primary Care:
Internal medicine: Eliquis, as well as other brands that have experienced patent-based expirations or loss of regulatory exclusivity.
Migraine: Nurtec ODT/Vydura and Zavzpret
Vaccines: the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba
Treatment for COVID-19: Paxlovid
Specialty Care:
Inflammation & immunology: Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa and Velsipity
Rare disease: the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla and Hympavzi
Hospital: Sulperazon, Zavicefta, Octagam, Zithromax, Medrol and Panzyga
Oncology: Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna
For additional information on our operating segments and products, including product revenues, see Note 17, and for additional information on the key operational revenue drivers of our business, see the Analysis of the Consolidated Statements of Operations section within MD&A. For a discussion of the risks associated with our dependence on certain of our major products, see the Item 1A. Risk Factors—Concentration section.

Pfizer Inc.
2024 Form 10-K
4


RESEARCH AND DEVELOPMENT
R&D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients’ lives as we work to translate advanced science and technologies into the medicines and vaccines that may be the most impactful for patients. In addition to discovering and developing new products, our R&D efforts seek to add value to our existing products by improving their safety, efficacy and ease of dosing and by discovering potential new indications.
Our R&D Priorities and Strategy. Our R&D priorities include:
delivering a pipeline of highly differentiated medicines and vaccines where we have a unique opportunity to bring the most important new therapies to patients in need;
advancing our capabilities that can position us for long-term R&D leadership; and
advancing new models for partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.
To that end, our R&D primarily focuses on our main therapeutic areas, which are oncology, internal medicine (including cardiovascular and migraine), vaccines and inflammation and immunology.
While a significant portion of our R&D is internal, we also seek promising chemical and biological lead molecules and innovative technologies developed by others to incorporate into our discovery and development processes or projects, as well as our portfolio. We do so by entering into collaboration, alliance and license agreements with universities, biotechnology companies and other firms as well as through acquisitions and investments. These arrangements allow us to share knowledge, risk and cost. They also enable us to access external scientific and technological expertise, as well as provide us the opportunity to advance our own products and in-licensed or acquired products. For information on certain of these collaborations, alliances and license arrangements and investments, see Note 2.
Our R&D Operations. In 2024, we continued to enhance our global R&D operations and pursued strategies to improve R&D productivity and advance a sustainable and value-creating pipeline. Oncology was organized in an end-to-end Oncology R&D (ORD) organization, spanning discovery to late-phase clinical development. Pfizer Research and Development (PRD) managed the same for our remaining therapeutic areas in addition to certain platform organizations. Effective January 1, 2025, ORD and PRD were consolidated into a single R&D organization to further strengthen Pfizer’s capabilities and leadership in discovering and developing breakthrough medicines and vaccines. As part of these changes, we are now evaluating how our simplified structure and sharpened focus might lead to improvements in productivity and potential efficiencies. We expect any potential savings identified through these efforts to be reinvested in our R&D portfolio.
We manage R&D operations on a total-company basis through the organizations described above. The Portfolio Management Team (PMT), currently chaired by our Chief Strategy and Innovation Officer, Executive Vice President, is accountable for aligning resources across R&D, and for helping to ensure optimal capital allocation across the R&D portfolio. We believe that this approach also serves to maximize accountability and flexibility.
We do not disaggregate total R&D expense by development phase or by therapeutic area since, as described above, we manage our R&D strategy and operations collectively under the governance of the PMT and do not manage our R&D operational spend independently by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, we believe that any prior-period information about R&D expense by development phase or by therapeutic area would not necessarily be representative of future spending.
For additional information on our R&D operations, including R&D related costs and expenses, see the Costs and ExpensesResearch and Development Expenses section within MD&A and Note 17.
Our R&D Pipeline. The process of drug, vaccine and biological product discovery from initiation through development and to potential regulatory approval is lengthy and can take more than ten years. As of February 4, 2025, we had the following number of projects in various stages of R&D:
2024 Pipeline 10K.jpg
Development of a single compound is often pursued as part of multiple programs. While our product candidates may or may not receive regulatory approval, new candidates entering clinical development phases are the foundation for future products. Information concerning several of our drug, vaccine and biological candidates in development, as well as supplemental filings for existing products, is set forth in the Product Developments section within MD&A. The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable.
For information on the risks associated with R&D, see the Item 1A. Risk Factors—Research and Development section.
COLLABORATION AND CO-PROMOTION AGREEMENTS
We use collaboration and/or co-promotion arrangements to enhance our development, R&D, sales and distribution of certain biopharmaceutical products, which include, among others, the following:
Comirnaty is an mRNA-based coronavirus vaccine to help prevent COVID-19, which is being jointly developed and commercialized with BioNTech. Pfizer and BioNTech equally share the costs of development for the Comirnaty program. Comirnaty has been granted an approval or an authorization in many countries around the world in populations varying by country. We also share gross profits equally from commercialization of Comirnaty (excluding China, Hong Kong, Macau and Taiwan, where we do not have rights), subject to regulatory authorizations or approvals market by market. For discussion on Comirnaty, see the Overview of Our Performance, Operating Environment, Strategy and Outlook—COVID-19 section within MD&A.

Pfizer Inc.
2024 Form 10-K
5


Eliquis (apixaban) is part of the Novel Oral Anticoagulant market and was jointly developed and commercialized with BMS as an alternative treatment option to warfarin in appropriate patients. We fund between 50% and 60% of all development costs depending on the study, and profits and losses are shared equally except in certain countries where we commercialize Eliquis and pay a percentage of net sales to BMS. In certain smaller markets we have full commercialization rights and BMS supplies the product to us at cost plus a percentage of the net sales to end-customers.
Xtandi (enzalutamide) is an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells that is being developed and commercialized in collaboration with Astellas. We share equally in the gross profits and losses related to U.S. net sales and also share equally all Xtandi commercialization costs attributable to the U.S. market, subject to certain exceptions. In addition, we share certain development and other collaboration expenses. For international net sales we receive royalties based on a tiered percentage.
Orgovyx (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer that is being developed and commercialized with SMPS. The companies equally share profits and allowable expenses in the U.S. for Orgovyx. Pfizer does not have rights outside of this market. Separately, in December 2024, the companies terminated their collaboration with respect to the relugolix combination tablet.
Padcev (enfortumab vedotin-ejfv) is a first-in-class ADC that is directed to Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer, that is being co-developed and jointly commercialized with Astellas. In the U.S., Padcev has been approved for use with Keytruda (pembrolizumab) for adult patients with locally advanced or metastatic urothelial cancer. Other approvals and indications for Padcev vary by market. In the U.S., Pfizer and Astellas jointly promote, and we record net sales and are responsible for all U.S. distribution activities for Padcev. The companies each bear the costs of their own sales organizations in the U.S., and equally share certain other costs associated with commercializing and any profits realized for Padcev in the U.S. Outside the U.S., we have commercialization rights in all countries in North and South America, and Astellas has commercialization rights in the rest of the world. The agreement between us and Astellas provides that the companies will effectively equally share in profits realized in markets outside of the U.S. through: (i) a costs-incurred and profit-sharing mechanism based on product sales and costs of commercialization in certain markets and (ii) a royalty-payment mechanism intended to approximate an equal profit share for both parties in the remaining markets.
Adcetris (brentuximab vedotin) is being developed and commercialized in collaboration with Takeda. Pfizer has commercialization rights for Adcetris in the U.S. and its territories and in Canada. Takeda has commercialization rights in the rest of the world and pays Pfizer a royalty based on a percentage of Takeda's net sales of Adcetris in its licensed territories, based on annual net sales tiers.
In addition, we have collaboration and/or co-promotion arrangements with respect to certain other biopharmaceutical products, including, among others, certain of those described in the Item 1. Business—Patents and Other Intellectual Property Rights section.
Revenues associated with these arrangements are included in Alliance revenues (except in certain markets where we have direct sales and except for the majority of revenues for Comirnaty and Padcev, which are included in Product revenues). In addition, we have collaboration arrangements for the development and commercialization of certain pipeline products that are in development stage, including, among others certain of those described in the Product Developments section within MD&A. For further discussion of collaboration and co-promotion agreements, see the Item 1. Business—Patents and Other Intellectual Property Rights section, the Item 1A. Risk Factors—Collaborations and Other Relationships with Third Parties section and Notes 2 and 17.
INTERNATIONAL OPERATIONS
Our operations are conducted globally, and we supply our medicines and vaccines to approximately 200 countries and territories. Emerging markets are an important component of our strategy for global leadership, and our commercial structure recognizes that the demographics and rising economic power of the fastest-growing emerging markets are becoming more closely aligned with the profile found within developed markets. Urbanization and the rise of the middle class in emerging markets provide potential growth opportunities for our products.
Revenues from operations outside the U.S. of $24.9 billion, $31.4 billion and $57.9 billion accounted for 39%, 53% and 57% of Total revenues in 2024, 2023 and 2022, respectively. Revenues exceeded $500 million in each of 11, 14 and 24 countries outside the U.S. in 2024, 2023 and 2022, respectively. The decrease in the number of countries exceeding $500 million in revenues from 2023 to 2024 was primarily driven by decreases in international revenues related to Comirnaty and Paxlovid. As a percentage of Total revenues, China was our largest market outside the U.S. (representing 4% of total revenues) in 2024, and Japan was our largest market outside the U.S. in 2023 and 2022 (representing 6% and 8% of total revenues, respectively). For a geographic breakdown of Total revenues, see the Total Revenues by Geography section within MD&A and Note 17B.
Our international operations are subject to risks inherent in carrying on business in other countries. See the Item 1A. Risk FactorsGlobal Operations and Item 1. BusinessGovernment Regulation and Price Constraints sections.
SALES AND MARKETING
Our prescription biopharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain of these government contracts may be renegotiated or terminated at the discretion of a government entity. For more information, see Note 1G and Note 17C.
We also seek to gain access for our products on formularies, which are lists of approved medicines available to members of healthcare programs or PBMs in the U.S. Insurers and PBMs who design and negotiate formularies on their behalf use various benefit designs, such as tiered co-pays for formulary products, to drive utilization of products in preferred formulary positions, typically in exchange for a discount off the price of the medicine in the form of a rebate agreement. We may also work with payors on disease management programs that help to develop tools and materials to educate patients and physicians on key disease areas. For information on our significant customers, see Note 17C.
We promote our products to healthcare providers and patients consistent with applicable laws. Through our marketing organizations, we explain the approved uses, benefits and risks of our products to healthcare providers and patients and, in the U.S., to MCOs that provide insurance coverage, such as hospitals, integrated delivery systems, PBMs and health plans; and employers and government agencies who hire MCOs to provide health benefits to their employees. In the U.S. and select international markets, we market directly to consumers through direct-to-consumer advertising that seeks to communicate the approved uses, benefits and risks of our products while motivating people to have

Pfizer Inc.
2024 Form 10-K
6


meaningful conversations with their doctors. In addition, we sponsor general advertising to educate the public on disease awareness, prevention and wellness, important public health issues and our patient assistance programs.
As part of our commitment to engaging our customers in a manner they prefer, we take an omnichannel approach, including both virtual and in person interactions, and see generally positive customer response to both approaches.
PATENTS AND OTHER INTELLECTUAL PROPERTY RIGHTS
Patents. We own or have co-promotion and/or license rights related to a number of patents covering pharmaceutical and other products, their uses, formulations, and product manufacturing processes.
Patents for individual products extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The scope of protection afforded by a patent can vary from country to country and depends on the patent type, the scope of its patent claims and the availability of legal remedies. Patent term extensions (PTE) may be available in some countries to compensate for a loss of patent term due to delay in a product’s approval due to the regulatory requirements, while patent term adjustment may be available in some countries to compensate for administrative delays during prosecution of patents. One of the primary considerations in limiting our operations in some countries outside the U.S. is the lack of effective intellectual property protection for our products, although international and U.S. free trade agreements have included some global protection of intellectual property rights. See the Item 1. BusinessGovernment Regulation and Price Constraints section.
In various markets, a period of regulatory exclusivity may be provided for drugs or vaccines upon approval. The scope and term of such exclusivity will vary but, in general, the period will run concurrently with the term of any existing patent rights associated with the drug at the time of approval.
Based on current sales and other factors, and considering the competition with products sold by our competitors, the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires, are as follows:
Product
U.S. Basic Product Patent Expiration Year(1)
Major Europe Basic Product Patent Expiration Year(1)
Japan Basic Product Patent Expiration Year(1)
Inlyta202520252025
Xeljanz
2026
2028(2)
2025
Prevnar 13/Prevenar 132026
(3)
2029
Eliquis
2026(4)
2026(5)
2026
Ibrance202720282028
Xtandi(6)
2027
(6)
(6)
Vyndaqel/Vyndamax/Vynmac
2025(7)
(2028 pending PTE)
2026
2026/2029(8)
Nurtec ODT/Vydura
2030
(2034 pending PTE)
2035
2030(9)
Braftovi(10)
2030
(2031 pending PTE)
(10)
(10)
Mektovi(10)
2026
(2027 pending PTE)(11)
(10)
(10)
Talzenna
2029
(2032 pending PTE)
2034
2029
(2034 pending PTE)
Lorbrena203320342036
Padcev(12)
2033
(12)
(12)
Tukysa(13)
2031
(2034 pending PTE)
2031
2026(9)
Zavzpret
2031
(2034 pending PTE)
2031(9)
2031(9)
Velsipity
2030
(2035 pending PTE)
2029
(2034 pending SPC)
2029(9)
Prevnar 20/Apexxnar
2033
(2035 pending PTE)
2037
2033
(2038 pending PTE)
Ngenla(14)
2035(2)
2032(2)
2030(2)
Cibinqo
2034
(2036 pending PTE)
2036
2038
Tivdak(15)
2033(2)
(15)
(15)
Litfulo
2034
(2037 pending PTE)
2038
2039
Abrysvo
2036
(2037 pending PTE)
(16)
2036
(2039 pending PTE)
Elrexfio
2036
(2037 pending PTE)
2036
(2038 pending SPC)
2036
(2038 pending PTE)
Hympavzi
2036
(2038 pending PTE)
(16)
2036

Pfizer Inc.
2024 Form 10-K
7


Product
U.S. Basic Product Patent Expiration Year(1)
Major Europe Basic Product Patent Expiration Year(1)
Japan Basic Product Patent Expiration Year(1)
Comirnaty(17)
2041
(18)(19)
2041
Paxlovid204120412041
(1)Unless otherwise indicated, the years pertain to the basic product patent expiration, including granted PTEs, supplementary protection certificates (SPC) or pediatric exclusivity periods. SPCs are included when granted in three out of five major European markets (France, Germany, Italy, Spain and the U.K.). Noted in parentheses is the projected year of expiry of the earliest pending patent term extension in the U.S. or Japan and/or SPC application in Europe, the term of which, if granted, may be shorter than originally requested due to a number of factors. In some instances, there are later-expiring patents relating to our products which may or may not protect our product from generic or biosimilar competition after the expiration of the basic patent.
(2)Expiry is provided by regulatory exclusivity in this market.
(3)The Europe patent that covers the combination of the 13 serotype conjugates of Prevenar 13 was revoked following an opposition and has now been withdrawn. There are other Europe patents and pending applications covering the formulation, various aspects of the manufacturing process, and the combination of serotype conjugates of Prevenar 13 that remain in force.
(4)Eliquis was developed and is being commercialized in collaboration with BMS. In the U.S., we and BMS previously settled certain patent litigations with a number of generic companies permitting their launch of a generic version of Eliquis on April 1, 2028 (the settled generic companies). We continued to litigate against three remaining generic companies and following the resolution of the litigation in our favor, the three generic companies are not permitted to launch their products until the 2031 expiration date of the formulation patent. Both the composition of matter patent expiring in November 2026 and the formulation patent expiring in 2031 may be subject to future challenges. While we cannot predict the outcome of any potential future litigation, there are certain potential alternatives that might occur which could potentially permit generic launch prior to April 1, 2028: (i) if the formulation patent is held invalid or not infringed in future litigation, through appeal, the settled generic companies and any successful future litigant would be permitted to launch on November 21, 2026; or (ii) if both patents are held invalid or not infringed in future litigation, through appeal, the settled generic companies and any successful future litigant could launch products immediately upon such an adverse decision. Refer to Note 16A1 for more information.
(5)On October 31, 2023, the U.K. Supreme Court refused BMS’s permission to appeal in relation to the judgment that found the apixaban basic product patent and associated SPC invalid. Additional challenges are pending in other jurisdictions.
(6)Xtandi is being developed and commercialized in collaboration with Astellas, which has exclusive commercialization rights for Xtandi outside the U.S. Pfizer receives tiered royalties as a percentage of international Xtandi net sales.
(7)Interim patent term extension requests have been granted extending the expiry from December 2024 to December 2025 and Pfizer has filed applications for patent term extension to 2028.
(8)Vyndaqel (tafamidis meglumine) basic patent expiry in Japan is August 2026 for treatment of polyneuropathy. Vynmac (tafamidis) was approved in Japan for treatment of cardiomyopathy with regulatory exclusivity expiring in March 2029.
(9)Product not yet approved or authorized in this market.
(10)We have exclusive rights to Braftovi and Mektovi in the U.S., Canada and certain emerging markets. Pierre Fabre has exclusive rights to commercialize both products in Europe and Ono has exclusive rights to commercialize both products in Japan. We receive royalties from Pierre Fabre and Ono on sales of Braftovi and Mektovi in a majority of markets outside the U.S.
(11)Mektovi U.S. expiry is provided by a composition of matter patent. Interim patent term extension requests have been granted extending the expiry from March 2025 to March 2026 and Pfizer has filed an application for patent term extension to 2027. Other U.S. patents remain in force beyond the composition of matter patent expiry. Those patents have been challenged in litigation. Refer to Note 16A1 for more information.
(12)Padcev is being commercialized in collaboration with Astellas. Pfizer has co-promotion rights in the U.S. Outside the U.S., Pfizer has commercialization rights in all countries in North and South America, and Astellas has commercialization rights in the rest of the world, including Europe, Asia, Australia and Africa.
(13)In September 2020, Seagen and Merck began a collaboration to commercialize Tukysa. As of December 31, 2023, this collaboration ended and all commercialization rights were returned to Seagen (Pfizer).
(14)Ngenla is being developed in collaboration with OPKO Health, Inc.
(15)Tivdak is commercialized in collaboration with Genmab. Pfizer has co-promotion rights in the U.S. Outside the U.S., Genmab has the sole right to promote Tivdak for second-line plus mCC and has co-promotion rights for other indications in all territories except certain territories where Zai Lab Limited (Zai Lab) has commercialization rights (mainland China, Hong Kong, Macau, and Taiwan). Pfizer and Genmab equally share all costs and profits for Tivdak in the U.S., Europe, China (including the payments from Zai Lab described below), and Japan; provided that Genmab will be solely responsible for all costs of development, manufacturing and commercialization of second-line plus mCC outside the U.S. and the Zai Lab territories. Genmab will pay Pfizer a royalty-based percentage of aggregate net sales of Tivdak for second-line plus mCC outside the U.S. and the Zai Labs territories. In markets outside the U.S. other than Europe, China, and Japan, Pfizer will pay Genmab a royalty based on a percentage of aggregate net sales of Tivdak for indications other than second-line plus mCC. Further, pursuant to the agreement with Zai Lab, Pfizer is entitled to receive potential development, regulatory and commercial milestone payments, and tiered royalties on net sales of Tivdak in the Zai Lab territories, which will be shared equally with Genmab.
(16)The basic product patent application has been filed in this market. If granted, a full term is expected in this market.
(17)Product is being commercialized in collaboration with BioNTech. The Comirnaty trademark covers marketed variants.
(18)The basic product patent has been granted in the U.K. and expires in 2041. In the other major markets, a patent application has been filed. If granted, a full term is expected.
(19)Pfizer does not have co-promotion rights for this product in Germany.
For information regarding profit sharing and royalty arrangements for certain of these products, see Item 1. Business—Collaboration and Co-Promotion Agreements.
Loss of Intellectual Property Rights. The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Once patent protection has expired or has been lost prior to the expiration date as a result of a legal challenge, we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price. The date at which generic or biosimilar competition commences may be different from the date that the patent or regulatory exclusivity expires. However, when generic or biosimilar competition does commence, the resulting price competition can substantially decrease our revenues for the impacted products, often in a very short period of time. Also, if one of our product-related patents is found to be invalid by judicial, court, regulatory or administrative proceedings, generic or biosimilar products could be introduced, resulting in the erosion of sales of our existing products. Additionally, we could be subject to claims that our intellectual property rights infringe third party patents.
Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent-based or regulatory exclusivity

Pfizer Inc.
2024 Form 10-K
8


expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries in 2025 and anticipate a more significant impact of reduced revenues from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations. There is no assurance that a particular product will maintain market exclusivity for the full time period that appears in the estimates included in this Form 10-K or that we assume when we provide our financial guidance. For additional information on the impact of loss of patent-based exclusivity or regulatory exclusivity on our revenues, see the Overview of Our Performance, Operating Environment, Strategy and Outlook—Our 2023 Performance section within MD&A.
We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access. See the Item 1A. Risk FactorsCompetitive Products, Intellectual Property Protection and Third-Party Intellectual Property Claims sections and Note 16A1.
Trademarks. Our products are sold under brand-name and logo trademarks and trade dress. Registrations generally are for fixed, but renewable, terms and protection is provided in some countries for as long as the mark is used while in others, for as long as it is registered. Protecting our trademarks is of material importance to us.
COMPETITION
Our business is conducted in intensely competitive and highly regulated markets. Many of our products face competition in the form of branded or generic drugs or biosimilars that treat similar diseases or indications. The principal forms of competition include efficacy, safety, ease of use and cost. Though the means of competition vary among our products, demonstrating the value of our products is a critical factor for success.
We compete with other companies that manufacture and sell products that treat or prevent diseases or indications similar to those treated or prevented by our major products. These competitors include other worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus and generic drug and biosimilar manufacturers. Our competitors also may devote substantial funds and resources to R&D and their successful R&D could result in erosion of the sales of our existing products and potential sales of our products in development, as well as product obsolescence. In addition, several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration.
To help address competitive trends we continually emphasize innovation, which is underscored by our multi-billion-dollar investment in R&D, as well as our business development transactions, both designed to result in a strong and differentiated product pipeline. Our investment in research continues even after drug or vaccine approval as we seek to further demonstrate the value of our products for the conditions they treat or prevent, as well as investigating potential new applications. We educate patients, physicians, payors and global health authorities on the benefits and risks of our medicines and vaccines, and seek to continually enhance the organizational effectiveness of our biopharmaceutical functions, including our efforts to effectively launch and market our products to our customers.
Operating conditions have also shifted as a result of increased global competitive pressures, industry regulation and cost containment. We continue to evaluate, adapt and improve our organization and business practices in an effort to better meet customer and public needs. We believe that we have taken an industry-leading role in evolving our ethical approaches to U.S. direct-to-consumer advertising, interactions with, and payments to, healthcare professionals and medical education grants. We also continue to support programs to help address patient affordability and access barriers, as we strive to advance fundamental health system change through our support for better healthcare solutions. For example, our Accord for a Healthier World program aims to provide our full portfolio of patented and off-patent medicines and vaccines for which Pfizer holds global rights on a not-for-profit basis to 1.2 billion people living in 45 lower-income countries around the world.
Our vaccines have and may continue to face competition, including from the introduction of alternative vaccines or “next-generation” vaccines prior to or after the expiration of their patents, which may adversely affect our future results.
Our biosimilars, which include biosimilars of certain inflammation & immunology and oncology biologic medicines, compete with branded products from competitors, as well as other generics and biosimilars manufacturers. We seek to maximize the opportunity to establish a “first-to-market” or early market position for our biosimilars to provide customers a lower-cost alternative immediately when available and also to potentially provide us with higher levels of sales and profitability until other competitors enter the market.
Generic Products. Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection and often charge much less. Several competitors regularly challenge our product patents before their expiration. Generic competitors often operate without large R&D expenses, as well as without costs of conveying medical information about products to the medical community. In addition, the approval process in the U.S. and in the EU exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy data of the innovator product. In China, for example, given the expansion of the QCE process and continuation of the VBP program, we expect to continue to face intensified competition by certain generic manufacturers in 2025 and beyond, which has and may continue to result in price cuts and volume loss of some of our products. In addition, generic versions of competitors’ branded products have and may continue to compete with our products.
Commercial and government payors typically encourage the use of generics as alternatives to brand-name drugs in their healthcare programs, including Medicaid in the U.S., and U.S. laws generally allow, and in some cases require, pharmacists to substitute generic drugs for brand-name drugs. In a small subset of states, prescribing physicians are able to expressly prevent such substitution. Similar rules also apply in several EU member states, where national authorities typically encourage and incentivize the use of generic products.
Biosimilars. Certain of our biologic products, including Enbrel (we market Enbrel outside the U.S. and Canada), already face, or may face in the
future, competition from biosimilars (also referred to as follow-on biologics). Biosimilars are versions of biologic medicines that have been developed and proven to be highly similar to the original biologic in terms of safety and efficacy and that have no clinically meaningful differences in safety, purity or potency. Biosimilars have the potential to offer high-quality, lower-cost alternatives to innovative biologic medicines. In the U.S., biosimilars referencing innovative biologic products are approved by the FDA under the U.S. Public Health Service Act, whereas in the EU the EMA is responsible for evaluating the majority of applications for biosimilars through the centralized procedure.
PRICING PRESSURES AND MANAGED CARE ORGANIZATIONS
Commercial Pricing Pressures. Pricing and access pressures in the commercial sector continue to be significant. Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Many employers have adopted or make available high deductible health plans, which can increase out-of-pocket costs for

Pfizer Inc.
2024 Form 10-K
9


medicines, or are using utilization management tools or limiting access on formularies. This trend is likely to continue. Private third-party payors, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates for payors and a reduction in demand for our products, including denial of coverage of our products, if lower cost alternatives are available. Payors often require significant discounts, or rebates, from our prices in exchange for more favorable formulary placement. Pricing pressures also may occur as a result of highly competitive biopharmaceutical markets and increasing concentration of insurers and PBMs. Healthcare provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review processes.
We believe medicines and vaccines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We work with law makers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and help ensure access to medicines and vaccines within an efficient and affordable healthcare system. This includes assessing our go-to market model to help address patient affordability challenges. We have engaged with major payors and the U.S. government to explore opportunities to improve access and reimbursement in an effort to drive pro-patient policies. In addition, in response to the evolving U.S. and global healthcare spending landscape, we work with health authorities, health technology assessment and quality measurement bodies and major U.S. payors throughout the product-development process to better understand how these entities value our compounds and products. Further, we are developing stronger support designed to demonstrate the value of the medicines and vaccines that we discover or develop, register and manufacture.
Managed Care Organizations. The evolution of managed care in the U.S. has been a major factor in the competitiveness of the healthcare marketplace. Approximately 317 million people in the U.S. now have some form of health insurance coverage, and the marketing of prescription drugs and vaccines to both consumers and the entities that manage coverage in the U.S. continues to grow in importance. In particular, the influence of MCOs has increased in recent years due to the growing number of patients receiving coverage through MCOs. At the same time, consolidation in the MCO industry has resulted in fewer, even larger MCOs, which enhances those MCOs’ ability to negotiate lower pricing and further increases their importance to our business. Since MCOs purport to seek to contain and reduce healthcare expenditures, their growing influence has increased downward pressure on drug prices, as well as negatively impacted revenues.
MCOs and their PBMs typically negotiate prices with pharmaceutical providers by using formularies (which are lists of approved medicines available to MCO members), clinical protocols (which require prior authorization for a branded product if a generic product is available or require the patient to first fail on one or more generic products before permitting access to a branded medicine), long-term contracts and their ability to influence volume and market share of prescription drugs. In addition, by placing branded medicines on higher-tier or non-preferred status in their formularies, MCOs transfer to the patient higher patient out-of-pocket expenses. This financial disincentive is a tool for MCOs to manage drug costs and channel patients to medicines preferred by the MCOs. We expect payment reforms for MCOs will continue to evolve with increased emphasis on expanded participation and on removing barriers to equitable healthcare.
The breadth of the products covered by formularies can vary considerably from one MCO to another, and many formularies include alternative and competitive products for treatment of particular medical problems. MCOs emphasize primary and preventive care, out-patient treatment and procedures performed at doctors’ offices and clinics as ways to manage costs. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed, and drugs that can help in chronic care management and reduce the need for hospitalization, professional therapy or surgery may become favored first-line treatments for certain diseases. At the same time, MCOs may seek to exclude high-cost drugs from formularies in their efforts to manage and lower their costs.
Exclusion of a product from a formulary or other restrictions can significantly impact drug usage in the MCO or PBM managed patient population and beyond. Consequently, pharmaceutical companies compete to gain access to formularies for their products, typically on the basis of unique product features, such as greater efficacy, better patient ease of use, or fewer side effects, as well as the overall cost of the therapy. We continue to seek to ensure that our major products are included on MCO formularies. However, our branded products are increasingly being placed on the higher tiers or in a non-preferred status. Continuing efforts by managed care entities to contain or reduce costs of healthcare and/or impose price controls may adversely affect demand for our products and our financial performance. See the Item 1A. Risk FactorsManaged Care Trends section.
RAW MATERIALS
We procure raw materials essential to our business from numerous suppliers worldwide. In general, these materials have been available in sufficient quantities to support our demand and in many cases are available from multiple suppliers. We do not anticipate the availability of raw materials to have a significant impact on our operations in 2025, but are monitoring potential supply chain disruptions as a result of ongoing geopolitical and trade negotiations, which could, among other things, impact costs. We are continuing to monitor and implement mitigation strategies to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible.
GOVERNMENT REGULATION AND PRICE CONSTRAINTS
We are subject to extensive regulation by government authorities in the countries in which we do business. This includes laws and regulations governing the operations of biopharmaceutical companies, such as the approval, manufacturing and marketing of products, pricing (including discounts and rebates) and price reporting, interactions with healthcare professionals, institutions, and referral sources, reporting of remuneration provided to healthcare providers and academic medical centers, financial assistance provided to patients, clinical research, data privacy and information security, among others. These laws and regulations may require administrative guidance for implementation, and a failure to comply could subject us to legal and/or administrative actions. Enforcement measures may include substantial fines and/or penalties, orders to stop non-compliant activities, criminal charges, warning letters, product recalls or seizures, delays in product approvals, exclusion from participation in government programs or contracts as well as limitations on conducting business in applicable jurisdictions, and could result in harm to our reputation and business. See Note 16A. Compliance with these laws and regulations is costly, and requires significant technical expertise and capital investment to ensure compliance.

Pfizer Inc.
2024 Form 10-K
10


In the U.S.
Drug and Biologic Regulation. The FDA, pursuant to the FFDCA, the Public Health Service Act and other federal statutes and regulations, extensively regulates pre- and post-marketing activities related to our biopharmaceutical products and devices. The statutes and regulations govern areas such as safety and efficacy, clinical trials, advertising and promotion, quality control, manufacturing, labeling, distribution, post-marketing safety surveillance and reporting, and record keeping. Other U.S. federal agencies, including the DEA, may also regulate certain of our products and activities.
For a biopharmaceutical company to market a drug or a biologic product, including vaccines, the FDA must evaluate whether the product is safe and effective for its intended use. Absent statutory exclusivity for a competing product, if the FDA determines that the drug or biologic is safe and effective, the FDA generally will approve the product’s NDA or BLA (or supplemental NDA or supplemental BLA), as appropriate.
A drug or biologic may be subject to post marketing commitments, which are studies or clinical trials that the product sponsor agrees to conduct, or post marketing requirements, which are studies or clinical trials that are required as a condition of approval. In addition, we are also required to report adverse events and comply with cGMPs (the FDA regulations that govern all aspects of manufacturing quality for pharmaceuticals) and the Drug Supply Chain Security Act (the law that, among other things, sets forth requirements related to product tracing, product identifiers and verification for manufacturers, wholesale distributors, third-party logistics providers, re-packagers and dispensers to facilitate the tracing of product through the pharmaceutical distribution supply chain), as well as advertising and promotion regulations. See the Item 1A. Risk FactorsDevelopment, Regulatory Approval and Marketing of Products and Post-Authorization/Approval Data sections.
We are also responsible for monitoring, reviewing, and the periodic reporting of adverse drug experience, or pharmacovigilance, including information received from any source, such as commercial marketing experience, postmarketing clinical investigations, postmarketing epidemiological or surveillance studies, reports in the scientific literature, and unpublished scientific papers.
In the context of public health emergencies, like the COVID-19 pandemic, we may apply to the FDA for an EUA which, if granted, allows for the distribution and use of our products during the declared emergency, in accordance with the conditions set forth in the EUA, unless the EUA is terminated by the government. Although the criteria for an EUA differ from the criteria for approval of an NDA or BLA, EUAs nevertheless require the development and submission of data to satisfy the relevant FDA standards, and a number of ongoing obligations. The FDA generally expects EUA holders to work toward submission of full applications, such as a BLA or an NDA, as soon as possible.
Biosimilar Regulation. The FDA is responsible for approval of biosimilars. Innovator biologics, or reference products, are entitled to certain exclusivity periods. Applications for biosimilars may not be submitted until four years after the date on which the reference product was first licensed and may not be approved until 12 years after the reference product was first licensed.
Sales and Marketing Regulations. Our marketing practices are subject to federal and state laws, such as the Anti-Kickback Statute (AKS), Civil Monetary Penalties Law and False Claims Act, intended to prevent fraud and abuse in the healthcare industry. These laws can apply to both our direct-to-consumer marketing practices as well as our marketing to clinicians and healthcare facilities. The AKS prohibits soliciting, offering, receiving, or paying anything of value to generate business that may be paid for, in whole or in part, by a federal healthcare program. The Civil Monetary Penalties Law covers a variety of conduct, often violations under other laws, and includes penalties for AKS violations as well as causing the submission of false claims. The False Claims Act generally prohibits anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for goods or services, including to government payors, such as Medicare and Medicaid, that are false or fraudulent including false certifications of compliance with applicable law. The federal government and states also regulate sales and marketing activities and financial interactions between manufacturers and healthcare providers and academic medical centers, requiring disclosure to government authorities and the public of such interactions, and the adoption of compliance standards or programs. State attorneys general have also taken action to regulate the marketing of prescription drugs under state consumer protection and false advertising laws.
Pricing, Reimbursement and Access Regulations. Pricing and reimbursement for our products depend in part on government regulation. Any significant efforts at the federal or state levels to reform the healthcare system by changing the way healthcare is provided or funded or to expand controls on drug pricing, government reimbursement, and access to medicines and vaccines on public and private insurance plans could have a material impact on us.
We must offer discounts or rebates on purchases of pharmaceutical products under various government programs including Medicare, Medicaid, the Veterans Administration and the 340B Program. We also must report specific prices to state and federal government agencies. The calculations necessary to determine the prices reported are complex and the failure to do so accurately may expose us to enforcement measures. See the discussion regarding rebates in the Product Revenue Deductions section within MD&A and Note 1G.
The drug pricing provisions of the IRA are being implemented over the next several years. The IRA includes several provisions to lower prescription drug costs for Medicare patients and to reduce drug spending by the federal government. Among other things, the IRA enhances the Medicare Part D benefit by eliminating the coverage gap (“donut hole”) beginning in 2025, adds a maximum out-of-pocket cap for Medicare beneficiaries (set at $2,000 for 2025), and creates a new program, the Medicare Prescription Payment Plan, that allows patients to pay their cost-sharing over time. These changes also include a new Medicare Part D Manufacturer Discount Program, which will change our discounting obligations for Medicare Part D utilization of our drugs. Specifically, this program requires manufacturers to provide a 10% discount on branded prescriptions in the initial coverage phase and a 20% discount in the catastrophic phase. The IRA also imposes rebates under Medicare Part B and Medicare Part D on drug price increases that outpace inflation, and directs HHS to set the prices of certain high-expenditure, single-source drugs and biologics covered under Medicare, known as the MDPNP. In August 2023, CMS published the first ten medicines subject to the MDPNP, which included Eliquis. In August 2024, the government released the new Medicare price for Eliquis, which, effective January 1, 2026, will be required to be offered to all Medicare beneficiaries and to covered entities participating in the 340B Program that dispense Eliquis to a Medicare beneficiary if that maximum fair price is lower than the discounted price such entities are offered under the 340B Program ceiling price calculation. The Eliquis Medicare price is factored into our long-term financial planning, in accordance with our standard financial reporting and forecasting protocols. On January 17, 2025, CMS announced the selection of another 15 drugs from Medicare Part D for the maximum fair price, with prices to be set and effective on January 1, 2027. Ibrance and Xtandi were included in the list of 15 drugs selected. Another 15 drugs from Medicare Part B or Medicare Part D will be selected by February 1, 2026, for the maximum price to be set and in effect by January 1, 2028. It is possible that more of our products could be selected in future years, which could, among other things, lead to lower revenues prior to expiry of intellectual property protections. The MDPNP is currently subject to legal challenges and therefore, the outcome of the MDPNP remains uncertain. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. We anticipate a net unfavorable impact to revenue in 2025 of approximately $1 billion, year-over-year, related to the Medicare Part D redesign changes that take effect in 2025. See the discussion regarding

Pfizer Inc.
2024 Form 10-K
11


Changes to the MDRP or the 340B Program could have a material impact on our business. For example, certain changes finalized by CMS in a December 2020 final rule, including which products qualify as so-called “line extension” drugs subject to increased rebate liability, may have a material adverse impact on our business. Additionally, in September 2024, CMS finalized a new rule that, among other items, expands the scope of medications considered to be “covered outpatient drugs” that could be subject to rebates under the MDRP and imposes penalties on covered outpatient drugs that CMS determines to be “misclassified.” Many pharmaceutical manufacturers believe the 340B Program continues to expand beyond the original intent of serving low-income/uninsured patients. There has been limited government intervention to control this unintended growth. Various potential changes impacting the scope of the 340B Program are undergoing review or are the subject of litigation, and their status is unclear. In 2022, we implemented a policy to help improve contract pharmacy integrity. The HHS Health Resources and Services Administration (HRSA), which administers the 340B Program, sent letters to numerous manufacturers (not including Pfizer) that have also implemented contract pharmacy policies and integrity initiatives; the letters expressed HRSA’s view that those manufacturers’ policies were in violation of the 340B Program statute. Several manufacturers have challenged HRSA’s enforcement letters in federal court and litigation is ongoing in certain of those cases, and were resolved in favor of the manufacturers in others. We believe that our policy is consistent with the statute. In addition, some states have enacted laws opposing manufacturer restrictions on contract pharmacy transactions in their states. At least one state has begun to pursue enforcement proceedings under its law. Several stakeholders have challenged such laws and litigation is ongoing in certain jurisdictions. Additionally, other states have considered and could enact similar laws going forward, although any such laws also may be subject to legal challenges. Additional legal or legislative developments at the federal or state level with respect to the 340B Program may have an adverse impact on our integrity initiative, and we may face enforcement action or penalties, depending upon such developments. The 340B Program continues to be a subject of congressional scrutiny and inquiries, litigation, and other developments, any or all of which could affect the scope of the 340B Program and Pfizer’s obligation to offer discounts to 340B Program-covered entities under the 340B Program. See the Item 1A. Risk FactorsPricing and Reimbursement section.
States seek to control healthcare costs related to Medicaid and other state regulated healthcare programs. A majority of states use preferred drug lists to manage access to pharmaceutical products under Medicaid, including some of our products. States may seek to negotiate supplemental rebate agreements that are larger than the minimum federal requirement for preferred formulary access. Preferred access to our products under the Medicaid managed care programs are often determined by the managed care health plans contracted by the state to administer benefits, which may also require supplemental rebates for preferred formulary access. We expect states will continue to seek cost cutting, which may focus on managed care capitation payments, supplemental rebates, and/or formulary management.
In the U.S., we expect to see continued focus by the U.S. government on regulating pricing and access to medicine, in addition to actions already taken, which could result in legislative and regulatory changes. Government and private payors routinely seek to manage utilization and control the costs of our products. There is considerable public and government scrutiny of pharmaceutical pricing and intellectual property and actions being taken at the state and federal level. Further efforts by states and the federal government to regulate prices or payment for pharmaceutical products, including proposed actions to facilitate drug importation or establish upper pricing limits that cap reimbursement to lower reference prices, require deep discounts, impose financial penalties related to pricing practices, and require manufacturers to report and make public price increases and sometimes a written justification for the increase, could adversely affect our business if implemented. Further, commercial payors often follow Medicare coverage and reimbursement policies when setting their own payment rates. Any reduction in cost or other containment measures may similarly be adopted by commercial plans. Payors may continue to promote generic drugs and biosimilars more aggressively to generate savings and attempt to stimulate additional price competition. In addition, we expect that consolidation and integration among pharmacy chains, wholesalers and PBMs will increase pricing pressures in the industry. See the Item 1A. Risk FactorsManaged Care Trends section.
Anti-Corruption. The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.
Data Privacy. The number of privacy and data security laws and regulations in the U.S. to which we are subject on the federal and state level continues to increase. We routinely collect and use sensitive personal information relating to health. The legislative, regulatory and litigation landscape for privacy and data protection requirements is rapidly evolving and changing, and may limit our ability to use data globally or across borders. Data protection requirements are not universal and can conflict between jurisdictions. Compliance with those laws and regulations is made more complex by the lack of consistent standards, common definitions, or clear regulatory expectations. At the same time, enforcement of these laws and regulations is increasing and litigation is becoming more common. Any failure or perceived failure by us to comply with applicable privacy and data protection laws and regulations, including cybersecurity breaches or incidents, could subject us to significant fines and penalties, and/or litigation, as well as negatively impact our reputation.
Outside the U.S.
New Drug Approvals. In the EU, the EMA conducts the scientific evaluation, supervision and safety monitoring of our innovative medicinal products that are eligible for the centralized marketing authorization procedure. Through the centralized procedure, pharmaceutical companies may submit to the EMA a single application for a marketing authorization valid in all the EU and the European Economic Area (EEA) countries. The EC makes a legally binding decision based on the EMA's recommendation. The centralized procedure is mandatory for certain new products and optional for others. In the U.K., the Medicines and Healthcare Products Regulatory Agency is the sole regulatory authority. In Japan, the Pharmaceuticals and Medical Device Agency is involved in a wide range of regulatory activities, including clinical studies, approvals, post-marketing reviews and pharmaceutical safety. In China, the National Medical Product Administration is the primary regulatory authority for approving and supervising medicines. Health authorities in many middle- and lower-income countries might require marketing approval or scientific opinions by a recognized regulatory authority (e.g., the FDA or EMA/EC) before they begin reviewing or approving applications. By way of example, the EMA, in cooperation with the WHO, can provide scientific opinions on high priority human medicines, including vaccines, for markets outside the EU.
In April 2023, the EC adopted a proposal to revise the EU pharmaceutical legislation. In April 2024, the European Parliament introduced amendments to the EC's proposal. The EU legislative process remains ongoing, with several stages still required before the reform can receive final approval. Once completed, the reform is likely to be the most comprehensive overhaul of EU medicines regulation in over 20 years, with a wide range of impacts including on approval procedures, regulatory data protection, and environmental protection measures. Once approved, certain provisions of the reform could potentially have an adverse impact on our business.

Pfizer Inc.
2024 Form 10-K
12


Pharmacovigilance. In the EU, the EMA’s PRAC is responsible for reviewing and making recommendations on product safety issues. Specifically, the PRAC focuses on detecting, assessing and communicating the risks associated with adverse reactions of medicinal products, while considering their therapeutic effects. It also evaluates post-authorization safety studies and conducts pharmacovigilance audits. Outside developed markets, pharmacovigilance requirements vary and are generally not as extensive, but there is a trend toward increasing regulation.
Pricing and Reimbursement. Certain governments, including in the different EU member states, the U.K., Japan, China and Canada, provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power to regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global financing pressures. Governments globally may use a variety of measures to control costs, including, among others, legislative or regulatory pricing reforms, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, “international reference pricing” (i.e., the practice of a country linking its regulated medicine prices to those of other countries), QCE processes and VBP. In addition, the international patchwork of price regulation, differing economic conditions and incomplete value assessments across countries has led to varying access to quality medicines in many markets and some third-party trade in our products between countries. Several important multilateral organizations such as the WHO scrutinize international pharmaceutical pricing through policy recommendations and sponsorship of programs, such as “The Oslo Medicines Initiative” (OMI) which aimed to ensure “affordability for high-priced medicines”. The OMI concluded its work in September 2022, and the WHO/Europe Access to Novel Medicines Platform was established to enhance affordable and equitable access to effective, innovative and high-priced medicinal products in the region.
In China, pricing pressures have increased in recent years because of an overall focus on healthcare cost containment with the central government emphasizing improved health outcomes and decreased drug prices as key indicators of progress towards its healthcare reform. State owned hospitals and the state insurance program account for the vast majority of all drug purchases. For patented innovative products, drug prices have decreased dramatically as a result of adding innovative drugs (including oncology medicines and medicines for chronic diseases) to the National Reimbursement Drug List via access-price negotiation. A centralized VBP program with a tendering process implemented at both the national level and the provincial level aims to contain healthcare costs by driving utilization of generics that have passed QCE. This has resulted in further lowering the price of medicines, especially off-patent medicines; this trend is expected to continue. China is continuing its use of Health Technology Assessment and is controlling mark-ups within the country using a two-invoice limited system, aiming to regulate the pricing of pharmaceutical products and certain types of medical devices. Pfizer, along with most off-patent originators, has mostly not been successful in the VBP bidding process. The government has indicated that additional drugs which are past patent-based exclusivity expiry (including biological products) could be subjected to VBP qualification in future rounds. Certain of our products, such as Xeljanz, Unasyn, Hemabate and Ibrance, were included as candidates in the tenth national VBP round in 2024, and Pfizer was not successful in the bidding process for such products. While certain details of future QCE expansion have been made available, we are unable to determine the impact on our business of the various pricing measures underway.
Healthcare Provider Transparency and Disclosures. Several countries have implemented laws requiring (or industry trade associations have recommended) disclosure of transfers of value made by pharmaceutical companies to healthcare providers and/or healthcare organizations, such as academic teaching hospitals.
Intellectual Property. Reliable patent protection and enforcement around the world are among the key factors we consider for continued business and R&D investment. The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (WTO-TRIPS) requires participant countries to provide patent and other intellectual property-related protection for pharmaceutical products by law, with a time-limited exemption provided for least-developed countries. While some countries have made improvements, we still face patent grant, enforcement and other intellectual property challenges in many countries.
While the global intellectual property policy environment has generally improved following implementation of WTO-TRIPS and bilateral/multilateral trade agreements, our growth and ability to bring new product innovation to patients depends on maintaining those standards and further progress in intellectual property protection. In certain developed international markets, governments maintain relatively effective intellectual property policies. However, in the EU, ongoing review of pharmaceutical legislation may reduce the basic period of regulatory data protection. In several emerging market countries and multilateral institutions, governments continue to address the role of intellectual property in the context of, for example, access to medicines.
Considerable political and economic pressure has weakened current intellectual property protection in some countries and has led to policies such as more restrictive standards for obtaining patents and more difficult procedures for patenting biopharmaceutical inventions, restrictions on patenting certain types of inventions, revocation of patents, laws or regulations that promote or provide broad discretion to issue a compulsory license, weak intellectual property enforcement and failure to implement effective regulatory data protection. Our industry advocacy efforts focus on seeking a fair and transparent business environment for foreign manufacturers, underscoring the importance of strong intellectual property systems for all innovative industries (both domestic and foreign) and helping improve patients’ access to innovative medicines and vaccines.
Data Privacy. We are subject to extensive privacy and data protection laws and regulations around the world concerning the collection, use and sharing of personal data. We routinely collect and use sensitive personal information relating to health. The legislative, regulatory and litigation landscape for privacy and data protection requirements is rapidly evolving and changing, and may limit our ability to use data globally or across borders. Data protection requirements are not universal and can conflict between jurisdictions. Compliance with those laws and regulations is made more complex by the lack of consistent standards, common definitions, or clear regulatory expectations. At the same time, enforcement of these laws and regulations is increasing and fines and penalties are also increasing. Any failure or perceived failure by us to comply with applicable privacy and data protection laws and regulations, including cybersecurity breaches or incidents, could subject us to significant fines and penalties, and/or litigation, as well as negatively impact our reputation.
ENVIRONMENTAL MATTERS
Our operations are affected by national, state and/or local environmental laws. We have made, and intend to continue to make, the expenditures necessary for compliance with applicable laws. We also are cleaning up environmental contamination from past industrial activity at certain sites. We incurred capital and operational expenditures in 2024 for environmental compliance purposes and for the clean-up of certain past industrial activity as follows: $100 million in environment-related capital expenditures and $174 million in other environment-related expenses.
While capital expenditures or operating costs for environmental compliance cannot be predicted with certainty, we do not currently anticipate they will have a material effect on our capital expenditures or financial position. See also Note 16A3.

Pfizer Inc.
2024 Form 10-K
13


As a science guided organization, we take a proactive approach to our environmental sustainability initiatives. In 2022, we announced a goal to further reduce greenhouse gas (GHG) emissions and achieve the Science Based Target Initiative’s voluntary Net-Zero Standard by 2040. As part of this goal, Pfizer aims to decrease its GHG emissions by 95% and its value chain emissions by 90% from 2019 levels by 2040. To support our goal, we are developing and implementing our emission reduction plan, which will include strategies to achieve reductions throughout our value chain including investing in new technologies and innovative climate solutions, and setting expectations for our suppliers to establish science-aligned GHG emission reduction goals. Our emission reduction plan-related expenses and capital spending incurred for 2024 were not material to our consolidated financial statements. While we expect to incur incremental capital and operational expenditures to meet our goal, we do not currently anticipate they will have a material effect on our financial position in the near term. Longer term uncertainties such as the likelihood of commercially available technologies make it difficult to predict the financial impact of meeting the goal, and we will continue to assess and monitor the financial impact of the emission reduction plan.
For a discussion of the risks associated with climate change, see the Item 1A. Risk Factors—Climate Change and Sustainability section.
OUR PEOPLE
Our purpose is: Breakthroughs that change patients’ lives. These breakthroughs are delivered through the collaboration of our talented workforce. As of December 31, 2024, we employed approximately 81,000 people worldwide. Our ability to successfully deliver on our purpose is dependent on our people. We work to create an environment that prioritizes colleagues' health and wellness. Our people-centric approach touches every aspect of the employee experience — including recruiting, benefits, compensation and development. Creating a purpose-driven workplace that attracts, nurtures, and retains top talent is a priority. Our vibrant and supportive work culture is designed to empower colleagues to innovate, collaborate, and contribute meaningfully to improving global health. We invest in comprehensive development programs, provide merit-based opportunities for advancement, and encourage work-life integration through flexible work arrangements.
Culture. We cultivate community in our workplace and our purpose of delivering breakthroughs that change patients’ lives. As we work to bring together people with different perspectives and experiences we foster a collaborative environment based on merit. We continue to execute a merit-based talent approach, focusing on identifying candidates with the right qualifications and ensuring they are considered for the opportunities based on their skills, abilities, and performance. We aim to provide everyone with an opportunity to demonstrate their merit. Our leaders set the tone for the company, embracing accountability and transparency, while promoting a vibrant culture in which colleagues are free to speak up and are encouraged to share views and raise concerns without fear of retaliation.
Colleague Engagement. Open communication and feedback are essential elements of our commitment to performance, colleague engagement, and teamwork. Pfizer managers discuss colleague performance and leadership assessments regularly, with the intent to encourage breakthrough goals and foster leadership. We understand that communication goes both ways: equally important is our commitment to listening and responding to colleague feedback, to foster a healthy work environment with the power to attract and retain top talent. We are passionate about creating safe spaces at work, so our colleagues feel able and encouraged to provide the company with feedback and raise concerns and questions. The Office of the Ombuds is a resource colleagues, at any level, can connect with to get information and guidance to help them address and resolve work-related issues. We also host company-wide safe space calls and provide various other public, private, and anonymous channels for colleagues to speak up without fear of retaliation.
Our annual engagement survey, Pfizer Pulse, provides a forum for our colleagues to give structured feedback and allows us to measure and track priority areas and equip leaders with actionable insights. In addition, we ask for feedback at various points in the employee lifecycle through focus groups, surveys, and colleague forums. The information we receive helps enable us to adapt to the real-time needs of our colleagues and continuously improve our ways of working.
Pfizer prioritizes colleague recognition to drive engagement, a sense of belonging, motivation, and productivity. Our global rewards and recognition program, Bravo, lets colleagues celebrate and acknowledge each other for demonstrating Pfizer values in a way that makes an impact on the company, a colleague, a team or a patient.
Performance and Leadership. In 2024, we introduced our Actionable Attitudes leadership mindset: anchor in trust, challenge convention, embrace uncertainty, engage with compassion, progress over perfection, and rise above. Complementing our Pfizer values and behaviors, our Actionable Attitudes leadership mindset embodies the attitudes every colleague should aspire to demonstrate, to foster a more dynamic, innovative, and compassionate place to work. In addition, in 2024, we expanded our “Project-Based Ways of Working,” which is designed to empower cross-functional teams to drive decisions within established guardrails and provides access to leadership for removing roadblocks, allowing colleagues to take on leadership roles and decision responsibilities through training, coaching, and a robust support network.
We are committed to helping our colleagues reach their full potential by rewarding both their performance and leadership skills and by providing opportunities for growth and development. Our performance management approach—called Performance and Leadership Insights—is based on six-month semesters during which our colleagues and their managers set goals, receive feedback and meet to discuss performance. These conversations are meant to help colleagues grow and develop by evaluating performance (what the colleague achieved, measured by outcomes), leadership (how they achieved it, taking into account Pfizer’s values of courage, excellence, equity and joy), and identifying areas of growth that help move colleagues towards fulfilling their career goals and their potential.
Growth and Development. Supporting colleagues’ ongoing growth not only supports their individual success but also cultivates a resilient and adaptable workforce that can thrive in the face of change. As we navigate the evolving landscape of our industry, we recognize that providing our colleagues with opportunities for learning, skill-building, and growth is essential to their engagement, productivity, and overall job satisfaction. Investing in career growth and development reaffirms our commitment to our colleagues, demonstrates our belief in their potential, and supports them in being motivated, agile, and equipped with the necessary skills to tackle new challenges and seize emerging opportunities. Our perspective on career growth continues to shift from a traditional, linear view to one that is built on aspirations and embraces a variety of experiences. We actively encourage growth opportunities and part-time or temporary projects that allow colleagues to expand their expertise and build new skills while remaining in their current roles. We also promote diagonal moves, where colleagues pursue new roles in different job functions to gain a holistic understanding of the enterprise. By fostering an environment that encourages continuous learning, embraces flexibility, and empowers decision-making at all levels, we are not just preparing our workforce for the future—we are actively shaping it. We believe this approach helps ensure that Pfizer remains at the forefront of innovation, ready to tackle the health challenges of tomorrow with a skilled, adaptable, and purpose-driven team.
Health, Safety and Well-Being. At Pfizer, protecting the health, safety, and well-being of colleagues and contingent workers, all of whom are essential to driving our business forward, is an integral part of how we operate. Pfizer's Global Environment, Health & Safety (EHS) Policy and

Pfizer Inc.
2024 Form 10-K
14


supporting standards outline our approach to assessment, evaluation, elimination, and mitigation of EHS risks across our operations globally. Our leadership is accountable for EHS compliance and risk management. Colleagues and contingent workers receive EHS training relevant to their job roles, including measures to prevent workplace incidents and injuries. In addition, we conduct workplace assessments, inspections, and audits to evaluate and continuously improve our EHS arrangements.
We are committed to supporting and encouraging our colleagues' well-being. We use results from Pfizer Pulse and other colleague feedback forums to inform the wellness services we offer, such as (i) a Wellness Day for every colleague; (ii) on-site health clinics for colleagues in select locations, with access to certain vaccinations, where allowed by law; (iii) digital accessibility cafés providing colleagues with disabilities tools and equipment to do their jobs effectively; (iv) measures to assist those with neurodiverse conditions, such as sensory rooms and noise cancelling headphones; (v) a toolkit to aid in accommodation needs, education for managers and additional tools to help those who need any type of assistance to perform their roles; this includes on demand American Sign Language (ASL) services; (vi) mental health resources, including a manager/team toolkit designed to facilitate conversations, actively support coworkers, and provide local resources for colleagues to access services; (vii) programming through Employee Assistance Program (EAP) providers, including our mental health partner, THRIVE, our fitness partner, Exos, and our healthcare partner, Kepro; (viii) financial support, including short-term loans and natural disaster relief; and (ix) work policies to help enable colleagues to work effectively from home and their local offices, including our "Flex10" program that offers colleagues in hybrid roles 10 workdays per year to work from a different location within their country.
Pay Equity. Our commitment to pay equity for all colleagues is based in our values and our intention to continue to build a highly motivated workforce. We are committed to equitable pay practices at Pfizer for employees based on role, education, experience, performance, and location and we conduct and report publicly on pay equity on an annual basis.
ITEM 1A.RISK FACTORS
This section describes the material risks to our business, which should be considered carefully in addition to the other information in this report and our other filings with the SEC. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties. Additionally, our business is subject to general risks applicable to any company, such as economic conditions, geopolitical events, extreme weather and natural disasters. If known or unknown risks or uncertainties materialize, our business operations, financial condition, operating results (including components of our financial results), cash flows, prospects, reputation or credit ratings could be adversely affected now and in the future, potentially in a material way. The following discussion of risk factors contains forward-looking statements, as discussed in the Forward-Looking Information and Factors that May Affect Future Results section.
RISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS:
MANAGED CARE TRENDS
Private payors, such as health plans, and other managed care entities, such as PBMs, continue to take action to manage the utilization and costs of drugs in the U.S., the single largest market for biopharmaceutical products. The negotiating power of MCOs, PBMs and other private third-party payors has increased due to consolidation, and they, along with state and federal governments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of deductibles, utilization management tools, cost sharing or formulary placement. They may demand rebates and/or fees from biopharmaceutical manufacturers for preferred placement on a drug formulary. The growing availability and use of higher cost innovative specialty pharmaceutical medicines that treat rare or life threatening conditions also has generated increased payor interest in the development of cost-containment strategies. These initiatives have increased consumers’ interest in drug prices and input in medication choices, as they pay for a larger portion of their prescription costs and may cause them to favor lower-cost generic alternatives. We may fail to obtain or maintain timely or adequate pricing or formulary placement of our products, or fail to obtain such formulary placement at favorable pricing net of rebates.
Third-party payors also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing and value-based pricing/contracting to improve their cost containment efforts and cost efficiency. Such payors are also increasingly imposing utilization management tools requiring prior authorization for a branded product or requiring the patient to first fail on one or more other products before permitting access to a particular branded medicine. As the U.S. private third-party payor market consolidates further, and as the IRA prices become publicly available, we may face greater pricing pressure from private third-party payors as they continue to drive more of their patients to use lower cost alternatives or seek even larger rebates to control costs or offset losses from the IRA. For additional information on the IRA, see the Item 1. Business––Pricing Pressures and Managed Care Organizations and ––Government Regulation and Price Constraints and Item 1A. Risk Factors––Pricing and Reimbursement sections.
Also, business arrangements in this area are subject to a high degree of government scrutiny, and available safe harbors under applicable federal and state fraud and abuse laws are subject to change through legislative and regulatory action, as well as evolving judicial interpretations. Our approach to these arrangements may also be informed by such government and industry guidance.
COMPETITIVE PRODUCTS
Competitive product launches have and may erode future sales of our products, including our existing products and those currently under development, or result in product obsolescence. Such launches continue to occur, and potentially competitive products are in various stages of development. We cannot predict with accuracy the timing or impact of the introduction of competitive products that treat or prevent diseases and conditions like those treated or prevented by our in-line products and product candidates.
Some of our competitors may have competitive, technical or other advantages over us for the development of technologies and processes or greater experience in particular therapeutic areas, and consolidation among certain pharmaceutical and biotechnology companies can enhance such advantages. These advantages may make it difficult for us to compete with them successfully to discover, develop and market new products and for our current products to compete with new products or indications they may bring to market. Our products and product candidates compete, and may compete in the future, against products or product candidates that offer higher rebates or discounts, exclusionary contracting, lower prices, equivalent or superior efficacy, better safety profiles, easier administration, earlier market availability or other competitive features, including potential preference to prescribe existing competitor treatments over our novel therapies. For example, with the growing competition in the vaccine space, we are subject to increasing discounts to meet competitive dynamics and to help ensure our vaccines are available in retail pharmacies. If we are unable to compete effectively, this could reduce actual or anticipated future sales, which could negatively impact our results of operations.

Pfizer Inc.
2024 Form 10-K
15


In addition, competition from manufacturers of generic drugs, including from generic versions of competitors’ branded products that lose their market exclusivity, is a major challenge for our branded products. Certain of our products have experienced significant generic competition over the last few years. We anticipate a more significant impact of reduced revenues from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations. See the Item 1. Business—Patents and Other Intellectual Property Rights section. In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts and volume loss of some of our products.
In addition, our patented products may face generic or biosimilar competition before patent-based and/or regulatory exclusivity expires, including from “at-risk” launch (despite pending patent infringement litigation against the generic or biosimilar product) by a manufacturer of a generic or biosimilar version of one of our patented products. Generic and biosimilar manufacturers have filed or could file applications with the FDA seeking approval of product candidates that they claim do not infringe our or our collaboration and licensing partners’ patents or claim that our or our collaboration and licensing partners’ patents are not valid. We and our licensing and collaboration partners also face challenges in various jurisdictions by generic drug manufacturers to patents covering products for which we have patent rights, licenses or co-promotion rights. See Note 16A1.
We may become subject to competition from biosimilars referencing our biologic products if competitors are able to obtain marketing approval for such biosimilars.
We also commercialize biosimilar products that compete with products of others, including other biosimilar products. The number of current and forthcoming competing biosimilars, coupled with Medicare’s average sales price-based provider reimbursement methodology, is expected to increase pricing pressures on our biosimilar products. Uptake of our biosimilars may be lower due to various factors, such as access challenges where our product may not receive appropriate coverage/reimbursement access or remains in a disadvantaged position relative to an innovator product.
For additional information on competition our products face, see the Item 1. BusinessCompetition section.
CONCENTRATION
We recorded revenues of more than $1 billion for each of 11 products that collectively accounted for 66% of Total revenues in 2024. For example, Eliquis accounted for 12% of Total revenues in 2024. See Notes 1 and 17. If these products or any of our other major products were to, or continue to (if applicable), experience loss of patent protection (if applicable), changes in prescription or vaccination purchasing or growth rates, reduced product demand, material product liability litigation, unexpected side effects or safety concerns, regulatory proceedings or investigations, lower governmental and/or regulatory confidence, negative publicity affecting doctor or patient confidence, pressure from competitive products, changes in recommendations and coverage, changes in labeling, pricing and access pressures, including those related to the IRA, or supply shortages or if a new, more effective product should be introduced, the adverse impact on our revenues could be significant and our revenue forecasts and expectations could prove to be inaccurate and we may fail to meet these expectations. In particular, certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent-based or regulatory exclusivity expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries in 2025 and anticipate a more significant impact of reduced revenues from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations. In addition, patents covering a number of our best-selling products are, or have been, the subject of pending legal challenges. For additional information on our patents, see the Item 1. BusinessPatents and Other Intellectual Property Rights section. For Comirnaty and Paxlovid, while we believe that these products have the potential to provide ongoing stable revenue streams for Pfizer for the foreseeable future, revenues of these products have decreased substantially over time. For Paxlovid, utilization is expected to follow infection trends, and revenues may fluctuate based on the timing, duration and severity of COVID-19 infections. For information on risks associated with Comirnaty and Paxlovid, see the COVID-19 section below.
In addition, certain of our customers account for a significant portion of our revenues. If one of our significant customers should encounter financial or other difficulties, it might decrease the amount of business such customer does with us and/or we might be unable to timely collect all the amounts that such customer owes us or at all, which could negatively impact our results of operations. In addition, we expect that consolidation and integration of pharmacy chains and wholesalers will increase competitive and pricing pressures on pharmaceutical manufacturers, including us. See Note 17C for a discussion of our significant customers.
RESEARCH AND DEVELOPMENT
The discovery and development of new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our business. Our product lines must be replenished over time to offset revenue losses when products lose exclusivity or market share or to respond to healthcare and innovation trends, as well as to provide for earnings growth, primarily through internal R&D or through collaborations, acquisitions, JVs, licensing or other arrangements. Growth depends in large part on our ability to identify and develop new products or new indications for existing products that address unmet medical needs and receive reimbursement from payors. However, balancing current growth, investment for future growth and the delivery of shareholder return remains a major challenge. The costs of product development continue to be high and are growing, as are regulatory requirements in many therapeutic areas, which may affect the complexity of drug trials, and the number of candidates we are able to fund as well as the sustainability of the R&D portfolio. Decisions made early in the development process of a drug or vaccine candidate can have a substantial impact on the marketing strategy and payor reimbursement possibilities if the candidate receives regulatory approval. We try to plan clinical trials prudently and to reasonably anticipate and address challenges, but there is no assurance that an optimal balance between trial conduct, speed and desired outcome will be achieved. In addition, potential quality issues may be identified in the course of a clinical trial that cannot be remediated to the satisfaction of a regulatory authority that may take actions within the scope of its enforcement authority, including excluding data and placing restrictions on future clinical trials.
Additionally, our product candidates can fail at any stage of the R&D process, and may not receive regulatory approval even after many years of R&D. We may fail to correctly identify compounds or indications for which our science is promising or allocate R&D investment resources efficiently, and failure to invest in the right technology platforms, therapeutic areas, product classes, geographic markets and/or licensing opportunities could adversely impact the productivity of our pipeline. Further, even if we identify areas with the greatest commercial potential, the scientific approach may not succeed despite the significant investment required for R&D, and the product may not be as competitive as expected because of the highly dynamic regulatory and market environments and the hurdles in terms of access, coverage and reimbursement.

Pfizer Inc.
2024 Form 10-K
16


GLOBAL OPERATIONS
We operate on a global scale and could be affected by currency and interest rate fluctuations; capital and exchange controls; local and global economic conditions including inflation, recession, volatility and/or lack of liquidity in capital markets; expropriation and other restrictive government actions; changes in intellectual property; legal protections and remedies; trade regulations; tariffs; tax laws and regulations; and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as impacts of political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and their economic consequences, geopolitical instability, terrorist activity, unstable governments and legal systems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related to climate change.
Some emerging market countries may be particularly vulnerable to periods of financial, economic or political instability or significant currency fluctuations or may have limited resources for healthcare spending. As a result of these and other factors, our strategy to grow in emerging markets may not be successful, and any growth rates in these markets may not be sustainable. Additionally, local economic conditions may adversely affect the ability of payors, as well as our distributors, customers, suppliers and service providers, to pay for our products, or otherwise to buy necessary inventory or raw materials, and to perform their obligations under agreements with us.
Government financing and economic pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through health technology assessments) or other means of cost control. For additional information on government pricing pressures, see the Item 1. Business—Government Regulation and Price Constraints section.
We continue to monitor the global trade environment and potential trade conflicts, sanctions and impediments that could impact our business. If trade restrictions or tariffs reduce global economic activity, potential impacts could include declining sales; increased costs; volatility in foreign exchange rates; a decline in the value of our financial assets and pension plan investments; required increases of our pension funding obligations; increased government cost control efforts; delays or failures in the performance of customers, suppliers and other third parties on whom we may depend for the performance of our business; and the risk that our allowance for doubtful accounts may not be adequate. In addition, issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs, could have a material adverse effect on our business, earnings and financial guidance. The actual impact of the new tariffs on our business is subject to a number of factors including, but not limited to, restrictions on trade, the effective date and duration of such tariffs, countries included in the scope of tariffs, changes to amounts of tariffs, and potential retaliatory tariffs imposed by other countries.
We operate in many countries and transact in many different currencies. Changes in the value of those currencies relative to the U.S. dollar, or high inflation or deflation in those countries, can impact our revenues, costs and expenses and our financial guidance. Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to exchange rate changes. In 2024, 39% of our total revenues were derived from international operations, including 19% from Europe and 13% from China, Japan and the rest of the Asia Pacific region. Future changes in exchange rates or economic conditions and the impact they may have on our results of operations, financial condition or business are difficult to predict. For additional information about our exposure to foreign currency risk, see the Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk section within MD&A.
In addition, our borrowing, pension benefit and postretirement benefit obligations and interest-bearing investments are subject to risk from changes in interest and exchange rates. The risks related to interest-bearing investments and borrowings and the measures we have taken to help contain them are discussed in the Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk section within MD&A and Note 7E. For additional details on critical accounting estimates and assumptions for our benefit plans, see the Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions—Benefit Plans section within MD&A and Note 11.
PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
We could encounter difficulties, delays or inefficiencies in our supply chain, product manufacturing and distribution networks, as well as sales or marketing, due to regulatory actions, shut-downs, work stoppages or strikes, approval delays, withdrawals, recalls, penalties, supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on, reputational harm, the impact to our facilities due to health pandemics or natural or man-made disasters, including as a result of climate change, product liability or unanticipated costs. Examples of such difficulties or delays include the inability to increase or maintain production capacity commensurate with demand; challenges related to component materials to maintain supply and/or appropriate quality standards throughout our supply network and/or comply with applicable regulations; inability to supply certain products due to voluntary product recalls or withdrawals, including, for example, our voluntary withdrawal of all lots of Oxbryta in all markets where it is approved; and supply chain disruptions at our facilities or at a supplier or vendor. In addition, we engage contract manufacturers, and, from time to time, our contract manufacturers may face difficulties or are unable to manufacture our products at the necessary quantity or quality levels.
Regulatory agencies periodically inspect our manufacturing facilities, as well as third-party facilities that we rely on, to evaluate compliance with cGMP or other applicable requirements. Failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, product recalls, delays or denials of product approvals, import bans or denials of import certifications. In response to requests from various regulatory authorities, manufacturers across the pharmaceutical industry, including Pfizer, are evaluating their product portfolios for the potential presence or formation of nitrosamines and we are actively engaging with regulatory authorities on this topic. If nitrosamines are detected above certain levels in our products, this may lead to market action for such products. For example, in 2021, Pfizer recalled all lots of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the acceptable intake limits communicated by various regulatory authorities. Regulatory authorities have since issued updated guidance on nitrosamine acceptable intake levels. With this guidance, which included an updated intake level for N-nitroso-varenicline, we have started making regulatory submissions to potentially enable Chantix to return to market in the U.S. and in certain international markets.
COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES
We depend on third-party collaborators, service providers, and others in the research, development, manufacturing and commercialization of our products and product candidates and also enter into JVs and other business development transactions. To achieve expected longer-term benefits, we may make substantial upfront payments as part of these transactions, which may negatively impact our earnings or cash flows. We rely heavily on these parties for multiple aspects of our drug development, manufacturing and commercialization activities, but we do not control many aspects of those activities. We also outsource certain services, including activities related to transaction processing, accounting, IT, manufacturing, clinical trial recruitment and execution, clinical lab services, non-clinical research, safety services, integrated facilities

Pfizer Inc.
2024 Form 10-K
17


management and other areas. In conducting clinical trials, we may depend on contract research organizations to handle regulatory filings, monitor site performance and raise potential quality matters relating to clinical trials. Failure by one or more of the third-party collaborators, service providers and others to complete activities on schedule or in accordance with our expectations or to meet their contractual or other obligations to us; failure of one or more of these parties to comply with applicable laws or regulations; disruptions in one or more of these parties’ businesses, including unexpected demand for or shortage of raw materials or components, cyber-attacks on supplier systems, labor disputes or shortage and inclement weather, as well as natural or man-made disasters or pandemics; or any disruption in the relationships between us and these parties have or could delay or prevent the development, approval, manufacturing or commercialization of our products and product candidates, expose us to suboptimal quality of service delivery or deliverables, result in repercussions such as missed deadlines or other timeliness issues, erroneous data and supply disruptions, and could also result in non-compliance with legal or regulatory requirements or industry standards, including Good Clinical Practice (GCP) and other requirements, or subject us to reputational harm, all with potential negative implications for our product pipeline and business. Further, our revenues will be adversely affected by the termination or expiration of collaboration and co-promotion agreements that we have entered into and that we may enter into from time to time.
COUNTERFEIT PRODUCTS
Our reputation, in-line and pipeline portfolios render our medicines and vaccines prime targets for counterfeiters. Counterfeits pose a significant risk to patient health and safety because of the conditions under which they are manufactured—often in unregulated, unlicensed, uninspected, and unsanitary sites—as well as the lack of regulation of their contents. Failure to mitigate this threat could adversely impact consumers who use our products, potentially causing them harm. This situation, in turn, may result in the loss of patient confidence in the Pfizer name and in the integrity of our medicines and vaccines, and potentially impact our business through lost sales, product recalls, and possible litigation. The prevalence of counterfeit medicines is an industry-wide issue due to a variety of factors, including the adoption of e-commerce. As consumers increasingly turn to the internet as a source for many products including medicines, they are at the same time increasingly exposed to fake medicines via the internet as criminals increasingly distribute counterfeit and substandard medicines through “rogue” online pharmacies. The internet exposes patients to greater risk as it is a preferred vehicle for dangerous counterfeit offers and scams that target unsuspecting consumers. Traffic to these generally deceptive pharmacy sites is largely driven by misplaced trust in sophisticated internet retailers and social media offers coupled with the convenience e-commerce affords consumers. Counterfeiters generally target any medicine or vaccine boasting strong demand and we have observed heightened counterfeit and fraud attempts to our internal medicine portfolio, as well as products utilized in the treatment of COVID-19.
We consistently invest in an enterprise-wide strategy to aggressively combat counterfeit threats by educating patients and healthcare providers about the risks, investing in innovative technologies to detect and disrupt sophisticated internet offers and scams, proactively monitoring and interdicting supply with the help of law enforcement, and advising legislators and regulators. However, our efforts and those of others may not be entirely successful, and the presence of counterfeit medicines may continue to increase.
RISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS:
PRICING AND REIMBURSEMENT
Our future results could be adversely affected by changes in U.S. and international governmental regulations that mandate price controls, create coverage criteria, or limit patient access to our products. In addition to the expansion of price controls in the U.S. in the IRA, the adoption of more restrictive coverage policies and price controls in new and existing jurisdictions, or the failure to obtain or maintain coverage and pricing could also adversely impact revenue. We expect pricing pressures and other cost containment measures for drugs and vaccines will continue.
In the U.S., pharmaceutical product pricing is subject to government and public scrutiny and calls for reform, and many of our products are subject to increasing pricing pressures as a result. We expect to see continued focus by the U.S. government on regulating pricing and access to medicine. For example, the drug pricing provisions of the IRA are being implemented over the next several years. The IRA directs HHS to set the prices of certain high-expenditure, single-source drugs and biologics covered under Medicare. The IRA also imposes rebates under Medicare Part B and Medicare Part D which require manufacturers to pay rebates if price increases outpace inflation relative to a benchmark period, and replaces the Medicare Part D coverage gap discount program with a new discounting program. The drug pricing provisions of the IRA began to be implemented in 2022 and implementation efforts will continue in coming years. In August 2023, CMS published the first ten medicines subject to the MDPNP, which included Eliquis. In August 2024, the government released the new Medicare price for Eliquis, which will become effective January 1, 2026. On January 17, 2025, CMS announced the selection of another 15 drugs from Medicare Part D for the maximum fair price, with prices to be set and effective on January 1, 2027. Ibrance and Xtandi were included in the list of 15 drugs selected. Another 15 drugs from Medicare Part B or Medicare Part D will be selected by February 1, 2026, for the maximum price to be set and in effect by January 1, 2028. It is possible that more of our products could be selected in future years, which could, among other things, lead to lower revenues prior to expiry of intellectual property protections. Health plans may also require rebates in addition to the maximum fair price for preferred placement on a Medicare plan formulary. The MDPNP is currently subject to legal challenges and therefore, the outcome remains uncertain. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. For additional information, see the Item 1. BusinessGovernment Regulation and Price Constraints section.
Payors may give preference to generic drugs and biosimilars more aggressively to generate savings and attempt to stimulate additional price competition. In addition, we expect that consolidation and integration among pharmacy chains, wholesalers and PBMs will increase pricing pressures in the industry. Some states have implemented, and others are considering, patient access constraints or cost cutting under state regulated programs including the Medicaid program. States have continued to focus on addressing drug costs, generally by increasing price transparency or attempting to limit drug price increases for state-regulated insurance. Measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation and prescription drug affordability boards (PDABs) that seek to impose reimbursement limits for certain drugs, could adversely affect our business. For additional information on U.S. pricing and reimbursement, see the Item 1. BusinessGovernment Regulation and Price Constraints section.
We encounter similar regulatory and legislative issues in most other countries in which we operate. In certain markets, such as in EU member states, the U.K., Japan, China, Canada, Australia and New Zealand, governments have significant power as large single payors to regulate prices, access criteria, or impose other means of cost control, particularly as a result of recent global financing pressures. For example, the QCE and VBP tender process in China has resulted in significant price cuts for off-patent medicines. Additionally, in the EU, the EC proposed the largest reform of EU pharmaceutical legislation in 20 years. In April 2024, the European Parliament introduced amendments to the EC’s proposal. The EU legislative process remains ongoing, with several stages still required before the reform can receive final approval. This reform may alter

Pfizer Inc.
2024 Form 10-K
18


regulatory exclusivity periods for our products and may add burdensome obligations that impact access. In addition, with the European Regulation on Health Technology Assessment (EU HTA-R) taking effect in January 2025, we are engaging and monitoring application of the EU’s new clinical assessment program to new oncology products and certain biologic products submitted to the EMA. For additional information regarding these government initiatives, see the Item 1. BusinessGovernment Regulation and Price Constraints section. We anticipate that these and similar initiatives will continue to increase pricing and access pressures globally. In addition, in many countries, with respect to our vaccines, we participate in a tender process for selection in national immunization programs. Failure to win national immunization tenders or to obtain acceptable pricing, as well as recent entry of additional competitors, could adversely affect our business.
U.S. HEALTHCARE REGULATION
The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. Any significant additional efforts at the U.S. federal or state levels to reform the healthcare system by changing the way healthcare is provided or funded could have a material impact on us. For additional information on U.S. healthcare regulation, see the Item 1. Business––Government Regulation and Price Constraints section. Other U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect our business, including, among others, general budget control actions, changes in patent laws, the importation of prescription drugs to the U.S. at prices that are regulated by foreign governments, revisions to reimbursement of biopharmaceuticals under government programs that could reference international prices or require new discounts, limitations on interactions with healthcare professionals and other industry stakeholders, restrictions on pharmaceutical advertising, or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines. In addition, we may face increased risks to, among other things, our business, revenue, earnings, reputation or financial guidance, as a result of potential changes to vaccine or other healthcare policy in the U.S.
Any additional reduction of U.S. federal spending on entitlement programs beyond the IRA, including Medicare, Medicaid, or any other publicly funded or subsidized health programs, and the 340B Program, may affect payment for our products or services provided using our products. Any other significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented could have an adverse impact on our results of operations. The IRA is being implemented largely through government guidance and as its effect on Medicare and commercial markets evolve, we will continue to evaluate the potential impacts to our business.
We expect additional drug cost containment efforts at both the federal and state levels. Further, commercial payors often follow Medicare coverage policy and payment limitations when setting their own payment rates. Any reduction in cost or other containment measures may similarly be adopted by commercial plans. Coverage policies and reimbursement rates for commercial plans may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products, less favorable coverage policies and reimbursement rates may be implemented in the future.
DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. The outcome is inherently uncertain and involves a high degree of risk due to the following factors, among others:
The process from early discovery to design and adequate implementation of clinical trials to regulatory approval can take many years and have high costs.
We may have difficulties recruiting and enrolling patients for clinical trials on a consistent basis.
Product candidates can and do fail at any stage of the process, including as the result of unfavorable pre-clinical and clinical trial results, or unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data, including results that may not support further clinical development of the product candidate or indication.
We may need to amend our clinical trial protocols or conduct additional clinical trials under certain circumstances, for example, to further assess appropriate dosage or collect additional safety data.
We may not be able to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates.
We may not be able to successfully address all the comments received from regulatory authorities such as the FDA and the EMA, or be able to obtain approval for new products and indications from regulators.
Regulatory approvals of our products depend on myriad factors, including regulatory determinations as to the product’s safety and efficacy. In the context of public health emergencies like the COVID-19 pandemic, regulators evaluate various factors and criteria to potentially allow for marketing authorization on an emergency or conditional basis. Additionally, clinical trial and other product data are subject to differing interpretations and assessments by regulatory authorities. As a result of regulatory interpretations and assessments or other developments that may occur during the review process, or even after a product is authorized or approved for marketing, a product’s commercial potential could be adversely affected by potential emerging concerns or regulatory decisions regarding or impacting the scope of indicated patient populations, labeling or marketing, manufacturing processes, safety issues and/or other matters, including decisions relating to emerging developments regarding potential product impurities. Also, certain of our products have received and may in the future receive approvals under accelerated approval pathways where continued approval may be contingent upon confirmatory studies demonstrating the anticipated clinical benefit and/or safety profile.
We may not be able to receive or maintain favorable recommendations by technical or advisory committees, such as the ACIP or an FDA Advisory Committee, which may impact the availability or commercial potential of our products and product candidates. Further, claims and concerns that may arise regarding the safety and/or efficacy of in-line products and product candidates can negatively impact current or future product sales, as applicable, and potentially lead to regulator-directed risk evaluations and assessments, asset impairments, and/or consumer fraud, product liability and other litigation and claims, as well as product recalls or withdrawals, including our voluntary withdrawal of all lots of Oxbrtya in all markets where it is approved, and any regulatory or other impact on Oxbryta or other sickle cell disease assets. Regulatory requirements may also result in a more challenging, expensive and lengthy regulatory approval process than anticipated due to requests for, among other things, additional or more extensive clinical trials prior to granting approval, or increased post-approval requirements. For these and other reasons discussed in this Risk Factors section, we may not obtain the approvals we expect within the timeframe we anticipate, or at all.

Pfizer Inc.
2024 Form 10-K
19


POST-AUTHORIZATION/APPROVAL DATA
As a condition to granting marketing authorization or approval of a product, the FDA may require, or the sponsor may voluntarily agree to undertake, post-marketing commitments such as additional clinical trials or other studies. The results generated in these trials have in the past impacted certain of our products and could impact our products in the future, such as by resulting in the loss of marketing approval, changes in labeling, and/or new or increased concerns about safety and/or efficacy, including newly discovered adverse events. Regulatory agencies in countries outside the U.S. often have similar regulations and may impose comparable requirements, although there are differences between the U.S., the EU and other international regulatory requirements, which may contribute to inconsistency or uncertainty in the marketability of our products across different jurisdictions. Post-marketing studies and clinical trials, whether conducted by us or by others, whether mandated by regulatory agencies or conducted voluntarily, and other emerging data about products, such as adverse event reports, may also adversely affect the availability or commercial potential of our products. Further, if safety or efficacy concerns are raised about a product in the same class as one of our products, those concerns could implicate the entire class; and this, in turn, could have an adverse impact on the availability or commercial viability of our product(s) or product candidates as well as other products in the class. The potential regulatory, commercial or other implications of post-marketing study results typically cannot immediately be determined. In September 2024, we made the decision to voluntarily withdraw Oxbryta in all markets where it is approved based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. For more information, see the Product Developments section within MD&A.
The terms of our EUA for Comirnaty require that we conduct post-observational studies to evaluate the association between the Pfizer-BioNTech COVID-19 Vaccine (Original monovalent), Pfizer-BioNTech COVID-19 Vaccine, Bivalent, and the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), and a pre-specified list of adverse events of special interest, including myocarditis and pericarditis, along with deaths and hospitalizations, and severe COVID-19. The required study populations include individuals specified in our September 2023 authorization letter (reissued) as well as populations of interest, such as healthcare workers, pregnant women, immunocompromised individuals and subpopulations with specific comorbidities. Additionally, in relation to the FDA approval for Comirnaty, we are required to complete certain post marketing study requirements and commitments through 2024 and beyond.
LEGAL MATTERS
We are and may be involved in various legal proceedings, including patent litigation, product liability and other product-related litigation, including personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims, commercial and other asserted and unasserted matters, environmental, government and tax investigations, employment litigation, tax litigation and other legal proceedings that arise from time to time in the ordinary course of our business. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe that our claims and defenses in matters in which we are a defendant are substantial, we have in the past and could in the future incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations.
Claims against our patents include challenges to the coverage and/or validity of our patents on various products or processes. There can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the product at issue, which could lead to a significant loss of sales of that product and could materially affect future results of operations.
We are also involved in government investigations that arise in the ordinary course of our business. There continues to be a significant volume of government investigations and litigation against companies operating in our industry, both in the U.S. and around the world. Government investigations and actions have and could result in substantial criminal and civil fines and/or criminal charges, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements and other disciplinary actions, as well as reputational harm, including as a result of increased public interest in the matter. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.
Our sales and marketing activities, the pricing of our products and other aspects of our business are subject to extensive regulation under the FFDCA, the MDRP, the FCPA and other federal and state statutes, including those discussed elsewhere in this Form 10-K, as well as the AKS, anti-bribery laws, the False Claims Act, consumer protection statutes and similar laws in international jurisdictions. In addition to the potential for changes to relevant laws, the compliance and enforcement landscape is informed by government litigation, settlement precedent, advisory opinions, and special fraud alerts. Our approach to certain practices may evolve over time in light of these types of developments.
Requirements or industry standards in the U.S. and certain jurisdictions abroad require pharmaceutical manufacturers to track and disclose financial interactions with healthcare professionals and healthcare providers and can increase government and public scrutiny of such financial interactions. If an interaction is found to be improper, government enforcement actions and penalties could result. Like many companies in our industry, we have from time to time received, and may receive in the future, inquiries and subpoenas and other types of information demands from government authorities. In addition, we have been and may in the future be subject to claims and other actions related to our business activities, brought by governmental authorities, as well as consumers and private payors. In some instances, we have incurred significant expense, civil payments, fines and other adverse consequences as a result of these claims, actions and inquiries. Such claims, actions and inquiries may relate to alleged non-compliance with laws and regulations associated with the dissemination of product (approved and unapproved) information, potentially resulting in government enforcement action and reputational damage. These risks may be heightened by the use of AI in our operations as well as in our digital marketing, including social media, mobile applications and blogger outreach, as well as direct-to-consumer marketing and digital platform offerings.
In connection with the resolution of a U.S. government investigation concerning independent copay assistance organizations that provide financial assistance to Medicare patients, in 2018, we entered into a Corporate Integrity Agreement with the Office of the Inspector General of the HHS (OIG), which expired in May 2023. Pfizer submitted its final annual report in October 2023 and the OIG officially closed the matter in January 2025.
We and certain of our subsidiaries are also subject to numerous contingencies arising in the ordinary course of business relating to legal claims and proceedings, including environmental contingencies. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. While we have accrued for worldwide legal liabilities, no guarantee exists that additional costs will not be incurred or additional payments will not be required beyond the amounts accrued.
For additional information, including information regarding certain legal proceedings in which we are involved in, see Note 16A.

Pfizer Inc.
2024 Form 10-K
20


RISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY:
INTELLECTUAL PROPERTY PROTECTION
Our success largely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from launching generic or biosimilar versions of our branded products, from using our proprietary technologies or from marketing products that are very similar or identical to ours. Our currently pending or future patent applications may not result in issued patents or be granted on a timely basis. Similarly, any term extensions that we seek may not be granted on a timely basis, if at all, and any term adjustments related to patent office delays in obtaining a patent may be reduced or eliminated entirely due to risks associated with changes in law relating to patent terms. In addition, our issued patents may not contain claims sufficiently broad to protect us against claims regarding validity, enforceability, scope and effective term made by parties with similar technologies or products or provide us with any competitive advantage, including patent-based exclusivity in a particular technology or product area.
Further, legal or regulatory action by various stakeholders or governments could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products. For example, the WTO’s June 2022 Ministerial Decision on the Agreement on Trade-Related Aspects of Intellectual Property Rights seeks to make it easier for certain WTO members to issue a compulsory license on COVID-19 vaccines.
The scope of our patent claims also may vary between countries, as individual countries have distinct patent laws, and our ability to enforce our patents depends on the laws of each country, its enforcement practices, and the extent to which certain countries engage in policies or practices that weaken a country’s intellectual property framework (e.g., laws or regulations that promote or provide broad discretion to issue a compulsory license). In countries that provide some form of regulatory exclusivity, mechanisms exist permitting some form of challenge to our patents by competitors or generic drug marketers prior to or immediately following the expiration of such regulatory exclusivity, and generic companies are employing aggressive strategies, such as “at-risk” launches that challenge our patent rights. Most of the suits involve claims by generic drug manufacturers that patents covering our products, uses, processes or dosage forms are invalid and/or do not cover the product of the generic or biosimilar drug manufacturer. Independent actions have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. Such claims may also be brought as counterclaims to actions we bring to enforce our patents. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payors, governments or other parties are seeking damages from us for alleged delay of generic entry. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents or a competitors’ patents is found to be invalid in such proceedings, generic or biosimilar products could be introduced into the market resulting in the erosion of sales of our existing products. For additional information, including information regarding certain legal proceedings in which we are involved, see Note 16A1. Further, if we are unable to maintain our existing license agreements or other agreements pursuant to which third parties grant us rights to intellectual property, our operating results and financial condition could be adversely affected.
We currently hold trademark registrations and have trademark applications pending in many jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our trademarks and trade dress to differentiate us from our competitors increases and, as a result, our business could be adversely affected if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our rights. We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their relationship with us. Despite these efforts and precautions, we may be unable to prevent a third-party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization, and legal remedies may not adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop substantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.
THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS
A properly functioning intellectual property regime is essential to our business model. We are committed to respecting the valid intellectual property rights of other companies, but the patent granting process is imperfect. Accordingly, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by others that we believe were improperly granted, including challenges through negotiation and litigation, and such challenges may not always be successful.
Part of our business depends upon identifying biosimilar opportunities and launching products to take advantage of those opportunities, which may involve litigation, associated costs and time delays, and may ultimately not be successful. These opportunities may arise in situations where patent protection of equivalent branded products has expired or been declared invalid, or where products do not infringe the patents of others. In some circumstances we may take action, such as litigation, asserting that our products do not infringe patents of existing products or that those patents are invalid or unenforceable in order to achieve a “first-to-market” or early market position for our products.
Third parties may claim that our products infringe one or more patents owned or controlled by them. Claims of intellectual property infringement can be costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant royalty payments or damages or potential licensing agreements. For example, our R&D in a therapeutic area may not be first and another company or entity may have obtained relevant patents before us. We are involved in patent-related disputes with third parties over our attempts to market pharmaceutical products, including related to Abrysvo, Comirnaty and Paxlovid. As we expand our mRNA portfolio, patent-related disputes may increase. Once we have final regulatory approval of the related products, we may decide to commercially market these products even though associated legal proceedings (including any appeals) have not been resolved (i.e., “at-risk” launch). If one of our marketed products (or a product of our collaboration/licensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.

Pfizer Inc.
2024 Form 10-K
21


INFORMATION TECHNOLOGY AND SECURITY
Significant disruptions of IT systems or breaches of information security could adversely affect our business. We extensively rely upon sophisticated IT systems (including cloud services) to operate our business. We produce, collect, process, store and transmit large amounts of confidential information (including personal information and intellectual property), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality, integrity and availability of such confidential information. We develop and operate digital systems to engage patients, healthcare providers, governments, payors and supply chain partners to conduct business and deliver medicines, digital diagnostics, clinical trials and digital therapies. Such systems include mobile applications, wearable devices, internet websites and other digital technologies that may be targets of attack. We have outsourced significant elements of our operations, including significant elements of our IT infrastructure and, as a result, we manage relationships with many third-party providers who may or could have access to our confidential information. We rely on technology developed, supplied and/or maintained by third-parties that may make us vulnerable to “supply chain” style cyber-attacks. Further, technology and security vulnerabilities of acquisitions, business partners or third-party providers may not be identified during due diligence or soon enough to mitigate exploitation. The size and complexity of our IT and information security systems, and those of our third-party providers (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by, but not limited to, our employees, contingent workers, service providers, business partners, customers or malicious attackers. As a global pharmaceutical company, our systems and assets are the target of frequent cyber-attacks. Such cyber-attacks are of ever-increasing levels of sophistication, including the use of adversarial AI techniques, and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage, extortion, property destruction and personal information theft) and expertise, including, but not limited to, organized criminal groups, “hacktivists,” nation states, employees, business partners and others. Due to the nature of some of these attacks, there is a risk that they may remain undetected for a period of time. While we have invested in the protection of data and IT and develop and maintain systems and controls, our efforts, like those of other similar companies, have not always and may not in the future prevent service interruptions, extortion, theft of confidential, personal or proprietary information, compromise of data integrity or unauthorized information disclosure. Any technology service interruption or breach of our systems could adversely affect our business operations and/or result in potential legal liability, the loss of personal data, confidential information or intellectual property. Such incidents could require disclosure to government authorities and/or regulators and could require notification to impacted individuals and any incident could result in financial, legal, business and reputational harm to us. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.
AI is increasingly being used in the biopharmaceutical and global healthcare industries. As with many developing technologies, AI presents risks and challenges. For example, algorithms may be flawed or trained on content without the necessary intellectual property rights or other legal rights or permissions; data sets may not be appropriate for the intended use, of poor quality, contain biased information, or become corrupted during a cyber-attack; and inappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. If the outputs that AI produces or assists in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm. Furthermore, use of AI may lead to the release of confidential information which may impact our ability to realize the benefits of our data, including intellectual property.
GENERAL RISKS
BUSINESS DEVELOPMENT ACTIVITIES AND STRATEGIC GOALS
We have established significant growth goals, which we plan to achieve, in part, by not only advancing our own product pipelines and maximizing the value of our existing products, but also through various forms of business development activities, which can include alliances, licenses, JVs, collaborations, equity- or debt-based investments, dispositions, divestments, mergers and acquisitions. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. The success of our business development activities is dependent on the availability and accurate evaluation of appropriate opportunities, competition from others that are seeking similar opportunities and our ability to successfully identify, structure and execute transactions, including the ability to satisfy closing conditions in the anticipated timeframes or at all, and our ability to successfully integrate acquired businesses and develop and commercialize acquired products. Pursuing, executing and consummating these transactions may require substantial investment, which may require us to obtain additional equity or debt financing, which has in the past and could in the future result in increased leverage and/or a downgrade of our credit ratings and could limit our ability to obtain future financing. We have incurred substantial indebtedness to fund our acquisition of Seagen. We financed a portion of the transaction with the proceeds from the $31 billion of long-term debt issued in May 2023, plus additional short-term indebtedness issued prior to the acquisition. The amount of debt that we have incurred could have significant consequences including, among other things, reducing our operating or financial flexibility, requiring a portion of our cash flow from operations to make interest payments and reducing the cash flow available to fund capital expenditures and other corporate purposes and to grow our business. To the extent we incur additional indebtedness or interest rates increase, these risks could increase further.
The success of our business development transactions depends on our ability to realize the anticipated benefits of these transactions and is subject to numerous risks and uncertainties, many of which are outside of our control. Unsuccessful clinical trials, regulatory hurdles, new information and commercialization challenges, among other factors, may adversely impact revenue and income contribution from business development transactions, including from acquired products and businesses, and may lead to impairment of acquired assets. We may fail to generate expected revenue growth for our existing products, product pipeline and contribution from these transactions or from acquired products or businesses or we may fail to achieve anticipated cost savings, within expected time frames or at all, which may impact our ability to meet our growth objectives. In certain transactions, we may agree to provide certain transition services for an extended period of time, which may divert our focus and resources that would otherwise be invested into maintaining or growing our business. Similarly, the accretive impact anticipated from certain transactions may not be realized or may be delayed. Integration of acquired products or businesses may result in the loss of key employees, the disruption of ongoing business, including third-party relationships, or inconsistencies in standards, controls, procedures and policies. Further, while we seek to mitigate risks and liabilities through, among other things, due diligence, we may be exposed to risks and liabilities as a result of business development transactions. There is no assurance that we will be able to acquire attractive businesses or enter into strategic business relationships on favorable terms ahead of our competitors, or that such acquisitions or strategic business development relationships will be accretive to earnings or improve our competitive position.
Where we invest in or otherwise obtain debt or equity securities of third parties in connection with business development transactions, such as our ownership interest in Haleon, we may be unable to direct or influence the management, operational decisions and policies of such companies

Pfizer Inc.
2024 Form 10-K
22


and the value of the acquired securities will fluctuate and may lose value. Any future distribution or sale of such securities will be subject to prevailing market conditions and other factors, including the size of our ownership stake, at the time of such distribution or sale and there is no assurance as to the price that such securities will ultimately be sold or that such securities will be sold at all.
PANDEMICS
Pandemics, such as the COVID-19 pandemic, have impacted and may in the future impact our business, operations and financial condition and results. Related risks and challenges for our business include, among others: uncertainty regarding the severity and duration of a pandemic; impacts to business operations; decreased demand for certain of our products; increased costs of doing business; manufacturing disruptions and delays; supply chain disruptions and shortages, including challenges related to reliance on third-party suppliers resulting in reduced availability of materials or components used in the development, manufacturing, distribution or administration of our products; evolving macroeconomic factors and conditions, including general economic uncertainty, unemployment rates and recessionary pressures; changes in labor markets, including challenges related to our human capital and talent development; unknown consequences on our business performance and initiatives stemming from the substantial investment of time and other resources to any potential pandemic response; increased difficulty and uncertainty regarding predicting or estimating future performance; pace of post-pandemic recovery, disruption and volatility within the financial or credit markets; and our financial performance in general.
COVID-19
We face risks and uncertainties related to our COVID-19 products, including Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, including, among others, the risk that as the market for COVID-19 products remains endemic and seasonal, demand for our COVID-19 products has and may continue to be reduced or not meet expectations, which has and may continue to lead to reduced revenues, excess inventory or other unanticipated charges; risks related to our ability to develop and commercialize variant adapted vaccines, combinations and/or treatments; uncertainties related to recommendations and coverage for, and the public’s adherence to, vaccines, boosters, treatments or combinations; risks related to our ability to accurately predict revenue for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments; whether and when EUA or biologics license applications or amendments to any such applications may be filed in particular jurisdictions for Comirnaty or any other potential vaccine or vaccine candidates, including those related to potential future annual boosters, re-vaccinations, or vaccines in additional populations, and if obtained, whether or when such EUA or licenses, or existing EUAs, will expire or terminate; whether and when additional supply or purchase agreements will be reached or existing agreements will be modified; potential third-party royalties or other claims related to Comirnaty or Paxlovid; and the other risks and uncertainties discussed throughout this Item 1A. Risk Factors.
RESPONSIBLE BUSINESS GROWTH
Pfizer is subject to transitional and physical risks related to climate change. Transitional risks include, for example, a disorderly global transition away from fossil fuels that may result in increased energy prices; customer preference for low or no-carbon products; stakeholder pressure to decarbonize assets; or new legal or regulatory requirements that result in new or expanded carbon pricing, taxes, restrictions on GHG emissions, and increased GHG disclosure and transparency. These risks could increase operating costs, including the cost of our electricity and energy use, or otherwise increase compliance costs. Physical risks to our operations include water stress and drought; flooding and storm surge; wildfires; extreme temperatures and storms, which could impact pharmaceutical production, increase costs, or disrupt supply chains of medicines for patients. For example, our manufacturing facility in Rocky Mount, NC was damaged by a tornado in July 2023. For additional details on the impact of the tornado in Rocky Mount, NC, see the Overview of Our Performance, Operating Environment, Strategy and OutlookOur Operating Environment section within MD&A. Our supply chain is subject to these same transitional and physical risks and would likely pass along any increased costs to us.
In June 2022, Pfizer established our fourth consecutive GHG reduction goal with new near- and long-term targets to achieve the Science Based Target Initiative’s voluntary Net-Zero Standard by 2040. While we are working to develop and implement emission reduction plans to achieve our voluntary climate goals, various factors, including the long time horizons and commercial availability of new technologies to enable the emission reductions, in the time and scale needed, may present inherent risk in our ability to meet these goals. Additionally, success may depend on the actions of governments and third parties and may require, among other things, significant capital investment; R&D; and government policies and incentives to foster innovation and reduce costs of technologies that may not currently exist or be available at scale.
Certain governmental authorities, non-governmental organizations, customers, investors, employees, and other stakeholders are increasingly sensitive to matters perceived to be related to responsible business growth, such as equitable access to medicines and vaccines, product quality and safety, human capital, diversity, equity and inclusion, environmental stewardship, support for local communities, value chain environmental and social due diligence, and corporate governance and transparency. In addition, governments and the public expect companies like us to report on our business practices with respect to human rights, responsible sourcing and environmental impact, as well as the actions of our third-party contractors and suppliers around the world. This focus may lead to new expectations or requirements that could result in increased costs associated with research, development, manufacture, or distribution of our products. Our ability to compete could also be affected by changing customer preferences and requirements, such as growing demand for companies to establish validated Net Zero targets or offer more sustainable products. While we are committed to responsible business growth, if we do not meet, or are perceived not to meet, our goals or other stakeholder expectations in these key areas, we risk negative stakeholder reaction, including from proxy advisory services, as well as damage to our brand and reputation, reduced demand for our products or other negative impacts on our business and operations. While we monitor a broad range of corporate responsibility matters, we cannot be certain that we will manage such matters successfully, or that we will successfully meet the expectations of investors, employees, consumers, governments and other stakeholders.
MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS
Changes in the fair value of certain equity investments that are recognized in net income may result in increased volatility of our income. See Note 4 and the Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk section within MD&A.
Our pension benefit obligations and postretirement benefit obligations are subject to volatility from changes in the fair value of equity investments and other investment risk in the assets funding these plans, as well as changes in the appropriate discount rate. See the Significant Accounting Policies and Application of Critical Accounting Estimates and AssumptionsBenefit Plans section within MD&A and Note 11.

Pfizer Inc.
2024 Form 10-K
23


COST AND EXPENSE CONTROL AND UNUSUAL EVENTS
Growth in costs and expenses, changes in product and geographic mix and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product withdrawals, recalls and other unusual events that could result from evolving business strategies, evaluation of asset realization and organizational restructuring could adversely affect future results. Such risks and uncertainties include, in particular, our ability to realize the projected benefits of our cost-reduction and productivity initiatives, including our enterprise-wide cost realignment program and manufacturing optimization program, other corporate strategic initiatives and any acquisitions, divestitures or other initiatives, as well as potential disruption of ongoing business, such as potential impacts on our ability to deliver on our pipeline as planned. Additionally, as a result of these initiatives, we may experience a loss of continuity, loss of accumulated knowledge or intellectual property and/or inefficiency, adverse effects on employee morale, loss of key employees and/or other retention issues during transitional periods. Reorganizations and restructurings can require a significant amount of time and focus, which may divert attention from operating and growing our business. If we fail to achieve some or all of the expected benefits of restructuring, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows.
INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
Our consolidated balance sheet contains significant amounts of intangible assets, including IPR&D and goodwill. For IPR&D assets, the risk of failure is significant, and there can be no certainty that these assets ultimately will yield successful products. Our ability to realize value on these significant investments is often contingent upon, among other things, regulatory approvals and market acceptance. As such, IPR&D assets may become impaired and/or be written off in the future if the associated R&D effort is abandoned or is curtailed. For goodwill, all reporting units can confront events and circumstances that can lead to a goodwill impairment charge such as, among other things, unanticipated competition, an adverse action or assessment by a regulator, a significant adverse change in legal matters or in the business climate and/or a failure to replace the contributions of products that lose market exclusivity. Our other intangible assets, including developed technology rights and brands, face similar risks for impairment. Our equity-method investments may also be subject to impairment charges that may result from the occurrence of unexpected adverse events or management decisions that impact our estimates of expected cash flows to be generated from these investments. We may recognize impairment charges as a result of a weak economic environment, challenging market conditions, decisions by management, or events related to particular customers or asset types, such as the development of competing assets by us or others, regulatory actions or product recalls or withdrawals. Any such impairment charge of our intangible assets, goodwill and equity-method investments may be significant. See Note 4 for a discussion of recent impairments of intangible assets. For additional details, see the Significant Accounting Policies and Application of Critical Accounting Estimates and AssumptionsAsset Impairments section within MD&A.
CHANGES IN LAWS AND ACCOUNTING STANDARDS
Our future results could be adversely affected by changes in laws, regulations or policies, or their interpretation, including, among others, changes in accounting standards, tariffs, tax laws and regulations internationally and in the U.S., including, without limitation, the IRA, the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024 and potential changes to existing tax laws, tariffs, competition laws, privacy laws and environmental laws or changes to other laws, regulations and policies in the U.S., including by the U.S. Presidential administration and Congress, as well as in other countries. For example, issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs, could have a material adverse effect on our business, earnings and financial guidance. The actual impact of the new tariffs on our business is subject to a number of factors including, but not limited to, restrictions on trade, the effective date and duration of such tariffs, countries included in the scope of tariffs, changes to amounts of tariffs, and potential retaliatory tariffs imposed by other countries. See Government Regulation and Price Constraints for additional information regarding privacy and other laws. For additional information on changes in tax laws or rates or accounting standards, see the Provision/(Benefit) for Taxes on Income and New Accounting Standards sections within MD&A and Note 1B.
ITEM 1C.
CYBERSECURITY
Managing cybersecurity risk is a crucial part of our overall strategy for safely operating our business. We incorporate cybersecurity practices into our Enterprise Risk Management (ERM) program. Management is responsible for assessing and managing risk, including through the ERM program, subject to oversight by our BOD. Our cybersecurity policies and practices are aligned with NIST (National Institute of Standards and Technology) industry standards.
Consistent with our overall ERM program and practices, our cybersecurity program includes:
Vigilance: We maintain a global cybersecurity operation that endeavors to detect, prevent, contain, and respond to cybersecurity threats and incidents in a prompt and effective manner with the goal of minimizing business disruptions.
External Collaboration: We collaborate with public and private entities, including intelligence and law enforcement agencies, industry groups and third-party service providers to identify, assess and mitigate cybersecurity risks.
Systems Safeguards: We deploy technical safeguards that are designed to protect our information systems, products, operations and sensitive information from cybersecurity threats. These include firewalls, intrusion prevention and detection systems, disaster recovery capabilities, malware and ransomware prevention, access controls and data protection. We continuously conduct vulnerability assessments to identify new risks and periodically test the efficacy of our safeguards through both internal and external penetration tests.
Education: We provide periodic training for all personnel regarding cybersecurity threats, with such training appropriate to the roles, responsibilities and access of the relevant Company personnel. Our policies require all workers to report any real or suspected cybersecurity events.
Supplier Ecosystem Management: We extend our cybersecurity management control expectations to our supply chain ecosystem, as appropriate. This includes identifying cybersecurity risks presented by third parties.
Incident Response Planning: We have established, and maintain and periodically test, incident response plans that direct our response to cybersecurity events and incidents. Such plans include the protocol by which certain significant or potentially material incidents would be communicated to executive management, our BOD, external regulators and shareholders, as appropriate.
Enterprise-Wide Coordination: We engage relevant stakeholders from across the Company to identify emerging risks and respond to cybersecurity threats. This cross-functional approach includes personnel from our R&D, manufacturing, commercial, technology, legal, compliance, internal audit and other business functions.

Pfizer Inc.
2024 Form 10-K
24


Governance: Our BOD’s oversight of cybersecurity risk management is led by the Audit Committee, which oversees our ERM program. Cybersecurity threats, risks and mitigation are periodically reviewed by the Audit Committee and such reviews include both internal and independent assessment of risks, controls and effectiveness.
Our risk assessment efforts have indicated that we are a target for theft of intellectual property, financial resources, personal information, and trade secrets from a wide range of actors including nation states, organized crime, malicious insiders and activists. The impacts of attacks, abuse and misuse of Pfizer’s systems and information could include, without limitation, loss of assets, operational disruption and damage to Pfizer’s reputation.
A key element of managing cybersecurity risk is the ongoing assessment and testing of our processes and practices through auditing, assessments, drills and other exercises focused on evaluating the sufficiency and effectiveness of our risk mitigation. We regularly engage third parties to perform assessments of our cybersecurity measures, including information security maturity assessments and independent reviews of our information security control environment and operating effectiveness. Certain results of such assessments and reviews are reported by the Chief Information Security Officer (CISO) to certain senior leaders, the Audit Committee and the BOD, as appropriate, and we make adjustments to our cybersecurity processes and practices as necessary based on the information provided by the third-party assessments and reviews.
The Audit Committee oversees cybersecurity risk management, including the policies, processes and practices that management implements to prevent, detect and address risks from cybersecurity threats. The Audit Committee receives periodic briefings on, and discusses with our CISO, cybersecurity risks and risk management practices, including, for example, recent developments in the external cybersecurity threat landscape, evolving standards, vulnerability assessments, third-party and independent reviews, technological trends and considerations arising from our supplier ecosystem. The Audit Committee may also promptly receive information regarding certain significant or potentially material cybersecurity incidents that may occur, including any ongoing updates regarding the same.
Our CISO is a member of our management team who is principally responsible for overseeing our cybersecurity risk management program, in partnership with other business leaders across the Company. We believe our CISO and the information security organization have the appropriate expertise, background and depth of experience relating to monitoring the prevention, mitigation, detection and remediation of cybersecurity incidents to manage risks arising from cybersecurity threats. The CISO works in coordination with other members of the management team, including, among others, the Chief Digital Officer, the Chief Financial Officer and the Chief Legal Officer and their designees.
Our CISO, along with leaders from our privacy and corporate compliance functions, collaborate to implement a program designed to manage our exposure to cybersecurity risks and to promptly respond to cybersecurity incidents. Prompt response to incidents is delivered by multi-disciplinary teams in accordance with our incident response plan. Through ongoing communications with these teams during incidents, the CISO monitors the triage, mitigation and remediation of cybersecurity incidents, and reports such incidents to executive management, the Audit Committee and other Pfizer colleagues in accordance with our cybersecurity policies and procedures, as is appropriate.
For the fiscal year ended December 31, 2024, we are not aware of any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the Company, including our business strategy, results of operations, or financial condition. For further discussion of the risks associated with cybersecurity incidents, see the Item 1A. Risk Factors—Information Technology and Security section in this Form 10-K.
ITEM 2.PROPERTIES
Our global headquarters are located in New York City. We own and lease space globally for sales and marketing, customer service, regulatory compliance, R&D, manufacturing and distribution and corporate enabling functions. In many locations, our business and operations are co-located to achieve synergy and operational efficiencies. We continue to advance our global workplace strategy to provide workplaces that promote our forward-thinking and highly inclusive culture. As of December 31, 2024, we had 251 owned and leased properties worldwide, amounting to approximately 37 million square feet.
As of December 31, 2024, PGS had responsibility for 37 plants around the world, which manufacture products for our commercial divisions, including in Belgium, Germany, India, Ireland, Italy, Japan, Singapore and the U.S. The leadership team for PGS is primarily located in New York City. PGS also operates multiple distribution facilities around the world. PGS continuously evaluates it network and capacity to meet Pfizer's ever changing needs and help inform future decisions.
In the U.S., our R&D facilities contain an aggregate of approximately 9 million square feet, with the majority of that area owned by Pfizer. Outside of the U.S., we lease R&D labs in the U.K., India and Belgium.
In general, we believe that our properties, including the principal properties described above, are well-maintained, adequate and suitable for their current requirements and for our operations in the foreseeable future. See Note 9 for amounts invested in land, buildings and equipment.
ITEM 3.LEGAL PROCEEDINGS
Certain legal proceedings in which we are involved are discussed in Note 16A.

Pfizer Inc.
2024 Form 10-K
25


INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The executive officers of the Company are set forth in this table. Each holds the office or offices indicated until his or her successor is chosen and qualified at the regular meeting of the BOD to be held on the date of the 2025 Annual Meeting of Shareholders, or until his or her earlier death, resignation or removal. Each of the executive officers is a member of the Pfizer Executive Leadership Team.
NameAgePosition
Albert Bourla, DVM, Ph.D.
63
Chairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018. Group President, Pfizer Innovative Health from June 2016 until December 2017. Group President, Global Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June 2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Our Director since February 2018.
Andrew Baum, MA, BM ChB
55
Chief Strategy and Innovation Officer and Executive Vice President since 2024. Prior to joining Pfizer, he was Head of Global Healthcare - Managing Director Equity Research at Citigroup from 2011 until 2024.
Chris Boshoff, MD, FRCP, FMedSci, Ph.D.
61
Chief Scientific Officer and President, Research & Development, since January 2025. Chief Oncology Officer, Executive Vice President from December 2023 until December 2024. Chief Oncology Research and Development Officer and Executive Vice President from July 2023 until December 2023. Senior Vice President, Oncology, from 2017 until 2023.
David M. Denton59
Chief Financial Officer, Executive Vice President since May 2022. Executive Vice President, Chief Financial Officer, Lowe’s Companies, Inc., from November 2018 until April 2022; Executive Vice President and Chief Financial Officer, CVS Health Corporation (a diversified health solutions company), from January 2010 until November 2018. Served as Director of Haleon plc from March 2023 to December 2024.
Alexandre de Germay57
Chief International Commercial Officer, Executive Vice President since December 2023. Chief Executive Officer, Laboratoires Majorelle (a specialty pharma company based in France dedicated to women’s health and urology) from 2021 until January 2024 (assisting with transition matters after December 15, 2023). From 2020 until 2021 was Senior Vice President; Global Franchise Head of Cardiology, Transplant and Established Products, and from 2016 until 2020 was Head of Mature Markets General Medicines of Sanofi. Regional President of Asia-Pacific of Pfizer Inc. from 2013 until 2016.
Lidia Fonseca56
Chief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officer and Senior Vice President of Quest Diagnostics Incorporated from 2014 to 2018. Senior Vice President of Laboratory Corporation of America Holdings from 2008 until March 2013. Director of Medtronic plc.
Douglas M. Lankler59
Chief Legal Officer, Executive Vice President since January 2025. General Counsel, Executive Vice President from December 2013 until December 2024. Corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013.
Aamir Malik49
Chief U.S. Commercial Officer, Executive Vice President since December 2023. Chief Business Innovation Officer, Executive Vice President from August 2021 until December 2023. Various U.S. geographic leadership roles with McKinsey & Company from 2019 to 2021; previously co-led McKinsey & Company’s Global Pharmaceuticals & Medical Products practice from 2015 to 2018.
Michael McDermott59
Chief Global Supply and Quality Officer, Executive Vice President since January 2025. Chief Global Supply Officer, Executive Vice President from 2022 until December 2024. President of Pfizer Global Supply from 2018 until 2021. Vice President of Pfizer Global Supply from 2014 until 2018. Vice President of the Biotechnology Unit from 2012 until 2014.
Payal Sahni50
Chief People Experience Officer, Executive Vice President since January 2022. Chief Human Resources Officer, Executive Vice President from June 2020 to December 2021. From May 2016 until June 2020 served as Senior Vice President of Human Resources for multiple operating units. Vice President of Human Resources, Vaccines, Oncology & Consumer from 2015 until 2016. Ms. Sahni has served in a number of positions in the Human Resources organization with increasing responsibility since joining Pfizer in 1997.
Sally Susman63
Chief Corporate Affairs Officer, Executive Vice President since January 2019. Executive Vice President, Corporate Affairs (formerly Policy, External Affairs and Communications) from December 2010 until December 2018. Senior Vice President, Policy, External Affairs and Communications from December 2009 until December 2010. Director of UL Solutions Inc.

Pfizer Inc.
2024 Form 10-K
26


PART II
ITEM 5.MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
The principal market for our common stock is the NYSE. Our common stock currently trades on the NYSE under the symbol “PFE”. As of February 20, 2025, there were 113,116 holders of record of our common stock.

The following summarizes purchases of our common stock during the fourth quarter of 2024:
Period
Total Number
of Shares
Purchased(a)
Average Price
Paid per
    Share(a)
Total Number of
Shares Purchased as
Part of Publicly
    Announced Plan
Approximate Value of Shares
that May Yet Be Purchased
    Under the Plan(b)
September 30 through October 27, 202433,110$29.04  $3,292,882,444 
October 28 through November 30, 202434,233$27.85  $3,292,882,444 
December 1 through December 31, 202463,672$26.21  $3,292,882,444 
Total131,015 $27.36  
(a)Represents (i) 127,726 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 3,289 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.
(b)See Note 12.
PEER GROUP PERFORMANCE GRAPH
The following graph assumes a $100 investment on December 31, 2019, and reinvestment of all dividends, in each of the Company’s Common Stock, a composite peer group of the major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Roche Holding AG and Sanofi, the S&P 500 Index and the NYSE Arca Pharmaceutical Index (DRG index).
543
Five Year Performance
 
201920202021202220232024
PFIZER        $100.0$103.4$172.5$154.5$90.8$88.8
PEER GROUP$100.0$105.5$126.6$147.5$170.1$177.4
S&P 500      $100.0$118.4$152.3$124.7$157.5$196.8
DRG Index$100.0$108.7$134.2$144.5$155.7$163.6

ITEM 6.[RESERVED]

Pfizer Inc.
2024 Form 10-K
27


ITEM 7.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
GENERAL
The following MD&A is intended to assist the reader in understanding our financial condition and results of operations, including an evaluation of the amounts and certainty of cash flows from operations and from outside sources, and is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related notes in Item 8. Financial Statements and Supplementary Data in this Form 10-K. Discussions of 2022 items and year-to-year comparisons between 2023 and 2022 that are not included in this Form 10-K can be found within MD&A in our 2023 Form 10-K.
References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and because they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.
In the first quarter of 2024, we reclassified royalty income (substantially all of which is related to our Biopharma segment) from Other (income)/deductions––net and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of operations. Prior-period amounts have been recast to conform to the current presentation.
OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK
Financial Highlights––The following is a summary of certain financial performance metrics (in billions, except per share data):
2024 Total Revenues––$63.6 billion2024 Net Cash Flow from Operations––$12.7 billion
An increase of 7% compared to 2023An increase of 46% compared to 2023
209210
2024 Reported Diluted EPS––$1.412024 Adjusted Diluted EPS (Non-GAAP)––$3.11**
An increase of over 100% compared to 2023An increase of 69% compared to 2023
214215
** For additional information regarding Adjusted diluted EPS (which is a non-GAAP financial measure), including reconciliations of certain GAAP Reported to non- GAAP Adjusted information, see the Non-GAAP Financial Measure: Adjusted Income section within MD&A.
Our Business and Strategy––Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives. See the Item 1. Business––About Pfizer section. As a science-driven global biopharmaceutical company, we remain focused on advancing our pipeline, supporting our marketed brands and deploying capital responsibly, with a focus on initiatives that can help contribute to our long-term revenue and future growth. Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients, and we continuously evaluate how we can best collaborate with patients, physicians and payors to support and expand patient access to reliable, affordable healthcare around the world. In addition, we continually seek to expand and broaden our product portfolio offerings through prioritized development of our pipeline and business development opportunities targeted at critical unmet patient needs. As a result, our commercial organizational structure and R&D operations are critical to the successful execution of our business strategy. Our ability to fulfill our purpose, Breakthroughs that change patients’ lives, remains a core focus and underscores our commitment to addressing the needs of society to help sustain long-term value creation for all stakeholders.
Our 2025 key priorities are:
1.Improve R&D productivity with sharpened focus
2.Expand margins and maximize operational efficiency
3.Achieve commercial excellence in our key categories
4.Optimize capital allocation.

Pfizer Inc.
2024 Form 10-K
28


One way we believe we will be more efficient, effective and able to execute on these strategic priorities is through technology, including AI.
In 2024, we managed our commercial operations through a global structure consisting of three operating segments: Biopharma, PC1 and Pfizer Ignite. Biopharma was the only reportable segment. See Note 17A and the Item 1. Business––Commercial Operations section. At the beginning of 2025, we made the following changes within our Biopharma reportable segment that went into effect on January 1, 2025 to support our continued focus on commercial execution and to further strengthen Pfizer’s capabilities and leadership in discovering and developing breakthrough medicines and vaccines:
transitioned the Pfizer U.S. Oncology commercial organization and the global Oncology marketing organization, which were part of the former Pfizer Oncology Division, into the Pfizer U.S. Commercial Division, which now focuses on the commercialization of Pfizer’s entire product portfolio in the U.S. and is led by the Chief U.S. Commercial Officer, Executive Vice President; and
combined our global ORD and PRD organizations to form a single Pfizer R&D organization that is responsible for all R&D activities across all therapeutic areas.
In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program (Realigning Our Cost Base Program) that aims to realign our costs with our longer-term revenue expectations. In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold (Manufacturing Optimization Program), which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. See Note 3. For a description of anticipated savings related to these programs, see the Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives section within MD&A.
R&D: We believe we have a strong pipeline and are well-positioned for future growth. R&D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients’ lives as we work to translate advanced science and technologies into the medicines and vaccines that may be the most impactful for patients. Innovation, drug discovery and development are critical to our success. In addition to discovering and developing new products, our R&D efforts seek to add value to our existing products by improving their effectiveness and ease of dosing and by discovering potential new indications. See the Item 1. BusinessResearch and Development section for our R&D priorities and strategy.
We seek to leverage a strong pipeline, organize around expected operational growth drivers and capitalize on trends creating long-term growth opportunities, including:
an aging global population that is generating increased demand for innovative medicines and vaccines that address patients’ unmet needs; and
advances in both biological science and platform technologies that are enhancing the delivery of potential breakthrough new medicines and vaccines.
Our Business Development Initiatives––We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our business strategy. See Note 2 for significant recent activities.
Our 2024 Performance
Total Revenues––Total revenues increased $4.1 billion, or 7%, to $63.6 billion in 2024 from $59.6 billion in 2023, reflecting an operational increase of $4.4 billion, or 7%, partially offset by an unfavorable impact of foreign exchange of $349 million, or approximately 1%. The operational increase was primarily driven by Paxlovid, the addition of legacy Seagen revenues in full-year 2024 following the acquisition in December 2023, and growth from the Vyndaqel family and Eliquis, partially offset by declines in Comirnaty. The operational increase for Paxlovid was primarily due to: (i) a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023 related to the expected return of an estimated 6.5 million treatment courses of EUA labeled U.S. government inventory and (ii) revenue in 2024 of $1.2 billion from two one-time items: a $771 million favorable final adjustment recorded in the first quarter of 2024 to the aforementioned $3.5 billion revenue reversal; and $442 million from the one-time contractual delivery of treatment courses to the U.S. SNS. See Note 17C. Excluding contributions from Comirnaty and Paxlovid, Total revenues increased 12% operationally.
The following chart outlines the components of the net change in Total revenues:
7491
See the Total Revenues by Geography and Total Revenues––Selected Product Discussion sections within MD&A for more information, including a discussion of key drivers of our revenue performance. Certain of our vaccines, including Comirnaty, are subject to seasonality of demand, with a greater portion of revenues anticipated in the fall and winter seasons, and Paxlovid revenues trend with infection rates. See also The Global

Pfizer Inc.
2024 Form 10-K
29


Economic Environment––COVID-19 section below for information about our COVID-19 products. For information regarding the primary indications or class of certain products, see Note 17C.
Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income––The increase in Income from continuing operations before provision/(benefit) for taxes on income of $7.0 billion, to $8.0 billion in 2024 from $1.1 billion in 2023, was primarily attributable to (i) a decrease in Cost of Sales, (ii) higher revenues and (iii) a decrease in Restructuring charges and certain acquisition-related costs, partially offset by (iv) higher net interest expense, (v) net periodic benefit costs associated with pension and other postretirement plans incurred in 2024 versus net periodic benefit credits in 2023, (vi) lower net gains on equity securities and (vii) an increase in Amortization of intangible assets.
See the Analysis of the Consolidated Statements of Operations section within MD&A and Note 4. For information on our tax provision and effective tax rate, see the Provision/(Benefit) for Taxes on Income section within MD&A and Note 5.
Our Operating Environment––We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below. See also the Item 1. Business––Government Regulation and Price Constraints and Item 1A. Risk Factors sections.
Regulatory Environment––Pipeline Productivity––Our product lines must be replenished over time to offset revenue losses when products lose exclusivity or market share or to respond to healthcare and innovation trends, as well as to provide for earnings growth, primarily through internal R&D or through collaborations, acquisitions, JVs, licensing or other arrangements. As a result, we devote considerable resources to our R&D activities which, while essential to our growth, incorporate a high degree of risk and cost, including whether a particular product candidate or new indication for an in-line product will achieve the desired clinical endpoint or safety profile, will be approved by regulators or will be successful commercially. Clinical trials are conducted to determine, among other things, whether an investigational drug, vaccine or device is safe and effective for a particular patient population. After a product has been approved or authorized and launched, we continue to monitor its safety as long as it is available to patients, including conducting postmarketing trials, voluntarily or pursuant to a regulatory request. For the entire life of the product, we collect safety data and report safety information to the FDA and other regulators. Regulatory authorities evaluate potential safety concerns and take any regulatory action deemed necessary and appropriate. Such action(s) may include: updating a product’s labeling, restricting its use, communicating new safety information or, in rare cases, seeking to suspend or remove a product from the market.
Intellectual Property Rights and Collaboration/Licensing Rights––The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments, and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent-based or regulatory exclusivity expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries in 2025 and anticipate a more significant impact of reduced revenues from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations. We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access.
For additional information on patent rights we consider most significant to our business as a whole, see the Item 1. Business––Patents and Other Intellectual Property Rights section. For a discussion of recent developments with respect to patent litigation involving certain of our products, see Note 16A1.
Regulatory Environment/Pricing and Access––Government and Other Payor Group Pressures––The pricing of medicines and vaccines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, vaccines, medical services and hospital services, continues to be important to payors, governments, patients, and other stakeholders. Federal and state governments and private third-party payors in the U.S. continue to take action to manage the utilization and cost of drugs, including increasingly employing formularies to control costs and encourage utilization of certain drugs, including through the use of deductibles, utilization management tools, cost sharing or formulary placement. We consider a number of factors impacting the pricing of our medicines and vaccines. Within the U.S., we often engage with patients, doctors and healthcare plans. We also often provide significant discounts from the list price to insurers, including PBMs and MCOs. The price that patients pay in the U.S. for prescribed medicines and vaccines is ultimately set by healthcare providers and insurers, including government healthcare programs. Governments globally, as well as private third-party payors in the U.S., may use a variety of measures to control costs, including, among others, legislative or regulatory pricing reforms, drug formularies (including tiering and utilization management tools), cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, “international reference pricing” (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement. We anticipate that these and similar initiatives will continue to increase pricing and access pressures globally. In the U.S., we expect to see continued focus by the U.S. government on regulating drug pricing and access to medicine. The drug pricing provisions of the IRA are being implemented over the next several years. In August 2023, CMS published the first ten medicines subject to the MDPNP, which requires manufacturers of select drugs to engage in a process with the federal government to set new Medicare prices which would go into effect in 2026. Eliquis was among the first ten medicines subject to MDPNP. In August 2024, the government released the new Medicare price for Eliquis, which, effective January 1, 2026, will be required to be offered to all Medicare beneficiaries and to covered entities participating in the 340B Program that dispense Eliquis to a Medicare beneficiary if that maximum fair price is lower than the discounted price such entities are offered under the 340B Program ceiling price calculation. The Eliquis Medicare price is factored into our long-term financial planning, in accordance with our standard financial reporting and forecasting protocols. On January 17, 2025, CMS announced the selection of another 15 drugs from Medicare Part D for the maximum fair price, with prices to be set and effective on January 1, 2027. Ibrance and Xtandi were included in the list of 15 drugs selected. Another 15 drugs from Medicare Part B or Medicare Part D will be selected by February 1, 2026, for the maximum price to be set and in effect by January 1, 2028. It is possible that more of our products could be selected in future years, which could, among other things, lead to lower revenues prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. The IRA made significant changes to the Medicare Part D benefit design, which will impact Pfizer revenues in 2025, including: an expected favorable impact from the $2,000 annual out-of-pocket cap and new Prescription Payment Plan, more than offset by an expected unfavorable impact from the sunsetting of the Coverage Gap Discount Program and the addition of new manufacturer discounts in the initial and catastrophic coverage phases. We anticipate a net unfavorable impact to revenue in 2025 of approximately $1 billion, year-over-year, related to the Medicare Part D Redesign changes that take effect in 2025. We expect these changes will more acutely impact our higher-priced medicines as they are expected to reach catastrophic coverage earlier in the year. In addition, changes to the MDRP or the 340B Program, including legal or legislative developments at the federal or state level with respect to the 340B Program, could

Pfizer Inc.
2024 Form 10-K
30


Impact of the July 2023 Tornado in Rocky Mount, North Carolina (NC)––Our manufacturing facility in Rocky Mount, NC was damaged by a tornado in July 2023. The facility is a key producer of sterile injectables and is responsible for manufacturing nearly 25 percent of all our sterile injectables—including anesthesia, analgesia, and micronutrients. Supply of medicines has recovered from the impact of the tornado. We incurred losses in 2023 and 2024 that were partially offset by insurance recoveries received.
Product Supply––We periodically encounter supply delays, disruptions and shortages, including due to voluntary product recalls and natural or man-made disasters. In response to requests from various regulatory authorities, manufacturers across the pharmaceutical industry, including Pfizer, are evaluating their product portfolios for the potential presence or formation of nitrosamines and we are actively engaging with regulatory authorities on this topic. If nitrosamines are detected above certain levels in our products, this may lead to market action for such products. For example, in 2021, Pfizer recalled all lots of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline, at or above acceptable intake limits communicated by various regulatory authorities. Regulatory authorities have since issued updated guidance on nitrosamine acceptable intake levels. With this guidance, which included an updated intake level for N-nitroso-varenicline, we have started making regulatory submissions to potentially enable Chantix to return to market in the U.S. and in certain international markets.
Except for the impact of the tornado in Rocky Mount, NC discussed above, we have not seen a significant disruption of our supply chain in 2024 and through the date of filing of this Form 10-K, and all of our manufacturing sites globally have continued to operate at or near normal levels. We do not anticipate the availability of raw materials to have a significant impact on our operations in 2025, but are monitoring potential supply chain disruptions as a result of ongoing geopolitical and trade negotiations, which could, among other things, impact costs. We are continuing to monitor and implement mitigation strategies to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible. For information on risks related to product manufacturing, see the Item 1A. Risk Factors––Product Manufacturing, Sales and Marketing Risks section.
Voluntary Withdrawal of Oxbryta––See the Product Developments section within MD&A.
The Global Economic Environment––In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to economic cycles. Certain factors in the global economic environment that may impact our global operations include, among other things, currency and interest rate fluctuations, capital and exchange controls, local and global economic conditions including inflation, recession, volatility and/or lack of liquidity in capital markets, expropriation and other restrictive government actions, changes in intellectual property, legal protections and remedies, trade regulations, tariffs, tax laws and regulations and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as impacts of political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and their economic consequences, geopolitical instability, terrorist activity, unstable governments and legal systems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related to climate change. Government pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria or other means of cost control. In addition, issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs, could have a material adverse effect on our business, earnings and financial guidance. The actual impact of the new tariffs on our business is subject to a number of factors including, but not limited to, restrictions on trade, the effective date and duration of such tariffs, countries included in the scope of tariffs, changes to amounts of tariffs, and potential retaliatory tariffs imposed by other countries. We are evaluating opportunities and developing plans which may help mitigate the potential impact of tariffs on our business and operations. For additional information on risks related to our global operations and changes in laws, see the Item 1A. Risk Factors—Global Operations and ––Changes in Laws and Accounting Standards sections.
COVID-19––In response to COVID-19, we developed Paxlovid and collaborated with BioNTech to jointly develop Comirnaty. As part of our strategy for COVID-19, we are continuing to make significant investments in breakthrough science. This includes continuing to evaluate Comirnaty and Paxlovid, including against new variants of concern, developing variant adapted vaccine candidates and developing potential combination respiratory vaccines and potential next generation vaccines and therapies. We are also evaluating Paxlovid for certain pediatric patients. See the Product Developments section within MD&A.
In 2023, we principally sold Comirnaty globally under government contracts. In September 2023, Comirnaty transitioned to traditional commercial market sales in the U.S., triggered by the expiration of contracts and the COVID-19 vaccines from Pfizer and BioNTech purchased through them becoming either depleted or not used following the introduction of a new variant vaccine. Internationally, sales of Comirnaty in international developed markets were generally under government contracts in 2023 and 2024, and in emerging markets, under a combination of private channels and government contracts; in both cases, we started transitioning to commercial markets in 2024. Due to the commercial market transition as well as the seasonality of demand for COVID-19 vaccinations, the majority of our global revenues for Comirnaty were recorded in the fourth quarter of 2024. In 2025, for Comirnaty we expect vaccination rates and market share in commercial markets and revenue phasing similar to 2024, primarily concentrated in the second-half of the year. We have assumed no material U.S. policy changes for our vaccines portfolio in 2025 for purposes of our financial guidance, but see Item 1A. Risk Factors—U.S. Healthcare Regulation for a description of risks and uncertainties that could impact revenue from our portfolio of vaccines.
In 2023, we principally sold Paxlovid globally to government agencies. On October 13, 2023, we announced an amended agreement with the U.S. government, which facilitated the transition of Paxlovid to traditional commercial markets in the U.S. in November 2023, with minimal uptake of NDA-labeled commercial product before January 1, 2024 (see Note 17C). Internationally, for Paxlovid, most markets have now transitioned to commercial markets, and we are expecting most revenue for Paxlovid to be generated through commercial channels. In 2025, we expect utilization for Paxlovid to follow infection rates and stable market share, and revenues may fluctuate based on the timing, duration and severity of COVID-19 cases.
For information on risks associated with our COVID-19 products, as well as COVID-19 intellectual property disputes, see the Item 1A. Risk FactorsCOVID-19, Intellectual Property Protection and ––Third-Party Intellectual Property Claims sections as well as Notes 16A1 and 17C.
Israel/Hamas Conflict––Our local operations have been impacted by the armed conflict between Israel and Hamas that began on October 7, 2023. For the years ended December 31, 2024 and 2023, the business of our Israeli subsidiary represented less than 1% of our consolidated revenues and assets. We are closely monitoring developments in this conflict, including evaluating potential impacts to our business, customers, suppliers, employees, and operations in Israel and elsewhere in the Middle East that may impact global operations. At this time, longer term impacts from these events to the Company are uncertain and subject to change.

Pfizer Inc.
2024 Form 10-K
31


Russia/Ukraine Conflict––Our local operations have been impacted by the armed conflict between Russia and Ukraine. For the years ended December 31, 2024 and 2023, the business of our Russia and Ukraine subsidiaries represented less than 1% of our consolidated revenues and assets. While we are monitoring the effects of the conflict between Russia and Ukraine, the situation continues to evolve and the long-term implications, including the broader economic consequences of the conflict, potential additional sanctions, and actions by our customers or suppliers (including financial institutions) are difficult to predict at this time.
For information on risks associated with these conflicts, see the Item 1A. Risk Factors—Global Operations section.
SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS
Following is a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements. Also, see Note 1C.
For a description of our significant accounting policies, see Note 1. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions
(
Note 1D); Fair Value (Note 1E); Revenues (Note 1G); Asset Impairments (Note 1M); Tax Assets and Liabilities and Income Tax Contingencies (Note 1Q); Pension and Postretirement Benefit Plans (Note 1R); and Legal and Environmental Contingencies (Note 1S).
For a discussion of recently adopted accounting standards, see Note 1B.
Acquisitions
We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair value as of the acquisition date. To estimate fair value, we utilize an exit price approach from the perspective of a market participant. For further detail on acquisition accounting, see Note 1D. For further detail on the techniques and methodologies that we use to estimate fair value, see Note 1E. Historically, intangible assets have been the most significant fair values within our business combinations. We utilize an income approach to estimate the acquisition date fair value of each identifiable intangible asset. Some of the more significant estimates and assumptions inherent in this approach include the amount and timing of projected net cash flows, the discount rate, the tax rate, and, for IPR&D assets, the probability of technical and regulatory success (PTRS). All of these judgments and estimates can materially impact our results of operations. For further information on our process to estimate the fair value of intangible assets, see Asset Impairments below.
We estimate the fair value of acquired inventory, including finished goods and work in process, by determining the estimated selling price when completed, less an estimate of costs to be incurred to complete and sell the inventory, and an estimate of a reasonable profit allowance for those manufacturing and selling efforts. The fair value of inventory is recognized in our results of operations as the inventory is sold. Some of the more significant estimates and assumptions inherent in the estimate of the fair value of inventory include stage of completion, costs to complete, costs to dispose and selling price.
We estimate the fair value of acquired PP&E using a combination of the cost and market approaches. Some of the more significant estimates and assumptions inherent in these approaches are the values of asset replacement costs, comparable assets and estimated remaining economic lives of the assets.
Revenues
Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate estimates of our future experience, our results could be materially affected. The potential of our estimates to vary (sensitivity) differs by program, product, type of customer and geographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this lag, our recording of adjustments to reflect actual amounts can incorporate revisions of several prior quarters. Rebate accruals are product specific and, therefore for any period, are impacted by the mix of products sold as well as the forecasted channel mix for each individual product. For further information, see the Product Revenue Deductions section within MD&A and Note 1G.
Asset Impairments
We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in Note 1M.
Examples of events or circumstances that may be indicative of impairment include:
A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely result in generic competition earlier than expected.
A significant adverse change in the extent or manner in which an asset is used such as a restriction imposed by the FDA or other regulatory authorities, withdrawals or other unusual items that could affect our ability to manufacture or sell a product.
An expectation of losses or reduced profits associated with an asset. This could result, for example, from a change in development plans or a change in a government reimbursement program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor’s product that impacts projected revenue growth, as well as the lack of acceptance of a product by patients, physicians and payors. For IPR&D projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or additional expenditures to commercialize the product.

Pfizer Inc.
2024 Form 10-K
32


Changes in development plans and/or de-prioritization of certain assets.
Identifiable Intangible Assets––We use an income approach, specifically the discounted cash flow method to determine the fair value of intangible assets, other than goodwill. We start with a forecast of all the expected net cash flows associated with the asset, which incorporates the consideration of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions that impact our fair value estimates include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological advancements and risk associated with IPR&D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the jurisdictional mix of the projected cash flows.
While all intangible assets other than goodwill can face events and circumstances that can lead to impairment, those that are most at risk of impairment include IPR&D assets (approximately $18.9 billion as of December 31, 2024) and newly acquired or recently impaired indefinite-lived brand assets. IPR&D assets are high-risk assets, given the uncertain nature of R&D. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each reporting period. As such, immediately after acquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment charge.
Goodwill––Our goodwill impairment review work as of December 31, 2024 concluded that none of our goodwill was impaired and we do not believe the risk of impairment is significant at this time, as the fair value of each of our reporting units is significantly higher than their respective net book values.
In our review, we first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Qualitative factors that we consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then perform a quantitative fair value test.
When we are required to determine the fair value of a reporting unit, we typically use the income approach. The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, we use the discounted cash flow method. We start with a forecast of all the expected net cash flows for the reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
For all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of subsequent goodwill impairment testing. For a list of these factors, see the Forward-Looking Information and Factors That May Affect Future Results and the Item 1A. Risk Factors sections.
Benefit Plans
For a description of our different benefit plans, see Note 11.
Our assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made in determining the costs of our benefit plans can materially impact our results of operations.
The following provides (i) at the end of each year, the expected annual rate of return on plan assets for the following year, (ii) the actual annual rate of return on plan assets achieved in each year, and (iii) the weighted-average discount rate used to measure the benefit obligations at the end of each year for our U.S. pension plans and our international pension plans(a):
202420232022
U.S. Pension Plans
Expected annual rate of return on plan assets7.7 %8.0 %7.5 %
Actual annual rate of return on plan assets1.3 10.4 (22.4)
Discount rate used to measure the plan obligations5.7 5.4 5.4 
International Pension Plans
Expected annual rate of return on plan assets4.9 5.1 4.5 
Actual annual rate of return on plan assets6.4 (4.6)(26.0)
Discount rate used to measure the plan obligations4.1 4.4 3.8 
(a)For detailed assumptions associated with our benefit plans, see Note 11B.
Expected Annual Rate of Return on Plan Assets––The assumptions for the expected annual rate of return on all of our plan assets reflect our actual historical return experience and our long-term assessment of forward-looking return expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our targeted asset allocation in our respective plans.
The expected annual rate of return on plan assets for our U.S. plans and international plans is applied to the fair value of plan assets at each year-end and the resulting amount is reflected in our net periodic benefit costs in the following year. Differences between the actual rate of return on plan assets and the expected annual rate of return on plan assets are immediately recognized through earnings upon remeasurement.

Pfizer Inc.
2024 Form 10-K
33


The following illustrates the sensitivity of net periodic benefit costs to a 50 basis point decline in our assumption for the expected annual rate of return on plan assets, holding all other assumptions constant (in millions, pre-tax):
AssumptionChange
Increase in 2025
Net Periodic
Benefit Costs
Expected annual rate of return on plan assets(a)
50 basis point decline$86
(a)The estimate excludes any potential mark-to-market adjustments.

The actual return on plan assets was $652 million during 2024.
Discount Rate Used to Measure Plan Obligations––The weighted-average discount rate used to measure the plan obligations for our U.S. defined benefit plans is determined at least annually and evaluated and modified, as required, to reflect the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better, that reflect the rates at which the pension benefits could be effectively settled. The discount rate used to measure the plan obligations for our significant international plans is determined at least annually by reference to investment grade corporate bonds, rated AA/Aa or better, including, when there is sufficient data, a yield-curve approach. These discount rate determinations are made in consideration of local requirements. The measurement of plan obligations at the end of the year will affect (i) the actuarial (gains)/losses recognized in our net periodic benefit cost for that year and (ii) the amount of service cost and interest cost reflected in our net periodic benefit costs in the following year.
The following illustrates the sensitivity of net periodic benefit costs and benefit obligations to a 10 basis point decline in our assumption for the discount rate, holding all other assumptions constant (in millions, pre-tax):
AssumptionChange
Decrease in 2025 Net Periodic Benefit Costs
Increase to 2024 Benefit Obligations
Discount rate10 basis point decline$5$208

The change in the discount rates used in measuring our plan obligations as of December 31, 2024 resulted in an increase in the measurement of our aggregate plan obligations by approximately $25 million.
Income Tax Assets and Liabilities
Income tax assets and liabilities include income tax valuation allowances and accruals for uncertain tax positions. See Notes 1Q and 5, as well as the Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk section within MD&A.
Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and indemnifications. See Notes 1Q, 1S, 5D and 16.
ANALYSIS OF THE CONSOLIDATED STATEMENTS OF OPERATIONS
Total Revenues by Geography
The following presents worldwide Total revenues by geography:
 Year Ended December 31,% Change
 WorldwideU.S.InternationalWorldwideU.S.International
(MILLIONS)20242023202220242023202220242023202224/2323/2224/2323/2224/2323/22
Operating segments:
Biopharma
$62,400 $58,237 $99,826 $38,332 $27,749 $42,920 $24,068 $30,488 $56,905 7 (42)38 (35)(21)(46)
Pfizer CentreOne
1,146 1,272 1,342 278 352 390 868 920 952 (10)(5)(21)(10)(6)(3)
Pfizer Ignite
82 44 82 44  — — 85 *85 *
Total revenues$63,627 $59,553 $101,175 $38,691 $28,145 $43,317 $24,936 $31,408 $57,858 7 (41)37 (35)(21)(46)
2024 v. 2023
The following provides an analysis of the worldwide change in Total revenues by geographic areas from 2023 to 2024:
(MILLIONS)WorldwideU.S.International
Operational growth/(decline):
Worldwide growth from Paxlovid
$4,452 $5,905 $(1,453)
Increase in revenues from legacy Seagen, which was acquired in December 2023
3,223 3,071 153 
Worldwide growth from the Vyndaqel family, Eliquis, Xtandi and Nurtec ODT/Vydura, partially offset by declines from Xeljanz, Ibrance, Abrysvo, Inlyta and the Prevnar family
2,403 1,770 633 
Worldwide declines from Comirnaty
(5,907)(400)(5,507)
Decline in oncology biosimilars, largely due to lower net price in the U.S.(362)(338)(24)
Other operational factors, net614 538 76 
Operational growth/(decline), net
4,423 10,546 (6,123)
Unfavorable impact of foreign exchange(349) (349)
Total revenues increase/(decrease)
$4,074 $10,546 $(6,472)

Pfizer Inc.
2024 Form 10-K
34


2023 v. 2022
The following provides an analysis of the worldwide change in Total revenues by geographic areas from 2022 to 2023:
(MILLIONS)WorldwideU.S.International
Operational growth/(decline):
Worldwide declines from Comirnaty
$(26,427)$(6,374)$(20,053)
Worldwide declines from Paxlovid
(17,506)(11,803)(5,703)
Worldwide growth from the Vyndaqel family, Eliquis, the Prevnar family and Inlyta, partially offset by worldwide declines from Ibrance and Xeljanz
1,079 1,081 (2)
Increase in revenues from Nurtec ODT/Vydura and Oxbryta, which were acquired in the fourth quarter of 2022
972 949 23 
Revenues from Abrysvo, primarily driven by launch of the older adult indication in the U.S. in July 2023
890 888 
Revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023
132 132 — 
Other operational factors, net
260 (45)305 
Operational growth/(decline), net
(40,600)(15,172)(25,428)
Unfavorable impact of foreign exchange(1,022)— (1,022)
Total revenues increase/(decrease)
$(41,621)$(15,172)$(26,450)
See the Total Revenues––Selected Product Discussion section within MD&A for additional analysis and Note 17C.
Product Revenue Deductions––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these product revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.
The following presents information about product revenue deductions:
  Year Ended December 31,
(MILLIONS)202420232022
Medicare rebates$4,145 $997 $838 
Medicaid and related state program rebates2,252 1,655 973 
Performance-based contract rebates6,497 5,159 3,575 
Chargebacks12,698 9,828 7,560 
Sales allowances6,444 6,790 5,460 
Sales returns and cash discounts
1,852 5,619 1,290 
Total(a)
$33,888 $30,048 $19,697 
(a)The increase in revenue deductions in 2024 was primarily driven by the transition of Paxlovid and Comirnaty to commercial markets, an increase in sales from legacy Seagen products acquired in December 2023, sales growth from the Vyndaqel family, and higher sales of acquired products, partially offset by a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash Paxlovid revenue reversal of $3.5 billion recorded in the fourth quarter of 2023 (see Note 17C).
Product revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.
For information on our accruals for product revenue deductions, including the balance sheet classification of these accruals, see Note 1G.
Total Revenues—Selected Product Discussion
Biopharma
Revenue
(MILLIONS)Year Ended Dec. 31,% Change
ProductGlobal
Revenues
Region20242023TotalOper.Operational Results Commentary
Eliquis
$7,366

Up 10%

(operationally)
U.S.$4,803 $4,228 14 
Growth driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to loss of patent-based exclusivity and generic competition in certain international markets.
Int’l.2,563 2,519 2 3 
Worldwide$7,366 $6,747 9 10 
Prevnar family
$6,411

Down 1%

(operationally)
U.S.$4,233 $4,265 (1)
Declines driven by fewer adult vaccinations in the U.S. and lower pediatric indication sales in most international developed markets and certain emerging markets, partially offset by growth in the pediatric indication in the U.S. reflecting recovered market share as a result of the Prevnar 20 launch in 2023, as well as strong uptake of the adult indication in certain international markets.
Int’l.2,178 2,236 (3)(1)
Worldwide$6,411 $6,501 (1)(1)

Pfizer Inc.
2024 Form 10-K
35


Revenue
(MILLIONS)Year Ended Dec. 31,% Change
ProductGlobal
Revenues
Region20242023TotalOper.Operational Results Commentary
Paxlovid
$5,716

Up *

(operationally)
U.S.$4,616 $(1,289)*
Growth primarily driven by:
• a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023 (see Note 17C);
• a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023; and
• $442 million from the one-time contractual delivery of treatment courses to the U.S. SNS in the third quarter of 2024,
partially offset by:
• lower contractual deliveries in most international markets as a result of the transition to traditional commercial market sales; and
• lower demand globally, largely in China due to the non-recurrent surge in COVID-19 infection during the first quarter of 2023 and transition to the out-of-pocket market in the second quarter of 2023.
Int’l.1,100 2,568 (57)(57)
Worldwide$5,716 $1,279 **
Vyndaqel family
$5,451

Up 65%

(operationally)
U.S.$3,547 $1,863 90 
Growth largely driven by strong demand with continuing uptake in patient diagnosis, primarily in the U.S. and international developed markets, as well as increased affordability in the U.S.
Int’l.1,904 1,458 31 32 
Worldwide$5,451 $3,321 64 65 
Comirnaty
$5,353

Down 53%

(operationally)
U.S.$2,004 $2,404 (17)Declines largely driven by lower contractual deliveries in international markets as well as a decrease in vaccinations globally.
Int’l.3,349 8,816 (62)(62)
Worldwide$5,353 $11,220 (52)(53)
Ibrance
$4,367

Down 8%
 
(operationally)
U.S.$2,849 $3,151 (10)
Declines primarily driven by lower demand due to competitive pressures mainly in the U.S., price decreases in certain international developed markets and generic penetration in certain emerging markets.
Int’l.1,518 1,602 (5)(4)
Worldwide$4,367 $4,753 (8)(8)
Xtandi
$2,039

Up 23%

(operationally)
U.S.$2,039 $1,659 23 
Growth largely driven by strong demand due to uptake of the nmCSPC indication following approval in the fourth quarter of 2023 and increased affordability in the U.S.
Int’l. — 
Worldwide$2,039 $1,659 23 23 
Padcev
$1,588

Up *

(operationally)
U.S.$1,561 $53 *Growth driven by the acquisition of Seagen in the fourth quarter of 2023 as well as strong demand.
Int’l.27 — **
Worldwide$1,588 $53 **
Nurtec ODT/Vydura
$1,263

Up 36%

(operationally)
U.S.$1,193 $908 31 Growth primarily driven by strong demand in the U.S. and, to a much lesser extent, recent launches in international markets, partially offset by lower net price in the U.S. due to unfavorable changes in channel mix.
Int’l.69 20 **
Worldwide$1,263 $928 36 36 
Xeljanz
$1,168

Down 31%

(operationally)
U.S.$680 $1,154 (41)Declines primarily driven by lower demand globally resulting from ongoing shifts in prescribing patterns related to label changes, as well as lower net price in the U.S. and the impact of regulatory exclusivity expiry in Canada.
Int’l.488 549 (11)(9)
Worldwide$1,168 $1,703 (31)(31)
Adcetris
$1,089

Up *

(operationally)
U.S.$1,059 $56 *Growth driven by the acquisition of Seagen in the fourth quarter of 2023.
Int’l.30 — **
Worldwide$1,089 $56 **

Pfizer Inc.
2024 Form 10-K
36


Revenue
(MILLIONS)Year Ended Dec. 31,% Change
ProductGlobal
Revenues
Region20242023TotalOper.Operational Results Commentary
Inlyta
$978

Down 5%

(operationally)
U.S.$588 $642 (8)
Declines primarily driven by lower demand in the U.S. as well as lower volumes and lower net price in international markets, partially offset by strong growth in China.
Int’l.391 394 (1)1 
Worldwide$978 $1,036 (6)(5)
Abrysvo
$755

Down 15%

(operationally)
U.S.$594 $888 (33)Decline primarily driven by a significant reduction in vaccination rates in the U.S. for the older adult indication, partially offset by strong demand for the maternal indication in the U.S. (launched in December 2023), and launch uptake for both indications in certain international markets.
Int’l.160 **
Worldwide$755 $890 (15)(15)
Pfizer CentreOne
Revenue
(MILLIONS)Year Ended Dec. 31,% Change
Operating SegmentGlobal
Revenues
Region20242023TotalOper.Operational Results Commentary
PC1
$1,146

Down 10%

(operationally)
U.S.$278 $352 (21)Declines primarily driven by lower manufacturing of divested and other third-party products under manufacturing and supply agreements, partially offset by growth in manufacturing-related services.
Int’l.868 920 (6)(5)
Worldwide$1,146 $1,272 (10)(10)
See the Item 1. BusinessPatents and Other Intellectual Property Rights section for information regarding the expiration of various patent rights, Note 16 for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above and Note 17C for the primary indications or class of the selected products discussed above.
Costs and Expenses
Costs and expenses follow:
Year Ended December 31,% Change
(MILLIONS)20242023202224/2323/22
Cost of sales
$17,851 $24,954 $34,344 (28)(27)
Percentage of Total revenues
28.1 %41.9 %33.9 %
Selling, informational and administrative expenses
14,730 14,771 13,677  
Research and development expenses
10,822 10,679 11,428 1 (7)
Acquired in-process research and development expenses
108 194 953 (44)(80)
Amortization of intangible assets
5,286 4,733 3,609 12 31 
Restructuring charges and certain acquisition-related
costs
2,419 2,943 1,375 (18)*
Other (income)/deductions—net
4,388 222 1,062 *(79)
2024 v. 2023
Cost of Sales
Cost of sales decreased $7.1 billion, primarily due to:
the non-recurrence of a non-cash charge of $6.2 billion in 2023 related to Paxlovid and Comirnaty recorded for inventory write-offs and related charges ($5.0 billion for Paxlovid and $1.2 billion for Comirnaty); and
a favorable change in sales mix of $2.6 billion, primarily driven by lower sales of Comirnaty,
partially offset by:
an impact of $1.9 billion from our Seagen acquisition, inclusive of the amortization of the fair value step-up of inventory.
The decrease in Cost of sales as a percentage of revenues reflects the non-recurrence of the aforementioned non-cash charge of $6.2 billion, as well as significantly lower sales of Comirnaty.
Certain of our vaccines, including Comirnaty, are subject to seasonality of demand, with a greater portion of revenues and related cost of sales anticipated in the fall and winter seasons. See also Overview of Our Performance, Operating Environment, Strategy and Outlook—The Global Economic Environment––COVID-19 section for information about our COVID-19 products.

Pfizer Inc.
2024 Form 10-K
37


Selling, Informational and Administrative Expenses
Selling, informational and administrative expenses decreased $41 million, mostly due to:
a decrease of $790 million due to lower promotional and marketing spend for various products, including Comirnaty and Paxlovid,
partially offset by:
higher compensation-related expenses of $630 million; and
an increase of $140 million for corporate enabling functions primarily driven by our acquisition of Seagen.
Research and Development Expenses
Research and development expenses increased $143 million, primarily due to:
a net increase in spending of $1.1 billion mainly to develop certain product candidates acquired from Seagen; and
an increase of $680 million in compensation-related expenses,
partially offset by:
lower spending of $1.6 billion as a result of our cost realignment program and on various product candidates, primarily ongoing vaccine programs.
Amortization of Intangible Assets
Amortization of intangible assets increased $553 million, primarily due to:
an increase of $570 million from our December 2023 acquisition of Seagen; and
an increase of $470 million related to assets reclassified in 2023 from IPR&D to developed technology rights and from indefinite-lived to finite-lived brands,
partially offset by:
a decrease of $570 million related to changes in asset lives and fully amortized assets.
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
Realigning our Cost Base Program––This program is expected to deliver total net cost savings of approximately $4.5 billion by the end of 2025, most of which was achieved by year-end 2024.
Manufacturing Optimization Program––We expect to begin to achieve initial savings from Phase 1 of this multi-phased program in the latter part of 2025 and continue to expect approximately $1.5 billion in savings from this first phase by the end of 2027.
Certain qualifying costs for these programs in all periods since inception were recorded and reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the Non-GAAP Financial Measure: Adjusted Income section within MD&A.
For a description of our programs, as well as the anticipated and actual costs, see Note 3A. The program savings discussed above may be rounded and represent approximations. In addition to these programs, we continuously monitor our operations for cost reduction and/or productivity opportunities in light of patent-based and regulatory exclusivity expiries as well as the expiration of collaborative arrangements for various products. Long-term improvement in gross margin will remain a key focus for the Company over the next few years.
Seagen acquisition–– In connection with our acquisition of Seagen, we are focusing our efforts on achieving an appropriate cost structure for the combined company. We expect to generate approximately $1 billion of annual cost synergies, to be achieved by 2026. The one-time costs to generate these synergies are expected to be approximately $1.7 billion, incurred primarily from 2023 through 2025.
Other (Income)/Deductions––Net
2024 v. 2023
The unfavorable period-over-period change of $4.2 billion was primarily driven by (i) higher net interest expense of $2.0 billion, (ii) an unfavorable impact of $760 million due to net periodic benefit costs associated with pension and postretirement plans in 2024 versus net periodic benefit credits in 2023, (iii) lower net gains on equity securities of $580 million, (iv) a charge of $420 million in 2024 related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program and (v) lower Haleon equity method income of $400 million, partially offset by (vi) gains of $945 million in 2024 on the partial sales of our investment in Haleon.
2023 v. 2022
The favorable period-over period change of $840 million was mainly driven by a favorable impact of $2.9 billion due to net gains on equity securities in 2023 versus net losses recognized on equity securities in 2022 and lower net interest expense of $400 million, partially offset by higher intangible asset impairment charges of $2.6 billion.
See Note 4.
Provision/(Benefit) for Taxes on Income
 Year Ended December 31,% Change
(MILLIONS)20242023202224/2323/22
Provision/(benefit) for taxes on income$(28)$(1,115)$3,328 (97)*
Effective tax rate on continuing operations
(0.4)%*9.6 %

For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, and cash paid for income taxes, net of refunds, see Note 5.

Pfizer Inc.
2024 Form 10-K
38


Changes in Tax Laws––Many countries outside the U.S. have enacted legislation for global minimum taxation resulting from the Organization for Economic Co-operation and Development’s (OECD) Base Erosion and Profit Shifting “Pillar 2” project. The EU has approved a directive requiring member states to incorporate the OECD provisions into their respective domestic laws, and countries outside the EU are also enacting the provisions into their domestic law. The provisions are generally effective for Pfizer in 2024, though significant details and guidance around the provisions are still pending. Income tax expense could be adversely affected as the legislation becomes effective in countries in which we do business, and such impact could be material to our results of operations. We continue to monitor pending OECD guidance and legislation enactment and implementation by individual countries.
PRODUCT DEVELOPMENTS
A comprehensive update of Pfizer’s development pipeline was published as of February 4, 2025 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.
This section provides information as of the date of this filing about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan.
The table below includes filing and approval milestones for products that have occurred in the last twelve months and generally do not include approvals that may have occurred prior to that time. The table includes filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).

Pfizer Inc.
2024 Form 10-K
39


Products
PRODUCTINDICATION OR PROPOSED INDICATIONAPPROVED/FILED^
U.S.EUJAPAN
Prevnar 20/Prevenar 20
(Vaccine)
Active immunization to prevent invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older.
Approved
June
2021
Approved
February
2022
Approved
August
2024
Active immunization to prevent invasive pneumococcal disease caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in Prevnar(a).
Approved
April
2023
Approved
March
2024
Approved
March
2024
TicoVac
(Vaccine)
Active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older
Approved
August
2021
Approved
March
2024
Nurtec ODT/Vydura
(rimegepant)
Acute treatment of migraine with or without aura in adults
Approved
February
2020
Approved
April
2022
Filed November 2024
Prevention of episodic migraine in adults
Approved
May
2021
Approved
April
2022
Filed November 2024
Abrysvo
(Vaccine)
Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older
Approved
May
2023
Approved
August
2023
Approved
March
2024
Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk of lower respiratory tract disease caused by RSV
Approved
October
2024
Filed
June
2024

Velsipity (etrasimod)Moderately to severely active ulcerative colitis in adults
Approved
October
2023
Approved
February
2024
Filed
June
2024
Braftovi (encorafenib) and Mektovi (binimetinib)(b)
BRAFV600E-mutant metastatic non-small cell lung cancer in adult patients
Approved
October
2023
Approved
August
2024
Braftovi (encorafenib),
Erbitux (cetuximab)(c) and mFOLFOX6
First-line BRAFV600E-mutant mCRC
Approved
December 2024
Elrexfio (elranatamab)
Triple-class relapsed/refractory multiple myeloma in adult patients
Approved
August
2023
Approved
December
2023
Approved
March
2024
Xtandi (enzalutamide)(d)
nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR)
Approved
November
2023
Approved
April
2024
Hympavzi
(marstacimab-hncq)
Hemophilia A and B without inhibitors
Approved
October
2024
Approved
November
2024
Approved
December
2024
Emblaveo
(aztreonam-avibactam)(e)
Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options
Approved February 2025
Approved
April
2024
Padcev
(enfortumab vedotin-ejfv)(f)
In combination with Keytruda®(g) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults
Approved
December
2023
Approved
August
2024
Approved
September
2024
Tivdak
(tisotumab vedotin-tftv)(h)
Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Approved
April
2024
Filed
February
2024
Filed
April
2024
Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted(i)
Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older
Approved
August
2024
Approved September 2024

Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adaptedActive immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older
Approved
July
2024
Approved
August
2024
Adcetris
(brentuximab vedotin)(j)
Relapsed/refractory diffuse large B-cell lymphoma
Approved
February
2025
Paxlovid (nirmatrelvir; ritonavir)
COVID-19 infection in high-risk children (6-11 years of age: >88 lbs.)
Filed February 2025
Filed January 2025
^    For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission.
(a)Listed indication applies to U.S. only. For the EU, approved indications are pneumococcal invasive disease pneumonia and otitis media. For Japan, approved indication is invasive pneumococcal disease.

Pfizer Inc.
2024 Form 10-K
40


(b)Pierre Fabre is the Marketing Authorization Holder for Braftovi (encorafenib) and Mektovi (binimetinib) in the EU. We have exclusive rights to Braftovi and Mektovi in the U.S., Canada and certain emerging markets, and Ono, Medison Pharma and Pierre Fabre have exclusive rights in all other markets.
(c)Erbitux® is a registered trademark of ImClone LLC. We have exclusive rights to Braftovi in the U.S., Canada, and certain emerging markets, and Ono. Medison Pharma and Pierre Fabre have exclusive rights in all other markets.
(d)Being jointly developed and commercialized with Astellas.
(e)Being developed in collaboration with AbbVie. AbbVie has the exclusive commercialization rights in the U.S. and Canada; Pfizer leads the joint development program and has commercialization rights in all other countries.
(f)Being jointly developed and commercialized with Astellas.
(g)Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
(h)Being developed in collaboration with Genmab A/S. The April 2024 approval date in the U.S. refers to the conversion of a prior accelerated approval to full approval.
(i)In September 2024, the EC approved the Pfizer/BioNTech Omicron KP.2-adapted monovalent COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. U.S. approval (August 2024) is for individuals 12 years of age and older, with EUA granted for individuals 6 months through 11 years of age.
(j)Being developed in collaboration with Takeda. Takeda has ex-U.S./Canada rights.
Pfizer submitted its intent to withdraw Penbraya from the EU market. The EC has confirmed the withdrawal of the Penbraya EU Marketing Authorisation Application with an effective date of February 20, 2025.
In February 2025, Pfizer decided to terminate development and commercialization of Beqvez (fidanacogene elaparvovec) and elected to terminate the license agreement between Pfizer and Spark Therapeutics, Inc. effective as of August 6, 2025.
In December 2024, Pfizer submitted a withdrawal of the Ngenla (somatrogon) filing for adult human growth hormone deficiency in the EU.
The following provides information about additional indications and new drug candidates in late-stage development:
PRODUCT/CANDIDATEPROPOSED DISEASE AREA
LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS
FOR IN-LINE AND IN-REGISTRATION PRODUCTS
Ibrance (palbociclib)(a)
ER+/HER2+ metastatic breast cancer
Talzenna (talazoparib)Combination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC
Litfulo (ritlecitinib)Vitiligo
Elrexfio (elranatamab)Multiple myeloma double-class exposed
Newly diagnosed multiple myeloma post-transplant maintenance
Newly diagnosed multiple myeloma transplant-ineligible
2nd line + relapsed refractory multiple myeloma
Eliquis (apixaban)(b)
Venous thromboembolism (pediatric)
Padcev (enfortumab vedotin)(c)
Cisplatin-ineligible/decline muscle-invasive bladder cancer
Cisplatin-eligible muscle-invasive bladder cancer
Tukysa (tucatinib)HER2+ adjuvant breast cancer
2nd line/3rd line HER2+ metastatic breast cancer
1st line HER2+ maintenance metastatic breast cancer
1st line HER2+ metastatic colorectal cancer 
Hympavzi
(marstacimab-hncq)
Hemophilia (pediatric)
Hemophilia (inhibitor cohort)
NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENTPF-06425090 (vaccine)
Immunization to prevent primary clostridioides difficile infection
sasanlimab (PF-06801591)Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer
VLA15 (PF-07307405) vaccine(d)
Immunization to prevent Lyme disease
vepdegestrant (PF-07850327)(e)
Breast cancer metastatic - 2nd line ER+/HER2-
inclacumab (PF-07940370)Sickle cell disease
Ibrance + vepdegestrant(e)
ER+/HER2- metastatic breast cancer
dazukibart (PF-06823859)Dermatomyositis, polymyositis
disitamab vedotin(f)
1st line HER2 (≥IHC1+) metastatic urothelial cancer
sigvotatug vedotin (PF-08046047)
2nd line+ metastatic non-small cell lung cancer
osivelotor (PF-07940367)Sickle cell disease
atirmociclib (PF-07220060)2nd line metastatic breast cancer
ibuzatrelvir (PF-07817883)
COVID-19 infection
mevrometostat (PF-06821497) + enzalutamide
1st line/2nd line metastatic castration resistant prostate cancer post-Abiraterone
mevrometostat (PF-06821497) + enzalutamide
1st line metastatic castration resistant prostate cancer neoadjuvant hormonal therapy naïve
atirmociclib (PF-07220060)
1st line metastatic breast cancer
(a)Ibrance for ER+/HER2+ metastatic breast cancer is being developed in collaboration with Alliance Foundation Trials, LLC.
(b)Eliquis is being developed in collaboration with BMS.
(c)Padcev is being jointly developed and commercialized with Astellas.
(d)VLA15 is being developed in collaboration with Valneva SE.
(e)Vepdegestrant is being developed in collaboration with Arvinas.
(f)Disitamab vedotin is being developed in collaboration with RemeGen Co., Ltd.

Pfizer Inc.
2024 Form 10-K
41


In December 2024, Pfizer decided to terminate development of giroctocogene fitelparvovec (PF-07055480) and elected to terminate the collaboration and license agreement between Pfizer and Sangamo Therapeutics, Inc. effective as of April 21, 2025.
In August 2024, Pfizer announced Phase 3 top-line results for Pfizer and BioNTech’s combination mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines. In November 2024, PF-07926307 (COVID-19/mRNA flu combo vaccine) reverted from Phase 3 to Phase 1 clinical trials and has been removed from the table above.
In September 2024, Pfizer announced that it was voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease in all markets where it is approved. Pfizer also discontinued all active voxelotor clinical trials and expanded access programs worldwide. Pfizer’s decision was based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggested an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing. Pfizer has notified regulatory authorities about these findings and its decision to voluntarily withdraw Oxbryta from the market and discontinue distribution and clinical studies while further reviewing the available data and investigating the findings. We are working with the FDA, EMA and other global regulatory authorities and expect the assessment to be completed in the first half of 2025.
In July 2024, the EMA initiated a referral procedure under Article 20 of Regulation (EC) No 726/2004 for Oxbryta (voxelotor) to review the product’s benefits and risks. In October 2024, the EC suspended the Oxbryta marketing authorization while the EMA’s review of data is ongoing. In addition, the FDA has initiated an evaluation of newly identified safety signals. The FDA also has placed the Oxbryta (voxelotor) investigational new drug application on clinical hold following Pfizer’s market withdrawal. Pfizer is working with the EMA, FDA, and other regulators globally in relation to this matter.
The FDA has recently issued a partial clinical hold for osivelotor, which prohibits Pfizer from enrolling new participants into osivelotor clinical studies at this time. Study participants currently enrolled can continue on the study drug. Communication with the FDA is ongoing.
In October 2024, Pfizer stopped two clinical trials with sisunatovir (PF-07923568) following observed drug-drug interactions. Since then Pfizer has decided to terminate development of sisunatovir.
For additional information about our R&D organization, see Note 17 and the Item 1. BusinessResearch and Development section. For additional information regarding certain collaboration arrangements, see Item 1. BusinessCollaboration and Co-Promotion Agreements.
NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME
Adjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP Reported performance measures. As such, we believe that investors’ understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations––the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide––prior to considering certain income statement elements as follows:
MeasureDefinitionRelevance of Metrics to Our Business Performance
Adjusted income
Net income attributable to Pfizer Inc. common shareholders(a)
before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items
Provides investors useful information to:
evaluate the normal recurring operational activities, and their components, on a comparable year-over-year basis
assist in modeling expected future performance on a normalized basis
Provides investors insight into the way we manage our budgeting and forecasting, how we evaluate and manage our recurring operations and how we reward and compensate our senior management(b)
Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses and Adjusted other (income)/deductions––net
Cost of sales, Selling, informational and administrative expenses, Research and development expenses and Other (income)/deductions––net (a), each before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure
Adjusted diluted EPS
EPS attributable to Pfizer Inc. common shareholders––diluted (a) before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items
(a)Most directly comparable GAAP measure.
(b)The short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part versus three budgeted metrics, one of which, for the 2024 performance year, was Adjusted diluted EPS (as defined for annual incentive compensation purposes), which is derived from Adjusted income and accounted for 40% of the bonus pool funding tied to financial performance. Additionally, for the 2024 performance year, the payout for performance share awards was determined in part by Adjusted net income, which is derived from Adjusted income. Since 2022, we no longer exclude any expenses for acquired IPR&D from our non-GAAP Adjusted results but we continue to exclude certain of these expenses for our financial results for annual incentive compensation purposes. The bonus pool funding is largely based on financial performance, as measured by three metrics, modified by performance against certain of our non-financial metrics, and may be further modified by our Compensation Committee’s assessment of other factors.

Pfizer Inc.
2024 Form 10-K
42


Adjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their most directly comparable GAAP measures of Net income attributable to Pfizer Inc. common shareholders, components of Net income attributable to Pfizer Inc. common shareholders and EPS attributable to Pfizer Inc. common shareholders—diluted, respectively.
We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.
Adjusted Income and Adjusted Diluted EPS
Amortization of Intangible Assets—Adjusted income excludes all amortization of intangible assets.
Acquisition-Related Items––Adjusted income excludes certain acquisition-related items, which are composed of transaction, integration, restructuring charges and additional depreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as a result of an acquisition. We have made no adjustments for resulting synergies.
The significant costs incurred in connection with a business combination result primarily from the need to eliminate duplicate assets, activities or employees––a natural result of acquiring a fully integrated set of activities. For this reason, we believe that such costs incurred can be viewed differently in the context of an acquisition from those costs incurred in other, more normal, business contexts. The integration and restructuring costs for a business combination may occur over several years, with the more significant impacts typically ending within three years of the relevant transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy.
Acquisition-related items may include purchase accounting impacts such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration.
Discontinued Operations––Adjusted income excludes the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our product portfolio for strategic fit with our operations, we do not build or run our business with the intent to discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.
Certain Significant Items––Adjusted income excludes certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and qualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs based on reorganizations of the business, cost productivity or in response to generic or biosimilar entry or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition, or legal matters related to divested products or businesses. Gains and losses on equity securities and pension and postretirement actuarial remeasurement gains and losses have a very high degree of inherent market volatility, which we do not control and cannot predict with any level of certainty, and we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. Unusual items represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. See the Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items below for a non-inclusive list of certain significant items.

Pfizer Inc.
2024 Form 10-K
43


Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items
Year Ended December 31, 2024
Data presented will not (in all cases) aggregate to totals.
MILLIONS, EXCEPT PER SHARE DATA
Cost of sales(a)
Selling, informational and administrative expenses(a)
Other (income)/deductions––net(a)
Net income attributable to Pfizer Inc. common shareholders(a), (b), (c)
Earnings per common share attributable to Pfizer Inc. common shareholders––diluted
GAAP Reported$17,851 $14,730 $4,388 $8,031 $1.41 
Amortization of intangible assets— — — 5,286 
Acquisition-related items(1,341)(10)(45)1,938 
Discontinued operations
— — — (14)
Certain significant items:
Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring(d)
(134)(90)— 2,213 
Certain asset impairments(e)
— — (3,295)3,295 
(Gains)/losses on equity securities(e)
— — 1,008 (1,008)
Actuarial valuation and other pension and postretirement plan (gains)/losses— — (579)579 
Other44 

(13)(445)
(f)
430 
Income tax provision—non-GAAP items
(3,035)
Non-GAAP Adjusted$16,420 $14,617 $1,031 $17,716 $3.11 
Year Ended December 31, 2023
Data presented will not (in all cases) aggregate to totals.
MILLIONS, EXCEPT PER SHARE DATA
Cost of sales(a)
Selling, informational and administrative expenses(a)
Other (income)/deductions––net(a)
Net income attributable to Pfizer Inc. common shareholders(a), (b), (c)
Earnings per common share attributable to Pfizer Inc. common shareholders––diluted
GAAP Reported$24,954 $14,771 $222 $2,119 $0.37 
Amortization of intangible assets— — — 4,733 
Acquisition-related items(629)(11)(28)1,874 
Discontinued operations
— — — (11)
Certain significant items:
Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring(d)
(98)(290)— 2,227 
Certain asset impairments(e)
— — (3,024)3,024 
(Gains)/losses on equity securities(e)
— — 1,588 (1,588)
Actuarial valuation and other pension and postretirement plan (gains)/losses— — 265 (265)
Other(238)
(g)
(24)(246)
(f)
518 
Income tax provision—non-GAAP items
(2,131)
Non-GAAP Adjusted$23,988 $14,446 $(1,224)$10,501 $1.84 

Pfizer Inc.
2024 Form 10-K
44


Year Ended December 31, 2022
Data presented will not (in all cases) aggregate to totals.
MILLIONS, EXCEPT PER SHARE DATA
Cost of sales(a)
Selling, informational and administrative expenses(a)
Other (income)/deductions––net(a)
Net income attributable to Pfizer Inc. common shareholders(a), (b), (c)
Earnings per common share attributable to Pfizer Inc. common shareholders––diluted
GAAP Reported$34,344 $13,677 $1,062 $31,372 $5.47 
Amortization of intangible assets— — — 3,609 
Acquisition-related items(119)(7)(74)832 
Discontinued operations
— — — (21)
Certain significant items:
Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring(d)
(88)(562)— 1,396 
Certain asset impairments(e)
— — (421)421 
(Gains)/losses on equity securities(e)
— — (1,270)1,270 
Actuarial valuation and other pension and postretirement plan (gains)/losses— — 230 (230)
Other(40)(59)(636)
(f)
752 
Income tax provision—non-GAAP items
(1,683)
Non-GAAP Adjusted$34,096 $13,049 $(1,109)$37,717 $6.58 
(a)Items that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax. Our effective tax rates for GAAP Reported income from continuing operations were: (0.4)% in 2024, (105.4)% in 2023 and 9.6% in 2022. See Note 5. Our effective tax rates for non-GAAP Adjusted income were: 14.5% in 2024, 9.0% in 2023 and 11.7% in 2022.
(b)Includes reconciling amounts for Research and development expenses that are not material to our non-GAAP consolidated results of operations.
(c)For 2024, the total acquisition-related items of $1.9 billion include reconciling amounts for Restructuring charges and certain acquisition-related costs of $514 million, mainly composed of $427 million of integration costs and other charges. For 2023, the total acquisition-related items of $1.9 billion included reconciling amounts for Restructuring charges and certain acquisition-related costs of $1.2 billion, mainly composed of $785 million of integration costs and other charges, $190 million of transaction costs and $125 million of employee termination-related charges. For 2022, the total acquisition-related items of $832 million included reconciling amounts for Restructuring charges and certain acquisition-related costs of $631 million, composed of $348 million of integration costs and other charges, $144 million of transaction costs and $138 million of employee termination-related charges. See Note 3.
(d)Includes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions. See Note 3.
(e)See Note 4.
(f)For 2024, the total adjustment of $445 million includes (i) net gains of $825 million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945 million less (b) $120 million recognized in our adjusted income in the fourth quarter representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares, (ii) charges of $567 million for certain legal matters, primarily representing certain product liability expenses related to products discontinued and/or divested by Pfizer, (iii) a charge of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program and (iv) charges of $312 million mostly related to (a) our equity-method accounting pro-rata share of intangible asset amortization, impairments and restructuring costs recorded by Haleon, as well as (b) adjustments to our equity-method basis differences and (c) Pfizer's share of investee capital transactions recognized by Haleon. For 2023, the total adjustments of $246 million included charges of (i) $474 million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition matters and (ii) $127 million mostly related to our equity-method accounting pro-rata share of intangible asset amortization and impairments, costs of separating from GSK and restructuring costs recorded by Haleon, partially offset by: (i) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion and (ii) dividend income of $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary. For 2022, the total adjustments of $636 million included charges of (i) $307 million mostly representing our equity-method accounting pro rata share of restructuring charges and costs of separating from GSK recorded by Haleon/the Consumer Healthcare JV and adjustments to our equity-method basis differences which are also related to the separation of Haleon/the Consumer Healthcare JV from GSK and (ii) $230 million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(g)For 2023, the total adjustment of $238 million mainly includes $286 million in inventory losses, overhead costs related to the period in which the facility could not operate, and incremental costs resulting from tornado damage to our manufacturing facility in Rocky Mount, NC, partially offset by insurance recoveries.

Pfizer Inc.
2024 Form 10-K
45


ANALYSIS OF THE CONSOLIDATED STATEMENTS OF CASH FLOWS
 Year Ended December 31,
(MILLIONS)202420232022
Drivers of change 2024 v. 2023
Cash provided by/(used in):
Operating activities
$12,744 $8,700 $29,267 
The change was driven primarily by an increase in net income adjusted for non-cash items partially offset by the timing of receipts and payments in the ordinary course of business, including a decrease in advance payments for Comirnaty and Paxlovid and net changes in inventory greater than one year (see Note 8A).
Investing activities
$2,652 $(32,278)$(15,783)
The change was driven mainly by $43.4 billion cash paid in 2023 for the acquisition of Seagen, net of cash acquired (see Note 2A) and $7.0 billion of proceeds from the partial sales of our investment in Haleon in 2024, partially offset by $16.3 billion greater net purchases of short-term investments in 2024.
Financing activities
$(17,140)$26,066 $(14,834)
The change was driven mostly by $30.8 billion of proceeds from the issuance of long-term debt in May of 2023 for the acquisition of Seagen and $12.6 billion greater net repayments of short-term borrowings in 2024.
ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK
Our historically robust operating cash flows, which we expect to continue over time, is a key strength of our liquidity and capital resources and our primary funding source. We continue to believe that with our ongoing operating cash flows, together with our financial assets, access to capital markets, revolving credit agreement, and available lines of credit, we have and will maintain the ability to meet our liquidity needs to support ongoing operations, our capital allocation objectives, and our contractual and other obligations for the foreseeable future.
We focus efforts to optimize operating cash flows through achieving working capital efficiencies that target accounts receivable, inventories, accounts payable, and other working capital. Excess cash from operating cash flows is invested in money market funds and available-for-sale debt securities which consist of primarily high-quality, highly liquid, well-diversified debt securities. We have taken, and will continue to take, a conservative approach to our financial investments and monitoring of our liquidity position in response to market changes. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings.
Additionally, we may obtain funding through short-term or long-term sources from our access to the capital markets, banking relationships and relationships with other financial intermediaries to meet our liquidity needs.
Diverse sources of funds:Related disclosure presented in this Form 10-K
Internal sources:
Operating cash flows
Cash and cash equivalents
Money market funds
Available-for-sale debt securities
Equity investments
External sources:
Short-term funding:
Commercial paper
Revolving credit facilities
Lines of credit
Long-term funding:
Long-term debt
Equity
For additional information about the sources and uses of our funds and capital resources, see the Analysis of the Consolidated Statements of Cash Flows section within MD&A.
Credit Ratings––The cost and availability of financing are influenced by credit ratings, and an increase or decrease in our credit rating could have a beneficial or adverse effect on financing. Our long-term debt is rated high-quality by both S&P and Moody’s.
As of the date of the filing of this Form 10-K, the following ratings have been assigned to our commercial paper and senior unsecured long-term debt:
NAME OF RATING AGENCYPfizer Short-Term RatingPfizer Long-Term RatingOutlook/Watch
Moody’sP-1
A2
Stable Outlook
S&P
A-1
A
Stable Outlook
These ratings are not a recommendation to buy, sell or hold securities and the ratings are subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.

Pfizer Inc.
2024 Form 10-K
46


Capital Allocation Framework––Our capital allocation framework is primarily devised to enhance shareholder value and is based on three core pillars: maintaining and growing our dividend over time, reinvesting in the business and making share repurchases after de-levering our balance sheet. See the Overview of Our Performance, Operating Environment, Strategy and OutlookOur Business and Strategy section within MD&A.
Dividends—Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our business. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer’s BOD and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events. On December 12, 2024, our BOD declared a first-quarter dividend of $0.43 per share, payable on March 7, 2025, to shareholders of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be our 345th consecutive quarterly dividend.
Common Stock Purchases—As of December 31, 2024, our remaining share-purchase authorization was $3.3 billion with no repurchases in 2024. See Note 12.
Haleon—After our sales of a portion of our Haleon shares in March and October 2024, we owned approximately 15% of the outstanding voting shares of Haleon as of December 31, 2024. See Note 2C. With the reduction in our Haleon ownership percentage and board representation after the October 2024 sale, we discontinued the application of the equity method to our Haleon investment, and in the fourth quarter of 2024 began to account for the investment as an equity security with a readily determinable fair value, which is carried at fair value, with changes in fair value reported in Other (income)/deductions––net. In the first quarter of 2025, we sold an additional portion of our investment in Haleon for $3.0 billion further reducing our ownership interest to approximately 7%. Pfizer intends to use the proceeds to support its capital allocation priorities. We intend to monetize our remaining Haleon investment in a prudent fashion during 2025.
Off-Balance Sheet Arrangements, Contractual, and Other Obligations––In the ordinary course of business, (i) we enter into off-balance sheet arrangements that may result in contractual and other obligations and (ii) in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities. For more information on guarantees and indemnifications, see Note 16B.
Additionally, certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products. Furthermore, collaboration, licensing or other R&D arrangements may give rise to potential milestone payments. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization milestones, which may span several years and which may never occur.
Our significant contractual and other obligations as of December 31, 2024 consisted of:
Long-term debt, including current portion (see Note 7D) and related interest payments;
Estimated cash payments related to the TCJA repatriation estimated tax liability (see Note 5). Estimated future payments related to the TCJA repatriation tax liability that will occur after December 31, 2024 total $4.7 billion, of which an estimated $2.1 billion is to be paid in the next twelve months and an estimated $2.6 billion is to be paid in periods thereafter. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards;
Certain commitments totaling $4.1 billion, of which an estimated $1.0 billion is to be paid in the next twelve months, and $3.1 billion in periods thereafter (see Note 16C);
Purchases of PP&E (see Note 9). In 2025, we expect to spend approximately $2.8 billion on PP&E; and
Future minimum rental commitments under non-cancelable operating leases (see Note 15).
Global Economic Conditions––We have operations in countries that have hyperinflationary economies. The impact to Pfizer is not considered material. See the Item 1A. Risk Factors––Global Operations section.
Market Risk––We are subject to foreign exchange risk, interest rate risk, and equity price risk. The objective of our financial risk management program is to minimize the impact of foreign exchange rate and interest rate movements on our earnings. We address such exposures through a combination of operational means and financial instruments. For more information on how we manage our foreign exchange and interest rate risks, see Notes 1F and 7E, as well as the Item 1A. Risk Factors—Global Operations section for key currencies in which we operate. Our sensitivity analyses of such risks are discussed below.
Foreign Exchange Risk—The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to foreign exchange rate changes. In this analysis, holding all other assumptions constant and assuming that a change in one currency’s rate relative to the U.S. dollar would not have any effect on another currency’s rates relative to the U.S. dollar, if the dollar were to move against all other currencies by 10%, as of December 31, 2024, the expected impact on our net income would not be significant.
Interest Rate Risk—The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to interest rate changes. In this analysis, holding all other assumptions constant and assuming a parallel shift in the interest rate curve for all maturities and for all instruments, if there were a one hundred basis point change in interest rates as of December 31, 2024, the expected impact on our net income would not be significant.
Equity Price Risk––We hold long-term investments in equity securities with readily determinable fair values in life science companies as a result of certain business development transactions. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. From time to time, we will sell such equity securities based on our business considerations, which may include limiting our price risk. Our equity securities with readily determinable fair values are analyzed at year-end to determine their sensitivity to equity price rate changes. In this sensitivity analysis, the expected impact on our net income would not be significant.

Pfizer Inc.
2024 Form 10-K
47


NEW ACCOUNTING STANDARDS
Recently Adopted Accounting Standards
See Note 1B.
Recently Issued Accounting Standards, Not Adopted as of December 31, 2024
Standard/DescriptionEffective DateEffect on the Financial Statements
In December 2023, the FASB issued final guidance to improve income tax disclosures. The final guidance requires enhanced disclosures primarily related to existing rate reconciliation and income taxes paid information.
2025 for annual reports. Early adoption is permitted.
This new guidance will result in increased disclosures in the notes to our financial statements.
In November 2024, the FASB issued final guidance which requires disaggregated disclosures of certain categories of expenses that are included in expense line items on the face of the income statement. The disclosures are required on an annual and interim basis. The guidance also requires the total amount of selling expenses to be disclosed and, on an annual basis, the definition of selling expenses.
2027 for annual reports and 2028 for interim reports. Early adoption is permitted.
This new guidance will result in increased disclosures in the notes to our financial statements.
ITEM 7A.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The information required by this Item is incorporated by reference to the discussion in the Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk section within MD&A.

Pfizer Inc.
2024 Form 10-K
48


ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders
Pfizer Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Pfizer Inc. and Subsidiary Companies (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 27, 2025 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Evaluation of the U.S. Medicare, Medicaid, and performance-based contract rebates accrual
As discussed in Note 1G to the consolidated financial statements, the Company records estimated deductions for Medicare, Medicaid, and performance-based contract rebates (collectively, U.S. rebates) as a reduction to gross product revenues. The accrual for U.S. rebates is recorded in the same period that the corresponding revenues are recognized. The length of time between when a sale is made and when the U.S. rebate is paid by the Company can be as long as one year, which increases the need for significant management judgment and knowledge of market conditions and practices in estimating the accrual.
We identified the evaluation of the U.S. rebates accrual as a critical audit matter because the evaluation of the product-specific experience ratio assumption involved especially challenging auditor judgment. The product-specific experience ratio assumption relates to estimating which of the Company’s revenue transactions will ultimately be subject to a related rebate.
The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company’s U.S. rebates accrual process related to the development of the product-specific experience ratio assumptions. We estimated the U.S. rebates accrual using internal information and historical data and compared the result to the Company’s estimated U.S. rebates accrual. We evaluated the Company’s ability to accurately estimate the accrual for U.S. rebates by comparing historically recorded accruals to the actual amount that was ultimately paid by the Company.
Evaluation of gross unrecognized tax benefits
As discussed in Notes 5D and 1Q, the Company’s tax positions are subject to audit by local taxing authorities in each respective tax jurisdiction, and the resolution of such audits may span multiple years. Since tax law is complex and often subject to varied interpretations and judgments, it is uncertain whether some of the Company’s tax positions will be sustained upon audit. As of December 31, 2024, the Company has recorded gross unrecognized tax benefits, excluding associated interest, of $4.5 billion.
We identified the evaluation of certain of the Company’s gross unrecognized tax benefits as a critical audit matter because a high degree of audit effort, including specialized skills and knowledge, and complex auditor judgment was required in evaluating the Company’s interpretation of tax law and its estimate of the ultimate resolution of its tax positions.
The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of an internal control over the Company’s liability for unrecognized tax position process related to (1) interpretation of tax law, (2) evaluation of which of the Company’s tax positions may not be sustained upon audit, and (3) estimation and recording of the gross

Pfizer Inc.
2024 Form 10-K
49


Report of Independent Registered Public Accounting Firm
unrecognized tax benefits. We involved tax and valuation professionals with specialized skills and knowledge who assisted in evaluating the Company’s interpretation of tax laws, including the assessment of transfer pricing practices in accordance with applicable tax laws and regulations. We inspected settlements with applicable taxing authorities, including assessing the expiration of statutes of limitations. We tested the calculation of the liability for uncertain tax positions, including an evaluation of the Company’s assessment of the technical merits of tax positions and estimates of the amount of tax benefits expected to be sustained.
Evaluation of product liability and other product-related litigation
As discussed in Notes 1S and 16 to the consolidated financial statements, the Company is involved in product liability and other product-related litigation, which can include personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims, among others. Certain of these pending product and other product-related legal proceedings could result in losses that could be substantial. The accrued liability and/or disclosure for the pending product liability and other product-related legal proceedings requires a complex series of judgments by the Company about future events, which involves a number of uncertainties.
We identified the evaluation of product liability and other product-related litigation as a critical audit matter. Challenging auditor judgment was required to evaluate the Company’s judgments about future events and uncertainties.
The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company’s product liability and other product-related litigation processes, including controls related to (1) the evaluation of information from external and internal legal counsel, (2) forward-looking expectations, and (3) new legal proceedings, or other legal proceedings not currently reserved or disclosed. We read letters received directly from the Company’s external and internal legal counsel that described the Company’s probable or reasonably possible legal contingency to pending product liability and other product-related legal proceedings. We inspected the Company’s minutes from meetings of the Audit Committee, which included the status of key litigation matters. We evaluated the Company’s ability to estimate its monetary exposure to pending product and other product-related legal proceedings by comparing historically recorded liabilities to actual monetary amounts incurred upon resolution of prior legal matters. We analyzed relevant publicly available information about the Company, its competitors, and the industry.
Evaluation of the fair value measurement of the developed technology rights and in-process research and development intangible assets acquired in the Seagen business combination
As discussed in Note 2A to the consolidated financial statements, on December 14, 2023, the Company acquired Seagen Inc. and its subsidiaries (Seagen). The total fair value of consideration transferred was $44.2 billion. Of that, the Company recorded $7.5 billion of developed technology rights with an estimated weighted-average life of approximately 18 years and $19.9 billion of in-process research and development (IPR&D). The preliminary estimates of the fair value of intangible assets were finalized during the measurement period in 2024. As discussed in Note 1M, the Company performs impairment testing for indefinite-lived intangible assets at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
We identified the evaluation of the fair value measurement of Seagen acquired developed technology rights and IPR&D as a critical audit matter. A high degree of subjective auditor judgment was required to evaluate certain key assumptions used to estimate the acquisition-date fair value of the acquired developed technology rights and IPR&D, as well as the fair value for impairment testing purposes. Specifically, the key assumptions for certain IPR&D assets, including revenue growth rates, probability of technical and regulatory success (PTRS) rates, and the discount rate, and the key assumptions for certain developed technology rights, including revenue growth rates and the discount rate, represented subjective determinations of future market and economic conditions. Changes to those assumptions could have had a significant effect on the determination of the fair value measurements.
The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s valuation process, including controls related to the development of the key assumptions for certain IPR&D assets and developed technology rights. We performed sensitivity analyses over the key assumptions for certain IPR&D assets and developed technology rights to assess the impact of changes in those key assumptions on the Company’s determination of the fair value of the IPR&D and developed technology rights, respectively. We evaluated the reasonableness of the Company’s forecasted revenue growth rates by comparing them to historical results, comparable products and peer companies, analyst expectations, industry related third-party data, and the assumptions used in prior periods. Further, we evaluated the PTRS rates for certain IPR&D assets by considering the phase of development of the clinical projects and the Company's history of obtaining regulatory approval and comparing them to PTRS rates derived from analyst reports and other industry related third-party data and the assumptions used in prior periods. We evaluated the data sources used by management in determining the key assumptions for certain IPR&D assets and developed technology rights by comparing to industry standards and evidence obtained in other areas of the audit. In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:
(1) evaluating the discount rates used by the Company for certain IPR&D and developed technology rights by comparing them against discount rate ranges that were independently developed using publicly available market data for comparable entities
(2) testing the source information underlying the determination of the discount rates.
 kpmgsignatureq42019a01-keep.jpg
We have not been able to determine the specific year that we or our predecessor firms began serving as the Company’s auditor, however, we are aware that we or our predecessor firms have served as the Company’s auditor since at least 1942.
New York, New York
February 27, 2025

Pfizer Inc.
2024 Form 10-K
50


Consolidated Statements of Operations
Pfizer Inc. and Subsidiary Companies

 Year Ended December 31,
(MILLIONS, EXCEPT PER SHARE DATA)202420232022
Revenues:
Product revenues
$53,816 $50,914 $91,793 
Alliance revenues
8,388 7,582 8,537 
Royalty revenues(a)
1,423 1,058 845 
Total revenues
63,627 59,553 101,175 
Costs and expenses:  
Cost of sales(b), (c)
17,851 24,954 34,344 
Selling, informational and administrative expenses(b)
14,730 14,771 13,677 
Research and development expenses(b)
10,822 10,679 11,428 
Acquired in-process research and development expenses
108 194 953 
Amortization of intangible assets5,286 4,733 3,609 
Restructuring charges and certain acquisition-related costs
2,419 2,943 1,375 
Other (income)/deductions––net4,388 222 1,062 
Income from continuing operations before provision/(benefit) for taxes on income8,023 1,058 34,729 
Provision/(benefit) for taxes on income(28)(1,115)3,328 
Income from continuing operations8,051 2,172 31,401 
Discontinued operations––net of tax11 (15)6 
Net income before allocation to noncontrolling interests8,062 2,158 31,407 
Less: Net income attributable to noncontrolling interests31 39 35 
Net income attributable to Pfizer Inc. common shareholders$8,031 $2,119 $31,372 
Earnings per common share––basic:
   
Income from continuing operations attributable to Pfizer Inc. common shareholders$1.42 $0.38 $5.59 
Discontinued operations––net of tax   
Net income attributable to Pfizer Inc. common shareholders$1.42 $0.38 $5.59 
Earnings per common share––diluted:
  
Income from continuing operations attributable to Pfizer Inc. common shareholders$1.41 $0.37 $5.47 
Discontinued operations––net of tax   
Net income attributable to Pfizer Inc. common shareholders$1.41 $0.37 $5.47 
Weighted-average shares––basic5,664 5,643 5,608 
Weighted-average shares––diluted5,700 5,709 5,733 
(a)See Note 1A.
(b)Exclusive of amortization of intangible assets.
(c)See Note 17A.
See Accompanying Notes.

Pfizer Inc.
2024 Form 10-K
51


Consolidated Statements of Comprehensive Income
Pfizer Inc. and Subsidiary Companies

Year Ended December 31,
(MILLIONS)202420232022
Net income before allocation to noncontrolling interests$8,062 $2,158 $31,407 
Foreign currency translation adjustments, net32 452 (2,328)
Unrealized holding gains/(losses) on derivative financial instruments, net499 626 1,444 
Reclassification adjustments for (gains)/losses included in net income(a)
(159)(413)(2,062)
 341 213 (618)
Unrealized holding gains/(losses) on available-for-sale securities, net(152)(121)(1,306)
Reclassification adjustments for (gains)/losses included in net income(b)
42 (141)1,809 
(111)(261)502 
Benefit plans: prior service (costs)/credits and other, net193 (25)(24)
Reclassification adjustments related to amortization of prior service costs and other, net(109)(117)(129)
Reclassification adjustments related to curtailments of prior service costs and other, net (15)(12)
 84 (157)(166)
Other comprehensive income/(loss), before tax347 246 (2,609)
Tax provision/(benefit) on other comprehensive income/(loss)231 (85)(187)
Other comprehensive income/(loss) before allocation to noncontrolling interests$116 $331 $(2,422)
   
Comprehensive income/(loss) before allocation to noncontrolling interests$8,178 $2,488 $28,985 
Less: Comprehensive income/(loss) attributable to noncontrolling interests28 26 20 
Comprehensive income/(loss) attributable to Pfizer Inc.$8,149 $2,462 $28,965 
(a)Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions—net.
See Accompanying Notes.

Pfizer Inc.
2024 Form 10-K
52


Consolidated Balance Sheets
Pfizer Inc. and Subsidiary Companies

As of December 31,
(MILLIONS, EXCEPT PER SHARE DATA)20242023
Assets
Cash and cash equivalents$1,043 $2,853 
Short-term investments19,434 9,837 
Trade accounts receivable, net of allowance for doubtful accounts: 2024—$438; 2023—$470
11,463 11,566 
Inventories10,851 10,189 
Current tax assets3,314 3,978 
Other current assets4,253 4,911 
Total current assets50,358 43,333 
Equity-method investments217 11,637 
Long-term investments2,010 3,731 
Property, plant and equipment, net
18,393 18,940 
Identifiable intangible assets, net
55,411 64,900 
Goodwill68,527 67,783 
Noncurrent deferred tax assets and other noncurrent tax assets8,662 3,706 
Other noncurrent assets9,817 12,471 
Total assets$213,396 $226,501 
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2024—$3,747; 2023—$2,254
$6,946 $10,350 
Trade accounts payable5,633 6,710 
Dividends payable2,437 2,372 
Income taxes payable2,910 2,349 
Accrued compensation and related items3,838 2,776 
Deferred revenues1,511 2,700 
Other current liabilities19,720 20,537 
Total current liabilities42,995 47,794 
Long-term debt57,405 61,538 
Pension and postretirement benefit obligations2,115 2,167 
Noncurrent deferred tax liabilities2,122 640 
Other taxes payable6,112 8,534 
Other noncurrent liabilities14,150 16,539 
Total liabilities124,899 137,213 
Commitments and Contingencies
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2024—9,593; 2023—9,562
480 478 
Additional paid-in capital93,603 92,631 
Treasury stock, shares at cost: 2024—3,926; 2023—3,916
(114,763)(114,487)
Retained earnings116,725 118,353 
Accumulated other comprehensive loss(7,842)(7,961)
Total Pfizer Inc. shareholders’ equity88,203 89,014 
Equity attributable to noncontrolling interests294 274 
Total equity88,497 89,288 
Total liabilities and equity$213,396 $226,501 
See Accompanying Notes.

Pfizer Inc.
2024 Form 10-K
53


Consolidated Statements of Equity
Pfizer Inc. and Subsidiary Companies

 PFIZER INC. SHAREHOLDERS 
Common Stock Treasury Stock   
(MILLIONS, EXCEPT PER SHARE DATA)
SharesPar ValueAdd’l
Paid-In
Capital
SharesCostRetained EarningsAccum.
Other
Comp. Loss
Share -
holders’
Equity
Non-controlling InterestsTotal
Equity
Balance, January 1, 2022
9,471 $473 $90,591 (3,851)$(111,361)$103,394 $(5,897)$77,201 $262 $77,462 
Net income31,372 31,372 35 31,407 
Other comprehensive income/(loss), net of tax
(2,407)(2,407)(15)(2,422)
Cash dividends declared, per share: $1.61
Common stock
(9,037)(9,037)(9,037)
Noncontrolling interests— (13)(13)
Share-based payment transactions48 2 1,192 (13)(608)(73)513 513 
Purchases of common stock
(39)(2,000)(2,000)(2,000)
Other— — 19 —   19 (13)6 
Balance, December 31, 2022
9,519 476 91,802 (3,903)(113,969)125,656 (8,304)95,661 256 95,916 
Net income2,119 2,119 39 2,158 
Other comprehensive income/(loss), net of tax
343 343 (12)331 
Cash dividends declared, per share: $1.65
Common stock
(9,316)(9,316)(9,316)
Noncontrolling interests
— (8)(8)
Share-based payment transactions
43 2 829 (12)(518)(106)208 208 
Other— —  — —     
Balance, December 31, 2023
9,562 478 92,631 (3,916)(114,487)118,353 (7,961)89,014 274 89,288 
Net income8,031 8,031 31 8,062 
Other comprehensive income/(loss), net of tax
118 118 (3)116 
Cash dividends declared, per share: $1.69
Common stock
(9,577)(9,577)(9,577)
Noncontrolling interests
 (7)(7)
Share-based payment transactions
31 2 972 (10)(276)(107)591 591 
Other   25 25 (1)23 
Balance, December 31, 2024
9,593 $480 $93,603 (3,926)$(114,763)$116,725 $(7,842)$88,203 $294 $88,497 

See Accompanying Notes.

Pfizer Inc.
2024 Form 10-K
54


Consolidated Statements of Cash Flows
Pfizer Inc. and Subsidiary Companies


 Year Ended December 31,
(MILLIONS)202420232022
Operating Activities  
Net income before allocation to noncontrolling interests$8,062 $2,158 $31,407 
Discontinued operations—net of tax11 (15)6 
Net income from continuing operations before allocation to noncontrolling interests8,051 2,172 31,401 
Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
  
Depreciation and amortization7,013 6,290 5,064 
Asset write-offs and impairments4,242 3,408 550 
Deferred taxes(2,102)(3,442)(3,764)
Share-based compensation expense877 525 872 
Benefit plan contributions in excess of expense/income(12)(787)(1,158)
Inventory write-offs and related charges associated with COVID-19 products(a)
 6,199 1,183 
Other adjustments, net(2,260)(3,492)758 
Other changes in assets and liabilities, net of acquisitions and divestitures:
Trade accounts receivable(109)347 261 
Inventories(a)
(854)(1,169)(591)
Other assets
3,380 (663)(4,506)
Trade accounts payable(1,023)(300)1,191 
Other liabilities(b)
(3,115)595 (1,449)
Other tax accounts, net(1,345)(982)(545)
Net cash provided by/(used in) operating activities
12,744 8,700 29,267 
Investing Activities  
Purchases of property, plant and equipment(2,909)(3,907)(3,236)
Purchases of short-term investments(10,133)(30,974)(36,384)
Proceeds from redemptions/sales of short-term investments4,128 39,264 44,821 
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less3,136 5,174 (483)
Purchases of long-term investments(180)(204)(1,913)
Proceeds from redemptions/sales of long-term investments1,570 1,979 641 
Proceeds from partial sales of investment in Haleon(c)
7,040   
Acquisitions of businesses, net of cash acquired (43,430)(22,997)
Dividend received from the Consumer Healthcare JV(c)
  3,960 
Other investing activities, net2 (179)(192)
Net cash provided by/(used in) investing activities
2,652 (32,278)(15,783)
Financing Activities  
Proceeds from short-term borrowings8,907 4,525 3,891 
Payments on short-term borrowings(11,226)(3)(3,887)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less(2,590)3,161 (222)
Proceeds from issuance of long-term debt
 30,831  
Payments on long-term debt(2,250)(2,569)(3,298)
Purchases of common stock  (2,000)
Cash dividends paid(9,512)(9,247)(8,983)
Other financing activities, net
(469)(631)(335)
Net cash provided by/(used in) financing activities(17,140)26,066 (14,834)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(66)(40)(165)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents
(1,810)2,448 (1,515)
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period2,917 468 1,983 
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,107 $2,917 $468 
- Continued -

Pfizer Inc.
2024 Form 10-K
55


Consolidated Statements of Cash Flows
Pfizer Inc. and Subsidiary Companies

Year Ended December 31,
202420232022
Supplemental Cash Flow Information  
Cash paid/(received) during the period for:
Income taxes$3,605 $3,147 $7,867 
Interest paid3,227 2,215 1,442 
Interest rate hedges178 134 54 
Non-cash transaction:
Right-of-use assets obtained in exchange for lease liabilities$283 $614 $752 
(a)See Note 17A.
(b)See Note 17C.
(c)See Note 2C.
See Accompanying Notes.

Pfizer Inc.
2024 Form 10-K
56


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP. The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. All significant transactions among our subsidiaries have been eliminated.
We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See Note 17A.
On December 14, 2023, we completed the acquisition of Seagen. In addition, other acquisitions and business development activities completed in 2024, 2023 and 2022 impacted financial results in the periods presented. See Note 2.
We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:
in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from Other (income)/deductions––net and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of operations, and reclassified the associated royalty receivables from Other current assets to Trade accounts receivable, less allowance for doubtful accounts in our consolidated balance sheet; and
segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see Notes 9 and 17).
Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
B. New Accounting Standards Adopted in 2024
On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.
In the fourth quarter of 2024, we adopted a new accounting standard which requires the disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, other segment items by reportable segment and a description of its composition. See Note 17A.
C. Estimates and Assumptions
In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of operations, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of operations. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation, development of competing assets by us or others, regulatory actions, or product recalls or withdrawals. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.
D. Acquisitions
Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed in Acquired in-process research and development expenses.
Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See Note 16D. Any liability

Pfizer Inc.
2024 Form 10-K
57


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net.
E. Fair Value
We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.
When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:
Income approach, which is based on the present value of a future stream of net cash flows.
Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:
Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves.
Equity securities with readily determinable fair values—quoted market prices and observable NAV prices.
Derivative assets and liabilities—third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.
Money market funds—observable NAV prices.
We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.
F. Foreign Currency Translation
For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss). The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.
G. Revenues and Trade Accounts Receivable
Revenue Recognition––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors’ locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In bill-and-hold arrangements which are part of the U.S. SNS, we recognize revenue for the product sale when the product is initially placed into the U.S. SNS and we provide a rotation service to maintain an agreed upon level of shelf life for product in the stockpile. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.
Our Sales Contracts––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns may occur due to patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment.
Deductions from Revenues––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and

Pfizer Inc.
2024 Form 10-K
58


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these product revenue deductions on gross sales for a reporting period.
Provisions for pharmaceutical sales returns––Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.
We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.
The following outlines our common sales arrangements:
Customers––Our prescription biopharmaceutical products, with the exception of Paxlovid in 2022 and 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In 2022 and 2023, we principally sold Paxlovid globally to government agencies. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain products in our portfolio are subject to seasonality of demand and Paxlovid revenues trend with infection rates. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs in the U.S; and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented).
Specifically:
In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales in prior periods to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” and as of December 31, 2024 in the initial coverage and catastrophic phases under the Manufacturer Discount Program based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap or from the manufacturer’s discount, respectively. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.
Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.
Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.
We recorded revenues of more than $1 billion for each of 11 products in 2024, for each of nine products in 2023 and for each of ten products in 2022, and these revenues represented 66%, 64% and 82% of our Total revenues in 2024, 2023 and 2022, respectively. See Note 17C. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.
Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
  As of December 31,
(MILLIONS)20242023
Reserve against Trade accounts receivable, less allowance for doubtful accounts
$1,627 $1,770 
Other current liabilities:
Accrued rebates7,195 5,546 
Other accruals972 902 
Other noncurrent liabilities
1,029 796 
Total accrued rebates and other sales-related accruals$10,822 $9,014 
Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Product revenues.
Trade Accounts Receivable—Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.

Pfizer Inc.
2024 Form 10-K
59


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
During 2024 and 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.
H. Collaborative Arrangements
Payments to and from our collaboration partners are presented in our consolidated statements of operations based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-commercialization agreements, we record the amounts received for our share of gross profits from our collaboration partners as Alliance revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as Cost of sales. Royalty payments received from collaboration partners are included in Royalty revenues.
Reimbursements to or from our collaboration partners for development costs are typically recorded in Research and development expenses. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as Acquired in-process research and development expenses. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in Identifiable intangible assets—developed technology rights. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in Other (income)/deductions—net over the development period for the products, when our performance obligations include providing R&D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in Other (income)/deductions—net immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.
I. Cost of Sales and Inventories
Inventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary. Inventories that are not expected to be sold within 12 months are classified as Other noncurrent assets. See Note 8A.
J. Selling, Informational and Administrative Expenses
Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, digital and legal defense. Advertising expenses totaled approximately $3.3 billion in 2024, $3.7 billion in 2023 and $2.8 billion in 2022. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.
K. Research and Development Expenses
R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as R&D activities performed in connection with certain licensing arrangements.
L. Acquired In-Process Research and Development Expenses
Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing and collaboration arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. Acquired in-process research and development expenses includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&D.
M. Long-Lived Assets
Long-lived assets include:
Property, plant and equipment, net—These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a

Pfizer Inc.
2024 Form 10-K
60


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
Identifiable intangible assets, net—These assets are recorded at fair value at acquisition. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.
Goodwill—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.
Amortization of finite-lived acquired intangible assets is included in Amortization of intangible assets.
We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
Specifically:
For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.
For indefinite-lived intangible assets, such as brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.
For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.
N. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
We incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.
Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired company. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred.
Our business may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as our corporate enabling functions.
O. Cash Equivalents and Statement of Cash Flows
Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments.
Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.
P. Investments and Derivative Financial Instruments
The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:
Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in Other (income)/deductions—net.
Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.
Held-to-maturity debt securities, which are carried at amortized cost.
Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus adjustments resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

Pfizer Inc.
2024 Form 10-K
61


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in Other (income)/deductions—net. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.
Realized gains or losses on sales of investments are determined by using the specific identification cost method.
We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, if and when a decline in fair value is determined, an impairment charge is recorded and a new cost basis in the investment is established. For equity-method investments, an impairment charge is recorded only if and when a decline in fair value is determined to be other-than-temporary.
Derivative financial instruments are carried at fair value in certain balance sheet categories (see Note 7A), with changes in fair value reported in net income or, for certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7E).
Q. Tax Assets and Liabilities and Income Tax Contingencies
Tax Assets and Liabilities––Current tax assets primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of operations when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.
Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.
The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.
Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.
Other taxes payable as of December 31, 2024 and 2023 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. See Note 5D for uncertain tax positions and Note 5A for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.
Income Tax Contingencies––We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.
We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision/(benefit) for taxes on income and are classified on our consolidated balance sheet with the related tax liability.
Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.
R. Pension and Postretirement Benefit Plans
The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. Net periodic pension and postretirement benefit costs other than the service costs are recognized in Other (income)/deductions—net. We immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (mark-to-market accounting). Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions––net. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of

Pfizer Inc.
2024 Form 10-K
62


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value.
S. Legal and Environmental Contingencies
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial and other asserted or unasserted matters, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.
T. Share-Based Payments
Our compensation programs include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis or on an accelerated attribution approach over the vesting terms with the related costs recorded in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.
Note 2. Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement

A. Acquisitions
Seagen––On December 14, 2023 (the acquisition date), we acquired Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash. The total fair value of the consideration transferred was $44.2 billion ($43.4 billion, net of cash acquired). In addition, in connection with the acquisition, $476 million in post-closing compensation expense for Seagen employee incentive awards was recorded in Restructuring charges and certain acquisition-related costs (see Note 3).
Seagen’s principal business was the development, manufacture, marketing and distribution of targeted cancer therapeutics, primarily using ADC technology. Seagen’s portfolio includes four approved medicines as well as a pipeline of product candidates. Clinical development programs are ongoing for each of these approved medicines for potential new or expanded indications and for several product candidates. We believe our acquisition of Seagen will strengthen our oncology capabilities by allowing us to combine Seagen’s ADC technology with the resources and scale of the Pfizer enterprise and to advance more potential breakthroughs to patients with cancer.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in 2024 to the amounts initially recorded in 2023 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.
(MILLIONS)
Amounts Recognized
as of Acquisition Date
(as previously reported as of December 31, 2023)
Measurement Period Adjustments(a)
Amounts Recognized as of Acquisition Date (as adjusted) Final
Working capital, excluding inventories(b)
$736 $(115)$621 
Inventories(c)
4,195 (922)3,273 
Property, plant and equipment
524 (243)280 
Identifiable intangible assets, excluding in-process research and development(d)
7,970 (50)7,920 
In-process research and development
20,800 (900)19,900 
Other noncurrent assets
174 (115)59 
Net income tax accounts(e)
(6,123)1,343 (4,779)
Other noncurrent liabilities(167)(20)(187)
Total identifiable net assets28,108 (1,022)27,086 
Goodwill16,126 1,022 17,148 
Net assets acquired/total consideration transferred$44,234 $ $44,234 
(a)The changes in the estimated fair values are to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
(b)Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities.
(c)As adjusted, comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories.
(d)As adjusted, comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.
(e)As adjusted, included primarily in Noncurrent deferred tax liabilities. The measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments.
As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $597 million.

Pfizer Inc.
2024 Form 10-K
63


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
In the ordinary course of business, Seagen may incur liabilities for environmental, legal and tax matters, as well as guarantees and indemnifications. These matters may include contingencies. Except as specifically excluded by the relevant accounting standard, contingencies are required to be measured at fair value as of the acquisition date if the acquisition-date fair value of the asset or liability arising from a contingency can be determined. If the acquisition-date fair value of the asset or liability cannot be determined, the asset or liability would be recognized at the acquisition date if both of the following criteria are met: (i) it is probable that an asset existed or that a liability had been incurred at the acquisition date, and (ii) the amount of the asset or liability can be reasonably estimated.
Environmental Matters—In the ordinary course of business, Seagen may incur liabilities for environmental matters such as remediation work, asset retirement obligations and environmental guarantees and indemnifications.
Legal Matters—Seagen is involved in various legal proceedings, including patent, intellectual property, and product liability matters of a nature considered normal to its business. The contingencies arising from legal matters are not significant to our consolidated financial statements.
Tax Matters—In the ordinary course of business, Seagen incurs liabilities for income taxes. Income taxes are exceptions to both the recognition and fair value measurement principles associated with the accounting for business combinations. Reserves for income tax contingencies continue to be measured under the benefit recognition model previously used by Seagen (see Note 1Q). Net liabilities for income taxes as of the acquisition date were $4.8 billion, including $48 million for uncertain tax positions. The net tax liability includes $6.3 billion for the tax impact of fair value adjustments, partially offset by $1.5 billion for deferred tax assets on which Seagen had recognized a valuation allowance.
Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of Seagen includes the following:
the expected specific synergies and other benefits that we believe will result from combining the operations of Seagen with the operations of Pfizer;
any intangible assets that do not qualify for separate recognition, as well as future, as yet unidentified projects and products; and
the value of the going-concern element of Seagen’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).
Goodwill is not amortized and is not deductible for tax purposes. All of the goodwill related to the acquisition of Seagen is related to our Biopharma segment (see Note 10).
Actual and Pro Forma Impact of AcquisitionThe following table presents information for Seagen’s operations that are included in Pfizer’s consolidated statements of operations beginning from the acquisition date, December 14, 2023, through Pfizer’s year-end in 2023:
(MILLIONS)
December 31,
2023
Revenues$132 
Net loss attributable to Pfizer Inc. common shareholders(a)
(746)
(a)Includes restructuring, integration and acquisition-related costs ($614 million pre-tax) and purchase accounting charges related to (i) the fair value adjustment for acquisition-date inventory estimated to have been sold ($109 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Seagen ($25 million pre-tax); as well as (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Seagen ($2 million pre-tax).
The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:
Unaudited Supplemental Pro Forma Consolidated Results
Year Ended December 31,
(MILLIONS, EXCEPT PER SHARE DATA)
20232022
Revenues
$61,893 $103,137 
Net income/(loss) attributable to Pfizer Inc. common shareholders
(1,481)27,870 
Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders
(0.26)4.86 
The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company’s results of operations would have been had the acquisition occurred on January 1, 2022, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma information reflected here due to many factors.
The unaudited supplemental pro forma financial information includes various assumptions, including those related to the purchase price allocation of the assets acquired and the liabilities assumed from Seagen. The historical U.S. GAAP financial information of Pfizer and Seagen was adjusted, primarily for the following pre-tax adjustments for the years ended December 31, 2023 and 2022:
Additional amortization expense of approximately $553 million and $576 million, respectively, related to the fair value of identifiable intangible assets acquired.
Additional expense related to the fair value adjustment to acquisition-date inventory estimated to have been sold of approximately $755 million and $934 million, respectively.
Additional estimated interest expense of approximately $984 million and $2.0 billion, respectively, related to the debt issued by Pfizer and the commercial paper borrowings to partially finance the acquisition.

Pfizer Inc.
2024 Form 10-K
64


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Elimination of interest income of approximately $1.2 billion and $267 million, respectively, related to the debt issuance proceeds that were invested prior to the acquisition date and associated with money market funds under the assumption that a portion of these funds would have been liquidated to partially finance the acquisition.
The above adjustments were then adjusted for the applicable tax impact using an estimated weighted-average statutory tax rate applied to the applicable pro forma adjustments.
The acquisition of Seagen had no impact on Pfizer’s weighted-average shares as no shares were issued.
GBT––On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, starting with sickle cell disease, for $68.50 per share in cash. The total fair value of the consideration transferred was $5.7 billion ($5.2 billion, net of cash acquired). In addition, $136 million in payments to GBT employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs (see Note 3).
The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $4.4 billion in Identifiable intangible assets, net, consisting of $3.0 billion of IPR&D and $1.4 billion of developed technology rights with a useful life of six years, (ii) $1.1 billion of Goodwill, (iii) $644 million of inventories to be sold over approximately three years, (iv) $516 million of net deferred tax liabilities and (v) $331 million of assumed long-term debt that was paid in full in the fourth quarter of 2022.
Biohaven––On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy approved for both acute treatment of migraine and prevention of episodic migraine in adults. The transaction included the acquisition of Biohaven’s CGRP programs, including rimegepant, zavegepant and a portfolio of five pre-clinical CGRP assets. Under the terms of the agreement, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5 billion, plus repayment of third-party debt of $863 million and redemption of Biohaven’s redeemable preferred stock for $495 million. Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing Biohaven Ltd.’s shares to Biohaven shareholders. Biohaven Ltd. became a new publicly traded company that retained Biohaven’s non-CGRP development stage pipeline compounds. Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.’s shares in the distribution.
The total fair value of the consideration transferred was $11.8 billion, which includes the fair value of Pfizer’s previous investment in Biohaven on the acquisition date of approximately $300 million. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $12.1 billion in Identifiable intangible assets, consisting of $11.6 billion of developed technology rights with a useful life of 11 years and $450 million of IPR&D, (ii) $823 million of Goodwill, (iii) $813 million of inventories to be sold over approximately two years, (iv) $398 million of trade accounts receivable, (v) $1.4 billion of assumed long-term debt that was paid in full in the fourth quarter of 2022, (vi) $544 million of net deferred tax liabilities and (vii) $526 million of Other current liabilities.
Arena––On March 11, 2022, we acquired Arena, a clinical stage company with development-stage therapeutic candidates in gastroenterology, dermatology and cardiology, for $100 per share in cash. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired). In addition, $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs (see
Note 3).
The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $5.5 billion in Identifiable intangible assets, consisting of $5.0 billion of IPR&D and $460 million of indefinite-lived licensing agreements and other, (ii) $1.0 billion of Goodwill and (iii) $490 million of net deferred tax liabilities.
ReViral––On June 9, 2022, we acquired ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel antiviral therapeutics that target respiratory syncytial virus, for a total consideration of up to $536 million, including upfront payments of $436 million upon closing (including a base payment of $425 million plus working capital adjustments) and an additional $100 million contingent upon a future development milestone for a secondary pipeline asset. It was subsequently determined the applicable milestone was not achieved.
We accounted for the transaction as an asset acquisition since the lead asset, sisunatovir, represented substantially all of the fair value of the gross assets acquired. At the acquisition date, we recorded a $426 million charge representing an acquired IPR&D asset with no alternative use in Acquired in-process research and development expenses, which is presented as a cash outflow from operating activities. Other assets acquired and liabilities assumed were not significant.
Pro forma information for the aforementioned acquisitions (except for Seagen) has not been presented because these acquisitions were not material to our consolidated financial statements.
B. Divestitures
Divestiture of Early-Stage Rare Disease Gene Therapy Portfolio––On September 19, 2023, we completed an agreement with Alexion, under which Alexion purchased and licensed the assets of our early-stage rare disease gene therapy portfolio. Under the terms of the agreement, Alexion will pay us total consideration of up to $1 billion, consisting of an upfront payment of $300 million which was paid at closing and future contingent milestone payments, plus tiered royalties based on annual net sales of the assets. In connection with the closing of the transaction, Pfizer recognized a $222 million pre-tax gain in Other (income)/deductions––net (see Note 4).

Pfizer Inc.
2024 Form 10-K
65


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Upjohn Separation and Combination with Mylan––In connection with the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, Pfizer and Viatris entered into various agreements, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. The terms of the MSAs range in initial duration from four to seven years post-separation. Services under the TSAs were largely completed as of December 31, 2023. Amounts recorded under the above agreements in 2024, 2023 and 2022 were not material to our operations. Net amounts due to Viatris under the above agreements were $105 million as of December 31, 2024 and $33 million as of December 31, 2023. The cash flows associated with the above agreements are included in Net cash provided by/(used in) operating activities.
C. Equity-Method Investments
Haleon––Haleon, is an independent, publicly traded company listed on the London Stock Exchange that holds the joint historical consumer healthcare business of GSK and Pfizer. We owned 32% of Haleon as of December 31, 2023. In March 2024, we sold approximately 30% of our investment in Haleon through the sale of 791 million ordinary shares in a global public offering, and the sale of 102 million ordinary shares directly to Haleon, for $3.5 billion. In October 2024, we sold approximately 34% of our remaining investment in Haleon through the sale of 640 million ordinary shares in a global public offering, and the sale of 61 million ordinary shares directly to Haleon, for $3.5 billion. We recognized total gains on these sales of our Haleon shares of $945 million during 2024 in Other (income)/deductions––net (see Note 4). After the October 2024 share sale, we owned approximately 15% of the outstanding voting shares of Haleon as of December 31, 2024.
Through the third quarter of 2024, we accounted for our Haleon investment under the equity method and recorded our share of earnings from Haleon on a quarterly basis on a one-quarter lag in Other (income)/deductions––net. As Haleon is a foreign investee whose reporting currency is the U.K. pound, we translated its financial statements into U.S. dollars and recognized the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. With the reduction in our Haleon ownership percentage and board representation after the October 2024 sale, we no longer have the ability to exercise significant influence over the operating and financial policies of Haleon. As a result, we discontinued the application of the equity method to our Haleon investment, and began to account for the investment as an equity security with a readily determinable fair value, which is carried at fair value, with changes in fair value reported in Other (income)/deductions––net. See Note 4.
The following table summarizes the change in the carrying value of our investment in Haleon:
Year Ended December 31,
(MILLIONS)
20242023
Beginning carrying value reported in Equity-method investments
$11,451 $10,824 
Carrying value of shares sold
(6,113) 
Dividends
(212)(153)
Currency translation adjustments and other(a)
341 293 
Basis difference adjustments and amortization(b), (c)
(91)(2)
Pfizer share of Haleon investee capital transaction(b), (d)
(44) 
Pfizer share of Haleon earnings(b)
224 489 
Reclassification of accumulated other comprehensive income balances in Equity-method investments(e)
(143) 
Transfer of carrying value to Short-term investments(f)
(5,411) 
Ending carrying value
$ $11,451 
(a)See Note 6.
(b)Included in Other (income)/deductions––net.
(c)Adjustments in 2024 include (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities.
(d)In 2024, includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.
(e)The 2024 activity primarily represent foreign currency translation balances in Accumulated other comprehensive income related to the equity-method investment in Haleon that were reclassified into Equity-method investments upon our loss of significant influence over Haleon and our discontinuance of the equity method for the Haleon investment.
(f)The final carrying value of our equity-method investment in Haleon was reclassified to Short-term investments and is being accounted for as an equity investment with a readily determinable fair value.

Pfizer Inc.
2024 Form 10-K
66


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Summarized financial information for Haleon as of September 30, 2024, the most recent period available, and as of September 30, 2023 and for the periods ending September 30, 2024, 2023, and 2022 is as follows:
(MILLIONS)September 30, 2024September 30, 2023
Current assets$7,813 $5,876 
Noncurrent assets37,572 36,954 
Total assets
$45,385 $42,830 
Current liabilities$7,468 $6,117 
Noncurrent liabilities15,511 15,744 
Total liabilities
$22,979 $21,862 
Equity attributable to shareholders$22,129 $20,719 
Equity attributable to noncontrolling interests277 249 
Total net equity$22,406 $20,968 
For the Twelve Months Ended
(MILLIONS)September 30, 2024September 30, 2023September 30, 2022
Net sales$14,252 $13,921 $13,566 
Cost of sales(5,656)(5,580)(5,081)
Gross profit$8,596 $8,341 $8,486 
Income from continuing operations1,668 1,606 1,745 
Net income1,668 1,606 1,745 
Income attributable to shareholders1,600 1,528 1,675 
In connection with GSK’s previously announced planned demerger of at least 80% of GSK’s 68% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $8.75 billion in U.S. dollar-denominated senior notes of various maturities, €2.35 billion in euro-denominated senior notes of various maturities and £700 million in U.K. pound-denominated senior notes of various maturities (collectively, the “notes”). The notes were guaranteed by GSK generally up to and excluding the date of the demerger (the “Guarantee Assumption Date”). We agreed to indemnify GSK for 32% (representing our pro rata equity interest in the Consumer Healthcare JV at that time) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity was provided solely for the benefit of GSK. Neither we, nor any of our subsidiaries, were an issuer or guarantor of any of the notes.
Following its issuance of the notes in March 2022, which fell in our international second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of £2.9 billion ($3.7 billion as of the end of our second quarter of 2022), at an interest rate of 1.365% per annum payable semi-annually in arrears. In conjunction with the demerger, we received £3.5 billion ($4.2 billion) in dividends from the JV in July 2022, of which $4.0 billion related to a one-time pre-separation dividend, which decreased the carrying value of our investment and are included in Net cash provided by/(used in) investing activities. Simultaneous with the receipt of the dividends, we repaid the £2.9 billion loan from the JV. GSK similarly received pro rata dividends and simultaneously repaid its pro rata loan from the JV. In conjunction with these transactions, our indemnification of GSK’s guarantee discussed above was terminated.
Investment in ViiV––In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately 11.7% of ViiV, and prior to 2016 we accounted for our investment under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to zero due to the recognition of cumulative equity-method losses and dividends, and therefore we no longer record our proportionate share of ViiV’s net income (loss) in our results of operations. Since 2016, we have recognized dividends from ViiV as income in Other (income)/deductions––net when earned, including dividends of $272 million in 2024, $265 million in 2023 and $314 million in 2022 (see
Note 4).
Summarized financial information for our equity-method investee, ViiV, as of December 31, 2024 and 2023 and for the years ending December 31, 2024, 2023, and 2022 is as follows:
As of December 31,
(MILLIONS)20242023
Current assets$4,338 $4,237 
Noncurrent assets3,223 3,009 
Total assets
$7,561 $7,245 
Current liabilities$4,280 $4,085 
Noncurrent liabilities6,205 5,998 
Total liabilities
$10,485 $10,083 
Total net equity/(deficit) attributable to shareholders$(2,924)$(2,838)

Pfizer Inc.
2024 Form 10-K
67


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Year Ended December 31,
(MILLIONS)202420232022
Net sales$8,971 $7,845 $6,955 
Cost of sales(1,360)(1,060)(819)
Gross profit$7,611 $6,785 $6,135 
Income from continuing operations3,062 3,090 3,108 
Net income3,062 3,090 3,108 
Income attributable to shareholders3,062 3,090 3,108 
D. Collaborative Arrangements
We enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product or vaccine.
Collaboration with Biohaven––In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven and certain of its subsidiaries to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Under the terms of the agreement, Biohaven would lead R&D globally and we would have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January 4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263 million for the upfront payment and premium paid on our equity investment in Acquired in-process research and development expenses. In October 2022, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5 billion. See Note 2A.
Summarized Financial Information for Collaborative Arrangements
The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:
Year Ended December 31,
(MILLIONS)202420232022
Product revenues(a)
$175 $212 $437 
Alliance revenues(b)
8,388 7,582 8,537 
Royalty revenues(c)
923 605 614 
Total revenues from collaborative arrangements$9,486 $8,400 $9,588 
Cost of sales(d)
$(2,901)$(4,277)$(15,589)
Selling, informational and administrative expenses(e)
(335)(267)(196)
Research and development expenses(f)
282 219 272 
Acquired in-process research and development expenses(g)
2 (13)(339)
Restructuring charges and certain acquisition-related costs(h)
(45)  
Other income/(deductions)—net
(15)25 50 
(a)Represents sales to our partners of products manufactured by us.
(b)Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2024 was primarily driven by an increase in Alliance revenues from Eliquis and Xtandi, partially offset by a decrease in Alliance revenues from Bavencio. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis.
(c)Primarily relates to royalties from our collaboration partners.
(d)Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decreases in 2024 and in 2023 primarily relate to Comirnaty.
(e)Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
(f)Represents net reimbursements from our partners for research and development expenses incurred.
(g)Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.
(h)Relates to exit costs associated with terminating a collaboration with SMPS.
The amounts outlined in the above table do not include transactions with third parties other than our collaboration partners, or other costs for the products under the collaborative arrangements.
E. Research and Development Arrangement
Research and Development Funding Arrangement with Blackstone––In April 2023, we entered into an arrangement with Blackstone under which we will receive up to a total of $550 million in 2023 through 2026 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. The reduction to Research and development expenses in 2024 and 2023 was $135 million and $175 million,

Pfizer Inc.
2024 Form 10-K
68


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
respectively. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $468 million contingent upon the successful results of the clinical trials. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $550 million in total based on achievement of certain levels of cumulative applicable net sales, as well as royalties based on a mid-to-high single digit percentage of the applicable net sales. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product, and royalties on net sales will be recorded as Cost of sales when incurred.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Realigning our Cost Base Program
In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this multi-year effort to continue primarily through 2025 and to total approximately $2.9 billion, primarily representing cash expenditures for severance, exit and implementation costs as well as asset write downs of which $2.2 billion is associated with our Biopharma segment. From the start of this program through December 31, 2024, we incurred costs under this program of $2.6 billion, of which $2.1 billion is associated with our Biopharma segment (including $2.0 billion of restructuring charges).
B. Manufacturing Optimization Program
In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $1.6 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. These costs were recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026. From the start of this program through December 31, 2024, we incurred costs under this program of $1.2 billion, substantially all of which is restructuring costs for our Biopharma segment.
C. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Year Ended December 31,
(MILLIONS)202420232022
Restructuring charges/(credits):
Employee terminations$1,152 $1,622 $776 
Asset impairments432 227 52 
Exit costs
403 119 54 
Restructuring charges/(credits)(a)
1,987 1,968 882 
Transaction costs(b)
5 190 144 
Integration costs and other(c)
427 785 348 
Restructuring charges and certain acquisition-related costs
2,419 2,943 1,375 
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net
7 (7)(9)
Additional depreciation––asset restructuring recorded in our consolidated statements of operations as follows(d):
Cost of sales14 31 34 
Selling, informational and administrative expenses5 1 2 
Total additional depreciation––asset restructuring
19 32 36 
Implementation costs recorded in our consolidated statements of operations as follows(e):
Cost of sales120 67 54 
Selling, informational and administrative expenses90 289 560 
Research and development expenses84 101 2 
Total implementation costs
294 457 616 
Total costs associated with acquisitions and cost-reduction/productivity initiatives$2,738 $3,426 $2,018 
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).
(b)Represents external costs for banking, legal, accounting and other similar services.
(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2023 costs mostly relate to our acquisition of Seagen, including $476 million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of 2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our acquisitions of Arena and GBT, including $138 million in payments to Arena employees in the first quarter of 2022 and $136 million in payments to GBT employees in the fourth quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See Note 2A.

Pfizer Inc.
2024 Form 10-K
69


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
Costs
Asset
Impairment
Charges
Exit CostsAccrual
Balance, January 1, 2023
$1,196 $ $8 $1,204 
Provision1,622 227 119 1,968 
Utilization and other(a)
(840)(227)(116)(1,184)
Balance, December 31, 2023(b)
1,978  11 1,988 
Provision1,152 432 403 1,987 
Utilization and other(a)
(1,083)(432)(341)(1,856)
Balance, December 31, 2024(c)
$2,046 $ $74 $2,120 
(a)Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.
(b)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).
(c)Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
Note 4. Other (Income)/Deductions—Net
Components of Other (income)/deductions––net include:
Year Ended December 31,
(MILLIONS)202420232022
Interest income$(545)$(1,624)$(251)
Interest expense(a)
3,091 2,209 1,238 
Net interest expense(b)
2,546 585 987 
Net (gains)/losses recognized during the period on equity securities(c)
(1,008)(1,590)1,273 
Income from collaborations, out-licensing arrangements and sales of compound/product rights
(42)(154)(188)
Net periodic benefit costs/(credits) other than service costs154 (610)(849)
Certain legal matters, net(d)
567 474 230 
Certain asset impairments(e)
3,295 3,024 421 
Haleon equity method (income)/loss(f)
(102)(505)(436)
Other, net(g)
(1,022)(1,002)(378)
Other (income)/deductions––net
$4,388 $222 $1,062 
(a)Capitalized interest totaled $182 million in 2024, $160 million in 2023 and $124 million in 2022.
(b)The increase in net interest expense in 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $8 billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen.
(c)2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see Note 2C). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas.
(d)2024 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(e)The amount for 2024 represents intangible asset impairment charges, and includes $2.9 billion recorded in the fourth quarter associated with our Biopharma segment, due to changes in development plans and updated long-range commercial forecasts, composed of: (i) $1.0 billion for B7H4V (felmetatug vedotin), a Phase 1 IPR&D asset, (ii) $475 million for Medrol, a finite-lived brand, (iii) $435 million for Zavzpret nasal spray developed technology rights, (iv) $400 million and $200 million for Tukysa and disitamab vedotin, respectively, IPR&D assets reflecting emerging competition, as well as (v) other developed technology rights, IPR&D impairments and a finite-lived licensing agreement totaling $436 million which also includes de-prioritization of certain assets. 2024 also includes a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The amount for 2023 primarily represented intangible asset impairment charges of $3.0 billion, of which $2.9 billion was associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: (i) $1.4 billion for etrasimod (Velsipity) IPR&D, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 developed technology rights due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) $486 million for various other IPR&D assets and developed technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also included $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset impairment charges associated with our Biopharma segment of $200 million for an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million

Pfizer Inc.
2024 Form 10-K
70


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics.
(f)See Note 2C.
(g)The amount for 2024 primarily includes, among other things, (i) gains of $945 million on the partial sales of our investment in Haleon in March and October 2024, (ii) dividend income of $272 million from our investment in ViiV and (iii) a charge of $420 million recorded in the third quarter related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. 2023 included, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included, among other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the fair value of contingent consideration.
Additional information about the intangible assets that were impaired during 2024 follows:
Year Ended
Fair Value(a)
December 31, 2024
(MILLIONS)AmountLevel 1Level 2Level 3Impairment
IPR&D(b)
$4,900 $ $ $4,900 $1,873 
Developed technology rights(b)
524   524 943 
Finite-lived brand(b)
270   270 475 
Finite-lived licensing agreement(b)
    5 
Total$5,694 $ $ $5,694 $3,295 
(a)The fair value amounts are presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
(b)Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
Note 5. Tax Matters
A. Taxes on Income from Continuing Operations
Components of Income from continuing operations before provision/(benefit) for taxes on income include:
 Year Ended December 31,
(MILLIONS)202420232022
United States$(637)$(4,411)$5,032 
International8,660 5,469 29,697 
Income from continuing operations before provision/(benefit) for taxes on income(a), (b)
$8,023 $1,058 $34,729 
(a)2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
(b)2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.
Components of Provision/(benefit) for taxes on income based on the location of the taxing authorities include:
 Year Ended December 31,
(MILLIONS)202420232022
United States
Current income taxes:
Federal
$453 $1,321 $2,744 
State and local
32 (135)(20)
Deferred income taxes:
Federal
(1,909)(2,606)(3,271)
State and local
(293)(184)(310)
Total U.S. tax provision/(benefit)(1,717)(1,605)(857)
International
Current income taxes
1,588 1,142 4,368 
Deferred income taxes
100 (652)(183)
Total international tax provision/(benefit)1,689 490 4,185 
Provision/(benefit) for taxes on income
$(28)$(1,115)$3,328 

Pfizer Inc.
2024 Form 10-K
71


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
The changes in Provision/(benefit) for taxes on income impacting the effective tax rate year-over-year are summarized below:
2024 v. 2023
The tax benefit of $28 million for 2024 compared to the tax benefit of $1.1 billion for 2023 was primarily a result of changes in the jurisdictional mix of earnings partially offset by a tax benefit related to the Transition Tax liability under the TCJA.
2023 v. 2022
The tax benefit of $1.1 billion for 2023 compared to the tax provision of $3.3 billion for 2022 was primarily a result of changes in the jurisdictional mix of earnings and the resolution of uncertain tax positions in various markets. The 2023 pre-tax income included a greater percentage of expenses taxed at higher rates as compared to the 2022 pre-tax income, resulting in a 2023 tax benefit compared to the 2022 tax provision. These expenses included amortization expense, acquisition-related costs, restructuring charges and intangible asset impairment charges. The tax benefit for 2023 and the tax provision for 2022 included tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years. The tax provision for 2022 also included the closing of U.S. IRS audits covering five tax years.
In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in Provision/(benefit) for taxes on income (see Note 2A).
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The sixth annual installment was paid by its April 15, 2024 due date. The seventh annual installment is due April 15, 2025 and is reported in current Income taxes payable as of December 31, 2024. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.
Cash paid for income taxes, net of refunds, consisted of:
Year Ended December 31,
(MILLIONS)202420232022
United States$2,593 $1,923 $3,867 
International1,012 1,224 4,000 
Total$3,605 $3,147 $7,867 
B. Tax Rate Reconciliation
The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows:
 Year Ended December 31,
2024
2023^
2022
U.S. statutory income tax rate21.0 %21.0 %21.0 %
Taxation of non-U.S. operations(a), (b)
(7.9)(21.1)(5.0)
Transition Tax liability(c)
(6.0)  
Tax settlements and resolution of certain tax positions(c)
(2.4)(40.3)(3.0)
Foreign-Derived Intangible Income deduction(d)
(1.2)(33.1)(1.9)
State & local taxes(e)
(2.5)(22.4) 
Charitable contributions
(1.7)(7.3)(0.5)
U.S. R&D tax credit(1.8)(15.8)(0.6)
Interest(f)
2.2 13.5 0.2 
All other, net(g)
0.1 0.2 (0.6)
Effective tax rate for income from continuing operations
(0.4)%(105.4)%9.6 %
^ The higher rate percentages for the 2023 reconciling items are significantly impacted by the lower domestic and international Income from continuing operations before provision/(benefit) for taxes on income (see Note 5A).
(a)For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income.
(b)In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We have Puerto Rican tax incentives pursuant to a grant that expires during 2053. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we have incentive tax rates effective through 2048 on income from manufacturing and other operations.

Pfizer Inc.
2024 Form 10-K
72


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
(c)See Note 5A.
(d)The higher rate benefit from the Foreign-Derived Intangible Income deduction in 2022 is mainly the result of the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.
(e)Includes the impact of U.S. state and local taxes and changes in the state valuation allowances including those related to the acquisition of Seagen.
(f)Includes changes in interest related to our uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”.
(g)All other, net is primarily due to routine business operations.
C. Deferred Taxes
Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:
2024 Deferred Tax^2023 Deferred Tax^
(MILLIONS)Assets(Liabilities)Assets(Liabilities)
Prepaid/deferred items(a)
$2,988 $(847)$2,658 $(654)
Accrued/deferred royalties1,306  1,655 — 
Deferred revenues
300  471 — 
Inventories(b)
992 (702)1,210 (1,060)
Intangible assets(c)
1,435 (9,066)1,526 (11,605)
Property, plant and equipment265 (1,751)168 (2,039)
Employee benefits(d)
1,002 (274)1,085 (287)
Restructurings and other charges462  537 — 
Legal and product liability reserves378  430 — 
Research and development(e)
7,635  6,275 — 
Net operating loss/tax credit carryforwards(f)
2,028  2,708 — 
Unremitted earnings (69)— (60)
State and local tax adjustments161  119 — 
Investments
73 (248)133 (395)
All other87 (66)62 (72)
19,112 (13,023)19,037 (16,172)
Valuation allowances(1,638) (1,738)— 
Total deferred taxes$17,474 $(13,023)$17,299 $(16,172)
Net deferred tax asset/(liability)(g), (h)
$4,451 $1,128 
^ The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See Note 1Q.
(a)The increase in net deferred tax assets in 2024 is primarily related to temporary differences associated with the timing of accruals recorded in the ordinary course of business.
(b)The increase in net deferred tax assets in 2024 is primarily due to measurement period adjustments of inventories related to Seagen. See Note 2A.
(c)The decrease in net deferred tax liabilities in 2024 is primarily due to amortization of intangible assets and certain impairment charges, as well as the measurement period adjustments of intangible assets related to Seagen.
(d)The decrease in net deferred tax assets in 2024 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See Note 11.
(e)The increase in deferred tax assets in 2024 is primarily related to the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.
(f)The amounts in 2024 and 2023 are reduced for unrecognized tax benefits of $575 million and $1.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
(g)In 2024, Noncurrent deferred tax assets and other noncurrent tax assets ($6.6 billion), and Noncurrent deferred tax liabilities ($2.1 billion). In 2023, Noncurrent deferred tax assets and other noncurrent tax assets ($1.8 billion), and Noncurrent deferred tax liabilities ($640 million).
(h)Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.3 billion and $11.1 billion for 2024 and 2023 respectively, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.
We have carryforwards, primarily related to net operating and capital losses, general business credits, foreign tax credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2025 to 2044. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section 382.
As of December 31, 2024, we have not made a U.S. tax provision on $58.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2024 is not practicable. The amount of indefinitely reinvested earnings is based on estimates and assumptions and subject to management evaluation, and is subject to change in the normal course of business based on operational cash flow, completion of local statutory financial statements and the finalization of tax returns and audits, among other things. Accordingly, we regularly update our earnings and profits analysis for such events.
D. Tax Contingencies
For a description of our accounting policies associated with accounting for income tax contingencies, see Note 1Q.

Pfizer Inc.
2024 Form 10-K
73


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Uncertain Tax Positions
As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2024, we had $2.0 billion and as of December 31, 2023, we had $3.1 billion in net unrecognized tax benefits, excluding associated interest.
Tax assets for uncertain tax positions represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. In 2024, tax assets for uncertain tax positions also include the expected filing of an amended income tax return relating to the Transition Tax liability under the TCJA. As of December 31, 2024, we had $2.5 billion in assets associated with uncertain tax positions mainly included in Noncurrent deferred tax assets and other noncurrent tax assets. As of December 31, 2023, we had $1.7 billion in assets associated with uncertain tax positions mainly included in Noncurrent deferred tax assets and other noncurrent tax assets.
The majority of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.
The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:
(MILLIONS)202420232022
Balance, beginning$(4,802)$(4,494)$(6,068)
Acquisitions
8 (46)(52)
Increases based on tax positions taken during a prior period(a), (b)
(934)(158)(67)
Decreases based on tax positions taken during a prior period(a), (c)
599 310 1,339 
Decreases based on settlements for a prior period(c), (d)
911 85 842 
Increases based on tax positions taken during the current period(a)
(433)(515)(701)
Impact of foreign exchange52 (44)90 
Other, net(a), (e)
70 58 122 
Balance, ending(f)
$(4,530)$(4,802)$(4,494)
(a)Primarily included in Provision/(benefit) for taxes on income.
(b)In 2024, the amount includes a gross unrecognized tax benefit associated with the expected filing of an amended income tax return related to the Transition Tax liability under the TCJA.
(c)Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See Note 5A.
(d)Primarily related to cash payments and reductions of tax attributes.
(e)Primarily related to decreases as a result of a lapse of applicable statutes of limitations.
(f)In 2024, included in Income taxes payable ($103 million), Other current assets ($0.4 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.5 billion), Noncurrent deferred tax liabilities ($3 million) and Other taxes payable ($2.9 billion). In 2023, included in Income taxes payable ($94 million), Other current assets ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.3 billion), Noncurrent deferred tax liabilities ($4 million) and Other taxes payable ($3.4 billion).
Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in Provision/(benefit) for taxes on income. In 2024, we recorded a net increase in interest of $91 million. In 2023, we recorded a net increase in interest of $64 million. In 2022, we recorded a net decrease in interest of $17 million. Gross accrued interest totaled $636 million as of December 31, 2024 (reflecting a decrease of $56 million as a result of cash payments) and gross accrued interest totaled $605 million as of December 31, 2023 (reflecting a decrease of $11 million as a result of cash payments). In 2024 and 2023, these amounts were substantially all included in Other taxes payable. Accrued penalties are not significant. See also Note 5A.
Status of Tax Matters and Potential Impact on Accruals for Uncertain Tax Positions
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. During the third quarter of 2024, we effectively settled the audit of Pfizer’s federal income tax returns for years 2016-2018. Tax years 2019-2024 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions such as Canada (2017-2024), Europe (2012-2024, primarily in Ireland, the U.K., France, Italy, Spain and Germany), Asia Pacific (2014-2024, primarily in Australia, China, Japan and Singapore) and Latin America (1998-2024, primarily in Brazil).
Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $200 million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.


Pfizer Inc.
2024 Form 10-K
74


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of the Tax provision/(benefit) on other comprehensive income/(loss) include:
 Year Ended December 31,
(MILLIONS)202420232022
Foreign currency translation adjustments, net(a)
$156 $(33)$(126)
Unrealized holding gains/(losses) on derivative financial instruments, net96 111 183 
Reclassification adjustments for (gains)/losses included in net income(29)(93)(270)
 67 18 (87)
Unrealized holding gains/(losses) on available-for-sale securities, net(19)(15)(164)
Reclassification adjustments for (gains)/losses included in net income5 (18)226 
 (14)(33)62 
Benefit plans: prior service (costs)/credits and other, net45 (5)(5)
Reclassification adjustments related to amortization of prior service costs and other, net(26)(28)(29)
Reclassification adjustments related to curtailments of prior service costs and other, net2 (4)(3)
 22 (37)(37)
Tax provision/(benefit) on other comprehensive income/(loss)$231 $(85)$(187)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)
Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale Securities
Prior Service (Costs)/Credits and Other
Accumulated Other Comprehensive Income/(Loss)
Balance, January 1, 2022
$(6,172)$119 $(220)$377 $(5,897)
Other comprehensive income/(loss)(b)
(2,188)(531)440 (129)(2,407)
Balance, December 31, 2022
(8,360)(412)220 248 (8,304)
Other comprehensive income/(loss)(b)
497 195 (229)(120)343 
Balance, December 31, 2023
(7,863)(217)(9)128 (7,961)
Other comprehensive income/(loss)(b)
(121)274 (97)63 118 
Balance, December 31, 2024
$(7,984)$57 $(106)$191 $(7,842)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program and gains/(losses) related to our investment in Haleon (see Note 2C).


Pfizer Inc.
2024 Form 10-K
75


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Note 7. Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
As of December 31, 2024As of December 31, 2023
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair value(a)
$7,848 $6,456 $1,392 $5,124 $ $5,124 
Available-for-sale debt securities:
Government and agency—non-U.S.6,855  6,855 817  817 
Government and agency—U.S.2,853  2,853 2,601  2,601 
Corporate and other1,173  1,173 982  982 
10,881  10,881 4,400  4,400 
Total short-term investments18,729 6,456 12,273 9,524  9,524 
Other current assets
Derivative assets:
Foreign exchange contracts1,056  1,056 298  298 
Total other current assets1,056  1,056 298  298 
Long-term investments
Equity securities with readily determinable fair values(b)
1,246 1,246  2,779 2,772 7 
Available-for-sale debt securities:
Government and agency—non-U.S.   124  124 
Corporate and other   26  26 
   150  150 
Total long-term investments1,246 1,246  2,929 2,772 156 
Other noncurrent assets
Derivative assets:
Interest rate contracts13  13 144  144 
Foreign exchange contracts447  447 258  258 
Total derivative assets460  460 402  402 
Insurance contracts(c)
875  875 790  790 
Total other noncurrent assets1,335  1,335 1,191  1,191 
Total assets$22,366 $7,701 $14,665 $13,943 $2,772 $11,170 
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$28 $ $28 $16 $ $16 
Foreign exchange contracts217  217 404  404 
Total other current liabilities245  245 420  420 
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts397  397 275  275 
Foreign exchange contracts723  723 725  725 
Total other noncurrent liabilities1,121  1,121 1,000  1,000 
Total liabilities$1,366 $ $1,366 $1,420 $ $1,420 
(a)Includes money market funds. As of December 31, 2024, short-term equity securities include our investment in Haleon of $6.5 billion. See Note 2C.
(b)Long-term equity securities of $133 million as of December 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis––The carrying value of Long-term debt, excluding the current portion was $57 billion as of December 31, 2024 and $62 billion as of December 31, 2023. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $54 billion as of December 31, 2024 and $61 billion as of December 31, 2023.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2024 and 2023. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.

Pfizer Inc.
2024 Form 10-K
76


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
B. Investments
Total Short-Term, Long-Term and Equity-Method Investments
The following summarizes our investments by classification type:
As of December 31,
(MILLIONS)20242023
Short-term investments
Equity securities with readily determinable fair values(a)
$7,848 $5,124 
Available-for-sale debt securities10,881 4,400 
Held-to-maturity debt securities705 313 
Total Short-term investments$19,434 $9,837 
Long-term investments
Equity securities with readily determinable fair values(b)
$1,246 $2,779 
Available-for-sale debt securities 150 
Held-to-maturity debt securities45 47 
Private equity securities at cost(b)
719 755 
Total Long-term investments
$2,010 $3,731 
Equity-method investments(a)
217 11,637 
Total long-term investments and equity-method investments$2,228 $15,368 
Held-to-maturity cash equivalents$184 $207 
(a)As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
(b)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
As of December 31, 2024As of December 31, 2023
Gross UnrealizedMaturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5
Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$6,970 $8 $(123)$6,855 $6,855 $ $ $953 $2 $(14)$941 
Government and agency––U.S.
2,853   2,853 2,853   2,601   2,601 
Corporate and other1,179  (6)1,173 1,173   1,006 4 (2)1,007 
Held-to-maturity debt securities
Time deposits and other
697   697 657 21 19 561   561 
Government and agency––non-U.S.
237   237 232 4 1 4   4 
Total debt securities$11,935 $8 $(129)$11,814 $11,770 $25 $20 $5,126 $6 $(16)$5,115 
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Year Ended December 31,
(MILLIONS)202420232022
Net (gains)/losses recognized during the period on equity securities(a)
$(1,008)$(1,590)$1,273 
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(1,122)(1,754)(126)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)
$114 $165 $1,400 
(a)Reported in Other (income)/deductions––net. See Note 4.
(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $360 million and upward adjustments of $222 million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022.

Pfizer Inc.
2024 Form 10-K
77


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
C. Short-Term Borrowings
Short-term borrowings include:
As of December 31,
(MILLIONS)20242023
Commercial paper, principal amount(a)
$2,453 $7,965 
Current portion of long-term debt, principal amount3,750 2,250 
Other short-term borrowings, principal amount(b)
755 252 
Total short-term borrowings, principal amount
6,957 10,467 
Net fair value adjustments related to hedging and purchase accounting
 5 
Net unamortized discounts, premiums and debt issuance costs(12)(121)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted
$6,946 $10,350 
(a)Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see Note 2A). The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94% as of December 31, 2024 and 5.37% as of December 31, 2023.
(b)Primarily includes cash collateral. See Note 7F.
As of December 31, 2024, we had access to a total of $15 billion in committed U.S. revolving credit facilities, consisting of an $8 billion facility maturing in October 2025 (subsequently terminated by Pfizer in February 2025), and a $7 billion facility maturing in October 2029, which may be used for general corporate purposes including to support our global commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional $276 million in lines of credit, of which $243 million expire within one year. Essentially all lines of credit were unused as of December 31, 2024.
D. Long-Term Debt
The following outlines our senior unsecured long-term debt(a) and the weighted-average stated interest rate by maturity:
As of December 31,
(MILLIONS)20242023
Notes due 2025 (3.9% for 2023)(b)
$ $3,750 
Notes due 2026 (3.7% for 2024 and 2023)
6,000 6,000 
Notes due 2027 (2.2% for 2024 and 2.1% for 2023)
980 1,029 
Notes due 2028 (4.6% for 2024 and 2023)
5,660 5,660 
Notes due 2029 (3.5% for 2024 and 2023)
1,750 1,750 
Notes due 2030 (3.6% for 2024 and 2023)
5,250 5,250 
Notes due 2031-2035 (4.5% for 2024 and 2023)
6,750 6,750 
Notes due 2036-2040 (5.4% for 2024 and 2023)
9,534 9,543 
Notes due 2041-2045 (4.3% for 2024 and 2023)
6,474 6,501 
Notes due 2046-2050 (3.7% for 2024 and 2023)
4,750 4,750 
Notes due 2051-2063 (5.3% for 2024 and 2023)
10,000 10,000 
Total long-term debt, principal amount57,147 60,982 
Net fair value adjustments related to hedging and purchase accounting701 1,039 
Net unamortized discounts, premiums and debt issuance costs(444)(483)
Total long-term debt, carried at historical proceeds, as adjusted$57,405 $61,538 
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023))
$3,747 $2,254 
(a)Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.
(b)Reclassified to the current portion of long-term debt.
Issuance—In May 2023, we issued, through our wholly-owned finance subsidiary, PIE, $31 billion principal amount of senior unsecured notes at an effective interest rate of 4.93% as part of the financing for our acquisition of Seagen. The notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc. PIE was formed to finance a portion of the consideration for the acquisition of Seagen and has no assets or operations, and will have no assets or operations, other than as related to the issuance, administration and repayment of the notes and any other debt securities that it may issue in the future.
E. Derivative Financial Instruments and Hedging Activities
Foreign Exchange Risk––A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Chinese renminbi, Japanese yen, Canadian dollar and Swedish krona, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments of our foreign business entities.

Pfizer Inc.
2024 Form 10-K
78


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Changes in fair value are reported in earnings or in Other comprehensive income/(loss), depending on the nature and purpose of the financial instrument (hedge or offset relationship). For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize the excluded amount through an amortization approach in earnings. The hedge relationships are as follows:
Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged item. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.
Generally, we record in Other comprehensive income/(loss) gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts into earnings in the same period or periods during which the hedged transaction affects earnings.
We record in Other comprehensive income/(loss)––Foreign currency translation adjustments, net the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments.
For foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses immediately into earnings along with the earnings impact of the items they generally offset. These contracts take the opposite currency position of that reflected on the balance sheet to counterbalance the effect of any currency movement.
Interest Rate Risk––Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.
We recognize the change in fair value on interest rate contracts that are designated as fair value hedges in earnings, as well as the offsetting earnings impact of the hedged risk attributable to the hedged item.
The following summarizes the fair value of the derivative financial instruments and notional amounts:
(MILLIONS)
As of December 31, 2024
As of December 31, 2023
Fair ValueFair Value
NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,991 $1,250 $719 $18,750 $403 $916 
Interest rate contracts
6,750 13 425 6,750 144 290 
1,263 1,144 546 1,206 
Derivatives not designated as hedging instruments:
Foreign exchange contracts
$26,335 253 221 $25,609 154 214 
Total$1,516 $1,366 $700 $1,420 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.

Pfizer Inc.
2024 Form 10-K
79


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:
 

Gains/(Losses)
Recognized in OID
(a)
Gains/(Losses)
Recognized in OCI
(a)
Gains/(Losses)
Reclassified from
OCI into OID and COS
(a)
Year Ended December 31,
(MILLIONS)202420232024202320242023
Derivative Financial Instruments in Cash Flow Hedge Relationships:
      
Interest rate contracts$ $— $ $68 $ $1 
Foreign exchange contracts(b)
 — 466 380 124 236 
Amount excluded from effectiveness testing and amortized into earnings(c)
 — 34 178 34 177 
Derivative Financial Instruments in Fair Value Hedge Relationships:
Interest rate contracts(253)196  —  — 
Hedged item 253 (196) —  — 
Derivative Financial Instruments in Net Investment Hedge Relationships:
Foreign exchange contracts — 498 (393)  
Amount excluded from effectiveness testing and amortized into earnings(c)
 — 119 137 154 136 
Non-Derivative Financial Instruments in Net Investment Hedge Relationships(d):
Foreign currency short-term borrowings —     
Foreign currency long-term debt — 49 (29)  
Derivative Financial Instruments Not Designated as Hedges:
Foreign exchange contracts50 164  —  — 
$50 $164 $1,166 $341 $313 $549 
(a)OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss).
(b)The amounts reclassified from OCI into COS were a net gain of $119 million in 2024 and a net gain of $253 million in 2023. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $330 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 18 years and relates to foreign currency debt.
(c)The amounts reclassified from OCI were reclassified into OID.
(d)Long-term debt includes foreign currency borrowings which are used in net investment hedges; the related carrying values as of December 31, 2024 and December 31, 2023 were $777 million and $824 million, respectively.
The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:
As of December 31, 2024
As of December 31, 2023
Cumulative Amount of Fair
Value Hedging Adjustment
Increase/(Decrease) to
Carrying Amount
Cumulative Amount of Fair
Value Hedging Adjustment Increase/(Decrease) to
Carrying Amount
(MILLIONS)
Carrying Amount of Hedged Assets/Liabilities(a)
Active
Hedging
Relationships
Discontinued Hedging Relationships
Carrying Amount of Hedged Assets/Liabilities(a)
Active Hedging RelationshipsDiscontinued Hedging Relationships
Long-term debt$7,154 $(384)$891 $7,196 $(131)$957 
(a)Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
F. Credit Risk
On an ongoing basis, we monitor and review the credit risk of our customers, financial institutions and exposures in our investment portfolio.
With respect to our trade accounts receivable, we monitor the creditworthiness of our customers to which we grant credit in the normal course of business. In general, there is no requirement for collateral from customers. For additional information on our trade accounts receivable and allowance for credit losses, see Note 1G. A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see Note 17C.

Pfizer Inc.
2024 Form 10-K
80


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
With respect to our investments, we monitor concentrations of credit risk associated with government, government agency, and corporate issuers of securities. Investments are placed in instruments that are investment grade and are primarily short in duration. Exposure limits are established to limit a concentration with any single credit counterparty. As of December 31, 2024, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by the U.S., Canada, and the U.K.
With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of December 31, 2024, the aggregate fair value of these derivative financial instruments that are in a net payable position was $741 million, for which we have posted collateral of $720 million with a corresponding amount reported in Short-term investments. As of December 31, 2024, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $594 million, for which we have received collateral of $716 million with a corresponding amount reported in Short-term borrowings, including current portion of long-term debt.
Note 8. Other Financial Information
A. Inventories
The following summarizes the components of Inventories:
As of December 31,
(MILLIONS)20242023
Finished goods$3,775 $3,495 
Work-in-process6,101 5,688 
Raw materials and supplies976 1,007 
Inventories(a)
$10,851 $10,189 
Noncurrent inventories not included above(b)
$2,663 $4,568 
(a)The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches.
(b)Included in Other noncurrent assets. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See Note 2A. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
B. Other Current Liabilities
Other current liabilities include, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $1.3 billion as of December 31, 2024 and $2.0 billion as of December 31, 2023.
C. Supplier Finance Program Obligation
We maintain voluntary supply chain finance agreements with several participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Pfizer to these financial institutions. Our suppliers negotiate their financing agreements directly with the respective financial institutions and we are not a party to these agreements. We have no economic interest in our suppliers’ decision to participate and we pay the financial institutions the stated amount of confirmed invoices on the original maturity dates, which is generally within 90 to 120 days of the invoice date. The agreements with the financial institutions do not require Pfizer to provide assets pledged as security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in such financing arrangements are recorded within trade payables in our consolidated balance sheet.
The following summarizes the changes in outstanding trade payables to suppliers who participate in these financing arrangements for the year ended December 31, 2024
(MILLIONS)
Total
Confirmed obligations outstanding, December 31, 2023
$791 
Invoices confirmed during the year
2,638 
Confirmed invoices paid during the year
(2,740)
Confirmed obligations outstanding, December 31, 2024
$688 

Pfizer Inc.
2024 Form 10-K
81


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Note 9. Property, Plant and Equipment, Net
The following summarizes the components of Property, plant and equipment, net:
 Useful LivesAs of December 31,
(MILLIONS)(Years)  20242023
Land-$291 $353 
Buildings
33-50
9,036 9,046 
Machinery and equipment
8-20
15,095 14,263 
Furniture, fixtures and other
3-12.5
5,516 5,399 
Construction in progress-4,937 5,925 
34,876 34,985 
Less: Accumulated depreciation16,483 16,045 
Property, plant and equipment, net
$18,393 $18,940 
The following provides Property, plant and equipment, net by geographic area:
 As of December 31,
(MILLIONS)20242023
United States$9,748 $10,674 
International:
Developed Markets7,187 6,713 
Emerging Markets1,458 1,554 
Property, plant and equipment, net
$18,393 $18,940 
Note 10. Identifiable Intangible Assets, Net and Goodwill
A. Identifiable Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2024As of December 31, 2023
(MILLIONS)Gross
Carrying
Amount
Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount
Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$99,397 $(65,044)$34,353 $99,267 $(60,493)$38,773 
Brands(b)
1,277 (992)285 922 (877)45 
Licensing agreements and other
2,724 (1,513)1,210 2,756 (1,458)1,297 
103,397 (67,549)35,848 102,944 (62,828)40,116 
Indefinite-lived intangible assets
Brands(b)
  827 827 
IPR&D(c)
18,893 18,893 23,193 23,193 
Licensing agreements and other
670 670 763 763 
19,563 19,563 24,784 24,784 
Identifiable intangible assets(d)
$122,961 $(67,549)$55,411 $127,728 $(62,828)$64,900 
(a)The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see Note 4).
(b)The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see Note 4).
(c)The decrease in the gross carrying amount reflects impairments of $1.9 billion (see Note 4), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see Note 2A), and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna).
(d)The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see Note 4) and measurement period adjustments related to our acquisition of Seagen of $950 million (see Note 2A).
Developed Technology Rights––Developed technology rights represent the cost for developed technology acquired from third parties and can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing our commercialized products. The significant components of developed technology rights are the following: Nurtec ODT/Vydura, Adcetris, Padcev, Xtandi, Velsipity and Braftovi/Mektovi. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain prescription pharmaceutical products.
Brands––Brands represent the cost for tradenames and know-how, as the products themselves do not receive patent protection. The significant components of Finite-lived brands primarily include Medrol.
IPR&D––IPR&D assets represent the acquisition date fair value (less impairments) of R&D assets acquired through business combinations that have not yet received regulatory approval in a major market which could include both new investigational products and additional

Pfizer Inc.
2024 Form 10-K
82


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
indications for in-line products. The significant components of IPR&D are SGN-B6A, disitamab vedotin, GBT601 and Tukysa. IPR&D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&D effort. Accordingly, during the development period after the date of acquisition, these assets are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify it out of IPR&D and begin amortization. If the associated R&D effort is abandoned, the related IPR&D assets will be written-off, and we will record an impairment charge. IPR&D assets are high-risk assets, given the uncertain nature of R&D. Accordingly, IPR&D assets may become impaired and/or be written-off in the future.
Licensing Agreements––Licensing agreements for developed technology and for technology in development primarily relate to out-licensing arrangements acquired from third parties, including from acquisitions. These assets represent the cost for the license, where we acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partners. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will be written-off, and we will record an impairment charge.
Amortization––The weighted-average life for our total finite-lived intangible assets and for the largest component, developed technology rights, is approximately 10 years.
The following provides the expected annual amortization expense:
(MILLIONS)20252026202720282029
Amortization expense$4,838 $4,716 $4,125 $3,776 $2,829 
B. Goodwill
The following summarizes the changes in the carrying amount of Goodwill:
(MILLIONS)
Total(a)
Balance, January 1, 2023
$51,375 
Additions(b)
16,117 
Impact of foreign exchange and other
292 
Balance, December 31, 2023
67,783
Additions(b)
1,022 
Impact of foreign exchange
(278)
Balance, December 31, 2024
$68,527 
(a)As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 17A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
(b)Additions primarily represent our acquisition of Seagen in 2023 and measurement period adjustments related to our acquisition of Seagen in 2024 (see
Note 2A).
Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans
The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans.

Pfizer Inc.
2024 Form 10-K
83


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
A. Components of Net Periodic Benefit Cost/(Credit) and Changes in Other Comprehensive Income/(Loss)
Pension Plans
Postretirement Plans
U.S.International
Year Ended December 31,
(MILLIONS)202420232022202420232022202420232022
Service cost$ $ $ $87 $85 $116 $14 $12 $29 
Interest cost553 589 534 312 287 157 23 21 27 
Expected return on plan assets
(832)(778)(862)(322)(304)(296)(51)(44)(47)
Amortization of prior service cost/(credit)1 2 2 4  (1)(113)(119)(130)
Actuarial (gains)/losses(a)
396 (410)225 33 102 (11)144 51 (440)
Curtailments   (4)(2)(11) (12)(18)
Special termination benefits
 6 18 10  1   1 
Net periodic benefit cost/(credit) reported in income117 (592)(84)120 169 (45)18 (90)(578)
Cost/(credit) reported in Other comprehensive income/(loss)
(1)(2)(2)(4)31 (1)(80)128 169 
Cost/(credit) recognized in Comprehensive income
$116 $(594)$(86)$117 $199 $(46)$(62)$38 $(410)
(a)Reflects: (i) actuarial remeasurement net losses in 2024, primarily due to unfavorable asset performance for the U.S. pension plans and decreases in discount rates for the international pension plans, partially offset by increases in discount rates for the U.S. pension plans and favorable asset performance for the international pension plans and postretirement plans, (ii) actuarial remeasurement net gains in 2023, primarily due to favorable asset performance in the U.S. and increases in discount rates for the international plans, partially offset by unfavorable asset performance for certain international plans, and (iii) actuarial remeasurement net gains in 2022, primarily due to increases in discount rates, partially offset by unfavorable asset performance.
The components of net periodic benefit cost/(credit) other than the service cost component are included in Other (income)/deductions––net (see Note 4).
B. Actuarial Assumptions
Pension PlansPostretirement Plans
U.S.International
Year Ended December 31,
(PERCENTAGES)202420232022202420232022202420232022
Weighted-average assumptions used to determine net periodic benefit cost:
Discount rate:
Pension plans/postretirement plans5.4 %5.4 %2.9 %5.4 %5.5 %2.9 %
Interest cost4.4 %3.8 %1.5 %
Service cost3.9 %3.6 %1.7 %
Expected return on plan assets8.0 %7.5 %6.3 %5.1 %4.5 %3.1 %8.0 %7.5 %6.3 %
Rate of compensation increase(a)
3.2 %3.0 %2.8 %
Weighted-average assumptions used to determine benefit obligations at fiscal year-end:
Discount rate5.7 %5.4 %5.4 %4.1 %4.4 %3.8 %5.5 %5.4 %5.5 %
Rate of compensation increase(a)
3.1 %3.2 %3.0 %
(a)The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.
The assumptions are reviewed at least annually. We revise these assumptions based on an annual evaluation of long-term trends as well as market conditions that may have an impact on the cost of providing retirement benefits.
The weighted-average discount rate for our U.S. defined benefit plans is set with reference to the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2024 resulted in higher discount rates for the U.S. pension plans and lower discount rates for the international pension plans as compared to the prior year.

Pfizer Inc.
2024 Form 10-K
84


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:
As of December 31,
20242023
Healthcare cost trend rate assumed for next year 7.5 %7.9 %
Rate to which the cost trend rate is assumed to decline4.0 %4.0 %
Year that the rate reaches the ultimate trend rate2047 2047 
C. Obligations and Funded Status
The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
 Pension Plans Postretirement Plans
 U.S. International
Year Ended December 31,
(MILLIONS)202420232024202320242023
Change in benefit obligation(a)
Benefit obligation, beginning$10,756 $11,420 $7,292 $7,497 $450 $410 
Service cost  87 85 14 12 
Interest cost553 589 312 287 23 21 
Employee contributions  16 11 61 52 
Plan amendments   25 (193) 
Changes in actuarial assumptions and other(b)
(299)(127)119 (518)199 96 
Foreign exchange impact(1) (106)280 (2)(1)
Acquisitions/divestitures, net  77 13  — 
Curtailments and special termination benefits 6 7   (3)
Settlements
(756)(675)(69)(56)  
Benefits paid(473)(457)(371)(334)(67)(137)
Benefit obligation, ending(a)
9,781 10,756 7,363 7,292 486 450 
Change in plan assets
Fair value of plan assets, beginning
10,935 10,871 6,552 6,865 636 647 
Actual return on plan assets138 1,061 408 (316)105 89 
Company contributions103 134 164 154  (15)
Employee contributions  16 11 61 52 
Foreign exchange impact  (65)214   
Acquisitions/divestitures, net — 62 13   
Settlements
(756)(675)(69)(56)  
Benefits paid(473)(457)(371)(334)(67)(137)
Fair value of plan assets, ending9,948 10,935 6,696 6,552 736 636 
Funded status$167 $179 $(667)$(740)$251 $186 
Amounts recorded in our consolidated balance sheet:
Noncurrent assets$934 $1,010 $728 $644 $330 $266 
Current liabilities(90)(94)(31)(28)(5)(6)
Noncurrent liabilities(678)(738)(1,364)(1,355)(74)(74)
Funded status$167 $179 $(667)$(740)$251 $186 
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
Prior service (costs)/credits$(2)$(2)$(61)$(65)$365 $285 
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):
Fair value of plan assets
$ $— $456 $579 
ABO768 831 1,752 1,834 
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):
Fair value of plan assets$ $— $690 $964 
PBO768 831 2,084 2,347 
(a)For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.

Pfizer Inc.
2024 Form 10-K
85


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
(b)For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.
(c)Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.
D. Plan Assets
The following provides the components of plan assets:
As of December 31, 2024As of December 31, 2023
    Fair ValueFair Value
(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)Target Allocation PercentageTotalLevel 1Level
2
Level 3
Assets Measured at NAV(a)
TotalLevel 1Level
 2
Level 3
Assets Measured at NAV(a)
U.S. pension plans
Cash and cash equivalents0-10%$533 $56 $477 $ $ $606 $47 $559 $ $ 
Equity securities:10-40%
Global equity securities1,341 1,341    1,537 1,537 — 1  
Equity commingled funds97  97   100  100   
Fixed income securities:45-80%
Corporate debt securities2,878 4 2,874   3,668 1 3,667 — — 
Government and agency obligations(b)
2,059  2,059   1,971  1,971   
Fixed income commingled funds42  12  30 25  14  11 
Other investments:5-35%
Partnership investments(c)
2,665    2,665 2,449    2,449 
Insurance contracts     99  99   
Other commingled funds(d)
333    333 479  —  479 
Total100 %$9,948 $1,401 $5,518 $ $3,028 $10,935 $1,585 $6,410 $1 $2,939 
International pension plans
Cash and cash equivalents0-10%$310 $138 $172 $ $ $268 $120 $148 $ $ 
Equity securities:10-20%
Equity commingled funds704  619  86 633  587  46 
Fixed income securities:45-70%
Corporate debt securities638  633 5  617  617   
Government and agency obligations(b)
960 1 960   848  848   
Fixed income commingled funds1,750  1,064  686 1,852  872  980 
Other investments:15-35%
Partnership investments(c)
147  2  145 145  2  142 
Insurance contracts1,221  45 1,176  1,151  55 1,096  
Other(d)
965 35 147 252 531 1,039  167 244 628 
Total100 %$6,696 $174 $3,642 $1,433 $1,447 $6,552 $120 $3,295 $1,340 $1,796 
U.S. postretirement plans(e)
Cash and cash equivalents0-5%$12 $ $12 $ $ $3 $1 $2 $ $ 
Insurance contracts95-100%724  724   633 — 633   
Total100 %$736 $ $736 $ $ $636 $1 $635 $ $ 
(a)Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.
(b)Government and agency obligations are inclusive of repurchase agreements.
(c)Mainly includes investments in private equity, private debt and real estate.
(d)Mostly includes investments in hedge funds and real estate.
(e)Reflects postretirement plan assets, which support our U.S. retiree medical plans.

Pfizer Inc.
2024 Form 10-K
86


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:
International Pension Plans
Year Ended December 31,
(MILLIONS)20242023
Fair value, beginning$1,340 $1,455 
Actual return on plan assets:
Assets held, ending8 (96)
Assets sold during the period (3)
Purchases, sales, and settlements, net
(79)(155)
Transfer into/(out of) Level 3168 81 
Exchange rate changes(5)59 
Fair value, ending$1,433 $1,340 
The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:
Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.
Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.
Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.
Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Level 3 investments may include securities or insurance contracts that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.
Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.
Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.
Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.
E. Cash Flows
It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.

Pfizer Inc.
2024 Form 10-K
87


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
The following provides the expected future cash flow information related to our benefit plans:
  Pension PlansPostretirement Plans
(MILLIONS)U.S.International
Expected employer contributions:
2025
$90 $144 $40 
Expected benefit payments:
2025$871 $384 $44 
2026858 366 47 
2027844 384 49 
2028
825 385 50 
2029
815 392 50 
2030–2034
3,760 2,067 245 
The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation.
F. Defined Contribution Plans
We have defined contribution plans in the U.S. and other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. We also offer a Retirement Savings Contribution which is an annual non-contributory employer contribution in the U.S. and Puerto Rico. We recorded charges related to the employer contributions to global defined contribution plans of $800 million in 2024, $843 million in 2023 and $770 million in 2022.
Note 12. Equity
A. Common Stock Purchases
We have authorization to purchase our common stock through privately negotiated transactions or in the open market as circumstances and prices warrant. Purchased shares under a share-purchase plan, which is authorized by our BOD, are available for general corporate purposes. In December 2018, the BOD authorized a $10 billion share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019.
In the first quarter of 2022, we purchased 39 million shares of our common stock at a cost of $2 billion under our publicly announced share-purchase plan. Our remaining share-purchase authorization was $3.3 billion as of December 31, 2024.
B. Preferred Stock
We have 27 million authorized shares of preferred stock without par value; no shares were issued or outstanding as of December 31, 2024 and 2023.
C. Employee Stock Ownership Plans
We have one ESOP that holds common stock of the Company (Common ESOP). As of December 31, 2024, all shares of common stock held by the Common ESOP have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was $16 million for 2024, $20 million for 2023 and $19 million for 2022.
Note 13. Share-Based Payments
Our compensation programs can include share-based payment awards with value that is determined by reference to the fair value of our shares and that provide for the grant of shares or options to acquire shares or similar arrangements. Our share-based awards are designed based on competitive survey data or industry peer groups used for compensation purposes, and are allocated between different long-term incentive awards, generally in the form of Total Shareholder Return Units (TSRUs), Restricted Stock Units (RSUs), Portfolio Performance Shares (PPSs), Performance Share Awards (PSAs), Breakthrough Performance Awards (BPAs) and stock options, as determined by the Compensation Committee of our BOD. No BPAs were granted in 2024 and no BPAs were outstanding as of December 31, 2024.
The Amended and Restated 2019 Stock Plan (2019 Plan) replaced and superseded the original 2019 Stock Plan. The 2019 Plan provides for 320 million shares to be authorized for grants plus any shares remaining available for grant under the original 2019 Stock Plan as of April 25, 2024 (the carryforward shares). The RSUs count as three shares, and PPSs, PSAs and BPAs count as three shares times the maximum potential payout, while TSRUs and stock options count as one share, toward the maximum shares available under the 2019 Plan. As of December 31, 2024, 441 million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.

Pfizer Inc.
2024 Form 10-K
88


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
A summary of the awards and valuation details:
Awarded toTermsValuationRecognition and Presentation
Total Shareholder Return Units (TSRUs)
Senior and other key management and select employees
Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the five or seven-year term, if and to the extent the total value is positive.
Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.
Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant. Certain 2022 and 2023 five-year grants were modified during 2024 (for active colleagues) to vest on the fifth anniversary and settle on the seventh anniversary of the grant.
Retirement-eligible holders can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs’ original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.
As of the grant date using a Monte Carlo simulation model
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Restricted Stock Units (RSUs)
Select employees
Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.
For RSUs granted before 2022, generally in all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date. Beginning in 2022, generally in all instances, the units vest and distribute one-third per year for three years on each of the three annual anniversaries from the date of grant assuming continuous service from the grant date.
As of the grant date using the closing price of our common stock
Amortized on a straight-line basis for RSUs granted before 2022, and on an accelerated attribution approach for RSUs granted beginning in 2022, over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Portfolio Performance Shares (PPSs)
Select employees
Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.
For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a three or five-year performance period from the year of the grant date, as applicable.
The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management’s assessment of the probability that the specified performance criteria will be achieved.
Performance Share Awards (PSAs)
Senior and other key management
Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:
a.Adjusted net income over three one-year periods; and
b.TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the three-year performance period.
PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. PSA awards granted in 2022 and 2023 were modified during 2024 (for active colleagues) to vest on the fifth anniversary of the grant.
The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved.

Pfizer Inc.
2024 Form 10-K
89


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Awarded toTermsValuationRecognition and Presentation
Breakthrough Performance Awards (BPAs)
Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)
Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.
For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the one-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer’s product pipeline during the performance period.
The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved and/or management’s assessment of the probable vesting term.
Stock Options
Select employees
Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.
Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.
Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years.
As of the grant date using the Black-Scholes-Merton option-pricing model
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:
(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION AND YEARS)
TSRUsRSUsPPSsPSAsStock Options
Year Ended December 31,202420232022202420232022202420232022202420232022202420232022
Total fair value of shares vested(a)
$7.05$10.71$11.72$469$505$345$176$116$145$ $58$57$4.08$7.88$9.44
Total intrinsic value of options exercised or share units converted$29$755$1,131$123$250$280$ $102$247
Cash received upon exercise$ $181$260
Tax benefits realized from exercise$ $20$46
Compensation cost recognized/(reduced), pre-tax
$246$244$255$394$437$402$252$(138)$144$(21)$(5)$73$4$4$4
Total compensation cost related to nonvested awards not yet recognized, pre-tax$270$192$179$214$212$266$107$81$135$40$22$38$4$4$3
Weighted-average period over which cost is expected to be recognized (years)2.11.71.71.81.81.71.91.81.71.71.81.81.71.71.7
(a)Weighted-average GDFV per TSRUs and stock options.
Total share-based payment expense was $877 million, $525 million and $872 million in 2024, 2023 and 2022, respectively. Tax benefit for share-based compensation expense was $165 million, $93 million and $160 million in 2024, 2023 and 2022, respectively.
The table above excludes total expense due to the modification for share-based awards in connection with our cost reduction/productivity initiatives, which was not significant for all years presented and is recorded in Restructuring charges and certain acquisition-related costs (see Note 3). Amounts capitalized as part of inventory cost were not significant for any period presented.
Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:
TSRUsStock Options
Year Ended December 31,202420232022202420232022
Expected dividend yield (based on a constant dividend yield during the expected term)
6.06 %3.80 %3.42 %6.06 %3.80 %3.42 %
Risk-free interest rate (based on interpolated yield on U.S. Treasury zero-coupon issues)
4.31 %4.08 %1.87 %4.32 %4.03 %1.93 %
Expected stock price volatility (based on implied volatility, after consideration of historical volatility)
26.56 %23.23 %29.20 %26.56 %23.23 %29.21 %
TSRUs contractual/stock options expected term, years (based on historical exercise and post-vesting termination patterns for stock options)
5.155.155.176.506.506.50

Pfizer Inc.
2024 Form 10-K
90


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Summary of all TSRU, RSU, PPS and PSA activity during 2024 (with the shares granted representing the maximum award that could be achieved for PPSs and PSAs):
TSRUsRSUs
PPSs(a)
PSAs
TSRUs Per TSRU, Weighted AverageShares  Weighted Avg. GDFV per shareShares Weighted Avg. Intrinsic Value per shareShares Weighted Avg. Intrinsic Value per share
(Thousands)GDFVGrant Price(Thousands)(Thousands)(Thousands)
Nonvested, December 31, 2023
77,673$9.67 $39.92 25,844$40.08 22,225$28.79 4,734$28.79 
Granted43,6747.05 26.90 17,07326.97 13,53526.92 2,59726.89 
Vested(31,076)7.42 33.87 (16,874)37.89 (6,329)27.76   
Reinvested dividend equivalents1,541 28.17 
Forfeited(5,370)8.66 33.90 (2,024)32.20 (3,274)28.03 (1,810)27.79 
Nonvested, December 31, 2024
84,902$9.63 $35.87 25,561$32.67 26,156$26.53 5,521$26.53 
(a)Vested and non-vested shares outstanding, but not paid as of December 31, 2024 were 33.9 million.
Summary of TSRU and PTU information as of December 31, 2024(a), (b):
TSRUs
(Thousands)
PTUs
(Thousands)
Weighted-Average
Grant Price
Per TSRU
Weighted-Average
Remaining Contractual Term (Years)
Aggregate Intrinsic Value (Millions)(c)
TSRUs Outstanding167,977 $34.17 2.5$122 
TSRUs Vested83,075 32.44 0.786 
TSRUs Expected to vest(d)
80,014 $35.93 4.334 
Outstanding PTUs converted from TSRUs exercised586 0.2$16 
(a)In 2024, we settled 2,419,674 TSRUs with a weighted-average grant price of $27.76 per unit.
(b)In 2024, 1,150,382 TSRUs with a weighted-average grant price of $31.54 per unit were converted into 100,307 PTUs.
(c)Market price of our underlying common stock less grant price plus dividend equivalents to date.
(d)The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.
Summary of all stock option activity during 2024:
Shares
(Thousands)
Weighted-Average
Exercise Price
Per Share
Weighted-Average
Remaining Contractual Term
(Years)
Aggregate
Intrinsic Value(a)
(Millions)
Outstanding, December 31, 2023
28,452 $32.66 
Granted1,372 26.90 
Exercised(4)29.06 
Forfeited(235)33.52 
Expired(9,964)30.69   
Outstanding, December 31, 2024
19,621 33.24 1.9$ 
Vested and expected to vest, December 31, 2024(b)
19,510 33.26 1.9 
Exercisable, December 31, 2024
17,447 $33.12 1.1$ 
(a)Market price of our underlying common stock less exercise price.
(b)The number of options expected to vest takes into account an estimate of expected forfeitures.
Note 14. Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
The following presents the detailed calculation of EPS:
 Year Ended December 31,
(MILLIONS)
202420232022
EPS Numerator  
Income from continuing operations attributable to Pfizer Inc. common shareholders$8,020 $2,134 $31,366 
Discontinued operations––net of tax11 (15)6 
Net income attributable to Pfizer Inc. common shareholders$8,031 $2,119 $31,372 
EPS Denominator  
Weighted-average common shares outstanding––Basic
5,664 5,643 5,608 
Common-share equivalents36 66 125 
Weighted-average common shares outstanding––Diluted
5,700 5,709 5,733 
Anti-dilutive common stock equivalents(a)
24 9 1 

Pfizer Inc.
2024 Form 10-K
91


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
Note 15. Leases
We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $517 million in 2024, $444 million in 2023 and $536 million in 2022. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.
We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.
For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:
As of December 31,
(MILLIONS)Balance Sheet Classification20242023
ROU assetsOther noncurrent assets$2,289 $2,924 
Lease liabilities (short-term)Other current liabilities356 527 
Lease liabilities (long-term)Other noncurrent liabilities2,286 2,626 
Components of total lease cost includes:
Year Ended December 31,
(MILLIONS)202420232022
Operating lease cost$683 $863 $714 
Variable lease cost517 444 536 
Sublease income(23)(24)(32)
Total lease cost$1,177 $1,283 $1,218 
Other supplemental information follows:
As of December 31,
(MILLIONS)20242023
Operating leases
Weighted-Average Remaining Contractual Lease Term (Years)10.210.8
Weighted-Average Discount Rate3.7 %3.8 %
Year Ended December 31,
(MILLIONS)202420232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$601 $744 $617 
(Gains)/losses on sale and leaseback transactions, net29 (49)11 

Pfizer Inc.
2024 Form 10-K
92


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2024:
(MILLIONS)
PeriodOperating Lease Liabilities
Next one year(a)
$443 
1-2 years406 
2-3 years361 
3-4 years281 
4-5 years239 
Thereafter1,468 
Total undiscounted lease payments3,197 
Less: Imputed interest
556 
Present value of minimum lease payments2,642 
Less: Current portion
356 
Noncurrent portion$2,286 
(a)Reflects lease payments due within 12 months subsequent to the balance sheet date.
Note 16. Contingencies and Certain Commitments
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and indemnifications. The following outlines our legal contingencies, guarantees and indemnifications. For a discussion of our tax contingencies, see Note 5D.
A. Legal Proceedings
Our legal contingencies include, but are not limited to, the following:
Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions.
Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.
Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.
Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.
Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges.
We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions.
The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some

Pfizer Inc.
2024 Form 10-K
93


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.
A1. Legal Proceedings––Patent Litigation
We are involved in suits relating to our patents (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights), including but not limited to, those discussed below. We face claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. In May 2023, the Court of Appeal dismissed BMS’s appeal and in October 2023, the Supreme Court refused BMS permission to appeal. Additional challenges are pending in other jurisdictions. Also, in July 2022, CureVac AG (CureVac) brought a patent infringement action against BioNTech and certain of its subsidiaries in the German Regional Court alleging that Comirnaty infringes certain German utility model patents and certain expired and unexpired European patents. Additional challenges involving Comirnaty patents may be filed against us and/or BioNTech in other jurisdictions in the future. Adverse decisions in these matters could have a material adverse effect on our results of operations. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payors, governments or other parties are seeking damages from us for allegedly causing delay of generic entry.
We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, as well as court proceedings relating to our intellectual property or the intellectual property rights of others, including challenges to such rights initiated by us. Also, if one of our patents (or one of our collaboration/licensing partner’s patents) is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office, as well as outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than anticipated. In the event that any of the patents are found valid and infringed, a competitor’s vaccine, if approved, might be prohibited from entering the market or a competitor might be required to pay us a royalty.
We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. If one of our marketed products (or a product of our collaboration/licensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.
Actions In Which We Are The Plaintiff
Xeljanz (tofacitinib)
Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications (ANDAs) with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.
In August 2024, we brought a patent infringement action against SpecGx LLC (SpecGX) asserting the infringement and validity of our composition of matter patent, covering immediate release formulations of tofacitinib that was challenged by SpecGX in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg immediate release tablets. In November 2024, we settled the action against SpecGX on terms not material to us.
In October 2024, we brought a patent infringement action against Breckenridge Pharmaceutical, Inc. (Breckenridge) asserting the infringement and validity of our composition of patent, covering immediate release formulations of tofacitinib that was challenged by Breckenridge in its ANDA seeking approval to market a generic version of tofacitinib 10 mg immediate release tablets. In November 2024, we settled the action against Breckenridge on terms not material to us.
In December 2024, we brought a patent infringement action against Alkem Laboratories Ltd. (Alkem) asserting the infringement and validity of our composition of matter patent, covering immediate release formulations of tofacitinib that was challenged by Alkem in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg immediate release tablets.
Mektovi (binimetinib)
Beginning in August 2022, two generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Mektovi. The companies assert the invalidity and non-infringement of two method of use patents expiring in 2030, a method of use patent expiring in 2031, two method of use patents expiring in 2033, and a product by process patent expiring in 2033. Beginning in September 2022, we brought patent infringement actions against both of the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of all six patents. In January 2025, we settled with one of the generic companies on terms not material to us.
In August 2022, we received notice from Teva Pharmaceuticals, Inc. (Teva) that it had filed an ANDA seeking approval to market a generic version of Mektovi. Teva asserts the invalidity and non-infringement of two method of use patents expiring in 2033 and a product by process patent expiring in 2033. In June 2023, we brought a patent infringement action against Teva in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the three patents.

Pfizer Inc.
2024 Form 10-K
94


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Vyndaqel-Vyndamax (tafamidis/tafamidis meglumine)
Beginning in June 2023, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of tafamidis capsules (61 mg) or tafamidis meglumine capsules (20 mg), challenging some or all of the patents listed in the FDA’s Orange Book for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine). Scripps Research Institute (Scripps) owns the composition of matter patent and the method of treatment patents covering the products, and Pfizer is the exclusive licensee. Pfizer separately owns the crystalline form patent. Beginning in August 2023, we and Scripps brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents in suit. Pfizer is the sole plaintiff in actions that assert only the infringement and validity of the crystalline form patent.
Oxbryta (voxelotor)
In January 2024, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, and Zydus Worldwide DMCC (collectively, Zydus) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Ltd. (collectively, MSN) separately notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of voxelotor tablets, challenging some of the patents listed in the FDA’s Orange Book for Oxbryta (voxelotor tablets in 300 mg and 500 mg strengths and/or for oral suspension) on non-infringement grounds. In March 2024, we filed patent infringement actions against both generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the challenged patents. Zydus and MSN have not challenged our composition of matter patents or method of treatment patents for Oxbryta.
Nurtec (rimegepant)
In April 2024, Rubicon Research Private Limited, Teva Pharmaceuticals, Inc., Changzhou Pharmaceutical Factory, Natco Pharma Limited and Natco Pharma, Inc., MSN, Aurobindo Pharma Limited, Apitoria Pharma Private Limited and Aurobindo Pharma U.S.A. Inc. (collectively, Aurobindo) and Apotex Inc. and Apotex Corp. (collectively, Apotex) notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of rimegepant orally disintegrating tablets, claiming noninfringement and/or challenging the validity of some or all of the patents listed in the FDA’s Orange Book for Nurtec (rimegepant orally disintegrating tablets Eq 75 mg base). In May 2024, we filed patent infringement actions against all the generic filers in the U.S. District Court for the District of Delaware.
Xtandi (enzalutamide)
Beginning in August 2024, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Xtandi, challenging some or all of the patents listed in the FDA’s Orange Book for Xtandi. Beginning in August 2024, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of New Jersey, asserting the validity and infringement of the patents in suit.
Inlyta (axitinib)
In October 2024, Sandoz Inc. (Sandoz) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Sandoz asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In November 2024, we filed suit against Sandoz in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.
Actions in Which We are the Defendant
Comirnaty (tozinameran)
In March 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia & Upjohn Company LLC, our wholly owned subsidiary, alleging that Comirnaty infringes a U.S. patent issued in February 2022, and seeking unspecified monetary damages. In July 2022, Alnylam filed a second complaint in the U.S. District Court for the District of Delaware against Pfizer, Pharmacia & Upjohn Company LLC, BioNTech and BioNTech Manufacturing GmbH, alleging that Comirnaty infringes a U.S. patent issued in July 2022, and seeking unspecified monetary damages. In May 2023, Alnylam filed a separate complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia & Upjohn Company LLC alleging that Comirnaty infringes four additional U.S. patents issued on various dates in 2023 and seeking unspecified monetary damages.
In August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Massachusetts, alleging that Comirnaty infringes three U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In March 2024, the U.S. Patent Office Patent Trial & Appeal Board instituted a review of two of the three patents in suit.
In August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, alleging that Comirnaty infringes two European patents. In September 2022, ModernaTX filed patent infringement actions in the U.K. and in the Netherlands against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, on the same two European patents. In its complaints, ModernaTX stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In November 2023, one of the European patents was revoked by the European Patent Office. In December 2023, the other European patent was declared invalid by a court in the Netherlands (the invalidity decision is limited to the Netherlands). In July 2024, the U.K. court revoked one patent, ruling that it was invalid, and held that the other patent was valid and infringed. ModernaTX has also filed additional patent infringement actions against Pfizer and BioNTech in certain other ex-U.S. jurisdictions.
In April 2023, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech alleging that Comirnaty and its manufacture infringe five U.S. patents, and seeking unspecified monetary damages.
In April 2024, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC (collectively, GSK Group) sued Pfizer and Pharmacia & Upjohn Company LLC, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Delaware, alleging that Comirnaty infringes five U.S. patents and seeking unspecified money damages. In August 2024, GSK Group filed an amended complaint alleging that Comirnaty infringes three additional U.S. patents.
In January 2025, Promosome LLC filed a complaint in the Unified Patent Court, Local Division Munich, against Pfizer and BioNTech and certain of their subsidiaries alleging that Comirnaty infringes a European patent that is in force only in France, Germany and Sweden, and seeking unspecified monetary damages in connection with the manufacture and sale of Comirnaty in France, Germany and Sweden.

Pfizer Inc.
2024 Form 10-K
95


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Paxlovid
In June 2022, Enanta Pharmaceuticals, Inc. (Enanta) filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes a U.S. patent issued in June 2022, and seeking unspecified monetary damages. In December 2024, the District Court issued an order granting Pfizer’s motion for summary judgment, finding Enanta’s patent invalid.
Abrysvo
In August 2023, GSK Group filed a complaint in the U.S. District Court for the District of Delaware against Pfizer alleging that the active ingredient in Abrysvo infringes four U.S. patents. In November 2023, GSK Group amended its complaint to assert infringement of two additional patents. In November 2024, the GSK Group filed a second amended complaint, adding a seventh patent to the lawsuit. The second amended complaint seeks unspecified monetary damages and a permanent injunction against sales of Abrysvo for use in adults in age ranges for which GSK Group’s Arexvy product is also indicated.
In addition, we have challenged certain of GSK’s RSV vaccine patents in certain ex-U.S. jurisdictions, including the U.K., the Netherlands, Belgium and the Unified Patent Court, and GSK has asserted that Abrysvo infringes these patents. In October 2024, the U.K. Court held that two of GSK’s U.K. patents were invalid and not infringed.
Matters Involving Pfizer and its Collaboration/Licensing Partners
Comirnaty (tozinameran)
In July 2022, Pfizer, BioNTech and BioNTech Manufacturing GmbH filed a declaratory judgment complaint against CureVac in the U.S. District Court for the District of Massachusetts seeking a judgment of non-infringement for three U.S. patents relating to Comirnaty. In May 2023, the case was transferred to the U.S. District Court for the Eastern District of Virginia. Also in May 2023, CureVac asserted that Comirnaty infringes the three patents that were the subject of our declaratory judgment complaint, and in May and July 2023, CureVac asserted that Comirnaty infringes a number of additional U.S. patents.
In the U.K., Pfizer and BioNTech have sued CureVac seeking a judgment of invalidity of several patents and CureVac has made certain infringement counterclaims. In September 2024, the U.K. Court held that both of the CureVac patents in suit are invalid.
A2. Legal Proceedings––Product Litigation
We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.
Asbestos
Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.
Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.
There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.
Lipitor
In 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy Laboratories Limited, among others, that asserted claims and sought relief on behalf of the State of West Virginia and residents of that state alleging delay in the launch of generic Lipitor, in violation of state antitrust, consumer protection and various other laws. In December 2024, we reached an agreement to settle this matter on terms not material to Pfizer.
Docetaxel
A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. Hospira is a wholly-owned subsidiary that we acquired in September 2015. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.
In 2016, the federal cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Eastern District of Louisiana.
Zantac
A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to Johnson & Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson & Johnson in connection with the sale. Plaintiffs in these cases seek compensatory and punitive damages.
In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Southern District of Florida (the Federal MDL Court). Plaintiffs in the MDL filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In December 2022,

Pfizer Inc.
2024 Form 10-K
96


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
the Federal MDL Court granted defendants’ Daubert motions to exclude plaintiffs’ expert testimony and motion for summary judgment on general causation, which has resulted in the dismissal of all complaints in the litigation. Plaintiffs have appealed the Federal MDL Court’s rulings.
In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants’ sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts. The large majority of the state court cases have been filed in the Superior Court of Delaware in New Castle County.
Many of these Zantac-related cases have been outstanding for a number of years and could take many more years to resolve. From time to time, Pfizer has explored and will continue to explore opportunistic settlements of these matters. As of January 2025, Pfizer had settled, or entered into definitive agreements or agreements-in-principle to settle, subject to certain conditions, a substantial majority of the cases filed in state courts in which the plaintiff alleges use of a Pfizer product. The remaining unresolved state court cases continue in various state courts.
Chantix
Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer’s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. In December 2022, the federal actions were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Southern District of New York. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix. The class action in Israel has been dismissed.
Depo-Provera
A number of lawsuits have been filed against Pfizer and certain subsidiaries in various federal and state courts alleging that plaintiffs who used the injectable version of Depo-Provera (active ingredient medroxyprogesterone acetate, or MPA) for contraception developed meningioma. The cases also name other defendants, including the manufacturers of generic versions of injectable MPA for contraception. Plaintiffs assert claims against Pfizer relating to both Depo-Provera and generic MPA products, and seek compensatory and punitive damages. In February 2025, the federal cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Northern District of Florida.
A3. Legal Proceedings––Commercial and Other Matters
Monsanto-Related Matters
In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.
In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.
In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation. In 2018, Bayer AG acquired Monsanto Company (New Monsanto), which is now a subsidiary of Bayer AG. Since the acquisition, New Monsanto has continued to defend and indemnify Pharmacia for these liabilities.
Environmental Matters
In 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as Wyeth Holdings Corporation and American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of administrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency, the New Jersey Department of Environmental Protection and/or federal and state natural resource trustees to perform remedial design, removal and remedial actions, and related environmental remediation activities, and to resolve alleged damages to natural resources, at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.
We are also party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.

Pfizer Inc.
2024 Form 10-K
97


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Contracts with Iraqi Ministry of Health
In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health and seeks monetary relief. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of plaintiffs’ claims. In January 2022, the Court of Appeals reversed the District Court’s decision. In June 2024, the U.S. Supreme Court issued an order granting certiorari, vacating the Court of Appeals’ decision, and remanding the case to the Court of Appeals.
Allergan Complaint for Indemnity
In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer’s acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.
Breach of Contract – Comirnaty
In 2023, Pfizer and BioNTech Manufacturing GmbH initiated separate formal proceedings against the Republic of Poland, the Republic of Romania and Hungary in Belgium’s Court of First Instance of Brussels. Pfizer and BioNTech are seeking an order from the Court holding those countries to their commitments for COVID-19 vaccine orders, which were placed as part of their contracts signed in 2021.
A4. Legal Proceedings––Government Investigations
Like other multi-national pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.
Greenstone Antitrust Litigation
In 2019 and 2020, Attorneys General of more than 50 states and territories filed two complaints in the U.S. District Court for the District of Connecticut against a number of pharmaceutical companies, including Pfizer and Greenstone—a former Pfizer subsidiary that sold generic drugs. As to Greenstone and Pfizer, the complaints allege anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. The State Attorney General complaints were initially transferred to an MDL in the U.S. District Court for the Eastern District of Pennsylvania for coordinated pre-trial proceedings but were transferred back to the District of Connecticut in April 2024. The Greenstone antitrust litigation also includes civil complaints filed in federal and state court by private and governmental plaintiffs against Pfizer, Greenstone, and a number of other defendants. These related civil lawsuits assert allegations that generally overlap with those asserted by the State Attorneys General. All of the related federal lawsuits are part of the MDL pending in Pennsylvania.
Subpoena relating to Tris Pharma/Quillivant XR
In October 2018, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records in response to this request.
Government Inquiries relating to Meridian Medical Technologies
In February 2019, we received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office for the SDNY. The CID seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at Pfizer’s former Meridian site. In August 2019, we received a HIPAA subpoena issued by the U.S. Attorney’s Office for the Eastern District of Missouri, in coordination with the Department of Justice’s Consumer Protection Branch, seeking similar records and information. We have produced records in response to these and subsequent requests.
U.S. Department of Justice Inquiries relating to India Operations
In March 2020, we received an informal request from the U.S. Department of Justice’s Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney’s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We have produced records pursuant to these requests.
Zantac––State of New Mexico and Mayor and City Council of Baltimore Civil Actions
See Legal Proceedings––Product Litigation––Zantac above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions.
Government Inquiries relating to Biohaven
In June 2022, the U.S. Department of Justice’s Commercial Litigation Branch and the U.S. Attorney’s Office for the Western District of New York issued a CID to Biohaven. The CID seeks records and information related to, among other things, Biohaven’s engagements with healthcare professionals and co-pay coupons cards prior to Pfizer’s acquisition of Biohaven. In March 2023, the California Department of Insurance issued a subpoena seeking records similar to those requested by the CID. Biohaven is a wholly-owned subsidiary that we acquired in October 2022. We have produced records in response to these requests. In January 2025, Biohaven entered into civil settlement agreements with the U.S., numerous states, and the California Department of Insurance to resolve these matters. Pursuant to these settlement agreements, $59.7 million, plus interest, was paid to the U.S. and participating states, and $3.3 million was paid to the California Department of Insurance. The settlement agreements relate to alleged conduct at Biohaven before Pfizer’s acquisition of the company and do not include an admission of liability by Biohaven.

Pfizer Inc.
2024 Form 10-K
98


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Government Inquiries relating to Xeljanz
In April 2023, we received a HIPAA subpoena issued by the U.S. Attorney’s Office for the Western District of Virginia, in coordination with the Department of Justice’s Commercial Litigation Branch, seeking records and information related to programs Pfizer sponsored in retail pharmacies relating to Xeljanz. We have produced records pursuant to this request.
B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2024, the estimated fair value of these indemnification obligations is not material to Pfizer.
In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.
See Note 7D for information on Pfizer Inc.’s guarantee of the debt issued by PIE in May 2023. We have also guaranteed the long-term debt of certain subsidiaries of Pfizer and certain companies that we acquired and that now are subsidiaries of Pfizer. See Note 7D.
C. Certain Commitments
As of December 31, 2024, we had commitments totaling $4.1 billion that are legally binding and enforceable. These commitments include purchase obligations for goods and services and payments relating to potential milestone payments deemed reasonably likely to occur.
See Note 5A for information on the TCJA repatriation tax liability.
D. Contingent Consideration for Acquisitions
We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. See Note 1D. The estimated fair value of contingent consideration as of December 31, 2024 is $517 million, of which $39 million is recorded in Other current liabilities and $477 million in Other noncurrent liabilities, and as of December 31, 2023 was $692 million, of which $179 million was recorded in Other current liabilities and $512 million in Other noncurrent liabilities. The decrease in the contingent consideration balance from December 31, 2023 is primarily due to payments made upon the achievement of certain sales-based milestones.
E. Insurance
Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued.
Note 17. Segment, Geographic and Other Revenue Information
A. Segment Information
We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Pfizer Ignite is an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with Pfizer’s R&D focus areas. Prior to June 2024, PC1 and Pfizer Ignite were managed together by a single manager as part of the former Business Innovation operating segment. Biopharma is the only reportable segment. Pfizer’s CODM is the Chairman and Chief Executive Officer. Our CODM uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. The CODM uses segment revenues and earnings in the annual budgeting process when setting strategic goals for the company and considers periodic budget-to-actual variances in segment revenues and earnings when assessing performance of the segments and making decisions about allocating resources to the operating segments. By analyzing segment financial results, the CODM can discern trends, which can inform decisions that align with the company’s goals and objectives, and help ensure risks are managed appropriately. We regularly review our operating segments and the approach used by management to evaluate performance and allocate resources.
Our commercial divisions market, sell and distribute our products, and global operating functions are responsible for the research, development, manufacturing and supply of our products. Each operating segment is supported by our global corporate enabling functions. At the beginning of 2024, we made changes in our commercial organization to incorporate Seagen and improve focus, speed and execution. The commercial structure within our Biopharma reportable segment in 2024 was comprised of the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division:
Pfizer Oncology Division combined the U.S. Oncology commercial organizations, global Oncology marketing organizations and global and U.S. Oncology medical affairs from both Pfizer and Seagen.
Pfizer U.S. Commercial Division included the U.S. Primary Care and U.S. Specialty Care customer groups, the Chief Marketing Office, the Global Chief Medical Affairs Office and Global Access & Value.
Pfizer International Commercial Division included the ex-U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio in all international markets.

Pfizer Inc.
2024 Form 10-K
99


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Beginning January 1, 2024, Biopharma’s earnings include costs related to manufacturing and supply, sales and marketing activities, R&D, and medical and safety activities that are associated with products in our Biopharma segment. Prior to 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations in 2024 were presented as part of Other business activities. We have reclassified our prior period segment information to conform to the current period presentation.
ORD was responsible in 2024 for discovery to late-phase clinical development for oncology research projects for our global portfolio along with facilitating regulatory submissions and interactions with regulatory agencies for these projects. R&D spending may include upfront and milestone payments for intellectual property rights for oncology projects.
PRD was responsible in 2024 for discovery to late-phase clinical development research projects for all therapeutic areas other than oncology for our global portfolio, along with facilitating regulatory submissions and interactions with regulatory agencies for these projects. R&D spending may include upfront and milestone payments for intellectual property rights related to non-oncology projects. PRD also had responsibility for certain science-based and other services organizations, which provide end-to-end technical expertise and other services to both ORD and PRD projects, as well as the Worldwide Medical and Safety group, which helps ensure that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payors and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines.
Other Business Activities––Other business activities include the operating results of PC1 and Pfizer Ignite as well as certain pre-tax costs not allocated to our operating segment results, such as costs associated with:
corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement, among others) and other corporate costs, including, but not limited to, all strategy, business development and portfolio management capabilities and certain compensation, as well as interest income and expense, and gains and losses on investments; and
our share of earnings from Haleon/the Consumer Healthcare JV (see Note 2C).
Reconciling Items––Reconciling items include the following items, transactions and events that are not allocated to our operating segments: (i) all amortization of intangible assets; (ii) acquisition-related items, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company, and which may also include purchase accounting impacts, such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such certain significant items can include, but are not limited to, pension and postretirement actuarial remeasurement gains and losses, non-acquisition-related restructuring costs, net gains and losses on investments in equity securities, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.
Segment Assets––We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $213 billion as of December 31, 2024 and $227 billion as of December 31, 2023.
Selected Statement of Operations Information
The following table provides selected information by reportable segment:
 
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
Year Ended December 31,Year Ended December 31,Year Ended December 31,
(MILLIONS)
20242023 2022 20242023 202220242023 2022
Reportable Segment:
Biopharma(c)
$62,400 $58,237 $99,826 $28,139 $15,923 $47,939 $1,360 $1,213 $1,107 
Other business activities(d)
1,228 1,316 1,349 (7,382)(4,342)(5,162)340 323 332 
Reconciling Items:
Amortization of intangible assets(5,286)(4,733)(3,609)5,286 4,733 3,609 
Acquisition-related items(1,938)(1,874)(832)12 (11)(20)
Certain significant items(e)
(5,510)(3,917)(3,608)14 32 36 
$63,627 $59,553 $101,175 $8,023 $1,058 $34,729 $7,013 $6,290 $5,064 
(a)Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $331 million and $294 million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
(c)Biopharma’s revenues and earnings in 2024 reflect a non-cash favorable product return adjustment of $771 million recorded in the first quarter of 2024 and in 2023 reflected a non-cash revenue reversal of $3.5 billion (see Note 17C). In 2023, Biopharma earnings included approximately $6.2 billion of inventory write-offs and related charges to Cost of sales mainly due to lower-than-expected demand for our COVID-19 products. In 2022, Biopharma earnings included COVID-19-related charges of approximately $1.7 billion to Cost of sales, composed of (i) inventory write-offs of approximately $1.2 billion related to COVID-19

Pfizer Inc.
2024 Form 10-K
100


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for Paxlovid. Biopharma’s earnings also include dividend income from our investment in ViiV of $272 million in 2024, $265 million in 2023 and $314 million in 2022.
(d)Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.
(e)Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in 2024 include, among other items: (i) intangible asset impairment charges of $3.3 billion recorded in Other (income)/deductions––net, (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs), (iii) actuarial valuation and other postretirement plan losses of $579 million recorded in Other (income)/deductions––net, (iv) charges for certain legal matters of $567 million recorded in Other (income)/deductions––net, and (v) a charge in Other (income)/deductions––net of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program, partially offset by (vi) net gains on equity securities of $1.0 billion and (vii) net gains of $825 million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945 million less (b) $120 million in the fourth quarter (included in Other business activities) representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares. Earnings in 2023 included, among other items: (i) intangible asset impairment charges of $3.0 billion recorded in Other (income)/deductions––net and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion ($290 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in Other (income)/deductions––net. Earnings in 2022 included, among other items: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.4 billion ($562 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs) and (ii) net losses on equity securities of $1.3 billion recorded in Other (income)/deductions––net. See Notes 3 and 4.
The following provides Biopharma reportable segment information regularly provided to the CODM:
Year Ended December 31,
(MILLIONS)202420232022
Biopharma reportable segment:
Biopharma total revenues$62,400 $58,237 $99,826 
Less:
Cost of sales14,997 22,666 32,859 
Selling, informational and administrative expenses10,040 10,235 9,207 
Research and development expenses9,532 9,763 10,324 
Acquired in-process research and development expenses108 194 181 
Other (income)/deductions––net
(416)(543)(685)
Biopharma earnings$28,139 $15,923 $47,939 
Revenues - Comirnaty
$5,353 $11,220 $37,809 
Revenues - Paxlovid
$5,716 $1,279 $18,933 
Revenues - excluding Comirnaty and Paxlovid
$51,331 $45,738 $43,084 
B. Geographic Information
The following summarizes revenues by geographic area:
 Year Ended December 31,
(MILLIONS)202420232022
United States$38,691 $28,145 $43,317 
International:
Developed Markets
16,057 20,910 40,534 
Emerging Markets8,879 10,498 17,324 
Total revenues$63,627 $59,553 $101,175 
Revenues exceeded $500 million in each of 11, 14 and 24 countries outside the U.S. in 2024, 2023 and 2022, respectively. The U.S. is the only country to contribute more than 10% of total revenue in 2024, 2023 and 2022. As a percentage of Total revenues, China was our largest market outside the U.S. (representing 4% of total revenues) in 2024, and Japan was our largest market outside the U.S. in 2023 and 2022 (representing 6% and 8% of total revenues, respectively).
C. Other Revenue Information
Significant Customers
We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of Comirnaty with multiple developed and emerging nations around the world and are continuing to deliver doses of Comirnaty under such agreements. This includes supply agreements entered into in November 2020 and February and May 2021 with the EC for Comirnaty on behalf of the different EU member states and certain other countries. Each EU member state submits its own Comirnaty vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC. In May 2023, we and BioNTech amended our contract with the EC to deliver COVID-19 vaccines to the EU. The amended agreement includes rephasing of delivery of doses annually through 2026 and an aggregate volume reduction, providing additional flexibility for those EU member states who agreed to the amended agreement. The EC will maintain access to future adapted COVID-19 vaccines and the ability to donate doses, in alignment with the original agreement.

Pfizer Inc.
2024 Form 10-K
101


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
In 2022 and 2023, we had entered into agreements to supply pre-specified treatment courses of Paxlovid with government and government sponsored customers in multiple developed and emerging nations around the world, which represented most Paxlovid revenues in 2022 and 2023, while commercialization began in some markets in 2023. In October 2023, we announced an amended agreement with the U.S. government, which facilitated the transition of Paxlovid to traditional commercial markets in the U.S. starting in November 2023, with prices negotiated with commercial payors and a copay assistance program for eligible privately insured patients, as the U.S. government began to discontinue the distribution of EUA-labeled Paxlovid. We ensured commercial readiness by providing NDA-labeled commercial supply by the end of 2023. However, EUA-labeled Paxlovid remained available free-of-charge to all eligible patients until the end of 2023, and therefore, there was only minimal uptake of NDA-labeled commercial product before January 1, 2024. In connection with this agreement, we recorded a non-cash revenue reversal of $3.5 billion in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory. In the first quarter of 2024, we recorded a non-cash favorable final adjustment of $771 million to reflect 5.1 million EUA-labeled treatment courses returned through February 29, 2024, which were converted to a volume-based credit that supports continued access to Paxlovid through a U.S. government patient assistance program operated by Pfizer. In the third quarter of 2024, in connection with this amended agreement, we also supplied at no cost to the U.S. government or taxpayers a U.S. SNS of 1.0 million treatment courses to enable future pandemic preparedness through 2028, and recorded revenue of $442 million. While we are recognizing revenue as these treatment courses are delivered, there is no cash consideration for these treatment courses.
The following summarizes revenue, as a percentage of Total revenues, for our three largest U.S. wholesaler customers and the U.S. government, which was concentrated in our Biopharma operating segment:
 Year Ended December 31,
202420232022
McKesson, Inc.
23 %16 %8 %
Cencora, Inc.
17 %12 %5 %
Cardinal Health, Inc.14 %10 %4 %
U.S. government(a)
6 % 23 %
(a) The decrease in revenues from the U.S. government as a percentage of Total revenues for 2024 and 2023 compared to 2022 was primarily due to the transition of Comirnaty and Paxlovid to commercial market sales in the second half of 2023 as well as the revenue reversal for Paxlovid in the fourth quarter of 2023.
Collectively, our three largest U.S. wholesaler customers represented 34% and 42% of total trade accounts receivable as of December 31, 2024 and December 31, 2023, respectively. Accounts receivable from the U.S. government as of December 31, 2024 and December 31, 2023 were not material to our consolidated financial statements.
Significant Revenues by Product
The following provides detailed revenue information for several of our major products:
(MILLIONS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202420232022
TOTAL REVENUES$63,627 $59,553 $101,175 
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)
$62,400 $58,237 $99,826 
Primary Care$30,135 $30,799 $73,181 
Eliquis(a)
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism7,366 6,747 6,480 
Prevnar family
Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae
6,411 6,501 6,342 
Paxlovid(b)
COVID-19 in certain high-risk patients
5,716 1,279 18,933 
Comirnaty
Active immunization to prevent COVID-19
5,353 11,220 37,809 
Nurtec ODT/VyduraAcute treatment of migraine and prevention of episodic migraine1,263 928 213 
Abrysvo
Active immunization to prevent RSV infection
755 890  
Premarin family
Symptoms of menopause380 397 455 
BMP2
Bone graft for spinal fusion
352 338 277 
FSME-IMMUN/TicoVacActive immunization to prevent tick-borne encephalitis disease280 268 200 
All other Primary CareVarious2,259 2,233 2,473 
Specialty Care$16,652 $14,988 $13,851 
Vyndaqel familyATTR-CM and polyneuropathy5,451 3,321 2,447 
Xeljanz
RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis1,168 1,703 1,796 
Enbrel (Outside the U.S. and Canada)
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis
690 830 1,003 
Sulperazon
Bacterial infections637 757 786 
ZaviceftaBacterial infections586 511 412 
Octagam(c)
Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults
509 245 186 
Inflectra
Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis
509 490 532 
ZithromaxBacterial infections480 406 331 

Pfizer Inc.
2024 Form 10-K
102


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
(MILLIONS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202420232022
Genotropin
Replacement of human growth hormone470 539 360 
BeneFIXHemophilia B381 424 425 
Cibinqo
Atopic dermatitis
215 128 27 
Oxbryta(d)
Sickle cell disease201 328 73 
All other Hospital(e)
Various
4,448 4,514 4,730 
All other Specialty CareVarious907 792 743 
Oncology$15,612 $12,450 $12,794 
IbranceHR-positive/HER2-negative metastatic breast cancer4,367 4,753 5,120 
Xtandi(f)
mCRPC, nmCRPC, mCSPC, nmCSPC
2,039 1,659 1,650 
Padcev
Locally advanced or metastatic urothelial cancer
1,588 53  
Adcetris
Hodgkin lymphoma and certain T-cell lymphomas
1,089 56  
Oncology biosimilars(g)
Various
1,037 1,407 1,753 
Inlyta
Advanced RCC978 1,036 1,003 
Lorbrena
ALK-positive metastatic NSCLC
731 539 343 
Bosulif
Philadelphia chromosome–positive chronic myelogenous leukemia645 645 575 
Braftovi/Mektovi
Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux (cetuximab)(h) (after prior therapy) or cetuximab and mFOLFOX6
607 477 456 
Tukysa
Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer480 18  
Elrexfio
Relapsed or refractory multiple myeloma
133 10  
Tivdak
Recurrent or mCC
131 4  
Talzenna
In combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC; treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer
117 64 48 
All other OncologyVarious1,670 1,729 1,846 
PFIZER CENTREONE(i)
$1,146 $1,272 $1,342 
PFIZER IGNITE
$82 $44 $7 
BIOPHARMA
$62,400 $58,237 $99,826 
PFIZER U.S. COMMERCIAL DIVISION (U.S. Primary Care and U.S. Specialty Care)
26,765 19,299 34,337 
PFIZER ONCOLOGY DIVISION
11,567 8,450 8,583 
PFIZER INTERNATIONAL COMMERCIAL DIVISION
24,068 30,488 56,905 
Total Alliance revenues included above$8,388 $7,582 $8,537 
Total Royalty revenues included above
$1,423 $1,058 $845 
(a)Reflects Alliance revenues and product revenues.
(b)2024 includes (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.
(c)2024 includes $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.
(d)In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of expanded access programs worldwide, based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing.
(e)Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.
(f)Primarily reflects Alliance revenues and royalty revenues.
(g)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.
(h)Erbitux is a registered trademark of ImClone LLC.
(i)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
Remaining Performance Obligations––Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty and Paxlovid to our customers totaled approximately $4 billion and $1 billion, respectively, as of December 31, 2024, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of these amounts, current contract terms provide for expected delivery of product with contracted revenue from 2025 through 2028, the timing of which may be renegotiated. Remaining performance obligations are based on foreign exchange rates as of the end of our fiscal fourth quarter of 2024 and exclude arrangements with an original expected contract duration of less than one year. Remaining performance obligations associated with contracts for other products and services were not significant as of December 31, 2024 or 2023.

Pfizer Inc.
2024 Form 10-K
103


Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Deferred Revenues–– Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers for supply of Paxlovid and Comirnaty. The deferred revenues related to Paxlovid and Comirnaty totaled $2.2 billion as of December 31, 2024, with $1.4 billion and $785 million recorded in current liabilities and noncurrent liabilities, respectively. The deferred revenues related to Paxlovid and Comirnaty totaled $5.1 billion as of December 31, 2023, with $2.6 billion and $2.5 billion recorded in current liabilities and noncurrent liabilities, respectively. The decrease in Paxlovid and Comirnaty deferred revenues during full-year 2024 was primarily driven by amounts recognized in Product revenues as we delivered the products to our customers (including $442 million associated with the U.S. SNS for Paxlovid) as well as the aforementioned $771 million favorable final adjustment recorded in the first quarter of 2024 for Paxlovid, partially offset by additional advance payments received in 2024 as we entered into amended contracts. During 2024, we recognized revenue of approximately $2.9 billion that was included in the balance of Paxlovid and Comirnaty deferred revenues as of December 31, 2023. The Paxlovid and Comirnaty deferred revenues as of December 31, 2024 will be recognized in Product revenues proportionately as we transfer control of the products to our customers and satisfy our performance obligations under the contracts, with the amounts included in current liabilities expected to be recognized in Product revenues within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in Product revenues from December 2025 (which falls in our international first quarter of 2026) through 2028. Deferred revenues associated with contracts for other products were not significant as of December 31, 2024 or December 31, 2023.

Pfizer Inc.
2024 Form 10-K
104


Selected Quarterly Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies

 Quarter
(MILLIONS, EXCEPT PER COMMON SHARE DATA)FirstSecondThirdFourth
2024(a)
Total revenues
$14,879 $13,283 $17,702 $17,763 
Costs and expenses(b)
11,355 12,133 12,674 17,023 
Restructuring charges and certain acquisition-related costs(c)
102 1,254 313 750 
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)
3,421 (103)4,715 (10)
Provision/(benefit) for taxes on income/(loss)(d)
293 (134)234 (421)
Income/(loss) from continuing operations3,128 31 4,481 411 
Discontinued operations––net of tax
(5)17 (8)7 
Net income/(loss) before allocation to noncontrolling interests3,123 48 4,473 418 
Less: Net income attributable to noncontrolling interests8 7 8 8 
Net income/(loss) attributable to Pfizer Inc. common shareholders$3,115 $41 $4,465 $410 
Earnings/(loss) per common share—basic:
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders
$0.55 $0.01 $0.79 $0.07 
Discontinued operations––net of tax    
Net income/(loss) attributable to Pfizer Inc. common shareholders$0.55 $0.01 $0.79 $0.07 
Earnings/(loss) per common share—diluted:
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders
$0.55 $0.01 $0.79 $0.07 
Discontinued operations––net of tax    
Net income/(loss) attributable to Pfizer Inc. common shareholders
$0.55 $0.01 $0.78 $0.07 
(a)Business development activities impacted our results of operations in 2024. See Note 1A. Due to the commercial market transition as well as the seasonality of demand for COVID-19 vaccinations, the majority of our global revenues for Comirnaty were recorded in the fourth quarter of 2024.
(b)The fourth quarter historically reflects higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development expenses. Cost of sales for all quarters reflects higher costs from our Seagen acquisition, inclusive of the amortization of the fair value step-up of inventory. See Note 2A. Certain asset impairments totaled $2.9 billion in the fourth quarter. See Note 4.
(c)The second quarter of 2024 primarily includes employee termination costs associated with our Manufacturing Optimization Program. The fourth quarter of 2024 primarily includes charges for asset impairments, exit costs and employee termination costs associated with our Realigning our Cost Base Program. See
Note 3.
(d)All periods reflect changes primarily the result of jurisdictional mix of earnings. The third quarter reflects tax benefits related to the closing of the IRS audits covering multiple tax years and the fourth quarter reflects tax benefits related to the Transition Tax liability under the TCJA. See Note 5A.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.

Pfizer Inc.
2024 Form 10-K
105


Selected Quarterly Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies

Quarter
(MILLIONS, EXCEPT PER COMMON SHARE DATA)FirstSecondThirdFourth
2023(a)
Total revenues
$18,486 $13,007 $13,491 $14,570 
Costs and expenses(b)
12,207 10,524 16,688 16,133 
Restructuring charges and certain acquisition-related costs(c)
214 155 2,566 
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)6,270 2,269 (3,352)(4,129)
Provision/(benefit) for taxes on income/(loss)(d)
715 (71)(964)(795)
Income/(loss) from continuing operations5,555 2,340 (2,388)(3,335)
Discontinued operations––net of tax
(2)12 (26)
Net income/(loss) before allocation to noncontrolling interests5,556 2,338 (2,376)(3,361)
Less: Net income attributable to noncontrolling interests13 11 
Net income/(loss) attributable to Pfizer Inc. common shareholders$5,543 $2,327 $(2,382)$(3,369)
Earnings/(loss) per common share—basic:
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders$0.98 $0.41 $(0.42)$(0.59)
Discontinued operations––net of tax— — — — 
Net income/(loss) attributable to Pfizer Inc. common shareholders$0.98 $0.41 $(0.42)$(0.60)
Earnings/(loss) per common share—diluted:
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders$0.97 $0.41 $(0.42)$(0.59)
Discontinued operations––net of tax— — — — 
Net income/(loss) attributable to Pfizer Inc. common shareholders$0.97 $0.41 $(0.42)$(0.60)
(a)On December 14, 2023, we completed the acquisition of Seagen. In addition, other business development activities impacted our results of operations in 2023. See Note 1A. Due to the commercial market transition as well as the seasonality of demand for COVID-19 vaccinations, the majority of our global revenues for Comirnaty were recorded in the second half of 2023.
(b)The fourth quarter historically reflects higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development expenses. The third quarter of 2023 reflects a non-cash charge of $5.6 billion to Cost of sales for inventory write-offs and related charges ($4.7 billion for Paxlovid and $0.9 billion for Comirnaty). Certain asset impairments totaled $2.8 billion in the fourth quarter of 2023 recorded in Other (income)/deductions—net. See Note 4.
(c)The fourth quarter of 2023 primarily includes (i) charges of $1.5 billion for employee termination costs associated with our Realigning our Cost Base Program and (ii) integration and other costs of $587 million, mostly related to our acquisition of Seagen. See Note 3.
(d)All periods reflect changes primarily the result of the jurisdictional mix of earnings and the second quarter reflects the tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years. See Note 5A.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.
ITEM 9.CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A.CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
As of the end of the period covered by this Form 10-K, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.
Changes in Internal Controls
During our most recent fiscal quarter, there has not been any change in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Pfizer Inc.
2024 Form 10-K
106



Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders
Pfizer Inc.:

Opinion on Internal Control Over Financial Reporting
We have audited Pfizer Inc. and Subsidiary Companies’ (the Company) internal control over financial reporting as of December 31, 2024, based on criteria established in Internal ControlIntegrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements), and our report dated February 27, 2025 expressed an unqualified opinion on those consolidated financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 Image8.jpg
New York, New York
February 27, 2025


Pfizer Inc.
2024 Form 10-K
107



Management’s Report on Internal Control Over Financial Reporting
Management’s Report
We prepared and are responsible for the financial statements that appear in this Form 10-K. These financial statements are in conformity with accounting principles generally accepted in the United States of America and, therefore, include amounts based on informed judgments and estimates. We also accept responsibility for the preparation of other financial information that is included in this document.
Report on Internal Control Over Financial Reporting
The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. The Company’s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013). Based on our assessment and those criteria, management believes that the Company maintained effective internal control over financial reporting as of December 31, 2024.
The Company’s independent auditors have issued their auditors’ report on the Company’s internal control over financial reporting. That report appears above in this Form 10-K.
Albert Bourla's signature.jpg
Albert Bourla 
Chairman and Chief Executive Officer 
David Denton.jpg
Jennifer Damico signature.jpg
David M. DentonJennifer B. Damico
Principal Financial OfficerPrincipal Accounting Officer
February 27, 2025

Pfizer Inc.
2024 Form 10-K
108


ITEM 9B.
OTHER INFORMATION
During the three months ended December 31, 2024, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
PART III
ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Information about our Directors is incorporated by reference from the discussion under the heading Item 1Election of Directors in our Proxy Statement. Information about the Pfizer Policies on Business Conduct governing our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, the Code of Business Conduct and Ethics for Members of the Board of Directors and our other governance practices and policies, including our Insider Trading Policy, is incorporated by reference from the discussions under the headings Governance Pfizer Policies on Business Conduct,Code of Conduct for Directors and —Other Governance Practices and Policies in our Proxy Statement. Information regarding the procedures by which our shareholders may recommend nominees to our Board of Directors is incorporated by reference from the discussion under the headings Item 1Election of DirectorsCriteria for Board Membership and Annual Meeting Information—Submitting Proxy Proposals and Director Nominations for the 2026 Annual Meeting in our Proxy Statement. Information about our Audit Committee, including the members of the Committee, and our Audit Committee financial experts, is incorporated by reference from the discussion under the heading Governance OverviewBoard and Committee InformationBoard Committees—The Audit Committee in our Proxy Statement. The balance of the information required by this item is contained in the discussion entitled Information about Our Executive Officers in this Form 10-K.
ITEM 11.EXECUTIVE COMPENSATION
Information about Director and executive compensation is incorporated by reference from the discussion under the headings Non-Employee Director Compensation; Executive Compensation; and Governance Overview—Board and Committee Information—Board CommitteesThe Compensation CommitteeCompensation Committee Interlocks and Insider Participation in our Proxy Statement.
ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Information required by this item is incorporated by reference from the discussion under the headings Executive CompensationCompensation Tables—Equity Compensation Plan Information and Securities Ownership in our Proxy Statement.
ITEM 13.CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Information about certain relationships and transactions with related parties is incorporated by reference from the discussion under the headings Governance OverviewOther Governance Practices and Policies—Related Person Transactions and Indemnification and Transactions with Related Persons in our Proxy Statement. Information about director independence is incorporated by reference from the discussion under the heading Item 1Election of DirectorsDirector Independence in our Proxy Statement.
ITEM 14.PRINCIPAL ACCOUNTING FEES AND SERVICES
Our independent registered public accounting firm is KPMG LLP, New York, NY, Auditor Firm ID: 185. Information about the fees for professional services rendered by our independent registered public accounting firm in 2024 and 2023 is incorporated by reference from the discussion under the heading Item 2Ratification of Selection of Independent Registered Public Accounting FirmAudit and Non-Audit Fees in our Proxy Statement. Our Audit Committee’s policy on pre-approval of audit and permissible non-audit services of our independent registered public accounting firm is incorporated by reference from the discussion under the heading Item 2Ratification of Selection of Independent Registered Public Accounting FirmPolicy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services in our Proxy Statement.
PART IV
ITEM 15.EXHIBITS, FINANCIAL STATEMENT SCHEDULES
15(a)(1) Financial Statements. The following consolidated financial statements, related notes and report of independent registered public accounting firm are set forth in Item 8. Financial Statements and Supplementary Data in this Form 10-K:

Pfizer Inc.
2024 Form 10-K
109


15(a)(2) Financial Statement Schedules. Schedules are omitted because they are not required or because the information is provided elsewhere in the financial statements. The financial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a significant subsidiary.
15(a)(3) Exhibits. These exhibits are available upon request. Requests should be directed to our Corporate Secretary, Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192. The exhibit numbers preceded by an asterisk (*) indicate exhibits filed with this Form 10-K. All other exhibit numbers indicate exhibits filed by incorporation by reference. Exhibit numbers 10.1 through 10.47 are management contracts or compensatory plans or arrangements.
Stock and Asset Purchase Agreement, dated December 19, 2018, by and among us, GlaxoSmithKline plc and GlaxoSmithKline Consumer Healthcare Holdings Limited is incorporated by reference from our 2018 Annual Report on Form 10-K. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Stock and Asset Purchase Agreement.)
Agreement and Plan of Merger, by and among Pfizer Inc., Aris Merger Sub, Inc. and Seagen Inc., dated as of March 12, 2023 is incorporated by reference from our Current Report on Form 8-K filed on March 13, 2023.
Our Restated Certificate of Incorporation dated December 14, 2020, is incorporated by reference from our Current Report on Form 8-K filed on December 14, 2020.
Our By-laws, as amended on December 9, 2022, are incorporated by reference from our Current Report on Form 8-K filed on
December 13, 2022.
Indenture, dated as of January 30, 2001, between us and The Chase Manhattan Bank, is incorporated by reference from our Current Report on Form 8-K filed on January 30, 2001.
First Supplemental Indenture, dated as of March 24, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 28, 2009.
Second Supplemental Indenture, dated as of June 2, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2009.
Third Supplemental Indenture, dated as of June 3, 2013, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2013.
Fourth Supplemental Indenture, dated as of May 15, 2014, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on May 15, 2014.
Fifth Supplemental Indenture, dated as of October 5, 2015, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on October 6, 2015.
Sixth Supplemental Indenture, dated as of June 3, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2016.
Seventh Supplemental Indenture, dated as of November 21, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on November 21, 2016.
Eighth Supplemental Indenture, dated as of March 17, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (successor to the Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on March 17, 2017.
Ninth Supplemental Indenture, dated as of March 6, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent and calculation agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on March 6, 2017.
Tenth Supplemental Indenture, dated as of December 19, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on December 19, 2017.
Indenture, dated as of April 10, 1992, between Wyeth (formerly American Home Products Corporation) and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3, filed on January 18, 1995.
Supplemental Indenture, dated as of October 13, 1992, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3, filed on January 18, 1995.
Fifth Supplemental Indenture, dated as of December 16, 2003, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s 2003 Annual Report on Form 10-K.

Pfizer Inc.
2024 Form 10-K
110


Sixth Supplemental Indenture, dated as of November 14, 2005, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Current Report on Form 8-K filed on November 15, 2005.
Seventh Supplemental Indenture, dated as of March 27, 2007, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Current Report on Form 8-K filed on March 28, 2007.
Eighth Supplemental Indenture, dated as of October 30, 2009, between Wyeth, us and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, formerly The Chase Manhattan Bank), as trustee, to Indenture dated as of April 10, 1992 (as amended on October 13, 1992), is incorporated by reference from our Current Report on Form 8-K filed on November 3, 2009.
Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on September 7, 2018.
First Supplemental Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on September 7, 2018.
Second Supplemental Indenture, dated as of March 11, 2019, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on March 11, 2019.
Third Supplemental Indenture, dated as of March 27, 2020, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on March 27, 2020.
Fourth Supplemental Indenture, dated as of May 28, 2020, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on May 28, 2020.
Fifth Supplemental Indenture, dated as of August 18, 2021 between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on August 18, 2021.
Indenture, dated as of May 19, 2023, among Pfizer Investment Enterprises Pte. Ltd., Pfizer Inc. and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on May 19, 2023.
First Supplemental Indenture, dated as of May 19, 2023, among Pfizer Investment Enterprises Pte. Ltd., Pfizer Inc. and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on May 19, 2023.
Description of Pfizer’s Securities.
4.27
Except as set forth in Exhibits 4.1-4.26 above, the instruments defining the rights of holders of long-term debt securities of the Company and its subsidiaries have been omitted. We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.
2001 Stock and Incentive Plan is incorporated by reference from our Proxy Statement for the 2001 Annual Meeting of Shareholders.
Pfizer Inc. 2004 Stock Plan, as Amended and Restated is incorporated by reference from our 2011 Annual Report on Form 10-K.
Amendment No. 1 to Pfizer 2004 Stock Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.
Pfizer Inc. 2014 Stock Plan is incorporated by reference from our Proxy Statement for the 2014 Annual Meeting of Shareholders.
Amendment No. 1 to Pfizer Inc. 2014 Stock Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.
Form of Acknowledgment and Consent and Summary of Key Terms for Grants of RSUs, TSRUs, PPSs and PSAs is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 2, 2023.
Form of Executive Grant Letter is incorporated by reference from our 2015 Annual Report on Form 10-K.
Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2017 Annual Report on Form 10-K.
Amendment No. 1 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2018 Annual Report on Form 10-K.
Amendment No. 2 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2020 Annual Report on Form 10-K.
Amendment No. 3 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2022 Annual Report on Form 10-K.
Amendment No. 4 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2023 Annual Report on Form 10-K.
Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2016.
Amendment No. 1 to the Pfizer Supplemental Savings Plan (Amended and Restated as of January 1, 2016), is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended October 1, 2017.
Amendment No. 2 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2017 Annual Report on Form 10-K.
Amendment No. 3 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended September 30, 2018.
Amendment No. 4 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.
Amendment No. 5 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.

Pfizer Inc.
2024 Form 10-K
111


Amendment No. 6 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 30, 2019.
Amendment No. 7 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2019 Annual Report on Form 10-K.
Amendment No. 8 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.
Amendment No. 9 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.
Amendment No. 10 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2022 Annual Report on Form 10-K.
Amended and Restated Pfizer Inc. Global Performance Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended October 1, 2023.
Amended and Restated Deferred Compensation Plan is incorporated by reference from our 2012 Annual Report on Form 10-K.
Amendment to Amended and Restated Deferred Compensation Plan, dated June 20, 2013, is incorporated by reference from our 2013 Annual Report on Form 10-K.
Amendment No. 2 to Amended and Restated Deferred Compensation Plan, dated April 27, 2016, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended July 3, 2016.
Amendment No. 3 to Amended and Restated Deferred Compensation Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.
Amended and Restated Deferred Compensation Plan (adopted in 2024) is incorporated by reference from our 2023 Annual Report on Form 10-K.
Wyeth 2005 (409A) Deferred Compensation Plan (frozen as of January 2012), together with certain Amendments, is incorporated by reference from our 2013 Annual Report on Form 10-K.
Amendment No. 2 to Wyeth 2005 (409A) Deferred Compensation Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.
Amended and Restated Wyeth Supplemental Employee Savings Plan (effective as of January 1, 2005 and frozen as of January 2012), together with all material Amendments is incorporated by reference from our 2011 Annual Report on Form 10-K.
Amendment to Amended and Restated Wyeth Supplemental Employee Savings Plan, dated June 20, 2013, is incorporated by reference from our 2013 Annual Report on Form 10-K.
The form of Indemnification Agreement with each of our non-employee Directors is incorporated by reference from our 1996 Annual Report on Form 10-K.
The form of Indemnification Agreement with each of the Named Executive Officers identified in our Proxy Statement for the 2024 Annual Meeting of Shareholders is incorporated by reference from our 1997 Annual Report on Form 10-K.
Pfizer Inc. Executive Severance Plan is incorporated by referenced from our Current Report on Form 8-K filed on February 20, 2009.
Amendment No. 1 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.
Amendment No. 2 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2019 Annual Report on Form 10-K.
Amendment No. 3 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.
Amendment No. 4 to the Pfizer Inc. Executive Severance Plan is incorporate by reference from our 2022 Annual Report on Form 10-K.
Annual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) as amended, is incorporated by reference from our 2008 Annual Report on Form 10-K.
Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended, is incorporated by reference from our 2022 Annual Report on Form 10-K.
Offer Letter to G. Mikael Dolsten, dated April 6, 2009, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2011.
Pfizer Inc. 2019 Stock Plan is incorporated by reference from our Proxy Statement for the 2019 Annual Meeting of Shareholders.
Pfizer Inc. Amended and Restated 2019 Stock Plan is incorporated by reference from our Proxy Statement for the 2024 Annual Meeting of Shareholders.
Time Sharing Agreement, dated July 9, 2020, between Pfizer Inc. and Albert Bourla is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 28, 2020.
Pfizer Inc. Executive Officer Cash Severance Policy is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended July 2, 2023.
Corporate Policy 604A: Prohibition on Insider Trading.
Subsidiaries of the Company.
Subsidiary Issuers of Guaranteed Securities.
Consent of Independent Registered Public Accounting Firm.
Power of Attorney (included as part of signature page).
Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Pfizer Inc.
2024 Form 10-K
112


Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Pfizer Inc. Recoupment Policy.
Exhibit 101:
*101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
*101.SCHInline XBRL Taxonomy Extension Schema
*101.CALInline XBRL Taxonomy Extension Calculation Linkbase
*101.LABInline XBRL Taxonomy Extension Label Linkbase
*101.PREInline XBRL Taxonomy Extension Presentation Linkbase
*101.DEFInline XBRL Taxonomy Extension Definition Document
104Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
ITEM 16.FORM 10-K SUMMARY
None.
SIGNATURES

Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.
Pfizer Inc.
Dated: February 27, 2025
By:/S/    MARGARET M. MADDEN
Margaret M. Madden
Senior Vice President and Corporate Secretary
Chief Governance Counsel

We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date indicated.

Pfizer Inc.
2024 Form 10-K
113


SignatureTitleDate
/S/    ALBERT BOURLA
Albert Bourla
Chairman, Chief Executive Officer and Director
(Principal Executive Officer)
February 27, 2025
/S/    DAVID M. DENTON
David M. Denton
Chief Financial Officer, Executive Vice President
(Principal Financial Officer)
February 27, 2025
/S/    JENNIFER B. DAMICO
Jennifer B. Damico
Senior Vice President and Controller
(Principal Accounting Officer)
February 27, 2025
/S/    RONALD E. BLAYLOCK
Ronald E. Blaylock
DirectorFebruary 27, 2025
/S/    MORTIMER J. BUCKLEY
Mortimer J. Buckley
Director
February 27, 2025
/S/    SUSAN DESMOND-HELLMANN
Susan Desmond-Hellmann
DirectorFebruary 27, 2025
/S/    JOSEPH J. ECHEVARRIA
Joseph J. Echevarria
DirectorFebruary 27, 2025
/S/    SCOTT GOTTLIEB
Scott Gottlieb
DirectorFebruary 27, 2025
/S/    HELEN H. HOBBS
Helen H. Hobbs
DirectorFebruary 27, 2025
/S/    SUSAN HOCKFIELD
Susan Hockfield
DirectorFebruary 27, 2025
/S/    DAN R. LITTMAN
Dan R. Littman
DirectorFebruary 27, 2025
/S/    SHANTANU NARAYEN
Shantanu Narayen
DirectorFebruary 27, 2025
/S/    SUZANNE NORA JOHNSON
Suzanne Nora Johnson
DirectorFebruary 27, 2025
/S/    JAMES QUINCEY
James Quincey
DirectorFebruary 27, 2025
/S/    JAMES C. SMITH
James C. Smith
Director
February 27, 2025
/S/    CYRUS TARAPOREVALA
Cyrus Taraporevala
DirectorFebruary 27, 2025

Pfizer Inc.
2024 Form 10-K
114
EX-4.26 2 pfe-exh426x12312024x10k.htm EX-4.26 Document

EXHIBIT 4.26
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
As of February 27, 2025, Pfizer Inc. has common stock and its 1.000% Notes due 2027 (the “notes”) registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following descriptions of our common stock and the notes are summaries and do not purport to be complete. The description of our common stock is subject to and qualified in its entirety by reference to our restated certificate of incorporation (the “Certificate of Incorporation”), and our bylaws, as amended (the “Bylaws”), and the description of the notes is subject to and qualified in its entirety by reference to the base indenture (as defined below) and the ninth supplemental indenture (as defined below), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.25 is a part. We encourage you to read the Certificate of Incorporation, the Bylaws, the applicable provisions of the Delaware General Corporation Law (the “DGCL”), the base indenture and the ninth supplemental indenture for additional information. References in this section to “Pfizer,” “we,” “us” and “our” are to Pfizer Inc., unless otherwise stated or the context so requires.
DESCRIPTION OF CAPITAL STOCK
Common Stock
Under the Certificate of Incorporation, we are authorized to issue up to 12 billion shares of common stock, par value $0.05 per share. The common stock is not redeemable, does not have any conversion rights and is not subject to call. Holders of shares of common stock have no preemptive rights to maintain their percentage of ownership in future offerings or sales of our stock. Holders of shares of common stock have one vote per share in all elections of Directors and on all other matters submitted to a vote of our stockholders. The holders of common stock are entitled to receive dividends, if any, as and when may be declared from time to time by our Board of Directors, out of funds legally available therefor. Upon liquidation, dissolution or winding up of our affairs, the holders of common stock will be entitled to participate equally and ratably, in proportion to the number of shares held, in our net assets available for distribution to holders of common stock. The shares of common stock currently outstanding are fully paid and nonassessable. The common stock is traded on the New York Stock Exchange under the trading symbol “PFE.”
Preferred Stock
Under the Certificate of Incorporation, we are authorized to issue up to 27 million shares of preferred stock, without par value. The preferred stock may be issued in one or more series, and the Board of Directors of Pfizer is expressly authorized (i) to fix the descriptions, powers, preferences, rights, qualifications, limitations, and restrictions with respect to any series of preferred stock and (ii) to specify the number of shares of any series of preferred stock.
Anti-takeover Effects of the Certificate of Incorporation, Bylaws and Delaware Law
Certificate of Incorporation and Bylaws. Various provisions contained in the Certificate of Incorporation and the Bylaws could delay or discourage some transactions involving an actual or potential change in control of us or a change in our management and may limit the ability of our stockholders to remove current management or approve transactions that our stockholders may deem to be in their best interests. Among other things, these provisions:
limit the right of stockholders to call special meetings of stockholders to holders of at least 10% of the total number of shares of stock entitled to vote on the matter to be brought before the proposed special meeting;
authorize our Board of Directors to establish one or more series of preferred stock without stockholder approval;
authorize the Board of Directors to issue dividends in the form of stock purchase or similar rights, including rights that would have the effect of making an attempt to acquire us more costly;
grant to the Board of Directors, and not to the stockholders, the sole power to set the number of Directors;
require that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing; and
subject to the rights of the holders of any one or more series of preferred stock then outstanding, allow our Directors, and not our stockholders, to fill vacancies on our Board of Directors, including vacancies resulting from the removal of one or more Directors or an increase in the number of Directors constituting the whole Board of Directors.
Delaware Law. We are a Delaware corporation and consequently are also subject to certain anti-takeover provisions of the DGCL. Subject to certain exceptions, Section 203 of the DGCL prevents a publicly-held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for three years following the date that the person became an interested stockholder, unless (a) the interested stockholder attained such status with the approval of the corporation’s board of directors, (b) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, exclusive of shares owned by directors who are also officers and by certain employee stock plans or (c) at or subsequent to such time, the business combination is approved by the board of directors and authorized by the affirmative vote at a stockholders’ meeting, and not by written consent, of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder. A “business combination” includes, among other things, a merger or consolidation involving the corporation and the “interested stockholder” and the sale of more than 10% of the corporation’s assets. In general, an “interested stockholder” is any entity or person beneficially owning 15% or more of the corporation’s outstanding voting stock, and any entity or person affiliated with or controlling or controlled by such



entity or person. Section 203 of the DGCL makes it more difficult for an interested stockholder to effect various business combinations with a corporation for a three-year period. This statute could prohibit or delay mergers or other takeover or change in control attempts not approved in advance by our Board of Directors, and, as a result, could discourage attempts to acquire us, which could depress the market price of our common stock.
DESCRIPTION OF DEBT SECURITIES
Reference should be made to the indenture dated as of January 30, 2001, between Pfizer and The Bank of New York Mellon (formerly known as The Bank of New York), as successor to JPMorgan Chase Bank (formerly known as The Chase Manhattan Bank), as trustee, which we refer to as the “base indenture,” as supplemented by the ninth supplemental indenture, dated as of March 6, 2017, among Pfizer Inc., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent, which we refer to as the “ninth supplemental indenture.” When we refer to the “indenture,” we mean the base indenture, as supplemented by the ninth supplemental indenture. The following description is a summary of selected portions of the base indenture and the ninth supplemental indenture. It does not restate the base indenture or the ninth supplemental indenture, and those documents, not this description, define the rights of a holder of the notes.
Principal, Maturity and Interest
The notes were limited to €750,000,000 aggregate principal amount. The notes will mature on March 6, 2027. We issued the notes in denominations of €100,000 and in integral multiples of €1,000 in excess thereof.
Interest on the notes accrues at the annual rate of 1.000%. Interest on the notes is payable on March 6 of each year. Interest on the notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes to, but excluding, the next scheduled interest payment date. This payment convention is referred to as ACTUAL/ACTUAL (ICMA) (as defined in the rulebook of the International Capital Market Association).
We make each interest payment to the holders of record of the notes at the close of business on the 15th calendar day (whether or not a business day) preceding the relevant interest payment date.
The Bank of New York Mellon, London Branch, acts as our paying agent with respect to the notes. Upon notice to the trustee, we may change any paying agent. Payments of principal, interest and premium, if any, will be made by us through the paying agent to Euroclear Bank S.A./N.V. (the “Euroclear Operator”), as operator of the Euroclear System (“Euroclear”) and/or Clearstream Banking, Société Anonyme, Luxembourg (“Clearstream”) as described under “—Book-Entry.”
Issuance in Euros
Principal, premium, if any, and interest payments and additional amounts, if any, in respect of the notes are payable in euros.
If the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or the euro is no longer used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. In such circumstances, the amount payable on any date in euros will be converted to U.S. dollars on the basis of the most recently available market exchange rate for euros, as determined by us in our sole discretion. Any payment in respect of the notes so made in U.S. dollars does not constitute an event of default under the indenture or the notes. Neither the trustee nor the paying agent is responsible for obtaining exchange rates, effecting conversions or otherwise handling redenominations.
Payment of Additional Amounts
All payments in respect of the notes are made by or on behalf of us without withholding or deduction for, or on account of, any present or future taxes, duties, assessments or governmental charges of whatever nature, imposed or levied by the United States or any taxing authority thereof or therein, unless such withholding or deduction is required by law. If such withholding or deduction is required by law, we pay to a beneficial owner who is not a United States person such additional amounts on the notes as are necessary in order that the net payment of the principal of, and premium or redemption price, if any, and interest on, such notes to such beneficial owner, after such withholding or deduction (including any withholding or deduction on such additional amounts), will not be less than the amount provided in such notes to be then due and payable; provided, however, that the foregoing obligation to pay additional amounts will not apply:
a)to any tax, assessment or other governmental charge that would not have been imposed but for the beneficial owner, or a fiduciary, settlor, beneficiary, member or shareholder of the beneficial owner if the beneficial owner is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered by a fiduciary holder, being considered as (i) having a current or former connection with the United States (other than a connection arising solely as a result of the ownership of such notes, the receipt of any payment or the enforcement of any rights thereunder), including being or having been a citizen or resident of the United States, or being or having been engaged in a trade or business in the United States or having or having had a permanent establishment in the United States; (ii) being a controlled foreign corporation related to Pfizer directly, indirectly or constructively through stock ownership for U.S. federal income tax purposes; (iii) being an owner of a 10% or greater interest in voting stock of Pfizer within the meaning of Section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) or any successor provision; or (iv) being a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business;
b)to any holder that is not the sole beneficial owner of such notes, or a portion of such notes, or that is a fiduciary, partnership or limited liability company, but only to the extent that a beneficiary or settlor with respect to the fiduciary, a beneficial owner or a member of the partnership or limited liability company would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly from Pfizer its beneficial or distributive share of the payment;
- 2 -


c)to any tax, assessment or other governmental charge imposed by reason of the holder’s or beneficial owner’s past or present status as a passive foreign investment company, a controlled foreign corporation, a foreign tax exempt organization or a personal holding company with respect to the United States or as a corporation that accumulates earnings to avoid U.S. federal income tax;
d)to any tax, assessment or other governmental charge that would not have been imposed but for the failure of the holder or beneficial owner of the applicable notes to comply with any applicable certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner of such notes, if compliance is timely requested by Pfizer and required by statute, by regulation of the United States or any taxing authority therein or by an applicable income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental charge;
e)to any tax, assessment or other governmental charge that is imposed otherwise than by withholding or deducting from the payment;
f)to any estate, inheritance, gift, sales, transfer, wealth, capital gains or personal property tax or similar tax, assessment or other governmental charge;
g)to any tax, assessment or other governmental charge required to be withheld by any paying agent from any payment of principal of or interest on any such note, if such payment can be made without such withholding by at least one other paying agent in a Member State of the European Union;
h)to any tax, assessment or other governmental charge that is imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later;
i)to any tax, assessment or other governmental charge that would not have been imposed but for the presentation by the holder of any note, where presentation is required, for payment on a date more than 30 days after the date on which payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later, except to the extent that the holder or beneficial owner thereof would have been entitled to additional amounts had the note been presented for payment on the last day of such 30 day period;
j)to any withholding or deduction that is imposed on a payment pursuant to Sections 1471 through 1474 of the Code and related Treasury regulations and pronouncements or any successor provisions thereto (that are substantively comparable and not materially more onerous to comply with) and any regulations or official law, agreement or interpretations thereof in any jurisdiction implementing an intergovernmental approach thereto; or
k)in the case of any combination of the above listed items.
Except as specifically provided under this heading “—Payment of Additional Amounts,” we are not required to make any payment for any tax, duty, assessment or governmental charge of whatever nature imposed by any government or a political subdivision or taxing authority of or in any government or political subdivision.
As used under this heading “—Payment of Additional Amounts” and under the heading “—Optional Redemption of Notes; Redemption for Tax Reasons; No Sinking Fund,” the term “United States” means the United States of America, any state thereof, and the District of Columbia, and the term “United States person” means (i) any individual who is a citizen or resident of the United States for U.S. federal income tax purposes, (ii) a corporation, partnership or other entity created or organized in or under the laws of the United States, any state thereof or the District of Columbia (other than a partnership that is not treated as a United States person for U.S. federal income tax purposes), (iii) any estate the income of which is subject to U.S. federal income taxation regardless of its source, or (iv) any trust if a U.S. court can exercise primary supervision over the administration of the trust and one or more United States persons can control all substantial trust decisions, or if a valid election is in place to treat the trust as a United States person.
Ranking
The notes are unsecured general obligations of Pfizer and rank equally with all other unsecured and unsubordinated indebtedness of Pfizer from time to time outstanding.
Listing
The notes are listed on the NYSE. We have no obligation to maintain such listing, and we may delist the notes at any time.
Covenants
The indenture contains a provision that restricts our ability to consolidate with or merge into any other person or convey or transfer our properties and assets as an entirety or substantially as an entirety to any other person. The indenture does not restrict our ability to convey or transfer our properties and assets other than as an entirety or substantially as an entirety to any other person. See “Article VIII - Consolidation, Merger, Conveyance or Transfer” in the base indenture. The indenture contains no other restrictive covenants, including those that would afford holders of the notes protection in the event of a highly-leveraged transaction involving Pfizer or any of its affiliates or other events involving us that may adversely affect our creditworthiness or the value of the notes. The indenture also does not contain any covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders, current ratios or acquisitions and divestitures. The notes do not have the benefit of covenants that relate to subsidiary guarantees, liens and sale leaseback transactions that apply to other of our existing unsecured and unsubordinated notes.
- 3 -


Pfizer may, without the consent of the holders of notes of any series, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the notes of any series (except for the issue date and the public offering price). Any additional notes having such similar terms, together with the notes of the applicable series, will constitute a single series of debt securities under the indenture. No additional notes of any series may be issued if an event of default has occurred with respect to the notes of that series. Pfizer will not issue any additional notes intended to form a single series with the notes of any series, unless such further notes will be fungible with all notes of the same series for U.S. federal income tax purposes.
Optional Redemption of Notes; Redemption for Tax Reasons; No Sinking Fund
At our option, we may redeem the notes (together, the redemption notes), in whole, at any time, or in part, from time to time, prior to December 6, 2026 (three months prior to the maturity date). The redemption price will be equal to the greater of the following amounts:
100% of the principal amount of the redemption notes being redeemed on the redemption date; and
the sum of the present values of the remaining scheduled payments of principal and interest on the redemption notes being redeemed on that redemption date (not including the amount, if any, of accrued and unpaid interest to, but excluding, the redemption date) discounted to the redemption date on an annual basis at a rate equal to the sum of the Comparable Government Bond Rate plus 15 basis points;
plus, in each case, accrued and unpaid interest on the redemption notes being redeemed to, but excluding, the redemption date.
At any time on or after December 6, 2026 (three months prior to the maturity date), we may redeem the redemption notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the redemption notes to be redeemed, plus in each case, accrued and unpaid interest on the redemption notes being redeemed to, but excluding, the redemption date.
Notwithstanding the foregoing, installments of interest on the applicable redemption notes that are due and payable on interest payment dates falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date according to the applicable redemption notes and the indenture. The redemption prices for the redemption notes will be calculated on the basis of a 365-day year or a 366-day year, as applicable, and the actual number of days elapsed.
We will mail notice of any redemption at least 10 days, but not more than 60 days, before the redemption date to each registered holder of the redemption notes to be redeemed. Once notice of redemption is mailed, the redemption notes called for redemption will become due and payable on the redemption date at the applicable redemption price, plus accrued and unpaid interest applicable to such redemption notes to, but excluding, the redemption date.
“Comparable Government Bond” means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an Independent Investment Banker, a German government bond whose maturity is closest to the maturity of the redemption notes to be redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such Independent Investment Banker may, with the advice of three brokers of, and/or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.
“Comparable Government Bond Rate” means the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the fixed rate notes to be redeemed, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond on the basis of the middle market price of the Comparable Government Bond prevailing at 11:00 a.m. (London time) on such business day as determined by an Independent Investment Banker.
“Independent Investment Banker” means one of the Reference Treasury Dealers appointed by us to act as the “Independent Investment Banker.”
“Reference Treasury Dealer” means each of Barclays Bank PLC, BNP Paribas, Goldman, Sachs & Co. and J.P. Morgan Securities plc (or their respective affiliates that are Primary Treasury Dealers), and their respective successors; provided, however, that if any of the foregoing shall cease to be a broker or dealer of, and/or market maker in, German government bonds (a “Primary Treasury Dealer”), we will substitute therefor another Primary Treasury Dealer.
On and after the redemption date, interest will cease to accrue on the redemption notes or any portion of the redemption notes called for redemption (unless we default in the payment of the redemption price and accrued and unpaid interest). On or before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the redemption price of and accrued and unpaid interest on the redemption notes to be redeemed on that date. If fewer than all of the redemption notes are to be redeemed, the redemption notes to be redeemed shall be selected by Euroclear and/or Clearstream, in the case of redemption notes represented by a global security, or by the trustee by a method the trustee deems to be fair and appropriate, in the case of redemption notes that are not represented by a global security.
The notes are not entitled to the benefit of a sinking fund.
Redemption for Tax Reasons
If, as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated under the laws) of the United States (or any taxing authority thereof or therein), or any change in, or amendments to, an official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after February 28, 2017, we become or, based upon a written opinion of independent tax counsel of recognized standing selected by us, will become obligated to pay additional amounts as described herein under the heading “—Payment of Additional Amounts” with respect to any series of the notes, then we may at our option, having given not less than 10 nor more than 60 days prior notice to holders, redeem, in whole, but not in part, the applicable series of notes at a
- 4 -


redemption price equal to 100% of the principal amount, together with accrued and unpaid interest (including any additional amounts) on such notes to, but excluding, the redemption date.
Book-Entry
Global Clearance and Settlement
The notes were issued in the form of one or more global notes in fully registered form, without coupons, and are deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear and Clearstream. Except as described herein, certificates will not be issued in exchange for beneficial interests in the global notes representing the notes.
Except as set forth below, the global notes representing the notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees.
Beneficial interests in the global notes representing the notes are represented, and transfers of such beneficial interests are effected, through accounts of financial institutions acting on behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those beneficial interests are in denominations of €100,000 and integral multiples of €1,000 in excess thereof. Investors may hold the notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through organizations that are participants in such systems.
For so long as any series of the notes is represented by a global note deposited with, and registered in the name of a nominee for, a common depositary for Euroclear and/or Clearstream, each person (other than Euroclear or Clearstream) who is for the time being shown in the records of Euroclear or of Clearstream as the holder of a particular nominal amount of the notes (in which regard any certificate or other document issued by Euroclear or Clearstream as to the nominal amount of the notes standing to the account of any person shall be conclusive and binding for all purposes save in the case of manifest error) shall upon their receipt of a certificate or other document be treated by Pfizer and the trustee as the holder of such nominal amount of the notes and the registered holder of the global note representing such notes shall be deemed not to be the holder for all purposes other than with respect to the payment of principal or interest on such nominal amount of the notes, for which purpose the registered holder of the relevant global note shall be treated by Pfizer and the trustee as the holder of such nominal amount of notes in accordance with and subject to the terms of the global note representing the notes, and the expressions “noteholder” and “holder of notes” and related expressions shall be construed accordingly.
The information in this section concerning Euroclear and Clearstream Banking and their book-entry systems and procedures has been obtained from sources that we believe to be reliable. We are not responsible for the accuracy or completeness of this information.
We have been advised by Clearstream and Euroclear, respectively, as follows:
Clearstream has advised that:
It is incorporated under the laws of Luxembourg and licensed as a bank and professional depositary. Clearstream holds securities for its participating organizations and facilitates the clearance and settlement of securities transactions among its participants through electronic book-entry changes in accounts of its participants, thereby eliminating the need for physical movement of certificates.
Clearstream provides to its participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream interfaces with domestic markets in several countries.
Clearstream has established an electronic bridge with the Euroclear Operator to facilitate the settlement of trades between the nominees of Clearstream and Euroclear.
As a registered bank in Luxembourg, Clearstream is subject to regulation by the Luxembourg Commission for the Supervision of the Financial Sector.
Clearstream customers are recognized financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations and may include the underwriters. Indirect access to Clearstream is also available to others, such as banks, brokers, dealers and trust companies that clear through, or maintain a custodial relationship with, a Clearstream participant, either directly or indirectly.
Distributions with respect to the notes held beneficially through Clearstream will be credited to cash accounts of Clearstream participants in accordance with its rules and procedures.
Euroclear has advised that:
It was created in 1968 to hold securities for its participants and to clear and settle transactions between Euroclear participants through simultaneous electronic book-entry delivery against payment, thereby eliminating the need for physical movement of certificates and any risk from lack of simultaneous transfers of securities and cash.
Euroclear includes various other services, including securities lending and borrowing and interfaces with domestic markets in several countries.

- 5 -


Euroclear is operated by the Euroclear Operator. All operations are conducted by the Euroclear Operator, and all Euroclear securities clearance accounts and Euroclear cash accounts are accounts with the Euroclear Operator.
Securities clearance accounts and cash accounts with the Euroclear Operator are governed by the Terms and Conditions Governing Use of Euroclear and the related operating procedures of Euroclear, and applicable Belgian law (collectively, the “Terms and Conditions”). The Terms and Conditions govern transfers of securities and cash within Euroclear, withdrawals of securities and cash from Euroclear, and receipts of payments with respect to securities in Euroclear. All securities in Euroclear are held on a fungible basis without attribution of specific certificates to specific securities clearance accounts. The Euroclear Operator acts under the Terms and Conditions only on behalf of Euroclear participants, and has no records of or relationship with persons holding through Euroclear participants.
Euroclear participants include banks (including central banks), securities brokers and dealers and other professional financial intermediaries and may include the underwriters. Indirect access to Euroclear is also available to other firms that clear through or maintain a custodial relationship with a Euroclear participant, either directly or indirectly.
Distributions with respect to the notes held beneficially through Euroclear will be credited to the cash accounts of Euroclear participants in accordance with the Terms and Conditions.
Euroclear and Clearstream Arrangements
So long as Euroclear or Clearstream or their nominee or their common depositary is the registered holder of the global notes representing the notes, Euroclear, Clearstream or such nominee, as the case may be, will be considered the sole owner or holder of the notes represented by such global notes for all purposes under the indenture and the notes. Payments of principal, interest and additional amounts, if any, in respect of the global notes representing the notes are made to Euroclear, Clearstream, such nominee or such common depositary, as the case may be, as registered holder thereof. Neither Pfizer nor the trustee, or any affiliate of any of the above or any person by whom any of the above is controlled (as such term is defined in the Securities Act) has any responsibility or liability for any records relating to or payments made on account of beneficial ownership interests in the global notes representing the notes or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests.
Distributions of principal, premium, if any, and interest with respect to the global notes representing the notes are credited in euros to the extent received by Euroclear or Clearstream from the paying agent to the cash accounts of Euroclear or Clearstream customers in accordance with the relevant system’s rules and procedures.
Because Euroclear and Clearstream can only act on behalf of participants, who in turn act on behalf of indirect participants, the ability of a person having an interest in the global notes representing the notes to pledge such interest to persons or entities which do not participate in the relevant clearing system, or otherwise take actions in respect of such interest, may be affected by the lack of a physical certificate in respect of such interest.
Secondary Market Trading
Because the purchaser determines the place of delivery, it is important to establish at the time of trading of any notes where both the purchaser’s and seller’s accounts are located to ensure that settlement can be made on the desired value date.
We understand that secondary market trading between Clearstream and/or Euroclear participants occurs in the ordinary way following the applicable rules and operating procedures of Clearstream and Euroclear. Secondary market trading is settled using procedures applicable to conventional eurobonds in global registered form.
The holder of the notes should be aware that investors are only able to make and receive deliveries, payments and other communications involving the notes through Clearstream and Euroclear on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for business in the United States.
In addition, because of time-zone differences, there may be problems with completing transactions involving Clearstream and Euroclear on the same business day as in the United States. U.S. investors who wish to transfer their interests in the notes, or to make or receive a payment or delivery of the notes, on a particular day, may find that the transactions are not performed until the next business day in Luxembourg or Brussels, depending on whether Clearstream or Euroclear is used.
Clearstream or Euroclear credits payments to the cash accounts of Clearstream customers or Euroclear participants, as applicable, in accordance with the relevant system’s rules and procedures, to the extent received by its depositary. Clearstream or the Euroclear Operator, as the case may be, takes any other action permitted to be taken by a holder under the indenture on behalf of a Clearstream customer or Euroclear participant only in accordance with its relevant rules and procedures.
Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate transfers of the notes among participants of Clearstream and Euroclear. However, they are under no obligation to perform or continue to perform those procedures, and they may discontinue those procedures at any time.
Exchange of Global Notes for Certificated Notes
Subject to certain conditions, the notes represented by the global notes are exchangeable for certificated notes in definitive form of like tenor in minimum denominations of €100,000 principal amount and multiples of €1,000 in excess thereof if:

- 6 -


the common depositary notifies us that it is no longer willing or able to act as a depositary for such global notes or ceases to be a clearing agency registered under the Exchange Act and we fail to appoint a successor common depositary within 90 days;
an event of default has occurred and is continuing and the common depositary requests the issuance of certificated notes; or
we determine not to have the notes represented by a global note.
In all cases, certificated notes delivered in exchange for any global note or beneficial interest therein will be registered in the names, and issued in any approved denominations, requested by or on behalf of the common depositary (in accordance with its customary procedures).
Payments (including principal, premium and interest) and transfers with respect to the notes in certificated form may be executed at the office or agency maintained for such purpose in London (initially the corporate trust office of the paying agent) or, at our option, by check mailed to the holders thereof at the respective addresses set forth in the register of holders of the notes (maintained by the registrar), provided that all payments (including principal, premium and interest) on the notes in certificated form, for which the holders thereof have given wire transfer instructions, are required to be made by wire transfer of immediately available funds to the accounts specified by the holders thereof. No service charge is made for any registration of transfer, but payment of a sum sufficient to cover any tax or governmental charge payable in connection with such registration may be required.
Modification of Indenture
Under the indenture, the rights of the holders of the notes may be modified through a supplemental indenture if the holders of a majority in aggregate principal amount of the outstanding notes of all series affected by the modification (voting as one class) consent to it. No modification of the maturity date or principal or interest payment terms, no modification of the currency for payment, no impairment of the right to sue for the enforcement of payment at the maturity of the debt security, no modification of any conversion rights, no modification reducing the percentage required for any such supplemental indenture or the percentage required for the waiver of certain defaults, and no modification of the foregoing provisions or any other provisions relating to the waiver of past defaults or the waiver of certain covenants, is effective against any holder without its consent.
Events of Default
Each of the following will constitute an Event of Default under the indenture with respect to the notes of the applicable series:
we fail to make the principal or any premium payment on any note when due;
we fail to make any sinking fund payment for 60 days after payment was due by the terms of any note;
we fail to pay interest on any note for 60 days after payment was due;
we fail to perform any other covenant in the indenture and this failure continues for 90 days after we receive written notice of it; or
we, or a court, take certain actions relating to the bankruptcy, insolvency or reorganization of our company.
A default under our other indebtedness will not be a default under the indenture for the notes, and a default under one series of the notes will not necessarily be a default under another series. The trustee may withhold notice to the holders of notes of the applicable series of any default (except for defaults that involve our failure to pay principal or interest) if it considers such withholding of notice to be in the best interests of the holders.
If an Event of Default with respect to outstanding notes of any series occurs and is continuing, then the trustee or the holders of at least 33% in principal amount of outstanding notes of that series may declare, in a written notice, the principal amount (or, if any of the notes of that series are original issue discount securities, such portion of the principal amount of such notes) plus accrued and unpaid interest on all notes of that series to be immediately due and payable. At any time after a declaration of acceleration with respect to notes of any series has been made, the holders of a majority in principal amount of the outstanding notes may rescind and annul the acceleration if:
the holders act before the trustee has obtained a judgment or decree for payment of the money due;
we have paid or deposited with the trustee a sum sufficient to pay overdue interest and overdue principal other than the accelerated interest and principal; and
we have cured or the holders have waived all Events of Default, other than the non-payment of accelerated principal and interest with respect to notes of that series, as provided in the indenture.
If a default in the performance or breach of the indenture shall have occurred and be continuing, the holders of not less than a majority in principal amount of the outstanding notes of all series affected thereby, by notice to the trustee, may waive any past Event of Default or its consequences under the indenture. However, an Event of Default cannot be waived with respect to any series of notes in the following two circumstances:
a failure to pay the principal of, and premium, if any, or interest on any security or in the payment of any sinking fund installment; or
a covenant or provision that cannot be modified or amended without the consent of each holder of outstanding notes of that series.
- 7 -


Other than its duties in case of a default, the trustee is not obligated to exercise any of its rights or powers under the indenture at the request, order or direction of any holders, unless the holders offer the trustee reasonable indemnity. Holders of a majority in principal amount outstanding of any series of notes may, subject to certain limitations, direct the time, method and place of conducting any proceeding or any remedy available to the trustee, or exercising any power conferred upon the trustee, for such applicable series of notes.
We are required to deliver an annual officers’ certificate to the trustee, stating whether we are in default in the performance and observance of any of the terms, provisions and conditions of the indenture, and, if we are in default, specifying all such defaults and the nature and status thereof.
Defeasance
When we use the term defeasance, we mean discharge from some or all of our obligations under the indenture. Subject to certain additional conditions, if we irrevocably deposit with the trustee sufficient cash or government securities to pay the principal, interest, any premium and any other sums due to the stated maturity date or a redemption date of the notes of a particular series, then at our option:
we will be discharged from our obligations with respect to the notes of such series; or
we will no longer be under any obligation to comply with certain restrictive covenants under the indenture, and certain events of default will no longer apply to us.
To exercise our defeasance option, we must deliver to the trustee an officer’s certificate and an opinion of counsel, each stating that all conditions precedent related to the defeasance have been complied with.
- 8 -
EX-19 3 pfe-exh19x12312024x10k.htm EX-19 Document

EXHIBIT 19

CORPORATE POLICY 604A: PROHIBITION ON INSIDER TRADING

Version: 2.0
Effective Date: 08/03/2005
Last Updated: 12/13/2024
Sponsoring Division: Legal Division
Policy Contact:
Contact Email
Purpose
This Policy governs transactions in (1) Pfizer securities while in possession of material nonpublic information (or MNPI) relating to Pfizer and (2) the securities of any other publicly-traded company with which Pfizer has an existing or potential business relationship while in possession of MNPI regarding that company that was obtained in the course of employment with Pfizer or the performance of services on Pfizer’s behalf.
While this Policy focuses on trading by individuals and entities with relationships to Pfizer, Pfizer also seeks to comply with all applicable laws when Pfizer transacts in its own securities. Pfizer strives to avoid engaging in transactions in respect of Pfizer securities, or adopting any securities repurchase plans, when it is in possession of MNPI concerning itself, other than in compliance with applicable law.
Information is generally considered material if there is a substantial likelihood that a reasonable investor would consider it important in determining whether or not to buy, sell or hold a company’s stock. Any information, whether positive or negative, for which there exists a substantial likelihood that a reasonable investor would view the information as significantly altering the total mix of disclosed information is typically considered material. With respect to contingent or speculative events, a materiality assessment requires balancing the probability that the event will occur and the anticipated magnitude of the event. (See “Glossary” below for a definition of “material” information.) Further, information is “nonpublic” until it has been adequately disseminated to the public and the public has had time to absorb the information. Generally, information should not be considered public until one full trading day has elapsed after it is disseminated. (See the Glossary below for a definition of “nonpublic” information.) A matter that is not material to Pfizer may be material to a company with which Pfizer has an existing or potential business relationship, such as an alliance partner, customer, supplier or potential acquisition or collaboration candidate (such a company, an “Other Relevant Company” and collectively, “Other Relevant Companies”). Please also refer to Corporate Policy 401 - Global Safeguarding Sensitive Information Policy, for a discussion of what constitutes “sensitive information” and guidance on the appropriate classification of materials.
Federal securities laws restrict trading on the basis of MNPI. Violators of insider trading laws are subject to potential imprisonment, criminal fines, civil penalties and civil enforcement. Pfizer takes seriously its obligation to prevent insider trading violations. In light of the severity of the possible sanctions, Pfizer has established this Policy to assist colleagues in complying with the law. This Policy is not intended to replace the individual responsibility to understand and comply with legal prohibitions on insider trading.
Scope
This Policy applies to all Colleagues, Directors and Contracted Resources globally (collectively “Insiders”) as well as their spouses and minor children, anyone who lives in a household with or is financially dependent on, and any entity controlled by, a colleague, Director or Contracted Resource (collectively “Affiliated Persons”). For purposes of this Policy, “transactions” and “trading” include gifts of securities, such as gifts to trusts for estate planning purposes, as well as donations to a charitable organization.
Raising Concerns: If you believe that trading in the securities of Pfizer or of another company in violation of this Policy may have taken place, you must immediately report the incident in accordance with the Blue Book and Corporate Policy 201 – Integrity, Compliance Reporting Obligations and No Retaliation Policy. Reporting



channels may vary by market and its local privacy laws. Questions regarding this Policy should be directed to any attorney in the Corporate Governance Department.
Non-compliance: You must comply with this Policy. Failure to comply with this Policy can result in disciplinary consequences, up to and including termination.
Guiding Principles
These Guiding Principles should always be followed when considering transactions in the securities of Pfizer or Other Relevant Companies:

Act with Integrity
Insiders should always act with integrity
Insider must not disclose MNPI to anyone outside of Pfizer, including Affiliated Persons, friends, anyone acting on the Insider’s behalf, analysts, investors, members of the investment community or news media other than in accordance with Pfizer policy. Please also refer to Corporate Policy 604B – Treatment and Disclosure of Material Nonpublic Information – Regulation Fair Disclosure.
Ensure Legitimate Purpose
Insiders should transact only as permitted by this Policy
In general, Insiders can only trade when they are not in possession of MNPI and are not subject to a special blackout (as discussed below). Covered Persons (as defined in the Glossary) are also required to limit their trades to Open Window Periods (as discussed below) and are required to obtain pre-clearance from Pfizer prior to trading, even during Open Window Periods.
Prior to any trades, MNPI must be adequately disseminated and absorbed by the marketplace and will not be considered public until one full trading day has elapsed following its public disclosure.
Policy
Prohibition on Transacting in Securities While in Possession of Material Nonpublic Information
Pfizer’s MNPI must always be handled in an appropriate manner. Pfizer’s policy is that Insiders must not:
Trade, directly or indirectly, in Pfizer securities while aware of MNPI relating to the Company or advise anyone else to do so.
Trade, directly or indirectly in the securities of any Other Relevant Company or advise anyone else to do so, while in possession of MNPI relating to that company that was obtained in the course of employment with Pfizer or the performance of services on Pfizer’s behalf.
Directly or indirectly provide to anyone who may trade while aware of such information (“tip”) MNPI relating to Pfizer or MNPI relating to any Other Relevant Company that was obtained in the course of employment with Pfizer or the performance of services on Pfizer’s behalf.
This Policy relates not only to Pfizer’s common stock but also to any other securities issued by Pfizer, as well as any derivative securities, such as hedging transactions, short-sales, options, swaps or other securities that derive value by reference to securities issued by Pfizer. Transactions subject to this Policy include bona fide gifts, and references in this Policy to “trade,” “trading,” “transact,” “transactions,” and “transacting” include the gifting of securities.
All Insiders have a duty to maintain the confidentiality of all nonpublic information relating to Pfizer or relating to Other Relevant Companies and obtained through an existing or potential relationship with Pfizer. As such, disclosure of any MNPI to anyone outside the Company except as otherwise permitted in accordance with Corporate Policy 401 - Global Safeguarding Sensitive Information Policy and Corporate Policy 604B – Treatment and Disclosure of Material Nonpublic Information- Regulation Fair Disclosure, is prohibited.
Please also refer to Corporate Policy 401 concerning the obligation of Colleagues to safeguard all proprietary/confidential information, regardless of its materiality.
- 2 -


Prohibited Transactions
Some common transactions in Pfizer securities that are prohibited while an Insider is aware of MNPI relating to the Company include:
Purchases and sales of Pfizer securities, including the sale of shares received upon the exercise of employee stock options or upon the vesting of equity awards under Company compensation plans.
Transferring existing balances into or out of, or making withdrawals from, the Pfizer stock fund and Pfizer stock unit fund under the Savings Plan, Supplemental Savings Plan and Deferred Compensation Plan, as applicable. (This prohibition does not apply to transfers or withdrawals involving existing balances in funds other than the Pfizer stock fund and the Pfizer stock unit fund.) In addition, you may not make any change that affects the amount of your contributions or the Company matching contributions to those funds.
Voluntary cash investments (starting, ceasing or changing participation levels) under the Computershare Investment Program (formerly, Pfizer’s Shareholder Investment Program.)
Engaging in “hedging” transactions directly relating to Pfizer securities (e.g., options, puts, calls, straddles, collars, forwards, swaps, short-sales or other securities whose value is derived by reference to securities issued by Pfizer). Please refer to Corporate Policy 605 - Trading in Pfizer Stock Derivatives concerning trading in Pfizer derivative securities.
Permitted Transactions
Some common transactions in Pfizer securities that are permitted while an Insider is aware of MNPI relating to the Company include:
The exercise of employee stock options using cash, if the shares received upon exercise are retained by the Insider.
Regular, periodic employee contributions and Company matching contributions to the Pfizer stock fund under the Savings Plan or the Pfizer stock unit fund under the Supplemental Savings Plan. Insiders, however, may not make any change that affects the amount of their contributions or the Company matching contributions to those funds while in possession of MNPI relating to Pfizer.
The reinvestment of dividends under the Computershare Investment Program (formerly, Pfizer’s Shareholder Investment Program) if the reinvestment election was made prior to becoming aware of the MNPI relating to Pfizer.
Event-Specific Restricted Trading Periods (Special Blackouts)
From time-to-time, the Company may decide to impose an event-specific restricted trading period (or “special blackout”) on those who are aware of particular information that the Company determines may be considered MNPI. A special blackout may be imposed with respect to transactions in Pfizer securities or the securities of an Other Relevant Company and may be in connection with potential acquisitions, financial developments, clinical trial results, anticipated positive or negative public announcements or other material developments. If you are subject to a special blackout, you may not trade in Pfizer securities (or the securities of particular Other Relevant Company, if applicable) until you are notified that the special blackout has been lifted.
The existence of a special blackout will not be generally announced. You will be notified if you are subject to a special blackout. Any person made aware of a special blackout should not disclose the existence of the blackout to anyone else. Even if you have not received notice of a special blackout or have received notice indicating a previous special blackout has been lifted, you could still possess MNPI relating to Pfizer. If you have MNPI relating to Pfizer, you are prohibited from trading regardless of whether or not you are currently under the restrictions of a special blackout.
Post-Termination Trading
Insiders who are aware of MNPI relating to Pfizer when their employment or service relationship terminates may not trade in Pfizer securities until that information has become public or is no longer material.
- 3 -


Covered Persons
Covered Persons (as defined in the Glossary) are Insiders who are subject to additional requirements under this Policy. These additional requirements include making all trades within Open Window Periods (as defined below) and obtaining pre-clearance from the Company before trading in Pfizer securities. These requirements are further discussed below.
Regular Quarterly Trading Window Periods
In addition to any restrictions imposed by special trading blackouts, Covered Persons must confine their trading in Pfizer securities to a period in which there is no regular quarterly trading blackout imposed (an “Open Window Period”). A regular quarterly trading blackout with respect to trading in Pfizer securities by Covered Persons is imposed beginning two weeks prior to the end of each fiscal quarter and ending after a full trading day following Pfizer’s public disclosure of its financial results for that fiscal quarter (or, in the case of the fourth fiscal quarter, the full fiscal year). Pfizer’s practice is to notify Covered Persons when the blackout period begins and ends, but absence of such notice does not alter these restrictions.
For the avoidance of doubt, even during an Open Window Period, Covered Persons cannot transact in Pfizer securities if they possess MNPI or are subject to a special blackout, unless such transactions are made pursuant to a pre-arranged, “automatic-pilot” basis pursuant to a plan, contract or instruction that meets the requirements of SEC Rule 10b5-1 in accordance with Pfizer’s Policy Relating to Rule 10b5-1 Trading Plans.
Pre-Clearance of Transactions
Covered Persons may not trade in Pfizer securities unless the transaction is cleared in advance by the Corporate Secretary or his or her designee in the Corporate Governance Department.
This pre-clearance requirement applies regardless of whether (i) a Covered Person possesses MNPI relating to Pfizer or (ii) the Covered Person’s trade occurs during an Open Window Period.
- 4 -


References

ReferenceName/Location
Corporate Policy #108 U.S. (including Puerto Rico) Staff Augmentation Contingent Worker Engagement
Policy Point
Corporate Policy #401 Global Safeguarding Sensitive Information
Policy Point
Corporate Policy #604B Treatment and Disclosure of Material Nonpublic Information - Regulation Fair Disclosure
Policy Point
Corporate Policy #605 Trading in Pfizer Stock Derivatives
Policy Point
Blue Book: Pfizer’s Code of Conduct
Blue Book
Pfizer Policy Relating to Rule 10b5-1 Trading Plans
Rule 10b5-1 Policy
Glossary

Term
Definition
Contracted Resource
Any non-employee (also referred to as a Contingent Worker, Staff Augmentation Worker or Supplier Worker ) engaged to provide services for or on behalf of Pfizer, including, without limitation:
Agency temporaries – hourly workers engaged through temporary staffing agencies;
Professional service consultants – individuals provided through external consulting firms who provide professional expert advice;
Outsourced service providers/Vendor (e.g., catering, building maintenance);
Independent Contractors;
Leased personnel – former Pfizer employees who have been transferred as part of a divestiture and who are helping transition operations to the new organization;
Secondees – law firm or other professional service employees who are on temporary engagement at Pfizer under a short-term contract; and
Certain interns based in student worker programs; consult with your PX representative for the correct classification.
For further information, refer to CP 108 and CP 401.
- 5 -


Term
Definition
Covered Person
Any Insider in the following roles:
any Directors or officers of the Company who are subject to Section 16 of the Securities Exchange Act of 1934;
such other colleagues who the Company’s General Counsel or Corporate Secretary may designate from time to time as a “Covered Person”; and
Affiliated Persons of the individuals listed above.
Material Information
Material information is information for which there is a substantial likelihood that a reasonable investor would consider the information important in determining whether or not to buy, sell or hold a company’s stock. Any information, whether positive or negative, for which there exists a substantial likelihood that a reasonable investor would view the information as significantly altering the total mix of disclosed information is typically considered material. With respect to contingent or speculative events, a materiality assessment requires balancing the probability that the event will occur and the anticipated magnitude of the event.
Examples of information that may be considered to be material include, among others: financial results; financial forecasts; changes in dividend policy; stock splits; stock repurchases; mergers, acquisitions and tender offers; acquisitions or dispositions of significant assets; major changes in business strategy; changes in senior management; important product developments; significant clinical trial results, regulatory filings and regulatory decisions relating to important in-line drugs or drug candidates; major cybersecurity or data breach incidents; major litigation developments and information that would be properly classified as “Highly Confidential / Restricted Distribution” under CP401.
Nonpublic Information
Information is considered nonpublic until it has been adequately disseminated to the public and the public has had time to absorb the information. Adequate public dissemination includes Company press releases, filings with the SEC and webcast meetings or conference calls if the public is allowed to listen and is given adequate advance notice. Generally, information should not be considered public until one full trading day has elapsed after it is disseminated.
For example, if the Company issues a press release before the market opens on a Tuesday, the information would be considered public when the market opens on Wednesday. If, however, the Company issues a press release after trading begins Tuesday, the information would not be considered public until the market opens on Thursday.
Trading Day
A day on which the New York Stock Exchange is open for trading and during which trading of the applicable Pfizer securities has not been halted.
12/2024

- 6 -


PFIZER POLICY RELATING TO RULE 10b5-1 TRADING PLANS
This Pfizer Policy Relating to Rule 10b5-1 Trading Plans (the “Policy”) shall be attached to each Rule
10b5-1 trading plan (each a “Plan”) between an employee or a member of the Board of Directors (each a “Plan Participant”) of Pfizer Inc. (“Pfizer”) and XXXXXXXXXXXXXXXXXX (“Service Provider”).
This Policy sets forth certain restrictions applicable to each Plan, some of which are included in the Plan and some of which are in addition to the provisions of the Plan.
By entering into a Plan with Service Provider, a Plan Participant will be deemed to have agreed to the provisions of this Policy.
Restrictions Related to Each Plan
(a) Establishment of a Plan
The Plan Participant may provide notice to Service Provider (the “Establishment Notice”) of an intention to establish a Plan only at a time (i) when there is no Pfizer stock-trading blackout applicable to the Plan Participant in effect, (ii) when the Plan Participant is not aware of any material nonpublic information concerning Pfizer, and (iii) following approval from Pfizer’s Corporate Secretary or his or her delegate in accordance with Pfizer’s pre-clearance review process.
The first transaction under the Plan shall not occur until after:
ofor a director or Section 16 officer, the later of (a) 90 days after the adoption, amendment or modification of the plan or (b) two business days following Pfizer’s filing of the Form 10-Q or 10-K for the quarter in which the plan was adopted or amended, for a maximum of 120 days after receipt of the Establishment Notice by Service Provider; or
ofor all other individuals, 60 calendar days after receipt of the Establishment Notice by Service Provider.
(b)Modification of a Plan
The Plan Participant may provide notice to Service Provider (the “Modification Notice”) of an intention to modify a Plan only at a time (i) when there is no Pfizer stock-trading blackout applicable to the Plan Participant in effect and (ii) when the Plan Participant is not aware of any material nonpublic information concerning Pfizer.
A modified Plan will be treated as a new Plan subject to the same waiting period after receipt of the Modification Notice by Service Provider , as described in section (a) above.
(c)Termination of a Plan
The Plan Participant may provide notice to Service Provider (the “Termination Notice”) of an intention to terminate a Plan following review of such proposed Plan termination by Pfizer’s Corporate Secretary or his or her delegate in accordance with Pfizer’s pre-clearance review process.
(d)One Rule 10b5-1 Trading Plan at a Time
The Plan Participant shall not establish a Plan if any other Rule 10b5-1 trading plan or plans with respect to Pfizer stock are in effect between the Plan Participant and Service Provider or anyone else.
While a Plan is in effect, the Plan Participant shall not enter into any other Rule 10b5-1 trading plan with respect to Pfizer stock with Service Provider or anyone else.
The Plan Participant may:
oHave an additional plan providing only for eligible sell-to-cover transactions, where the plan provides for sales of securities as are necessary to satisfy tax withholding obligations arising exclusively from the vesting of a compensatory stock award (“Sell-to-Cover Transactions”); and
oEnter into one later-commencing plan so that the waiting period of the later plan can begin to run while an existing plan is in place, provided that the Plan Participant does not early terminate the first plan, in which case a full waiting period from the time of such termination must occur.
- 7 -


(e)Single Transaction Plans Restricted
In any 12-month period, the Plan Participant shall not establish more than one Plan designed to sell or purchase all of the securities subject to the Plan in a single transaction (a “single transaction plan”), unless the Plan is for a Sell-to-Cover Transaction. Single transaction plans are generally discouraged.
(f)No Same-Way Transactions Outside a Plan
While a Plan is in effect, the Plan Participant shall not engage in any transaction (e.g., a sale or a purchase) in Pfizer stock outside the Plan that is the same type of transaction in Pfizer stock that is covered by the Plan, except, as applicable, for transactions under the Pfizer Qualified Savings Plan or the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan.
(g)Directors and Section 16 Officers
Directors and Section 16 officers should be aware that approval or adoption of a Plan in no way reduces or eliminates such person’s obligations under Section 16 of the Exchange Act, including such person’s disclosure and short-swing trading liabilities thereunder. If any questions arise, such person should consult with their own counsel in implementing a Plan. In addition, a Plan Participant who is a director or Section 16 officer must agree to cooperate with Pfizer in any reporting of the Rule 10b5-1 Plan in Pfizer’s filings with the U.S. Securities and Exchange Commission.
- 8 -
EX-21 4 pfe-exh21x123124x10k.htm EX-21 Document

EXHIBIT 21
The following is a list of subsidiaries of the Company as of December 31, 2024 omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.
Company Name
Where Incorporated
or Organized
356 Royalty Inc.Delaware
Agouron Pharmaceuticals, LLCCalifornia
AH Robins LLCDelaware
AHP Manufacturing B.V.Netherlands
Alpharma Pharmaceuticals LLCDelaware
American Food Industries LLCDelaware
Amplyx Pharmaceuticals, Inc.Delaware
Anacor Pharmaceuticals, LLCDelaware
Arena Pharmaceuticals, Inc.Delaware
Arixa Pharmaceuticals, Inc.Delaware
Array BioPharma Inc.Delaware
Bamboo Therapeutics, Inc.Delaware
Biohaven Pharmaceutical Holding Company LimitedBritish Virgin Islands
Biohaven Pharmaceutical Ireland Designated Activity CompanyIreland
Blue Whale Re Ltd.Vermont
C.P. Pharmaceuticals International C.V.Netherlands
CICL CorporationDelaware
COC I CorporationDelaware
Coley Pharmaceutical Group, Inc.Delaware
Cyanamid de Argentina, S.A.Delaware
Digital Health LLCDelaware
Distribuidora Mercantil Centro Americana, S.A.Delaware
Encysive Pharmaceuticals Inc.Delaware
FoldRx Pharmaceuticals, LLCDelaware
Fort Dodge Manufatura Ltda.Brazil
G. D. Searle International Capital LLCDelaware
Genetics Institute, LLCDelaware
GenTrac, Inc.Wisconsin
GI Europe, Inc.Delaware
GI Japan, Inc.Delaware
Global Blood Therapeutics, Inc.Delaware
Hospira Adelaide Pty LtdAustralia
Hospira Australia Pty LtdAustralia
Hospira Benelux BVBelgium
Hospira Holdings (S.A.) Pty LtdAustralia
Hospira Philippines, Inc.Philippines
Hospira Pte. Ltd.Singapore
Hospira Puerto Rico, LLCDelaware
Hospira UK LimitedUnited Kingdom
Hospira Worldwide, LLCDelaware
Hospira Zagreb d.o.o.Croatia



Hospira, Inc.Delaware
Ignite Immunotherapy, Inc.Delaware
InnoPharma, Inc.Delaware
International Affiliated Corporation LLCDelaware
John Wyeth & Brother LimitedUnited Kingdom
King Pharmaceuticals Holdings LLCDelaware
King Pharmaceuticals LLCDelaware
King Pharmaceuticals Research and Development, LLCDelaware
Laboratoires Pfizer, S.A.Morocco
Laboratorios Pfizer Ltda.Brazil
Laboratórios Pfizer, Lda.Portugal
Laboratorios Wyeth LLCPennsylvania
Mayne Pharma IP Holdings (Euro) Pty LtdAustralia
Medivation Field Solutions LLCDelaware
Medivation LLCDelaware
Medivation Neurology LLCDelaware
Medivation Prostate Therapeutics LLCDelaware
Medivation Services LLCDelaware
Medivation Technologies LLCDelaware
Monarch Pharmaceuticals, LLCTennessee
MPP Trustee LimitedUnited Kingdom
MTG Divestitures LLCDelaware
PAH USA IN8 LLCDelaware
Parke, Davis & Company LLCMichigan
Parkedale Pharmaceuticals, Inc.Michigan
PBG Puerto Rico LLCPuerto Rico
P-D Co., LLCDelaware
Peak Enterprises LLCDelaware
PF ARGENTUM ACQUISITION ULCCanada
PF Argentum US CorporationDelaware
PF OFG South Korea 1 B.V.Netherlands
PF PRISM C.V.Netherlands
PF PRISM Holdings B.V.Netherlands
PF PRISM IMB B.V.Netherlands
PfizerFrance
Pfizer (Beijing) Research and Development Co., LtdPeople's Republic of China
Pfizer (China) Research and Development Co. Ltd.People's Republic of China
Pfizer (Hangzhou) Innovation Technology Co., Ltd.People's Republic of China
Pfizer (Malaysia) Sdn BhdMalaysia
Pfizer (North Carolina) LLCDelaware
Pfizer (Perth) Pty LtdAustralia
Pfizer (Thailand) LimitedThailand
PFIZER (VIETNAM) LIMITED COMPANYVietnam
Pfizer (Wuhan) Research and Development Co. Ltd.People's Republic of China
Pfizer ABSweden
Pfizer AGSwitzerland
Pfizer Anti-Infectives ABSweden
- 2 -


Pfizer ApSDenmark
Pfizer ASNorway
Pfizer Asia Manufacturing Pte. Ltd.Singapore
Pfizer Australia Holdings B.V.Netherlands
Pfizer Australia Holdings Pty LimitedAustralia
Pfizer Australia Investments Pty LtdAustralia
Pfizer Australia Pty LtdAustralia
Pfizer B.V.Netherlands
Pfizer Biopharma Egypt LLCEgypt
Pfizer Biopharmaceuticals Egypt LLCEgypt
Pfizer Biossimilares Participações Ltda.Brazil
Pfizer Bolivia S.A.Bolivia
Pfizer Brasil Ltda.Brazil
Pfizer Business Service (Dalian) Co., Ltd.People's Republic of China
Pfizer Canada ULC / Pfizer Canada SRICanada
Pfizer Chile S.A.Chile
Pfizer Cia. Ltda.Ecuador
Pfizer Colombia Spinco I LLCPennsylvania
Pfizer Consumer HealthcareUnited Kingdom
Pfizer Corporation Austria Gesellschaft m.b.H.Austria
Pfizer Corporation Hong Kong LimitedHong Kong
Pfizer Corporation S. de R.L.Panama
Pfizer Croatia d.o.o.Croatia
Pfizer Deutschland GmbHGermany
Pfizer Development Services (UK) LimitedUnited Kingdom
Pfizer Eastern Investments B.V.Netherlands
Pfizer Europe MA EEIGBelgium
Pfizer Export B.V.Netherlands
Pfizer Free Zone Panama, S. de R.L.Panama
Pfizer Global Holdings B.V.Netherlands
Pfizer Global Holdings Pte. Ltd.Singapore
Pfizer Global Supply Japan Inc.Japan
Pfizer H.C.P. CorporationNew York
Pfizer Health ABSweden
Pfizer Health Solutions Inc.Delaware
Pfizer Healthcare India Private LimitedIndia
Pfizer Healthcare Ireland Unlimited CompanyIreland
Pfizer Hellas, A.E.Greece
Pfizer Himalaya Holdings Coöperatief U.A.Netherlands
Pfizer Holding FranceFrance
Pfizer Holdings CorporationDelaware
Pfizer Holdings International LLCDelaware
Pfizer Holdings International Luxembourg (PHIL) SARLLuxembourg
Pfizer Holdings International Pte. Ltd.Singapore
Pfizer Holdings Singapore LLCDelaware
Pfizer Innovations LLCRussia
Pfizer Intermediate Holdings 1 Pte. Ltd.Singapore
- 3 -


Pfizer Intermediate Holdings 2 Pte. Ltd.Singapore
Pfizer International LLCNew York
Pfizer International OperationsFrance
Pfizer Investment Capital Unlimited CompanyIreland
Pfizer Investment Co., Ltd.People’s Republic of China
Pfizer Investment Enterprises Holdings LLCDelaware
Pfizer Investment Enterprises Holdings Pte. Ltd.Singapore
Pfizer Investment Enterprises Pte. Ltd.Singapore
Pfizer Investments CorporationDelaware
Pfizer Ireland PFE Holding 1 LLCDelaware
Pfizer Ireland PFE Holding 2 LLCDelaware
Pfizer Ireland Pharmaceuticals Unlimited CompanyIreland
Pfizer Ireland Ventures Unlimited CompanyIreland
Pfizer Italia S.r.l.Italy
Pfizer Japan Inc.Japan
Pfizer Kazakhstan LLPKazakhstan
Pfizer Laboratories (Pty) LimitedSouth Africa
Pfizer Laboratories LimitedKenya
Pfizer Leasing Ireland LimitedIreland
Pfizer Leasing UK LimitedUnited Kingdom
Pfizer LimitedIndia
Pfizer LimitedTaiwan
Pfizer LimitedUnited Kingdom
Pfizer Luxco Holdings SARLLuxembourg
Pfizer Luxembourg Global Holdings S.à r.l.Luxembourg
Pfizer Luxembourg SARLLuxembourg
Pfizer Manufacturing Austria G.m.b.H.Austria
Pfizer Manufacturing Belgium N.V.Belgium
Pfizer Manufacturing Deutschland GmbHGermany
Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG
Germany
Pfizer Manufacturing Holdings LLCDelaware
Pfizer Manufacturing Ireland Unlimited CompanyIreland
Pfizer Manufacturing LLCDelaware
Pfizer Manufacturing Services Unlimited CompanyIreland
Pfizer MAP Holding, Inc.Delaware
Pfizer Medicamentos Genericos e Participacoes Ltda.Brazil
Pfizer Mexico Holding B.V.Netherlands
Pfizer Middle East and North Africa Regional Headquarter CompanySaudi Arabia
Pfizer Namibia (Proprietary) LimitedNamibia
Pfizer New Zealand LimitedNew Zealand
Pfizer North America Services LLCDelaware
Pfizer OTC B.V.Netherlands
Pfizer Overseas LLCDelaware
Pfizer OyFinland
Pfizer Pakistan LimitedPakistan
Pfizer Payroll Services LLCDelaware
Pfizer PFE CIA. Ltda.Ecuador
- 4 -


Pfizer PFE Eastern Investments B.V.Netherlands
Pfizer PFE Global Holdings B.V.Netherlands
Pfizer PFE İlaçları Anonim ŞirketiTurkey
Pfizer PFE Pharmaceuticals Israel Holding LLCDelaware
Pfizer PFE Pharmaceuticals Israel Ltd.Israel
Pfizer PFE Service Company Holding B.V.Netherlands
Pfizer PFE Spain B.V.Netherlands
Pfizer Pharma GmbHGermany
Pfizer Pharmaceutical (Wuxi) Co., Ltd.People’s Republic of China
Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC)Hungary
Pfizer Pharmaceuticals (Namibia) (Proprietary) LimitedNamibia
Pfizer Pharmaceuticals Global B.V.Netherlands
Pfizer Pharmaceuticals Israel Ltd.Israel
Pfizer Pharmaceuticals Korea LimitedRepublic of Korea
Pfizer Pharmaceuticals Science and Technology Co., Ltd.People's Republic of China
Pfizer Pharmaceuticals Tunisie SarlTunisia
Pfizer Pigments Inc.Delaware
Pfizer Polska Sp. z.o.o.Poland
Pfizer Prev - Sociedade de Previdencia PrivadaBrazil
Pfizer Private LimitedSingapore
Pfizer Production LLCDelaware
Pfizer Products Inc.Connecticut
Pfizer Products India Private LimitedIndia
Pfizer R&D Japan G.K.Japan
Pfizer R&D UK LimitedUnited Kingdom
Pfizer Research (NC), Inc.Delaware
Pfizer Romania SRLRomania
Pfizer S.A.Peru
Pfizer S.A.S.Colombia
Pfizer S.G.P.S. Lda.Portugal
Pfizer S.R.L.Argentina
Pfizer S.r.l.Italy
Pfizer SA (Belgium)Belgium
Pfizer Saudi LimitedSaudi Arabia
Pfizer Saudi Trading LLCSaudi Arabia
Pfizer Service Company BVBelgium
Pfizer Service Company Ireland Unlimited CompanyIreland
Pfizer Shareholdings Intermediate SARLLuxembourg
Pfizer Singapore Holding Pte. Ltd.Singapore
Pfizer Specialties LimitedNigeria
Pfizer Specialty UK LimitedUnited Kingdom
Pfizer SRB d.o.o.Serbia
Pfizer Strategic Investment Holdings LLCDelaware
Pfizer Trading Polska sp.z.o.o.Poland
Pfizer Tunisie SATunisia
Pfizer Venezuela, S.A.Venezuela
- 5 -


Pfizer Ventures (US) LLCDelaware
Pfizer Ventures LLCDelaware
Pfizer Worldwide Services Unlimited CompanyIreland
Pfizer Zona Franca, S.A.Costa Rica
Pfizer, Inc.Philippines
Pfizer, S.A.Costa Rica
Pfizer, S.A. de C.V.Mexico
Pfizer, S.L.U.Spain
Pharmacia & Upjohn Company LLCDelaware
Pharmacia & Upjohn LLCDelaware
Pharmacia Brasil Ltda.Brazil
Pharmacia Hepar LLCDelaware
Pharmacia Inter-American LLCPennsylvania
Pharmacia International B.V.Netherlands
Pharmacia LimitedUnited Kingdom
Pharmacia LLCDelaware
PHIVCO Corp.Delaware
PHIVCO Luxembourg S.à r.l.Luxembourg
PIMB OFG Spain Holding, S.L.Spain
PT. Pfizer IndonesiaIndonesia
Purepac Pharmaceutical Holdings LLCDelaware
PZR Property LimitedUnited Kingdom
Renrall LLCWyoming
ResApp Health LimitedAustralia
ReViral LimitedUnited Kingdom
Rinat Neuroscience Corp.Delaware
Seagen B.V.Netherlands
Seagen Inc.Delaware
Seagen International GmbHSwitzerland
Seagen U.K. Ltd.United Kingdom
SeaGen US Holdings, LLCDelaware
Servicios P&U, S. de R.L. de C.V.Mexico
Shiley LLCCalifornia
Sinergis Farma-Produtos Farmaceuticos, Lda.Portugal
Solinor LLCDelaware
Sugen LLCDelaware
Tabor LLCDelaware
The Pfizer Incubator LLCDelaware
Trillium Therapeutics ULCCanada
Vicuron Holdings LLCDelaware
Warner Lambert del Uruguay S.A.Uruguay
Warner-Lambert Company GmbHSwitzerland
Warner-Lambert Company LLCDelaware
W-L LLCDelaware
Wyeth (Asia) LimitedDelaware
Wyeth Ayerst Inc.Delaware
Wyeth Farma, S.A.Spain
- 6 -


Wyeth Holdings LLCMaine
Wyeth Lederle S.r.l.Italy
Wyeth LLCDelaware
Wyeth Pakistan LimitedPakistan
Wyeth Pharmaceuticals LLCDelaware
Wyeth Subsidiary Illinois CorporationIllinois
Wyeth-Ayerst (Asia) LLCDelaware
Wyeth-Ayerst International LLCDelaware
Wyeth-Ayerst Promotions LimitedDelaware

- 7 -
EX-22 5 pfe-exh22x123124x10k.htm EX-22 Document

EXHIBIT 22
Subsidiary Issuers of Guaranteed Securities
As of December 31, 2024, Pfizer Inc. (Parent Guarantor) was the unconditional and irrevocable guarantor of the following unsecured registered notes issued by wholly-owned subsidiaries of Parent Guarantor:
Name of Subsidiary Issuer
State of Formation of Issuer
Description of Registered Notes
Pharmacia LLC
Delaware
6.75% Debentures due 2027
Pharmacia LLC
Delaware
6.60% Debentures due 2028
Wyeth LLC
Delaware
6.50% Notes due 2034
Wyeth LLC
Delaware
6.00% Notes due 2036
Wyeth LLC
Delaware
5.95% Notes due 2037
Pfizer Investment Enterprises Pte. Ltd.
Republic of Singapore
4.650% Notes due 2025
Pfizer Investment Enterprises Pte. Ltd.
Republic of Singapore
4.450% Notes due 2026
Pfizer Investment Enterprises Pte. Ltd.
Republic of Singapore
4.450% Notes due 2028
Pfizer Investment Enterprises Pte. Ltd.
Republic of Singapore
4.650% Notes due 2030
Pfizer Investment Enterprises Pte. Ltd.
Republic of Singapore
4.750% Notes due 2033
Pfizer Investment Enterprises Pte. Ltd.
Republic of Singapore
5.110% Notes due 2043
Pfizer Investment Enterprises Pte. Ltd.
Republic of Singapore
5.300% Notes due 2053
Pfizer Investment Enterprises Pte. Ltd.
Republic of Singapore
5.340% Notes due 2063

EX-23 6 pfe-exh23x12312024x10k.htm EX-23 Document

EXHIBIT 23

Consent of Independent Registered Public Accounting Firm


We consent to the incorporation by reference in the registration statements listed below of our reports dated February 27, 2025, with respect to the consolidated financial statements of Pfizer Inc. and Subsidiary Companies and the effectiveness of internal control over financial reporting.

-Form S-8 dated October 27, 1983 (File No. 2-87473),
-Form S-8 dated March 22, 1990 (File No. 33-34139),
-Form S-8 dated January 24, 1991 (File No. 33-38708),
-Form S-8 dated November 18, 1991 (File No. 33-44053),
-Form S-8 dated May 27, 1993 (File No. 33-49631),
-Form S-8 dated May 19, 1994 (File No. 33-53713),
-Form S-8 dated October 5, 1994 (File No. 33-55771),
-Form S-8 dated December 20, 1994 (File No. 33-56979),
-Form S-8 dated March 29, 1996 (File No. 333-02061),
-Form S-8 dated September 25, 1997 (File No. 333-36371),
-Form S-8 dated June 19, 2000 (File No. 333-39606),
-Form S-8 dated April 27, 2001 (File No. 333-59660),
-Form S-8 dated April 16, 2003 (File No. 333-104582),
-Form S-8 dated November 18, 2003 (File No. 333-110571),
-Form S-8 dated December 18, 2003 (File No. 333-111333),
-Form S-8 dated April 26, 2004 (File No. 333-114852),
-Form S-8 dated March 1, 2007 (File No. 333-140987),
-Form S-4 dated March 27, 2009 (File No. 333-158237),
-Form S-8 dated October 16, 2009 (File No. 333-162519),
-Form S-8 dated October 16, 2009 (File No. 333-162520),
-Form S-8 dated October 16, 2009 (File No. 333-162521),
-Form S-8 dated March 1, 2010 (File No. 333-165121),
-Form S-8 dated March 2, 2015 (File No. 333-202437),
-Form S-4 dated September 3, 2015 (File No. 333-206758),
-Form S-8 dated August 8, 2019 (File No. 333-233166),
-Form S-8 dated August 8, 2019 (File No. 333-202437),
-Form S-3 ASR dated February 26, 2021 (File No. 333-253605),
-Form S-8 dated February 24, 2023 (File No. 333-270024),
-Form S-3ASR dated February 23, 2024 (File No. 333-277323),
-Form S-8 dated February 23, 2024 (File No. 333-277321), and
-Form S-8 dated May 9, 2024 (File No. 333-279242)



/s/ KPMG LLP
New York, New York February 27, 2025

EX-31.1 7 pfe-exh311x12312024x10k.htm EX-31.1 Document

EXHIBIT 31.1
Certification by the Chief Executive Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Albert Bourla, certify that:
1.I have reviewed this Annual Report on Form 10-K of Pfizer Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: February 27, 2025
/s/ ALBERT BOURLA
Albert Bourla
Chairman and Chief Executive Officer


EX-31.2 8 pfe-exh312x12312024x10k.htm EX-31.2 Document

EXHIBIT 31.2
Certification by the Chief Financial Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, David M. Denton, certify that:
1.I have reviewed this Annual Report on Form 10-K of Pfizer Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: February 27, 2025
/s/ DAVID M. DENTON
David M. Denton
Chief Financial Officer, Executive Vice President

EX-32.1 9 pfe-exh321x12312024x10k.htm EX-32.1 Document

EXHIBIT 32.1
Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
    Pursuant to 18 U.S.C. Section 1350, I, Albert Bourla, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.
/s/ ALBERT BOURLA
Albert Bourla
Chairman and Chief Executive Officer
February 27, 2025
    This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.


EX-32.2 10 pfe-exh322x12312024x10k.htm EX-32.2 Document

EXHIBIT 32.2
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
    Pursuant to 18 U.S.C. Section 1350, I, David M. Denton, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.
/s/DAVID M. DENTON
David M. Denton
Chief Financial Officer, Executive Vice President
February 27, 2025
    This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.


EX-97 11 pfe-exh97x12312024x10k.htm EX-97 Document

EXHIBIT 97
PFIZER INC.
RECOUPMENT POLICY
As required by Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time, and the related rules or regulations promulgated by the SEC and the NYSE, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) adopts this Recoupment Policy (this “Policy”) to be applied to the Executive Officers of the Company, effective as of the Effective Date (as defined below), pursuant to the recommendation and approval of the Compensation Committee (the “Committee”) and the Committee’s recommendation that the Board so approve.
1.Definitions
For purposes of this Policy, the following definitions shall apply:
a)Company Group” means the Company and each of its Subsidiaries, as applicable.
b)Covered Compensation” means any Incentive-Based Compensation granted, vested or paid to a person who served as an Executive Officer at any time during the performance period for the Incentive-Based Compensation and that was Received (i) on or after the Effective Date, (ii) after the person became an Executive Officer and (iii) at a time that the Company had a class of securities listed on a national securities exchange or a national securities association.
c)Effective Date” means the date on which the new NYSE listing standard 303A.14 becomes effective, related to recovery of Erroneously Awarded Incentive-Based Executive Compensation.
d)Erroneously Awarded Compensation” means the amount of Covered Compensation granted, vested or paid to a person during the fiscal period when the applicable Financial Reporting Measure relating to such Covered Compensation was attained that exceeds the amount of Covered Compensation that otherwise would have been granted, vested or paid to the person had such amount been determined based on the applicable Restatement, computed without regard to any taxes paid (i.e., on a pre-tax basis). For Covered Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Restatement, the Committee will determine the amount of such Covered Compensation that constitutes Erroneously Awarded Compensation, if any, based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Covered Compensation was granted, vested or paid and the Committee shall maintain documentation of such determination and provide such documentation to the NYSE.
e)Exchange Act” means the Securities Exchange Act of 1934.
f)Executive Officer means each “officer” of the Company as defined under Rule 16a-1(f) under Section 16 of the Exchange Act, which shall be deemed to include any individuals identified by the Company as executive officers pursuant to Item 401(b) of Regulation S-K under the Exchange Act. Both current and former Executive Officers are subject to the Policy in accordance with its terms.
g)Financial Reporting Measure” means (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures and may consist of GAAP or non-GAAP financial measures (as defined under Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Exchange Act), (ii) stock price or (iii) total shareholder return. Financial Reporting Measures may or may not be filed with the SEC and may be presented outside the Company’s financial statements, such as in Managements’ Discussion and Analysis of Financial Conditions and Result of Operations or in the performance graph required under Item 201(e) of Regulation S-K under the Exchange Act.
h)Incentive-Based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. In addition, for purposes of this Policy, Incentive-Based Compensation is deemed “Received” in the Company’s fiscal period during which the Financial Reporting Measure specified in or otherwise relating to the Incentive-Based Compensation award is attained, even if the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.
i)Home Country” means the Company’s jurisdiction of incorporation.
j)Lookback Period” means the three completed fiscal years (plus any transition period of less than nine months that is within or immediately following the three completed fiscal years and that results from a change in the Company’s fiscal year) immediately preceding the date on which the Company is required to prepare a Restatement for a given reporting period, with such date being the earlier of: (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Restatement.



Recovery of any Erroneously Awarded Compensation under the Policy is not dependent on if or when the Restatement is actually filed.
k)NYSE” means the New York Stock Exchange.
l)Restatement” means a required accounting restatement of any Company financial statement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including (i) to correct an error in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as a “Big R” restatement) or (ii) to correct an error in previously issued financial statements that is not material to the previously issued financial statements but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as a “little r” restatement). Changes to the Company’s financial statements that do not represent error corrections under the then-current relevant accounting standards will not constitute Restatements. Recovery of any Erroneously Awarded Compensation under the Policy is not dependent on fraud or misconduct by any person in connection with the Restatement.
m)SEC” means the United States Securities and Exchange Commission.
n)Subsidiary” means any domestic or foreign corporation, partnership, association, joint stock company, joint venture, trust or unincorporated organization “affiliated” with the Company, that is, directly or indirectly, through one or more intermediaries, “controlling”, “controlled by” or “under common control with”, the Company. “Control” for this purpose means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such person, whether through the ownership of voting securities, contract or otherwise.
2.Recoupment of Erroneously Awarded Compensation
In the event of a Restatement, any Erroneously Awarded Compensation Received during the Lookback Period prior to the Restatement (a) that is then-outstanding but has not yet been paid shall be automatically and immediately forfeited; and (b) that has been paid to any person, shall be subject to reasonably prompt repayment to the Company Group in accordance with Section 3 of this Policy. The Committee must pursue (and shall not have the discretion to waive) the forfeiture and/or repayment of such Erroneously Awarded Compensation in accordance with Section 3 of this Policy, except as provided below.
Notwithstanding the foregoing, the Committee (or, if the Committee is not a committee of the Board responsible for the Company’s executive compensation decisions and composed entirely of independent directors, a majority of the independent directors serving on the Board) may determine not to pursue the forfeiture and/or recovery of Erroneously Awarded Compensation from any person if the Committee determines that such forfeiture and/or recovery would be impracticable due to any of the following circumstances: (i) the direct expense paid to a third party (for example, reasonable legal expenses and consulting fees) to assist in enforcing the Policy would exceed the amount to be recovered (following reasonable attempts by the Company Group to recover such Erroneously Awarded Compensation, the documentation of such attempts, and the provision of such documentation to the NYSE) (ii) pursuing such recovery would violate the Company’s Home Country laws adopted prior to November 28, 2022 (provided that the Company obtains an opinion of Home Country counsel acceptable to the NYSE that recovery would result in such a violation and provides such opinion to the NYSE), or (iii) recovery would likely cause any otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.
3.Means of Repayment
In the event that the Committee determines that any person shall repay any Erroneously Awarded Compensation, the Committee shall provide written notice to such person by email or certified mail to the physical address on file with the Company Group for such person, and the person shall satisfy such repayment in a manner and on such terms as required by the Committee, and the Company Group shall be entitled to set off the repayment amount against any amount owed to the person by the Company Group, to require the forfeiture of any award granted by the Company Group to the person, or to take any and all necessary actions to reasonably promptly recoup the repayment amount from the person, in each case, to the fullest extent permitted under applicable law, including without limitation, Section 409A of the Internal Revenue Code and the regulations and guidance thereunder. If the Committee does not specify a repayment timing in the written notice described above, the applicable person shall be required to repay the Erroneously Awarded Compensation to the Company Group by wire, cash or cashier’s check no later than thirty (30) days after receipt of such notice.
4.No Indemnification
No person shall be indemnified, insured or reimbursed by the Company Group in respect of any loss of compensation by such person in accordance with this Policy, nor shall any person receive any advancement of expenses for disputes related to any loss of compensation by such person in accordance with this Policy, and no person shall be paid or reimbursed by the Company Group for any premiums paid by such person for any third-party insurance policy covering potential recovery obligations under this Policy. For this purpose, “indemnification” includes any modification to current compensation arrangements or other means that would amount to de facto indemnification (for example, providing the person a new cash award which would be cancelled to effect the recovery of any Erroneously Awarded Compensation). In no event shall the Company Group be required to award any person an additional payment if any Restatement would result in a higher incentive compensation payment.
- 2 -


5.Miscellaneous
The Board has the authority to amend this Policy as provided by Section 6 below. This Policy generally will be administered and interpreted by the Committee, provided that the Board may, from time to time, exercise discretion to administer and interpret this Policy, in which case, all references herein to “Committee” shall be deemed to refer to the Board. Any determination by the Committee with respect to this Policy shall be final, conclusive and binding on all interested parties. Any discretionary determinations of the Committee under this Policy, if any, need not be uniform with respect to all persons, and may be made selectively amongst persons, whether or not such persons are similarly situated.
This Policy is intended to satisfy the requirements of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time, and any related rules or regulations promulgated by the SEC or the NYSE, including any additional or new requirements that become effective after the Effective Date which upon effectiveness shall be deemed to automatically amend this Policy to the extent necessary to comply with such additional or new requirements.
The provisions in this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to applicable law. The invalidity or unenforceability of any provision of this Policy shall not affect the validity or enforceability of any other provision of this Policy. Recoupment of Erroneously Awarded Compensation under this Policy is not dependent upon the Company Group satisfying any conditions in this Policy, including any requirements to provide applicable documentation to the NYSE.
The rights of the Company Group under this Policy to seek forfeiture or reimbursement are separate from and in addition to, and not in lieu of, any rights of recoupment, or remedies or rights other than recoupment, that may be available to the Company Group pursuant to the terms of any law, government regulation or stock exchange listing requirement or any other policy, code of conduct, charter, employee handbook, employment agreement, equity award agreement (including without limitation, the Executive Long-Term Incentive Award Grant Agreements issued under the Pfizer Inc. 2014 Stock Plan, the Pfizer Inc. 2019 Stock Plan and any successor plan, and the related Executive Points of Interest documents), the Company Group’s Global Performance Plan, or other plan or agreement of the Company Group (each an “Other Recoupment Policy”). To the extent that Erroneously Awarded Compensation is also subject to recoupment pursuant to any Other Recoupment Policy, the Company Group shall not recover compensation, or obtain payment, reimbursement or restitution, in an amount that exceeds the greater of the maximum amount recoupable under this Policy or any Other Recoupment Policy.
6.Amendment and Termination
To the extent permitted by, and in a manner consistent with applicable law, including SEC and NYSE rules, the Board may terminate, suspend or amend this Policy at any time in its discretion.
7.Successors
This Policy shall be binding and enforceable against all persons and their respective beneficiaries, heirs, executors, administrators or other legal representatives with respect to any Covered Compensation granted, vested or paid to or administered by such persons or entities.
- 3 -


Pfizer Inc.
RECOUPMENT POLICY
ACKNOWLEDGMENT, CONSENT AND AGREEMENT
I acknowledge that I have received and reviewed a copy of the Pfizer Inc. Recoupment Policy (as may be amended from time to time, the “Policy”) and I have been given an opportunity to ask questions about the Policy and review it with my counsel. I knowingly, voluntarily and irrevocably consent to and agree to be bound by and subject to the Policy’s terms and conditions, including that I will return any Erroneously Awarded Compensation that is required to be repaid in accordance with the Policy. I further acknowledge, understand and agree that (i) the compensation that I receive, have received or may become entitled to receive from the Company Group is subject to the Policy, and the Policy may affect such compensation; and (ii) I have no right to indemnification, insurance payments or other reimbursement by or from the Company Group for any compensation that is subject to recoupment and/or forfeiture under the Policy. Capitalized terms not defined herein have the meanings set forth in the Policy.

Signed:        _________________________________________
Print Name:     _________________________________________
Date:        _________________________________________

EX-101.SCH 12 pfe-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Statements of Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Consolidated Statements of Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Other (Income)/Deductions—Net link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Tax Matters link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Other Financial Information link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Identifiable Intangible Assets, Net and Goodwill link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Contingencies and Certain Commitments link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Segment, Geographic and Other Revenue Information link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Other (Income)/Deductions—Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Tax Matters (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Other Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Property, Plant and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Identifiable Intangible Assets, Net and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Segment, Geographic and Other Revenue Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Summarized Financial Information of Equity Method Investee (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Collaborative Arrangements (Detail) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Research and Development Arrangement (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Other (Income)/Deductions—Net - Schedule of Other Nonoperating Income (Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - Other (Income)/Deductions—Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Other (Income)/Deductions—Net - Schedule of Additional Information About Intangible Assets Impaired (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - Tax Matters - Provision for Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Tax Matters - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - Tax Matters - Schedule of Cash Paid for Income Taxes, Net of Refunds (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - Tax Matters - Deferred Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - Financial Instruments - Investments - Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9955567 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955568 - Disclosure - Financial Instruments - Short-Term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9955569 - Disclosure - Financial Instruments - Short-Term Borrowings - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955570 - Disclosure - Financial Instruments - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955571 - Disclosure - Financial Instruments - Long-Term Debt, Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 9955572 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955573 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) link:presentationLink link:calculationLink link:definitionLink 9955574 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) link:presentationLink link:calculationLink link:definitionLink 9955575 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955576 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9955577 - Disclosure - Financial Instruments - Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9955578 - Disclosure - Other Financial Information - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9955579 - Disclosure - Other Financial Information - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955580 - Disclosure - Other Financial Information - Supplier Finance Program Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9955581 - Disclosure - Property, Plant and Equipment - Components of Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9955582 - Disclosure - Property, Plant and Equipment - Long-lived Assets by Geographic Areas, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9955583 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955584 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink 9955585 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955586 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Expected Annual Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955587 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955588 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9955589 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9955590 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9955591 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 9955592 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955593 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 9955594 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9955595 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955596 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955597 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9955598 - Disclosure - Share-Based Payments - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 9955599 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details) link:presentationLink link:calculationLink link:definitionLink 9955600 - Disclosure - Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955601 - Disclosure - Share-Based Payments - Schedule of Valuation Assumptions (Detail) link:presentationLink link:calculationLink link:definitionLink 9955602 - Disclosure - Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 9955603 - Disclosure - Share-Based Payments - Summary of TSRU and PTU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955604 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 9955605 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) link:presentationLink link:calculationLink link:definitionLink 9955606 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955607 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955608 - Disclosure - Leases - Schedule of Lease Costs and Other Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955609 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9955609 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9955610 - Disclosure - Contingencies and Certain Commitments - Patent Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 9955611 - Disclosure - Contingencies and Certain Commitments - Legal Proceedings-Government Investigations (Details) link:presentationLink link:calculationLink link:definitionLink 9955612 - Disclosure - Contingencies and Certain Commitments - Certain Commitments and Contingent Consideration for Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9955613 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 9955614 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9955615 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9955616 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Geographic Area (Detail) link:presentationLink link:calculationLink link:definitionLink 9955617 - Disclosure - Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9955618 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Product (Detail) link:presentationLink link:calculationLink link:definitionLink 9955619 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Product - Footnotes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 pfe-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 14 pfe-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 15 pfe-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Vested and expected to vest, end of period, weighted-average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Transforming to a More Focused Company Plan [Member] Transforming to a More Focused Company Plan [Member] Transforming to a More Focused Company Plan Payments on long-term debt Repayments of Long-Term Debt Amount of remaining shares authorized in stock purchase plan, value Share Repurchase Program, Remaining Authorized, Amount Confirmed obligations outstanding, December 31, 2023 Confirmed obligations outstanding, December 31, 2024 Supplier Finance Program, Obligation, Current Number of patents found infringed Loss Contingency, Patents Found Infringed, Number Repatriation tax liability Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability Net Sales and Royalty Agreement Terms [Member] Net Sales and Royalty Agreement Terms [Member] Net Sales and Royalty Agreement Terms Cover [Abstract] Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Identifiable intangible assets, net of adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred, Net of Adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred, Net of Adjustments IPR&D [Member] In Process Research and Development [Member] Schedule of Future Minimum Rental Payments for Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] International [Member] Foreign Plan [Member] Schedule of Indefinite-Lived Intangible Assets [Table] Intangible Asset, Indefinite-Lived [Table] Inventories - Deferred tax assets Deferred Tax Assets, Inventory Derivative, Amount of Gains/(Losses) on hedged item Recognized in OID Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Trading Symbol Trading Symbol Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Fair Value Hedging [Member] Fair Value Hedging [Member] Realized gain Less: Net (gains)/losses recognized during the period on equity securities sold during the period Equity Securities, FV-NI, Realized Gain (Loss) Comprehensive income/(loss) before allocation to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest U.S. and Participating States [Member] U.S. and Participating States [Member] U.S. and Participating States Haleon [Member] Haleon [Member] Haleon Non-NEOs Non-NEOs [Member] Pfizer Ignite [Member] Pfizer Ignite [Member] Pfizer Ignite Tax benefit for share-based compensation expense Share-Based Payment Arrangement, Expense, Tax Benefit Employee Stock Ownership Plan (ESOP), Plan [Domain] Employee Stock Ownership Plan (ESOP), Plan [Domain] United States Domestic Income Taxes [Abstract] Domestic Income Taxes [Abstract] Cash dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Disposal Group Name [Domain] Disposal Group Name [Domain] Short-term Investments [Member] Short-Term Investments [Member] Income Tax Examination [Line Items] Income Tax Examination [Line Items] Schedule of Accrued Liabilities [Line Items] Schedule Of Accrued Liabilities [Line Items] [Line Items] for Schedule Of Accrued Liabilities [Table] Other comprehensive income (loss), derivatives qualifying as hedges, tax, total Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Trade accounts receivable Increase (Decrease) in Accounts Receivable Net (gains)/losses recognized during the period on equity securities Net (gains)/losses recognized during the period on equity securities Equity Securities, FV-NI, Gain (Loss) Property, Plant and Equipment, Impairment Property, Plant and Equipment, Impairment [Policy Text Block] Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract] Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract] Telavant Holdings, Inc. [Member] Telavant Holdings, Inc. [Member] Telavant Holdings, Inc. Cost of Sales and Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Enbrel (Outside the U.S. and Canada) [Member] Enbrel [Member] Enbrel [Member] Schedule of Gains and Losses on Investment Securities Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block] Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block] Income from continuing operations Net income from continuing operations before allocation to noncontrolling interests Income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Hedging Relationship [Domain] Hedging Relationship [Domain] Cash received upon exercise Proceeds from Stock Options Exercised Land [Member] Land [Member] Portfolio Performance Shares [Member] Portfolio Performance Shares [Member] Portfolio Performance Shares [Member] Other comprehensive income/(loss), before tax Other Comprehensive Income (Loss), before Tax Award Timing Disclosures [Line Items] Net Investment Hedging [Member] Net Investment Hedging [Member] Common ESOP Plan [Member] Common ESOP Plan [Member] Common ESOP Plan [Member] Amount of Gains/(Losses) Recognized in OID Derivative, Gain (Loss) on Derivative, Net Investment, Name [Domain] Investment, Name [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Charges to cost of sales related to raw materials Charges For Excess Raw Materials Charges For Excess Raw Materials Lease liabilities (long-term), statement of financial position Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Schedule of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Table] Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract] Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract] Debt securities, fair value Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Segment Reporting Segment Reporting, Policy [Policy Text Block] Tivdak [Member] Tivdak [Member] Tivdak Plan Name [Domain] Plan Name [Domain] United States [Member] U.S. [Member] UNITED STATES Common-share equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Net income tax accounts Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Income Tax Accounts Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Income Tax Accounts Other noncurrent assets Total other noncurrent assets Other Assets, Noncurrent Leases [Abstract] Leases [Abstract] Finite-lived intangible assets, gross carrying amount Finite-Lived Intangible Assets, Gross Amounts paid in settlement agreement Payments for Legal Settlements Foreign Currency Short-Term Borrowings [Member] Foreign Currency Short Term Borrowings [Member] Foreign currency short - term borrowings [Member] Operating Segments [Member] Operating Segments [Member] Units settled, shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares Number of shares earned as a percentage of initial award Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award Net cash provided by/(used in) operating activities Net Cash Provided by (Used in) Operating Activities Total Alliance revenues [Member] Total Alliance Biopharmaceuticals [Member] Total Alliance Biopharmaceuticals [Member] State and local tax adjustments - Deferred tax assets Deferred Tax Assets, State and Local Taxes Adjustments Deferred Tax Assets, State and Local Taxes Adjustments Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] California Department of Insurance [Member] California Department of Insurance [Member] California Department of Insurance Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Property, plant and equipment - Deferred tax assets Deferred Tax Assets, Property, Plant and Equipment Other Stockholders' Equity, Other Award Timing Method Award Timing Method [Text Block] Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net Net periodic benefit cost/(credit) reported in income Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Exercisable, end of period, weighted-average exercise price per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Restructuring Type [Axis] Restructuring Type [Axis] Units granted upon conversion, shares Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Cash proceeds from disposal Proceeds from Divestiture of Businesses Benefit plan contributions in excess of expense/income Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense) The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments). Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Restructuring, integration and acquisition-related costs [Member] Restructuring, integration and acquisition-related costs [Member] Restructuring, integration and acquisition-related costs Units expected to vest, shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Compensation Amount Outstanding Recovery Compensation Amount Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Equity method investment, ownership percentage sold Equity Method Investment, Percentage Of Holdings Sold Equity Method Investment, Percentage Of Holdings Sold Government and Government Sponsored [Member] Government and Government Sponsored [Member] Government and Government Sponsored Expected return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Anti-dilutive common stock equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche One [Member] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset acquisition, contingent consideration Asset Acquisition, Consideration Transferred, Contingent Consideration Number of countries with revenue exceeding $500 million Concentration Risk, Revenues, $500,000,000 or More, Number of Countries Concentration Risk, Revenues, $500,000,000 or More, Number of Countries Credit Facility [Domain] Credit Facility [Domain] Current tax assets Other Tax Assets, Current Other Tax Assets, Current Granted, weighted-average grant-date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Private equity securities at cost Private Equity Investments Private Equity Investments Goodwill Beginning balance Ending balance Goodwill Amount of shares authorized in stock purchase plan, value Share Repurchase Program, Authorized, Amount Senior Notes, USD Denominated [Member] Consumer Healthcare JV Senior Notes, USD Denominated [Member] Consumer Healthcare JV Senior Notes, USD Denominated Specialty Care [Member] Specialty Care [Member] Specialty Care Fixed income commingled funds [Member] Fixed Income Securities [Member] Entity Information [Line Items] Entity Information [Line Items] Stock Options [Member] Share-Based Payment Arrangement, Option [Member] Acquisitions Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition Carrying value of shares sold Equity Method Investment, Amount Sold Other financing activities, net Proceeds from (Payments for) Other Financing Activities Comprehensive income/(loss) attributable to Pfizer Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension Plans [Member] Pension Plan [Member] Reinvested dividend equivalents, shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period All other, net Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Contractual Maturities of Available-for-sale and Held-to-maturity Securities Investments Classified by Contractual Maturity Date [Table Text Block] Award Type [Axis] Award Type [Axis] Senior Unsecured Debt, Due 2031-2035 [Member] Senior Unsecured Debt, Due 2031-2035 [Member] Senior Unsecured Debt, Due 2031-2035 Corporate and Other [Member] Corporate debt [Member] Corporate Debt Securities [Member] Net deferred tax liability Deferred Tax Liabilities, Net Impact of foreign exchange and other Goodwill, Foreign Currency Translation Gain (Loss) Charitable contributions Effective Income Tax Rate Reconciliation, Charitable Contributions, Percent Effective Income Tax Rate Reconciliation, Charitable Contributions, Percent Senior Notes, GBP Denominated [Member] Consumer Healthcare JV Senior Notes, GBP Denominated [Member] Consumer Healthcare JV Senior Notes, GBP Denominated Earnings per common share––basic: EPS Numerator Earnings Per Share, Basic [Abstract] Work-in-process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Reclassification adjustments related to curtailments of prior service costs and other, net Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits. ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities Equity attributable to noncontrolling interests Equity, Attributable to Noncontrolling Interest Nonvested, beginning of period, grant price (in dollars per share) Nonvested, end of period, grant price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Acquired intangible assets, useful life Acquired intangible assets, estimated weighted-average useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member] GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC US Patent Infringement Case [Member] GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC US Patent Infringement Case Schedule of Derivative Assets at Fair Value Schedule of Derivative Assets at Fair Value [Table Text Block] Lease liabilities (short-term) Less: Current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Number of shares counted toward maximum Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee Short-term investments Total Short-term investments Other Short-Term Investments Consideration transferred, including equity interest held prior to business combination Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held before Combination Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss) Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block] Total property, plant and equipment before accumulated depreciation Property, Plant and Equipment, Gross Exercised, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Assumed long-term debt, paid in full Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Unrealized holding gains/(losses) on derivative financial instruments, net Derivative, Amount of Gains/(Losses) Recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Finite-lived Finite-Lived Intangible Assets, Fair Value Disclosure Employee contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Debt Instrument [Line Items] Debt Instrument [Line Items] Reclassification adjustments related to amortization of prior service costs and other, net Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax Benefit plans: prior service (costs)/credits and other, net Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted-Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Total Shareholder Return Units, Vesting Period One Total Shareholder Return Units, Vesting Period One [Member] Total Shareholder Return Units, Vesting Period One Research and Development Expense [Member] Research and Development Expense [Member] Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average shares––diluted (in shares) Weighted-average common shares outstanding––Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Expected cost Restructuring and Related Cost, Expected Cost Working capital, excluding inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital, Excluding Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital, Excluding Inventories Other (Income)/Deductions--net [Member] Other Nonoperating Income (Expense) [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Research and development arrangement, maximum funding amount Research And Development Arrangement, Maximum Funding Amount Research And Development Arrangement, Maximum Funding Amount Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Total Pfizer Inc. shareholders’ equity Equity attributable to shareholders Equity, Attributable to Parent Net fair value adjustments related to hedging and purchase accounting Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting Subtotal - Deferred tax assets Deferred Tax Assets, Gross Available-for-sale securities, debt maturities, within 1 year, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Financial Instruments Financial Instruments Disclosure [Text Block] Litigation Case [Axis] Litigation Case [Axis] Units exercised and converted, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted Reclassification of accumulated other comprehensive income balances in Equity-method investments OCI, Equity Method Investment, before Tax Current derivative assets Derivative Asset, Current Schedule of Goodwill Schedule of Goodwill [Table Text Block] Equity Method Investment, Summarized Financial Information [Abstract] Equity Method Investment, Summarized Financial Information [Abstract] Line of credit facility, due to expire within one year Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year Concentration Risk Type [Domain] Concentration Risk Type [Domain] Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Reclassification adjustments related to curtailments of prior service costs and other, net Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax Upfront payment to collaborators Payments to Collaborators, Upfront Payment Payments to Collaborators, Upfront Payment Selling, informational and administrative expenses Selling, informational and administrative expenses Selling, General and Administrative Expense Number of employee stock ownership plans Number of Employee Stock Ownership Plans Number of Employee Stock Ownership Plans Information related to the funded status of pension plans with a PBO in excess of plan assets(c): Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Defined contribution plan, cost recognized Defined Contribution Plan, Cost Unrecognized accrued interest decrease as a result of cash payments Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual Pfizer Versus Several Generic Manufacturers [Member] Pfizer and Versus Several Generic Manufacturers [Member] Pfizer and Versus Several Generic Manufacturers Cost of Sales [Member] Cost of Sales [Member] Product [Member] Product [Member] Cash and cash equivalents [Member] Defined Benefit Plan, Cash and Cash Equivalents [Member] Sale of Stock [Domain] Sale of Stock [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Invoices confirmed during the year Supplier Finance Program, Obligation, Addition Cash dividends declared: Dividends [Abstract] All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Business acquisition, per share in cash (in dollars per share) Business Acquisition, Share Price Schedule of Restructuring Reserve by Type of Cost Schedule of Restructuring Reserve by Type of Cost [Table Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Available-For-Sale Securities [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Ibrance [Member] Ibrance [Member] Ibrance [Member] Outstanding, end of period, weighted-average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Other comprehensive income/(loss) before allocation to noncontrolling interests Other comprehensive income/(loss), net of tax Other comprehensive income/(loss) Other Comprehensive Income (Loss), Net of Tax Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Number of shares outstanding (in shares) Units outstanding, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Net income tax accounts Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Income Tax Accounts Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Income Tax Accounts Document Type Document Type Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Derivative Contract [Domain] Derivative Contract [Domain] Changes in actuarial assumptions and other Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) GSK [Member] GSK [Member] GSK [Member] Schedule of Segment Reporting Information by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Amortization of intangible assets Amortization Of Intangible Assets Not Associated With Single Function The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses. Derivative liability, statement of financial position Derivative Liability, Statement of Financial Position [Extensible Enumeration] Purchases of long-term investments Payments to Acquire Marketable Securities Net loss attributable to Pfizer Inc. common shareholders Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Contingent consideration liability, noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Available-for-sale debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Schedule of Expected Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Sales [Member] Sales [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum [Member] Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Gain Contingencies, Nature [Axis] Gain Contingencies, Nature [Axis] Supplier finance program, payment timing, period Supplier Finance Program, Payment Timing, Period Finite-lived intangible assets, net Finite-Lived Intangible Assets, Net Furniture, fixtures and other [Member] Furniture and Fixtures [Member] Developed Markets [Member] International Developed Markets [Member] International Developed Markets Trade accounts payable Accounts Payable, Current Certain legal matters, net Gain (Loss) from Litigation Settlement Debt securities maturities, over 1 to 5 years, fair value Debt Securities Maturities, Year Two Through Five, Fair Value Debt Securities Maturities, Year Two Through Five, Fair Value Expired, weighted-average exercise price per share (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Interest Effective Income Tax Rate Reconciliation, Deduction, Interest, Percent Effective Income Tax Rate Reconciliation, Deduction, Interest, Percent Total lease cost Lease, Cost Dividend income Dividend income Investment Income, Dividend Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income from continuing operations before provision/(benefit) for taxes on income Earnings Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Breakthrough Performance Awards (BPAs) [Member] Breakthrough Performance Awards [Member] Breakthrough Performance Awards Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Fair value of previously held equity interest in acquiree Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Property, plant and equipment - Deferred tax liabilities Deferred Tax Liabilities, Property, Plant and Equipment Name Outstanding Recovery, Individual Name Variable lease cost Variable Lease, Cost Etrasimod (Velsipity) [Member] Etrasimod (Velsipity) [Member] Etrasimod (Velsipity) Net assets acquired/total consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Title of Individual [Axis] Title and Position [Axis] Acquisitions/divestitures, net Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation Post closing compensation expense Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Schedule of Cash Paid for Income Taxes, Net of Refunds Schedule of Cash Paid for Income Taxes, Net of Refunds [Table Text Block] Schedule of Cash Paid for Income Taxes, Net of Refunds Award Timing Predetermined Award Timing Predetermined [Flag] Held-to-maturity debt securities Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent Subsequent Event Type [Domain] Subsequent Event Type [Domain] Foreign currency translation adjustments, net Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Expected benefit payments: Defined Benefit Plan, Expected Future Employer Contributions [Abstract] Partnership Interest [Member] Partnership Interest [Member] Utilization and other Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment Investment, Name [Axis] Investment, Name [Axis] Forfeited, weighted-average intrinsic value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share Amortization of prior service cost/(credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Net income attributable to Pfizer Inc. common shareholders (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Revenues and Collaborative Arrangements Revenue from Contract with Customer [Policy Text Block] United States Income (Loss) from Continuing Operations before Income Taxes, Domestic 1.365% Consumer Healthcare JV Loan [Member] 1.365% Consumer Healthcare JV Loan [Member] 1.365% Consumer Healthcare JV Loan Restructuring charges and certain acquisition-related costs Restructuring Charges and Certain Acquisition-Related Costs Restructuring Charges and Certain Acquisition-Related Costs Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Exercisable, end of period, weighted-average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Award vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Retirement Benefits [Abstract] Retirement Benefits [Abstract] Total intrinsic value of options exercised or share units converted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value Net gain on sale of equity method investment Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee, Net Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee, Net Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Tax Expense/(Benefit) on Other Comprehensive Income/(Loss) Other Comprehensive Income (Loss), Tax [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Restructuring Charges and Acquisition-Related Costs [Member] Restructuring Charges And Acquisition-Related Costs [Member] Restructuring Charges And Acquisition-Related Costs [Member] Other commingled funds [Member] Other Commingled Funds [Member] Other Commingled Funds [Member] Cencora, Inc. [Member] Cencora, Inc. [Member] Cencora, Inc. Schedule of Components of Inventories, Noncurrent Schedule of Inventory, Noncurrent [Table Text Block] All other - Deferred tax liabilities Deferred Tax Liabilities, Other Total fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Net income before allocation to noncontrolling interests Net income before allocation to noncontrolling interests Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Inventories Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Threshold for disclosure of proceedings under environmental laws Site Contingency, Regulatory Proceedings, Disclosure Threshold Site Contingency, Regulatory Proceedings, Disclosure Threshold Derivative, Amount of Gains/(Losses) Recognized in OID Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Provision/(benefit) for taxes on income Provision/(benefit) for taxes on income Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Noncurrent Deferred Tax Assets and Other Noncurrent Tax Assets [Member] Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member] Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member] Derivative, notional amount Derivative, Notional Amount Available-for-sale debt securities Debt Securities, Available-for-Sale, Current Derivative asset Derivative Asset Weighted-average period over which cost is expected to be recognized (years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Revenues Revenues—Revenues Revenue from Contract with Customer, Excluding Assessed Tax Prepaid/deferred items - Deferred tax assets Deferred Tax Assets, Tax Deferred Expense Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Available-for-sale securities, debt maturities, over 5 years, fair value Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value Three Largest U.S. Wholesaler Customers [Member] Three Largest US Wholesale Customers [Member] Three Largest US Wholesale Customers [Member] Inventory write-offs and related charges associated with COVID-19 products Write-offs Inventory Write-down Held-to-maturity Securities Debt Securities, Held-to-Maturity [Table Text Block] Proceeds from redemptions/sales of long-term investments Proceeds from Sale, Maturity and Collection of Long-Term Investments Net cash provided by/(used in) investing activities Net Cash Provided by (Used in) Investing Activities Interest expense Interest Expense, Operating and Nonoperating Discount rate: Service cost Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate Number of additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Business Acquisition [Line Items] Business Acquisition [Line Items] Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member] Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member] Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile Restructuring costs incurred to date Restructuring and Related Cost, Cost Incurred to Date All Adjustments to Compensation All Adjustments to Compensation [Member] Summarized Financial Information of Equity Method Investments Equity Method Investments [Table Text Block] Accrued compensation and related items Employee-related Liabilities, Current Additional paid-in capital Additional Paid in Capital Units vested, shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Agreement [Domain] Agreement [Domain] Agreement Reversal of revenue Contract With Customer, Refund Recorded During Period Contract With Customer, Refund Recorded During Period Schedule of Other Nonoperating Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Restructuring charge (credit) Total restructuring charges/(credits) Provision Restructuring Charges Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Carrying Amount of Hedged Assets/Liabilities Hedged Liability, Fair Value Hedge Legal Entity [Axis] Legal Entity [Axis] Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Disposed of by Sale, Not Discontinued Operations [Member] Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] All other Hospital [Member] Other Hospital [Member] Other Hospital Derivative Financial Instruments [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Government and agency - U.S. [Member] US Government Agencies Debt Securities [Member] Debt Securities, Held-to-maturity, Maturity [Abstract] Debt Securities, Held-to-Maturity, Maturity [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Net periodic benefit costs/(credits) other than service costs Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Net operating loss/tax credit carryforwards - Deferred tax assets Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Current portion of long-term debt, principal amount Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting Schedule of Health Care Cost Trend Rates Schedule of Health Care Cost Trend Rates [Table Text Block] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Reclassification adjustments related to amortization of prior service costs and other, net Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Financial Instruments [Domain] Financial Instruments [Domain] Gain Contingency, Nature [Domain] Gain Contingency, Nature [Domain] Vesting [Domain] Vesting [Domain] Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Equity Liabilities and Equity [Abstract] Vested, weighted-average intrinsic value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share International International Income Taxes [Abstract] International Income Taxes [Abstract] Octagam [Member] Octagam [Member] Octagam Restatement Determination Date Restatement Determination Date Vested and expected to vest, end of period, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Estimated Fair Value [Member] Estimate of Fair Value Measurement [Member] Available-for-sale debt securities Debt Securities, Available-for-Sale, Noncurrent Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Interest rate contracts [Member] Interest Rate Contract [Member] Acquired inventory, selling period Acquired Inventory, Selling Period Acquired Inventory, Selling Period Other Developed Technology Rights, In-Process Research and Development and Finite-Lived Licensing Agreement [Member] Other Developed Technology Rights, In-Process Research and Development and Finite-Lived Licensing Agreement [Member] Other Developed Technology Rights, In-Process Research and Development and Finite-Lived Licensing Agreement Schedule of Available-for-sale Securities Reconciliation Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share) Outstanding, end of period, weighted-average exercise price per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Concentration Risk [Table] Concentration Risk [Table] ROU assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] International Commercial Division International Commercial Division [Member] International Commercial Division Outstanding, beginning of period, shares Outstanding, end of period, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Investments - Deferred tax assets Deferred Tax Assets, Equity Method Investments Units vested, weighted average grant price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price Vyndaqel Family [Member] Vyndaqel [Member] Vyndaqel [Member] Number of patents allegedly infringed Loss Contingency, Patents Allegedly Infringed, Number Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Other noncurrent liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Plan amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Dividends payable Dividends Payable, Current Other Financial Information Additional Financial Information Disclosure [Text Block] Prior Service (Costs)/Credits and Other [Member] Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member] Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders Earnings Per Share [Text Block] Paxlovid [Member] Paxlovid [Member] Paxlovid Subsequent Event [Member] Subsequent Event [Member] Costs and expenses: Costs and Expenses [Abstract] Operating lease term, option to extend Lessee, Operating Lease, Option To Extend, Term Lessee, Operating Lease, Option To Extend, Term Granted, weighted-average grant-date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsegments [Domain] Subsegments [Domain] Schedule of Derivative Liabilities at Fair Value Schedule of Derivative Liabilities at Fair Value [Table Text Block] Tax Assets and Liabilities and Income Tax Contingencies Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total costs associated with acquisitions and cost-reduction/productivity initiatives Restructuring Charges, Acquisition Related Costs and Implementation Costs Restructuring Charges, Acquisition Related Costs and Implementation Costs Segments [Domain] Segments [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] U.S. Commercial Division U.S. Commercial Division [Member] U.S. Commercial Division Tax provision/(benefit) on other comprehensive income/(loss) Tax provision/(benefit) on other comprehensive income/(loss) Other Comprehensive Income (Loss), Tax Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Expiring 2030 [Member] Expiring 2030 [Member] Expiring 2030 Payment for asset acquisition, base payment Payments for Asset Acquisitions, Before Working Capital Adjustments Payments for Asset Acquisitions, Before Working Capital Adjustments 3-4 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four Discontinued operations––net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share PEO PEO [Member] Arbutus and Genevant U.S. Patent Infringement Case [Member] Arbutus and Genevant U.S. Patent Infringement Case [Member] Arbutus and Genevant U.S. Patent Infringement Case Confirmed invoices paid during the year Supplier Finance Program, Obligation, Settlement Non-Derivative, Amount of Gains/(Losses) Recognized in OCI Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax Name Trading Arrangement, Individual Name Oxbryta [Member] Oxbryta [Member] Oxbryta Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Number of patents allegedly infringed upon Gain Contingency, Patents Allegedly Infringed upon, Number Haleon equity method (income)/loss Income (Loss) From Equity Method Investments, Net Excess Basis Amortization Income (Loss) From Equity Method Investments, Net Excess Basis Amortization Current inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Current Property, Plant and Equipment by Type [Axis] Long-Lived Tangible Asset [Axis] Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax Entity Public Float Entity Public Float Disposal Group Name [Axis] Disposal Group Name [Axis] ModernaTX European Patent Infringement Case [Member] ModernaTX European Patent Infringement Case [Member] ModernaTX European Patent Infringement Case Amount of Gains/(Losses) Recognized in OCI Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax Impact of foreign exchange Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation Pfizer share of Haleon earnings Income (Loss) from Equity Method Investments Treasury stock, shares at cost: 2024—3,926; 2023—3,916 Treasury Stock, Common, Value Exercisable, end of period, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Number of patents under review Loss Contingency, Patents Under Review Loss Contingency, Patents Under Review Benefit obligation, beginning Benefit obligation, ending Defined Benefit Plan, Benefit Obligation Schedules of Concentration of Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Share-Based Payment Arrangement, Tranche Three [Member] Share-Based Payment Arrangement, Tranche Three [Member] Cash dividends paid Payments of Ordinary Dividends Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit Decrease in Unrecognized Tax Benefits is Reasonably Possible (Gains)/losses on sale and leaseback transactions, net Sale and Leaseback Transaction, Gain (Loss), Net Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number All other Specialty Care [Member] Other Specialty Care [Member] Other Specialty Care Intangible assets, gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax Valuation allowances Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Exit Costs [Member] Other Restructuring [Member] Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Derivatives in a net liability position Derivative, Net Liability Position, Aggregate Fair Value Intangible Asset, Statement Of Income Or Comprehensive Income Extensible Enumeration, Not Disclosed Flag Intangible Asset, Statement Of Income Or Comprehensive Income Extensible Enumeration, Not Disclosed Flag Intangible Asset, Statement Of Income Or Comprehensive Income Extensible Enumeration, Not Disclosed Flag Other changes in assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Interest Income [Member] Interest Income [Member] Derivatives in a net receivable position Derivative, Net Receivable Position, Aggregate Fair Value Derivative, Net Receivable Position, Aggregate Fair Value Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Schedule of Property, Plant and Equipment, Net by Geographic Area Long-Lived Assets by Geographic Areas [Table Text Block] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Common Stock [Member] Common Stock [Member] Common Stock [Member] Other Financial Information [Abstract] Other Financial Information 1-2 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two Inflectra [Member] Inflectra/Remsima [Member] Inflectra/Remsima [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] PSAs Granted in 2022 and 2023 [Member] PSAs Granted in 2022 and 2023 [Member] PSAs Granted in 2022 and 2023 Line of Credit [Member] Line of Credit [Member] Currency translation adjustments and other Equity Method Investment, Increase (Decrease), Foreign Currency Translation Equity Method Investment, Increase (Decrease), Foreign Currency Translation Segment Reporting [Abstract] Segment Reporting [Abstract] Comirnaty [Member] Comirnaty [Member] Comirnaty Entity Central Index Key Entity Central Index Key Biohaven [Member] Biohaven [Member] Biohaven Held-to-maturity securities, debt maturities, within 1 year, fair value Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Schedule of Components of Inventories, Current Schedule of Inventory, Current [Table Text Block] Remaining period of hedging exposure Derivative, Remaining Maturity Foreign Currency Translation Adjustments [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Pfizer Versus Teva Pharmaceuticals, Inc. [Member] Pfizer Versus Teva Pharmaceuticals, Inc. [Member] Pfizer Versus Teva Pharmaceuticals, Inc. Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Segment, Geographic and Other Revenue Information Segment Reporting Disclosure [Text Block] Current portion of long-term debt Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023)) Long-Term Debt, Current Maturities Income from continuing operations attributable to Pfizer Inc. common shareholders Income Loss From Continuing Operations Available To Common Stockholders Basic This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any. Held-to-maturity securities, debt maturities, over 5 years, fair value Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value Units exercised and converted, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Measurement Basis [Axis] Measurement Basis [Axis] Basis difference adjustments and amortization Equity Method Investment, Increase (Decrease), Basis Difference Adjustments and Amortization Equity Method Investment, Increase (Decrease), Basis Difference Adjustments and Amortization Title Trading Arrangement, Individual Title Number of complaints Number of Complaints Number of Complaints Notes Due 2027, 1.000% [Member] Notes Due 2027, 1.000% [Member] Notes Due 2027, 1.000% [Member] Senior Unsecured Debt, Due 2036-2040 [Member] Senior Unsecured Debt, Due 2036-2040 [Member] Senior Unsecured Debt, Due 2036-2040 Unsecured Debt [Member] Unsecured Debt [Member] Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Long-term investments Long-term investments Other Long-Term Investments Geographic Concentration Risk [Member] Geographic Concentration Risk [Member] Uncertain tax positions Balance, beginning Balance, ending Unrecognized tax benefits Unrecognized Tax Benefits Less: Comprehensive income/(loss) attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest City Area Code City Area Code Bosulif [Member] Bosulif [Member] Bosulif [Member] Auditor location Auditor Location Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] In-process research and development, measurement period adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, In-Process Research and Development, Net of Adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, In-Process Research and Development, Net of Adjustments Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring Fair value of contingent consideration Business Combination, Contingent Consideration, Liability Mektovi [Member] Mektovi [Member] Mektovi [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Schedule of Available for sale Securities and Held to maturity Securities [Line Items] Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items] Schedule of Available for sale Securities and Held to maturity Securities [Line Items] Purchases of short-term investments Payments to Acquire Short-Term Investments Schedule of Net Periodic Benefit Costs Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] US Government [Member] US Government [Member] US Government Discount rate: Interest cost Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate Other tax accounts, net Increase (Decrease) in Accrued Taxes Payable Purchases of common stock Payments for Repurchase of Common Stock Clinical Trial Agreement Terms [Member] Clinical Trial Agreement Terms [Member] Clinical Trial Agreement Terms Pension and Postretirement Benefit Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] Unremitted earnings - Deferred tax liabilities Deferred Tax Liabilities, Undistributed Foreign Earnings Statement of Cash Flows Derivatives, Reporting of Derivative Activity [Policy Text Block] Long-term debt Total long-term debt, carried at historical proceeds, as adjusted Long-Term Debt, Excluding Current Maturities Committed investment from collaborator Collaborative Arrangement, Committed Investment From Collaborator, Amount Collaborative Arrangement, Committed Investment From Collaborator, Amount Trade Accounts Receivable Receivable [Policy Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Weighted Avg. GDFV per share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Profit Units [Member] Profit Units [Member] Profit Units [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Earnings Per Share [Abstract] Earnings Per Share [Abstract] BeneFIX [Member] Bene F I X [Member] Bene F I X [Member] Equity [Abstract] Equity [Abstract] Senior Unsecured Debt, Due 2046-2050 [Member] Senior Unsecured Debt, Due 2046-2050 [Member] Senior Unsecured Debt, Due 2046-2050 Retained earnings Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Revenue [Member] Revenue from Contract with Customer Benchmark [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Inventories Increase (Decrease) in Inventories Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date Equity Securities, FV-NI, Unrealized Gain (Loss) Xeljanz [Member] Xeljanz [Member] Xeljanz [Member] Government and agency debt - non-U.S. [Member] Debt Security, Government, Non-US [Member] Expiring 2033 [Member] Expiring 2033 [Member] Expiring 2033 Acquisitions/divestitures, net Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Short-term Borrowings Schedule of Short-Term Debt [Table Text Block] Equity Awards Adjustments Equity Awards Adjustments [Member] Present value of minimum lease payments Operating Lease, Liability Debt securities, amortized cost Debt Securities, Amortized Cost Basis Debt Securities, Amortized Cost Basis Purchases, sales, and settlements, net Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement Underlying Securities Award Underlying Securities Amount Performance Share Awards [Member] Performance Shares [Member] Other noncurrent liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Liabilities Units exercised, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Braftovi/Mektovi [Member] Braftovi/Mektovi [Member] Braftovi [Member] Weighted-average assumptions used to determine net periodic benefit cost: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Common stock Dividends, Common Stock, Cash Asset write-offs and impairments Asset Write-Offs And Asset Impairment Charges Asset Write-Offs And Asset Impairment Charges Amendment Flag Amendment Flag Commercial paper, principal amount Commercial Paper Employee contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Trade accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Machinery and equipment [Member] Machinery and Equipment [Member] Fixed income securities [Member] Defined Benefit Plan, Debt Security [Member] Selling, Informational and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Other (Income)/Deductions—Net Other Income and Other Expense Disclosure [Text Block] Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Number of shares sold in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Plan Asset Measurement [Domain] Fair Value Hierarchy and NAV [Domain] ViiV [Member] ViiV [Member] ViiV [Member] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward] Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward] Debt instrument, face amount Debt Instrument, Face Amount Noncurrent derivative liabilities Derivative Liability, Noncurrent Proceeds from short-term borrowings Proceeds from Short-Term Debt Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Advertising expense Advertising Expense Restricted Stock Units Granted Before 2022 [Member] Restricted Stock Units Granted Before 2022 [Member] Restricted Stock Units Granted Before 2022 Brand [Member] Brand [Member] Brand Developed Markets [Member] Developed Markets [Member] Developed Rest Of World [Member] International Income Tax Paid, Foreign, after Refund Received Integration costs and other Business Combination, Integration Related Costs Equity method, adjusted income Equity Method Investee, Adjusted Income Equity Method Investee, Adjusted Income ESOP compensation expense Employee Stock Ownership Plan (ESOP), Compensation Expense Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost), Net of Reimbursement Research and Development Expense (Excluding Acquired in Process Cost), Net of Reimbursement Discontinued operations––net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Finite-lived intangible assets period increase (decrease) Finite-Lived Intangible Assets, Period Increase (Decrease) Schedule of Amounts Recognized in Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Expiration Period [Axis] Expiration Period [Axis] Expiration Period Granted, weighted-average intrinsic value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Litigation Status [Axis] Litigation Status [Axis] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor name Auditor Name Forfeited, weighted-average grant date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Pre-tax gain expected to be reclassified within the next 12 months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Current income taxes: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Other current liabilities [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Debt securities maturities, within 1 year, fair value Debt Securities Maturities, Next Twelve Months, Fair Value Debt Securities Maturities, Next Twelve Months, Fair Value Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Nimbus [Member] Nimbus [Member] Nimbus Other Current Tax Assets [Member] Current Tax Assets [Member] Current Tax Assets [Member] Oncology Biosimilars [Member] Oncology Biosimilars [Member] Oncology Biosimilars Useful lives (years) Property, Plant and Equipment, Useful Life Shares (Thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Total short-term investments Short-term Investments Excluding Held-To-Maturity Securities Short-term Investments Excluding Held-To-Maturity Securities Acquired in-process research and development expenses Research and Development Expense, Acquired in Process Cost, Reimbursement (Write-off) Research and Development Expense, Acquired in Process Cost, Reimbursement (Write-off) Fair Value Measurement [Domain] Fair Value Measurement [Domain] Schedule of Short-term Debt [Table] Short-Term Debt [Table] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Deferred revenues - Deferred tax assets Deferred Tax Assets, Deferred Income Adjustment to cost of sales Inventory Write-Down and Other Charges Inventory Write-Down and Other Charges Acquisition-Related Items [Member] Reconciling Items, Acquisition Related Costs [Member] Reconciling Items, Acquisition Related Costs Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Gain Contingencies [Line Items] Gain Contingencies [Line Items] Net income attributable to Pfizer Inc. common shareholders Net Income (Loss) Available to Common Stockholders, Basic Units outstanding, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Cibinqo [Member] Cibinqo [Member] Cibinqo Foreign exchange impact Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] EPS Denominator Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Total assets Assets Accrued rebates Accrued Rebates Accrued Rebates Cost of sales Cost of sales Cost of Goods and Services Sold Cost/(credit) recognized in Comprehensive income Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax Reclassification adjustments for (gains)/losses included in net income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Amortization of Intangible Assets [Member] Reconciling Items, Amortization of Intangible Assets [Member] Reconciling Items, Amortization of Intangible Assets Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Commitments and Contingencies Commitments and Contingencies Share-Based Payments Share-Based Payment Arrangement [Policy Text Block] Equity commingled funds [Member] Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member] Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member] Foreign Currency Long-Term Debt [Member] Foreign Currency Debt [Member] Foreign currency long - term debt [Member] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] BioNTech [Member] BioNTech [Member] BionTech [Member] Termination Date Trading Arrangement Termination Date Oncology Division Oncology Division [Member] Oncology Division Gain Contingencies [Table] Gain Contingencies [Table] Indefinite-lived and definite-lived Deferred Tax Assets, Indefinite-Lived and Definite-Lived Deferred Tax Assets, Indefinite-Lived and Definite-Lived Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Reduction for unrecognized tax benefit Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Axis] Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Axis] Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Total identifiable net assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Assets Excluding Goodwill Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Assets Excluding Goodwill Long-term investments Long-Term Investments [Abstract] Available-for-sale securities, debt maturities, over 1 to 5 years, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] All other Oncology [Member] Other Oncology Products [Member] Other Oncology Products [Member] Net income attributable to Pfizer Inc. common shareholders Income attributable to shareholders Net Income (Loss) Attributable to Parent Alliance revenues Revenues—Alliance revenues Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Trading Arrangement: Trading Arrangement [Axis] Transition Service Agreement [Member] Transition Service Agreement [Member] Transition Service Agreement 2030–2034 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Held-to-maturity securities, gross unrealized gains Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Entity File Number Entity File Number Impairment, Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag Impairment, Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag Impairment, Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Realigning Our Cost Base Program [Member] Realigning Our Cost Base Program [Member] Realigning Our Cost Base Program Transfer of carrying value to Short-term investments Equity Method Investment, Increase (Decrease), Transfer To Investments Equity Method Investment, Increase (Decrease), Transfer To Investments Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Non-controlling Interests [Member] Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Units vested, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms Pfizer CentreOne [Member] Pfizer CentreOne [Member] Pfizer CentreOne Federal Current Federal Tax Expense (Benefit) Implementation costs Implementation Costs Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Operating lease term Lessee, Operating Lease, Term of Contract Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Weighted-Average Remaining Contractual Lease Term (Years) Operating Lease, Weighted Average Remaining Lease Term Award Date [Domain] Award Date [Domain] Investments Investment, Policy [Policy Text Block] Other adjustments, net Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Deferred Tax Liabilities Components of Deferred Tax Liabilities [Abstract] Schedule of Expected Future Cash Flow Information Schedule of Expected Benefit Payments [Table Text Block] Decreases based on tax positions taken during a prior period Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Genotropin [Member] Genotropin [Member] Genotropin [Member] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share EPS Numerator––Diluted Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Cost of sales Cost of Revenue Summary of Investments Marketable Securities [Table Text Block] Transaction costs Business Combination, Acquisition Related Costs, Transaction Costs This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services. Adjustment to Compensation: Adjustment to Compensation [Axis] Trade accounts receivable, less allowance for doubtful accounts [Member] Accounts Receivable [Member] Accounts Receivable [Member] Less: Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Investments - Deferred tax liabilities Deferred Tax Liabilities, Investment in Noncontrolled Affiliates Litigation Case [Domain] Litigation Case [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Granted, grant price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price Weighted-average shares––basic (in shares) Weighted-average common shares outstanding––Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Unrealized holding gains/(losses) on available-for-sale securities, net OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Share payout measures, adjusted net income, period Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period Noncurrent inventories not included above Inventory, Noncurrent Greenstone Antitrust Litigation [Member] Greenstone Antitrust Litigation [Member] Greenstone Antitrust Litigation Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Equity and debt securities, target allocation percentage Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Senior Unsecured Debt, Due 2030 [Member] Senior Unsecured Debt, Due 2030 [Member] Senior Unsecured Debt, Due 2030 Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress [Member] Construction in Progress [Member] Revenue [Member] Revenue Benchmark [Member] Gross contractual amount receivable Business Combination, Acquired Receivables, Gross Contractual Amount Forfeited, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Research and development arrangement, funding to offset costs incurred Research and Development Arrangement, Funding to Offset Costs Incurred Research and Development Arrangement, Funding to Offset Costs Incurred Agreement [Axis] Agreement [Axis] Agreement Entity Filer Category Entity Filer Category Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Collateral posted Collateral Already Posted, Aggregate Fair Value Loss Contingencies [Line Items] Loss Contingencies [Line Items] Noncurrent derivative assets Derivative Asset, Noncurrent Supplemental Cash Flow Information Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Transition Tax liability Effective Income Tax Rate Reconciliation, Tax Transition Liability, Percent Effective Income Tax Rate Reconciliation, Tax Transition Liability, Percent Global equity securities [Member] Defined Benefit Plan, Equity Securities, Global Equity Securities [Member] Defined Benefit Plan, Equity Securities, Global Equity Securities Additions Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Available-for-sale debt securities, gross unrealized loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Lease Costs and Other Supplemental Information Lease, Cost [Table Text Block] Excluding Comirnaty and Paxlovid [Member] Excluding Comirnaty and Paxlovid [Member] Excluding Comirnaty and Paxlovid Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer, Net of Reimbursements Defined Benefit Plan, Plan Assets, Contributions by Employer, Net of Reimbursements Other current liabilities Other current liabilities Other Liabilities, Current Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Hedged Liability, Statement of Financial Position [Extensible Enumeration] Hedged Liability, Statement of Financial Position [Extensible Enumeration] Sale of Equity-Method Investment in Public Stock Offering Sale of Equity-Method Investment in Public Stock Offering [Member] Sale of Equity-Method Investment in Public Stock Offering All Trading Arrangements All Trading Arrangements [Member] Other, net Other income, net Other Nonoperating Income (Expense), Net Other Nonoperating Income (Expense), Net Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Basic and Diluted Earning Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Income taxes Total Income Taxes Paid, Net Goodwill Goodwill, Measurement Period Adjustment Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share) Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Equity-method investments Beginning carrying value reported in Equity-method investments Ending carrying value Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Derivative [Table] Derivative [Table] Income Tax Contingency [Table] Income Tax Contingency [Table] Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Deferred income taxes: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Certain Significant Items [Member] Reconciling Items, Other [Member] Reconciling Items, Other Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Medrol [Member] Medrol [Member] Medrol [Member] Other Performance Measure, Amount Other Performance Measure, Amount Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Net periodic benefit, actuarial valuation and other pension and postretirement plan, gain (loss) Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit Leases Lessee, Operating Leases [Text Block] Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Total international tax provision/(benefit) Foreign Income Tax Expense (Benefit), Continuing Operations Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Operating lease cost Operating Lease, Cost Lease liabilities (long-term) Noncurrent portion Operating Lease, Liability, Noncurrent Shares available for award Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Curtailments and special termination benefits Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits Cash Flow Hedging [Member] Cash Flow Hedging [Member] Restructuring charges: Restructuring Charges [Abstract] Noncurrent assets Assets, Noncurrent Deferred revenues Deferred revenues, current Contract with Customer, Liability, Current Loans Payable [Member] Loans Payable [Member] Service cost Defined Benefit Plan, Service Cost Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Entity Tax Identification Number Entity Tax Identification Number Equity securities [Member] Defined Benefit Plan, Equity Securities [Member] Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Increases based on tax positions taken during a prior period Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Purchases of common stock (in shares) Shares repurchased (in shares) Treasury Stock, Shares, Acquired Retirement Plan Type [Axis] Retirement Plan Type [Axis] Deferred income taxes Deferred Foreign Income Tax Expense (Benefit) Rate to which the cost trend rate is assumed to decline Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Maximum potential consideration Research And Development Arrangement, Contingent Payments, Maximum Exposure1 Research And Development Arrangement, Contingent Payments, Maximum Exposure1 Manufacturing Optimization Program - Phase One [Member] Manufacturing Optimization Program - Phase One [Member] Manufacturing Optimization Program - Phase One Selling, Informational and Administrative Expenses [Member] Selling, informational and administrative expenses [Member] Selling, General and Administrative Expenses [Member] Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Award settlement period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Settlement Period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Settlement Period Total short-term borrowings, principal amount Short-term Debt, Gross Short-term Debt, Gross Treasury Stock [Member] Treasury Stock, Common [Member] Schedule of Derivative Financial Instruments Schedule of Derivative Instruments [Table Text Block] Income taxes payable Taxes Payable, Current Government and agency obligations [Member] US Treasury Securities [Member] Schedule of Lease Assets and Liabilities Lease, Assets and Liabilities, Lessee [Table Text Block] Lease, Assets and Liabilities, Lessee Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Other current assets Other Assets, Current Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Held-to-maturity securities, amortized cost Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Available-for-sale securities, debt securities Available-for-sale securities, debt maturities Available-for-sale securities, debt maturities Debt Securities, Available-for-Sale Brands [Member] Trade Names [Member] Trade Names [Member] Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Pro Forma net loss attributable to Pfizer Inc. common shareholders Net income/(loss) attributable to Pfizer Inc. common shareholders Business Acquisition, Pro Forma Net Income (Loss) Revenue [Member] Revenue, Product and Service Benchmark [Member] Share payout measures, adjusted net income, number of periods Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Repayment of assumed debt Business Combination, Consideration Transferred, Debt Repayment Business Combination, Consideration Transferred, Debt Repayment Outstanding, end of period, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Business acquisition, equity consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Earnings per common share––diluted: Earnings Per Share, Diluted [Abstract] Non-cash transaction: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Developed Technology Rights [Member] Developed Technology Rights [Member] Units exercised, weighted average grant price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price Geographical [Axis] Geographical [Axis] Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Restructuring and Related Costs [Table Text Block] Net deferred tax asset Net deferred tax asset Deferred Tax Assets, Net Unrecognized tax benefits excluding associated interest Unrecognized Tax Benefits, Excluding Interest Unrecognized Tax Benefits, Excluding Interest Period of continuing involvement after disposal Discontinued Operation, Period of Continuing Involvement after Disposal Pre-tax gain on divestiture Gain (Loss) on Disposition of Business Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Award Date [Axis] Award Date [Axis] Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Licensing Agreements and Other [Member] Licensing Agreements And Other [Member] Licensing Agreements And Other [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Contingent consideration liability, current Business Combination, Contingent Consideration, Liability, Current Number of patents found not infringed Loss Contingency, Patents Found Not Infringed, Number Amount of Gains/(Losses) Reclassified from OCI into OID and COS Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax ModernaTX U.S. Patent Infringement Case [Member] ModernaTX U.S. Patent Infringement Case [Member] ModernaTX U.S. Patent Infringement Case Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Other noncurrent assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Prior service (costs)/credits Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Units expected to vest, weighted average grant price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price Tukysa [Member] Tukysa [Member] Tukysa Sale of Equity-Method Investment in Private Placement Sale of Equity-Method Investment in Private Placement [Member] Sale of Equity-Method Investment in Private Placement 4-5 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period Cash and cash equivalents and restricted cash and cash equivalents, at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Interest rate, percentage Debt, Weighted Average Interest Rate McKesson, Inc. [Member] McKesson, Inc. [Member] McKesson, Inc. [Member] Equity securities Equity securities with readily determinable fair values Equity Securities, FV-NI, Current Other noncurrent assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Assets Total compensation cost related to nonvested awards not yet recognized, pre-tax Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current income taxes Current Foreign Tax Expense (Benefit) Asset Impairment Charges [Member] Asset Impairments [Member] Asset impairments [Member] Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Credit Facility, Maturing October 2029 [Member] Credit Facility, Maturing October 2029 [Member] Credit Facility, Maturing October 2029 Insurance contracts [Member] Insurance Contracts [Member] Insurance Contracts [Member] Treasury stock (in shares) Beginning balance, treasury (in shares) Ending balance, treasury (in shares) Treasury Stock, Common, Shares Derivative, Amount of Gains/(Losses) on interest rate contract Recognized in OID Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Unrecognized tax benefits, interest on income taxes accrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued Cardinal Health, Inc. [Member] Cardinal Health, Inc. [Member] Cardinal Health, Inc. [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Developed Technology Rights and Other Intangible Assets [Member] Developed Technology Rights and Other Intangible Assets [Member] Developed Technology Rights and Other Intangible Assets Product and Service [Domain] Product and Service [Domain] Units expected to vest, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest Vested, weighted-average grant-date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Biopharma [Member] Biopharma Segment [Member] Biopharma Segment [Member] Assets held, ending Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Depo-Medrol [Member] Depo-Medrol [Member] Depo-Medrol Raw materials and supplies Inventory, Raw Materials and Supplies, Net of Reserves Security Exchange Name Security Exchange Name Unrealized holding gains/(losses) on available-for-sale securities, net OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Exercised, weighted-average exercise price per share (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price FSME-IMMUN/TicoVac [Member] FSME/IMMUN-TicoVac [Member] FSME/IMMUN-TicoVac [Member] Settled litigation, number of companies Settled Litigation, Number of Companies Settled Litigation, Number of Companies Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Settled Litigation [Member] Settled Litigation [Member] Long-term equity securities held in trust Equity Securities, FV-NI, Restricted, Noncurrent Equity Securities, FV-NI, Restricted, Noncurrent State and local Current State and Local Tax Expense (Benefit) Top Ten Products [Member] Top Ten Products [Member] Top Ten Products Number of measures used to determine share payout Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout talazoparib (Talzenna) [Member] talazoparib (Talzenna) [Member] talazoparib (Talzenna) Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Loss contingency, patents allegedly infringed and subsequently revoked Loss Contingency, Patents Allegedly Infringed And Subsequently Revoked, Number Loss Contingency, Patents Allegedly Infringed And Subsequently Revoked, Number Subsegments [Axis] Subsegments [Axis] Dividends received, total Proceeds from Equity Method Investment, Distribution, Total Proceeds from Equity Method Investment, Distribution, Total Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Charge related to expected sale of facilities Gain (Loss) on Sale of Properties Manufacturing Optimization Program [Member] Manufacturing Optimization Program [Member] Manufacturing Optimization Program Premarin Family [Member] Premarin Family [Member] Premarin family [Member] Common stock, shares, issued (in shares) Beginning balance, common (in shares) Ending balance, common (in shares) Common Stock, Shares, Issued Other, net Unrecognized Tax Benefits, Period Increase (Decrease), Other Unrecognized Tax Benefits, Period Increase (Decrease), Other Zavicefta [Member] Zavicefta [Member] Zavicefta Entity [Domain] Entity [Domain] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Concentration risk, percentage Concentration risk, percentage Concentration Risk, Percentage Supply commitment, minimum amount committed, number of treatment courses Supply Commitment, Remaining Minimum Amount Committed, Number Of Treatment Courses Supply Commitment, Remaining Minimum Amount Committed, Number Of Treatment Courses Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Immediate Recognition of Actuarial Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Immediate Recognition of Actuarial Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Total liabilities Derivative liability Derivative Liability Hedged Item [Domain] Hedged Item [Domain] [Domain] for Hedged Item [Axis] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Assets sold during the period Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold Estimated government emergency use authorization inventory to be returned to company, number of treatment courses Government Emergency Use Authorization Inventory To Be Returned To Company, Number Of Treatment Courses Government Emergency Use Authorization Inventory To Be Returned To Company, Number Of Treatment Courses Common stock, shares authorized (in shares) Common Stock, Shares Authorized Zithromax [Member] Zithromax Zmax [Member] Zithromax / Zmax [Member] Information related to the funded status of pension plans with an ABO in excess of plan assets(c): Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Acquisitions of businesses, net of cash acquired Business acquisition, cash payment, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Fair Value Adjustment to Inventory [Member] Fair Value Adjustment to Inventory [Member] Top Eleven Products Top Eleven Products [Member] Top Eleven Products Intangible assets - Deferred tax assets Deferred Tax Assets, Goodwill and Intangible Assets Vested, grant price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Employee benefits - Deferred tax liabilities Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Teva Pharmaceuticals, Inc. [Member] Teva Pharmaceuticals, Inc. [Member] Teva Pharmaceuticals, Inc. Entity Voluntary Filers Entity Voluntary Filers All other Primary Care [Member] Other Primary Care Products [Member] Other Primary Care Products Actuarial (gains)/losses Defined Benefit Plan, Amortization of Gain (Loss) Hedging Designation [Domain] Hedging Designation [Domain] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Total accrued rebates and other sales-related accruals Rebates And Other Sales-Related Accruals Certain accrued rebates and accrued sales returns Deferred taxes Deferred Income Tax Expense (Benefit) Credit Facility, Maturing October 2025 [Member] Credit Facility, Maturing October 2025 [Member] Credit Facility, Maturing October 2025 Hospira [Member] Hospira [Member] Hospira [Member] Amortization Expense [Member] Amortization Expense [Member] Amortization Expense Property, Plant and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Reclassification adjustments for (gains)/losses included in net income Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Deferred tax assets associated with unrecognized tax benefits Deferred Tax Assets Associated With Unrecognized Tax Benefits Deferred Tax Assets Associated With Unrecognized Tax Benefits Schedule of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Tax benefits realized from exercise Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Short-term borrowings, including current portion of long-term debt: 2024—$3,747; 2023—$2,254 Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted Debt, Current Other investments [Member] Defined Benefit Plan, Other Investments [Member] Defined Benefit Plan, Other Investments Recurring [Member] Fair Value, Recurring [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Cash payment to collaborators Prepayments and Payments to Collaborators, Cash Prepayments and Payments to Collaborators, Cash Trade accounts receivable, net of allowance for doubtful accounts: 2024—$438; 2023—$470 Accounts Receivable, after Allowance for Credit Loss, Current Granted, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Pfizer share of Haleon investee capital transaction Equity Method Investment, Increase (Decrease), Investee Capital Transaction Equity Method Investment, Increase (Decrease), Investee Capital Transaction Certain asset impairments Asset Impairment Charges Other liabilities Increase (Decrease) in Other Operating Liabilities Long-term debt, carrying value Long-Term Debt Unrealized holding gains/(losses) on derivative financial instruments, net Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax disitamab vedotin [Member] disitamab vedotin [Member] disitamab vedotin Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Arena [Member] Arena [Member] Arena Fair value of plan assets, beginning Fair value of plan assets, ending Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Senior Unsecured Debt, Due 2041-2045 [Member] Senior Unsecured Debt, Due 2041-2045 [Member] Senior Unsecured Debt, Due 2041-2045 Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss: Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract] Schedule of Valuation Assumptions Schedule of Share-based Payment Award, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Valuation Assumptions Commercialization Partner Commercialization Partner [Member] Commercialization Partner Commercial Paper [Member] Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Document Annual Report Document Annual Report Other comprehensive income (loss), benefit plans, prior service (costs)/credits, before tax, total Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax Vested, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period ReViral [Member] ReViral Asset Acquisition [Member] ReViral Asset Acquisition Shareholders’ Equity [Member] Parent [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Total indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Transfer into/(out of) Level 3 Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3 Amortization expense for finite-lived intangible assets Amortization of Intangible Assets Deferred revenues Contract with Customer, Liability Legal and Environmental Contingencies Commitments and Contingencies, Policy [Policy Text Block] Government Inquires Relating to Biohaven [Member] Government Inquires Relating to Biohaven [Member] Government Inquires Relating to Biohaven Fair Value Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Sulperazon [Member] Sulperazon [Member] Sulperazon [Member] Other accruals Other Accruals Other Accruals PEO Name PEO Name Primary Care [Member] Primary Care [Member] Primary Care Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Total Shareholder Return Units (TSRUs) [Member] Total Shareholder Return Units (TSRUs) [Member] Total Shareholder Return Units (TSRUs) [Member] Long-term purchase commitment, amount Long-Term Purchase Commitment, Amount Held-to-maturity debt securities Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current Licensing Agreements [Member] Licensing Agreements [Member] Share-based payment transactions (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Identifiable intangible assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Intangibles, measurement period adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles, Net of Adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles, Net of Adjustments Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Pension and postretirement benefit obligations Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Non-PEO NEO Non-PEO NEO [Member] Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Name [Axis] Add’l Paid-In Capital [Member] Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Debt securities maturities, over 5 years, fair value Debt Securities Maturities, After Year Five, Fair Value Debt Securities Maturities, After Year Five, Fair Value Debt securities, gross unrealized losses Debt Securities, Accumulated Gross Unrealized Loss Debt Securities, Accumulated Gross Unrealized Loss Collaborative Arrangement [Member] Collaborative Arrangement [Member] Pension and Postretirement Benefit Plans and Defined Contribution Plans Retirement Benefits [Text Block] Net deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Short-term Debt [Line Items] Short-Term Debt [Line Items] New Accounting Standard Adopted in 2024 New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Title of Individual [Domain] Title and Position [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-lived intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Reclassification, Other Reclassification, Other [Member] Type of Restructuring [Domain] Type of Restructuring [Domain] United States Income Tax Paid, Federal, after Refund Received Number of operating segments Number of Operating Segments Units converted and exercised, shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number Deferred Tax Assets Components of Deferred Tax Assets [Abstract] Pending Litigation [Member] Pending Litigation [Member] Patent Infringement [Member] Patent Infringement [Member] Patent Infringement [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Foreign-Derived Intangible Income deduction Effective Income Tax Rate Reconciliation, FDII, Percent Top Nine Products [Member] Top Nine Products [Member] Top Nine Products Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Employee Termination Costs [Member] Employee Severance [Member] China [Member] CHINA Generic Sterile Injectable Product [Member] Generic Sterile Injectable Product [Member] Generic Sterile Injectable Product [Member] Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Restructuring and Related Activities Disclosure [Text Block] Expiration Period [Domain] Expiration Period [Domain] Expiration Period [Domain] Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Schedule of Share-based Payment Arrangement Activity Share-Based Payment Arrangement, Activity [Table Text Block] Assets Measured at NAV [Member] Fair Value Measured at Net Asset Value Per Share [Member] Total deferred taxes - Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Share-Based Payment Arrangement, Tranche Two [Member] Share-Based Payment Arrangement, Tranche Two [Member] Cash collateral received Securities Received as Collateral Number of companies in litigation case Number of Companies in Litigation Case Number of Companies in Litigation Case Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Units vested, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Other Business Activities [Member] Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Hedged Item [Axis] Hedged Item [Axis] Hedged Item [Axis] Short-term investments Short-Term Investments [Abstract] Cash paid/(received) during the period for: Supplemental Cash Flow Information [Abstract] Net income attributable to Pfizer Inc. common shareholders and assumed conversions Net Income (Loss) Available to Common Stockholders, Diluted Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract] Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract] Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract] Indefinite-lived intangible assets, period increase (decrease) Indefinite-Lived Intangible Assets, Period Increase (Decrease) Decreases based on settlements for a prior period Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Domain] Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Domain] Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Domain] Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk Derivative Instruments, Gain (Loss) [Table Text Block] Research and development - Deferred tax assets Deferred Tax Asset, In-Process Research and Development Seagen [Member] Seagen [Member] Seagen Interest costs capitalized Interest Costs Capitalized Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Proceeds from redemptions/sales of short-term investments Proceeds from Sale, Maturity and Collection of Short-Term Investments Accrued/deferred royalties - Deferred tax assets Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Royalties Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Royalties Auditor firm ID Auditor Firm ID Effective tax rate for income from continuing operations Effective Income Tax Rate Reconciliation, Percent Deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets PBO Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Blackstone [Member] Blackstone [Member] Blackstone Legal and product liability reserves - Deferred tax assets Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves Research and development expenses Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Total liabilities and equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Defined Benefit Plan, Fair Value of Plan Assets by Measurement [Axis] Fair Value Hierarchy and NAV [Axis] Hedging Designation [Axis] Hedging Designation [Axis] Current derivative liabilities Derivative Liability, Current Discontinued operations––net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Vested and expected to vest, end of period, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Expected to Vest, Outstanding, Number Right-of-use assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Other Taxes Payable [Member] Other Taxes Payable [Member] Other Taxes Payable [Member] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Individual: Individual [Axis] Favorable adjustment for government emergency use authorization inventory returned to the company during the period Contract With Customer, Favorable Adjustment For Government Emergency Use Authorization Inventory Returned To The Company During The Period Contract With Customer, Favorable Adjustment For Government Emergency Use Authorization Inventory Returned To The Company During The Period Accum. Other Comp. Loss [Member] Accumulated Other Comprehensive Income/(Loss) [Member] AOCI Attributable to Parent [Member] Forfeited, weighted-average exercise price per share (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Contractual term/expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories Inventories Inventory, Net Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Other comprehensive income (loss), available-for-sale securities, tax, total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Nontrade payables Accounts Payable, Other Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions Income Loss From Continuing Operations Available To Common Stockholders diluted This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any. Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Trading day average Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Schedule of Components of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Sublease income Sublease Income Lorbrena [Member] Lorbrena [Member] Lorbrena Derivative term of contract Derivative, Term of Contract Derivative Financial Instruments Derivatives, Policy [Policy Text Block] GBT [Member] GBT [Member] GBT Net unamortized discounts, premiums and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Minimum [Member] Minimum [Member] Depreciation Expense [Member] Depreciation Expense [Member] Depreciation Expense Royalty [Member] Royalty [Member] Adoption Date Trading Arrangement Adoption Date Deferred revenues, noncurrent Contract with Customer, Liability, Noncurrent 2-3 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three Asset impairments Restructuring, Asset Impairment Charges Restructuring, Asset Impairment Charges Cumulative impairment losses and downward price adjustments on equity securities Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount Certain TSRUs Granted in 2022 and 2023 [Member] Certain TSRUs Granted in 2022 and 2023 [Member] Certain TSRUs Granted in 2022 and 2023 Foreign currency translation adjustments, net Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Prevnar 13 [Member] Prevnar 13 [Member] Prevnar 13 Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Revenues Business Acquisition, Pro Forma Revenue Schedule of Share-based Compensation Awards and Valuation Details Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Income from collaborations, out-licensing arrangements and sales of compound/product rights Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights Derivative Instrument [Axis] Derivative Instrument [Axis] U.S. statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Total long-term debt, principal amount Long-Term Debt, Gross Dividend received from the Consumer Healthcare JV Proceeds from Equity Method Investment, Distribution, Return of Capital Exercise Price Award Exercise Price Grant Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract] Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Healthcare cost trend rate assumed for next year Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Arrangement Duration Trading Arrangement Duration Cost/(credit) reported in Other comprehensive income/(loss) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Identifiable Intangible Assets, Net and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Held-to-maturity cash equivalents Held-To-Maturity Cash Equivalents Held-To-Maturity Cash Equivalents Total long-term investments and equity-method investments Long-Term Investments Adcetris [Member] Adcetris [Member] Adcetris Derivative asset, statement of financial position Derivative Asset, Statement of Financial Position [Extensible Enumeration] Weighted Avg. Intrinsic Value per share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Loss contingency, patents ruled invalid and subsequently revoked Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Repurchased debt Debt Instrument, Repurchase Amount 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Reporting Unit [Axis] Reporting Unit [Axis] Buildings [Member] Building [Member] Held-to-maturity securities, gross unrealized losses Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entities [Table] Entities [Table] Foreign exchange impact Exchange rate changes Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Other (income)/deductions––net Other income/(deductions)—net Other (income)/deductions––net Other Nonoperating Income (Expense) Postretirement Plans [Member] Other Postretirement Benefits Plan [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Identifiable intangible assets, net Identifiable Intangible Assets, Net Intangible Assets, Net (Excluding Goodwill) Derivative, Amount of Gains/(Losses) Recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Padcev [Member] Padcev [Member] Padcev Reclassification adjustments for (gains)/losses included in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block] One-time Termination Benefits One-time Termination Benefits [Member] Manufacturing and Supply Agreement [Member] Manufacturing and Supply Agreement [Member] Manufacturing and Supply Agreement Available-for-sale debt securities, gross unrealized gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Oncology [Member] Oncology [Member] Oncology [Member] Total compensation cost related to nonvested awards not yet recognized, pre-tax Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Number of facilities for sale Number of Real Estate Properties, Held-for-Sale Number of Real Estate Properties, Held-for-Sale Unremitted earnings of international subsidiaries Undistributed Earnings of Foreign Subsidiaries Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value Change in plan assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Current liabilities Liability, Defined Benefit Plan, Current Inventories - Deferred tax liabilities Deferred Tax Liabilities, Inventory Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Paxlovid and Comirnaty [Member] Paxlovid and Comirnaty [Member] Paxlovid and Comirnaty Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders Business Acquisition, Pro Forma Earnings Per Share, Diluted Noncurrent liabilities Liabilities, Noncurrent Emerging Markets [Member] International Emerging Markets [Member] Emerging Markets [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Patent Invalidity And Non Infringement [Member] Patent Invalidity And Non Infringement [Member] Patent Invalidity And Non Infringement Management [Member] Management [Member] Noncurrent deferred tax liabilities Deferred Income Tax Liabilities, Net Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Interest Expense [Member] Interest Expense [Member] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Taxation of non-U.S. operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Award requisite service period Award requisite service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Other assets Increase (Decrease) in Other Operating Assets Intangible assets, fair value Intangible Assets, Fair Value Disclosure Intangible Assets, Fair Value Disclosure Noncurrent inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Noncurrent Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Noncurrent Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment of Non-Infringement [Member] Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member] Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement Exit costs Business Exit Costs Identifiable intangible assets, excluding in-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Senior Notes, EUR Denominated [Member] Consumer Healthcare JV Senior Notes, EUR Denominated [Member] Consumer Healthcare JV Senior Notes, EUR Denominated Federal Deferred Federal Income Tax Expense (Benefit) Property, plant and equipment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Information About Balance Sheet Classification of Accruals Schedule of Accrued Liabilities [Table Text Block] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Maximum consideration to be received from divestiture Proceeds And Milestone Payments Expected to Be Received From Divestiture of Business, Maximum Proceeds And Milestone Payments Expected to Be Received From Divestiture of Business, Maximum Contingencies and Certain Commitments Commitments and Contingencies Disclosure [Text Block] Prepaid/deferred items - Deferred tax liabilities Deferred Tax Liabilities, Prepaid Expenses Forfeited, grant price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price Change in benefit obligation Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Measure: Measure [Axis] Schedule of Additional Information About Intangible Assets Impaired Schedule of Impaired Intangible Assets [Table Text Block] Share-based payment transactions Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Increases based on tax positions taken during the current period Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Units outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Insurance contracts Life Settlement Contracts, Fair Value 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year One Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] ROU assets, statement of financial position Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Inventories Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Income Tax Examination [Table] Income Tax, Examination [Table] Senior Unsecured Debt, Due 2029 [Member] Senior Unsecured Debt, Due 2029 [Member] Senior Unsecured Debt, Due 2029 Noncurrent Deferred Tax Liabilities [Member] Noncurrent Deferred Tax Liabilities [Member] Noncurrent Deferred Tax Liabilities [Member] Other [Member] Other Security Investments [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Units expected to vest, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Reclassification, Type [Domain] Reclassification, Type [Domain] ABO Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Equity Component [Domain] Equity Component [Domain] Funded status Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Japan [Member] JAPAN Class of Treasury Stock [Table] Class of Treasury Stock [Table] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Change in fair value of fair value contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability BMP2 [Member] BMP2 [Member] BMP2 [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Government emergency use authorization inventory returned to the company during the period, number of treatment courses Government Emergency Use Authorization Inventory Returned To The Company During The Period, Number Of Treatment Courses Government Emergency Use Authorization Inventory Returned To The Company During The Period, Number Of Treatment Courses 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Total long-term investments Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments Supplier Finance Program [Table] Supplier Finance Program [Table] IPR&D Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure Statement [Table] Statement [Table] Outside United States [Member] Non-United States [Member] Non-United States [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Benefit plans: prior service (costs)/credits and other, net Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax Debt securities, gross unrealized gains Debt Securities, Accumulated Gross Unrealized Gain Debt Securities, Accumulated Gross Unrealized Gain Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Net interest expense Interest Income (Expense), Operating and Nonoperating Cumulative upward price adjustments on equity securities Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Payments to acquire asset Payments to Acquire Productive Assets Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Audit Information [Abstract] Audit Information [Abstract] Total current assets Current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes [Member] Senior Notes [Member] Available-for-sale Securities, Debt Maturities [Abstract] Available-for-Sale Securities, Debt Maturities [Abstract] Senior Unsecured Debt, Due 2051-2063 [Member] Senior Unsecured Debt, Due 2051-2063 [Member] Senior Unsecured Debt, Due 2051-2063 Tax settlements and resolution of certain tax positions Effective Income Tax Rate Reconciliation, Tax Settlement, Percent B7H4V (felmetatug vedotin) [Member] B7H4V (felmetatug vedotin) [Member] B7H4V (felmetatug vedotin) Increase (decrease) of interest on income taxes expense Unrecognized Tax Benefits, Interest on Income Taxes Expense Revenues subsequent to acquisition Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Reclassification adjustments for (gains)/losses included in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax Other short-term borrowings Other short-term borrowings, principal amount Other Short-Term Borrowings Cerevel Therapeutics Holdings, Inc. [Member] Cerevel Therapeutics Holdings, Inc. [Member] Cerevel Therapeutics Holdings, Inc. Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Reclassification, Type [Axis] Reclassification, Type [Axis] Time deposits and other [Member] Bank Time Deposits [Member] Tax Matters Income Tax Disclosure [Text Block] Net assets acquired/total consideration transferred Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Including Goodwill Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Including Goodwill Other taxes payable Liability for Uncertainty in Income Taxes, Noncurrent Schedule of Significant Product Revenues Revenue from External Customers by Products and Services [Table Text Block] Domestic Plan [Member] Domestic Plan [Member] Acquired In-Process Research and Development Expenses In Process Research and Development, Policy [Policy Text Block] Schedule of Changes in Outstanding Trade Payables Supplier Finance Program [Table Text Block] Xtandi [Member] Xtandi [Member] Xtandi Alliance Revenues [Member] Other noncurrent liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Inlyta [Member] Inlyta [Member] Inlyta [Member] Weighted-Average Discount Rate Operating Lease, Weighted Average Discount Rate, Percent Net cash provided by/(used in) financing activities Net Cash Provided by (Used in) Financing Activities Proceeds from partial sales of investment in Haleon Proceeds from Sale of Equity Method Investments Credit Facility [Axis] Credit Facility [Axis] Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows Restructuring and Related Cost, Accelerated Depreciation Senior Unsecured Debt, Due 2027 [Member] Senior Unsecured Debt, Due 2027 [Member] Senior Unsecured Debt, Due 2027 Long-term debt, excluding the current portion Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Business acquisition, cash payment, gross Business acquisition, cash payment Payments to Acquire Businesses, Gross Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Prevnar Family [Member] Prevnar Prevenar Family [Member] Prevnar/Prevenar Family 13 [Member] Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block] Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Elrexfio [Member] Elrexfio [Member] Elrexfio State and local Deferred State and Local Income Tax Expense (Benefit) Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk [Member] Customer Concentration Risk [Member] Noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Vested and expected to vest, end of period, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Geographical [Domain] Geographical [Domain] Consolidation Consolidation, Policy [Policy Text Block] Total U.S. tax provision/(benefit) Domestic Income Tax Expense (Benefit), Continued Operations Domestic Income Tax Expense (Benefit), Continued Operations Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Income Taxes Payable [Member] Income Taxes Payable [Member] Income Taxes Payable [Member] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.05 par value; 12,000 shares authorized; issued: 2024—9,593; 2023—9,562 Common Stock, Value, Issued Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Next one year Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months Expected contributions in 2025 Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Amounts recorded in our consolidated balance sheet: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Schedule of Available for sale Securities and Held to maturity Securities [Table] Schedule Of Available For Sale Securities And Held To Maturity Securities [Table] Schedule of Available for sale Securities and Held to maturity Securities [Table] Shares issued in acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Equity securities with readily determinable fair values Equity Securities, FV-NI, Noncurrent State & local taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Exercisable, end of period, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] All other - Deferred tax assets Deferred Tax Assets, Other Other In Process Research and Development and Developed Technology Rights [Member] Other In Process Research and Development and Developed Technology Rights [Member] Other In Process Research and Development and Developed Technology Rights Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Intangible asset impairments Impairment of Intangible Assets (Excluding Goodwill) Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] 2029 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Implementation costs recorded in our consolidated statements of income as follows: Implementation Cost [Abstract] Implementation Cost [Abstract] Viatris [Member] Viatris [Member] Viatris Lease liabilities (short-term), statement of financial position Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Reporting Unit [Domain] Reporting Unit [Domain] Deferred tax liabilities, gross Deferred Tax Liabilities, Gross Net income attributable to Pfizer Inc. common shareholders (in dollars per share) Earnings Per Share, Basic Total Shareholder Return Units, Vesting Period Two Total Shareholder Return Units, Vesting Period Two [Member] Total Shareholder Return Units, Vesting Period Two Operating cash flows from operating leases Operating Lease, Payments Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Contractual term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period BioNTech and Cerevel Therapeutics, LLC [Member] BioNTech and Cerevel Therapeutics, LLC [Member] BioNTech and Cerevel Therapeutics, LLC Acquired in-process research and development expenses Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Intangible assets - Deferred tax liabilities Deferred Tax Liabilities, Intangible Assets Total current liabilities Current liabilities Liabilities, Current Dividends Proceeds from Equity Method Investment, Distribution Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Number of shares granted in period (in shares) Granted, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Actual return on plan assets: Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract] Supplier Finance Program [Line Items] Supplier Finance Program [Line Items] Senior Unsecured Debt, Due 2028 [Member] Senior Unsecured Debt, Due 2028 [Member] Senior Unsecured Debt, Due 2028 Held-to-maturity securities, fair value Debt Securities, Held-to-Maturity, Fair Value Measurement Period Adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract] Acquisitions Business Combinations Policy [Policy Text Block] Discount rate: Pension plans/postretirement plans Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Payments on short-term borrowings Repayments of Short-Term Debt Total revenues Revenues: Total revenues Revenues Share-Based Payments Share-Based Payment Arrangement [Text Block] Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Entity Address, City or Town Entity Address, City or Town Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block] Leases Lessee, Leases [Policy Text Block] Schedule of Share-based Compensation, Stock Options, Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Eliquis [Member] Eliquis [Member] Eliquis Net deferred tax liabilities, gross Business Combination, Identifiable Asset Acquired and Liability Assumed, Deferred Tax Liabilities, Gross Business Combination, Identifiable Asset Acquired and Liability Assumed, Deferred Tax Liabilities, Gross Total intrinsic value of options exercised or share units converted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Compensation cost recognized/(reduced), pre-tax Share-Based Payment Arrangement, Expense Granted, weighted-average exercise price per share (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Comprehensive Income (Loss) Note [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Forfeited, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Haleon/Consumer Healthcare JV [Member] Consumer Healthcare JV / Haleon [Member] Consumer Healthcare JV / Haleon Weighted-average assumptions used to determine benefit obligations at fiscal year-end: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Special termination benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract] Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract] Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract] Alnylam Patent Infringement Case [Member] Alnylam Patent Infringement Case [Member] Alnylam Patent Infringement Case Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Document Fiscal Year Focus Document Fiscal Year Focus Employee benefits - Deferred tax assets Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Product Concentration Risk [Member] Product Concentration Risk [Member] Purchases of common stock Shares repurchased, cost Treasury Stock, Value, Acquired, Cost Method Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Senior Unsecured Debt, Due 2026 [Member] Senior Unsecured Debt, Due 2026 [Member] Senior Unsecured Debt, Due 2026 Restructurings and other charges - Deferred tax assets Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Employee terminations Severance Costs Zavzpret [Member] Zavzpret [Member] Zavzpret International Income (Loss) from Continuing Operations before Income Taxes, Foreign 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Nurtec ODT/Vydura [Member] Nurtec ODT/Vydura [Member] Nurtec ODT/Vydura Number of approved medicines Number of Approved Medicines Number of Approved Medicines Working capital, excluding inventories Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital, Excluding Inventories Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital, Excluding Inventories Finished goods Inventory, Finished Goods, Net of Reserves Paxlovid, EUA-Labeled [Member] Paxlovid, EUA-Labeled [Member] Paxlovid, EUA-Labeled Total undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Nonvested, beginning of period, shares Nonvested, end of period, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restructuring charges and certain acquisition-related costs Restructuring charges and certain acquisition-related costs Restructuring Charges And Acquisition Related Costs This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities. Expired, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Gain on sale of equity method investment Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee Reconciling Items [Member] Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Senior Unsecured Debt, Due 2025 [Member] Senior Unsecured Debt, Due 2025 [Member] Senior Unsecured Debt, Due 2025 ViiV [Member] ViiV Healthcare Limited [Member] ViiV Healthcare Limited [Member] Noncurrent deferred tax assets and other noncurrent tax assets Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent Defined benefit plan, accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Deferred revenue, revenue recognized Contract with Customer, Liability, Revenue Recognized Concentration risk, amount Concentration Risk, Amount Concentration Risk, Amount Units outstanding, weighted average grant price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price Foreign exchange contracts [Member] Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Reclassification Adjustments Reclassification, Comparability Adjustment [Policy Text Block] Document Transition Report Document Transition Report Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] U.S. R&D tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Percent Customer [Domain] Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Current Reporting Status Entity Current Reporting Status Retained Earnings [Member] Retained Earnings [Member] Long-term Investments [Member] Long-term Investments [Member] Long-term Investments [Member] Litigation Status [Domain] Litigation Status [Domain] Abrysvo [Member] Abrysvo [Member] Abrysvo Asset Acquisition [Domain] Asset Acquisition [Domain] 2019 Stock Plan [Member] 2019 Stock Plan [Member] 2019 Stock Plan [Member] Proposed percent of ownership disposal Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Restricted Stock Units (RSUs) [Member] Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Supplier Finance Program, Obligation [Roll Forward] Supplier Finance Program, Obligation [Roll Forward] Executive Category: Executive Category [Axis] Other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Units settled, weighted average grant price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price Schedule of Provision for Taxes on Income Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Beginning balance Ending balance Restructuring reserve Restructuring Reserve Talzenna [Member] Talzenna [Member] Talzenna Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Interest rate hedges Interest Paid (Received), Interest Rate Hedges Interest Paid (Received), Interest Rate Hedges Company Selected Measure Name Company Selected Measure Name EX-101.PRE 16 pfe-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 17 pfe-20241231_g1.jpg begin 644 pfe-20241231_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1"B17AI9@ 34T *@ @ ! $[ ( M 0 (2H=I 0 ! (6IR= $ @ 0>NH< < @, /@ M 2!3+@ >H< < @, (; G)E4WI.5&-Z:V,Y9"<_ M/@T*/'@Z>&UP;65T82!X;6QN&UL;G,Z&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R M9R]D8R]E;&5M96YT)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,! M!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_ !$( :\#XP,!(@ "$0$#$0'_Q ? ! M!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0#!04$! M 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9 M&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G* MTM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$! 0$! 0$! M 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G< 0(#$00% M(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J"@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@ , P$ A$#$0 _ /I&BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "HY[B&UA,MU-'#&O5Y&"J/Q-25P'Q M;U$V^@6UBI^:ZFW-_NJ,_P R*Z<)0>)KQI+JV[ M_P"[*I_K5E75QE&##U!S7S%3XY9(7W1.R-ZJ<&OI9<.+I4_#_@GS$>)7]JE^ M/_ /INBOG6+Q+KD BUB^4#H/M#8'ZUH6WQ \3VV-NJ/(/25%?/XD9KFEP]7 M7PS3^\ZH\28=_%!K[G_D>]45XS!\6-?BQYL5G,.^Z-@3^35LVWQB7 %WH[ ] MVBGS^A']:XYY)C8;1OZ-?J=E//,#/>37JG^ESTVBN*L_BIX>N/\ CX^TVI_Z M:19'_CI-;EEXNT#4!_HVK6Q/]UWV-^38-<-3!8FE\<&OD=]/'86K\%1/YFS1 M34D25 T;JZGH5.0:=7(=@4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 5XK\4M1^V>+S;J^4M(ECQV#'YC_ #'Y5[1) M(L43R2'"HI9CZ 5\W:I>G4M7N[U@0;B9I,'L"<@5])P_1YJ\JK^ROS/F>(JW M+0C27VG^"*E%%%?:GPP4444 %%%% !1110!8M;^[L7WV5U-;L>IBD*Y_*M^Q M^(7B2QP!?FX0?PW"!_UZ_K7,45C4P]&K_$BGZHWI8BM1_AS:]&>E6'Q@N$4+ MJ>F1RGN\#E/T.?YUTMA\3?#EX%$T\MHYXQ/&75R3!U-DX^C_SN M>K1SW&T]VI>J_P K'TK::C97Z[K&[@N%]8I W\JLU\R12R02"2&1HW7D,C8( M_&NATWQ]XBTP!4OVN$_N7(\S]3S^M>16X=J+6E-/UT/8H\24WI6@UZ:_Y'O5 M%>9:9\7T.Q-7TYE_O26S9_\ '3_C78:7XST'5^+748EDZ>7,?+;\ >OX5XU? M+L50^.#MWW7X'MT,RPF(TA-7[/1_B;M% (/3FBN ] **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@#G?'FHG3/!E](AQ)*GDK_P "X/Z9->!UZC\7 M]1'EZ?IJMR2T[KZ#[J_^S5Y=7WF14?9X3G>\G?\ 0_/\_K>TQ?(MHJWZA111 M7NG@!1110 4444 %%%% !1110 4444 %%%% !1110!KZ7XHUK1F'V#4)D0<> M6QW)_P!\GBNTTGXNRKM36K ..\ML<'_OD_XUYI17#B,OPV(_B05^^S._#YAB ML-_#F[=MT?0>D>+]$UL 65]'YI./*D^1\_0]?PK;KYBKH-'\<:]HN%@O&GA! M_P!5%[&0G&]?GC/]1^5=O:7MM?P":RN(YXCT>-@P_2OG<1A*^&=JL6OR^\^D MP^,H8E7I23_/[B>BBBN4Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KZA=K8:;Y)R34=?J5"DJ-*--=$D?D]>JZU651]6V%%%%;&(4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 5;T_5+[2K@3Z==2V\@.A_#'TKT72M7X_?\ YGTQ17D_A_XK7,!2#Q!#]HCZ?:(@ X^J]#^E>EZ7K%AK M-J+C3+F.=.^T\K[$=17R>*P&(PC_ 'D=._0^NPF88?%K]W+7L]R[1117"=X4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !7'?$_419>#I( GWC^@Q^-=C7.^*_",7BM;99[R6W%O MN*A%!!)QR<_2NS!3IPQ$)U?A3N<>.A5J8:<*2]YJWW_\ \#HKU";X.C&;?63 MGT>W_J&K/F^$6KJ3Y-]9N.V[_\ EFNJ&,PT_AJ+[TBPS1W M$*2P2+)&XRKH<@CU!KYDK=\.^+M3\-SC[)+YEN3E[>0Y1OIZ'W%?-8[(H3O/ M#Z/MT_X!]/@,_G3M#$ZKOU^??\SZ!HK!\->+]-\2V_\ HK^5];U?(5*4Z4W"HK-'V5*K"M!3INZ84445F:!1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7C208=58 M>A&:S+OPQH=]G[3I5JY/4B(*3^(K5HJX5)P=XMHB=.$U::3]3C[WX8>'+K_4 MPS6A_P"F,I_DV:PKWX/)@G3]58'LL\6?U'^%>FT5W4\TQE/:H_GK^9Y]3*L% M5WIKY:?D>)WWPO\ $5IS!'#=K_TQDP?R;%<[?:#JNF_\?^G7$ _O/&<'\>E? M1U! (P1D5Z5+B#$1_B13_ \RKP[AY?PY-?C_ %]Y\Q4E?1-_X8T34B3>Z9;R M,>K!-K'\1@US.H?";1[@LUC<7%HQZ+D.H_ \_K7JT<_PT]*BCC,/7_AS3_/[CQJV"Q-#^)!K\OO*%%%%=1R!1110 4444 %%%% !1 M110 4444 %%%% !1110!+;W$UI<)/;2-%*ARKH<$&O5_!WQ(COS'8:\RQ7/" MI<=%D/H?0_I7D=%<.,P-'&0Y:BUZ/JCOP6/K8.?-3>G5=&?3P.>E%>2^!OB$ M]BT>F:[(7MC\L5PQR8O8^W\J]95E=0R$,K#((/45\#C,%5P=3DG\GW/T+!8Z MEC*?/3^:["T445Q'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 44$A023@#J37"^*/C'X,\*F2*YU1 M;R[CX-M9#S6SZ$_=!^I%;4Y2X;S"HKN*CZO_*YFZT$? M6=%?'1^._P 0]V?[='T^R0__ !-:%C^T5XZM2//EL;P=_.ML?^@D5O+A;')7 M3B_F_P#(GVT3ZUHKYXT3]J%]P3Q%X?!7O+8R\_\ ?#?_ !5>M^$_B9X5\9JJ M:-J:?:2,FTF_=RC_ (">OX9KR<5E.-PJYJL';NM5^!I&I&6S.LHHHKS"PHHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHI&=5&68+]30 M%4Y=6TZ#_77]LG^]*H_K5.3Q M=X?B^_K%GGT$H/\ *M8T:LOABW\C*5:E'XI)?,V**YYO'?AE.NK0_@&/\A49 M^(7A)>U.7W,R>-PRWJ1^]'2T5S7_"P_"__ $%%_P"_ M3_X4Y?'_ (8;IJL?XHX_I1]3Q/\ S[E]S%]=PO\ S\C]Z.CHK"3QKX M/4;*7_57EN_^[*I_K5@.K?=8'Z&LG%K=&JE&6S,#4_ WA_5 QFT^.*1O^6D' MR$?EQ^EZ31;U M95ZB&<8;Z;AQ_*N&U/0=3T:39J5E+!Z,5RI^A'%>_A\=A\3_ Y:]NOW'SV( MP&)PW\6#MWZ?>9U%%%=IPA1110 4444 %%%% !1110 4444 %>B?#SQPUG+' MH^K2YMW.V"9S_JS_ '3[?RKSNBN7%86GBJ3IU/\ ACJPF*J82JJE/_ASZ>HK MAOAMXK.KZ>=-OI,WEJOR,3S(G^(Z5W-?G&)P\\-5=*>Z/TS"XB&)I*K#9A11 M17.=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 5RWCCXAZ'X"TW[1K$^ZX<'R+2(YDE/L.P]SQ63\4_BC9?#W2=D6 MRYUBX4_9K8GA?]M_]D?K7R)K>MZCXBU:;4M8NGNKJ9LL[G]!Z >E?39/D>%' MUY]J]KTSX*^ M,MUC&@0W3 A(.,CVKKR[-L/F%U3NFNC)G3<-RA3HI9(95EA=HY$(974X*GU!IM%>L M0>^?"?X\7$5S!H?C>X\Z%R$@U%_O(>PD]1_M=N_K7T8K!U#*05(R".]?GO7U M+^SUX\E\0>')O#^IS&2\TM1Y+N?FDA/ '_ 3Q]"*^#XAR>%.'UN@K+[2_5?J M=-*HW[K/9****^(.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHKE/$/Q"TC0RT,;_;;I>/*A/"GW;H/YUM1H5:\N M2E&[,:V(I4(\]65D=76;J7B'2=(4G4;^&$C^ MEC_P !'->.ZU\0]=U'X>F]:\K>2_S/F<3Q'!:4(W\W_E M_P ,>NZA\6M*@8KI]I/=D=&;"+^O/Z5S5[\6-;G8BTAMK5.WREV'XGC]*X6B MO:I9/@Z7V+^NO_ /#K9SC:OV[>FG_!-VZ\:>(KLGS=6N #VC;8/_ !W%9-Q> M75VV;JYFG/K)(6_G4%%>C"C2I_!%+T1YLZU6I\:V"L\H9%S@#UQGKBO.:]0^$&FD+J&I.O!*P(WZM_[+7D9 MI"A2PLYN"OLM%U/9RJ=>KBX04W;=ZO9:GIU%%%?GQ^BA3)8HYXFCF19(V&&5 MQD$?2GT4;!N<;K7PST34PSV:MI\YZ&'[F?=?\,5Y[KGP\US1MTB0_;;=>?,M MQD@>Z]:]THKU\-G&*P^C?,NS_P ]SQL5DV$Q&J7*^Z_RV/F(@JQ# @CJ#VI* M^@=;\&Z+KP9KRU"3G_EO#\K_ )]_QKS77OACJNF;IM-(U" [)\K\_\ ,^5Q>28G#^]%X>7[EM!G!FD/0?3N3Z5T MDDBQ1M)(P1%!9F8X [U\:_%[Q])XZ\92O;N?[,LB8;-.Q&>7^K$?EBO:R;+ M7C\1:7P1U?\ E\S.I/E1R>O:[?\ B77+G5M6G,UU@ X K.HHK] M8C&,(J,59(X0KVSX!_#"/7[P^)]=@WV%K)BTA<<32#^(CNJ_S^E>1Z%I%QK^ MOV6DV0S/>3+$GMD]?P'-?=.@Z-:^'M LM)L$V6]I$(T'KCJ?J3S7S'$>8RPM M!4:;M*?X+_@_YFU&',[LT****_-#L(KJYBL[.:ZN7"0PH9)&/15 R37PGXMU MK_A(_&&JZP%VK>73RHI[*3P/RQ7U1\>]9DTCX3WJP,5DOI4M<@]%)RWZ*1^- M?']?H'"N%4:4\0]WHOE_7X'+7EK8****^S.<*] ^"&K-I/Q;TG!PEV6M7]PR M\?\ CP6O/ZZSX76\ES\5/#L<0RPOHW./13N/Z UR8Z,986I&6W*_R*C\2/MV MBBBOQ<] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "JVH:A:Z78R7=_,L,,8RS-_(>I]J=>WD&GV4MW=R".&%2SL>PKPGQ;X MLNO$^HEF+1V<9Q!#GH/4^I->IEV7SQL^T5N_T7F>5F690P-/O)[+]7Y&GXK^ M(M]K3/;:87L['IP')25D?GN(Q-7$SYZKNPHHHK< MYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *][\!:=_9O@RQ1AAYE\YO MJW(_3%>'Z79MJ.K6MFG6>98_S.*^D8HUAA2*,;410J@=@*^6XBK6A"DNNOW' MUG#=&\YUGTT^\=1117QY]F%%%% !1110 4444 8NN^$M(\01G[=; 38XGC^5 MQ^/?\:\L\1_#C5=&#SV8^WVHYW1K\ZCW7_"O;:*]/!YGB,+I%WCV?]:'EXS* M\-BU>2M+NOZU/F(C!P>#25[IXE\ Z7KX::-19WAZ31CAC_M#O]>M>1Z_X7U/ MPY<;+^']V3\DZ>R4<&T^K7^9[V01*-2U60DF\N7E&>P+' _+%?6\+X6-7$3JS5U%?B_^&9A6E96+?\ PG7B MO_H9-5_\#)/\:/\ A.O%?_0R:K_X&2?XU@T5^@?5Z/\ (ON1RW9O?\)UXK_Z M&35?_ R3_&C_ (3KQ7_T,FJ_^!DG^-8-%'U>C_(ON079O?\ "=>*_P#H9-5_ M\#)/\:/^$Z\5_P#0R:K_ .!DG^-8-%'U>C_(ON079O?\)UXK_P"ADU7_ ,#) M/\:MVOQ,\;6;!H/%&I\=GN"X_)LBN6HI/#4)*S@ON0I^%?VCO#>KR);Z_;2Z-.Q \PGS(2?]X#(_$?C7RQ1 M7EXG(L!B%\'*^ZT_X'X%JK)'Z!VEY;7]JES8W$5Q!(,I+$X96'L14U?$7@?X MCZ]X#OUDTJY,EHS9FLI23'(._'8^XKZV\"^/-)\>Z&M_I3[)4PMQ;.?GA;T/ MJ/0]Z^$S3):V7OG^*'?_ #.F%12.GHHHKPC4***1F"(62?M!> M-_\ A'?!ZZ+92E;[5@48J>4A'WC^/3\Z^4JZ_P"*'BU_&7C_ %#458FV1_(M MAG@1KP#^/)_&N0K];R; K!82,&O>>K]7_D<-27-(****]@S/9/V;?#HU+QQ= M:Q/'NBTR#]V2.DC\#_QW=7U+7E?[/7A_^Q_AE'>R+B;59FN#G^Z/E7^1/XUZ MI7Y/GN)^L8^;6T=%\O\ @W.ZDK1"BBBO$-#S#]H+29M3^%-S+;J6:QN([A@! M_",J?RW9_"OD6OT$NK:&]M);6ZC66&9#'(C#(92,$5\E?$[X-:MX.OY[W2+> M6^T1F+))&-S0#^ZX'/'][I7W7#.8TH0>%J.SO=>?D,[J*YOX9 M-,T@$%[B9-K2#T13USZ]*^L=#T2P\.Z+;:7I,"P6ENFU$'ZD^I/4FOD.(,WI MPHRPM%WE+1^2_P V;TJ;;YF7Z***_.SK"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBJ^H7L>G:;<7L^?+MXVD;'< 9II.3LA2:B MKL\O^*GB0W%ZNAVK_NH,/<8_B?J%^@'/U/M7G-37=U)>WLUU.VZ29S(Y/J3F MH:_3<'AHX6A&E'IOZ]3\MQN)EBJ\JLNNWIT"BBBNLXPHHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** .T^%VG&\\7BX(REG$TASZGY1_,_E7M5>?\ MPDTX0:#=7[#Y[F78/]U1_B3^5>@5^?9S6]KC)+I'3^OF?HV24?98*+>\M?Z^ M04445XY[(4444 %%%% !1110 4444 %175K!>V[P7<231.,,CC(-2T4TVG=" M:35F>3^+?AC):A[WP\&EA'+6Q.67_=/?Z=:\Z92C%6!5@<$$=*^G:XWQAX M M=?1[NP"VVH 9R!A9?9O?WKZC+L[<;4\3MW_S_P SY3,LB4KU<+H^W^7^1XG1 M5B]L;G3KR2UO86AFC.&1A5>OKTU)71\:TXNSW"BBBF(4 LP"C))P!7T=H=B- M,T&RLU&/)A53]<<_KFO#?!FG?VIXOT^ KN02B1Q_LKR?Y5] U\AQ%6O*%)>O M^7ZGV7#=&T9UGZ?J_P! HHHKY4^M"BBB@ HHHH X?XQ:\?#_ ,*]7N$;$MQ' M]ECY[R':?T)/X5\75]$_M/Z[MM=%T*)^79[J50>P^5?YM^5?.U?IW#6']E@> M=[R;?RV..L[RL%%%%?2F(5[!\.O@2?'/A&/7+G6'L!-*ZQQK;[]RJ<;LY'?/ MY5Y BL[JB LS' [FONSP7HJ^'?!.D:4@P;:U17_ -\C+?J37S?$&85<%1@J M+M*3_!;[_(UI04GJ>.?\,MV__0T2?^ 8_P#BJK7G[++O!T+7-]8?:K->MS:'S%4>K# MJOXBN&K]"&574JX#*1@@C(-?./QS^$5OI=O)XJ\,6XBM]V;ZUC'RQY_Y:*.P MSU';K7TV4\1?6*BH8E)2>S6S\C&=*RNCP6BBBOL# *Z'P1XQU#P/XF@U;37) M"G;/#GY9H^ZG^A[&N>HJ*E.%6#A-73!.SNC[YT'6K/Q%H5IJVFR>9;748D0] MQGL?<'BM"OGW]F;Q8[IJ'A:ZDRJ#[5:@GISAQ_(_G7T%7X_F6#>"Q4J/1;>G M0[X2YHW"O/\ XU^*#X7^&=\\+[;J^_T2'!Y&X'<1]%S^E>@5\O\ [2OB,W_C M&ST.)OW6FP;Y #_RTDP?T4#\ZZ,EPOUK'0B]EJ_E_P $527+$\6HHHK];.$* MGLK26_U"WL[==TMQ(L2+ZEC@?SJ"O0_@=H?]M_%?32R[HK'==R9']T?+_P"/ M%:Y\566'H3JO[*;'%7=CZXT33(M%T&QTVW $=I D*@?[( J]117XM*3DW)[L M]$****D H(!!!&0>H-%% '-ZE\._"&KRF34/#FGRR'JXA",?J5QFGZ9X!\)Z M-('TWP]I\$@.0_D*S#Z$Y-=#16_UFOR\G.[=KL5D'3I1116 PHHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7XM:S_9?A&*U M0XDU*Z2V'/( !=OT3'XUW5?.O[0/B1%^(WAW3!+B.PC\Z8 \*TK8Y^BJ#]&K MU\FP_P!8QL(]%K]W_!L M)[+Y@(KR,'R9P/T/J*\-U+3;K2=0DL[^(Q31G!![^X]17TA<7,%I TUU-'#$ M@RSR,%4#W)KQ'XJ?$SP+=I';V=TU_J43 +/:+NC5<\AFZ$?3-?49'BL1S^P4 M7*/Y?\ ^=SC*XXB+K4])K\?^"K5R?PVT[[!X-MW*X>Z9IF_'@?H!765^<9I6]MC)O MHM/N/TS*:/L<'"/5Z_>%%%%>:>F%%%% !115+6M2CT?0K[49B EK;O,2?]E2 M:<8N345U ^1/C?K@USXL:F4;=%9;;1.?[G7_ ,>+5Y]4][=RW]_/>7!W2W$C M2.?4LT;GZF-:X"OVG"5'6 MP].H]VD_O1YTE9M!11172([CX-ZJ=(^+.B2AL+-,;=_<."O\R*^T:^$?!;,O MCW0"GWO[2M\?]_%K[NK\]XK@EB*<^Z_)_P#!.JALQDTR6\$DTK;8XU+,Q[ # M)KX1\6:U)XB\7:IJTK%C=7+NN>RY^4?@,5]=?O^$?^%FL7"-MEGB^RQ_6 M3Y?Y$G\*^+:[.%,/:%2N^NB_-_H37>J04445]L6=+2 M,D=@-S?S6OG:OM'X.Z%_8'PKT>!TV33Q?:91C^)SN_D0*^:XFQ'LL#R+>32_ M4VHJ\KG<4445^8G8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 5\/?$K7?^$C^).MZDIS&]TT<1 M]43Y%/XA0?QK[!\=ZX?#?@+6=61Q'+;6CF)CVD(VI_X\17PN2222'UJ5WZ+\W^AS5WLCU7PYJ8U71892V94'ERC_:'^/6M6O+_"^MG1]2_>D_9I ML+(/3T;\*]>TG1M1UQP-*M)+D'^-!\H^IZ5])B%&BW*3LC\^Q^!G1Q'+!74M MO\BC17I&E?".YE ?6+Y8!_SS@&YOS/'\Z[#3OA]X=TX*18BXD'\=PV_].GZ5 MX%?.\)2TB^9^7^9T4,BQE76245Y_Y'AD%K/=2;+:&29O2-2Q_2MNU\#>)+O' MEZ5,@/>7"?SKWJ&V@MD"6\,<2CH$0*/TJ2O)J<15'_#@EZZ_Y'KTN&Z:_B3; M]-/\SQFW^%&O2X,\EI /0R%C^@K4@^#TI_X^M61?^N<)/\R*]2HKAGG>-EM) M+T7^9WPR+ QWBWZM_I8\ZC^#]@/];JERW^ZBK_C5I/A+HB_?N;Q_^!*/Z5W= M%<[S3&O>HSI64X%;4U^)Q2_"KPZ.OVMO^VO_ -:G_P#"K/#G]RZ_[_?_ %J[ M*BL_[1Q?_/Q_>:?V;@_^?:^XXP_"SPX?X;H?]MO_ *U1M\*/#Y^Z]VO_ &U' M^%=O13_M'&+_ )>/[Q/+<&_^7:^XX)_A'HS?L3_J]5N%_W MHU/^%>C45:S7&K_EX_P,WE.!?_+M?B>73?!YQ_Q[ZNI_WXOT5O'.\;'>5_DC&61X&6T;?-GB$_PQ\20YVV\,P_V)A_7%6O"@ ML? WB;SO&MU;Z0\D#"U^U2A1(<@,0?8?SKV6OD7]H'7!J_Q4N;>-MT>FPI:C MGC=]YOU;'X5[&78K$9M.6%J646G=KO\ @GK^W\C] :*^$;;QIXGL\?9O$.IICH!=N?ZUJP_%CQW;X$?B M>_P.S2;OYBN67">(7PU%^/\ P1^W78^V:*^,XOC;\0HNGB.5O]^")OYK5N/X M]_$!.NK1/_O6L?\ 05B^%<:MI1^]_P"0_;Q/L&BOD5?VA/'PZWMH?K:K2_\ M#0OCW_G[L_\ P%6H_P!5\=WC][_R'[:)]B6T0_P#9:I<+8U[RC][_ ,A>VB?9-%?%$_Q;\>7 (D\3WP!_ MN,$_D!6-=^,/$E]G[7KVI2@]0UT^/RS6\.$\0_BJ)?>_\A>W78^Y[K4K&Q4M M>WD%N!U,LH7^=);%V7JD#^:?\ QW-?%4L\TQS-*\A]78FH MZ[J7"=)?Q*K?HK?YDNN^B/J;5_VE?"EFK+I5G?Z@XZ'8(D/XDY_2O/=<_:4\ M47ZM'HUE9Z6IZ/@S./Q/'Z5XW17KT,@R^CKRW"$:<>6"LO(SW.X\#:R75M,G;)4%H2?3N/Z MUW-K;O>7D-M$,O,X11[DXKQ:PNWL;^&YC^]$X;Z^U?17PSLUU;Q=93 9BA3[ M3G\/E_4BO*S"2P].5;LFSY7,,#?&0Y-IO\>I[C9VRV=C!;1C"PQJ@^@&*FHH MK\D;;=V?=I)*R"BBBD,**** "O,/V@==_LCX6W%LC[9=2E2V7'=<[F_1F54TG3X]*T6RT^$ 1VL"0KCT50/Z5;K\6Q==XC$3JO M[3;/1BK*P4445S#"BBL?Q9X@@\+^%-0UFZ("6L)< _Q-T5?Q.!5PA*Y)R:AK] MJP]+V-&%/LDON1YS=W<****V$=;\+=/.I_%+P_;J,XO$E/L$^;^E?;E?+?[- M>@M?>.[K6'7]UIML0IQ_')P/T#5]25^;<45E/&*FOLK\7K_D==%6C<^?_P!I M_7=MKHV@Q/\ ZQFNI5![#Y5_FU?.U>@?&[71KOQ6U-HVW0V96T3G^X,-_P"/ M;J\_K[/)L/\ 5\#3@]VKOYZG/4=Y,****]8@MZ3!;W6L6<%].MO;23HLTS=$ M0D9/X"OLB#XL?#ZWMXX8O$UBJ1H$4 MP ,#M7Q917CYEE-/,7'VDFN6^UNII M"HX;'VM_PM[P#_T-%E^;?X4?\+>\ _\ 0T67YM_A7Q317D_ZJ87^>7X?Y%^W MEV/M;_A;W@'_ *&BR_-O\*/^%O> ?^AHLOS;_"OBFBC_ %4PO\\OP_R#V\NQ M]K?\+>\ _P#0T67YM_A1_P +>\ _]#19?FW^%?%-%'^JF%_GE^'^0>WEV/M; M_A;W@'_H:++\V_PJQ8_$_P %ZG?PV5AXAM)[F=PD42;B78] .*^(:]4_9YT/ M^U/BA'>.FZ'38'G)QT8C:O\ ,G\*Y<9PYA,-AYUG.7NJ_3_(J-:3=CZUK%\0 M>+] \*F >(=4@L#<9\KS2?GQC.,#W%;5?*7[1VMG4?B2FGJV8]-M4CP#_$_S MG]"OY5\UE. 6/Q*HR=E9MV_KN;5)7X?Y'/[>78^UO^%O> ?^AHLOS;_"C_A;W@'_ *&B MR_-O\*^*:*/]5,+_ #R_#_(/;R['VM_PM[P#_P!#19?FW^%'_"WO /\ T-%E M^;?X5\4T4?ZJ87^>7X?Y![>78^UO^%O> ?\ H:++\V_PH_X6]X!_Z&BR_-O\ M*^*:*/\ 53"_SR_#_(/;R['VM_PM[P#_ -#19?FW^%'_ M[P#_T-%E^;?X5 M\4T4?ZJ87^>7X?Y![>78^UO^%O> ?^AHLOS;_"NJT[4;35M.AOM.F$]K.NZ* M0 @./49[5\F?!KX82>.==%]J<;+HEDX,IQCSW'(C'MZ^WUKZZBBC@A2*%%2- M%"JJC 4#H *^5S?!X7!5%1HRG*4E=CJ*.E>/_ !'^/>F>&7ET MSPRL>J:FN5>7.883Z$C[Q]A^=>=A<'7Q=3V=&-W^7J5*2BKL]8OM0L]+LWNM M1NH;6WC&6EF<(H_$UYIKW[0G@O1W:*REN-6E7_GUCPG_ 'TV/TS7S'XD\7Z[ MXMOC=:_J,UVV?E1CA$]E4<"L6OM\)PK2BKXF5WV6B_S_ ".>5=]#W^]_:CN3 M(1IWAF()V:>Z)/Y!?ZU47]J+60WS^';$CT$[BO"Z*]A9#EJ5O9?B_P#,S]K/ MN?1FF_M16CL!J_AR:(=VMK@/C\"!7?\ AWXU>"/$;K%%JHL9V.!%?+Y1)],_ M=/YU\:45R5^&L#47N)Q?D_\ .Y2K26Y^A"LKH&1@RL,@@Y!%+7Q?X%^+/B3P M-<(EM:=GY[&X8E,?[)ZJ?IQ[5]6>"/'6C^/-$&H:/+AUP)[9S^\A;T(_D M>AKXS,LFQ&7^\_>AW7Z]CHA44CI****\0T"BBH;NZBL;*>[N6V0P1M)(WHJC M)/Y"FDV[(#G-2^)G@W1]2FL-2\0VEO=0-MEB8G*'T.!57_A;W@'_ *&BR_-O M\*^-];U)]9U^_P!3F^_>7,D[>Q9B?ZU1K]!APIAW%\ _]#19?FW^%'_"WO /_0T67YM_A7Q315_ZJ87^>7X?Y"]O+L?=.A>._#'B M:^:ST'6;>^N$C,C1Q9R%! SR/4BN@KP#]E[1%6RUO773YGD2SB;'0 ;V_/YOKB.W@C&7EE<*JCW)KSC6_C]X&T>1HH;R?4Y%_P"?*++?'GB#QK?&XUR^>1,YCMD.V*,>@7^IYKG*^GPG"M-1YL3*[[+;[_\ MAC&5=_9/IP?M/>'3)@Z+J03/WLIG\LUV/A?XS>#?%4Z6UKJ)L[J0X6"]7RV8 M^@/0G\:^,J <'(X-=M7AC SC:%XOUO\ F2JTNI^A-%?/OP$^*MW>7L?A#Q%< M-.S*?L%Q(E?05? X_ U<#7=&I\GW7KUK]HS73J?Q,& MG(?W6EVR18S_ !O\['\F4?A7DM?K&0X?V&7P[RU^_;\+'#5=YL*]W^!/Q:CT MORO"?B294M7;%C=/@")C_P LV/H3T/8G'3IX117=CL%2QM%T:G_#/N3&3B[H M_0FBOG+X/?''[&L'AWQI<$P#"6NH2'/E^B2'T]&[=_6OHQ'61 \;!E89# Y! M%?E&/P%; U?9U5Z/HSNC)25T+1117 4%%%% !1110 4444 %%%% !1110 44 M44 0WEU'8V,]U.=L<$;2.?0 9/\ *O@K6M4EUO7K[5+CB6\N'G8>A9B# M4.LG^"U_R"%%5*L9O[.OX6.NHHHK\U/2"BBB@ HHHH "<#)KXA^)NN?\)#\2 MM:OP^^(W+11'_83Y1_+/XU]?^.=;7PYX%UC5"<-;VKE/]\C"_J17PL26)).2 M>I-?<<)X?6I7?HOS?Z'-7>R$HHHK[LY@KT3X%Z$-;^*^G&1=T5B&NWX[J/E_ M\>(KSNOHW]F#0O+T[6==D3F61;6)CZ*-S?J5_*O)SK$?5\!4EU:M]^A=-7DC MWRBBBOR([PHHK%\1^,-!\)V9N->U."T7&51FR[^P4I_"H_B9\==0\6Q M2Z5X>233M*;Y9')Q+<#T./NK["O(J^_R/(I8>2Q.)7O=%V\WYG+4J7T04445 M]B#F\'?#VVBNH]E]>G[3_P#P#H5#3<^ /+?^XWY4>6_] MQORK[_\ L%G_ ,^D'_?L4?8+/_GT@_[]BH_UM7_/G_R;_@#]AYGP 48#)5@/ MI3:^M/C]J-KHGPNN((8(4GU&9+9"J $#.YOT7'XU\EU]+E>/>/H>VY.57MO? M]$8SCRNP4445Z9 5]-_LRZ%]D\):EK4B_/?7 B0_[$8_Q8_E7S)UZ5]Q_#G0 MQX<^'>C:=LV.ELKRC_;;YF_4FOEN*,1[/!JDMY/\%K^=C:BKRN=([K'&SR$* MJ@EB>PKX2\6ZG+KWC#5=4<,?M5U)(N1T7<<#\L5]WD C!&0:K_8+/_GU@_[] MBOD,HS2.6RE-PYF_.UOP9T5(6_]QORH\M_[C?E7W_\ 8+/_ )](/^_8 MH^P6?_/I!_W[%?0?ZVK_ )\_^3?\ R]AYGP!Y;_W&_*CRW_N-^5??_V"S_Y] M(/\ OV*CN(-.M+:2XN8;:*&)2[R.B@*!R230N+4]%1_\F_X >P\SX#*LOWE( M^HI*] ^+?Q"7QOXC,>FQK!H]FQ6V15"^:>\C>Y[>@KS^OL:UJM MOIVFP-/=7+A(XU'))K[-^&OP_L_A_P"&([*(++?38>\N0.9']!_LCH/_ *]> M'G.:1P%&T?CEM_F:4X['U)/)-:+,%4L MQ &23VI:\&^/_Q0>PC?PAH,Y6>5OS?!X6MF&)5..[ MU;_-L[)24%+84N-/TQH+1QE;FZ;RT8>HSR?P%=1 M=?LV>,X+%M0-EK^GS64^,@2#AAZ@C@CZ5EU]P?$+P39>.O"5SIMU& MGVD(7M)R.8I .#GT/0^QKXCGADMKB2"92DD;%&4]B#@BOKLGS59C2;:M*.Z_ M5&%2'(R.N@\%>,=1\#^)8-6TQSA3MGA)^6:/NI_IZ&N?HKV*E.%6#A-73,T[ M:GWQH&N6?B30+/5],??;7<8D3/4>H/N#D'Z5HU\]_LR^*W;^T?"US("JC[7: M@]1R X^GW3^=?0E?C^98-X+%2H]%MZ/8[X2YHW"N!^-FNMH/PGU62)MLUXJV M@! QW(QV-?.^H:A=ZMJ$]]J-P]S=3N7DED.2Q-:&O:U MJ/C'Q,]Y,CRSW#+%!;Q@ML4<)&H]A@5[5X&_9OCGL([[QO\+23 MRV4) NK>9@S1*> X/<9P"/?->)UZV#QE'&TO:T7=$2BXNS"BBBNLDNZ+J$FD MZ]8:A Q62UN(YE(/=6!_I7WX.17P3X;TN76_%&F:9 A=[NZCBP!V+ $_@,FO MO8<"O@N+7'GI+K9_I;]3IH;,****^).D**** "FRR)#"\LK!$12S,QP !U-. MKB_B[K(T+X4:[6W^S1@'DM*0GZ!B?PK:A2=:K&DMY-+[Q-V5SX]\2ZN^ MO^*-3U:5BQO+J289[ L2!^ P/PK,HHK]KA%0BHQV1YP44450!7JWPN^-NH># M&BTO7/,O]%SM49S);#_9SU7_ &?RKRFBN;%86CBZ;I5E=?UL.,G%W1]]:+KF MF^(M+BU'1;R.[M91E9(S^A'4'V-7Z^&/!_CG7? ^IB[T*[**Q'FV[\QS#T9? MZ]:^HOA[\9= \<1QVLKKINK8PUI,W$A]4;O].M?F^9Y#7P3^*VLS!]T5M+]EB]EC^4_P#CVX_C7#U^OY1A_J^! MIPZVO]^IP5'>384445ZA 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%*JEV"J"S$X ZT =/\ #GPK)XQ\=Z=I2H6A,@DN2/X8EY;_ _&OM]$6.-4 MC4*J@!0.PKR[X'?#EO!OALZEJD075M24,ZD4T5S8G"4<7#V=:-UO_ %8<9.+NCW?_ (:CU3_H6K/_ ,"6_P *JW/[3WB) MU(M=%TV$^KL[_P!17B5%<"R/+E_RZ7WO_,OVD^YZ'K/QR\>:PK)_:_V&,_PV M<8C_ /'NOZUP5U>7-]<-/>W$MQ,YRTDKEF/XFH:*]"CA:&'5J4%'T1#DWN%% M%%= @HK1T;0-5\0WRV>B6$][.Q^[$A./J>@'UKWWX??LZ0VCQ:CXYD6XD&&7 M3XFRBG_;;^+Z#CW->=CLRPV!C>K+7MU948.6QYY\*_A!J'CJ]2^U%)+30XVR M\Q&&GQ_"G]37UKING6FD:;!8:; EO:VZ!(XD& H%2P016MND%M$D44:A4C1< M*H'0 5)7YGF>:5LPJ7EI%;+^NIVP@H(*^9/VFM>^U>+--T6-ODL;IPOA_:8QU7M%?B M]/\ ,SK.T;',T445^DG(%=7\,-#_ .$B^)6BV#)OB^TK+*/]A/F/\L?C7*5[ MI^S'H/VCQ%JNNR+\MI +>,_[3G)_1?UKSLTQ'U;!5*G6VGJ]$7!7DD?2O3I1 M117XZ=X4444 ?-/[3FN?:/$6E:)&^4M(#<2 =F&5UGQ/US_A(?B7 MK5^C[XCK//F[R;"BBBO1).B\ :&WB M/Q_HVF*,K+=(9/\ <4[F_0&ON8 *H & !@"OF#]F?0_MOC:_U=URNGVVQ#C^ M.0X_D&_.OJ"OS?BC$>TQ:I+[*_%Z_E8ZZ*M&X4445\H;A1110 5\W_'SXI_; MII?".@3_ .CQMB_F0_ZQA_RS!]!W]^.U=Q\;OBB/!^CG1M&F']M7J?>4\VT9 M_B]F/;\Z^3V9G8LY+,QR2>YK[;AW*.=K&5EI]E?K_DI^E<>.QE/!4 M'6J=/Q?8J,7)V1W'P.^%H\*Z6NOZW#_Q.+Q/W<;CFVC/;V8]_P O6O7J**_( ML7BJF+K.M5>K_#R.Z,5%61S/Q!\70^"/!5[K$N&E1?+MXS_'*W"CZ=S[ U\1 MWM[<:C?SWM[*TUQ<2&221CRS$Y)KV7]I3Q4U_P"*[7P[ _[C38Q+* >LKC// MT7'YFO$Z_1.',"L/A%5DO>GK\NG^9RUI7E8****^E,3N/A'X+'C;Q];6ERFZ MPM1]HN^.&13PG_ C@?3-?9Z(L4:QQJ%10 J@< >E?/GP#\0>$?"7A.[N-:UV MRM-1OY\M%*^&2-.%!_$L?QKU;_A:_@3_ *&G3O\ O[7YMG\L3BL6XQA)QCHM M'\W_ %V.NE:,3KZ*Y#_A:_@3_H:=._[^T?\ "U_ G_0TZ=_W]KY_ZGB?^?+2<>J:ZHQK-.. MAQM%%%??G*=K\']6_L?XL:%.6PDUQ]F;W\P%!^I%?:E?!?A:0Q>,-&D7JE_ MP_"1:^]*_/N+*:5>G/NK?<_^"=5!Z,*^,?C/KHU_XK:O+&28K5Q:1Y/:,;3^ M;;C^-?7VOZHFB>'-1U23&VSMI)^3UVJ3C]*^"[FXDN[J6XG8O+,Y=V/4DG)- M5PIA[U:E=]%;[_\ A@KO1(BHHHK[\Y0HHKN_A#X&_P"$X\=06]U&6TVS N+P MXX90>$S_ +1X^F:QQ%>&'I2JU-DKC2;=D>M? +X7)IUC%XNUV &\N%S81./] M2A_Y:8_O'MZ#ZU[I2(BQQJD:A54850, "EK\?QV,J8VNZU3KMY+L=\8J*LB" M^LK?4=/N+*]C66WN(VBE1APRL,$?E7Q%X^\&WG@;Q;=:3=JQA#%[68CB:(GY M6^O8^X-?(+-9U7)CD!VR1'U5NU>ADV:O+JKYE>$M_P#, MBI#G1\)T5]*W/[+^CO<%K3Q!>Q19^Y)$KD#Z\?RKIO"OP$\(>&[I+NXCEU:Y MC.5:\(**?4(!C\\U]E4XEP$8(_M/V;R>#='O5^Y!?&-O^!H2 M/_0*]?)5%YC2YN_Z&=3X&?,E%%%?KAPA1110 4444 %*K,C!D)5E.00<$&DH MH ]A\ ?M ZSX>\NQ\3J^KZ>,*)2?W\8_WC]X>QY]Z^C/#'C+0O&%@+O0-0CN M5Q\\><21^S*>17PE5O3-5O\ 1;]+W2;R:SN8S\LL+E6'Y5\UF'#N'Q5YTOH/UKX+&Y9BL$_P!]'3NMOO.F,XRV-6BBBO.+"BBB M@ HHHH *R_$VKQZ!X6U+59CA;.V>7ZD*<#\\5J5Y-^T7KW]E_#3^SXS^\U2Y M2$\]$7YV/_CH'XUV8&A]9Q,*/=K[NOX$R=HMGRE+*\\SRS,7DD8LS$Y)).2: M9117[/L>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1172>$O 'B+QK M>"'0[!Y(L_/QSJ(TDBI&I=V.%51DD^E? M1OP9^"C:?)!XE\7VX%R,/:6+C_5GL[CU]!V[UUWPY^"NB^"!'?7VW4]8'/VA MU^2$_P"PO;ZGGZ5Z97P6<<0^VBZ&%TCU??T\CJITK:R"BBBOC3H"BBB@ HHH MH *9-*L$$DLAPD:EF)[ #-/KBOB[KG_"/_"W6;E'VS2P_9XN?XG.W^1)_"MJ M%)UJL:4=Y-+[Q-V5SY!\4ZRWB'Q9JFKMG_3+EY5SV4G@?EBLFBBOVN$%"*C' M9'G!1115 :^@>%-<\4RS1^']-GOW@4-((A]P'IFMS_A47CW_ *%B^_[Y'^-> MX?LU:']A\"WFK.N)-1N2%./X(^!^I:O9J^)S#B2MAL5.C2BFHNVM_GU[G1&B MG&[/BG_A47CW_H6+[_OD?XT?\*B\>_\ 0L7W_?(_QK[6HKA_UKQ7\D?Q_P R M_81[GQ3_ ,*B\>_]"Q>_D/\ &K=M\$?B!=, /#\D8]99HTQ^;5]ET5+XKQ=M M(1_'_,/81/EK2OV:?%5W@ZG?Z?8+W 9I6'X ?K7H?A[]F_POIA276KFYU:5 M>2A/E1G\!S^M>Q45YU?/\PKJW/RKRT_'?\2U2@BCI.B:9H-F+31K"WLH!_RS M@C"@_7'6KU%%>+*3D[R=V:!1114@*U98_]]OE7]2*^ M&B222>2:^G?VF=<^R>#].T:-OFO[DR.,_P $8_Q8?E7S%7Z3POA_9X-U7O)_ M@M/SN<=9WE8****^J,0KZ\^ .A?V/\++6X=-LVHROGV4N MI:E;65N,RW,JQ(/=C@?SK[UTC3X])T6RT^ 1VL"0J!Z*H']*^.XJQ'+0A17 MVG?[O^'.B@M;ERBBBOSTZ@K"\;:T/#O@?5]5SAK:U=D_WB,+^I%;M>-_M*:Z M;#P':Z5$^'U*Z&\ ]40;C^NVN[+\/]9Q=.EW?X=?P)F[1;/EMF+L68Y+'))[ MTE%%?LIYX445)!"]Q<1PQ#=)(X11ZDG HV ^K?V==#_LSX9_;I$VRZE[?W=#T M(JT4@HHHKC*"N3^(OCRR\ >%Y=1N2LEW)E+2W)YEDQ_Z".I-;NN:U8^'=%N= M5U680VMLA=V/?V'J3T KXN^(/CF^\>^*)=3O"4MUREK;YXBCSP/J>I/K7OY+ ME3Q];FG\$=_/R_S,JD^5>9AZQJ][KVL7.IZI.T]U4YDD(^6)!U9O8?SXJ:E2-.#G-V2!:G M2_"3X;3^/_$8:Y5H]'LV#74O3?Z1J?4]_0?A7V':VL%C:16MG$D,$*!(XT&% M50, 5E^%/"^G^#_ [;:/I,>V&%?F@Y7 MV.8HKI_^%;^,_P#H6=2_\!VH_P"%;^,_^A9U+_P':CZUA_YU]Z#E?8J^![1K M[Q_H-L@R9-1@!^GF D_EFONROECX,?#SQ#:?%'3[[6=%N[.ULUDF,EQ$54MM M*J.>^6'Y5]3U\!Q1B(5<3",'=)=/-_\ .JBFD>5_M#ZV-+^%TEDC[9=3N$@ M !Y*@[V/T^4#\:^2J]N_::UW[7XNTW18S\EA;&9_]^0]/^^57\Z\1KZCA[#^ MQP$6]Y7?^7X(QJN\PHHHKWS(*^O_ (%>$!X7^'5OH4C]VO\ MWSS]6-?+_@;P_P#\)3XYTG1BK-'=7"B;;U$8^9S_ -\@U]T1QK%$L<:A410J MJ.@ KXOBK%N,(8:/75^G3\?R.BA'6XZBBBO@#J"BBB@ HHHH **** "BBB@ MHHHH *XGXO\ AQO$_P +]5M(5+7$""Z@ &26C^; 'J5W#\:[:BMJ%:5"K&K' M>+3^X35U8_/:BO0?C+X%;P3XYF^SQD:9J!:XM#V7)^9/^ D_D17GU?LV'KPQ M%*-:GLT>>TT[,****W$%%%% !1110 4444 %7=*UG4M#OEO-'O9[*X7I) Y4 M_IU'M5*BE**DK25T![MX._:4U"SV6WC&R%]%P/M=L D@'J5Z-^&*]R\,>//# M?C"W$F@ZI#._\4#'9*OU0\_TKX7J2"XFM9UFMI7AE0Y5XV*LI]B*^:QO#>$Q M%Y4O$_C_P"+?#WEP:E(FM6B\%;KB0#VD'/YYKVK MPK\>O!_B(QPWEPVCW;<>7><)GVD''YXKX[&9%C<+KR\R[K7\-SHC5C(]-HJ. M"XANH%FMI8YHG&5>-@RGZ$5)7A[&@5\O?M+Z[]M\;6&D1R9CT^UWNH/220Y. M?^ JOYU]0UY?XM^ _A[Q;KUWK%U?ZC!>7;!I"CJ5! & 5Z8 KVLEQ6'PF+] MM7V2=M+ZO_@7,ZD7*-D?(U%?0]W^RW&238>)V4=EFM,_J&'\JQ;O]F+Q#'G[ M'K6GS^@=73^AK[^&?9=/:I]Z?^1R^RGV/$J*]6G_ &<_'<6?+33Y_P#KG=8_ M]" K.G^!'Q!@S_Q)5D_ZYW,9_P#9JZHYI@9;58_>B>278\ZHKMI?@[X_A^]X M:NB/561OY&JDGPP\;Q_>\,:C^$)/\JV6-PKVJ1^]"Y9=CE**Z4_#GQDIP?#& MJ_A:N?Z4J_#?QF_W?#&J?C;,*KZUA_YU]Z#E?8YFBNOB^%'CJ;[GAB__ .!( M%_F:OP?!'X@SXQX?DC_ZZ31K_P"S5$L=A([U8_>A\LNQP-%>I6W[._CV?'F6 MUC;Y_P">MVI_]!S6[8_LPZ_+@ZAK=A;^HC1Y/\*Y9YQE\-ZJ^6OY#]G-]#Q" MBOI;3/V8-'AP=6UZ\NCW6")8@?SW&NQTGX&^ M)8.NC_ &QQ_%>2M)^G3]*\ MZKQ-@(?!>7HO\[%JC)GR!9V%YJ$PAL+2>ZE/1(8RY_(5Z'X<^ OC77BDES9I MI5NW)DO'PV/]P9/YXKZST_2=.TJ$1:98VUG&/X8(E0?H*MUXF(XJK2TH04?- MZ_Y?J:*@NIY%X3_9W\,:(8Y]=>36KI>=L@V0@_[@Z_B37J]K:6]C:I;64$=O M!&,)'$@55'L!4U%?,8G&8C%2YJTV_P"NVQLHJ.P4445R%!1110 4444 %%%% M !7@7[3^N!+#1M"C?YI)&NI5![ ;5S^);\J]]KXZ^.>N?VW\5]156S%8!;1. M?[HRW_CQ-?1\-X?VV/4GM%-_HOS,:SM$\[HHHK]0.,*55+N%499C@ =S25U? MPRT$^(_B3HNG[=T9N%EE'^PGSM^@K.M4C1IRJ2V2;^X$KNQ]@>!M$7P[X%T? M2U7:UO:H)!_MD9;]2:WJ**_$ZDW4FYRW;N>BM$%%%%0,**** "BBB@ HHHH M***BN[F.SLI[F8XCAC:1R>P R?Y4TFW9 ?)W[0NN_P!K?%"2TC?=#IL"0 >C MGYF_F!^%>65H:_JLFN>(M0U28DO>7#S'/;=)W M=PHHHKJ$>B? O0QK?Q7TXNNZ*Q#7;\(K[%KP3]F#0O+TS6-=E3Y MII%MHF([*-S?J1^5>]U^7\1XCVV/<5M%)?J_S.VBK1"BBBOG#4*^5/VC]=&I M?$6+38FS'IELJ,,_QO\ ,?T*_E7U3)(L432.<*H+$GL!7PAXNUEO$/C'5=6< MY^UW3R+[+G@?EBOK>%L/SXJ59_97XO\ X%S"L[1L8]%%%?HQR!7:_"'11KWQ M5T2UD0O%',;B3V$8+C/X@#\:XJO?OV8-"+WVLZ[+'\L:+:PL?4_,_P"FW\Z\ MS-L1]7P-2IUM9>KT+IJ\DCZ+HHHK\?.\*1W6.-GD8(BC+,QP /6EKP'X^_%/ MR(Y?!^@3_O7&-0GC;[H_YY ^I[_EZUW8'!5,=75&G\WV7 M,]:.E:3*PT6R0C^M;8>2A6A)]&OS$]CX)HI6!5BK<$'!I*_;3S@K2\ M..(_%.E.QPJWL))_X&*S:='(T4BR1G#*0RGT(J9QYHM=P/T&'W1]*6J.B7Z: MIH-A?Q$%+JWCE4C_ &E!_K5ZOQ"47%M,](****D HHHH **** "BBN=\?ZXO MAOX?ZSJC,5:&U<1$?\]&&U/_ !XBM*=.56:A'=NWWB;LKGQ]\1M=/B/XC:UJ M7F>9')=,D3#H8T^5/_'5%EZRD2ZGH(Y!]*^^J\Y^+7PKM?B!I/VFS"0:W:H?L\QX$H_Y MYO[>A[?G7T^19Q]3G[&L_:/J4^GZG;O;75 MNY26*08*FJM?I::DKK8XPHHHI@%%%% !1110 4444 %%%% !1110!M^'_&7B M'PM.)=!U:YM,')C5\QM]4/!_*O6_#7[36HV^R'Q3I45XO0W%H?+?ZE3P?PQ7 MA-%>?BLMPF+_ (T$WWV?WHJ,Y1V/M'PY\8?!7B;:EIJ\=K.W_+"]_3:7,W5;R+"@_P"\,C\\5\YB,DQ^'^*G==UK_P $V52+ZGIE%5-. MU;3M7@\[2KZVO(_[]O*KC]#5NO'<7%V9H%%%%( HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH IZOJ$6DZ+>:A.=L=K \K$^B@FO@J M_O9=1U*YO;EMTUQ*TKGU+')_G7UK\?=>&C?"N[@5MLNI2+:ICT)W-_XZI_.O MD*OT+A7#\M"=9_:=ODO^'.2N];!1117V)@%>Y?LQZ%]I\2:KKY8XY*YVK^BY_&OG^(L1[' 22WE M9?Y_@C6DKR/3J***_+#M"BBB@ HHHH **** "BBB@ K@?C7KIT'X4ZH\;[9K MM1:Q\]=YP?\ QW=7?5\\?M/Z\&FT;08VY0-=RC/K\J_R:O5R?#_6,=3ATO=_ M+4BH[19\^T445^O' %%%;'A+1F\0^,-*TE5W"ZNDC;_=S\Q_+-3.:A%SELM0 MW/K[X2Z#_P ([\+]&M'7;+)#]HE_WI/F_D0/PKLZ;%&L,*11C"(H51Z 4ZOQ M2O5=:K*K+>3;^\]%*RL%%%%8C..^+&N?\(_\+]:NU?9*\!@B]V?Y?Y$G\*^) MZ^D/VGM<\K2-'T.-OFGE:YD'^RHVK^K'\J^;Z_3.&T>\G?Y+3_ #.. ML[RL%%%%?3F(5]C? W0_[$^$^F[UQ+?;KM^.N\_+_P".A:^1=(T^35M:LM/A M!,EU.D*@>K,!_6OO6PLXM.TZWL[=0L5O$L2 =@HP/Y5\9Q7B.6C3H+J[_=_P MYT4%JV6***Y[QOXRT_P/X8GU;4FR5&V"$'YII#T4?U/85\'3ISJS4(*[>QTM MV5VODKT,A_IZGZ5\A3327$\DT[M)+(Q9W8Y M+$\DDUH^)/$6H>*O$%UJ^K2F6XN'R?1!V4>@ XK+K]8RG+89?0Y=Y/=_IZ(X M:D^=A1117KD!7LOP*^%I\2:DOB37(/\ B56C_N(G'%S(/YJ/U/'K7'?#'X?W M'C[Q.ELQ:'3;&/B+K&FE-D0N&E MA';RW^9?T./PKEJ^E_VC_ [:CI%OXJT^'=/8CRKL*.6B)^5O^ DG\#[5\T5^ MO93C%C,'"IU6C]5_5S@J1Y96"BBBO5(/JG]G?QE'K/@LZ!P5\&>&?$NI>$O$%OK&C3>75=>ZL.X-?6G@+XP>'/&MK'& M;F/3]4P!)9W#AEKXN\2?%OQ1XF\16FIW5WY$=E M.L]M:0$K'&5.1Q_$?'M:M_$7AVPU>SSY-Y LJ@]5R.0?<'BO0S'**V7 MTX3J._-VZ/L1"HIO0T:\7_:8UPV7@FPTB,X;4;K>_ND8SC_OIE_*O:*^3OVB M]<_M/XG&QCDW1:9;)#@'@.WSM^/S ?A6W#^']MF$6]HZ_=M^-A57:!Y/1117 MZH<05);P2W5S%;VZ&269PB(.K,3@#\ZCKN_@QH7]O?%?2(F&8K5S=R?2,9'_ M (]M'XUAB*RH4957]E-_<-*[L?7OA_2H]#\-Z=I<( 2SMHX1COM4#-:-%%?B MLI.4G)[L]$****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH X#XG?"G M3/B#I_G+ML]8A3$%V!][_8?U7]1V]*^2O$?AK5?"FLRZ9KEH]M/S?K7GU%85L+0K MJU6"EZH:DUL?0.C_ +4,H*IK_AY&'\4MG,1_XZV?YUWVD?'WP'JC!9=0FT]S MVO("H_-RO2>0()U M<_D#FM.OSX21XFW1NR,.ZG!KH=*^(7B[12O]F^(=0B5>B&/6X3E M_P NJOWK]5_D:*OW1]S45\EZ9^T3XYL6'VN6RU!1VGMPN?Q3%=9I_P"U'*,# M5?#2'U:VN2/T8'^=>35X;S"GM%2]'_G8T5:#/HBBO(K']I+P7N M^!64?BK'^5=+8_&7P#?@>7XCMHF/\-PK1X_%@!^M>;4RS&T_BI2^XI3B^IW% M%8]GXO\ #FH$"QU[39R>@2Z0D_AFM=6#J&4A@>A!ZUQ2A.#M)6+%HHHJ "BB MB@ HHHH **** "BBB@ HHH/ H ^:_P!IW7?/U[2=#C;Y;:%KB0?[3G _1?UK MPJNM^*6N?\)#\3=;OE??$+@PQ'_83Y1C\L_C7)5^Q97A_J^"IT^MM?5ZLX)N M\FPHHHKT2">RM9+_ %"WM(!F2XE6) .Y8X'\Z^]=%TV/1M"L=-AQY=I;I"N/ M]E0/Z5\B? _0AKOQ6TP2)NAL]UV_']P?+_X\17V17Y_Q7B.:K3H+HK_?_P , M=5!:-A1117QAT!1110 4444 %%%% !1110 5\7_&37?[?^*NKS*VZ*VD^RQD M'C$?!_7-?7GB75H]!\+ZEJDIPMI;/*/J!P/SQ7P=/-)?XCV&7SMO+3[]_PN:4 ME>9[%1117Y0=P4456U*^BTS2[J^N3MBMH6E<^RC)_E32;=D!\D?'G73K7Q6O MHE;=%IR+:)[$#+?^/,:\VJUJE_+JFK7=_.=TES,\K$^K$G^M5:_:<)06'P\* M2^RDCSI.[N%%%%=(CTSX!:$=8^*EI.Z[H=.C>Y?COC:OZMG\*^O:\)_9BT'R M-!U;79%^:ZF6VC)_NH,G]6_2O=B<#)X%?EO$6(]MCY16T4E^K_%G;15HE;4= M1M=)TVXO]0F6"VMT,DLCG 4"OC3XG_$*Z^('B=[DEH].MR4L[3_OLT?:KC_GO)_WV:BHI60$OVJX_Y[R?]]FC[5Y5^6\0UU5Q\DMHV7^?XL[:2M$CN+>*[MI+>YC66&5"CH MPR&4C!!KY#^+GPJNO FKO>Z?&\VA7+YAEQGR"?\ EFW]#WK[ JO?6%KJ=C+9 MZA;QW-M,I62*1'L>?K7B%_IU[I5X]IJ=K-:7$9^:*9"C#\#7Z?@\PP^ M-AS497\NJ^1QRBX[E:E!*D$'!'0BDHKN).ATSQ]XLT= FF^(=1@1>B"X8J/P M/%:$_P 6O'=Q'L?Q/? 8Q\C[3^8KCJ*YI83#R?-*FF_1#YGW+VH:WJNK/NU3 M4KN\/_3>9G_F:HT5-:VEQ?726UE!)<3R'"11(69C[ 5NE&$=-$(AKZ9_9I\4 MF^\.7WARX9C)I[^=!D_\LW/('T;)_P"!5PW@G]GGQ!KCQW/B9CHUD>3&1NG< M>FWHOX\^U?1OA7P=HG@S2Q8Z!9);I_'(>9)3ZLW4U\9Q!FF#JT'AH/FEY;+Y M_P"1T4H23N;,TR6]O)-,VV.-2[,>P R37P;XEU=M?\4ZGJSC!O+J28#/0%B0 M/P%?7_Q@UT^'_A7K-S&P6:>+[+']9#M./?:6/X5\64<)X>T*E=]79?+5_F@K MO5(****^U.<*^@_V7]"4OK>OR1_,NRSA?TS\[C_T"OGROLOX*:$V@_"C28Y4 M"S7:F[DQW\PY7/OMVU\WQ+B/98%P6\FE^K_(UHJ\COJ***_,#M"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** ([BWANK=X+F))HI%*O&ZAE M8>A!KPGXB?L[079EU+P*5MYCEGTZ1L(W^XW\)]CQ]*]ZHKNP>/Q&"GST96\N MC]43**DM3X!U/2K_ $74)+'5K2:SNHCAXID*L/\ /K52ONGQ7X(T#QI8&VU^ MP2<@?NYE^62,^JL.1].E?.?CK]GW7_#IDN_#A;6K <[%7$\8]U_B^H_*OT'+ M^(<-BK0J^Y+SV?H_\SEG2<=CR*BG.CQ2,DBLCJ<,K#!!]"*;7TAB%%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 H)!R#@U8@ MU*^M3FVO;B$_],Y67^1JM12:3W Z"U\>>+++'V7Q)JD>.F+M_P#&OHO]GW5O M$?B'P_J6J^(]5N+^'SU@MA.V=I498_\ CR_E7RI7VM\)-#&@?"W1;4IMEE@% MQ+_O2?-_(@?A7R?$OL:.$2C%QPG_"E/A[_ -"W#_W^E_\ BJ/^%*?#W_H6 MX?\ O]+_ /%5W=%']H8S_G[+_P "?^8QSGASP!X8\(WCN,5^J\/X?V& BWO+7[]OPL<55WF%%%%>\9#HT:618XP6=B%4#N3 M7W;X.T9/#W@O2=*1=IMK5$?W;&6/YDU\@?"G0?\ A(OB=HUFR[HDG$\O^['\ MQ_EC\:^V:^#XLQ%Y4Z"]7^2_4Z:"W84445\0=(55U+3K75],N-/U&+SK6Y0Q MRQEB-RGJ,CFK5%--Q=T!PG_"E/A[_P!"W#_W^E_^*H_X4I\/?^A;A_[_ $O_ M ,57=T5V?VAC/^?LO_ G_F3RQ['"?\*4^'O_ $+ MQPG_ I3X>_]"W#_ -_I?_BJ/^%*?#W_ *%N'_O]+_\ %5W=%']H8S_G[+_P M)_YARQ['"?\ "E/A[_T+QPG_ I3X>_]"W#_ -_I?_BJ/^%*?#W_ *%N'_O] M+_\ %5W=%']H8S_G[+_P)_YARQ['"?\ "E/A[_T+IK0HHKDE*4Y.4G=LH****D K,UGPWHWB*V,&MZ9:WT>.DT88CZ'J/ MPK3HJHRE!\T79@>2:S^SCX-U%B^GO>Z6WI#+O7\GR?UKE;O]ELY/V'Q1@=A- M:9_DU?0M%>M2SO,*2LJK^=G^9FZ<'T/FH_LO:QNX\161'KY#?XU>M/V6Y,@W M_B=<=Q#:?U+5]#T5O+B+,FK<_P""_P A>RAV/(M&_9O\':>P?4IK[5&_NRR" M-?R3!_6O1]$\*Z%X;@$6AZ5:V2XP3%& Q^K=3^-:U%>9B,?BL3_&J-_/3[MB MU&*V04445QE&3XB\+Z/XLT]+'Q!9K>6R2"58V=E 8 @'Y2.Q-_\ M0MP_]_I?_BJ[NBNFGB\12CRTZC2\FT)Q3W1PG_"E/A[_ -"W#_W^E_\ BJ/^ M%*?#W_H6X?\ O]+_ /%5W=%:?VAC/^?LO_ G_F+ECV.$_P"%*?#W_H6X?^_T MO_Q5=O;V\5K:Q6]N@CBA0(B#HJ@8 _*I**QJXBM6LJLW*W=MC22V"BBBL!A1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <;X MS^%?A?QO&[ZE9""](PM[;824?7LWX@U\^>,_@#XG\-E[C1U_MNQ!)#6ZXF0? M[2=_^ YKZUHKV<#G6+P7NQE>/9_IV,Y4XR/SXDC>*1HY49'4X96&"#]*;7V] MXL^&OA;QG&QUG3(_M)7"W,-*TJ,9^U721M[+GD_EFON]$6.-4C4*B@! M5 X ]*^5OV<-"_M+XBRZE(/W>F6S.#C^-_E'Z%C^%?5=?G/%.(Y\5&BOLK\7 M_P "QUT5:-PHHHKY(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH *1F"*68X"C)/I2URGQ-UW_A'?AKK6H*VV06YBB_WW^4 M?SS^%:T:;JU(TX[MI?>)NRN?('CK7/\ A(_'>L:J#E+BZ^@/\ !/&&Q[CT/N*\B\4_LU:+?^9/X6OY=+F) MR()LRP_0'[P_,_2O;:*[L+F&*PCO1FUY=/NV)E&,MSXN\3_!_P 9^%3(]WI3 MW=JG_+S9?O4(]<#YA^(%<0RE6(8$$=01TK]"*YCQ'\./"?BO<^M:+;RSL,&X MC7RY?^^EP?SKZK"\5R6F)A\U_D_\S"5#LSX=HKZ)\1?LPPN3+X5UMH_2"_7< M/P=>GY&O*O$/PD\:^&M[WNB33P*?]?:?OE(]?EY ^H%?3X;-\%B=*=17[/1_ MC^AC*G*.Z.+HI71HW*NI5@<$$8(I*]0@**** "BBB@ HHHH **** "BBB@ H MHHH ***5$,DBH@RS' 'J: /J7]FS0A8> ;K59$Q+J5T=K'O&@P/U+5['6'X+ MT3_A'/!&D:00%>UM420#^_C+?^/$UN5^-9AB/K.+J5>[_#I^!Z$5:*04445P ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%>%_M.Z[]G\/:3HD3X:ZG,\JC^Z@P/U;]*]TKY"^/NN_VQ\5+N!&S%IL:VJ_ M4?,WZL1^%?0\.X?VV/C)[1N_T7XLRJNT3S.BBBOU(X@JUI=A)JFKV=A "9+J M=(5QZLP']:JUZ5\!-"&L_%6SED3=#I\;W3<< @87_P >(_*N;%UUA\/.J_LI ML<5=V/K;3;&/3-*M;& 8BMH4B0#T4 #^56:**_%FVW=GHA1112 **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** ,+7?!'AKQ-DZYHMG=OC E>("0#V<J[Z#J%YIDI MY59")XQ[8.&_\>KVBBN[#YCB\-_"J->73[GH2X1>Z/E#7/V<_&6F9;3#::M' MV\F3RW_[Y? _(FO/=8\)>(- D9-9T:]L]O5I8&"GZ-T/X&OO&D95=<, P/4$ M5[]#BK%0TJQ4OP?^7X&3H1Z'Y[T5]P:Q\,_!FN[SJ/AVQ9Y/O2Q1^4Y/KN7! MKA-7_9I\*7:.=*O=0TZ0_=!<2H/P(R?^^J]RCQ1@YZ5$X_BOP_R,G1ET/EJB MO;M4_9B\06ZEM)UJPO6F.OGV[QX_,51KT8R4 ME>+N0%%%%, HHHH *ZWX7:&/$7Q-T2P==T7V@2RC_83YS_+'XUR5>[?LPZ'Y M^O:OKG:99R?5B3_ %KZ MW^.NO#1/A3J"*VV;4"MI'S_>.6_\=!KX\K]!X4P_+1G7?5V^[_ASEKO5(*** M*^R.<*^D_P!F+0?(T+5M=D7FZF6WC/\ LH,G]6'Y5\V5]M_"W0AX=^&>C6)3 M;(;<32C_ &W^8_SQ7R_$^(]G@O9K>3_!:_Y&U%7E@K)GG-_\!OA_?,6&CO:N>]O?_'37T_17;#B+,8[S3^2 M)]C ^2;C]G;Q[#_J[>QG_P"N=V!_Z$!7O'P<\%WG@CP&MCJL:QW\\[SSHK!M MI^Z!D<'A0?QKOJ*QQN=XK&T?8U;6O?1?\$<:<8NZ"BBBO%- HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YQ_:?UWS M=4T?0HVRL$;74@'JQVK^@/YUX)79?%C7?^$@^*&M7:OOACG,$1_V4^7^8)_& MN-K]ARK#_5\%3I];7?J]3@F[R;"BBBO2(-WP5HC^(O&^D:4B[A<72!_]P'+? MH#7W6BJB*B !5& !V%?+?[->A_;_ ![=ZJZY33;8[3C^.3Y1^@:OJ6OSCBG$ M>TQ<:2^ROQ?_ +'715HW"BBBODS<**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "L;QAK2^'?!NJZLQQ]EM7= M?][&%_4BMFO'_P!I'7CIWP^@TR)L2:E1@JCU).!0!]5? MLXZ$--^'#ZC(FV74KEGR1U1?E7]0Q_&O7*R?"NCKX?\ "6EZ2@Q]DMDC;W8# MD_GFM:OQC'8CZSBJE7NW]W3\#T(JT4@HHHKC*"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY6_:0UX:E\0H M-,B?,>F6P5AGI(_S']-M?5-?-OBOX"^-O$OBW4]8>[TD?;+AY5#3OD*3\H^Y MV&*^BX>J8>CBG6KR4;+2_=_\ RJIN-D>$45[!_PS3XT_Y_-(_P# B3_XBC_A MFGQI_P _FD?^!$G_ ,17WO\ ;&7_ //U'+[.?8\?KM?A#H7_ D/Q2T>U==T M4,OVF7_=C^;^8 _&NK_X9I\:?\_FD?\ @1)_\17H_P &OA%JO@'6]0U+7Y;. M626!8;?[,[-MR7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4ZYSQE\1 M/#7P\AT^7Q+K5IHT>H7265JUW)M$LSG"H/\ 'H,C)KHZ^=/&FAV_Q4\%_%WQ M9J8D;3TTC4-"T4J 3';0*QGGCR2-TMQ'][NMO%0!]%4M9'A'5AKWA71M3564 M7ME!(KSPYI=W-IGA?391%K6J6SM'/=S8!-E XY10"/-E!R,[%PV MXKB_$KPIHGA/6/A7%H&D6FEZ@/$\4-M_9\:0/Y)MYVN0< %D,:L6'? /4"@# MVBBBB@ HHHH **** "BN+@\;75Y\7;SPG;VT36%AHL6I7EUN/F)--,Z0Q@=, M%89F)]A7:4 %%%% !117%?&3QG+X"^'.KZK:%/[494LM-60C:][<2+!;*<]O M-D3/MF@#S37O =W^T;X@U_4)?$.L^'-$T"XDTWPU/H]RT##4(CB?4&QQ*$D! MA1'RF(Y20=X(] ^"7CK4/&W@UDU^.&W\7:-<;* /6:*** "BBB@ HHHH **** "BBB@ M HHHH \P_:$^)US\,_!=B-,M7O?$/B+5+;P[I$*-MVW5R2JRL<'Y8U#RGU$9 M'&:L^+O"MIX-_9]\0>']/7%GI_AJZM8N "0MLXW''Y(Z_Z MAZ #X3_\DK\&_P#8%LO_ $0E0_%#Q'>Z'H$-GHYQXAUF==,TWC(CE<$M,1W6 M)%>4^HCQWJ;X3_\ )+/!WY8FO M-_#-Q_PM#XU:IKRJLGA[P8LNBZ;-C(N-1DVF]E4^D2JD Q_$9QVK4^,WC#5- M/M=,\*>%Y"GC'Q,[VME,$WKI\"@?:+YQD#;$C# /WI'C7^*NO\&>$=.\!^%= M-\/Z1$8=/L(1%$&.7;NSN?XG9B69CR68D]: ,KQ]XVG\._V?I6D6BZGXHU9G MCTZQD?9& HS)/,PY6&,$%B!DEE5+_A-X+N_',?CO4-8U.PDMVN M=)N[:W33;Q7F2-H8XEC\R)FWX1A(S;L9W9(/4?"B-O%FN>)_'=P5E74+M],T MA@;,)I2>ZF/^Z*R/$,C?&'XNV7AVW+'PIX*NH=3UB=20EWJ8 M >UM >XB!$\@[-Y _O4 >RT4E+0 445#>7<5A:S7,[B*"%&DDD8X"J!DDGZ" M@#S+X1QIJGQ ^*WB 2"03:W#I495]R^7:6L2D8ZJ1+).".G&1UY]3KS?]GJW MN6^%.E:I?0F"^UR2XUR:-OO*;J=YU4\ Y"2(O/(V@=J](H **** "OGK]H;4 MG\1?'#X$> XF8Q7&N3^)+Y%X_%4=7<_*B@L>!5?X3^!;CP3X?N M&U6ZCU#Q+J]T^IZS>QJ0DMTX *H#R(XT5(T']V-<\DUXMX1\?77PKU.X\2?& M'P=X@TO7;I!;W'C-O*U'3+:'AO*7[,6-G &/)9 &*[G=C@U]+:?J%KJUC;WM MC<0WEG<1K-#<6\@>.5&&596'!!!R".M %FBBB@ HHHH **** ,SQ+XDT_P ( MZ#?ZUJURMIIUC"T\\S9.% Z #DD] HY)( Y->?Z?X?\ &_Q C.L:GXCU#P- M[++IVAZ7% TT"#.TWDDB/YCMD%HTVJOW%?",\J.--T#321F[O MI 1&,?W$PTCG^%(W/:@"7X(^.+WXC?"_0_$&HQQ1:A<))%^!=#\.QR_:/[.M(X)+C;M\^0#,DI'J[EF/ MNQKI: "BBB@#Y$\'_%G6]8_:S^,U]HG@;Q#XMAT>#3/"UL]K]FMK>%X1-/N_#CQJ.W)@>@#*^$NH7.@_ KPM?>(+BU,EIH-O/E5M/*_'SQ\EW&$D^&/A.\'V)HF!BUO58B09..&M[9AA>S3J6Z1+N -_ MX0^%=4N+S4O'OBJU^R^*]?54CL9.6TG3U.8+(')^;DR2$<&1V[*M;WQ@\3S> M#OA?XGU:U;9?6]A*+0Y S<,-D(Y(&3(R#D]Z[&O$/VM?&UCX5^'6F6,UN-7U M+6->TRTLO#T+)]JU9A>1.\$(8@9VH26) 0 L3Q0!<\1:M=_#+P=X2^&?@Z2" MX\<7E@ECIWFJ7CM(88U6;4)QG/EID=>7D=$_B)'2Z7I_AK]GOX6SM/3NVZ2:0@9DFED;/ RS, !T%>2WO@G7_A#H=W\6-4UF2;X@ZE MJ%DNMVGVEI]--K+=I"NGPAQN2.$3L4==I:3*;82W&ORZ;H%F;EYIK8(EHDN& CC\Z99-\A"!H5R: +]K\3_B';_$/P%I^ MKZ=HMC#XJFN6D\,HLLFH:98Q0-)]JEN QC+!_)C= @4-.JJ[$9/J5CXXM+[Q M_JWA+R)HK_3["UU'S7V^7-%,\R#9SG*M"0^-WAD\ M=Z]%'#):6\GF6VC62$M%8P-CYL%BTDG'F2$GA0@'EOQ.U37/$O[5&H^!_"6H M3Z-K>I>$K&*^U>%?GTO3?M5TTUQ$Q&/.8[(8\YPTA?&$((!]+67B'2]2U&]T M^TU*TNK^Q*BZM8)T>6W+9V^8H.5S@XR!G!KPC]I#X876H:#K.I2^._&+3:Q) M#HUAH.GZHME9*]U(D &V.+<^ [,2Y;@-VZ>H_#_X+^"?A?)YWA?PU8:1>-;" MTFOH8A]IN4#%_P!]*?FE8L2Q9R2222>:S/B HU_XI?#S06A6:WMI;KQ!<;@< M+]GC$4/8C/FW*L,D?ZO(Z$4 3?#/X,V_PJF$>E>*?$VH:.EHMI%I&M:D;Z" M)@(T;2 R*0HVXW[2#TR,UZ)24M !1110 AKY]_9#G?Q%9>./%;SK<#5]8;:\ M;R[2HW3<))]W_CY(XXX]J]:^*FN-X8^&/B_65W;M.T>\NQM;:.HOA]X7EU'[.^H:E,ZVFFZ;"?WM]=OQ%"H]SR3_ JK,>%->5^%?A[) MI7C+PCX,UF_.HQVNF7?B;5]NY$U/59+N(F5QT=$=Y"$/3,>&M O[EEU?Q%<2 MV^G6L4;2-*8HFED8X'RHJKRQP 64=2*LZUXUT#PWINKZCJNLV&GV.CIYNHW% MQ7&DWT- MM(P."!,\(CQ[[L>]>B?$KQ=)X-\'7>HVD0NM4E*6FFVW7S[N5A' G4<%V4GT M4,>U=2RAE((R#P01UKQ?XL^+]&T?XF:#=^([^/3_ WX1T^;Q!>2S(64W4I- MM:(H ):0AKG:@RS-MV@F@#JK231_@+\*_/UF^EG@T^,S7MYY9DN+Z[DO\ Q(\16WCWQO92Z1;VY+^&_"=QC=IR$$?:[L X M:[=2<+R(5)49(=1\(_"7QIKND';JNFZ+>7EHWEA\2QPNR':?O8(! MQWH Y_XC?M&>$/AKK TBZ;4-9U=0'N;+0K)[U[",C/FW3(-MNF.&_VEO"_C+Q%H?A_1(+Z]U[4'9KC32B)+I]J(O-%Y-\VTP.&B"21EULO\0OC3\1O%^JZ(="OQ8:9I^B6-W&([N+12LDTTVSF:&XU"U@E7K').JL/P)HH X7]G706\-_!W0;)S(9B; MFXE\T8822W,LKCZ!G8#VQ71_$[/_ K?Q4 CR%M*NE"1H79B86 4 DD^@KI M:6@#YQ_:0\-^(/%%M\)/#\&L_P#".^&K_7K6VU2[L7DCU3=]FF*QP,/E16"L MK,?F7.5Y&:]^T#0=/\+Z+8Z1I-G#I^EV,*6UK:6ZA8X8T 544=@ !63\0_ M MO\0O#4FE37=QILZ30WEIJ%IM\ZTN89%DBF3<"I*NHX(((R",$UXMJ'QF\>^' M?B%9> ;B[\/ZAJ=P55=;_LJ:) /FY:W%RH(Y! (Y% 'EOQ8O(_B%\3O!GPZLF M\^*QO(?$_B+8 R06MNQ:TBD]YKE8R%ZE8)#T'.E\8-+UW1?$WA3Q]X=TN?7Y MM"%S::GHUFRBYO-/N%0R&'<0K2QR0Q.J$C< Z@Y(KK/ /PS\,?#*PNK3PUI, M6FQW-N5/'>N-\(_#:_T?XW?$+QO?SV]Q#KEIIEAIJKS);P6R M2F1&XX#2S.W!/:O2:* "N9M_"9'Q$O?$TQB9FTR'3;;:#O11*\DN?9B8\8_N MUTU% !1110 4444 >0?M>1SW'[,?Q,MK:9[>:YT*YMEDC!9E\Q=AP!R>&/ Z MUIZ7XSMO#/AK2- \,^&MEON 9G M;'SS, S 8 5?EJM\2OACKWB;Q-I'B/PIXL7PEK=G9W.FRW$NG+?)+;3-&YPC M.H617B1E8Y'4%2#7I-% '*_#7X<:5\+O#2Z/I;7%P9)GN[S4+V3S;J_NI#F6 MXG?^*1SU/ '":_^RKX1\3>*-3U#4M0UZXT+5+L:C?^$?[18:-=W0VD MS2P 9?<44M&6\MB,E#DU[+10!P/@GP?J/A7XC>.[H1Q#P]KDEGJ-LR,-R7*P M"WG0KUQM@@8'I\Q ''-3X(^#]7\*6?C.?7+86VH:SXIU'5!B<3;[=Y ELV1T M_<1Q#;VQ@UZ310!#=Q236\J0S&WE9&5)0H8HQ'#8/!P><&OF[X4_"V&^_:-\ M?:KXVU63QSXG\/1Z6NEW^H01P):1R0RL&BMXP(PVYI0)2"XRX##D5]+UY[XV M^$*-'\1:KX0\4PVAL3J6E>4ZW%OOWB*>&9'CD"L6*DKN4NV#R00# MT$D+UZ5'=6T5Y;R03QI-!*I22.10RNI&""#U!%>>*]+H \F\*?LN?#OP?J]GJ-MI-SJ$V MG2;]+AUC4;B_M]+X 5;6&9V2$+@;=H!7H"!70>/O@GX)^*%Y;7GB;P_;ZC?6 M\?DQ7BO)!<+&6W>7YL;*Q3/.TG'7CFNYHH XW2?@[X(T.PBLK+PGH\=O'G:' 3LHY&.3DDLP+,? GRAPHIC 19 pfe-20241231_g11.jpg begin 644 pfe-20241231_g11.jpg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pfe-20241231_g12.jpg begin 644 pfe-20241231_g12.jpg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end GRAPHIC 21 pfe-20241231_g2.jpg begin 644 pfe-20241231_g2.jpg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end GRAPHIC 22 pfe-20241231_g3.jpg begin 644 pfe-20241231_g3.jpg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end GRAPHIC 23 pfe-20241231_g4.jpg begin 644 pfe-20241231_g4.jpg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end GRAPHIC 24 pfe-20241231_g5.jpg begin 644 pfe-20241231_g5.jpg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end GRAPHIC 25 pfe-20241231_g6.jpg begin 644 pfe-20241231_g6.jpg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end GRAPHIC 26 pfe-20241231_g7.jpg begin 644 pfe-20241231_g7.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@! M% *@ P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH *YGXR_$RQ^#?PNUOXH:GIDU[;Z+9&YEM8'" MO( 0, G@'FNFKRC]N?\ Y-'\>_\ 8!?_ -#6@#TKPYK,7B/P]8>(8(6C2_LH MKA(W.2@= P!]QFKM87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ MT-: .Z^%W_),_#O_ & K3_T2E;M?RO67_!4'_@HGIUG%I]A^VG\1X8((ECAB MC\57 5$48"@;N ,5+_P]._X*/?]'M_$K_PJ[C_XJOT+_B'F8?\ /Z/X_P"1 M^=?\1'R[_GS/\/\ ,_J_Z/;^)7_A5W'_Q5'_#T[_@H]_T> MW\2O_"KN/_BJ/^(>9A_S^C^/^0?\1'R[_GS/\/\ ,_J_Z/ M;^)7_A5W'_Q5'_#T[_@H]_T>W\2O_"KN/_BJ/^(>9A_S^C^/^0?\1'R[_GS/ M\/\ ,_J_Z/;^)7_A5W'_Q5'_#T[_@H]_T>W\2O_"KN/_BJ M/^(>9A_S^C^/^0?\1'R[_GS/\/\ ,_J_Z/;^)7_A5W'_Q5 M'_#T[_@H]_T>W\2O_"KN/_BJ/^(>9A_S^C^/^0?\1'R[_GS/\/\ ,_J_Z/;^)7_A5W'_Q5'_#T[_@H]_T>W\2O_"KN/_BJ/^(>9A_S^C^/ M^0?\1'R[_GS/\/\ ,_J_Z/;^)7_A5W'_Q5'_#T[_@H]_T> MW\2O_"KN/_BJ/^(>9A_S^C^/^0?\1'R[_GS/\/\ ,_J_Z/ M;^)7_A5W'_Q5'_#T[_@H]_T>W\2O_"KN/_BJ/^(>9A_S^C^/^0?\1'R[_GS/ M\/\ ,_J_Z/;^)7_A5W'_Q5'_#T[_@H]_T>W\2O_"KN/_BJ M/^(>9A_S^C^/^0?\1'R[_GS/\/\ ,_J_Z/;^)7_A5W'_Q5 M'_#T[_@H]_T>W\2O_"KN/_BJ/^(>9A_S^C^/^0?\1'R[_GS/\/\ ,_J_Z/;^)7_A5W'_Q5'_#T[_@H]_T>W\2O_"KN/_BJ/^(>9A_S^C^/ M^0?\1'R[_GS/\/\ ,_J_Z/;^)7_A5W'_Q5'_#T[_@H]_T> MW\2O_"KN/_BJ/^(>9A_S^C^/^0?\1'R[_GS/\/\ ,_J_Z/ M;^)7_A5W'_Q5'_#T[_@H]_T>W\2O_"KN/_BJ/^(>9A_S^C^/^0?\1'R[_GS/ M\/\ ,_JVN/+T6^ECWHS$-MDC1QGH5![5^^M?+9YDU;(\7&A5DI-Q4KJ_5M=?0^KR+. MZ.?826(I1<4I.-G;HD^GJ%%%%>,>T%%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% 'AG[5/_!2W]A3]B;Q+I_@K]I[]I+0O"^N: MI9M>66A.D]W?-; D&X:WM8Y)4BRK 2,H0E& /RG'=?#?]IK]GGXO_!"/]I;X M:?&GPUK'P_DTZ:_/C"TU>(Z?%;PAC-)),2%B$>Q_,#E3&48,%(./(_'W@O\ M8D_X)M^+_C1_P4Z^-'CIM$O/'-OIK>,O$GB.\68PPV-O]GM=/T] @D ? Q;H M7:67! )QC\POBA\)OB_X9_X),^/O$7CSX6)< +*%(&64 'ZI_LS_P#!4W_@GS^V+\1)OA+^ MS;^U-X;\3^)(K-[N/1H#-;S7=NC%7FMA<1I]JC4@Y>'>H')..:D_:C_X*A_L M!_L7>,[?X<_M+_M.:!X:\0W-A]N&A>7<7EY%:\XN)8;6.5X(C@XDD"J<'!.# M7SO_ ,%R/#7ASX0>$/V6OCK\./#UEI&O_#G]I[P=IOAN?3;586@TJ]>2RO-- MCV ;+>: JC1K@$1KQQ7L/Q!T3]AG_@E'#\:?^"A/Q>\87&FW7Q)UBWU#Q=K& MMW*75Y?SPVPM[/2=/C"+)(-J8BM@6.68Y"@E0#W_ .$GQ>^%OQZ^'.D_%[X+ M?$#2?%/A?7+;[1I&O:'?)<6MU'DJ2CH2"0P96'564J0""*QK/]IWX":C^TA= M_LAZ?\3].G^)-AX3'B:_\)PEWN+;2C.EN+F0A=B R21@(S!R'#!=IS7Y^?L* M_$/X@?\ !+K_ ()G>,OCK\5/@?+/BMXF#MY-_KUUXOC25;=&_P!5:P0P6]I @"@0VL? )- 'ZQ4444 %>4?M MS_\ )H_CW_L O_Z&M=)\9OB;XO\ AEIEE?\ A#X.ZUXQDNIVCFMM%DC5K=0N M0[;R.">.*^?/VK?VC_BQXK_9U\7>'-;_ &2?&&AVEWI+1SZM?7$!AM5W+\[A M3G'T]: /YG:***_IP_EL**** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH ^QO^" ?_ "EN^$W_ ''O_3#J-?THLRJI9F M&22>E?S7?\$ _P#E+=\)O^X]_P"F'4:_HA_:(^&FK?&C]G_QU\'=!\2-HU]X ML\':GHUEJZ9S8RW5I+ DXQSE&<-QS\M?CWB#_P CJG_U[7_I4S]F\.O^1)4_ MZ^/_ -)@?+NB_P#!P?\ \$G/$'[7/_#'&E?M4:3)K;0QI;^)^!X?N-0:X:#^ MS8[_ #L:X&U7W8\@K(H69GR@]X_:W_;P_8__ &$/"MAXS_:Z_: \/^!K'5;A MH=*&K3LT]\ZX+B&")7EE";EW%$(3&1G:*V$9C M.&B'[J_ME?L0_LA_%Z;PS_P4QM/V9KWX\^+OAO\ #L1_"[P2FM?:=.UZVE1W MMPL%RLL#R-]I\P7+JS#;&Y+>6N/A#[X^B?V9OVKOV&0!E)CD56PRG&""?0J_'7_@U M\\20VWP]^(OB/XF1W^O_ +.T.ESVB^ K))[YH%C62-$D5C=-%F%=J);P9V^8 MBC]$_P#@HI^S/^T/^UU^ST/@7^SE^U5J7P-8ICNM;A3Y3.%,1#8.,G[6_[;O[*_P"PGX%TWXD_ MM8_&&Q\':/K&M1:3I5S=VMQ8!-VP[O-.)* /Z'**** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@#\L_P!JW]EK_@J]\6?^"G%Y^U)XF_8T M^'GQ?^''@"2.'X#^#/%'Q:&F:?HLZ@>;K<]H+65;F_D?)C>3_4+M"@LJ.OMW MQ\_9P_;@_P""G'[ _CSX&_M2_"/P?\%_B#%K6GZK\,=0\/\ C-M>M8=0L)H; MRUN9W%O&8U,\1A=0CD1NS $X%?;U% 'Y[>(O@7_P4Q_X*+_&'X*Z%^V[^S7X M*^$GP^^#GCZQ\=>)Y]#^(*Z[/XSUW3TD%A%:11PI]CLA,[32+<,SD;$Y*ECY MG\:OV8?^"N7C3_@IUXA_;*\<_L3_ X^+WAGP=?M9_L^>'_$_P 7QIVG^%;5 M'(.JBR%I*LFHW&V.4S2'=#PJ_;) M;II'C6T1!L=F@+#!C))-?IG10 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W M/_R:/X]_[ +_ /H:T ?R?45]]:+_ ,&W'_!2#7]&M-=L(? ?D7MK'/#O\4L# ML=0PR/)X."*M?\0T7_!2O_GCX!_\*IO_ (S7]!_ZQ9%_T$P^]'\[?ZMY]_T# M3^YGY]T5^@G_ !#1?\%*_P#GCX!_\*IO_C-'_$-%_P %*_\ GCX!_P#"J;_X MS1_K%D7_ $$P^]!_JWGW_0-/[F?GW17Z"?\ $-%_P4K_ .>/@'_PJF_^,T?\ M0T7_ 4K_P">/@'_ ,*IO_C-'^L61?\ 03#[T'^K>??] T_N9^?=%?H)_P 0 MT7_!2O\ YX^ ?_"J;_XS1_Q#1?\ !2O_ )X^ ?\ PJF_^,T?ZQ9%_P!!,/O0 M?ZMY]_T#3^YGY]T5^@G_ !#1?\%*_P#GCX!_\*IO_C-'_$-%_P %*_\ GCX! M_P#"J;_XS1_K%D7_ $$P^]!_JWGW_0-/[F?GW17Z"?\ $-%_P4K_ .>/@'_P MJF_^,T?\0T7_ 4K_P">/@'_ ,*IO_C-'^L61?\ 03#[T'^K>??] T_N9^?= M%?H)_P 0T7_!2O\ YX^ ?_"J;_XS1_Q#1?\ !2O_ )X^ ?\ PJF_^,T?ZQ9% M_P!!,/O0?ZMY]_T#3^YGY]T5^@G_ !#1?\%*_P#GCX!_\*IO_C-'_$-%_P % M*_\ GCX!_P#"J;_XS1_K%D7_ $$P^]!_JWGW_0-/[F?GW17Z"?\ $-%_P4K_ M .>/@'_PJF_^,T?\0T7_ 4K_P">/@'_ ,*IO_C-'^L61?\ 03#[T'^K>??] M T_N9^?=%?H)_P 0T7_!2O\ YX^ ?_"J;_XS1_Q#1?\ !2O_ )X^ ?\ PJF_ M^,T?ZQ9%_P!!,/O0?ZMY]_T#3^YGY]T5^@G_ !#1?\%*_P#GCX!_\*IO_C-' M_$-%_P %*_\ GCX!_P#"J;_XS1_K%D7_ $$P^]!_JWGW_0-/[F?GW17Z"?\ M$-%_P4K_ .>/@'_PJF_^,T?\0T7_ 4K_P">/@'_ ,*IO_C-'^L61?\ 03#[ MT'^K>??] T_N9^?=%?H)_P 0T7_!2O\ YX^ ?_"J;_XS1_Q#1?\ !2O_ )X^ M ?\ PJF_^,T?ZQ9%_P!!,/O0?ZMY]_T#3^YG _\ ! /_ )2W?";_ +CW_IAU M&OZ*_C9\/M5^+/P<\5?"[0O'^K^%+[Q%X=O=-L?%&@7+0WVCS30/&EY;NK*5 MEB9A(I!'S(*_)?\ X)5?\$.?VX/V/?V]O ?[1GQ@B\(#PYX=_M3^T3I?B!IY M_P#2-+N[6/:AB7=^\F3/(P,GM7['U^6\;XW"8[-85,/-3BH)73OKS2T_$_5N M!L#B\!E,Z>(@X26?@W7?@7X^\026FEZU#:VS6T M.H?*\<;3F,KNW21E'MXF7>&=*_1NBOCC[,_,3_@FK_P33_X*'?!;XG?M)?\ M!3K]J34O!5O^T9\9O#-S:>$?!GA^7@GG[/Y. M[G[VZO8J* /S_P#^"0O_ 3K_:3_ &-/VZ_VU?C]\;-,TB#P[\%[@D]J_0"B@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MKRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P M[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: M.Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ M /0UH [GX8.B_#7PZK, 1H5ID$_],4K=\R/_ )Z+^=>.45[O]C+^?\/^"?-? MZPO_ )]_C_P#V/S(_P#GHOYT>9'_ ,]%_.O'**/[&7\_X?\ !#_6%_\ /O\ M'_@'L?F1_P#/1?SH\R/_ )Z+^=>.44?V,OY_P_X(?ZPO_GW^/_ /8_,C_P"> MB_G1YD?_ #T7\Z\.44?V,OY_P /^"'^L+_Y]_C_ , ]C\R/_GHOYT>9'_ST7\Z\B_G7CE%']C+^?\/^"'^L+_ .?? MX_\ /8_,C_YZ+^= ="4BX56!+<.%7P#_P6-_9GUS]B+XB?MJ_%#P[XE\#1?"'6 M+O0OB=X&UVSC;6-%URW>*/\ LU41S'/)-)/ D+JX23SDR4(<+?\ VY/VX?@C M^P)J$?ACX4?!>'QM\>OBU.!X.^&/@VPACU;Q7=QH8TN[Z95_)OVF/&%CK_Q ^+G[8'A+QS\>-0TM"NF0 M2W>JVZM8VX;G[);A+>-2WWF#-P"J@ ^R?A3_ ,%5_B='\;OA]\(/VTOV!_&/ MP.M?B],]I\,O$FM>*-/U6UOM0$33IIMZMJV_3;R2)28XI VY@R9W*0+?Q4_X M*@?%/4?VC_&W[,O[#7["WB3XX:M\,%MH_B-K5OXQTW0-+TJ]N(?.BT^&XO6_ MTNZ\LAG1%"Q[@&<'('$_\' 0<_!K]GA=+/\ Q.C^V'\/O^$WOBW3M=T_6I;.$3W-E)/9-_HEVD)\P1 M.I5@K!7)P&M?\$\?V0/#_P"P#^S+_P (Q^U9\4O#6M_$'XH_%&Z\8>/M=U&2 M&"RU/QEJLJ,8;%)\9*F***%0 [F+>JJ6V+\U_MA^'OVF?V9/^"JW[.7[6W[; M/Q+T;XI_#+7/BQ=> ?A/X?\ #NC_ -B2?#_6]?26*SNYHMTQU@FWB:!YGDC$ M?S2)$&(% 'ZB4444 %>4?MS_ /)H_CW_ + +_P#H:UTGQFT3XY:WIEE%\#O& M^BZ'=I.QOI=:TQKE98]O"J 1M.>?$#XS^#]0T6/2 M6.HV5CX<>*:://M3%EH7A?1+O5M:O2A;R+2VA:::3 Y. MU$8X'/%?F+:?\%]OVSK?Q):_'WQ#_P $SKF/X"WWP_TOQ>AT_P 91W7BVW\/ MW^IR6=OKC621>7*KJ$?["C&1$82&8KD+^EGQRTKX5:_\%O%WA_XZZAIUIX)U M'PU?6GBZYUB_6UM(],E@>.Y,TS,JQ1^4S[G) 49.1BOQYDTG]N?_ ((^?%_5 M/B1^RU\<_"7[1OP>^&G[-.FZY;:7XVB%EJUOX BU*\DBM=.U*Q9H+R2"-7E2 MXECVM 0B(=B*?CC[\_5[]IO]L[]FO]C[X$7/[1_[0?Q1L/#_ (7AM%FM)KEL M7&HNR;H[>U@_UEQ.XQMB12Q[@ $C&_X)W?MEZ3_P4&_8U\$_MAZ%X#N/#-EX MUM[R>UT.[OUN9;9(;VXM1ND5$!+"#>0!A=^W+8W&P/ O[,O[9O@?X:?M?:_\ M)])\0W%EX7'B+X;ZGXATU)I]&34K6"?SHE?*/VIM&_8R_ M;(_8S\0_!'QWXP\.W>M?#]+WQ58:[IWB*"T"M>01W=D=L=U"K!VA9?N#=NP4 MW>=?\%^+R'QS\(?@]^RQX(\.2S?%/XE?&O28_@_XE&K_ &*+P?KEB)+M==D? MRI?,6W17_<;"91*0,$ UY#KGAG]IK]C7_@K'\ ?C=_P4^^.6F?&JS\2Z#K?A M'X6^*_#'AQ?#\7@?6)+,W%Y++ID1F^UF\@A\D3K-E I!B4;: /KK_@JS_P % M1?@M_P $HOV:7^/?Q2T>X\0:I?WRV/A7P9IMVL5WK-QC?+M8JWEQ11!I9)2I M50%'+.@/T=X&HM3MY'9Y_LWV5=0U PF MYGD$K;8UA@#X5EK]X/V*?VD_@K^UE^S3X8^,W[/_ (T_M_PU=6(LX-2_LZYM M=TUO^YF7R[F..0;9$92\BD:*!=JLRIM$ MCC>X9@#7JVG_ /!-K6/B7^R1\0?V0/VYOVLO&'QQT7Q\%1]6U[2M/TR\TE$$ M;Q&V-E$J"2.>-+A'=6Q(@R"!BOJ*B@#XS^$W_!*+XDCXV_#_ .+W[:'[?7C7 MXYVOPAG>[^&'AO7O#>G:9;:??F(PIJ-\UHN_4[R.([4FE(VL6?!9B3Q6M?\ M!$WXUV/[7OQ0_;+^#W_!4SXB^"?$_P 4]3$NL-8>"]%O&MK&)B+73HIKN&21 M+>"/8@52H;RU9@6 (_0&B@#Y+\3_ /!+2^^.W['FM_LI?MF_M@^._BE?7GBN M'Q#X9^(T]E8Z3K/A>]MUA-I)9-9Q+&KPRQR2!F5BWVB13E2 ,OX>?\$J_B5X MC^/7@;X]?MW_ +=_BOXZS_"R].H?#CPY?>$]-T+2].U+88UU.YAL4_TV\12? M+D=@L9+,J FOLBB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_ M]@%__0UH I45T?ACX?OXD\-:?XB751"+^QAN1"8=VS>@;;G(SC.,XJ]_PJ63 M_H/+_P" W_V5?5_VC@OY_P '_D?$?V1F'\GXK_,XZBNQ_P"%2R?]!Y?_ &_ M^RH_X5+)_P!!Y?\ P&_^RH_M'!?S_@_\@_LC,/Y/Q7^9QU%=C_PJ63_H/+_X M#?\ V5'_ J63_H/+_X#?_94?VC@OY_P?^0?V1F'\GXK_,XZBNQ_X5+)_P!! MY?\ P&_^RH_X5+)_T'E_\!O_ +*C^T<%_/\ @_\ (/[(S#^3\5_F<=178_\ M"I9/^@\O_@-_]E1_PJ63_H/+_P" W_V5']HX+^?\'_D']D9A_)^*_P SCJ*[ M'_A4LG_0>7_P&_\ LJ/^%2R?]!Y?_ ;_ .RH_M'!?S_@_P#(/[(S#^3\5_F< M=178_P#"I9/^@\O_ (#?_94?\*ED_P"@\O\ X#?_ &5']HX+^?\ !_Y!_9&8 M?R?BO\SCJV?A_P#\C=:?]M/_ $6U;'_"I9/^@\O_ (#?_95<\/?#Q]"UB'53 MJPE\K=\@@QG*D=<^]8U\?A)T)Q4M6GT?;T-\-E>.IXF$I0T33W7?U+OQ)^'? M@SXO?#O7OA1\1]!AU7P]XGT:ZTG7=,N,^7=V=Q$T,T+8(.&C=E."#S7YD6?_ M ;]?&^;XHS?L]>(/V__ (C7G[-J_#"Q\,C2'LM+36+K1X-2GN%\,2:@B"<6 MB*RGSQ&&:*3R 0B@#]4:*^:/L#+T'P;X<\)^"[+X?>$]*ATW2-,TN/3M,L;5 M,1VMM'&(XXT'950 >@KR+]B#]B31/V&?V'/#/[$G@#XE:KJ%IX6T:^L=/\ M%%S!'%=[KBXN)_.VI\H9&G.,?W!7N-% 'RK\5/\ @EQI'QY_8]\#?LY_&K]I MSQ[KGCCX<:]%X@\'?'!;F*+Q%8:U#-+)!>YVM&^$E,+1,"KQ@=&"LN?\&?\ M@F%\0D_:5\*?M7_MO_MM>)OCIXI^'5I=0_#>QOO"FG:#I.@S747DW%[]CL5Q M<7;1Y02R-A QVH"$*_75% 'D7[>7[(WAS]O']D7QO^R-XM\7WN@Z=XWTR.RN MM7TZ!)9[95GBFW(K_*3F(#GL37J/A[1X_#V@6.@0S-(EC9Q6Z2,,%@B!03]< M5_\ 8!?_ M -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"2 M9^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_ M'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2 ME;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH Y_X>?MX_L<:9X MT/3K_P#:-\+13V^CVT[>W(K>K" MBBBOR0_80HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^,_B?=_P#!53]I M[]KSQ]\*?@)\3K+]GWX6?#RTTZ#2/'&L?#2/7[[QWJ-S 9IWMENI8X8K.V.( MB5!=I ?FPWR>-:'_ ,%F?VA/A-^P#\=_&/QK\$^&?%7QJ^"'QAD^%6EOX=CD MM]'\8:W-/;06%T(RY:#)N@\\ ?*^0X5D+JJ^C?MV?\%!_B_X[_:'O?\ @F1_ MP3O\0:%IGQ+ATR"Y^)_Q8\2S1_V3\,].N5S&XC=A]MU22,[X+8?*,J[_ "A] MGB'_ 4A_8Z^!W[#W_!'CPYI'[/FL7'B30_A5\<_"GC[XD>))KX7^I:Y,NKP MG4=5O9$),LS>:)'/\,<8 PD8P >I^)OCC_P4J_X)R_&#X*:]^VQ^TUX.^+OP M\^,/CVQ\">*(='^'L>A3^#==U!)#8S6DL4S_ &NR,T9AD-PH=5V/G+%1V7C& M3_@K/^U;^T[\2_"GP9^+MA^SK\,OA]>V^E>$M;UGX71:]J/CF[:W66XOA]KF MCBBL8W81IY0+R%6)=>@X_P#X+B^*O"WQC\(_LL? KX;^)+'6==^)'[3O@[4_ M#<&EW:3M<:39/)>WFIQ["=]M# %=I%R )%YYJY^VM^WM\9?V@?VB=<_X)C_\ M$[/'.C>&?$VCVL(^,WQRURXC^Q?#ZVN%)6ULHV9?MNKR1Y*("$AZL0P69MIY!<6H:)EE$P+(NTAB6R/4;'Q? M^P?_ ,$.O^";YU'0M?EN/ _@K]UYME=IJ.L>*M=NGW%2RD?:;^ZF?:#X(? G2M?AN;/X M>VUTH1[BY<-_IFL3)A7D VQ_=49"+" ??]%%% !7E'[<_P#R:/X]_P"P"_\ MZ&M=)\9O@9X0^.>F66D^+]4UJUCL9VFA;1=6DM&9BNTABGWACL:^?/VK?V*? MA/\ #[]G7Q=XTT3Q)XPFN].TEIH([[Q3/-"S!E&'1CAAST- 'Y$T445_IP?Y M9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !7]%E?SIU_197\Q_2-_YE?_ ''_ /<)_4WT M:?\ F:_]P/\ W,?C]\:OVA/V_?VZ?VK?%>C?";]O+4/@GH'P[_:SM_A3X:\& M^%/#EEOI3XL?MN_\%!/V3/\ M@GA\/4^/?PI\'W_[4/Q"\?67PY\)Z;:WX;0]1UB[N)DMM4G\ALQ6XM(6NI8T M(PRE 8PPV_.O[:/PM_X)T?\ !2#]HRP^)WPIT?QC\+/C1X-_:AM_AE\1_&_A MK6CX>\20B#3KUTOT^SS21RQ-Y$?V:]FC+LD#J,*"M> _'3XC_&+]KC_@G?\ M ;XB_M0?'W5M;\%_"S]NR7P/XA^-VEW)L)]9\&B6?34\0/I:%X6 MT[P[??#S4(X?,MY8TCNV-Y;2R9A:)E:=.'YP0?KSX@^-=$^&O@+6_B-XEF\O M3M TBYU+4),XVP01-+(?P537YD_M#_LE?LK_ /!/G_@I%^Q_J?\ P3?\#:7X M#\8_$#QK=Z#XT\*>$+MUM_$O@U=/EFN[N\M][+,+9DCD2X8;B[9+,57;]Q_M MD_%']FV]_9-^-.E?%CQ#<:YX6T'P-J=M\3](\%7HN-6L=-FLY1<+Y<+^9#*; M._#L/B&'X:S?" MB&[U.RL)LR0D@7Z2.&@V2!_+ P_?&3[=^V%^TI^V'\1O^"E?A/\ X)E?LG_& M/P_\)EN/A#),*AB!3L_&WPBTO_@I?_P5OT?]EW_@HW>7.CQ? M"SX!Z%XI\#^$=#U!M%O=L7R7]J8[PQ02(;'_$_B[X#?$*/PYL>&K^1(IKG1M7U6":74=*N+U%#7TB/$K!YB\T8'ER.Q Q^BU !1110 44 M44 %%%% !1110!\P_%C_ ((P?\$M/CK\2=:^,'Q>_8F\%^(/$WB*_>]UO6M0 MMI6FO)V^](Y$@&37H'[/W[ W[&?[+'PW\0_![X ?LX^%_#?A7Q:[MXF\/6MA MYEIJF^'R7$\4I99%:+Y"I&"O!%>O44 > ?LS?\$LO^">_P"QS\1+GXM?LU?L MJ^&/"OB2XM9+5=8M8Y9IK6!V+/#;F=W^RQL2(O$FK7&IZ[J]];2M->W<\C2RS.?,Y9G9F/;FOJ6B@# MYL_X<^_\$R_^%&?\,S_\,:^#_P#A O\ A+/^$F_X186\OV7^U_LPM?MFW?GS M/('EYS]WM6;\-_\ @B;_ ,$I/A#\0=$^*WPT_8:\$:-XB\-ZM;ZGH6KV=K*) M;*[@D62*9"9" RNJL..HKZEHH **** "O*/VY_\ DT?Q[_V 7_\ 0UKU>O*/ MVY_^31_'O_8!?_T-: /PJHK]6O!7_!&#]D'Q!X-TG7K_ %+QB)[W3(+B81ZU M"%WO&K' \C@9-:?_ Y)_8V_Z"?C3_P=P_\ QBO[2_XCOP)WJ_\ @'_VQ_$' M_$ ./^U+_P &?_:GY)45^MO_ Y)_8V_Z"?C3_P=P_\ QBC_ (K_X!_P#;!_Q #C_M2_\ !G_VI^25%?K; M_P .2?V-O^@GXT_\'K_ . ?_;!_Q #C_M2_\&?_ &I^25%?K;_PY)_8V_Z" M?C3_ ,'K M_P" ?_;!_P 0 X_[4O\ P9_]J?DE17ZV_P##DG]C;_H)^-/_ =P_P#QBC_A MR3^QM_T$_&G_ (.X?_C%'_$=^!.]7_P#_P"V#_B ''_:E_X,_P#M3\DJ*_6W M_AR3^QM_T$_&G_@[A_\ C%'_ Y)_8V_Z"?C3_P=P_\ QBC_ (COP)WJ_P#@ M'_VP?\0 X_[4O_!G_P!J?DE17ZV_\.2?V-O^@GXT_P#!W#_\8H_XK_X!_\ ;!_Q M #C_ +4O_!G_ -J?DE17ZV_\.2?V-O\ H)^-/_!W#_\ &*/^')/[&W_03\:? M^#N'_P",4?\ $=^!.]7_ , _^V#_ (@!Q_VI?^#/_M3\DJ*_6W_AR3^QM_T$ M_&G_ (.X?_C%'_#DG]C;_H)^-/\ P=P__&*/^([\"=ZO_@'_ -L'_$ ./^U+ M_P &?_:GY)45^MO_ Y)_8V_Z"?C3_P=P_\ QBC_ (+_'F1<;?4O[-YOW7M.;FCR_'[.UM7?X7<_;_ :X S_@;Z]_:?)^ M^]ER\LN;X/:7OHK?$K'R?^V]_P $8/V#_P!O+XH^'OC-\8O@GH9\2Z;KEK<^ M(M8MK.2*X\1Z?##+%_9]V\$L1D0[H\2/O95A5!\IQ7O=O^S=^S]:_ I?V88/ M@MX77X=+H_\ 90\#_P!B0G2_L6.8#;;?+*'J1CD\]>:[6BOQ8_<#PC]EG_@F M/^P1^Q3XLO?'O[+_ .S#X<\*:[J%G]DGUFV26XNTMMP8V\4UP\CPPD@$Q1E4 M.U?E^48]!\!?LX? SX7^./&OQ)\ _#'2],USXC7D-UXYU*WB)?6IH8VBC>?< M2&*HS*. ,$UVU% 'S5\-_P#@CK_P3#^$/QDM?C[\-_V+/!6E>*-/U%K_ $N[ MALG:WTZ[8@F>UM'_P#8 M!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA? M"[_DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*^L+' M5+233]3LHKBWE7;+!/&'1QZ%3P14M% #8HHH(E@@C5$10J(@P% Z #L*=110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D! end GRAPHIC 27 pfe-20241231_g8.jpg begin 644 pfe-20241231_g8.jpg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end GRAPHIC 28 pfe-20241231_g9.jpg begin 644 pfe-20241231_g9.jpg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end XML 30 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover Page - USD ($)
$ in Billions
12 Months Ended
Dec. 31, 2024
Feb. 20, 2025
Jun. 30, 2024
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-3619    
Entity Registrant Name PFIZER INC    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 13-5315170    
Entity Address, Address Line One 66 Hudson Boulevard East    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10001-2192    
City Area Code 212    
Local Phone Number 733-2323    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 158
Entity Common Stock, Shares Outstanding   5,667,340,414  
Documents Incorporated by Reference
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Proxy Statement for the 2025 Annual Meeting of ShareholdersPart III
   
Entity Central Index Key 0000078003    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
Common Stock [Member]      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $0.05 par value    
Trading Symbol PFE    
Security Exchange Name NYSE    
Notes Due 2027, 1.000% [Member]      
Entity Information [Line Items]      
Title of 12(b) Security 1.000% Notes due 2027    
Trading Symbol PFE27    
Security Exchange Name NYSE    
XML 31 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Audit Information
12 Months Ended
Dec. 31, 2024
Audit Information [Abstract]  
Auditor name KPMG LLP
Auditor location New York, NY
Auditor firm ID 185
XML 32 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Alliance revenues $ 8,388 $ 7,582 $ 8,537
Total revenues 63,627 59,553 101,175
Costs and expenses:      
Cost of sales [1],[2] 17,851 24,954 34,344
Selling, informational and administrative expenses [1] 14,730 14,771 13,677
Research and development expenses [1] 10,822 10,679 11,428
Acquired in-process research and development expenses 108 194 953
Amortization of intangible assets 5,286 4,733 3,609
Restructuring charges and certain acquisition-related costs 2,419 2,943 1,375
Other (income)/deductions––net 4,388 222 1,062
Income from continuing operations before provision/(benefit) for taxes on income [3],[4],[5] 8,023 1,058 34,729
Provision/(benefit) for taxes on income (28) (1,115) 3,328
Income from continuing operations 8,051 2,172 31,401
Discontinued operations––net of tax 11 (15) 6
Net income before allocation to noncontrolling interests 8,062 2,158 31,407
Less: Net income attributable to noncontrolling interests 31 39 35
Net income attributable to Pfizer Inc. common shareholders $ 8,031 $ 2,119 $ 31,372
Earnings per common share––basic:      
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 1.42 $ 0.38 $ 5.59
Discontinued operations––net of tax (in dollars per share) 0 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 1.42 0.38 5.59
Earnings per common share––diluted:      
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 1.41 0.37 5.47
Discontinued operations––net of tax (in dollars per share) 0 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 1.41 $ 0.37 $ 5.47
Weighted-average shares––basic (in shares) 5,664 5,643 5,608
Weighted-average shares––diluted (in shares) 5,700 5,709 5,733
Product [Member]      
Revenues $ 53,816 $ 50,914 $ 91,793
Royalty [Member]      
Revenues [6] $ 1,423 $ 1,058 $ 845
[1] Exclusive of amortization of intangible assets.
[2] See Note 17A.
[3] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
[4] 2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.
[5] 2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
[6] See Note 1A.
XML 33 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]      
Net income before allocation to noncontrolling interests $ 8,062 $ 2,158 $ 31,407
Foreign currency translation adjustments, net 32 452 (2,328)
Unrealized holding gains/(losses) on derivative financial instruments, net 499 626 1,444
Reclassification adjustments for (gains)/losses included in net income [1] (159) (413) (2,062)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total 341 213 (618)
Unrealized holding gains/(losses) on available-for-sale securities, net (152) (121) (1,306)
Reclassification adjustments for (gains)/losses included in net income [2] 42 (141) 1,809
Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total (111) (261) 502
Benefit plans: prior service (costs)/credits and other, net 193 (25) (24)
Reclassification adjustments related to amortization of prior service costs and other, net (109) (117) (129)
Reclassification adjustments related to curtailments of prior service costs and other, net 0 (15) (12)
Other comprehensive income (loss), benefit plans, prior service (costs)/credits, before tax, total 84 (157) (166)
Other comprehensive income/(loss), before tax 347 246 (2,609)
Tax provision/(benefit) on other comprehensive income/(loss) 231 (85) (187)
Other comprehensive income/(loss) before allocation to noncontrolling interests 116 331 (2,422)
Comprehensive income/(loss) before allocation to noncontrolling interests 8,178 2,488 28,985
Less: Comprehensive income/(loss) attributable to noncontrolling interests 28 26 20
Comprehensive income/(loss) attributable to Pfizer Inc. $ 8,149 $ 2,462 $ 28,965
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2] Reclassified into Other (income)/deductions—net.
XML 34 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Assets    
Cash and cash equivalents $ 1,043 $ 2,853
Short-term investments 19,434 9,837
Trade accounts receivable, net of allowance for doubtful accounts: 2024—$438; 2023—$470 11,463 11,566
Inventories [1] 10,851 10,189
Current tax assets 3,314 3,978
Other current assets 4,253 4,911
Total current assets 50,358 43,333
Equity-method investments [2] 217 11,637
Long-term investments 2,010 3,731
Property, plant and equipment, net 18,393 18,940
Identifiable intangible assets, net [3] 55,411 64,900
Goodwill 68,527 67,783 [4]
Noncurrent deferred tax assets and other noncurrent tax assets 8,662 3,706
Other noncurrent assets 9,817 12,471
Total assets 213,396 226,501
Liabilities and Equity    
Short-term borrowings, including current portion of long-term debt: 2024—$3,747; 2023—$2,254 6,946 10,350
Trade accounts payable 5,633 6,710
Dividends payable 2,437 2,372
Income taxes payable 2,910 2,349
Accrued compensation and related items 3,838 2,776
Deferred revenues 1,511 2,700
Other current liabilities 19,720 20,537
Total current liabilities 42,995 47,794
Long-term debt 57,405 61,538
Pension and postretirement benefit obligations 2,115 2,167
Noncurrent deferred tax liabilities 2,122 640
Other taxes payable 6,112 8,534
Other noncurrent liabilities 14,150 16,539
Total liabilities 124,899 137,213
Commitments and Contingencies
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2024—9,593; 2023—9,562 480 478
Additional paid-in capital 93,603 92,631
Treasury stock, shares at cost: 2024—3,926; 2023—3,916 (114,763) (114,487)
Retained earnings 116,725 118,353
Accumulated other comprehensive loss (7,842) (7,961)
Total Pfizer Inc. shareholders’ equity 88,203 89,014
Equity attributable to noncontrolling interests 294 274
Total equity 88,497 89,288
Total liabilities and equity $ 213,396 $ 226,501
[1] The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches.
[2] As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
[3] The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see Note 4) and measurement period adjustments related to our acquisition of Seagen of $950 million (see Note 2A).
[4] As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 17A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
XML 35 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 438 $ 470
Current portion of long-term debt $ 3,747 $ 2,254
Common stock, par value (in dollars per share) $ 0.05 $ 0.05
Common stock, shares authorized (in shares) 12,000,000,000 12,000,000,000
Common stock, shares, issued (in shares) 9,593,000,000 9,562,000,000
Treasury stock (in shares) 3,926,000,000 3,916,000,000
XML 36 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Equity - USD ($)
shares in Millions, $ in Millions
Total
Shareholders’ Equity [Member]
Common Stock [Member]
Add’l Paid-In Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
Accum. Other Comp. Loss [Member]
Non-controlling Interests [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance, treasury (in shares)         (3,851)      
Beginning balance, common (in shares) at Dec. 31, 2021     9,471          
Beginning balance at Dec. 31, 2021 $ 77,462 $ 77,201 $ 473 $ 90,591 $ (111,361) $ 103,394 $ (5,897) $ 262
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 31,407 31,372       31,372   35
Other comprehensive income/(loss), net of tax (2,422) (2,407)         (2,407) [1] (15)
Cash dividends declared:                
Common stock (9,037) (9,037)       (9,037)    
Noncontrolling interests (13)             (13)
Share-based payment transactions (in shares)     48   (13)      
Share-based payment transactions 513 513 $ 2 1,192 $ (608) (73)    
Purchases of common stock (in shares)         (39)      
Purchases of common stock (2,000) (2,000)     $ (2,000)      
Other 6 19   19 $ 0 0   (13)
Ending balance, common (in shares) at Dec. 31, 2022     9,519          
Ending balance, treasury (in shares) at Dec. 31, 2022         (3,903)      
Ending balance at Dec. 31, 2022 95,916 95,661 $ 476 91,802 $ (113,969) 125,656 (8,304) 256
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance, treasury (in shares)         (3,903)      
Net income 2,158 2,119       2,119   39
Other comprehensive income/(loss), net of tax 331 343         343 [1] (12)
Cash dividends declared:                
Common stock (9,316) (9,316)       (9,316)    
Noncontrolling interests (8)             (8)
Share-based payment transactions (in shares)     43   (12)      
Share-based payment transactions 208 208 $ 2 829 $ (518) (106)    
Other $ 0 0   0   0   0
Ending balance, common (in shares) at Dec. 31, 2023 9,562   9,562          
Ending balance, treasury (in shares) at Dec. 31, 2023 (3,916)       (3,916)      
Ending balance at Dec. 31, 2023 $ 89,288 89,014 $ 478 92,631 $ (114,487) 118,353 (7,961) 274
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance, treasury (in shares) (3,916)       (3,916)      
Net income $ 8,062 8,031       8,031   31
Other comprehensive income/(loss), net of tax 116 118         118 [1] (3)
Cash dividends declared:                
Common stock (9,577) (9,577)       (9,577)    
Noncontrolling interests (7)             (7)
Share-based payment transactions (in shares)     31   (10)      
Share-based payment transactions 591 591 $ 2 972 $ (276) (107)    
Other $ 23 25   0   25   (1)
Ending balance, common (in shares) at Dec. 31, 2024 9,593   9,593          
Ending balance, treasury (in shares) at Dec. 31, 2024 (3,926)       (3,926)      
Ending balance at Dec. 31, 2024 $ 88,497 $ 88,203 $ 480 $ 93,603 $ (114,763) $ 116,725 $ (7,842) $ 294
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance, treasury (in shares) (3,926)       (3,926)      
[1] Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program and gains/(losses) related to our investment in Haleon (see Note 2C).
XML 37 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Equity (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]      
Cash dividends declared per share (in dollars per share) $ 1.69 $ 1.65 $ 1.61
XML 38 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Operating Activities      
Net income before allocation to noncontrolling interests $ 8,062 $ 2,158 $ 31,407
Discontinued operations––net of tax 11 (15) 6
Net income from continuing operations before allocation to noncontrolling interests 8,051 2,172 31,401
Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:      
Depreciation and amortization [1] 7,013 6,290 5,064
Asset write-offs and impairments 4,242 3,408 550
Deferred taxes (2,102) (3,442) (3,764)
Share-based compensation expense 877 525 872
Benefit plan contributions in excess of expense/income (12) (787) (1,158)
Inventory write-offs and related charges associated with COVID-19 products [2] 0 6,199 1,183
Other adjustments, net (2,260) (3,492) 758
Other changes in assets and liabilities, net of acquisitions and divestitures:      
Trade accounts receivable (109) 347 261
Inventories [2] (854) (1,169) (591)
Other assets 3,380 (663) (4,506)
Trade accounts payable (1,023) (300) 1,191
Other liabilities [3] (3,115) 595 (1,449)
Other tax accounts, net (1,345) (982) (545)
Net cash provided by/(used in) operating activities 12,744 8,700 29,267
Investing Activities      
Purchases of property, plant and equipment (2,909) (3,907) (3,236)
Purchases of short-term investments (10,133) (30,974) (36,384)
Proceeds from redemptions/sales of short-term investments 4,128 39,264 44,821
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less 3,136 5,174 (483)
Purchases of long-term investments (180) (204) (1,913)
Proceeds from redemptions/sales of long-term investments 1,570 1,979 641
Proceeds from partial sales of investment in Haleon [4] 7,040 0 0
Acquisitions of businesses, net of cash acquired 0 (43,430) (22,997)
Dividend received from the Consumer Healthcare JV [4] 0 0 3,960
Other investing activities, net 2 (179) (192)
Net cash provided by/(used in) investing activities 2,652 (32,278) (15,783)
Financing Activities      
Proceeds from short-term borrowings 8,907 4,525 3,891
Payments on short-term borrowings (11,226) (3) (3,887)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less (2,590) 3,161 (222)
Proceeds from issuance of long-term debt 0 30,831 0
Payments on long-term debt (2,250) (2,569) (3,298)
Purchases of common stock 0 0 (2,000)
Cash dividends paid (9,512) (9,247) (8,983)
Other financing activities, net (469) (631) (335)
Net cash provided by/(used in) financing activities (17,140) 26,066 (14,834)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents (66) (40) (165)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents (1,810) 2,448 (1,515)
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period 2,917 468 1,983
Cash and cash equivalents and restricted cash and cash equivalents, at end of period 1,107 2,917 468
Cash paid/(received) during the period for:      
Income taxes 3,605 3,147 7,867
Interest paid 3,227 2,215 1,442
Interest rate hedges 178 134 54
Non-cash transaction:      
Right-of-use assets obtained in exchange for lease liabilities $ 283 $ 614 $ 752
[1] Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $331 million and $294 million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
[2] See Note 17A.
[3] See Note 17C.
[4] See Note 2C.
XML 39 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Significant Accounting Policies
12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP. The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. All significant transactions among our subsidiaries have been eliminated.
We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See Note 17A.
On December 14, 2023, we completed the acquisition of Seagen. In addition, other acquisitions and business development activities completed in 2024, 2023 and 2022 impacted financial results in the periods presented. See Note 2.
We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:
in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from Other (income)/deductions––net and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of operations, and reclassified the associated royalty receivables from Other current assets to Trade accounts receivable, less allowance for doubtful accounts in our consolidated balance sheet; and
segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see Notes 9 and 17).
Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
B. New Accounting Standards Adopted in 2024
On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.
In the fourth quarter of 2024, we adopted a new accounting standard which requires the disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, other segment items by reportable segment and a description of its composition. See Note 17A.
C. Estimates and Assumptions
In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of operations, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of operations. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation, development of competing assets by us or others, regulatory actions, or product recalls or withdrawals. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.
D. Acquisitions
Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed in Acquired in-process research and development expenses.
Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See Note 16D. Any liability
resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net.
E. Fair Value
We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.
When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:
Income approach, which is based on the present value of a future stream of net cash flows.
Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:
Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves.
Equity securities with readily determinable fair values—quoted market prices and observable NAV prices.
Derivative assets and liabilities—third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.
Money market funds—observable NAV prices.
We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.
F. Foreign Currency Translation
For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss). The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.
G. Revenues and Trade Accounts Receivable
Revenue Recognition––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors’ locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In bill-and-hold arrangements which are part of the U.S. SNS, we recognize revenue for the product sale when the product is initially placed into the U.S. SNS and we provide a rotation service to maintain an agreed upon level of shelf life for product in the stockpile. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.
Our Sales Contracts––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns may occur due to patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment.
Deductions from Revenues––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and
sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these product revenue deductions on gross sales for a reporting period.
Provisions for pharmaceutical sales returns––Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.
We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.
The following outlines our common sales arrangements:
Customers––Our prescription biopharmaceutical products, with the exception of Paxlovid in 2022 and 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In 2022 and 2023, we principally sold Paxlovid globally to government agencies. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain products in our portfolio are subject to seasonality of demand and Paxlovid revenues trend with infection rates. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs in the U.S; and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented).
Specifically:
In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales in prior periods to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” and as of December 31, 2024 in the initial coverage and catastrophic phases under the Manufacturer Discount Program based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap or from the manufacturer’s discount, respectively. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.
Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.
Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.
We recorded revenues of more than $1 billion for each of 11 products in 2024, for each of nine products in 2023 and for each of ten products in 2022, and these revenues represented 66%, 64% and 82% of our Total revenues in 2024, 2023 and 2022, respectively. See Note 17C. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.
Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
  As of December 31,
(MILLIONS)20242023
Reserve against Trade accounts receivable, less allowance for doubtful accounts
$1,627 $1,770 
Other current liabilities:
Accrued rebates7,195 5,546 
Other accruals972 902 
Other noncurrent liabilities
1,029 796 
Total accrued rebates and other sales-related accruals$10,822 $9,014 
Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Product revenues.
Trade Accounts Receivable—Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
During 2024 and 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.
H. Collaborative Arrangements
Payments to and from our collaboration partners are presented in our consolidated statements of operations based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-commercialization agreements, we record the amounts received for our share of gross profits from our collaboration partners as Alliance revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as Cost of sales. Royalty payments received from collaboration partners are included in Royalty revenues.
Reimbursements to or from our collaboration partners for development costs are typically recorded in Research and development expenses. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as Acquired in-process research and development expenses. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in Identifiable intangible assets—developed technology rights. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in Other (income)/deductions—net over the development period for the products, when our performance obligations include providing R&D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in Other (income)/deductions—net immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.
I. Cost of Sales and Inventories
Inventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary. Inventories that are not expected to be sold within 12 months are classified as Other noncurrent assets. See Note 8A.
J. Selling, Informational and Administrative Expenses
Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, digital and legal defense. Advertising expenses totaled approximately $3.3 billion in 2024, $3.7 billion in 2023 and $2.8 billion in 2022. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.
K. Research and Development Expenses
R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as R&D activities performed in connection with certain licensing arrangements.
L. Acquired In-Process Research and Development Expenses
Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing and collaboration arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. Acquired in-process research and development expenses includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&D.
M. Long-Lived Assets
Long-lived assets include:
Property, plant and equipment, net—These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a
straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
Identifiable intangible assets, net—These assets are recorded at fair value at acquisition. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.
Goodwill—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.
Amortization of finite-lived acquired intangible assets is included in Amortization of intangible assets.
We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
Specifically:
For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.
For indefinite-lived intangible assets, such as brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.
For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.
N. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
We incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.
Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired company. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred.
Our business may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as our corporate enabling functions.
O. Cash Equivalents and Statement of Cash Flows
Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments.
Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.
P. Investments and Derivative Financial Instruments
The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:
Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in Other (income)/deductions—net.
Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.
Held-to-maturity debt securities, which are carried at amortized cost.
Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus adjustments resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in Other (income)/deductions—net. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.
Realized gains or losses on sales of investments are determined by using the specific identification cost method.
We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, if and when a decline in fair value is determined, an impairment charge is recorded and a new cost basis in the investment is established. For equity-method investments, an impairment charge is recorded only if and when a decline in fair value is determined to be other-than-temporary.
Derivative financial instruments are carried at fair value in certain balance sheet categories (see Note 7A), with changes in fair value reported in net income or, for certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7E).
Q. Tax Assets and Liabilities and Income Tax Contingencies
Tax Assets and Liabilities––Current tax assets primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of operations when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.
Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.
The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.
Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.
Other taxes payable as of December 31, 2024 and 2023 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. See Note 5D for uncertain tax positions and Note 5A for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.
Income Tax Contingencies––We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.
We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision/(benefit) for taxes on income and are classified on our consolidated balance sheet with the related tax liability.
Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.
R. Pension and Postretirement Benefit Plans
The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. Net periodic pension and postretirement benefit costs other than the service costs are recognized in Other (income)/deductions—net. We immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (mark-to-market accounting). Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions––net. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of
providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value.
S. Legal and Environmental Contingencies
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial and other asserted or unasserted matters, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.
T. Share-Based Payments
Our compensation programs include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis or on an accelerated attribution approach over the vesting terms with the related costs recorded in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.
XML 40 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement
12 Months Ended
Dec. 31, 2024
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]  
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement
A. Acquisitions
Seagen––On December 14, 2023 (the acquisition date), we acquired Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash. The total fair value of the consideration transferred was $44.2 billion ($43.4 billion, net of cash acquired). In addition, in connection with the acquisition, $476 million in post-closing compensation expense for Seagen employee incentive awards was recorded in Restructuring charges and certain acquisition-related costs (see Note 3).
Seagen’s principal business was the development, manufacture, marketing and distribution of targeted cancer therapeutics, primarily using ADC technology. Seagen’s portfolio includes four approved medicines as well as a pipeline of product candidates. Clinical development programs are ongoing for each of these approved medicines for potential new or expanded indications and for several product candidates. We believe our acquisition of Seagen will strengthen our oncology capabilities by allowing us to combine Seagen’s ADC technology with the resources and scale of the Pfizer enterprise and to advance more potential breakthroughs to patients with cancer.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in 2024 to the amounts initially recorded in 2023 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.
(MILLIONS)
Amounts Recognized
as of Acquisition Date
(as previously reported as of December 31, 2023)
Measurement Period Adjustments(a)
Amounts Recognized as of Acquisition Date (as adjusted) Final
Working capital, excluding inventories(b)
$736 $(115)$621 
Inventories(c)
4,195 (922)3,273 
Property, plant and equipment
524 (243)280 
Identifiable intangible assets, excluding in-process research and development(d)
7,970 (50)7,920 
In-process research and development
20,800 (900)19,900 
Other noncurrent assets
174 (115)59 
Net income tax accounts(e)
(6,123)1,343 (4,779)
Other noncurrent liabilities(167)(20)(187)
Total identifiable net assets28,108 (1,022)27,086 
Goodwill16,126 1,022 17,148 
Net assets acquired/total consideration transferred$44,234 $ $44,234 
(a)The changes in the estimated fair values are to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
(b)Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities.
(c)As adjusted, comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories.
(d)As adjusted, comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.
(e)As adjusted, included primarily in Noncurrent deferred tax liabilities. The measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments.
As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $597 million.
In the ordinary course of business, Seagen may incur liabilities for environmental, legal and tax matters, as well as guarantees and indemnifications. These matters may include contingencies. Except as specifically excluded by the relevant accounting standard, contingencies are required to be measured at fair value as of the acquisition date if the acquisition-date fair value of the asset or liability arising from a contingency can be determined. If the acquisition-date fair value of the asset or liability cannot be determined, the asset or liability would be recognized at the acquisition date if both of the following criteria are met: (i) it is probable that an asset existed or that a liability had been incurred at the acquisition date, and (ii) the amount of the asset or liability can be reasonably estimated.
Environmental Matters—In the ordinary course of business, Seagen may incur liabilities for environmental matters such as remediation work, asset retirement obligations and environmental guarantees and indemnifications.
Legal Matters—Seagen is involved in various legal proceedings, including patent, intellectual property, and product liability matters of a nature considered normal to its business. The contingencies arising from legal matters are not significant to our consolidated financial statements.
Tax Matters—In the ordinary course of business, Seagen incurs liabilities for income taxes. Income taxes are exceptions to both the recognition and fair value measurement principles associated with the accounting for business combinations. Reserves for income tax contingencies continue to be measured under the benefit recognition model previously used by Seagen (see Note 1Q). Net liabilities for income taxes as of the acquisition date were $4.8 billion, including $48 million for uncertain tax positions. The net tax liability includes $6.3 billion for the tax impact of fair value adjustments, partially offset by $1.5 billion for deferred tax assets on which Seagen had recognized a valuation allowance.
Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of Seagen includes the following:
the expected specific synergies and other benefits that we believe will result from combining the operations of Seagen with the operations of Pfizer;
any intangible assets that do not qualify for separate recognition, as well as future, as yet unidentified projects and products; and
the value of the going-concern element of Seagen’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).
Goodwill is not amortized and is not deductible for tax purposes. All of the goodwill related to the acquisition of Seagen is related to our Biopharma segment (see Note 10).
Actual and Pro Forma Impact of Acquisition—The following table presents information for Seagen’s operations that are included in Pfizer’s consolidated statements of operations beginning from the acquisition date, December 14, 2023, through Pfizer’s year-end in 2023:
(MILLIONS)
December 31,
2023
Revenues$132 
Net loss attributable to Pfizer Inc. common shareholders(a)
(746)
(a)Includes restructuring, integration and acquisition-related costs ($614 million pre-tax) and purchase accounting charges related to (i) the fair value adjustment for acquisition-date inventory estimated to have been sold ($109 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Seagen ($25 million pre-tax); as well as (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Seagen ($2 million pre-tax).
The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:
Unaudited Supplemental Pro Forma Consolidated Results
Year Ended December 31,
(MILLIONS, EXCEPT PER SHARE DATA)
20232022
Revenues
$61,893 $103,137 
Net income/(loss) attributable to Pfizer Inc. common shareholders
(1,481)27,870 
Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders
(0.26)4.86 
The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company’s results of operations would have been had the acquisition occurred on January 1, 2022, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma information reflected here due to many factors.
The unaudited supplemental pro forma financial information includes various assumptions, including those related to the purchase price allocation of the assets acquired and the liabilities assumed from Seagen. The historical U.S. GAAP financial information of Pfizer and Seagen was adjusted, primarily for the following pre-tax adjustments for the years ended December 31, 2023 and 2022:
Additional amortization expense of approximately $553 million and $576 million, respectively, related to the fair value of identifiable intangible assets acquired.
Additional expense related to the fair value adjustment to acquisition-date inventory estimated to have been sold of approximately $755 million and $934 million, respectively.
Additional estimated interest expense of approximately $984 million and $2.0 billion, respectively, related to the debt issued by Pfizer and the commercial paper borrowings to partially finance the acquisition.
Elimination of interest income of approximately $1.2 billion and $267 million, respectively, related to the debt issuance proceeds that were invested prior to the acquisition date and associated with money market funds under the assumption that a portion of these funds would have been liquidated to partially finance the acquisition.
The above adjustments were then adjusted for the applicable tax impact using an estimated weighted-average statutory tax rate applied to the applicable pro forma adjustments.
The acquisition of Seagen had no impact on Pfizer’s weighted-average shares as no shares were issued.
GBT––On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, starting with sickle cell disease, for $68.50 per share in cash. The total fair value of the consideration transferred was $5.7 billion ($5.2 billion, net of cash acquired). In addition, $136 million in payments to GBT employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs (see Note 3).
The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $4.4 billion in Identifiable intangible assets, net, consisting of $3.0 billion of IPR&D and $1.4 billion of developed technology rights with a useful life of six years, (ii) $1.1 billion of Goodwill, (iii) $644 million of inventories to be sold over approximately three years, (iv) $516 million of net deferred tax liabilities and (v) $331 million of assumed long-term debt that was paid in full in the fourth quarter of 2022.
Biohaven––On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy approved for both acute treatment of migraine and prevention of episodic migraine in adults. The transaction included the acquisition of Biohaven’s CGRP programs, including rimegepant, zavegepant and a portfolio of five pre-clinical CGRP assets. Under the terms of the agreement, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5 billion, plus repayment of third-party debt of $863 million and redemption of Biohaven’s redeemable preferred stock for $495 million. Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing Biohaven Ltd.’s shares to Biohaven shareholders. Biohaven Ltd. became a new publicly traded company that retained Biohaven’s non-CGRP development stage pipeline compounds. Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.’s shares in the distribution.
The total fair value of the consideration transferred was $11.8 billion, which includes the fair value of Pfizer’s previous investment in Biohaven on the acquisition date of approximately $300 million. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $12.1 billion in Identifiable intangible assets, consisting of $11.6 billion of developed technology rights with a useful life of 11 years and $450 million of IPR&D, (ii) $823 million of Goodwill, (iii) $813 million of inventories to be sold over approximately two years, (iv) $398 million of trade accounts receivable, (v) $1.4 billion of assumed long-term debt that was paid in full in the fourth quarter of 2022, (vi) $544 million of net deferred tax liabilities and (vii) $526 million of Other current liabilities.
Arena––On March 11, 2022, we acquired Arena, a clinical stage company with development-stage therapeutic candidates in gastroenterology, dermatology and cardiology, for $100 per share in cash. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired). In addition, $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs (see
Note 3).
The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $5.5 billion in Identifiable intangible assets, consisting of $5.0 billion of IPR&D and $460 million of indefinite-lived licensing agreements and other, (ii) $1.0 billion of Goodwill and (iii) $490 million of net deferred tax liabilities.
ReViral––On June 9, 2022, we acquired ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel antiviral therapeutics that target respiratory syncytial virus, for a total consideration of up to $536 million, including upfront payments of $436 million upon closing (including a base payment of $425 million plus working capital adjustments) and an additional $100 million contingent upon a future development milestone for a secondary pipeline asset. It was subsequently determined the applicable milestone was not achieved.
We accounted for the transaction as an asset acquisition since the lead asset, sisunatovir, represented substantially all of the fair value of the gross assets acquired. At the acquisition date, we recorded a $426 million charge representing an acquired IPR&D asset with no alternative use in Acquired in-process research and development expenses, which is presented as a cash outflow from operating activities. Other assets acquired and liabilities assumed were not significant.
Pro forma information for the aforementioned acquisitions (except for Seagen) has not been presented because these acquisitions were not material to our consolidated financial statements.
Divestitures
Divestiture of Early-Stage Rare Disease Gene Therapy Portfolio––On September 19, 2023, we completed an agreement with Alexion, under which Alexion purchased and licensed the assets of our early-stage rare disease gene therapy portfolio. Under the terms of the agreement, Alexion will pay us total consideration of up to $1 billion, consisting of an upfront payment of $300 million which was paid at closing and future contingent milestone payments, plus tiered royalties based on annual net sales of the assets. In connection with the closing of the transaction, Pfizer recognized a $222 million pre-tax gain in Other (income)/deductions––net (see Note 4).
Upjohn Separation and Combination with Mylan––In connection with the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, Pfizer and Viatris entered into various agreements, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. The terms of the MSAs range in initial duration from four to seven years post-separation. Services under the TSAs were largely completed as of December 31, 2023. Amounts recorded under the above agreements in 2024, 2023 and 2022 were not material to our operations. Net amounts due to Viatris under the above agreements were $105 million as of December 31, 2024 and $33 million as of December 31, 2023. The cash flows associated with the above agreements are included in Net cash provided by/(used in) operating activities.
Equity-Method Investments
Haleon––Haleon, is an independent, publicly traded company listed on the London Stock Exchange that holds the joint historical consumer healthcare business of GSK and Pfizer. We owned 32% of Haleon as of December 31, 2023. In March 2024, we sold approximately 30% of our investment in Haleon through the sale of 791 million ordinary shares in a global public offering, and the sale of 102 million ordinary shares directly to Haleon, for $3.5 billion. In October 2024, we sold approximately 34% of our remaining investment in Haleon through the sale of 640 million ordinary shares in a global public offering, and the sale of 61 million ordinary shares directly to Haleon, for $3.5 billion. We recognized total gains on these sales of our Haleon shares of $945 million during 2024 in Other (income)/deductions––net (see Note 4). After the October 2024 share sale, we owned approximately 15% of the outstanding voting shares of Haleon as of December 31, 2024.
Through the third quarter of 2024, we accounted for our Haleon investment under the equity method and recorded our share of earnings from Haleon on a quarterly basis on a one-quarter lag in Other (income)/deductions––net. As Haleon is a foreign investee whose reporting currency is the U.K. pound, we translated its financial statements into U.S. dollars and recognized the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. With the reduction in our Haleon ownership percentage and board representation after the October 2024 sale, we no longer have the ability to exercise significant influence over the operating and financial policies of Haleon. As a result, we discontinued the application of the equity method to our Haleon investment, and began to account for the investment as an equity security with a readily determinable fair value, which is carried at fair value, with changes in fair value reported in Other (income)/deductions––net. See Note 4.
The following table summarizes the change in the carrying value of our investment in Haleon:
Year Ended December 31,
(MILLIONS)
20242023
Beginning carrying value reported in Equity-method investments
$11,451 $10,824 
Carrying value of shares sold
(6,113)— 
Dividends
(212)(153)
Currency translation adjustments and other(a)
341 293 
Basis difference adjustments and amortization(b), (c)
(91)(2)
Pfizer share of Haleon investee capital transaction(b), (d)
(44)— 
Pfizer share of Haleon earnings(b)
224 489 
Reclassification of accumulated other comprehensive income balances in Equity-method investments(e)
(143)— 
Transfer of carrying value to Short-term investments(f)
(5,411)— 
Ending carrying value
$ $11,451 
(a)See Note 6.
(b)Included in Other (income)/deductions––net.
(c)Adjustments in 2024 include (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities.
(d)In 2024, includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.
(e)The 2024 activity primarily represent foreign currency translation balances in Accumulated other comprehensive income related to the equity-method investment in Haleon that were reclassified into Equity-method investments upon our loss of significant influence over Haleon and our discontinuance of the equity method for the Haleon investment.
(f)The final carrying value of our equity-method investment in Haleon was reclassified to Short-term investments and is being accounted for as an equity investment with a readily determinable fair value.
Summarized financial information for Haleon as of September 30, 2024, the most recent period available, and as of September 30, 2023 and for the periods ending September 30, 2024, 2023, and 2022 is as follows:
(MILLIONS)September 30, 2024September 30, 2023
Current assets$7,813 $5,876 
Noncurrent assets37,572 36,954 
Total assets
$45,385 $42,830 
Current liabilities$7,468 $6,117 
Noncurrent liabilities15,511 15,744 
Total liabilities
$22,979 $21,862 
Equity attributable to shareholders$22,129 $20,719 
Equity attributable to noncontrolling interests277 249 
Total net equity$22,406 $20,968 
For the Twelve Months Ended
(MILLIONS)September 30, 2024September 30, 2023September 30, 2022
Net sales$14,252 $13,921 $13,566 
Cost of sales(5,656)(5,580)(5,081)
Gross profit$8,596 $8,341 $8,486 
Income from continuing operations1,668 1,606 1,745 
Net income1,668 1,606 1,745 
Income attributable to shareholders1,600 1,528 1,675 
In connection with GSK’s previously announced planned demerger of at least 80% of GSK’s 68% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $8.75 billion in U.S. dollar-denominated senior notes of various maturities, €2.35 billion in euro-denominated senior notes of various maturities and £700 million in U.K. pound-denominated senior notes of various maturities (collectively, the “notes”). The notes were guaranteed by GSK generally up to and excluding the date of the demerger (the “Guarantee Assumption Date”). We agreed to indemnify GSK for 32% (representing our pro rata equity interest in the Consumer Healthcare JV at that time) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity was provided solely for the benefit of GSK. Neither we, nor any of our subsidiaries, were an issuer or guarantor of any of the notes.
Following its issuance of the notes in March 2022, which fell in our international second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of £2.9 billion ($3.7 billion as of the end of our second quarter of 2022), at an interest rate of 1.365% per annum payable semi-annually in arrears. In conjunction with the demerger, we received £3.5 billion ($4.2 billion) in dividends from the JV in July 2022, of which $4.0 billion related to a one-time pre-separation dividend, which decreased the carrying value of our investment and are included in Net cash provided by/(used in) investing activities. Simultaneous with the receipt of the dividends, we repaid the £2.9 billion loan from the JV. GSK similarly received pro rata dividends and simultaneously repaid its pro rata loan from the JV. In conjunction with these transactions, our indemnification of GSK’s guarantee discussed above was terminated.
Investment in ViiV––In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately 11.7% of ViiV, and prior to 2016 we accounted for our investment under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to zero due to the recognition of cumulative equity-method losses and dividends, and therefore we no longer record our proportionate share of ViiV’s net income (loss) in our results of operations. Since 2016, we have recognized dividends from ViiV as income in Other (income)/deductions––net when earned, including dividends of $272 million in 2024, $265 million in 2023 and $314 million in 2022 (see
Note 4).
Summarized financial information for our equity-method investee, ViiV, as of December 31, 2024 and 2023 and for the years ending December 31, 2024, 2023, and 2022 is as follows:
As of December 31,
(MILLIONS)20242023
Current assets$4,338 $4,237 
Noncurrent assets3,223 3,009 
Total assets
$7,561 $7,245 
Current liabilities$4,280 $4,085 
Noncurrent liabilities6,205 5,998 
Total liabilities
$10,485 $10,083 
Total net equity/(deficit) attributable to shareholders$(2,924)$(2,838)
Year Ended December 31,
(MILLIONS)202420232022
Net sales$8,971 $7,845 $6,955 
Cost of sales(1,360)(1,060)(819)
Gross profit$7,611 $6,785 $6,135 
Income from continuing operations3,062 3,090 3,108 
Net income3,062 3,090 3,108 
Income attributable to shareholders3,062 3,090 3,108 
Collaborative Arrangements
We enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product or vaccine.
Collaboration with Biohaven––In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven and certain of its subsidiaries to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Under the terms of the agreement, Biohaven would lead R&D globally and we would have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January 4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263 million for the upfront payment and premium paid on our equity investment in Acquired in-process research and development expenses. In October 2022, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5 billion. See Note 2A.
Summarized Financial Information for Collaborative Arrangements
The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:
Year Ended December 31,
(MILLIONS)202420232022
Product revenues(a)
$175 $212 $437 
Alliance revenues(b)
8,388 7,582 8,537 
Royalty revenues(c)
923 605 614 
Total revenues from collaborative arrangements$9,486 $8,400 $9,588 
Cost of sales(d)
$(2,901)$(4,277)$(15,589)
Selling, informational and administrative expenses(e)
(335)(267)(196)
Research and development expenses(f)
282 219 272 
Acquired in-process research and development expenses(g)
2 (13)(339)
Restructuring charges and certain acquisition-related costs(h)
(45)— — 
Other income/(deductions)—net
(15)25 50 
(a)Represents sales to our partners of products manufactured by us.
(b)Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2024 was primarily driven by an increase in Alliance revenues from Eliquis and Xtandi, partially offset by a decrease in Alliance revenues from Bavencio. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis.
(c)Primarily relates to royalties from our collaboration partners.
(d)Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decreases in 2024 and in 2023 primarily relate to Comirnaty.
(e)Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
(f)Represents net reimbursements from our partners for research and development expenses incurred.
(g)Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.
(h)Relates to exit costs associated with terminating a collaboration with SMPS.
The amounts outlined in the above table do not include transactions with third parties other than our collaboration partners, or other costs for the products under the collaborative arrangements.
Research and Development Arrangement
Research and Development Funding Arrangement with Blackstone––In April 2023, we entered into an arrangement with Blackstone under which we will receive up to a total of $550 million in 2023 through 2026 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. The reduction to Research and development expenses in 2024 and 2023 was $135 million and $175 million,
respectively. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $468 million contingent upon the successful results of the clinical trials. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $550 million in total based on achievement of certain levels of cumulative applicable net sales, as well as royalties based on a mid-to-high single digit percentage of the applicable net sales. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product, and royalties on net sales will be recorded as Cost of sales when incurred.
XML 41 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Realigning our Cost Base Program
In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this multi-year effort to continue primarily through 2025 and to total approximately $2.9 billion, primarily representing cash expenditures for severance, exit and implementation costs as well as asset write downs of which $2.2 billion is associated with our Biopharma segment. From the start of this program through December 31, 2024, we incurred costs under this program of $2.6 billion, of which $2.1 billion is associated with our Biopharma segment (including $2.0 billion of restructuring charges).
B. Manufacturing Optimization Program
In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $1.6 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. These costs were recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026. From the start of this program through December 31, 2024, we incurred costs under this program of $1.2 billion, substantially all of which is restructuring costs for our Biopharma segment.
C. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Year Ended December 31,
(MILLIONS)202420232022
Restructuring charges/(credits):
Employee terminations$1,152 $1,622 $776 
Asset impairments432 227 52 
Exit costs
403 119 54 
Restructuring charges/(credits)(a)
1,987 1,968 882 
Transaction costs(b)
5 190 144 
Integration costs and other(c)
427 785 348 
Restructuring charges and certain acquisition-related costs
2,419 2,943 1,375 
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net
7 (7)(9)
Additional depreciation––asset restructuring recorded in our consolidated statements of operations as follows(d):
Cost of sales14 31 34 
Selling, informational and administrative expenses5 
Total additional depreciation––asset restructuring
19 32 36 
Implementation costs recorded in our consolidated statements of operations as follows(e):
Cost of sales120 67 54 
Selling, informational and administrative expenses90 289 560 
Research and development expenses84 101 
Total implementation costs
294 457 616 
Total costs associated with acquisitions and cost-reduction/productivity initiatives$2,738 $3,426 $2,018 
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).
(b)Represents external costs for banking, legal, accounting and other similar services.
(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2023 costs mostly relate to our acquisition of Seagen, including $476 million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of 2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our acquisitions of Arena and GBT, including $138 million in payments to Arena employees in the first quarter of 2022 and $136 million in payments to GBT employees in the fourth quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See Note 2A.
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
Costs
Asset
Impairment
Charges
Exit CostsAccrual
Balance, January 1, 2023
$1,196 $— $$1,204 
Provision1,622 227 119 1,968 
Utilization and other(a)
(840)(227)(116)(1,184)
Balance, December 31, 2023(b)
1,978 — 11 1,988 
Provision1,152 432 403 1,987 
Utilization and other(a)
(1,083)(432)(341)(1,856)
Balance, December 31, 2024(c)
$2,046 $ $74 $2,120 
(a)Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.
(b)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).
(c)Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
XML 42 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income)/Deductions—Net
12 Months Ended
Dec. 31, 2024
Other Income and Expenses [Abstract]  
Other (Income)/Deductions—Net Other (Income)/Deductions—Net
Components of Other (income)/deductions––net include:
Year Ended December 31,
(MILLIONS)202420232022
Interest income$(545)$(1,624)$(251)
Interest expense(a)
3,091 2,209 1,238 
Net interest expense(b)
2,546 585 987 
Net (gains)/losses recognized during the period on equity securities(c)
(1,008)(1,590)1,273 
Income from collaborations, out-licensing arrangements and sales of compound/product rights
(42)(154)(188)
Net periodic benefit costs/(credits) other than service costs154 (610)(849)
Certain legal matters, net(d)
567 474 230 
Certain asset impairments(e)
3,295 3,024 421 
Haleon equity method (income)/loss(f)
(102)(505)(436)
Other, net(g)
(1,022)(1,002)(378)
Other (income)/deductions––net
$4,388 $222 $1,062 
(a)Capitalized interest totaled $182 million in 2024, $160 million in 2023 and $124 million in 2022.
(b)The increase in net interest expense in 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $8 billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen.
(c)2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see Note 2C). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas.
(d)2024 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(e)The amount for 2024 represents intangible asset impairment charges, and includes $2.9 billion recorded in the fourth quarter associated with our Biopharma segment, due to changes in development plans and updated long-range commercial forecasts, composed of: (i) $1.0 billion for B7H4V (felmetatug vedotin), a Phase 1 IPR&D asset, (ii) $475 million for Medrol, a finite-lived brand, (iii) $435 million for Zavzpret nasal spray developed technology rights, (iv) $400 million and $200 million for Tukysa and disitamab vedotin, respectively, IPR&D assets reflecting emerging competition, as well as (v) other developed technology rights, IPR&D impairments and a finite-lived licensing agreement totaling $436 million which also includes de-prioritization of certain assets. 2024 also includes a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The amount for 2023 primarily represented intangible asset impairment charges of $3.0 billion, of which $2.9 billion was associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: (i) $1.4 billion for etrasimod (Velsipity) IPR&D, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 developed technology rights due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) $486 million for various other IPR&D assets and developed technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also included $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset impairment charges associated with our Biopharma segment of $200 million for an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million
associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics.
(f)See Note 2C.
(g)The amount for 2024 primarily includes, among other things, (i) gains of $945 million on the partial sales of our investment in Haleon in March and October 2024, (ii) dividend income of $272 million from our investment in ViiV and (iii) a charge of $420 million recorded in the third quarter related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. 2023 included, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included, among other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the fair value of contingent consideration.
Additional information about the intangible assets that were impaired during 2024 follows:
Year Ended
Fair Value(a)
December 31, 2024
(MILLIONS)AmountLevel 1Level 2Level 3Impairment
IPR&D(b)
$4,900 $ $ $4,900 $1,873 
Developed technology rights(b)
524   524 943 
Finite-lived brand(b)
270   270 475 
Finite-lived licensing agreement(b)
    5 
Total$5,694 $ $ $5,694 $3,295 
(a)The fair value amounts are presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
(b)Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
XML 43 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Tax Matters Tax Matters
A. Taxes on Income from Continuing Operations
Components of Income from continuing operations before provision/(benefit) for taxes on income include:
 Year Ended December 31,
(MILLIONS)202420232022
United States$(637)$(4,411)$5,032 
International8,660 5,469 29,697 
Income from continuing operations before provision/(benefit) for taxes on income(a), (b)
$8,023 $1,058 $34,729 
(a)2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
(b)2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.
Components of Provision/(benefit) for taxes on income based on the location of the taxing authorities include:
 Year Ended December 31,
(MILLIONS)202420232022
United States
Current income taxes:
Federal
$453 $1,321 $2,744 
State and local
32 (135)(20)
Deferred income taxes:
Federal
(1,909)(2,606)(3,271)
State and local
(293)(184)(310)
Total U.S. tax provision/(benefit)(1,717)(1,605)(857)
International
Current income taxes
1,588 1,142 4,368 
Deferred income taxes
100 (652)(183)
Total international tax provision/(benefit)1,689 490 4,185 
Provision/(benefit) for taxes on income
$(28)$(1,115)$3,328 
The changes in Provision/(benefit) for taxes on income impacting the effective tax rate year-over-year are summarized below:
2024 v. 2023
The tax benefit of $28 million for 2024 compared to the tax benefit of $1.1 billion for 2023 was primarily a result of changes in the jurisdictional mix of earnings partially offset by a tax benefit related to the Transition Tax liability under the TCJA.
2023 v. 2022
The tax benefit of $1.1 billion for 2023 compared to the tax provision of $3.3 billion for 2022 was primarily a result of changes in the jurisdictional mix of earnings and the resolution of uncertain tax positions in various markets. The 2023 pre-tax income included a greater percentage of expenses taxed at higher rates as compared to the 2022 pre-tax income, resulting in a 2023 tax benefit compared to the 2022 tax provision. These expenses included amortization expense, acquisition-related costs, restructuring charges and intangible asset impairment charges. The tax benefit for 2023 and the tax provision for 2022 included tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years. The tax provision for 2022 also included the closing of U.S. IRS audits covering five tax years.
In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in Provision/(benefit) for taxes on income (see Note 2A).
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The sixth annual installment was paid by its April 15, 2024 due date. The seventh annual installment is due April 15, 2025 and is reported in current Income taxes payable as of December 31, 2024. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.
Cash paid for income taxes, net of refunds, consisted of:
Year Ended December 31,
(MILLIONS)202420232022
United States$2,593 $1,923 $3,867 
International1,012 1,224 4,000 
Total$3,605 $3,147 $7,867 
B. Tax Rate Reconciliation
The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows:
 Year Ended December 31,
2024
2023^
2022
U.S. statutory income tax rate21.0 %21.0 %21.0 %
Taxation of non-U.S. operations(a), (b)
(7.9)(21.1)(5.0)
Transition Tax liability(c)
(6.0)— — 
Tax settlements and resolution of certain tax positions(c)
(2.4)(40.3)(3.0)
Foreign-Derived Intangible Income deduction(d)
(1.2)(33.1)(1.9)
State & local taxes(e)
(2.5)(22.4)— 
Charitable contributions
(1.7)(7.3)(0.5)
U.S. R&D tax credit(1.8)(15.8)(0.6)
Interest(f)
2.2 13.5 0.2 
All other, net(g)
0.1 0.2 (0.6)
Effective tax rate for income from continuing operations
(0.4)%(105.4)%9.6 %
^ The higher rate percentages for the 2023 reconciling items are significantly impacted by the lower domestic and international Income from continuing operations before provision/(benefit) for taxes on income (see Note 5A).
(a)For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income.
(b)In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We have Puerto Rican tax incentives pursuant to a grant that expires during 2053. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we have incentive tax rates effective through 2048 on income from manufacturing and other operations.
(c)See Note 5A.
(d)The higher rate benefit from the Foreign-Derived Intangible Income deduction in 2022 is mainly the result of the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.
(e)Includes the impact of U.S. state and local taxes and changes in the state valuation allowances including those related to the acquisition of Seagen.
(f)Includes changes in interest related to our uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”.
(g)All other, net is primarily due to routine business operations.
C. Deferred Taxes
Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:
2024 Deferred Tax^2023 Deferred Tax^
(MILLIONS)Assets(Liabilities)Assets(Liabilities)
Prepaid/deferred items(a)
$2,988 $(847)$2,658 $(654)
Accrued/deferred royalties1,306  1,655 — 
Deferred revenues
300  471 — 
Inventories(b)
992 (702)1,210 (1,060)
Intangible assets(c)
1,435 (9,066)1,526 (11,605)
Property, plant and equipment265 (1,751)168 (2,039)
Employee benefits(d)
1,002 (274)1,085 (287)
Restructurings and other charges462  537 — 
Legal and product liability reserves378  430 — 
Research and development(e)
7,635  6,275 — 
Net operating loss/tax credit carryforwards(f)
2,028  2,708 — 
Unremitted earnings (69)— (60)
State and local tax adjustments161  119 — 
Investments
73 (248)133 (395)
All other87 (66)62 (72)
19,112 (13,023)19,037 (16,172)
Valuation allowances(1,638) (1,738)— 
Total deferred taxes$17,474 $(13,023)$17,299 $(16,172)
Net deferred tax asset/(liability)(g), (h)
$4,451 $1,128 
^ The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See Note 1Q.
(a)The increase in net deferred tax assets in 2024 is primarily related to temporary differences associated with the timing of accruals recorded in the ordinary course of business.
(b)The increase in net deferred tax assets in 2024 is primarily due to measurement period adjustments of inventories related to Seagen. See Note 2A.
(c)The decrease in net deferred tax liabilities in 2024 is primarily due to amortization of intangible assets and certain impairment charges, as well as the measurement period adjustments of intangible assets related to Seagen.
(d)The decrease in net deferred tax assets in 2024 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See Note 11.
(e)The increase in deferred tax assets in 2024 is primarily related to the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.
(f)The amounts in 2024 and 2023 are reduced for unrecognized tax benefits of $575 million and $1.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
(g)In 2024, Noncurrent deferred tax assets and other noncurrent tax assets ($6.6 billion), and Noncurrent deferred tax liabilities ($2.1 billion). In 2023, Noncurrent deferred tax assets and other noncurrent tax assets ($1.8 billion), and Noncurrent deferred tax liabilities ($640 million).
(h)Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.3 billion and $11.1 billion for 2024 and 2023 respectively, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.
We have carryforwards, primarily related to net operating and capital losses, general business credits, foreign tax credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2025 to 2044. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section 382.
As of December 31, 2024, we have not made a U.S. tax provision on $58.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2024 is not practicable. The amount of indefinitely reinvested earnings is based on estimates and assumptions and subject to management evaluation, and is subject to change in the normal course of business based on operational cash flow, completion of local statutory financial statements and the finalization of tax returns and audits, among other things. Accordingly, we regularly update our earnings and profits analysis for such events.
D. Tax Contingencies
For a description of our accounting policies associated with accounting for income tax contingencies, see Note 1Q.
Uncertain Tax Positions
As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2024, we had $2.0 billion and as of December 31, 2023, we had $3.1 billion in net unrecognized tax benefits, excluding associated interest.
Tax assets for uncertain tax positions represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. In 2024, tax assets for uncertain tax positions also include the expected filing of an amended income tax return relating to the Transition Tax liability under the TCJA. As of December 31, 2024, we had $2.5 billion in assets associated with uncertain tax positions mainly included in Noncurrent deferred tax assets and other noncurrent tax assets. As of December 31, 2023, we had $1.7 billion in assets associated with uncertain tax positions mainly included in Noncurrent deferred tax assets and other noncurrent tax assets.
The majority of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.
The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:
(MILLIONS)202420232022
Balance, beginning$(4,802)$(4,494)$(6,068)
Acquisitions
8 (46)(52)
Increases based on tax positions taken during a prior period(a), (b)
(934)(158)(67)
Decreases based on tax positions taken during a prior period(a), (c)
599 310 1,339 
Decreases based on settlements for a prior period(c), (d)
911 85 842 
Increases based on tax positions taken during the current period(a)
(433)(515)(701)
Impact of foreign exchange52 (44)90 
Other, net(a), (e)
70 58 122 
Balance, ending(f)
$(4,530)$(4,802)$(4,494)
(a)Primarily included in Provision/(benefit) for taxes on income.
(b)In 2024, the amount includes a gross unrecognized tax benefit associated with the expected filing of an amended income tax return related to the Transition Tax liability under the TCJA.
(c)Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See Note 5A.
(d)Primarily related to cash payments and reductions of tax attributes.
(e)Primarily related to decreases as a result of a lapse of applicable statutes of limitations.
(f)In 2024, included in Income taxes payable ($103 million), Other current assets ($0.4 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.5 billion), Noncurrent deferred tax liabilities ($3 million) and Other taxes payable ($2.9 billion). In 2023, included in Income taxes payable ($94 million), Other current assets ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.3 billion), Noncurrent deferred tax liabilities ($4 million) and Other taxes payable ($3.4 billion).
Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in Provision/(benefit) for taxes on income. In 2024, we recorded a net increase in interest of $91 million. In 2023, we recorded a net increase in interest of $64 million. In 2022, we recorded a net decrease in interest of $17 million. Gross accrued interest totaled $636 million as of December 31, 2024 (reflecting a decrease of $56 million as a result of cash payments) and gross accrued interest totaled $605 million as of December 31, 2023 (reflecting a decrease of $11 million as a result of cash payments). In 2024 and 2023, these amounts were substantially all included in Other taxes payable. Accrued penalties are not significant. See also Note 5A.
Status of Tax Matters and Potential Impact on Accruals for Uncertain Tax Positions
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. During the third quarter of 2024, we effectively settled the audit of Pfizer’s federal income tax returns for years 2016-2018. Tax years 2019-2024 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions such as Canada (2017-2024), Europe (2012-2024, primarily in Ireland, the U.K., France, Italy, Spain and Germany), Asia Pacific (2014-2024, primarily in Australia, China, Japan and Singapore) and Latin America (1998-2024, primarily in Brazil).
Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $200 million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.
E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of the Tax provision/(benefit) on other comprehensive income/(loss) include:
 Year Ended December 31,
(MILLIONS)202420232022
Foreign currency translation adjustments, net(a)
$156 $(33)$(126)
Unrealized holding gains/(losses) on derivative financial instruments, net96 111 183 
Reclassification adjustments for (gains)/losses included in net income(29)(93)(270)
 67 18 (87)
Unrealized holding gains/(losses) on available-for-sale securities, net(19)(15)(164)
Reclassification adjustments for (gains)/losses included in net income5 (18)226 
 (14)(33)62 
Benefit plans: prior service (costs)/credits and other, net45 (5)(5)
Reclassification adjustments related to amortization of prior service costs and other, net(26)(28)(29)
Reclassification adjustments related to curtailments of prior service costs and other, net2 (4)(3)
 22 (37)(37)
Tax provision/(benefit) on other comprehensive income/(loss)$231 $(85)$(187)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
XML 44 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)
Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale Securities
Prior Service (Costs)/Credits and Other
Accumulated Other Comprehensive Income/(Loss)
Balance, January 1, 2022
$(6,172)$119 $(220)$377 $(5,897)
Other comprehensive income/(loss)(b)
(2,188)(531)440 (129)(2,407)
Balance, December 31, 2022
(8,360)(412)220 248 (8,304)
Other comprehensive income/(loss)(b)
497 195 (229)(120)343 
Balance, December 31, 2023
(7,863)(217)(9)128 (7,961)
Other comprehensive income/(loss)(b)
(121)274 (97)63 118 
Balance, December 31, 2024
$(7,984)$57 $(106)$191 $(7,842)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program and gains/(losses) related to our investment in Haleon (see Note 2C).
XML 45 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments
12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Financial Instruments Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
As of December 31, 2024As of December 31, 2023
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair value(a)
$7,848 $6,456 $1,392 $5,124 $— $5,124 
Available-for-sale debt securities:
Government and agency—non-U.S.6,855  6,855 817 — 817 
Government and agency—U.S.2,853  2,853 2,601 — 2,601 
Corporate and other1,173  1,173 982 — 982 
10,881  10,881 4,400 — 4,400 
Total short-term investments18,729 6,456 12,273 9,524 — 9,524 
Other current assets
Derivative assets:
Foreign exchange contracts1,056  1,056 298 — 298 
Total other current assets1,056  1,056 298 — 298 
Long-term investments
Equity securities with readily determinable fair values(b)
1,246 1,246  2,779 2,772 
Available-for-sale debt securities:
Government and agency—non-U.S.   124 — 124 
Corporate and other   26 — 26 
   150 — 150 
Total long-term investments1,246 1,246  2,929 2,772 156 
Other noncurrent assets
Derivative assets:
Interest rate contracts13  13 144 — 144 
Foreign exchange contracts447  447 258 — 258 
Total derivative assets460  460 402 — 402 
Insurance contracts(c)
875  875 790 — 790 
Total other noncurrent assets1,335  1,335 1,191 — 1,191 
Total assets$22,366 $7,701 $14,665 $13,943 $2,772 $11,170 
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$28 $ $28 $16 $— $16 
Foreign exchange contracts217  217 404 — 404 
Total other current liabilities245  245 420 — 420 
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts397  397 275 — 275 
Foreign exchange contracts723  723 725 — 725 
Total other noncurrent liabilities1,121  1,121 1,000 — 1,000 
Total liabilities$1,366 $ $1,366 $1,420 $— $1,420 
(a)Includes money market funds. As of December 31, 2024, short-term equity securities include our investment in Haleon of $6.5 billion. See Note 2C.
(b)Long-term equity securities of $133 million as of December 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis––The carrying value of Long-term debt, excluding the current portion was $57 billion as of December 31, 2024 and $62 billion as of December 31, 2023. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $54 billion as of December 31, 2024 and $61 billion as of December 31, 2023.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2024 and 2023. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term, Long-Term and Equity-Method Investments
The following summarizes our investments by classification type:
As of December 31,
(MILLIONS)20242023
Short-term investments
Equity securities with readily determinable fair values(a)
$7,848 $5,124 
Available-for-sale debt securities10,881 4,400 
Held-to-maturity debt securities705 313 
Total Short-term investments$19,434 $9,837 
Long-term investments
Equity securities with readily determinable fair values(b)
$1,246 $2,779 
Available-for-sale debt securities 150 
Held-to-maturity debt securities45 47 
Private equity securities at cost(b)
719 755 
Total Long-term investments
$2,010 $3,731 
Equity-method investments(a)
217 11,637 
Total long-term investments and equity-method investments$2,228 $15,368 
Held-to-maturity cash equivalents$184 $207 
(a)As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
(b)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
As of December 31, 2024As of December 31, 2023
Gross UnrealizedMaturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5
Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$6,970 $8 $(123)$6,855 $6,855 $ $ $953 $$(14)$941 
Government and agency––U.S.
2,853   2,853 2,853   2,601 — — 2,601 
Corporate and other1,179  (6)1,173 1,173   1,006 (2)1,007 
Held-to-maturity debt securities
Time deposits and other
697   697 657 21 19 561 — — 561 
Government and agency––non-U.S.
237   237 232 4 1 — — 
Total debt securities$11,935 $8 $(129)$11,814 $11,770 $25 $20 $5,126 $$(16)$5,115 
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Year Ended December 31,
(MILLIONS)202420232022
Net (gains)/losses recognized during the period on equity securities(a)
$(1,008)$(1,590)$1,273 
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(1,122)(1,754)(126)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)
$114 $165 $1,400 
(a)Reported in Other (income)/deductions––net. See Note 4.
(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $360 million and upward adjustments of $222 million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022.
C. Short-Term Borrowings
Short-term borrowings include:
As of December 31,
(MILLIONS)20242023
Commercial paper, principal amount(a)
$2,453 $7,965 
Current portion of long-term debt, principal amount3,750 2,250 
Other short-term borrowings, principal amount(b)
755 252 
Total short-term borrowings, principal amount
6,957 10,467 
Net fair value adjustments related to hedging and purchase accounting
 
Net unamortized discounts, premiums and debt issuance costs(12)(121)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted
$6,946 $10,350 
(a)Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see Note 2A). The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94% as of December 31, 2024 and 5.37% as of December 31, 2023.
(b)Primarily includes cash collateral. See Note 7F.
As of December 31, 2024, we had access to a total of $15 billion in committed U.S. revolving credit facilities, consisting of an $8 billion facility maturing in October 2025 (subsequently terminated by Pfizer in February 2025), and a $7 billion facility maturing in October 2029, which may be used for general corporate purposes including to support our global commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional $276 million in lines of credit, of which $243 million expire within one year. Essentially all lines of credit were unused as of December 31, 2024.
D. Long-Term Debt
The following outlines our senior unsecured long-term debt(a) and the weighted-average stated interest rate by maturity:
As of December 31,
(MILLIONS)20242023
Notes due 2025 (3.9% for 2023)(b)
$ $3,750 
Notes due 2026 (3.7% for 2024 and 2023)
6,000 6,000 
Notes due 2027 (2.2% for 2024 and 2.1% for 2023)
980 1,029 
Notes due 2028 (4.6% for 2024 and 2023)
5,660 5,660 
Notes due 2029 (3.5% for 2024 and 2023)
1,750 1,750 
Notes due 2030 (3.6% for 2024 and 2023)
5,250 5,250 
Notes due 2031-2035 (4.5% for 2024 and 2023)
6,750 6,750 
Notes due 2036-2040 (5.4% for 2024 and 2023)
9,534 9,543 
Notes due 2041-2045 (4.3% for 2024 and 2023)
6,474 6,501 
Notes due 2046-2050 (3.7% for 2024 and 2023)
4,750 4,750 
Notes due 2051-2063 (5.3% for 2024 and 2023)
10,000 10,000 
Total long-term debt, principal amount57,147 60,982 
Net fair value adjustments related to hedging and purchase accounting701 1,039 
Net unamortized discounts, premiums and debt issuance costs(444)(483)
Total long-term debt, carried at historical proceeds, as adjusted$57,405 $61,538 
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023))
$3,747 $2,254 
(a)Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.
(b)Reclassified to the current portion of long-term debt.
Issuance—In May 2023, we issued, through our wholly-owned finance subsidiary, PIE, $31 billion principal amount of senior unsecured notes at an effective interest rate of 4.93% as part of the financing for our acquisition of Seagen. The notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc. PIE was formed to finance a portion of the consideration for the acquisition of Seagen and has no assets or operations, and will have no assets or operations, other than as related to the issuance, administration and repayment of the notes and any other debt securities that it may issue in the future.
E. Derivative Financial Instruments and Hedging Activities
Foreign Exchange Risk––A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Chinese renminbi, Japanese yen, Canadian dollar and Swedish krona, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments of our foreign business entities.
Changes in fair value are reported in earnings or in Other comprehensive income/(loss), depending on the nature and purpose of the financial instrument (hedge or offset relationship). For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize the excluded amount through an amortization approach in earnings. The hedge relationships are as follows:
Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged item. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.
Generally, we record in Other comprehensive income/(loss) gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts into earnings in the same period or periods during which the hedged transaction affects earnings.
We record in Other comprehensive income/(loss)––Foreign currency translation adjustments, net the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments.
For foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses immediately into earnings along with the earnings impact of the items they generally offset. These contracts take the opposite currency position of that reflected on the balance sheet to counterbalance the effect of any currency movement.
Interest Rate Risk––Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.
We recognize the change in fair value on interest rate contracts that are designated as fair value hedges in earnings, as well as the offsetting earnings impact of the hedged risk attributable to the hedged item.
The following summarizes the fair value of the derivative financial instruments and notional amounts:
(MILLIONS)
As of December 31, 2024
As of December 31, 2023
Fair ValueFair Value
NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,991 $1,250 $719 $18,750 $403 $916 
Interest rate contracts
6,750 13 425 6,750 144 290 
1,263 1,144 546 1,206 
Derivatives not designated as hedging instruments:
Foreign exchange contracts
$26,335 253 221 $25,609 154 214 
Total$1,516 $1,366 $700 $1,420 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.
The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:
 

Gains/(Losses)
Recognized in OID
(a)
Gains/(Losses)
Recognized in OCI
(a)
Gains/(Losses)
Reclassified from
OCI into OID and COS
(a)
Year Ended December 31,
(MILLIONS)202420232024202320242023
Derivative Financial Instruments in Cash Flow Hedge Relationships:
      
Interest rate contracts$ $— $ $68 $ $
Foreign exchange contracts(b)
 — 466 380 124 236 
Amount excluded from effectiveness testing and amortized into earnings(c)
 — 34 178 34 177 
Derivative Financial Instruments in Fair Value Hedge Relationships:
Interest rate contracts(253)196  —  — 
Hedged item 253 (196) —  — 
Derivative Financial Instruments in Net Investment Hedge Relationships:
Foreign exchange contracts — 498 (393) — 
Amount excluded from effectiveness testing and amortized into earnings(c)
 — 119 137 154 136 
Non-Derivative Financial Instruments in Net Investment Hedge Relationships(d):
Foreign currency short-term borrowings —  —  — 
Foreign currency long-term debt — 49 (29) — 
Derivative Financial Instruments Not Designated as Hedges:
Foreign exchange contracts50 164  —  — 
$50 $164 $1,166 $341 $313 $549 
(a)OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss).
(b)The amounts reclassified from OCI into COS were a net gain of $119 million in 2024 and a net gain of $253 million in 2023. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $330 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 18 years and relates to foreign currency debt.
(c)The amounts reclassified from OCI were reclassified into OID.
(d)Long-term debt includes foreign currency borrowings which are used in net investment hedges; the related carrying values as of December 31, 2024 and December 31, 2023 were $777 million and $824 million, respectively.
The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:
As of December 31, 2024
As of December 31, 2023
Cumulative Amount of Fair
Value Hedging Adjustment
Increase/(Decrease) to
Carrying Amount
Cumulative Amount of Fair
Value Hedging Adjustment Increase/(Decrease) to
Carrying Amount
(MILLIONS)
Carrying Amount of Hedged Assets/Liabilities(a)
Active
Hedging
Relationships
Discontinued Hedging Relationships
Carrying Amount of Hedged Assets/Liabilities(a)
Active Hedging RelationshipsDiscontinued Hedging Relationships
Long-term debt$7,154 $(384)$891 $7,196 $(131)$957 
(a)Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
F. Credit Risk
On an ongoing basis, we monitor and review the credit risk of our customers, financial institutions and exposures in our investment portfolio.
With respect to our trade accounts receivable, we monitor the creditworthiness of our customers to which we grant credit in the normal course of business. In general, there is no requirement for collateral from customers. For additional information on our trade accounts receivable and allowance for credit losses, see Note 1G. A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see Note 17C.
With respect to our investments, we monitor concentrations of credit risk associated with government, government agency, and corporate issuers of securities. Investments are placed in instruments that are investment grade and are primarily short in duration. Exposure limits are established to limit a concentration with any single credit counterparty. As of December 31, 2024, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by the U.S., Canada, and the U.K.
With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of December 31, 2024, the aggregate fair value of these derivative financial instruments that are in a net payable position was $741 million, for which we have posted collateral of $720 million with a corresponding amount reported in Short-term investments. As of December 31, 2024, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $594 million, for which we have received collateral of $716 million with a corresponding amount reported in Short-term borrowings, including current portion of long-term debt.
XML 46 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Financial Information
12 Months Ended
Dec. 31, 2024
Other Financial Information [Abstract]  
Other Financial Information Other Financial Information
A. Inventories
The following summarizes the components of Inventories:
As of December 31,
(MILLIONS)20242023
Finished goods$3,775 $3,495 
Work-in-process6,101 5,688 
Raw materials and supplies976 1,007 
Inventories(a)
$10,851 $10,189 
Noncurrent inventories not included above(b)
$2,663 $4,568 
(a)The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches.
(b)Included in Other noncurrent assets. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See Note 2A. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
B. Other Current Liabilities
Other current liabilities include, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $1.3 billion as of December 31, 2024 and $2.0 billion as of December 31, 2023.
C. Supplier Finance Program Obligation
We maintain voluntary supply chain finance agreements with several participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Pfizer to these financial institutions. Our suppliers negotiate their financing agreements directly with the respective financial institutions and we are not a party to these agreements. We have no economic interest in our suppliers’ decision to participate and we pay the financial institutions the stated amount of confirmed invoices on the original maturity dates, which is generally within 90 to 120 days of the invoice date. The agreements with the financial institutions do not require Pfizer to provide assets pledged as security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in such financing arrangements are recorded within trade payables in our consolidated balance sheet.
The following summarizes the changes in outstanding trade payables to suppliers who participate in these financing arrangements for the year ended December 31, 2024
(MILLIONS)
Total
Confirmed obligations outstanding, December 31, 2023
$791 
Invoices confirmed during the year
2,638 
Confirmed invoices paid during the year
(2,740)
Confirmed obligations outstanding, December 31, 2024
$688 
XML 47 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1
Property, Plant and Equipment, Net
12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, Net Property, Plant and Equipment, Net
The following summarizes the components of Property, plant and equipment, net:
 Useful LivesAs of December 31,
(MILLIONS)(Years)  20242023
Land-$291 $353 
Buildings
33-50
9,036 9,046 
Machinery and equipment
8-20
15,095 14,263 
Furniture, fixtures and other
3-12.5
5,516 5,399 
Construction in progress-4,937 5,925 
34,876 34,985 
Less: Accumulated depreciation16,483 16,045 
Property, plant and equipment, net
$18,393 $18,940 
The following provides Property, plant and equipment, net by geographic area:
 As of December 31,
(MILLIONS)20242023
United States$9,748 $10,674 
International:
Developed Markets7,187 6,713 
Emerging Markets1,458 1,554 
Property, plant and equipment, net
$18,393 $18,940 
XML 48 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
Identifiable Intangible Assets, Net and Goodwill
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Identifiable Intangible Assets, Net and Goodwill Identifiable Intangible Assets, Net and Goodwill
A. Identifiable Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2024As of December 31, 2023
(MILLIONS)Gross
Carrying
Amount
Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount
Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$99,397 $(65,044)$34,353 $99,267 $(60,493)$38,773 
Brands(b)
1,277 (992)285 922 (877)45 
Licensing agreements and other
2,724 (1,513)1,210 2,756 (1,458)1,297 
103,397 (67,549)35,848 102,944 (62,828)40,116 
Indefinite-lived intangible assets
Brands(b)
  827 827 
IPR&D(c)
18,893 18,893 23,193 23,193 
Licensing agreements and other
670 670 763 763 
19,563 19,563 24,784 24,784 
Identifiable intangible assets(d)
$122,961 $(67,549)$55,411 $127,728 $(62,828)$64,900 
(a)The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see Note 4).
(b)The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see Note 4).
(c)The decrease in the gross carrying amount reflects impairments of $1.9 billion (see Note 4), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see Note 2A), and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna).
(d)The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see Note 4) and measurement period adjustments related to our acquisition of Seagen of $950 million (see Note 2A).
Developed Technology Rights––Developed technology rights represent the cost for developed technology acquired from third parties and can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing our commercialized products. The significant components of developed technology rights are the following: Nurtec ODT/Vydura, Adcetris, Padcev, Xtandi, Velsipity and Braftovi/Mektovi. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain prescription pharmaceutical products.
Brands––Brands represent the cost for tradenames and know-how, as the products themselves do not receive patent protection. The significant components of Finite-lived brands primarily include Medrol.
IPR&D––IPR&D assets represent the acquisition date fair value (less impairments) of R&D assets acquired through business combinations that have not yet received regulatory approval in a major market which could include both new investigational products and additional
indications for in-line products. The significant components of IPR&D are SGN-B6A, disitamab vedotin, GBT601 and Tukysa. IPR&D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&D effort. Accordingly, during the development period after the date of acquisition, these assets are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify it out of IPR&D and begin amortization. If the associated R&D effort is abandoned, the related IPR&D assets will be written-off, and we will record an impairment charge. IPR&D assets are high-risk assets, given the uncertain nature of R&D. Accordingly, IPR&D assets may become impaired and/or be written-off in the future.
Licensing Agreements––Licensing agreements for developed technology and for technology in development primarily relate to out-licensing arrangements acquired from third parties, including from acquisitions. These assets represent the cost for the license, where we acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partners. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will be written-off, and we will record an impairment charge.
Amortization––The weighted-average life for our total finite-lived intangible assets and for the largest component, developed technology rights, is approximately 10 years.
The following provides the expected annual amortization expense:
(MILLIONS)20252026202720282029
Amortization expense$4,838 $4,716 $4,125 $3,776 $2,829 
B. Goodwill
The following summarizes the changes in the carrying amount of Goodwill:
(MILLIONS)
Total(a)
Balance, January 1, 2023
$51,375 
Additions(b)
16,117 
Impact of foreign exchange and other
292 
Balance, December 31, 2023
67,783
Additions(b)
1,022 
Impact of foreign exchange
(278)
Balance, December 31, 2024
$68,527 
(a)As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 17A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
(b)Additions primarily represent our acquisition of Seagen in 2023 and measurement period adjustments related to our acquisition of Seagen in 2024 (see
Note 2A).
XML 49 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans
12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Pension and Postretirement Benefit Plans and Defined Contribution Plans Pension and Postretirement Benefit Plans and Defined Contribution Plans
The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans.
A. Components of Net Periodic Benefit Cost/(Credit) and Changes in Other Comprehensive Income/(Loss)
Pension Plans
Postretirement Plans
U.S.International
Year Ended December 31,
(MILLIONS)202420232022202420232022202420232022
Service cost$ $— $— $87 $85 $116 $14 $12 $29 
Interest cost553 589 534 312 287 157 23 21 27 
Expected return on plan assets
(832)(778)(862)(322)(304)(296)(51)(44)(47)
Amortization of prior service cost/(credit)1 4 — (1)(113)(119)(130)
Actuarial (gains)/losses(a)
396 (410)225 33 102 (11)144 51 (440)
Curtailments — — (4)(2)(11) (12)(18)
Special termination benefits
 18 10 —  — 
Net periodic benefit cost/(credit) reported in income117 (592)(84)120 169 (45)18 (90)(578)
Cost/(credit) reported in Other comprehensive income/(loss)
(1)(2)(2)(4)31 (1)(80)128 169 
Cost/(credit) recognized in Comprehensive income
$116 $(594)$(86)$117 $199 $(46)$(62)$38 $(410)
(a)Reflects: (i) actuarial remeasurement net losses in 2024, primarily due to unfavorable asset performance for the U.S. pension plans and decreases in discount rates for the international pension plans, partially offset by increases in discount rates for the U.S. pension plans and favorable asset performance for the international pension plans and postretirement plans, (ii) actuarial remeasurement net gains in 2023, primarily due to favorable asset performance in the U.S. and increases in discount rates for the international plans, partially offset by unfavorable asset performance for certain international plans, and (iii) actuarial remeasurement net gains in 2022, primarily due to increases in discount rates, partially offset by unfavorable asset performance.
The components of net periodic benefit cost/(credit) other than the service cost component are included in Other (income)/deductions––net (see Note 4).
B. Actuarial Assumptions
Pension PlansPostretirement Plans
U.S.International
Year Ended December 31,
(PERCENTAGES)202420232022202420232022202420232022
Weighted-average assumptions used to determine net periodic benefit cost:
Discount rate:
Pension plans/postretirement plans5.4 %5.4 %2.9 %5.4 %5.5 %2.9 %
Interest cost4.4 %3.8 %1.5 %
Service cost3.9 %3.6 %1.7 %
Expected return on plan assets8.0 %7.5 %6.3 %5.1 %4.5 %3.1 %8.0 %7.5 %6.3 %
Rate of compensation increase(a)
3.2 %3.0 %2.8 %
Weighted-average assumptions used to determine benefit obligations at fiscal year-end:
Discount rate5.7 %5.4 %5.4 %4.1 %4.4 %3.8 %5.5 %5.4 %5.5 %
Rate of compensation increase(a)
3.1 %3.2 %3.0 %
(a)The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.
The assumptions are reviewed at least annually. We revise these assumptions based on an annual evaluation of long-term trends as well as market conditions that may have an impact on the cost of providing retirement benefits.
The weighted-average discount rate for our U.S. defined benefit plans is set with reference to the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2024 resulted in higher discount rates for the U.S. pension plans and lower discount rates for the international pension plans as compared to the prior year.
The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:
As of December 31,
20242023
Healthcare cost trend rate assumed for next year 7.5 %7.9 %
Rate to which the cost trend rate is assumed to decline4.0 %4.0 %
Year that the rate reaches the ultimate trend rate2047 2047 
C. Obligations and Funded Status
The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
 Pension Plans Postretirement Plans
 U.S. International
Year Ended December 31,
(MILLIONS)202420232024202320242023
Change in benefit obligation(a)
Benefit obligation, beginning$10,756 $11,420 $7,292 $7,497 $450 $410 
Service cost — 87 85 14 12 
Interest cost553 589 312 287 23 21 
Employee contributions — 16 11 61 52 
Plan amendments —  25 (193)— 
Changes in actuarial assumptions and other(b)
(299)(127)119 (518)199 96 
Foreign exchange impact(1)— (106)280 (2)(1)
Acquisitions/divestitures, net — 77 13  — 
Curtailments and special termination benefits 7 —  (3)
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Benefit obligation, ending(a)
9,781 10,756 7,363 7,292 486 450 
Change in plan assets
Fair value of plan assets, beginning
10,935 10,871 6,552 6,865 636 647 
Actual return on plan assets138 1,061 408 (316)105 89 
Company contributions103 134 164 154  (15)
Employee contributions — 16 11 61 52 
Foreign exchange impact — (65)214  — 
Acquisitions/divestitures, net — 62 13  — 
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Fair value of plan assets, ending9,948 10,935 6,696 6,552 736 636 
Funded status$167 $179 $(667)$(740)$251 $186 
Amounts recorded in our consolidated balance sheet:
Noncurrent assets$934 $1,010 $728 $644 $330 $266 
Current liabilities(90)(94)(31)(28)(5)(6)
Noncurrent liabilities(678)(738)(1,364)(1,355)(74)(74)
Funded status$167 $179 $(667)$(740)$251 $186 
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
Prior service (costs)/credits$(2)$(2)$(61)$(65)$365 $285 
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):
Fair value of plan assets
$ $— $456 $579 
ABO768 831 1,752 1,834 
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):
Fair value of plan assets$ $— $690 $964 
PBO768 831 2,084 2,347 
(a)For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.
(b)For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.
(c)Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.
D. Plan Assets
The following provides the components of plan assets:
As of December 31, 2024As of December 31, 2023
    Fair ValueFair Value
(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)Target Allocation PercentageTotalLevel 1Level
2
Level 3
Assets Measured at NAV(a)
TotalLevel 1Level
 2
Level 3
Assets Measured at NAV(a)
U.S. pension plans
Cash and cash equivalents0-10%$533 $56 $477 $ $ $606 $47 $559 $— $— 
Equity securities:10-40%
Global equity securities1,341 1,341    1,537 1,537 — — 
Equity commingled funds97  97   100 — 100 — — 
Fixed income securities:45-80%
Corporate debt securities2,878 4 2,874   3,668 3,667 — — 
Government and agency obligations(b)
2,059  2,059   1,971 — 1,971 — — 
Fixed income commingled funds42  12  30 25 — 14 — 11 
Other investments:5-35%
Partnership investments(c)
2,665    2,665 2,449 — — — 2,449 
Insurance contracts     99 — 99 — — 
Other commingled funds(d)
333    333 479 — — — 479 
Total100 %$9,948 $1,401 $5,518 $ $3,028 $10,935 $1,585 $6,410 $$2,939 
International pension plans
Cash and cash equivalents0-10%$310 $138 $172 $ $ $268 $120 $148 $— $— 
Equity securities:10-20%
Equity commingled funds704  619  86 633 — 587 — 46 
Fixed income securities:45-70%
Corporate debt securities638  633 5  617 — 617 — — 
Government and agency obligations(b)
960 1 960   848 — 848 — — 
Fixed income commingled funds1,750  1,064  686 1,852 — 872 — 980 
Other investments:15-35%
Partnership investments(c)
147  2  145 145 — — 142 
Insurance contracts1,221  45 1,176  1,151 — 55 1,096 — 
Other(d)
965 35 147 252 531 1,039 — 167 244 628 
Total100 %$6,696 $174 $3,642 $1,433 $1,447 $6,552 $120 $3,295 $1,340 $1,796 
U.S. postretirement plans(e)
Cash and cash equivalents0-5%$12 $ $12 $ $ $$$$— $— 
Insurance contracts95-100%724  724   633 — 633 — — 
Total100 %$736 $ $736 $ $ $636 $$635 $— $— 
(a)Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.
(b)Government and agency obligations are inclusive of repurchase agreements.
(c)Mainly includes investments in private equity, private debt and real estate.
(d)Mostly includes investments in hedge funds and real estate.
(e)Reflects postretirement plan assets, which support our U.S. retiree medical plans.
The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:
International Pension Plans
Year Ended December 31,
(MILLIONS)20242023
Fair value, beginning$1,340 $1,455 
Actual return on plan assets:
Assets held, ending8 (96)
Assets sold during the period (3)
Purchases, sales, and settlements, net
(79)(155)
Transfer into/(out of) Level 3168 81 
Exchange rate changes(5)59 
Fair value, ending$1,433 $1,340 
The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:
Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.
Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.
Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.
Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Level 3 investments may include securities or insurance contracts that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.
Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.
Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.
Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.
E. Cash Flows
It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.
The following provides the expected future cash flow information related to our benefit plans:
  Pension PlansPostretirement Plans
(MILLIONS)U.S.International
Expected employer contributions:
2025
$90 $144 $40 
Expected benefit payments:
2025$871 $384 $44 
2026858 366 47 
2027844 384 49 
2028
825 385 50 
2029
815 392 50 
2030–2034
3,760 2,067 245 
The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation.
F. Defined Contribution Plans
We have defined contribution plans in the U.S. and other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. We also offer a Retirement Savings Contribution which is an annual non-contributory employer contribution in the U.S. and Puerto Rico. We recorded charges related to the employer contributions to global defined contribution plans of $800 million in 2024, $843 million in 2023 and $770 million in 2022.
XML 50 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Equity Equity
A. Common Stock Purchases
We have authorization to purchase our common stock through privately negotiated transactions or in the open market as circumstances and prices warrant. Purchased shares under a share-purchase plan, which is authorized by our BOD, are available for general corporate purposes. In December 2018, the BOD authorized a $10 billion share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019.
In the first quarter of 2022, we purchased 39 million shares of our common stock at a cost of $2 billion under our publicly announced share-purchase plan. Our remaining share-purchase authorization was $3.3 billion as of December 31, 2024.
B. Preferred Stock
We have 27 million authorized shares of preferred stock without par value; no shares were issued or outstanding as of December 31, 2024 and 2023.
C. Employee Stock Ownership Plans
We have one ESOP that holds common stock of the Company (Common ESOP). As of December 31, 2024, all shares of common stock held by the Common ESOP have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was $16 million for 2024, $20 million for 2023 and $19 million for 2022.
XML 51 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Payments Share-Based Payments
Our compensation programs can include share-based payment awards with value that is determined by reference to the fair value of our shares and that provide for the grant of shares or options to acquire shares or similar arrangements. Our share-based awards are designed based on competitive survey data or industry peer groups used for compensation purposes, and are allocated between different long-term incentive awards, generally in the form of Total Shareholder Return Units (TSRUs), Restricted Stock Units (RSUs), Portfolio Performance Shares (PPSs), Performance Share Awards (PSAs), Breakthrough Performance Awards (BPAs) and stock options, as determined by the Compensation Committee of our BOD. No BPAs were granted in 2024 and no BPAs were outstanding as of December 31, 2024.
The Amended and Restated 2019 Stock Plan (2019 Plan) replaced and superseded the original 2019 Stock Plan. The 2019 Plan provides for 320 million shares to be authorized for grants plus any shares remaining available for grant under the original 2019 Stock Plan as of April 25, 2024 (the carryforward shares). The RSUs count as three shares, and PPSs, PSAs and BPAs count as three shares times the maximum potential payout, while TSRUs and stock options count as one share, toward the maximum shares available under the 2019 Plan. As of December 31, 2024, 441 million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.
A summary of the awards and valuation details:
Awarded toTermsValuationRecognition and Presentation
Total Shareholder Return Units (TSRUs)
Senior and other key management and select employees
Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the five or seven-year term, if and to the extent the total value is positive.
Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.
Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant. Certain 2022 and 2023 five-year grants were modified during 2024 (for active colleagues) to vest on the fifth anniversary and settle on the seventh anniversary of the grant.
Retirement-eligible holders can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs’ original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.
As of the grant date using a Monte Carlo simulation model
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Restricted Stock Units (RSUs)
Select employees
Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.
For RSUs granted before 2022, generally in all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date. Beginning in 2022, generally in all instances, the units vest and distribute one-third per year for three years on each of the three annual anniversaries from the date of grant assuming continuous service from the grant date.
As of the grant date using the closing price of our common stock
Amortized on a straight-line basis for RSUs granted before 2022, and on an accelerated attribution approach for RSUs granted beginning in 2022, over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Portfolio Performance Shares (PPSs)
Select employees
Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.
For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a three or five-year performance period from the year of the grant date, as applicable.
The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management’s assessment of the probability that the specified performance criteria will be achieved.
Performance Share Awards (PSAs)
Senior and other key management
Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:
a.Adjusted net income over three one-year periods; and
b.TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the three-year performance period.
PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. PSA awards granted in 2022 and 2023 were modified during 2024 (for active colleagues) to vest on the fifth anniversary of the grant.
The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved.
Awarded toTermsValuationRecognition and Presentation
Breakthrough Performance Awards (BPAs)
Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)
Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.
For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the one-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer’s product pipeline during the performance period.
The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved and/or management’s assessment of the probable vesting term.
Stock Options
Select employees
Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.
Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.
Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years.
As of the grant date using the Black-Scholes-Merton option-pricing model
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:
(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION AND YEARS)
TSRUsRSUsPPSsPSAsStock Options
Year Ended December 31,202420232022202420232022202420232022202420232022202420232022
Total fair value of shares vested(a)
$7.05$10.71$11.72$469$505$345$176$116$145$ $58$57$4.08$7.88$9.44
Total intrinsic value of options exercised or share units converted$29$755$1,131$123$250$280$ $102$247
Cash received upon exercise$ $181$260
Tax benefits realized from exercise$ $20$46
Compensation cost recognized/(reduced), pre-tax
$246$244$255$394$437$402$252$(138)$144$(21)$(5)$73$4$4$4
Total compensation cost related to nonvested awards not yet recognized, pre-tax$270$192$179$214$212$266$107$81$135$40$22$38$4$4$3
Weighted-average period over which cost is expected to be recognized (years)2.11.71.71.81.81.71.91.81.71.71.81.81.71.71.7
(a)Weighted-average GDFV per TSRUs and stock options.
Total share-based payment expense was $877 million, $525 million and $872 million in 2024, 2023 and 2022, respectively. Tax benefit for share-based compensation expense was $165 million, $93 million and $160 million in 2024, 2023 and 2022, respectively.
The table above excludes total expense due to the modification for share-based awards in connection with our cost reduction/productivity initiatives, which was not significant for all years presented and is recorded in Restructuring charges and certain acquisition-related costs (see Note 3). Amounts capitalized as part of inventory cost were not significant for any period presented.
Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:
TSRUsStock Options
Year Ended December 31,202420232022202420232022
Expected dividend yield (based on a constant dividend yield during the expected term)
6.06 %3.80 %3.42 %6.06 %3.80 %3.42 %
Risk-free interest rate (based on interpolated yield on U.S. Treasury zero-coupon issues)
4.31 %4.08 %1.87 %4.32 %4.03 %1.93 %
Expected stock price volatility (based on implied volatility, after consideration of historical volatility)
26.56 %23.23 %29.20 %26.56 %23.23 %29.21 %
TSRUs contractual/stock options expected term, years (based on historical exercise and post-vesting termination patterns for stock options)
5.155.155.176.506.506.50
Summary of all TSRU, RSU, PPS and PSA activity during 2024 (with the shares granted representing the maximum award that could be achieved for PPSs and PSAs):
TSRUsRSUs
PPSs(a)
PSAs
TSRUs Per TSRU, Weighted AverageShares  Weighted Avg. GDFV per shareShares Weighted Avg. Intrinsic Value per shareShares Weighted Avg. Intrinsic Value per share
(Thousands)GDFVGrant Price(Thousands)(Thousands)(Thousands)
Nonvested, December 31, 2023
77,673$9.67 $39.92 25,844$40.08 22,225$28.79 4,734$28.79 
Granted43,6747.05 26.90 17,07326.97 13,53526.92 2,59726.89 
Vested(31,076)7.42 33.87 (16,874)37.89 (6,329)27.76   
Reinvested dividend equivalents1,541 28.17 
Forfeited(5,370)8.66 33.90 (2,024)32.20 (3,274)28.03 (1,810)27.79 
Nonvested, December 31, 2024
84,902$9.63 $35.87 25,561$32.67 26,156$26.53 5,521$26.53 
(a)Vested and non-vested shares outstanding, but not paid as of December 31, 2024 were 33.9 million.
Summary of TSRU and PTU information as of December 31, 2024(a), (b):
TSRUs
(Thousands)
PTUs
(Thousands)
Weighted-Average
Grant Price
Per TSRU
Weighted-Average
Remaining Contractual Term (Years)
Aggregate Intrinsic Value (Millions)(c)
TSRUs Outstanding167,977 $34.17 2.5$122 
TSRUs Vested83,075 32.44 0.786 
TSRUs Expected to vest(d)
80,014 $35.93 4.334 
Outstanding PTUs converted from TSRUs exercised586 0.2$16 
(a)In 2024, we settled 2,419,674 TSRUs with a weighted-average grant price of $27.76 per unit.
(b)In 2024, 1,150,382 TSRUs with a weighted-average grant price of $31.54 per unit were converted into 100,307 PTUs.
(c)Market price of our underlying common stock less grant price plus dividend equivalents to date.
(d)The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.
Summary of all stock option activity during 2024:
Shares
(Thousands)
Weighted-Average
Exercise Price
Per Share
Weighted-Average
Remaining Contractual Term
(Years)
Aggregate
Intrinsic Value(a)
(Millions)
Outstanding, December 31, 2023
28,452 $32.66 
Granted1,372 26.90 
Exercised(4)29.06 
Forfeited(235)33.52 
Expired(9,964)30.69   
Outstanding, December 31, 2024
19,621 33.24 1.9$ 
Vested and expected to vest, December 31, 2024(b)
19,510 33.26 1.9 
Exercisable, December 31, 2024
17,447 $33.12 1.1$ 
(a)Market price of our underlying common stock less exercise price.
(b)The number of options expected to vest takes into account an estimate of expected forfeitures.
XML 52 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
The following presents the detailed calculation of EPS:
 Year Ended December 31,
(MILLIONS)
202420232022
EPS Numerator  
Income from continuing operations attributable to Pfizer Inc. common shareholders$8,020 $2,134 $31,366 
Discontinued operations––net of tax11 (15)
Net income attributable to Pfizer Inc. common shareholders$8,031 $2,119 $31,372 
EPS Denominator  
Weighted-average common shares outstanding––Basic
5,664 5,643 5,608 
Common-share equivalents36 66 125 
Weighted-average common shares outstanding––Diluted
5,700 5,709 5,733 
Anti-dilutive common stock equivalents(a)
24 
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
XML 53 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases
12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Leases Leases
We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $517 million in 2024, $444 million in 2023 and $536 million in 2022. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.
We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.
For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:
As of December 31,
(MILLIONS)Balance Sheet Classification20242023
ROU assetsOther noncurrent assets$2,289 $2,924 
Lease liabilities (short-term)Other current liabilities356 527 
Lease liabilities (long-term)Other noncurrent liabilities2,286 2,626 
Components of total lease cost includes:
Year Ended December 31,
(MILLIONS)202420232022
Operating lease cost$683 $863 $714 
Variable lease cost517 444 536 
Sublease income(23)(24)(32)
Total lease cost$1,177 $1,283 $1,218 
Other supplemental information follows:
As of December 31,
(MILLIONS)20242023
Operating leases
Weighted-Average Remaining Contractual Lease Term (Years)10.210.8
Weighted-Average Discount Rate3.7 %3.8 %
Year Ended December 31,
(MILLIONS)202420232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$601 $744 $617 
(Gains)/losses on sale and leaseback transactions, net29 (49)11 
The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2024:
(MILLIONS)
PeriodOperating Lease Liabilities
Next one year(a)
$443 
1-2 years406 
2-3 years361 
3-4 years281 
4-5 years239 
Thereafter1,468 
Total undiscounted lease payments3,197 
Less: Imputed interest
556 
Present value of minimum lease payments2,642 
Less: Current portion
356 
Noncurrent portion$2,286 
(a)Reflects lease payments due within 12 months subsequent to the balance sheet date.
XML 54 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
Contingencies and Certain Commitments
12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and Certain Commitments Contingencies and Certain Commitments
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and indemnifications. The following outlines our legal contingencies, guarantees and indemnifications. For a discussion of our tax contingencies, see Note 5D.
A. Legal Proceedings
Our legal contingencies include, but are not limited to, the following:
Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions.
Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.
Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.
Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.
Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges.
We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions.
The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some
of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.
A1. Legal Proceedings––Patent Litigation
We are involved in suits relating to our patents (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights), including but not limited to, those discussed below. We face claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. In May 2023, the Court of Appeal dismissed BMS’s appeal and in October 2023, the Supreme Court refused BMS permission to appeal. Additional challenges are pending in other jurisdictions. Also, in July 2022, CureVac AG (CureVac) brought a patent infringement action against BioNTech and certain of its subsidiaries in the German Regional Court alleging that Comirnaty infringes certain German utility model patents and certain expired and unexpired European patents. Additional challenges involving Comirnaty patents may be filed against us and/or BioNTech in other jurisdictions in the future. Adverse decisions in these matters could have a material adverse effect on our results of operations. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payors, governments or other parties are seeking damages from us for allegedly causing delay of generic entry.
We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, as well as court proceedings relating to our intellectual property or the intellectual property rights of others, including challenges to such rights initiated by us. Also, if one of our patents (or one of our collaboration/licensing partner’s patents) is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office, as well as outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than anticipated. In the event that any of the patents are found valid and infringed, a competitor’s vaccine, if approved, might be prohibited from entering the market or a competitor might be required to pay us a royalty.
We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. If one of our marketed products (or a product of our collaboration/licensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.
Actions In Which We Are The Plaintiff
Xeljanz (tofacitinib)
Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications (ANDAs) with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.
In August 2024, we brought a patent infringement action against SpecGx LLC (SpecGX) asserting the infringement and validity of our composition of matter patent, covering immediate release formulations of tofacitinib that was challenged by SpecGX in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg immediate release tablets. In November 2024, we settled the action against SpecGX on terms not material to us.
In October 2024, we brought a patent infringement action against Breckenridge Pharmaceutical, Inc. (Breckenridge) asserting the infringement and validity of our composition of patent, covering immediate release formulations of tofacitinib that was challenged by Breckenridge in its ANDA seeking approval to market a generic version of tofacitinib 10 mg immediate release tablets. In November 2024, we settled the action against Breckenridge on terms not material to us.
In December 2024, we brought a patent infringement action against Alkem Laboratories Ltd. (Alkem) asserting the infringement and validity of our composition of matter patent, covering immediate release formulations of tofacitinib that was challenged by Alkem in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg immediate release tablets.
Mektovi (binimetinib)
Beginning in August 2022, two generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Mektovi. The companies assert the invalidity and non-infringement of two method of use patents expiring in 2030, a method of use patent expiring in 2031, two method of use patents expiring in 2033, and a product by process patent expiring in 2033. Beginning in September 2022, we brought patent infringement actions against both of the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of all six patents. In January 2025, we settled with one of the generic companies on terms not material to us.
In August 2022, we received notice from Teva Pharmaceuticals, Inc. (Teva) that it had filed an ANDA seeking approval to market a generic version of Mektovi. Teva asserts the invalidity and non-infringement of two method of use patents expiring in 2033 and a product by process patent expiring in 2033. In June 2023, we brought a patent infringement action against Teva in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the three patents.
Vyndaqel-Vyndamax (tafamidis/tafamidis meglumine)
Beginning in June 2023, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of tafamidis capsules (61 mg) or tafamidis meglumine capsules (20 mg), challenging some or all of the patents listed in the FDA’s Orange Book for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine). Scripps Research Institute (Scripps) owns the composition of matter patent and the method of treatment patents covering the products, and Pfizer is the exclusive licensee. Pfizer separately owns the crystalline form patent. Beginning in August 2023, we and Scripps brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents in suit. Pfizer is the sole plaintiff in actions that assert only the infringement and validity of the crystalline form patent.
Oxbryta (voxelotor)
In January 2024, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, and Zydus Worldwide DMCC (collectively, Zydus) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Ltd. (collectively, MSN) separately notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of voxelotor tablets, challenging some of the patents listed in the FDA’s Orange Book for Oxbryta (voxelotor tablets in 300 mg and 500 mg strengths and/or for oral suspension) on non-infringement grounds. In March 2024, we filed patent infringement actions against both generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the challenged patents. Zydus and MSN have not challenged our composition of matter patents or method of treatment patents for Oxbryta.
Nurtec (rimegepant)
In April 2024, Rubicon Research Private Limited, Teva Pharmaceuticals, Inc., Changzhou Pharmaceutical Factory, Natco Pharma Limited and Natco Pharma, Inc., MSN, Aurobindo Pharma Limited, Apitoria Pharma Private Limited and Aurobindo Pharma U.S.A. Inc. (collectively, Aurobindo) and Apotex Inc. and Apotex Corp. (collectively, Apotex) notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of rimegepant orally disintegrating tablets, claiming noninfringement and/or challenging the validity of some or all of the patents listed in the FDA’s Orange Book for Nurtec (rimegepant orally disintegrating tablets Eq 75 mg base). In May 2024, we filed patent infringement actions against all the generic filers in the U.S. District Court for the District of Delaware.
Xtandi (enzalutamide)
Beginning in August 2024, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Xtandi, challenging some or all of the patents listed in the FDA’s Orange Book for Xtandi. Beginning in August 2024, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of New Jersey, asserting the validity and infringement of the patents in suit.
Inlyta (axitinib)
In October 2024, Sandoz Inc. (Sandoz) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Sandoz asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In November 2024, we filed suit against Sandoz in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.
Actions in Which We are the Defendant
Comirnaty (tozinameran)
In March 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia & Upjohn Company LLC, our wholly owned subsidiary, alleging that Comirnaty infringes a U.S. patent issued in February 2022, and seeking unspecified monetary damages. In July 2022, Alnylam filed a second complaint in the U.S. District Court for the District of Delaware against Pfizer, Pharmacia & Upjohn Company LLC, BioNTech and BioNTech Manufacturing GmbH, alleging that Comirnaty infringes a U.S. patent issued in July 2022, and seeking unspecified monetary damages. In May 2023, Alnylam filed a separate complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia & Upjohn Company LLC alleging that Comirnaty infringes four additional U.S. patents issued on various dates in 2023 and seeking unspecified monetary damages.
In August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Massachusetts, alleging that Comirnaty infringes three U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In March 2024, the U.S. Patent Office Patent Trial & Appeal Board instituted a review of two of the three patents in suit.
In August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, alleging that Comirnaty infringes two European patents. In September 2022, ModernaTX filed patent infringement actions in the U.K. and in the Netherlands against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, on the same two European patents. In its complaints, ModernaTX stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In November 2023, one of the European patents was revoked by the European Patent Office. In December 2023, the other European patent was declared invalid by a court in the Netherlands (the invalidity decision is limited to the Netherlands). In July 2024, the U.K. court revoked one patent, ruling that it was invalid, and held that the other patent was valid and infringed. ModernaTX has also filed additional patent infringement actions against Pfizer and BioNTech in certain other ex-U.S. jurisdictions.
In April 2023, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech alleging that Comirnaty and its manufacture infringe five U.S. patents, and seeking unspecified monetary damages.
In April 2024, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC (collectively, GSK Group) sued Pfizer and Pharmacia & Upjohn Company LLC, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Delaware, alleging that Comirnaty infringes five U.S. patents and seeking unspecified money damages. In August 2024, GSK Group filed an amended complaint alleging that Comirnaty infringes three additional U.S. patents.
In January 2025, Promosome LLC filed a complaint in the Unified Patent Court, Local Division Munich, against Pfizer and BioNTech and certain of their subsidiaries alleging that Comirnaty infringes a European patent that is in force only in France, Germany and Sweden, and seeking unspecified monetary damages in connection with the manufacture and sale of Comirnaty in France, Germany and Sweden.
Paxlovid
In June 2022, Enanta Pharmaceuticals, Inc. (Enanta) filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes a U.S. patent issued in June 2022, and seeking unspecified monetary damages. In December 2024, the District Court issued an order granting Pfizer’s motion for summary judgment, finding Enanta’s patent invalid.
Abrysvo
In August 2023, GSK Group filed a complaint in the U.S. District Court for the District of Delaware against Pfizer alleging that the active ingredient in Abrysvo infringes four U.S. patents. In November 2023, GSK Group amended its complaint to assert infringement of two additional patents. In November 2024, the GSK Group filed a second amended complaint, adding a seventh patent to the lawsuit. The second amended complaint seeks unspecified monetary damages and a permanent injunction against sales of Abrysvo for use in adults in age ranges for which GSK Group’s Arexvy product is also indicated.
In addition, we have challenged certain of GSK’s RSV vaccine patents in certain ex-U.S. jurisdictions, including the U.K., the Netherlands, Belgium and the Unified Patent Court, and GSK has asserted that Abrysvo infringes these patents. In October 2024, the U.K. Court held that two of GSK’s U.K. patents were invalid and not infringed.
Matters Involving Pfizer and its Collaboration/Licensing Partners
Comirnaty (tozinameran)
In July 2022, Pfizer, BioNTech and BioNTech Manufacturing GmbH filed a declaratory judgment complaint against CureVac in the U.S. District Court for the District of Massachusetts seeking a judgment of non-infringement for three U.S. patents relating to Comirnaty. In May 2023, the case was transferred to the U.S. District Court for the Eastern District of Virginia. Also in May 2023, CureVac asserted that Comirnaty infringes the three patents that were the subject of our declaratory judgment complaint, and in May and July 2023, CureVac asserted that Comirnaty infringes a number of additional U.S. patents.
In the U.K., Pfizer and BioNTech have sued CureVac seeking a judgment of invalidity of several patents and CureVac has made certain infringement counterclaims. In September 2024, the U.K. Court held that both of the CureVac patents in suit are invalid.
A2. Legal Proceedings––Product Litigation
We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.
Asbestos
Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.
Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.
There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.
Lipitor
In 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy Laboratories Limited, among others, that asserted claims and sought relief on behalf of the State of West Virginia and residents of that state alleging delay in the launch of generic Lipitor, in violation of state antitrust, consumer protection and various other laws. In December 2024, we reached an agreement to settle this matter on terms not material to Pfizer.
Docetaxel
A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. Hospira is a wholly-owned subsidiary that we acquired in September 2015. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.
In 2016, the federal cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Eastern District of Louisiana.
Zantac
A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to Johnson & Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson & Johnson in connection with the sale. Plaintiffs in these cases seek compensatory and punitive damages.
In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Southern District of Florida (the Federal MDL Court). Plaintiffs in the MDL filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In December 2022,
the Federal MDL Court granted defendants’ Daubert motions to exclude plaintiffs’ expert testimony and motion for summary judgment on general causation, which has resulted in the dismissal of all complaints in the litigation. Plaintiffs have appealed the Federal MDL Court’s rulings.
In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants’ sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts. The large majority of the state court cases have been filed in the Superior Court of Delaware in New Castle County.
Many of these Zantac-related cases have been outstanding for a number of years and could take many more years to resolve. From time to time, Pfizer has explored and will continue to explore opportunistic settlements of these matters. As of January 2025, Pfizer had settled, or entered into definitive agreements or agreements-in-principle to settle, subject to certain conditions, a substantial majority of the cases filed in state courts in which the plaintiff alleges use of a Pfizer product. The remaining unresolved state court cases continue in various state courts.
Chantix
Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer’s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. In December 2022, the federal actions were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Southern District of New York. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix. The class action in Israel has been dismissed.
Depo-Provera
A number of lawsuits have been filed against Pfizer and certain subsidiaries in various federal and state courts alleging that plaintiffs who used the injectable version of Depo-Provera (active ingredient medroxyprogesterone acetate, or MPA) for contraception developed meningioma. The cases also name other defendants, including the manufacturers of generic versions of injectable MPA for contraception. Plaintiffs assert claims against Pfizer relating to both Depo-Provera and generic MPA products, and seek compensatory and punitive damages. In February 2025, the federal cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Northern District of Florida.
A3. Legal Proceedings––Commercial and Other Matters
Monsanto-Related Matters
In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.
In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.
In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation. In 2018, Bayer AG acquired Monsanto Company (New Monsanto), which is now a subsidiary of Bayer AG. Since the acquisition, New Monsanto has continued to defend and indemnify Pharmacia for these liabilities.
Environmental Matters
In 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as Wyeth Holdings Corporation and American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of administrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency, the New Jersey Department of Environmental Protection and/or federal and state natural resource trustees to perform remedial design, removal and remedial actions, and related environmental remediation activities, and to resolve alleged damages to natural resources, at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.
We are also party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.
Contracts with Iraqi Ministry of Health
In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health and seeks monetary relief. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of plaintiffs’ claims. In January 2022, the Court of Appeals reversed the District Court’s decision. In June 2024, the U.S. Supreme Court issued an order granting certiorari, vacating the Court of Appeals’ decision, and remanding the case to the Court of Appeals.
Allergan Complaint for Indemnity
In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer’s acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.
Breach of Contract – Comirnaty
In 2023, Pfizer and BioNTech Manufacturing GmbH initiated separate formal proceedings against the Republic of Poland, the Republic of Romania and Hungary in Belgium’s Court of First Instance of Brussels. Pfizer and BioNTech are seeking an order from the Court holding those countries to their commitments for COVID-19 vaccine orders, which were placed as part of their contracts signed in 2021.
A4. Legal Proceedings––Government Investigations
Like other multi-national pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.
Greenstone Antitrust Litigation
In 2019 and 2020, Attorneys General of more than 50 states and territories filed two complaints in the U.S. District Court for the District of Connecticut against a number of pharmaceutical companies, including Pfizer and Greenstone—a former Pfizer subsidiary that sold generic drugs. As to Greenstone and Pfizer, the complaints allege anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. The State Attorney General complaints were initially transferred to an MDL in the U.S. District Court for the Eastern District of Pennsylvania for coordinated pre-trial proceedings but were transferred back to the District of Connecticut in April 2024. The Greenstone antitrust litigation also includes civil complaints filed in federal and state court by private and governmental plaintiffs against Pfizer, Greenstone, and a number of other defendants. These related civil lawsuits assert allegations that generally overlap with those asserted by the State Attorneys General. All of the related federal lawsuits are part of the MDL pending in Pennsylvania.
Subpoena relating to Tris Pharma/Quillivant XR
In October 2018, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records in response to this request.
Government Inquiries relating to Meridian Medical Technologies
In February 2019, we received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office for the SDNY. The CID seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at Pfizer’s former Meridian site. In August 2019, we received a HIPAA subpoena issued by the U.S. Attorney’s Office for the Eastern District of Missouri, in coordination with the Department of Justice’s Consumer Protection Branch, seeking similar records and information. We have produced records in response to these and subsequent requests.
U.S. Department of Justice Inquiries relating to India Operations
In March 2020, we received an informal request from the U.S. Department of Justice’s Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney’s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We have produced records pursuant to these requests.
Zantac––State of New Mexico and Mayor and City Council of Baltimore Civil Actions
See Legal Proceedings––Product Litigation––Zantac above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions.
Government Inquiries relating to Biohaven
In June 2022, the U.S. Department of Justice’s Commercial Litigation Branch and the U.S. Attorney’s Office for the Western District of New York issued a CID to Biohaven. The CID seeks records and information related to, among other things, Biohaven’s engagements with healthcare professionals and co-pay coupons cards prior to Pfizer’s acquisition of Biohaven. In March 2023, the California Department of Insurance issued a subpoena seeking records similar to those requested by the CID. Biohaven is a wholly-owned subsidiary that we acquired in October 2022. We have produced records in response to these requests. In January 2025, Biohaven entered into civil settlement agreements with the U.S., numerous states, and the California Department of Insurance to resolve these matters. Pursuant to these settlement agreements, $59.7 million, plus interest, was paid to the U.S. and participating states, and $3.3 million was paid to the California Department of Insurance. The settlement agreements relate to alleged conduct at Biohaven before Pfizer’s acquisition of the company and do not include an admission of liability by Biohaven.
Government Inquiries relating to Xeljanz
In April 2023, we received a HIPAA subpoena issued by the U.S. Attorney’s Office for the Western District of Virginia, in coordination with the Department of Justice’s Commercial Litigation Branch, seeking records and information related to programs Pfizer sponsored in retail pharmacies relating to Xeljanz. We have produced records pursuant to this request.
B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2024, the estimated fair value of these indemnification obligations is not material to Pfizer.
In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.
See Note 7D for information on Pfizer Inc.’s guarantee of the debt issued by PIE in May 2023. We have also guaranteed the long-term debt of certain subsidiaries of Pfizer and certain companies that we acquired and that now are subsidiaries of Pfizer. See Note 7D.
C. Certain Commitments
As of December 31, 2024, we had commitments totaling $4.1 billion that are legally binding and enforceable. These commitments include purchase obligations for goods and services and payments relating to potential milestone payments deemed reasonably likely to occur.
See Note 5A for information on the TCJA repatriation tax liability.
D. Contingent Consideration for Acquisitions
We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. See Note 1D. The estimated fair value of contingent consideration as of December 31, 2024 is $517 million, of which $39 million is recorded in Other current liabilities and $477 million in Other noncurrent liabilities, and as of December 31, 2023 was $692 million, of which $179 million was recorded in Other current liabilities and $512 million in Other noncurrent liabilities. The decrease in the contingent consideration balance from December 31, 2023 is primarily due to payments made upon the achievement of certain sales-based milestones.
E. Insurance
Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued.
XML 55 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment, Geographic and Other Revenue Information Segment, Geographic and Other Revenue Information
A. Segment Information
We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Pfizer Ignite is an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with Pfizer’s R&D focus areas. Prior to June 2024, PC1 and Pfizer Ignite were managed together by a single manager as part of the former Business Innovation operating segment. Biopharma is the only reportable segment. Pfizer’s CODM is the Chairman and Chief Executive Officer. Our CODM uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. The CODM uses segment revenues and earnings in the annual budgeting process when setting strategic goals for the company and considers periodic budget-to-actual variances in segment revenues and earnings when assessing performance of the segments and making decisions about allocating resources to the operating segments. By analyzing segment financial results, the CODM can discern trends, which can inform decisions that align with the company’s goals and objectives, and help ensure risks are managed appropriately. We regularly review our operating segments and the approach used by management to evaluate performance and allocate resources.
Our commercial divisions market, sell and distribute our products, and global operating functions are responsible for the research, development, manufacturing and supply of our products. Each operating segment is supported by our global corporate enabling functions. At the beginning of 2024, we made changes in our commercial organization to incorporate Seagen and improve focus, speed and execution. The commercial structure within our Biopharma reportable segment in 2024 was comprised of the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division:
Pfizer Oncology Division combined the U.S. Oncology commercial organizations, global Oncology marketing organizations and global and U.S. Oncology medical affairs from both Pfizer and Seagen.
Pfizer U.S. Commercial Division included the U.S. Primary Care and U.S. Specialty Care customer groups, the Chief Marketing Office, the Global Chief Medical Affairs Office and Global Access & Value.
Pfizer International Commercial Division included the ex-U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio in all international markets.
Beginning January 1, 2024, Biopharma’s earnings include costs related to manufacturing and supply, sales and marketing activities, R&D, and medical and safety activities that are associated with products in our Biopharma segment. Prior to 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations in 2024 were presented as part of Other business activities. We have reclassified our prior period segment information to conform to the current period presentation.
ORD was responsible in 2024 for discovery to late-phase clinical development for oncology research projects for our global portfolio along with facilitating regulatory submissions and interactions with regulatory agencies for these projects. R&D spending may include upfront and milestone payments for intellectual property rights for oncology projects.
PRD was responsible in 2024 for discovery to late-phase clinical development research projects for all therapeutic areas other than oncology for our global portfolio, along with facilitating regulatory submissions and interactions with regulatory agencies for these projects. R&D spending may include upfront and milestone payments for intellectual property rights related to non-oncology projects. PRD also had responsibility for certain science-based and other services organizations, which provide end-to-end technical expertise and other services to both ORD and PRD projects, as well as the Worldwide Medical and Safety group, which helps ensure that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payors and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines.
Other Business Activities––Other business activities include the operating results of PC1 and Pfizer Ignite as well as certain pre-tax costs not allocated to our operating segment results, such as costs associated with:
corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement, among others) and other corporate costs, including, but not limited to, all strategy, business development and portfolio management capabilities and certain compensation, as well as interest income and expense, and gains and losses on investments; and
our share of earnings from Haleon/the Consumer Healthcare JV (see Note 2C).
Reconciling Items––Reconciling items include the following items, transactions and events that are not allocated to our operating segments: (i) all amortization of intangible assets; (ii) acquisition-related items, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company, and which may also include purchase accounting impacts, such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such certain significant items can include, but are not limited to, pension and postretirement actuarial remeasurement gains and losses, non-acquisition-related restructuring costs, net gains and losses on investments in equity securities, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.
Segment Assets––We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $213 billion as of December 31, 2024 and $227 billion as of December 31, 2023.
Selected Statement of Operations Information
The following table provides selected information by reportable segment:
 
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
Year Ended December 31,Year Ended December 31,Year Ended December 31,
(MILLIONS)
20242023 2022 20242023 202220242023 2022
Reportable Segment:
Biopharma(c)
$62,400 $58,237 $99,826 $28,139 $15,923 $47,939 $1,360 $1,213 $1,107 
Other business activities(d)
1,228 1,316 1,349 (7,382)(4,342)(5,162)340 323 332 
Reconciling Items:
Amortization of intangible assets(5,286)(4,733)(3,609)5,286 4,733 3,609 
Acquisition-related items(1,938)(1,874)(832)12 (11)(20)
Certain significant items(e)
(5,510)(3,917)(3,608)14 32 36 
$63,627 $59,553 $101,175 $8,023 $1,058 $34,729 $7,013 $6,290 $5,064 
(a)Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $331 million and $294 million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
(c)Biopharma’s revenues and earnings in 2024 reflect a non-cash favorable product return adjustment of $771 million recorded in the first quarter of 2024 and in 2023 reflected a non-cash revenue reversal of $3.5 billion (see Note 17C). In 2023, Biopharma earnings included approximately $6.2 billion of inventory write-offs and related charges to Cost of sales mainly due to lower-than-expected demand for our COVID-19 products. In 2022, Biopharma earnings included COVID-19-related charges of approximately $1.7 billion to Cost of sales, composed of (i) inventory write-offs of approximately $1.2 billion related to COVID-19
products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for Paxlovid. Biopharma’s earnings also include dividend income from our investment in ViiV of $272 million in 2024, $265 million in 2023 and $314 million in 2022.
(d)Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.
(e)Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in 2024 include, among other items: (i) intangible asset impairment charges of $3.3 billion recorded in Other (income)/deductions––net, (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs), (iii) actuarial valuation and other postretirement plan losses of $579 million recorded in Other (income)/deductions––net, (iv) charges for certain legal matters of $567 million recorded in Other (income)/deductions––net, and (v) a charge in Other (income)/deductions––net of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program, partially offset by (vi) net gains on equity securities of $1.0 billion and (vii) net gains of $825 million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945 million less (b) $120 million in the fourth quarter (included in Other business activities) representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares. Earnings in 2023 included, among other items: (i) intangible asset impairment charges of $3.0 billion recorded in Other (income)/deductions––net and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion ($290 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in Other (income)/deductions––net. Earnings in 2022 included, among other items: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.4 billion ($562 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs) and (ii) net losses on equity securities of $1.3 billion recorded in Other (income)/deductions––net. See Notes 3 and 4.
The following provides Biopharma reportable segment information regularly provided to the CODM:
Year Ended December 31,
(MILLIONS)202420232022
Biopharma reportable segment:
Biopharma total revenues$62,400 $58,237 $99,826 
Less:
Cost of sales14,997 22,666 32,859 
Selling, informational and administrative expenses10,040 10,235 9,207 
Research and development expenses9,532 9,763 10,324 
Acquired in-process research and development expenses108 194 181 
Other (income)/deductions––net
(416)(543)(685)
Biopharma earnings$28,139 $15,923 $47,939 
Revenues - Comirnaty
$5,353 $11,220 $37,809 
Revenues - Paxlovid
$5,716 $1,279 $18,933 
Revenues - excluding Comirnaty and Paxlovid
$51,331 $45,738 $43,084 
Geographic Information
The following summarizes revenues by geographic area:
 Year Ended December 31,
(MILLIONS)202420232022
United States$38,691 $28,145 $43,317 
International:
Developed Markets
16,057 20,910 40,534 
Emerging Markets8,879 10,498 17,324 
Total revenues$63,627 $59,553 $101,175 
Revenues exceeded $500 million in each of 11, 14 and 24 countries outside the U.S. in 2024, 2023 and 2022, respectively. The U.S. is the only country to contribute more than 10% of total revenue in 2024, 2023 and 2022. As a percentage of Total revenues, China was our largest market outside the U.S. (representing 4% of total revenues) in 2024, and Japan was our largest market outside the U.S. in 2023 and 2022 (representing 6% and 8% of total revenues, respectively).
Other Revenue Information
Significant Customers
We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of Comirnaty with multiple developed and emerging nations around the world and are continuing to deliver doses of Comirnaty under such agreements. This includes supply agreements entered into in November 2020 and February and May 2021 with the EC for Comirnaty on behalf of the different EU member states and certain other countries. Each EU member state submits its own Comirnaty vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC. In May 2023, we and BioNTech amended our contract with the EC to deliver COVID-19 vaccines to the EU. The amended agreement includes rephasing of delivery of doses annually through 2026 and an aggregate volume reduction, providing additional flexibility for those EU member states who agreed to the amended agreement. The EC will maintain access to future adapted COVID-19 vaccines and the ability to donate doses, in alignment with the original agreement.
In 2022 and 2023, we had entered into agreements to supply pre-specified treatment courses of Paxlovid with government and government sponsored customers in multiple developed and emerging nations around the world, which represented most Paxlovid revenues in 2022 and 2023, while commercialization began in some markets in 2023. In October 2023, we announced an amended agreement with the U.S. government, which facilitated the transition of Paxlovid to traditional commercial markets in the U.S. starting in November 2023, with prices negotiated with commercial payors and a copay assistance program for eligible privately insured patients, as the U.S. government began to discontinue the distribution of EUA-labeled Paxlovid. We ensured commercial readiness by providing NDA-labeled commercial supply by the end of 2023. However, EUA-labeled Paxlovid remained available free-of-charge to all eligible patients until the end of 2023, and therefore, there was only minimal uptake of NDA-labeled commercial product before January 1, 2024. In connection with this agreement, we recorded a non-cash revenue reversal of $3.5 billion in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory. In the first quarter of 2024, we recorded a non-cash favorable final adjustment of $771 million to reflect 5.1 million EUA-labeled treatment courses returned through February 29, 2024, which were converted to a volume-based credit that supports continued access to Paxlovid through a U.S. government patient assistance program operated by Pfizer. In the third quarter of 2024, in connection with this amended agreement, we also supplied at no cost to the U.S. government or taxpayers a U.S. SNS of 1.0 million treatment courses to enable future pandemic preparedness through 2028, and recorded revenue of $442 million. While we are recognizing revenue as these treatment courses are delivered, there is no cash consideration for these treatment courses.
The following summarizes revenue, as a percentage of Total revenues, for our three largest U.S. wholesaler customers and the U.S. government, which was concentrated in our Biopharma operating segment:
 Year Ended December 31,
202420232022
McKesson, Inc.
23 %16 %%
Cencora, Inc.
17 %12 %%
Cardinal Health, Inc.14 %10 %%
U.S. government(a)
6 %— 23 %
(a) The decrease in revenues from the U.S. government as a percentage of Total revenues for 2024 and 2023 compared to 2022 was primarily due to the transition of Comirnaty and Paxlovid to commercial market sales in the second half of 2023 as well as the revenue reversal for Paxlovid in the fourth quarter of 2023.
Collectively, our three largest U.S. wholesaler customers represented 34% and 42% of total trade accounts receivable as of December 31, 2024 and December 31, 2023, respectively. Accounts receivable from the U.S. government as of December 31, 2024 and December 31, 2023 were not material to our consolidated financial statements.
Significant Revenues by Product
The following provides detailed revenue information for several of our major products:
(MILLIONS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202420232022
TOTAL REVENUES$63,627 $59,553 $101,175 
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)
$62,400 $58,237 $99,826 
Primary Care$30,135 $30,799 $73,181 
Eliquis(a)
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism7,366 6,747 6,480 
Prevnar family
Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae
6,411 6,501 6,342 
Paxlovid(b)
COVID-19 in certain high-risk patients
5,716 1,279 18,933 
Comirnaty
Active immunization to prevent COVID-19
5,353 11,220 37,809 
Nurtec ODT/VyduraAcute treatment of migraine and prevention of episodic migraine1,263 928 213 
Abrysvo
Active immunization to prevent RSV infection
755 890 — 
Premarin family
Symptoms of menopause380 397 455 
BMP2
Bone graft for spinal fusion
352 338 277 
FSME-IMMUN/TicoVacActive immunization to prevent tick-borne encephalitis disease280 268 200 
All other Primary CareVarious2,259 2,233 2,473 
Specialty Care$16,652 $14,988 $13,851 
Vyndaqel familyATTR-CM and polyneuropathy5,451 3,321 2,447 
Xeljanz
RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis1,168 1,703 1,796 
Enbrel (Outside the U.S. and Canada)
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis
690 830 1,003 
Sulperazon
Bacterial infections637 757 786 
ZaviceftaBacterial infections586 511 412 
Octagam(c)
Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults
509 245 186 
Inflectra
Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis
509 490 532 
ZithromaxBacterial infections480 406 331 
(MILLIONS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202420232022
Genotropin
Replacement of human growth hormone470 539 360 
BeneFIXHemophilia B381 424 425 
Cibinqo
Atopic dermatitis
215 128 27 
Oxbryta(d)
Sickle cell disease201 328 73 
All other Hospital(e)
Various
4,448 4,514 4,730 
All other Specialty CareVarious907 792 743 
Oncology$15,612 $12,450 $12,794 
IbranceHR-positive/HER2-negative metastatic breast cancer4,367 4,753 5,120 
Xtandi(f)
mCRPC, nmCRPC, mCSPC, nmCSPC
2,039 1,659 1,650 
Padcev
Locally advanced or metastatic urothelial cancer
1,588 53 — 
Adcetris
Hodgkin lymphoma and certain T-cell lymphomas
1,089 56 — 
Oncology biosimilars(g)
Various
1,037 1,407 1,753 
Inlyta
Advanced RCC978 1,036 1,003 
Lorbrena
ALK-positive metastatic NSCLC
731 539 343 
Bosulif
Philadelphia chromosome–positive chronic myelogenous leukemia645 645 575 
Braftovi/Mektovi
Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux (cetuximab)(h) (after prior therapy) or cetuximab and mFOLFOX6
607 477 456 
Tukysa
Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer480 18 — 
Elrexfio
Relapsed or refractory multiple myeloma
133 10 — 
Tivdak
Recurrent or mCC
131 — 
Talzenna
In combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC; treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer
117 64 48 
All other OncologyVarious1,670 1,729 1,846 
PFIZER CENTREONE(i)
$1,146 $1,272 $1,342 
PFIZER IGNITE
$82 $44 $
BIOPHARMA
$62,400 $58,237 $99,826 
PFIZER U.S. COMMERCIAL DIVISION (U.S. Primary Care and U.S. Specialty Care)
26,765 19,299 34,337 
PFIZER ONCOLOGY DIVISION
11,567 8,450 8,583 
PFIZER INTERNATIONAL COMMERCIAL DIVISION
24,068 30,488 56,905 
Total Alliance revenues included above$8,388 $7,582 $8,537 
Total Royalty revenues included above
$1,423 $1,058 $845 
(a)Reflects Alliance revenues and product revenues.
(b)2024 includes (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.
(c)2024 includes $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.
(d)In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of expanded access programs worldwide, based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing.
(e)Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.
(f)Primarily reflects Alliance revenues and royalty revenues.
(g)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.
(h)Erbitux is a registered trademark of ImClone LLC.
(i)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
Remaining Performance Obligations––Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty and Paxlovid to our customers totaled approximately $4 billion and $1 billion, respectively, as of December 31, 2024, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of these amounts, current contract terms provide for expected delivery of product with contracted revenue from 2025 through 2028, the timing of which may be renegotiated. Remaining performance obligations are based on foreign exchange rates as of the end of our fiscal fourth quarter of 2024 and exclude arrangements with an original expected contract duration of less than one year. Remaining performance obligations associated with contracts for other products and services were not significant as of December 31, 2024 or 2023.
Deferred Revenues–– Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers for supply of Paxlovid and Comirnaty. The deferred revenues related to Paxlovid and Comirnaty totaled $2.2 billion as of December 31, 2024, with $1.4 billion and $785 million recorded in current liabilities and noncurrent liabilities, respectively. The deferred revenues related to Paxlovid and Comirnaty totaled $5.1 billion as of December 31, 2023, with $2.6 billion and $2.5 billion recorded in current liabilities and noncurrent liabilities, respectively. The decrease in Paxlovid and Comirnaty deferred revenues during full-year 2024 was primarily driven by amounts recognized in Product revenues as we delivered the products to our customers (including $442 million associated with the U.S. SNS for Paxlovid) as well as the aforementioned $771 million favorable final adjustment recorded in the first quarter of 2024 for Paxlovid, partially offset by additional advance payments received in 2024 as we entered into amended contracts. During 2024, we recognized revenue of approximately $2.9 billion that was included in the balance of Paxlovid and Comirnaty deferred revenues as of December 31, 2023. The Paxlovid and Comirnaty deferred revenues as of December 31, 2024 will be recognized in Product revenues proportionately as we transfer control of the products to our customers and satisfy our performance obligations under the contracts, with the amounts included in current liabilities expected to be recognized in Product revenues within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in Product revenues from December 2025 (which falls in our international first quarter of 2026) through 2028. Deferred revenues associated with contracts for other products were not significant as of December 31, 2024 or December 31, 2023.
XML 56 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure      
Income attributable to shareholders $ 8,031 $ 2,119 $ 31,372
XML 57 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 58 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Policies and Procedures
12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 59 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Managing cybersecurity risk is a crucial part of our overall strategy for safely operating our business. We incorporate cybersecurity practices into our Enterprise Risk Management (ERM) program. Management is responsible for assessing and managing risk, including through the ERM program, subject to oversight by our BOD. Our cybersecurity policies and practices are aligned with NIST (National Institute of Standards and Technology) industry standards.
Consistent with our overall ERM program and practices, our cybersecurity program includes:
Vigilance: We maintain a global cybersecurity operation that endeavors to detect, prevent, contain, and respond to cybersecurity threats and incidents in a prompt and effective manner with the goal of minimizing business disruptions.
External Collaboration: We collaborate with public and private entities, including intelligence and law enforcement agencies, industry groups and third-party service providers to identify, assess and mitigate cybersecurity risks.
Systems Safeguards: We deploy technical safeguards that are designed to protect our information systems, products, operations and sensitive information from cybersecurity threats. These include firewalls, intrusion prevention and detection systems, disaster recovery capabilities, malware and ransomware prevention, access controls and data protection. We continuously conduct vulnerability assessments to identify new risks and periodically test the efficacy of our safeguards through both internal and external penetration tests.
Education: We provide periodic training for all personnel regarding cybersecurity threats, with such training appropriate to the roles, responsibilities and access of the relevant Company personnel. Our policies require all workers to report any real or suspected cybersecurity events.
Supplier Ecosystem Management: We extend our cybersecurity management control expectations to our supply chain ecosystem, as appropriate. This includes identifying cybersecurity risks presented by third parties.
Incident Response Planning: We have established, and maintain and periodically test, incident response plans that direct our response to cybersecurity events and incidents. Such plans include the protocol by which certain significant or potentially material incidents would be communicated to executive management, our BOD, external regulators and shareholders, as appropriate.
Enterprise-Wide Coordination: We engage relevant stakeholders from across the Company to identify emerging risks and respond to cybersecurity threats. This cross-functional approach includes personnel from our R&D, manufacturing, commercial, technology, legal, compliance, internal audit and other business functions.
Governance: Our BOD’s oversight of cybersecurity risk management is led by the Audit Committee, which oversees our ERM program. Cybersecurity threats, risks and mitigation are periodically reviewed by the Audit Committee and such reviews include both internal and independent assessment of risks, controls and effectiveness.
Our risk assessment efforts have indicated that we are a target for theft of intellectual property, financial resources, personal information, and trade secrets from a wide range of actors including nation states, organized crime, malicious insiders and activists. The impacts of attacks, abuse and misuse of Pfizer’s systems and information could include, without limitation, loss of assets, operational disruption and damage to Pfizer’s reputation.
A key element of managing cybersecurity risk is the ongoing assessment and testing of our processes and practices through auditing, assessments, drills and other exercises focused on evaluating the sufficiency and effectiveness of our risk mitigation. We regularly engage third parties to perform assessments of our cybersecurity measures, including information security maturity assessments and independent reviews of our information security control environment and operating effectiveness. Certain results of such assessments and reviews are reported by the Chief Information Security Officer (CISO) to certain senior leaders, the Audit Committee and the BOD, as appropriate, and we make adjustments to our cybersecurity processes and practices as necessary based on the information provided by the third-party assessments and reviews.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block]
Managing cybersecurity risk is a crucial part of our overall strategy for safely operating our business. We incorporate cybersecurity practices into our Enterprise Risk Management (ERM) program. Management is responsible for assessing and managing risk, including through the ERM program, subject to oversight by our BOD. Our cybersecurity policies and practices are aligned with NIST (National Institute of Standards and Technology) industry standards.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block] Governance: Our BOD’s oversight of cybersecurity risk management is led by the Audit Committee, which oversees our ERM program. Cybersecurity threats, risks and mitigation are periodically reviewed by the Audit Committee and such reviews include both internal and independent assessment of risks, controls and effectiveness.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] The Audit Committee oversees cybersecurity risk management, including the policies, processes and practices that management implements to prevent, detect and address risks from cybersecurity threats.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] The Audit Committee receives periodic briefings on, and discusses with our CISO, cybersecurity risks and risk management practices, including, for example, recent developments in the external cybersecurity threat landscape, evolving standards, vulnerability assessments, third-party and independent reviews, technological trends and considerations arising from our supplier ecosystem. The Audit Committee may also promptly receive information regarding certain significant or potentially material cybersecurity incidents that may occur, including any ongoing updates regarding the same.
Cybersecurity Risk Role of Management [Text Block]
Our CISO is a member of our management team who is principally responsible for overseeing our cybersecurity risk management program, in partnership with other business leaders across the Company. We believe our CISO and the information security organization have the appropriate expertise, background and depth of experience relating to monitoring the prevention, mitigation, detection and remediation of cybersecurity incidents to manage risks arising from cybersecurity threats. The CISO works in coordination with other members of the management team, including, among others, the Chief Digital Officer, the Chief Financial Officer and the Chief Legal Officer and their designees.
Our CISO, along with leaders from our privacy and corporate compliance functions, collaborate to implement a program designed to manage our exposure to cybersecurity risks and to promptly respond to cybersecurity incidents. Prompt response to incidents is delivered by multi-disciplinary teams in accordance with our incident response plan. Through ongoing communications with these teams during incidents, the CISO monitors the triage, mitigation and remediation of cybersecurity incidents, and reports such incidents to executive management, the Audit Committee and other Pfizer colleagues in accordance with our cybersecurity policies and procedures, as is appropriate.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Our CISO is a member of our management team who is principally responsible for overseeing our cybersecurity risk management program, in partnership with other business leaders across the Company.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] We believe our CISO and the information security organization have the appropriate expertise, background and depth of experience relating to monitoring the prevention, mitigation, detection and remediation of cybersecurity incidents to manage risks arising from cybersecurity threats.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] The CISO works in coordination with other members of the management team, including, among others, the Chief Digital Officer, the Chief Financial Officer and the Chief Legal Officer and their designees.
Our CISO, along with leaders from our privacy and corporate compliance functions, collaborate to implement a program designed to manage our exposure to cybersecurity risks and to promptly respond to cybersecurity incidents. Prompt response to incidents is delivered by multi-disciplinary teams in accordance with our incident response plan. Through ongoing communications with these teams during incidents, the CISO monitors the triage, mitigation and remediation of cybersecurity incidents, and reports such incidents to executive management, the Audit Committee and other Pfizer colleagues in accordance with our cybersecurity policies and procedures, as is appropriate.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
XML 60 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP.
Consolidation The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. All significant transactions among our subsidiaries have been eliminated.
Segment Reporting We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment.
Reclassification Adjustments
We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:
in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from Other (income)/deductions––net and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of operations, and reclassified the associated royalty receivables from Other current assets to Trade accounts receivable, less allowance for doubtful accounts in our consolidated balance sheet; and
segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see Notes 9 and 17).
Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
New Accounting Standard Adopted in 2024 New Accounting Standards Adopted in 2024
On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.
In the fourth quarter of 2024, we adopted a new accounting standard which requires the disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, other segment items by reportable segment and a description of its composition. See Note 17A.
Estimates and Assumptions Estimates and Assumptions
In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of operations, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of operations. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation, development of competing assets by us or others, regulatory actions, or product recalls or withdrawals. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.
Acquisitions Acquisitions
Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed in Acquired in-process research and development expenses.
Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See Note 16D. Any liability
resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net.
Fair Value Fair Value
We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.
When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:
Income approach, which is based on the present value of a future stream of net cash flows.
Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:
Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves.
Equity securities with readily determinable fair values—quoted market prices and observable NAV prices.
Derivative assets and liabilities—third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.
Money market funds—observable NAV prices.
We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.
Foreign Currency Translation Foreign Currency Translation
For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss). The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.
Revenues and Collaborative Arrangements
Revenue Recognition––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors’ locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In bill-and-hold arrangements which are part of the U.S. SNS, we recognize revenue for the product sale when the product is initially placed into the U.S. SNS and we provide a rotation service to maintain an agreed upon level of shelf life for product in the stockpile. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.
Our Sales Contracts––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns may occur due to patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment.
Deductions from Revenues––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and
sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these product revenue deductions on gross sales for a reporting period.
Provisions for pharmaceutical sales returns––Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.
We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.
The following outlines our common sales arrangements:
Customers––Our prescription biopharmaceutical products, with the exception of Paxlovid in 2022 and 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In 2022 and 2023, we principally sold Paxlovid globally to government agencies. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain products in our portfolio are subject to seasonality of demand and Paxlovid revenues trend with infection rates. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs in the U.S; and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented).
Specifically:
In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales in prior periods to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” and as of December 31, 2024 in the initial coverage and catastrophic phases under the Manufacturer Discount Program based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap or from the manufacturer’s discount, respectively. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.
Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.
Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.
We recorded revenues of more than $1 billion for each of 11 products in 2024, for each of nine products in 2023 and for each of ten products in 2022, and these revenues represented 66%, 64% and 82% of our Total revenues in 2024, 2023 and 2022, respectively. See Note 17C. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.
Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Product revenues.
Collaborative Arrangements
Payments to and from our collaboration partners are presented in our consolidated statements of operations based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-commercialization agreements, we record the amounts received for our share of gross profits from our collaboration partners as Alliance revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as Cost of sales. Royalty payments received from collaboration partners are included in Royalty revenues.
Reimbursements to or from our collaboration partners for development costs are typically recorded in Research and development expenses. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as Acquired in-process research and development expenses. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in Identifiable intangible assets—developed technology rights. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in Other (income)/deductions—net over the development period for the products, when our performance obligations include providing R&D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in Other (income)/deductions—net immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.
Trade Accounts Receivable
Trade Accounts Receivable—Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
During 2024 and 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.
Cost of Sales and Inventories Cost of Sales and Inventories
Inventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary. Inventories that are not expected to be sold within 12 months are classified as Other noncurrent assets. See Note 8A.
Selling, Informational and Administrative Expenses Selling, Informational and Administrative ExpensesSelling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, digital and legal defense.
Research and Development Expenses Research and Development Expenses
R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as R&D activities performed in connection with certain licensing arrangements.
Acquired In-Process Research and Development Expenses Acquired In-Process Research and Development Expenses
Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing and collaboration arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. Acquired in-process research and development expenses includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&D.
Property, Plant and Equipment Property, plant and equipment, net—These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a
straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
Intangible Assets and Goodwill Identifiable intangible assets, net—These assets are recorded at fair value at acquisition. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.
Goodwill—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.
Amortization of finite-lived acquired intangible assets is included in Amortization of intangible assets.
Specifically:
For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.
For indefinite-lived intangible assets, such as brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.
For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.
Property, Plant and Equipment, Impairment
We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
We incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.
Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired company. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred.
Our business may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as our corporate enabling functions.
Cash Equivalents
Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments.
Statement of Cash Flows
Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.
Investments Investments and Derivative Financial Instruments
The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:
Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in Other (income)/deductions—net.
Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.
Held-to-maturity debt securities, which are carried at amortized cost.
Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus adjustments resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in Other (income)/deductions—net. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.
Realized gains or losses on sales of investments are determined by using the specific identification cost method.
We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, if and when a decline in fair value is determined, an impairment charge is recorded and a new cost basis in the investment is established. For equity-method investments, an impairment charge is recorded only if and when a decline in fair value is determined to be other-than-temporary.
Derivative Financial Instruments Derivative financial instruments are carried at fair value in certain balance sheet categories (see Note 7A), with changes in fair value reported in net income or, for certain qualifying hedging relationships, in Other comprehensive income/(loss)
Tax Assets and Liabilities and Income Tax Contingencies Tax Assets and Liabilities and Income Tax Contingencies
Tax Assets and Liabilities––Current tax assets primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of operations when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.
Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.
The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.
Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.
Other taxes payable as of December 31, 2024 and 2023 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. See Note 5D for uncertain tax positions and Note 5A for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.
Income Tax Contingencies––We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.
We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision/(benefit) for taxes on income and are classified on our consolidated balance sheet with the related tax liability.
Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.
Pension and Postretirement Benefit Plans Pension and Postretirement Benefit Plans
The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. Net periodic pension and postretirement benefit costs other than the service costs are recognized in Other (income)/deductions—net. We immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (mark-to-market accounting). Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions––net. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of
providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value.
Legal and Environmental Contingencies Legal and Environmental Contingencies
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial and other asserted or unasserted matters, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Share-Based Payments Share-Based Payments
Our compensation programs include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis or on an accelerated attribution approach over the vesting terms with the related costs recorded in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.
Leases
We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $517 million in 2024, $444 million in 2023 and $536 million in 2022. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.
We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.
XML 61 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Information About Balance Sheet Classification of Accruals
Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
  As of December 31,
(MILLIONS)20242023
Reserve against Trade accounts receivable, less allowance for doubtful accounts
$1,627 $1,770 
Other current liabilities:
Accrued rebates7,195 5,546 
Other accruals972 902 
Other noncurrent liabilities
1,029 796 
Total accrued rebates and other sales-related accruals$10,822 $9,014 
XML 62 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement (Tables)
12 Months Ended
Dec. 31, 2024
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in 2024 to the amounts initially recorded in 2023 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.
(MILLIONS)
Amounts Recognized
as of Acquisition Date
(as previously reported as of December 31, 2023)
Measurement Period Adjustments(a)
Amounts Recognized as of Acquisition Date (as adjusted) Final
Working capital, excluding inventories(b)
$736 $(115)$621 
Inventories(c)
4,195 (922)3,273 
Property, plant and equipment
524 (243)280 
Identifiable intangible assets, excluding in-process research and development(d)
7,970 (50)7,920 
In-process research and development
20,800 (900)19,900 
Other noncurrent assets
174 (115)59 
Net income tax accounts(e)
(6,123)1,343 (4,779)
Other noncurrent liabilities(167)(20)(187)
Total identifiable net assets28,108 (1,022)27,086 
Goodwill16,126 1,022 17,148 
Net assets acquired/total consideration transferred$44,234 $ $44,234 
(a)The changes in the estimated fair values are to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
(b)Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities.
(c)As adjusted, comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories.
(d)As adjusted, comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.
(e)As adjusted, included primarily in Noncurrent deferred tax liabilities. The measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments.
Schedule of Pro Forma Information The following table presents information for Seagen’s operations that are included in Pfizer’s consolidated statements of operations beginning from the acquisition date, December 14, 2023, through Pfizer’s year-end in 2023:
(MILLIONS)
December 31,
2023
Revenues$132 
Net loss attributable to Pfizer Inc. common shareholders(a)
(746)
(a)Includes restructuring, integration and acquisition-related costs ($614 million pre-tax) and purchase accounting charges related to (i) the fair value adjustment for acquisition-date inventory estimated to have been sold ($109 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Seagen ($25 million pre-tax); as well as (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Seagen ($2 million pre-tax).
The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:
Unaudited Supplemental Pro Forma Consolidated Results
Year Ended December 31,
(MILLIONS, EXCEPT PER SHARE DATA)
20232022
Revenues
$61,893 $103,137 
Net income/(loss) attributable to Pfizer Inc. common shareholders
(1,481)27,870 
Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders
(0.26)4.86 
Summarized Financial Information of Equity Method Investments
The following table summarizes the change in the carrying value of our investment in Haleon:
Year Ended December 31,
(MILLIONS)
20242023
Beginning carrying value reported in Equity-method investments
$11,451 $10,824 
Carrying value of shares sold
(6,113)— 
Dividends
(212)(153)
Currency translation adjustments and other(a)
341 293 
Basis difference adjustments and amortization(b), (c)
(91)(2)
Pfizer share of Haleon investee capital transaction(b), (d)
(44)— 
Pfizer share of Haleon earnings(b)
224 489 
Reclassification of accumulated other comprehensive income balances in Equity-method investments(e)
(143)— 
Transfer of carrying value to Short-term investments(f)
(5,411)— 
Ending carrying value
$ $11,451 
(a)See Note 6.
(b)Included in Other (income)/deductions––net.
(c)Adjustments in 2024 include (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities.
(d)In 2024, includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.
(e)The 2024 activity primarily represent foreign currency translation balances in Accumulated other comprehensive income related to the equity-method investment in Haleon that were reclassified into Equity-method investments upon our loss of significant influence over Haleon and our discontinuance of the equity method for the Haleon investment.
(f)The final carrying value of our equity-method investment in Haleon was reclassified to Short-term investments and is being accounted for as an equity investment with a readily determinable fair value.
Summarized financial information for Haleon as of September 30, 2024, the most recent period available, and as of September 30, 2023 and for the periods ending September 30, 2024, 2023, and 2022 is as follows:
(MILLIONS)September 30, 2024September 30, 2023
Current assets$7,813 $5,876 
Noncurrent assets37,572 36,954 
Total assets
$45,385 $42,830 
Current liabilities$7,468 $6,117 
Noncurrent liabilities15,511 15,744 
Total liabilities
$22,979 $21,862 
Equity attributable to shareholders$22,129 $20,719 
Equity attributable to noncontrolling interests277 249 
Total net equity$22,406 $20,968 
For the Twelve Months Ended
(MILLIONS)September 30, 2024September 30, 2023September 30, 2022
Net sales$14,252 $13,921 $13,566 
Cost of sales(5,656)(5,580)(5,081)
Gross profit$8,596 $8,341 $8,486 
Income from continuing operations1,668 1,606 1,745 
Net income1,668 1,606 1,745 
Income attributable to shareholders1,600 1,528 1,675 
Summarized financial information for our equity-method investee, ViiV, as of December 31, 2024 and 2023 and for the years ending December 31, 2024, 2023, and 2022 is as follows:
As of December 31,
(MILLIONS)20242023
Current assets$4,338 $4,237 
Noncurrent assets3,223 3,009 
Total assets
$7,561 $7,245 
Current liabilities$4,280 $4,085 
Noncurrent liabilities6,205 5,998 
Total liabilities
$10,485 $10,083 
Total net equity/(deficit) attributable to shareholders$(2,924)$(2,838)
Year Ended December 31,
(MILLIONS)202420232022
Net sales$8,971 $7,845 $6,955 
Cost of sales(1,360)(1,060)(819)
Gross profit$7,611 $6,785 $6,135 
Income from continuing operations3,062 3,090 3,108 
Net income3,062 3,090 3,108 
Income attributable to shareholders3,062 3,090 3,108 
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:
Year Ended December 31,
(MILLIONS)202420232022
Product revenues(a)
$175 $212 $437 
Alliance revenues(b)
8,388 7,582 8,537 
Royalty revenues(c)
923 605 614 
Total revenues from collaborative arrangements$9,486 $8,400 $9,588 
Cost of sales(d)
$(2,901)$(4,277)$(15,589)
Selling, informational and administrative expenses(e)
(335)(267)(196)
Research and development expenses(f)
282 219 272 
Acquired in-process research and development expenses(g)
2 (13)(339)
Restructuring charges and certain acquisition-related costs(h)
(45)— — 
Other income/(deductions)—net
(15)25 50 
(a)Represents sales to our partners of products manufactured by us.
(b)Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2024 was primarily driven by an increase in Alliance revenues from Eliquis and Xtandi, partially offset by a decrease in Alliance revenues from Bavencio. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis.
(c)Primarily relates to royalties from our collaboration partners.
(d)Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decreases in 2024 and in 2023 primarily relate to Comirnaty.
(e)Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
(f)Represents net reimbursements from our partners for research and development expenses incurred.
(g)Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.
(h)Relates to exit costs associated with terminating a collaboration with SMPS.
XML 63 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)
12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Year Ended December 31,
(MILLIONS)202420232022
Restructuring charges/(credits):
Employee terminations$1,152 $1,622 $776 
Asset impairments432 227 52 
Exit costs
403 119 54 
Restructuring charges/(credits)(a)
1,987 1,968 882 
Transaction costs(b)
5 190 144 
Integration costs and other(c)
427 785 348 
Restructuring charges and certain acquisition-related costs
2,419 2,943 1,375 
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net
7 (7)(9)
Additional depreciation––asset restructuring recorded in our consolidated statements of operations as follows(d):
Cost of sales14 31 34 
Selling, informational and administrative expenses5 
Total additional depreciation––asset restructuring
19 32 36 
Implementation costs recorded in our consolidated statements of operations as follows(e):
Cost of sales120 67 54 
Selling, informational and administrative expenses90 289 560 
Research and development expenses84 101 
Total implementation costs
294 457 616 
Total costs associated with acquisitions and cost-reduction/productivity initiatives$2,738 $3,426 $2,018 
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).
(b)Represents external costs for banking, legal, accounting and other similar services.
(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2023 costs mostly relate to our acquisition of Seagen, including $476 million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of 2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our acquisitions of Arena and GBT, including $138 million in payments to Arena employees in the first quarter of 2022 and $136 million in payments to GBT employees in the fourth quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See Note 2A.
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Restructuring Reserve by Type of Cost
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
Costs
Asset
Impairment
Charges
Exit CostsAccrual
Balance, January 1, 2023
$1,196 $— $$1,204 
Provision1,622 227 119 1,968 
Utilization and other(a)
(840)(227)(116)(1,184)
Balance, December 31, 2023(b)
1,978 — 11 1,988 
Provision1,152 432 403 1,987 
Utilization and other(a)
(1,083)(432)(341)(1,856)
Balance, December 31, 2024(c)
$2,046 $ $74 $2,120 
(a)Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.
(b)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).
(c)Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
XML 64 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income)/Deductions—Net (Tables)
12 Months Ended
Dec. 31, 2024
Other Income and Expenses [Abstract]  
Schedule of Other Nonoperating Income (Expense)
Components of Other (income)/deductions––net include:
Year Ended December 31,
(MILLIONS)202420232022
Interest income$(545)$(1,624)$(251)
Interest expense(a)
3,091 2,209 1,238 
Net interest expense(b)
2,546 585 987 
Net (gains)/losses recognized during the period on equity securities(c)
(1,008)(1,590)1,273 
Income from collaborations, out-licensing arrangements and sales of compound/product rights
(42)(154)(188)
Net periodic benefit costs/(credits) other than service costs154 (610)(849)
Certain legal matters, net(d)
567 474 230 
Certain asset impairments(e)
3,295 3,024 421 
Haleon equity method (income)/loss(f)
(102)(505)(436)
Other, net(g)
(1,022)(1,002)(378)
Other (income)/deductions––net
$4,388 $222 $1,062 
(a)Capitalized interest totaled $182 million in 2024, $160 million in 2023 and $124 million in 2022.
(b)The increase in net interest expense in 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $8 billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen.
(c)2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see Note 2C). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas.
(d)2024 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(e)The amount for 2024 represents intangible asset impairment charges, and includes $2.9 billion recorded in the fourth quarter associated with our Biopharma segment, due to changes in development plans and updated long-range commercial forecasts, composed of: (i) $1.0 billion for B7H4V (felmetatug vedotin), a Phase 1 IPR&D asset, (ii) $475 million for Medrol, a finite-lived brand, (iii) $435 million for Zavzpret nasal spray developed technology rights, (iv) $400 million and $200 million for Tukysa and disitamab vedotin, respectively, IPR&D assets reflecting emerging competition, as well as (v) other developed technology rights, IPR&D impairments and a finite-lived licensing agreement totaling $436 million which also includes de-prioritization of certain assets. 2024 also includes a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The amount for 2023 primarily represented intangible asset impairment charges of $3.0 billion, of which $2.9 billion was associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: (i) $1.4 billion for etrasimod (Velsipity) IPR&D, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 developed technology rights due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) $486 million for various other IPR&D assets and developed technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also included $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset impairment charges associated with our Biopharma segment of $200 million for an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million
associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics.
(f)See Note 2C.
(g)The amount for 2024 primarily includes, among other things, (i) gains of $945 million on the partial sales of our investment in Haleon in March and October 2024, (ii) dividend income of $272 million from our investment in ViiV and (iii) a charge of $420 million recorded in the third quarter related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. 2023 included, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included, among other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the fair value of contingent consideration.
Schedule of Additional Information About Intangible Assets Impaired
Additional information about the intangible assets that were impaired during 2024 follows:
Year Ended
Fair Value(a)
December 31, 2024
(MILLIONS)AmountLevel 1Level 2Level 3Impairment
IPR&D(b)
$4,900 $ $ $4,900 $1,873 
Developed technology rights(b)
524   524 943 
Finite-lived brand(b)
270   270 475 
Finite-lived licensing agreement(b)
    5 
Total$5,694 $ $ $5,694 $3,295 
(a)The fair value amounts are presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
(b)Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
XML 65 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign
Components of Income from continuing operations before provision/(benefit) for taxes on income include:
 Year Ended December 31,
(MILLIONS)202420232022
United States$(637)$(4,411)$5,032 
International8,660 5,469 29,697 
Income from continuing operations before provision/(benefit) for taxes on income(a), (b)
$8,023 $1,058 $34,729 
(a)2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
(b)2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.
Schedule of Provision for Taxes on Income
Components of Provision/(benefit) for taxes on income based on the location of the taxing authorities include:
 Year Ended December 31,
(MILLIONS)202420232022
United States
Current income taxes:
Federal
$453 $1,321 $2,744 
State and local
32 (135)(20)
Deferred income taxes:
Federal
(1,909)(2,606)(3,271)
State and local
(293)(184)(310)
Total U.S. tax provision/(benefit)(1,717)(1,605)(857)
International
Current income taxes
1,588 1,142 4,368 
Deferred income taxes
100 (652)(183)
Total international tax provision/(benefit)1,689 490 4,185 
Provision/(benefit) for taxes on income
$(28)$(1,115)$3,328 
Schedule of Cash Paid for Income Taxes, Net of Refunds
Cash paid for income taxes, net of refunds, consisted of:
Year Ended December 31,
(MILLIONS)202420232022
United States$2,593 $1,923 $3,867 
International1,012 1,224 4,000 
Total$3,605 $3,147 $7,867 
Schedule of Effective Income Tax Rate Reconciliation
The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows:
 Year Ended December 31,
2024
2023^
2022
U.S. statutory income tax rate21.0 %21.0 %21.0 %
Taxation of non-U.S. operations(a), (b)
(7.9)(21.1)(5.0)
Transition Tax liability(c)
(6.0)— — 
Tax settlements and resolution of certain tax positions(c)
(2.4)(40.3)(3.0)
Foreign-Derived Intangible Income deduction(d)
(1.2)(33.1)(1.9)
State & local taxes(e)
(2.5)(22.4)— 
Charitable contributions
(1.7)(7.3)(0.5)
U.S. R&D tax credit(1.8)(15.8)(0.6)
Interest(f)
2.2 13.5 0.2 
All other, net(g)
0.1 0.2 (0.6)
Effective tax rate for income from continuing operations
(0.4)%(105.4)%9.6 %
^ The higher rate percentages for the 2023 reconciling items are significantly impacted by the lower domestic and international Income from continuing operations before provision/(benefit) for taxes on income (see Note 5A).
(a)For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income.
(b)In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We have Puerto Rican tax incentives pursuant to a grant that expires during 2053. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we have incentive tax rates effective through 2048 on income from manufacturing and other operations.
(c)See Note 5A.
(d)The higher rate benefit from the Foreign-Derived Intangible Income deduction in 2022 is mainly the result of the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.
(e)Includes the impact of U.S. state and local taxes and changes in the state valuation allowances including those related to the acquisition of Seagen.
(f)Includes changes in interest related to our uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”.
(g)All other, net is primarily due to routine business operations.
Schedule of Deferred Tax Assets and Liabilities
Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:
2024 Deferred Tax^2023 Deferred Tax^
(MILLIONS)Assets(Liabilities)Assets(Liabilities)
Prepaid/deferred items(a)
$2,988 $(847)$2,658 $(654)
Accrued/deferred royalties1,306  1,655 — 
Deferred revenues
300  471 — 
Inventories(b)
992 (702)1,210 (1,060)
Intangible assets(c)
1,435 (9,066)1,526 (11,605)
Property, plant and equipment265 (1,751)168 (2,039)
Employee benefits(d)
1,002 (274)1,085 (287)
Restructurings and other charges462  537 — 
Legal and product liability reserves378  430 — 
Research and development(e)
7,635  6,275 — 
Net operating loss/tax credit carryforwards(f)
2,028  2,708 — 
Unremitted earnings (69)— (60)
State and local tax adjustments161  119 — 
Investments
73 (248)133 (395)
All other87 (66)62 (72)
19,112 (13,023)19,037 (16,172)
Valuation allowances(1,638) (1,738)— 
Total deferred taxes$17,474 $(13,023)$17,299 $(16,172)
Net deferred tax asset/(liability)(g), (h)
$4,451 $1,128 
^ The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See Note 1Q.
(a)The increase in net deferred tax assets in 2024 is primarily related to temporary differences associated with the timing of accruals recorded in the ordinary course of business.
(b)The increase in net deferred tax assets in 2024 is primarily due to measurement period adjustments of inventories related to Seagen. See Note 2A.
(c)The decrease in net deferred tax liabilities in 2024 is primarily due to amortization of intangible assets and certain impairment charges, as well as the measurement period adjustments of intangible assets related to Seagen.
(d)The decrease in net deferred tax assets in 2024 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See Note 11.
(e)The increase in deferred tax assets in 2024 is primarily related to the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.
(f)The amounts in 2024 and 2023 are reduced for unrecognized tax benefits of $575 million and $1.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
(g)In 2024, Noncurrent deferred tax assets and other noncurrent tax assets ($6.6 billion), and Noncurrent deferred tax liabilities ($2.1 billion). In 2023, Noncurrent deferred tax assets and other noncurrent tax assets ($1.8 billion), and Noncurrent deferred tax liabilities ($640 million).
(h)Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.3 billion and $11.1 billion for 2024 and 2023 respectively, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.
Schedule of Unrecognized Tax Benefits Roll Forward
The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:
(MILLIONS)202420232022
Balance, beginning$(4,802)$(4,494)$(6,068)
Acquisitions
8 (46)(52)
Increases based on tax positions taken during a prior period(a), (b)
(934)(158)(67)
Decreases based on tax positions taken during a prior period(a), (c)
599 310 1,339 
Decreases based on settlements for a prior period(c), (d)
911 85 842 
Increases based on tax positions taken during the current period(a)
(433)(515)(701)
Impact of foreign exchange52 (44)90 
Other, net(a), (e)
70 58 122 
Balance, ending(f)
$(4,530)$(4,802)$(4,494)
(a)Primarily included in Provision/(benefit) for taxes on income.
(b)In 2024, the amount includes a gross unrecognized tax benefit associated with the expected filing of an amended income tax return related to the Transition Tax liability under the TCJA.
(c)Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See Note 5A.
(d)Primarily related to cash payments and reductions of tax attributes.
(e)Primarily related to decreases as a result of a lapse of applicable statutes of limitations.
(f)In 2024, included in Income taxes payable ($103 million), Other current assets ($0.4 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.5 billion), Noncurrent deferred tax liabilities ($3 million) and Other taxes payable ($2.9 billion). In 2023, included in Income taxes payable ($94 million), Other current assets ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.3 billion), Noncurrent deferred tax liabilities ($4 million) and Other taxes payable ($3.4 billion).
Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)
Components of the Tax provision/(benefit) on other comprehensive income/(loss) include:
 Year Ended December 31,
(MILLIONS)202420232022
Foreign currency translation adjustments, net(a)
$156 $(33)$(126)
Unrealized holding gains/(losses) on derivative financial instruments, net96 111 183 
Reclassification adjustments for (gains)/losses included in net income(29)(93)(270)
 67 18 (87)
Unrealized holding gains/(losses) on available-for-sale securities, net(19)(15)(164)
Reclassification adjustments for (gains)/losses included in net income5 (18)226 
 (14)(33)62 
Benefit plans: prior service (costs)/credits and other, net45 (5)(5)
Reclassification adjustments related to amortization of prior service costs and other, net(26)(28)(29)
Reclassification adjustments related to curtailments of prior service costs and other, net2 (4)(3)
 22 (37)(37)
Tax provision/(benefit) on other comprehensive income/(loss)$231 $(85)$(187)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
XML 66 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)
Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale Securities
Prior Service (Costs)/Credits and Other
Accumulated Other Comprehensive Income/(Loss)
Balance, January 1, 2022
$(6,172)$119 $(220)$377 $(5,897)
Other comprehensive income/(loss)(b)
(2,188)(531)440 (129)(2,407)
Balance, December 31, 2022
(8,360)(412)220 248 (8,304)
Other comprehensive income/(loss)(b)
497 195 (229)(120)343 
Balance, December 31, 2023
(7,863)(217)(9)128 (7,961)
Other comprehensive income/(loss)(b)
(121)274 (97)63 118 
Balance, December 31, 2024
$(7,984)$57 $(106)$191 $(7,842)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program and gains/(losses) related to our investment in Haleon (see Note 2C).
XML 67 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
As of December 31, 2024As of December 31, 2023
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair value(a)
$7,848 $6,456 $1,392 $5,124 $— $5,124 
Available-for-sale debt securities:
Government and agency—non-U.S.6,855  6,855 817 — 817 
Government and agency—U.S.2,853  2,853 2,601 — 2,601 
Corporate and other1,173  1,173 982 — 982 
10,881  10,881 4,400 — 4,400 
Total short-term investments18,729 6,456 12,273 9,524 — 9,524 
Other current assets
Derivative assets:
Foreign exchange contracts1,056  1,056 298 — 298 
Total other current assets1,056  1,056 298 — 298 
Long-term investments
Equity securities with readily determinable fair values(b)
1,246 1,246  2,779 2,772 
Available-for-sale debt securities:
Government and agency—non-U.S.   124 — 124 
Corporate and other   26 — 26 
   150 — 150 
Total long-term investments1,246 1,246  2,929 2,772 156 
Other noncurrent assets
Derivative assets:
Interest rate contracts13  13 144 — 144 
Foreign exchange contracts447  447 258 — 258 
Total derivative assets460  460 402 — 402 
Insurance contracts(c)
875  875 790 — 790 
Total other noncurrent assets1,335  1,335 1,191 — 1,191 
Total assets$22,366 $7,701 $14,665 $13,943 $2,772 $11,170 
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$28 $ $28 $16 $— $16 
Foreign exchange contracts217  217 404 — 404 
Total other current liabilities245  245 420 — 420 
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts397  397 275 — 275 
Foreign exchange contracts723  723 725 — 725 
Total other noncurrent liabilities1,121  1,121 1,000 — 1,000 
Total liabilities$1,366 $ $1,366 $1,420 $— $1,420 
(a)Includes money market funds. As of December 31, 2024, short-term equity securities include our investment in Haleon of $6.5 billion. See Note 2C.
(b)Long-term equity securities of $133 million as of December 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).
Summary of Investments
The following summarizes our investments by classification type:
As of December 31,
(MILLIONS)20242023
Short-term investments
Equity securities with readily determinable fair values(a)
$7,848 $5,124 
Available-for-sale debt securities10,881 4,400 
Held-to-maturity debt securities705 313 
Total Short-term investments$19,434 $9,837 
Long-term investments
Equity securities with readily determinable fair values(b)
$1,246 $2,779 
Available-for-sale debt securities 150 
Held-to-maturity debt securities45 47 
Private equity securities at cost(b)
719 755 
Total Long-term investments
$2,010 $3,731 
Equity-method investments(a)
217 11,637 
Total long-term investments and equity-method investments$2,228 $15,368 
Held-to-maturity cash equivalents$184 $207 
(a)As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
(b)Represent investments in the life sciences sector.
Contractual Maturities of Available-for-sale and Held-to-maturity Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
As of December 31, 2024As of December 31, 2023
Gross UnrealizedMaturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5
Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$6,970 $8 $(123)$6,855 $6,855 $ $ $953 $$(14)$941 
Government and agency––U.S.
2,853   2,853 2,853   2,601 — — 2,601 
Corporate and other1,179  (6)1,173 1,173   1,006 (2)1,007 
Held-to-maturity debt securities
Time deposits and other
697   697 657 21 19 561 — — 561 
Government and agency––non-U.S.
237   237 232 4 1 — — 
Total debt securities$11,935 $8 $(129)$11,814 $11,770 $25 $20 $5,126 $$(16)$5,115 
Schedule of Available-for-sale Securities Reconciliation
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
As of December 31, 2024As of December 31, 2023
Gross UnrealizedMaturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5
Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$6,970 $8 $(123)$6,855 $6,855 $ $ $953 $$(14)$941 
Government and agency––U.S.
2,853   2,853 2,853   2,601 — — 2,601 
Corporate and other1,179  (6)1,173 1,173   1,006 (2)1,007 
Held-to-maturity debt securities
Time deposits and other
697   697 657 21 19 561 — — 561 
Government and agency––non-U.S.
237   237 232 4 1 — — 
Total debt securities$11,935 $8 $(129)$11,814 $11,770 $25 $20 $5,126 $$(16)$5,115 
Held-to-maturity Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
As of December 31, 2024As of December 31, 2023
Gross UnrealizedMaturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5
Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$6,970 $8 $(123)$6,855 $6,855 $ $ $953 $$(14)$941 
Government and agency––U.S.
2,853   2,853 2,853   2,601 — — 2,601 
Corporate and other1,179  (6)1,173 1,173   1,006 (2)1,007 
Held-to-maturity debt securities
Time deposits and other
697   697 657 21 19 561 — — 561 
Government and agency––non-U.S.
237   237 232 4 1 — — 
Total debt securities$11,935 $8 $(129)$11,814 $11,770 $25 $20 $5,126 $$(16)$5,115 
Schedule of Gains and Losses on Investment Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Year Ended December 31,
(MILLIONS)202420232022
Net (gains)/losses recognized during the period on equity securities(a)
$(1,008)$(1,590)$1,273 
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(1,122)(1,754)(126)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)
$114 $165 $1,400 
(a)Reported in Other (income)/deductions––net. See Note 4.
(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $360 million and upward adjustments of $222 million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022.
Schedule of Short-term Borrowings
Short-term borrowings include:
As of December 31,
(MILLIONS)20242023
Commercial paper, principal amount(a)
$2,453 $7,965 
Current portion of long-term debt, principal amount3,750 2,250 
Other short-term borrowings, principal amount(b)
755 252 
Total short-term borrowings, principal amount
6,957 10,467 
Net fair value adjustments related to hedging and purchase accounting
 
Net unamortized discounts, premiums and debt issuance costs(12)(121)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted
$6,946 $10,350 
(a)Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see Note 2A). The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94% as of December 31, 2024 and 5.37% as of December 31, 2023.
(b)Primarily includes cash collateral. See Note 7F.
Schedule of Long-term Debt Instruments
The following outlines our senior unsecured long-term debt(a) and the weighted-average stated interest rate by maturity:
As of December 31,
(MILLIONS)20242023
Notes due 2025 (3.9% for 2023)(b)
$ $3,750 
Notes due 2026 (3.7% for 2024 and 2023)
6,000 6,000 
Notes due 2027 (2.2% for 2024 and 2.1% for 2023)
980 1,029 
Notes due 2028 (4.6% for 2024 and 2023)
5,660 5,660 
Notes due 2029 (3.5% for 2024 and 2023)
1,750 1,750 
Notes due 2030 (3.6% for 2024 and 2023)
5,250 5,250 
Notes due 2031-2035 (4.5% for 2024 and 2023)
6,750 6,750 
Notes due 2036-2040 (5.4% for 2024 and 2023)
9,534 9,543 
Notes due 2041-2045 (4.3% for 2024 and 2023)
6,474 6,501 
Notes due 2046-2050 (3.7% for 2024 and 2023)
4,750 4,750 
Notes due 2051-2063 (5.3% for 2024 and 2023)
10,000 10,000 
Total long-term debt, principal amount57,147 60,982 
Net fair value adjustments related to hedging and purchase accounting701 1,039 
Net unamortized discounts, premiums and debt issuance costs(444)(483)
Total long-term debt, carried at historical proceeds, as adjusted$57,405 $61,538 
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023))
$3,747 $2,254 
(a)Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.
(b)Reclassified to the current portion of long-term debt.
Schedule of Derivative Financial Instruments
The following summarizes the fair value of the derivative financial instruments and notional amounts:
(MILLIONS)
As of December 31, 2024
As of December 31, 2023
Fair ValueFair Value
NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,991 $1,250 $719 $18,750 $403 $916 
Interest rate contracts
6,750 13 425 6,750 144 290 
1,263 1,144 546 1,206 
Derivatives not designated as hedging instruments:
Foreign exchange contracts
$26,335 253 221 $25,609 154 214 
Total$1,516 $1,366 $700 $1,420 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.
Schedule of Derivative Assets at Fair Value
The following summarizes the fair value of the derivative financial instruments and notional amounts:
(MILLIONS)
As of December 31, 2024
As of December 31, 2023
Fair ValueFair Value
NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,991 $1,250 $719 $18,750 $403 $916 
Interest rate contracts
6,750 13 425 6,750 144 290 
1,263 1,144 546 1,206 
Derivatives not designated as hedging instruments:
Foreign exchange contracts
$26,335 253 221 $25,609 154 214 
Total$1,516 $1,366 $700 $1,420 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.
Schedule of Derivative Liabilities at Fair Value
The following summarizes the fair value of the derivative financial instruments and notional amounts:
(MILLIONS)
As of December 31, 2024
As of December 31, 2023
Fair ValueFair Value
NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,991 $1,250 $719 $18,750 $403 $916 
Interest rate contracts
6,750 13 425 6,750 144 290 
1,263 1,144 546 1,206 
Derivatives not designated as hedging instruments:
Foreign exchange contracts
$26,335 253 221 $25,609 154 214 
Total$1,516 $1,366 $700 $1,420 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.
Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk
The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:
 

Gains/(Losses)
Recognized in OID
(a)
Gains/(Losses)
Recognized in OCI
(a)
Gains/(Losses)
Reclassified from
OCI into OID and COS
(a)
Year Ended December 31,
(MILLIONS)202420232024202320242023
Derivative Financial Instruments in Cash Flow Hedge Relationships:
      
Interest rate contracts$ $— $ $68 $ $
Foreign exchange contracts(b)
 — 466 380 124 236 
Amount excluded from effectiveness testing and amortized into earnings(c)
 — 34 178 34 177 
Derivative Financial Instruments in Fair Value Hedge Relationships:
Interest rate contracts(253)196  —  — 
Hedged item 253 (196) —  — 
Derivative Financial Instruments in Net Investment Hedge Relationships:
Foreign exchange contracts — 498 (393) — 
Amount excluded from effectiveness testing and amortized into earnings(c)
 — 119 137 154 136 
Non-Derivative Financial Instruments in Net Investment Hedge Relationships(d):
Foreign currency short-term borrowings —  —  — 
Foreign currency long-term debt — 49 (29) — 
Derivative Financial Instruments Not Designated as Hedges:
Foreign exchange contracts50 164  —  — 
$50 $164 $1,166 $341 $313 $549 
(a)OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss).
(b)The amounts reclassified from OCI into COS were a net gain of $119 million in 2024 and a net gain of $253 million in 2023. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $330 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 18 years and relates to foreign currency debt.
(c)The amounts reclassified from OCI were reclassified into OID.
(d)Long-term debt includes foreign currency borrowings which are used in net investment hedges; the related carrying values as of December 31, 2024 and December 31, 2023 were $777 million and $824 million, respectively.
Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges
The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:
As of December 31, 2024
As of December 31, 2023
Cumulative Amount of Fair
Value Hedging Adjustment
Increase/(Decrease) to
Carrying Amount
Cumulative Amount of Fair
Value Hedging Adjustment Increase/(Decrease) to
Carrying Amount
(MILLIONS)
Carrying Amount of Hedged Assets/Liabilities(a)
Active
Hedging
Relationships
Discontinued Hedging Relationships
Carrying Amount of Hedged Assets/Liabilities(a)
Active Hedging RelationshipsDiscontinued Hedging Relationships
Long-term debt$7,154 $(384)$891 $7,196 $(131)$957 
(a)Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges
The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:
As of December 31, 2024
As of December 31, 2023
Cumulative Amount of Fair
Value Hedging Adjustment
Increase/(Decrease) to
Carrying Amount
Cumulative Amount of Fair
Value Hedging Adjustment Increase/(Decrease) to
Carrying Amount
(MILLIONS)
Carrying Amount of Hedged Assets/Liabilities(a)
Active
Hedging
Relationships
Discontinued Hedging Relationships
Carrying Amount of Hedged Assets/Liabilities(a)
Active Hedging RelationshipsDiscontinued Hedging Relationships
Long-term debt$7,154 $(384)$891 $7,196 $(131)$957 
(a)Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
XML 68 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Financial Information (Tables)
12 Months Ended
Dec. 31, 2024
Other Financial Information [Abstract]  
Schedule of Components of Inventories, Current
The following summarizes the components of Inventories:
As of December 31,
(MILLIONS)20242023
Finished goods$3,775 $3,495 
Work-in-process6,101 5,688 
Raw materials and supplies976 1,007 
Inventories(a)
$10,851 $10,189 
Noncurrent inventories not included above(b)
$2,663 $4,568 
(a)The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches.
(b)Included in Other noncurrent assets. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See Note 2A. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
Schedule of Components of Inventories, Noncurrent
The following summarizes the components of Inventories:
As of December 31,
(MILLIONS)20242023
Finished goods$3,775 $3,495 
Work-in-process6,101 5,688 
Raw materials and supplies976 1,007 
Inventories(a)
$10,851 $10,189 
Noncurrent inventories not included above(b)
$2,663 $4,568 
(a)The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches.
(b)Included in Other noncurrent assets. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See Note 2A. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
Schedule of Changes in Outstanding Trade Payables
The following summarizes the changes in outstanding trade payables to suppliers who participate in these financing arrangements for the year ended December 31, 2024
(MILLIONS)
Total
Confirmed obligations outstanding, December 31, 2023
$791 
Invoices confirmed during the year
2,638 
Confirmed invoices paid during the year
(2,740)
Confirmed obligations outstanding, December 31, 2024
$688 
XML 69 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Property, Plant and Equipment, Net (Tables)
12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Components of Property, Plant and Equipment, Net
The following summarizes the components of Property, plant and equipment, net:
 Useful LivesAs of December 31,
(MILLIONS)(Years)  20242023
Land-$291 $353 
Buildings
33-50
9,036 9,046 
Machinery and equipment
8-20
15,095 14,263 
Furniture, fixtures and other
3-12.5
5,516 5,399 
Construction in progress-4,937 5,925 
34,876 34,985 
Less: Accumulated depreciation16,483 16,045 
Property, plant and equipment, net
$18,393 $18,940 
Schedule of Property, Plant and Equipment, Net by Geographic Area
The following provides Property, plant and equipment, net by geographic area:
 As of December 31,
(MILLIONS)20242023
United States$9,748 $10,674 
International:
Developed Markets7,187 6,713 
Emerging Markets1,458 1,554 
Property, plant and equipment, net
$18,393 $18,940 
XML 70 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
Identifiable Intangible Assets, Net and Goodwill (Tables)
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2024As of December 31, 2023
(MILLIONS)Gross
Carrying
Amount
Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount
Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$99,397 $(65,044)$34,353 $99,267 $(60,493)$38,773 
Brands(b)
1,277 (992)285 922 (877)45 
Licensing agreements and other
2,724 (1,513)1,210 2,756 (1,458)1,297 
103,397 (67,549)35,848 102,944 (62,828)40,116 
Indefinite-lived intangible assets
Brands(b)
  827 827 
IPR&D(c)
18,893 18,893 23,193 23,193 
Licensing agreements and other
670 670 763 763 
19,563 19,563 24,784 24,784 
Identifiable intangible assets(d)
$122,961 $(67,549)$55,411 $127,728 $(62,828)$64,900 
(a)The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see Note 4).
(b)The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see Note 4).
(c)The decrease in the gross carrying amount reflects impairments of $1.9 billion (see Note 4), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see Note 2A), and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna).
(d)The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see Note 4) and measurement period adjustments related to our acquisition of Seagen of $950 million (see Note 2A).
Schedule of Indefinite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2024As of December 31, 2023
(MILLIONS)Gross
Carrying
Amount
Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount
Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$99,397 $(65,044)$34,353 $99,267 $(60,493)$38,773 
Brands(b)
1,277 (992)285 922 (877)45 
Licensing agreements and other
2,724 (1,513)1,210 2,756 (1,458)1,297 
103,397 (67,549)35,848 102,944 (62,828)40,116 
Indefinite-lived intangible assets
Brands(b)
  827 827 
IPR&D(c)
18,893 18,893 23,193 23,193 
Licensing agreements and other
670 670 763 763 
19,563 19,563 24,784 24,784 
Identifiable intangible assets(d)
$122,961 $(67,549)$55,411 $127,728 $(62,828)$64,900 
(a)The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see Note 4).
(b)The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see Note 4).
(c)The decrease in the gross carrying amount reflects impairments of $1.9 billion (see Note 4), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see Note 2A), and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna).
(d)The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see Note 4) and measurement period adjustments related to our acquisition of Seagen of $950 million (see Note 2A).
Schedule of Expected Amortization Expense
The following provides the expected annual amortization expense:
(MILLIONS)20252026202720282029
Amortization expense$4,838 $4,716 $4,125 $3,776 $2,829 
Schedule of Goodwill
The following summarizes the changes in the carrying amount of Goodwill:
(MILLIONS)
Total(a)
Balance, January 1, 2023
$51,375 
Additions(b)
16,117 
Impact of foreign exchange and other
292 
Balance, December 31, 2023
67,783
Additions(b)
1,022 
Impact of foreign exchange
(278)
Balance, December 31, 2024
$68,527 
(a)As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 17A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
(b)Additions primarily represent our acquisition of Seagen in 2023 and measurement period adjustments related to our acquisition of Seagen in 2024 (see
Note 2A).
XML 71 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)
12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Schedule of Net Periodic Benefit Costs
Pension Plans
Postretirement Plans
U.S.International
Year Ended December 31,
(MILLIONS)202420232022202420232022202420232022
Service cost$ $— $— $87 $85 $116 $14 $12 $29 
Interest cost553 589 534 312 287 157 23 21 27 
Expected return on plan assets
(832)(778)(862)(322)(304)(296)(51)(44)(47)
Amortization of prior service cost/(credit)1 4 — (1)(113)(119)(130)
Actuarial (gains)/losses(a)
396 (410)225 33 102 (11)144 51 (440)
Curtailments — — (4)(2)(11) (12)(18)
Special termination benefits
 18 10 —  — 
Net periodic benefit cost/(credit) reported in income117 (592)(84)120 169 (45)18 (90)(578)
Cost/(credit) reported in Other comprehensive income/(loss)
(1)(2)(2)(4)31 (1)(80)128 169 
Cost/(credit) recognized in Comprehensive income
$116 $(594)$(86)$117 $199 $(46)$(62)$38 $(410)
(a)Reflects: (i) actuarial remeasurement net losses in 2024, primarily due to unfavorable asset performance for the U.S. pension plans and decreases in discount rates for the international pension plans, partially offset by increases in discount rates for the U.S. pension plans and favorable asset performance for the international pension plans and postretirement plans, (ii) actuarial remeasurement net gains in 2023, primarily due to favorable asset performance in the U.S. and increases in discount rates for the international plans, partially offset by unfavorable asset performance for certain international plans, and (iii) actuarial remeasurement net gains in 2022, primarily due to increases in discount rates, partially offset by unfavorable asset performance.
Schedule of Assumptions Used
Pension PlansPostretirement Plans
U.S.International
Year Ended December 31,
(PERCENTAGES)202420232022202420232022202420232022
Weighted-average assumptions used to determine net periodic benefit cost:
Discount rate:
Pension plans/postretirement plans5.4 %5.4 %2.9 %5.4 %5.5 %2.9 %
Interest cost4.4 %3.8 %1.5 %
Service cost3.9 %3.6 %1.7 %
Expected return on plan assets8.0 %7.5 %6.3 %5.1 %4.5 %3.1 %8.0 %7.5 %6.3 %
Rate of compensation increase(a)
3.2 %3.0 %2.8 %
Weighted-average assumptions used to determine benefit obligations at fiscal year-end:
Discount rate5.7 %5.4 %5.4 %4.1 %4.4 %3.8 %5.5 %5.4 %5.5 %
Rate of compensation increase(a)
3.1 %3.2 %3.0 %
(a)The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.
Schedule of Health Care Cost Trend Rates
The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:
As of December 31,
20242023
Healthcare cost trend rate assumed for next year 7.5 %7.9 %
Rate to which the cost trend rate is assumed to decline4.0 %4.0 %
Year that the rate reaches the ultimate trend rate2047 2047 
Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans
The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
 Pension Plans Postretirement Plans
 U.S. International
Year Ended December 31,
(MILLIONS)202420232024202320242023
Change in benefit obligation(a)
Benefit obligation, beginning$10,756 $11,420 $7,292 $7,497 $450 $410 
Service cost — 87 85 14 12 
Interest cost553 589 312 287 23 21 
Employee contributions — 16 11 61 52 
Plan amendments —  25 (193)— 
Changes in actuarial assumptions and other(b)
(299)(127)119 (518)199 96 
Foreign exchange impact(1)— (106)280 (2)(1)
Acquisitions/divestitures, net — 77 13  — 
Curtailments and special termination benefits 7 —  (3)
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Benefit obligation, ending(a)
9,781 10,756 7,363 7,292 486 450 
Change in plan assets
Fair value of plan assets, beginning
10,935 10,871 6,552 6,865 636 647 
Actual return on plan assets138 1,061 408 (316)105 89 
Company contributions103 134 164 154  (15)
Employee contributions — 16 11 61 52 
Foreign exchange impact — (65)214  — 
Acquisitions/divestitures, net — 62 13  — 
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Fair value of plan assets, ending9,948 10,935 6,696 6,552 736 636 
Funded status$167 $179 $(667)$(740)$251 $186 
Amounts recorded in our consolidated balance sheet:
Noncurrent assets$934 $1,010 $728 $644 $330 $266 
Current liabilities(90)(94)(31)(28)(5)(6)
Noncurrent liabilities(678)(738)(1,364)(1,355)(74)(74)
Funded status$167 $179 $(667)$(740)$251 $186 
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
Prior service (costs)/credits$(2)$(2)$(61)$(65)$365 $285 
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):
Fair value of plan assets
$ $— $456 $579 
ABO768 831 1,752 1,834 
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):
Fair value of plan assets$ $— $690 $964 
PBO768 831 2,084 2,347 
(a)For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.
(b)For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.
(c)Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.
Schedule of Amounts Recognized in Balance Sheet
The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
 Pension Plans Postretirement Plans
 U.S. International
Year Ended December 31,
(MILLIONS)202420232024202320242023
Change in benefit obligation(a)
Benefit obligation, beginning$10,756 $11,420 $7,292 $7,497 $450 $410 
Service cost — 87 85 14 12 
Interest cost553 589 312 287 23 21 
Employee contributions — 16 11 61 52 
Plan amendments —  25 (193)— 
Changes in actuarial assumptions and other(b)
(299)(127)119 (518)199 96 
Foreign exchange impact(1)— (106)280 (2)(1)
Acquisitions/divestitures, net — 77 13  — 
Curtailments and special termination benefits 7 —  (3)
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Benefit obligation, ending(a)
9,781 10,756 7,363 7,292 486 450 
Change in plan assets
Fair value of plan assets, beginning
10,935 10,871 6,552 6,865 636 647 
Actual return on plan assets138 1,061 408 (316)105 89 
Company contributions103 134 164 154  (15)
Employee contributions — 16 11 61 52 
Foreign exchange impact — (65)214  — 
Acquisitions/divestitures, net — 62 13  — 
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Fair value of plan assets, ending9,948 10,935 6,696 6,552 736 636 
Funded status$167 $179 $(667)$(740)$251 $186 
Amounts recorded in our consolidated balance sheet:
Noncurrent assets$934 $1,010 $728 $644 $330 $266 
Current liabilities(90)(94)(31)(28)(5)(6)
Noncurrent liabilities(678)(738)(1,364)(1,355)(74)(74)
Funded status$167 $179 $(667)$(740)$251 $186 
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
Prior service (costs)/credits$(2)$(2)$(61)$(65)$365 $285 
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):
Fair value of plan assets
$ $— $456 $579 
ABO768 831 1,752 1,834 
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):
Fair value of plan assets$ $— $690 $964 
PBO768 831 2,084 2,347 
(a)For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.
(b)For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.
(c)Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.
Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)
The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
 Pension Plans Postretirement Plans
 U.S. International
Year Ended December 31,
(MILLIONS)202420232024202320242023
Change in benefit obligation(a)
Benefit obligation, beginning$10,756 $11,420 $7,292 $7,497 $450 $410 
Service cost — 87 85 14 12 
Interest cost553 589 312 287 23 21 
Employee contributions — 16 11 61 52 
Plan amendments —  25 (193)— 
Changes in actuarial assumptions and other(b)
(299)(127)119 (518)199 96 
Foreign exchange impact(1)— (106)280 (2)(1)
Acquisitions/divestitures, net — 77 13  — 
Curtailments and special termination benefits 7 —  (3)
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Benefit obligation, ending(a)
9,781 10,756 7,363 7,292 486 450 
Change in plan assets
Fair value of plan assets, beginning
10,935 10,871 6,552 6,865 636 647 
Actual return on plan assets138 1,061 408 (316)105 89 
Company contributions103 134 164 154  (15)
Employee contributions — 16 11 61 52 
Foreign exchange impact — (65)214  — 
Acquisitions/divestitures, net — 62 13  — 
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Fair value of plan assets, ending9,948 10,935 6,696 6,552 736 636 
Funded status$167 $179 $(667)$(740)$251 $186 
Amounts recorded in our consolidated balance sheet:
Noncurrent assets$934 $1,010 $728 $644 $330 $266 
Current liabilities(90)(94)(31)(28)(5)(6)
Noncurrent liabilities(678)(738)(1,364)(1,355)(74)(74)
Funded status$167 $179 $(667)$(740)$251 $186 
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
Prior service (costs)/credits$(2)$(2)$(61)$(65)$365 $285 
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):
Fair value of plan assets
$ $— $456 $579 
ABO768 831 1,752 1,834 
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):
Fair value of plan assets$ $— $690 $964 
PBO768 831 2,084 2,347 
(a)For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.
(b)For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.
(c)Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets
The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
 Pension Plans Postretirement Plans
 U.S. International
Year Ended December 31,
(MILLIONS)202420232024202320242023
Change in benefit obligation(a)
Benefit obligation, beginning$10,756 $11,420 $7,292 $7,497 $450 $410 
Service cost — 87 85 14 12 
Interest cost553 589 312 287 23 21 
Employee contributions — 16 11 61 52 
Plan amendments —  25 (193)— 
Changes in actuarial assumptions and other(b)
(299)(127)119 (518)199 96 
Foreign exchange impact(1)— (106)280 (2)(1)
Acquisitions/divestitures, net — 77 13  — 
Curtailments and special termination benefits 7 —  (3)
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Benefit obligation, ending(a)
9,781 10,756 7,363 7,292 486 450 
Change in plan assets
Fair value of plan assets, beginning
10,935 10,871 6,552 6,865 636 647 
Actual return on plan assets138 1,061 408 (316)105 89 
Company contributions103 134 164 154  (15)
Employee contributions — 16 11 61 52 
Foreign exchange impact — (65)214  — 
Acquisitions/divestitures, net — 62 13  — 
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Fair value of plan assets, ending9,948 10,935 6,696 6,552 736 636 
Funded status$167 $179 $(667)$(740)$251 $186 
Amounts recorded in our consolidated balance sheet:
Noncurrent assets$934 $1,010 $728 $644 $330 $266 
Current liabilities(90)(94)(31)(28)(5)(6)
Noncurrent liabilities(678)(738)(1,364)(1,355)(74)(74)
Funded status$167 $179 $(667)$(740)$251 $186 
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
Prior service (costs)/credits$(2)$(2)$(61)$(65)$365 $285 
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):
Fair value of plan assets
$ $— $456 $579 
ABO768 831 1,752 1,834 
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):
Fair value of plan assets$ $— $690 $964 
PBO768 831 2,084 2,347 
(a)For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.
(b)For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.
(c)Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets
The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
 Pension Plans Postretirement Plans
 U.S. International
Year Ended December 31,
(MILLIONS)202420232024202320242023
Change in benefit obligation(a)
Benefit obligation, beginning$10,756 $11,420 $7,292 $7,497 $450 $410 
Service cost — 87 85 14 12 
Interest cost553 589 312 287 23 21 
Employee contributions — 16 11 61 52 
Plan amendments —  25 (193)— 
Changes in actuarial assumptions and other(b)
(299)(127)119 (518)199 96 
Foreign exchange impact(1)— (106)280 (2)(1)
Acquisitions/divestitures, net — 77 13  — 
Curtailments and special termination benefits 7 —  (3)
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Benefit obligation, ending(a)
9,781 10,756 7,363 7,292 486 450 
Change in plan assets
Fair value of plan assets, beginning
10,935 10,871 6,552 6,865 636 647 
Actual return on plan assets138 1,061 408 (316)105 89 
Company contributions103 134 164 154  (15)
Employee contributions — 16 11 61 52 
Foreign exchange impact — (65)214  — 
Acquisitions/divestitures, net — 62 13  — 
Settlements
(756)(675)(69)(56) — 
Benefits paid(473)(457)(371)(334)(67)(137)
Fair value of plan assets, ending9,948 10,935 6,696 6,552 736 636 
Funded status$167 $179 $(667)$(740)$251 $186 
Amounts recorded in our consolidated balance sheet:
Noncurrent assets$934 $1,010 $728 $644 $330 $266 
Current liabilities(90)(94)(31)(28)(5)(6)
Noncurrent liabilities(678)(738)(1,364)(1,355)(74)(74)
Funded status$167 $179 $(667)$(740)$251 $186 
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
Prior service (costs)/credits$(2)$(2)$(61)$(65)$365 $285 
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):
Fair value of plan assets
$ $— $456 $579 
ABO768 831 1,752 1,834 
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):
Fair value of plan assets$ $— $690 $964 
PBO768 831 2,084 2,347 
(a)For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.
(b)For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.
(c)Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.
Schedule of Allocation of Plan Assets
The following provides the components of plan assets:
As of December 31, 2024As of December 31, 2023
    Fair ValueFair Value
(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)Target Allocation PercentageTotalLevel 1Level
2
Level 3
Assets Measured at NAV(a)
TotalLevel 1Level
 2
Level 3
Assets Measured at NAV(a)
U.S. pension plans
Cash and cash equivalents0-10%$533 $56 $477 $ $ $606 $47 $559 $— $— 
Equity securities:10-40%
Global equity securities1,341 1,341    1,537 1,537 — — 
Equity commingled funds97  97   100 — 100 — — 
Fixed income securities:45-80%
Corporate debt securities2,878 4 2,874   3,668 3,667 — — 
Government and agency obligations(b)
2,059  2,059   1,971 — 1,971 — — 
Fixed income commingled funds42  12  30 25 — 14 — 11 
Other investments:5-35%
Partnership investments(c)
2,665    2,665 2,449 — — — 2,449 
Insurance contracts     99 — 99 — — 
Other commingled funds(d)
333    333 479 — — — 479 
Total100 %$9,948 $1,401 $5,518 $ $3,028 $10,935 $1,585 $6,410 $$2,939 
International pension plans
Cash and cash equivalents0-10%$310 $138 $172 $ $ $268 $120 $148 $— $— 
Equity securities:10-20%
Equity commingled funds704  619  86 633 — 587 — 46 
Fixed income securities:45-70%
Corporate debt securities638  633 5  617 — 617 — — 
Government and agency obligations(b)
960 1 960   848 — 848 — — 
Fixed income commingled funds1,750  1,064  686 1,852 — 872 — 980 
Other investments:15-35%
Partnership investments(c)
147  2  145 145 — — 142 
Insurance contracts1,221  45 1,176  1,151 — 55 1,096 — 
Other(d)
965 35 147 252 531 1,039 — 167 244 628 
Total100 %$6,696 $174 $3,642 $1,433 $1,447 $6,552 $120 $3,295 $1,340 $1,796 
U.S. postretirement plans(e)
Cash and cash equivalents0-5%$12 $ $12 $ $ $$$$— $— 
Insurance contracts95-100%724  724   633 — 633 — — 
Total100 %$736 $ $736 $ $ $636 $$635 $— $— 
(a)Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.
(b)Government and agency obligations are inclusive of repurchase agreements.
(c)Mainly includes investments in private equity, private debt and real estate.
(d)Mostly includes investments in hedge funds and real estate.
(e)Reflects postretirement plan assets, which support our U.S. retiree medical plans.
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets
The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:
International Pension Plans
Year Ended December 31,
(MILLIONS)20242023
Fair value, beginning$1,340 $1,455 
Actual return on plan assets:
Assets held, ending8 (96)
Assets sold during the period (3)
Purchases, sales, and settlements, net
(79)(155)
Transfer into/(out of) Level 3168 81 
Exchange rate changes(5)59 
Fair value, ending$1,433 $1,340 
Schedule of Expected Future Cash Flow Information
The following provides the expected future cash flow information related to our benefit plans:
  Pension PlansPostretirement Plans
(MILLIONS)U.S.International
Expected employer contributions:
2025
$90 $144 $40 
Expected benefit payments:
2025$871 $384 $44 
2026858 366 47 
2027844 384 49 
2028
825 385 50 
2029
815 392 50 
2030–2034
3,760 2,067 245 
XML 72 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation Awards and Valuation Details
A summary of the awards and valuation details:
Awarded toTermsValuationRecognition and Presentation
Total Shareholder Return Units (TSRUs)
Senior and other key management and select employees
Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the five or seven-year term, if and to the extent the total value is positive.
Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.
Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant. Certain 2022 and 2023 five-year grants were modified during 2024 (for active colleagues) to vest on the fifth anniversary and settle on the seventh anniversary of the grant.
Retirement-eligible holders can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs’ original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.
As of the grant date using a Monte Carlo simulation model
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Restricted Stock Units (RSUs)
Select employees
Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.
For RSUs granted before 2022, generally in all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date. Beginning in 2022, generally in all instances, the units vest and distribute one-third per year for three years on each of the three annual anniversaries from the date of grant assuming continuous service from the grant date.
As of the grant date using the closing price of our common stock
Amortized on a straight-line basis for RSUs granted before 2022, and on an accelerated attribution approach for RSUs granted beginning in 2022, over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Portfolio Performance Shares (PPSs)
Select employees
Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.
For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a three or five-year performance period from the year of the grant date, as applicable.
The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management’s assessment of the probability that the specified performance criteria will be achieved.
Performance Share Awards (PSAs)
Senior and other key management
Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:
a.Adjusted net income over three one-year periods; and
b.TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the three-year performance period.
PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. PSA awards granted in 2022 and 2023 were modified during 2024 (for active colleagues) to vest on the fifth anniversary of the grant.
The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved.
Awarded toTermsValuationRecognition and Presentation
Breakthrough Performance Awards (BPAs)
Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)
Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.
For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the one-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer’s product pipeline during the performance period.
The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.
As of the grant date using the intrinsic value method using the closing price of our common stock
Amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved and/or management’s assessment of the probable vesting term.
Stock Options
Select employees
Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.
Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.
Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years.
As of the grant date using the Black-Scholes-Merton option-pricing model
Amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
Schedule of Share-based Payment Arrangement Activity
The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:
(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION AND YEARS)
TSRUsRSUsPPSsPSAsStock Options
Year Ended December 31,202420232022202420232022202420232022202420232022202420232022
Total fair value of shares vested(a)
$7.05$10.71$11.72$469$505$345$176$116$145$ $58$57$4.08$7.88$9.44
Total intrinsic value of options exercised or share units converted$29$755$1,131$123$250$280$ $102$247
Cash received upon exercise$ $181$260
Tax benefits realized from exercise$ $20$46
Compensation cost recognized/(reduced), pre-tax
$246$244$255$394$437$402$252$(138)$144$(21)$(5)$73$4$4$4
Total compensation cost related to nonvested awards not yet recognized, pre-tax$270$192$179$214$212$266$107$81$135$40$22$38$4$4$3
Weighted-average period over which cost is expected to be recognized (years)2.11.71.71.81.81.71.91.81.71.71.81.81.71.71.7
(a)Weighted-average GDFV per TSRUs and stock options.
Summary of all TSRU, RSU, PPS and PSA activity during 2024 (with the shares granted representing the maximum award that could be achieved for PPSs and PSAs):
TSRUsRSUs
PPSs(a)
PSAs
TSRUs Per TSRU, Weighted AverageShares  Weighted Avg. GDFV per shareShares Weighted Avg. Intrinsic Value per shareShares Weighted Avg. Intrinsic Value per share
(Thousands)GDFVGrant Price(Thousands)(Thousands)(Thousands)
Nonvested, December 31, 2023
77,673$9.67 $39.92 25,844$40.08 22,225$28.79 4,734$28.79 
Granted43,6747.05 26.90 17,07326.97 13,53526.92 2,59726.89 
Vested(31,076)7.42 33.87 (16,874)37.89 (6,329)27.76   
Reinvested dividend equivalents1,541 28.17 
Forfeited(5,370)8.66 33.90 (2,024)32.20 (3,274)28.03 (1,810)27.79 
Nonvested, December 31, 2024
84,902$9.63 $35.87 25,561$32.67 26,156$26.53 5,521$26.53 
(a)Vested and non-vested shares outstanding, but not paid as of December 31, 2024 were 33.9 million.
Summary of TSRU and PTU information as of December 31, 2024(a), (b):
TSRUs
(Thousands)
PTUs
(Thousands)
Weighted-Average
Grant Price
Per TSRU
Weighted-Average
Remaining Contractual Term (Years)
Aggregate Intrinsic Value (Millions)(c)
TSRUs Outstanding167,977 $34.17 2.5$122 
TSRUs Vested83,075 32.44 0.786 
TSRUs Expected to vest(d)
80,014 $35.93 4.334 
Outstanding PTUs converted from TSRUs exercised586 0.2$16 
(a)In 2024, we settled 2,419,674 TSRUs with a weighted-average grant price of $27.76 per unit.
(b)In 2024, 1,150,382 TSRUs with a weighted-average grant price of $31.54 per unit were converted into 100,307 PTUs.
(c)Market price of our underlying common stock less grant price plus dividend equivalents to date.
(d)The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.
Schedule of Valuation Assumptions
Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:
TSRUsStock Options
Year Ended December 31,202420232022202420232022
Expected dividend yield (based on a constant dividend yield during the expected term)
6.06 %3.80 %3.42 %6.06 %3.80 %3.42 %
Risk-free interest rate (based on interpolated yield on U.S. Treasury zero-coupon issues)
4.31 %4.08 %1.87 %4.32 %4.03 %1.93 %
Expected stock price volatility (based on implied volatility, after consideration of historical volatility)
26.56 %23.23 %29.20 %26.56 %23.23 %29.21 %
TSRUs contractual/stock options expected term, years (based on historical exercise and post-vesting termination patterns for stock options)
5.155.155.176.506.506.50
Schedule of Share-based Compensation, Stock Options, Activity
Summary of all stock option activity during 2024:
Shares
(Thousands)
Weighted-Average
Exercise Price
Per Share
Weighted-Average
Remaining Contractual Term
(Years)
Aggregate
Intrinsic Value(a)
(Millions)
Outstanding, December 31, 2023
28,452 $32.66 
Granted1,372 26.90 
Exercised(4)29.06 
Forfeited(235)33.52 
Expired(9,964)30.69   
Outstanding, December 31, 2024
19,621 33.24 1.9$ 
Vested and expected to vest, December 31, 2024(b)
19,510 33.26 1.9 
Exercisable, December 31, 2024
17,447 $33.12 1.1$ 
(a)Market price of our underlying common stock less exercise price.
(b)The number of options expected to vest takes into account an estimate of expected forfeitures.
XML 73 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earning Per Share
The following presents the detailed calculation of EPS:
 Year Ended December 31,
(MILLIONS)
202420232022
EPS Numerator  
Income from continuing operations attributable to Pfizer Inc. common shareholders$8,020 $2,134 $31,366 
Discontinued operations––net of tax11 (15)
Net income attributable to Pfizer Inc. common shareholders$8,031 $2,119 $31,372 
EPS Denominator  
Weighted-average common shares outstanding––Basic
5,664 5,643 5,608 
Common-share equivalents36 66 125 
Weighted-average common shares outstanding––Diluted
5,700 5,709 5,733 
Anti-dilutive common stock equivalents(a)
24 
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
XML 74 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases (Tables)
12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Schedule of Lease Assets and Liabilities
For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:
As of December 31,
(MILLIONS)Balance Sheet Classification20242023
ROU assetsOther noncurrent assets$2,289 $2,924 
Lease liabilities (short-term)Other current liabilities356 527 
Lease liabilities (long-term)Other noncurrent liabilities2,286 2,626 
Schedule of Lease Costs and Other Supplemental Information
Components of total lease cost includes:
Year Ended December 31,
(MILLIONS)202420232022
Operating lease cost$683 $863 $714 
Variable lease cost517 444 536 
Sublease income(23)(24)(32)
Total lease cost$1,177 $1,283 $1,218 
Other supplemental information follows:
As of December 31,
(MILLIONS)20242023
Operating leases
Weighted-Average Remaining Contractual Lease Term (Years)10.210.8
Weighted-Average Discount Rate3.7 %3.8 %
Year Ended December 31,
(MILLIONS)202420232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$601 $744 $617 
(Gains)/losses on sale and leaseback transactions, net29 (49)11 
Schedule of Future Minimum Rental Payments for Operating Leases
The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2024:
(MILLIONS)
PeriodOperating Lease Liabilities
Next one year(a)
$443 
1-2 years406 
2-3 years361 
3-4 years281 
4-5 years239 
Thereafter1,468 
Total undiscounted lease payments3,197 
Less: Imputed interest
556 
Present value of minimum lease payments2,642 
Less: Current portion
356 
Noncurrent portion$2,286 
(a)Reflects lease payments due within 12 months subsequent to the balance sheet date.
XML 75 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Segment
The following table provides selected information by reportable segment:
 
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
Year Ended December 31,Year Ended December 31,Year Ended December 31,
(MILLIONS)
20242023 2022 20242023 202220242023 2022
Reportable Segment:
Biopharma(c)
$62,400 $58,237 $99,826 $28,139 $15,923 $47,939 $1,360 $1,213 $1,107 
Other business activities(d)
1,228 1,316 1,349 (7,382)(4,342)(5,162)340 323 332 
Reconciling Items:
Amortization of intangible assets(5,286)(4,733)(3,609)5,286 4,733 3,609 
Acquisition-related items(1,938)(1,874)(832)12 (11)(20)
Certain significant items(e)
(5,510)(3,917)(3,608)14 32 36 
$63,627 $59,553 $101,175 $8,023 $1,058 $34,729 $7,013 $6,290 $5,064 
(a)Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $331 million and $294 million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
(c)Biopharma’s revenues and earnings in 2024 reflect a non-cash favorable product return adjustment of $771 million recorded in the first quarter of 2024 and in 2023 reflected a non-cash revenue reversal of $3.5 billion (see Note 17C). In 2023, Biopharma earnings included approximately $6.2 billion of inventory write-offs and related charges to Cost of sales mainly due to lower-than-expected demand for our COVID-19 products. In 2022, Biopharma earnings included COVID-19-related charges of approximately $1.7 billion to Cost of sales, composed of (i) inventory write-offs of approximately $1.2 billion related to COVID-19
products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for Paxlovid. Biopharma’s earnings also include dividend income from our investment in ViiV of $272 million in 2024, $265 million in 2023 and $314 million in 2022.
(d)Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.
(e)Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in 2024 include, among other items: (i) intangible asset impairment charges of $3.3 billion recorded in Other (income)/deductions––net, (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs), (iii) actuarial valuation and other postretirement plan losses of $579 million recorded in Other (income)/deductions––net, (iv) charges for certain legal matters of $567 million recorded in Other (income)/deductions––net, and (v) a charge in Other (income)/deductions––net of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program, partially offset by (vi) net gains on equity securities of $1.0 billion and (vii) net gains of $825 million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945 million less (b) $120 million in the fourth quarter (included in Other business activities) representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares. Earnings in 2023 included, among other items: (i) intangible asset impairment charges of $3.0 billion recorded in Other (income)/deductions––net and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion ($290 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in Other (income)/deductions––net. Earnings in 2022 included, among other items: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.4 billion ($562 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs) and (ii) net losses on equity securities of $1.3 billion recorded in Other (income)/deductions––net. See Notes 3 and 4.
The following provides Biopharma reportable segment information regularly provided to the CODM:
Year Ended December 31,
(MILLIONS)202420232022
Biopharma reportable segment:
Biopharma total revenues$62,400 $58,237 $99,826 
Less:
Cost of sales14,997 22,666 32,859 
Selling, informational and administrative expenses10,040 10,235 9,207 
Research and development expenses9,532 9,763 10,324 
Acquired in-process research and development expenses108 194 181 
Other (income)/deductions––net
(416)(543)(685)
Biopharma earnings$28,139 $15,923 $47,939 
Revenues - Comirnaty
$5,353 $11,220 $37,809 
Revenues - Paxlovid
$5,716 $1,279 $18,933 
Revenues - excluding Comirnaty and Paxlovid
$51,331 $45,738 $43,084 
Revenue from External Customers by Geographic Areas
The following summarizes revenues by geographic area:
 Year Ended December 31,
(MILLIONS)202420232022
United States$38,691 $28,145 $43,317 
International:
Developed Markets
16,057 20,910 40,534 
Emerging Markets8,879 10,498 17,324 
Total revenues$63,627 $59,553 $101,175 
Schedules of Concentration of Risk
The following summarizes revenue, as a percentage of Total revenues, for our three largest U.S. wholesaler customers and the U.S. government, which was concentrated in our Biopharma operating segment:
 Year Ended December 31,
202420232022
McKesson, Inc.
23 %16 %%
Cencora, Inc.
17 %12 %%
Cardinal Health, Inc.14 %10 %%
U.S. government(a)
6 %— 23 %
Schedule of Significant Product Revenues
The following provides detailed revenue information for several of our major products:
(MILLIONS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202420232022
TOTAL REVENUES$63,627 $59,553 $101,175 
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)
$62,400 $58,237 $99,826 
Primary Care$30,135 $30,799 $73,181 
Eliquis(a)
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism7,366 6,747 6,480 
Prevnar family
Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae
6,411 6,501 6,342 
Paxlovid(b)
COVID-19 in certain high-risk patients
5,716 1,279 18,933 
Comirnaty
Active immunization to prevent COVID-19
5,353 11,220 37,809 
Nurtec ODT/VyduraAcute treatment of migraine and prevention of episodic migraine1,263 928 213 
Abrysvo
Active immunization to prevent RSV infection
755 890 — 
Premarin family
Symptoms of menopause380 397 455 
BMP2
Bone graft for spinal fusion
352 338 277 
FSME-IMMUN/TicoVacActive immunization to prevent tick-borne encephalitis disease280 268 200 
All other Primary CareVarious2,259 2,233 2,473 
Specialty Care$16,652 $14,988 $13,851 
Vyndaqel familyATTR-CM and polyneuropathy5,451 3,321 2,447 
Xeljanz
RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis1,168 1,703 1,796 
Enbrel (Outside the U.S. and Canada)
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis
690 830 1,003 
Sulperazon
Bacterial infections637 757 786 
ZaviceftaBacterial infections586 511 412 
Octagam(c)
Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults
509 245 186 
Inflectra
Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis
509 490 532 
ZithromaxBacterial infections480 406 331 
(MILLIONS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202420232022
Genotropin
Replacement of human growth hormone470 539 360 
BeneFIXHemophilia B381 424 425 
Cibinqo
Atopic dermatitis
215 128 27 
Oxbryta(d)
Sickle cell disease201 328 73 
All other Hospital(e)
Various
4,448 4,514 4,730 
All other Specialty CareVarious907 792 743 
Oncology$15,612 $12,450 $12,794 
IbranceHR-positive/HER2-negative metastatic breast cancer4,367 4,753 5,120 
Xtandi(f)
mCRPC, nmCRPC, mCSPC, nmCSPC
2,039 1,659 1,650 
Padcev
Locally advanced or metastatic urothelial cancer
1,588 53 — 
Adcetris
Hodgkin lymphoma and certain T-cell lymphomas
1,089 56 — 
Oncology biosimilars(g)
Various
1,037 1,407 1,753 
Inlyta
Advanced RCC978 1,036 1,003 
Lorbrena
ALK-positive metastatic NSCLC
731 539 343 
Bosulif
Philadelphia chromosome–positive chronic myelogenous leukemia645 645 575 
Braftovi/Mektovi
Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux (cetuximab)(h) (after prior therapy) or cetuximab and mFOLFOX6
607 477 456 
Tukysa
Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer480 18 — 
Elrexfio
Relapsed or refractory multiple myeloma
133 10 — 
Tivdak
Recurrent or mCC
131 — 
Talzenna
In combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC; treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer
117 64 48 
All other OncologyVarious1,670 1,729 1,846 
PFIZER CENTREONE(i)
$1,146 $1,272 $1,342 
PFIZER IGNITE
$82 $44 $
BIOPHARMA
$62,400 $58,237 $99,826 
PFIZER U.S. COMMERCIAL DIVISION (U.S. Primary Care and U.S. Specialty Care)
26,765 19,299 34,337 
PFIZER ONCOLOGY DIVISION
11,567 8,450 8,583 
PFIZER INTERNATIONAL COMMERCIAL DIVISION
24,068 30,488 56,905 
Total Alliance revenues included above$8,388 $7,582 $8,537 
Total Royalty revenues included above
$1,423 $1,058 $845 
(a)Reflects Alliance revenues and product revenues.
(b)2024 includes (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.
(c)2024 includes $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.
(d)In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of expanded access programs worldwide, based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing.
(e)Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.
(f)Primarily reflects Alliance revenues and royalty revenues.
(g)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.
(h)Erbitux is a registered trademark of ImClone LLC.
(i)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
XML 76 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Significant Accounting Policies - Narrative (Details)
$ in Billions
12 Months Ended
Dec. 31, 2024
segment
Dec. 31, 2024
USD ($)
Dec. 31, 2024
Dec. 31, 2024
operatingSegment
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Number of operating segments 3     3    
Advertising expense   $ 3.3     $ 3.7 $ 2.8
Revenue [Member] | Top Ten Products [Member] | Product Concentration Risk [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Concentration risk, amount           $ 1.0
Concentration risk, percentage           82.00%
Revenue [Member] | Top Nine Products [Member] | Product Concentration Risk [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Concentration risk, amount         $ 1.0  
Concentration risk, percentage         64.00%  
Revenue [Member] | Top Eleven Products | Product Concentration Risk [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Concentration risk, amount   $ 1.0        
Concentration risk, percentage     66.00%      
XML 77 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Schedule of Accrued Liabilities [Line Items]    
Total accrued rebates and other sales-related accruals $ 10,822 $ 9,014
Trade accounts receivable, less allowance for doubtful accounts [Member]    
Schedule of Accrued Liabilities [Line Items]    
Total accrued rebates and other sales-related accruals 1,627 1,770
Other current liabilities [Member]    
Schedule of Accrued Liabilities [Line Items]    
Accrued rebates 7,195 5,546
Other accruals 972 902
Other noncurrent liabilities [Member]    
Schedule of Accrued Liabilities [Line Items]    
Total accrued rebates and other sales-related accruals $ 1,029 $ 796
XML 78 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Acquisitions (Details)
$ / shares in Units, shares in Thousands, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 14, 2023
USD ($)
medicine
$ / shares
Oct. 05, 2022
USD ($)
$ / shares
Oct. 03, 2022
USD ($)
Jun. 09, 2022
USD ($)
Mar. 11, 2022
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
shares
Oct. 31, 2022
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Business Acquisition [Line Items]                        
Business acquisition, cash payment, net of cash acquired                 $ 0 $ 43,430 $ 22,997  
Uncertain tax positions           $ 4,802 [1]   $ 4,802 [1] 4,530 [1] 4,802 [1] 4,494 [1] $ 6,068
Goodwill           $ 67,783 [2]   67,783 [2] 68,527 67,783 [2] 51,375 [2]  
Acquired in-process research and development expenses                 108 194 953  
ReViral [Member]                        
Business Acquisition [Line Items]                        
Asset acquisition, consideration transferred       $ 536                
Payments to acquire asset       436                
Payment for asset acquisition, base payment       425                
Asset acquisition, contingent consideration       100                
Acquired in-process research and development expenses       $ 426                
Seagen [Member]                        
Business Acquisition [Line Items]                        
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 229                      
Business acquisition, cash payment, gross $ 44,200                      
Business acquisition, cash payment, net of cash acquired $ 43,400                      
Post closing compensation expense               $ 476        
Number of approved medicines | medicine 4                      
Gross contractual amount receivable $ 597                      
Net deferred tax liabilities 4,800                      
Uncertain tax positions 48                      
Net deferred tax liabilities, gross (6,300)                      
Deferred tax assets 1,500                      
Pro Forma net loss attributable to Pfizer Inc. common shareholders                   1,481 (27,870)  
Shares issued in acquisition (in shares) | shares           0            
Goodwill 16,126               17,148      
Inventories [3] $ 4,195               3,273      
Seagen [Member] | Amortization Expense [Member]                        
Business Acquisition [Line Items]                        
Pro Forma net loss attributable to Pfizer Inc. common shareholders                   553 576  
Seagen [Member] | Fair Value Adjustment to Inventory [Member]                        
Business Acquisition [Line Items]                        
Pro Forma net loss attributable to Pfizer Inc. common shareholders                   755 934  
Seagen [Member] | Interest Expense [Member]                        
Business Acquisition [Line Items]                        
Pro Forma net loss attributable to Pfizer Inc. common shareholders                   984 2,000  
Seagen [Member] | Interest Income [Member]                        
Business Acquisition [Line Items]                        
Pro Forma net loss attributable to Pfizer Inc. common shareholders                   $ 1,200 $ 267  
GBT [Member]                        
Business Acquisition [Line Items]                        
Business acquisition, per share in cash (in dollars per share) | $ / shares   $ 68.50                    
Business acquisition, cash payment, gross   $ 5,700                    
Business acquisition, cash payment, net of cash acquired   5,200                    
Net deferred tax liabilities   516                    
Intangible assets   4,400                    
Goodwill   1,100                    
Inventories   $ 644                    
Acquired inventory, selling period   3 years                    
Assumed long-term debt, paid in full   $ 331                    
Biohaven [Member]                        
Business Acquisition [Line Items]                        
Business acquisition, per share in cash (in dollars per share) | $ / shares             $ 148.50          
Business acquisition, cash payment, gross             $ 11,500          
Net deferred tax liabilities     $ 544                  
Intangible assets     12,100                  
Goodwill     823                  
Inventories     $ 813                  
Acquired inventory, selling period     2 years                  
Assumed long-term debt, paid in full     $ 1,400                  
Repayment of assumed debt     863                  
Business acquisition, equity consideration     495                  
Consideration transferred, including equity interest held prior to business combination     11,800                  
Fair value of previously held equity interest in acquiree     300                  
Trade accounts receivable     398                  
Other current liabilities     526                  
Arena [Member]                        
Business Acquisition [Line Items]                        
Business acquisition, per share in cash (in dollars per share) | $ / shares         $ 100              
Business acquisition, cash payment, gross         $ 6,600              
Business acquisition, cash payment, net of cash acquired         6,200              
Post closing compensation expense         138              
Net deferred tax liabilities         490              
Intangible assets         5,500              
Goodwill         1,000              
Developed Technology Rights [Member] | Seagen [Member]                        
Business Acquisition [Line Items]                        
Acquired intangible assets, useful life 18 years                      
Developed Technology Rights [Member] | GBT [Member]                        
Business Acquisition [Line Items]                        
Intangible assets   $ 1,400                    
Acquired intangible assets, useful life   6 years                    
Developed Technology Rights [Member] | Biohaven [Member]                        
Business Acquisition [Line Items]                        
Intangible assets     $ 11,600                  
Acquired intangible assets, useful life     11 years                  
IPR&D [Member] | Seagen [Member]                        
Business Acquisition [Line Items]                        
Intangible assets $ 20,800               $ 19,900      
IPR&D [Member] | GBT [Member]                        
Business Acquisition [Line Items]                        
Intangible assets   $ 3,000                    
IPR&D [Member] | Biohaven [Member]                        
Business Acquisition [Line Items]                        
Intangible assets     $ 450                  
IPR&D [Member] | Arena [Member]                        
Business Acquisition [Line Items]                        
Intangible assets         5,000              
Licensing Agreements [Member] | Arena [Member]                        
Business Acquisition [Line Items]                        
Intangible assets         $ 460              
[1] In 2024, included in Income taxes payable ($103 million), Other current assets ($0.4 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.5 billion), Noncurrent deferred tax liabilities ($3 million) and Other taxes payable ($2.9 billion). In 2023, included in Income taxes payable ($94 million), Other current assets ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.3 billion), Noncurrent deferred tax liabilities ($4 million) and Other taxes payable ($3.4 billion).
[2] As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 17A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
[3] As adjusted, comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories.
XML 79 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
[1]
Dec. 14, 2023
Dec. 31, 2022
[1]
Business Acquisition [Line Items]        
Goodwill $ 68,527 $ 67,783   $ 51,375
Seagen [Member]        
Business Acquisition [Line Items]        
Working capital, excluding inventories [2] 621   $ 736  
Inventories [3] 3,273   4,195  
Property, plant and equipment 280   524  
Other noncurrent assets 59   174  
Net income tax accounts [4] (4,779)   (6,123)  
Other noncurrent liabilities (187)   (167)  
Total identifiable net assets 27,086   28,108  
Goodwill 17,148   16,126  
Net assets acquired/total consideration transferred 44,234   44,234  
Measurement Period Adjustments        
Working capital, excluding inventories [2],[5] (115)      
Inventories [3],[5] (922)      
Property, plant and equipment [5] (243)      
Other noncurrent assets [5] (115)      
Net income tax accounts [4],[5] 1,343      
Other noncurrent liabilities [5] (20)      
Total identifiable net assets [5] (1,022)      
Goodwill [5] 1,022      
Net assets acquired/total consideration transferred [5] 0      
Seagen [Member] | IPR&D [Member]        
Business Acquisition [Line Items]        
Intangible assets 19,900   20,800  
Measurement Period Adjustments        
Identifiable intangible assets [5] (900)      
Seagen [Member] | Developed Technology Rights and Other Intangible Assets [Member]        
Business Acquisition [Line Items]        
Intangible assets [6] 7,920   $ 7,970  
Measurement Period Adjustments        
Identifiable intangible assets [5],[6] $ (50)      
[1] As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 17A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
[2] Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities.
[3] As adjusted, comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories.
[4] As adjusted, included primarily in Noncurrent deferred tax liabilities. The measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments.
[5] The changes in the estimated fair values are to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
[6] As adjusted, comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.
XML 80 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation - Footnotes (Details) - Seagen [Member]
$ in Billions
Dec. 14, 2023
USD ($)
Business Acquisition [Line Items]  
Current inventories $ 1.1
Noncurrent inventories 2.1
Developed Technology Rights [Member]  
Business Acquisition [Line Items]  
Identifiable intangible assets, excluding in-process research and development $ 7.5
Acquired intangible assets, estimated weighted-average useful life 18 years
XML 81 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information (Details) - Seagen [Member] - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Revenues subsequent to acquisition $ 132    
Net loss attributable to Pfizer Inc. common shareholders $ (746)    
Revenues   $ 61,893 $ 103,137
Net income/(loss) attributable to Pfizer Inc. common shareholders   $ (1,481) $ 27,870
Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders   $ (0.26) $ 4.86
XML 82 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information - Footnotes (Details) - Seagen [Member]
$ in Millions
1 Months Ended
Dec. 31, 2023
USD ($)
Business Acquisition [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders $ (746)
Restructuring, integration and acquisition-related costs [Member]  
Business Acquisition [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders 614
Fair Value Adjustment to Inventory [Member]  
Business Acquisition [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders 109
Amortization Expense [Member]  
Business Acquisition [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders 25
Depreciation Expense [Member]  
Business Acquisition [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders $ 2
XML 83 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Divestitures (Details) - USD ($)
$ in Millions
12 Months Ended
Sep. 19, 2023
Dec. 31, 2023
Dec. 31, 2020
Dec. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Maximum consideration to be received from divestiture $ 1,000      
Cash proceeds from disposal 300      
Pre-tax gain on divestiture $ 222 $ 222    
Viatris [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Nontrade payables   $ 33   $ 105
Viatris [Member] | Minimum [Member] | Manufacturing and Supply Agreement [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal     4 years  
Viatris [Member] | Maximum [Member] | Manufacturing and Supply Agreement [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal     7 years  
XML 84 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Sep. 29, 2024
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]        
Beginning carrying value reported in Equity-method investments [1]     $ 11,637  
Reclassification of accumulated other comprehensive income balances in Equity-method investments [2]     (143) $ 0
Transfer of carrying value to Short-term investments [3]     (5,411) 0
Ending carrying value [1]     217 11,637
Haleon [Member]        
Schedule of Equity Method Investments [Line Items]        
Beginning carrying value reported in Equity-method investments     11,451 10,824
Carrying value of shares sold     (6,113) 0
Dividends     (212) (153)
Currency translation adjustments and other [4]     341 293
Basis difference adjustments and amortization [5],[6]     (91) (2)
Pfizer share of Haleon investee capital transaction $ 46 $ (91) (44) [5],[7] 0 [5],[7]
Pfizer share of Haleon earnings [5]     224 489
Ending carrying value     $ 0 $ 11,451
[1] As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
[2] The 2024 activity primarily represent foreign currency translation balances in Accumulated other comprehensive income related to the equity-method investment in Haleon that were reclassified into Equity-method investments upon our loss of significant influence over Haleon and our discontinuance of the equity method for the Haleon investment.
[3] The final carrying value of our equity-method investment in Haleon was reclassified to Short-term investments and is being accounted for as an equity investment with a readily determinable fair value.
[4] See Note 6.
[5] Included in Other (income)/deductions––net.
[6] Adjustments in 2024 include (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities.
[7] In 2024, includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.
XML 85 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment - Footnotes (Details) - Haleon [Member] - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Sep. 29, 2024
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Oct. 31, 2024
Schedule of Equity Method Investments [Line Items]          
Pfizer share of Haleon investee capital transaction $ 46 $ (91) $ (44) [1],[2] $ 0 [1],[2]  
Equity method investment, ownership percentage     23.00% 32.00% 15.00%
[1] In 2024, includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.
[2] Included in Other (income)/deductions––net.
XML 86 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Summarized Financial Information of Equity Method Investee (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Sep. 29, 2024
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Sep. 30, 2024
Dec. 31, 2021
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]                
Current assets $ 50,358   $ 43,333          
Total assets 213,396   226,501          
Current liabilities 42,995   47,794          
Total liabilities 124,899   137,213          
Equity attributable to shareholders 88,203   89,014          
Equity attributable to noncontrolling interests 294   274          
Total equity 88,497   89,288   $ 95,916     $ 77,462
Equity Method Investment, Summarized Financial Information [Abstract]                
Revenues: 63,627   59,553   101,175      
Income from continuing operations 8,051   2,172   31,401      
Net income 8,062   2,158   31,407      
Income attributable to shareholders 8,031   2,119   31,372      
Haleon [Member]                
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]                
Current assets       $ 5,876     $ 7,813  
Noncurrent assets       36,954     37,572  
Total assets       42,830     45,385  
Current liabilities       6,117     7,468  
Noncurrent liabilities       15,744     15,511  
Total liabilities       21,862     22,979  
Equity attributable to shareholders       20,719     22,129  
Equity attributable to noncontrolling interests       249     277  
Total equity       20,968     $ 22,406  
Equity Method Investment, Summarized Financial Information [Abstract]                
Revenues:   $ 14,252   13,921        
Cost of sales   (5,656)   (5,580)        
Gross profit   8,596   8,341        
Income from continuing operations   1,668   1,606        
Net income   1,668   1,606        
Income attributable to shareholders   $ 1,600   $ 1,528        
Haleon/Consumer Healthcare JV [Member]                
Equity Method Investment, Summarized Financial Information [Abstract]                
Revenues:           $ 13,566    
Cost of sales           (5,081)    
Gross profit           8,486    
Income from continuing operations           1,745    
Net income           1,745    
Income attributable to shareholders           $ 1,675    
ViiV [Member]                
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]                
Current assets 4,338   4,237          
Noncurrent assets 3,223   3,009          
Total assets 7,561   7,245          
Current liabilities 4,280   4,085          
Noncurrent liabilities 6,205   5,998          
Total liabilities 10,485   10,083          
Equity attributable to shareholders (2,924)   (2,838)          
Equity Method Investment, Summarized Financial Information [Abstract]                
Revenues: 8,971   7,845   6,955      
Cost of sales (1,360)   (1,060)   (819)      
Gross profit 7,611   6,785   6,135      
Income from continuing operations 3,062   3,090   3,108      
Net income 3,062   3,090   3,108      
Income attributable to shareholders $ 3,062   $ 3,090   $ 3,108      
XML 87 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Equity Method Investments (Details)
€ in Millions, £ in Millions, shares in Millions
1 Months Ended 12 Months Ended
Oct. 31, 2024
USD ($)
shares
Mar. 31, 2024
USD ($)
shares
Jul. 31, 2022
USD ($)
Jul. 31, 2022
GBP (£)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jul. 02, 2023
USD ($)
Jul. 02, 2023
GBP (£)
Mar. 31, 2022
USD ($)
Mar. 31, 2022
EUR (€)
Mar. 31, 2022
GBP (£)
Jul. 31, 2019
Dec. 31, 2016
USD ($)
Schedule of Equity Method Investments [Line Items]                            
Proceeds from partial sales of investment in Haleon [1]         $ 7,040,000,000 $ 0 $ 0              
Other short-term borrowings [2]         755,000,000 252,000,000                
Dividend received from the Consumer Healthcare JV [1]         0 0 3,960,000,000              
Equity-method investments [3]         $ 217,000,000 11,637,000,000                
1.365% Consumer Healthcare JV Loan [Member] | Loans Payable [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Debt instrument, face amount | £                 £ 2,900          
Other short-term borrowings               $ 3,700,000,000            
Stated interest rate               1.365% 1.365%          
Repurchased debt | £       £ 2,900                    
Haleon/Consumer Healthcare JV [Member] | Senior Notes, USD Denominated [Member] | Senior Notes [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Debt instrument, face amount                   $ 8,750,000,000        
Haleon/Consumer Healthcare JV [Member] | Senior Notes, EUR Denominated [Member] | Senior Notes [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Debt instrument, face amount | €                     € 2,350      
Haleon/Consumer Healthcare JV [Member] | Senior Notes, GBP Denominated [Member] | Senior Notes [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Debt instrument, face amount | £                       £ 700    
Disposed of by Sale, Not Discontinued Operations [Member] | Haleon/Consumer Healthcare JV [Member] | GSK [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Proposed percent of ownership disposal                   80.00% 80.00% 80.00%    
Haleon/Consumer Healthcare JV [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Equity method investment, ownership percentage                   32.00% 32.00% 32.00%    
Dividends received, total     $ 4,200,000,000 £ 3,500                    
Dividend received from the Consumer Healthcare JV     $ 4,000,000,000                      
Haleon/Consumer Healthcare JV [Member] | GSK [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Equity method investment, ownership percentage                         68.00%  
ViiV [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Equity method investment, ownership percentage         11.70%                  
Equity-method investments                           $ 0
Dividend income         $ (272,000,000) $ (265,000,000) (314,000,000)              
Haleon [Member]                            
Schedule of Equity Method Investments [Line Items]                            
Equity method investment, ownership percentage 15.00%       23.00% 32.00%                
Equity method investment, ownership percentage sold 34.00% 30.00%                        
Proceeds from partial sales of investment in Haleon $ 3,500,000,000 $ 3,500,000,000                        
Gain on sale of equity method investment         $ 945,000,000                  
Equity-method investments         $ 0 $ 11,451,000,000 $ 10,824,000,000              
Haleon [Member] | Sale of Equity-Method Investment in Private Placement                            
Schedule of Equity Method Investments [Line Items]                            
Number of shares sold in transaction (in shares) | shares 61 102                        
Haleon [Member] | Sale of Equity-Method Investment in Public Stock Offering                            
Schedule of Equity Method Investments [Line Items]                            
Number of shares sold in transaction (in shares) | shares 640 791                        
[1] See Note 2C.
[2] Primarily includes cash collateral. See Note 7F.
[3] As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
XML 88 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Collaborative Arrangements (Detail) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Jan. 04, 2022
Oct. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Acquired in-process research and development expenses     $ 108 $ 194 $ 953
Biohaven [Member] | Collaborative Arrangement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cash payment to collaborators $ 500        
Upfront payment to collaborators 150        
Committed investment from collaborator 350        
Acquired in-process research and development expenses $ 263        
Biohaven [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Business acquisition, per share in cash (in dollars per share)   $ 148.50      
Business acquisition, cash payment   $ 11,500      
XML 89 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Alliance revenues $ 8,388 $ 7,582 $ 8,537
Total revenues 63,627 59,553 101,175
Cost of sales [1],[2] (17,851) (24,954) (34,344)
Selling, informational and administrative expenses [1] (14,730) (14,771) (13,677)
Other income/(deductions)—net (4,388) (222) (1,062)
Product [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Revenues 53,816 50,914 91,793
Royalty [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Revenues [3] 1,423 1,058 845
Collaborative Arrangement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Alliance revenues [4] 8,388 7,582 8,537
Total revenues 9,486 8,400 9,588
Cost of sales [5] (2,901) (4,277) (15,589)
Selling, informational and administrative expenses [6] (335) (267) (196)
Research and development expenses [7] 282 219 272
Acquired in-process research and development expenses [8] 2 (13) (339)
Restructuring charges and certain acquisition-related costs [9] 45 0 0
Other income/(deductions)—net (15) 25 50
Collaborative Arrangement [Member] | Product [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Revenues [10] 175 212 437
Collaborative Arrangement [Member] | Royalty [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Revenues [11] $ 923 $ 605 $ 614
[1] Exclusive of amortization of intangible assets.
[2] See Note 17A.
[3] See Note 1A.
[4] Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2024 was primarily driven by an increase in Alliance revenues from Eliquis and Xtandi, partially offset by a decrease in Alliance revenues from Bavencio. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis.
[5] Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decreases in 2024 and in 2023 primarily relate to Comirnaty.
[6] Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
[7] Represents net reimbursements from our partners for research and development expenses incurred.
[8] Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.
[9] Relates to exit costs associated with terminating a collaboration with SMPS.
[10] Represents sales to our partners of products manufactured by us.
[11] Primarily relates to royalties from our collaboration partners.
XML 90 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Research and Development Arrangement (Details) - Blackstone [Member] - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Apr. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development arrangement, maximum funding amount $ 550    
Research and development arrangement, funding to offset costs incurred   $ 135 $ 175
Clinical Trial Agreement Terms [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Maximum potential consideration 468    
Net Sales and Royalty Agreement Terms [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Maximum potential consideration $ 550    
XML 91 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) - USD ($)
$ in Millions
12 Months Ended 15 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2024
Restructuring Cost and Reserve [Line Items]        
Restructuring charge (credit) [1] $ 1,987 $ 1,968 $ 882  
Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring charge (credit) 1,800   $ 796  
Realigning Our Cost Base Program [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs incurred to date 2,600     $ 2,600
Expected cost 2,900     2,900
Realigning Our Cost Base Program [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs incurred to date 2,100     2,100
Expected cost 2,200     2,200
Restructuring charge (credit) 571 $ 1,400   2,000
Manufacturing Optimization Program - Phase One [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected cost 1,600     1,600
Manufacturing Optimization Program [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs incurred to date 1,200     $ 1,200
Restructuring charge (credit) $ 1,200      
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).
XML 92 R63.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Restructuring charges:      
Employee terminations $ 1,152 $ 1,622 $ 776
Asset impairments 432 227 52
Exit costs 403 119 54
Total restructuring charges/(credits) [1] 1,987 1,968 882
Transaction costs [2] 5 190 144
Integration costs and other [3] 427 785 348
Restructuring charges and certain acquisition-related costs 2,419 2,943 1,375
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows [4] 19 32 36
Implementation costs recorded in our consolidated statements of income as follows:      
Implementation costs [5] 294 457 616
Total costs associated with acquisitions and cost-reduction/productivity initiatives 2,738 3,426 2,018
Other (Income)/Deductions--net [Member]      
Restructuring charges:      
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net 7 (7) (9)
Cost of Sales [Member]      
Restructuring charges:      
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows [4] 14 31 34
Implementation costs recorded in our consolidated statements of income as follows:      
Implementation costs [5] 120 67 54
Selling, Informational and Administrative Expenses [Member]      
Restructuring charges:      
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows [4] 5 1 2
Implementation costs recorded in our consolidated statements of income as follows:      
Implementation costs [5] 90 289 560
Research and Development Expense [Member]      
Implementation costs recorded in our consolidated statements of income as follows:      
Implementation costs [5] $ 84 $ 101 $ 2
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).
[2] Represents external costs for banking, legal, accounting and other similar services.
[3] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2023 costs mostly relate to our acquisition of Seagen, including $476 million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of 2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our acquisitions of Arena and GBT, including $138 million in payments to Arena employees in the first quarter of 2022 and $136 million in payments to GBT employees in the fourth quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See Note 2A.
[4] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5] Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
XML 93 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended 15 Months Ended
Oct. 05, 2022
Mar. 11, 2022
Dec. 31, 2023
Dec. 31, 2022
Apr. 03, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2024
Restructuring Cost and Reserve [Line Items]                  
Restructuring charge (credit) [1]           $ 1,987 $ 1,968 $ 882  
Seagen [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Post closing compensation expense     $ 476            
Seagen [Member] | Restructuring Charges and Acquisition-Related Costs [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Post closing compensation expense     $ 476            
Arena [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Post closing compensation expense   $ 138              
Arena [Member] | Restructuring Charges and Acquisition-Related Costs [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Post closing compensation expense         $ 138        
GBT [Member] | Restructuring Charges and Acquisition-Related Costs [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Post closing compensation expense $ 136     $ 136          
Biopharma [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring charge (credit)           1,800   796  
Biopharma [Member] | Manufacturing Optimization Program [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring charge (credit)           1,200      
Biopharma [Member] | Realigning Our Cost Base Program [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring charge (credit)           $ 571 1,400   $ 2,000
Biopharma [Member] | Realigning Our Cost Base Program [Member] | One-time Termination Benefits                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring charge (credit)                 $ 1,500
Biopharma [Member] | Transforming to a More Focused Company Plan [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring charge (credit)             $ 3 $ 601  
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).
XML 94 R65.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Restructuring Reserve [Roll Forward]      
Beginning balance $ 1,988 [1] $ 1,204  
Provision [2] 1,987 1,968 $ 882
Utilization and other [3] (1,856) (1,184)  
Ending balance 2,120 [4] 1,988 [1] 1,204
Employee Termination Costs [Member]      
Restructuring Reserve [Roll Forward]      
Beginning balance 1,978 [1] 1,196  
Provision 1,152 1,622  
Utilization and other [3] (1,083) (840)  
Ending balance 2,046 [4] 1,978 [1] 1,196
Asset Impairment Charges [Member]      
Restructuring Reserve [Roll Forward]      
Beginning balance 0 [1] 0  
Provision 432 227  
Utilization and other [3] (432) (227)  
Ending balance 0 [4] 0 [1] 0
Exit Costs [Member]      
Restructuring Reserve [Roll Forward]      
Beginning balance 11 [1] 8  
Provision 403 119  
Utilization and other [3] (341) (116)  
Ending balance $ 74 [4] $ 11 [1] $ 8
[1] Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).
[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).
[3] Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.
[4] Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
XML 95 R66.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]      
Restructuring reserve $ 2,120 [1] $ 1,988 [2] $ 1,204
Other Current Liabilities [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring reserve 1,700 1,300  
Other Noncurrent Liabilities [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring reserve $ 437 $ 663  
[1] Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
[2] Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).
XML 96 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income)/Deductions—Net - Schedule of Other Nonoperating Income (Expense) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Income and Expenses [Abstract]      
Interest income $ (545) $ (1,624) $ (251)
Interest expense [1] 3,091 2,209 1,238
Net interest expense [2] 2,546 585 987
Net (gains)/losses recognized during the period on equity securities [3] (1,008) [4] (1,590) [4] 1,273
Income from collaborations, out-licensing arrangements and sales of compound/product rights (42) (154) (188)
Net periodic benefit costs/(credits) other than service costs 154 (610) (849)
Certain legal matters, net [5] 567 474 230
Certain asset impairments [6] 3,295 3,024 421
Haleon equity method (income)/loss [7] (102) (505) (436)
Other, net [8] (1,022) (1,002) (378)
Other (income)/deductions––net $ 4,388 $ 222 $ 1,062
Impairment, Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag Consolidated Statements of Operations    
[1] Capitalized interest totaled $182 million in 2024, $160 million in 2023 and $124 million in 2022.
[2] The increase in net interest expense in 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $8 billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen.
[3]
(c)2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see Note 2C). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas.
[4] Reported in Other (income)/deductions––net. See Note 4.
[5] 2024 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
[6] The amount for 2024 represents intangible asset impairment charges, and includes $2.9 billion recorded in the fourth quarter associated with our Biopharma segment, due to changes in development plans and updated long-range commercial forecasts, composed of: (i) $1.0 billion for B7H4V (felmetatug vedotin), a Phase 1 IPR&D asset, (ii) $475 million for Medrol, a finite-lived brand, (iii) $435 million for Zavzpret nasal spray developed technology rights, (iv) $400 million and $200 million for Tukysa and disitamab vedotin, respectively, IPR&D assets reflecting emerging competition, as well as (v) other developed technology rights, IPR&D impairments and a finite-lived licensing agreement totaling $436 million which also includes de-prioritization of certain assets. 2024 also includes a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The amount for 2023 primarily represented intangible asset impairment charges of $3.0 billion, of which $2.9 billion was associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: (i) $1.4 billion for etrasimod (Velsipity) IPR&D, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 developed technology rights due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) $486 million for various other IPR&D assets and developed technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also included $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset impairment charges associated with our Biopharma segment of $200 million for an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million
associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics.
[7] See Note 2C.
[8] The amount for 2024 primarily includes, among other things, (i) gains of $945 million on the partial sales of our investment in Haleon in March and October 2024, (ii) dividend income of $272 million from our investment in ViiV and (iii) a charge of $420 million recorded in the third quarter related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. 2023 included, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included, among other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the fair value of contingent consideration.
XML 97 R68.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income)/Deductions—Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 14, 2023
USD ($)
Sep. 19, 2023
USD ($)
Dec. 31, 2024
USD ($)
Sep. 29, 2024
USD ($)
facility
Dec. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
May 31, 2023
USD ($)
Derivative [Line Items]                  
Interest costs capitalized           $ 182 $ 160 $ 124  
Business acquisition, cash payment, net of cash acquired           0 43,430 22,997  
Commercial paper, principal amount [1]     $ 2,453   $ 7,965 2,453 7,965    
Realized gain           1,122 1,754 126  
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date [2]           114 165 1,400  
Intangible asset impairments           3,295 3,000    
Charge related to expected sale of facilities       $ 420          
Number of facilities for sale | facility       1          
Pre-tax gain on divestiture   $ 222         222    
Other income, net [3]           $ 1,022 $ 1,002 378  
Intangible Asset, Statement Of Income Or Comprehensive Income Extensible Enumeration, Not Disclosed Flag           Consolidated Statements of Operations Consolidated Statements of Operations    
Unsecured Debt [Member]                  
Derivative [Line Items]                  
Debt instrument, face amount                 $ 31,000
Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments     2,900   2,800   $ 2,900    
Biopharma [Member] | Other Developed Technology Rights, In-Process Research and Development and Finite-Lived Licensing Agreement [Member]                  
Derivative [Line Items]                  
Intangible asset impairments           $ 436      
Biopharma [Member] | Other In Process Research and Development and Developed Technology Rights [Member]                  
Derivative [Line Items]                  
Intangible asset impairments             486    
Transition Service Agreement [Member]                  
Derivative [Line Items]                  
Other income, net               142  
IPR&D [Member]                  
Derivative [Line Items]                  
Intangible asset impairments [4]           1,873      
IPR&D [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments           240 128 200 [4]  
IPR&D [Member] | B7H4V (felmetatug vedotin) [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments     1,000            
IPR&D [Member] | Tukysa [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments     400            
IPR&D [Member] | disitamab vedotin [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments           200      
IPR&D [Member] | Etrasimod (Velsipity) [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments             1,400    
Developed Technology Rights [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments               171  
Haleon [Member]                  
Derivative [Line Items]                  
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date           (1,000)      
Gain on sale of equity method investment           945      
Telavant Holdings, Inc. [Member]                  
Derivative [Line Items]                  
Realized gain             1,700    
Cerevel Therapeutics Holdings, Inc. [Member]                  
Derivative [Line Items]                  
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date             (297)    
BioNTech [Member]                  
Derivative [Line Items]                  
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date             292    
BioNTech and Cerevel Therapeutics, LLC [Member]                  
Derivative [Line Items]                  
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date               986  
ViiV [Member]                  
Derivative [Line Items]                  
Dividend income           272 265 314  
ViiV [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Dividend income           272 265 314  
Nimbus [Member]                  
Derivative [Line Items]                  
Dividend income             211    
Brand [Member]                  
Derivative [Line Items]                  
Intangible asset impairments [4]           475      
Brand [Member] | Medrol [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments     475            
Developed Technology Rights [Member]                  
Derivative [Line Items]                  
Intangible asset impairments [4]           943      
Developed Technology Rights [Member] | Zavzpret [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments     $ 435            
Developed Technology Rights [Member] | Prevnar 13 [Member] | Biopharma [Member]                  
Derivative [Line Items]                  
Intangible asset impairments             964    
Licensing Agreements and Other [Member]                  
Derivative [Line Items]                  
Intangible asset impairments [4]           $ 5      
Seagen [Member]                  
Derivative [Line Items]                  
Business acquisition, cash payment, net of cash acquired $ 43,400                
Commercial paper, principal amount         $ 8,000   $ 8,000    
Hospira [Member] | Licensing Agreements and Other [Member] | Generic Sterile Injectable Product [Member]                  
Derivative [Line Items]                  
Intangible asset impairments               50  
ViiV [Member]                  
Derivative [Line Items]                  
Change in fair value of fair value contingent consideration liabilities               $ 77  
[1] Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see Note 2A). The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94% as of December 31, 2024 and 5.37% as of December 31, 2023.
[2] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $360 million and upward adjustments of $222 million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022
[3] The amount for 2024 primarily includes, among other things, (i) gains of $945 million on the partial sales of our investment in Haleon in March and October 2024, (ii) dividend income of $272 million from our investment in ViiV and (iii) a charge of $420 million recorded in the third quarter related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. 2023 included, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included, among other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the fair value of contingent consideration.
[4] Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
XML 98 R69.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income)/Deductions—Net - Schedule of Additional Information About Intangible Assets Impaired (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Intangible assets, fair value [1] $ 5,694  
Intangible asset impairments 3,295 $ 3,000
Developed Technology Rights [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 524  
Intangible asset impairments [2] 943  
Brand [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 270  
Intangible asset impairments [2] 475  
Licensing Agreements and Other [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 0  
Intangible asset impairments [2] 5  
IPR&D [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
IPR&D [1],[2] 4,900  
Intangible asset impairments [2] 1,873  
Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Intangible assets, fair value [1] 0  
Level 1 [Member] | Developed Technology Rights [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 0  
Level 1 [Member] | Brand [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 0  
Level 1 [Member] | Licensing Agreements and Other [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 0  
Level 1 [Member] | IPR&D [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
IPR&D [1],[2] 0  
Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Intangible assets, fair value [1] 0  
Level 2 [Member] | Developed Technology Rights [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 0  
Level 2 [Member] | Brand [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 0  
Level 2 [Member] | Licensing Agreements and Other [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 0  
Level 2 [Member] | IPR&D [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
IPR&D [1],[2] 0  
Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Intangible assets, fair value [1] 5,694  
Level 3 [Member] | Developed Technology Rights [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 524  
Level 3 [Member] | Brand [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 270  
Level 3 [Member] | Licensing Agreements and Other [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Finite-lived [1],[2] 0  
Level 3 [Member] | IPR&D [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
IPR&D [1],[2] $ 4,900  
[1] The fair value amounts are presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
[2] Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
XML 99 R70.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
United States $ (637) $ (4,411) $ 5,032
International 8,660 5,469 29,697
Income from continuing operations before provision/(benefit) for taxes on income [1],[2],[3] $ 8,023 $ 1,058 $ 34,729
[1] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
[2] 2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.
[3] 2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
XML 100 R71.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Provision for Taxes on Income (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current income taxes:      
Federal $ 453 $ 1,321 $ 2,744
State and local 32 (135) (20)
Deferred income taxes:      
Federal (1,909) (2,606) (3,271)
State and local (293) (184) (310)
Total U.S. tax provision/(benefit) (1,717) (1,605) (857)
International      
Current income taxes 1,588 1,142 4,368
Deferred income taxes 100 (652) (183)
Total international tax provision/(benefit) 1,689 490 4,185
Provision/(benefit) for taxes on income $ (28) $ (1,115) $ 3,328
XML 101 R72.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Contingency [Line Items]      
Provision/(benefit) for taxes on income $ (28) $ (1,115) $ 3,328
Repatriation tax liability 15,000    
Unremitted earnings of international subsidiaries 58,000    
Unrecognized tax benefits excluding associated interest 2,000 3,100  
Deferred tax assets associated with unrecognized tax benefits 2,500 1,700  
Increase (decrease) of interest on income taxes expense 91 64 $ (17)
Unrecognized tax benefits, interest on income taxes accrued 636 605  
Unrecognized accrued interest decrease as a result of cash payments 56 $ 11  
Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit $ 200    
XML 102 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Schedule of Cash Paid for Income Taxes, Net of Refunds (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
United States $ 2,593 $ 1,923 $ 3,867
International 1,012 1,224 4,000
Total $ 3,605 $ 3,147 $ 7,867
XML 103 R74.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Tax Rate Reconciliation (Details)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
[1]
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
U.S. statutory income tax rate 21.00% 21.00% 21.00%
Taxation of non-U.S. operations [2],[3] (7.90%) (21.10%) (5.00%)
Transition Tax liability [4] (6.00%) 0.00% 0.00%
Tax settlements and resolution of certain tax positions [4] (2.40%) (40.30%) (3.00%)
Foreign-Derived Intangible Income deduction [5] (1.20%) (33.10%) (1.90%)
State & local taxes [6] (2.50%) (22.40%) 0.00%
Charitable contributions (1.70%) (7.30%) (0.50%)
U.S. R&D tax credit (1.80%) (15.80%) (0.60%)
Interest [7] 2.20% 13.50% 0.20%
All other, net [8] 0.10% 0.20% (0.60%)
Effective tax rate for income from continuing operations (0.40%) (105.40%) 9.60%
[1] The higher rate percentages for the 2023 reconciling items are significantly impacted by the lower domestic and international Income from continuing operations before provision/(benefit) for taxes on income (see Note 5A).
[2] For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income.
[3] In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We have Puerto Rican tax incentives pursuant to a grant that expires during 2053. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we have incentive tax rates effective through 2048 on income from manufacturing and other operations.
[4] See Note 5A.
[5] The higher rate benefit from the Foreign-Derived Intangible Income deduction in 2022 is mainly the result of the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.
[6] Includes the impact of U.S. state and local taxes and changes in the state valuation allowances including those related to the acquisition of Seagen.
[7] Includes changes in interest related to our uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”.
[8] All other, net is primarily due to routine business operations.
XML 104 R75.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Deferred Taxes (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Deferred Tax Assets    
Prepaid/deferred items - Deferred tax assets [1],[2] $ 2,988 $ 2,658
Accrued/deferred royalties - Deferred tax assets [2] 1,306 1,655
Deferred revenues - Deferred tax assets [2] 300 471
Inventories - Deferred tax assets [2],[3] 992 1,210
Intangible assets - Deferred tax assets [2],[4] 1,435 1,526
Property, plant and equipment - Deferred tax assets [2] 265 168
Employee benefits - Deferred tax assets [2],[5] 1,002 1,085
Restructurings and other charges - Deferred tax assets [2] 462 537
Legal and product liability reserves - Deferred tax assets [2] 378 430
Research and development - Deferred tax assets [2],[6] 7,635 6,275
Net operating loss/tax credit carryforwards - Deferred tax assets [2],[7] 2,028 2,708
State and local tax adjustments - Deferred tax assets [2] 161 119
Investments - Deferred tax assets [2] 73 133
All other - Deferred tax assets [2] 87 62
Subtotal - Deferred tax assets [2] 19,112 19,037
Valuation allowances [2] (1,638) (1,738)
Total deferred taxes - Deferred tax assets [2] 17,474 17,299
Deferred Tax Liabilities    
Prepaid/deferred items - Deferred tax liabilities [1],[2] (847) (654)
Inventories - Deferred tax liabilities [2],[3] (702) (1,060)
Intangible assets - Deferred tax liabilities [2],[4] (9,066) (11,605)
Property, plant and equipment - Deferred tax liabilities [2] (1,751) (2,039)
Employee benefits - Deferred tax liabilities [2],[5] (274) (287)
Unremitted earnings - Deferred tax liabilities [2] (69) (60)
Investments - Deferred tax liabilities [2] (248) (395)
All other - Deferred tax liabilities [2] (66) (72)
Deferred tax liabilities, gross [2] (13,023) (16,172)
Net deferred tax asset [2],[8],[9] $ 4,451 $ 1,128
[1] The increase in net deferred tax assets in 2024 is primarily related to temporary differences associated with the timing of accruals recorded in the ordinary course of business.
[2] The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See Note 1Q.
[3] The increase in net deferred tax assets in 2024 is primarily due to measurement period adjustments of inventories related to Seagen. See Note 2A.
[4] The decrease in net deferred tax liabilities in 2024 is primarily due to amortization of intangible assets and certain impairment charges, as well as the measurement period adjustments of intangible assets related to Seagen.
[5] The decrease in net deferred tax assets in 2024 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See Note 11.
[6] The increase in deferred tax assets in 2024 is primarily related to the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021.
[7] The amounts in 2024 and 2023 are reduced for unrecognized tax benefits of $575 million and $1.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
[8] Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.3 billion and $11.1 billion for 2024 and 2023 respectively, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.
[9] In 2024, Noncurrent deferred tax assets and other noncurrent tax assets ($6.6 billion), and Noncurrent deferred tax liabilities ($2.1 billion). In 2023, Noncurrent deferred tax assets and other noncurrent tax assets ($1.8 billion), and Noncurrent deferred tax liabilities ($640 million).
XML 105 R76.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Deferred Taxes - Footnotes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Examination [Line Items]    
Reduction for unrecognized tax benefit $ 575 $ 1,300
Net deferred tax asset [1],[2],[3] 4,451 1,128
Indefinite-lived and definite-lived 11,300 11,100
Noncurrent Deferred Tax Assets and Other Noncurrent Tax Assets [Member]    
Income Tax Examination [Line Items]    
Net deferred tax asset 6,600 1,800
Noncurrent Deferred Tax Liabilities [Member]    
Income Tax Examination [Line Items]    
Net deferred tax liability $ 2,100 $ 640
[1] Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.3 billion and $11.1 billion for 2024 and 2023 respectively, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.
[2] In 2024, Noncurrent deferred tax assets and other noncurrent tax assets ($6.6 billion), and Noncurrent deferred tax liabilities ($2.1 billion). In 2023, Noncurrent deferred tax assets and other noncurrent tax assets ($1.8 billion), and Noncurrent deferred tax liabilities ($640 million).
[3] The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See Note 1Q.
XML 106 R77.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance, beginning $ (4,802) [1] $ (4,494) [1] $ (6,068)
Acquisitions 8 (46) (52)
Increases based on tax positions taken during a prior period [2],[3] (934) (158) (67)
Decreases based on tax positions taken during a prior period [3],[4] 599 310 1,339
Decreases based on settlements for a prior period [4],[5] 911 85 842
Increases based on tax positions taken during the current period [3] (433) (515) (701)
Impact of foreign exchange 52 (44) 90
Other, net [3],[6] 70 58 122
Balance, ending [1] $ (4,530) $ (4,802) $ (4,494)
[1] In 2024, included in Income taxes payable ($103 million), Other current assets ($0.4 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.5 billion), Noncurrent deferred tax liabilities ($3 million) and Other taxes payable ($2.9 billion). In 2023, included in Income taxes payable ($94 million), Other current assets ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.3 billion), Noncurrent deferred tax liabilities ($4 million) and Other taxes payable ($3.4 billion).
[2] In 2024, the amount includes a gross unrecognized tax benefit associated with the expected filing of an amended income tax return related to the Transition Tax liability under the TCJA.
[3] Primarily included in Provision/(benefit) for taxes on income.
[4] Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See Note 5A.
[5] Primarily related to cash payments and reductions of tax attributes.
[6] Primarily related to decreases as a result of a lapse of applicable statutes of limitations.
XML 107 R78.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
[1]
Dec. 31, 2021
Income Tax Contingency [Line Items]        
Unrecognized tax benefits $ 4,530.0 [1] $ 4,802.0 [1] $ 4,494.0 $ 6,068.0
Income Taxes Payable [Member]        
Income Tax Contingency [Line Items]        
Unrecognized tax benefits 103.0 94.0    
Other Current Tax Assets [Member]        
Income Tax Contingency [Line Items]        
Unrecognized tax benefits 0.4 1.0    
Noncurrent Deferred Tax Assets and Other Noncurrent Tax Assets [Member]        
Income Tax Contingency [Line Items]        
Unrecognized tax benefits 1,500.0 1,300.0    
Noncurrent Deferred Tax Liabilities [Member]        
Income Tax Contingency [Line Items]        
Unrecognized tax benefits 3.0 4.0    
Other Taxes Payable [Member]        
Income Tax Contingency [Line Items]        
Unrecognized tax benefits $ 2,900.0 $ 3,400.0    
[1] In 2024, included in Income taxes payable ($103 million), Other current assets ($0.4 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.5 billion), Noncurrent deferred tax liabilities ($3 million) and Other taxes payable ($2.9 billion). In 2023, included in Income taxes payable ($94 million), Other current assets ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.3 billion), Noncurrent deferred tax liabilities ($4 million) and Other taxes payable ($3.4 billion).
XML 108 R79.htm IDEA: XBRL DOCUMENT v3.25.0.1
Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)      
Foreign currency translation adjustments, net [1] $ 156 $ (33) $ (126)
Unrealized holding gains/(losses) on derivative financial instruments, net 96 111 183
Reclassification adjustments for (gains)/losses included in net income (29) (93) (270)
Other comprehensive income (loss), derivatives qualifying as hedges, tax, total 67 18 (87)
Unrealized holding gains/(losses) on available-for-sale securities, net (19) (15) (164)
Reclassification adjustments for (gains)/losses included in net income 5 (18) 226
Other comprehensive income (loss), available-for-sale securities, tax, total (14) (33) 62
Benefit plans: prior service (costs)/credits and other, net 45 (5) (5)
Reclassification adjustments related to amortization of prior service costs and other, net (26) (28) (29)
Reclassification adjustments related to curtailments of prior service costs and other, net 2 (4) (3)
Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax 22 (37) (37)
Tax provision/(benefit) on other comprehensive income/(loss) $ 231 $ (85) $ (187)
[1] Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
XML 109 R80.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance $ 89,288 $ 95,916 $ 77,462
Other comprehensive income/(loss) 116 331 (2,422)
Ending balance 88,497 89,288 95,916
Accumulated Other Comprehensive Income/(Loss) [Member]      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (7,961) (8,304) (5,897)
Other comprehensive income/(loss) [1] 118 343 (2,407)
Ending balance (7,842) (7,961) (8,304)
Foreign Currency Translation Adjustments [Member]      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance [2] (7,863) (8,360) (6,172)
Other comprehensive income/(loss) [1],[2] (121) 497 (2,188)
Ending balance [2] (7,984) (7,863) (8,360)
Derivative Financial Instruments [Member]      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (217) (412) 119
Other comprehensive income/(loss) [1] 274 195 (531)
Ending balance 57 (217) (412)
Available-For-Sale Securities [Member]      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (9) 220 (220)
Other comprehensive income/(loss) [1] (97) (229) 440
Ending balance (106) (9) 220
Prior Service (Costs)/Credits and Other [Member]      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance 128 248 377
Other comprehensive income/(loss) [1] 63 (120) (129)
Ending balance $ 191 $ 128 $ 248
[1] Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program and gains/(losses) related to our investment in Haleon (see Note 2C).
[2] Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
XML 110 R81.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities [1] $ 7,848 $ 5,124
Total other noncurrent assets 9,817 12,471
Total assets 213,396 226,501
Total liabilities $ 1,366 $ 1,420
Derivative asset, statement of financial position Other current assets, Total other noncurrent assets Other current assets, Total other noncurrent assets
Derivative liability, statement of financial position Other current liabilities, Other noncurrent liabilities Other current liabilities, Other noncurrent liabilities
Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets $ 1,056 $ 298
Noncurrent derivative assets 460 402
Insurance contracts [2] 875 790
Total other noncurrent assets 1,335 1,191
Total assets 22,366 13,943
Current derivative liabilities 245 420
Noncurrent derivative liabilities 1,121 1,000
Total liabilities 1,366 1,420
Recurring [Member] | Interest rate contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent derivative assets 13 144
Current derivative liabilities 28 16
Noncurrent derivative liabilities 397 275
Recurring [Member] | Foreign exchange contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 1,056 298
Noncurrent derivative assets 447 258
Current derivative liabilities 217 404
Noncurrent derivative liabilities 723 725
Government and agency debt - non-U.S. [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 6,855 941
Government and agency - U.S. [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 2,853 2,601
Corporate and Other [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 1,173 1,007
Level 1 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 0 0
Noncurrent derivative assets 0 0
Insurance contracts [2] 0 0
Total other noncurrent assets 0 0
Total assets 7,701 2,772
Current derivative liabilities 0 0
Noncurrent derivative liabilities 0 0
Total liabilities 0 0
Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent derivative assets 0 0
Current derivative liabilities 0 0
Noncurrent derivative liabilities 0 0
Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 0 0
Noncurrent derivative assets 0 0
Current derivative liabilities 0 0
Noncurrent derivative liabilities 0 0
Level 2 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 1,056 298
Noncurrent derivative assets 460 402
Insurance contracts [2] 875 790
Total other noncurrent assets 1,335 1,191
Total assets 14,665 11,170
Current derivative liabilities 245 420
Noncurrent derivative liabilities 1,121 1,000
Total liabilities 1,366 1,420
Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent derivative assets 13 144
Current derivative liabilities 28 16
Noncurrent derivative liabilities 397 275
Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 1,056 298
Noncurrent derivative assets 447 258
Current derivative liabilities 217 404
Noncurrent derivative liabilities 723 725
Short-term Investments [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities [3] 7,848 5,124
Available-for-sale securities, debt securities 10,881 4,400
Total short-term investments 18,729 9,524
Short-term Investments [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 6,855 817
Short-term Investments [Member] | Government and agency - U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 2,853 2,601
Short-term Investments [Member] | Corporate and Other [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 1,173 982
Short-term Investments [Member] | Level 1 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities [3] 6,456 0
Available-for-sale securities, debt securities 0 0
Total short-term investments 6,456 0
Short-term Investments [Member] | Level 1 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 0 0
Short-term Investments [Member] | Level 1 [Member] | Government and agency - U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 0 0
Short-term Investments [Member] | Level 1 [Member] | Corporate and Other [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 0 0
Short-term Investments [Member] | Level 2 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities [3] 1,392 5,124
Available-for-sale securities, debt securities 10,881 4,400
Total short-term investments 12,273 9,524
Short-term Investments [Member] | Level 2 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 6,855 817
Short-term Investments [Member] | Level 2 [Member] | Government and agency - U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 2,853 2,601
Short-term Investments [Member] | Level 2 [Member] | Corporate and Other [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 1,173 982
Long-term Investments [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities [4] 1,246 2,779
Available-for-sale securities, debt securities 0 150
Total long-term investments 1,246 2,929
Long-term Investments [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 0 124
Long-term Investments [Member] | Corporate and Other [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 0 26
Long-term Investments [Member] | Level 1 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities [4] 1,246 2,772
Available-for-sale securities, debt securities 0 0
Total long-term investments 1,246 2,772
Long-term Investments [Member] | Level 1 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 0 0
Long-term Investments [Member] | Level 1 [Member] | Corporate and Other [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 0 0
Long-term Investments [Member] | Level 2 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities [4] 0 7
Available-for-sale securities, debt securities 0 150
Total long-term investments 0 156
Long-term Investments [Member] | Level 2 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities 0 124
Long-term Investments [Member] | Level 2 [Member] | Corporate and Other [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale securities, debt securities $ 0 $ 26
[1] As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
[2] Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).
[3] Includes money market funds. As of December 31, 2024, short-term equity securities include our investment in Haleon of $6.5 billion. See Note 2C.
[4] Long-term equity securities of $133 million as of December 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.
XML 111 R82.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [1] $ 7,848 $ 5,124
Haleon [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [2] 6,500  
Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term equity securities held in trust 133 130
Recurring [Member] | Short-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [2] 7,848 5,124
Recurring [Member] | Short-term Investments [Member] | Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [2] $ 6,456 $ 0
[1] As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
[2] Includes money market funds. As of December 31, 2024, short-term equity securities include our investment in Haleon of $6.5 billion. See Note 2C.
XML 112 R83.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt $ 57,405 $ 61,538
Level 2 [Member] | Estimated Fair Value [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, excluding the current portion $ 54,000 $ 61,000
XML 113 R84.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Short-term investments    
Equity securities with readily determinable fair values [1] $ 7,848 $ 5,124
Available-for-sale debt securities 10,881 4,400
Held-to-maturity debt securities 705 313
Total Short-term investments 19,434 9,837
Long-term investments    
Equity securities with readily determinable fair values [2] 1,246 2,779
Available-for-sale debt securities 0 150
Held-to-maturity debt securities 45 47
Private equity securities at cost [2] 719 755
Long-term investments 2,010 3,731
Equity-method investments [1] 217 11,637
Total long-term investments and equity-method investments 2,228 15,368
Held-to-maturity cash equivalents $ 184 $ 207
[1] As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
[2] Represent investments in the life sciences sector.
XML 114 R85.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Investments - Debt Securities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]    
Debt securities, amortized cost $ 11,935 $ 5,126
Debt securities, gross unrealized gains 8 6
Debt securities, gross unrealized losses (129) (16)
Debt securities, fair value 11,814 5,115
Debt securities maturities, within 1 year, fair value 11,770  
Debt securities maturities, over 1 to 5 years, fair value 25  
Debt securities maturities, over 5 years, fair value 20  
Government and agency debt - non-U.S. [Member]    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Available-for-sale debt securities, amortized cost 6,970 953
Available-for-sale debt securities, gross unrealized gain 8 2
Available-for-sale debt securities, gross unrealized loss (123) (14)
Available-for-sale securities, debt maturities 6,855 941
Available-for-sale Securities, Debt Maturities [Abstract]    
Available-for-sale securities, debt maturities, within 1 year, fair value 6,855  
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value 0  
Available-for-sale securities, debt maturities, over 5 years, fair value 0  
Available-for-sale securities, debt maturities 6,855 941
Debt Securities, Held-to-maturity, Maturity [Abstract]    
Held-to-maturity securities, amortized cost 237 4
Held-to-maturity securities, gross unrealized gains 0 0
Held-to-maturity securities, gross unrealized losses 0 0
Held-to-maturity securities, fair value 237 4
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]    
Held-to-maturity securities, debt maturities, within 1 year, fair value 232  
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value 4  
Held-to-maturity securities, debt maturities, over 5 years, fair value 1  
Government and agency - U.S. [Member]    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Available-for-sale debt securities, amortized cost 2,853 2,601
Available-for-sale debt securities, gross unrealized gain 0 0
Available-for-sale debt securities, gross unrealized loss 0 0
Available-for-sale securities, debt maturities 2,853 2,601
Available-for-sale Securities, Debt Maturities [Abstract]    
Available-for-sale securities, debt maturities, within 1 year, fair value 2,853  
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value 0  
Available-for-sale securities, debt maturities, over 5 years, fair value 0  
Available-for-sale securities, debt maturities 2,853 2,601
Corporate and Other [Member]    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Available-for-sale debt securities, amortized cost 1,179 1,006
Available-for-sale debt securities, gross unrealized gain 0 4
Available-for-sale debt securities, gross unrealized loss (6) (2)
Available-for-sale securities, debt maturities 1,173 1,007
Available-for-sale Securities, Debt Maturities [Abstract]    
Available-for-sale securities, debt maturities, within 1 year, fair value 1,173  
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value 0  
Available-for-sale securities, debt maturities, over 5 years, fair value 0  
Available-for-sale securities, debt maturities 1,173 1,007
Time deposits and other [Member]    
Debt Securities, Held-to-maturity, Maturity [Abstract]    
Held-to-maturity securities, amortized cost 697 561
Held-to-maturity securities, gross unrealized gains 0 0
Held-to-maturity securities, gross unrealized losses 0 0
Held-to-maturity securities, fair value 697 $ 561
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]    
Held-to-maturity securities, debt maturities, within 1 year, fair value 657  
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value 21  
Held-to-maturity securities, debt maturities, over 5 years, fair value $ 19  
XML 115 R86.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Fair Value Disclosures [Abstract]      
Net (gains)/losses recognized during the period on equity securities [1] $ (1,008) [2] $ (1,590) [2] $ 1,273
Less: Net (gains)/losses recognized during the period on equity securities sold during the period (1,122) (1,754) (126)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date [3] $ 114 $ 165 $ 1,400
[1]
(c)2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see Note 2C). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas.
[2] Reported in Other (income)/deductions––net. See Note 4.
[3] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $360 million and upward adjustments of $222 million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022
XML 116 R87.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Fair Value Disclosures [Abstract]  
Cumulative impairment losses and downward price adjustments on equity securities $ 360
Cumulative upward price adjustments on equity securities $ 222
XML 117 R88.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Short-Term Borrowings (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Short-term Debt [Line Items]    
Commercial paper, principal amount [1] $ 2,453 $ 7,965
Current portion of long-term debt, principal amount 3,750 2,250
Other short-term borrowings, principal amount [2] 755 252
Total short-term borrowings, principal amount 6,957 10,467
Net fair value adjustments related to hedging and purchase accounting 0 5
Net unamortized discounts, premiums and debt issuance costs (12) (121)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted 6,946 $ 10,350
Revolving Credit Facility [Member]    
Short-term Debt [Line Items]    
Line of credit facility, maximum borrowing capacity 15,000  
Line of Credit [Member]    
Short-term Debt [Line Items]    
Line of credit facility, maximum borrowing capacity 276  
Line of credit facility, due to expire within one year 243  
Credit Facility, Maturing October 2025 [Member] | Revolving Credit Facility [Member]    
Short-term Debt [Line Items]    
Line of credit facility, maximum borrowing capacity 8,000  
Credit Facility, Maturing October 2029 [Member] | Revolving Credit Facility [Member]    
Short-term Debt [Line Items]    
Line of credit facility, maximum borrowing capacity $ 7,000  
[1] Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see Note 2A). The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94% as of December 31, 2024 and 5.37% as of December 31, 2023.
[2] Primarily includes cash collateral. See Note 7F.
XML 118 R89.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Short-Term Borrowings - Footnotes (Details)
Dec. 31, 2024
Dec. 31, 2023
May 31, 2023
Short-term Debt [Line Items]      
Effective interest rate     4.93%
Commercial Paper [Member]      
Short-term Debt [Line Items]      
Effective interest rate 4.94% 5.37%  
XML 119 R90.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Long-Term Debt (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Net fair value adjustments related to hedging and purchase accounting $ 0 $ 5
Net unamortized discounts, premiums and debt issuance costs (12) (121)
Total long-term debt, carried at historical proceeds, as adjusted 57,405 61,538
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023)) $ 3,747 2,254
Unsecured Debt [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 3.90%  
Total long-term debt, principal amount [1] $ 57,147 60,982
Net fair value adjustments related to hedging and purchase accounting 701 [1] 1,039
Net unamortized discounts, premiums and debt issuance costs [1] (444) (483)
Total long-term debt, carried at historical proceeds, as adjusted [1] 57,405 61,538
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023)) [1] 3,747 $ 2,254
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2025 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage   3.90%
Total long-term debt, principal amount [1],[2] $ 0 $ 3,750
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2026 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 3.70% 3.70%
Total long-term debt, principal amount [1] $ 6,000 $ 6,000
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2027 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 2.20% 2.10%
Total long-term debt, principal amount [1] $ 980 $ 1,029
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2028 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 4.60% 4.60%
Total long-term debt, principal amount [1] $ 5,660 $ 5,660
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2029 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 3.50% 3.50%
Total long-term debt, principal amount [1] $ 1,750 $ 1,750
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2030 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 3.60% 3.60%
Total long-term debt, principal amount [1] $ 5,250 $ 5,250
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2031-2035 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 4.50% 4.50%
Total long-term debt, principal amount [1] $ 6,750 $ 6,750
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2036-2040 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 5.40% 5.40%
Total long-term debt, principal amount [1] $ 9,534 $ 9,543
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2041-2045 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 4.30% 4.30%
Total long-term debt, principal amount [1] $ 6,474 $ 6,501
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2046-2050 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 3.70% 3.70%
Total long-term debt, principal amount [1] $ 4,750 $ 4,750
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2051-2063 [Member]    
Debt Instrument [Line Items]    
Interest rate, percentage 5.30% 5.30%
Total long-term debt, principal amount [1] $ 10,000 $ 10,000
[1] Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.
[2] Reclassified to the current portion of long-term debt.
XML 120 R91.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Long-Term Debt, Issuances (Details)
$ in Millions
May 31, 2023
USD ($)
Debt Instrument [Line Items]  
Effective interest rate 4.93%
Unsecured Debt [Member]  
Debt Instrument [Line Items]  
Debt instrument, face amount $ 31,000
XML 121 R92.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)
12 Months Ended
Dec. 31, 2024
Foreign Exchange Contract [Member]  
Derivative [Line Items]  
Derivative term of contract 2 years
XML 122 R93.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Derivative [Line Items]    
Derivative asset $ 1,516 $ 700
Derivative liability 1,366 1,420
Designated as Hedging Instrument [Member]    
Derivative [Line Items]    
Derivative asset 1,263 546
Derivative liability 1,144 1,206
Foreign exchange contracts [Member] | Designated as Hedging Instrument [Member]    
Derivative [Line Items]    
Derivative, notional amount [1] 23,991 18,750
Derivative asset [1] 1,250 403
Derivative liability [1] 719 916
Foreign exchange contracts [Member] | Not Designated as Hedging Instrument [Member]    
Derivative [Line Items]    
Derivative, notional amount 26,335 25,609
Derivative asset 253 154
Derivative liability 221 214
Interest rate contracts [Member] | Designated as Hedging Instrument [Member]    
Derivative [Line Items]    
Derivative, notional amount 6,750 6,750
Derivative asset 13 144
Derivative liability 425 290
Sales [Member] | Foreign exchange contracts [Member] | Designated as Hedging Instrument [Member]    
Derivative [Line Items]    
Derivative, notional amount $ 5,000 $ 4,900
[1] The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.
XML 123 R94.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Gains/(Losses) Recognized in OID [1] $ 50 $ 164  
Derivative, Amount of Gains/(Losses) Recognized in OCI 499 626 $ 1,444
Amount of Gains/(Losses) Recognized in OCI [1] 1,166 341  
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [2] 159 413 $ 2,062
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1] $ 313 $ 549  
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other income/(deductions)—net Other income/(deductions)—net  
Designated as Hedging Instrument [Member] | Foreign Currency Short-Term Borrowings [Member]      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Non-Derivative, Amount of Gains/(Losses) Recognized in OCI [1],[3] $ 0 $ 0  
Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1],[3] 0 0  
Designated as Hedging Instrument [Member] | Foreign Currency Long-Term Debt [Member]      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Non-Derivative, Amount of Gains/(Losses) Recognized in OCI [1],[3] 49 (29)  
Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1],[3] 0 0  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, Amount of Gains/(Losses) Recognized in OID [1] 50 164  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts [Member]      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, Amount of Gains/(Losses) Recognized in OCI [1] 0 68  
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1] 0 1  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, Amount of Gains/(Losses) Recognized in OCI [1],[4] 466 380  
Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings [1],[5] 34 178  
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1],[4] 124 236  
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing [1],[5] 34 177  
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts [Member]      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, Amount of Gains/(Losses) on interest rate contract Recognized in OID [1] (253) 196  
Derivative, Amount of Gains/(Losses) on hedged item Recognized in OID [1] 253 (196)  
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings [1],[5] 119 137  
Derivative, Amount of Gains/(Losses) Recognized in OCI [1] 498 (393)  
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing [1],[5] 154 136  
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1] $ 0 $ 0  
[1] OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss).
[2] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[3] Long-term debt includes foreign currency borrowings which are used in net investment hedges; the related carrying values as of December 31, 2024 and December 31, 2023 were $777 million and $824 million, respectively.
[4] The amounts reclassified from OCI into COS were a net gain of $119 million in 2024 and a net gain of $253 million in 2023. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $330 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 18 years and relates to foreign currency debt.
[5] The amounts reclassified from OCI were reclassified into OID.
XML 124 R95.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative [Line Items]      
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1] $ 159 $ 413 $ 2,062
Foreign Currency Long-Term Debt [Member]      
Derivative [Line Items]      
Long-term debt, carrying value 777 824  
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]      
Derivative [Line Items]      
Pre-tax gain expected to be reclassified within the next 12 months $ 330    
Remaining period of hedging exposure 18 years    
Designated as Hedging Instrument [Member] | Cost of Sales [Member] | Foreign Exchange Contract [Member]      
Derivative [Line Items]      
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS $ 119 [2] $ 253  
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2] OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss).
XML 125 R96.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Fair Value Disclosures [Abstract]    
Hedged Liability, Statement of Financial Position [Extensible Enumeration] Long-term debt Long-term debt
Carrying Amount of Hedged Assets/Liabilities [1] $ 7,154 $ 7,196
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability (384) (131)
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability $ 891 $ 957
[1] Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
XML 126 R97.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Credit Risk (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Fair Value Disclosures [Abstract]  
Derivatives in a net liability position $ 741
Collateral posted 720
Derivatives in a net receivable position 594
Cash collateral received $ 716
XML 127 R98.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Financial Information - Inventories (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Other Financial Information [Abstract]    
Finished goods $ 3,775 $ 3,495
Work-in-process 6,101 5,688
Raw materials and supplies 976 1,007
Inventories [1] 10,851 10,189
Noncurrent inventories not included above [2] $ 2,663 $ 4,568
[1] The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches.
[2] Included in Other noncurrent assets. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See Note 2A. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
XML 128 R99.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Financial Information - Other Current Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Other current liabilities $ 19,720 $ 20,537
BioNTech [Member] | Comirnaty [Member] | Collaborative Arrangement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Other current liabilities $ 1,300 $ 2,000
XML 129 R100.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Financial Information - Supplier Finance Program Obligation (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Supplier Finance Program [Line Items]    
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Trade accounts payable Trade accounts payable
Supplier Finance Program, Obligation [Roll Forward]    
Confirmed obligations outstanding, December 31, 2023 $ 791  
Invoices confirmed during the year 2,638  
Confirmed invoices paid during the year (2,740)  
Confirmed obligations outstanding, December 31, 2024 $ 688  
Minimum [Member]    
Supplier Finance Program [Line Items]    
Supplier finance program, payment timing, period 90 days  
Maximum [Member]    
Supplier Finance Program [Line Items]    
Supplier finance program, payment timing, period 120 days  
XML 130 R101.htm IDEA: XBRL DOCUMENT v3.25.0.1
Property, Plant and Equipment - Components of Property, Plant and Equipment, Net (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment before accumulated depreciation $ 34,876 $ 34,985
Less: Accumulated depreciation 16,483 16,045
Property, plant and equipment, net 18,393 18,940
Land [Member]    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment before accumulated depreciation 291 353
Buildings [Member]    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment before accumulated depreciation 9,036 9,046
Machinery and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment before accumulated depreciation 15,095 14,263
Furniture, fixtures and other [Member]    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment before accumulated depreciation 5,516 5,399
Construction in progress [Member]    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment before accumulated depreciation $ 4,937 $ 5,925
Minimum [Member] | Buildings [Member]    
Property, Plant and Equipment [Line Items]    
Useful lives (years) 33 years  
Minimum [Member] | Machinery and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Useful lives (years) 8 years  
Minimum [Member] | Furniture, fixtures and other [Member]    
Property, Plant and Equipment [Line Items]    
Useful lives (years) 3 years  
Maximum [Member] | Buildings [Member]    
Property, Plant and Equipment [Line Items]    
Useful lives (years) 50 years  
Maximum [Member] | Machinery and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Useful lives (years) 20 years  
Maximum [Member] | Furniture, fixtures and other [Member]    
Property, Plant and Equipment [Line Items]    
Useful lives (years) 12 years 6 months  
XML 131 R102.htm IDEA: XBRL DOCUMENT v3.25.0.1
Property, Plant and Equipment - Long-lived Assets by Geographic Areas, Net (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, net $ 18,393 $ 18,940
United States [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, net 9,748 10,674
Developed Markets [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, net 7,187 6,713
Emerging Markets [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, net $ 1,458 $ 1,554
XML 132 R103.htm IDEA: XBRL DOCUMENT v3.25.0.1
Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount $ 103,397 $ 102,944
Finite-lived intangible assets, accumulated amortization [1] (67,549) (62,828)
Finite-lived intangible assets, net 35,848 40,116
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets 19,563 24,784
Intangible assets, gross carrying amount [1] 122,961 127,728
Identifiable Intangible Assets, Net [1] 55,411 64,900
Brands [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets [2] 0 827
IPR&D [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets [3] 18,893 23,193
Licensing Agreements and Other [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets 670 763
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount [4] 99,397 99,267
Finite-lived intangible assets, accumulated amortization [4] (65,044) (60,493)
Finite-lived intangible assets, net [4] 34,353 38,773
Brands [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount [2] 1,277 922
Finite-lived intangible assets, accumulated amortization [2] (992) (877)
Finite-lived intangible assets, net [2] 285 45
Licensing Agreements and Other [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount 2,724 2,756
Finite-lived intangible assets, accumulated amortization (1,513) (1,458)
Finite-lived intangible assets, net $ 1,210 $ 1,297
[1] The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see Note 4) and measurement period adjustments related to our acquisition of Seagen of $950 million (see Note 2A).
[2] The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see Note 4).
[3] The decrease in the gross carrying amount reflects impairments of $1.9 billion (see Note 4), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see Note 2A), and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna).
[4] The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see Note 4).
XML 133 R104.htm IDEA: XBRL DOCUMENT v3.25.0.1
Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Intangible asset impairments $ 3,295 $ 3,000
Amortization expense for finite-lived intangible assets 5,300  
Seagen [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangibles, measurement period adjustments 740  
In-process research and development, measurement period adjustments 1,700  
Identifiable intangible assets, net of adjustments 950  
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible asset impairments [1] 943  
Trade Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets period increase (decrease) 827  
Brand [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible asset impairments [1] 475  
IPR&D [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible asset impairments [1] 1,873  
talazoparib (Talzenna) [Member] | Developed Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets period increase (decrease) 727  
talazoparib (Talzenna) [Member] | IPR&D [Member]    
Finite-Lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets, period increase (decrease) (727)  
Depo-Medrol [Member] | Trade Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets, period increase (decrease) $ (827)  
[1] Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
XML 134 R105.htm IDEA: XBRL DOCUMENT v3.25.0.1
Identifiable Intangible Assets, Net and Goodwill - Narrative (Details)
Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 10 years
Developed Technology Rights [Member]  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 10 years
XML 135 R106.htm IDEA: XBRL DOCUMENT v3.25.0.1
Identifiable Intangible Assets, Net and Goodwill - Expected Annual Amortization Expense (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2025 $ 4,838
2026 4,716
2027 4,125
2028 3,776
2029 $ 2,829
XML 136 R107.htm IDEA: XBRL DOCUMENT v3.25.0.1
Identifiable Intangible Assets, Net and Goodwill - Goodwill (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Goodwill [Roll Forward]    
Beginning balance [1] $ 67,783 $ 51,375
Additions [1],[2] 1,022 16,117
Impact of foreign exchange and other [1] (278) 292
Ending balance $ 68,527 $ 67,783 [1]
[1] As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 17A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
[2] Additions primarily represent our acquisition of Seagen in 2023 and measurement period adjustments related to our acquisition of Seagen in 2024 (see
Note 2A).
XML 137 R108.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Postretirement Plans [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 14 $ 12 $ 29
Interest cost 23 21 27
Expected return on plan assets (51) (44) (47)
Amortization of prior service cost/(credit) (113) (119) (130)
Actuarial (gains)/losses [1] 144 51 (440)
Curtailments 0 (12) (18)
Special termination benefits 0 0 1
Net periodic benefit cost/(credit) reported in income 18 (90) (578)
Cost/(credit) reported in Other comprehensive income/(loss) (80) 128 169
Cost/(credit) recognized in Comprehensive income (62) 38 (410)
U.S. [Member] | Pension Plans [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 0 0 0
Interest cost 553 589 534
Expected return on plan assets (832) (778) (862)
Amortization of prior service cost/(credit) 1 2 2
Actuarial (gains)/losses [1] 396 (410) 225
Curtailments 0 0 0
Special termination benefits 0 6 18
Net periodic benefit cost/(credit) reported in income 117 (592) (84)
Cost/(credit) reported in Other comprehensive income/(loss) (1) (2) (2)
Cost/(credit) recognized in Comprehensive income 116 (594) (86)
International [Member] | Pension Plans [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 87 85 116
Interest cost 312 287 157
Expected return on plan assets (322) (304) (296)
Amortization of prior service cost/(credit) 4 0 (1)
Actuarial (gains)/losses [1] 33 102 (11)
Curtailments (4) (2) (11)
Special termination benefits 10 0 1
Net periodic benefit cost/(credit) reported in income 120 169 (45)
Cost/(credit) reported in Other comprehensive income/(loss) (4) 31 (1)
Cost/(credit) recognized in Comprehensive income $ 117 $ 199 $ (46)
[1] Reflects: (i) actuarial remeasurement net losses in 2024, primarily due to unfavorable asset performance for the U.S. pension plans and decreases in discount rates for the international pension plans, partially offset by increases in discount rates for the U.S. pension plans and favorable asset performance for the international pension plans and postretirement plans, (ii) actuarial remeasurement net gains in 2023, primarily due to favorable asset performance in the U.S. and increases in discount rates for the international plans, partially offset by unfavorable asset performance for certain international plans, and (iii) actuarial remeasurement net gains in 2022, primarily due to increases in discount rates, partially offset by unfavorable asset performance.
XML 138 R109.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Postretirement Plans [Member]      
Weighted-average assumptions used to determine net periodic benefit cost:      
Discount rate: Pension plans/postretirement plans 5.40% 5.50% 2.90%
Expected return on plan assets 8.00% 7.50% 6.30%
Weighted-average assumptions used to determine benefit obligations at fiscal year-end:      
Discount rate 5.50% 5.40% 5.50%
U.S. [Member] | Pension Plans [Member]      
Weighted-average assumptions used to determine net periodic benefit cost:      
Discount rate: Pension plans/postretirement plans 5.40% 5.40% 2.90%
Expected return on plan assets 8.00% 7.50% 6.30%
Weighted-average assumptions used to determine benefit obligations at fiscal year-end:      
Discount rate 5.70% 5.40% 5.40%
International [Member] | Pension Plans [Member]      
Weighted-average assumptions used to determine net periodic benefit cost:      
Discount rate: Interest cost 4.40% 3.80% 1.50%
Discount rate: Service cost 3.90% 3.60% 1.70%
Expected return on plan assets 5.10% 4.50% 3.10%
Rate of compensation increase [1] 3.20% 3.00% 2.80%
Weighted-average assumptions used to determine benefit obligations at fiscal year-end:      
Discount rate 4.10% 4.40% 3.80%
Rate of compensation increase [1] 3.10% 3.20% 3.00%
[1] The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.
XML 139 R110.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details) - Postretirement Plans [Member]
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]    
Healthcare cost trend rate assumed for next year 7.50% 7.90%
Rate to which the cost trend rate is assumed to decline 4.00% 4.00%
XML 140 R111.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Amounts recorded in our consolidated balance sheet:      
Noncurrent liabilities $ (2,115) $ (2,167)  
Postretirement Plans [Member]      
Change in benefit obligation      
Benefit obligation, beginning [1] 450 410  
Service cost 14 12 $ 29
Interest cost 23 21 27
Employee contributions 61 52  
Plan amendments (193) 0  
Changes in actuarial assumptions and other [2] 199 96  
Foreign exchange impact (2) (1)  
Acquisitions/divestitures, net 0    
Curtailments and special termination benefits 0 (3)  
Settlements 0 0  
Benefits paid (67) (137)  
Benefit obligation, ending [1] 486 450 410
Change in plan assets      
Fair value of plan assets, beginning 636 647  
Actual return on plan assets 105 89  
Company contributions 0 (15)  
Employee contributions 61 52  
Foreign exchange impact 0 0  
Acquisitions/divestitures, net 0 0  
Settlements 0 0  
Benefits paid (67) (137)  
Fair value of plan assets, ending 736 636 647
Funded status 251 186  
Amounts recorded in our consolidated balance sheet:      
Noncurrent assets 330 266  
Current liabilities (5) (6)  
Noncurrent liabilities (74) (74)  
Funded status 251 186  
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:      
Prior service (costs)/credits 365 285  
U.S. [Member] | Pension Plans [Member]      
Change in benefit obligation      
Benefit obligation, beginning [1] 10,756 11,420  
Service cost 0 0 0
Interest cost 553 589 534
Employee contributions 0 0  
Plan amendments 0 0  
Changes in actuarial assumptions and other [2] (299) (127)  
Foreign exchange impact (1) 0  
Acquisitions/divestitures, net 0 0  
Curtailments and special termination benefits 0 6  
Settlements (756) (675)  
Benefits paid (473) (457)  
Benefit obligation, ending [1] 9,781 10,756 11,420
Change in plan assets      
Fair value of plan assets, beginning 10,935 10,871  
Actual return on plan assets 138 1,061  
Company contributions 103 134  
Employee contributions 0 0  
Foreign exchange impact 0 0  
Settlements (756) (675)  
Benefits paid (473) (457)  
Fair value of plan assets, ending 9,948 10,935 10,871
Funded status 167 179  
Amounts recorded in our consolidated balance sheet:      
Noncurrent assets 934 1,010  
Current liabilities (90) (94)  
Noncurrent liabilities (678) (738)  
Funded status 167 179  
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:      
Prior service (costs)/credits (2) (2)  
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):      
ABO [3] 768 831  
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):      
PBO [3] 768 831  
U.S. [Member] | Postretirement Plans [Member]      
Change in plan assets      
Fair value of plan assets, beginning 636    
Fair value of plan assets, ending 736 636  
International [Member] | Pension Plans [Member]      
Change in benefit obligation      
Benefit obligation, beginning [1] 7,292 7,497  
Service cost 87 85 116
Interest cost 312 287 157
Employee contributions 16 11  
Plan amendments 0 25  
Changes in actuarial assumptions and other [2] 119 (518)  
Foreign exchange impact (106) 280  
Acquisitions/divestitures, net 77 13  
Curtailments and special termination benefits 7 0  
Settlements (69) (56)  
Benefits paid (371) (334)  
Benefit obligation, ending [1] 7,363 7,292 7,497
Change in plan assets      
Fair value of plan assets, beginning 6,552 6,865  
Actual return on plan assets 408 (316)  
Company contributions 164 154  
Employee contributions 16 11  
Foreign exchange impact (65) 214  
Acquisitions/divestitures, net 62 13  
Settlements (69) (56)  
Benefits paid (371) (334)  
Fair value of plan assets, ending 6,696 6,552 $ 6,865
Funded status (667) (740)  
Amounts recorded in our consolidated balance sheet:      
Noncurrent assets 728 644  
Current liabilities (31) (28)  
Noncurrent liabilities (1,364) (1,355)  
Funded status (667) (740)  
Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:      
Prior service (costs)/credits (61) (65)  
Information related to the funded status of pension plans with an ABO in excess of plan assets(c):      
Fair value of plan assets [3] 456 579  
ABO [3] 1,752 1,834  
Information related to the funded status of pension plans with a PBO in excess of plan assets(c):      
Fair value of plan assets [3] 690 964  
PBO [3] 2,084 2,347  
Defined benefit plan, accumulated benefit obligation $ 7,100 $ 7,000  
[1] For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.
[2] For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.
[3] Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.
XML 141 R112.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Postretirement Plans [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 736 $ 636 $ 647
U.S. [Member] | Pension Plans [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 9,948 10,935 10,871
U.S. [Member] | Pension Plans [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 100.00%    
U.S. [Member] | Pension Plans [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 1,401 1,585  
U.S. [Member] | Pension Plans [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 5,518 6,410  
U.S. [Member] | Pension Plans [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 1  
U.S. [Member] | Pension Plans [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] 3,028 2,939  
U.S. [Member] | Pension Plans [Member] | Cash and cash equivalents [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 533 606  
U.S. [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 0.00%    
U.S. [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 56 47  
U.S. [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 477 559  
U.S. [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
U.S. [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] $ 0 0  
U.S. [Member] | Pension Plans [Member] | Equity securities [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 10.00%    
U.S. [Member] | Pension Plans [Member] | Global equity securities [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 1,341 1,537  
U.S. [Member] | Pension Plans [Member] | Global equity securities [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,341 1,537  
U.S. [Member] | Pension Plans [Member] | Global equity securities [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0    
U.S. [Member] | Pension Plans [Member] | Global equity securities [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 1  
U.S. [Member] | Pension Plans [Member] | Global equity securities [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] 0 0  
U.S. [Member] | Pension Plans [Member] | Equity commingled funds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 97 100  
U.S. [Member] | Pension Plans [Member] | Equity commingled funds [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
U.S. [Member] | Pension Plans [Member] | Equity commingled funds [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 97 100  
U.S. [Member] | Pension Plans [Member] | Equity commingled funds [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
U.S. [Member] | Pension Plans [Member] | Equity commingled funds [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] $ 0 0  
U.S. [Member] | Pension Plans [Member] | Fixed income securities [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 45.00%    
U.S. [Member] | Pension Plans [Member] | Corporate debt [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 2,878 3,668  
U.S. [Member] | Pension Plans [Member] | Corporate debt [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 1  
U.S. [Member] | Pension Plans [Member] | Corporate debt [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,874 3,667  
U.S. [Member] | Pension Plans [Member] | Corporate debt [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0    
U.S. [Member] | Pension Plans [Member] | Corporate debt [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] 0    
U.S. [Member] | Pension Plans [Member] | Government and agency obligations [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [2] 2,059 1,971  
U.S. [Member] | Pension Plans [Member] | Government and agency obligations [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [2] 0 0  
U.S. [Member] | Pension Plans [Member] | Government and agency obligations [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [2] 2,059 1,971  
U.S. [Member] | Pension Plans [Member] | Government and agency obligations [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [2] 0 0  
U.S. [Member] | Pension Plans [Member] | Government and agency obligations [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1],[2] 0 0  
U.S. [Member] | Pension Plans [Member] | Fixed income commingled funds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 42 25  
U.S. [Member] | Pension Plans [Member] | Fixed income commingled funds [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
U.S. [Member] | Pension Plans [Member] | Fixed income commingled funds [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 12 14  
U.S. [Member] | Pension Plans [Member] | Fixed income commingled funds [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
U.S. [Member] | Pension Plans [Member] | Fixed income commingled funds [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] $ 30 11  
U.S. [Member] | Pension Plans [Member] | Other investments [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 5.00%    
U.S. [Member] | Pension Plans [Member] | Partnership Interest [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [3] $ 2,665 2,449  
U.S. [Member] | Pension Plans [Member] | Partnership Interest [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [3] 0 0  
U.S. [Member] | Pension Plans [Member] | Partnership Interest [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [3]   0  
U.S. [Member] | Pension Plans [Member] | Partnership Interest [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [3] 0 0  
U.S. [Member] | Pension Plans [Member] | Partnership Interest [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1],[3] 2,665 2,449  
U.S. [Member] | Pension Plans [Member] | Insurance contracts [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 99  
U.S. [Member] | Pension Plans [Member] | Insurance contracts [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
U.S. [Member] | Pension Plans [Member] | Insurance contracts [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 99  
U.S. [Member] | Pension Plans [Member] | Insurance contracts [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
U.S. [Member] | Pension Plans [Member] | Insurance contracts [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] 0 0  
U.S. [Member] | Pension Plans [Member] | Other commingled funds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [4] 333 479  
U.S. [Member] | Pension Plans [Member] | Other commingled funds [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [4] 0 0  
U.S. [Member] | Pension Plans [Member] | Other commingled funds [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [4] 0 0  
U.S. [Member] | Pension Plans [Member] | Other commingled funds [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1],[4] 333 479  
U.S. [Member] | Postretirement Plans [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 736 636  
U.S. [Member] | Postretirement Plans [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 100.00%    
U.S. [Member] | Postretirement Plans [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 0 1  
U.S. [Member] | Postretirement Plans [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 736 635  
U.S. [Member] | Postretirement Plans [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
U.S. [Member] | Postretirement Plans [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1]   0  
U.S. [Member] | Postretirement Plans [Member] | Cash and cash equivalents [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [5] $ 12 3  
U.S. [Member] | Postretirement Plans [Member] | Cash and cash equivalents [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 0.00%    
U.S. [Member] | Postretirement Plans [Member] | Cash and cash equivalents [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [5] $ 0 1  
U.S. [Member] | Postretirement Plans [Member] | Cash and cash equivalents [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [5] 12 2  
U.S. [Member] | Postretirement Plans [Member] | Cash and cash equivalents [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [5]   0  
U.S. [Member] | Postretirement Plans [Member] | Cash and cash equivalents [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1],[5]   0  
U.S. [Member] | Postretirement Plans [Member] | Insurance contracts [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [5] $ 724 633  
U.S. [Member] | Postretirement Plans [Member] | Insurance contracts [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 95.00%    
U.S. [Member] | Postretirement Plans [Member] | Insurance contracts [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [5] $ 0    
U.S. [Member] | Postretirement Plans [Member] | Insurance contracts [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [5] 724 633  
U.S. [Member] | Postretirement Plans [Member] | Insurance contracts [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [5]   0  
U.S. [Member] | Postretirement Plans [Member] | Insurance contracts [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1],[5]   0  
International [Member] | Pension Plans [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 6,696 6,552 6,865
International [Member] | Pension Plans [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 100.00%    
International [Member] | Pension Plans [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 174 120  
International [Member] | Pension Plans [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,642 3,295  
International [Member] | Pension Plans [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,433 1,340 $ 1,455
International [Member] | Pension Plans [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] 1,447 1,796  
International [Member] | Pension Plans [Member] | Cash and cash equivalents [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 310 268  
International [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 0.00%    
International [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 138 120  
International [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 172 148  
International [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International [Member] | Pension Plans [Member] | Cash and cash equivalents [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] $ 0 0  
International [Member] | Pension Plans [Member] | Equity securities [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 10.00%    
International [Member] | Pension Plans [Member] | Equity commingled funds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 704 633  
International [Member] | Pension Plans [Member] | Equity commingled funds [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International [Member] | Pension Plans [Member] | Equity commingled funds [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 619 587  
International [Member] | Pension Plans [Member] | Equity commingled funds [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International [Member] | Pension Plans [Member] | Equity commingled funds [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] $ 86 46  
International [Member] | Pension Plans [Member] | Fixed income securities [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 45.00%    
International [Member] | Pension Plans [Member] | Corporate debt [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 638 617  
International [Member] | Pension Plans [Member] | Corporate debt [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International [Member] | Pension Plans [Member] | Corporate debt [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 633 617  
International [Member] | Pension Plans [Member] | Corporate debt [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 5 0  
International [Member] | Pension Plans [Member] | Corporate debt [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] 0 0  
International [Member] | Pension Plans [Member] | Government and agency obligations [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [2] 960 848  
International [Member] | Pension Plans [Member] | Government and agency obligations [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [2] 1 0  
International [Member] | Pension Plans [Member] | Government and agency obligations [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [2] 960 848  
International [Member] | Pension Plans [Member] | Government and agency obligations [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [2] 0 0  
International [Member] | Pension Plans [Member] | Government and agency obligations [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1],[2] 0 0  
International [Member] | Pension Plans [Member] | Fixed income commingled funds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,750 1,852  
International [Member] | Pension Plans [Member] | Fixed income commingled funds [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International [Member] | Pension Plans [Member] | Fixed income commingled funds [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,064 872  
International [Member] | Pension Plans [Member] | Fixed income commingled funds [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International [Member] | Pension Plans [Member] | Fixed income commingled funds [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] $ 686 980  
International [Member] | Pension Plans [Member] | Other investments [Member] | Minimum [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Equity and debt securities, target allocation percentage 15.00%    
International [Member] | Pension Plans [Member] | Partnership Interest [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [3] $ 147 145  
International [Member] | Pension Plans [Member] | Partnership Interest [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [3] 0 0  
International [Member] | Pension Plans [Member] | Partnership Interest [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [3] 2 2  
International [Member] | Pension Plans [Member] | Partnership Interest [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [3] 0 0  
International [Member] | Pension Plans [Member] | Partnership Interest [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1],[3] 145 142  
International [Member] | Pension Plans [Member] | Insurance contracts [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,221 1,151  
International [Member] | Pension Plans [Member] | Insurance contracts [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International [Member] | Pension Plans [Member] | Insurance contracts [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 45 55  
International [Member] | Pension Plans [Member] | Insurance contracts [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,176 1,096  
International [Member] | Pension Plans [Member] | Insurance contracts [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1] 0 0  
International [Member] | Pension Plans [Member] | Other [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [4] 965 1,039  
International [Member] | Pension Plans [Member] | Other [Member] | Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [4] 35 0  
International [Member] | Pension Plans [Member] | Other [Member] | Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [4] 147 167  
International [Member] | Pension Plans [Member] | Other [Member] | Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [4] 252 244  
International [Member] | Pension Plans [Member] | Other [Member] | Assets Measured at NAV [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1],[4] $ 531 $ 628  
[1] Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.
[2] Government and agency obligations are inclusive of repurchase agreements.
[3] Mainly includes investments in private equity, private debt and real estate.
[4] Mostly includes investments in hedge funds and real estate.
[5] Reflects postretirement plan assets, which support our U.S. retiree medical plans.
XML 142 R113.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)
Dec. 31, 2024
Minimum [Member] | U.S. [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 100.00%
Minimum [Member] | U.S. [Member] | Postretirement Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 100.00%
Minimum [Member] | U.S. [Member] | Cash and cash equivalents [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 0.00%
Minimum [Member] | U.S. [Member] | Cash and cash equivalents [Member] | Postretirement Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 0.00%
Minimum [Member] | U.S. [Member] | Equity securities [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 10.00%
Minimum [Member] | U.S. [Member] | Fixed income securities [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 45.00%
Minimum [Member] | U.S. [Member] | Other investments [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 5.00%
Minimum [Member] | U.S. [Member] | Insurance contracts [Member] | Postretirement Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 95.00%
Minimum [Member] | International [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 100.00%
Minimum [Member] | International [Member] | Cash and cash equivalents [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 0.00%
Minimum [Member] | International [Member] | Equity securities [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 10.00%
Minimum [Member] | International [Member] | Fixed income securities [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 45.00%
Minimum [Member] | International [Member] | Other investments [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 15.00%
Maximum [Member] | U.S. [Member] | Cash and cash equivalents [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 10.00%
Maximum [Member] | U.S. [Member] | Cash and cash equivalents [Member] | Postretirement Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 5.00%
Maximum [Member] | U.S. [Member] | Equity securities [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 40.00%
Maximum [Member] | U.S. [Member] | Fixed income securities [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 80.00%
Maximum [Member] | U.S. [Member] | Other investments [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 35.00%
Maximum [Member] | U.S. [Member] | Insurance contracts [Member] | Postretirement Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 100.00%
Maximum [Member] | International [Member] | Cash and cash equivalents [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 10.00%
Maximum [Member] | International [Member] | Equity securities [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 20.00%
Maximum [Member] | International [Member] | Fixed income securities [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 70.00%
Maximum [Member] | International [Member] | Other investments [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Equity and debt securities, target allocation percentage 35.00%
XML 143 R114.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details) - International [Member] - Pension Plans [Member] - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]    
Fair value of plan assets, beginning $ 6,552 $ 6,865
Actual return on plan assets:    
Exchange rate changes (65) 214
Fair value of plan assets, ending 6,696 6,552
Level 3 [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]    
Fair value of plan assets, beginning 1,340 1,455
Actual return on plan assets:    
Assets held, ending 8 (96)
Assets sold during the period 0 (3)
Purchases, sales, and settlements, net (79) (155)
Transfer into/(out of) Level 3 168 81
Exchange rate changes (5) 59
Fair value of plan assets, ending $ 1,433 $ 1,340
XML 144 R115.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Postretirement Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Expected contributions in 2025 $ 40
Expected benefit payments:  
2025 44
2026 47
2027 49
2028 50
2029 50
2030–2034 245
U.S. [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Expected contributions in 2025 90
Expected benefit payments:  
2025 871
2026 858
2027 844
2028 825
2029 815
2030–2034 3,760
International [Member] | Pension Plans [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Expected contributions in 2025 144
Expected benefit payments:  
2025 384
2026 366
2027 384
2028 385
2029 392
2030–2034 $ 2,067
XML 145 R116.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Retirement Benefits [Abstract]      
Defined contribution plan, cost recognized $ 800 $ 843 $ 770
XML 146 R117.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity (Details)
3 Months Ended 12 Months Ended
Apr. 03, 2022
USD ($)
shares
Dec. 31, 2024
USD ($)
employeeStockOwnershipPlan
shares
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2018
USD ($)
Equity, Class of Treasury Stock [Line Items]          
Amount of shares authorized in stock purchase plan, value | $         $ 10,000,000,000
Shares repurchased (in shares) | shares 39,000,000        
Shares repurchased, cost | $ $ 2,000,000,000     $ 2,000,000,000  
Amount of remaining shares authorized in stock purchase plan, value | $   $ 3,300,000,000      
Preferred stock, shares authorized (in shares) | shares   27,000,000 27,000,000    
Preferred stock, shares issued (in shares) | shares   0 0    
Preferred stock, shares outstanding (in shares) | shares   0 0    
Number of employee stock ownership plans | employeeStockOwnershipPlan   1      
Common ESOP Plan [Member]          
Equity, Class of Treasury Stock [Line Items]          
ESOP compensation expense | $   $ 16,000,000 $ 20,000,000 $ 19,000,000  
XML 147 R118.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments - Narrative (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares available for award 441,000,000    
Compensation cost recognized/(reduced), pre-tax $ 877 $ 525 $ 872
Tax benefit for share-based compensation expense $ 165 93 160
2019 Stock Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of additional shares authorized 320,000,000    
Restricted Stock Units (RSUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares granted in period (in shares) 17,073,000    
Compensation cost recognized/(reduced), pre-tax $ 394 437 402
Restricted Stock Units (RSUs) [Member] | 2019 Stock Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares counted toward maximum 3    
Portfolio Performance Shares [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares granted in period (in shares) [1] 13,535,000    
Compensation cost recognized/(reduced), pre-tax $ 252 (138) 144
Portfolio Performance Shares [Member] | 2019 Stock Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares counted toward maximum 3    
Performance Share Awards [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares granted in period (in shares) 2,597,000    
Award requisite service period 3 years    
Compensation cost recognized/(reduced), pre-tax $ (21) (5) 73
Performance Share Awards [Member] | 2019 Stock Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares counted toward maximum 3    
Breakthrough Performance Awards (BPAs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares granted in period (in shares) 0    
Number of shares outstanding (in shares) 0    
Award requisite service period 1 year    
Breakthrough Performance Awards (BPAs) [Member] | 2019 Stock Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares counted toward maximum 3    
Total Shareholder Return Units (TSRUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares granted in period (in shares) 43,674,000    
Number of shares outstanding (in shares) [2],[3] 167,977,000    
Compensation cost recognized/(reduced), pre-tax $ 246 244 255
Total Shareholder Return Units (TSRUs) [Member] | 2019 Stock Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares counted toward maximum 1    
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Compensation cost recognized/(reduced), pre-tax $ 4 $ 4 $ 4
Stock Options [Member] | 2019 Stock Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares counted toward maximum 1    
[1] Vested and non-vested shares outstanding, but not paid as of December 31, 2024 were 33.9 million.
[2] In 2024, 1,150,382 TSRUs with a weighted-average grant price of $31.54 per unit were converted into 100,307 PTUs.
[3] In 2024, we settled 2,419,674 TSRUs with a weighted-average grant price of $27.76 per unit.
XML 148 R119.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)
12 Months Ended
Dec. 31, 2024
tradingDay
measure
period
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Granted, shares 1,372,000
Management [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Granted, shares 0
Total Shareholder Return Units (TSRUs) [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Trading day average | tradingDay 20
Award vesting period 3 years
Total Shareholder Return Units (TSRUs) [Member] | Total Shareholder Return Units, Vesting Period One  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award settlement period 5 years
Total Shareholder Return Units (TSRUs) [Member] | Total Shareholder Return Units, Vesting Period Two  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award settlement period 7 years
Total Shareholder Return Units (TSRUs) [Member] | Certain TSRUs Granted in 2022 and 2023 [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award settlement period 7 years
Award vesting period 5 years
Total Shareholder Return Units (TSRUs) [Member] | Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Contractual term (years) 5 years
Total Shareholder Return Units (TSRUs) [Member] | Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Contractual term (years) 7 years
Restricted Stock Units (RSUs) [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting period 3 years
Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting percentage 33.00%
Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Two [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting percentage 33.00%
Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Three [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting percentage 33.00%
Restricted Stock Units (RSUs) [Member] | Restricted Stock Units Granted Before 2022 [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting period 3 years
Portfolio Performance Shares [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting period 3 years
Portfolio Performance Shares [Member] | Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award requisite service period 3 years
Number of shares earned as a percentage of initial award 0.00%
Portfolio Performance Shares [Member] | Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award requisite service period 5 years
Number of shares earned as a percentage of initial award 200.00%
Performance Share Awards [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting period 3 years
Award requisite service period 3 years
Number of measures used to determine share payout | measure 2
Share payout measures, adjusted net income, number of periods | period 3
Share payout measures, adjusted net income, period 1 year
Performance Share Awards [Member] | PSAs Granted in 2022 and 2023 [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting period 5 years
Performance Share Awards [Member] | Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares earned as a percentage of initial award 0.00%
Performance Share Awards [Member] | Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares earned as a percentage of initial award 200.00%
Breakthrough Performance Awards (BPAs) [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award requisite service period 1 year
Breakthrough Performance Awards (BPAs) [Member] | Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares earned as a percentage of initial award 0.00%
Breakthrough Performance Awards (BPAs) [Member] | Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares earned as a percentage of initial award 600.00%
Stock Options [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Contractual term (years) 10 years
Award vesting period 3 years
XML 149 R120.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Compensation cost recognized/(reduced), pre-tax $ 877 $ 525 $ 872
Total Shareholder Return Units (TSRUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Granted, weighted-average grant-date fair value per share (in dollars per share) [1] $ 7.05 $ 10.71 $ 11.72
Total intrinsic value of options exercised or share units converted $ 29 $ 755 $ 1,131
Compensation cost recognized/(reduced), pre-tax 246 244 255
Total compensation cost related to nonvested awards not yet recognized, pre-tax $ 270 $ 192 $ 179
Weighted-average period over which cost is expected to be recognized (years) 2 years 1 month 6 days 1 year 8 months 12 days 1 year 8 months 12 days
Restricted Stock Units (RSUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Granted, weighted-average grant-date fair value per share (in dollars per share) $ 26.97    
Total fair value of shares vested [1] $ 469 $ 505 $ 345
Compensation cost recognized/(reduced), pre-tax 394 437 402
Total compensation cost related to nonvested awards not yet recognized, pre-tax $ 214 $ 212 $ 266
Weighted-average period over which cost is expected to be recognized (years) 1 year 9 months 18 days 1 year 9 months 18 days 1 year 8 months 12 days
Portfolio Performance Shares [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total fair value of shares vested [1] $ 176 $ 116 $ 145
Total intrinsic value of options exercised or share units converted 123 250 280
Compensation cost recognized/(reduced), pre-tax 252 (138) 144
Total compensation cost related to nonvested awards not yet recognized, pre-tax $ 107 $ 81 $ 135
Weighted-average period over which cost is expected to be recognized (years) 1 year 10 months 24 days 1 year 9 months 18 days 1 year 8 months 12 days
Performance Share Awards [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total fair value of shares vested [1] $ 0 $ 58 $ 57
Compensation cost recognized/(reduced), pre-tax (21) (5) 73
Total compensation cost related to nonvested awards not yet recognized, pre-tax $ 40 $ 22 $ 38
Weighted-average period over which cost is expected to be recognized (years) 1 year 8 months 12 days 1 year 9 months 18 days 1 year 9 months 18 days
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Granted, weighted-average grant-date fair value per share (in dollars per share) [1] $ 4.08 $ 7.88 $ 9.44
Total intrinsic value of options exercised or share units converted $ 0 $ 102 $ 247
Cash received upon exercise 0 181 260
Tax benefits realized from exercise 0 20 46
Compensation cost recognized/(reduced), pre-tax 4 4 4
Total compensation cost related to nonvested awards not yet recognized, pre-tax $ 4 $ 4 $ 3
Weighted-average period over which cost is expected to be recognized (years) 1 year 8 months 12 days 1 year 8 months 12 days 1 year 8 months 12 days
[1] Weighted-average GDFV per TSRUs and stock options.
XML 150 R121.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments - Schedule of Valuation Assumptions (Detail)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Total Shareholder Return Units (TSRUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected dividend yield 6.06% 3.80% 3.42%
Risk-free interest rate 4.31% 4.08% 1.87%
Expected stock price volatility 26.56% 23.23% 29.20%
Contractual term/expected term 5 years 1 month 24 days 5 years 1 month 24 days 5 years 2 months 1 day
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected dividend yield 6.06% 3.80% 3.42%
Risk-free interest rate 4.32% 4.03% 1.93%
Expected stock price volatility 26.56% 23.23% 29.21%
Contractual term/expected term 6 years 6 months 6 years 6 months 6 years 6 months
XML 151 R122.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail) - $ / shares
shares in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Total Shareholder Return Units (TSRUs) [Member]      
Number of Shares      
Nonvested, beginning of period, shares 77,673    
Granted, shares 43,674    
Vested, shares (31,076)    
Forfeited, shares (5,370)    
Nonvested, end of period, shares 84,902 77,673  
Weighted Avg. GDFV per share      
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) $ 9.67    
Granted, weighted-average grant-date fair value per share (in dollars per share) [1] 7.05 $ 10.71 $ 11.72
Vested, weighted-average grant-date fair value per share (in dollars per share) 7.42    
Forfeited, weighted-average grant date fair value per share (in dollars per share) 8.66    
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) 9.63 9.67  
Grant Price      
Nonvested, beginning of period, grant price (in dollars per share) 39.92    
Granted, grant price (in dollars per share) 26.90    
Vested, grant price (in dollars per share) 33.87    
Forfeited, grant price (in dollars per share) 33.90    
Nonvested, end of period, grant price (in dollars per share) $ 35.87 $ 39.92  
Restricted Stock Units [Member]      
Number of Shares      
Nonvested, beginning of period, shares 25,844    
Granted, shares 17,073    
Vested, shares (16,874)    
Reinvested dividend equivalents, shares 1,541    
Forfeited, shares (2,024)    
Nonvested, end of period, shares 25,561 25,844  
Weighted Avg. GDFV per share      
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) $ 40.08    
Granted, weighted-average grant-date fair value per share (in dollars per share) 26.97    
Vested, weighted-average grant-date fair value per share (in dollars per share) 37.89    
Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share) 28.17    
Forfeited, weighted-average grant date fair value per share (in dollars per share) 32.20    
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) $ 32.67 $ 40.08  
Portfolio Performance Shares [Member]      
Number of Shares      
Nonvested, beginning of period, shares [2] 22,225    
Granted, shares [2] 13,535    
Vested, shares [2] (6,329)    
Forfeited, shares [2] (3,274)    
Nonvested, end of period, shares [2] 26,156 22,225  
Weighted Avg. Intrinsic Value per share      
Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share) [2] $ 28.79    
Granted, weighted-average intrinsic value per share (in dollars per share) [2] 26.92    
Vested, weighted-average intrinsic value per share (in dollars per share) [2] 27.76    
Forfeited, weighted-average intrinsic value per share (in dollars per share) [2] 28.03    
Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share) [2] $ 26.53 $ 28.79  
Vested and expected to vest, end of period, shares 33,900    
Performance Share Awards [Member]      
Number of Shares      
Nonvested, beginning of period, shares 4,734    
Granted, shares 2,597    
Vested, shares 0    
Forfeited, shares (1,810)    
Nonvested, end of period, shares 5,521 4,734  
Weighted Avg. Intrinsic Value per share      
Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share) $ 28.79    
Granted, weighted-average intrinsic value per share (in dollars per share) 26.89    
Vested, weighted-average intrinsic value per share (in dollars per share) 0    
Forfeited, weighted-average intrinsic value per share (in dollars per share) 27.79    
Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share) $ 26.53 $ 28.79  
[1] Weighted-average GDFV per TSRUs and stock options.
[2] Vested and non-vested shares outstanding, but not paid as of December 31, 2024 were 33.9 million.
XML 152 R123.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments - Summary of TSRU and PTU Activity (Details)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Total Shareholder Return Units (TSRUs) [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Units outstanding, shares 167,977,000 [1],[2]
Units vested, shares 83,075,000 [1],[2]
Units expected to vest, shares 80,014,000 [1],[2],[3]
Units outstanding, weighted average grant price (in dollars per share) | $ / shares $ 34.17 [1],[2]
Units vested, weighted average grant price (in dollars per share) | $ / shares 32.44 [1],[2]
Units expected to vest, weighted average grant price (in dollars per share) | $ / shares $ 35.93 [1],[2],[3]
Units outstanding, weighted average remaining contractual term 2 years 6 months [1],[2]
Units vested, weighted average remaining contractual term 8 months 12 days [1],[2]
Units expected to vest, weighted average remaining contractual term 4 years 3 months 18 days [1],[2],[3]
Units outstanding, aggregate intrinsic value | $ $ 122 [1],[2],[4]
Units vested, aggregate intrinsic value | $ 86 [1],[2],[4]
Units expected to vest, aggregate intrinsic value | $ $ 34 [1],[2],[3],[4]
Units settled, shares 2,419,674
Units settled, weighted average grant price (in dollars per share) | $ / shares $ 27.76
Units exercised, shares 1,150,382
Units exercised, weighted average grant price (in dollars per share) | $ / shares $ 31.54
Profit Units [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Units converted and exercised, shares 586,000 [1],[2]
Units exercised and converted, weighted average remaining contractual term 2 months 12 days [1],[2]
Units exercised and converted, aggregate intrinsic value | $ $ 16 [1],[2],[4]
Units granted upon conversion, shares 100,307
[1] In 2024, 1,150,382 TSRUs with a weighted-average grant price of $31.54 per unit were converted into 100,307 PTUs.
[2] In 2024, we settled 2,419,674 TSRUs with a weighted-average grant price of $27.76 per unit.
[3] The number of TSRUs expected to vest takes into account an estimate of expected forfeitures
[4] Market price of our underlying common stock less grant price plus dividend equivalents to date.
XML 153 R124.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Shares (Thousands)  
Outstanding, beginning of period, shares | shares 28,452
Granted, shares | shares 1,372
Exercised, shares | shares (4)
Forfeited, shares | shares (235)
Expired, shares | shares (9,964)
Outstanding, end of period, shares | shares 19,621
Vested and expected to vest, end of period, shares | shares 19,510 [1]
Exercisable, end of period, shares | shares 17,447
Weighted-Average Exercise Price Per Share  
Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share) | $ / shares $ 32.66
Granted, weighted-average exercise price per share (in dollars per share) | $ / shares 26.90
Exercised, weighted-average exercise price per share (in dollars per share) | $ / shares 29.06
Forfeited, weighted-average exercise price per share (in dollars per share) | $ / shares 33.52
Expired, weighted-average exercise price per share (in dollars per share) | $ / shares 30.69
Outstanding, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares 33.24
Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares 33.26 [1]
Exercisable, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares $ 33.12
Outstanding, end of period, weighted-average remaining contractual term 1 year 10 months 24 days
Vested and expected to vest, end of period, weighted-average remaining contractual term 1 year 10 months 24 days [1]
Exercisable, end of period, weighted-average remaining contractual term 1 year 1 month 6 days
Outstanding, end of period, aggregate intrinsic value | $ $ 0 [2]
Vested and expected to vest, end of period, aggregate intrinsic value | $ 0 [1],[2]
Exercisable, end of period, aggregate intrinsic value | $ $ 0 [2]
[1] The number of options expected to vest takes into account an estimate of expected forfeitures.
[2] Market price of our underlying common stock less exercise price.
XML 154 R125.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
EPS Numerator      
Income from continuing operations attributable to Pfizer Inc. common shareholders $ 8,020 $ 2,134 $ 31,366
Discontinued operations––net of tax 11 (15) 6
Net income attributable to Pfizer Inc. common shareholders 8,031 2,119 31,372
EPS Numerator––Diluted      
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions 8,020 2,134 31,366
Discontinued operations––net of tax 11 (15) 6
Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 8,031 $ 2,119 $ 31,372
EPS Denominator      
Weighted-average common shares outstanding––Basic (in shares) 5,664 5,643 5,608
Common-share equivalents (in shares) 36 66 125
Weighted-average common shares outstanding––Diluted (in shares) 5,700 5,709 5,733
Anti-dilutive common stock equivalents (in shares) [1] 24 9 1
[1] These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
XML 155 R126.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Lessee, Lease, Description [Line Items]      
Variable lease cost $ 517 $ 444 $ 536
Minimum [Member]      
Lessee, Lease, Description [Line Items]      
Operating lease term 1 year    
Operating lease term, option to extend 5 years    
Maximum [Member]      
Lessee, Lease, Description [Line Items]      
Operating lease term 30 years    
Operating lease term, option to extend 10 years    
XML 156 R127.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Schedule of Lease Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Leases [Abstract]    
ROU assets $ 2,289 $ 2,924
Lease liabilities (short-term) 356 527
Lease liabilities (long-term) $ 2,286 $ 2,626
ROU assets, statement of financial position Other Assets, Noncurrent Other Assets, Noncurrent
Lease liabilities (short-term), statement of financial position Other current liabilities Other current liabilities
Lease liabilities (long-term), statement of financial position Other noncurrent liabilities Other noncurrent liabilities
XML 157 R128.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Schedule of Lease Costs and Other Supplemental Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]      
Operating lease cost $ 683 $ 863 $ 714
Variable lease cost 517 444 536
Sublease income (23) (24) (32)
Total lease cost $ 1,177 $ 1,283 1,218
Weighted-Average Remaining Contractual Lease Term (Years) 10 years 2 months 12 days 10 years 9 months 18 days  
Weighted-Average Discount Rate 3.70% 3.80%  
Operating cash flows from operating leases $ 601 $ 744 617
(Gains)/losses on sale and leaseback transactions, net $ 29 $ (49) $ 11
XML 158 R129.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Leases [Abstract]    
Next one year [1] $ 443  
1-2 years 406  
2-3 years 361  
3-4 years 281  
4-5 years 239  
Thereafter 1,468  
Total undiscounted lease payments 3,197  
Less: Imputed interest 556  
Present value of minimum lease payments 2,642  
Less: Current portion 356 $ 527
Noncurrent portion $ 2,286 $ 2,626
[1] Reflects lease payments due within 12 months subsequent to the balance sheet date.
XML 159 R130.htm IDEA: XBRL DOCUMENT v3.25.0.1
Contingencies and Certain Commitments - Patent Litigation (Details)
$ in Millions
1 Months Ended
Jan. 31, 2025
company
Nov. 30, 2024
patent
Oct. 31, 2024
patent
Aug. 31, 2024
patent
Jul. 31, 2024
patent
Apr. 30, 2024
patent
Mar. 31, 2024
patent
Nov. 30, 2023
Patent
patent
Aug. 31, 2023
patent
Jun. 30, 2023
patent
May 31, 2023
Patent
patent
Apr. 30, 2023
patent
Sep. 30, 2022
patent
Aug. 31, 2022
patent
company
Jul. 31, 2022
patent
Dec. 31, 2024
USD ($)
Gain Contingencies [Line Items]                                
Threshold for disclosure of proceedings under environmental laws | $                               $ 1
Loss contingency, patents allegedly infringed and subsequently revoked | Patent               1                
Mektovi [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]                                
Gain Contingencies [Line Items]                                
Number of companies in litigation case | company                           2    
Number of patents allegedly infringed upon                         6      
Mektovi [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] | Expiring 2030 [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed upon                           2    
Mektovi [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] | Expiring 2033 [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed upon                           2    
Mektovi [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Settled Litigation [Member] | Subsequent Event [Member]                                
Gain Contingencies [Line Items]                                
Settled litigation, number of companies | company 1                              
Mektovi [Member] | Pfizer Versus Teva Pharmaceuticals, Inc. [Member] | Patent Invalidity And Non Infringement [Member] | Pending Litigation [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed upon                   3            
Mektovi [Member] | Pfizer Versus Teva Pharmaceuticals, Inc. [Member] | Patent Invalidity And Non Infringement [Member] | Pending Litigation [Member] | Teva Pharmaceuticals, Inc. [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed upon                           2    
Comirnaty [Member] | Alnylam Patent Infringement Case [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed | Patent                     4          
Comirnaty [Member] | ModernaTX U.S. Patent Infringement Case [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed                           3    
Number of patents under review             2                  
Comirnaty [Member] | ModernaTX European Patent Infringement Case [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed                         2 2    
Loss contingency, patents ruled invalid and subsequently revoked         1                      
Comirnaty [Member] | Arbutus and Genevant U.S. Patent Infringement Case [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed                       5        
Comirnaty [Member] | GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed       3   5                    
Comirnaty [Member] | Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment of Non-Infringement [Member]                                
Gain Contingencies [Line Items]                                
Number of patents found not infringed                             3  
Number of patents found infringed                     3          
Abrysvo [Member] | GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member]                                
Gain Contingencies [Line Items]                                
Number of patents allegedly infringed   7           2 4              
Number of patents found not infringed     2                          
XML 160 R131.htm IDEA: XBRL DOCUMENT v3.25.0.1
Contingencies and Certain Commitments - Legal Proceedings-Government Investigations (Details)
$ in Millions
1 Months Ended
Jan. 31, 2025
USD ($)
Dec. 31, 2020
complaint
Greenstone Antitrust Litigation [Member] | Pending Litigation [Member]    
Loss Contingencies [Line Items]    
Number of complaints | complaint   2
Government Inquires Relating to Biohaven [Member] | Settled Litigation [Member] | U.S. and Participating States [Member] | Subsequent Event [Member]    
Loss Contingencies [Line Items]    
Amounts paid in settlement agreement $ 59.7  
Government Inquires Relating to Biohaven [Member] | Settled Litigation [Member] | California Department of Insurance [Member] | Subsequent Event [Member]    
Loss Contingencies [Line Items]    
Amounts paid in settlement agreement $ 3.3  
XML 161 R132.htm IDEA: XBRL DOCUMENT v3.25.0.1
Contingencies and Certain Commitments - Certain Commitments and Contingent Consideration for Acquisitions (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
Long-term purchase commitment, amount $ 4,100  
Fair value of contingent consideration 517 $ 692
Contingent consideration liability, current 39 179
Contingent consideration liability, noncurrent $ 477 $ 512
XML 162 R133.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information - Narrative (Detail)
treatmentCourse in Millions, $ in Millions
2 Months Ended 3 Months Ended 12 Months Ended
Feb. 29, 2024
treatmentCourse
Sep. 29, 2024
USD ($)
treatmentCourse
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
country
Dec. 31, 2024
USD ($)
country
segment
Dec. 31, 2024
USD ($)
country
Dec. 31, 2024
USD ($)
country
operatingSegment
Dec. 31, 2023
USD ($)
treatmentCourse
country
Dec. 31, 2022
country
Segment Reporting Information [Line Items]                  
Number of operating segments         3   3    
Total assets       $ 213,396 $ 213,396 $ 213,396 $ 213,396 $ 226,501  
Deferred revenues, current       1,511 1,511 1,511 1,511 2,700  
Paxlovid, EUA-Labeled [Member]                  
Segment Reporting Information [Line Items]                  
Reversal of revenue               $ 3,500  
Estimated government emergency use authorization inventory to be returned to company, number of treatment courses | treatmentCourse               6.5  
Favorable adjustment for government emergency use authorization inventory returned to the company during the period     $ 771 771          
Government emergency use authorization inventory returned to the company during the period, number of treatment courses | treatmentCourse 5.1                
Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member]                  
Segment Reporting Information [Line Items]                  
Supply commitment, minimum amount committed, number of treatment courses | treatmentCourse   1.0              
Revenues   $ 442   442          
Comirnaty [Member]                  
Segment Reporting Information [Line Items]                  
Remaining performance obligation       4,000 4,000 4,000 4,000    
Paxlovid [Member]                  
Segment Reporting Information [Line Items]                  
Remaining performance obligation       1,000 1,000 1,000 1,000    
Government and Government Sponsored [Member] | Paxlovid and Comirnaty [Member]                  
Segment Reporting Information [Line Items]                  
Deferred revenues       2,200 2,200 2,200 2,200 $ 5,100  
Deferred revenues, current       1,400 1,400 1,400 1,400 2,600  
Deferred revenues, noncurrent       785 $ 785 $ 785 $ 785 $ 2,500  
Deferred revenue, revenue recognized       $ 2,900          
Geographic Concentration Risk [Member] | Revenue [Member] | Outside United States [Member]                  
Segment Reporting Information [Line Items]                  
Number of countries with revenue exceeding $500 million | country       11 11 11 11 14 24
Geographic Concentration Risk [Member] | Revenue [Member] | U.S. [Member]                  
Segment Reporting Information [Line Items]                  
Concentration risk, percentage           10.00%   10.00% 10.00%
Geographic Concentration Risk [Member] | Revenue [Member] | China [Member]                  
Segment Reporting Information [Line Items]                  
Concentration risk, percentage           4.00%      
Geographic Concentration Risk [Member] | Revenue [Member] | Japan [Member]                  
Segment Reporting Information [Line Items]                  
Concentration risk, percentage               6.00% 8.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest U.S. Wholesaler Customers [Member]                  
Segment Reporting Information [Line Items]                  
Concentration risk, percentage           34.00%   42.00%  
XML 163 R134.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 29, 2024
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]            
Revenues:       $ 63,627 $ 59,553 $ 101,175
Earnings [1],[2],[3]       8,023 1,058 34,729
Depreciation and amortization [4]       7,013 6,290 5,064
Write-offs [5]       0 6,199 1,183
Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring       2,200 2,200 1,400
Net periodic benefit, actuarial valuation and other pension and postretirement plan, gain (loss)       $ (579)    
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Immediate Recognition of Actuarial Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]       Other income/(deductions)—net    
Charge related to expected sale of facilities   $ 420        
Certain legal matters, net [6]       $ 567 474 230
Net (gains)/losses recognized during the period on equity securities [7]       (1,008) [8] (1,590) [8] 1,273
Certain asset impairments [9]       3,295 3,024 421
Selling, informational and administrative expenses [Member]            
Segment Reporting Information [Line Items]            
Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring         290 562
Paxlovid, EUA-Labeled [Member]            
Segment Reporting Information [Line Items]            
Reversal of revenue         3,500  
Favorable adjustment for government emergency use authorization inventory returned to the company during the period     $ 771 771    
ViiV [Member]            
Segment Reporting Information [Line Items]            
Dividend income       272 265 314
Haleon [Member]            
Segment Reporting Information [Line Items]            
Net gain on sale of equity method investment       825    
Gain on sale of equity method investment       945    
Equity method, adjusted income $ 120          
Other Business Activities [Member]            
Segment Reporting Information [Line Items]            
Revenues: [10]       1,228 1,316 1,349
Earnings [1],[10]       (7,382) (4,342) (5,162)
Depreciation and amortization [4],[10]       340 323 332
Write-offs         6,200 1,200
Adjustment to cost of sales           1,700
Other Business Activities [Member] | Reclassification, Other            
Segment Reporting Information [Line Items]            
Earnings         14,700 9,200
Depreciation and amortization         331 294
Other Business Activities [Member] | Paxlovid [Member]            
Segment Reporting Information [Line Items]            
Charges to cost of sales related to raw materials           500
Reconciling Items [Member] | Amortization of Intangible Assets [Member]            
Segment Reporting Information [Line Items]            
Earnings [1]       (5,286) (4,733) (3,609)
Depreciation and amortization [4]       5,286 4,733 3,609
Reconciling Items [Member] | Acquisition-Related Items [Member]            
Segment Reporting Information [Line Items]            
Earnings [1]       (1,938) (1,874) (832)
Depreciation and amortization [4]       12 (11) (20)
Reconciling Items [Member] | Certain Significant Items [Member]            
Segment Reporting Information [Line Items]            
Earnings [1],[11]       (5,510) (3,917) (3,608)
Depreciation and amortization [4],[11]       14 32 36
Biopharma [Member]            
Segment Reporting Information [Line Items]            
Revenues:       62,400 58,237 99,826
Earnings       28,139 15,923 47,939
Biopharma [Member] | Paxlovid, EUA-Labeled [Member]            
Segment Reporting Information [Line Items]            
Reversal of revenue         3,500  
Favorable adjustment for government emergency use authorization inventory returned to the company during the period     $ 771 771    
Biopharma [Member] | ViiV [Member]            
Segment Reporting Information [Line Items]            
Dividend income       272 265 314
Biopharma [Member] | Operating Segments [Member]            
Segment Reporting Information [Line Items]            
Revenues: [12]       62,400 58,237 99,826
Earnings [1],[12]       28,139 15,923 47,939
Depreciation and amortization [4],[12]       $ 1,360 $ 1,213 $ 1,107
[1] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
[2] 2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.
[3] 2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
[4] Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $331 million and $294 million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
[5] See Note 17A.
[6] 2024 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
[7]
(c)2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see Note 2C). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas.
[8] Reported in Other (income)/deductions––net. See Note 4.
[9] The amount for 2024 represents intangible asset impairment charges, and includes $2.9 billion recorded in the fourth quarter associated with our Biopharma segment, due to changes in development plans and updated long-range commercial forecasts, composed of: (i) $1.0 billion for B7H4V (felmetatug vedotin), a Phase 1 IPR&D asset, (ii) $475 million for Medrol, a finite-lived brand, (iii) $435 million for Zavzpret nasal spray developed technology rights, (iv) $400 million and $200 million for Tukysa and disitamab vedotin, respectively, IPR&D assets reflecting emerging competition, as well as (v) other developed technology rights, IPR&D impairments and a finite-lived licensing agreement totaling $436 million which also includes de-prioritization of certain assets. 2024 also includes a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The amount for 2023 primarily represented intangible asset impairment charges of $3.0 billion, of which $2.9 billion was associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: (i) $1.4 billion for etrasimod (Velsipity) IPR&D, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 developed technology rights due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) $486 million for various other IPR&D assets and developed technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also included $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset impairment charges associated with our Biopharma segment of $200 million for an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million
associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics.
[10] Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.
[11] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in 2024 include, among other items: (i) intangible asset impairment charges of $3.3 billion recorded in Other (income)/deductions––net, (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs), (iii) actuarial valuation and other postretirement plan losses of $579 million recorded in Other (income)/deductions––net, (iv) charges for certain legal matters of $567 million recorded in Other (income)/deductions––net, and (v) a charge in Other (income)/deductions––net of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program, partially offset by (vi) net gains on equity securities of $1.0 billion and (vii) net gains of $825 million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945 million less (b) $120 million in the fourth quarter (included in Other business activities) representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares. Earnings in 2023 included, among other items: (i) intangible asset impairment charges of $3.0 billion recorded in Other (income)/deductions––net and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion ($290 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in Other (income)/deductions––net. Earnings in 2022 included, among other items: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.4 billion ($562 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs) and (ii) net losses on equity securities of $1.3 billion recorded in Other (income)/deductions––net. See Notes 3 and 4
[12] Biopharma’s revenues and earnings in 2024 reflect a non-cash favorable product return adjustment of $771 million recorded in the first quarter of 2024 and in 2023 reflected a non-cash revenue reversal of $3.5 billion (see Note 17C). In 2023, Biopharma earnings included approximately $6.2 billion of inventory write-offs and related charges to Cost of sales mainly due to lower-than-expected demand for our COVID-19 products. In 2022, Biopharma earnings included COVID-19-related charges of approximately $1.7 billion to Cost of sales, composed of (i) inventory write-offs of approximately $1.2 billion related to COVID-19
products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for Paxlovid. Biopharma’s earnings also include dividend income from our investment in ViiV of $272 million in 2024, $265 million in 2023 and $314 million in 2022.
XML 164 R135.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Total revenues $ 63,627 $ 59,553 $ 101,175
Cost of sales [1],[2] 17,851 24,954 34,344
Selling, informational and administrative expenses [1] 14,730 14,771 13,677
Research and development expenses [1] 10,822 10,679 11,428
Acquired in-process research and development expenses 108 194 953
Other (income)/deductions––net 4,388 222 1,062
Income from continuing operations before provision/(benefit) for taxes on income [3],[4],[5] 8,023 1,058 34,729
Biopharma [Member]      
Segment Reporting Information [Line Items]      
Total revenues 62,400 58,237 99,826
Cost of sales 14,997 22,666 32,859
Selling, informational and administrative expenses 10,040 10,235 9,207
Research and development expenses 9,532 9,763 10,324
Acquired in-process research and development expenses 108 194 181
Other (income)/deductions––net (416) (543) (685)
Income from continuing operations before provision/(benefit) for taxes on income 28,139 15,923 47,939
Biopharma [Member] | Primary Care [Member]      
Segment Reporting Information [Line Items]      
Total revenues 30,135 30,799 73,181
Biopharma [Member] | Comirnaty [Member] | Primary Care [Member]      
Segment Reporting Information [Line Items]      
Total revenues 5,353 11,220 37,809
Biopharma [Member] | Paxlovid [Member] | Primary Care [Member]      
Segment Reporting Information [Line Items]      
Total revenues [6] 5,716 1,279 18,933
Biopharma [Member] | Excluding Comirnaty and Paxlovid [Member] | Primary Care [Member]      
Segment Reporting Information [Line Items]      
Total revenues $ 51,331 $ 45,738 $ 43,084
[1] Exclusive of amortization of intangible assets.
[2] See Note 17A.
[3] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.
[4] 2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.
[5] 2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
[6] 2024 includes (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.
XML 165 R136.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information - Revenues by Geographic Area (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues: $ 63,627 $ 59,553 $ 101,175
United States [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues: 38,691 28,145 43,317
Developed Markets [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues: 16,057 20,910 40,534
Emerging Markets [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues: $ 8,879 $ 10,498 $ 17,324
XML 166 R137.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details) - Revenue [Member] - Customer Concentration Risk [Member]
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
McKesson, Inc. [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 23.00% 16.00% 8.00%
Cencora, Inc. [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 17.00% 12.00% 5.00%
Cardinal Health, Inc. [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 14.00% 10.00% 4.00%
US Government [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 6.00% 0.00% 23.00%
XML 167 R138.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information - Revenues by Product (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue from External Customer [Line Items]      
Revenues: $ 63,627 $ 59,553 $ 101,175
Alliance revenues 8,388 7,582 8,537
Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 62,400 58,237 99,826
Biopharma [Member] | U.S. Commercial Division      
Revenue from External Customer [Line Items]      
Revenues: 26,765 19,299 34,337
Biopharma [Member] | Oncology Division      
Revenue from External Customer [Line Items]      
Revenues: 11,567 8,450 8,583
Biopharma [Member] | International Commercial Division      
Revenue from External Customer [Line Items]      
Revenues: 24,068 30,488 56,905
Pfizer CentreOne [Member]      
Revenue from External Customer [Line Items]      
Revenues: [1] 1,146 1,272 1,342
Pfizer Ignite [Member]      
Revenue from External Customer [Line Items]      
Revenues: 82 44 7
Total Alliance revenues [Member]      
Revenue from External Customer [Line Items]      
Alliance revenues 8,388 7,582 8,537
Royalty [Member]      
Revenue from External Customer [Line Items]      
Revenues [2] 1,423 1,058 845
Primary Care [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 30,135 30,799 73,181
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [3] 7,366 6,747 6,480
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 6,411 6,501 6,342
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [4] 5,716 1,279 18,933
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 5,353 11,220 37,809
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,263 928 213
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 755 890 0
Primary Care [Member] | Premarin Family [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 380 397 455
Primary Care [Member] | BMP2 [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 352 338 277
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 280 268 200
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 2,259 2,233 2,473
Specialty Care [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 16,652 14,988 13,851
Specialty Care [Member] | Vyndaqel Family [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 5,451 3,321 2,447
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,168 1,703 1,796
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 690 830 1,003
Specialty Care [Member] | Sulperazon [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 637 757 786
Specialty Care [Member] | Zavicefta [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 586 511 412
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [5] 509 245 186
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 509 490 532
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 480 406 331
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 470 539 360
Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 381 424 425
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 215 128 27
Specialty Care [Member] | Oxbryta [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [6] 201 328 73
Specialty Care [Member] | All other Hospital [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [7] 4,448 4,514 4,730
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 907 792 743
Oncology [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 15,612 12,450 12,794
Oncology [Member] | Ibrance [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 4,367 4,753 5,120
Oncology [Member] | Xtandi [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [8] 2,039 1,659 1,650
Oncology [Member] | Padcev [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,588 53 0
Oncology [Member] | Adcetris [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,089 56 0
Oncology [Member] | Oncology Biosimilars [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [9] 1,037 1,407 1,753
Oncology [Member] | Inlyta [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 978 1,036 1,003
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 731 539 343
Oncology [Member] | Bosulif [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 645 645 575
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [10] 607 477 456
Oncology [Member] | Tukysa [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 480 18 0
Oncology [Member] | Elrexfio [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 133 10 0
Oncology [Member] | Tivdak [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 131 4 0
Oncology [Member] | Talzenna [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 117 64 48
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: $ 1,670 $ 1,729 $ 1,846
[1] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
[2] See Note 1A.
[3] Reflects Alliance revenues and product revenues.
[4] 2024 includes (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.
[5] 2024 includes $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.
[6] In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of expanded access programs worldwide, based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing.
[7] Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.
[8] Primarily reflects Alliance revenues and royalty revenues.
[9] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.
[10]
(h)Erbitux is a registered trademark of ImClone LLC.
XML 168 R139.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment, Geographic and Other Revenue Information - Revenues by Product - Footnotes (Details)
treatmentCourse in Millions, $ in Millions
2 Months Ended 3 Months Ended 12 Months Ended
Feb. 29, 2024
treatmentCourse
Sep. 29, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
treatmentCourse
Dec. 31, 2022
USD ($)
Revenue from External Customer [Line Items]            
Total revenues       $ 63,627 $ 59,553 $ 101,175
Paxlovid, EUA-Labeled [Member]            
Revenue from External Customer [Line Items]            
Reversal of revenue         $ 3,500  
Estimated government emergency use authorization inventory to be returned to company, number of treatment courses | treatmentCourse         6.5  
Favorable adjustment for government emergency use authorization inventory returned to the company during the period     $ 771 771    
Government emergency use authorization inventory returned to the company during the period, number of treatment courses | treatmentCourse 5.1          
Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member]            
Revenue from External Customer [Line Items]            
Revenues   $ 442   442    
Biopharma [Member]            
Revenue from External Customer [Line Items]            
Total revenues       62,400 $ 58,237 99,826
Biopharma [Member] | Specialty Care [Member]            
Revenue from External Customer [Line Items]            
Total revenues       16,652 14,988 13,851
Biopharma [Member] | Paxlovid, EUA-Labeled [Member]            
Revenue from External Customer [Line Items]            
Reversal of revenue         3,500  
Favorable adjustment for government emergency use authorization inventory returned to the company during the period     $ 771 771    
Biopharma [Member] | Octagam [Member] | Specialty Care [Member]            
Revenue from External Customer [Line Items]            
Total revenues [1]       509 $ 245 $ 186
Biopharma [Member] | Octagam [Member] | Specialty Care [Member] | Commercialization Partner            
Revenue from External Customer [Line Items]            
Total revenues       $ 129    
[1] 2024 includes $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.
EXCEL 169 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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

A;Q!N'O;V5X@.5NIDLB;$^A M:HEZDU6*;F N,\O)LR-WA=\]9>IXIA*6>]/H!X&[OAWA"PJ^N[2MU/UNR3CS M="T^:YQY,SO3><-&5++M&M;=C\8C; \J]@U9[:YUPQ(^#9CSG+EPYM(%YG*R MG58J+QGW)CIG(YR-<#;21392JE4;"SX26L$I?$0#G41*%I24;GW/*9I3]%NF M:!8$O?5J'!'U43>^.\1.V+4LGY-)P(.1%R(JP8R13EM-&[G-XXO5T7O94+^3$@N*R0'RC4 M$['$L&M.;)S8ND9L+&BMJ6@9,*]-[LIWMV^BL6C'IA=!RY[P*Y.>:S(")"C./6'8@+(%[$E\(7"%8 M$)\(:S NYK"!KB^\N)NE)4R)8*_@G D^'G_G;CQA;CNF,\,/_ "^PMY._E$3 M(_H'RU>CMRG>V^GW?V]P[M=C,D>;KNS@B(XI)5L,??=,1!-00WC_6"K^/SX_ M?$>4?(<;_;9T9S]BT FF^WMH.W0YZT?M#Q"%;.8(Z?5[X]?L7VPH6M^)H-(0S M0OX2Y?)'3XZ^'L)7-\G/%6THBDKJ5Z.A6/)S52EWIZQ%B>/A2)3YH@HL2AE* MDG[R5JGE'9*8H:V(![RX;&T'2W%:C#U^7Q"0:L$-@:\@7!5C6 M#)5/E+'NG'Z$C#+ZYV:GBPKOGL#\\W^YV;+5A1D('D&UE?)8$C*E?>%('QCR M;+G!C8F^'*Q(L' MP7:>B1]0SMH7%B!Z!;@5/M@C]-%P@06WO3T0F\7J;Y#3 M9!Q.WIBW:C= U:/P'2T; ME8X=V"B9;U2QC9(JC28+ :H2^:B2S<')"$ASW'/>, M0P&C8]S[L&CX6[T$@ GR?4F3*P4 :O7O%S;&Z>W5O>8; W92$ZZS74DQ4'PB MOG\KL-"2<==3?GNN^=^)5H/MT,2^Q1),*M&?A T'^Z*4[/):6B-[XSV@VJ&) MG \($0&AJ"^>_M+5SE]M]TYEQX9BLG0? MTCDI@0-[N3P1"NJ,(VM:W)'%2W*:=X5U,%^JV(:+* MFL+8L[0/[]$M@DQ)3BX\"=9@90PU%?6&@YF[;N"X 0G/S1EH.IYT^-DW%]]A M$03KVYN;EY>7X<^IMQRZWM.--!K)-QY\?;/]+9L7UPJ]=OP0I.&8VJ#?J.%& M,,M/8*CO[194,E?Z"QB3GO#.=F;NBOQR8Q%K0\'/,C>BR&;5.)&WZM8X)&A\ M$X;"(R%YN)C/ZW[YD%T TW0]FOEZ"T8 \4*R_-5LVY*$A8>BY+]L795%HBD: MF4Y519[+T[DNZN)X/!=5S9+&YO]*. WC,W(1,+Y,EO96P>/="9,81[M6]KWW M]5R4X:8*#Z.J\'AP,&<[9-_.22>?Z1'!G<)[/-,*CK5GSX@P6YC.$WR9ZN5[ ML8.%N\&L<=."#0&M*"#>RG;H]7/3]H1G;/+A#X4['Y//X[G& B:A]M$U"(]] MP3^BHDDX+L%>K>%JFE!.Y[!;[HOS8GJ68%K_VD29YGC#O[#J6G*LJOTS?+-O MX8M]B+W7KG7)PVZ-J,7=.=:':)%?<>/N=@N]W[W6W1Q4J$3 M &=+?"_/I@3XMN\\%/8[[/=C$$C?"@HA@+QP M7/_EKDG(@'TD@1!UF-=+;Q3FK<9YV_%\^Y1Z.=Q3V]F8H0LLQ@4CTE;%H88> M_20;VM4L_?=A."!2RD?[2\PI:-^;('E)R)PFOTZ]F\GA4ND?G:B^DHTAB#LV ME4#:4!EK3&X%JQH;Z5^=+"K*+#D!.P[U9A =AFR=#!NEFDZG4S 40RNAPAB% MG,Y?Y_!;3P"1,2R0+!&]+95=*:];>3.*QM *5]"^*\!$,=T$<#?Y6 M-D;4^)XU"")-RRHC.JI,COV)IXIRH8!"C)DAT54+;Z]^/I'!%-20'P,3^XS= MFLL7\]5'DHT7KP)WBY8ZUFC,-8L?QW86)8P]?^WE\%T&&J,H%MI?M 9H@=X] MB#3TT&"?">'CKLKY<5?EG%CF;B,..+W<;*0YQF2H"'[<3'W;LDWO%=X()+Z3 MJ'_.H?ENB#QI*,EL1![K6YTNR8U$WI&*$V(FSN.,LK4].R=[)F\X4K6VFJ.L MR@,YU&SA*V+=!;N/EL'@.VC7PF^NY]&J MWBI- +9Z_.-L0:S-DGR9TSOCC;$W0$JYOZ07+_=OG-8,8ZB-I+*DILE#51HS MJU@O=Z=,/74TU)73RN6%%B65UWB3-=*I9?0I48/V1;Q"TD/#5ICN2 \L1>HU M85.QGA5:9'J/5/Y;ZCS:4DN:]!65.05>D5ZRH/9ZBM*KT5GKMZM@:7JC%=?Q MCA8-OC08"*#_4#-G#2J+UT_=TISZ4\>=2;:'VC8L9E.XI/ M"SNGF],=-IX'NEN\&=K2=9Y"T\\BTR!;F6A=Q6B=NU?O>)!/L.5!Y(Z*3F0_ M(^3W;7^YSR38!9CW467_&^U.9WUW_R#64]C:\NO&FRU J[J;S?#$X,/RY";V M)G)?4VL=.5*GH*M&V1&&+E/IV#SYLVKUW48 2ZBI22D /HFG;.;.,:=XT391\"1I9G5D39OYUO3<_DFL MP7^(YZ;2F!95]4GONRH4N+[>(%L_%YDI"-1[DY)N_Y9R\$:9]P;.))HT*UBV M3W>8:NMD96]640T9')9@^_[&=+"NS?5C"=)M8]9M[PB9XQ\YI(N_[P_G0W0V M7\.#P:(Y_&ET*#@DV(?C3"4,;,C*NT&VL2M@@5E]C,&@8'=02>0- R_8,#!T MD]2A%95*K,](X.U'&;RHK\_R K^-JW9]869ZGDUH<\2%[0>NA\?_!5AEO<0D0A4I+NST4D7KIE&1WV(X89)=NN\1[#_)6 M:!<+9IU%^1)U>,IETQHN37!OO<^9/NIFGS,T/,(V.0$=KKKQ@H7P[XWI@9Z( M.F/8,\07UO#)=K!J-%L:E$P -^TV8L[^O;'#3<4?/1+SB3C".Y\WR:JO21;\ M*VJ2)=U=I$O6+T,!!_*&OR'6P 32@7,70/Z36=C0"(N&B!\(\)H$FRG-CBI9 M #R!'Y@.M5A>4/U?@S7PT\9N-LM7(9,I R.=8HKQ(5^6=3G.F)73-OE#M+AO M\*S?MTO^"JN#[^ U=LQY(,6XL]R;*$,CV1+ZOQO7RVKI2GCRB69Z-ROJ9BQ] M4DK=)Z7T)NI03H8-_UM(?P]YN-O1M]7U+4V8B=T49E\] )2'/=FB2F9?F)G^ M0J E^H A<\D;-]8JDR1YV[A1^]B^SHVENIK%FD T[&,\U0%$2>\ HJ;5CT== MWUZ(L# M#-D3GW;0,>$/]&*6;:,GZX=VCW',M3_!JWR9WWO$LH./YLQ>VL'K MGR9(\\T^H^_>7,,WP>N.:1LQGHTMGI-Q0&$:M0.T0P7"INVA_CY\' H>>7:7 MS]3=29\JS,/'VL3OX^I]VZ?#5^!5X?!*ONVXYK<=]R;)T:N[EXW>Y!4[^X5S M:.#UO\P"%T\73E8%]7HS]!ML,X36_ M]*FT-LMNA5;S5FB]25)2%]X* T"^L&<+^/Y5F!)AX\,FH&D"1@@R?7@=;^U2 M'72]@;]AV\^]HQPHPM^LT4U.39FGI3NEEQQIJGLO^U!X< 04/W3CX'*TB?+A MB#=?$F2J/A#D,[8:=9]M[%&ZP5#M[H[PQ)*GHY]V1U0ZG;A+0N]-)"WIBMRU MZ8330"Y&&5#XXGW\:W@F;-Z%UJ# ,]R"[_%A0[Z[O_]XU5#XW?>!]@ B0'[PQ_$FA,TY-PZ% M8X;R/$P*(>$P]%&F29R\:Q)W0H2HZ2)DW,4F4A^& E8FA3VD/L2"6F=UCSJT M/OR4_E'JJ&#_*/T"_:,J]FK3I*$V,ICU:CK=7ZUPKR9Q**EE'][(HMK90*K9 M#-+OU&6X7%+6B[Z%+S>ID3->?NN1@Z-M^_B[;MX^ZX\$#%LWU5#7^@ZWCCL6VQM M2&2SEW:4'PRZD],.]#8_#>]+Q7;&$1#?@H7F6C2IVOLN&MQ>HX"]Y: M[%C*G4.$!5*L5#FK\]$5-AJ[H+8S+J_M&")[;4\W22ZL@O63V8@-CK\-D!>B1E"B]4H7]2C&*.DQ6)Z9X%;@8J\1&Y'/82))3 MC$>]B:%S.<7E5"I3J%E.C<7>1.R/I*0;DLNI4G)*KR"G5.;!HWR3TPN[\_3ID=S:776Y5>I1IRG(L_-0M_7'J5DEY&!>FE ML1<;XPK22V>_# U]A&E-D[GTJEMZ:4UR#QUUWSH%+KQ/XR\GA9XL_(PM_ M7'J5D5[RJ(+T8I_/HXU*2R]X-_;+H&E%W/:ZA/1J,GRN2:C[ILU=X=+K;4JO M(VY2-_[D+/QQZ55*>HD#^*-\2JHR8I^DH95/TE!&[),T-!7=A]P :UZ$'8&J M;A9"DS2X <9%6 8WJ1M_6A;^N @K)<+&(,*4\E:8,F*?J:'I%408^S0,S<"^ M1\D&55R$U2_"FHR?ZYB]T5?EM)/F(NQMBK"S$H3*XD^D^$MIF\%%6!D1IJ 5 MIE2QPM@G<>CEDSB4$?LD#ITF<22!Q458_2*LR20.74$M6-&X".,B+)6IU8T_ M.@I3'25SEKD(*R7"T I3JUAA[#,Y]/*9',J(?2:'KO%JKTN)L"8CZ3H8_0IW M)'(1EL74ZL:?D84_+L+*B# 5K;"Q7$&$L4_G,"JD1$F M-AE.-\*!,R->L3K+H)M,5#*QVTOJBDF90=H)%MZ9S5!JNNP9?!@Q>;#+;P4 _VZAO MZ,DV!E?8<*DY^X7@? ';$Y[-)1@QX>!L+FS*B:KS?> M;&'Z!&>!X$G"YWP6/%O^CW,*#HGG(QS1/_"$[O8']$=X*' F7Z,CN=N=2"H% MC7L3+<5/W1'NSQ7TIO@W"_B5Y>X:;>0@7TS_P=8M67[] A\ M5.')RMZL?,JS4:L7;-_?F,Z,P)OZ@<]Y]KXI>8U*^]_WI_,A.IROX<\E %1E81#*268#1S07Z\GG:I9<*B92VXG MSL!22#9(+O^KKC/[=%?-#,PJ&T=#!<+"]@/7PS7B5#"@> OD ([#I4*;6!59 M_AEF>?NZ)]??V[Q%/94;<%'AX"R%4N>4,DHKF^J$>5)B MR,1%>YJWCR29-31O$>4UX%UC17EB;S(6^ZJ#.SQ'NPCO'#;83J^&*J?M,RF.'X(T'*NX[5]PHOR! MWBG8_G;H_?)5\(A%R(K.GIZ^TBGS 2ALKT)@KPC^_=FD87WZN]6:4M :]%3B M"^LE_GHV\S:HD(*.MW'6IKV?/#O< 3FVG=>*G>E)[,C=Q,XW,EN:OF_/[3!/ M .<-S_+,FI/'?G,P;;W",/F*$H+>IN@P^=YDZZ;?S>)K6"][<(0_S5=J-/6% M%T)C>\3JPP& /O:TH,.S7Q8NT._ ?7'@<.:V0V-__F;JVY8---L7OC[\WA?^ M4D;\2=)A:9UQ.MKQT9R1H]$11DS,X3"K9#J",+67RXB+'"0A(I(2 \$=FG]/ M69( JB>9(44>S;:&ZTK;P0=5\,KIUXR;P+]OU_"5>#@O%RSD=*MXC.7)1C*( M\]]HU*]-C[XNTE-X(@S%'".>K0='ERV0>8= M%]_9)X OXDNOH8G1QP ]> M !'PJV>2_3,7'H'/ 1B8!ZE+^.AMY!ON9JULQX:#"]>&-_?(VGS%8]PN/]I# MQZ)B+KPQ%8MT?^ %X%MX$(C)0%@!$5+: \B%I[4)8 ^'1WX,.&,$F.ULS-". M0[:&4+!U518)F'ID.E45>2Y/Y[JHB^/Q7%0U2QJ;_RM)1F][GZ/;;,$DJS(J MHM%7Q+H+=A]KO0HL5#&T>=TL-)3A0&)N>!2W8$42+Y25OP^%#_"09RI=A8\A M_H$-["DN/)XH T6X0X*CYW*X[)FGRT?7@GX[P^\\9 /B)"-]L M_P<5+>+[Z#^-2Y@[P8 V<0'HA#T /Y3+89 MA#:E?OIJYGQN+VT3*0MX"_D)6E1(G^$;'_R6;+W1.-^A MT3Y"X_;.H?XS>PUU'>3*?M9E<#)P2]B$%:#W"445Y5:K-<@"Y,WA?LY<5+3A M(;#M_F9)^91'5L3$%Z2,"\0=\$4G?/7M\_O((LTG$Q]X<%_@FY^,/9J#&FBDG @3KN,!!0^:*=PFEEC\L3GF-ALSAM7,/#PX? M%@E/I&FNA$J6$$X[%&VY.]EX;A]VZV]#H C@6'WA?@$/A0.&+8=]F=I]X?^9 M\';XT2MQX'N 'JA;3K2[%"F/+\2R_87PPP.)'$JXR&]_*$NW>)V9U,%_\C"H MQ@-(6:/,0AJ$8_5>!1\4#S]\+U $UHBU7P\T[(3BDZ+K;/ ! I>7-@,@-:Q=@^D3:@(]0GY@6M;>R![ :-; MV,+V^S9:GB H\'1W!P%"&_:))%E.;-MPKZ8;'R\#C@.R$25$(L01!I>LINI/AZXW\NO+WK#N34U"/F MCX$YAS.]-9_/E,8 /J)0JJ"S)S2I+<6N?JBD[5Q&\$2H6IPRL-.KM MAO"2AI+,1GBQOI521'@=*2LA9N+;<$1?F7 MQGT$?=#+U\1!U*"Y2IUG)OJ_MH6":.4?^3$/C"_AW;')%>K6P$ 7]OJ7(8KD M3&.4 @TMD=#(AX]#$\K9^HOGGKL*78^^#S; UL<7/G+G+*;F0>@(G+E/#KQ] M:.K]W&92A3?;N@7"VV,*?^1"7(/18LX6<D<=->J<,]&&.\KC?YZS9225%P>(C4C*2'BP0"-.^>@E'H MU<4CL@@ZOZC\QM/:/EA_21!#Y_@]7'7ESS"#P[.DF%+61NSMVYP-4 M6=0W,_V%, =VN26^B%>'@6?TUZ*0";FT'[HS=[09>8M\ME8<\6<<*).3;1;TUP<7O6SJGH;"KZ9]=(YS 6\_'8TQ_WI\NV!-!H5TR@EV.K'O1V=N8A*1\&('(:O>L_A]5 MC7*#SH"0AK[$,ME"-VH;B M8@+'_!'I66OJJ"=[BMXZ[L/[FFB7S)<@",*<";QF:B[#A)H% 71A(!.12KSM MYW215'C@/3 JL[OYRGVF?J!37OZ%QX%G--A;A"&?S'=(&;&PN;_@"/=)CQ:,OKF]W#$Y=Q,@ Z*WH!R3>@WV2YJ^"M0K%BX55I$;E5S:/X[SF/P7 MQ=2H4#FR0F)7@AW0UMW\2Z_"9/HTB4W0[Z('# M;$^;VAIT16FO2C.#\$91]+Y2##86D [O-M@]KT2H^7VM='02I/\\9G7IIJ!S M=,3GV:*T(.R%+)?XWR,#,H-A1BB@61 YMN31QI\*(XO'0>3'&=QHLR1?YOMP M\B< DKVD4=F[?8>9[_CT[W"KWY;N[,<^D(SM3(D_,]?H;/8VI,=@!7N'Q[*9TIZH)YYX@8"P80RUD536I:Z,AF,CW=^=Y0?/_EQ5QDP\ZMI0 M5U6^)KZF*U^37B'C(1$BBGB$>+*LNWT%;-^IY8NN=91X_F:%.L5_B)^B_01% MM!*:T^B&B=-;4_3V()6B7 9)._9R3"/L^;OY[L^'3Y\>OGQ^3/05JO2FJ=VA M1#4#>FD!2O:[627]Y#S@IJ<.W-'$M0]D1K :09#%/BV,+YN'TMW=/]1-I,.; MU'D>&>V M2N0G5 ^59IQ0P3YOC=)<*W8Q,VV-*CB-H[S%>T(= ^6TGOKIN<7[M77EO+Y- M$&6.AGK#A)6E6''"*K-?Z83%MI-I+6]5,LBT=XL>1Y-3 HFW#"GJS%DC56_/ ME]!SJTRE (\M3=11LGVA1QU''7GHBY/,1CW)H8X[O*DR/:Y MUA[2T]#/I-QJA;PIK7E:O$-CM8SU (=]-&D5L!1 MR%'('(5Y:@).294Z.T^0C^IEKH#J#4EC:90EC5MB'?$3+R[1)!$D6LKL;7Z4 M+3W*'+$@2;V)9#1,FLVF)->5U7.NOE(B':\=N&6ASA@U!QXEF08>QYU5NLLE M:;9=)^<8+\R;RP(=0QW]-%',@7ZVS&#QLQAU=(T(&"@HH/2?KVNJO8FJE/1L MMP]6' @-<,,Q%?NC=H&E:$_JZU)]K^?Z:_S9=1?+%.J\UT3!#+^^#6"_)@IK M36P\O^R$UW*\U71726PJJ*#U)M*X+\L\HL6CJPW ]825J@,2U<[Z&SD,NP3# MO&B. 5B4>'D;3XCMH*-(:DAUD$?(L/OC4;*8AD>Q6WKDV>)7QH0$E24P^ZH,IWEN\%&[ 5:2;5#H_KN!H4ZD15^ MTS,1W+(',+MI:Q1K1LZZ<;M45&I.UI)ILI::4KS6$8.U+".LV[O"B9T3 M>^W$?DZ>ADRSUN0QI_B2%,]*3;CD?:IHCZW@)^6\%(J*,13N',SOV\SA-S;;>Y=.YVY"C.B,99KGC-S/0#.B_S&4[9 M]5[I-&)?>#%]X2_E7,GR 67I; -!1HRXM-Y$'6:1%M#LDDZP3A]&1*=AE7PQ MI:D7TWL399@5WCK]8O)^KF4,][NMH%YD?"LH:C<&EE M!DC*QE!59"8C\41MJ(PU)K>"58V-]*].C]=+\TJ+5$0%R$" &QJR==*'G"J< M5K9E+3,9K&)H\^(,UBAD7G^=PV\]X<&9#8N[DBD[3GG=RIN1IA/N]J+*1+?S MMBI=LZ(<\R-P,4$<#?Y6=I!;XWO6((@T(VN,VJ%Z%?]SX>TUK2P?U7TW8^N;[_X.RHZLM\1VI?B46-AU<3DX'3Y+@?@9] M-U"L#,?B:;P4_UQ5RMTI:U'Z4-=.*V!\37Q-W5^35-L,[Q176/O#O3AQ NJNUZFL6FT-;9?+T.9M9 MPE"$79P-[)^#!1A,Q+E%D:^,"OQ&;-25C^;*7T-2^!22 OWH&YFY3P['#UTQ690829+Y5 M'%4<51Q5[=FJ@J@J[B4I^;;5&P<=IF8UWDMH'WR(!?)B<0BTK>Y-?R%\7+HO MPA_4?_6-:J:NXR_L=APZ'#H<.APZ M=4&GG$T?%@:,VA@IR1N;QSL"EGZO5I*T+HG2>X;.2=Y4JCU5/.U!7Q8**/I: MTM^'\ZA+HX1%_[V<6JXOP8)XF*/ID05Q?)HJ-W-7!(,Z:)VB<4IMTVW:W&\$ MTRGV<9X9-5CO'.N[^?.PFF-N_R36X#_$<]/*OQ0IQFV[63#-V>]UL=]RA)4S MY)HQ8:40D-R;C/6V-H?CPN/2&&^C\#A&=XCYLI)#X9*#2PXN.8I050KUJ+U) MLHMR&V9BL@K^,"O"9S4SHO4I3M/B:7-OI/V(U'H366]X8CEG69=C6>4T=QTT=ZFS0Y$YOVH] MORH'1QS((Y><2MLQ4U*46Y!(&';*0OMRN;&BLAH!*(K,T,)SB.\+ ?$#K*#% MVAISY<)+AL5;@2L0TW/@J^X8HS-NC')C].H9/3=&KT:SVR=Z_QZQ:/RAZX"T M@!]Y!%C;!Q+^-Q2H=Q8VH*))X-FV@#H"6X K>]?, QI3]FI"*(XGTUH;@>8\ MK1F>%L/*27M!E3A#XPRM<896&)XXL$?3^'"^,M/K+O(SON@2/VO88=*5PLN/ MINT)_S"7&W+9RDL.V2M9-*]S>C-*^+MR:HYQK.;XL&SXV[&^;Z&0V':-XV<^"N^JLC;^ZJYT3#B::%1',U.C%^_\ V_]PJ&.1=+5JG*Y=<_YU/?RKG)&75.HK&'EE4:BE*_=9-AY74;B* MPDF]_YK[KV*W[L;_)7Z3D0*L^!X(OF.1!U MYD!\)@%\]$S"["B>!\$7S?,@]A24W]:#>VBY@<<-/.X5J36L(8O5LZ1!P._E M^UF-"52]-U&,9*D')_SK(?R2$0^I8,2C(8 :O8EL%$]XXQRLXQR,22?)\8AW MDGP+K.U,SM8>O(K9>&U1I@UON\';;ER#F./6[=5) F[=7HUN6$]3@['4FXBB MP=7!*V8"C:F#-4$4*]7EABO5.5-K&U,KVMA@K !<5-YX@W.T9CE:87QBD>*% M^D@>)9WPQAM\T3SII#(7^NPZ S:))YWQFEB_-"Y&>5(.7_1;3\J9;3R/.+-7 MP5^X7C (B+<2IJ[GN2]QGRMW87(7YO7I^MR%V2YK7TZWIM9S3]=,AR7KO,4VHT6F0;<8N06X_7R0VXQMDM54B^H=2>%BS;"V@ZN$%TQ M RA9VI&83W]4VG$IH(J]B90$*B_QN':.QD2'UB1N_+T%7G.\I "IW,>4N!$PXFFPT3#FRB_R5_E'/O4]2SB#4*8H M/L-S-=$F$+=*+ M6K)5[I/'.W)O&OT "W)&Z*\1?'=I6XEG9I)_TT9L.D/_2UF>RG1?6BCARM@* M.275>TMA/T[GP$&?:@F,NVR.LD0'.XE]%H.X-CZ0?MR9?.!JR/U\UT#.++=J MY*Y5,/ROD,JX&.9BF+$8+A4NQ\XVL7^5+Q9Q-JN!Y0:#:"6IM*X#K??%<;*K M!)?N7+ISZ=Y*Z5X_%TEA%-@W6A&Y4L"5 JX4M$\I.)% EZ1E?02T+'9V+/,5 M,&)#PU9Z"K: "&GWUS:2YR$*QO;VY>7EZ&/Z?>/#US?:W;%Y<*_3:\4.0AF.:5?KEX8/P?P6*;^&=34']RXU%K W%G!^% M QT2]!F*J-URZ6UN[0#V>E9::#6T;[T);$O87M]VA!;L0H'#:GR+<&M@6<%^ /\),X;=N>"NB1=VSVO!'@Z;WZ'[+X] :?>N'^!N/ +7]_M"RZ"U M79V/JVLWB(;"E_N''>N:Q66S$)+&S;LEB-Y?#CV^(*W4PJWDUL0T70R"_**%^+!;P7@YL(3J)&(SK^4 M2UW-B5"=4FKO37_Q<>F^%"T52]%B,X84"+"]2UP[O)(TDI1P,,T9KZF,+OJ: MUV_Z/"B/NHJTGJEG]W?XLY1(GU8>/!)GV&IXC2G_"XA9^Z]TIO(LO) M[(C=WK_8P2+B^0[<2Q E847O%NYMR-[;P-=KD?TG'XEH7)D_[=5F)2R)\Q0L M\.0#>T4$%WBR\+*P9PO$#*)I$2:P"^[&0PRY_@8^A W$C7TV82U3>VD'KXCU M^2; +Q/XG,&Q"W,X=]A[7S#7:\^%AP-HEZ]"!+?/FQ6\RBP-7UFA]6];>OK3 MA,?"$L2#,!SLS>S6VGA(-C'88';];DYH]-0)I2V?> M-R6&9R?%L-8U,6PHQ<1PDB_OV''!TU^9'A#-UB.#59U7@0?K)![TKN$A5,L^ M'73:VAH,?I+\]PV<(PZ)[''CA[8%ZC#VOF?\@M;$OJ=<,F0I%K!!SWM%5OIL M+C?P )-:'1_(C*RFP'5EL;]7BHX_E4-0EM2.B0#3@HB\7B= MCS,XX+Y M';VIWV$%ORW=V8_8!H!B3V!?UK 8> [I55YX7!EK8-UZ8MWT%*C7^,B1#2Q@ M::Y]O3@ M\%MQ"-K13?)S21F.1"GUJ]%0+/FYJI:[(FM1XF@H2WK[%J5I!E\4/SZVB])/ M+RJ]NL3("!*+!P&PX^A7^^*WJ+#.@1-2W0.L^Q4P/KC:!\UDM0G5-P&4-#2M M]B.MT(!!DVUYK-T(Z!]F#JF::% M-3,?4_G(8QI^[)(9[#?QFLQ^N4O7' MW8+F& SB4_M+A3>H\DHQIW*E'(J<< M2<&N)XQ:NQ2+_-=XEP07+IB%D#S.RV>=W>\9;C1]']CQ]L']U9MK,!^MARUK*[>&U\)4,XM86OU)-U^=;X2H:10?E*94IX M0_PDH[EI.7[">]6\R5_Q8W^3O^+'_B9_=4YGJE.%-:V(*]#;%,]%.W@V)E - M[)^#A6U9Q+G%(*XQ*O ;\3BE8B=3#_^3JZ=D[#GS,N'"I]B*&K\F"H2+[T@+ MC<92I<$9PQ6WV1*A";4UG5X/I*-9(T:XP3-"?HM M$W2-*D'+ M&@<\V^0EQ%OX,AZ\#.U;M/$ @CYP&.+!=?/=6%W;\0,[V-#D$WJ/;7\%[%%! M+XM5%*]=+Y@#HW.'13:HX:G!_[2#Q;;R=EMY%'@FT)\YF^U*[8G]C(SU8.OV M^_4"+[B ._M^8M/PEKNF%$^>"=L1[?&VPP?:74L@B8WG$[Q\NO'IK8;"@R,\ M$8=XYK*//_4(]J!PL O*OS>V1\M[_RI_I6_1M$MP*-Q1PXQV18I8$07_/ ?\4W.)L/=I MIP0+)"VEK)<%: [892YJN?*$36><4.R>0VL^[?ESL-(8V^5T5B,X)>QM'=*9 M=G\9C!YE"J>J8-%"H@M5<:C1UBP)/7I;>$QMK-B%VUK'_27F%(R/39"\)'SU M"6O M%FP5H?:C(5OETYA7MF4M,PV@#OY4MD&Y\SQH$D3[*JDT^='_$_UQX>T_( M$QE,/6+^&)AS.--;<_EBOOI(?'&#!/A4]-"Q1FL&LSAK;(_0!K?GK[T<#LI MLHABH9U"N49-D/MX[]A=!QQAWRXGSS+;.[2:-,YB[(+J6X^;J6];MNF]"M@: MTW1B)4&)E:=1;S>$ES249#;"B_6ME"+"ZTA9"3%S5FGU+B:02>4G'$XG/$LM M\#7L_22'CAEX&T1MU#::-GF.^69,WW>!@I&:J>6P-T3ZL;\+P.J\5CM7%>VV M;?NXP?OW@7O_??@XC.\P'!=Y%>#['R00YF" P"F:V!]WN<3_^OA+VHLOZF&S MWTAZ"I8P?:6+P_OVA7O3,2TS/*_PT[_E^LPBAH0(;!>RK5V_TR/'8;@# $Z/ M1"W,Z>&F>Q7 M%4'R)Q &'CXU*8$TX'K'C"S[QQ>0$E&OP]W,%"Q6I22)8%V9@!PO\88A9@?^ M9HTX@SLX\)R(I)![82-CD'?8H1;VFO73*>QGP7E).[VO*^SWD)FX(XBCT MY1$D&RJ2ZG#2E*PX$AY1NH6U0C$A?@D79Q7J*L"ATV@KYB)E3UXXL^J M+[M MGL:.MO01Z(.JD36M^@1MA>]>+W4][A2R;]'3[OP]Q95_5Q'H3V; M&F]GI5#92'L>'WCZ#QL)%G*W%HUXJ[W*T=XZ/"/4CZWO^_*7ZJ][MXM=[!P$ M#_L8!F;5+*GVD&R1JX^D9% ?/L1G''7.3=L*%;9BQGHKP@$[>U='[%7B"1(' MR0^G+,GP=,RH2WI&+_Y>W]7L/I&$%&YV1]I+#J^+Q[ MXF?7F>4\5$YKUYQI_#?(/,H9CN7UK MTO0*\97,UJ#9+48K]%IJ0]_=<([8"F3\=G18"X1Z"GMJ;*=NLT();>TCG.H[ M+873MC2E3)HMO(BUU\)O3,GMGC[*\+M,PF^S+\1 M6-XS\1.YKFMKQ0NBZ1JV7I]^.D6FETJ[V4V/]]5NU4.,8J5$QDM18 MI'RK+AIHKTY;,,SK>C\&MC-8>^Z,^&>W,);RNZ?D4ODU2R?<[@?G:[C99]*# MUIN,^^*HLVTZFA,_*?!L'PH;Y,HL4:CW)FI_K.OEN/);9[O?S!?_W&[\G6,]1MM^1 4I0#=Z$T-+QETYL^7,E@'@2K)= MS( 5^Z-1R5X&+66[S7"K(ZX&GE.9D(G&S4U]7.VC'< MR\:];)=5,2K1G43I3M2-+OG33C9C2GE^%U20DWC99T?1E.1(]Z"U$V&&)+$$ M<^H^D\ZH(]/BZDCATV;6:WETV-(KJZ-=:WAG$]V6R^S)F]%T=F19GO'*O8G4 M'X_ECNL[9X.EH3:4>7SBFM@!PUZ4G:'Z)O6L,ZA>Z4V4OCHNZ2>_)*V]]?:3 MQJB;[28 D!UL(8#$WT@DM6'($B2 MJ(M1 9]TQ[@/75$ _@; L[;-"K?D0/S QN!S&'@&XMBLUE%GAH/& 1Z\/G"R MJ!8^;&\12H:PD#]J;WQ6>^+,XKOW5=G]Q*:NF$E&GGEV[]48FC M;O&SK&5Z>S&]?NOUZB/ZL!L&71GVZL6BX6W#[6V_"-!2?K/=S]_);+'%K0 V MK8\LUYW;@>"OX3WH5_?NRL:&(,!0PQKQP(7= >(I50RN*/*!+:$?VQ)T)V. MN"]C3Q@Q>T+M3<1ATH<06A/3J S<3.\C0.F^Y'LI#;W7N#>1ALEV$D7>2R[: M64<])*].L/C/CP^>:;-&[ CD#VSUV:H\:3V'QH*?Z:L3S\R@]H&[3]> 1X]MSV5M3 >'9M;.+LAKW67<\&L,)-@,=@ MEPW0H%&QV?)PT*VC?NO1)J&!/]/=M(-RH$XM*-Q6I<%%#T"1*>E5P4;#V*.)MYYL;>37[#'B$I'&KK[C' M?8(?>"5A3WWV=82W4!P(QV6 MT7;TI$=@3V\5 J"2'5"01QT.,63A#&Q;BJ%][$_C MAGV(K*2D3$\C'\KFR8GE0Z7?&45-Q6,;9FLR\O^LV6Z2;/\9MS:7@CEC^]U0 MBK5GR(35H;X,2KH92#'-TGBG!D77"W=J&/240='N!X>[(IB5=$50^CVC3-MI MLXI2/6&Z'FSCCTD>W^6>719_F>_JI&ABQU8I[W/Y6L*\,LN7F(N\GC*F:VHW M<"VGX!OKK7!&Q<=^3J3)]/1W=#//PE"5Q\*;9>^GC5WG;3R5(,G,W;2/5TDM MZ]7/%[SY"8+9ELS6(=[$)]*I6D7IC(R,Z==ER^)$/6/:+*]_7'MN6V<./!&N ML&,%>Q9GW_SYI_/883T]LW!=@Q)5,ZGINH:65#,1<^XHXDV 96G9Q*&G.+38 M@.GS6'0]V/8;"T.'^R?%F55#9C6T='C]X,#I"[%-OL'2UU+D7<(.SG([JY[1 M7:H M%W#NYNHGV[)5._ZJZ?/LD,837NMX0KGX>,(B,P>&FYD#--20AAK24,.S;R7L4$-Q9HJ8O>-%)ZG: M ##7EX"DUZ^.Y8:/[O3]7RM[B4QY=(Z(,LB8(Z(,TG-$UK?O2OP!G(\VC^A* MGUF8-ESWZAPRAWSP9Q4L@SCXJEDO:.0O@E"%*((H,:YBH/0&PV(#'>H?#2&K M/:5?S$ZN?U'#GCX4;TW#X:"X$X#E/9DQ))JAT43-_58@+C<"D6T%HHL"L>'@ M1UVC-00(!!:)]@A6Y2)(]OX? 9NM'.D3CDZM=<=H7LIYJ451*\5RLHGXG/#F M7\SR@U\BX9%;A%S? !0:%T/C8HJ^[RICT8_?@-3\YF9F>'(*@R*B;;E9VE!IZ7KE 6B]7.+U+6M&'EK&9V M1JI^Z-RWD#T[A;C5/H!>W8__WQU?C-ZO:3%R9Z2GCLM2:>PYWS]+:NUJ0J MMSLI[B,T_;#R@8HKGW6E&6PU_!%UHN+-?4A]GZF^C9I4YA#<[J+J.]49 ML**UF-BEJJ>3 J]4@9N-2D^MC\-B=9G\;M+?,0('_681B,&[KFH6''IUZ^H; MSV6$_K8;.6^P5\&X^/,TMR!X+YN*OWGM,V@VZJLI.(+%5-,SI7% GB_9J@'?SM,/P#>.]QX<$+_X=_?I OB[,D)G &76W8VMFG M9((WK!0NAU6#8[6OB66L7^, ]-H.QM8S8%RT^^0T@W/-D&U%O?D%AIZ+7:E^ M0=_R,RLA6G'BS+"KFJTU ZJ$3OO&H+="2-0W"EUL67!!/[V4+#"Y+# S>A)7 M-AB]-C?^>%_-0BV'/GGN,[9.F#[R85CO7G]CV!UU.; \?Y.5,CKF.'C[Q!+F M^O5D+@GGB#]OY C.K+.HA0\UI#F\6=20IMJ.+$)5K]35CJ6"7BQ"[1,U8N'M MO,!#8-.H]6[9.J^ZD_CM#CR)[TM64>.E-NA,ZC*>JC2TML^)N'S%0D55"F*( M,NI$ GS89(!75SHCN=\=&-H5EUXL DX?UE !)T#Y6_98Z9PC4;%/AW C$^5^T9F) MOWG>],5V',#(1S>TW&<;-BRJ\#LZ-1'[\J2F)NIF>FKB1SR38<]L7NVW?804 M/8./3>2&UWHAY68H1D_.6I!R;-PAEF340;)R%FF$;F!$S^=O]P"*C/EX56?T MV)..[V1JG_)CX-MDSJ8KAWV9?80'SFS,J_-*SWU$'"KQ'*2H7G8!'TH\O,WU MI8K94_3JIC%64\II]E3Y^#3&BY27#OO%;M7(HI2^*=BBC-Y0&0JV)B$W"A7D+O:4*"UPOR6A4"5Z6H7B;G;^/_?O1 MD^7[K[!8_H_'A;?*-6+AADK$#TBD;:^*]OZ3QP3=PZZ1&^[D- M:MP>SV9+,>+9L)R;KO6F*]Q). M8M(_+,Z-:F] :=S TX9I VX6H^L$$K%0FDA6^<1N?%WF[^2/BQHD9 MK=4;/7@DIJL8%+2J(#5S1:@M9@2= =N#1E &5DTTT)6K".A<(V::@@PW0M+P M@#N.E(P1=#ZFD99 @$8(6D[:@QBE/VP(:QU Z MHV&&;71YM[K%A&Z*SH?4A-H9"39IKAVNZ"=[PMP CU99SSYC"WZ6"D\\>^&< M^>3WG9,:.M4:K'*_S]# 6.H:2CH]>M/FTLW;\,42_6? MJK@M\'[W.D9O1W) M+10#4DTAJDQLVN!=ZA0YW1#FIL7@35N<2M.JV."J6!^04WEII[(\Z2M39\-# M;5O)YVR!!"BE@TRN@S+JAD7P2<\Y2I'#B,E[=$H,<-7?[[)R[3+LXX 0MVR;F>[D%M_C]SJ;085;0:E:V:P9F*M.[.'5'Z0Z5 M_+XLX:?](J>4LM0[(ZW?E>6",; Z\2+N!.YS^WILFR-3;X];7%N%W9*N^DE7 M4;5!!PAN*7^J&2>&@)]HC/_^Y\19X:ZLIQCLJO*9_9--[_[#?"]3BP_0U1PJ MLO*VK3ZO2#&<2_^>6.@"+&00"U$^N! ME[ >=A@Y=%7;KKH*WX[.RM88GQW4']4PL7;%H%-A G@YY"4)S"8ZL0D9JTG0 MG3B^6PGH!IV1,2 OAX!3%#C&!8!#Q^Q$/.Q1O].,YWC-KIX!MY8HQ[8<=1*Y MGI,X4T#.-(DSZ91$(Z6IUK7&+;[G%9SE>"$U2I.TJ,BCY\]$?X8J1I_F*D?'0L,F_M M^!W/DBTMG=16T8YMP%[)FN&%TCHS5/GE@,\1WQG7!\U[+V6&9_4+8]%K$?L9]P[%>GVJO& MZC6 W[2NV4^7*PJJ\WAVXC[$./TZR W_LY?GND/ /YAK)K!=C.X_W,$'U5"_ MWB"^M1%U0)*9YX6N%[*(9.Z=J2"1H\_^\/ =YF&X?+B_?WEYZ?T<^T[/\Y_O ME7Y?O??AZ_OUM=6\N)'KM9-$4'H#';?]^QSS*A.?P7O"'U((_WY&RTV:6+[_ MRD\%+,"K"?$J0#4+I+\581_CP/SNY8P]O%L%L,8@>/(68]OEFNFK[_VP _C# M5K.U=)0X?-I5"3_)6OF1- M_EK9$;+PQ]^8]_V4/=55F MAF:P\5C7U)DZG@WEH3P8S&3=F"H#Z__*V##[,_*A\OCW>ZO*F$"YM^J,?CE% M[:H9NS/"PSK(N*$/]Y@Q'^&WZ=B \)RR'\SQEHA5-IF[L);G5XE+] "O+<31 MFC$L;8]^Y4ST,98WO[+HOYGL:18MRDT)F@#D-_Q5L'@@_Q+E/DB0C&XBAT4* M"#0)8&3]QUM:OCV6WGRWG/\PU[5^Z4KP"JU MRVBEH!H9EI_A6V!5:G8?JB.:P_<6DKW?"WG,^Z6B@L_Z&+7-[VP*B*M#NYPZ ML7>V=M$Z(\U(SS[>; D -NNM2>ENNA$&I,A? LRJ7M62&Q89T@,?CR!V_W! F;Y MD_FC._TU"@7@UP?#9$ELX]#A7MI4V6";PF0M8)$FPF2G>.0*@U2R(7Z0:EA= MD"JW[;6P_&?;7:>AP-5\>Q76V/2H-::WS1K;Q@"VUE@@+7U IP\/E*8KAFQI M)0H')/9SR5RXL"@_RL=-L&1Q0MH(R]1+9F>D]S*"C[%>ZIYE,YY8[MD6H]+O MC-0CJR=U>-T6(U>&59A-18'=7#KVR7,#&TC#?_$]UOD^FZ:-SH*U$0JF'?1# MA1&4>[@->_)H\B&&QN?5 FX^2?_[F*E2<1U2P>3QKQL;^/O6!OZ#V\!\U(K\ M-OY/X\7OOQZQSGVV],'#=*/\P,0+0FY%9AKT7(Z!'(A"VN'<]J=1=)I%32%WXX](N ==:16PK@1T^Y.%70F,,P=_=^^A0X%N!3XY *'!?[WTO>EJ M M>A@,+B_.@A-LA$!T-+*\O!:T#\AJ_P RN47I@TMWZP[3I?[' .;Q@L>?[# M6]\RV+LG+F 9>=OP)OQ6_#YC!F)Z+1ZG/>E_8%$>7@._@H2#"4['.X-ZR FR_'G"-KPJ-GV*W36K(56*^PBR%[]GS8U.Z6.AA9 M0U4"JP%&F B@/S3S0OU)+0%T2&!M0 9PN@%W;4%=70)?K3?L';'>\%",NGS MRH?KI"^_?K__Y^MTY5M=Z7$Z8:%OPYJ^6O#GCZ[T?\!XFMI=Z9_,">RE#41 M\KSSK5D(FN?^=_8G_K=#>^L);S1#R L0)\% M(;P .PU4JH+"V#%)5ZD5$%96.Z$)3N?(GXF@ <+GH(;-_'M)=>KR[D%BFK" M-SB"3;1MNT>[Q94MT72]"XN1:!&')$;H WW0(HG8]$_7>[F;>R]=R0J2[,S_ ML0#6_P$73CT)9#_<<<* D8#4(3>H?- 'W# X!>L/&4FDK1.T%D51(JTUM-X$ M5BY,[FV )^K8L$?XI%$[!<)),_"K).!=<#W?."@C$U[<+TBMO=MMI'0X][W5 M\UP:QT8L$GEMQ2;%,4+EE6W@,H4_GK% GDN1M> SK= 5/P;$!GIF4Q+,GWB M:\;_W]M:=_1E;D_F\'8K9[H!)Z!N+KGL!3X C@CM9_[:"1G%N0F]__CSO6X4 M8!ZAFV"[*RL*#B6 '3]]N6V7;QK_T=MT)&HO MO,.MX>CK[;)Z_6AI<;>5^,GQUSWXZC[]N6KVP%;._*K?DS,_/W0KV>AI Z.2 M6\&J!F;V5^M;Y>LK@P$RF=>3A^B4 KA-=7JTKTQFP?C"GDZ=@S$OS30*^#]F MKA.N7V=PK2^!B]K;+YH__+8\0I;QNJ4W(^NDQV8O$DR3^,D$9![SZ]FJ;-&B M]!5-^@#>N"3W[_Z[:,>:QO>L01 -E8S=R#CRD/S?N;\M17AF=V.?67_>@5W+ M_ ?+>;%> V2^I 4!.RVI;8!X\ M@=EHN>!2'5QY%O>V0WDI/46M1GE5?2LMC_+:,U8BS"2EE9FGEU[R'-3N8/4L M+M\SFC8].W7S3ND4\@TN8TC:X'A/8OL8?2]8(5Z4]FL;X[T3CEK"EP!W_]MO MG^_>#1Z[TA0="&MAC24PYSV@1U?Z[=WW05_F_/M]]>=K8/6DE"."]_#9VGOP MI#&XH0Y\%\5AK"!=;1G_$$/>#O=>@M4$PSVSE;,.\/#@O!^Y-F-XO.?RZ#XL MGG\4!!X(012(Z\6P&6Q]V),PENXC\)Q7>*.5CZ&:D&?F-M4:FQP!JI#H2_28 MX-X)+ZJ+7P0L^9+H\<0Y/'APM/JMIP,[.\901Q15V?5ZX&:O2Q0WX .F;/^!*)/"1@Y@39@%C+[X-]H][Y\UF44G$^EU\C,@#==V$RXO%V?XS.X#>.;#.G6\'?\8? M=J5GP&E43[=RU_L,+O#*9PG7>0]LJ5LOK%=8* ":Q2M!Z$?QS=WUKVOW9BM\ M0FM"(]MQ1X^;H-^%HR29$Y@.1] !-3Q8MOT(*+$C*3;AJPB/40XQ!#FV>8[O M8]E_/.OI<$B^&\<8\#?\VX2LB0+&6V%S**8'_X@>C)P+@H$AYA.!FT2,/X*2 MY'NOEK/.""#P-I%<$+]+;_=EO=V =J2,QZ^)Y^+B\7U:QI-GN M H:EC^N15!O32 Z@$$!9#4Q63ESO2LESA&0DR7C& T.JF;")?I8Z>[#_$ M:W+73TK5Q$+XO<\2JFV15\G:F O+*;3/H@O8],X"9P04=00E9'1,J(0>O-9Q M1 1; 88]UB>J;,CQ9(?N,1.8O1]5"+V'3VF[W#[=XXW^3.Q?-@7%DRL)?K+_HH= MO/[QT^?/G[Y_"W5 JSLR^8?N%%HPP3I.J7T%9UV*N=.#6BG&M%,Y=\HLH<>RF\[UC_>=*Z'JX#9-[L9CAIK/CZ/#FU)Y9_:".]W& MAI2-[(N '-G4'(:T%_\9;OS]!0LM?X>GS$NO.),/D,D->4!,3DQ.3-X")I_[C!5G

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

  • -;@WQ_RE$3(']8G>2B5X\GR,,KU^OJU0.*'( MN1*/V@^MV__S#Z4J?U2J>?+7"CZ=+W?=6Y9<)O6^W]XVNG]LD*4Z3Y]U>-]2 MCM,6)E+/A4@=UZ'EY336O,RLI9EY*\/.E\;6:W_M-!Z^=UN]I;&OS<_=X\I^ MQT 3@U2/_AU:'FMHQHJ79R%5R?4D13\;G"=1TZ28&?0="#K3/1$?%9 Q8\0[=,1L8?Q@W@U)=9(QV%?$@8CUX/Q#[![D0]W..SP M8S EW:=E$C@2!-;ULJ9OEE"W\E%E5:YL*65/U[:30*WIY8JR/H\PIUC(5*V, M@\/M(B]MEOI\&$V_>IS) _E@ZQI[HUTE!Q)SD:W66'-(^*')*7N.GZ<[ MB*@>P.S(-]O+WB7?Q>5_07'YVNBV'J3;LG3;N+YN=;+8ZT!6<^&7.QNK;D'V M@7$5L#6%P5*'J2(]ZE@@[7^W3,K7'AUI%G8^X'\29\ _)/W(^)^@$<##@!/9 M4WCNUE>T#QT6YVVZH>-3.X?V612]Z+^TQ/01EH@3J2^#^!05UL?5Y0EI3%=* M(7])&E&/@C;CL\Z.MCT%^G#\P K" /AX:,-"A&L^@UQ?MAP$SYK>3=*['M* MS%&D*XU!B7(>[6F)]7\,O)"R*VSR- QMB43UZSXSDB7XRI8FK+B='QTW7GX< M_(#S8LTB0[^$UCD^&=4M/S;533(A)E?T+&> &7JQ*H;CF[*'PA3YB3)<RERK#?YA6BP]5#'HD5(4H> M1G%3IW68[;E/T>?W9P(^6(%]LI-'!U(.)UU]#84O M2!U0/"TF=.3-8\5[?$;V/-7*]E@YAP#=LP.I =['TS1&QO#%Q2BO+?=$,C0^A9;K%V;UG.:8U(?;RU>?;#[SN M?TUBU[2TY)5^'=KL)_GGI&#ANO%[^QI=;M>MSL-=YY# <$U^ FCC4, DCLUE*_,R+Z+!TJT '@0[[0(=?6YU.^TNK*WT&KFSNT[BYEEIEZ?--XX^;N^9O<\ZRO2%"UW6(/6#CL,G4=LT?[P<1$E-!L'1! M6%IYSRQ]>]=]:-^"J/\5F.E[\[>;UA^'X>E;%U9J#%(>!Q*:/VPZW3E3[SEQ M:Y&SCQZK!'\7@[+6\'?O>Z_1 2N_=WO7N;[XUKJYN6UT#FKO]T*X&8Q]?^PZ M@XMOU+;'Q'E'9K\0X$5C\'>MD_]ZUVO=?T.IV6I^:_W>Z';;!_7S_^KZ=#)B MXS%']"?QX(F"N8LX%\'MOKOEC:%%[(%BZB',1+%UXEKX&ANZ6I9OVP\-MX\"I M,0X;B14$8R)<9(6?J;__WT:GTY(Z=]V&].O=MT[OL&FLO?!_B>-0J>-Z1/K5'3G^ M>\IE%=[N]-L_7'0:!9K"?&?T'+,/>2C"'86[/Q^V1G/ M*KMM/WP[/#_C2,96,!()9H*W!6^_C;>;?W2_]Z0'L*SO[[JMWQLW#>F0#-Z< M>J$O/8!Q/7$]^I.\IUK3$Y/:*]OSBJ9)\9M%TR31-$DT32K.FNVU:5(E8SE> M:)ITV7<'4_C/*!C;G_X?4$L#!!0 ( &UIM'P!X'S4 $>M @ 0 M<&9E+3(P,C0Q,C,Q+GAS9.U]:W/;.++H]_T5O+E5MV:KXB1V'I/,G9E3\BOQ M63]4EIR9NU].020D84,1&I!TK/SZVPV0(BD^0%*4!(^T53NQ)*#1+S0:C4;C MU_]ZFKG6(Q4^X]YO+XY?O7EA4<_F#O,FO[UX&%X>?7SQ7[__XQ^__J^CHS]/ M[Z^M7?T[OU'YXC\?"S_LM]^?/_6.2%C"?3)_\6W MIW1&+"#-\W]Y\G][,0V"^2^O7W___OW5][>ON)B\/GGSYOCUGS?7 ]GT1=36 M9=ZW3.NGD7#C]F]?X\\CXM.X^7Q,,ZWG8_:#BE@G8"<10LYM0_+NX$O[_&WW&@-T=OCH].CG-=]3U/CMZ\/@E"/J=C$KK0)?3^"HG+QHPZH$$N11W)-$C]'! Q MH<$MF5%_3FP]"W__AV6A6-ELSD5@>;F.8^*/)**^"&2W%Y92@6MNDT!J-K;T M8YIR[5]3-_#QTQ%^>O7D.R]>UQ\U](\FA,P;C9SNHT:/OFF"094:%:%1V 4_ M'<7]CO"KH^,34(K6."2SI!D.<;\U<2B<&65"T?64G_UUT5A.L\9H1#T;H5$\ M;6O*(NZ 0GC?9$"?VJ\F_/&US4,O$(LZDZ&H2_RAR33( EO PC ^\L-1(Q06 M3C3\LGMK#!S*F@P=-\<_6H]);:?)F'%S_*-@3.)Y/)#]\9OHN_F<>6.NOH"O M<+;^$D_9>SJ.EY#<$AHMN,>?/GUZ+7^%U49V)L(6W*75C5_/!9]3$3#JIY=? M"6 JZ/BW%[ ('\5+Q?_,!7T%B,0M)>,FA(/7:C[W.FVB=N4;NABAVX;EPXRA)DKX^QOYOV/K*-EJ'%FRIX5= M?WV]VF$%5.A3Y\[[7?Z].K6CSE&3BHXK_*G=+SN9"KM%7\9\K.!N+W18<.7A M7DIB4H_)N5Y:7I]D>2T!6"D(>\3R,^[YW&4.[FP'0(3R17GD@D]KF MJ3Y K?1.ZDLO ]]2 ^RI'$^)B[O0P932H,54RW;7RNAME8PB6)8"=I!'X/>) M *JF-&" YYK"R<+22NI=?4E9/V5@_W-/)99EG<5B#^]=/GW-=W$!(Q6:C\W\#, JB7![I&D M3HG/@*/]%!'$I ]\LV'/74]V;0!KI?D1MV+,MUWN MAX+"!SD*"B\]C@4#6:F1K&0H*QYKCT3=[!.@T\,.;50W,(&5%6$G%D7A9$C$KP4QE&:1QDXVQV=$2 MO==I_*P4@GND=9)]*H1P'O/%OZ4U[59I;ZV$CU M')_\7X"Z1V(9DJ<;$@14U)RTJ?9:UI^LLAXZ6U'O/6(Q^$#A#+&@L6U+1=6N MN>]?/-ENB'E-MQR4T@N@-T"97'G *#!'-26S_C!:@;[-K]?+,9?V,1TRQ&%A MY8X'MK(C6\NA]T@;+AEXX[!VN%<>KC322ZDGX,*>6IF]6Y79$HR5@K-' I!Z MFN)EPU.L\NY:4;PO7HK2 MG'HZV^.E->]%W8,8+SA(Z^],]K>P>5$+1B^; J MEAC<2TL"E [=$N1+:[\Q-! R;DQO>4>C!, M@)KNRZT\C$EA=^6I7%K<7.%/-2?BFH-H)9X+0T4C2JEFQ[2B0>4D]J.]OQS7 M2@^L?MXC16ARYE+S;.5#+I"S=RHB$<$&R?W50!12=I*CVH%W%+C8H+&JTS#:.P]4H5K"I.@ID2CMEK!Y,(8 MJN,><1772]!$ZN'Y#<9>P3LFS$-58T$#8U<#CE8:N1A$!J@*OBJP5@KN'@EK M0"=(\F?*)X+,IW@.IP)"]_21>B%MO.-M E KOEPX(H+^TDK@I\+MT1![NC-N M<9*[\:/BFD?&[]\?YQ:TUD?&UD_Q7_N4RM%".$/T"#8G^PB\5O*Y%7,-R:LQ M]TGNVSRC;Z(P.\!+JVD%)Q*[RB#81U7=_!%^$P7=&C9:MRCBA0E&321>D5_K2!SASN%J0K[*)72I(/&JUL%$*U\FBEE8O>J.[[R.H&1[Z-C&9CL%JAY4(\C<^3]U&^ M+<[^;HE0IR/GX, R=W.'C+F!M#J0"P"U/VX\LI;#6S]%"!P4HU)>\(T(J7-/ M1R1(SEODM\3U-ZTM]4;7JE!WU]M5_!%QLB*D4N8GQFLO=6N;Y\>9L9JHX*Z1 MU&JJ07?F5P8_*/6&]:4?XJ\^[0MFTY[K1I5TC=5O#;XZ57^;BV'N5-5C:BQ) MCI70<]#[W>C1)>>!QV&!?6X3((>X=B;DPK^&SH0C:TG;859L6KD$QVKB#4F]87\ZF^!?#@JUG1(@%\R9?B1O2N%[LZFC& M*GY;0K23(W?UXLIM22IJ2J\.00.$\DP_3/?B5J;(NW4RIT@ M/L^I=7#"MJ>4@W V(P(FA5.43ENDFK39L>ES(48[N0IR\W-!E_MQ,@=..]T8I2M*H>E9./^35EGQ7?S%%^'L%;SS3K MKH 2J?Y!\S?D=]A3ZH0NQ6?,RL'(NWG%/P\%)M7;9N=X;(1*W1Q[9];)>E5(]G!:;+[PQTI2 MLBGU2%;1TBIT[C!]RX5)"O*K#XK:I49(*&8I:1HEK8+FSKNWKJ *X$$Y-Z4) M*Q%ZH[1T%3>MNNZZT%.LK@71_X/J=JD>F1&RUTM,T> J%+6*G#M@WKHB9P=< MO2EST.:-JXJAAKD6KEK]SIWRFJ+?>VZYRTKN)7$SV>*6>UB^A@2R0!BVOGB: M4\]O=JS:U6!:;]8I!)@-E*D>:50LU=OZ*<+FGWNYUU]7ANU27CH?5:M" MN0/"S:C0OJ>-Z 7;U.=>K"<-]*OC,74J]3YW])2NN7H4&R#$PDK0L!(\+(6(M<3$@H^6Q,6" M#[$!VVOMZ5HSUI=Z[J D*_6#,,N%V:ZP2D5_K;"JWF7>^PHH"6-31_?$G_8) MZ '_=DX#>4YM[-G-9\^NV-6%II9N+.&>EBY\0NI4%O^?B.Z=C*L#K ME*K=4FR%,+3BRL55L^**@49KXD%*2PZWVZ?7!::56^73 3FY[?LN.F%[UNSP M\6?!??_!$_#UQ,/,>V@:5:9M*]DV0VCEG8O89>6]8DUA792C6NEA99=XX(,: MU);1NC-]K;&TBI&+PZVK& =;D7*$Y%8SH#,_"J!F'NI0_BB^UM'>TVHX@%8= M3^C^&L_#M,P^;2CT73J\:$@\;JKMVCV M4$LN"QZ367ZG LK$&69II7H%^!SL&\M M]"IU0V4PY0)=V-DU]R;X+U&O3JU[([O[8;7:E(N/EFE3^I8S/L("J!PA#B\M MQ$;^N7PDZW WNJ8BG=-1,,#Y)J=FE[I2#%FK#KGX:SUUP-&L9+B#J/,"P0@' M<3&^\9DPFQG,UY2[G8"KB;,9;6@]N%9A@J3(&1)C-0J)7&R(J3P M69_(F!PTJU/A=N=H=XJ%5M=R0><-Z]K!N\Y+7"[\0UCL3[D0_#N^SK6V%E7 MU.I$S4=P8X\%1[&280YB+1=!=U:B#G"MH'.1Y&:"/LSEO%S0<4<^H?>VMI"+ M@.F$^G,N_ELF5+G'D#*5KN9!@GFF7_E^" TZF*^54+4RK1V%S MB$GG5+!'F5M8]"NX,5^H,Y'7O.05JM;/SFUH;*VJU Z:)LB4-$&7+D+(2C#: M]^3,PMCX,@(YUHHX\HYO.>)#W-X,7V_K(#S?&0I:#:L=+$U'0.\2X M61%R!U5K;4)V8+5JJU+M2&E+8W50F]8R[&ZKTL'86D6J'6-MJTB'O4Y>=&LY_PBA"-.9BN2 A,SO0HC:#:=6F=J0U&3TZP4N-+R\NI-8ZA<-! M2V+!">JPX)[YW];7@1PHK81KQS<5; N![Z7H9&98BNG+>[08^/4"+IJZ$DT M:L58Y1Z&0@!MJ02&;@2K :X5B+([&[DLDGS*V1KCZ)3@H^Y\&6U$L3C1@WDI6T< MV4J&WDMU #;,J0@6?9=@ 029TS)7Q=-G<^[AHH>OW)=C:95CUPD M-(;ZTI)PE_DR\V5U]1@##$)4ME873@_:DA(-QI-=\'H=E?@V6GRF.+WF4V;W M!"5^9XK28""MCN1"H#H=D5%S.7JNUGL! MG@ W/W/N?&>N>XF#4LE)^/;*B]!0WZQV;:0X&\9!JU.YH&<:H7R1&:4LJ&Q)?/A0#8U('2]()-@IQCG;'TI5,88SR6Y.'V,TCR(\K26B M5@K3@SXV5X OE+C!U":"XI0>"NHY6'IL1^I8'QN=-G[*A<&[T\8$2VD'+8FG MJMAVT,:UY)^<.6"KRQ VU\X >!%N50OU6&BU+Q]E[TS[4MC)Q@H_2R%X4+KF MXL;_M BH=CZJ5JGR8?G.E K_W>>(Z9K"C.^^#_$%DD#RL>>ZW%;3]!X?=L3N MP92")VTCFR:P 8"/J:SC5878BA9N!'&M(N?. KI3Y.3>OR))*;65(LI25$E0 M0(B5$(:['?PFFW9=,#4.,Z.V@O4\XBY\YO/QV53RG7D#-O'8F-G$"U)W8B6_ MG0?X?9)J\.#QD4_%HXK*S,/MVNB-(:^=(;FSBNYF2$R4K!VMR+*89Z7PSEQ5 M5J19DK9,HS1UEB+OL'0TU[$XWGL9XA/$6,S[TN7?4SDZVU3XVLAH%3AW<-*= M B\CY I+50 =\3(G JQC4Z9.%7&M;/5"N!Z.52NX@0<(\DD"M&&K1[-AO<24G M.?*W$?Z&R9)@C22NO>]$.&CZT(5*KYZ-9M@&QM4J1"Z27Z(0Z6,BU40B8Z6Q ML10ZTO8N$;(B5 X37TDTG,V(6/#Q.0G(LC91(MVH70^F'[CK\L_H?=)U56GM M@36Z].%-+@Y?IDL*%7G1&9!)%T%*JU;4PTJA%-\R/"PCJ_9A.=]R!RCKVYX* MV%J=R$7':]B7Q'84G+$+CW8LK4+D(ML-%YPZ5F'/=22V],/! M_0/NU88/7:\AY9"U\L\%A/6+!(ZF=GS#A\,*T,Q#' 3<_G:G3.CFS$+-$;7* MD8N%KN&-OK0D)E:$RLN]MA(71'A8AZXO7].8@920:[U Q44PKAOPOA3]E6>G M6DRYZ\C7N9H$"KH92ZLLN;AC/#">\U@*L-(.*STXNIEJ>'S8Y56F883"7MJ6 M:PI3J&5@L*2O5H2Y^)X"M/?A.<6&Q-+*ST7%_5M(J0%4K?QR0;ZE_-(66GY9 M]AS 0;R1(&2>+7!'WN&65[6E21['W XR*7E_W)JI;$W>NBX&T:I&+*1:J172D%XUM MJ<$3)P\+!2W'CR'LH>?6@<3^YWAKR@%#'=1CF^J!9YO >K93*9OG5$!+/#0 MJ64JK:-/ JP9 .VJ&'2'KQ.#8YST>+,6'*EB$:S4L/A&; A_YH]4>/B32OJ)4XL[5HBFPVH5)1="KJLH$A,KA:@0H6RS'^#S>)N ?SE,T<:88X>7,_^*V0^VX16=8")5M%RH>FZBE;TK6R] MQ,_*("A7KS2*>ZE^ SI!5B6U8^)MR3U]I%Y(4YN"=ND2[>%K524?Q5:#O4R7 MPDDV.]&(*_6X]CO)HKYT4A%GU>F>SO&F/+[XNVPT6D0_-COCV#066DW*A[Q; M:%(F'J[Z6TOT,FU'BV6#@\VI*^\D%?J4\?F40(L(4%2EH6&>SX:1T.I<+G*^ MMLZEDL67V"T5+<;OH''5PHZ^R15TV]"BIQE.JT6YX'T;+8J1**@B=U@5:YD& MO++"/;S7I)Q+/FY?/FALY&5+RPR,@' MDVP'O[T(1$A?6!Z9T=]>E#;WF.MBCD;<_&DD7/;+7)8D0B1_>^&$RL*_L/P0 M8+- WNKY+'@X_^V%:LX".GMA!:IY(([P+__X%X?/"/.NX$>$].)U&2V]T&%! M2BEZ$0EEQ)2W[YP:]0V QTVGGI!4.;F[<:[0&<<[X-QFF'K]!PNF P#JTLO0 MLQ5&";5CXOH)N>M!;<(3]=N(N%BL''Z@(Q8TXM2,>S!;Q4+/JWN*[UO808BL M/9OB?7*_YSFI&%V4I"Z/L4N9TQ2,H=Q0CQ/P&9BM*5ZX>P1+#4:=XJ/%9R'& M.EV9^KM\UV4L^*QW=W:57!"4(,IO"<)LP9IH0*<84/'(;)F8H-X5&5'XE0[) M4RF;C<%O#?G9$M8F!0@8JDD9/?M0S; 0W1C>&8R0Z)YQ\"0-R-Q]+6X!=7LSEA AM&1JC%S8XW#B5DIZ@#=\L-,:6B MF!NEQ"O*YA_0I.'6Y_:U4T8W"<9/;UB >IJ;7=UGPX)1.SVMT MW+%*QJ'>NS&6@$'K!LN!@=4!N3N!-Y)T<#E9N MB%+/2BW)BUR,R.%HR+'.QS-D_IS343"@=N0V# 5!Z[&TU\DOEU]OKVJR;!V0 MAG EF2>YNX"RWD/1[?#&4[ ]:$.XE+I+T\OK0[_%;4V(^P)FM^!2U":CJ+$A=%RX>(I1FY+BYAM7E9"^36HV.']@P"2^#1$5 M6*_G<\$?J7,#5L[&6%VI1:WHT<"Z-C"CS OHA(I6D=#T@VZ)5@E\4W#IFRSD M?I4ZJ3/&E-L"R%4<=VQR2$/7JI@<#+-Z 1>+ 75=\+O44V057D5UMPWYA'&G M5MJ3N08V%)AI(,6%<:)[.E>QCR:Z41.@J1N@U.'>JHGV3V6>Q1])3>VIQUT^6=SC0VG+?<-J)E;U$M(:G $+ M3,$LN*@<>[2@"8F MK]L)L&%$#,U!ZI81TOPFB6=*?;\IV<R=J=I5?,](%R-O",R 4<$[G@N)EL[JA M\XH.!I#S%1 33".PE49&G&!,!%6/03RQTI/\E4;=I"DH9\.#BX;XK'A2#>@8\^'S:[XH'Q:!,X$'O^.V']T787W.B<1UJ=36!1KP3 M<3S0^T;U+MFO0%AZ;PQ7>/"G_* MY@EE,93R>\L=#]-U'G?*B-1F7;IZ3+'H =]EN9XA#RKXTPJ6H3O/OHCSA-%K MC:.=0YY4R.#"QQH)%=RH#<'4X^(2I!_F8P$:W]A5HHYJF.J@&S6/1.DR-0HZ,!Y(&)DK?=,5;&%[#]7#2AL6YO PC5 M1@*CT^++T)/VO'I-;0G-5.=#2TY$QY!CA5(:2'MSI=*TRO=V:T)]MLQ*GIR+ M?=)(&V"YDV7KCMNSK YL0],=[BEQ\8TB;W(7"I0UUIJ"!7\BR$R7'Z?O:8") MR23SW,T#-HN.TB-4^U- ^TZW"C:%\@P(7X]@@PA=??5+6W2BL+4)X=QF5?(; MI*_6AF4<%QI6[:[5UU2//'_B6B*M5'I+]99E'9"&27=5C MQ^?+>=0J*E@7M3542(7&IUCQB._>#1?TDMOX-!$6 MCB7> M_?T)0L; +"!%._8J$U2UI9:Q,HB1U_X'Y&1:-7O=*KDDR 23ZGLF63 MO$]M0+VS<4S=T"5UD[/Q;TPMNF8V7FX &N/ !KHV,NAQ-Y9EEF$/&Y7M5-4[ M*MX%Z':8Y\'.DMRL6QIE47 <**JN M@UC=TU2B$^.Z4N9F "NH;'H7E2Z_*ZIR?O$4X$?H=.%AZHRDX)8'T=L U+ET MR:3*P=G"X#OV^+YP?\Z$IL+@2B,3UK>OC'W5IB5_-0GC4UCO-+EMF28&1#** M%QQI3ZH)J='1!)$,P3M_)%X09P_!Q-4XM.4=#!#7&148#AX"E\F< G3;KTU9 MO;X&$'G*^"W60M-&U3*M3-"V&"=U1KO*[>OKLWHD:;N;0.LM'LOKS@4S;4Q0 MK9^_O/MZ2=T9>"=!./E*'0[NDD8JE7T,(.J&.H*[FN!ZIHT)^O-O\O@#'"I- M['RUE0'L'H;?%K[&GQ! /]U83_T'VH'B%(4G-#<8:K7 MV00S)6-8,M ;/3YOT]#IZGC)3:18KJHUT/(@QU4HZHZNZVDGGPQA@/>0^L;3P\3+_LR0-)D-Q?B-:/3&W,K0I M+-:34\J)&ESL +H!C(J?/,#LH@L? W]XC88*K$GVA;KX%"4&X+5/)FC[;R@. M6/L%A5T$6/^^8=552WM)F,!'$FGR+&U=MA3W-?.R!2PB6&')3KW.JLN&J.RR M8RGF<,N^CGJ6+S)0?D^O!2A#$P/D,^4J>0=+6M26M+[?CL6=U)1,/#-M? /J2$+=-9T@ MH\:)>4S#&,R/S6OKJQ,'H$/RK=I2>LW3&9W.7+RAM MXKQV,XZA/G_A'C1%<8L=;$%O$_9W[;8CI78$4VUR-J3CO5#3P0T-"N6(7SF8 MDN'^U.?Z7-0",M.(E6[SLELY6-%#%\6/Z>JIBT/-MX]UX9JZ8VQ*V!@(:U%! MONMAGAD[^Q*Q56IET*XIRRI!F+=2+9]QF!W(KEITMC&ZJ9.B MBC)0FH P5Q[9+[<.4]5(EG=@:SS6D?GXYC)3H5H0L+EU]LK>3.9X:-1-1XTK _ M3 8T5HSG)N&LLF(]6T3]D;B55&IZF4GJP)Y2)\0*X;U'6 P1P2BE+#-'RZ;O M$#N45A[O!'8W&;G3!1Z/A"/:/B-W37*NP4/$04HSF;N#O^,\F"7Z8R[\#/KG M=!1$F",Q8U@M_A\EXA+\LF666NG\6A>LF1,0Q1F C[,JSK58M1Y0,QF%N*E!=S'FK.)@I!A44NR2VS$51RN1-[NR CZ@X>7/R M7A-^KMO=A'"4#ME/Z]'ZR21:X[@/&HOHC""Q%,L(T"T-EIJ=2B*)*AP.^1?J M3%29MWXH;*P_#<JC-\J0TY;7)H0YVB98@2:9<^C#Z:F6IJ*%6(X96'9?YD M-+Y :I&P2",]61>LH=S"/3\?KQH+6:K]E O!OV-143*'7X+%>4B'_.)IS@3% MM8=Y=Q[%%;Q\;G4"W%#.J2!;4 M_=R2NI^?!74?6U+W\5E0IW&(]/T,N.Q=AN3;-^V(2_J93-PQ_+^EUM^(%1ZSRQ,;,CN^QM,V[ MZV313R8@-*W;%H(;FBJZK7QMD<_,1 M#>5Q1G, ?0J?L&@E5_=N>I.)H!,2U#JS:PS)T/,B/F-8\$=3A#77S(2%=UF; M[H:(;]J;%66M3: D4W;I8D8%ALEK456GIPD4#D&9?_ Y$6P$?_Z@GJ MP8!-X3F=\SI5N_/M#$"^X(6_ON"/S&>JZA>^!D94:0VP9L1-#FGD C%W:9 Z MU4E*X>$-F[MQG3OP6\3 T*6H:PY4UO'4U57:;> MD9#JHV.H= KN!?I^.)OC(/X#OF-(7%OF[B2EWS O%2MU(E^PM%"32X^?,QFQWT^#(]F)>P+,M7D3A=1 MC1PA+?X]Q1=_A$^U18PZ ?]LUI2&4S/AQN:F?WJ,9\/'U13=SRX'3%:_U6VJ MUH-JPGY83X/Z#+J +S.[U+D,/6=MQE0"-9,OT4,%-6_0U^]O K57G@]C>+8J M\ G$:*,]9>U-H"8.*-=7V*H>)E"$J''O8G#7US^D7MS6!"K4^Q9\'!?#&P3< M_G;WW:/"G[*YK+"A>1M#T[=!:'L3SV+TN0C&W&6\3X7<_,($&4R)T*TC^GXF M2.\4O-)O@;H6E4*T)VMEZMZJK='5!!J'/""N9/V4NPX^2@\>CO?@@8L]'-P_ M:,BLV]L$2GLG;XX_R4FDMRC%;4V@0C+[E.#&/E5WLR=@;9JHZCV+I$F?+&3] M']0Z-;W.<-./ET+PJRC=/38T2CD_ R1H 4H;&YZ*BQ<[P&53M_\E2C76)8H; M5$]J=X3>E7?RYN0$=JOPCR8KK6YO XXJDI(MUJ:AN!,(#D M_J#70J:Z7@805F&FO^*FUINH:H5WGJ;>7PM SXC\X7?>#?DI0 :0+Q$>59CI MT2)IDC;39V! MK8QMA UI0V2*BIA.=8XL#Y55CF',"#7SJVY5;Q,)(UC>>BNCH793MKS)V!MB M<$,+WX;*8A,Z3$RH]+^44R!]<+RXXC.[.HUT5^@8>ERTN07NGC)Y D#Q!(TY MU'/PH>@:,V+[V.PXM+!5JEE$]1\4WY2F3N1 RXWL>:U$;%/1W;"/)&G:I;F[ M"P/TQ''C4\0-63WIGKON9?Y!ELP%27,0W'%!SPTZ]SS2XU(^[&+'40.IKK># M[:=0%0O\UCR0M%8:E36ELP74#+)SF^'$5ZFE1@JI-FI_>R&!$1]39JJPD98H Q*SY./*MKR5!2_2KE2*F2R@_UL?=0V M$T2NNWWJ"SYF@=Q]:P[L\@V-.=G?B,>G)*@BS#MP.+/#[U9)-D=E/#L".3OJ MS-8MHF$ TS=BFRZ>J+"9+\W3,N2V,TM9B8T!(MB(PM79[>]@'M1#ZWGL9DAN>ZY2)P(T$%TSY+@1S5Z66\H&;;(*OX,95Q,O,RM# M;4Z/2]E2H-X[F&;-T#-8>!O1:96UN;LXSLKX?Y=LB54EC,C'".#SBXV MY$ I"[!Z5+#C'9,>J6$9MC1G3CY6'.O20??P-INTT1V+%52NIX7@H^ M0T^0>2&^;36/ZCSYRW=>AUS=6Y9WH]1]$A^63&:7Y8977 MTA5X4]EW37V?TH@:;W*-!774U,&GBP+J.95[I[K==[Z7N:'? O[(JH_X5AJ9 M<+S7&XF%_ZBY8+;2R(#+8_TQ^T$%.-Y?81*$X(K@&N=^IAX@8=\0+QSC3E? MCYI#U\9P3!":PEJA/*2/I _+P(S8% :R8?: 3:E#=9W^!HBZYWH+E\SZL/_" M"I)CS(F0+<[ %FCTMDY7 TB\X0[6[!W^^3!H0V;M[B;H[A+9BU#P.27>6A37 M V("W3TQ"H,0J\>A=7D$+[&=L)O#,8'ZSRYYXH,9"Z;_:C@M5O4Y6U-D$#)6Y L_Z=Q:*6AE&@*:52U-($"MJX M_L:[^P/HKL(@$WS;ZYY.L$PT%PM9.AY3YB<^EHEV.=XL'DX%]3$64A[C:PO/ MT#>45>+>W1@CEL1C%,1WS8*H=#&Z+YK*?94]=W[?71TI)&CE<"Z7!D ML+E$=!" 9FH"LOI^!A!W!G-JS(7'R#F= Z9J][NLQ:PIMEBOLP%DIE=0%WI4 MU*XO:KKC(L"PH<7+5%CE4:]V)8V-\/+!):771$RH'SP,_@#GE/K$I6=@ZOA, M>\!1M[<)E"8F#N-URP^#.?=\#CYU70-9W=L$2OODR>6/S+EXZ%V3$?RJH:V\ MO4G4W)['V#T,!D %3%1FW\K!B2M/K>?,U5C'=K ,,)8QXO7(,U%\,HVQUN.? M53T,$ 7XPE@R4(URS_QOX.]2+Z3^^S?1_[BX 9,0EWN3%9]%U>9R#8@[7@7C MK.\_6#"-C?X]'8>>SF# 4ET6-Y^'91N>)L<$0#%>N2/'*! M."7/!%YRT80'"?W#*8U8H#0+/K?0T2UA9&KV5<>$;E3]UQI_UR&,03B?N^H9 M)8G8\M;-#?QW%LYZ,UP1U._+V]<-&-D9_!U;#5PM/)NYT6F9#WC#1E]I FZ" MXW=[U3-FNCK^;6"9X''E,$_>=)-!'T[G 9T+QDS1!&5BE M;-K@B(;R^#/,,SS"N//.F3_GRH3=C>4F_\K#@H*$1^!,!4YFX7RAQ@VD-,DK;FT#-PR#9*&N. M1PM:&C AH@?1@QI6J["I"4*X T5W^403^EYM90+F%R[#K9]F^D3@/Q3^O20SYNH.'JJZF""*VU $U+X['WY=X&":0^?BQB;0 1P&WX)Y-852 MT-8$*DYO^IJW(-,M3,#XNZV4"95\7GD/^HFXU):NM3,#\3^K^AW@_JA%?:60"WA?>2.CXG6UC M:# MT,5[ZS]T.8SY=B9@_V_RR&PZ#C1K6*Z9";C?V0&9D)G&U&0;&> 077ECE]J MZCV=^6 "=9OEXM8F".#?#!^9GY&G?\/_-0I4U-0$&CY3CP>"SYDN,3?7S@3L M3ZE'+Z_^U'@_V48FX'W&1LS[2U./8J61 5/W#H L=+9RI9$)[);^UA?NSUE M- ML85,36(]X-0A E+,@\/"7*)+7J_H8 Y5YZK-?G9-B:H_#47 ML%'R-'BOMC(!\U/NARX;:UR:;",C\!9DK,I^U2@15M+8!#HN7$&?QDSCFZVV M,F"B#MFC0[YI[LEDVIB -'%_4$\W3U=;&8"X]*]BR]T@ZE?6Q0355Y5QSO * M +WS=.?RQ8W-H>-J@E?=ZA"1;6D"!4,.NX^>ZS)T@,$OF&=K66AF2[W.)M") M]V QG1=K^1(7'YS&RC/ZN[/E?4PP#=$4KT=.66L#",DDJC054\W.!I"9(!>E M5>.U;$^7LJOKM57"?GT-=/GVE,[([__X_U!+ P04 " !A@UM:M.3:9@)4 M #<= , % '!F92TR,#(T,3(S,5]C86PN>&UL[+U;;7KT>"=X(D+I% 4K76 MU10)@L@OPK_P?<;[ZX66'887YA]^GJ[,?5F?X MPS\6W3^G7\,/[V9A51;=9X#_[/_LY>++MV[ZZ6SU@V!"7[[M\K?=OW&O52G, M@]!9@L(LP'ECP 2ILHRA<*7^GT__ALYAE*6 5T&!TBY#L+S_+DFG91:A]!\Z MF\[_^6_U2PQ+_(&&-U_V/_['7\Y6JR__]N./O__^^[_^$;O9ORZZ3S\*QN2/ ME^_^R\7;_[CW_M]E_V[NO?^Q_^W56Y?336^DC^4__N]??_F0SO!S@.E\N0KS M5!^PG/[;LG_QET4*JW[6G\3UPX/OJ#_!Y=N@O@1<@.3_^LOG;68?F/OWPI%8Q07*RA_-];?.B/ MUW!3F*7S6?_Z+_3SQ4=7=$V1XQ\KG&=<3]3ELV>+=.M-LRJF17?YE[,0<=:_ M.CE?PJ<0ODS>T'KYC+\LELO7W>(S@5A-Y^>T?JX?2^^8G=K%;= M-)ZO0ISAQ\5O"_J ^8J&0$_X]&:^P@Z7JXG7UA3C.;AH&*A@&3AC.025 R(C MND=]>];KU"QI;GJ*E+",/4\N8/Y8Y?$CSE;+RU=Z"?72&78D:\D..;\_(2D< M7+_O8_@#ES__L>K"HB.@H?OVAHBP?&"2LX\ZBC2#_3WV)&*_\L/OV-5QQ?:?CVVT*5[R^NVIKEXQX_+ M\\^?^\^$*0&Y_/M"0QG=JE@MQDFD-?%I0MNL# +Z\Q]?<+[$GW".9;J:%,V* M+)EV2!,,@9$*?)(",'=4\\^,:P.(JAFG?@[=G' LWV'WX2QT^&HZ.R?W M9R)U)$)+(CB/&I0J&;RA&3!!,::Y,>AS8]X\ &5X\Y\>>/&L_KD395%'23*@ MD0I020G:D'D!JU'GB%%X)HYNU-\!.2;MW()#N]O:ATBML05]"?/5=)G62#%? M _T-5V\++?"[@#DB-V@DL2$G4,Z1?A$B F>6HS'"9JX&I=E.<,>DHH%+)34^BIQ9-.Y64#$(RF>P2&8N3(3+9.@IQ_?1C+J%)LED6 M9 %2SKV$"T09 LTT,TR*Q#V:$ZZ9,6GE/?EQR+K823P#Z>!F;CEC0CB9/!3: M5T#Y:N*[$"&Q1(9?L*AR:^_M&/'3TVKN04AY$I$?D;[[1Q4M%HODKH#'R$ ) MC>"**!!<)L^&,\YD>*[AZ=UG^N5B27KJKXM%7KZ8YP_8?9TF7'Y8S/+$2#(/ M)!J()I/QR)(!)YP!%G-P'(,,'!M/U,-H=MQ%3AWT/ X][ZJ 1L)LMHP_8#^V MO^*++.J+90[H..*7_<+>AJORS4_58=#B8 MOU\*3EY\KE;:__3S];;0^,/\TY0LM1H>7='LK.B;19K6Q(P:1OU R&?X^GR> MZA],A-!%2L^![#,DN"I!9)@A+EE.*Z;W.*M@ZX)93DIVTKOB09/_ H530@M M(DB29]0R:TQ^"PKN]M1M.*?_S)P;4(C-MNVWJS/L:-R+]3S54=<)NC0E6,XJ M*A5IP(I5EY1!S12!Y!73'@O7N?4YS..(MB&=&4V.T&GVWH8R'=@\[+7OI1'0 MP_YX%N8?S[K%^:>SG\Z7TWEO$WR.-%]U0O_135)IAC-B(JL/7014G1 MA]UIOIPM+!J.6;4^OF@]AFVX;/^L"G04Q&F?FZ19$ Y= $1:@0IY N_)IG!! M\L2L\:'YX>[FW*3-='-_0W7%U/S,0E,BMYEB"\KR?*PD/(2D-B MPOBB$D,3&U/E%H"FH]DJ )ZYH.G-&K"PFHI(+F @RP>X8DD:HQ,+K>, .X,< M571T?\+<)?ZPPAKBU+GD+'7P&3 J"RKG#*X>]@G&,84B4=K6!L!#I\ZG/=1J M1X(]9W>P;+"?PG*:)D[+(DF- [IL:$2Z0#3>@D7/I90!HT\#YX+U0(Z2"=8_ M:9W6$4)BDFM'(C %%%DMM 5% VB5LZ[$%-7Q*VAN01Q3OL'AW-DK!VQ/>9TJ M ^P&W%B"-F@E2&YIA9=$=K O!IA#&3@M]N):GSGN#79,ZG9HH@TEPSN4^_+R1?[O\^6J0EW[334;2D0G74P%6-$!E"D< MB!,<(B_:"!\$LZVMZ6;@FX0U-P#Y^[S#,".)Y[\M9O4$ZJ]A.J_HWLYOX.FF M2_K5JSYN2PMNNLC7L\H92]YY4\TALJ\$J?JHJI;/25B9G&2Y]:X\V&#&M'^? MAO<;0ZTRPLE],R71?R7T]EW85>O'WYYF*VWY;K(5Z/QV1T M3%L:#_-8 R0&@M(,F*"]!TT2,K=VOX8;S:BR3\:]$HY,G:,LA:L$8L:L2KZP M6FY%7YPB$SXX 2$8;[S,-HG6"8O;X!IR['78LF0TS L0H>9-9Z_!.57(^<;>U%;@5L3![C2?FSGZB.PJ*787GV>K;X_6^8/^&E0?6BK+"[N\%<#Z)F MTHI4T_;[N*15@081',@432E9HS+VB'S;8PA'G]'UD^_MV?.^ZM=$I$D4$63, MOI;,)(A)2G "BS'(./IRZOE\; #/Q849FNN[J(1A67(ZU?'P3"+7C"=C(&EM M0$G#(&JG@'-+R!4RS=BI6;ZEPABQ.0ZLM:'7H_ &7"D^_4LDH%YQA5X7L^>"XO$'YT@Y""E5RK' MYAU^&@]A3/M6*Q[>KY$ZG=2/L4BW NTD=];6,Z&0"'1B"F*1!D+BM'LZAZ6T MKK@Z$/*H]IL3<+.Y6(_LDF-B)6H;P"*9:/TR\9J4>,VWMP:B5+GVP4N2D9XA@9[:*-S%E1RO\[,?-P\V]QK*O]D2 M?H5E.L=\T2CQW2S,7WQ>G,]7U39=?)K7$Z8W\X=&2AKJ73===!?EQK5LY&6' M>7HCY*^,\WW9G,XV@Q+.0A!DTA9DR>6@4+C6O5@&'M*HMJ/A63XF@AQEX]KM M2,MZSVV4$:0T#I0OH08A)&2+FAGOE)3'/'8\(*GAR<+A9T[DT\A\<,H28I+/ M_.5YU^$\??O8A?DRI,M86?UI+=.MXFI30+22>+I#09L,)J:P6OP-E,7,J&(T\RZ>;]7P8>TIA\H#&MEVVU MU"F8U:1%PJ/NX'FW(@NCKQ2],BC*16[2N_KNQ3S,UX6C[VA\':ZF':ZMCJMY M6-+0'IR+>)W8%VQ0.@>0Q0E05BN2AX]DG6BR3GC)@=\)(VSLO3"2X8S*VQKC M>AJ1K':BWG%\N1M=5NXG!5Z,_L63HW_]R.BOI4=N;-8V6U Z%-(XW(%WS(*Q MQBLEK?6\=2GU6,8^JA948URE8Q/83F0]QMG57@=PF9N4)*_-CVJ/\^(2.!8U M(-:[[#S/N7DWF$&/70^J/\[1QY2IHRUXK*[7HST^ M'IQECU0P[R*?XV:99\/HZ?6R+9MH@)[5RGDRFG.4!05*)O0QA,>% R5\ M ">5!0Q11"&R<:EUS$0?! @!%-:&VUR&B1[>R.:,>T?K3C0:.Y;1N2QZQOFIG5?K)O8<#6)2AB5 M2LVDC154O<>3H0$3O4F*IV)*:Y_X"4AC.O1LQ8J64FA&C4L,W\@A_3OMIS4, M-:\=(Q;K7J,WN2ME5,XF"Z*P6HQ<>^!Y0FE,*BP$P949:A/< MZ8C@];;R:M MI=../HOYIX_8?7Z%<74#2Q'.T= *&(F2[%KN(&I2>I9[KJ1VRK+6OLIF)#MV M&WX>I#A\SMMU5GLLWG4_Q+?@JDE(8@Z(O+QC,>>4;7VB!I M GQ,;85;L>OX$FU&QG57]DD)C!'I$VAOZI6D*D+T44"]2<]:SHW,K5V;]9,/ M[\IUI[\\7M_M6^^,^7TZFTT\U]I5B28C2+:DV&M(6]*7X%EVQA3>_IKSIW&- MR97;@P?WFVLU%D63P^M+"[*6&US"NERHUZ_=V!*TB[H8"X59K.D_&F(@ U,G M9JV(KGA]QZ[?>,B\XV/'Y-$=0(6A)[RMIW\/"BM9-C%WJ3::\7=MRVC-6WW[%U=DBWP0C M9);:V)JXY,B&Y+2'N$C^A=4Y"^0^.M5ZYWX RIBN_F@@_A83/I!Z-U%C1J> M\=H$G+01#2M9"%YC9#X@5ZV+BA]1[_M$+K[2IRRZ;]7^$2RHJ,CK<:G0:N(L M@K/4L,*=:-R&Y^?SQ12+VD?+]@,2>,]QVP_IPMNA6=]6G"#)'3N.R M6&_>-(8,7ILBV!@TJF@/6?:A5]#;.J M3%ZL7H:N^S:=?_JO,#O'B5!D J48P7A>B_ZE)K.8W&"KHK7$5J=C:[V^%;#Q MQ1E:<*.]3-H9JRE=EF8@ 8NSFE9[.6;+97+:D4EN:K@K*3)&8N* '*WRI?ZR M=?+08WC&%ZEH08YF$FC&B0^K1?KGV6)&$[I<>U;[=6?CDFR6:$&:>O&8]IE, M67+#3(J*5TM&F-;'F6V0MY^_B=:%N4)V$3.Y3P SX J20<>YY"IYDWQK+_ ^ MBC&Y3R?@V-V%=Z"8FBVW7Z?S1==/P&4K.2?0..$@!E5O[&,9HDP92BD2?1') MA-8I5G8PS@@R"#TV-)):!4 MH;66>0I3PS%/,+C@>GL::^Y3+AF"80&$EJA#*+(T#Y\^6*DQFHJ&PYGP2)G# M3E/>LDKU\W0=!*E6$J**.5:7T& M^@B<,:G)03G12B1CLU%+SL6AY2"L05#.U+N0:D/A4'L\."00]($DGBG&?R9(DD](Y6BPL0K#*0.[OHB>(0K8^06F_*5=ML)CWG[L. M76 .61E!PPBB)L?Y!%Z["-8*ERT-53=W;^YB&-/V?*#<-RG?O:>[7:0HY[XP M)A6E^,W\9ODQ7838A'9^-T(I&%@E,Q@"A% N>U#X+7M9KA%H'B39#&=-N MW)@"+2:_&1,^=AB6Y]VW?HQK&X38-&&F:"RL:TC M/@]A&55#G,9D:#+_S=CP'FOE&N;+:[!?I'3^N4XVYEI3DJ:K271)T-X;01=! M^S\W&;QWDC9?IM$(EK'Y]O TJC$=0S4F2&.1M#QLN,2Q50\-Z:SGGIR*7-L[ M*5]4O4.=]CEFDT[%RMC\1OH=(8[IO*KUEC.@L(8(B5T>F7AM$@;,$#AZ\C@L M;8ZU;L,QV@NYSC:6UJ1YJOW%'EML^ .7[\*WZM-<#BSZ8HP,'I+/O)X/&HB6 M%2#71YZ'\:8[.P#I7]O7SUPTMOECW[^,EM\0WR/_?+;,,R #9P<1)V#;GZ ] "4D8:I6G"BQ>0W3^.X@T48+V4A&,4S M<@A"#7AYHR&PJ)72VL;F:F(SDC$9VXUYT&#J&W8#BE>I(PR+2X$VK9AX .5J M5,!R^N(+#3(IPW3KT/:-QX_),&Z]\/>WF^7)%/=H7MVU4. M&29RRW@!+FM>(08'Y*C5XSIC BK%;'-:;(-K3!5HC3G27"Q':A#Z845?^T/> M1;F\0._01J&;/[-MP] M<#=J'%I3,^D![[I%-?[R3]_^OJQ=WUY/YV&>IO-/ M+]**S,(^=4)C%#F2X2>R\/7$D>Q )1CH2 :@]=&GJ!LON^W1-6A0D!#SLC9' M?X]?PK=^]M^6JT*6NDG^&E;]S2!OYA]I@/@KK8JSY=ON%^R;,H;R&="%>;5G$- M0JJ:!> #S45D$&+AA50NL\V+,1\$,Z9PR0GHM+]@VO'D@L^O%QV1^[Q+9V&) M;\N-X_8)V?*J*.U %,=!Q1K60:O)R"O<&M09[Q:_'4Z8)U&-ZFSS6-1I*ZM! M=,T-C+V7L&D.LG"HZ[5]UK.:NE$*!*82H(^<<^4"#6) #;0%Q#&%:DZ@EUH+ ML>$Y^_7^>[-/Z$09I;R5Y#GD>ANJ$#7](UFPZ+)R++$<6U/J(2P[1GV^"\W4 M1"Z#L.3V%LL9(V9F#>2_U@M#&2?UJ"PDJ:.S63+A6F=./PAFQ_C0=\>3_273 MW/AY6]YVF8;:?;LZT)@HS#8;*T$:HT!)EFO:@(!B,0?I'(N^=9^B1^#L&"CZ M+LC22CJ#V#EOELOS>D'+'7U'@V(J6 .%U7)W'\F&SUF"TR81-HPEM3YL>AK5 MF!H=G<"::2"J9A1Z8/AOOV 75G>&;UQT.GCPMC:\MY&#+V3/JY@="XHE[5K? M*[<]NB;'-[5,@1ZWSJ/Z^8\O.%_BQ$CKC2)K4I'W BH'0RL[&TC!1NLD8ZD, MW%IYM6H;Q;JZ< T"Z$ M#Y'5.AL!46@+TG+%2Q(YF_:=N;:&]PQB7:VY-)3P!F37BY2Z\[XC]E4:W 2+ M2"&[2$X,N2Z*60]!%$].C'(J//Y2YAVU?%Y>1:Z3P1,<52:_@,FG:'-MY"-6O,K,B=2.Y=]OGO; MT,;F0;8TY& M,"E5Z_N%MD,VIA2H4VY0AXGL"'2Z[KLUX=ZKS%R I'4MBHJB%D5YD"GR9(*+ ML;G;N0VNYQ .QZ7]I170R9=M.OM->>KQ>_SB3+9,),<#2]+4"46<)D%4/7. MSXA)I@&7H2EA=%(%30T5.U"9,V*\BN BHS%B*.5N)MU&$WEPH%L%%-EWLHV- M3_3#W3A]@>8"VZ1PH8SL6P\DFJXH:>)0&\ @0I*1^VA;Y]@] 6DKYITX<[.U M_FLII8;4^=)AFO;31-_/<+5F^HO/M9/3_ZQ5=+$HA&,26%B3&L&+4B &U"DR M)-RM=\UM<&U%HN\LAMU<7D<[&KFX4X8Y-$I!J+:YBT4&(QH'1Y&>:H%(N MQSX5V72?[ -L.G4.Y[&/1/806DM"732TJ,?FZP:'YX3I ASMSGNUG4LQIIRC M!AEC!%H)DA9'"% ;">>B&,O-TSV'&"W'G_H'W!*:; MIA7FB_L);K]PXYWOL)O6B[7N+M^+P?_\1SH+\T_X/JSPYU(PK2;>>JNRMV"- M)S<\%@ZC8^TF:W9@23YX_/0\5_]#TW)1)F6C_%\@XB" 934-4X'4PD)3G)>BHI6P= MCMBW#/>T62S/GYZ'BK]=_ZY^B&_+S6&_G1\TP9/BR&I410&-R- ZL[3BG#=@ MT&F?>/[ 88QIN*R9T3X4Q/J%'8%T@I%[A&X];4_1I80'6TL3@66778F MI-;)T/O:%?M7WWQQYJ5<5]!^#=T_L0]"?,!TWET8:J9HS,Y"Z(\^DZ3O MM"I0C!4I&X;.MUY/6P';T43_/LETL,2&:(IPLY"HC]1NFH:22^&663 \F5I* M)&J'#P]6T;0$GV2*K2,].T)\#NT2AB+8$%(<3F\1U"_8K;Z]FX7YBHR7:JY\ MJ6^9A"#1II1!1EG3>NK=J%('LEV$926B<;IU[^/MT3V'?/+!-5@;V0W3 X@L MWG63HM6W_O:JV8RL:9K*BT+LU=U-G!OC'6;@^0!D1(09.KB+Z MY LWS.BAN?<@N&>0TCXTT]H([MA:KM9^WUT'RO@4;;T0S=3C4*83A!Q$;62# MR9B4W*F4W :T8^H5.BX==ZAH!Z'BYC5RU<'B;?=JNKQ.>WR/-#(:RN6=5DFC M"B5'H#E*9(M: U'3K$D,L2@R)B)KW3BS&?AGD(0_)%&/)_@VR=F;O:1-D9W: MRO=M-_TTG8?9Q5*DB7M;[K>\-)QAX)DTOZ<]0%EKP4=E (5S(F2+J.XXQ)OS ML0? MF,=P+-V5$8AW^%);]O9-+TN%U/FAAX/(!$[B: M)2$N:@++5WS1=?6@JO]%Z(^A,-2FG?/\"K_B;-&'!FZ\Z=:SZO5ULWT:CY\: M\>%MS4\]@EMSWJAI^B757RX^1]*O]7GO,2T^S6GH^0U9!JMIF=;8]SH!^'(9 MD*5[\V;I):WH_O["OJ[A8_CC9@<5FXQGTEDPNEXS+:T";W(&GJ/U-I)G+UI? M^C;\J XQ;3:@NX=I Z1OCP+Z:[=8U@A*%)%K57<\!LHE#B$)#C86IWF,&L,V M!6?#(1Q33N+(N'_3.AH)19K92 --]4550K$N)DZSG#U-L-(Q0B@T0E.XT *+ M,M@Z7C+H@$9U[#K253(^9GTGUMZ[BP;N[[IIPA>S?FWW-6;/P?![ OSSL@%W MD<2!YN #>T[O>=62YS![,R^+;JTPWLQI_&%VT?2C+Y^A^:DEB/@B__?Y>NCD M.:W7T,]_7.3=_76QR+]/9[.)*U'Z4B((C;P6^AOPS&6P*AI:_%E+[_8S4@;! M.\#>=P#.-_,5\6-*"FTYX;PDE\D-=59ITDZ9@1-> TLEZVQ4L:QU!=M@@QF# M83C:5;#%IG<"2C6)\S:?[ZNJ^LNF1),D4'H?)=A0S0NO-?B8:U%T,C(@-RSX M4^B;>TA'8?>-?A&,D#5#^DD'C.OAO!];,#,,&62H/"BD2!<%,9J++KY MO21'&MH8RG9&OX3&3+<1[BI7O^(8ZJ"0UEV"L[(_R'<1"JL+QH!GC MQNN[1SE'V%8V0AU#9<_HU\08:3/^M7 SC,-$R@EIFI,FBU%95B#$VN/:&!N3 M9IFE/8//@^ =Q858__^RV)=!([6YKOI>3H)W"E$60)YTO2;^190U&&Y*M$@)A))62TI"-C ME*GYE>&;#P6>91Y#4\;=W07WDM&IU^"#,X$RH:Z)I-DJ!2K+ ,[2<*1B28F$ M/IDQIS#=6W.G;;8T1KZ>DC$CM-9>+N;+:;YHI?BQ"_/E5,?YFX-?SPS_HB]Q804TH4(IMY#IP*3$*Q-Y!4K M74),.=Z]YVU$Y^4GZD#R7);$H(=:+0C5;$^^?/IE5LLU^FO,9+)'HUV0'M@Z MCY^1R6Y1@I!6268SC\H.9-(]"NP[/9H=EM3#B7ZTEJ+/9.]:K2"3M5%3&3EX MM IJ$O<&\H6_GVV13$;'# L?FUD>>88("DS+4,L4NZY M,0Z(^COP')NP_XF=;RR\&:>FV71ZTI^K3(I$*WQ"<(8STJ+*UY-%^HX+S9&< M[11'[:H^.+)1[,!C6C@C)M8H%\W#Z2E%)ZFP2/ !:?:#*F1YQ S!1R.EC5'F5@8\B%^MY73!M6C7+!/)"_XI.S.4EPV9$C8)2#:%R$D@Q30KEDC]QWD>A@N2\MBQ'VO>L!I]= *>BSM);8UT\LE>^ M;[&%^3/Y$Z,CQTCU_66QU/K-_;;V\2S,KR*EFGM=G&<06(F@A*YQ3)F!L80I M)UXU[>>#)>QI3IM$Y:2!H*3 %$5D8<$S70,9TZK&OS.\J_,-GO)F% M

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ͩ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

      G+_)(O]5U'SL >O[-P0':E?3?^MTN$)& MOU)>51]+!8NS)C$RO%Z\'YH<%^! ; SYMS[Z,O#[".MZU K!9,8H_W69_N48,K& MP@ MLL,!,B);_/VW[I&_^J'KK*N#S)FLU5<9B])W75L\]?3%"'/@E.]7DW)>_0/(_B>R< MD!XB/ULBZ4&B;4B.<*TX%?1A*%-#!9$-_.7/)WGV'S*A@-I&4D*S:-]3YG4N^FJ<, MR'0=&@SQM>\R&S#&@5(WY1?'GUEFU)Y[5.5D._1LG2Y1V?1E"+F(@6C&067$ ME^M0%T4-$8SRWG&B;+CT^$/SZ;L$7OV!OLZ//UV"C@A71G,P]7G8* MSN+GB530S>)SQ&IWN5-OH3C?=K\O$UV#/!3MBW)N ?6L9IDI?#KG''FG[^[N MOL3AL4RNV>!V=G2\-7 GEE1"4R/6$S?,R$'PF/NMGM3G+)05T&M'*6GMJPL: MS%6"O8W;ISP]^6LVM.=?.U%1Q-I2?6'!PA6YLQ[&+XQ<-(/=Y((LEFU:[2"D M"RK'6D6S:/4#A@CW+O47ST#,('@7MK0];);YIB=52:_27!)Y4ZRW7ZI+YKQ1 M,XV)#9"==Q2$C\P^#@<+H[Q,<:!Q!.N&2"RN;@]6RF<=NG;XE:B:95UPJ.L6 MK9]<:5W/[@[PI'.88R_AY6TM4)E#4\I0--&KM3"^MMYDDKDA SA[$FZS'->[3^7E9\]?Y]F)[@T(V9G35:+_,* M!>JLM M+5/%1[BJO;W.*W.@+*]**^ZM.^>^K/:8 KL M0NZ1;,"!!Z2Q5AR0:^'O$3@W>+ ;R:F@VN'J_8/\2-<+6J;EX)R#)3E:A[93 M#Q2F&M_:)ODP[<2=S&Z6%=9-TQ/G0_Z$?RO'/H@\:7V@RM?05&AF>5N:IK<$ MXD),(J41(EE?H(*=4U\S36P>9K]?VBE?F7(S^H9C(V29,MM'&J!EN]JK >X7 M:?TX,!&(K2;4(2;G2+"747.(ZF!F9?X>>]BF>7I)4D1&<4V61[OV!S]ZJ,)- MY;+A7[O:&.6A\5"(#:FGJZF+,=O. @&WO?%]N_OS\EUVNE'Y5U>W7G(PF_AU M\"HPM=@XNX:#]O\KZT_/[^:^5U(C*YFFBMC#@XUD#=N3A6EFBO73"P:*BKPO MF@UY>*YKW[)0UNB@@:Y2U/T?Z01-[V0(VW' OCR,HEO&3"#*Z[I0S2AH\/ZM M H\H(U>X8ZH@[7YXVE1Y&7USINS9H9<6R^ZY?M\L^O64A=:-)S)*MUZ[[QE$6YZ\YV G!J1MK[Y@XF6SO=@_ M;L+1P/W2D@7TX#7K].'WT-:&U>%H)$5Q2VVE>9:#S(W4A;,ETJ< M$VJU+NZ82;/MC[V6QX($5L,31>&#OQQ)C2$I'/.>OL:NSN)/D)95"+3EAJ>- MS#/@#10R[3EK+I$?&1&8A!T)V1^2%]7**_]&#^MCD 9Z>I)]G2R? MFKW_XG\#;E([VO@T37&O'WM(H99<^O23OKS!D><-BVN'E$I@\1LPG*:*48;28D;D:!4LR!)I-CUQ2+<4+W\[:I48ZFO]I-&S /R]< MX590(9ALB"NNJ!P.>IU6Y;Q5R'PI32ZKUF%]=MZ1FO MTNT:&D:5,X2!Q*.2L':PV#S5U@G^ABFH%E(U5H%-D*;]K4]Z&K#_=5KOV5)Q MH>4WS>EW6<7/#+]G4N9Y;O1Q57^TU+2M5O8S/ :6C=E M-GB8TJU:QYY;LR10FW:=QSU>&$A;E.:PKF('Y5-7>X_SZBJ^;K[$/-?ZK,4K M]G:U[P1^Y)I_@21@L-$%T>]JGALI[$/B1>'H0D*57]&UL%&:W3Q[Z>M/VZES M1.Y"%G<4"X=Q'J & MP-

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Ņ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�SX<)PY/TF]CN22/IC/MU>J,_?.^6HOW]QO%JB*Q^2:V M%_(#V=PTO^'Z@DA29H+ /*-JIY %4<:I1%!(G/-41BC!D4=K,!<>K+3&RU[H0Y33-!D8B@Q$2Y!KK*>QFED?HC M3P2-,>?(Z4@S.-C^VVU+N8:QAGM6 WM7= M#_5;#9UFIOU]P.B!#P:!=B(GTI-N+3Z@/-\KO,;P4_Z[7(XS_C_W==?;J]4N MU-FVAQ-Q5,1Q F.**$3*'8-8$@D9DH@5N4P$=HHTVA =6?%TLM3V3.AEM#\[ M<'/PG0"UTS&A87+3+2$0?%D*- M=KE>\7NVW30?M#)/RB(F!20EEA#%&86$2JPT1)HJIUF6W#YP>83&R I!404U M6=#2M8_L'8-E.((90%BW97U 3H]0YC&![<.9 03W"VFZ3+13,'- HIZ YK$W M)PMJ#K#>#6P./>H=W!3KM6GQ4/NV/9VPYRB-,AGC')8BRG6I)J1\4,R@)%%1 M"BQIR@K':*4U\='#C[MN[G7$$$#0L@>VY&?S4^<8HCVXUD'!42!SCO+5R.B. M+C6Q&6@Y,5>0.G@.7$+P"=LY0Q N#F=/>NK FC,H!R)E[F-X%%?51[F4; 37 M*1QBN3';R-EZK0B8(C4;^KA_IG')SOXB:W,Q:?MXOMQLUV;_V9B^,]L;LM0M M:E?+S1]BLQ6\6M9YGO\IJNL;]>^S![$FU^(W16![N:Z8F"/!,,MI!&,BE=64 MQ!S2.$.0DRPGG)98X,2Z+NNKBS.R:JRYF(%K31#<:8HF,82O%@NRWNC$]SI) MQ#)'Y&V 9E/O]=69'$^#&[ZA81QTI0-=\0!]!-T'&Q&!D7$&:BE!1\RZ;Q?0 M@H)&TAFH9=5'.[6T,]#*"QJ!@9$8&)'_K;XAAV*UK\[L^ ;^O]\WY58N]\U, M85^EW==G)A )$BEO M,$M@ED>8E21.XD1XG$A:DI_F,+)#^M3TD<,@^J:"^&,RSIV]V4Z1ZPMY>^[& MS-;HQ6"TS(O#5%\YBZ(7BN&,B/[7/7N:K9;7RMNX_2CH]DH-H*L]D#9*88=(3-L3K$?(%[V_^IYUC[IT@CN=TIGJ7^TO M/OW4QHKH&BUDV2J)S:?;N\7J48CVWSICGA8%41N_U$?3*%6[/Y,1+&0D4YRC M@DEBWR4],'<>QH&;$F@) MI0?!XN=BX//,8<#8[WS;L MSI[ZGSH@W;*H7,QV[MH?O=X$V<A*4[F:8\$ M5==M'HN$1ZJ%>""7RD&_)4S<;RM&%IOS)6LOBB4T2W.BS-8"QQ!%:IIQD6.( MD@SC2*(R+JT,V"%"8R==*-+@&6U37^5O/CD)?8!99&($@L$Q'6,R!!Q2,P(A MX9F?<1210&D:%M+UY6KTO3Y=PH:%$$^R-FR>=]-1^][C?ZP6]VJ6UX^?JX72 M 7.,:8X3983CA"N;G!2)+L$EH12"E)C(G)'<1CD=I3"R5JII@AU14%.U6X?' M8>E704&$==,]KG):+[-!67K*2JMW:R=:_67O.Q\?<9(E-RA0N]:&'W0W!$SX M_7)=W:K!/I"U>)9R)XF4C.$<8LQSY0%C":G(4\ADQA(B2,02JZ*DPZ1&7G9G MBP58F4.VA@.@6?#8!@< &S8%PL'@MB O7DI_0H[F SV]D X./PL@AY8PI@$ M=@+V& 4# TQF%M@)TC4,+-\(5L:S4^_Y0NJ^8!M=)E%LYAF5 ND3O"2-,NW' M4(C3HH!4^3:<<58J"G:!/ _JHP?J]CT&WUUKLK_\NC"$3Z[3>11/WQ.]TS * M>*K7941?8NLT9QRU@.:0_.-5S#Q*^;5+9 Y!8E$3@U7Z4S*1+>TC8Y^MX\'F_1?N>J(EFXL>- M$-LO>H9T8I(^=8Y)@HI"K5>6"*Y<&4D@*1"#)>,9+8LT3:55/O00H9$7;4,6 M&+J@)>QU.'\4*KM5&P( MU7[I&ORYVJIR&NKYW)5W^W?H3$#+4JA3_"'9 ZT MHH^2F71%#PG[?$4//N\>GO@NJ)KRS=F2&U_B!UF(S?>Z#&(%Q)TX8^;!@ 9Z. 8A_2" R.7USC M@UAOM5-SZ$MJ?V:^I::@>*!HAX/L/2$/FU$FBWLXB-0-?KB\=MJ]UKJS^17Y MV1P?-Z[1G)$XR4610ZH;E2B$)<3L_[#W[KUQX\C>\%9]8O,.$@\D-9 M5Y>TM,$/+76_>0L3.3WWFYZB]BHMIF=$/]55>NXV>P?H6CZU7'_$5 ]>_Q6O M]8R/6[I>$5Y)729MPAT+2@1-! M&RY Q\8,=(R EA.@6'$XNC!5Z7DO: 1%V1F&5]>1N5,T@JX<'2,CG?GQABR% M'O"(3)\TF5=D*5K?,[*]U=YJ_GU5/Y45[@ZQ29J1, HA)QF2MI'+ %%$ 2PP MS9,P*VB*F*EMW'GRV/G9AI;#\MV5_[PA/YE%.,IF?]T?O\!^=??/>UI'JZM<+:*4YCB 41A++XC$ F)USLMQ M$@28RJ6>&:_TDU3&KE3I'TUV7K[]BCFMI//FP(OH=J9A=*G-;887Z=WLQS$M M^+$A9X4:L">G[YW,MIQEOV]GSE_LB&5]:H;X^[*FBU7]7/4&0\=AR"E'".9% M*IV.@$0P3Z,"%@%-,YY23",V_\8KLC)&5K8@;_.I]IDP_E([9IH&Z;5.*VX8 MTMC EBC*-KHU2]>,I2\[PS:H*+!E!?PYRI!L%R7X@E&V(3TMC+*#4@Y@E%V> MX69W=/Y8]015_$'!^G_C39Y)%;DHM.:/B]5?ZC2=J](7]<,OG"YP79>B; [A MWG&QJE1::IY23HF*?5+.(X@RC& 12R\IBR,9)!5<1"RQ*X3SQYS1&KRD3FZ? M,L ;&-M:0SKLEL^!7QW+,L3'+,4BJC((0KC&)(P M3"$.B&"8)UD4&3FWK_3F+LG\5^4W2?$;UX5[S\WYOZ[S^OF'IM+K1[!E3KXP MM>3![?6-?&7K%;B]>:_-[O7MUU=[>69;UNN\$KL-K3EQW6&R.Y=H"BAGS4@ MQ2O0S,[ZY94SL,_S#!#-M3K6\+?Q^5>EIVW1(V.3;IK^%;J_I8Y P5MI>5T_ M/S8 5;\KU"N\H&J83KF\/YBFH_9_9:.^R UJCM.8,$8C&"!U+"/B#.*H"&&. MDQQ'.$Y(8-0_XYVSL4UV2PI4DM;%=>B.RC>SN:^B4CN3>Z*&?D# \:9?5X@;!]68(=G8//@U &L%^.H2L:0^;?.(FVH.>DH<'^-FDSJ$K:^\^E:J3A9< M\7?[,-=;$_A12OWA.Z]H6?-;\74M&6A1K.Y0+F)&,0T8Q $HL(AI07 M29P+P4.KH>?>.!O9CMWU_%%0<;S0N[[.Q_*6'SM+YN^5F-FX5U&TG?5K1@N\ MVQTML,5>GX&.(;69--S,^HZ7/_OG75F>+*,_OB:UF=[5N6]-_1-P3;"2]?6S M=#F7ZSD.@I '60Y%&*4092B%F"0)% G/D@)1%J+(KE"B]_31ZR"^/JRJ=0.5 M3595M?JK7-[7L_;H4"7B:,,(>%(U*0W8Q&*#KLTDI_^EZHW1?_Y''H71W_Y/ M/,M0]C?UH[C[432+$F2;0]WJ-XG2E <\AGFHYD!A$D!5]0JC-,JC(A$X$'(G M4EV'HVIW2\%\+]&MD)=K6,W\KBIU+HC7X*&LI4U3('7@J5I1SIE\&*[;LV#; MX=]]19NFFYW49YOV4%*W9'QF>@]X]Y:KW3YYXFSK@4B'^=+#2YPRGGM95WW< MI:;GMB4(;:%BBF)44+E4BU :183S%.9%+(-=E@B!PS3,>6&1XS0B.K)3V!P9 MEUNJ#I6=QOHS2E)ZUXJ/ YU&33?3J,DJ]^A=7<[91A.U>]24 MN4,KX?:RA7;WNOF(FV'COW*LJNGTD[]PM=O+7;]K[1SF)2")B M&(M,S6G!!.*"(YC$&1<\C\,$81LK,$AMY.7?:_'O40=_*OI ,V!I#X959V8( MO"G$S@)[R3Y(^ESQIR:AJ7!3VMQF?;>Z M5F.89?2O7J$N!9RK8 @15L 40[E5L\AX0K@)(JS+,$Y1L0X2C*F.O+2UV6S M+2=@O0*T3]\\!#!7XOE0:135V!F!'@NZBKMC0FEHAXVF[G@,/9G'2J/HRRU8 M\J4WJZ#)6OZ!J,G\69.%3=;B]>,F^YO=?*4KJBOTE ?&RV_J\/LWODE2QCC- M0Y(2F-$80212"G%:4!C$"5;6W8S[RC.=_/N* OL/*U!Q9LY6K[4:6=B.ZK@ M2T^'6,AW JYV5-ABIZC:^Q'2RR;">W+ !DE-ZG^9"+WO?AG=XV8\CA\)]DZ7 MW[UL+^D/]FX/!O6$[OJF'=_]2R6_E'E LZ2(BQ22I BDKT9BF >,0<(X"01! M 46IW0G?"%R.?E*H:7(V [7BS!+ ;HS78F:17EG5=H:L7QFQ,VRQQR\@+^!H M!85B>M;62TCSUC"N>C\;UM5/)//^S-V(FO5D):&_8:JK3.L; AC,=->FYX)JYKKS=/1/G M_$+,+/44:K8SQV-JV-K<7JH>3S;5F8U)#>>ERMJWCA<_SSZ7J YUB^_\O7# MBFW/)F^6M.+2!+_GS9_-;SB_QD_E&B]D3"DM-]5YGBSEG!=I!@N2QA!%5'JL M2'JQ([>(7<3Y-.:5Z[4Q@PQEH6.L5*>BALYHK\$/'WX\ST+$(6A[!W:MHW#SA M.:7FW?*@4[P!JQRI+Y4-I$XO)C%91M67,OJ)5F_/=,R_JBWLYO$)EY6B>RV- MZCVOYR3E+ CR"&:<%%!N) ',PR*$,6)%)' >1HD10O"O M&,68\M2E*;8J.5*H8OT(-[NB(M@[7CVJ;H$Y1QE#%&5J+&@$$2YRA4--8(H3 MCG**HR0+[4X\^H\?_:CBTY'VF1?UY7]357YVIF)'+V:VP%56N\6NA51D@*+C M;R$?X][32MUY]*1+\9A0^VOMZ#43(9XVR&_[>' *>#&.%6(0R2%E.95N-XIA M@5(&49:C-.-(1-1J[*<_UD;>XA5J1]M^_;!:Z$ZY^P8R<]%"9JZ6-V!F;BT$S6XC,0^S,UP7-/*O*UP+- M/,W8VP;-/*O0BT$SSU-P:&Y4T!SX$9,_.%M)OZKM,LE0F,KP"4GG1V'@IQC# M',1A'*(#X3TU$0Z*,]0R>/S&Z1H$!QG?:0<MU^1 :&8N#VL4_0E.U5A48]2/G/5;FJ0(NU(3?_VM"3&E+"L-GP)+^= MW3 3W6/CGH&41]R.FM.?[E???I9WMQX'95M'8^B9DRPZ Z&Z56=RJ<-4K8HO MNP%K2*0YRS(F0Z50ADII@"&AE,(D"!(UUZ;@A5%#W=YS1UZ#FI++T*B>Y.>W M94=Y+,\*F*>A5H=\#XVQZET]W>"J0Q9W1E4=^;4OS/I- M6^ZM:$&>^;J>YQ'.92E7*\B1_UR(IJRCZOEPNR^7]I9#TQW5+TB*A.6:0 MBB2!*(]3B"-,($^D,^E*'%[\M:X4MPI@X; MWC_S*)![?8"ZL>0%0PD/X@BB6&'>13&2GBSE,)0F&#,>4IH$IOZK"<&1'=N& M!;#A 33X;I(-H/B BA$'9]%(E><=8M\*LC,7KZD;ZS]O$JL>N1;1%[F]+'XX<%?S&USI?TZ9K5+:F:?3= MS-.Z(O6ZPG0]9Q$5,4\B*%0>'X4\@R0F J:I"..4\8QAJQF$$_$]=O*OXE - M8I%,/:V6.@$F'3JY0O44G6\FQUZHB5_,> .]1N'ZM<=]C?DJ#(:!C4K>P>%O)Z/15&^]' M!0\PR5.8I:':1XH$%B)B,& Q19SBK#";P'Z>U,A[Q %QT%(WMU!G5'7>[OM3 M@)U-/RF[0Y;HC!+,3; _9;B95_L/PLIVFHDW8!?//& RFV&=[AEO;9 M/OPS?MJ:*2[M49KF,,%1"%$H&"P2%DB#Q4,<$I0FA57)^U$JDUDHH(DZ@J$? M5Y!9]N)BL5WMDJG$UF'_H$2>@O3C-"8-J0?%W ^ AR]VJUY\MQ3K^HK]XV-O MPJ9%]>*1VR>J7NQ&N_9K^6;@XVJU7JX&1L8;*V%XX7F2WV[9F8DN@SF?\T,- M)'6N8#SVS$DK& >$VJ]@'+K4?NGI>6$Z:E -3[SZLE[^47_FO/JE6CT_62]% MP\>-O#2[(6@;-L 7OGZNEN"/&BAF@.;&?&F:*NG\4AU!/W9+UTPU(RQ=2\F= MEK(ICZO=TF>\G+]OHYZKY?(9+[YP-0MP7G"*LBA1\ TR2$ MIN\@QZMS*@;%N'%UUS M<'/VK$I(I=/ZI ^?Z_;P^0H(_KWJ!_ZOJAMXI7J!"_\#+%I[[#X45R#IX M[CD)XH@FTF>G08X@XG$,<4822&)&$X33!$NN6IMOME=-Q;K#IF6W7S7D)AYS M8/O^S#:9-_5.7FL@0HN?VA.F!41;2W&VXQ(:B;;C$M[ G 3'M_#:PQ-LV?[W MF*C@^#*\C5EPI6]?1/"%_U%6>*$[7:ZH)%N7BL"F-87E)&0%9%&>0I3)OQ5! MB""+\XAGL0QVS%'%!RF-G)UH:3LY7:SI1V C=PL#W"WE5@7C;@ M315N50,G5>*G:L!(NH&B@>'[)ZL9,!*C7S)@=H.;A_P9JR%A[8=&:1!F!4\A M"15,98 9S#$-I"TJ>)@G(B:Q49O/;'YZV>1:#^S+_M9Y*FZ5 CN*,7,/ M7<6U/*#45$:H!CC&OB??9^?1D_HGQX3:]R&.7C-QP+EIB^V5,7XIZW]^K+@, MEN6"D-[(%QE\S7-4I(+E(40DQ! E409)+@//-$9%$D>()W8#.T?G>&R_0Y*$ M0M*4H49#%%38M#9ANM#QMV0,?/CSYG&;BI MPMM TOR$T\U<%/.X6@#Q^?X*@'0$Y.$7-7O^/HOSF5\BNOG2MO13_P;7]3S MA&0!IR&'&2-JD"C"$ <4PP2+-,E$3O/0JA#=@8>Q+51+7]FDU<\_K)[7__D? M81K\;25^!)H!$%]ZNGY>S:XGYEZ59V>BSH(\==I39]IR796+LL4[/S:C18VF M;V_K9*J:?6(%U#L!)J_#P^&WL4)'.] ^S\$K'U(;J^C\P;/YHQSGN#VNJG7; MM',K]NWKG&"2!#D5L"B8@(@C-1P*<_G/*"U83E.<%U;SW ;)C6S'^L0!_ZY\ M8ZZ7E4_'ZXQ"S&I7E*24'L M.NT&J(U=;LS;;;-J9S7;=MH-*>R4WNC;-ET^1UM62*DHR4N/0S>?UYM2CIR[81)LEP M$/$D@4G$N0%_XG?XP7 2P8^++^5U6JI M#X 78( MO,773B''^GXMGV!?"O3+ZANOELWTZ?]]+N5']H4O].#)N]6[(JE0NRD)(TSP.,Y$P;G;.9T=V9!.S901TG(".%2"#\XX9AQ(: M"]4.FYKQ%&9G9MZ&KLQKC\;1F5LADJGN_-0EV4L^4*1D\;#)*I;L!>R7+SG< M[>;$;4[E>IF?QG;O.QM8)EG$8Y)"*D, P1C>,8H2@WZ@2UICRR M?=V>H-OY:>::,W/31M&'G?GL%1/TF)C&/;,6WY-W9DYW4N?,6AW[OIG] ^P[ MQJ^?*U4%]K&L*5[\#\?5AR5[KRIW4HICH68%YR0,(&*Q*M N& QYE%.>4H$2 M(T=LB,C(9J$E"QJZ0!&6,1X#[XT+I08U-&P3?,EM&:2YB&S537Y.)J>.\I,/ MG:RK_)Q8_<[RL]>Z[>.?>%US?OO$*^TE?%*'>IM$S^]+)LFI%D/./GRG\M*F MX7">!3$)1"9@AC(*D9!1$PX9AI2%482*G" MJJ;2R&ZO=].NV;X_NL[LC$##S@QL& *:HUXF=P;Z7(&&+>_SA"Y2BR??P(V' M2?V$B]2T[S-<]C '6/+GA:+UKTW73I3+R(XG,632@X H3R/I-Q " TY1DJ4Q M(T%L##*^]_"1SG47P*YD%I/8%$CH"9%M(:H=[?4*4 M(13K_5NFPZ0^P>P.PO2I:^R-@.XAO:*T>L:+>AXSQ(H ";GDLPRB0(8/15I0 M2,*TR%$62:[-=^(Y2,OT\\?;H$B M8P'#VHHQO#0=);!;E&>9M\-.W677#2NU?<9TV*B[3.]@H>[]RGXG^ER5C[AZ MN<85;YV5."-Y'.$"T .*H(/C M=JB,\YO312):K@7?TIGO51=)Z;9?]:7ULUN=%&)@QSJ\9[)=ZR2[_9WK]$5N M.36%9B+#X*OO93U/0B8XC80T @K]5(T"P%',U!23)!$D2D(SR)$CSQ[9#K24 MP)^*EF5#?U\#9MDL1[GL%K^A2-8YIR/,>\HD]9\\:7[HB$C[69]CEXS4R5^? M:@[5_[F35*^63/4EJ)W\_>H1E\MY$/ B"$@*TQ#%$(D@AB1! :2L2 D2(@LC M*X"-,9@<>0EKPD!1!G\V!"W7\2@OQLP@O+:Z[2R+C:;]M\Q?H(JINN1=6'Q; MC?$7*-FZ%_X26O;QRP%$O$;R_WU9KNN[KU]^KUM/%^% D$P:5!322+HR20YS MFC-8A 6A&(FT,"OD,2 M7/G7E%O$Y4MC5D&9G? #D9KA@R8+W^P$Z\=TEGR%C0JD[B#,&Q2R(D>2CO>P1/ M+0,*&[_E8 ;P\%&^FPK-O$6?BK$SD5HGBC3H:(/KGDZ\ES<8"NJKDN$I7+"U,N7[YRJGZL^1U6[(U)XEV_#UJ MQ&[UOU>R;^G-0*>=CA=M 52+M(9JJ[>S(*X6B]5?6'[VNM6_@>)O9U"T7/LS M&H;J\60SSE&;U&08BKYO,4QO<_0;2JI&,RSOK^XKW@1\K<.;%R(K(I&IL5E$ MY8PSJ HM89X3'B(1YY3E5@[#*4IC>PH=7; E[ @.>UI9AJZ!#Q58^@1.TMO[ M NY_3MR#;?_L#8[IZO6*_O.FKI\Y>R_MPO*^@:W7T49]/+5XMV5J.A"AIV9DT.H9X=!W'=I@J[^5,? M5Y7@I=RO?&*UNJO'5U[9@8-IT\;N*CK("E_P*#=#]NY96D=>U_*1I%SJ)WZN M5M]*-909+VZ6TC-]U#^]64KO!R^NJ*[CEJSIF5)/"[[FVS%G6_2?>DZB((T+ M58:-"G7V'M_#C$[0__!N-I]_X^E9L?U//"U$$490B&"58QK9<4%C0(H L# E- M4$")R$S/#R?C>NS]84MY!AZW'=?@2>_] &\Y,3]F/8]F/SS)'W\-T)/"U/0#$% MOM4_Z0$]>/D".NXZB!SS5B(K_0UOR6.JSFY7==0:^-,KBI"K/IRZGJP(3=8: MY2)^OW_*Z7[' 8HJG;]:7BV9;C;\O*K7%5^7C0:)*.3?0A2R-!-4))'=5/?IWLLE(]NW MI,!BR\!KO &S+.#D7[OMT>L&;>;XG),M$QZG>?K4B:\QH%YXFG9^J$\U'@P> M]?IP>R=8/D1U&O-56[Q@Z.?NW3;R-B&I0=TM_N'6W#W=E^R\!WJ!4';6H">/ MQ_J+ 1&<_,+]9TWF^IT0HN_=G;K$$37VY,RTWVLNGA>?2AG2\IB0*,\YI((% M$$7*/\L4'&04HB3D>8X*J\&*)D1'7E@80%\&E*0/7*LA<2^0&--2$Z+%VNAA .H6)M[W0S&A\>GQ>J% M<8Y'D)!<$QCQ(I=7@ M"@PNB6">%BP1*$:6\9T##R.;DXXCH%D"&YZ:(7X_*+9^U(@O3LW[+CHWLS$C M:]+.Y'A3HK7AN4 -GNR0"P>3FJ4+5+1OI2YYE./P0L;*MYCF:NRF]X+7V@FV6]KO3AJE>?=R]\YNR^7]\T0CM5261Z] M7W(1I#A093!!E$/$BA 62' HW9,@9WE>9+GE=&87-D:V#BU5T"?KY)$X*MG, M6HRO.CLSXJ(UA_G)EPCM;82R$Q,33U&^1%&'@Y0O>II]=9_J3]QVK[7];/)O M5ZIG0$T1^"AYV8S\F$=!GH29P##BL?1-4BS-$L]"&"5YQB.12[?%*'2R)SVR M*7J_VZ,*'C?LS( :F002\")9DO\2:I;--_.Q/@Y:'K9+X^K.SA;MM;>"7WMJ MT[PTPSX4-S-@.Q#)07/FU6?C:="MA,RW)JT*P-R4,5#%9?G R4JQW 3MUU,Y M/N%2RWQ%Y4?UO%#'Q[]4"H#S+(AAG"$$4YBDD/!8P M2,.<41PD 4JZP_$[%_,\3-_A$/SN8AL] _>*$_"\807(0+TV/1NWUK&M5?:@ M,C^0 SU&@.8$;%G1B (C*FMU=9UW/K7'FL7AUZ*F8V90M5VUN?+@59K MST7MOF2?HA)QB(VW4WQHH"RK>D.3YWF#=/C"Z>I^J9RF/AJ!KM.0#I:>$LXD MF[V"1_D[Z58B3&,9 MC*X5_J:9-1R?92N[N6'R#W!VS,SFV_KG=@9V./=FEOV MP0XH1R, Z"30>UN/3= *HA?,2K\PTA*'P\'PC?#KPT(,=(+,$"& M&(NRZXB.5;56&*HJ0/\D>;U9\\=ZG@6%2%C&(6-$!LDH#" )2 B#+$G"A/-" M8&8W9.,8F9']7DVTP376N:$_%6&@*5O/RSBJ)3.;>[GL=G:R$?O.3FR'X15# M4GD;/W&4R,0#)(8$/1P!,7BUVR+]C?^U[>_^7*V6\J^T 3[\O%J4]*7Y[S:& M(C@B48A#B(B:FQSB&.(XSR$+DR3F64)88C32P96!D1>V9*FJ'N0'U*=FO<6LEFJW],U=G9A3VM[?(R PT?X,_VSU$B5U=E>#(GUN0G M-32NRMDW0<[/<45-Q6O]].L%KNM;H>MQ=9T616'!!<:0IRF"*$NE%2IH!!GF M(8MY@&AH!7I\DM+8279%3B&X-!7E+I5NIY5DZ$/X$-TRFVXEM0,&Z1F)O"&- MGJ(S,9[H&7$/44//W6"W7.MJ/;\KUPM^*VZ6K/Q6LF>\^.]R_="O2KM;?9!6 M8_W23G1#/"CB/!"0\5! %&0$XB2G,"]Y<=R ME)Z+/H?7^LA:LEO]C8+:$P-=9>UQ -X%D@Y9!?G8GD60_]I: Q>*D]B'"U31 M68Q+'N&[W;=^]_(K_L>JTD9+[V]Q$J=%@0@,22+CD8!2B#G/(.=)1*4=H8@D M?KI^#VB/;$,&>UMK0%Z 9@,WSZ$=Z-3Z^LJ)W.T]2P!222<4B8P(A@"E$LU?;)DNT>@(!FJWL/#* M1)4^C=09;8QOJTXQ\%9,UAD%65BNKW$WY2^4VZL@80R#G 80B:R )$PS*$A2Q%E$>*&9BC:P\N0CFI4G_[)=>6T+V$:K@#<3SY(\.49K4 M\300>=_#-+G%;2W?R=MNQ1>N>L[I6@\7:U/-11['#&>)BG9C-92E@#A/4A@+ M40@F6V9+68O.K!,P[N);[V0SXKF:1F? MIC/I(CXK[OX2/G^#VP+6PQKX'?ZN$&P^#.BC3LN*:E/%F:WL M$=1AM\X;!G0)LF)A!EHFNBF@#1^@8\3?PK>4W),9,*4ZJ5&P5,6^B;"]W;$4 M\%FY#;?B]HFK9KKE_5=^WTQP2@+!0JYJ_A(F=_Q0(%BP ,& DJS@448YLX+7 M/4EI["R4IJLVO55'&=0M:VPF^(@J_GA+]E>TLZ#OOH+5^S#_S[K5, &5TJ' M#W'G[I$_W/WSG%2UKW35PO5I^XY7<5!L1YCBC41''L7PW22"- B4PCPH. M&8["*,H#$C&C0N!7DV "#Z0&M*.I"UYXQ\VL'6MNCK/Q.B]YV)K]6[PZ.RO9 M'TF_.V^JU_-/7D#_NLV(=276##2"@9YD;9)D+64#K7#RLDX\_65L!)R!1L2W M_F680[F\^2_$#1/F[7\I5E SK_J6!C!K7H>OR4;=%X3%1G%LQX5XC=EKTEKX*;(YH!?W9,>$7IL1#:&UB/" M0:H9O-P^A_$9K[D:)BW4^4L<^N*VN'U3@<[/L7U$N:?FTX)\V*!V1]!9XP@H8$1E? MH)2$L,@%@P4/0IK&N8@3*\#/BSD:^P!EJ,\?J+X:S:-"2=BYK&7S IB4R]^5 MX<',E&_ \@!G"N7[Q%VP4]CX0 R&_+P59 8[]5E -5@^V'$,HQ"<-F-+VL/K M+]***X0J26=1ZKWT(RO+SUQ^['F_A'JVRVX?4%NMP3A[IO8M5+9*-[.)8^C0K5R\ M8P3TBEH4+V"7F1GX^/[F9@9:ACR.8733A*\1C);4IQV_Z*::@]&+CH^QCSCO M5D^_25LG3:-::G4;610HC0EG%.:%'IN18HB#*($9%4FJBN$22DW#S:,4QBYJ M73T!111T5!W"KN.:.1]F7BROG3483U3S\/)BD=UBRP/1_024@](,1)/'[YLL ME!QDNQ]'#E_HB%%%'^1>K1 R-B-^VOSU#M!FVQ'';A5(YW.E MEWN"[K.X70 MV4?72SF*<0X3QJ471&D*5NY%-5\>K.L79CK.:=8 MD.O!"O'^3JLUQS/7F'EY>;%'8KZ?KO-[]=7;YF#ED=:,-O M+VY61_N/[<+H/6J2-7#(>O>Y'_F-?6[B%[[D54F_RH^K7/";Y3\X7:N-KHU< M6CM+&2DRGL20,YI!1-(->16W;$AZZL\B96<@_D4,UE>Q4JL?I[% M[D97K)%>P_25:H)LP+14\EA'#,<&P&4\%SPH(HAYJ"88I DDG%!(XR ,B.!9 MD5GU.KLP,;(1W6WGOW[ U3UO(O6FM:!Q^&6(M:*E1IG[JUP_-+.,&C#>NNTR MJ-?P2W<*]7/[YI14JE]!7JC'+5IF6IS>F5DT,?:;L+/6NR\!Z_;J%M-OPQ#8 M")G;AQ,M=KF/&^KW7F2M?1;<>:P>8\RS*1 M%Q@RE$7*GH00D[" E!*:H"1+4!'8C6X[1F;L8Z9>/R;M]VWR[^KOAC"E9S1E M> ITL?R6QSE:]'>[K:C;#K\9^$U^F;A^ !_.J,)AI-N0I-Y&NATE,O%(MR%! M#T>Z#5Y]Z8GTB9[.UH_?.[C$/.<)83F, RX@HCR%),X"2"*1YZ$,C02R GEQ M8V/",^:CC=F]WNV.0=?39"OM&QJ,T77JV:!T#$UT_.NB%>_GO%9,O-*!KHNB M3I_<.CW-<41#=TC<'0A?K7_C:WUBK'\LG2#-39N[C)(("Y90B(50)[=4P(*A M$*9A%B5!* ,D;(55:4=^9&/65F%LJB[P&OQV]8?C8:ZE8LWLU7CJLK-3V]J5 M76WQ=5/*TOY.LM/L"B,<#+NIPM?(!3OBTXY;<%+,P:@%MZ>X&:G5):L[C M, X1(3 /4@91)F)8Y(1!&5>FA6!IGB?%?+U:XX69J3E&Q,J@;$@9+Y,[=0M@ M'8+"&G_G-8!;2 7Y@W;FBYUM.:HO,PMRJ1;L[,01\(B9MA+2752?40OPLUBL M_E(5#/ZLPY"8GFS 41*3KO0A(??7\^"U/I,:&L/F3A6D//"[OU;M]I8AD8H\ MBR KA!KK%%)(2!+!."Y$$!9QBC,/F8ZCM"=)?PRX["T_0#+DZ$K8*/J21,G% MZO,<[%AISE,*95 'H^95CE-^ \F6096896"&'^%H?E3=JCX%ZO!ZK^KKU4*= M$%5X,6>,IRQED;0S*K<:)#G$ZF\Q"VF$BB(,,BL\FF%R8U>XJ20BW5 #U3EP M:1>-&9H.;WJPM!8;NAMH;>D[@2UICY;!2$1?QF"8V+3KWTCP@R5O=I?]>6R' M[:LL"5[*Y]\LMP@Y1JQ@A2,P !1NE6+VTGOA>JQ.O4U%G?@ /C\,R8["S86IW\L;'Z3:PJ$K+>8GWJ:&*_7JE=; MC]Q@;7\VON?SA 9!E@0,IB@J(,IX '/*8OF? I$<(2YR(P0O>])CAU*:G!J( MJSD E?RG;6+$6(NFZ9(Q=&.;1"'K'J;Q#'1L:*B&&6C5MF7%9QK%5GQOR15C MPA.G7&P5D99#E M".,<01K$"G@F+6">)1PR$N1Y(D3.D5&YW"O+,;*M:Z89?-.D9@!WG"CCU[ " MOBE>'!)%K_#*+9).;_M%NB>PSB/6[R6ZK!#K-P*"C81=ZW@CI.>TV.N])9\I MME>08OITW>N]JJ.IOU=DQQ7SOGI:*4_SM]6RG1W401=AD7":)9"&<0(1BB.( MLRR3?TM(5"08Q[%5!O$DI9&WFL:@O'NNRR6OZW['A-MQQ&F-F>T#7O1@FSS4 M9, 7+BDK>+[9%N%L>:\Q'&=@PYSHXG_QSE\QN<7H4RCR%YRZ<6[[.0DBKW-QQ.082 M<7LW3)9U.\YH/\5VX@K7Z%<:>@7,H3N;,S06$A M$@+S@N,DDL$K"2VK$4X3&[W\0)*&\L9'&3INB-N&C0.Z,HWM_&C -@!3PBNR MH$=WE/$T)@)ZBUT&2$T<8)P7^C *,+C'<4T_/STM="2!%^I$_.-B]=?-4JRJ MQR;2Z#[9."O2.$H%+**D@&KZ#,1A*"#'1<+S HFLL!I094AWBAJ )URRGW_H MCO]_!*SIB)8>/GAJ&OXD6_]EN?P-U6IH"?PKR](H]!@ 6FF*!=#C81P#82>W M+UMA2'5:LV&GB@,+8GF[Z["*=0.)_&E5UU??<+G0;16KZ]7CHPP\UBOZSX?5 M0CZO?E\NGE66,Q&XR7]0I\%N6_>*50PG]2U0F2O6;>;LN?1F3 =2W]8M9. MZ*U5WL9V)(7M&S&S2*/JV_5*OGIZ94BZB,BW0I>ME:=663F?V5KQ]6[%AP@%$(342VL9!;^5#.I^->ON?A]U6\/^^#+,OPSRE]_:_$+?4X5O_4JSR ME:_[D@;RHJ_$V&3YU]=5?#_/^\J-W_.<5KP*(IT_@E#)!"&._/JM4Z6KQ(+9XB1C<>)HT:+U+3?N1XV%*IWX*&7_RM?K)D57_W>Y?I#7*X#&9VEZFT:@.9V' U/ =@6T,GU?N1C:(&Z9 @X6DDF5;CE2"'F#P)%]A MU=I%.QOH]T69V<974[^=S>RSJ2$'.D:EM]RR"C:L K6(08_9!KFW81?T^/5G M2T=1HR<;ZY>W26WO*&K=M\GC$+'/])W9&Z0C_/'T;]^]_(K_L:JN%](Q:T%- M:9CF48X3F!(40,02!'$2<9@&.8](6F!D!E,W F_3.:XG/"Q]KO%Q^!(BPV;% M-]",.X#-^GZAYU-IK_B:?/O _Y9OR#RE]8IORBU7]3IOS"H#-9).!U)+OBE. MEC,:257]9-!8)"Z%>M6CQ'$S.'G3E_"+I* .\VZ6NE=/_>Q62/[PDI9X(<,R M7:0@U;K%(55=;T7!"LABQ"$*<":WUT# /* !#E'.,Y2XH0*QB MKOY9'WSS^D>5MGAN8-!60-=^RE<%;H50^(&;'"!>@':Z._CPG3ZHA)^Z;*<% M%GPIZW^ZHLKZ>M%F@=2KOCZ[S7?+8+\];:;?8E>], T*K6=5>0>H]<7?*V'7 M>E;O:5A;WX0\@4W>+#]7*\IK%<)Q^;@'=>S O_'%ZDEQ,\>4%$$4)A ':0A1 M3#-(TC2!89*'+!4,)\QJ6JDM R-;Z(ZH=LS8ENPH0)7G=&UF1X M5/ ,L.4&[.BVQ]"(0)>&JA@+!/,<^=<%R#14SEGP3-/GV*=WOG)\SY=M/Z5( M XJ$0##."ND\LHQ#580*(\JQ_$61I-@HB[[_X+%]/DW*87[BCO#G\QBN(MDM M<3_2F,?\KE*Y!>P--3^1]3'.!\+BG9&CI! "8L[41+&80LRB&(J(!BQ 2(29%8K^*4*C)U#;((SJ&8AT M2]CV5/^$GDP/[B^7WC8OV0K>#'^\-A#CXL[.$!^9GK M7;$@E@I[J;N0TC06)4""B$ I5-4@KS5,WT2:,P1F% MH\#J6/LV+].) QJ$F:#>0"'.D)L8 M&\),^$.(",/[W,R ]NTYJ_5)+E[P7[&:0+I^D4Z^*D#D>H2OFM*SJM;KW4[7 M>1:E)$D2!C,<$(BH=-F+B(FM,O>1EFMF8B%=N9H5WM*K9FH&.L'2C=L=;,7CO6">_/3'G0 MD2<+=@DGDQHW#RK;MWL^'FF?DCC(?LB_=#]K!UNJ-$@E:4E&KBBMGO&BUG]R M]F7U@A>ZTBS@$4H31&#$%6QMDL:0H"" *GVRW>S%>SJ^>62F_B(^E MW [9/$-Y4$2YV]F MI [%'[;X%PEE9[@[>3Z>D<=X>9_D_8C;67/ZT_WJF]R8R\;CE'_9.IJ'3YID M&9X4H%M-IR]PBW(_"*$<1G48KT *Y+I4M33731=>N;S?MN'-PSR-PSC#,,YE M9(L$3B$.DPRF 0ECS"(>A*D-\HDY::ME90]YLF%$NV$:^U.U9[0H*#KTHANN MP&K#EET(:Z%ILXAU'/W9K>"MZEI $[7!-]58';*J9F'6#2;P%XS:B^\I]K0@ M/&FH::^0_RTK^-(&>W$##@ *2XP_6>] M7BUY6[@9(,88#SG,,L$A0D4&BSQ,81QD>1$%&0ERXQ&S^P\?V9!OR3E4KQXH MXOQIT27B6?K77B6S@)B[0$)'\+<-14_X:R=A_S273I'!0OB((H@HBE1?B:&),81I+E ,<]8 M$B9&19:-4E,I':?K=/3*]TL,S:1*NT\DE--TMW^!7[8<+8])"F7 MH&NR5MQY!#SUH"-/>:A+.)DTL^1!9?NY(A^/=-MS^D<<2]8?T]$@3,_3* M) MD7$8TS"5\5R 8<[DQI(E440R%A9!$=I4PYPC.'(-S)VZ91.1E:V7R#5I._MU M5G-F1LJG/NPLT:<])7P85H*U:3&5S)/].$MN4B-A*OR^)3"^SVZY<\KF7YX7 M/ Q($EY5U5WUN%RSCPM\;^*;G+Y[;)=#86DIJC#LCW$ JO5''>6:]EX/B#^\ M2OU(;NDAG!4:_*DX\-"7>5Z\@8)2>7.[+BG;+L>!1TZR ,^+U"TY@RO=]M2/ MN*S^P(MG_NYE\]>_E[Q2._S+)[6_Z_'-(2U8GF(.,543]G 8PT)$& 8L*5), M2"ABHW%2=F1'7K&*,M"DP8:VWEU^N_K#:MZUI3*9R$62IA&,BYA"E$81E)X) MA2'*!*=YBCA)[>)?_^IT"G6/GXWWU+Q[VJW11#FNGZO&:(RH0Z*3NCYTB]IT@R[O=K+0"X91!U7M>E_=-55ACE5F,$*5J M:@T.("IR!@D+!4R82'"6Y8(75OF%)DJ$!)+HP*TER(C[SN=T9:;KOM_O,_ M\B@,_];^L>1KY>&O\7=;E#D+)9L9AK%49V*ZZ;%$[-!9^"W1GF2'X53 MVYVJ?%Y5VC>XVAO[_IM<3?(QDJ>%NJQ#7?,)O0&_ =Q:D)P;#LU?*(4"> MPS-$%G2^Y/LFJ_9'$"FF'!$Q;95NF$0<3Y66V43O6K3/,;KI MPE>RT9+ZM%E'-]48)';]0.O[A[P\K:!I?Q#VD_=PZJ*2%3;T-U*_>CV>5U+B90? M_-NS;@>)TJ*(DCB!.%43$7,N8,YC!M.P" (2Y3$VZPM]&^*,;$0;-IJ2D981 M%3FH[6L&N/RIC#::*;/(" M^M>U(@(MXZPMH>E/D ):3K"6@H)6TAEH/Z.K95.UWGU&?^C/J">QC&"US/]6 M'Y'%[(=79];F8W*<./'O]U'93<%X,^]P:/;&ZS,YW<2/UY=USZUZ8UPY]F:4 M]P_K6_%[W3B"MV2-55F&[M369!P6F>9 $,$Y)" MA/,(RG\**+(T"P,6BS#FEKT9[MR,7K"B>8,K 9]KWC8V@E7+H"IDY]U@2X4] MM]!3ZIV/NRYY*V:1YT2:MO-4-BJ6;#6A)[CM:?A#7\,;YH#F;GNZYK&'X'(= M^>HAN("3:7L(+E?900^!AT?:1["-.<;?>2VMMCI)Z8 DHV/IH73-I75J=SCSZ,G:'LQ$[+<_&-[A"]NP"]&^\/5SM;Q= M;M&MYGDH,,M$"BGE0OH+>0%)1'*("8HY201GTE^P.CZW(3_ZD?HF(U-IVF"U M!$^J:-]QS+2Y7LVB'.^Z\@@#N%%=PTI7^=,! _I&AG51Q6A(? .D7QE,[[Q2 MSN/A&3S#WE6X6;+R6\F><=.D8N@:[-XULBNP)?9?YMO]GESGMW=WD>Q6[9:. MMVK[T^P[[<][CYIL/SXN0G__/7&%?1BNL.LK3-<*5_+ZN5ZO'GGU$7];51K7 MF/WCN:FO^;BJ?EE]X]52PPO(:^[YDKZHE,'S^F%5E?]JX2>_R5^OJI=F8:J4 MZMT#5XE;O'QY+SV%Y;W\]V=]SCE/HD*&^!&# M,$RJ EA21+"I@G89CE) LP M,NIB?%4IQJZ]Z60 >".$3L[=;\0 O),#Z+QI7Q(]3E*+TKH/S4ZNCLOI&M7$ *!K:2@8UH M0"=^=[Z1C72@$P_;!7 M?U<#F;;7XVVR7-ZKJ[^?+7Q]9MS2&U=4+N7GA557M]?0YSI,BB%D.*9/_05$@+55,.60!"?(4BSB)F(WEGUJ L>/BAALU[>NO ME@N(&S8 ;_D 3_I,2$:U344U^*%< K9:+'!5;W]Z&A'S;7P(9H;T+;]>.WML M4O9:GZE[W52V]J322*AM@7TG&6A% YULS3&B/W/_6J_%TZXQ.?N3;CZO]7+V M][!7X^."K9"<+\@E^]QN )GT1+R&]4WI+:\>PSGA09@'60A%*!A$*QS4QF'T>FWCU$5?G2C&)>B.[2%SIW]QM?S MC&&1HP)#CM)(X6DR6&19#O-(I)3C) R%53-\_^&C'Z\WI*R["784$-$T$2+) M84%9 %$089@33& J"L1S^>\T*&QPSYT58(]Q[D6 M8Y][CU T6 ME8.@Q@OLG#1#BTS>VUM@\E_;Q77RL9,LL'-"=8OL['5N^[-\Y!.OUB^J3&ZM M&A[_][G4$QD3M6$H>%S:Y] MGN3XBU$S,-/%GNO-G(IF9,Z?B@V@^; \ C'0I=G^YU=#U@OX4N58[YCF\GK: M1PT(3KJ[FBM@?\^UN-,QI[/&:[[[$4=!@L,TE6YK6F00%8+ /, "2L#',>%TEKF:NP$]0^LW!2%E\9@4,"TT;R)P4\ MB,!/7^FV\$X=6JI#^JMON%RH$^F/J^HK7O"VUT;&9@IY%86,(!X6D! JP^R0 M,YAG*85Y47">LA S-2W9/,ITYF3DD+0I9: [I0QEB^2Z4*4,,X []J!85;"6 M#()ZP^%,(>#*_RC*=HO?_=V8V8A)-&YG2FZO;V;@/2=K\+6GP*L=_2IV9N 7 M7'8--?(%"&F?>Y6$>KZN/P-TL:(\V2EW/B8U9Q>K:]_J7?Y YSJYU?-RW?4" M-VPT0.+2"5*@RRT\?9$7N. T@&'&9/"2(PH+-4Z5!B$369&)(#6"#+ E/+(' M\YL^!6(HXZ%KL9TV=F]?J+"L1_15GF9&=NC;+ M2AE'2K/L[K?O7=I%[[YNH+O+Y?T6NWMCGNY6TH ]KI;]N8BL7#RO.9MGTGSP M F%84)%#E D!"T0+F)$<<\P9"YG1L;,_ED8_Y]#^DX; IQL6>Y,$ -XOB!3E MO^06+V_\2?EBDNNF>JIE6R<0L#I9^(IUYP79'ECH M=Z/+H16'8,MB;T+!UB=3?1<-FZ#/)V@9G?P-F+?=3/\FW'IH[A[*&O!%$V)7 M7'I!M:Y!4RUS;22B\,C4"QM:49L7)I=3MX3Z+^ROAY(^@$?\ O"B7@'" 6N[ MVG$MR7[CRV<.%FJ0=S"J;VZ+9U5,Q87@5 &N"=" /NF*.=P8J2GG M6I% =\3R)9,?/Z<+K'XA"3_A4F.;;3L<9Z 4\@$O/_EI2?+['0_T%WDB-%FS MD%_%]#M_/#_9+3QY]US+Y:EFJ3^2LIE=]H73U?U2;I7L1GZ(ZU*4> , WLU@ ME\Y/?U1SLVFJ8W-,6!)0'D$>APPB+%)8"$%@D*.VWY=,O[15UG-2H)RD*85%*/^#DHS#/">1M. %R3#)"%NEJ9&%8UDV-5S1HYJR_-K*UQW@HT M ]T[ES)U+39O\9U;SAMX:^_^DK$";^L;L)\;,.6[.#<>8!)>IIT",*5Z#\#^ M)R7N"Z!RBT#7_K#^C$LV#W!4%$F*H0AX E$184B".(-!S)(X3[,H3W@'3GEG M,W/:C+Z1.=E%I[RSW^([BCK5/$'VE6$GAY5Q'G+RS/V>"W/O^/?U.RG0/^<\0 G'+)9;<:[&U2<% M+$24PTP@+O(,HXA: 0&<)SEV71Y]X.QYP55Z6%GYU5)GT^6_!JM2AQ,,KMHU M,RM^=69G4,Z4ZMXU9T"2#Z 9F:)@]T#JL0MVMP3?1L'N@0*,"W8/[[3'J56+ MYDKW!B]>E WZH]:YTZ_;\]@OZ^7V$S?$L;5[ZL@V8CG:/(M(E').8%&D(419D$$<90E,2)ICGN$<">00N^Q2F29"Z6@Z MS:7?4XN9R^ @I5M*KY/L9E@R^ZK_HP+XJOC???BTU?Y'!3NH]#]^E?WIPZ=5 M12J^Q"TN7I8(1C F,(I2!E%!."QPPJ'((II$81!GQ'BZU>ZC1]Z2.V(.@YWV M5' ^U>XNF-WB\2>3>2K973:W?&]'ST_R]3CW QG2O1LF2V,>9[2?:SQQA6M" ML"J_Z4(JA:=Q*SH GWD:D(Q&3$":1RE$7/Z-Q)F +"=1D04((V[55WN*T,BK M?TM6(Q#I*K&6LFW"[X2B3!-\EXMOF]#K*,XT8D^3MC@CND/R;E@N;\FZ$V0F M3LX-"WN8C#MS_:5KMOZ\6I3T91OO91R' 2Z QV^5[B1Y<%W ] PU5\&?[YRAYL_-" M>E_-!X1>:3V?$OCTBCYYA[VG_MGN6OQZU6]KE4M+D]QD))8P#@."H@H8VI3%E#^."A80@0I7))2%[(U319+ M$@+/6]8 :WF3^]I3PU[3%\%4 W?9LBC]]-I^G[_L)9DZ ^/KW-%CD/K;XC)N)'10OJCOT8OP\UAX][]=R M63X^/W;N#B8X9RHSCQF5[H[\#Q;2\>%I@<(B3!&+(U/8O)TGC^SRM+0L/89# M^8?-S452V1D.8X</".,G\!#-[N\R;#OSLJ1A_X[O@%]G' >]6B*0-=Y>1] M:%HENX42)RDF(H8T4-"T(9-Q02%2F 0RJ(]8PL/<**P?I#)Z1+^E"UK"#C[W M:26=#R2\B&Z[)8\LM7GDX45ZMTCDF!;\A"9GA1H(54[?.UGH/*U=Y\]J>=\5*Q]/_CX1?:%;7<5NZJJ M*[;2"/7O991L6KQV>.?(*Z0C!10M\[*S(Q(.KX_+A;-;(%W73K\9R$Q6J]JP MTR(YU7\=>=QD-5ZG1>G7<0U;%1;&A)=W0GN 7^:'%1ZIE&"FEHV^U6IHHTV\=&4(_= MX, M?/YK=^#SAHD9^.V\IJRW/TNY/6V,IE0GW3(M5;&_F=K>[F8^/O&ZYKR%2UG> M?U*E;ALJ;6-=_?Z9WRR_-- [_\-Q=2=?&Y\7/,I('J>0)B&7CJWT:3'*,;\O7*7BZ5K/ M:M>M>C>/3[BL%+'K!US=\WI.<)P2$N0P)0F3[I ((68Q@JG(0U+D*1'". -H M0&_L*$01!>6&J@7>HHFRSF<"/:O ,ICO$Y\U[;5@2Q^T#/C5B7F>T+-NW#*& ME^K(*HEH(?% .M'D*9,E%BU$ZJ<8;6ZS-W2JFW#]LD7:5J[BZGG]A\G>K_Y::N $-1%VB]Q^O0&$O'I4)YCSE"SOAKBLD7E9"V;[0QRO&&T M!JLEX%H1O2$%YC9JRG=_WOZ_T3=JMX\T0O0F'H!6#-#* ?J"].:ZSOJ65 /V M7JE*D.[5:X%VIB+T/IM&J+?YWLWWN#?Z_MWVRK?X'5CMOZ_P-@;V\2FYF 45]_V*UR!O[Y]<\VJ-R^7=UR^_U[]4>+GF[&8IOX](4I=_Q.W)8%XD.:,! MAH)C#E'&$EAD80Q%$B"*LSC)"J,34G.28WL%#1- R M!4.%GM^O_:O),CO]RAHRW]G\:\IM4S+3F)_]PT[F =-O^*#)K+:=8'V#:WFG M_R%P'U<5+^^7S> 4^G(G>:@7#2K>QG2KD6-AD @D_P-16$ACBD@*\RP+((Y( MEC"*14*-3M,]\C2RM6VY +1E ZRW?/0#KIG"$?T'7&RP?*[)8OROID1<;/\\)WRNKX5&V_Y5FQQ_C2TVK;#-0ZXX&D2P1Q1 M96&+ F(2(1C@@HLL3 +YA]5 W!&8'-GD]J'[>DR##NRRQ[9R41K&U<7;6%GC M_&W1,"V1>,9XKV:&^K7?EIWE'D AU74APR]O]]WUWM:H<(-C:M@7;-$8+$X+ M?C2BD@\@E,:D99^5^%SQ;TMPFMG?S:+[R>QT67GTOZSE-LWK]?2_^@JOZG^O"_ MZY>KORI6RQ^SF^7UMXK]3]6:?U/48\?GCWV2H"=P*C^\%SEA[8[_P>MU,U=E MW0135;FJFCK*]@!3#\2H]85-JOAZ]8VK8GEUD05$LJOJAZW%5%JW/)@83>$> M>\U\J,X-7]F5Z'1(RQ>J90=S^=)G739.5$_"JTL=&WVN5A]7U2/^TK2YS&/$ MD8CB'(997$"493$D/"P@"?* 9T4BXQFK')0!S9$M74O%<<+GD*[,G!;/&K"S M.IM)G#WJ,S4& VCZH&7 _UA- VD]C\H*W0F.\OQN8A56_>]E>TQ^&U<.QS#C'O,BAT*>"E!>]=LWNHD7>WZS0_?\S4N%[:H69Y?GID!>\578IF3WC"Z?1_O M!L<0UMLYA.\.YQ".FHP>2:N^P+<\7]8_4+^8M6. MJ?]44G5$NKR_NJ]XP\K5DGW%"UXKG./'I]7SDLD]ACW3]9?R_F%=SZ,PI:P( M.8R+,(!(\!@6.,PA#L.<,A2B6-B,%/3/H9$)N1@,L2U$4-\7H#L M>TD;=L&67UTXK3D&M^UT./5Z6J;!E]=]/>9'"J_WFMQ.)%[E=5F=<8RCT8$C M$L\$)SMA&4=1_0.:D2A<"N*_1>+\4M;_U.<628$#P1(,.6,*@ROG,%=CK(*, M!WG*8RR5ZP;C?TALY%BF!^2_I>UTU#.H,<.8PY,>+ ,(%Q5<@-Y_6C;O^/U' M2+T2@O]IH4]C^ _!@L2"!CF@K$B9V'",YNU[X&GD4W$[S]] M_0G4'>5VU!U8X^^@,@8I\_D&S&S)Q'JU,SD;YKJZ9TD1*))@E\$9P&O0\@@V M3.[?- .?N:3C$W?)H_8\&34?'$UJ^SRJ<-]$^GRTCW$+US(4?E'.6=OGBY.$ M%R*#1"04(A['$.,@AH2(("EH') DGW_C%5FYC5'8)6>S2OM$C1=K,]MVL5K> M0SVC3(U!4),1I"$LG^1OL$7+M9'^3)TE/SJQLUR?E!KTO++W6@V_5-)?'VL8 MP7&A1IDTL$?J%<<('!=Z>$; B7O2O*LH[1FYK,,R/!3*=?,/$G3-"B20B[_O( HBBDLDH#! M4/Y31"@G*;4Z)O+&V=A!5@S]VLFU&N)B\V#/HS9-YU MYLGJ^>-K4A/I79W[]M0_ ?NB1'TR].%[136$@FFIX>Y=(UNV#]]EI%'6O $? M,2_ZVQ-MV.Y<)I6=X6B.? W%LJJH.RZ!4YW/ M4D^=I#:+M3=Z5+>)WCW@Y:W&Q*YOG]?U&B\5_/A_\VX M0HO\N*K4\^91$M"<(PX)IS)ZH9C#@B@?ILBRA!&",VJ$;/VFI!K9+&B:-C;A M32G'X'STS? ZGB4\7=W]:0%3:__6LH+6H%GH"?R#'1" M@U9JT/N6P)]*E\79[IOA>?QCX3?YJ5V16@.D>SCS>9.O<^!, M^NWP.MEQ]ML1^'.%M+!3O5E& M: *%6CHO=KJ<"'#"23G>,27LN'@EV @G59U&AG![G.M9F 9%:1$H%,)$D]N] MEA9:S>2]J_B2J3,WR8FTRNPW2?=C65.\4'U\MEO=7\<+"N=)IA_,\'\KR=N)W M$3,3GPGZ4-SAJ:&7I[J.8'S_W)1SVHU?[.X:V33U8\^.I.T$QHV YQ/<[K+9 MF85CDQ?/BN-?&PQ7T1#@1@%2/[' M%UKK)8R.O)25*?OY!RK]OW+](ZCXTZIJ$12:'!'=@1YM"AI__D&-V?C1'Z#K M12_2S!5Y"Z_'SAH=@W[]H6'Z1SWB8 :.^S%8R.] 540L$2S?YT MB+ ^-#P!3.Q%;+X9[%@?RK8!E/5"SVUW^&6U8G^5BX6D?;-/E^!0WD[3?FB?7Y/)91A7M)$Z%5\*K=[@NJ3Z7F =)+JV.:B-/ MBA@B%#!(XJR -,G"G$8DE#^QL4F6],3MSMMM*+)I6XHWNM^SH9AB@.6K.C_U9-$==>#)IMM0GM6F.JMDW:JZ/L:\W M^SM?L+O5KUB-TER_7./Z09V=?L,+=6HZSXM"D#014"'P0R0H@CDM,NEBX2 . M$\1P%IO6@ U2&CW=OF!PO8*/+75 )7D])K*E;UY2,ZRP86/B50UV9D-KX&X% M.\) 408?_&O O-#'FR;?UVYI:QCEV:J+7QLNCEZO[7SCXXIS\P'NE E=@9KVV!W8R"IM0\S M((LG/^48A4E]D0$1]_V-H4OM?8HK1KGT^^MN$$02!EF $?S_N7O3YC9R)6WT MKR#BO3'7CB!.UX):,.>3O'7[O&Y+8:M[[D1_8&"5:IHB-2Q2;RO,S@1]&WS-COWAAM"GZ,-#N MG'SDB7,S U6[+9L,]=?R4S$G40SB%C,8$Y8 M-,+2]$'-(@LMJP/1?0P-:DDUZ':'R3*I=(?1"]D$"V M&,%C ](U[9!C=YCY &.2;&?9.OQ>U?Q^[_*[@0=:?."/+4+0@3A(LJ/SV/*> M$,D1SH62)IU'WO'$2F>V^YIN][V(8O\\5W9>(6=5I87N19P@3&@>$ $S$G.U M3HH)S'DHS_H9>PVV^(;ZEUWZ-[]0W]=JO[-GVV47N MZAF#_%]P2<^V0\:YG6>-RCX0^]?5T;L-;#(.RC[ID91F^K6="YQXBLX+K1-=K6HK_7JM_F3U_$T^+ M/P7_NJYV(VF:L"3.$QBF20I1FC*( Q;"&',J"#1K\$UT385 MN@EXK/&!I0:HSX4TPKH00P^[%#?00(4- M-.#J[/Q=BAM\$U C'(UJ/$GBE@- ?4#Q%=Y]%3 MB\YAG$NAO-(/HO[S\_R*,9TQM%1N:G4E6CD48DIR&:O>RF&4$P81T8%/+, P M8RA$F 1I$%/+Z$T#L0//'Y4,0!K!:O*H)%N'6)KP9W:BX)\5.VO?R@=O6@1O M]0VI%@1H4$PJ+]-O%*6%WOZ")TV$CATS:4'$@5!)F[=]I/G^)A[5MW2OA#6) MJG,2Y4$P3-["!V(KC58KOLCH2W_;(T2ZZNS!Z<2XK6APU9_=_,P,W\=T'"3']YZP"V;Y/J9X?Y[OHV^Y M#>]/Q;Q8B2\Z0_7+.R2J_>6J^!]2GP;J72ZA4P!\4I_05%*F7( TAFF,U+"/ MHPCB--75D"C)\RSA(S3[/ MN<[#O2:S-A[/-$WV@7>'CJ.HLY-/N^\YMTE>7YX,)S9G36TG*L;.1Z=^GX5?$VDNXV/.S4>5&QOLCO\E-MXVKUK M_%TP_:>:'M6$N7Y8S\A*\-_F2\$6:BK]'\%_652B]1'DE*%01&&FQEX>ZTR! M,8(8LPA*RE&:"BYP1*=S<:?;N#4?@NZ(C#YF7'_,>[B,/^R]A CE!N($W.E: MEF"M\)&91@=T1D!;__Z,/C&S 0-3['Z \+U#93F? M'4^FZ P@HYJM\PE[:>(\M'A.EJI;\F.; *LMZC)5;@:B4:A=>J[^$_ 7(I8C27,(4[C$))0)B&F.<^DY1'^>8 &/\IO( #Q M@]WKNQ*@>'A4QNG<^B)6I,=8<&6C,)11@B!*\@32, NAE$&892@-\B@]K]++ M4)0[50INB*Z*N]1_MUQ*G4FWF?LR'HFV2ZI#:=#U?S?)C]MONL4'.@"!1MAD MRQRRG(L+68.5<[$"<^%R+B[$G2[GXM3J&44LOB[F3=K;^5WM S;1'E.<2BSS MD,&,1,K8A2R!>1Z$,(]D@@4*9(K"=H/)S-SU"W38/[(S:/6]Y#=UM8BWRNO@ M:U;=VORW_Y-'8?C/YH^YL)Q43O H6!!QRF(8IIG0)_ 9Q"(4,) )20*:4L&L M3N ]L.@^*=0Z',TFU3]?61VDV9-2E\-;(+FOOV_^1Z!D,^+0N ME@C&-SEN%!VT0XY-.9;!WF9:^[Y:L#^;J@]U.I#-;KM$>9I%DD*$J(2((@JI M#"6,$D)ID(4I$58G%$92!S9 .YD(NRC^WS;SC^NYA1FG9A;(.U-V-L<+2?95 MJFV4]E63VDCFN!6H;6C8JS=M];+KH>;NS8JO8O7Q!YNM]9EI6P-HFD1$QFF M84"C2*US4@GS($%0_4]D<92(F""[[5P3L8-OVNY4_RJV%XQ(LP%FO;@Q(I,' M*)-1C*#@H2(SEACB*,50)BCBF%"42&*34=\WE0XI]@W*J U I)GU]4V/G?$] M4E/NS0;"IK2#I<-1(Y\RFQ.POYQL\6[_FOT*G';B@&_"'XGVCW5 MN@;DRS*E5W.NB[I&A.01%Q$,2<[4JE-(B'%$89K%)"5QDH>A554T_Q '=@>W M&8@GS;UR[?)H8.5/U5&%*-_J&J]M:)@NV/O^L[^2O([]9K&.O5AON"QS=\OP M[A18JZW@%C.H0$^ZITJ;@KM[17GUG9[1JO">1^T(]7<= ;Z:RKOG$6Q3<_=, M2?:Y]VX(9^*IV:W2RVX24 0)U=99\@3FDXZM$ M.90UV5&^W\2=HY*=8?*CC7E>.%>MW+*\U=+\Y&@[A+PGX]K.XZ/E3SL$LIL- M[>"_^_?7]@S'IF:W+C-YI7R,3XOE=S(3:AV_"5?6,[](PR!+.8=Y0BA$3 :0 M1G$*69 BBB15JV[A<$MB"*PNIXXNUPM?SO4;>"50-AJ\N=/>W-N?ZJL3^JA7 M>>6U*Z=6Z\W1KS^/SKEGS_?I!NVHH;RZO?[;HJYKZFK<54=JY-6&9.=6QVA. MW;GYWA1(BE@_% MO!HH;3A.L]C'$99$$(5<0I*'%&(9I1NUWU$P*'#I&="[@J M]!#= MA$(%DNG$Y19[@(\DB(Y8*FCXLA K$,-?6UO#@E;MRE@J'R>VZ_Z7OV M+ORO9+Z6A.F+Y/.[*B_^X^/L^>IN*:JHB^8K3D6010%-H)0<0T10 '$J0D@B M*=,X%S051FEDC"4.; %V,-0)TBH48 /#87_4C,K3[J]W@NPLP@6Y,?>YLJ/=V>E;H^O9M;.:)Z7E5I=/\KN13>OZ.J)%#/M9C7;)CH!R\%,&S_K MG#:_;5+:Z .U^C!-;X(RAC(J"(.Q4/X3RG5-:7SI8/IMW-X+O5:KW-GB[KGQ W(NXSRF M%-(TXLIH1CFD)$AAEL<(TS 466!T;6B_Z<%7EK4P!P_I!06GW41WQ6Q7B+YT M,G?OW'5S\^/,=;1RVPZKT>.?O7AA-$?L,-"NQW7D"3?7ZN/#XVSQ+,1WL7PJ MF#A<[??KH@I4$KPJ[%M6]W>[__Y^4:Z^+E;_*5;;<,9M2_5++ZO_3E&$1<18 M &.22HA0H-RQ+ R@ODB?D2C#(<M6'&<*)5B*VG]8+<"\ MU0J0"J'ZQ0H\"_U,J\0$/"X%7/5X$Z_L\S!S!O\6G6YY@E75CW^W6S]^6_)X M C;J;,K*;Z+W:W#Z%$1](%^;C^!;YR/P7=_JXOQ[\D(OI\>HGNO%N^NEMWMY M0/8>B!3:?>J'DH5MIK$PT,/0**N6JK/D=40Z'L MX+'STRTH-G.LAR'.SKCN8 ?.[2UN0"_FQ!F[=3:Z^[)"[40/*K;:$_(2S_/ MH85SLJ)O4A6\(^J+TGZE$*NK.;_BO*C'VC9S<_GN6?WPN% ^S,_+Q?JQ_#QO MEE/ZF:IX_5KPZSJ/D_(W>K326I> OH,6I5 K=,$;+0"7;7 M5B_PA]8,5*HYI80?YX,Q,[VO]#.PL]VO\PMPS(<_:E]XS:\_#O(+Y.L?M4L. MY_\?%X+#E1"]!4)?;J9TMA+I\_:19J>QVBRI,_ILZ[#7FR>K[>;)-U$T.S(? M=/%6,>=E,;\1RV+!_T/-Y_=ZJ^9)J7(G?E;"5A\43Y](L?R=S-9JQ\"@Y]_N0":"% Q\;?_!"TNZ+Q*!8;?#?Q?\TG:W1%ZU;W==\7H M=0(?[X;2Z]3_P-[N*T?JJQ#0^ZK6RN?Y1L*UW):%^*:':]!LV=S. 7H+NE.;!ORA\8$&H,?=A_-9&JSXC#&0"Q>>L27L M=-$9ZQ;=+-V-OHI:9?TZD,)['U59E[Y9?2D(;4[FIU)F&1$R@D%(.$1$IW:- MTP2R*.58!C'CG-D5I3D?E-'P/:=P32,2S+8R[6R?!^+-;.!(9#K9PE;(\P0< M,8LU&'^VSA\;GFR>!T"CVCY_!+ZT@1Y;=O;ZA&I2YS_L--K^MKF._YX\%JOZ M+H3.JSA7G]NSC@PKITAY?$&<1#!%7$"49PCF.190,H2D%"%"469G!\\#-+@- M;,7I\"P(6EA@17ZXF\4S^\#8+1R:5U?7L*909Q+I()N #0*O7I\'$OQY?N> M&=O[\T#< 0_01ZNO-9RAKK:_SJ"!$:N47Z@KQ@\6.*?" M>IV7^,=L\51P!>?]XJ'0\:CM/5&,4RI3',$\(!E$E*:09"*&$0\92G,1$"G- MTX0?$S.P&6\%5T%'&]%.:;>/$G7ZK-F/^G:6< S-;=*/^V# -1GY(29\)2<_ MI5=OJO*C+X^8N/R4 KMIS$\^[>;LOEN7Q5R4Y17[[W515F;Q9KGXM%@^D#9D M^$8LJT.K#\5,1Q)/9OC'1)F K(D%#S@4D;,JJJI/83!7=!* MRN;2P$]O=*[QMYW@';*JXZJK9):K!;B1:A6RU#[//_2MX8?%O'ZP*==FYYDZ M=(F9DSDLT796LL4".F F^D(2J/!L;QXH1'4/+]' ",ZL:Y M$_32(SNC)3?#UMDW^*J4K;='ITF0Q"Q+.4Q)@B#"0025MT6AX#B2<1#3A*8V MMNN@E('-TU:0^\[B87;,S,C9.KL=BU1;?UN!_JQ KSZ>!OIA&:..Y5XU7P[7 M_H?MESN?NW?N/CZ(Y9T:\;^2Y9]BDRJ6A'F8L(#"("8,HB1@D":<0B)80"C) M4AQ3TV7/:7$#C]%6)FB$.KC_!I2=7@#Y)<)NX.[(!N,P8KXP\LN,VP+)GA.K M-9*YBCUK)8-&1ELSF2O473M9O.7F:GP3.FRO2<>I3R#4*DW]3BR?Q)?-/31$ MHRCFDD I\ER9-\H@9CB!)%&K*2E$DG&C71T;H0,;N1T(=?X;O=)O4)QQ/]"( M4#-GQ3=-=B;0!T/6_HR-RI[<&R.1HWH[-B2\='ZLWG79^EVIF>+S_(G,"J[+ MN,^Y\K$^SZ46U\T'G:.0,AEE,,Y277<@C&#.DA#2G/(DRT.6"XN-8#.A@V\+ M:QA@BP,H(-JK!UTH3INEAJ2:;!K[I\IV"_G2+-EL,/MGRW6[V80U7]O/=EKW M;D8;-C7BUK2=*LCAC(B,08XDAXC*&.5'_81+C M,.(9I\QH4^=0XP/;PZTXR]%\D(A^VW:N>G8VS$8SXZ'7IT*?*Z/>Z[@QZJ>M M"W.PR5&&6I\R[9#J?>:\P,Y-::7N7H]835D89;&($$RR((4H%0)BI/[&4ARJ M7X4/U8Y..IU]S&_N%^>MX]T[R=N+MY7ZH;Z2J,,PV4KP MWQ,+C2S8:^L8^SL8#?C\^DK\.\.78'OW$WL*#(! MF^[>Z@*T,O[,ZHC,>S+-8R >U;R/V 4OIX@Q1;M&T"LK*2MS4]K6;M763Y"9V3U;;8=3 M/"N-'>*V>S3R%F5]2,;(,=$]:NY',/<]['I.U5X@U%<&OS^JX;]8?M'=H^W' MCZ*Y QH$H(4 M_M @K$^G3M%H>C3ED1S;'$XDS+4U=N!U"EY(Y]&&:J_?Q1E^J)C*2(I MU?2_*;^MUIMZ^M:ZV$ EIDD8O//$AT*]J'=5"C*;AD)D$4X(I$0BB (1 M0LQX!CG/68J0B-6RSZJJD =0 QL6);$>* NI*P'!W_[Q_1]@L;D=8EGPQT["*<;)*1OWRNBW.B8X>9UU!!G_3YJJ+C ]*X!7$\ MDKA7V\9GVR/OL57_^2;J^.BV.D^=XBN<9CJ[.4T"700RA"CB.21!E,%,I(3* M("%J*37*KEH?RH&-;B4:+%O9H*R%ZWL92OI(VVB]O21C3$*,!8PE)TU]/QI(N_33]UT?XOZJF!MSA]L3_ZIF;=).Q\!5N8 M)LQ>>M.R%^/?8YO2A&9O&Y-&PIR3>2R%DO=!U']^GE?YE)J+W/.[.H7<-&$T M)(&(84!(!!%# <1)P"&E)$&,BCQ FW1%MU8I.0RD&QF$W=Q$M_:S9YV>UR4S MI2&'IMN7WBAQ+9)1R05O6@1O=:+)FIT-BB;+I-?<%!9J^TLM82)T[,P0%D0< M2.Q@\[;3127UM11T)NJF-F)9"B(((L#3)!DI2A M2/GBNF)FOY4PE&?E56^DVFSP-P@:XS#I%"RPNIQSDKA^"S$ '=9''2T35PT3 MG3/>+0*_I%A=6?))CEN4[=DDV5YA,E6Y_P[3R5;&O,1DJM*+6TS&K]F;O?9Z MMG+<:%'?E=K6]?W,]<:(+,A&>'6+>RET.HI.?%)UK-Q)QM:Y62Q%)B(2*&N) M]-EO+CG$49)#EB%"1"@C89[39F"LXP4D%MN4D>8F9>B>.FVC7Q'_=O9]DW.B M@WS2*=4.NN#;/.,M_.KB5D4<>ZS4VOHH.MYK>1 M*.^9&X=&,-J\.A*5W3EY+)$.=PRKA$3OBL776\'NE<#VK[^2^5J2YF[CSP_T ME]_5%+;6Z:/%[X3]:\WO]+"[EH>OA5&<)GD68$CB0$WC813"G",,.6:IC-(X MRV5H?"-Q$(@#S]XUZ EHL59&8_/##G*@H8,:.VC 3T +7Q\<*P7@N1?ZANGG MTT[ Y7O/;N[WUW'7K[GC+.YM7KP#'6]Y#MF1GBZ'#DIMWU72802/=_%T4.)V MKJD.*^F\7(P??Q2K*I%Y. WS)&8TD5 $*=%)D5)(4$X@BQ/$0Q;BA".77(M; M$0-/F%H08%J26Q+$#A=FYPOG:>BXH*RT?-^KI7-RPGU%/"$#_:U/#%'#XN%TP/(=6>4/U8S^=*.(?^,X$-.>+:QOE!AWB&S3?!_<[^R*:4XI8)'<18@B&*F#ZMQ BFE# 8L1XD,,2$1V(]XMU\T)TLR<8_]$V%G@3>:;!D#W[E![M_E-@^*M_Q0X9FI[SH1S M0NA%$N*8$7$L+X[AV]ZV!6Z6BZ>BK%('?YY+7:Y __:S6M\49';%V&*M2T/= M57@>9V(EKOA_KV49"),=4Z<&.G\!XD, M()%! GF4ITF,@UA&Y,QM@B%P#WVVULB=@$BE;VV=L @W2D\[; I;O' MQS9!1P?044+'2U1J@*T>8*O(!&Q5J=IH^KQ29U)U^L>3G>YCOV#(+AAN_V 0 MU)?>3QBR*PSV%P85[WB)E-T+OIZ):ZGD+]>BN[E1E1Z\%3]6[Q2M?T[C/,.Z MY!9DN%/7/!X]["LR9D[VJ=?0MNAN<]*?5QN/Y#V[(G,E/&K+Q9S KVO!T' @=9 M2%()B:Y3B@*F'%B:93 .LA1EL0@C%-C8'".I YL;+1QTI-L9$3/>S.R'=S8L MMRHU$57)SA>,*">MP@#^:/X_)<)C)'-5F6-'PTES8O>P07JH/;04O ME8Q?BYDH5XNY:"[T;C(*WB[>Z<0;0A\"?E+J?5!_*5?%:KU45JSUPGXE/XJ' M]<-4)(P03+A: D<((B$0S",:0HY$2K,X9I0:%__R#6Y@N]-( >J[* O>9!#2 M146I ,L&(M#?!^!;D!:!AKZ[ZO3!RR4[P,[4M4BK2A$;K&U.A'*;RE5UQ[LJ M"U'='1HQZ$#67E8+>@(:V!?L(XLPT OVE6, Z$7ZS"X ="!2^T(_?8L<+^AS M(+)VPCV'DN'H9"\>'HIJ_Z"L"GI7VPMBSI0SO[W-V5GATU#(-$,0YQ&'2(8$ MDD!0* .>YCBD,F!&MR["0%;P[6 MRFD4Q315%@B2G&4ZIQF%)&8(BBCC.,,,"[))C6-W)-XKUV@$[2;%L3UNJN3] MM"D+4^BZ?@""#U[KQ/23:W=T?CYAYYV<[Q6+:2"TY^<> SRM5/9\:MXO\R*' MYD8T'#LS-WO9?A>@2N9%>_)]E?1Y^TPWX9?>E%@]?Y[K.IO5@U46G]4]F5_7 M90D^+992J ')BWF=!^P_1'%WKWZ^>E(KY#OQLY*QNM&%5*9<)B$C8:"L$I(0 M!1F%.>$,,LFS (6(??>OE;?EQ6.S>OJB-[MGM> M!\[1]HA>A[H'-I9>%S#G96 Q%[P)H=21+._O-?S/\^97UW16W-4W<92#H'!I M_-,D1XB&:0Y3%B80I2&'E!$"*4H008P3$A@=V9P'8^C=J0J"MD&T!@$6&Q36 MZT$7EHT7B -S9[UBU'A ([T*[IN +9GM[[>PP!\:&&B0>=RP.H\:?RM+%Q!C M+S7/(.K VO.F^LJK]D8'5>O#+T&6\MZ=_-3,9+=?IMP!F: MV WJ1HBWVE!'@!\87H@,BVW"#H\MC .<#9.A*@Q#]Y# M1$]+OE",J#$EQX-$S9MP-$BZD/7GLEP+_J'*E%2O4*I\Q(>K0$P9C7/!TPS* M)$MT 2,"\U1*B+A(0ITR/6:YE5VRAC"T>>KL>3PV>QXKM48K"7.H">? L*$) M&I0WA\U*99TK-),ZA?CD<'6:[8IZ HA4W=/N$'E)-7X^.;[,DSV <:V4,T%[ MQLJ])3>;]=M\NG%U+T";Y]REZI>GWC*SB2/V@).=[.*K#N%;A/JN95/.9H.Q MCA5N4#9;Y]5+&Z#^[*5?XCS94$^@1K6K?HE\:6L]MWY&7KTKE_NI$<].$)+IF#X$B2I#R/FD$L209#+,\ MSEE $TJM2A1?4IF!_=C?YNK3 (NM/.5PM9AT-K\:E$UYH-= FDW!Q[]!O[H$ M!9Q5%]+PV':C)=BHV;KU'4T]EY&\<'_YK#9Y*57&+TIYX4X[6+ORTIC<)M:; M91/G5RVIZC7UU7IUOUCJ^7Z:9D*0) Y@AC):WQZ@*(M@*M*4(Y8Q1JUN#_2+ M&WARV@@'I98^J<8[(1=+G4YKBI*<1XAQF.E+_4A?,Z))J/Y#XH"D M,E>&Q*A0VT#X!C8O']2BYTE)?-)IBAYTWA=]2*)1E3^]T<"440%;<.W%W.OW MG[5GO #7GS_4EW*NO]O9'M_=:&:L+M@Y=M:M=C5WD+;I^ZIN>3L!"B_8 @85 MXDG5=9M'7@*? %I!U[LC_JSC0*1Z,J>^T8UJ?P>B]J7!'DJ,FX7_4DCQ7:Q6 ML\H-U5?"EH1UZG_^*M14PM^3Y?)9%T"NK-8TU_1&N824Z4($+,AU% "'<9X$ M.4$9$X+9F'$7$ /;:N5RKY=5.BC6PK&SN4[$FAG6H>FRLYX:#=C" 1L\W=*] M_@S@.>0]-)>G=66KYCA]AK]I[4^DFW_H;EC_U7\6-W^)69/ MXE>%[KZ]3HMO]:XYN _Q1D":[G'NV9)X8&"R6V0W/A MF&(GZDX'%[LU:V?[N"BF'^>K8O7\\4$L[W1]N.7BK]6]]A3)_'F:!90D:<0A M%GFH+T0H[RM6/E?*8A*1E$4Y-UHZGY SL%M52P:M:%#+!HUP,PMVBJE^R^11 M?SN+XZBZL4$Q5*PG %JU4-L(]9>M:3C5[BA#WE"Y=BB;/N[FGGR>R'9S!\9D#H[:]!A[64A,T/6K#T-1]T]>1:V MTD?U)!RI>>DYN#;CN#G_6*5SG-]]T6$VW_3US6OY6UD+^[XBJVK!=BT_%7,R M9P69M;$V'W^L],:3PO6E*%?36*V'",HEE"B.((J$A'F21)#S/))22,$"J]AI M3[@&-EO?KG_;E(PL6U!Z/UZVL#;!AY:;[9ZZQ7"3?7RR+3?76X"@0C@!%4:X MD%"AK$W=!'SO=L &ZB:F$/RQ10L^SG5MIVH3U*-Q],RCK_UT3ZC&W4?W2^7> M_KGGYE]#,1^]Z3]7'^CS-&$1)RS.(8H%@BB3"AWF8X"R,0ZMXBH%P M#NY3UG*L\Z(-U2UFQO@5D&UGG("00K(J^OK;O!1LO13\@Z"K#VNA*,--<6)$8&T#]-;F;0"UU6-M%.\Q[+:-C0:/;13K&NE;1\ M\XR;#)O+4GP;9=M^O%D2Q"22'*895:Y@A!*8,Q3",,YCA)B4/+3*;'5*X,!V MLHYIMQOJQEP9'DUX9,#RS*%2_KN>=>MKI1O)'D>SK9H^0^S[Q(T?,V^@_,$@ M>)/W'*/:15D*41T0?! E6Q:/VZV(+,88R22!*1>ZWE&$(?GU;05Y!YCZ1Q8\E/ MJ[P7,F[PR@ %09R38;?QG:O%[\H,OS._:T/81-Y*@XRKV\"&JTX"(CJE%+7YGX"_V@S\ MI,G OVSQ;6[A*(! 2;0H?_G*J/511.3U?@R6FW0&%1_\%'SHENW\O?K6]JH] M;-0''?W![=_Z6_-88^3U?G/#51MYS=^>W\(CE^G=@/\* V>B];:J>I4>,"@^='J$9BKVBU38/&6VU;/R\0(MZJ9#PMM M*::84"ZX#&&0R@ BKB_/A:F$$4IDGE+&$0UL=GJ.BQIX;.^G%M&BP1^U<,M= MGA["S#9Y_-!@-ZQ=&;#>X#FMG*?]G1Y!HV[OG%;XY>Z.P1N^KOW?Z(#MQ5S_ MM?R/8G5_Q92KOY[I+>.]0C_EY_G''TR4Y;74S]=7;C9;S'UO3KF(PU301 ?_ M4!W\$T =3MPP,AZW::]>%>NE]&*N@R!J7RSGN4P#GL DI1PBC".(LU#".$EH*G+" MXL#J(M!!*0-/&,T&V4:HH\=ZF" S&W^VVG8&V%YC:Q/9JY$G^W58QJC&I5?- MER.__V%?WFB=VTJGXFNJ'7R>OR,SG23N^[T0JVD>!VF 0@Q3H?Z#4GUW+^$2 M4A+0)!0B$I1.5XL5F;FZD2<06 WG#0[CC_O3>LZKW,ADM;:\EV=/IJL+YY$B M'[Y7 P?(Q;)VIL";-K3MN4KVVA9>4;[7B5O00WI9AJP-YAZ=DG]AO\:0GM,. MB6E#=B:KN@VW?)[^ZV::9(QBDDL8Q:ER&](D@X1E F99&B5I3K*,)R9NP[;) M@7V$?Y%'M#H0#_^(V&59KDCLL9=3([J>[+2>OT"_;GK-N"RBB(GCX4)9LM]'F0]3'KR8:&W@+=5H96 M -X\O05;#.:GK*?I.'W(ZI4)NZ':1\( 9ZS&FCH=L9YN?;035F-%NP>LYB]Y M2W2CXR^*^5V=#;HL>).-J1, 4KZ_UW_]W/B[U_+(*YNE4#B-\RS"@B"(/3B4.I;J+FBB#.99!(E4,HDTG.* MCN&- HCS&.,(9RS%PO1RQK;9@:V]%N1P/;NC=K])=5?&TN*=K8=YX+J;/FXQ MXV9Z645F[\/O"8KN/#Q://(^P&XH\(%_=4U[__U>S&9M#G=),QP@(F#.4P(1 M37/U-QY B:C(B]:9WBN)KJGM=]CH']7GZV@WNJW4;L.\77$PEBN-$ MA!0F) L@8CA3,R(*(0E3+'E WXZZ?1 M=$!Z(\=IA)[%B\/ -=+VC)'O[\^))+.?:I:DJ7H@Y M>]8YD9M"L$WRS"8OYC>Q6B_G@M\N;N]%8W<^K)?**U<_WXAEL>!?UWI.KW>! M5W7=K[4:GN4T#CF3428AB@(&U0S-(8[#4+G9C/&4YCC,C"\]CX1Y8".TU0*( M5@VP+L6F:G0;6]EH I:-*OH^X.I>;^!4V@!>J5/]ZK%2: +FE4IZS;]JE5*/ M5UJ9N]5C?1JGUQZOL,/M#&NGKS<:@"J/_4Y?;Y0 K1;@=@$4[M9= K4FU:]N MFKZNM0'7]0G8JJFE^$K[VGQ]]@K[W&WQ]]KZWFJ9.7(O]*QAQT(RV@)Y9&J[ MJ^^Q18]2S5.76/RD!$\%#P1-)851EJ<0932 A'(&8Q%G09:+A.1DT"J>+1(; MV^):O3,?M'KGAE.S(Y<1>+*;=\^IUJF17:Q),TA#=( 1B+@1%"1$GT?^71\^ #8K-9(]I'C MM_H5,%.8H09=+88:R>:^K>_N.+U>N2#)=O;QRX;9;J[+#5:@P<+;!6SA@BU> MH "#!O$VH\TKZ![S)<8%N\EM*7&![K):+0Q$:,^JP+?$T;S_@:CJ>OE#B7#S MYK^O'Q]GA5C6]U/$S7)QMR0/=7 Q2X(,,21A(J( HI"IJ2YD,>11%L6(!#RD M5C%V+";E9Q)L':JS90SY/GW"=I5._8 M0.67'K#)*X-4M-Z8FY\7"_Y7,9M](L7R=QU]N(TWG<:!8#)(!40!E1"I_X,T M5\YNDN=Q&$0!H\RHEHY'3 ,;B<\WW_Z-/#S^\X/7RM9&9)M9C9$IM+,N!A6P MWVQ=HA;BVPG0*$$%TR3XWG>9;!O2QBF=;83H-973MJ'0LL2V5=..#E![2[>> MO^,\C,.8I%"J13Q$<B_&NMF[*P=5\.6A[#8^KE-R4+$]/^3P4TY%K'0J<,&K%MOJ(IAP2I,0 M08+3%*(T8Q '4D(6"HESFM!02HN:5?L2!AY4U^N5CFL&M> Z[,:QZM(!=D[O M6IVML]TXTQDWAU'5JI[4>2H[EX^R5=VV6-1QM?IK0QUX;\Q24,=AOZC\U/.@ MV_2\F?";E*.Z5S\MQ7^O]>EHDSHHHBS!/,L@DLJX((;U73,>08I3E@04QU%H M9&$L9 YL0@F$D=U&RPH>.E+ MV+QJ9Q#*Y6I:Q5:*Y2-9KIZ_D@=Q]:,HIV&4!T2?P*5,(+U1$< \CM6/*8_# M-$)!GAD5@#HF8."AWA4)M$SPAY9J.,B/LM(_HGWH:C=\K=4T'KBG=.D;I>K= MS@A5/VU'Y]%F1QF*IY1JQ]W)YUP&V;QQQNIE4'93!)I'&9Y(A)(.%%+ M8Q;HDV_MK^ @H8RHL99DY@/ML)#!!UM'+*CD6LZJO0R9#+KS];8=> XJ6PZ^ M?IW.&H!'FAYQ$/8KMSL03SQKOZ0V2#E6S*NR&SH&<"GN=8;4)Z&O)3R(+XNR M_"I6-\MBL?PNED\%$^\7Y>K]4KVTNIKSZKU;\F.JIDL49\IMYDFL2Y\%!!)! MU#P:X1@E/.1Y'DWG=6W'TXOT43 ;#1A<#Y@NIDL_\.'C4@4-:( MP!NF,)5O?V(5K!*0.0<+C6P"YF)EOE >IWM/[S&\GBX;(%?C;E;&NJ33CAJ@ MU@.\T9J\G0"E#*BT 8TZ0.L#WM0:O:UB-J[KWE9JO;;>-M]F>76][K9M\SI[ MWVIG:-2>Z-EI&@?':#M7H]+:W0D;5["+6T%7G>BB;3+TGY=*^&_SI2 S#?)G M[=6R.*4L9ASF'&40)91 FH7*3Y"ZY$Z.E.-@% 9D*WC@M8"&HB;T%LL$W&D( M8+W! .X4"(N(22M23>;D8:BRG5H52]\[+'5+1U1(P!8*T%@&(LQF6AN&.-?9 MR1N!EE.*/0N],X-%'LE=^VTP_NN,5G*1HER=4,*KJS[- LH"3&+=$8\ MK!/DJ357*@1,198'H>(A#HU2-QQI?^A8J48:>%3B;..E=HDP.WLX0ST[@[?1 M3$N:=**XWY/'8M4,T_:A";A^K#)>J7^_8JOBJ3\]GT/PTD&MO04B[;8^(/PFGL1\+?2-HWDI]%>8AXBP!">0*6\&HA3',$\""7G&"<]$ MSG%&VBV06_.:#T<%.NQ?W-I?U-%KF:+]H$4MW&VT[C-F-V[="#AO!+<+NT;H MV^YHU3LV7Q?S1?L+_V/VJ,:>1^^^G(N,XZ/J'AO1QU\XI^[2=C;7!:(6:R6& M\&+V_$'H.Q?%7(F0-/.PK42"TC-@VX<:P>[YW=BSNX?R/+/*O"191'.$J3OEU2G57HC M)PH)Q#CD4HWT'$NCC):F H>/6-N*!UH^V(BWBA0U)M!LJ/NDQ6Z\G\.(?74Q M0S5]%1D[)6[<6F.&RN^5'#-]S_[@^FK-B]7GN5PL'^K2%+145 M)Y]UFU!K]_K]>KE4G3O-\R0(:,!AS/(H.R$N1OGC^(W].DOMOVJ#/X0;5>3M>''SHSF\*U M?$_*^T^SQ5_E9L*2:21HF%-(LU@7<4H)I"R*81A*B4B>1F%DM=#N$S;P^-JI M[:Z%@TJZ]01OQ)O9$/3%AMV(/(,(]SP-/1KZSMIP2-1E1""%AC.O34DPB]2^4&=V_/"IAZ*%=LWU2#(?L.:I:CE,K+>V'YC%-?(W'O?;''83'U-L;>4OWO@T=[E=B3# MEU=N*WYS*,0,9IA MR!)!E;. 4I@S%D(S53@.+[#!D,U<-3P60N@<4 -Q"%_DA&5 MIW<\?1/DY'%[U$;?GJU3HV9&VT:U4:J[I6KUGF-4 MJI2B"F.H@Y%OR8]O:FVFKP'.63$KJL]$_?*[6*UFHJDK0:3$1"80AY'.O$MS M2"6A,(M%' <134,96,6;6D,8V&HJ8:#<2JMBL?7CLW5U0K"0@(GEBA1SL%)/ M/B[*0O_>-I#4GG@S)VY8.NUL[ 9+&^NNJ=5PP"Z>ZJHRV$*:Z%)ES.L.JCLM MOD(V[0&,&XSI3-!>F*5[2_9NW;OL%_3[)S%[$&I.6]_]+OAB539D%,=Y MC'56< )1P!.81T3"D.$LYJD4:6RTVCPE:&"#5(D&;^1&.'BJI;]U*7O?1]AI MI\T7#7:&9#P&S%TS7TRXN63'&?'CB)EHU^. ];X^FN-EHD37X3)ZWLW1TI=U MV]P*RO@UJ1?*]K;1]7QC+$79W#F:$AJE>2!"&&94F:^4!Q#+7,)_"P7!*,Z6F=0]-+3.J4D%E4L+(9A'G(1Y CQ"-L8.>\(!S:!#9(2E&M: M5IEH5YMK,344.VOGOX?,;.%%>;?T)ANHH(-UHJ_=@ IN-QYP AK$>EIJ,8-2 M@P8=U$##UKE3-'!_UG0P3CW96O_X1K7$@]'[TDX/)\BU1C9=?9Z7J^5Z6TY% M)AE+&0L@R7$(42X32%*:09*Q*&2AX$)85=,[(&/HTPYV+_AZ5@W5;T83H7$ZO_# M5(=41Q!1'NN*4AQ2Q&B DY RD6XRRY@/_^$0&XV>%ZEI7-RR78P[>204$O"F M2K_W]J>94DAY;\I4S]:\SN(YK]+::&WMC,R O6QFJR[<:4XFSR!EZEY?;K$# M/="!1E]U:A5IHFQG-]B$5CKX2:8Z'M&>S.Z 0$>UWL,3_G(2&$'B&7/)]_O% M+Y7+Q5S&_*Z=)F" 2QQ$4H6 096FJG+] 0BQ9JJ8"F:C_VGB QP0- M[ ;6!J'4=28G+3%*)K/WF=Z<_'#?+WZ.6 M3[M]2,SX5K='V8,VL^]Y^_/A]V*I;_??JH;)HUBO"E;^LICIC)FELL?-H1^3 M5.(H4B.8BU1?I>/*Z-$DYL(G!@"]A %T,H 6A3P/8/QR. M38V8/'V [)L?NS%^06K,3Y9]4^1VPFQ E9^C9AMU>XZC91JGN$;35 M>][.<+9Y_S]S]:$HQY1LBEPWNY'\:LZ_J%\7LSHBNRS5-[57$;M._G]/YFU% M[&F* YP&H819))2SE.K[5S@)(,,84YDE2"167N6HZ <__M[4H'>Y"3UN1SH? M [V.[O%Q1-0IUM)5I4G3UIX/\2IBM*,.:/2I#N+;#F_OBM=>YTII!5JU!CU M&KXWACM<&A#[I0^>AN\6@T.I$4 XWC/ISV4BGF8159--G*6!SI&9 M02H%@2RB&0Y8S%%@5 C21?C $T:W.,?)C4^WDRXKJLWFA*$(M#/I?KFSOT_H M0(*ONX0VHL>]1^A RMX=0IX2S'.)9 )Y2 1$A#"H4W-"SI(L2V04HMPHK=])20,;F%HVT,+AGUHZ M:,6#6KZ9,3E-6+_E\$J#G9EP9\#8)!AK=V#\EX+]XV[Q])-JHQ[ZZB_;$7^Z MY5&&M[&"[5@V?\'-?WAYX'*KFJG3<09Y3&(U9 ,9$XBXI! 3@F"2!30A><9R M9N4K'!,T>!#AKM@)T(*=$G >IOX^I9BGN?JHF%'GY5/* MOIR#3S[ON%-%YG_>%@_B@ZAN6;;9:U 8LHPG,-%>#-J)0#5@N! MH M$*566TH'Q0P\9+5 P!N)VPK-CBE^CC!EN&=SMOZ6FRM*'JCT;R4.D/*G7RE? M>Q2'A8R[F="KZ-ZJO_]IU[IES36##T7)9HMRO12WXL?JG8+YYS3,L/*""8L^2'3CNCW[0M4]9#D-D@]:6VW5#M MW-O>RE6+8R495*(]CE@3#;T5)^L1-7)]LM-*[Y2K%A+]3M_6;O;]*9/DZ5.CKM7CUJU );OPD#WPPJ<)4JAR!CR29WV48K< LJ'1;#TT$#EV$_H&1'5[9 -# M_5SL9EJ8@"TS?EWL7PJF"BW>PHLPEC9' X9QT(G M,HT@R3"" N61#&6:H="J*/1@2 U[%;UA>TI3IU&H[MNUJ, &%J#/;9_4F^$MM"80 PRRXS0XC[[2RP^&<]PT M]4/3O9?N?G"!COD7E(AR5; ;-43:*J\L306C'":4ZVI.#,,\45ZD8#'1X=.Q MD,0J_<*>B($M;2L0:(F.IU@'>#$SB.=I:V?)+!6USZ5P5!=?J13V!8R;2>&H M@GN)%(X_Z7I0I4:U&LCE-U$*]?:]&MP?]'V+Q:->5-XL9@5[GO*0XCP@&'*< M4(C2E$ L2 IE(+*$)2C+A%7>/2.I@T>.-K'IG^>P00-:.-6$VP'4IH6S/N0R M(=?TM,LS9;;'7N 421-0@P!_-'\.="9FP8.WPS$3F2.?DEG0L']<9O.RXTIN M_?@X*\3R4S$G2B,E\&Y)'BK7=>O<8T1$BD(.8\YRB#!3=B7%$R;(S M**UTT(@'C?QAES<6*OM:J9B(''?184'"WOK!YEW[ _?_KQHBC:,K18)B3!", MPHSHPO 4$BX9I(S3&(4B"A.CI'&_/C M2U>MW,X4&^VN9K.BLD&;U*/^%C''E.HY@]MY?+2#L4,@NZ=5!__]C(0[VSWC MSNVYYGN)(Y'$(I401)F@S.L#1B(_6#O;GSR9LOF^@%T[B&TR>->];5:^/V:];/\]GSBK0+G8P(EO,8 M(BZD_D\ ,-CRP(:Q%.:SR=I0_O69U5MW-:LIMI9K5 /J="S0MUY?+05ZB&0W17JP7]W]*D>JT#*^=T778+I/T1Q M=[\2_$JM_,B=T)=,=""F+N+7E&6G6;,V1?8$>#)"%H)'-3_VA+PT/ XMN)F<*DI \%+' ];)]S_^][I8/?\J M5O<+)?%)-/4_IE'(@IAS 8,XU.X/"B%%@?HQB AE24;#V&JGV5CRP'Y/BZ.. MTGTDR^I.6:D0E759SA:(/N/_1?W:MCB=.<5F]F80XNS,S2YG;0&1&@:H<8 . M$'^FQEIW3Y;&7.ZHAL::CI=VQKX!-S/S?BEXL?I$6'7'I$JME 0AXFF<0)%2 M#A&-),Q3GL$T8I$@.,BSQ"K@<%_$P(:C%@A:B4Z)IP[P8F8$SM/6;K1;*FH] MJ(_KXFGT'A PZC ]KN#+\=CSI&L2.%V2C:W62^4UZ%C Y9.X8DS,],)&\ _B M<2E846^ I7G,HD 2R(,LA4@$".*$1I *$J=!) -,K$:DA>R!A^H5Y]4M-C6Q M\X[4?_L_>12&_VS^J))-@&47]+_]GS -_JGK#2^;,F=*0I5_HMZ"5K\KM\<3 ME;=077\DNES:;+;XRW)M8M-;9G9BH#ZP,R [(*KCGF^BSDG[?E&N= G9#2#0 M1>0SD9TU#=YRVYE+'CG=G34E^QGP[)NP/WWY+N:%OI1:ZJI@NE6Z^K 6BNAL M4\E&R)"1&/(H3R *(@Q)JE8FC+(01QR33!C=^S01-K"AJL6#C?RJC.D$* A M8W X\#C)WNDC'9^?9OB1YMN9W4O0!O1]KA8]L[W%L29N45GDV%G MQW;+4D^ %@DJF1[S8O2IY"L#QD$9X^:ZZ%-S+ZM%[\.N^?"_B;M"QY3,5U_) M@U#N1QY'(A4PY"F%"&$!T&H*62#EGM#VMR1C+[%PV.G,/^L#K[J>N//.=X&$&>JY7T[:*Y MN=NFSQ+ES\M%64X#P6.2T!2*,$HA2N,0DB F,,MS)"@+4AE@NUGQE,C!)\A- MSKLJR66=;&?2G(#6V";@3B.Q/'0X124E*&$BXC")<0Y1C"7$3&8P4:S&.0M# M$EKE7O!)I(,5.TVC9_X,SVH\LF)Y1--(!JM%6Z,-;(5/P,^]WY3]P8RAHK[. M8TZ)&_<8QE#YO=,7T_?LS*E@?'K%_^MV\74QOQ&+KV*ARP-]FF]O#QN,ZY.- M#+YEVV8]U%^P @%O/EZ#K^I_&H>8EW6H^*?%8C5?F,:GG6:F?UA[)<5N/%OR MX3E=N;'B/0Z/:J,9VHQO1_3IED<9RL8*MF/8_ 7['<^;I7B:DZ7^0Z@_/Y&' M8O;<[$^E,2%1%#%(4JPO_ 48TB@0$,F DYQBC#-INMG9(V?PH(M*,JA%.NSC M]5%T>D?3D^*6,W*C"V==D(_^DE&6'L.>S=0,N>GB?%R49*:W[E-HOL/J* MM,X'H@BMB_&\ZJ_KK'(/?X>OS%\)B+_'UW9N=8A+]ZE=Q8B+H;UD%8E+=]&) MRA(7A^>8&+@3)J3^/A/-S>ZK!WTJ7-_ZG@8"!YG,*-F)[8@82]?L+>_V5A)TM<:E2B[X=W5WVP4.VIE-UAKA6[Z M%;(>D >@>QIWW99''5X'5'HYB@X]8K])\W&V%#]DL6CV J,DS7 2Z/+N0091 M1B@D**U2/\DT%"EBF5'&@OVFAXY):80Y[(V^H.#T(MY=,;O1XD\G\Z6CNVYN MJ[=6GI]%TF'T/>N4%R^,ME0X#+3KK1]YPM5AKLN^53F.U$S[1;$XV]3';?+8 MOQ-SH><+*HD,!",PC(F$"(L(4D(RG2J2A$Q-G01;ALS8B!\\?*8"4;F'^ELR M+//I1*2I^SP,.;9N=%/=-&C>^O2I[4GPYEM;B![9Q[8G M9=_7=FC#(7CD+[+D/^N@O@]*SC:VVC1LY/#K _L,VYAJ??UN(4&% 'PP3E[4 MIWG_X/>DM-T8KP1VE/0:5&Z@D5NDQY$VQXOQZ%=J)[KCQ*..-^&;8EOO-=;Y MJMZ,^U:4?S;.G?+291QF%(:9#G$-D( 49S',@B /2"K"1!K%=QC*&WA0MM+! MCGB@Y3NFS-"ZPM>5OG1>?EHL]0_-[[MU@1G))>%I F.:(K5PCZDR!RR&,4\93H.( MIG8YFZT1#&P@.FG-J_OWEF'N]H0:N_'#T60YSU>"JUK+5?&]5K;>'J] MK^I M_MFK$^]&@3]/WE+^V.Z\&ST'?'K'AARK=MV3I7A'2L&[@<.= \!WS]M'F@CU MRA6Z?JS.#7\7I=ZE=7=W=+<:=\IL_*@!;SLF"U$YW' M)"%A$"HSEDF(!"*0Q@+!+$WRA$Q;)8\ D@+4)0M!#!4^\:X)5]%&;V^&_1U79VO<(+*\"[(?P=K706 MQ^YSC6:@4FT"&N4FH//%?.Q\,;]77TQ'R0G8J DV>OJ^B'SQOO)5UNUB>HQ; M*^[2W;57@.[B@-PFULT.P>?YHY+U1XA#I-KUK5 M1U1$-(_2U"I\I4?6P)-3)0I$CJOW/H[,9@)/FMO9ZNW6FHX\U'(GP)@(:P-J MH*(G$]A:=2F,\B .*<M- M9;M1:Z>M\3 UTJ9O@*H&.H-3_;0=F/UMCS(DC=1K!Z/9PXX[Y=U*/W7!ZFWX M?,089;G,82S3%"*:9OI8FT,<\)Q+DN$@M-LF[Q$V]!YY5[3E9G@?188[X9X4 MM]P&[TH=IZJ\B:*^-L+[1(V["VZ@]-X6N,D[]K%IRB;H"V?LR''U^_T(]2E. M M$*Q:1?BYD](3!>C0Z&B1@NX*=Z,)SVC%\!]:9YNRK>?K[EK"U84#RX*N_\6?3WQK'V$LS9G3=T.'=Q9%=XQC&X^\.K -J0C$7P0.IEV<^&[ MBOO]=_/HYD-:]QL0#PK;^PK'=?56>NB$7DZQS8?:&RVNN4>9;DQSWV-N2X-N MY@#E%WQ=S,GV-[?J;Z4NU*F6((WQSI.$IIG.W<18!%', YV[B4.>D4Q(0EB, MQ2KYS"BM\5*K:\Y9YA33J%( M$@$10Q3F<41@@G'.\BB6)#3.ZO^R\8&-4"5#;U*$T1OZ%K32S5/Z[Y'1;RW. M5='.%-AJ9Y7+_Y@:3GG\]QH;+8?_,36Z^?N//N-\6KM[8>+=\ZUJJ2[UF<=8 M!HC!- S5G)\Q DF2,YCEF))8YCG.K"XQ],@:_JSVY:T=+=FM]F M;*=B)PI?ON/:HI+%/:T^I?."P]N0KK@/ZX6$Q_[Y:L#_K2.V(B2SF M40:)&K4ZW[2 &(<,!I*D.>(BRX11 -0Q 8,/72T.E%K>!/P_P3^"1%?[KJ/E M_ZEFDTD0!*#4D:4E(.O5_6)9_(_@_P1%6:X%_W==4@U5I4*C?^))@N-_ZM_$ MV]^DD>WX?T&PZ:!WI\UVI%>,?:\9:\,?*S9\#O/#ZG@;VR^:'WE 'U9N?Q0? M><[>D?W0;%=^*E1[#ZN/R^5B^7ZQ7(K*4?XT(W=3F;$D2DD.(TP91*F,()8X M@D$>)&&:I9E 1M.QF;B!AW4+ "@$9,X*,JN37E2_J^" +1[PAT9D.$\;LGG: M-_;+D=T8]DJ/E2MMKK630QEK$M.L#2!A&$.HU F"2=9F.9&VX$>,0UL#S<725D7 BCF>MF3G)NFP;X' MS(SDR+Q:.F,'$C9,MC=V:X2@A0AV,#9FLX8)_K-OCO*0ZL&9M,&2/]@CNG Z M"&<*3R>(<&_:6]J:A\5:F>QO@BWNYGJ;Y//\'5&_9^+[O1"K*ZIKPK+5%,Y!Q*%N54$,)Q9IFVW1')P,:R00&4\ZZ)Y=I,JF>U[6SN M4JC?T1H7*#4PP["-\[O U6X.0*P/:]DRK?/A5(E2P)N-)_$6;-'J'MBN=!>R MLP"^6=15D, ?K1(>MZW/)G*X]#F&."Z=1L>.+H-T.I8-.MK(35V,:]G-6] - ME*W2%M!.VH)R,TI3Q@.)$@X9TVEZ4R$AYHF 21JPC.)((&*5&^<\. -;RSJE M"=U-:=*)X3 8ET/T@:&E'(U9.W-Y,$^,':GVQLX+%[XLWGE@QC5[7HC;LWU^ M6K6/X-_>$[AZ(L5,A^A^6BR_DYEHH@P*H>-W?A$S?KOXE:RJP(/M/]4W6K(@ M$S(3"&U7<>KKOH0O@YR^%!= M=KNI,BU6TV;9+:$[C;G$+"<9#%G*(8KR#.8\%I"D$FF7G1%D%0]C+'D,[[QL MPE[T,IIL98,WZN4T#%*6IAF& M24(01(@&D.AU>0 M;6A!1J+0TKZTJ+KY?30PL(MLTE,F3!LE-1DROZ;( UV^#-4Y4,8U8QY(VS-R M/MI\564(/OY0'VM1:J_B6,;Y)&2$\BR'8<1RB#B.8(Z16L9%.$ARM8ZCH=5M MI(MI,G@ T ; WZSL@,%'8+C(_#MTK?LQT:!E!W8^G[]OV0'SOGK=90<,]/C? M4'; O+M&*CM@ 5T!<^?%UPU72 ME&DD2(AHC'7040P18P3B* U@BDG$91+$86)E) Z+&3H2<%#1)D-_O/5MQON&VWU,K^6.*G3X?BO['U8)\\UO%\(N4BU[L.*'JO+ M?>1I^X":ZOW/\YOE@HFR_"9*H5Z_5\[%!UWF9/%8.1^;GY1@P>[GB]GB[OE; M<7>_:K,\97F21PGAD%$2Z@,%"G.!&4Q31-5XC@/"C4-J_$ :>/37V9\^ST$# M$[0XJT5*!VGW9SUD-F!!C=8A7Z6G/NLW+I?I"3M#]+^@$\R#:\;O#+?P&F^= MXB>LQB]M/8$UG@2-%EKCEYAN<(WGEMUUY;IJ7A9/I#XMT\GPVZR4 MOPA^IY/BZX.T*E1@&X;?&4Y!DNODMCDD,:,0Y8& - X09(E$@4RC&">IW>+Z M##0#&[,M-M !U\3M5O# %A_H #S#QIW7.Z8K^I$XMUWX#TJWPR:!!YJ\[26< M@V7D+0W@DQ5)+O)8O#?3''VRVUK68?UXL^%_%;#:E61YG M.<0I)$P$,&*1#!F*."56Q_)6T@?W[C9N2+4-"8H-.,L=23M.#7VX MH9BR=-XV,'2DP;[G]F:#!;1@CL>@VWMP+B3XL.37B9G2^ MBM5[4M[?Z'**7/!WS[^5VCUL;O]W+=[V[K6,1$(3HDP-B2'""84J3OEV#Y#*),H00#&6*(8H9@X1F M! I*&0]93-+0*@7$<5$#FYL#&<+=UW4]A)E9&#\TV%D25P;.3Y(^U#JJ1]!E M4Z2?7 $9O#%,6L'V'YHT"SH/UR>U#IN2D+*() +&%.40Y2R'.2&9\CFR*,H( M2EDJIT]B21>^D@D>06+S_7?Q& \#]15AOXD"CW%JNG\S.$^V.SNNAJ&\_$9UD;C9;_%4:YNH[P6V_C?+'F/6N2Y>LNCJS9?ZM$XI;U&OU0H!C MQ58W(NQ*MI[4KZ]HZ_&7QRO;>E*!G<*MIY^VMUZ_%V2U+-I G224&:,A@80P MG:,>!9!(EL 8LX!E41YDV.@R[%[+ ]NH1I9#A-.N_J>-BK-6=G;$ET+FQL)9 M,3?[T(CS8P@.8N\9^[O/CS;<#\+LCO###[BMIXZDAW]?W[C?Y'*]EIM,KFTB MUX\_5F)>ZCWE+T6YFB9Y2J(LSR GB$#$DUAOI 001X@O8P":E M0@=F_W]WW_KW-!Q5> MM'F.3'E)R9G)7[\ 'Q(M2Q0 @;1SM[9./#:)?H!H-!K=O^[8T\')[^J[=;6! M&FCC^\7>R=$^3KY#PWWH>+4[J'F;++.3VTM,@9W]&VM^T;&Y. ](O.<6O"N5 MD6JC%AX#1KX5Z>G@YXVM64^"OI5Y>#3T/KZ;8?XL'Y0946S\4A:;MHOR,@\H M#RCF,!0H@SB4F3HR\A &2/E@4G#)0ZO>0$=H3&PN=Q2!)NG8=ON8:LPLVH4" MVQDG6UFMSYQ*_HZ1>I-!O3.A3 MY7ZC[S@B@]&J5(:C_B2K'FV@X$O$,YZ+',$X$ G$1.0PRW6 -N89(Y*F<:Q. M-.9+^R@5J_W6?C'K[(H^LKII&]4TV'^;-?B4%W\VQ4G\;X!W;7HU6W?KE=)< MW8".BO5J1=7/RB5J_VB)/WID1@6M,(E_0 M6D=IS(N9-2;F,S"LT8?M Y7-AO=E_QU_EIMM56J7H,$*V:&,WORQ[F)?28Q$ MD&0)I!*E$"<80/T>KP*^S*D:"P_9C MSA9 =A9W&&1V'\1'(+J_>%^*)*0\31$DF N(42(A$4D*!8HREA!!D;@@K-R3 MF=@,[\.47&>ZYOIZ&^@Y ^O=7U::'\O3U0F=N41W731Q8:RV)SE5G/50I$FB MICLB+Q@#/11T/*+Y[&F[]2JY6#8(;#?WMS^7#X4N8;J17S<_*/[^9;(21P>8 M>"$V=,%-<:\_PY\_?GH_*,PS6WKCXH^O/&^2VRV\,:'![YH!T'#@(3)I).&1 M=5A+_K?;]>/?U?O=$E3&?K?RQD>=9>$9"=:O.[.'+T#P9>['5[MO+.$_3)&$QY"@/(>9!#$F@/!V>!")! <1VSVQW!O",5.M3@3Z19[WP-3^2 MK$]U'D6&]4K /ICT0['^J %YKDKQ1E8:HN?F3KE2#W*[*7C]X<.;[E >!B2) M:(JAD*DRI1KV+9."0$)QGH=!EF;FB&^&-"I M2L_'BB90E)V]>W$=F<>")M"56P3(3&=^HCZ60H_$>DQ'FBW"8RG:,*YC^ZIK M]LI1H#-=?-YT]JJD:)#1;NYH>7-7K;>W=S]LZZ*4=:W,/2O*YK/ZK2HV&UE> MY_D2(2YC1#CD64H@II)"EJ<4YB2B(4*$179]_WPS./7!M>,)%"5\Z+ $JR&6 MH!A@"K^T#29YGS(SQ_8E)\+.WI_$;FR8!8,I C?*2ZG5&4,[LBT&Y$:Q M#WK&P8!SM:S ?ZT+-$(\_LS9RM M-(URGZ[OY5-;EE?AG_>61OZDWG7-B&@D\\?[4]G37&N633MG4 MAU3QSVV]:"R*4>R" N>4H5!5-"#%BR#@L8*.._ VH4'SXCJ%AT\ M->A\P<$S8CV)#9Y[ULWG^E3IVZ3--UW-JC%E=3/%QC!\6J\*_FT?I4[3F 0! M(Q"1,-/'50FI=JUH$(LHS7*BW"L;7\J4\,1KNF=CT51TMY#*.U;L?"%C59KY M.%,HR&ZYC^I&_;+A _S>_=?KG8"K$CQY%,9D9_44;)5QZ %8OW]QSY)!MF4/ M&J;H'@*+'?Y[&="4!"G/(,)A#G&B;_)S2:!$48Y8*F3&DSY-VLS:7,R3T2I[ MFD9M9X@.@0?KPZXH@ZQJY]8HCO-A9K#FT;'GQ.QGX(63=&"Y3!_^F[4X\O-2 M?5TN4]]("Y@+!W:SCP.B77W84B(=G*(!Y'D60QQE*:024R@23K!@,8TR89,U M_IR$E1MEGS+>)NEU+;?=3=41U<0XH5BFRMOD20HQB5*8I1)!D=$X(90(EB,; MO_-"U3A<'4^@%#.#?)FH=A;VB5'MJ/DSI:HT\Z5C' MHKS S;>?Y>9NK2S?HVR/\V\+#;-8BOJZ>EO4;1&([IVYI!&26:9;SZDCGSH' M)A%D099!F5'$HA1E*4EW)6P6K>VMN'#PQF[L5^Z.NF7]BIU"S=;R!/IQ/1-R M*467B=IR!5JVP)ZO!1BRX[$8QDD+OJID[(C/6S[CI)AG=35NHS@FI?$[*;8K M>9V_T05C;%TUX/>#9 V-?O]1R7_BSX/[DOI&%ZCM(RQA(GB4)3E,"990N0\8 M$LD1C'%$44S4_^=&Y3DS\#JQ]]%SKF$LGO ^3+!J.U H]B$_]V]*M;-\4^C3TT'?2".3GO;'.7@%1WXC%9F=^\V&NJ B[8?SA1H_/"O4:%@= M=,C;Y:Q=/S1.YD]J"'UETQ5*2<)Y$.4AY#AC.@4XAC3*(AA2&G-$PS@,4NN" MM1D8G]AH?MSJW"$=%&@0>FIPJZFW>:@/+9""AO)I_^A2Y3;+W$HN@DQ**&6J M?/@P32').(9A2$.49BR3-++SX5_C[#IY^S^UT[GH9O"53J!A].853HK=ENJC MR+'=E8==8P=AGTX>C3.G)=*K>))2R!EGP6>EY!QLSU](.>-D'*VSG).^K[Y/ M5TT)=PM+22SS*A+@3L+ M4R>QMT7L58NAI&S0@_ISEW)FV#WE O6:6?QIE69GNX\W?M+_VW>[_=#4(T;@ ML]2KMU@573#H?R_>E[D*\K\$E1NFO ;+[0E?I?'<[_(C>;M@'' M)'TJW14Z6;NHLPR\<*E/?9W;4.TQ^"3KZ%_2M M/*= 0R_5GUHLG/U@1 MIF*.@$2<'6(V= A388:P$,;ON'DV_Y K<;/^F2K'21T:OV@B3=[KC[2H?J6K MK5P*'@D1! DD>9!#'" ."=;W7)@SAK)0HL0JS^LLQ8F-G*8/-VMXWW$ ZAT+ M"Y K)L"CYL+.OSFO1C,/QZMR; ]A; .^#'31*ZKG9@$T%^#74>U8^SK&$GOR M=L[3F]7?,1;_T.,Q?]'-,!S!)5!>U6.A2]+IZGV9]V 8[TM%EZZN.%]O2PUF MVO2!>%C)C1Q4KN^B$TG C?SLX=PWI9@ '/8,"TCC U;(,]WV#/ M^.().,,44:6)U>O)J$[%Y:RF>&)5'QKPJU.3A^?_9%FUGP,M-;:\=9VOI(//E!J^>!5GB MO+33V9^>T$N;D .!#:S X1O>[N7J>GO?W@#^HF\5Z8IO5PW\_$>Y:9V0@G?/ M:WPAC8ZM+].[/@S*GNQ>\A+F7OC/TH%B#^T0?5)S["W>- M0*[S+[IC^8VL[G5P9HEHKD[/402)[H6&(X$@0\H!2TD62$G##%.7LO"3!(T6 M]<45X'W;$]#T.>P[M .VKJKU'[H#G74/XA/J,[.+EVG#M1_Q3@Q"?HS-VA>%S<(WV*S[S@NJ ?9;F5]3)*6(PS'D$98WV BG/( M>,1A(B.:"$XS%%LAT/0#6WD_KK@S54?,=C5VLM,T" 2A(0QY&$",20()H1RF M(4\9IHPHM](NC]A%>J<\WYZ09>;63O0,\2#.10!1&NIT-QXH XY2R&.:Y9BG MZO\".X1LAVEW;5%YX;2;VEQ[B6Q-[!DQ'*SI4YZ]&<]NV)EMY5-AGIO&@[\[ MGDEW[:UTK?,^J?6S7&GG03M2];."A9!@(2 .A3(B81Q KM-& M:2:QR ,[(W(A1Y/;GB/9ZK:'RPMU;GB:G$^/=@O_:+K_H"+ ;YLUS^KP=0"\ MD)MY3WQ^5/?LB.=I6#?#MT> ;\/.;]2YLA"R[8;4P#>T<(G+$!&1)\JX!1)E MRDVB$:0T)S / I2D*6%A;N4KF!*>.N+>-&*@>SX6@ \Y 9L]*W;FS5BS9G9L M"GW9&:Q!SXI>54^8 #<&JK(V6+9R>[),QF1G-4&VRCBT-=;OVQD5(8OENW)3 M;+Y="5'INP/UXW5UL_ZC7*9A@F.18&4Z4ATBRG*8191!'F4T"C!2?I-1F'Z$ MQL2FHJ4*.K+JX]?_6E= DS8S#6/Z&;<"GJ2V6_!. ALO< .11AH[J+?;9:Q^ MV*_>L3%G6:@&0O5KTN11YZX.#4KCCXJM]W6]U7GGU_F'=7F[BSB&@J,L(AC& M7'*(LRS4N4X8)B),@BQD2F2C]H/F)"=>G$^1*8N.!1VU7"DFVL"M& M:NFK2 M;/?VJQ^[9?Q4->\'JM'TIXCGFDOKKV/#.8)S]VHP5,"1+@VF;UX*O/DNSR7? M7.=?BMNRR M.R\TOY9K5LGK44&WORX?MIGYSIP^DNB1W5[EV ,(H8\%#Q&.8 M$MKL[FIC#Y($1E&4D)#BF)I5F4S%X,2&9PBQV3+<7)7L609#GD'+M-I+6[:; M6OU]-:DKM*:GJ32S92\Y098A%I]S,Q.>IE^=>@?1],3>"R%G^E7N:;A,SW0< M.TTHGU+*#[KTO'[6SRL784[3$-* ZM-8&D,6(*+RJ,:,;,!GJ2U\Z-HM&AIESQ3?&H#H\'NSF2) TQ8A UCEF:,Y@1E,&[O"GH$N+4##YAXSJ>?4U?5RGAY;9VL.I7N]P5IT2M[K>"87ZE)- M>7>:G!EZ(3?I4@6>=HPN'MD>)N'=JM#Q[JZ,74J&22(XI"37O;;B%#)!0RBB ME(F8!GDFC<+0ST:>.OCC(^0$; M.,K["++ T^=G@Q$XRN80,^#X _:+^DAQRGNAID@=MFB/R=WW-;\J1=\VZUN3 M/:VQ"HXV :S6=;V4D8PSE"#(TXA#S#1F-LLHS%$0YC'/=#L^BUSF:;DU^HPO M3H3690OB1#?2!;C5C)@OWPFG[KQQ>^&9\%@6/&0;#*[F]11I3+D=ZZ#C?0%. M]T']Z=5,H;DY?QU3Z;8WO/B46FT^TVMZ9">;D/ALV^+T"ASNL3-0FQGVO3L: MO/LJ*U[4<@<0VR2"OR\W55'6!6_1;"))8HGS'*(XSW2>20RS!$L8IS+,XICR MT.YF>PZF)SX[M/GR14^R11'209)U5ZY35QC;U M;9:)-HR?O++IA[9C[O&J^8RF.\]JU<5IR%M(\1A@R2D.(@R"%) @I)'F$0YRC).!V MF<]&9"?>$YY8$[ZN-Z"2?'U;%G]*\??OU/:_Y5)\OP /RJZH$Y]EZK.98LTL MN']U>8YR=QQX3'FVDMA7PK,9T7G3G:T4\2S9V>[MB7S:^HR=>]KRX#=9W-XI MEJ^4VT5O96\$/U4%E\L@2G'.8JIRRAB&8D3O]V,_/$^ ML37;-;SYH^,!TI:)G6NK#)EB0W!(Z+:E5;W_K>]>1QXGWY.[^S)3 MZM_KK4W=WL.>. O0"P4ZJ7:>,6CDFM$']C\9<[G"'CE_71ZQ_RFQ=HPG8,%M M;]/\5?).8TH]R@;:3WY<;P8I#!E.0N7]$AA$&O8E911F*0]AQA*.28Q%%ELA MIIXC./$N, 0^K.OF',U76]&@.34M$C>*W*H%WU0T96V; MQ7M6RV:6WZ?N[,SU4R6UI,%W6EG? \W"1)7,I@)[,HEGR.Z=C@F&)*(!#DA5(;$J@WQ<3)3 M)YJNF_N: =4NGJW4GU%^K7>O)N7CI2Q@'SE_7 MR=/_E,S7M_4T"_:I?1J30E&I_B'I:G/'%3__]>L_Z$JNRR[C$^4QSF.20D1T M@EX:(\A$DD&"$I;B)*4L,*IK,"$VL4_9DOI[SP78LP'^ZU>'U-BSNALWY;XU M8GN./*J%OX.6_!3J,,\V\ZD6MYRQ,^KQD^IE*N9(PM;9(69+NS(59I@\9?R. M+^S[@_C= ;SS^W( \-R]= C5KP.F MSMAID&:78>#[8'-B8_K;X=T/'4"Q;[6GMED#(344B&Z-RCKX]?6.SQK0#LS]1% MVZ=V)T/4]\+D"R/K^U3T>81]K]0NZW4T@&J[^EK4RSAE,<-A!,.8!LK.!P&D M4<)@Q+&0,G(,7*IJW5M'I*GG[H7R=1C7:]'7>='O4 M*0Y?'B0OZ.JZTA=1VJ_9TM5-L+GS8G4/OY0^<41!VP M4IJ+GI_EYFZM=IY'V7;P_;*]OZ>5)J,V)EIJQ@9-@'^@*PU2^N5.RLTN8)5& MB$D<($AQ*"#.9 0922.(H@SE0C 49D:@H#Z9FMC$=_>^+9]@S^@"[%D%.UZ? MMO+NV 4-OR;1J^EF[OP-T4O,AYVA__]D*BR@;5Y@2AQ1<>:<&CN('<\Z'$/G M\45J/F ?S\IY@@GD>VS[?>]J57Y;T?M/=*,H*S)Z,VTR(M[06G9WQ3AB@F0B M@%&( XA%(B!+4GVZ83*C$>4()Z9;F@&]J7/=6PY RP(8\@ T$PZW[29*/+^[ M>%:-W<;Q0EHQ-_2>M>-FP\]IR8\]MA!UQ-2:C#*;%;40:6@@;5ZSLWV2B^7; M1R'JZ^IZ]J\K;^I.X+M_]S^;;U1^5J#]N].__J#_G*[Y1UOEFL]*Y8S^N MJS>/E?COJON #)U(3F\6WA3I_R5+4&@FE3=M\1ZM2-WM6GWLA="OHSH5I M,N-J4*XW[8-_Z K"SS)?2=YE=;:X*T_22-4&IG[Q*#5DTW]+6IG9$5_3-&Y] M7V"&+.,W,T_.>6MO;- \ZW:D,9*BU$5PN-@';GS1G\54>E96;TI]#VO?&^UM MM]W^V.08Z4_L1_6;>IG'B.UF M1Q6T9-OETQ V[XQV2COC5LN3S):6R%Y6S/]:FCG)VY':W5P#N02@U-"QUN-7W.#'&%U@OH&[K MVZH]M&?+Y:+Y>?>'CM/%4R]&WUKUW"W ;KXFN;#RK$1_MU.^&)O[*LJS0H_< M._FFX-RB4FSYYHU6C+[@TM0^%_6_>I1^*D5$ @I%DF&(A0QAEI,8)CP3&0U# MD1&K?/9Q$(=:/*6X21#Y9F90'\JL3-KEVC#I1&E@9#^FE".$9N[ M :6!X$>:3YJ\Y;;D;RI)ZVWUK6GVT< W]B#$^NZ[#?\OE>^DUGB(("6QA%@& MB?*K@E39@5R*) QPR *[FG$3LD9?^R7%WI_4[^^:IEWK'/#U_;WZY&O-D-W" M-U*A;N&F$Z\@I5)W.%'G2,8YA1E+!451BE&2+Q]EQ=:FUM.;"CN#,21NGD'5 M%,F#2CYTNA2+!K=R @V:&5#?6K$SHSWUMIW5HH7O7>SPXKNTII8+?_;41F9/ M5M6(Y*RVU48)AQ;6ZETW._NNZ2G^6R'DX+[TLWR4Y5;JKL+OOBH?IJ2K-UME M@>YE]:$HY?N-O*^74J:")$3" L$<L!NMB M=1U:LI^X?+ M^JH45YQ76[JJU:\VE3JQ-]G?;]0)Z5;62Q;P)$QR#$.$]=T$SR!EG$!$@T@F MZG2(4JN^O_Y8F]RO&Y"LFT#XNLD2X"WYF:XJ3.?)VU7%!-J?[*JBY[69G9[; MYM=[?D''\*Q7%99*G.^JPI2QUW958:E0AZL*6PJNEIEM]M!G'^F]?+N^IT6Y MQ('(A!0!)()*=5Q.*:0)"2%* L22. ]SGMO9V>.$ID[=4&0':(4+H"F#WUO: ME@?@D[HRM767:\#6$9E!:@ 7Q;$. MK=5H2=*8,A;F2FV9#F_I%DYJH<*=*O!B4$-N")QPH MQ&Q17B"F[3&O(]3$KCWN_B4A1GDJ!C0")G@\]\7+JB3D$#PY4<#YR MXBZ8W0+R)Y-Y^,-=-K=@1T_/3U3C./!Q$C,":40BSS M %(B*>24QYCD691G5EZQ.RL36Y"FW4N[#].5W49\@7K-]NQYE&9GG9XVAFGN MB_:,@3UG@#6L]8UD&N8:N'3-GC^GX'(5>?(?+F!D5E?CB4>1G0S;R/X M2E?WZVI3_#GL$-FDGZMGERC+PE#*!,I$P[:Q*(*$)A(&(4(Y"Q%&*+#+K'%C M9/)<&_6-$CN+YJA1,VLVO9;L+-DH(EO;#[:I,ALRM^AJ1-0[_FS898KQ9+\< MF9C5=EVFJ$.[=>%H[G5C+;[/NU*\I1NYQ $/\Q"G4->(08P2#+-$G;W2( P# MQ),TDT;QC),4I@X\]D54+5&@J )-UKYB[*E>QHV*%VDM@XRV@CK5BAT5YJ)* ML:DZPRZ=U9!A1]"&Y96S11FC[ .,Y M@7R%&D_2F3?H>$[<9^''LR_8!R(_;JN-Y-=O;W[])K85[4%Z9!C1G"J?'$58 M=Z35/>>8!EIF(<%I(-+4*/IPDL+$B[.E"131O[=4'6)YQS5S/DQYL;QV2W(Z M4+[!;$?":ZGVCFJ#0C0QCB''_0Q83H :[SJX>':JV< M^9^E*+B&B%^R-%8*4L8#QTFLX2L#F#%*()%!1'(6$<-,^%$JDYL235=O>K2C M#.Y[TC8K[)2.3 R*!\EMC4HO=$\4_.Q3:!O3XD%X5_/BH 1+2W-&N%%K<^K= M&2W.&?:?6IUS#]M;GKX5Q9OU/>ON\AOHW[JY3!@DU;\OBTU!5U>B_B@WUWF?BKWD"*,@002R1"=9LH1#1N, )JGNSIS+*,ZI7?K'69H3^P<] M87"K*=LF>IS7F%G,U+,>[';='?$%V&FCH;\ B@-]T.AY\)F?82RPMT2,\Q1G MSK@P5L'SU KS5^V/+Y_HUY5N5/+NEZMF+>E#41-YBQG#&><81IBKU1^Q -(\ MY# ,DX#D.14$&[5\&B,R\7+OR:J=_IU-%Y=]V'Y'8+?'*AS9U3 M'\*[.9%'E>#'LSLGU(@'=O+5V3RE<\P//9JSS[IY'A^4DR1EEQ=6WGZ05"WK M@K)B56R^?:+?]&37;[=R&44Q"S)E=A*<9Q CEL$,A1E,LQP3F@:!E.ERHZ&? MS=P/4\)61FE'WOC3;,&JMZ4HZL8#5(MSI5D!#QT+=FZ)L3K-?),IE&1GOUH. M%F#' VB86( =&PO=_)W)!B?*=L %J!O8-\O\E-EFF"1IB*,8P2!)U RC0$#*U81S M@3(4R" GA'8S_*XT!"Q\Q?/;R^ RNU*C,?Q5YM5LWWN5,V6W<3;\P8;!IRC2 M RD ^P:&SW62M#TV%GW'C8$T76^.C9('= (MP.!3:(7RF'XU]SSX2N>:C>]Y MT\/FGHYGZ6:S,V ?0CD&5-'@6"@6ZJ+%4UMIH-FF8G>9Y3PEH>X+$D5JHZ$1 MA20F,>1I0ED8)S0QJZJS)SUQN.4I\$L/U*/!8;BL-K0H =WS!:N6L0;XU>(N MSE+92"8!%QE2>WF00YSE$21YR"!/N$P1QY$(B,DA^SP7XXZ[@=T 9;$#O=?2C[OXD +U5'VV] ;)O Z8^866R.R^S:>A5 ME'S;0%#ISUR-7]SO/VJ- +;F1?.+/XK-'9!?BTU;FJK>%$7]L*[I2KNMK+]@ MIGQ3/"JUR:8)V1.&:_"PK>HM57)MUH""AVI]6]%[[0=M@!+Z0>FA[!CANJWW M>J6CK,J[NJF1?-7S6)5T-7JFY:TU)^9+#J?2H*:KQ^:9':Z9VM;"KV" M_R5+/9[RNV0#T;G03.IW[C5IK8Q.F0U/N[<5[-]ZXX^ZD8RBFG9UDH)(-JYWT_BW\"7[>X% MKB13I%9;(<%&;>>UG@XU:/O76C](:\!HJ2]"%V E;_65/=U?\P\PX9I71%$I M7I6>>_G.\J_&_T.N5OJ_LH,Y76B>JF;^U-?2#JRFIR@W\K;K;]#,?2N84KS6 MVS'*QTDN.I&;-7'TLU6+Z($V>M-??/VMUEBK UF'G.P_X+_YB6V[&9B1B+?E M@+/%P=T$'4;''4>8.<[5^;KOOCX471GV^[(ML5HJ)Q3E,@AAGDJJ\Z(YI"'3 MS5E$*.(H#?,TM6O/, &71GO8)=T<&IIR[B#&R+1,'*ZX4-4O%9C8A1X&C.L= ML&7]%80?SNOUI0,-(QS^-4(*YU7L+7A@0,J^.?/[LB[4DS<5U=N_XN*#8G3!5J:(*.Z'"YUIZ[ 9B)Z-0J=V38V3K@GA=MV-C6X&DW-^(G=<+2$"W7 MY:!V\WVY+^F\KMJP6=N\Y'T;()/+%.>"HX!"E) <8D0(9'D:099P2<(H822V MZI#IR,?$X2O-E6X[77?UQ;(-AM\W/#3U VUNIIV/X*IS,S]@!DW:V8Q&B1TN ME-+EV^;ON?*&J#G?@ M2X=SLW,_=S&7SU)+7:QTYK0VGUT"&\$B9XA$,!!9"G&2)T^:A/ M_K3C:3KUF5O-"=7H9DDG4*>5C754R(C=M1UQ-EOL*.K0/KL.X=RILBBE^$&6 MZH?-)_7=7''UC6V;Q(7NM]=L5=RVWSU-$6>2:+STG$ LE3.9AVW!TS@+5TFS2?)M^H9VCWE_6.)>M^DS;:-@NY3:=#:ZO=J*\C M"3XUZAOPLOO+]7GUN32%=-""O\:/-L3G;N[HH)@C#1Q=1G$S2KIY1$7YYK=B M<[?O.M[5#G:=R76,\+8L_I1BR7&6(Y%SF(:4*\O$(DB%0##)4Q+Q-)4QMC)* M=N2G-TKMYEVUA!?]#^J_/0MV1LA2NV9&:#J=V1FAGH\VE;+GY$GI<,<-^'Q> M?]96R$T-GJR0)?%9K9";8@ZMD.,H]L?9-UHJ3:M)XRSJ?UTUN>I+W5DR#J10 M!B;+(,:80Q8D J*<<222,(R3S/38>H+&Q/;D"550*;*++A'?_.QT2COGCY@> M9+:V!P-Q/S?B7GD2U_Q(Z$%LMZ.?@_A61[LS@HTW:EVX7>RI_4X)M/ M5<'E$G&,1)0$,).I,F-<6; L2RA$(A4QR6@FD#& [,N*,K&U_*4L=/G'GI$% M^*-C!="6%W"KF0$/FAOP75$"L5ZM:%7KBI,\,,=79!Z?SU\&/J)06=J*"1%33"_F6^&HO[[K_,U^-XF_X7^HKL;O!? MQ<2-Y0>\+(/S91^\BHEXDMOP.CAR[!W:=B!]][6MS.W/E]U->1A$@<0D@&D> M)!#G"8,DY!ED..24DI2DJ;!L$3I&S\8^.74"[:AK3/R&?%NXK.B[IHR.JT\= MB"7*D@S&6<0T?F@*,Y)SF# 44Y)$- VLT(.]*<\%-[A374\<[ )-4VC.+.;F M31]VKM(%JK#OB6HBHJ_6IZ.TYNUP:B+VLT:F1B^YV4EE:]=56__V6?(5K>LB M+WAKZ7>0Y6]ES:NBL=U+GF%.XC2"4@?F,5YG@1!!A'2;SCUCN@!VR%J3==5%(J+99P%<99(#E/"$,1!1)5O0C(H4B%PBC,I,.IQEV[,S9\=%T8+\RFN MTHW#_=G?OOP-?/X_]/[A/]XV6>Z\H6YGWBS5:V;2)M"6DQG;\=$VK9.-^=*L M@*>\+)H_M.PL-.H1]Y*??9DZ/)DL2^*SFBDWQ1R:)L=1[,Q1K9S[C_1>V;^? MZ3_759\@]79]3XMR&6(6,$%R&&4\AI@B 1E'"$9)( F*$R&QD;NX-#P3J7XN-8.2_O/ M'VA=U(U[LD0905F4,J@69P1Q&H>0QA&!(LX$)VD:L] H3<<[9U-?MB@^0<-H M@^+14F\JYX;L=.Z\[<6+M]DQO*1Y"9U;7NCX4;?]Y8YOU?BZ"/+&U[R71K[5 M^>R"R3L!^ZCONP8)^TU;^[8#^_FRH9MMO8Q2+F3"":0T3R&.H@2R%*>090(% M(M,@+T:73N<(36S^6M*@H[V'- (M=?,0\*BRSH>!?:G \D#D*+U5/-A$-*>8 M\.C L\6%3<0;QH:-GG?SACY+W8I"BG<=J'\/0D$22;(T@REF.<2!AB9!3,* MLS2BRK^1U"KV>YS,Y+? +5'04W5,!CFA(S,'XW+);>]SK86V]@S&9?*TS9\@ M,NN>/2[HX09\YFG[,H0/Z_)6???W[W?0IOVW%P0YH2@24- T@!@AI+92E,(\ MS*1$&<-$"-,*@9-4)EZ>FB[4A,& L@.8SFDMC:]0;[+;+=#IQ39/^/8BOELN MMJ,:K-*BSXHWDK%\^MW9DHG/LC_,\SW_L&,W:'5\:*O&6W^CB\JE&(L\XQ+* M3 J(1< A37,!8T%(3(4:*C4""!HG,[4%VA'MO%?+P.49'9DY")=+;FE_[(6V M;]4\*I.OQLS'B?MG<0KECUK7Y<=W9?QHE01^L $I9RJ!9H M!K,\8E#$0G!)$T:8L5/P9.2)EV%'RV$/?"K_^>W>62J[)>9+(/.-W%DPM\V[ M(^=GES[*^\C._/3YV7;CHVP.=^#C#[CMNDT(;]"JJMM11$1XG#,"$6)JU^6" M0,+5KIM*R3#-,Q&0R&;7/4YFZN6NB3YIX^BVZY[0D=FN>[GDEB;!7FCK77=< M)D^[[@DBL^ZZXX(>[KIGGG;8=<, D:91@@9:ZFQU)&@!30B64AB8S#?8P0F7I2:8M?]0]-TV;J.:<5@2[Y05KME.)&8%AOUA>*Z M[=?68MMMX",RC>WCQUZ;;SL?8?K)KC[VG ,0;]?G]J=JO7UXW[<:5;_5M9Y% MN97B^D&V2":?JK5Z5/WBCU*MY[OBHR'V499F$<"1["D'$&<<@HI"Q@ M4$8X"R.6HBPUJN'TS]K$]JKG0,-X:,HZS7C=<[/K)FR!-^MW7L[;O9?3MIW% M["F AM$%V+$*AKR"';,+L)N:';]@SS!X^])38X$4_&)3Y @D//=4V<$,3Z+- M,11BOP3G RF>1%%/,(RGH7!IA5*'$%C_J-3QKFOWW:?^->DLZ_+V0_$H19O@ MTJ9YI5&,PURC/L11"#'-8I@E/%"'XUBYW;%$ 3=J#>2'G8EWO6%13<\>T%\/ MZ!G<86JV4/;-+4O#9 Z1%?>2YJZM.FB45U3>.I-5?"-%,TQI<'$^_SEE_YH&A,<$A3#G$4)Q"B6D"5A M F*2)J1@,;(Z%+ B-KD"3T][>XPV^+_?:?HU]\[)_>,:2_G 8J2&,$L"B(= MU:&0! &'29H%.&=*@VHH*X@A;_IS@A@ZH<$I5&=F]+VIP\ZF7_@E.61,&8CI M+7%JC-;,^5,&8C]/HS)YRWDK26;V7[W_=E0^-NO5)CU"WDV: ,=[3@!'2N@XV4QZ%%SD66R4;/A*78:Y5D>63WJS?YL:J\!7P=1 M"\KSGCKM5?+LB.DPA)WID5PLWWV5?*L+X=_0C;Q=5]^NOA:UB>TX^?+$%F)' M$_1$_]W, IR6=GR=>Q'4;C4_EQ'\KBEZ6+-GI1FILE+O=HN2B_U:/#WB+"ON MK$#]NCK_H-O&_<.V+DI9UV_6]TPMU1;(JP>[>2]DN2GR0D=]NBI-G9=22?&T M6E/];7LO15?Q-?A#@\&\)%F6L3P(H$!$W_I2!DDD&.0L9AR%222I49N;&7F> MV RT&.Q]O];5GKB=.S#'Y)FY$:]L2NP,5L\\&'"_T D,!^AAY+T(;0M_S M"CHI%KN:T\$?%RWZOC_G94:]>W)ZYN!X5F=IQBDX=++F)/V"78G:9K5[)/\O MT,B6RDFWH+:"'+= M,O%7Z4-D_26,[UY_F?FU/$Y/T#>F;^S]I&W,E_[K>66-AZP_DQ?H.33EY_)Z MV@U-\-F\3*EKI6^SG?0C^^^ M:EEDATI[ ,@41CFG)D%VMWYV7&7+-/U?JQ MJ+7IRM>51CI5QS+UCY9-UU0R>^4;1N#G4:FE"S'0YIXM_:\!KFS'&OBN8^[[ MF2"QG?7D/8',GI,7RAYS5MGIU#'W(=W,X)NF#U']7N?X_E/J?(N.ROY2H=YA MREWGNOQEARSWX[84.C]#5[&W?SI8JIQG>9IP!$F:8X@#&L&,AI'.S4TC$LHL MRHVZ?,S![(R&]*JDJV]UT2Q\M>F!3BR=+J#_VQT$;:O6Q:#.MG_NT5ONKW!15ZVCV8^OA+,.BDWXI9D;]MEQI1BK-F;[RS%2-G;AD*#Y78F\+4H-%P<87>F;?8<G%-@^])@JJEZ4$U9COQI0+;[:!/9?U\1E:W MO.P3POA,QSXD,7\6]@DACR9?GWK6_LKJAJ[^E&5)>]C*3$@411A2+$*-4)5" M&L?J)Y2&*(_"."!&IX+G0T^\Y'IB#H 1!RHX?X'B+IC=TO(GDWFTWUTVMQ!\ M3\]/\/LX]R,1Z8,79@L3'V=T&+L]\81S5<7Z7FHWL#EJ?EBW+44[0";"J,!Y M',,P#]2.2P,*:< 22!(,E^6W]?JK6C M/(5/M-"-A*4N:.U_ISMG_4,*=:1XO M38N\?TRC('-WP[^BW-P03PJS%GDZ__@??_G[AU?@_O*__N?_^!___G\!_)]?WOWVTXM%.O^$ M\_5/SY<8UIA_^G.Z/OMI?88__6.Q_.?T2_CI[2RLRV+Y">!_=O_L^>+SM^7T MX]GZ)\&$OOBUBY\N_XU[K4IA'H3.$A1F ??_[U:US._KI8?OQ9,"9_OOCMOVQ__>NMW_]3=K_-O?<_=S^]_-75]*Y? MI(_E/_^?WW][G\[P4X#I?+4.\U076$W_;=5]\[=%"NM.ZM^EZZ=[?Z/^#2Y^ M#>JW@ N0_*]?5_DO__-__/331AS+Q0S?8?FI_O?O[UY?6_)SF?X+EW]-BT\_ MUQ___'Q!<'@;/E9BNW^\_O89_^,OJ^FGS[/+[YTML?S'7SZ7NJ907&Q6_+^O M_NW/5XM_7N**$-,Q^QM]8_L1=;%#",&O:YQGW+!WL<9LD:[]TJP*=[&\^)>S M$''6?7>2<3KI/OE97*V7(:TG2L0<#8%*2F]!F M$=6=+E:8_OIQ\>5G^N"?JS#J%YU4.HG<6FXCF,?!AD!T^V(@>B4@.NN--2$'KHZB^]IRU^G>U>FS9?IIL)?E^7B4PMMK1;?-HJY ME[N.M3695>Q^\U"EGZ_@8PB?)^])TEC-[O-96*W>E/?K1?KGLZ_3U41&EF,R M#(HV9#V]SN"9C^"23\8@,TSD!T!0PBIV5&]7VB !9^O5Q7>N(/%=8H:#R!'* M7?0AZ1% 9I?^%XM/83J?Q*!1J! @8N4@:@\QA@B2F6"QF)C%0X;N$*S EL6G3XMYQ\#O^"GB$"/DY4W^6*QQ]>(<26>6@@3&MBQX'Y&K;*'0]XB% MG*JI#6!1&2XXU\Z$[_B,#WS\7OH7(]=_*_$-B(#+(_;;ZWD-[2Y<>7Q-QG0U M84EQ984$8:4'E1'!.U= EFPLEQB%L\<[HG>N/0Q"VK@<#:4Z,#8ND@(?Z'$A^VA+=*$-+JXMNQ^%!/!!]-Q#L2X_%A&>:K:97+U@!&F53Q+@+#[AZ 1=-<1$"\N0(U#J"XA1-.1XX?<5E MD,)'S?11T+BYXEZ0,$\$$D>)("A'U2D#A"K*. Q>MY6BS)N'5"Z1+ SQ?G\_7R MV_-%Q@ES/L?$)119".65)R^T!)E=2D8SYRQO@)('B=@+-.Y)@::=T$>!H0_A MZ^M,LIR6Z>;6?FLCF2Y!%6T C2(A8^9XK08"?MD.EDFUXJ1 6V ECN6 MWB]/QIX45(Z5\)A@\IR^?+/\L/AS/B&4HT[:050N@"K.@7.> S#R%/)I;:0[I@ TAVA;Y9OEXLOTWG"2?)9!Z,M(-I<\X %0M8) M9-+6Z.RTD;$=2FZLOA]4GDJ>M9F&\EXZ/QKY6&)H:/;>Q'0%$/^%,7Z M2AE!HK .4/N,0O'BV)'ECSNK[8>&)Y-H/52. ^N_EA[/WIXMYA>I'LD3Q?$H M01?%*1[CC$Y%BL=X\"')PI(7Q]F'FRONAX.GDDT]2IX#8^$]IO,E"82+^&&Z MGN$D)ZL8+UCOD9"$X!+9,6E &"E"4LQ%"J9T\,E M.1)S\/)K.@OSC]BE?'FQ696$D)DW=+2A@8#$B>'>1D\A=63'!1MWK;H?()Y* M5O1HN8XBN/@'SF;_>TYQ]'L,*SKN\NO5ZKQ>%3&M92V)]%T=8XD27 P%C.,1 MN??,BA:)K7N6WP\I3RL/VD+2HX#,?RYFYZ2-97>SN%Q->/:;]SLNV9JA*PJ" M%70F)I,UXRZRTN#5TLUE]RL,>UKYSV,D.PIH;.M4-I4'];0DC9RO)L+$G%A& ML*605$HBJQAU %&??KG"HL70 "%WK[X?4)Y6%K2!G$>!E]=S^K20UM,O^"*L MPY:M20J%8>0.LA(%E/ .7(X:;'VUDZ5G'H^K"'IH]?WP\K12H0WD/ J\=';Q M>5CCQ\7RVT3$D)W@!DBUY(074R!H)R&D1-Z73U+YXVH+[UAT/W0\K>3GX5(= M!2C>?PJSV2_G*Y+&:C51VBM$9.!*?=!CO0;/G27)8+'"<'*G6ERC7%MT/U \ ME1SHL5(=!2A>?L+E1SH9?UTN_ER?/5]\^ASFWR;6\7IG[($3R$DDNOK:EK!M M0F0N2V2AA2-RY^+[@>2I)$A;27E@L+Q.9?GL/$_I-YZMU[C:*.35+'RD4%YP MFY$PSD($V@!D!XM,P+B-V:2KYTT8R'DGY^JOI_/WZT_KE MF2FY)9%H%SX"X;$E#P=&AR!D(')BJCYS"4JJHK%06@@S12:G<@\U?]@7$SI+[ MX>%II5H/E>@HX+#35>+]&9\77N-U=NG21 IA& \))8=1>S&@L\\@4*G MK"%>+$LM,FD/T+#?P\NGE7AM)O.1."FKJV)]S+]\>U#R5_&P+Z8X* M()L&!QLFC,G:6B6A*$&G*1<,O+ .M-,YJ&1C<+XA1':6W@\D3R5?VT;" \/D M&7&0.RYJ5"]4C#(K#1Q=)'S["%X1R'5DWC DTLMQ%X#7EML/#D\E,WNX))M! MX-]_OB5)XNN?AW4O[E*'.Q*Z3NU>38QO?42#7L8/DW5D2^/:8>[F I?]>'XN!XBH4+]$F:[PCDH<\_:A=OTKQ=*1S37)14) 27"]2< M# 13 L3$"=F17!Q]W.WLSF+#- UKIJ5KV_= $0YMOS=D_[9M@3[165-P3$P7 M50MDLZ7HAN4, E,1/BJ>Y'%%83<6'*9/6)\(.$B4XT#!J^GRT^L\H4"6V2(= M!!DIC-&U+U&M-I%617)<+^6HQF^:: M"[GLU[Q:E#>?<=-.8G7 H;['AS896? XTH\\^"\ZU=;LT2>\7/ 242$P+DW, M4&0H-3- 8++& N->!\YB=O&AM-TA/9SO(:59 _Q-NU7-0TJH*50)&@GDT8!# MT54R8N)28

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

      74F(-K:*EB7*FD&OD0. MP7H50DXLQM;=H$^IF!<]DWDV!XJ[.\#<'"H5="WMH6VSC;MHF->4W6H;E^$R@A!=P"6/_#KZN(KW9./;L_KJ[($+XL-@91;F>'% M@S<)(88BN70E)-%Z0^B+!/4$GS'Z7DTE_ Z0]&ZQI-OXFI,;#D)D14GE@:1" MEKS.5"2I*!"!.V:\UHSGQO!Y2L6\=JHY9@X46"PWWVO/#71\6"8 F7K M%$Z>"O$C,UA4S&M4,32W4+LIF;BZM12[2KU/A]7TE,X* M[6(3S_O+3[C>\4)Y)IU'D\A <"V)$ZD2^* 3&)NEC%I:AJW3 \_1,K,M;7\Y M-A'ZK/#9M@M5!F[/T[:W^\SD$I2P$CCG)!F4$ISB&H@';@,Z3G[&'O?:TY\\ M[^3%QO?0@8+K8-C'74&4V_!%_;!5T"Q9Q2WO%H MPKY-=>.IF&?NS$1P.J)".O#='W+[KV6XG9Q3"QLJ3Q_6^'EQ];D6$]:_NME< MA67".E=G0Z;]+)!@Z3(M$ *G*S9CK1QT"@I/'+W2W/K6$ST/)'F>Z343FK]C MJK"?5I-[7F>-AK)*P4/)0=4SER%(9B%ZU,16MY'71H2O*@=(P0G;.0R&D(,?DB M?>M,^A#ZYIDA,R&N)E/.W!D.XFNU)U\_UP6WO_S]9;'&!X-GST1QS-?Y=.B, M 96B \], I&$BDB\,GZG3;YY..5RX^?U]: M9AIM5C6;91V%!H4,:LX",##C) \LF=;[EV>K&\^,)>E10DF,#FYB":(2 82R M2BEM,C8O^3W1NO$AJ!A4-SY$!1W$I \YH'^TK0JQ2JJH*+ VVI,5*%&0 :@. M@73)F$QQ2V[=:[&3D(ZKQP?I^:6GR%%"[Q$Y-X_[%,*X4 0#)WP!Y9F\[F^D MR%9D"G$HBFF]V.X94CIZF1RGY-=@,T+B'0#GT?OJ31&'*D8S.C9@DZ(8Q'E- M<2_WP#T/Q:%T*%I?.3L)Z0PT8U3\\GOV"'EW )IG(A61B7I)9IR;VOYE0P+O M,H=0N D.7=&Z=3;J@**9>:J!FUFJ<6+O #P/L[:_+>DGX^;RCW")OY2"J78F M?Z 34C5VCF?66"E#5'3"/+F&7KD:_=*71 MY2G%^P\/Q_6-;E,LR*R!^OQ)P:N@(Y#I1N ?V[GZUV/?(PR=?>&*&;FCR]93P$;Q/$4JP4N1:Q:A:GXM==/34K#E" MN8^?60Z5=(=HN2W2-Z+(XCPD4TLJ=*'@(V8-]*WB8[91V-:N]6Y*YD7,X1I^ M!3(CQ-T!:/ZUW-2Y0+@M<[AMV(DR&L8\B$)Q)06IO@[X42 U:C2QZ)!:M[OL M(*,ON(S1[JJMJ#M RXY1"I'."7.*@0\U*L58]]Q%\F=#"9R,M_6YM3D:.9WD M2!W@AQNC Z7<'4[N]<1C,DG+0N>'L0!*60>NXCWI)+2-CB/[MQU*,DC'^PXE M&2+PF4M"/N)RL5H_N"5_OL)[@S)\1F?KPG<,TH/B2H KQH.V0;@2E;=ZGVDD MKWU.3\ 8J\G51&+M%2+FAA?NB@]:(?CB!*A<,G@>$YCHZ-M"8^;\$(B8'GIQ MCP>1,6+M%2+V]L%$%HE$-81DB)>BB9=@177\BT)RQGATAT#$#H#(9!U#QX/( M&+'V"A%W"W<=HO9<@5:.G#=!< ]&<[#:V\CI=UR90R#B!D!DLHZBXT%DC%A[ MA(<+I_V_= M;V538=XIN@9E B6Y@;!UQ.F[NDBKLMJK876/SYJWZ^9X4!DKWE[A8@13M_ W MEDM"/D5K-C&@X*R0$67D;'FAC<[$K"B'P.7>9\W;3',\N(P5;Z=P(44S=0M_ M%[.R+-7Y.KE66>A:'J8"A&@DSXS0_[A?:Q!<[G_6O"TP1X/+:/'V"A>"O[Z% M/\M)9U$X:*=-7=A'_E=][D"+LD2K-9I]=A[O\UDS+3D^/E[&RK=3O&C"OY$W M_$BZ+[-2'#A]'Q27$J(BIICV,6 41>I#?-S[GS735N*CXV6T?+M[]WGWO:H0 M>>8IR@ E6;*J83N=-!!77'K'LR166O<2/$-*3VFYUB^%X^3="6S^$Q?GGRXQ MO_F*ZW".]ZM'SZ3@6>A8P"=/GGOV$4*FD"^;R.OP:_+@6@_'>X6DGMZ(1JI] M!Y1:Z:"+L6(/A?0VK-??ZLRTZ\U5R:BB$#7DS,@.NQB)K\S!T=4;L'C+2^LA MG2_1T]-[4CLX-9'^[#/&#IQM5')BF$2M:_<9E#5DP;WA('/Q05E;=-EG+^01 MADT=R>H=AJ\C:Z03XWC0J*) /N)VUXT,FEQ('L#QDD%&RX3)6=O'(=U)3)LZ MTKO8%+?AM#KL9]S4_3:2WU?+=#,>2<:4BO0)DG** B:7P%?_USA7O"Y!.]G: M]NZFI*?'M38X:R#Q'@92W>/B=J965#E8KP-LEZTK[>WUQO6,26FA,U-^2M , M&5MVI+>V]H@9(^N&[ME1>_-NK]C&0WM>_(@C=.N]S-91VO:*1)L)-X7+0F"T M"-Y9\K.84I9KI9@X^;8]8YBP)D-(N=0>64OGK7APQA0>63"9MYZ!=V)M>P,P ML%?;W@"!=^"Q[VPU2@%%\#J!C77+7TP9?*Y[+X*VVG@3,T<)!.Y]=(*=*W'2I]*V]X@[>[1MC=$U!V@ MY;G 06?I5(AT<'Q,H#P9:^]U!.&83<%[FW':0>3#GN6.V\!W@%EJ(>_N8/-K M2'B3OP]U+W$P#@QS 53A D+=UJ8R':UBM!%NBMGANVCIR9\9J>@7P3-2ZMVA MY[5I0 6E9M609[5]$E(6G%49F"U9.-0BN&FSU"V&-1W]A:X=SEKJYW2F-?V, MZ\774%G=]:=AF6\W;55Q;'=T_1[6Z^T_:)LW:D#(1-FEUB(Z1@XJ9"&5+PS( M:M.Q2%I E(*1N\=S#.2X!=MZKM*T.:A;%=P, DR>154*E%@KSH),X"U]:4*R M*&0)4;=OHG] 0L>YIR&Z?WHECA=T%Q;WEOR[$_K'8O/?UZ-NHDM:L@1&"(J9 ML61PSE $HTUB0=4:GM9#75ZB9VZ_[0!%/PN: Z7>%8+>KI;;\W0OB":/@F>E M';!@%3D;AH)H)RWQ@MD%D9EZO&VC(8*>TM,+@@[5^K-P.E %'<#IU]4:%^?+ M7_Y.G\+R_#M#MTD4K] :3LQXS* XJNLU2=H3(R&2\]H\P_DB0;T ZE"]KZ92 M0@>(NI/271"D!-::>0Z\,#IM/GN(SB,DC)FKE*3B[;,13\B8.T"C/@C&BN-JBP4@:RCB$&)D'9C0W4KK@)Y@)O9N67JZ;D4I^WG4> M+_'321Q\#T%6Y=4 ^69M]^^K2D:XN,[F-:X[:4?/1&F$B01VC&P"*PJ=CPJR MV^[ZK-/0T4@P&:.PV@3Q>.S82643,$:3%4;0B2.9BA(@&J-!6:31BB^]>R"4,$/7/O9\WI8:Y6X7HRH?1\J&YVJGB$H#IPAC^&"]S<#L_Q29ED'%@OJXNG(H5[RI$T%.G04WC) M6E_V]SZ^!RB,T>'C93HC!=H!%EY,6]G #'>YOO&9^IK(%!T0[4$EER)CI@@_ MG2!Z[^7XIX MN-:'I(B'J* #.+VI/=! M*>(A2NBB\_]^+G<+9K+4R #)(P *(1A$+TE,#)6601FA9&,0[:9D M[K;^=AY2 TEWB9>;X\22=-(( YF;0+@O!IP7'DH2R6D718JM!]@\1\N\)JR% MGE^%S@BA=P">6P8PO[F=7W'G-]Y&FR)DFRU)1WLZ8F2!*=JDW]E0QZDHJ^/C M:8X-_.M7R>H-4F/T_\3%;JN,#O#U^VJ9OW-U.VY;.S+MT4#='@PJ:EE-L0#+ M(^.J2"MTZZKK'63,ZP=-@I]#A=T!7G:]$'MEHHR"$),U&,5\ M2=KSA.W7(3^DH9>0O#521DBXBU3.?8F$N+C8-IB<\>22]<$ VV[AS**V\_H$ M#E5FC.DB)Q@GNX.07N+OUF@9*^M3&@8TO*]I[HZO[AJ]9JO(LDA@+B% *C'7 M+;P! A8&]*U8DN3%X&G-&'KZ4+1YLTO@=Y]][7MJJY L.P=,UPE0#KR3"$EE)7E.BN%T%==#*.TE2)@41ON MZU. M.T#N#C9N=S=$D0Q+=6FE)GJO&X9NT\/(LRA9@4%%HA$Z@I?DB@OF>''):2M;U\+L)*2+ M[/RA2EZUEG@'L/GNDCSB0DL9(H_ B-R:=J[W.3=0)$K!,!33O(9J-R5=I.4; M Z>!S#M SN]X^=OR*UX/NW_("3/*T]6; !/=RHIQ!M%8 ^0;>&Y(,MZWSM _ M3\V\^9%I$-1(]AV@Z)FW^!Q=3,'R.E?1@.(J@Q?2@K=)EXBU#;!U$6).@AA.RBQ3BJW$9Q!"K15QDQ'Q ?9NG[AI.I@!NEY MWSJ8(4+O #S[E%Z0*!1RQ@$%66EEZQI%31>X-\)Z'DU&V;Y3X53K8 ;I?T0= MS!!E=("O7:49*8ADN8B L9:[)F8ANNS!IY(]67-;L#6>3J<.YA#\'"KL#O#R M8AM'EL+H&"WIUR"H@AJ<2PPL$YB#%K[H8R3@![5,'>%!C8WN__HYLA*S#(X)R%KI'-;7( @C #F0TB,6:-$ZZK4 MEO3/7';3 E"K3K0[\\">F_O_>DMC^O;QTVI]68?M_;1:KU=_D0QN9Y)P&3W+ MS@-B)/>7& 3'K8.HM-$E:N7%HY*;G8-\]OV\>1$V'QI6$ZNF+[C=WWXD8_2% M&=!%TN$M%&@%G36D:$W)EBOQ./NZ#[X&KI":S'_K$5 CA=^!*1[CQ[S[7LY> MBXAT(O"@2'1<>,AUSU:@@$DPB;J09WN,H?5[$SSW1NE>\F_3:+@#.+_=AEZ_ M+?^U7&.XJ!O<;VODWB\?UY;<$P<_HW#?).<$H&-T;+G@$%,,]4OFLS!H4NL) M &-I[24;,SF<'A>5'4.WG6/X;D[>;P]Y1GZFZOXG$B,D)2TH5ACXFKN(19OB M=)3TU1$A_ *IO22 >D)P*\UV ."= OY]=?GB8_7W8N;?\?(L:VZ#S %R+,2P M1@_>,%<;/KA#*9(R1_$KAA!]>F][;4!]7&UW!>^[TWNOYYL8\CYE8L!!YMY0 M%&D%19$*@1=50X!L99EN4.NK0U/%MHJP/XO;_\A.NWJ\_T^9]PN=F* M-*T^8V7M?MW]=WY_PD+1ZA^8+L)FLRB+=*WU9?XS_'W&0L#D4H;(!*O,9PB2 M)VI0H8C6B=3Z_*0.G%]&U@?5\*.AB[L!+[-\IY9>_T\55QES_XFJ)=8MJ M(L]K@S_C]7^OA?(F_]?5=;WXYD8>VOD4G;=@ZRH4Y4P!>FXTG?Q'XWAT##I+"D#510Z@C&B!QBG9^O MA",YB!(AH?!99Q[YX]D2AYV $33N!7__;PK_J77>N4NT,XYZS/:U-:RBHCM1 M>"ZT-(;T$ 3I@=4= CS3W9ZS$EH[6W+K1M()V=GO] .U5L)P)AK;UW*W&+.QW*G[ 9]PYH7 JX<(H.0A# M''D.3)8$*I7M4AL&,GMEF M:B7"<@/E S/] K[Q=*?U4P/],W/2\$"2F8(RU M$(JLD\%),\'Z*HYD@M0R9.Z/$"@?"/L?Z/6X'W5WX/H\?4+_2,K'JH7WY5HF M[W<)ZIAP:OFOJ]7E9=KT<9:'[=7N!"SH;I#"8IN@L"_/#]']\U?F<$%W8/B?F8)&$LFJD,NNM=CN5$_7VP!#S"8('8)I MON7N@ F$1TC+C5#N?G,%ATBZ2[SNX!"A=P">?4;9A928*B77$< DIY(#>)YC'<^A(Q+#Q?Z__9JC M]#]BKN 0972 K^M@Y'O(\FZ5[IV_',B=-AY8K%5+46EPQ=4&+WQNSAKWTEN=!*!!0TZBX."<+N"LT=/R&B2^",4?#CULN#I-T!7%X,A!)=1D#&C1/"1LZ/ ML<2IMS&GAQNP9E+O"D$[!M^QQ.LY"&-SC;;S3:5;- MD=%.F!W<,7?2N7O"%#$QZVP!;GBLX^[KB-9(YCRH3/\S):K6.P%WD-%+.WU+ M%V>*Z?([&/DC=%U["+^Z4$Y$DC3 M5>8/T6H'>'YT?^]D]L_53_=:<##_?+5>+,]_Q[\ON?@GF9)/FS-/GBH+'H%B M61*^005>.P=U@QI7V::,S5^MFU#>BTEN@^,9M-D!AN^D^ =69Z:NX0N7Q-;E M-WYFI,DJRCH"/==,3DC@2GU8-\&4X$+*N?5[X$OT])*O:(.W9I+O $7O5LOS M.JBWNK!G2I?Z%&K!R.UP?G)PG/(>M)!*F9R2M:WW&-S__%YWOU^>IB*[2?PF:QN=>'1)[!PRE[C>OOQGSR1 5W!POA&!5V01HF7&:0 MM5)U\0:"Y]R!Y%((YS&+YAO>IJRPNY[F^&X1XN*"[MU[A;+?-?1AM5E4]3Y3 M'FMSR:(.8Q+6@XK%@3/TN\R4U<*)9-44-5:'T-QQ#=\0=.VJKSF:*CLPN8_X M?7A!G!FK(D-'0N26.%*2D^L0$;0.3J%%3E[$M+A\2-"\H<*Q0'> $GI'U)UU M>MPU?*:EQ,2R!1MT #I&'*)AY+JZDKFSR7'=NBQY)*GS!A#SH+"1XOK#9Y4B MA=R+Y17F_5D6WJ*/!8K(6,4L(:+8[JU/3G#)16J=:VE ]KPAS;%P.[E"3Z<_ MZ2U1MMB^93<.=Y[\W*F"F9<9.$:H@H5'S0B44B&OA4,.?&8&ZOYWI9GT+)Q2 MJ/*@??O[F;EU:=^[R2<&26B+$X"FE2GT9,K&YCPX+11Z+W*EK5. MPPREL>-09 AZGL_L3:"J#@SQV]4%W<84-UV\N:!;.%?6:@GZ4\:$(XX4"@C. M5 ^C!(@V)J"+.7"B_L"$]!6%[R\P,NBH:#U)?)DW>-6@9WE*(,_N.,08PRJIA=^!_?91TSUV66! MFVON:C?-W3$ZXQY3+J6 K@4;VTI"IP4'$\F[5-XQ;+X][66*.@X'#KFY&JJA M3T]_6REQSULNJ_7G[8^LTWB6A-'%(<\;0WYZ Z]_-#,'^O[?1[[L^NSO.'02 M3;!! _(ZM4X:!3$A@5%ZA2X72Z#Z%M8W^I#%YA/F?ZQ6N4XG M>U_^(+VLO^+FS-EDO:FCEY0AX'.?(,1@P?'B;# 4@3=?&+8'6?/X[NVU_[1Y MJ:U&.K!OWUGZS]7ZOW];?EBO$FX>L>29U,G0[2I8UJ"P3CTB)ND>YRZYQ)G@ MK0O!]R!K'A_]B"!KI)&>0/9'^.N?U623V+:[?Z^^?+D@6_"0.2N=DB$:R#%[ M4,%0%"(2_:*=,\48+0*;"F[[$#B/&W]$X#774D\0K.O">%"8LU2 PL@Z0DN MP^B 91%Y5"47;:="V&Q[W(X(H*$R'H^/U66X:(R/U3)MRSPOSQB7W"N-X#6O M6^6$KSL[.12=M*J;@I"W[PA_0L8\Z]&.B99Q$C^Q..ZZ%/Z:S]N\[S0QW2N? M-&5\-X3)H\1ZR;L<)"I(SG "J*KS_+VK5Y% %YG"LD_GV>2QWL=$T<35!;XO MVZQ&7*VW2;4WZW7M";P=$%E/RC-__"?];D.$$$TW"^>-\'1JC .+0H#2C$.4 M3H 63CN9Z^+LUD:N/1<]1Y)#L/4DGS6OOF=TR#;KR[.WJZLE_212PN6WW\-G MW#9E&VU$T=E4^NGN1^X@,NE HW!>U?7"4NR#5_J >UBEK^YP^MQGS_O6.#<6 M5@T5,S.P_L O5^OTJ>ZK.%_C5CB/6;KIR\T662P4OCBTHF:, \1M*VW.J6ZU M$&6_:3^OH&UO@N:!8!N=KZ96P,POC#\M5K__B>G330.VLY*C8@ED$*ZVY$<( MG!7(5F*R:/Q^D]X?_M3Y]#^1RE9-Y#?S??)AON.=C< M'#+)$-%0-"WJ?:O0E+I)AH,+6;F@(Y:T5UG,?NAZ2L!\%]'A.GT*D ,%/+/A M>;OZO%@OP^6WFYO3L&*ESQY02@G*.@HVE+/ G):);E_A@]S#\CSZL;-K_% E MK=I(K(,L=1T<\[[0!L]=!M1Y2.)#$ M>4/Y!J!8'4]#'0#PN:-\PTWRLIJ!3/+2BD8-A5*]Q&,QWC;(#)>/=]9H-'G04K#!(614Z%U1 1"U#H*C+Y+9;MYZ(W M0.48^NW,C,\&C X.Q?:)X]XSW9[X\^\YV4W9T\V=(L>+Y.GQ^'R\6Y]<3 MQ=N_G._[D5,^H8]B^RAOZ74Z.X7+$;)GC- F/(3D,PB9,KD#,<947I'\<=[2 M=TKPVE1XGV,*H9!M,,1#-L2#=8%^E[2WBK%BFC^*/T].SZ_;0[3]Y'6[D0;F M?DVL-_HV@O,VTUV;12VPK6&<%A"UKA.VDM'<%V2Z15FLY":9)@_&=Q\YXY/@.&4]5O<(R1>-,@I2DK_,C8AVTR,%17.&EMIINQ@8J?_"A,RM]C,I6 M+>0WM^+#W_<)M\:PH!*XJ(EP*6UM4@P05.0^:1TT[M7P\IKB[W_H/$^[S10_ M6GX=Q,&[[=U=Z,:5B<1^ >DH?E.!)?"18)TYVKKUVCG?.M_S"DDSUP$T]@^F MT$.WL/H0OFV3!(O/B^7Y!UPO5OFL>(RH@@:3; '%ZVLG1@T2H_+>1T]'[R@ MVT%>3#Z>R1YM\?%0>J+WA^/37^%QNA\KE/X]N MK167(F*TD$LB*R!M@IA"+4XN1%T*KNR7&9S)6D]7U=,)(,?HZ4!K_S19UQ^^W 1Z&Y][]Y+.M$8M"QA>%[86"IY#+@&TM]XQ(P2YCXWOC%>):C>O MX-F/NLX':Z$83U*!5HG<%1<]!,P,"@]T#S@3>?,!=?O2-F]\TQ8WS\\7:*B? M'E[CK_>W6R6\8 @II>IC> M>2;(@%)\%;[C#O-=FI1,IQYA$ESMK,X8(M@S%Z7S&G59@Q2UC.U&4,D-_<3_8/: M@J!1&:D3W8:QUA:D!,X:#>B"2T46IL1>1O7T:C,&J>S9VHPA\IM;\0]J"Y@K M19GLP#IN:[HY0%0VU%(#YSFWD?F]\J6G5YLQ6O&CY==!_NA9D_?3M]ILM[T( MA7>9%T\P]C4EQIRH*S(,<,&RRX1MWCQYN0=9O.M,G33G*Z2 M4-G9!*EN+U )(SGF/D,)P M.H#4KU?KY>+R:HW$RJ^+O^OO;N<*!$5^H1::#DAZ^I =5("QW@Z>UJNP(T75HF>>F>O'PE0S372 JF=E]>Y[@:*33*/2LI9J15!%UHJ9 M0!$N"F^U0U]LZR$RKU/5RRRM.;(#XU33,]C^M<%R=?%N4?#,RD+!K.. 3CL* M,CB#F)(#8L@93H&&9:V]K3W(ZC3&&XF$?8$V4BT](^T?Z]5F>N,&N:KTAZF:).8\.)\35<&1U ZTU*5Y^OZN;,_#,2$6EQ M4\KWY0*W"EOF-Y]7Z\O%_VR__RSS9S[8(I)QD+VWY((P"YZI#+:NWO3,)<5: MS])H17NG06@;N,ZBX Z _2PC=1V50Y1&5K:_M M$BUNS-E6@,U]7PY51+.]8,>IRGRW6IY?7.\FWN#E)G[[!];RU"^?%NE-+9.> MIB!SP*=.68LYEOFCE6%RP3&8(("K2*%,$!J"< @1LS?.,(6Z=>EV/V68MDCA MZQP&IUQ-%]2MZTB_"&%](.Z]BZUK4'^4,LPAN!E=ACE$/S.7XWQO'+X[X.'B M>E:_=,$(HC]*4^JP]5131[4JS2EO?6*:[34=^I72G&<).)$RS4&Z7K46_-SH MP?/'+-QD-)TVGH>BR=FHU0&:&0JH+((7*2L9@R^E15'OLP3,5]W72+&KUE*> M$2JI;B!:?SO[U\?MLYFS3$"1==&P*!&V2XA$)50L MR+GTH*V2%#:$5&<\>_#<%+3.H^?[#!_=_=/GJ^]LJ_-&\IMYZ\UO=??87:<\;G+H^AE"G6<)(.Q9B@ZA*ID*('U49)",E>R@U*,I9"X M>'!14# C,,H@$#,V'\:Z-W7SWKO38>KYO&93?75@Y5_@YZ=O_PS_M5J_O0B; MS38[D[GSQF=&_E'UEH,A6Y-4 F9E*245:5SKO8P#R.LE&]H6(8_+8R=25]]( MO&/L_G9N3UY32@I0A;HI-TB*".L[J^7>!LEMP-8NZ$ 2YT7D9%#9'Y('ZZT# M6'[/+]6-[LO5Q>K\VQ^+\T_?4PC2>$S>(4B>\;K0S@6E((KL@O?%H&O]TO@* M2=W"[G XK*;330=0^W,=,E;1?$]/<2TPA S%U*63-A@(PA20Y*X(YIB-IO6L MU,GK\Y7^/WK7W;M5??NT'16W09E-%UJ+M3 MX$U@$*1&7?=42/LHIMJ90W[U@^:M-3P&8MK+NX/+YP7!W:6Q@BNE-D% -FJ[ M+B6!XYY0HI3QGHO(8^M@=!^Z>LDOS^7ZCU-0WZ"[KC57PH22; ;,08-*VD!4 MAM=#1"/R$9W\_4O_YW"O1J)@?Y@-5TG?$+M7.'Z_0/S,AH)U-!!$J1PH MY!FB+1RDCL7D7#2SK5WZX51VZYA-#L,6:CMT$O/4T*Q/.\:J4F(,P'R)H(0O M$ -YHE$@#_44!K-7>6$;&.[[RC:'9S%S3"('JS##F#Z)$LI9HH%9\\1W$ONP7B7<;/X@31$MG\BK MN7E*N3>^RZ28)9*#:UB@@\C(BXZ&DV>= S(R)/3'K6K0/ZQ0?*HX%I/8R[\ *#G J M[G(#T25AA--@:V._LLR"X_0E*HN\.*D3;W^A#:>SE\>,G@**<4KL'ZB__)TN MKNH4UMO\PIE/.A*/=(F;8,F92'00B2]P07HMD\7H6\]V'TICU^Y> ]0,@^EA M*NP"HCM>>79PE3TO1B$P[CFH4C+$R"T8:;@ND9$'W#I!N!]E\YKQXR4&)]!3 M!VGJ'9GVISP9N"2Q(1)/)F/4A45M6\_?W8>N>8<:S8>\@W74 MYYRCB;IJ?EVM+I>K2^RO(^D)9?VV)KTLQ%EZE+Q#(RQZ$*K4"9LF@ ]2@#7> M)R<"RN8S*7OM4:H=AU8Q?G?%BO\E6Z?+_^B.NOBW2]6">%XK07#%![WGN:ZOC54.!]P&8FN"ZX6!SDSWSB?- W -+CB3"B@3G@X<@ MDA!2L8"N(6J>$C#?I)W#=?H4( <*>.8L])_A(OS/BB2WB/3;_\'E,MQD0K5A MI6B1(1FOZ0IVLFX=E$ 2,4EDJ>7C)L>=V>=G/V!V%!RJN%5K*EA%7)9;T' A[_W/F&+K57_$$RZR+G M-:PH@=POQ;.*H)D@.%?$MZT=P@LL"5N78DY1AM1#"\08O^08:NL?E3N? M!+E&3,)JD+J^_"I;P,OB(=G,=+!"N'CD KG3+T$:!)L&)4A#=-@%3/ MY:R< ,:% L51@%-UH+I7,6@C4M:A.3!;E8]T5:PT"!ZCRD>&Z*H# #ZIP-(D M 7);+)2,VV.J(" C%T27$&W@:&7K1].^^J2/#:N#-- !@H;,QA"L6.U(3CE% M"2I[!B%Y,@FAH++)B^!;-^&WGGISA+UJD_I]4ZFK;R3N+@$SPAJ53"TVK=/Y MB3T7(_$H1$Q,*JZ;5V7^L%-O!D'EP*DW0_36 2Q?FZQ2E"^Q#FHWQ210SAIP M)3,@9D)0UOOB6U>=_U!3;P;!8>#4FR&ZZ0!J3WV))$*6%'YEG1W)AG.(T0=@ M@3CP7#EI6U]Q?7ESQP330=*?.7/[TSHL\_=Y[TRY2&YGDB+4NSQ#)*P#8U$$ M2?]+:9_I-O=^9+?=SLTP<(@,.[@X?KK:+)84VKY)__=JL5EL-5/-.D.3C AU MA@]%((H\2XA>";!HK EUKZ>)ZO> TW@]S&RA/F(XQ^7M]2J\ M1.$XF!S(LDH9P/F<@ LMN>4Y"IGW,%'W?V9_ZC] 5:L&>X6-[N M./Y*)[(NOOEM65;KS]OO_D9\+\+%F[3=E;58GO^V3*M:?GR);_)_76TNZY/ MG4AJO>[[:E",!,GJ:*GL13U\L7ZP+=[\EHP_=QLH]%<+5VT+!7.+ E>+$G"AULZ(@=\P' MRZPOSC3OI1]"X+R9E^D1.9FR?C!?]L7JER>NCF$E^<031%4+OVH)C \R ]-U MEV@PB'&?"'U6)N8-X4[*YYT.'!WT]_#^LJD*]X MC D"3S[LJ$,!7F9UEC[_Q'BB."Z 9,Z#JI/7G"',T<4L$C=1"M[:4O;:Y\^D MBLYD#RBJE8JL@&.,0Y+U:89,&"^MY]W^F'W^0S!U0)__$'UUX+(.J=T,5J$N M$4%;,E**"?++-;>@0@A::HJV\D[JR^$L*6C"% M]K*^<_L"/E:!EA2=9#H;<\2-,:==E3T(*@=690_16P>P?*WRER5EG,X!-(O$ M#OT?N+0J>D6W0(G@/0AM7 M1TUXB$4X8+)8;K7F_O%X\ E!=T=7MS?=2#3L#;>1JCGUI,PO?W_!5%?0+9=7 MX>)^>K?^R7)SE&3-WD0<-8DS3C2S)'>TT%X3,,%979U-'<$A>I"9LR2\$2FV MKOTY:G+GI36*3_7R.^G@S[_PXBO^<[6\_+0YTX;<$Y\Y>*TB&2A7(,2@0$O- MLG5UE7'KP;N'47Q*2: AV!NR'K.Q7KM863.,W_^#8?WG7ZNSG$.R1240H?8A MD,6#$.IS@I@Q7GA>T/H*>TV/!YJQVCQ5,%*Z,,SQS@%H$H ,[I6VDI% MHA49!%HF73&2A;T&5$X+UTKJ*DJC^H\+V,%Z/%6\TM^M8RI+E+Y V0:H3%" RJ,& M-!FER%+(8TY/>8'2>:OXNL;K4#TVQ.M,J8;;_QXCH_#XLXZ:.'B1T7GR \[G M.I(?1+T=%=I,0 L(J)6K0X(XMZW':QXU/W#[87^L+BY^7:W_"NM\IKE()A0- M$B-YV2G;.K8Y@+&I>,:X0MYZ3'(?2^D.5N(SH!@DT=%(^+)M8/IX&=:73?%P M,PP@_WRU7BS/K]NDSDQ(,CN=P#)&WH+D!D+D#!*2UQGK9'C6>ISB2_3TD7II MC9N#)=_1K4)RP<7Y\NT5T;!,W[9%P1=;#?TC+);O5IO-F35:V)08>,;JX"*+ MX$+04+R5/FE-L7?K^:_[4]='KJ0UPAIKI2.\G47GD]') _*ZOY/(!(].DK3H M?\G:J-54B[WZ2%,TMV)#)'J@%?MEF:<*V#[4'=JK)<4K'U;D^.$EW;"U&>$G M7&)97'ZXH",0:@]962PQOUTM+]>+>+5MB*A_=%L7LBH4]%Q?R8MT\V_?T@\\ M8#_@L2AK$ S.(L1&H>/;U>>:AK@^C\O\QW?B=X0$/#C);2&,.U57M:M8VVT3 M:)&S84JG_'C8T\&7R #RVO4,W"CJOOKN/NZFS$E*L@*<)T!9L^&%UP11,< B MR4+GY/'Q;,:&;0-[$#AO[# 5JI[O&VBMLPZ,]YW4*CL?OZR6F]7Z7?UGMS/I MLF4B*.D@N/J*B"F"U]) XEY:SFD3: Z(U93:Z1UNM_L5G%/. MD^?+92#WUT=R>AA%7][JS$(Q@HO6I45[D#4OY!H#80C,1FBE Z 1U;BY7*3* MT$TAN0LQ2I6(9%8HC%<4P3L7$)(PQ9D02VJ^;/?SO[U\>SDA4*$R.0-DN]L"40H0@YIJ@CA>1!O]23M,'TO\Y77__WS4^\ MALG-%W<(N?N\>1%QJ,96!XFO@XOB)A]SC_]DT5LB!HP/DH)NH<)T3,FUV=^IHX3.8=@.:A@/ZD?W7=@>;DA5RM ME^^W[NK-(-4B56;<>!"%G *5%0,GF8,HG;?\; YT-M=?E_?E0RYK@>:F5FCBYLQ(9E1B&02OC7](KG(H M*H-G20>9BN>^=> C22Q I,Z6<%L%$\Y& MPSA8:>IP]=_QI S-.\]^#MS/A88N_8G=M==G6;,4BE D MXCKB4@0&T0L#-B7K,_(B]/3.Q&[:]@*L^Y$ VT!'X[&WN@P7[=YO:H7T&C_5 MIZFON-T:@=7JW+Q5O5GF5QX.[O9&_(1EM<8_P]]G083@F8S M].&:X+5R@ M-9RKP$R*++;.=T[%RU[8]J>+[2XPT,$]3+'!U?*>3?GMF3-^*XQG1';'ORA* M6FL%V2&705D>Z2[P!E*PVM>M<$&W[E%IS<-^SP3L=,$_J]*;&8">^O#^$^M8 M;LQOON(ZG..;ZKNMZV*BS>;J\Y?ZU^;KQ!M V_R]>&,%.4,WGA;),>\%H*F@ M=\9"8#Z"L2:D''@*LO6#>K?=>$X26%WV(+*O%1-"0!"60[8,:^V93ZEU_\ / MVHTW!%6'=>,-T5D'GLKK;3XF*Q^Y#<#J2!-5!((WRI/K92)G*@NF6C_3_5#= M>(, ,;@;;XAV>H?;35U:*=9*3@*3M;J?#+: Z+R"R*QQS+#"S;0UR"?9C3<( M"".Z\89HI0.@[>@R0O*BC=/U#.8 2EA+Q->],0DE^B"U:#XLY!2[\08I^O5N MO"%2[Z,;SP673-8*,B.'0:7H@$+"3#%@/4/>!_YB#\3)=^,-TMC3;KPAXNO@ MHGC:&89)*2=E[4'DG Y 0'#>(CF,*NGL353-O>X3[,8[Y)HX3.8=@.:9[B!/ M=!L;!!13#"C,"6(.@5BA6$,6ENE@3=X]=6K=>.W\XU%ZZ!)--V=,$9U!U=6* MVR4*B!Q*Q7H$F\,HA/MQAND^:'=>$/4T &LQC1X:84\&),@6.9 &28A M:!9 .\NMDB70:9WBH?:'Z,8[!'Q3*ZL#/.[W?%>DY#'2J/Z?=O:+]:U/??=^&BW151^PNSY]Y KY] MEZ#HQA;,!9BHRSXM"<7I0A$S!=%8M):YV,D!VXR=4^@$' 2^5^$]#Q*Z/!2/ M>'^5\ZJ<;<%$N,0SSJ2P7B<0I0Z@9K6+TFA6QPZ;A#&ET'P"4EL.>H/^3,!\ MO6OB6"B9\8Q\*3B(\_L=GP_X]<4GJYT"'X2NTV8*!"8]8#=:[TSB$>QV&9C,G(+@P('$C#DZ8K_DQH!^ MAI3>NGM/"\\M]/M#.#&W+=/O5LOSVE1RVSI]VS;-!87804+.QI(\0AT7YC0I MQ&8=7TW'-@%+]Q]"0/T5^P\#P_O;5._R@GJA&"NCQ- W1T\Z_>QXO%^36J M;M4C78ZJ;ADSGDRV$LE Y$8 5]L,8'*87AH[??3DT[.<]!:<=)5W:J/_+D_! M\S?"$Z8?N*D)O2HV(&A9JTV2,76J4H9:&B'Q $/1 M#A:G?AY>,(Z!*[+,T0&WEBRDD@R"\P&RXP4%B27XUKV&$['2FUTX[;/2"#+- M3DY/G8K_@>'B\E,B7%3/\T^"1Z[BZJ%1<7_2YN]3'"G&&=H4T>:HI72@2RW7 M$#6"B!@@Y2"-3%:WGW'>;9MB5LXP%17%4,+6H6LUB:T\>.:%859Y85N7*?Z@ M;8I#4'58F^(0G77@ZSQ3 &J<8 6QFD%7@RIFH1;3@=(%60E%">QH_4DG#8F# M5+]?P?40/72)IML50XG\F*("..$I D"* 'RTY&"A5#IP6X1MG:\_J8+K07K> MM^!ZB- [ ,^88DMO%'/61PB8JW_,3%V5F,'2X0M.EVQ+_8%B?<19E*;+N\O/UER#!H:.#;4O. MB"F+V+HSY3"*>\N]'@RA5T$ZF3Z[1.^_+BX7GXF]9[CF9V1O3.&2^!*.3%%P M&;SR]"4+,=E@G-;3K\=XCLI[3H[2IWG[(_.1=%K?^K5^O:K;L(]%T-5]> M\G62YL]'#A3;#'G(J*5"0XXEVY)"ZP$O/V@><@BJ#LM##M%9!S[#ZW.8T(3B7%80 MB'Y0-IFZ?U/6Z2F),Y>3;7X@?ZAQ:8, ,7AE!., MSF J@((C%S9&G9K7KI_@N+1!BGY]7-H0J?QAE$!313P*("3PK M,47FF-$_]+BT01I[.BYMB/@ZN"B>CNZ2J9B4!,%>I/HF9 ,$P0UDC%FF4&=2 MZL;WQ F.2SODFCA,YAV YIG71 R96RT].7AU\Y01&IR, ISW%FM^R.O6\=KI MCTMKYQ^/TD.7:+HY8SKH++1+P%A=UE18A"BY!:FC%"$G:6/KI48G]7H_2,_[ MOMX/$7H'X'EU3I?2QC!4"%@8G2]>7YN9-Q#0"; !#E_K9'VXXQ+.P1\4RNK SSN M]PK'2O%,4]AAD*R"LH&8\J@@>"Z8XUQPT7K7R@\W+NT0?ZR]EKJ$WMM/87F. MO]VNVKS74;*ZN*#@YJ^PSF>216\H%@)3JPH5$08^8P;/>7$E2DWG;G(L[D/I M*12!#(+,ZPM56^NO2Y0^X>[,9&U-9@B6UQK7H@1XZ1W=^3(G95 '.WV;Z!.R M>L-?>W2\"LC#5#4:?5^V,P8^7H;UY408O#=7YXR\F5J&JB&(6B)CR,/QB1D@ M>Z.-8^0%L^EKC>X1U%M9T0RX&ZN>+N^[^S/)SISG7EB5(%%L!4I'!">D <$9 MY^3:AJBG]P3O4]3;?*X9T#9:05W"[8G@[A=;;7[Z5O_.![I9%VGQ)2SI?!%3 MC-7F9IDSR3(R\)Y^9\FET4S:4G#Z(3\#B>YM-E8/IKFAFKO$];:)_C,N99^>T5$+=.W7_Y.6^G6BOMK.6^>QFD,'45H08-)45"< MQC.$;!6PE(P(WI:DI\_RC"!\+R#;'QK(4ZM[?JCOGH+[T]6&OK/9O%U]CHOE M=3/ F_1_KQ:;Q6UCP,^+K[4JZ+)FA9\*H0@>=1*UY01E3<9YB+76QT6F2RD< M67I4YK#GT.-#*=L+U.X' '4'BNT6W8^YNIWI]#->_Y?D3D>^-KML?:]6OT3A M?J\![ < \Q$T./\E/2"QU]=KF0%PJA"(-:BQ)!C,] M3E\D<3^@_IN]6XW6X4DA]4R:6#!("1AU 14UA0&J2# R,*[(2ASC=6'DU?EC MOV@=IJL#7U)_6>:)*TY^#8OU_Q9BMKL4[DO3UB4[H3CPP4:R#BY! M-(5!SBXF@TD9.?T(DGVI[>T%]GB5)TWUV*47NI/#,R%3%,(J,#:02RW)S8Z. M3((I0LF"T9GFDS7W)*W7*I2V2'D]*7:PVCJN1MFFKB]N%]'NYZCK[9:<"9E-E-?=RKD[/AZ]*__R^\Z0B^HP4T((6G-74,@/RH5*M)3+! M<.:*&+>>>31)O=;;'-&Y.(XZN[R:[[V#W&,+ZQ9I:0MP#+5SL40(+A?09'%D M$$PFW;HK?D_2>BVJ.?)E>[C:>GX-N&/IP6,'LUJ6Z 4DR[&68)(?Y)R"9)3( M0F=M'J^VG]0S&/Q2-4-9S&P^P&C%]8S+W9D[16%FM#G670.N#M8A83J;H"3N M*<(T@F'/"=<9BE:Z2+@.45NWCU;WQPM?2 XBU"D'C#N(W@0(6A>O M= @R3A\_/:6KMQS6] ]1!^JF2W?QS>3-HL)#/ 4R!)LFS .18!C2QYB/N MU2UL?E\MTS8U<7D64F0J20:2[ HYS!'!D^4!S%PG79LJ]/0;;EXALK=7TTG ML\_.V6::[ "J-[.LWBSSCL%".T;(7.?2+M\M0EQ<+"X7N#D3*3IG709E:B5Y M3 $BDQHH!#0^A\A8\Y3_X53W]M!Z## ?6=>'!E"SX/L>L_<.=8I>H]094-9# MK>OLK.@]2#K:F@ZZR*YUP-^$\-Y\W1Y1?KC&NP#Z8&&?:<-=@T*S5]?/8*D;VYQ#/Y' TU.=[G6%V&B^-!=7MXZ]J7-7ZJ)_HK M_K9,J\_X.UY^6"]6ZWOC;-X2"XO+G["LUOAG^/MN(740SFN>(*&J*P]C *^D M!%:\34ZQDL,1G.HI6.OMI7>62/'(".G 6=]5*)>N/E]=5"LR7AQG66B6D FZ MGI@&)6P$;[T#GP!"U8.8$8]=BPW:/8\M@8ZOEIY?YPY_]<7'ZZ M)YTG_2:;WY:__)UPL[F?S_^N)8]H4I 1:F,4*!DSA,(E\((JDQO)2FR^@V8Z M=GJKSIC>Y,R#A"[-S.&B.#]?;\_N[B28UT$F MG-Y3FYC)WDS33/ ^PK%KA[59*_Z.(:*7_N59R,A4W30L>2WWY632(XLE4U*Z M/MD?H6=R)/&]540>P4,\@I;[A/?=-5#9_[!>_1>F72=YEQCNV6*KN'1>L#I] MVH%RQH,36D*0614TN4Y9.Z:%.829[OR[8X!SB,$X&E+Z]]I&B.+9OWV6D)D4 M P.1?5T?$,A81M)?':CQ_[/W9DUN)3F:Z%^Y-N_H]GTQFQ?E5JVYN<@D9<_M MIS!?X!*G0F0VR5"EYM=?.!DA181BX2']\#@I=5DKM9(.X ,<@&,QS*>2]1&J MD<8_E_ZG__?/WRSN?_56;_ M%Y?_EA8?MA]^K:=AGA]?V%9;NK9\N=U\N_FC+SK[$]:!AJN[U*YF'_ZZO%>\ M^E6/7O,C_/L75MQGTO5)OD+E<=F"?Z^QUCO_C\.,2WT%H7-NU6^>O^SR^Z(5 MGZV[],I*)C)PK^K(%(X0)9.0?.2.M!3 ..=ZB9';92+EOF0M*Q5LI8 M4(E\-!>4!%.8B3$GZ61KEW[0 :=UT\="U7U3.Y[,.KCWGUQ9OED6[+Q-+/ $ MFFZ)FO1R$&RB'U*1UAE%+E?K!^UG#S4M\$8$Q)/+E@^53N]PN]GHJE-P%C7A M(I&NYF+ *9,A"F,E%TZ*YALL=CA63[N7#P;"$)CM(94.@$:GKJW]J1)TO;E7 M8N&16;H#3*9H,=,=$+@T4)2PKA3.?&[>OO35*3J&T3Z"OA^5',;U"7&3:FW1 M\M/%GV\NK-&Y+H\&76J?:N(%?#8%,I/:\R U-T]=>"M,__9N\?'?KS]Q"Y/K M7WQ!R)?OFSC7>:#$%@>QKP-#<3W7YA;]"EW,FY7>PM5=)9$40%/H3":4>6U* MYKGUOLVO#M'3LO7V9N(PGG< FJ^WT6_N8*T,L45QL"%[4*Y&&.U-O8-I'\@]WRK410P>P>J#?[XX5?XA$$XWAGBE(2C&RY$Y3](F1;G)$ MIXNR*;1&VA['[,FU:@2^L875 1X?F._WZ?/CQ8]AC>\6RQFN-M>"Y*[8X"U@ M4 GJ6"'PA9%'P9EP)2?T13?&X8#C3=M'?#S?;"R)=0#&!\BXUF++BQ3:>K"1 M>*6,\Z15V8#6@@)AC$[PUK'CHX?IK8BJD?CO7[Q-9-$!J!Z8K!96[U_,<_W/ MS_]]-?L8+NMHR&O[S13Q!44$8[,")7T$'PP1JV7A,A3CCC#EYJD33@N_1K!X M?C%-*QEUB*< W.,P[T_S9( M*ZR_OZYKQXG;0T[1VP7; A5/CM0>343=@W'[ZQ\7'S[,YN\N,=$ALA* M0%)H[L@U5BX3R5@L%$[D!Q,"IM($BT\5)>H&\CF;6 524#F)6#*P1643#N8JM8XLG#]3;17NH_!=C":,# M9/WYYFW='7^U_-KZFR*=-$'51)*A<(@5,OQT!6!F&5,B#R&UMEF/GZ:W&[,Q MIAJ)H0- _3+[NX[ZJ:-SOB*%:;3H GD10I;J8V;R,3&!5DD$[[21J74;RA/' MZ6U"9&-(M1)$=\[^YOGDY;SN OIP*WL3+,MIX M?Y+7CG[]P]\W[7C&MJ[3:'R>$#NKY?JB+O";TR>]G_WU,; . HU&;.W ^]U0\GG03_Z:145E+ZOG)5"21R?(K7.)"9",_D/DE>!;N\#/ MG6D:3V9T8(TBD@X@]GFTVP^?/O_T/V:XI$.]__0K?L3+;8.1P!R=9* CJWD( M#'4H:8#H&";!@R6E:AUK[72R:1WGXQ74C""G+J:[?";FMTW"8KL \VL*;^KD MG%3$*P5)&])<-E@V%S40=H,*8A&J9YUKK(W+HS]8GC=(*T]C!X#' ' M2J2GJ_86*>+&:PB:D286B+EZ#4YZ<)P'<+IHF8/3+K>N6GWB.-.FQZ<%USX2 MZ11<\O,3N*\C+NKHBVKP49**),/ &\&=#\X&VSQ1_OAQIDV43PNN?232$[BN MF99?K'_']29CO/GM5[A\\Y[8?Y.98[RPN@25;2IZO>7@N78@DD_:!2%Y&MM+ M>_J$TP8-$T"PO=PFSL6_KFNG-]ZL4"['(#,(TIVZ)I*1*KE(3$JN<$=>@..[ M@.V9W/OG+YQV8]#X >?^W.T!$C?VE7LF@\U0C-U,,2#"=2;[*KB5HF2;<2<+ MM LHIO3'#Q#6?7'OP;F)!?[;;#[["IF=U@\TE5^7*'UX MBT^T)6I7-X1H^D&1DD/,QI!ZEZ*,MFB5'!V6^^]Y.F:1YN@X/%Q"#;/H/0UP M_G4Q?T>J\>%:/2M?ONCH:N,,U7^^?H]?%'91Z)>?.;JXQ='MM..[+#O&#.A1 MJ)A^C/3XPIE@$K53SFNK!8B8:MI%D->3*:!2#%&Z9$/AK5U,DEZD$ ?S.4-X6X/D/CXL![)Y0WA7%>YO#KXA.U#H+A M I YR7(B-5 [K8$XO5S>()$]FLL;PK^I!1_^OG5P;82+T1+JT2_.L@1_'\8'LAC5>"R-!9"5"V[M"J[^8I MJ9)4MER)UMF)-OLG.IFONX_7,(YT>H?;]7.[RREI(2S(9 HHH@E"LA($7<;H M(FHKQIWB?)+[)P8!88_]$T.DT@'0'IBK'V22GG,-66V>U^KVZ.1\[0UP3!67 M4#8?2WF"^R<&"?KY_1-#N-['_@DMDC4I)XAJT]HHB &U586;&)S.06;]U#/V MR>^?&"2QK_=/#&%?!X;BZUT(&=$9S1V(7!>V:RDA9I%!2L6%E@RM;/UB?8+[ M)PXQ$X?QO /0#!FN:E7&8#T'+(P"@L(<.!0.F&&68="NJ-9+!,YT&O(AGO18 M$NL C(^/CHB"NYA(JYP(=<%M+43#),%Z=%HZ5H39*6\W 'IG, UYD/AWGH8\ M1!8=@&K@I%TKZZ8@94'%6E+OF86ZJ@K(C=!2EUAB&G\B[2E.0QX$B\.F(0^1 M49<(?&2HI>&8DV<%7"ZDK\$172(7T$I*3(Y\SR?]]6]Q&G);U#602Y=X>V!^ ME[+&&A,1C"^9=(CB&A="!*FY5L$&B:%U!^HIC_ULB[,#Y7$J<\_0L"P4(B0N MRZ.LSG+NV3[8&8W/O4ZOBB%D3M]&@;+DH)S-X"R/ M( 0WQKML#=ME2-%!TZM&Z[1JCXTF?.S@KGID'U^*S$>%$F1,6 -D SX3@Z)R MBF<1D*[=45].!NV_[&0D3+OWN;WDT"6:KM4LF6"R< E,< 84\PH\-Q:L8D:P MNJY,M,X?G-3^RT%RWG7_Y1"F=P">9Q&5; M9]K/9__E(> ;6U@=X'&W7B26A)!"90HD6'W[=,3$D -$F:)W*A7M8V,$MFMV M[61B0MM7GD.EU"7T=FJ65"E[$T2F:&:ST)83@4&2@AEI3(F,%=;:>3O?9M=! MD&G3[#I$?LU0VE/'X8MYN/RTFJT6YW\CF;!K;\ M)_WYNUM_X<_Y(JYP^;$:E>W\IVU?V^HNTX[1=3@:)=-W'AY'2!-T'R:-.IDB M0,M L5VV#*+@&KPU*;F$!LU.#1#GT'U8C!5&U9R8Y.0;!L8H=G :''K#$\LF MW]_$\;W[\'!4'=9].$1F'3@YSQF#Z&3[L5!@!C M\+S72?M=NVMO+SETB::;$GXKHLG)0.::UZE&=?IQ8F"X%H&1H3:I=;;RI)[W M!LEYU^>](4SO #S/OBM9KZ((/D' 8FII*3$I*P7&"1VLED:7UM?9B3[O#9+\ MT.>](6+H %8[[DE1CNYY'QPDGPK4NM&Z <"!0JT<+XH4M+6%:KCSJ).VF4-N MP!'DU->6F9T&P#/DP0J;(,:B01DFB)=U&P53VO!BLXVM2QC.;^?1((PRJ*S^B9Y<"B2Z!4,. BK9:\Q+>9I=CG;2/GUXO+RE\7R7V&9+XSC6+?S@.3<;[,XGJ@& M4>I&V91=M../[SZ$@E.H=!@$L><;$H\E[R[1_O P:6DL"X4K**Q6#:<@(,00 MH7!N1?;6ZC(^C/=_W*I.^OQL+:65/K(,.7()BJ.%6,B+K_OY:H8,T8T/V>=.V=NP^H[0 MVU3 79K:QRA\LYY=7OX'7N8+RO-@;_(J,@'RQX8-I;"B M6$LNF2QB.J-[_[2]&=]><'N(4+N$[ZNK97H?5KAZ$RYQ]6*>W^!Z?;E-Q5RP MJ%5BUH.V]8F#EP2A" 8FL"200N#"6A<*#COAM'G[KGV$9H+M$K9OEV&^HK.L M?L#UOQ#GMS*(&S:O+E#JH'Q48$62VU7FO@[*85Z86+00/H\_I^W98TZ;#^L: MP&U%W"6*O[#VNL;IQRLZUSQ]VM!^N6'P/\)L_NMBM;K@2D0CE 6,,M?@-- - MYY#N&U:BM#$9U7I_SF$GGK9+K6MLCR;X+F'^<++%6^Y\L34I&0.Y3N3YNT2> M5,&L/#.*'*CQ&]KVSYN-MDNT:^ >+LH#\V8_SW.G_6T___T7IC7F7ZXH:L Z ML^^7R\6_7L[+8OEA6PH[5;_:SB>;OO]L/R9.T$_FLRFYFF(=&*D5HB$/VM0? MZNQDD9VRK1]8N^TGHX#7*JLME,TL"I$1HDX94LB6,M"VO.JI]L$" &]Y,- MD4[O<+NN1_(YZ*QMH.BSU')RXE7@TI-WY8R+(25DX[9OG&0_V2 @[-%/-D0J M'0#M@7T=B@?)2\RDB+S.+LP%8I0*@BVVQ MUX;J_-$/9U8"B^;H(T M&'E @5 "KT]/Y#!&AQ&8YAJ+-M*IUHO\3G"OS2%FXC">=P":1QKA,'F4/B8H M=2FF"J0TKL[;SHDNX.P\XZJCN;*=-)ZV\X_WDD.7:+K6,;2H(Q)#4M)UOE76 MX&MYOI;..NE=,F7<41Z=-YX.DO.NC:=#F-X!>)[M>(P<7[" M@+:)*>5#9KEU^]_YS)4]!'QC"ZL#/.[8E,$*.9!H0:I$1 E&H8M"#5I@2?O-;?4[_KW^A6@/E_^% M87GAHGPH8(Y.1N PV89W^@I&4M200JI!W M'@WWHO73TH%'[LT$CX>N@;:YI:B[&&XQD.!Z^;S]U^(BDA-OM::XDAQW4#80 MG5Y*\$EEATDE'5OG'/<[:6^6N%ZHP_F5QM;R(SL;H?01>"M:UT76@CB)" MK;79.*M4:/ULN.=1>^N-Z1G$@T5[LAB>?<0+3$S6]WEP&L-FXA@$R>JKK"8] MCJI(>^PTQ2-'[:T'IFL,#Q7M*6*X$ODE+;-Z^QZ7&,JZ#K6..7)>UTCHFEF7 M,9 /90-(C6B*)%G@^/WA^YV]MX:97E'>1OAGN1WJ][!9,D'72U:!L\@,:%,]#%,R^$"JPQ/]5#'F4FC]2'_$KI='Q/ CB:[VU[V; MDW#S10A)V2P-U#4#I*I)@]?,0]B8"Z^*32,YT$\?['2Z7(:@Z!&+VU!&?9K3 MG__[:K;^M+\QO/OO&YBR)P[4R!!MO^$S2JS6T3+R!+6N*T,X^M:VY>X)#S^HMH M9'%<:74/R,US\;8X3%MC1-(>=.:1U#=PH, J@$NJ,)Y]LC>)"#OCBX,60)%\)G^M4Y"AOR, MI_389_>,F'TEN&C(SAX,T\9[>,BN__JY:B60$<_2*@@F*%")@H*8#*F1\8I[ M8U"ZUH,:=CC6M*_,(]V$C:4Q(G#G&T)@,:X\.K!A=[CTYCVQ>?4B$1OI)&2.H_.&%6 RUAIG)2"$'$!;ACJX ME'EH;;N>.,ZT-FLL:+660V^0VDSKNJ&DILE^0](8HHE%X62H ;:JEMX6\$75 MJ]ZB<2HY$UJ_H>YRKFDK5XX*LA:2Z>()]&'+_!JK?SJ;O_MBHK_\G1MC[;VP MBGP*8)@HR-%>UG8B!KHDCTDXRYLOS]C_M-,6I(R-S2-)L0/[^.KF>V_;^L_D M76BD_RDIP12F0>58)T-0;!5<5D'*NMRS=:GJTR>:MHAD;-PUE$:GV'JY6EU5 M+X).*W),$.N\;>42([N>$8*BWR:2T(G6#X>/GV;:DHTI,+6'%#K%TQ]7Z]4Z MS#-9Y0LLQJ/7"$Y9,KW.:8B&4=2.0A7KC4JE=>+_F2/MA"Q[3LC:5QX3)U1_ MOZHYOT5Y/-6XNL @.(4[ HIQ%/F4%"%F-,!#KCY"B]2RBS*5, X:^D:9XY":(.0ZMY6)IVPJ76X M.?B0.T'0GQH$CR.S/JMH-O;Y!XI4\N<&O+LE=7M4UCS_F0VJ;08>O%$%SI>' MR#_*;4"\QLM:35MS%*O-R>+MDWVNWE )39)2@\^!@\)LP:L@ #4O,4IM@FU> M&7?0B=N-R?XBKSN%<"2R^;OMSIT?/GTETQ=U0/_VW46@=N0XU%T\DE3-!U)L M*PHP%I1RQ5@G6B_W:';XB7M_CX?9QR=N'U/\'5S_VY-_'F\62Q#>U>U1BEQ> M91PX$R6YO/4UVAJK>&OLWCE +U.VCPJ"12N)= "G_1GWA>QYKI[,[^'#S:"J MG(3AE@+[$NOB:RXTA?@IUR&O= +/D^:MRT?'H&-:"MJ$MT ,95M7K!#U"6RV'Z*YA,' MFMBL3HZ7KP9QMA+>Q&F?5XOENBPN9XM7N-RLU9DGW.:QKFD)RW^+G W#;LC1 MG&>* P4$DS6H4.TUUEI9@;S(DKBX_UCRH&7;X:NF+17H!E]C"&9BG+U=K,/E MAGGO%Y^.0YN%J_S5!*J3Q: M'EL74#UZF&EK"KJ!85NA=8"^&YYLDP#,.JE4!L-97?@JZJBW3&?/)A:5M>"B M]7JJV]_?R\J0*9-]>\NC(RQ=ZY=D/H<@$P1)T8T*-;!)I?H!*$2(P031O-:N MH_S:_I)\!!)[L'5B?^J%8-QO3.2M/C0,LE9#:,BVD(K4O5PA.@\)*>H(V1@M MR@[>TT.?W8? ]Y'3HB'3.K $/URM9G-<;;LL5K//&R*SR=;0+0CD]M.TLLZA"GOFA92ZA1LV\Z+&U6T.J*5Q!7':@B*G(-7 M)4$JQ26O+2NL=>_ZLX>:UE8U$?T.<-I?#A-?76\PO,,;Z\N8"RSH5 L)9%T- M:(%"S$A7N*-3.YW2?;_XP2OK]F?V)_X#1+5HP+<.#,FSMO@Q4_SKYR(^%,5A M(?UQ0FW8IB%&AV"D\%8'7U1I729U^*DG3FAV<1<>6?:GC/9M,>O+^6J]O-I( M9;/[Z^W[,-\F0E;_H(]8KU[.7^%RML@7B"4RE@I$%TDL1M'/2DC@H@XB*,Y= M\]OW6+1U_H[>&+.M5&9, )VR8OV^N&; UPSZTH6R[3BX2#')4,@S"];777U* MUGG@ANY7%ZRTKCZK]*)4 ^CJO'"@4X4:"SA]=*#OS94-P7^4%SEO/-SKMZ/; M#:@B62,8.D!GR$&-FL(=JQ!2UD(+3EXOS]UHT;/D=%[XT*ORM(7)*5] FQ]> MXS8FQ#>X_#A+N+V$^051FIPR&:1+$52FL' SR8)YG0MJ[7ANG;L;A9#.RSD"W52\;WY7^*2YOWHC) M?\T\6ED@F9H&*9E#3!C ..&\*B+E>"\I\'#ZZ/A'[[SX9!Q=.068G/(M("2707C!N+"HO3:]7#3/T-)Y MU4RG=TU+@'2@*"\N-W\'\\,,N>G(SEB*"XH!5X%8G7R!F),'KUQ J8S/432& M_6XGFW;HQ\0@'D%X'4#R<_G:UH][F+:WX>_K73:_D%0>HAJS5,':#*X4NK&D MD^""<"#1\Z)E\;IY=VB;DT\[D&1B2$\@_%.9(''S%K4H7]K*[\AHX[N%>:[S M'3>_<[TT9?]E+B,<8I09%6U9T\=0"^&$9S$F2+G."RO6@#.F@,6(3&M65Y8T MME_G,M0B:YM8/W=^'6@S$['A#+8:(OP-_ MYVZONXPB&,V)>[H6_FLM&2!15:/TB?Y5"+02!XQ)%2 M0254@9S)X5&>8L]0/*%)EH)!B\!R:Y_S\"DJIS7E8A\XMA=>[U-45+#,),. MYWJO*):(EFK6O.791RG+_8V,XTU1.:U!%ON:NZ8BZ<#0/3J4@_ ALL7*$-(2 MD3/$^K">HB\F:^^U:#[R^P#PG=:4BT.,6PN!G< 4%6<2.D&VF2PUA702=1T* M@\ #XU+7=VCI=K!LK::HG-9_)M8\&]GZWHMOISGV<=9O@J7 M&[,7@O2)AT@NC4MU]YPB#DBL8WFX,RBTPIW*[9X!P(-??B[#1_;U% Z72&^0 M^M^S]?O- WYM7WT_^^OMXN?Y>K;^=.V5)^6L%HB0(]9!"(+4K4X%(N5C0AA$ ML=O ^J%@>_I8TUU$#0#P%)P:2F/R2VL>MJIXDT;WY*\9M,"SB:"L,A HU(-< M+,5VW:GNL_?6W>_M""HMA;MHQ.D.,BX;L_Q36&^=^A*34TP'4+&N*LQ. M@7/$"I=,C.A*QM*ZLNW. >-W#O"!T4ENPGS,=@L0=G)WY!^!&7:SKRIL#@NH'MY9SD)E[, M,_U'WF0+"X\^45Q16*Q[MR@R##(A6$:6,S).D<8NX[)V^[9.8+&/,!>CX81>*E6UK$(3B8!LM0%K[7;92C+@*Z?- MU;9"S5@\GKK^XLV+IY1 9F0VD,DUD2GBEHX0>*98@1PU6Y\]2MQE_/[3WS)M MB-X*( TYV8%/\I\$]]G\W396-)Z;.@%7H=9T=$F.F4X>N$M.6*^,;#Y4[-;7 M3_QXW85[NZ\T^@'2S1X [Q1WQ@ 6310HP-H!(![1HXVBD"Z1OOTQ_YP_+\%E3OP1PA*3G#;@$U&:G2N!<1VT MUHWA,N!X78!I'Q#L5GY_L$1. FQO_[6X\=JRI,O8UH+MRC@O%?A0)\"3NZ9C MYM')UGF< <>;UHL^)MCVD\AI@(UP9;/,X"^>-AH\+I3VXW:_%^&0H2LV6AXPU"5.-?M:8H1@,P-AD3'C+;.^ MFPF8OPX:[C]>C7,7J8HCR[X7M'\]H^4KBN-]BG_^^Z_9O%^.8T\P0 MN:4Z'R5 (.\#5$:7?)3.A5$V6K0X?.?]PHU1]Q#HCPZ!'L:[/D5T?(3HS:ZU M19Z56=K\DSK%"']HXK&6H,]1_"I]>T.^$=WCA"R:>@X#(0R*FZ *^ MT$5H$OT^*D67X"X]H$<[<.?-RN/H0K^0Z$%/]IX#_0;7Z\O-7[NQ$"X:(M5 ML=F LAK!^9HC42J+*).S]YNZVDXX?O!4G;=/CXSX:83;B^NS-_5W@AU^$317 M&K4$CB52$"4#.-0S= M^_6*.) J:NB"LP6]"5Y"#):D(4H"[XD36K$JC\12&&7I4&M".N\][S0N: :- M7O2C^1Z,D$6PP4>P6>PG&]V8%Q;D45Y.9^M9^%R\V$7WC%+_ F@ MC&>@4E;@(B?#DGCQT;H4S2[#2/J@YN2GZ!\]_IX.3#T$Y_MP[(8AOV&H\X57 M?]*?KQ<_(1WK \EQ\X_H[R^NUAHBL\P8 MUK9!@0Z4E+QNR52@@S ^%:;C_3W>;=5CCS/OI"?^NYX<#Q@]*,P^(MF%+]>Y MP2P+9S8)$%J)V@U' :"J%<-2"@Q,^H+CK[;;Z:B[O06R<]6/CG!PRN'_@PO* M_[%LW\PEQ MT3#R'WM3TM6'#V'Y:5%^"NMPO;IDO?CZGOW"NA=I/?M8YS2T7)5T\"G&V974 MECE]+$OR#),T1M>149%"!>$R@L^4BQN)W')4VP+Z=R[(D1FIN(G%-VV3( M:501HLD&JN[7:2)&NN:OB-^7)0W$['C+DH:(OP/GZ.X.E>B0;D\O(,6ZV;+$ M#"XY!TE)%[DN3#7O0#K+94F#0/#DLJ0A$ND 3OLS[HDQQ\*7[)D6P$B':[NJ M!4_.'6"0,G+&B=>M-X^.04<'PTOV@]4QEB4-D7&_O2JWM_$D[STYLQ8$KR/% M9-W&(T4$7T+D@GF?TG,^\#>]+&D0(H8O2QHBG@X,Z]/[=B(3KF2-P%#5[E1K MZ+Z1Y/JHXG0ROB1LW:SRK2U+V@>.[84W];">YS;SZ!!L3(E#+EZ!B@(AU")I M:;+,PK&@=WII_ :7)>UK[IJ*I -#]Q@9J /G4DH(+ =0H9!+[5.$HA0&1.N# M:5UN]>TL2SK$N+406 >X>WP?"@5LRFF*WG)&!,4$D<0M.0XF>BS!54>Z,?(. M6V)S6HN4#L%>&Z%U@+X&3R'*H>0^!G#<9J+810B:-$]PZW34WE@_2N_F0:<^ MES4ZAR1\CBS[4T;[PU6";[]4"=Y]D_O?6"O7,5_W[&W^L Y:_"7,EIL&OPLO M.=I,EY30O,Y8+1[MN[7; MI(XNO9X]4M,X7[ADR1$(11A@=C/+)FB(43/PSJ/E7"=N[,DHZE.4=IXZ.56M M; :N7E1PGZ:N.[QXWC)%X5&QK,%9N5D$62 40[&<=D87Q;7$/(;.C4]:Y_FC M(RA99_ YU>K99^W.)M>[G2.QL3_KY6R^FJ4MAR2F+#$*""R:^@K'P:$3Q"OA MG+(1-;M7*M*VH/:@TW>>!AM'ATX$++U<4@=45_[\-R[3;(6K.W?V/9XDPV1M M. 89?4+">M6 MKO,SK?F""X/L_=M^/L'G&.9K2O=-[3^46YSX )%\11R)>!6V5HD[^@F0P98Z!(+ MRCGO6E<9-CO\R7=V'X+I:2#0 ?9?7&[^#N:'2?[Y[_I3!U M%JL.?T0<*1+RBN#Y'#S(Y)PM% M*2FU'@PU&;$GWV<]NKF?'&+GK(L743L9D5E@:C.#-Q3P%.?7D288& 7]$MVI MZ-KI-V5WJ4R#,'+.RK*-]G]9+*]_J_X]?A&53=RE @ESKIL+$D1!/^,,N69& M&&-:/V(-BFW:>#> MY8O&Z=$>3&(?;=B2EV0BBQ2.<%^705$X4I@ FV** 4WR[GL;]B,5>3&2^0@! M# 9!K,-"Y@4%2.T=Q7;TA\VCE.]MV$,Q.V(;]@#Q=^ 4W>W.M*$HX[T!PRWQ M,6<./A,?>4XN8A;.-5]2>YYMV$- \&0;]A")= "G40KU>ACVL#7L0K([1ACU$QB?2ABU5S-Q[P%PG1,EH("2MZ)=! MAA2%DCD]X\E^TVW8@Q"Q1QOV /%T8%@?;S@*GJOHHH4@Z9I12"1Y:2QD57AV MB$F7T?(,>W6)G5;[]3XP;"NT#M#7(->2G>:980#/ZWKAQ W$9!BP(A!]X,7S MULV,W[O$6OBC1Y;]*:/]6M QA^FGV<99SGUQ3*7IA Y]920Y&" M@1+6051(M[^..3'AJU7I11EV):IS%Z0Q2ELIR2B0.3<=>CU;_?.7)>++.1T0 M5^L-0XJPRR(2< BM>!!*8X./))@2Q*M"K)P'(WRZ1V)^ODVZRZ MT:,&L.E%D_;I/'N*)6]Q^8%?E$21H,\)9-8>E/0:G"0G.Z48:R3'E1]E=^C,]2$[O]?YKKCPVU M:?!&FL0//G: M/T0B'+IP+ ^ M/;?;&Y.$M;(RA^Z;P@L$F1TIMM(B)>V<:_WB_ZT-7=\'CNV%-_F*]F=G?.?L M"C6Z?-OI2UV<8YT#X()BU7B)OW3U^7 H[C\ :X_=HPW(/!M.WH6J_7VUN7+K# MK<_)@K.U_][&#-X*8@RF7+CV*F$W);5#B3M1!3L"PH^OC'O ;6\]_&O3_?YF M'9;KSK7Q[KC]"V\C$XQK$*4.=N2L@ N%HC";B34AL&1:=TP?B[;.\SO?@BX> M +9)DTCC<^;N?/T+Q9!B6NX@VKK3$+.%@"D"MR(Z7I0)Y73VJMREK?,DV+>@ MA@> ;;@:^JT:SO%=K8=H,VK^J?*V^$AYV\-<67_ARFN<74OPIF/AEJ7R+&.L ML_ASW?=L*,X(H3H-+A?E?4R>W^O=?GS2_+$/WWGB;WJ%.PU8G75,2.(K.+MM ME+SE)5J4D,DQ!Y58!*<#AV18%,7$K%+KE/'S2[ M$GT)FQYOLE8J\%P;)3P4DR1#&T/JI]-SE!Q-?V/VSTD7#X';@3F:G^2ST5GT,G6''D=\VS(8=]=EVT]D^R8;M_F[P;\H2C(GGLW8$ M[B;AGV<<.DZ"SP5"X'56093@6AC43D+!"YR+9+7&GPA)! <@O1.RUN+UWMYEMJ9NK-_MQI=Z?N5 M[2#DGK4;>"8$*.DX.,T$!&X-\H1"8.M!%SW0??;O@ M^R.A>.*WO<_^TR@\^^-JO5J'>9[-WSW$M5?+6;HC>68#)>'/.D[=JP[()+S\FT>A#9 M&K)9+ 97@Y&J9 TQBB$G#3.?IZ&:5[53ACN1XFA&V-O\O>SG;BUVIM=V\>& MI[(,6YZIHJPI48"W2((VC('/(8.+(9+ %=.L2;GVZ)1,\P+VC6AM7SCL_7[= MGUO;EX'GN86!Q%G[,>D[:OVM1_!UKY 62F>IF[[DZ#QM[5 M=\S (AHO-3(.V3@$Q92&F *#[$R*,7IAV+2/QXV"VN;/0M^(LO:"O;-. M]C MTCF;KV;IJ[R_9)&Q2!(V)KFZZ%5 =,&!%SY9S:/-:6=MG922$RWKZ#GM M.PJ(OHU7U[N\NA F*Y&4K*O5R/7'9"$H#!!XDMZAK.L+3^^)]2Z1YY@)'D<# MCO]\>@ <)\_]'KO6_!ZOO""/AUER*90KH.H+5.:A>S3O%TNJ6>HO0< M<\(GKK_-@'G6E^[="O%[7.(I1UML!A'K&'E6)S!O^M0E)B.4M>:$;MZG*#W' MY/")JV\S8)ZU^MZJ[[S'HJAE"LB)1NL2W@>-8)X:TO\F*>/Z]>7M3?NO4J<#TCJ:#2-I0(UF@&RB:_*2N!7+)B M,NO,[;T!/T=.".]*R8GV]O2<$!X%1">ST?OJPX>P_+0H=7,>4?OJ[9]W=U>O M[E*T[_[NY[]FG&W= \GK8S=W,1$Q:0F.DVE7,G#PN23@UA$"== 16W!X,G=W$,DT@&<]F?< M$WL#+8]>9*:!!4F*K37%&84K0,T#.3Q6)='[FWL0(H;OYAXBGHD!]VJY M*+/UAH+KPS/OO2[UC5*X1/>+)][4EA7!T,EH:[6>VP%;7WUPYQ/\C@FCPYA^ M"E?Q\YD2GHE=P@C(-A/OG";A= !=G3L/C;': M2E7& L[9]KALL]R;?[RZ\$)S;P('JRI'A"T0HM7 +4^F8%$!I]W0=?NTG;M% MXRA(IV X6_6X>?M9;]Y^K@U'??QEU=T,FE.4(C.#*)R!S+T0R)6(/$ZJ)@^= M^N0G!?6G+@>#HP>U&>7M].>_<9EFJ\WSZ8^U6F'Y92^1+)$970(X64B.AB-% M;(6$J5GD4DH>Q"YA\B2'/_F^JX.4J&NH]*!+HUB977I9+YR(J#QYL$E;K#4( MY,865L"@YTSIK()O,O9C5"I.OHBEORNJ.7C.2\V^*O=Y8J")%:Y@XI!1;D:( M(?CH&225,WG)RPW'"A028A M:ZEM!E_KZ41(UA9#O\Z[O,Q-3LA.>F:_Z]G$$#KE[/@!XT]>8WU_H]\G5WM3 MH'45+M_BDL0>)\ Y2]TVUT9^9-O8D M@$& .ELE?-+S>(QW%R:IP#5:BJ+KM&E-BA:R\""*H5\$1(>J7U?V,;)V>Y!F MWW6R*WSUH)K'RQOORD'&'"_)2' L,/(K<@+/"1,Q!Q_6M&.%")B,R9@766@W*LPB> M\0!6"<\8(U:Q459U3T3O;KIZ;E4L/7!^$-*^1:W<3UXAMZ3NIHOG5B)S2OCJP9D=)0YXA$5WPX,+IF/T*I&Q8J5. MLO0!0IWZG#TZ;A@K03[7@M\!&;NIV=D6T9P(?GI0M5$\^4=9]8"#?U$2GWY MNYXW3.B>!1:\VD[#NX<=S<-^EY$**_M:%9E;QI! XDPBJ/A7ZI#WHG$SD MLG N\YC:-/"\NS5B?R\,.1(B3F;$[/50ED5YF(UOUHOTSYLTRYWAK'&J(S/&490^8 MG/[VQP=7Z?UCN5BM+C)C7*/18",SH%C,X&SQD+7-5NM,U.C.].4!,DYTZ%._ M&G,H5/;6&0IMXJ+5[5)]XY>KU17FGZZ6Q-TM-=LWI=N.\Y?,GE$I95L8:)GK MF)Z4(!3!P(AC+ MSW__-5MN_LT7)F2F.$NB@,J"A,(8@V@M@LO,)E0\,"$ZTY<'R#C1>4K]ZLNA M4#D+??DZQD*Z3[W5"%8INF*+K:U-*4(JHA0TB2G7V^VR7RC>7V57O[IR&$PF M7D_9B@D[[Q"TL2")HV[M= A*2PG1LP0FYB*XE^3 -@]'CD3;M"'["6=^1P'/ M&>2"'^'+=AWI\:F<-N=PPHHV,J"^'96[*$$)P4V58EW$0"X]19A&@LPB!>9,"*6W9,2. MI)W-^^3!_=Z_7@.]B3#,HI&U8W?RFG:\EJ._+.YH6U"YV<"':G<#L^QYK/Q>,[<4=[D7FR),"@Z0?C,SA.\DPZ M#=\DC_!*1XY)I*==: T23%(JZ#8 M6*1/].,X,X2.2./9O$V?A'J."0P_"04=$X"GH*"-8G'%#$M&2(@D+%!>68@F2-!DS53D M+GK56]%NR]3/*;RW=Z&.$\#MFWFA?]JQ4(7%P#RP$A6Y_]%!"-*#D%)9$9!3 MG-Z9@AY&\;37Z F_AQP1:&=P03[_3/MT#MMR61@:B$KQZDY8\,D1RT0VQ4A5 M!W&?AEKN2/&TU^GYJ>480.M%+>/SW(J#'8G'AM^+B\Q)MB1/$*ZRR!H++I"P M74Z<&2NX&:>%^;AD3KOV;VH%[!A29Z!U@UV'QSC'+SR%T\QC!(Z:UQ' $:+/ M ABG2)M^(-ZISI2Q'?73KO@[81V="(#GJ[J/NQ>/@?MI]@.>GNF,#L!?5;9,TNSO<^X)97[Q1 9P.2+%X M=?J]8J"+<\FH)%F,G467CQ(S\5:_J35K'0>2K2.%2Z*32>2IGF>V(FW\IVPHAT'7^>KB+?N^L<8Q9V* &BU8EJA/KU/J($7\WI X%;[ZG%_Z;?_-RGF[]C?>+2P+4:CNI.MCW49W6),@=9"'@F!XI9B@(OHPG1/H;*TY)9\SFKK?(= /)15F2DI%MI[!\.2!IFWM:8*'^^:SG0 F'9I6 M!U>3@BX^X*^+U>H7XEV-]&?S*Z+MC[_PNFKKQ4=2UJK3;Q?7JERG:UVK\H;R M"V-%L%C(BBO#0:E 1CT;BG5B,E(AVAQW64?8XBQ]H>T 8"PFE%$''O!=FJNK MM"4;\Q>J?\?U'^5M^/M"*BV%)7\"I3%U5Q1I=6&DBT*"<-6O+8J3AYLL2):<(08G#*TS@0./.&W; MT'@H'%-2^P-QL0Z738#XT^SR:CW[B&\P72UGZQE^B0"3D!YK!IX1ET!A\1 B M]R#I!^N2M*KY$^[CI^G+R#5Q\QJQ?N)E-0=Z#[DRH6[G5CHQDQCH) NH6H 8 MG/5@K0K%9BU55./[>->GF7J'0!M##SGU.+!18#BNJ#IP\NY57FP'C_VQW?]T^WGY,S=-$>3#:D,Q ME*5H*@8!3A?Z952N9,>TEZV-X= S]A5O-'$(1Q53!R9Q5_JV@13#K)(GNK1* M%+11V 0QH8?DHE*1&^0R3(3!#E*!XV)E3V .%UROJ+PV]%^S,_^?J]6ZOE=> MU%?0$DR"$KP#E0HQ5!4.0EF.%J5(NO5#R)Y'G=9WG!ZIC879*V;_*(\1>I&3 MM3$PNI"2%:"D=G4WB8=BF+(ID\-B6H]=&'C$::_SZ3':2'@=.)LO*(3+7SGJ M/_^=+J\RYFW^X<-?5UOA_E&^\J0^+*Y((76QR+)"\#P1Y#)1E#"%7!).)"X)#S=:ON%HA;C[S)URE MY6Q3BO:V9@(ND@M>Q4C:P[T&Y3FA&$L"Z31*)E+"TOH!^(GC3!MX'"#W^X:E M%I"6>:%$QJT3J;63 9P!0WQ1B@EC(R.[12RTJ?> MP@C]Z@L^[GSAU$AH)+[%H;SL 0"_X6::?RHA%U8\*$LNFB(:("HI(&1!H84V M7+2#P/8KIP'! <*Z+^X].#>QP'^;S6$?F=+YU8Z/N(;-&"?U,+/OQ]Z^ Q!<9]9'4&*]9IR;YN9#-@ MC12*:2?D;M-&GQ/\[2^=)I?33/![\Z^#I,O#]QVYY_ARC1_(" KA=:P[C)72 ME3,)7+3TLR2T59P)$UK/'WGF2-,F_EK[!V/(H1M873]XS]]MZ*I]T+5K9WY= MO^8QQL09>%6SDX+B^. HCH\Q2,%Y%%RV7MKV_*EZ=#[W!,&# &LFD8D+M!ZB M9MMG]7;Q\R874&F[2$S$[*R#C"R!TJ(:XR2 BV(2C[:(^[LU'RS VNW;>C1, MAV%G)$YW8)_^,RQGU69OR*E=@Q=H"A=)6-#)!E!2"?"Z<&#%IL(\9N=;%ZI\ M=8AIWPO&M#Z'\;OGU.F;]![SU24NRN;7+XB'ZU68YU^)WMGE)JM\:%)UP%E9108=TV$7O7?KZN;V5_E#^O M^7H1C7>9F2K\3)&'E!X\0P2FLC)H4.?T%[R_Z^V6G']@[NK+O$ MW"CBIQ^OEI6K%XGNV8)" B\A@LH4@H84"G"ZBYE7@CG7NK3HZ1--[0^-A**# M&-\OC'Y?S-,U0<$;](E57RY2',"]!&]S!H$Y>NVR">%(2/IRJ*E=H['!M"?[ MN\/3/1O[AF2T&8[Q1_EE-@_S- N7KQ:K617<)GI8S:I7.".'D)=B;37$UM:Q MI#$EB$EK<"BM]K9$EEJ_1S8Z^K3E$<>Z+D<297<(OF_?!]!-]$4L&L%)1YIK ML8#3)(K (JL/QRPWW^GV4 Z>0$2T/W#&BM$BB* MZTE_'4F"85%!D_;JUDG_AL>?=IK_,5V%D41Z0NF6S<"O,,]_K-_C\LW57W]= M;O@1+E_.RV+Y8?.5C=,O0[YRK'3,WF2/DYY!02 2RH)1 D'IJ"F0C@@HBS,Q M.&-=ZTF48Z9G-OE)$7Q*44?PV1)-EI,/8W@$'3(F6!WPNSN 7*2;%N68@1:U,J]LO">X4 M3@2CH\VZZ.:NU= S=I4Z:.>D-!9.!U?4D_1M!I5OR?"]PF6JF6BAF8XF M":#SUA%C*4!@V4&T)J'((40IC@F^!\[85; _&O@.%4YWX+N9S'WA4 0CB@$; MZK8'91UX$PQ(KC%;(;.4K@@0A'+A"/W#.@W=)JE1:SRO8[633 M;DMKZ7ZW%T1KMWS4-.,O5^NK)5XW=[S>)-EN=*HLEG>5[;HDJD&F<9]O'2'9 M>##QX^0;.4\I%"TAT@T(*E#X%YQ64")9,5:(KU8VUOHQ^G(?R>_?M#NOF?M*HEZ#&P>)*R3!26A#(G2XK.NI>N;F2&8)80Z1-N; M9(2WLF#S 5?[G[:K'.[Q@3E88*<*S5\65\L+0UZX%BI Y'7H1# 1B#P-J&/( MFJA)S8N']CYL5XGDHP-SL+A.%I>SCWAA<[32&4TW0FW4474@6& %<@S(LG#* MLG$Z@/IZ./C;H^#=I4+'PU^3<34@<%[A+P+$Y(+W!8PM5=;<8^US2V!,!BX M4-;'YG[@(T?9"4_^!/#4@M4=6*]G^B-]5M*YNC+,$2$JASI-L630!J,063'F M6T^];="8RMGI F@?SD^Z577GCH<+KKGG='0@"TIAMY,,2!DXJ!)U8"@LFG%+ M4O;M3>6G\+C1EO\-(=7TB7>[*NP=SM,,:Q?%C[AKZ! M)>@HRT'.(%%T NAA+M*1$?*>92KLAY.L#3#?M]W"9 M?@V0 QD\\3C%W_"?Z\7'V?4(V\P5D]Q:"*C)G"IR]**L@W!-""R2AU=2><;M M^>I#)Y?VH0):M.#6Q&*F6W6VG(?UI^NC>Q>=T[Z U$E69]Z R\F!+LB#,X8Y MRW80]+V/G6Z:F A)R "8B6QEC //*(QC)$RO MK"M)F1U$?>=#IRE/&4?0^W-KX@O^2^SV8YW36*\R)VQ0)07@=5T!620+41NR M39%'IC E%G9Z%GWF9O_ZFZCG_=!D^;-/0 M+^=E62_OFO:K/+LF1WENA:O/&)LUMD5H\ X#**LB&A68O/]^^+#K^OQ73>?0 M-@=+:\9.G:!8$._GX>W_]^>;)TE*VDJK A&R&7.6!$(4+(*02A<1F?4Y[("5 M';]NFC+H4? R!H-[P=#!%6)\P$7FI_M/+>RVA8 MWBGI->1+IRE7'A<_S9D]]0VUC%?KJYIIJ([:QS!?/Z,AO,24T&HHK&[1UDZ" M\]P W;TV6>9E*G&7ZVK@]TY37#S.W34FRR>&TS\NP]^+-Q]FZ_?_+_TQ_C!; M7"[>S=+JS8M*[MT__/77'Y\AW'%T.OI:06UD+?#Q$#+%LSZQ)#P3'+/= 6M- M#S5-L?$H0)Q.6%U$Y<&/VDT@N&T'<1T5FGR);'S(%)I*7HCU+*NT>^[4^W315RB-& MBI.*KX-"YJ_RP3]\^CW4_,HF]Y>S0Q2& 4.NM_-P',\(07+#I16A-*]*??) MT_;Z-LR=MV=_=UBZ)N1:2[,+WC(*GIE(#%1PAIQ9;X#;3.%U43&DUB6I3QRG ML^J;_87^))SVE\#4-^M7'L)-TL[%$EAA@*;V$]O,P!GR87,LAF?CR(WEN]R- MCWQ^3[ X0'B+QISL! T?P^4LS]:?Z*I^^.IU.B2F%#F+49$G$** B$) *IQ4 M*1;'S"YYK5V_KZ>'W+9H:QTZP[D1X[2%VSVD?*B/9T)_UHE?(R8<[:0 MG:G[^.@"=CDJX*DVG7I#5_0N%

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pfe-20241231_htm.xml IDEA: XBRL DOCUMENT 0000078003 2024-01-01 2024-12-31 0000078003 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000078003 pfe:NotesDue20271.000Member 2024-01-01 2024-12-31 0000078003 2024-06-30 0000078003 2025-02-20 0000078003 us-gaap:ProductMember 2024-01-01 2024-12-31 0000078003 us-gaap:ProductMember 2023-01-01 2023-12-31 0000078003 us-gaap:ProductMember 2022-01-01 2022-12-31 0000078003 2023-01-01 2023-12-31 0000078003 2022-01-01 2022-12-31 0000078003 us-gaap:RoyaltyMember 2024-01-01 2024-12-31 0000078003 us-gaap:RoyaltyMember 2023-01-01 2023-12-31 0000078003 us-gaap:RoyaltyMember 2022-01-01 2022-12-31 0000078003 2024-12-31 0000078003 2023-12-31 0000078003 us-gaap:CommonStockMember 2021-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2021-12-31 0000078003 us-gaap:RetainedEarningsMember 2021-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000078003 us-gaap:ParentMember 2021-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2021-12-31 0000078003 2021-12-31 0000078003 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000078003 us-gaap:ParentMember 2022-01-01 2022-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000078003 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000078003 us-gaap:CommonStockMember 2022-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2022-12-31 0000078003 us-gaap:RetainedEarningsMember 2022-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000078003 us-gaap:ParentMember 2022-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2022-12-31 0000078003 2022-12-31 0000078003 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000078003 us-gaap:ParentMember 2023-01-01 2023-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000078003 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0000078003 us-gaap:CommonStockMember 2023-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2023-12-31 0000078003 us-gaap:RetainedEarningsMember 2023-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000078003 us-gaap:ParentMember 2023-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2023-12-31 0000078003 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000078003 us-gaap:ParentMember 2024-01-01 2024-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0000078003 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0000078003 us-gaap:CommonStockMember 2024-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2024-12-31 0000078003 us-gaap:RetainedEarningsMember 2024-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000078003 us-gaap:ParentMember 2024-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2024-12-31 0000078003 pfe:TopElevenProductsMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000078003 pfe:TopTenProductsMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000078003 pfe:TopNineProductsMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000078003 us-gaap:AccountsReceivableMember 2024-12-31 0000078003 us-gaap:AccountsReceivableMember 2023-12-31 0000078003 us-gaap:OtherCurrentLiabilitiesMember 2024-12-31 0000078003 us-gaap:OtherCurrentLiabilitiesMember 2023-12-31 0000078003 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-31 0000078003 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0000078003 pfe:SeagenMember 2023-12-14 0000078003 pfe:SeagenMember 2023-12-14 2023-12-14 0000078003 pfe:SeagenMember 2023-10-02 2023-12-31 0000078003 pfe:SeagenMember 2024-01-01 2024-12-31 0000078003 pfe:SeagenMember 2024-12-31 0000078003 pfe:SeagenMember pfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember 2023-12-14 0000078003 pfe:SeagenMember pfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember 2024-01-01 2024-12-31 0000078003 pfe:SeagenMember pfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember 2024-12-31 0000078003 pfe:SeagenMember us-gaap:InProcessResearchAndDevelopmentMember 2023-12-14 0000078003 pfe:SeagenMember us-gaap:InProcessResearchAndDevelopmentMember 2024-01-01 2024-12-31 0000078003 pfe:SeagenMember us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000078003 pfe:SeagenMember us-gaap:DevelopedTechnologyRightsMember 2023-12-14 0000078003 pfe:SeagenMember us-gaap:DevelopedTechnologyRightsMember 2023-12-14 2023-12-14 0000078003 pfe:SeagenMember 2023-12-14 2023-12-31 0000078003 pfe:SeagenMember pfe:RestructuringIntegrationAndAcquisitionRelatedCostsMember 2023-12-14 2023-12-31 0000078003 pfe:SeagenMember us-gaap:FairValueAdjustmentToInventoryMember 2023-12-14 2023-12-31 0000078003 pfe:SeagenMember pfe:AmortizationExpenseMember 2023-12-14 2023-12-31 0000078003 pfe:SeagenMember pfe:DepreciationExpenseMember 2023-12-14 2023-12-31 0000078003 pfe:SeagenMember 2023-01-01 2023-12-31 0000078003 pfe:SeagenMember 2022-01-01 2022-12-31 0000078003 pfe:SeagenMember pfe:AmortizationExpenseMember 2023-01-01 2023-12-31 0000078003 pfe:SeagenMember pfe:AmortizationExpenseMember 2022-01-01 2022-12-31 0000078003 pfe:SeagenMember us-gaap:FairValueAdjustmentToInventoryMember 2023-01-01 2023-12-31 0000078003 pfe:SeagenMember us-gaap:FairValueAdjustmentToInventoryMember 2022-01-01 2022-12-31 0000078003 pfe:SeagenMember us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000078003 pfe:SeagenMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000078003 pfe:SeagenMember us-gaap:InterestIncomeMember 2023-01-01 2023-12-31 0000078003 pfe:SeagenMember us-gaap:InterestIncomeMember 2022-01-01 2022-12-31 0000078003 pfe:GBTMember 2022-10-05 0000078003 pfe:GBTMember 2022-10-05 2022-10-05 0000078003 pfe:GBTMember pfe:RestructuringChargesAndAcquisitionRelatedCostsMember 2022-10-05 2022-10-05 0000078003 pfe:GBTMember us-gaap:InProcessResearchAndDevelopmentMember 2022-10-05 0000078003 pfe:GBTMember us-gaap:DevelopedTechnologyRightsMember 2022-10-05 0000078003 pfe:GBTMember us-gaap:DevelopedTechnologyRightsMember 2022-10-05 2022-10-05 0000078003 pfe:BiohavenMember 2022-10-31 0000078003 pfe:BiohavenMember 2022-10-01 2022-10-31 0000078003 pfe:BiohavenMember 2022-10-03 2022-10-03 0000078003 pfe:BiohavenMember 2022-10-03 0000078003 pfe:BiohavenMember us-gaap:DevelopedTechnologyRightsMember 2022-10-03 0000078003 pfe:BiohavenMember us-gaap:DevelopedTechnologyRightsMember 2022-10-03 2022-10-03 0000078003 pfe:BiohavenMember us-gaap:InProcessResearchAndDevelopmentMember 2022-10-03 0000078003 pfe:ArenaMember 2022-03-11 0000078003 pfe:ArenaMember 2022-03-11 2022-03-11 0000078003 pfe:ArenaMember us-gaap:InProcessResearchAndDevelopmentMember 2022-03-11 0000078003 pfe:ArenaMember us-gaap:LicensingAgreementsMember 2022-03-11 0000078003 pfe:ReViralAssetAcquisitionMember 2022-06-09 2022-06-09 0000078003 2023-09-19 0000078003 2023-09-19 2023-09-19 0000078003 pfe:ViatrisMember srt:MinimumMember pfe:ManufacturingAndSupplyAgreementMember 2020-01-01 2020-12-31 0000078003 pfe:ViatrisMember srt:MaximumMember pfe:ManufacturingAndSupplyAgreementMember 2020-01-01 2020-12-31 0000078003 pfe:ViatrisMember 2024-12-31 0000078003 pfe:ViatrisMember 2023-12-31 0000078003 pfe:HaleonMember 2023-12-31 0000078003 pfe:HaleonMember 2024-03-01 2024-03-31 0000078003 pfe:HaleonMember pfe:SaleOfEquityMethodInvestmentInPublicStockOfferingMember 2024-03-01 2024-03-31 0000078003 pfe:HaleonMember pfe:SaleOfEquityMethodInvestmentInPrivatePlacementMember 2024-03-01 2024-03-31 0000078003 pfe:HaleonMember 2024-10-01 2024-10-31 0000078003 pfe:HaleonMember pfe:SaleOfEquityMethodInvestmentInPublicStockOfferingMember 2024-10-01 2024-10-31 0000078003 pfe:HaleonMember pfe:SaleOfEquityMethodInvestmentInPrivatePlacementMember 2024-10-01 2024-10-31 0000078003 pfe:HaleonMember 2024-01-01 2024-12-31 0000078003 pfe:HaleonMember 2024-10-31 0000078003 pfe:HaleonMember 2022-12-31 0000078003 pfe:HaleonMember 2023-01-01 2023-12-31 0000078003 pfe:HaleonMember 2024-12-31 0000078003 pfe:HaleonMember 2024-04-01 2024-06-30 0000078003 pfe:HaleonMember 2024-07-01 2024-09-29 0000078003 pfe:HaleonMember 2024-09-30 0000078003 pfe:HaleonMember 2023-09-30 0000078003 pfe:HaleonMember 2023-10-02 2024-09-29 0000078003 pfe:HaleonMember 2022-10-01 2023-09-30 0000078003 pfe:ConsumerHealthcareJVHaleonMember 2021-10-01 2022-09-30 0000078003 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember pfe:ConsumerHealthcareJVHaleonMember pfe:GSKMember 2022-03-31 0000078003 pfe:ConsumerHealthcareJVHaleonMember pfe:GSKMember 2019-07-31 0000078003 pfe:ConsumerHealthcareJVSeniorNotesUSDDenominatedMember us-gaap:SeniorNotesMember pfe:ConsumerHealthcareJVHaleonMember 2022-03-31 0000078003 pfe:ConsumerHealthcareJVSeniorNotesEURDenominatedMember us-gaap:SeniorNotesMember pfe:ConsumerHealthcareJVHaleonMember 2022-03-31 0000078003 pfe:ConsumerHealthcareJVSeniorNotesGBPDenominatedMember us-gaap:SeniorNotesMember pfe:ConsumerHealthcareJVHaleonMember 2022-03-31 0000078003 pfe:ConsumerHealthcareJVHaleonMember 2022-03-31 0000078003 pfe:A1365ConsumerHealthcareJVLoanMember us-gaap:LoansPayableMember 2023-07-02 0000078003 pfe:ConsumerHealthcareJVHaleonMember 2022-07-01 2022-07-31 0000078003 pfe:A1365ConsumerHealthcareJVLoanMember us-gaap:LoansPayableMember 2022-07-31 0000078003 pfe:ViivHealthcareLimitedMember 2024-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2016-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2024-01-01 2024-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2023-01-01 2023-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2022-01-01 2022-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2024-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2023-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2024-01-01 2024-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2023-01-01 2023-12-31 0000078003 pfe:ViivHealthcareLimitedMember 2022-01-01 2022-12-31 0000078003 pfe:BiohavenMember us-gaap:CollaborativeArrangementMember 2022-01-04 2022-01-04 0000078003 pfe:BiohavenMember us-gaap:CollaborativeArrangementMember 2022-01-04 0000078003 us-gaap:ProductMember us-gaap:CollaborativeArrangementMember 2024-01-01 2024-12-31 0000078003 us-gaap:ProductMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-12-31 0000078003 us-gaap:ProductMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000078003 us-gaap:CollaborativeArrangementMember 2024-01-01 2024-12-31 0000078003 us-gaap:CollaborativeArrangementMember 2023-01-01 2023-12-31 0000078003 us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000078003 us-gaap:RoyaltyMember us-gaap:CollaborativeArrangementMember 2024-01-01 2024-12-31 0000078003 us-gaap:RoyaltyMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-12-31 0000078003 us-gaap:RoyaltyMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000078003 pfe:BlackstoneMember 2023-04-01 2023-04-30 0000078003 pfe:BlackstoneMember 2024-01-01 2024-12-31 0000078003 pfe:BlackstoneMember 2023-01-01 2023-12-31 0000078003 pfe:BlackstoneMember pfe:ClinicalTrialAgreementTermsMember 2023-04-30 0000078003 pfe:BlackstoneMember pfe:NetSalesAndRoyaltyAgreementTermsMember 2023-04-30 0000078003 pfe:RealigningOurCostBaseProgramMember 2024-12-31 0000078003 pfe:RealigningOurCostBaseProgramMember pfe:BiopharmaSegmentMember 2024-12-31 0000078003 pfe:RealigningOurCostBaseProgramMember pfe:BiopharmaSegmentMember 2023-10-02 2024-12-31 0000078003 pfe:ManufacturingOptimizationProgramPhaseOneMember pfe:BiopharmaSegmentMember 2024-12-31 0000078003 pfe:ManufacturingOptimizationProgramMember pfe:BiopharmaSegmentMember 2024-12-31 0000078003 us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-12-31 0000078003 us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-12-31 0000078003 us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000078003 us-gaap:CostOfSalesMember 2024-01-01 2024-12-31 0000078003 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000078003 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000078003 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0000078003 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0000078003 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000078003 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0000078003 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000078003 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000078003 pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:ManufacturingOptimizationProgramMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:RealigningOurCostBaseProgramMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 us-gaap:OneTimeTerminationBenefitsMember pfe:RealigningOurCostBaseProgramMember pfe:BiopharmaSegmentMember 2023-10-02 2024-12-31 0000078003 pfe:RealigningOurCostBaseProgramMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:TransformingToAMoreFocusedCompanyPlanMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:TransformingToAMoreFocusedCompanyPlanMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:SeagenMember pfe:RestructuringChargesAndAcquisitionRelatedCostsMember 2023-10-02 2023-12-31 0000078003 pfe:ArenaMember pfe:RestructuringChargesAndAcquisitionRelatedCostsMember 2022-01-01 2022-04-03 0000078003 pfe:GBTMember pfe:RestructuringChargesAndAcquisitionRelatedCostsMember 2022-10-03 2022-12-31 0000078003 us-gaap:EmployeeSeveranceMember 2022-12-31 0000078003 pfe:AssetImpairmentsMember 2022-12-31 0000078003 us-gaap:OtherRestructuringMember 2022-12-31 0000078003 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-12-31 0000078003 pfe:AssetImpairmentsMember 2023-01-01 2023-12-31 0000078003 us-gaap:OtherRestructuringMember 2023-01-01 2023-12-31 0000078003 us-gaap:EmployeeSeveranceMember 2023-12-31 0000078003 pfe:AssetImpairmentsMember 2023-12-31 0000078003 us-gaap:OtherRestructuringMember 2023-12-31 0000078003 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-12-31 0000078003 pfe:AssetImpairmentsMember 2024-01-01 2024-12-31 0000078003 us-gaap:OtherRestructuringMember 2024-01-01 2024-12-31 0000078003 us-gaap:EmployeeSeveranceMember 2024-12-31 0000078003 pfe:AssetImpairmentsMember 2024-12-31 0000078003 us-gaap:OtherRestructuringMember 2024-12-31 0000078003 us-gaap:UnsecuredDebtMember 2023-05-31 0000078003 pfe:SeagenMember 2023-12-31 0000078003 pfe:TelavantHoldingsIncMember 2023-01-01 2023-12-31 0000078003 pfe:CerevelTherapeuticsHoldingsIncMember 2023-01-01 2023-12-31 0000078003 pfe:BioNTechMember 2023-01-01 2023-12-31 0000078003 pfe:BioNTechAndCerevelTherapeuticsLLCMember 2022-01-01 2022-12-31 0000078003 pfe:BiopharmaSegmentMember 2024-09-30 2024-12-31 0000078003 pfe:B7H4VFelmetatugVedotinMember us-gaap:InProcessResearchAndDevelopmentMember pfe:BiopharmaSegmentMember 2024-09-30 2024-12-31 0000078003 pfe:MedrolMember pfe:BrandMember pfe:BiopharmaSegmentMember 2024-09-30 2024-12-31 0000078003 pfe:ZavzpretMember us-gaap:DevelopedTechnologyRightsMember pfe:BiopharmaSegmentMember 2024-09-30 2024-12-31 0000078003 pfe:TukysaMember us-gaap:InProcessResearchAndDevelopmentMember pfe:BiopharmaSegmentMember 2024-09-30 2024-12-31 0000078003 pfe:DisitamabVedotinMember us-gaap:InProcessResearchAndDevelopmentMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:OtherDevelopedTechnologyRightsInProcessResearchAndDevelopmentAndFiniteLivedLicensingAgreementMember 2024-01-01 2024-12-31 0000078003 us-gaap:InProcessResearchAndDevelopmentMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:BiopharmaSegmentMember 2023-10-02 2023-12-31 0000078003 pfe:EtrasimodVelsipityMember us-gaap:InProcessResearchAndDevelopmentMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:Prevnar13Member us-gaap:DevelopedTechnologyRightsMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:OtherInProcessResearchAndDevelopmentAndDevelopedTechnologyRightsMember 2023-01-01 2023-12-31 0000078003 us-gaap:InProcessResearchAndDevelopmentMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 us-gaap:InProcessResearchAndDevelopmentMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 us-gaap:DevelopedTechnologyRightsMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:GenericSterileInjectableProductMember pfe:HospiraMember pfe:LicensingAgreementsAndOtherMember 2022-01-01 2022-12-31 0000078003 2024-07-01 2024-09-29 0000078003 pfe:NimbusMember 2023-01-01 2023-12-31 0000078003 pfe:TransitionServiceAgreementMember 2022-01-01 2022-12-31 0000078003 pfe:ViiVMember 2022-01-01 2022-12-31 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel3Member us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2024-01-01 2024-12-31 0000078003 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel3Member us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000078003 us-gaap:DevelopedTechnologyRightsMember 2024-01-01 2024-12-31 0000078003 pfe:BrandMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member pfe:BrandMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member pfe:BrandMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel3Member pfe:BrandMember 2024-12-31 0000078003 pfe:BrandMember 2024-01-01 2024-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member pfe:LicensingAgreementsAndOtherMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member pfe:LicensingAgreementsAndOtherMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel3Member pfe:LicensingAgreementsAndOtherMember 2024-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2024-01-01 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000078003 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000078003 pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember 2024-12-31 0000078003 pfe:NoncurrentDeferredTaxLiabilitiesMember 2024-12-31 0000078003 pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember 2023-12-31 0000078003 pfe:NoncurrentDeferredTaxLiabilitiesMember 2023-12-31 0000078003 pfe:IncomeTaxesPayableMember 2024-12-31 0000078003 pfe:CurrentTaxAssetsMember 2024-12-31 0000078003 pfe:OtherTaxesPayableMember 2024-12-31 0000078003 pfe:IncomeTaxesPayableMember 2023-12-31 0000078003 pfe:CurrentTaxAssetsMember 2023-12-31 0000078003 pfe:OtherTaxesPayableMember 2023-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2021-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2022-01-01 2022-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2022-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2023-01-01 2023-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2023-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2024-01-01 2024-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000078003 us-gaap:BankTimeDepositsMember 2024-12-31 0000078003 us-gaap:BankTimeDepositsMember 2023-12-31 0000078003 us-gaap:CommercialPaperMember 2024-12-31 0000078003 us-gaap:CommercialPaperMember 2023-12-31 0000078003 us-gaap:RevolvingCreditFacilityMember 2024-12-31 0000078003 us-gaap:RevolvingCreditFacilityMember pfe:CreditFacilityMaturingOctober2025Member 2024-12-31 0000078003 us-gaap:RevolvingCreditFacilityMember pfe:CreditFacilityMaturingOctober2029Member 2024-12-31 0000078003 us-gaap:LineOfCreditMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2025Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2025Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2026Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2026Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2027Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2027Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2028Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2028Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2029Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2029Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2030Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue2030Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20312035Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20312035Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20362040Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20362040Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20412045Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20412045Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20462050Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20462050Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20512063Member us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 pfe:SeniorUnsecuredDebtDue20512063Member us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 us-gaap:UnsecuredDebtMember 2024-12-31 0000078003 us-gaap:UnsecuredDebtMember 2023-12-31 0000078003 2023-05-31 0000078003 us-gaap:ForeignExchangeContractMember 2024-01-01 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000078003 us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000078003 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesMember 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesMember 2023-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000078003 pfe:ForeignCurrencyShortTermBorrowingsMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-12-31 0000078003 pfe:ForeignCurrencyShortTermBorrowingsMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000078003 pfe:ForeignCurrencyDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-12-31 0000078003 pfe:ForeignCurrencyDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-01-01 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-01-01 2023-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-01-01 2024-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000078003 pfe:ForeignCurrencyDebtMember 2024-12-31 0000078003 pfe:ForeignCurrencyDebtMember 2023-12-31 0000078003 pfe:BioNTechMember pfe:ComirnatyMember us-gaap:CollaborativeArrangementMember 2024-12-31 0000078003 pfe:BioNTechMember pfe:ComirnatyMember us-gaap:CollaborativeArrangementMember 2023-12-31 0000078003 srt:MinimumMember 2024-12-31 0000078003 srt:MaximumMember 2024-12-31 0000078003 us-gaap:LandMember 2024-12-31 0000078003 us-gaap:LandMember 2023-12-31 0000078003 srt:MinimumMember us-gaap:BuildingMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:BuildingMember 2024-12-31 0000078003 us-gaap:BuildingMember 2024-12-31 0000078003 us-gaap:BuildingMember 2023-12-31 0000078003 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0000078003 us-gaap:MachineryAndEquipmentMember 2024-12-31 0000078003 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000078003 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-12-31 0000078003 us-gaap:FurnitureAndFixturesMember 2024-12-31 0000078003 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000078003 us-gaap:ConstructionInProgressMember 2024-12-31 0000078003 us-gaap:ConstructionInProgressMember 2023-12-31 0000078003 country:US 2024-12-31 0000078003 country:US 2023-12-31 0000078003 pfe:DevelopedMarketsMember 2024-12-31 0000078003 pfe:DevelopedMarketsMember 2023-12-31 0000078003 pfe:InternationalEmergingMarketsMember 2024-12-31 0000078003 pfe:InternationalEmergingMarketsMember 2023-12-31 0000078003 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000078003 us-gaap:TradeNamesMember 2024-12-31 0000078003 us-gaap:TradeNamesMember 2023-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2023-12-31 0000078003 us-gaap:TradeNamesMember 2024-12-31 0000078003 us-gaap:TradeNamesMember 2023-12-31 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2024-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2023-12-31 0000078003 pfe:TalazoparibTalzennaMember us-gaap:DevelopedTechnologyRightsMember 2024-01-01 2024-12-31 0000078003 pfe:TalazoparibTalzennaMember us-gaap:InProcessResearchAndDevelopmentMember 2024-01-01 2024-12-31 0000078003 pfe:DepoMedrolMember us-gaap:TradeNamesMember 2024-01-01 2024-12-31 0000078003 us-gaap:TradeNamesMember 2024-01-01 2024-12-31 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:OtherCommingledFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:OtherCommingledFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:OtherCommingledFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:OtherCommingledFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:OtherCommingledFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:OtherCommingledFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:OtherCommingledFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:OtherCommingledFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:MinimumMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:PartnershipInterestMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:PartnershipInterestMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 srt:MinimumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 pfe:InsuranceContractsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 pfe:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 srt:MinimumMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel1Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 us-gaap:FairValueInputsLevel2Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel1Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel2Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel3Member country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000078003 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000078003 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000078003 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000078003 srt:MinimumMember us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember us-gaap:DefinedBenefitPlanEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:DefinedBenefitPlanEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember us-gaap:DefinedBenefitPlanDebtSecurityMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:DefinedBenefitPlanDebtSecurityMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember pfe:DefinedBenefitPlanOtherInvestmentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember pfe:DefinedBenefitPlanOtherInvestmentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember us-gaap:DefinedBenefitPlanDebtSecurityMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:DefinedBenefitPlanDebtSecurityMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember pfe:DefinedBenefitPlanOtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember pfe:DefinedBenefitPlanOtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MinimumMember pfe:InsuranceContractsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 srt:MaximumMember pfe:InsuranceContractsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000078003 2018-12-31 0000078003 2022-01-01 2022-04-03 0000078003 pfe:CommonESOPPlanMember 2024-01-01 2024-12-31 0000078003 pfe:CommonESOPPlanMember 2023-01-01 2023-12-31 0000078003 pfe:CommonESOPPlanMember 2022-01-01 2022-12-31 0000078003 pfe:BreakthroughPerformanceAwardsMember 2024-01-01 2024-12-31 0000078003 pfe:BreakthroughPerformanceAwardsMember 2024-12-31 0000078003 pfe:A2019StockPlanMember 2024-01-01 2024-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember pfe:A2019StockPlanMember 2024-01-01 2024-12-31 0000078003 us-gaap:PerformanceSharesMember pfe:A2019StockPlanMember 2024-01-01 2024-12-31 0000078003 pfe:PortfolioPerformanceSharesMember pfe:A2019StockPlanMember 2024-01-01 2024-12-31 0000078003 pfe:BreakthroughPerformanceAwardsMember pfe:A2019StockPlanMember 2024-01-01 2024-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember pfe:A2019StockPlanMember 2024-01-01 2024-12-31 0000078003 us-gaap:EmployeeStockOptionMember pfe:A2019StockPlanMember 2024-01-01 2024-12-31 0000078003 srt:MinimumMember pfe:TotalShareholderReturnUnitsTSRUsMember 2024-01-01 2024-12-31 0000078003 srt:MaximumMember pfe:TotalShareholderReturnUnitsTSRUsMember 2024-01-01 2024-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember 2024-01-01 2024-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0000078003 srt:MinimumMember pfe:PortfolioPerformanceSharesMember 2024-01-01 2024-12-31 0000078003 srt:MaximumMember pfe:PortfolioPerformanceSharesMember 2024-01-01 2024-12-31 0000078003 us-gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0000078003 srt:MinimumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0000078003 srt:MaximumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0000078003 srt:MinimumMember pfe:BreakthroughPerformanceAwardsMember 2024-01-01 2024-12-31 0000078003 srt:MaximumMember pfe:BreakthroughPerformanceAwardsMember 2024-01-01 2024-12-31 0000078003 srt:ManagementMember 2024-01-01 2024-12-31 0000078003 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember 2023-01-01 2023-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember 2022-01-01 2022-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000078003 pfe:PortfolioPerformanceSharesMember 2024-01-01 2024-12-31 0000078003 pfe:PortfolioPerformanceSharesMember 2023-01-01 2023-12-31 0000078003 pfe:PortfolioPerformanceSharesMember 2022-01-01 2022-12-31 0000078003 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0000078003 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000078003 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000078003 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember 2024-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember 2023-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember 2022-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000078003 pfe:PortfolioPerformanceSharesMember 2024-12-31 0000078003 pfe:PortfolioPerformanceSharesMember 2023-12-31 0000078003 pfe:PortfolioPerformanceSharesMember 2022-12-31 0000078003 us-gaap:PerformanceSharesMember 2024-12-31 0000078003 us-gaap:PerformanceSharesMember 2023-12-31 0000078003 us-gaap:PerformanceSharesMember 2022-12-31 0000078003 us-gaap:EmployeeStockOptionMember 2024-12-31 0000078003 us-gaap:EmployeeStockOptionMember 2023-12-31 0000078003 us-gaap:EmployeeStockOptionMember 2022-12-31 0000078003 pfe:ProfitUnitsMember 2024-12-31 0000078003 pfe:ProfitUnitsMember 2024-01-01 2024-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember pfe:TotalShareholderReturnUnitsVestingPeriodOneMember 2024-12-31 0000078003 pfe:TotalShareholderReturnUnitsTSRUsMember pfe:TotalShareholderReturnUnitsVestingPeriodTwoMember 2024-12-31 0000078003 pfe:CertainTSRUsGrantedIn2022And2023Member pfe:TotalShareholderReturnUnitsTSRUsMember 2024-01-01 2024-12-31 0000078003 pfe:CertainTSRUsGrantedIn2022And2023Member pfe:TotalShareholderReturnUnitsTSRUsMember 2024-12-31 0000078003 pfe:RestrictedStockUnitsGrantedBefore2022Member us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-12-31 0000078003 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-01 2024-12-31 0000078003 pfe:PSAsGrantedIn2022And2023Member us-gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0000078003 srt:MinimumMember 2024-01-01 2024-12-31 0000078003 srt:MaximumMember 2024-01-01 2024-12-31 0000078003 pfe:PfizerAndVersusSeveralGenericManufacturersMember pfe:MektoviMember pfe:PatentInfringementMember us-gaap:PendingLitigationMember 2022-08-01 2022-08-31 0000078003 pfe:PfizerAndVersusSeveralGenericManufacturersMember pfe:MektoviMember pfe:PatentInfringementMember us-gaap:PendingLitigationMember pfe:Expiring2030Member 2022-08-01 2022-08-31 0000078003 pfe:PfizerAndVersusSeveralGenericManufacturersMember pfe:MektoviMember pfe:PatentInfringementMember us-gaap:PendingLitigationMember pfe:Expiring2033Member 2022-08-01 2022-08-31 0000078003 pfe:PfizerAndVersusSeveralGenericManufacturersMember pfe:MektoviMember pfe:PatentInfringementMember us-gaap:PendingLitigationMember 2022-09-01 2022-09-30 0000078003 pfe:PfizerAndVersusSeveralGenericManufacturersMember pfe:MektoviMember pfe:PatentInfringementMember us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000078003 pfe:PfizerVersusTevaPharmaceuticalsIncMember pfe:MektoviMember pfe:PatentInvalidityAndNonInfringementMember us-gaap:PendingLitigationMember pfe:TevaPharmaceuticalsIncMember 2022-08-01 2022-08-31 0000078003 pfe:PfizerVersusTevaPharmaceuticalsIncMember pfe:MektoviMember pfe:PatentInvalidityAndNonInfringementMember us-gaap:PendingLitigationMember 2023-06-01 2023-06-30 0000078003 pfe:AlnylamPatentInfringementCaseMember pfe:ComirnatyMember 2023-05-01 2023-05-31 0000078003 pfe:ModernaTXUSPatentInfringementCaseMember pfe:ComirnatyMember 2022-08-01 2022-08-31 0000078003 pfe:ModernaTXUSPatentInfringementCaseMember pfe:ComirnatyMember 2024-03-01 2024-03-31 0000078003 pfe:ModernaTXEuropeanPatentInfringementCaseMember pfe:ComirnatyMember 2022-08-01 2022-08-31 0000078003 pfe:ModernaTXEuropeanPatentInfringementCaseMember pfe:ComirnatyMember 2022-09-01 2022-09-30 0000078003 2023-11-01 2023-11-30 0000078003 pfe:ModernaTXEuropeanPatentInfringementCaseMember pfe:ComirnatyMember 2024-07-01 2024-07-31 0000078003 pfe:ArbutusAndGenevantUSPatentInfringementCaseMember pfe:ComirnatyMember 2023-04-01 2023-04-30 0000078003 pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember pfe:ComirnatyMember 2024-04-01 2024-04-30 0000078003 pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember pfe:ComirnatyMember 2024-08-01 2024-08-31 0000078003 pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember pfe:AbrysvoMember 2023-08-01 2023-08-31 0000078003 pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember pfe:AbrysvoMember 2023-11-01 2023-11-30 0000078003 pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember pfe:AbrysvoMember 2024-11-01 2024-11-30 0000078003 pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember pfe:AbrysvoMember 2024-10-01 2024-10-31 0000078003 pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember pfe:ComirnatyMember 2022-07-01 2022-07-31 0000078003 pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember pfe:ComirnatyMember 2023-05-01 2023-05-31 0000078003 pfe:GreenstoneAntitrustLitigationMember us-gaap:PendingLitigationMember 2020-12-31 0000078003 pfe:U.S.AndParticipatingStatesMember pfe:GovernmentInquiresRelatingToBiohavenMember us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000078003 pfe:CaliforniaDepartmentOfInsuranceMember pfe:GovernmentInquiresRelatingToBiohavenMember us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000078003 us-gaap:OperatingSegmentsMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 us-gaap:OperatingSegmentsMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 us-gaap:OperatingSegmentsMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-12-31 0000078003 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0000078003 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember 2024-01-01 2024-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember 2023-01-01 2023-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember 2022-01-01 2022-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAcquisitionRelatedCostsMember 2024-01-01 2024-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAcquisitionRelatedCostsMember 2023-01-01 2023-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAcquisitionRelatedCostsMember 2022-01-01 2022-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsOtherMember 2024-01-01 2024-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsOtherMember 2023-01-01 2023-12-31 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsOtherMember 2022-01-01 2022-12-31 0000078003 us-gaap:CorporateNonSegmentMember us-gaap:ReclassificationOtherMember 2023-01-01 2023-12-31 0000078003 us-gaap:CorporateNonSegmentMember us-gaap:ReclassificationOtherMember 2022-01-01 2022-12-31 0000078003 pfe:PaxlovidEUALabeledMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:PaxlovidEUALabeledMember pfe:BiopharmaSegmentMember 2024-01-01 2024-03-31 0000078003 pfe:PaxlovidEUALabeledMember pfe:BiopharmaSegmentMember 2023-12-31 0000078003 us-gaap:CorporateNonSegmentMember pfe:PaxlovidMember 2022-01-01 2022-12-31 0000078003 pfe:ViivHealthcareLimitedMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:ViivHealthcareLimitedMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:ViivHealthcareLimitedMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:HaleonMember 2024-09-30 2024-12-31 0000078003 pfe:ComirnatyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:ComirnatyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:ComirnatyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:PaxlovidMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:PaxlovidMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:PaxlovidMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:ExcludingComirnatyAndPaxlovidMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:ExcludingComirnatyAndPaxlovidMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:ExcludingComirnatyAndPaxlovidMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 country:US 2024-01-01 2024-12-31 0000078003 country:US 2023-01-01 2023-12-31 0000078003 country:US 2022-01-01 2022-12-31 0000078003 pfe:InternationalDevelopedMarketsMember 2024-01-01 2024-12-31 0000078003 pfe:InternationalDevelopedMarketsMember 2023-01-01 2023-12-31 0000078003 pfe:InternationalDevelopedMarketsMember 2022-01-01 2022-12-31 0000078003 pfe:InternationalEmergingMarketsMember 2024-01-01 2024-12-31 0000078003 pfe:InternationalEmergingMarketsMember 2023-01-01 2023-12-31 0000078003 pfe:InternationalEmergingMarketsMember 2022-01-01 2022-12-31 0000078003 pfe:NonUnitedStatesMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-12-31 0000078003 pfe:NonUnitedStatesMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-12-31 0000078003 pfe:NonUnitedStatesMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-12-31 0000078003 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000078003 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000078003 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000078003 country:CN us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000078003 country:JP us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000078003 country:JP us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000078003 pfe:PaxlovidEUALabeledMember 2023-12-31 0000078003 pfe:PaxlovidEUALabeledMember 2024-01-01 2024-03-31 0000078003 pfe:PaxlovidEUALabeledMember 2024-01-01 2024-02-29 0000078003 pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 2024-09-29 0000078003 pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 2024-07-01 2024-09-29 0000078003 pfe:McKessonInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000078003 pfe:McKessonInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000078003 pfe:McKessonInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000078003 pfe:CencoraInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000078003 pfe:CencoraInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000078003 pfe:CencoraInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000078003 pfe:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000078003 pfe:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000078003 pfe:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000078003 pfe:USGovernmentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000078003 pfe:USGovernmentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000078003 pfe:USGovernmentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000078003 pfe:ThreeLargestUSWholesaleCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000078003 pfe:ThreeLargestUSWholesaleCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000078003 pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:EliquisMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:EliquisMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:EliquisMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:PrevnarPrevenarFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:PrevnarPrevenarFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:PrevnarPrevenarFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:NurtecODTVyduraMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:NurtecODTVyduraMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:NurtecODTVyduraMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:AbrysvoMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:AbrysvoMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:AbrysvoMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:PremarinFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:PremarinFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:PremarinFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:BMP2Member pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:BMP2Member pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:BMP2Member pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:FSMEIMMUNTicoVacMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:FSMEIMMUNTicoVacMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:FSMEIMMUNTicoVacMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:OtherPrimaryCareProductsMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:OtherPrimaryCareProductsMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:OtherPrimaryCareProductsMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:VyndaqelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:VyndaqelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:VyndaqelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:XeljanzMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:XeljanzMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:XeljanzMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:EnbrelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:EnbrelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:EnbrelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:SulperazonMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:SulperazonMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:SulperazonMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:ZaviceftaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:ZaviceftaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:ZaviceftaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:OctagamMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:OctagamMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:OctagamMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:InflectraRemsimaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:InflectraRemsimaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:InflectraRemsimaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:ZithromaxZmaxMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:ZithromaxZmaxMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:ZithromaxZmaxMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:GenotropinMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:GenotropinMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:GenotropinMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:BeneFIXMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:BeneFIXMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:BeneFIXMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:CibinqoMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:CibinqoMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:CibinqoMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:OxbrytaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:OxbrytaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:OxbrytaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:OtherHospitalMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:OtherHospitalMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:OtherHospitalMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:OtherSpecialtyCareMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:OtherSpecialtyCareMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:OtherSpecialtyCareMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:IbranceMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:IbranceMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:IbranceMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:XtandiMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:XtandiMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:XtandiMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:PadcevMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:PadcevMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:PadcevMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:AdcetrisMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:AdcetrisMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:AdcetrisMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:OncologyBiosimilarsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:OncologyBiosimilarsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:OncologyBiosimilarsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:InlytaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:InlytaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:InlytaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:LorbrenaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:LorbrenaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:LorbrenaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:BosulifMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:BosulifMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:BosulifMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:BraftoviMektoviMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:BraftoviMektoviMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:BraftoviMektoviMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:TukysaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:TukysaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:TukysaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:ElrexfioMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:ElrexfioMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:ElrexfioMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:TivdakMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:TivdakMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:TivdakMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:TalzennaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:TalzennaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:TalzennaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:OtherOncologyProductsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:OtherOncologyProductsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2023-01-01 2023-12-31 0000078003 pfe:OtherOncologyProductsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2022-01-01 2022-12-31 0000078003 pfe:PfizerCentreOneMember 2024-01-01 2024-12-31 0000078003 pfe:PfizerCentreOneMember 2023-01-01 2023-12-31 0000078003 pfe:PfizerCentreOneMember 2022-01-01 2022-12-31 0000078003 pfe:PfizerIgniteMember 2024-01-01 2024-12-31 0000078003 pfe:PfizerIgniteMember 2023-01-01 2023-12-31 0000078003 pfe:PfizerIgniteMember 2022-01-01 2022-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:U.S.CommercialDivisionMember 2024-01-01 2024-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:U.S.CommercialDivisionMember 2023-01-01 2023-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:U.S.CommercialDivisionMember 2022-01-01 2022-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:OncologyDivisionMember 2024-01-01 2024-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:OncologyDivisionMember 2023-01-01 2023-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:OncologyDivisionMember 2022-01-01 2022-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:InternationalCommercialDivisionMember 2024-01-01 2024-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:InternationalCommercialDivisionMember 2023-01-01 2023-12-31 0000078003 pfe:BiopharmaSegmentMember pfe:InternationalCommercialDivisionMember 2022-01-01 2022-12-31 0000078003 pfe:TotalAllianceBiopharmaceuticalsMember 2024-01-01 2024-12-31 0000078003 pfe:TotalAllianceBiopharmaceuticalsMember 2023-01-01 2023-12-31 0000078003 pfe:TotalAllianceBiopharmaceuticalsMember 2022-01-01 2022-12-31 0000078003 pfe:PaxlovidEUALabeledMember 2024-01-01 2024-12-31 0000078003 pfe:CommercializationPartnerMember pfe:OctagamMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:ComirnatyMember 2024-12-31 0000078003 pfe:PaxlovidMember 2024-12-31 0000078003 pfe:GovernmentAndGovernmentSponsoredMember pfe:PaxlovidAndComirnatyMember 2024-12-31 0000078003 pfe:GovernmentAndGovernmentSponsoredMember pfe:PaxlovidAndComirnatyMember 2023-12-31 0000078003 pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 2024-01-01 2024-12-31 0000078003 pfe:GovernmentAndGovernmentSponsoredMember pfe:PaxlovidAndComirnatyMember 2024-01-01 2024-12-31 0000078003 2024-09-30 2024-12-31 iso4217:USD shares iso4217:USD shares pfe:segment pure pfe:medicine iso4217:EUR iso4217:GBP pfe:employeeStockOwnershipPlan pfe:tradingDay pfe:measure pfe:period pfe:company pfe:patent pfe:Patent pfe:complaint pfe:operatingSegment pfe:facility pfe:country pfe:treatmentCourse 0000078003 2024 FY false P4Y Consolidated Statements of Operations Consolidated Statements of Operations Consolidated Statements of Operations http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#AccountsPayableCurrent http://fasb.org/us-gaap/2024#AccountsPayableCurrent 0 0.10 0.10 0.40 0.45 0.80 0.05 0.35 0 0.10 0.10 0.20 0.45 0.70 0.15 0.35 0 0.05 0.95 1 P5Y P7Y P3Y P3Y P5Y P1Y P3Y P1Y P5Y P7Y P3Y P5Y P7Y P3Y 0.33 0.33 0.33 P3Y P3Y P5Y P3Y http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense 10-K true 2024-12-31 --12-31 false 1-3619 PFIZER INC DE 13-5315170 66 Hudson Boulevard East New York NY 10001-2192 212 733-2323 Common Stock, $0.05 par value PFE NYSE 1.000% Notes due 2027 PFE27 NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 158000000000 5667340414 <div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:489.75pt"><tr><td style="width:1.0pt"></td><td style="width:397.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:9pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Portions of the Proxy Statement for the 2025 Annual Meeting of Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Part III</span></td></tr></table></div> <div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Managing cybersecurity risk is a crucial part of our overall strategy for safely operating our business. We incorporate cybersecurity practices into our Enterprise Risk Management (ERM) program. Management is responsible for assessing and managing risk, including through the ERM program, subject to oversight by our BOD. Our cybersecurity policies and practices are aligned with NIST (National Institute of Standards and Technology) industry standards.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consistent with our overall ERM program and practices, our cybersecurity program includes:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Vigilance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We maintain a global cybersecurity operation that endeavors to detect, prevent, contain, and respond to cybersecurity threats and incidents in a prompt and effective manner with the goal of minimizing business disruptions.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">External Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We collaborate with public and private entities, including intelligence and law enforcement agencies, industry groups and third-party service providers to identify, assess and mitigate cybersecurity risks.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Systems Safeguards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We deploy technical safeguards that are designed to protect our information systems, products, operations and sensitive information from cybersecurity threats. These include firewalls, intrusion prevention and detection systems, disaster recovery capabilities, malware and ransomware prevention, access controls and data protection. We continuously conduct vulnerability assessments to identify new risks and periodically test the efficacy of our safeguards through both internal and external penetration tests.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Education</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We provide periodic training for all personnel regarding cybersecurity threats, with such training appropriate to the roles, responsibilities and access of the relevant Company personnel. Our policies require all workers to report any real or suspected cybersecurity events.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Supplier Ecosystem Management</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We extend our cybersecurity management control expectations to our supply chain ecosystem, as appropriate. This includes identifying cybersecurity risks presented by third parties.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Incident Response Planning</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We have established, and maintain and periodically test, incident response plans that direct our response to cybersecurity events and incidents. Such plans include the protocol by which certain significant or potentially material incidents would be communicated to executive management, our BOD, external regulators and shareholders, as appropriate.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Enterprise-Wide Coordination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We engage relevant stakeholders from across the Company to identify emerging risks and respond to cybersecurity threats. This cross-functional approach includes personnel from our R&amp;D, manufacturing, commercial, technology, legal, compliance, internal audit and other business functions.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Governance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Our BOD’s oversight of cybersecurity risk management is led by the Audit Committee, which oversees our ERM program. Cybersecurity threats, risks and mitigation are periodically reviewed by the Audit Committee and such reviews include both internal and independent assessment of risks, controls and effectiveness.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our risk assessment efforts have indicated that we are a target for theft of intellectual property, financial resources, personal information, and trade secrets from a wide range of actors including nation states, organized crime, malicious insiders and activists. The impacts of attacks, abuse and misuse of Pfizer’s systems and information could include, without limitation, loss of assets, operational disruption and damage to Pfizer’s reputation. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A key element of managing cybersecurity risk is the ongoing assessment and testing of our processes and practices through auditing, assessments, drills and other exercises focused on evaluating the sufficiency and effectiveness of our risk mitigation. We regularly engage third parties to perform assessments of our cybersecurity measures, including information security maturity assessments and independent reviews of our information security control environment and operating effectiveness. Certain results of such assessments and reviews are reported by the Chief Information Security Officer (CISO) to certain senior leaders, the Audit Committee and the BOD, as appropriate, and we make adjustments to our cybersecurity processes and practices as necessary based on the information provided by the third-party assessments and reviews.</span></div> <div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Managing cybersecurity risk is a crucial part of our overall strategy for safely operating our business. We incorporate cybersecurity practices into our Enterprise Risk Management (ERM) program. Management is responsible for assessing and managing risk, including through the ERM program, subject to oversight by our BOD. Our cybersecurity policies and practices are aligned with NIST (National Institute of Standards and Technology) industry standards.</span></div> true <span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Governance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Our BOD’s oversight of cybersecurity risk management is led by the Audit Committee, which oversees our ERM program. Cybersecurity threats, risks and mitigation are periodically reviewed by the Audit Committee and such reviews include both internal and independent assessment of risks, controls and effectiveness.</span> true true The Audit Committee oversees cybersecurity risk management, including the policies, processes and practices that management implements to prevent, detect and address risks from cybersecurity threats. The Audit Committee receives periodic briefings on, and discusses with our CISO, cybersecurity risks and risk management practices, including, for example, recent developments in the external cybersecurity threat landscape, evolving standards, vulnerability assessments, third-party and independent reviews, technological trends and considerations arising from our supplier ecosystem. The Audit Committee may also promptly receive information regarding certain significant or potentially material cybersecurity incidents that may occur, including any ongoing updates regarding the same. true <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our CISO is a member of our management team who is principally responsible for overseeing our cybersecurity risk management program, in partnership with other business leaders across the Company. We believe our CISO and the information security organization have the appropriate expertise, background and depth of experience relating to monitoring the prevention, mitigation, detection and remediation of cybersecurity incidents to manage risks arising from cybersecurity threats. The CISO works in coordination with other members of the management team, including, among others, the Chief Digital Officer, the Chief Financial Officer and the Chief Legal Officer and their designees. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our CISO, along with leaders from our privacy and corporate compliance functions, collaborate to implement a program designed to manage our exposure to cybersecurity risks and to promptly respond to cybersecurity incidents. Prompt response to incidents is delivered by multi-disciplinary teams in accordance with our incident response plan. Through ongoing communications with these teams during incidents, the CISO monitors the triage, mitigation and remediation of cybersecurity incidents, and reports such incidents to executive management, the Audit Committee and other Pfizer colleagues in accordance with our cybersecurity policies and procedures, as is appropriate.</span></div> Our CISO is a member of our management team who is principally responsible for overseeing our cybersecurity risk management program, in partnership with other business leaders across the Company. true We believe our CISO and the information security organization have the appropriate expertise, background and depth of experience relating to monitoring the prevention, mitigation, detection and remediation of cybersecurity incidents to manage risks arising from cybersecurity threats. The CISO works in coordination with other members of the management team, including, among others, the Chief Digital Officer, the Chief Financial Officer and the Chief Legal Officer and their designees. <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our CISO, along with leaders from our privacy and corporate compliance functions, collaborate to implement a program designed to manage our exposure to cybersecurity risks and to promptly respond to cybersecurity incidents. Prompt response to incidents is delivered by multi-disciplinary teams in accordance with our incident response plan. Through ongoing communications with these teams during incidents, the CISO monitors the triage, mitigation and remediation of cybersecurity incidents, and reports such incidents to executive management, the Audit Committee and other Pfizer colleagues in accordance with our cybersecurity policies and procedures, as is appropriate.</span></div> false 53816000000 50914000000 91793000000 8388000000 7582000000 8537000000 1423000000 1058000000 845000000 63627000000 59553000000 101175000000 17851000000 24954000000 34344000000 14730000000 14771000000 13677000000 10822000000 10679000000 11428000000 108000000 194000000 953000000 5286000000 4733000000 3609000000 2419000000 2943000000 1375000000 -4388000000 -222000000 -1062000000 8023000000 1058000000 34729000000 -28000000 -1115000000 3328000000 8051000000 2172000000 31401000000 11000000 -15000000 6000000 8062000000 2158000000 31407000000 31000000 39000000 35000000 8031000000 2119000000 31372000000 1.42 0.38 5.59 0 0 0 1.42 0.38 5.59 1.41 0.37 5.47 0 0 0 1.41 0.37 5.47 5664000000 5643000000 5608000000 5700000000 5709000000 5733000000 8062000000 2158000000 31407000000 32000000 452000000 -2328000000 499000000 626000000 1444000000 159000000 413000000 2062000000 341000000 213000000 -618000000 -152000000 -121000000 -1306000000 -42000000 141000000 -1809000000 -111000000 -261000000 502000000 -193000000 25000000 24000000 -109000000 -117000000 -129000000 0 -15000000 -12000000 -84000000 157000000 166000000 347000000 246000000 -2609000000 231000000 -85000000 -187000000 116000000 331000000 -2422000000 8178000000 2488000000 28985000000 28000000 26000000 20000000 8149000000 2462000000 28965000000 1043000000 2853000000 19434000000 9837000000 438000000 470000000 11463000000 11566000000 10851000000 10189000000 3314000000 3978000000 4253000000 4911000000 50358000000 43333000000 217000000 11637000000 2010000000 3731000000 18393000000 18940000000 55411000000 64900000000 68527000000 67783000000 8662000000 3706000000 9817000000 12471000000 213396000000 226501000000 3747000000 2254000000 6946000000 10350000000 5633000000 6710000000 2437000000 2372000000 2910000000 2349000000 3838000000 2776000000 1511000000 2700000000 19720000000 20537000000 42995000000 47794000000 57405000000 61538000000 2115000000 2167000000 2122000000 640000000 6112000000 8534000000 14150000000 16539000000 124899000000 137213000000 0.05 0.05 12000000000 12000000000 9593000000 9562000000 480000000 478000000 93603000000 92631000000 3926000000 3916000000 114763000000 114487000000 116725000000 118353000000 -7842000000 -7961000000 88203000000 89014000000 294000000 274000000 88497000000 89288000000 213396000000 226501000000 9471000000 473000000 90591000000 3851000000 -111361000000 103394000000 -5897000000 77201000000 262000000 77462000000 31372000000 31372000000 35000000 31407000000 -2407000000 -2407000000 -15000000 -2422000000 1.61 9037000000 9037000000 9037000000 13000000 13000000 48000000 2000000 1192000000 -13000000 -608000000 -73000000 513000000 513000000 39000000 2000000000 2000000000 2000000000 -19000000 0 0 -19000000 13000000 -6000000 9519000000 476000000 91802000000 3903000000 -113969000000 125656000000 -8304000000 95661000000 256000000 95916000000 2119000000 2119000000 39000000 2158000000 343000000 343000000 -12000000 331000000 1.65 9316000000 9316000000 9316000000 8000000 8000000 43000000 2000000 829000000 -12000000 -518000000 -106000000 208000000 208000000 0 0 0 0 0 9562000000 478000000 92631000000 3916000000 -114487000000 118353000000 -7961000000 89014000000 274000000 89288000000 8031000000 8031000000 31000000 8062000000 118000000 118000000 -3000000 116000000 1.69 9577000000 9577000000 9577000000 7000000 7000000 31000000 2000000 972000000 -10000000 -276000000 -107000000 591000000 591000000 0 -25000000 -25000000 1000000 -23000000 9593000000 480000000 93603000000 3926000000 -114763000000 116725000000 -7842000000 88203000000 294000000 88497000000 8062000000 2158000000 31407000000 11000000 -15000000 6000000 8051000000 2172000000 31401000000 7013000000 6290000000 5064000000 4242000000 3408000000 550000000 -2102000000 -3442000000 -3764000000 877000000 525000000 872000000 12000000 787000000 1158000000 0 6199000000 1183000000 2260000000 3492000000 -758000000 109000000 -347000000 -261000000 854000000 1169000000 591000000 -3380000000 663000000 4506000000 -1023000000 -300000000 1191000000 -3115000000 595000000 -1449000000 -1345000000 -982000000 -545000000 12744000000 8700000000 29267000000 2909000000 3907000000 3236000000 10133000000 30974000000 36384000000 4128000000 39264000000 44821000000 -3136000000 -5174000000 483000000 180000000 204000000 1913000000 1570000000 1979000000 641000000 7040000000 0 0 0 43430000000 22997000000 0 0 3960000000 -2000000 179000000 192000000 2652000000 -32278000000 -15783000000 8907000000 4525000000 3891000000 11226000000 3000000 3887000000 -2590000000 3161000000 -222000000 0 30831000000 0 2250000000 2569000000 3298000000 0 0 2000000000 9512000000 9247000000 8983000000 -469000000 -631000000 -335000000 -17140000000 26066000000 -14834000000 -66000000 -40000000 -165000000 -1810000000 2448000000 -1515000000 2917000000 468000000 1983000000 1107000000 2917000000 468000000 3605000000 3147000000 7867000000 3227000000 2215000000 1442000000 178000000 134000000 54000000 283000000 614000000 752000000 Basis of Presentation and Significant Accounting Policies<div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Basis of Presentation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP. The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. All significant transactions among our subsidiaries have been eliminated.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December 14, 2023, we completed the acquisition of Seagen. In addition, other acquisitions and business development activities completed in 2024, 2023 and 2022 impacted financial results in the periods presented. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and began presenting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Royalty revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as a separate line item within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our consolidated statements of operations, and reclassified the associated royalty receivables from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, less allowance for doubtful accounts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our consolidated balance sheet; and</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_238" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">1</a><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">. </span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New Accounting Standards Adopted in 2024</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">In the fourth quarter of 2024, we adopted a new accounting standard which requires the disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, other segment items by reportable segment and a description of its composition. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Note 17A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Estimates and Assumptions</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of operations, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of operations. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation, development of competing assets by us or others, regulatory actions, or product recalls or withdrawals. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Acquisitions</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_268" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16D</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Any liability </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Fair Value</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Income approach, which is based on the present value of a future stream of net cash flows. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity securities with readily determinable fair values—quoted market prices and observable NAV prices.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Derivative assets and liabilities—third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Money market funds—observable NAV prices.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and we translate non-monetary items at historical rates.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">G. Revenues and Trade Accounts Receivable</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors’ locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In bill-and-hold arrangements which are part of the U.S. SNS, we recognize revenue for the product sale when the product is initially placed into the U.S. SNS and we provide a rotation service to maintain an agreed upon level of shelf life for product in the stockpile. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our Sales Contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns may occur due to patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these product revenue deductions on gross sales for a reporting period. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provisions for pharmaceutical sales returns––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following outlines our common sales arrangements:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––Our prescription biopharmaceutical products, with the exception of Paxlovid in 2022 and 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In 2022 and 2023, we principally sold Paxlovid globally to government agencies. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain products in our portfolio are subject to seasonality of demand and Paxlovid revenues trend with infection rates. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs in the U.S; and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented).</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales in prior periods to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” and as of December 31, 2024 in the initial coverage and catastrophic phases under the Manufacturer Discount Program based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap or from the manufacturer’s discount, respectively. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recorded revenues of more than $1 billion for each of 11 products in 2024, for each of nine products in 2023 and for each of ten products in 2022, and these revenues represented 66%, 64% and 82% of our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in 2024, 2023 and 2022, respectively. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_280" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:70.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reserve against </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,627</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,770 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,546 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">972</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">902 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">796 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,822</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,014 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During 2024 and 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">H. Collaborative Arrangements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments to and from our collaboration partners are presented in our consolidated statements of operations based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-commercialization agreements, we record the amounts received for our share of gross profits from our collaboration partners as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenues,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Royalty payments received from collaboration partners are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Royalty revenues.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reimbursements to or from our collaboration partners for development costs are typically recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">in-process</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> r</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">esearch and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—developed technology rights. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">over the development period for the products, when our performance obligations include providing R&amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">I. Cost of Sales and Inventories</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary. Inventories that are not expected to be sold within 12 months are classified as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_235" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 8A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">J. Selling, Informational and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, digital and legal defense. Advertising expenses totaled approximately $3.3 billion in 2024, $3.7 billion in 2023 and $2.8 billion in 2022. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.</span></div><div style="margin-top:7pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">K. Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;D efforts, as well as R&amp;D activities performed in connection with certain licensing arrangements.</span></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">L. Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing and collaboration arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets, less accumulated amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&amp;D.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">M. Long-Lived Assets</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets include:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Property, plant and equipment, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a </span></div><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Identifiable intangible assets, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—These assets are recorded at fair value at acquisition. Intangible assets with finite lives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of finite-lived acquired intangible assets is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For indefinite-lived intangible assets, such as brands and IPR&amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">N. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired company. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our business may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as our corporate enabling functions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">O. Cash Equivalents and Statement of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">P. Investments and Derivative Financial Instruments</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">until realized.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Held-to-maturity debt securities, which are carried at amortized cost.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus adjustments resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Realized gains or losses on sales of investments are determined by using the specific identification cost method.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, if and when a decline in fair value is determined, an impairment charge is recorded and a new cost basis in the investment is established. For equity-method investments, an impairment charge is recorded only if and when a decline in fair value is determined to be other-than-temporary.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative financial instruments are carried at fair value in certain balance sheet categories (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_214" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), with changes in fair value reported in net income or, for certain qualifying hedging relationships, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_229" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7E</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Q. Tax Assets and Liabilities and Income Tax Contingencies</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Tax Assets and Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Current tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of operations when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Global Intangible Low-Taxed Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as of December 31, 2024 and 2023 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5D</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for uncertain tax positions and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Contingencies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and are classified on our consolidated balance sheet with the related tax liability.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R. Pension and Postretirement Benefit Plans</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. Net periodic pension and postretirement benefit costs other than the service costs are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. We immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (mark-to-market accounting). Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">S. Legal and Environmental Contingencies</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial and other asserted or unasserted matters, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">T. Share-Based Payments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our compensation programs include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis or on an accelerated attribution approach over the vesting terms with the related costs recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate.</span></div> The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP. The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. All significant transactions among our subsidiaries have been eliminated. We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. 3 <div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and began presenting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Royalty revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as a separate line item within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our consolidated statements of operations, and reclassified the associated royalty receivables from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, less allowance for doubtful accounts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our consolidated balance sheet; and</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_238" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">1</a><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div> <span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New Accounting Standards Adopted in 2024</span><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">In the fourth quarter of 2024, we adopted a new accounting standard which requires the disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, other segment items by reportable segment and a description of its composition. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Note 17A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">.</span></div> Estimates and Assumptions<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of operations, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of operations. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation, development of competing assets by us or others, regulatory actions, or product recalls or withdrawals. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div> Acquisitions<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_268" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16D</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Any liability </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div> Fair Value<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Income approach, which is based on the present value of a future stream of net cash flows. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity securities with readily determinable fair values—quoted market prices and observable NAV prices.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Derivative assets and liabilities—third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Money market funds—observable NAV prices.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.</span></div> Foreign Currency Translation<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and we translate non-monetary items at historical rates.</span></div> <div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors’ locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In bill-and-hold arrangements which are part of the U.S. SNS, we recognize revenue for the product sale when the product is initially placed into the U.S. SNS and we provide a rotation service to maintain an agreed upon level of shelf life for product in the stockpile. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our Sales Contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns may occur due to patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these product revenue deductions on gross sales for a reporting period. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provisions for pharmaceutical sales returns––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as patent-based expirations or loss of regulatory exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following outlines our common sales arrangements:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––Our prescription biopharmaceutical products, with the exception of Paxlovid in 2022 and 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In 2022 and 2023, we principally sold Paxlovid globally to government agencies. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain products in our portfolio are subject to seasonality of demand and Paxlovid revenues trend with infection rates. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs in the U.S; and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented).</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales in prior periods to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” and as of December 31, 2024 in the initial coverage and catastrophic phases under the Manufacturer Discount Program based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap or from the manufacturer’s discount, respectively. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recorded revenues of more than $1 billion for each of 11 products in 2024, for each of nine products in 2023 and for each of ten products in 2022, and these revenues represented 66%, 64% and 82% of our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in 2024, 2023 and 2022, respectively. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_280" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div>Collaborative Arrangements<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments to and from our collaboration partners are presented in our consolidated statements of operations based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-commercialization agreements, we record the amounts received for our share of gross profits from our collaboration partners as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenues,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Royalty payments received from collaboration partners are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Royalty revenues.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reimbursements to or from our collaboration partners for development costs are typically recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">in-process</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> r</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">esearch and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—developed technology rights. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">over the development period for the products, when our performance obligations include providing R&amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.</span></div> 1000000000 1000000000 1000000000 0.66 0.64 0.82 <div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:70.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reserve against </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,627</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,770 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,546 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">972</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">902 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">796 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,822</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,014 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1627000000 1770000000 7195000000 5546000000 972000000 902000000 1029000000 796000000 10822000000 9014000000 <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During 2024 and 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.</span></div> Cost of Sales and Inventories<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary. Inventories that are not expected to be sold within 12 months are classified as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_235" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 8A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div> Selling, Informational and Administrative ExpensesSelling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, digital and legal defense. 3300000000 3700000000 2800000000 Research and Development Expenses<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;D efforts, as well as R&amp;D activities performed in connection with certain licensing arrangements.</span></div> Acquired In-Process Research and Development Expenses<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing and collaboration arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets, less accumulated amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&amp;D.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Property, plant and equipment, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a </span><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Identifiable intangible assets, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—These assets are recorded at fair value at acquisition. Intangible assets with finite lives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.</span><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of finite-lived acquired intangible assets is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For indefinite-lived intangible assets, such as brands and IPR&amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.</span></div> <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div> Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired company. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our business may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as our corporate enabling functions.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.</span></div> Investments and Derivative Financial Instruments<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">until realized.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Held-to-maturity debt securities, which are carried at amortized cost.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus adjustments resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Realized gains or losses on sales of investments are determined by using the specific identification cost method.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, if and when a decline in fair value is determined, an impairment charge is recorded and a new cost basis in the investment is established. For equity-method investments, an impairment charge is recorded only if and when a decline in fair value is determined to be other-than-temporary.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative financial instruments are carried at fair value in certain balance sheet categories (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_214" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), with changes in fair value reported in net income or, for certain qualifying hedging relationships, in </span>Other comprehensive income/(loss) Tax Assets and Liabilities and Income Tax Contingencies<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Tax Assets and Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Current tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of operations when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Global Intangible Low-Taxed Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as of December 31, 2024 and 2023 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5D</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for uncertain tax positions and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Contingencies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and are classified on our consolidated balance sheet with the related tax liability.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div> Pension and Postretirement Benefit Plans<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. Net periodic pension and postretirement benefit costs other than the service costs are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. We immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (mark-to-market accounting). Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value.</span></div> Legal and Environmental Contingencies<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial and other asserted or unasserted matters, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.</span></div> Share-Based Payments<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our compensation programs include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis or on an accelerated attribution approach over the vesting terms with the related costs recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate.</span></div> Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement<div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Acquisitions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Seagen––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December 14, 2023 (the acquisition date), we acquired Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash. The total fair value of the consideration transferred was $44.2 billion ($43.4 billion, net of cash acquired). In addition, in connection with the acquisition, $476 million in post-closing compensation expense for Seagen employee incentive awards was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_199" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Seagen’s principal business was the development, manufacture, marketing and distribution of targeted cancer therapeutics, primarily using ADC technology. Seagen’s portfolio includes four approved medicines as well as a pipeline of product candidates. Clinical development programs are ongoing for each of these approved medicines for potential new or expanded indications and for several product candidates. We believe our acquisition of Seagen will strengthen our oncology capabilities by allowing us to combine Seagen’s ADC technology with the resources and scale of the Pfizer enterprise and to advance more potential breakthroughs to patients with cancer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in 2024 to the amounts initially recorded in 2023 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.789%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.044%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts Recognized </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as of Acquisition Date</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(as previously reported as of December 31, 2023)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Measurement Period Adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts Recognized as of Acquisition Date (as adjusted) Final</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Working capital, excluding inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">736 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(115)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">621</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,273</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property, plant and equipment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">524 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identifiable intangible assets, excluding in-process research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,970 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,920</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In-process research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,900</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">174 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income tax accounts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,123)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(167)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,108 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">27,086</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,148</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net assets acquired/total consideration transferred</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44,234 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">44,234</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The changes in the estimated fair values are to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">As adjusted, comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As adjusted, comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As adjusted, included primarily in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $597 million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the ordinary course of business, Seagen may incur liabilities for environmental, legal and tax matters, as well as guarantees and indemnifications. These matters may include contingencies. Except as specifically excluded by the relevant accounting standard, contingencies are required to be measured at fair value as of the acquisition date if the acquisition-date fair value of the asset or liability arising from a contingency can be determined. If the acquisition-date fair value of the asset or liability cannot be determined, the asset or liability would be recognized at the acquisition date if both of the following criteria are met: (i) it is probable that an asset existed or that a liability had been incurred at the acquisition date, and (ii) the amount of the asset or liability can be reasonably estimated. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Environmental Matters</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—In the ordinary course of business, Seagen may incur liabilities for environmental matters such as remediation work, asset retirement obligations and environmental guarantees and indemnifications. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Legal Matters</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—Seagen is involved in various legal proceedings, including patent, intellectual property, and product liability matters of a nature considered normal to its business. The contingencies arising from legal matters are not significant to our consolidated financial statements.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Tax Matters</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—In the ordinary course of business, Seagen incurs liabilities for income taxes. Income taxes are exceptions to both the recognition and fair value measurement principles associated with the accounting for business combinations. Reserves for income tax contingencies continue to be measured under the benefit recognition model previously used by Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1Q</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Net liabilities for income taxes as of the acquisition date were $4.8 billion, including $48 million for uncertain tax positions. The net tax liability includes $6.3 billion for the tax impact of fair value adjustments, partially offset by $1.5 billion for deferred tax assets on which Seagen had recognized a valuation allowance.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of Seagen includes the following: </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the expected specific synergies and other benefits that we believe will result from combining the operations of Seagen with the operations of Pfizer; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any intangible assets that do not qualify for separate recognition, as well as future, as yet unidentified projects and products; and </span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the value of the going-concern element of Seagen’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately). </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Goodwill is not amortized and is not deductible for tax purposes. All of the goodwill related to the acquisition of Seagen is related to our Biopharma segment (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_241" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Actual and Pro Forma Impact of Acquisition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—The following table presents information for Seagen’s operations that are included in Pfizer’s consolidated statements of operations beginning from the acquisition date, December 14, 2023, through Pfizer’s year-end in 2023: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:74.125%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">132 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(746)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes restructuring, integration and acquisition-related costs ($614 million pre-tax) and purchase accounting charges related to (i) the fair value adjustment for acquisition-date inventory estimated to have been sold ($109 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Seagen ($25 million pre-tax); as well as (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Seagen ($2 million pre-tax).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:23.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #211d1e;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #211d1e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unaudited Supplemental Pro Forma Consolidated Results</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61,893 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">103,137 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,481)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27,870 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.26)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.86 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company’s results of operations would have been had the acquisition occurred on January 1, 2022, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma information reflected here due to many factors. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The unaudited supplemental pro forma financial information includes various assumptions, including those related to the purchase price allocation of the assets acquired and the liabilities assumed from Seagen. The historical U.S. GAAP financial information of Pfizer and Seagen was adjusted, primarily for the following pre-tax adjustments for the years ended December 31, 2023 and 2022:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Additional amortization expense of approximately $553 million and $576 million, respectively, related to the fair value of identifiable intangible assets acquired.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Additional expense related to the fair value adjustment to acquisition-date inventory estimated to have been sold of approximately $755 million and $934 million, respectively.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Additional estimated interest expense of approximately $984 million and $2.0 billion, respectively, related to the debt issued by Pfizer and the commercial paper borrowings to partially finance the acquisition.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Elimination of interest income of approximately $1.2 billion and $267 million, respectively, related to the debt issuance proceeds that were invested prior to the acquisition date and associated with money market funds under the assumption that a portion of these funds would have been liquidated to partially finance the acquisition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above adjustments were then adjusted for the applicable tax impact using an estimated weighted-average statutory tax rate applied to the applicable pro forma adjustments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The acquisition of Seagen had no impact on Pfizer’s weighted-average shares as no shares were issued.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">GBT––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, starting with sickle cell disease, for $68.50 per share in cash. The total fair value of the consideration transferred was $5.7 billion ($5.2 billion, net of cash acquired). In addition, $136 million in payments to GBT employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_199" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $4.4 billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, consisting of $3.0 billion of IPR&amp;D and $1.4 billion of developed technology rights with a useful life of six years, (ii) $1.1 billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iii) $644 million of inventories to be sold over approximately three years, (iv) $516 million of net deferred tax liabilities and (v) $331 million of assumed long-term debt that was paid in full in the fourth quarter of 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Biohaven––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy approved for both acute treatment of migraine and prevention of episodic migraine in adults. The transaction included the acquisition of Biohaven’s CGRP programs, including rimegepant, zavegepant and a portfolio of five pre-clinical CGRP assets. Under the terms of the agreement, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5 billion, plus repayment of third-party debt of $863 million and redemption of Biohaven’s redeemable preferred stock for $495 million. Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing Biohaven Ltd.’s shares to Biohaven shareholders. Biohaven Ltd. became a new publicly traded company that retained Biohaven’s non-CGRP development stage pipeline compounds. Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.’s shares in the distribution.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The total fair value of the consideration transferred was $11.8 billion, which includes the fair value of Pfizer’s previous investment in Biohaven on the acquisition date of approximately $300 million. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $12.1 billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, consisting of $11.6 billion of developed technology rights with a useful life of 11 years and $450 million of IPR&amp;D, (ii) $823 million of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, (iii) $813 million of inventories to be sold over approximately two years, (iv) $398 million of trade accounts receivable, (v) $1.4 billion of assumed long-term debt that was paid in full in the fourth quarter of 2022, (vi) $544 million of net deferred tax liabilities and (vii) $526 million of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Arena––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On March 11, 2022, we acquired Arena, a clinical stage company with development-stage therapeutic candidates in gastroenterology, dermatology and cardiology, for $100 per share in cash. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired). In addition, $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see <br/></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_199" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we recorded: (i) $5.5 billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, consisting of $5.0 billion of IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and $460 million of indefinite-lived licensing agreements and other, (ii) $1.0 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and (iii) $490 million of net deferred tax liabilities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ReViral––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On June 9, 2022, we acquired ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel antiviral therapeutics that target respiratory syncytial virus, for a total consideration of up to $536 million, including upfront payments of $436 million upon closing (including a base payment of $425 million plus working capital adjustments) and an additional $100 million contingent upon a future development milestone for a secondary pipeline asset. It was subsequently determined the applicable milestone was not achieved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition since the lead asset, sisunatovir, represented substantially all of the fair value of the gross assets acquired. At the acquisition date, we recorded a $426 million charge representing an acquired IPR&amp;D asset with no alternative use in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which is presented as a cash outflow from operating activities. Other assets acquired and liabilities assumed were not significant.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pro forma information for the aforementioned acquisitions (except for Seagen) has not been presented because these acquisitions were not material to our consolidated financial statements.</span></div>Divestitures<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Early-Stage Rare Disease Gene Therapy Portfolio–</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">–On September 19, 2023, we completed an agreement with Alexion, under which Alexion purchased and licensed the assets of our early-stage rare disease gene therapy portfolio. Under the terms of the agreement, Alexion will pay us total consideration of up to $1 billion, consisting of an upfront payment of $300 million which was paid at closing and future contingent milestone payments, plus tiered royalties based on annual net sales of the assets. In connection with the closing of the transaction, Pfizer recognized a $222 million pre-tax gain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Upjohn Separation and Combination with Mylan––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, Pfizer and Viatris entered into various agreements, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. The terms of the MSAs range in initial duration from <span style="-sec-ix-hidden:f-704">four</span> to seven years post-separation. Services under the TSAs were largely completed as of December 31, 2023. Amounts recorded under the above agreements in 2024, 2023 and 2022 were not material to our operations. Net amounts due to Viatris under the above agreements were $105 million as of December 31, 2024 and $33 million as of December 31, 2023. The cash flows associated with the above agreements are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by/(used in) operating activities.</span></div>Equity-Method Investments<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Haleon––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Haleon, is an independent, publicly traded company listed on the London Stock Exchange that holds the joint historical consumer healthcare business of GSK and Pfizer. We owned 32% of Haleon as of December 31, 2023. In March 2024, we sold approximately 30% of our investment in Haleon through the sale of 791 million ordinary shares in a global public offering, and the sale of 102 million ordinary shares directly to Haleon, for $3.5 billion. In October 2024, we sold approximately 34% of our remaining investment in Haleon through the sale of 640 million ordinary shares in a global public offering, and the sale of 61 million ordinary shares directly to Haleon, for $3.5 billion. We recognized total gains on these sales of our Haleon shares of $945 million during 2024 in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). After the October 2024 share sale, we owned approximately 15% of the outstanding voting shares of Haleon as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Through the third quarter of 2024, we accounted for our Haleon investment under the equity method and recorded our share of earnings from Haleon on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As Haleon is a foreign investee whose reporting currency is the U.K. pound, we translated its financial statements into U.S. dollars and recognized the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. With the reduction in our Haleon ownership percentage and board representation after the October 2024 sale, we no longer have the ability to exercise significant influence over the operating and financial policies of Haleon. As a result, we discontinued the application of the equity method to our Haleon investment, and began to account for the investment as an equity security with a readily determinable fair value, which is carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:73.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the change in the carrying value of our investment in Haleon:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning carrying value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11,451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,824 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Carrying value of shares sold</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(6,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividends</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation adjustments and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">293 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Basis difference adjustments and amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer share of Haleon investee capital transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer share of Haleon earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">224</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">489 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification of accumulated other comprehensive income balances in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer of carrying value to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ending carrying value</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,451 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_211" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Adjustments in 2024 include (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The 2024 activity primarily represent foreign currency translation balances in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> related to the equity-method investment in Haleon that were reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> upon our loss of significant influence over Haleon and our discontinuance of the equity method for the Haleon investment.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">The final carrying value of our equity-method investment in Haleon was reclassified to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and is being accounted for as an equity investment with a readily determinable fair value.</span></div><div style="margin-bottom:3pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summarized financial information for Haleon as of September 30, 2024, the most recent period available, and as of September 30, 2023 and for the periods ending September 30, 2024, 2023, and 2022 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,813</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,876 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">37,572</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,954 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">45,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">42,830 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,468</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,117 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15,511</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,862 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22,129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,719 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">249 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total net equity</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22,406</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,968 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the Twelve Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,252</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,921 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,566 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,580)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,081)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,596</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,341 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,486 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,668</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,745 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,668</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,745 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,600</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,528 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,675 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with GSK’s previously announced planned demerger of at least 80% of GSK’s 68% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $8.75 billion in U.S. dollar-denominated senior notes of various maturities, €2.35 billion in euro-denominated senior notes of various maturities and £700 million in U.K. pound-denominated senior notes of various maturities (collectively, the “notes”). The notes were guaranteed by GSK generally up to and excluding the date of the demerger (the “Guarantee Assumption Date”). We agreed to indemnify GSK for 32% (representing our pro rata equity interest in the Consumer Healthcare JV at that time) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity was provided solely for the benefit of GSK. Neither we, nor any of our subsidiaries, were an issuer or guarantor of any of the notes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Following its issuance of the notes in March 2022, which fell in our international second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of £2.9 billion ($3.7 billion as of the end of our second quarter of 2022), at an interest rate of 1.365% per annum payable semi-annually in arrears. In conjunction with the demerger, we received £3.5 billion ($4.2 billion) in dividends from the JV in July 2022, of which $4.0 billion related to a one-time pre-separation dividend, which decreased the carrying value of our investment and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by/(used in) investing activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Simultaneous with the receipt of the dividends, we repaid the £2.9 billion loan from the JV. GSK similarly received pro rata dividends and simultaneously repaid its pro rata loan from the JV. In conjunction with these transactions, our indemnification of GSK’s guarantee discussed above was terminated.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investment in ViiV––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately 11.7% of ViiV, and prior to 2016 we accounted for our investment under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to zero due to the recognition of cumulative equity-method losses and dividends, and therefore we no longer record our proportionate share of ViiV’s net income (loss) in our results of operations. Since 2016, we have recognized dividends from ViiV as income in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when earned, including dividends of $272 million in 2024, $265 million in 2023 and $314 million in 2022 (see <br/></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.968%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summarized financial information for our equity-method investee, ViiV, as of December 31, 2024 and 2023 and for the years ending December 31, 2024, 2023, and 2022 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,338</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,237 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,223</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,561</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,245 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,085 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,205</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,998 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,485</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,083 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total net equity/(deficit) attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,838)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,971</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,845 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,955 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,060)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(819)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,611</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,785 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,135 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,062</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,090 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,062</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,090 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,062</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,090 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,108 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Collaborative Arrangements<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product or vaccine.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Biohaven––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven and certain of its subsidiaries to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Under the terms of the agreement, Biohaven would lead R&amp;D globally and we would have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January 4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263 million for the upfront payment and premium paid on our equity investment in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In October 2022, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5 billion. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Summarized Financial Information for Collaborative Arrangements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">175</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">437 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,388</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,582 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Royalty revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">923</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">605 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">614 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total revenues from collaborative arrangements</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,400 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,588 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,901)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,277)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,589)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">219 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">272 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(339)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other income/(deductions)—net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents sales to our partners of products manufactured by us.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2024 was primarily driven by an increase in Alliance revenues from Eliquis and Xtandi, partially offset by a decrease in Alliance revenues from Bavencio. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily relates to royalties from our collaboration partners.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decreases in 2024 and in 2023 primarily relate to Comirnaty.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Represents net reimbursements from our partners for research and development expenses incurred.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Relates to exit costs associated with terminating a collaboration with SMPS.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The amounts outlined in the above table do not include transactions with third parties other than our collaboration partners, or other costs for the products under the collaborative arrangements.</span></div>Research and Development Arrangement<div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Funding Arrangement with Blackstone––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In April 2023, we entered into an arrangement with Blackstone under which we will receive up to a total of $550 million in 2023 through 2026 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">using an attribution model over the period of the related expenses. The reduction to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in 2024 and 2023 was $135 million and $175 million, </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">respectively. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $468 million contingent upon the successful results of the clinical trials. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> over the shorter of the term of the agreement or estimated commercial life of the product. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $550 million in total based on achievement of certain levels of cumulative applicable net sales, as well as royalties based on a mid-to-high single digit percentage of the applicable net sales. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> over the shorter of the term of the agreement or estimated commercial life of the product, and royalties on net sales will be recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when incurred.</span></div> 229 44200000000 43400000000 476000000 4 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in 2024 to the amounts initially recorded in 2023 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.789%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.044%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts Recognized </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as of Acquisition Date</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(as previously reported as of December 31, 2023)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Measurement Period Adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts Recognized as of Acquisition Date (as adjusted) Final</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Working capital, excluding inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">736 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(115)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">621</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,273</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property, plant and equipment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">524 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identifiable intangible assets, excluding in-process research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,970 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,920</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In-process research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,900</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">174 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income tax accounts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,123)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(167)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,108 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">27,086</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,148</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net assets acquired/total consideration transferred</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44,234 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">44,234</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The changes in the estimated fair values are to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">As adjusted, comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As adjusted, comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As adjusted, included primarily in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments.</span></div> 736000000 -115000000 621000000 4195000000 -922000000 3273000000 524000000 -243000000 280000000 7970000000 -50000000 7920000000 20800000000 -900000000 19900000000 174000000 -115000000 59000000 6123000000 1343000000 4779000000 167000000 20000000 187000000 28108000000 -1022000000 27086000000 16126000000 1022000000 17148000000 44234000000 0 44234000000 1100000000 2100000000 7500000000 P18Y 597000000 4800000000 48000000 6300000000 1500000000 The following table presents information for Seagen’s operations that are included in Pfizer’s consolidated statements of operations beginning from the acquisition date, December 14, 2023, through Pfizer’s year-end in 2023: <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:74.125%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">132 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(746)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes restructuring, integration and acquisition-related costs ($614 million pre-tax) and purchase accounting charges related to (i) the fair value adjustment for acquisition-date inventory estimated to have been sold ($109 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Seagen ($25 million pre-tax); as well as (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Seagen ($2 million pre-tax).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:23.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #211d1e;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #211d1e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unaudited Supplemental Pro Forma Consolidated Results</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61,893 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">103,137 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,481)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27,870 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.26)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.86 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 132000000 -746000000 614000000 109000000 25000000 2000000 61893000000 103137000000 -1481000000 27870000000 -0.26 4.86 -553000000 -576000000 -755000000 -934000000 -984000000 -2000000000.0 -1200000000 -267000000 0 68.50 5700000000 5200000000 136000000 4400000000 3000000000.0 1400000000 P6Y 1100000000 644000000 P3Y 516000000 331000000 148.50 11500000000 863000000 495000000 11800000000 300000000 12100000000 11600000000 P11Y 450000000 823000000 813000000 P2Y 398000000 1400000000 544000000 526000000 100 6600000000 6200000000 138000000 5500000000 5000000000.0 460000000 1000000000.0 490000000 536000000 436000000 425000000 100000000 426000000 1000000000 300000000 222000000 P7Y 105000000 33000000 0.32 0.30 791000000 102000000 3500000000 0.34 640000000 61000000 3500000000 945000000 0.15 <div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:73.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table summarizes the change in the carrying value of our investment in Haleon:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning carrying value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11,451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,824 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Carrying value of shares sold</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(6,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividends</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation adjustments and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">293 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Basis difference adjustments and amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer share of Haleon investee capital transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer share of Haleon earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">224</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">489 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification of accumulated other comprehensive income balances in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer of carrying value to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ending carrying value</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,451 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_211" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Adjustments in 2024 include (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The 2024 activity primarily represent foreign currency translation balances in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> related to the equity-method investment in Haleon that were reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> upon our loss of significant influence over Haleon and our discontinuance of the equity method for the Haleon investment.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">The final carrying value of our equity-method investment in Haleon was reclassified to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and is being accounted for as an equity investment with a readily determinable fair value.</span></div><div style="margin-bottom:3pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summarized financial information for Haleon as of September 30, 2024, the most recent period available, and as of September 30, 2023 and for the periods ending September 30, 2024, 2023, and 2022 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,813</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,876 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">37,572</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,954 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">45,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">42,830 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,468</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,117 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15,511</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,862 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22,129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,719 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">249 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total net equity</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22,406</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,968 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the Twelve Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,252</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,921 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,566 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,580)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,081)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,596</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,341 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,486 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,668</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,745 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,668</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,745 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,600</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,528 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,675 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.968%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summarized financial information for our equity-method investee, ViiV, as of December 31, 2024 and 2023 and for the years ending December 31, 2024, 2023, and 2022 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,338</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,237 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,223</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,561</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,245 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,085 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,205</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,998 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,485</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,083 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total net equity/(deficit) attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,838)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,971</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,845 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,955 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,060)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(819)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,611</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,785 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,135 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,062</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,090 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,062</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,090 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,062</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,090 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,108 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11451000000 10824000000 6113000000 0 212000000 153000000 341000000 293000000 -91000000 -2000000 -44000000 0 224000000 489000000 -143000000 0 -5411000000 0 0 11451000000 -91000000 46000000 0.32 0.23 7813000000 5876000000 37572000000 36954000000 45385000000 42830000000 7468000000 6117000000 15511000000 15744000000 22979000000 21862000000 22129000000 20719000000 277000000 249000000 22406000000 20968000000 14252000000 13921000000 13566000000 5656000000 5580000000 5081000000 8596000000 8341000000 8486000000 1668000000 1606000000 1745000000 1668000000 1606000000 1745000000 1600000000 1528000000 1675000000 0.80 0.68 8750000000 2350000000 700000000 0.32 2900000000 3700000000 0.01365 3500000000 4200000000 4000000000 2900000000 0.117 0 272000000 265000000 314000000 4338000000 4237000000 3223000000 3009000000 7561000000 7245000000 4280000000 4085000000 6205000000 5998000000 10485000000 10083000000 -2924000000 -2838000000 8971000000 7845000000 6955000000 1360000000 1060000000 819000000 7611000000 6785000000 6135000000 3062000000 3090000000 3108000000 3062000000 3090000000 3108000000 3062000000 3090000000 3108000000 500000000 150000000 350000000 263000000 148.50 11500000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">175</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">437 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,388</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,582 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Royalty revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">923</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">605 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">614 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total revenues from collaborative arrangements</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,400 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,588 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,901)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,277)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,589)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">219 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">272 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(339)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other income/(deductions)—net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents sales to our partners of products manufactured by us.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2024 was primarily driven by an increase in Alliance revenues from Eliquis and Xtandi, partially offset by a decrease in Alliance revenues from Bavencio. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily relates to royalties from our collaboration partners.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decreases in 2024 and in 2023 primarily relate to Comirnaty.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Represents net reimbursements from our partners for research and development expenses incurred.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Relates to exit costs associated with terminating a collaboration with SMPS.</span></div> 175000000 212000000 437000000 8388000000 7582000000 8537000000 923000000 605000000 614000000 9486000000 8400000000 9588000000 2901000000 4277000000 15589000000 335000000 267000000 196000000 -282000000 -219000000 -272000000 2000000 -13000000 -339000000 45000000 0 0 -15000000 25000000 50000000 550000000 135000000 175000000 468000000 550000000 <span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Realigning our Cost Base Program</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this multi-year effort to continue primarily through 2025 and to total approximately $2.9 billion, primarily representing cash expenditures for severance, exit and implementation costs as well as asset write downs of which $2.2 billion is associated with our Biopharma segment. From the start of this program through December 31, 2024, we incurred costs under this program of $2.6 billion, of which $2.1 billion is associated with our Biopharma segment (including $2.0 billion of restructuring charges). </span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Manufacturing Optimization Program</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $1.6 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. These costs were recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026. From the start of this program through December 31, 2024, we incurred costs under this program of $1.2 billion, substantially all of which is restructuring costs for our Biopharma segment.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Key Activities</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,152</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,622 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">776 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exit costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">403</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,968 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">882 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transaction costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Integration costs and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">427</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">785 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">348 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,943 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,375 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional depreciation––asset restructuring</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">recorded in our consolidated statements of operations as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total additional depreciation––asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Implementation costs recorded in our consolidated statements of operations as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">289 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">560 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">84</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">457 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">616 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,738</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,426 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,018 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents external costs for banking, legal, accounting and other similar services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2023 costs mostly relate to our acquisition of Seagen, including $476 million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of 2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our acquisitions of Arena and GBT, including $138 million in payments to Arena employees in the first quarter of 2022 and $136 million in payments to GBT employees in the fourth quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:52.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, January 1, 2023 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,196 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,204 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,622 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,968 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(840)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(227)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(116)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,184)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,978 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,988 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,152</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">403</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance, December 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,046</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.3 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($663 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($1.7 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($437 million).</span></div> 2900000000 2200000000 2600000000 2100000000 2000000000.0 1600000000 1200000000 <div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,152</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,622 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">776 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exit costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">403</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,968 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">882 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transaction costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Integration costs and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">427</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">785 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">348 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,943 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,375 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional depreciation––asset restructuring</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">recorded in our consolidated statements of operations as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total additional depreciation––asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Implementation costs recorded in our consolidated statements of operations as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">289 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">560 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">84</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">457 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">616 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,738</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,426 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,018 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents external costs for banking, legal, accounting and other similar services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2023 costs mostly relate to our acquisition of Seagen, including $476 million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of 2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our acquisitions of Arena and GBT, including $138 million in payments to Arena employees in the first quarter of 2022 and $136 million in payments to GBT employees in the fourth quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div> 1152000000 1622000000 776000000 432000000 227000000 52000000 403000000 119000000 54000000 1987000000 1968000000 882000000 5000000 190000000 144000000 427000000 785000000 348000000 2419000000 2943000000 1375000000 7000000 -7000000 -9000000 14000000 31000000 34000000 5000000 1000000 2000000 19000000 32000000 36000000 120000000 67000000 54000000 90000000 289000000 560000000 84000000 101000000 2000000 294000000 457000000 616000000 2738000000 3426000000 2018000000 1800000000 1200000000 571000000 1500000000 1400000000 3000000 796000000 601000000 476000000 138000000 136000000 <div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:52.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, January 1, 2023 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,196 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,204 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,622 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,968 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(840)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(227)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(116)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,184)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,978 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,988 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,152</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">403</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance, December 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,046</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.3 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($663 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($1.7 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($437 million).</span></div> 1196000000 0 8000000 1204000000 1622000000 227000000 119000000 1968000000 840000000 227000000 116000000 1184000000 1978000000 0 11000000 1988000000 1152000000 432000000 403000000 1987000000 1083000000 432000000 341000000 1856000000 2046000000 0 74000000 2120000000 1300000000 663000000 1700000000 437000000 Other (Income)/Deductions—Net<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:63.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(545)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,624)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(251)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,091</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,209 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,238 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net interest expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">585 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">987 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,590)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,273 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(154)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(188)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net periodic benefit costs/(credits) other than service costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(610)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(849)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain legal matters, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">567</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">474 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,295</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Haleon equity method (income)/loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(505)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(436)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,002)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(378)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,388</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">222 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,062 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Capitalized interest totaled $182 million in 2024, $160 million in 2023 and $124 million in 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in net interest expense in 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $8 billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2024 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amount for 2024 represents intangible asset impairment charges, and includes $2.9 billion recorded in the fourth quarter associated with our Biopharma segment, due to changes in development plans and updated long-range commercial forecasts, composed of: (i) $1.0 billion for B7H4V (felmetatug vedotin), a Phase 1 IPR&amp;D asset, (ii) $475 million for Medrol, a finite-lived brand, (iii) $435 million for Zavzpret nasal spray developed technology rights, (iv) $400 million and $200 million for Tukysa and disitamab vedotin, respectively, IPR&amp;D assets reflecting emerging competition, as well as (v) other developed technology rights, IPR&amp;D impairments and a finite-lived licensing agreement totaling $436 million which also includes de-prioritization of certain assets. 2024 also includes a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&amp;D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The amount for 2023 primarily represented intangible asset impairment charges of $3.0 billion, of which $2.9 billion was associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: (i) $1.4 billion for etrasimod (Velsipity) IPR&amp;D, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 developed technology rights due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) $486 million for various other IPR&amp;D assets and developed technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also included $128 million associated with Other business activities, related to IPR&amp;D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset impairment charges associated with our Biopharma segment of $200 million for an IPR&amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amount for 2024 primarily includes, among other things, (i) gains of $945 million on the partial sales of our investment in Haleon in March and October 2024, (ii) dividend income of $272 million from our investment in ViiV and (iii) a charge of $420 million recorded in the third quarter related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023 included, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included, among other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the fair value of contingent consideration.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:38.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional information about the intangible assets that were impaired during 2024 follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,900</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,900</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,873</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">524</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">524</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">943</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finite-lived brand</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">270</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">270</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">475</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finite-lived licensing agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,694</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,694</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,295</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The fair value amounts are presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1E</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:63.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(545)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,624)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(251)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,091</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,209 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,238 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net interest expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">585 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">987 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,590)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,273 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(154)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(188)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net periodic benefit costs/(credits) other than service costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(610)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(849)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain legal matters, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">567</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">474 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,295</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Haleon equity method (income)/loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(505)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(436)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,002)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(378)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,388</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">222 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,062 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Capitalized interest totaled $182 million in 2024, $160 million in 2023 and $124 million in 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in net interest expense in 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $8 billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2024 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amount for 2024 represents intangible asset impairment charges, and includes $2.9 billion recorded in the fourth quarter associated with our Biopharma segment, due to changes in development plans and updated long-range commercial forecasts, composed of: (i) $1.0 billion for B7H4V (felmetatug vedotin), a Phase 1 IPR&amp;D asset, (ii) $475 million for Medrol, a finite-lived brand, (iii) $435 million for Zavzpret nasal spray developed technology rights, (iv) $400 million and $200 million for Tukysa and disitamab vedotin, respectively, IPR&amp;D assets reflecting emerging competition, as well as (v) other developed technology rights, IPR&amp;D impairments and a finite-lived licensing agreement totaling $436 million which also includes de-prioritization of certain assets. 2024 also includes a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&amp;D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The amount for 2023 primarily represented intangible asset impairment charges of $3.0 billion, of which $2.9 billion was associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: (i) $1.4 billion for etrasimod (Velsipity) IPR&amp;D, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 developed technology rights due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) $486 million for various other IPR&amp;D assets and developed technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also included $128 million associated with Other business activities, related to IPR&amp;D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset impairment charges associated with our Biopharma segment of $200 million for an IPR&amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amount for 2024 primarily includes, among other things, (i) gains of $945 million on the partial sales of our investment in Haleon in March and October 2024, (ii) dividend income of $272 million from our investment in ViiV and (iii) a charge of $420 million recorded in the third quarter related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023 included, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included, among other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the fair value of contingent consideration.</span></div> 545000000 1624000000 251000000 3091000000 2209000000 1238000000 -2546000000 -585000000 -987000000 1008000000 1590000000 -1273000000 42000000 154000000 188000000 154000000 -610000000 -849000000 -567000000 -474000000 -230000000 3295000000 3024000000 421000000 102000000 505000000 436000000 1022000000 1002000000 378000000 -4388000000 -222000000 -1062000000 182000000 160000000 124000000 43400000000 31000000000 8000000000 1000000000 1700000000 297000000 -292000000 -986000000 2900000000 1000000000.0 475000000 435000000 400000000 200000000 436000000 240000000 3000000000.0 2900000000 2800000000 1400000000 964000000 486000000 128000000 200000000 171000000 50000000 945000000 272000000 -420000000 265000000 211000000 222000000 314000000 142000000 77000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:38.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional information about the intangible assets that were impaired during 2024 follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,900</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,900</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,873</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">524</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">524</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">943</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finite-lived brand</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">270</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">270</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">475</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finite-lived licensing agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,694</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,694</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,295</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The fair value amounts are presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1E</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div> 4900000000 0 0 4900000000 1873000000 524000000 0 0 524000000 943000000 270000000 0 0 270000000 475000000 0 0 0 0 5000000 5694000000 0 0 5694000000 3295000000 Tax Matters<div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:67.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(637)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,411)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,032 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,660</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,469 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29,697 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,058 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,729 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2024 v. 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and asset impairment charges.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2023 v. 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, partially offset by a decrease in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and net gains on equity securities in 2023 versus net losses on equity securities in 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> based on the location of the taxing authorities include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current income taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,321 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,271)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(184)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(310)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total U.S. tax provision/(benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,717)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,605)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(857)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,368 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(652)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(183)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total international tax provision/(benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,689</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">490 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,185 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,115)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,328 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The changes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> impacting the effective tax rate year-over-year are summarized below:</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 v. 2023</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The tax benefit of $28 million for 2024 compared to the tax benefit of $1.1 billion for 2023 was primarily a result of changes in the jurisdictional mix of earnings partially offset by a tax benefit related to the Transition Tax liability under the TCJA.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2023 v. 2022</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The tax benefit of $1.1 billion for 2023 compared to the tax provision of $3.3 billion for 2022 was primarily a result of changes in the jurisdictional mix of earnings and the resolution of uncertain tax positions in various markets. The 2023 pre-tax income included a greater percentage of expenses taxed at higher rates as compared to the 2022 pre-tax income, resulting in a 2023 tax benefit compared to the 2022 tax provision. These expenses included amortization expense, acquisition-related costs, restructuring charges and intangible asset impairment charges. The tax benefit for 2023 and the tax provision for 2022 included tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years. The tax provision for 2022 also included the closing of U.S. IRS audits covering five tax years.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> all </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The sixth annual installment was paid by its April 15, 2024 due date. The seventh annual installment is due April 15, 2025 and is reported in current </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as of December 31, 2024. The remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"><tr><td style="width:1.0%"></td><td style="width:59.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for income taxes, net of refunds, consisted of:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,593</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,923 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,867 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,012</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,224 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,147 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,867 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Rate Reconciliation</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The reconciliation of the U.S. statutory income tax rate to our effective tax rate for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">^</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. statutory income tax rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21.0 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21.0 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Taxation of non-U.S. operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(21.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transition Tax liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax settlements and resolution of certain tax positions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(40.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign-Derived Intangible Income deduction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(33.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State &amp; local taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(22.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Charitable contributions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. R&amp;D tax credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Effective tax rate for income from continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(105.4)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.6 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">^</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> The higher rate percentages for the 2023 reconciling items are significantly impacted by the lower domestic and international </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for the components of pre-tax income and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We have Puerto Rican tax incentives pursuant to a grant that expires during 2053. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we have incentive tax rates effective through 2048 on income from manufacturing and other operations.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The higher rate benefit from the Foreign-Derived Intangible Income deduction in 2022 is mainly the result of the TCJA requirement to capitalize R&amp;D costs for tax years beginning after December 31, 2021.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes the impact of U.S. state and local taxes and changes in the state valuation allowances including those related to the acquisition of Seagen.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Includes changes in interest related to our uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”.</span></div><div style="margin-bottom:5pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">All other, net is primarily due to routine business operations.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Deferred Taxes</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:50.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Deferred Tax^</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023 Deferred Tax^</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Liabilities)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid/deferred items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,988</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(847)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,658 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(654)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued/deferred royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,306</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,655 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">300</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">471 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">992</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,210 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,060)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,435</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,526 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11,605)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">168 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,039)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee benefits</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,085 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructurings and other charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Legal and product liability reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">378</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,635</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net operating loss/tax credit carryforwards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,708 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unremitted earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State and local tax adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">161</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(395)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(13,023)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19,037 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(16,172)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Valuation allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,738)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,474</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(13,023)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,299 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(16,172)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net deferred tax asset/(liability)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g), (h)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,128 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">^</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1Q</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in net deferred tax assets in 2024 is primarily related to temporary differences associated with the timing of accruals recorded in the ordinary course of business.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in net deferred tax assets in 2024 is primarily due to measurement period adjustments of inventories related to Seagen. See</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </a><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </a><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease in net deferred tax liabilities in 2024 is primarily due to amortization of intangible assets and certain impairment charges, as well as the measurement period adjustments of intangible assets related to Seagen.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease in net deferred tax assets in 2024 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_244" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in deferred tax assets in 2024 is primarily related to the TCJA requirement to capitalize R&amp;D costs for tax years beginning after December 31, 2021.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">The amounts in 2024 and 2023 are reduced for unrecognized tax benefits of $575 million and $1.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($6.6 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.1 billion). In 2023, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.8 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($640 million).</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.3 billion and $11.1 billion for 2024 and 2023 respectively, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have carryforwards, primarily related to net operating and capital losses, general business credits, foreign tax credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2025 to 2044. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section 382.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2024, we have not made a U.S. tax provision on $58.0 billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2024 is not practicable. The amount of indefinitely reinvested earnings is based on estimates and assumptions and subject to management evaluation, and is subject to change in the normal course of business based on operational cash flow, completion of local statutory financial statements and the finalization of tax returns and audits, among other things. Accordingly, we regularly update our earnings and profits analysis for such events.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Tax Contingencies</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our accounting policies associated with accounting for income tax contingencies, see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1Q</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Uncertain Tax Positions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2024, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$2.0 billion and as of December 31, 2023, we had $3.1 billion in net unrecognized tax benefits, excluding associated interest.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Tax assets for uncertain tax positions represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. In 2024, tax assets for uncertain tax positions also include the expected filing of an amended income tax return relating to the Transition Tax liability under the TCJA. As of December 31, 2024, we had $2.5 billion in assets associated with uncertain tax positions mainly included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As of December 31, 2023, we had $1.7 billion in assets associated with uncertain tax positions mainly included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">The majority of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. </span></div><div style="margin-top:5pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"><tr><td style="width:1.0%"></td><td style="width:65.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,802)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,494)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,068)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(67)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Decreases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">599</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Decreases based on settlements for a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c), (d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">911</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increases based on tax positions taken during the current period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(515)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">122 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,530)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,802)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,494)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, the amount includes a gross unrecognized tax benefit associated with the expected filing of an amended income tax return related to the Transition Tax liability under the TCJA.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not</a><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">e 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily related to cash payments and reductions of tax attributes.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In 2024, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($103 million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.4 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.5 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.9 billion). In 2023, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($94 million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.3 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($4 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.4 billion).</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In 2024, we recorded a net increase in interest of $91 million. In 2023, we recorded a net increase in interest of $64 million. In 2022, we recorded a net decrease in interest of $17 million. Gross accrued interest totaled $636 million as of December 31, 2024 (reflecting a decrease of $56 million as a result of cash payments) and gross accrued interest totaled $605 million as of December 31, 2023 (reflecting a decrease of $11 million as a result of cash payments). In 2024 and 2023, these amounts were substantially all included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued penalties are not significant. See also </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Status of Tax Matters and Potential Impact on Accruals for Uncertain Tax Positions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. During the third quarter of 2024, we effectively settled the audit of Pfizer’s federal income tax returns for years 2016-2018. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax years 2019-2024 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions such as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Canada (2017-2024), Europe (2012-2024, primarily in Ireland, the U.K., France, Italy, Spain and Germany), Asia Pacific (2014-2024, primarily in Australia, China, Japan and Singapore) and Latin America (1998-2024, primarily in Brazil).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $200 million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:68.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Tax provision/(benefit) on other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">156</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(33)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(126)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">67</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(87)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(19)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(164)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">226 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(14)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(33)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">62 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit plans: prior service (costs)/credits and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(37)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(37)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">231</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(85)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(187)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.</span></div> <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:67.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(637)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,411)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,032 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,660</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,469 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29,697 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,058 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,729 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2024 v. 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and asset impairment charges.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2023 v. 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, partially offset by a decrease in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and net gains on equity securities in 2023 versus net losses on equity securities in 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> -637000000 -4411000000 5032000000 8660000000 5469000000 29697000000 8023000000 1058000000 34729000000 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> based on the location of the taxing authorities include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current income taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,321 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,271)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(184)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(310)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total U.S. tax provision/(benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,717)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,605)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(857)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,368 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(652)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(183)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total international tax provision/(benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,689</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">490 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,185 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,115)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,328 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 453000000 1321000000 2744000000 32000000 -135000000 -20000000 -1909000000 -2606000000 -3271000000 -293000000 -184000000 -310000000 -1717000000 -1605000000 -857000000 1588000000 1142000000 4368000000 100000000 -652000000 -183000000 1689000000 490000000 4185000000 -28000000 -1115000000 3328000000 -28000000 -1100000000 -1100000000 3300000000 15000000000 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"><tr><td style="width:1.0%"></td><td style="width:59.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for income taxes, net of refunds, consisted of:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,593</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,923 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,867 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,012</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,224 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,147 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,867 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2593000000 1923000000 3867000000 1012000000 1224000000 4000000000 3605000000 3147000000 7867000000 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The reconciliation of the U.S. statutory income tax rate to our effective tax rate for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">^</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. statutory income tax rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21.0 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21.0 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Taxation of non-U.S. operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(21.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transition Tax liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax settlements and resolution of certain tax positions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(40.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign-Derived Intangible Income deduction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(33.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State &amp; local taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(22.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Charitable contributions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. R&amp;D tax credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Effective tax rate for income from continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(105.4)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.6 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">^</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> The higher rate percentages for the 2023 reconciling items are significantly impacted by the lower domestic and international </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for the components of pre-tax income and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We have Puerto Rican tax incentives pursuant to a grant that expires during 2053. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we have incentive tax rates effective through 2048 on income from manufacturing and other operations.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The higher rate benefit from the Foreign-Derived Intangible Income deduction in 2022 is mainly the result of the TCJA requirement to capitalize R&amp;D costs for tax years beginning after December 31, 2021.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes the impact of U.S. state and local taxes and changes in the state valuation allowances including those related to the acquisition of Seagen.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Includes changes in interest related to our uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”.</span></div><div style="margin-bottom:5pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">All other, net is primarily due to routine business operations.</span></div> 0.210 0.210 0.210 -0.079 -0.211 -0.050 0.060 0 0 -0.024 -0.403 -0.030 0.012 0.331 0.019 -0.025 -0.224 0 0.017 0.073 0.005 0.018 0.158 0.006 0.022 0.135 0.002 0.001 0.002 -0.006 -0.004 -1.054 0.096 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:50.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Deferred Tax^</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023 Deferred Tax^</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Liabilities)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid/deferred items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,988</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(847)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,658 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(654)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued/deferred royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,306</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,655 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">300</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">471 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">992</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,210 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,060)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,435</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,526 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11,605)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">168 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,039)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee benefits</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,085 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructurings and other charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Legal and product liability reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">378</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,635</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net operating loss/tax credit carryforwards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,708 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unremitted earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State and local tax adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">161</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(395)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(13,023)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19,037 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(16,172)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Valuation allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,738)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,474</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(13,023)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,299 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(16,172)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net deferred tax asset/(liability)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g), (h)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,128 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">^</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1Q</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in net deferred tax assets in 2024 is primarily related to temporary differences associated with the timing of accruals recorded in the ordinary course of business.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in net deferred tax assets in 2024 is primarily due to measurement period adjustments of inventories related to Seagen. See</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </a><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </a><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease in net deferred tax liabilities in 2024 is primarily due to amortization of intangible assets and certain impairment charges, as well as the measurement period adjustments of intangible assets related to Seagen.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease in net deferred tax assets in 2024 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_244" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in deferred tax assets in 2024 is primarily related to the TCJA requirement to capitalize R&amp;D costs for tax years beginning after December 31, 2021.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">The amounts in 2024 and 2023 are reduced for unrecognized tax benefits of $575 million and $1.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($6.6 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.1 billion). In 2023, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.8 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($640 million).</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.3 billion and $11.1 billion for 2024 and 2023 respectively, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.</span></div> 2988000000 847000000 2658000000 654000000 1306000000 1655000000 300000000 471000000 992000000 702000000 1210000000 1060000000 1435000000 9066000000 1526000000 11605000000 265000000 1751000000 168000000 2039000000 1002000000 274000000 1085000000 287000000 462000000 537000000 378000000 430000000 7635000000 6275000000 2028000000 2708000000 69000000 60000000 161000000 119000000 73000000 248000000 133000000 395000000 87000000 66000000 62000000 72000000 19112000000 13023000000 19037000000 16172000000 1638000000 1738000000 17474000000 13023000000 17299000000 16172000000 4451000000 1128000000 575000000 1300000000 6600000000 2100000000 1800000000 640000000 11300000000 11100000000 58000000000.0 2000000000.0 3100000000 2500000000 1700000000 <div style="margin-top:5pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"><tr><td style="width:1.0%"></td><td style="width:65.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,802)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,494)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,068)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(67)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Decreases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">599</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Decreases based on settlements for a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c), (d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">911</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increases based on tax positions taken during the current period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(515)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">122 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,530)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,802)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,494)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, the amount includes a gross unrecognized tax benefit associated with the expected filing of an amended income tax return related to the Transition Tax liability under the TCJA.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not</a><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">e 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily related to cash payments and reductions of tax attributes.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In 2024, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($103 million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.4 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.5 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.9 billion). In 2023, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($94 million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.3 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($4 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.4 billion).</span></div> 4802000000 4494000000 6068000000 -8000000 46000000 52000000 934000000 158000000 67000000 599000000 310000000 1339000000 911000000 85000000 842000000 433000000 515000000 701000000 -52000000 44000000 -90000000 -70000000 -58000000 -122000000 4530000000 4802000000 4494000000 103000000 400000 1500000000 3000000 2900000000 94000000 1000000 1300000000 4000000 3400000000 91000000 64000000 -17000000 636000000 -56000000 605000000 -11000000 200000000 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:68.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Tax provision/(benefit) on other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">156</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(33)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(126)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">67</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(87)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(19)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(164)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">226 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(14)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(33)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">62 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit plans: prior service (costs)/credits and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(37)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(37)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">231</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(85)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(187)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.</span></div> 156000000 -33000000 -126000000 96000000 111000000 183000000 29000000 93000000 270000000 67000000 18000000 -87000000 -19000000 -15000000 -164000000 -5000000 18000000 -226000000 -14000000 -33000000 62000000 -45000000 5000000 5000000 -26000000 -28000000 -29000000 2000000 -4000000 -3000000 -22000000 37000000 37000000 231000000 -85000000 -187000000 Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:34.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Foreign Currency Translation Adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prior Service (Costs)/Credits and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance, January 1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(6,172)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">119 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(220)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">377 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(5,897)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,188)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(531)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(129)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,407)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(8,360)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(412)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">220 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">248 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(8,304)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(229)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">343 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(7,863)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(217)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(9)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">128 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(7,961)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">274</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">118</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Balance, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(7,984)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(106)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(7,842)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program and gains/(losses) related to our investment in Haleon (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">).</span></div> <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:34.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Foreign Currency Translation Adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prior Service (Costs)/Credits and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance, January 1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(6,172)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">119 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(220)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">377 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(5,897)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,188)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(531)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(129)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,407)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(8,360)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(412)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">220 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">248 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(8,304)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(229)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">343 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(7,863)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(217)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(9)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">128 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(7,961)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">274</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">118</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Balance, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(7,984)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(106)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(7,842)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program and gains/(losses) related to our investment in Haleon (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">).</span></div> -6172000000 119000000 -220000000 377000000 -5897000000 -2188000000 -531000000 440000000 -129000000 -2407000000 -8360000000 -412000000 220000000 248000000 -8304000000 497000000 195000000 -229000000 -120000000 343000000 -7863000000 -217000000 -9000000 128000000 -7961000000 -121000000 274000000 -97000000 63000000 118000000 -7984000000 57000000 -106000000 191000000 -7842000000 Financial Instruments<div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,848</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,392</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government and agency—non-U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government and agency—U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">982 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">982 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,400 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,400 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,273</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,524 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,524 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">298 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">298 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">298 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">298 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,779 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,772 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government and agency—non-U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,929 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,772 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">156 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">258 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">258 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">460</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">460</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">402 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">402 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Insurance contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">875</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">875</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">790 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">790 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,191 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,191 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1463"><span style="-sec-ix-hidden:f-1464">Total assets</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,665</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,943 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,772 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,170 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">404 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">404 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">245</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">245</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">420 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">420 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">723</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">723</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,121</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,121</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,000 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,000 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1507"><span style="-sec-ix-hidden:f-1508">Total liabilities</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,420 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,420 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes money market funds. As of December 31, 2024, short-term equity securities include our investment in Haleon of $6.5 billion. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Long-term equity securities of $133 million as of December 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The carrying value of Long-term debt, excluding the current portion was $57 billion as of December 31, 2024 and $62 billion as of December 31, 2023. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $54 billion as of December 31, 2024 and $61 billion as of December 31, 2023.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2024 and 2023. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total Short-Term, Long-Term and Equity-Method Investments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,848</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">705</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,434</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,837 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,779 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private equity securities at cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">755 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Total Long-term investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,010</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,731 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,637 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,228</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,368 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">184</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">207 </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As of December 31, 2024, our investment in Haleon is reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and as of December 31, 2023 was reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represent investments in the life sciences sector.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:21.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Over 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,970</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">953 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">941 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,179</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,006 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,007 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(129)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,814</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,770</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,126 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(16)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,115 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,008)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,590)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,273 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,754)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">165 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,400 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $360 million and upward adjustments of $222 million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial paper, principal amount</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,965 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">252 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,957</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,467 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,946</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">as of December 31, 2024 and 5.37% as of December 31, 2023. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes cash collateral. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_232" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7F</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div>As of December 31, 2024, we had access to a total of $15 billion in committed U.S. revolving credit facilities, consisting of an $8 billion facility maturing in October 2025 (subsequently terminated by Pfizer in February 2025), and a $7 billion facility maturing in October 2029, which may be used for general corporate purposes including to support our global commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional $276 million in lines of credit, of which $243 million expire within one year. Essentially all lines of credit were unused as of December 31, 2024.<div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following outlines our senior unsecured long-term debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the weighted-average stated interest rate by maturity:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2025 (3.9% for 2023)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,750 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2026 (3.7% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2027 (2.2% for 2024 and 2.1% for 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,029 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2028 (4.6% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,660</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,660 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2029 (3.5% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2030 (3.6% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2031-2035 (4.5% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2036-2040 (5.4% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,534</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,543 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2041-2045 (4.3% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,474</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2046-2050 (3.7% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2051-2063 (5.3% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">57,147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60,982 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,039 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(483)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">57,405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61,538 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023))</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,747</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,254 </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified to the current portion of long-term debt.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Issuance—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In May 2023, we issued, through our wholly-owned finance subsidiary, PIE, $31 billion principal amount of senior unsecured notes at an effective interest rate of 4.93% as part of the financing for our acquisition of Seagen. The notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc. PIE was formed to finance a portion of the consideration for the acquisition of Seagen and has no assets or operations, and will have no assets or operations, other than as related to the issuance, administration and repayment of the notes and any other debt securities that it may issue in the future.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Risk––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Chinese renminbi, Japanese yen, Canadian dollar and Swedish krona, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments of our foreign business entities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in fair value are reported in earnings or in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, depending on the nature and purpose of the financial instrument (hedge or offset relationship). For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize the excluded amount through an amortization approach in earnings. The hedge relationships are as follows: </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged item. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Generally, we record in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts into earnings in the same period or periods during which the hedged transaction affects earnings. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We record in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)––Foreign currency translation adjustments, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses immediately into earnings along with the earnings impact of the items they generally offset. These contracts take the opposite currency position of that reflected on the balance sheet to counterbalance the effect of any currency movement.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognize the change in fair value on interest rate contracts that are designated as fair value hedges in earnings, as well as the offsetting earnings impact of the hedged risk attributable to the hedged item.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:40.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the fair value of the derivative financial instruments and notional amounts:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23,991</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">403 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">916 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">290 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">546 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,206 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">221</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,609 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,516</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">700 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,420 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="-sec-ix-hidden:f-1740"><span style="-sec-ix-hidden:f-1741"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><br/>Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></span></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">380 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">124</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">236 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">177 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Hedged item </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(393)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">164 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,166</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">341 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">313</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">549 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">OID = Other (income)/deductions—net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amounts reclassified from OCI into COS were a net gain of $119 million in 2024 and a net gain of $253 million in 2023. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $330 million within the next 12 months into income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 18 years and relates to foreign currency debt.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI were reclassified into OID.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Long-term debt includes foreign currency borrowings which are used in net investment hedges; the related carrying values as of December 31, 2024 and December 31, 2023 were $777 million and $824 million, respectively.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:24.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Amount of Fair<br/>Value Hedging Adjustment<br/>Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cumulative Amount of Fair <br/>Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Active<br/>Hedging<br/>Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1790"><span style="-sec-ix-hidden:f-1791">Long-term debt</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(384)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,196 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(131)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">957 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Credit Risk</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On an ongoing basis, we monitor and review the credit risk of our customers, financial institutions and exposures in our investment portfolio.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our trade accounts receivable, we monitor the creditworthiness of our customers to which we grant credit in the normal course of business. In general, there is no requirement for collateral from customers. For additional information on our trade accounts receivable and allowance for credit losses, see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">G</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_280" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our investments, we monitor concentrations of credit risk associated with government, government agency, and corporate issuers of securities. Investments are placed in instruments that are investment grade and are primarily short in duration. Exposure limits are established to limit a concentration with any single credit counterparty. As of December 31, 2024, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by the U.S., Canada, and the U.K.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of December 31, 2024, the aggregate fair value of these derivative financial instruments that are in a net payable position was $741 million, for which we have posted collateral of $720 million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As of December 31, 2024, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $594 million, for which we have received collateral of $716 million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,848</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,392</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government and agency—non-U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government and agency—U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">982 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">982 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,400 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,400 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,273</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,524 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,524 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">298 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">298 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">298 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">298 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,779 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,772 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government and agency—non-U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,929 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,772 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">156 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">258 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">258 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">460</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">460</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">402 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">402 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Insurance contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">875</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">875</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">790 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">790 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,191 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,191 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1463"><span style="-sec-ix-hidden:f-1464">Total assets</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">22,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,665</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,943 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,772 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,170 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">404 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">404 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">245</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">245</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">420 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">420 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">723</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">723</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,121</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,121</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,000 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,000 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1507"><span style="-sec-ix-hidden:f-1508">Total liabilities</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,420 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,420 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes money market funds. As of December 31, 2024, short-term equity securities include our investment in Haleon of $6.5 billion. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Long-term equity securities of $133 million as of December 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> 7848000000 6456000000 1392000000 5124000000 0 5124000000 6855000000 0 6855000000 817000000 0 817000000 2853000000 0 2853000000 2601000000 0 2601000000 1173000000 0 1173000000 982000000 0 982000000 10881000000 0 10881000000 4400000000 0 4400000000 18729000000 6456000000 12273000000 9524000000 0 9524000000 1056000000 0 1056000000 298000000 0 298000000 1056000000 0 1056000000 298000000 0 298000000 1246000000 1246000000 0 2779000000 2772000000 7000000 0 0 0 124000000 0 124000000 0 0 0 26000000 0 26000000 0 0 0 150000000 0 150000000 1246000000 1246000000 0 2929000000 2772000000 156000000 13000000 0 13000000 144000000 0 144000000 447000000 0 447000000 258000000 0 258000000 460000000 0 460000000 402000000 0 402000000 875000000 0 875000000 790000000 0 790000000 1335000000 0 1335000000 1191000000 0 1191000000 22366000000 7701000000 14665000000 13943000000 2772000000 11170000000 28000000 0 28000000 16000000 0 16000000 217000000 0 217000000 404000000 0 404000000 245000000 0 245000000 420000000 0 420000000 397000000 0 397000000 275000000 0 275000000 723000000 0 723000000 725000000 0 725000000 1121000000 0 1121000000 1000000000 0 1000000000 1366000000 0 1366000000 1420000000 0 1420000000 6500000000 133000000 130000000 57000000000 62000000000 54000000000 61000000000 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,848</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">705</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,434</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,837 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,246</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,779 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private equity securities at cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">755 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Total Long-term investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,010</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,731 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,637 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,228</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,368 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">184</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">207 </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As of December 31, 2024, our investment in Haleon is reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and as of December 31, 2023 was reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represent investments in the life sciences sector.</span></div> 7848000000 5124000000 10881000000 4400000000 705000000 313000000 19434000000 9837000000 1246000000 2779000000 0 150000000 45000000 47000000 719000000 755000000 2010000000 3731000000 217000000 11637000000 2228000000 15368000000 184000000 207000000 <div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:21.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Over 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,970</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">953 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">941 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,179</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,006 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,007 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(129)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,814</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,770</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,126 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(16)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,115 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:21.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Over 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,970</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">953 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">941 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,179</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,006 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,007 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(129)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,814</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,770</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,126 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(16)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,115 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:21.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Over 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,970</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,855</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">953 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">941 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,179</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,006 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,007 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(129)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,814</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,770</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,126 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(16)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,115 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6970000000 8000000 123000000 6855000000 6855000000 0 0 953000000 2000000 14000000 941000000 2853000000 0 0 2853000000 2853000000 0 0 2601000000 0 0 2601000000 1179000000 0 6000000 1173000000 1173000000 0 0 1006000000 4000000 2000000 1007000000 697000000 0 0 697000000 657000000 21000000 19000000 561000000 0 0 561000000 237000000 0 0 237000000 232000000 4000000 1000000 4000000 0 0 4000000 11935000000 8000000 129000000 11814000000 11770000000 25000000 20000000 5126000000 6000000 16000000 5115000000 <div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,008)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,590)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,273 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,754)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">165 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,400 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $360 million and upward adjustments of $222 million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022.</span></div> 1008000000 1590000000 -1273000000 1122000000 1754000000 126000000 -114000000 -165000000 -1400000000 360000000 222000000 <div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial paper, principal amount</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,965 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">252 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,957</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,467 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,946</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">as of December 31, 2024 and 5.37% as of December 31, 2023. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes cash collateral. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_232" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7F</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div> 2453000000 7965000000 3750000000 2250000000 755000000 252000000 6957000000 10467000000 0 5000000 12000000 121000000 6946000000 10350000000 0.0494 0.0537 15000000000 8000000000 7000000000 276000000 243000000 <div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following outlines our senior unsecured long-term debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the weighted-average stated interest rate by maturity:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2025 (3.9% for 2023)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,750 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2026 (3.7% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2027 (2.2% for 2024 and 2.1% for 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,029 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2028 (4.6% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,660</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,660 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2029 (3.5% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2030 (3.6% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2031-2035 (4.5% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2036-2040 (5.4% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,534</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,543 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2041-2045 (4.3% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,474</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2046-2050 (3.7% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes due 2051-2063 (5.3% for 2024 and 2023)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">57,147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60,982 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,039 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(483)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">57,405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61,538 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023))</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,747</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,254 </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified to the current portion of long-term debt.</span></div> 0.039 0 3750000000 0.037 0.037 6000000000 6000000000 0.022 0.021 980000000 1029000000 0.046 0.046 5660000000 5660000000 0.035 0.035 1750000000 1750000000 0.036 0.036 5250000000 5250000000 0.045 0.045 6750000000 6750000000 0.054 0.054 9534000000 9543000000 0.043 0.043 6474000000 6501000000 0.037 0.037 4750000000 4750000000 0.053 0.053 10000000000 10000000000 57147000000 60982000000 701000000 1039000000 444000000 483000000 57405000000 61538000000 0.039 3747000000 2254000000 31000000000 0.0493 P2Y <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:40.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the fair value of the derivative financial instruments and notional amounts:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23,991</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">403 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">916 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">290 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">546 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,206 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">221</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,609 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,516</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">700 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,420 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:40.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the fair value of the derivative financial instruments and notional amounts:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23,991</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">403 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">916 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">290 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">546 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,206 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">221</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,609 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,516</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">700 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,420 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:40.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the fair value of the derivative financial instruments and notional amounts:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23,991</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">403 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">916 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">290 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">546 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,206 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">221</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,609 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,516</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">700 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,420 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023.</span></div> 23991000000 1250000000 719000000 18750000000 403000000 916000000 6750000000 13000000 425000000 6750000000 144000000 290000000 1263000000 1144000000 546000000 1206000000 26335000000 253000000 221000000 25609000000 154000000 214000000 1516000000 1366000000 700000000 1420000000 5000000000 4900000000 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="-sec-ix-hidden:f-1740"><span style="-sec-ix-hidden:f-1741"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><br/>Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></span></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">380 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">124</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">236 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">177 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Hedged item </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(393)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">164 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,166</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">341 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">313</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">549 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">OID = Other (income)/deductions—net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amounts reclassified from OCI into COS were a net gain of $119 million in 2024 and a net gain of $253 million in 2023. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $330 million within the next 12 months into income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 18 years and relates to foreign currency debt.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI were reclassified into OID.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Long-term debt includes foreign currency borrowings which are used in net investment hedges; the related carrying values as of December 31, 2024 and December 31, 2023 were $777 million and $824 million, respectively.</span></div> 0 68000000 0 1000000 466000000 380000000 124000000 236000000 34000000 178000000 34000000 177000000 -253000000 196000000 253000000 -196000000 498000000 -393000000 0 0 119000000 137000000 154000000 136000000 0 0 0 0 49000000 -29000000 0 0 50000000 164000000 50000000 164000000 1166000000 341000000 313000000 549000000 119000000 253000000 330000000 P18Y 777000000 824000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:24.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Amount of Fair<br/>Value Hedging Adjustment<br/>Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cumulative Amount of Fair <br/>Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Active<br/>Hedging<br/>Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1790"><span style="-sec-ix-hidden:f-1791">Long-term debt</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(384)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,196 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(131)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">957 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:24.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Amount of Fair<br/>Value Hedging Adjustment<br/>Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cumulative Amount of Fair <br/>Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Active<br/>Hedging<br/>Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1790"><span style="-sec-ix-hidden:f-1791">Long-term debt</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(384)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,196 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(131)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">957 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div> 7154000000 -384000000 891000000 7196000000 -131000000 957000000 741000000 720000000 594000000 716000000 <span style="color:#05497c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Financial Information</span><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Inventories</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,775</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,495 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,688 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">976</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,007 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,851</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,189 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,663</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,568 </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> include, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $1.3 billion as of December 31, 2024 and $2.0 billion as of December 31, 2023.</span></div><div style="margin-bottom:5pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Supplier Finance Program Obligation</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We maintain voluntary supply chain finance agreements with several participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Pfizer to these financial institutions. Our suppliers negotiate their financing agreements directly with the respective financial institutions and we are not a party to these agreements. We have no economic interest in our suppliers’ decision to participate and we pay the financial institutions the stated amount of confirmed invoices on the original maturity dates, which is generally within 90 to 120 days of the invoice date. The agreements with the financial institutions do not require Pfizer to provide assets pledged as security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in such financing arrangements are recorded within <span style="-sec-ix-hidden:f-1819"><span style="-sec-ix-hidden:f-1820">trade payables</span></span> in our consolidated balance sheet.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:76.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the changes in outstanding trade payables to suppliers who participate in these financing arrangements for the year ended December 31, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Confirmed obligations outstanding, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">791 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Invoices confirmed during the year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,638</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Confirmed invoices paid during the year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Confirmed obligations outstanding, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">688</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,775</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,495 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,688 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">976</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,007 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,851</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,189 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,663</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,568 </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.</span></div> <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,775</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,495 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,688 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">976</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,007 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,851</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,189 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,663</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,568 </span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.</span></div> 3775000000 3495000000 6101000000 5688000000 976000000 1007000000 10851000000 10189000000 2663000000 4568000000 1300000000 2000000000 P90D P120D <div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:76.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the changes in outstanding trade payables to suppliers who participate in these financing arrangements for the year ended December 31, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Confirmed obligations outstanding, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">791 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Invoices confirmed during the year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,638</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Confirmed invoices paid during the year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Confirmed obligations outstanding, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">688</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 791000000 2638000000 2740000000 688000000 Property, Plant and Equipment, Net<div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:62.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Useful Lives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Years)  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Land</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">291</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">353 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Buildings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33-50</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,036</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,046 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-20</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15,095</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Furniture, fixtures and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3-12.5</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,516</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,925 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34,876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,985 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16,483</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,045 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,393</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,940 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> by geographic area:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,748</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,674 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,713 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,458</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,554 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,393</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,940 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:62.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Useful Lives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Years)  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Land</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">291</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">353 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Buildings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33-50</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,036</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,046 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-20</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15,095</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Furniture, fixtures and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3-12.5</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,516</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,925 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34,876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,985 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16,483</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,045 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,393</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,940 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 291000000 353000000 P33Y P50Y 9036000000 9046000000 P8Y P20Y 15095000000 14263000000 P3Y P12Y6M 5516000000 5399000000 4937000000 5925000000 34876000000 34985000000 16483000000 16045000000 18393000000 18940000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> by geographic area:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,748</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,674 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,713 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,458</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,554 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,393</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,940 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9748000000 10674000000 7187000000 6713000000 1458000000 1554000000 18393000000 18940000000 Identifiable Intangible Assets, Net and Goodwill<div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Identifiable Intangible Assets</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identifiable<br/>Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identifiable</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intangible</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets, Net</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">99,397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34,353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">99,267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(60,493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,773 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">922 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(877)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,756 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,458)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,297 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103,397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67,549)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,848</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102,944 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(62,828)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40,116 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">827 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">827 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,893</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,893</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,784 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,784 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">122,961</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67,549)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">55,411</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127,728 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(62,828)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,900 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the transfer of IPR&amp;D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease in the gross carrying amount reflects impairments of $1.9 billion (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), and the transfer of IPR&amp;D to developed technology rights of $727 million for talazoparib (Talzenna). </span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">) and measurement period adjustments related to our acquisition of Seagen of $950 million (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Developed Technology Rights––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed technology rights represent the cost for developed technology acquired from third parties and can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing our commercialized products. The significant components of developed technology rights are the following: Nurtec ODT/Vydura, Adcetris, Padcev, Xtandi, Velsipity and Braftovi/Mektovi. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain prescription pharmaceutical products.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Brands––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands represent the cost for tradenames and know-how, as the products themselves do not receive patent protection. The significant components of Finite-lived brands primarily include Medrol.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPR&amp;D assets represent the acquisition date fair value (less impairments) of R&amp;D assets acquired through business combinations that have not yet received regulatory approval in a major market </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">which could include both new investigational products and additional </span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">indications for in-line products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The significant components of IPR&amp;D are SGN-B6A, disitamab vedotin, GBT601 and Tukysa. IPR&amp;D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&amp;D effort. Accordingly, during the development period after the date of acquisition, these assets are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify it out of IPR&amp;D and begin amortization. If the associated R&amp;D effort is abandoned, the related IPR&amp;D assets will be written-off, and we will record an impairment charge. IPR&amp;D assets are high-risk assets, given the uncertain nature of R&amp;D. Accordingly, IPR&amp;D assets may become impaired and/or be written-off in the future.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Licensing Agreements––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements for developed technology and for technology in development primarily relate to out-licensing arrangements acquired from third parties, including from acquisitions. These assets represent the cost for the license, where we acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partners. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will be written-off, and we will record an impairment charge.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average life for our total finite-lived intangible assets and for the largest component, developed technology rights, is approximately 10 years. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:40.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the expected annual amortization expense:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization expense</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,838 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,716 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,125 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,776 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Goodwill</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the changes in the carrying amount of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, January 1, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">51,375 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,117 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impact of foreign exchange and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">292 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">67,783</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impact of foreign exchange</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">68,527</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Additions primarily represent our acquisition of Seagen in 2023 and measurement period adjustments related to our acquisition of Seagen in 2024 (see <br/></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identifiable<br/>Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identifiable</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intangible</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets, Net</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">99,397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34,353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">99,267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(60,493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,773 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">922 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(877)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,756 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,458)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,297 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103,397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67,549)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,848</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102,944 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(62,828)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40,116 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">827 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">827 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,893</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,893</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,784 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,784 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">122,961</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67,549)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">55,411</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127,728 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(62,828)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,900 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the transfer of IPR&amp;D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease in the gross carrying amount reflects impairments of $1.9 billion (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), and the transfer of IPR&amp;D to developed technology rights of $727 million for talazoparib (Talzenna). </span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">) and measurement period adjustments related to our acquisition of Seagen of $950 million (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identifiable<br/>Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identifiable</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intangible</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets, Net</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">99,397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34,353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">99,267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(60,493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,773 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">922 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(877)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,756 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,458)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,297 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103,397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67,549)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,848</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102,944 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(62,828)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40,116 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">827 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">827 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,893</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,893</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,784 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,784 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">122,961</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67,549)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">55,411</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127,728 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(62,828)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,900 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the transfer of IPR&amp;D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease in the gross carrying amount reflects impairments of $1.9 billion (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), and the transfer of IPR&amp;D to developed technology rights of $727 million for talazoparib (Talzenna). </span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">) and measurement period adjustments related to our acquisition of Seagen of $950 million (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div> 99397000000 65044000000 34353000000 99267000000 60493000000 38773000000 1277000000 992000000 285000000 922000000 877000000 45000000 2724000000 1513000000 1210000000 2756000000 1458000000 1297000000 103397000000 67549000000 35848000000 102944000000 62828000000 40116000000 0 0 827000000 827000000 18893000000 18893000000 23193000000 23193000000 670000000 670000000 763000000 763000000 19563000000 19563000000 24784000000 24784000000 122961000000 67549000000 55411000000 127728000000 62828000000 64900000000 740000000 727000000 -727000000 943000000 -827000000 827000000 475000000 1900000000 1700000000 727000000 -727000000 5300000000 3300000000 950000000 P10Y P10Y <div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:40.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the expected annual amortization expense:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization expense</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,838 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,716 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,125 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,776 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4838000000 4716000000 4125000000 3776000000 2829000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes the changes in the carrying amount of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, January 1, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">51,375 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,117 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impact of foreign exchange and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">292 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">67,783</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impact of foreign exchange</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">68,527</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_271" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 17A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Additions primarily represent our acquisition of Seagen in 2023 and measurement period adjustments related to our acquisition of Seagen in 2024 (see <br/></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_181" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div> 51375000000 16117000000 292000000 67783000000 1022000000 -278000000 68527000000 Pension and Postretirement Benefit Plans and Defined Contribution Plans <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Components of Net Periodic Benefit Cost/(Credit) and Changes in Other Comprehensive Income/(Loss)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Postretirement Plans</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">116 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">553</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">534 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">312</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">157 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(862)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(304)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(296)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(130)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">396</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(410)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">51 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(592)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(84)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">169 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(45)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(90)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(578)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost/(credit) reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">169 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost/(credit) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive income</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(594)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(86)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">199 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(46)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(62)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(410)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects: (i) actuarial remeasurement net losses in 2024, primarily due to unfavorable asset performance for the U.S. pension plans and decreases in discount rates for the international pension plans, partially offset by increases in discount rates for the U.S. pension plans and favorable asset performance for the international pension plans and postretirement plans, (ii) actuarial remeasurement net gains in 2023, primarily due to favorable asset performance in the U.S. and increases in discount rates for the international plans, partially offset by unfavorable asset performance for certain international plans, and (iii) actuarial remeasurement net gains in 2022, primarily due to increases in discount rates, partially offset by unfavorable asset performance.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Actuarial Assumptions</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(PERCENTAGES)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Weighted-average assumptions used to determine net periodic benefit cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discount rate:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension plans/postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.2 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.0 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The assumptions are reviewed at least annually. We revise these assumptions based on an annual evaluation of long-term trends as well as market conditions that may have an impact on the cost of providing retirement benefits.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average discount rate for our U.S. defined benefit plans is set with reference to the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2024 resulted in higher discount rates for the U.S. pension plans and lower discount rates for the international pension plans as compared to the prior year.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Healthcare cost trend rate assumed for next year </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.9 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year that the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2047</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2047 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Obligations and Funded Status</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">450</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">553</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">312</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(518)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,756 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,292 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">450 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,871 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,061 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(316)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">105</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,935 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,696</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,552 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">636 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Amounts recorded in our consolidated balance sheet:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">644 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">330</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(94)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(738)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,355)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">579 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,752</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">964 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,347 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Plan Assets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:21.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the components of plan assets:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Target Allocation Percentage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level <br/>2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Level<br/> 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. pension plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">533</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">477</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">559 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10-40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Global equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45-80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,878</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,874</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,668 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,667 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,059</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,059</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">42</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5-35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,665</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,665</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,449 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,449 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other commingled funds</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,401</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10,935 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,585 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,410 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,939 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">International pension plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">310</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">172</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">268 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">120 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10-20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">619</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">633 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">587 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">46 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45-70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">638</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">633</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">617 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">617 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">960</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">960</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">848 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">848 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,064</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">686</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,852 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">872 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">980 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15-35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">145 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,221</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,176</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,151 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,096 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">965</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">252</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">531</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,039 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">167 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6,696</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,642</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,552 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">120 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,295 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,340 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,796 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. postretirement plans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">0-5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">95-100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">633 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">633 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">636 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">635 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Government and agency obligations are inclusive of repurchase agreements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Mainly includes investments in private equity, private debt and real estate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Mostly includes investments in hedge funds and real estate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects postretirement plan assets, which support our U.S. retiree medical plans.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value, beginning</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,455 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual return on plan assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets held, ending</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets sold during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases, sales, and settlements, net</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer into/(out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">81 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exchange rate changes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value, ending</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,340 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Level 3 investments may include securities or insurance contracts that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the expected future cash flow information related to our benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected employer contributions:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected benefit payments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">871 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">384 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">858 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">844 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">384 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2028</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">825 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">385 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">815 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2030–2034</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,760 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,067 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">245 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Defined Contribution Plans</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have defined contribution plans in the U.S. and other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. We also offer a Retirement Savings Contribution which is an annual non-contributory employer contribution in the U.S. and Puerto Rico. We recorded charges related to the employer contributions to global defined contribution plans of $800 million in 2024, $843 million in 2023 and $770 million in 2022.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Postretirement Plans</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">116 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">553</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">534 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">312</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">157 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(862)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(304)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(296)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(130)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">396</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(410)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">51 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(592)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(84)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">169 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(45)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(90)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(578)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost/(credit) reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">169 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost/(credit) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive income</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(594)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(86)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">199 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(46)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(62)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(410)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects: (i) actuarial remeasurement net losses in 2024, primarily due to unfavorable asset performance for the U.S. pension plans and decreases in discount rates for the international pension plans, partially offset by increases in discount rates for the U.S. pension plans and favorable asset performance for the international pension plans and postretirement plans, (ii) actuarial remeasurement net gains in 2023, primarily due to favorable asset performance in the U.S. and increases in discount rates for the international plans, partially offset by unfavorable asset performance for certain international plans, and (iii) actuarial remeasurement net gains in 2022, primarily due to increases in discount rates, partially offset by unfavorable asset performance.</span></div> 0 0 0 87000000 85000000 116000000 14000000 12000000 29000000 553000000 589000000 534000000 312000000 287000000 157000000 23000000 21000000 27000000 832000000 778000000 862000000 322000000 304000000 296000000 51000000 44000000 47000000 1000000 2000000 2000000 4000000 0 -1000000 -113000000 -119000000 -130000000 -396000000 410000000 -225000000 -33000000 -102000000 11000000 -144000000 -51000000 440000000 0 0 0 4000000 2000000 11000000 0 12000000 18000000 0 6000000 18000000 10000000 0 1000000 0 0 1000000 117000000 -592000000 -84000000 120000000 169000000 -45000000 18000000 -90000000 -578000000 -1000000 -2000000 -2000000 -4000000 31000000 -1000000 -80000000 128000000 169000000 116000000 -594000000 -86000000 117000000 199000000 -46000000 -62000000 38000000 -410000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(PERCENTAGES)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Weighted-average assumptions used to determine net periodic benefit cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discount rate:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension plans/postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.2 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.0 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.</span></div> 0.054 0.054 0.029 0.054 0.055 0.029 0.044 0.038 0.015 0.039 0.036 0.017 0.080 0.075 0.063 0.051 0.045 0.031 0.080 0.075 0.063 0.032 0.030 0.028 0.057 0.054 0.054 0.041 0.044 0.038 0.055 0.054 0.055 0.031 0.032 0.030 <div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Healthcare cost trend rate assumed for next year </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.9 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year that the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2047</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2047 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.075 0.079 0.040 0.040 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">450</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">553</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">312</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(518)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,756 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,292 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">450 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,871 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,061 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(316)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">105</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,935 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,696</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,552 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">636 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Amounts recorded in our consolidated balance sheet:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">644 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">330</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(94)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(738)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,355)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">579 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,752</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">964 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,347 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">450</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">553</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">312</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(518)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,756 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,292 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">450 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,871 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,061 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(316)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">105</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,935 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,696</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,552 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">636 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Amounts recorded in our consolidated balance sheet:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">644 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">330</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(94)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(738)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,355)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">579 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,752</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">964 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,347 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">450</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">553</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">312</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(518)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,756 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,292 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">450 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,871 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,061 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(316)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">105</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,935 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,696</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,552 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">636 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Amounts recorded in our consolidated balance sheet:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">644 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">330</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(94)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(738)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,355)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">579 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,752</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">964 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,347 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">450</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">553</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">312</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(518)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,756 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,292 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">450 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,871 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,061 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(316)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">105</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,935 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,696</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,552 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">636 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Amounts recorded in our consolidated balance sheet:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">644 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">330</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(94)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(738)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,355)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">579 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,752</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">964 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,347 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.</span></div> <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">450</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">553</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">589 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">312</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(518)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">280 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,756 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,292 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">450 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,871 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,061 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(316)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">105</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(675)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,935 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,696</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,552 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">636 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Amounts recorded in our consolidated balance sheet:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">644 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">330</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(94)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(738)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,355)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(667)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(740)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">579 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,752</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">964 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">831 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,347 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024.</span></div> 10756000000 11420000000 7292000000 7497000000 450000000 410000000 0 0 87000000 85000000 14000000 12000000 553000000 589000000 312000000 287000000 23000000 21000000 0 0 16000000 11000000 61000000 52000000 0 0 0 25000000 -193000000 0 299000000 127000000 -119000000 518000000 -199000000 -96000000 1000000 0 106000000 -280000000 2000000 1000000 0 0 -77000000 -13000000 0 0 6000000 7000000 0 0 -3000000 756000000 675000000 69000000 56000000 0 0 473000000 457000000 371000000 334000000 67000000 137000000 9781000000 10756000000 7363000000 7292000000 486000000 450000000 10935000000 10871000000 6552000000 6865000000 636000000 647000000 138000000 1061000000 408000000 -316000000 105000000 89000000 103000000 134000000 164000000 154000000 0 -15000000 0 0 16000000 11000000 61000000 52000000 0 0 -65000000 214000000 0 0 62000000 13000000 0 0 756000000 675000000 69000000 56000000 0 0 473000000 457000000 371000000 334000000 67000000 137000000 9948000000 10935000000 6696000000 6552000000 736000000 636000000 167000000 179000000 -667000000 -740000000 251000000 186000000 934000000 1010000000 728000000 644000000 330000000 266000000 90000000 94000000 31000000 28000000 5000000 6000000 678000000 738000000 1364000000 1355000000 74000000 74000000 167000000 179000000 -667000000 -740000000 251000000 186000000 2000000 2000000 61000000 65000000 -365000000 -285000000 456000000 579000000 768000000 831000000 1752000000 1834000000 690000000 964000000 768000000 831000000 2084000000 2347000000 7100000000 7000000000.0 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:21.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the components of plan assets:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Target Allocation Percentage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level <br/>2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Level<br/> 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. pension plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">533</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">477</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">559 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10-40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Global equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45-80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,878</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,874</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,668 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,667 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,059</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,059</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">42</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5-35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,665</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,665</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,449 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,449 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other commingled funds</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,401</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10,935 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,585 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,410 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,939 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">International pension plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">310</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">172</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">268 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">120 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10-20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">619</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">633 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">587 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">46 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45-70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">638</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">633</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">617 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">617 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">960</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">960</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">848 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">848 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,064</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">686</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,852 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">872 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">980 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15-35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">145 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,221</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,176</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,151 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,096 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">965</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">252</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">531</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,039 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">167 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">244 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6,696</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,642</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,552 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">120 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,295 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,340 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,796 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. postretirement plans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">0-5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">95-100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">633 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">633 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">736</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">636 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">635 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Government and agency obligations are inclusive of repurchase agreements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Mainly includes investments in private equity, private debt and real estate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Mostly includes investments in hedge funds and real estate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects postretirement plan assets, which support our U.S. retiree medical plans.</span></div> 533000000 56000000 477000000 0 0 606000000 47000000 559000000 0 0 1341000000 1341000000 0 0 0 1537000000 1537000000 1000000 0 97000000 0 97000000 0 0 100000000 0 100000000 0 0 2878000000 4000000 2874000000 0 0 3668000000 1000000 3667000000 2059000000 0 2059000000 0 0 1971000000 0 1971000000 0 0 42000000 12000000 0 30000000 25000000 0 14000000 0 11000000 2665000000 0 0 2665000000 2449000000 0 0 0 2449000000 0 0 0 0 0 99000000 0 99000000 0 0 333000000 0 0 333000000 479000000 0 0 479000000 1 9948000000 1401000000 5518000000 0 3028000000 10935000000 1585000000 6410000000 1000000 2939000000 310000000 138000000 172000000 0 0 268000000 120000000 148000000 0 0 704000000 0 619000000 0 86000000 633000000 0 587000000 0 46000000 638000000 0 633000000 5000000 0 617000000 0 617000000 0 0 960000000 1000000 960000000 0 0 848000000 0 848000000 0 0 1750000000 0 1064000000 0 686000000 1852000000 0 872000000 0 980000000 147000000 0 2000000 0 145000000 145000000 0 2000000 0 142000000 1221000000 0 45000000 1176000000 0 1151000000 0 55000000 1096000000 0 965000000 35000000 147000000 252000000 531000000 1039000000 0 167000000 244000000 628000000 1 6696000000 174000000 3642000000 1433000000 1447000000 6552000000 120000000 3295000000 1340000000 1796000000 12000000 0 12000000 3000000 1000000 2000000 0 0 724000000 0 724000000 633000000 633000000 0 0 1 736000000 0 736000000 636000000 1000000 635000000 0 0 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value, beginning</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,455 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual return on plan assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets held, ending</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets sold during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases, sales, and settlements, net</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer into/(out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">81 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exchange rate changes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value, ending</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,340 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1340000000 1455000000 8000000 -96000000 0 -3000000 -79000000 -155000000 168000000 81000000 -5000000 59000000 1433000000 1340000000 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides the expected future cash flow information related to our benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected employer contributions:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected benefit payments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">871 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">384 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">858 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">844 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">384 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2028</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">825 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">385 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">815 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2030–2034</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,760 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,067 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">245 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 90000000 144000000 40000000 871000000 384000000 44000000 858000000 366000000 47000000 844000000 384000000 49000000 825000000 385000000 50000000 815000000 392000000 50000000 3760000000 2067000000 245000000 800000000 843000000 770000000 Equity<div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Common Stock Purchases</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have authorization to purchase our common stock through privately negotiated transactions or in the open market as circumstances and prices warrant. Purchased shares under a share-purchase plan, which is authorized by our BOD, are available for general corporate purposes. In December 2018, the BOD authorized a $10 billion share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the first quarter of 2022, we purchased 39 million shares of our common stock at a cost of $2 billion under our publicly announced share-purchase plan. Our remaining share-purchase authorization was $3.3 billion as of December 31, 2024.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Preferred Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have 27 million authorized shares of preferred stock without par value; no shares were issued or outstanding as of December 31, 2024 and 2023.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Employee Stock Ownership Plans</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have one ESOP that holds common stock of the Company (Common ESOP). As of December 31, 2024, all shares of common stock held by the Common ESOP have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was $16 million for 2024, $20 million for 2023 and $19 million for 2022.</span></div> 10000000000 39000000 2000000000 3300000000 27000000 27000000 0 0 0 0 1 16000000 20000000 19000000 Share-Based Payments<div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our compensation programs can include share-based payment awards with value that is determined by reference to the fair value of our shares and that provide for the grant of shares or options to acquire shares or similar arrangements. Our share-based awards are designed based on competitive survey data or industry peer groups used for compensation purposes, and are allocated between different long-term incentive awards, generally in the form of Total Shareholder Return Units (TSRUs), Restricted Stock Units (RSUs), Portfolio Performance Shares (PPSs), Performance Share Awards (PSAs), Breakthrough Performance Awards (BPAs) and stock options, as determined by the Compensation Committee of our BOD. No BPAs were granted in 2024 and no BPAs were outstanding as of December 31, 2024.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Amended and Restated 2019 Stock Plan (2019 Plan) replaced and superseded the original 2019 Stock Plan. The 2019 Plan provides for 320 million shares to be authorized for grants plus any shares remaining available for grant under the original 2019 Stock Plan as of April 25, 2024 (the carryforward shares). The RSUs count as three shares, and PPSs, PSAs and BPAs count as three shares times the maximum potential payout, while TSRUs and stock options count as one share, toward the maximum shares available under the 2019 Plan. As of December 31, 2024, 441 million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A summary of the awards and valuation details:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total Shareholder Return Units (TSRUs)</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management and select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the <span style="-sec-ix-hidden:f-2547">five</span> or <span style="-sec-ix-hidden:f-2548">seven</span>-year term, if and to the extent the total value is positive.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant. Certain 2022 and 2023 five-year grants were modified during 2024 (for active colleagues) to vest on the fifth anniversary and settle on the seventh anniversary of the grant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Retirement-eligible holders can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs’ original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using a Monte Carlo simulation model</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted Stock Units (RSUs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For RSUs granted before 2022, generally in all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date. Beginning in 2022, generally in all instances, the units vest and distribute one-third per year for <span style="-sec-ix-hidden:f-2550">three</span> years on each of the three annual anniversaries from the date of grant assuming continuous service from the grant date.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis for RSUs granted before 2022, and on an accelerated attribution approach for RSUs granted beginning in 2022, over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portfolio Performance Shares (PPSs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a <span style="-sec-ix-hidden:f-2551">three</span> or <span style="-sec-ix-hidden:f-2552">five</span>-year performance period from the year of the grant date, as applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management’s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Performance Share Awards (PSAs)</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">Adjusted net income over three <span style="-sec-ix-hidden:f-2557">one</span>-year periods; and</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the <span style="-sec-ix-hidden:f-2558">three</span>-year performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. PSA awards granted in 2022 and 2023 were modified during 2024 (for active colleagues) to vest on the fifth anniversary of the grant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Breakthrough Performance Awards (BPAs)</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the <span style="-sec-ix-hidden:f-2561">one</span>-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer’s product pipeline during the performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the probable vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved and/or management’s assessment of the probable vesting term.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years. </span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the Black-Scholes-Merton option-pricing model</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="93" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION AND YEARS)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PPSs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PSAs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total fair value of shares vested</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$7.05</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$10.71</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$11.72</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$469</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$505</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$345</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$116</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$145</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$4.08</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$7.88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$9.44</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total intrinsic value of options exercised or share units converted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$755</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$1,131</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$250</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$280</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$102</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$247</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash received upon exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$181</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$260</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Tax benefits realized from exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$46</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Compensation cost recognized/(reduced), pre-tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$246</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$244</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$255</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$394</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$252</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$(138)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$(21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total compensation cost related to nonvested awards not yet recognized, pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$270</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$192</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$179</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$214</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$212</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$266</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$107</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$81</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$3</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Weighted-average period over which cost is expected to be recognized (years)</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">2.1</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">1.9</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Weighted-average GDFV per TSRUs and stock options.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total share-based payment expense was $877 million, $525 million and $872 million in 2024, 2023 and 2022, respectively. Tax benefit for share-based compensation expense was $165 million, $93 million and $160 million in 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The table above excludes total expense due to the modification for share-based awards in connection with our cost reduction/productivity initiatives, which was not significant for all years presented and is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_199" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Amounts capitalized as part of inventory cost were not significant for any period presented.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Expected dividend yield </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(based on a constant dividend yield during the expected term)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6.06</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.80 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.42 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6.06</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.80 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.42 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (based on interpolated yield on U.S. Treasury zero-coupon issues)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4.31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4.08 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4.32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4.03 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1.93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Expected stock price volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (based on implied volatility, after consideration of historical volatility)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23.23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23.23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TSRUs contractual/stock options expected term, years</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (based on historical exercise and post-vesting termination patterns for stock options) </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5.15</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5.15</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5.17</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6.50</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6.50</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6.50</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.796%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="57" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary of all TSRU, RSU, PPS and PSA activity during 2024 (with the shares granted representing the maximum award that could be achieved for PPSs and PSAs):</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PPSs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PSAs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">TSRUs </span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Per TSRU, Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> Weighted Avg. GDFV per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shares </span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">GDFV</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Grant Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nonvested, December 31, 2023</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">77,673</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9.67 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">39.92 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25,844</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40.08 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22,225</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28.79 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,734</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28.79 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">43,674</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7.05</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17,073</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13,535</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.92</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,597</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(31,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7.42</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(16,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">37.89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(6,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">27.76</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reinvested dividend equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28.17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(5,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8.66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(2,024)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">32.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(3,274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28.03</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1,810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">27.79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nonvested, December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">84,902</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9.63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">35.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">25,561</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">32.67</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26,156</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,521</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Vested and non-vested shares outstanding, but not paid as of December 31, 2024 were 33.9 million.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary of TSRU and PTU information as of December 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">TSRUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PTUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average<br/>Grant Price<br/>Per TSRU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Remaining Contractual Term </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Aggregate Intrinsic Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Millions)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167,977</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34.17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">83,075</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32.44</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs Expected to vest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">80,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35.93</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding PTUs converted from TSRUs exercised</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">586</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.2</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, we settled 2,419,674 TSRUs with a weighted-average grant price of $27.76 per unit.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, 1,150,382 TSRUs with a weighted-average grant price of $31.54 per unit were converted into 100,307 PTUs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Market price of our underlying common stock less grant price plus dividend equivalents to date.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary of all stock option activity during 2024:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Remaining Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Millions)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,452 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32.66 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">29.06</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">30.69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding, December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,621</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Vested and expected to vest, December 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Market price of our underlying common stock less exercise price.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The number of options expected to vest takes into account an estimate of expected forfeitures.</span></div> 0 0 320000000 3 3 3 3 1 1 441000000 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A summary of the awards and valuation details:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total Shareholder Return Units (TSRUs)</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management and select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the <span style="-sec-ix-hidden:f-2547">five</span> or <span style="-sec-ix-hidden:f-2548">seven</span>-year term, if and to the extent the total value is positive.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant. Certain 2022 and 2023 five-year grants were modified during 2024 (for active colleagues) to vest on the fifth anniversary and settle on the seventh anniversary of the grant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Retirement-eligible holders can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs’ original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using a Monte Carlo simulation model</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted Stock Units (RSUs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For RSUs granted before 2022, generally in all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date. Beginning in 2022, generally in all instances, the units vest and distribute one-third per year for <span style="-sec-ix-hidden:f-2550">three</span> years on each of the three annual anniversaries from the date of grant assuming continuous service from the grant date.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis for RSUs granted before 2022, and on an accelerated attribution approach for RSUs granted beginning in 2022, over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portfolio Performance Shares (PPSs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a <span style="-sec-ix-hidden:f-2551">three</span> or <span style="-sec-ix-hidden:f-2552">five</span>-year performance period from the year of the grant date, as applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management’s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Performance Share Awards (PSAs)</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">Adjusted net income over three <span style="-sec-ix-hidden:f-2557">one</span>-year periods; and</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the <span style="-sec-ix-hidden:f-2558">three</span>-year performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. PSA awards granted in 2022 and 2023 were modified during 2024 (for active colleagues) to vest on the fifth anniversary of the grant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Breakthrough Performance Awards (BPAs)</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the <span style="-sec-ix-hidden:f-2561">one</span>-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer’s product pipeline during the performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the probable vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management’s assessment of the probability that the specified performance criteria will be achieved and/or management’s assessment of the probable vesting term.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years. </span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the Black-Scholes-Merton option-pricing model</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr></table></div> 20 0 2 2 3 0 2 0 6 0 P10Y <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="93" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION AND YEARS)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PPSs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PSAs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total fair value of shares vested</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$7.05</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$10.71</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$11.72</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$469</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$505</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$345</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$116</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$145</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$4.08</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$7.88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$9.44</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total intrinsic value of options exercised or share units converted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$755</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$1,131</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$250</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$280</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$102</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$247</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash received upon exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$181</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$260</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Tax benefits realized from exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$46</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Compensation cost recognized/(reduced), pre-tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$246</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$244</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$255</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$394</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$252</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$(138)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$(21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total compensation cost related to nonvested awards not yet recognized, pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$270</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$192</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$179</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$214</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$212</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$266</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$107</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$81</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">$4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">$3</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Weighted-average period over which cost is expected to be recognized (years)</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">2.1</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">1.9</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:700;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.25pt;font-weight:400;line-height:120%">1.7</span></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Weighted-average GDFV per TSRUs and stock options.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.796%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="57" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary of all TSRU, RSU, PPS and PSA activity during 2024 (with the shares granted representing the maximum award that could be achieved for PPSs and PSAs):</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PPSs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PSAs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">TSRUs </span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Per TSRU, Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> Weighted Avg. GDFV per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shares </span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">GDFV</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Grant Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nonvested, December 31, 2023</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">77,673</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9.67 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">39.92 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25,844</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40.08 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">22,225</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28.79 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,734</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28.79 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">43,674</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7.05</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17,073</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13,535</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.92</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,597</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(31,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7.42</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(16,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">37.89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(6,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">27.76</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reinvested dividend equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28.17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(5,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8.66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(2,024)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">32.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(3,274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28.03</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1,810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">27.79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nonvested, December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">84,902</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9.63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">35.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">25,561</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">32.67</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26,156</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,521</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Vested and non-vested shares outstanding, but not paid as of December 31, 2024 were 33.9 million.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary of TSRU and PTU information as of December 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">TSRUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PTUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average<br/>Grant Price<br/>Per TSRU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Remaining Contractual Term </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Aggregate Intrinsic Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Millions)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">167,977</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34.17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">83,075</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32.44</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs Expected to vest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">80,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35.93</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding PTUs converted from TSRUs exercised</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">586</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.2</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, we settled 2,419,674 TSRUs with a weighted-average grant price of $27.76 per unit.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2024, 1,150,382 TSRUs with a weighted-average grant price of $31.54 per unit were converted into 100,307 PTUs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Market price of our underlying common stock less grant price plus dividend equivalents to date.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</span></div> 7.05 10.71 11.72 469000000 505000000 345000000 176000000 116000000 145000000 0 58000000 57000000 4.08 7.88 9.44 29000000 755000000 1131000000 123000000 250000000 280000000 0 102000000 247000000 0 181000000 260000000 0 20000000 46000000 246000000 244000000 255000000 394000000 437000000 402000000 252000000 -138000000 144000000 -21000000 -5000000 73000000 4000000 4000000 4000000 270000000 192000000 179000000 214000000 212000000 266000000 107000000 81000000 135000000 40000000 22000000 38000000 4000000 4000000 3000000 P2Y1M6D P1Y8M12D P1Y8M12D P1Y9M18D P1Y9M18D P1Y8M12D P1Y10M24D P1Y9M18D P1Y8M12D P1Y8M12D P1Y9M18D P1Y9M18D P1Y8M12D P1Y8M12D P1Y8M12D 877000000 525000000 872000000 165000000 93000000 160000000 <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Expected dividend yield </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(based on a constant dividend yield during the expected term)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6.06</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.80 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.42 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6.06</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.80 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.42 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (based on interpolated yield on U.S. Treasury zero-coupon issues)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4.31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4.08 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1.87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4.32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4.03 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1.93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Expected stock price volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (based on implied volatility, after consideration of historical volatility)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23.23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26.56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23.23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TSRUs contractual/stock options expected term, years</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (based on historical exercise and post-vesting termination patterns for stock options) </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5.15</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5.15</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5.17</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6.50</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6.50</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6.50</span></td></tr></table></div> 0.0606 0.0380 0.0342 0.0606 0.0380 0.0342 0.0431 0.0408 0.0187 0.0432 0.0403 0.0193 0.2656 0.2323 0.2920 0.2656 0.2323 0.2921 P5Y1M24D P5Y1M24D P5Y2M1D P6Y6M P6Y6M P6Y6M 77673000 9.67 39.92 25844000 40.08 22225000 28.79 4734000 28.79 43674000 7.05 26.90 17073000 26.97 13535000 26.92 2597000 26.89 31076000 7.42 33.87 16874000 37.89 6329000 27.76 0 0 1541000 28.17 5370000 8.66 33.90 2024000 32.20 3274000 28.03 1810000 27.79 84902000 9.63 35.87 25561000 32.67 26156000 26.53 5521000 26.53 33900000 167977000 34.17 P2Y6M 122000000 83075000 32.44 P0Y8M12D 86000000 80014000 35.93 P4Y3M18D 34000000 586000 P0Y2M12D 16000000 2419674 27.76 1150382 31.54 100307 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary of all stock option activity during 2024:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Remaining Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Millions)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,452 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32.66 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">29.06</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">30.69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding, December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,621</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Vested and expected to vest, December 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">33.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Market price of our underlying common stock less exercise price.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The number of options expected to vest takes into account an estimate of expected forfeitures.</span></div> 28452000 32.66 1372000 26.90 4000 29.06 235000 33.52 9964000 30.69 19621000 33.24 P1Y10M24D 0 19510000 33.26 P1Y10M24D 0 17447000 33.12 P1Y1M6D 0 Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:66.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">EPS:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">EPS Numerator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,031</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,119 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,372 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding––Basic</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,664</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,643 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,608 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common-share equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">125 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding––Diluted</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,709 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,733 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9 </span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div> <div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:66.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">EPS:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">EPS Numerator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,031</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,119 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,372 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding––Basic</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,664</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,643 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,608 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common-share equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">125 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding––Diluted</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,709 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,733 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9 </span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1 </span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div> 8020000000 8020000000 2134000000 2134000000 31366000000 31366000000 11000000 -15000000 6000000 8031000000 8031000000 2119000000 2119000000 31372000000 31372000000 5664000000 5643000000 5608000000 36000000 66000000 125000000 5700000000 5709000000 5733000000 24000000 9000000 1000000 Leases<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $517 million in 2024, $444 million in 2023 and $536 million in 2022. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ROU assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2816"><span style="-sec-ix-hidden:f-2817">Other noncurrent assets</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,289</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,924 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities (short-term)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2820"><span style="-sec-ix-hidden:f-2821">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">356</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities (long-term)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2824"><span style="-sec-ix-hidden:f-2825">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,626 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:52.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of total lease cost includes:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">683</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">863 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">714 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">444 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">536 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total lease cost</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,283 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,218 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other supplemental information follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average Remaining Contractual Lease Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.8</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average Discount Rate</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.8 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">617 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on sale and leaseback transactions, net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(49)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2024:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating Lease Liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Next one year</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">443</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1-2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">406</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2-3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">361</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3-4 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">281</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4-5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,468</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,197</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Imputed interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">556</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Present value of minimum lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,642</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Current portion</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">356</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span>Reflects lease payments due within 12 months subsequent to the balance sheet date. <div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $517 million in 2024, $444 million in 2023 and $536 million in 2022. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.</span></div> P1Y P30Y P5Y P10Y 517000000 444000000 536000000 <div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ROU assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2816"><span style="-sec-ix-hidden:f-2817">Other noncurrent assets</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,289</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,924 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities (short-term)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2820"><span style="-sec-ix-hidden:f-2821">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">356</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities (long-term)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2824"><span style="-sec-ix-hidden:f-2825">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,626 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2289000000 2924000000 356000000 527000000 2286000000 2626000000 <div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:52.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Components of total lease cost includes:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">683</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">863 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">714 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">444 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">536 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total lease cost</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,283 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,218 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other supplemental information follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average Remaining Contractual Lease Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.8</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-Average Discount Rate</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.8 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">617 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on sale and leaseback transactions, net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(49)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 683000000 863000000 714000000 517000000 444000000 536000000 23000000 24000000 32000000 1177000000 1283000000 1218000000 P10Y2M12D P10Y9M18D 0.037 0.038 601000000 744000000 617000000 -29000000 49000000 -11000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2024:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating Lease Liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Next one year</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">443</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1-2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">406</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2-3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">361</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3-4 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">281</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4-5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,468</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,197</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Imputed interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">556</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Present value of minimum lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,642</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Current portion</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">356</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span>Reflects lease payments due within 12 months subsequent to the balance sheet date. 443000000 406000000 361000000 281000000 239000000 1468000000 3197000000 556000000 2642000000 356000000 2286000000 Contingencies and Certain Commitments<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and indemnifications. The following outlines our legal contingencies, guarantees and indemnifications. For a discussion of our tax contingencies, see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5D</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings––Patent Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights), including but not limited to, those discussed below. We face claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. In May 2023, the Court of Appeal dismissed BMS’s appeal and in October 2023, the Supreme Court refused BMS permission to appeal. Additional challenges are pending in other jurisdictions. Also, in July 2022, CureVac AG (CureVac) brought a patent infringement action against BioNTech and certain of its subsidiaries in the German Regional Court alleging that Comirnaty infringes certain German utility model patents and certain expired and unexpired European patents. Additional challenges involving Comirnaty patents may be filed against us and/or BioNTech in other jurisdictions in the future. Adverse decisions in these matters could have a material adverse effect on our results of operations.</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payors, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, as well as court proceedings relating to our intellectual property or the intellectual property rights of others, including challenges to such rights initiated by us. Also, if one of our patents (or one of our collaboration/licensing partner’s patents) is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office, as well as outside the U.S.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than anticipated. In the event that any of the patents are found valid and infringed, a competitor’s vaccine, if approved, might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. If one of our marketed products (or a product of our collaboration/licensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications (ANDAs) with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2024, we brought a patent infringement action against SpecGx LLC (SpecGX) asserting the infringement and validity of our composition of matter patent, covering immediate release formulations of tofacitinib that was challenged by SpecGX in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg immediate release tablets. In November 2024, we settled the action against SpecGX on terms not material to us.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2024, we brought a patent infringement action against Breckenridge Pharmaceutical, Inc. (Breckenridge) asserting the infringement and validity of our composition of patent, covering immediate release formulations of tofacitinib that was challenged by Breckenridge in its ANDA seeking approval to market a generic version of tofacitinib 10 mg immediate release tablets. In November 2024, we settled the action against Breckenridge on terms not material to us.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In December 2024, we brought a patent infringement action against Alkem Laboratories Ltd. (Alkem) asserting the infringement and validity of our composition of matter patent, covering immediate release formulations of tofacitinib that was challenged by Alkem in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg immediate release tablets.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Mektovi (binimetinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in August 2022, two generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Mektovi. The companies assert the invalidity and non-infringement of two method of use patents expiring in 2030, a method of use patent expiring in 2031, two method of use patents expiring in 2033, and a product by process patent expiring in 2033. Beginning in September 2022, we brought patent infringement actions against both of the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of all six patents. In January 2025, we settled with one of the generic companies on terms not material to us.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2022, we received notice from Teva Pharmaceuticals, Inc. (Teva) that it had filed an ANDA seeking approval to market a generic version of Mektovi. Teva asserts the invalidity and non-infringement of two method of use patents expiring in 2033 and a product by process patent expiring in 2033. In June 2023, we brought a patent infringement action against Teva in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the three patents.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Vyndaqel-Vyndamax (tafamidis/tafamidis meglumine)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in June 2023, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of tafamidis capsules (61 mg) or tafamidis meglumine capsules (20 mg), challenging some or all of the patents listed in the FDA’s Orange Book for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine). Scripps Research Institute (Scripps) owns the composition of matter patent and the method of treatment patents covering the products, and Pfizer is the exclusive licensee. Pfizer separately owns the crystalline form patent. Beginning in August 2023, we and Scripps brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents in suit. Pfizer is the sole plaintiff in actions that assert only the infringement and validity of the crystalline form patent.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Oxbryta (voxelotor)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In January 2024, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, and Zydus Worldwide DMCC (collectively, Zydus) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Ltd. (collectively, MSN) separately notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of voxelotor tablets, challenging some of the patents listed in the FDA’s Orange Book for Oxbryta (voxelotor tablets in 300 mg and 500 mg strengths and/or for oral suspension) on non-infringement grounds. In March 2024, we filed patent infringement actions against both generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the challenged patents. Zydus and MSN have not challenged our composition of matter patents or method of treatment patents for Oxbryta.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nurtec (rimegepant)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In April 2024, Rubicon Research Private Limited, Teva Pharmaceuticals, Inc., Changzhou Pharmaceutical Factory, Natco Pharma Limited and Natco Pharma, Inc., MSN, Aurobindo Pharma Limited, Apitoria Pharma Private Limited and Aurobindo Pharma U.S.A. Inc. (collectively, Aurobindo) and Apotex Inc. and Apotex Corp. (collectively, Apotex) notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of rimegepant orally disintegrating tablets, claiming noninfringement and/or challenging the validity of some or all of the patents listed in the FDA’s Orange Book for Nurtec (rimegepant orally disintegrating tablets Eq 75 mg base). In May 2024, we filed patent infringement actions against all the generic filers in the U.S. District Court for the District of Delaware.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Xtandi (enzalutamide)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in August 2024, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Xtandi, challenging some or all of the patents listed in the FDA’s Orange Book for Xtandi. Beginning in August 2024, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of New Jersey, asserting the validity and infringement of the patents in suit.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Inlyta (axitinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2024, Sandoz Inc. (Sandoz) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Sandoz asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In November 2024, we filed suit against Sandoz in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Actions in Which We are the Defendant</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comirnaty (tozinameran)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia &amp; Upjohn Company LLC, our wholly owned subsidiary, alleging that Comirnaty infringes a U.S. patent issued in February 2022, and seeking unspecified monetary damages. In July 2022, Alnylam filed a second complaint in the U.S. District Court for the District of Delaware against Pfizer, Pharmacia &amp; Upjohn Company LLC, BioNTech and BioNTech Manufacturing GmbH, alleging that Comirnaty infringes a U.S. patent issued in July 2022, and seeking unspecified monetary damages. In May 2023, Alnylam filed a separate complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia &amp; Upjohn Company LLC alleging that Comirnaty infringes four additional U.S. patents issued on various dates in 2023 and seeking unspecified monetary damages.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Massachusetts, alleging that Comirnaty infringes three U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In March 2024, the U.S. Patent Office Patent Trial &amp; Appeal Board instituted a review of two of the three patents in suit.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, alleging that Comirnaty infringes two European patents. In September 2022, ModernaTX filed patent infringement actions in the U.K. and in the Netherlands against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, on the same two European patents. In its complaints, ModernaTX stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In November 2023, one of the European patents was revoked by the European Patent Office. In December 2023, the other European patent was declared invalid by a court in the Netherlands (the invalidity decision is limited to the Netherlands). In July 2024, the U.K. court revoked one patent, ruling that it was invalid, and held that the other patent was valid and infringed. ModernaTX has also filed additional patent infringement actions against Pfizer and BioNTech in certain other ex-U.S. jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In April 2023, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech alleging that Comirnaty and its manufacture infringe five U.S. patents, and seeking unspecified monetary damages.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In April 2024, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC (collectively, GSK Group) sued Pfizer and Pharmacia &amp; Upjohn Company LLC, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Delaware, alleging that Comirnaty infringes five U.S. patents and seeking unspecified money damages. In August 2024, GSK Group filed an amended complaint alleging that Comirnaty infringes three additional U.S. patents.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In January 2025, Promosome LLC filed a complaint in the Unified Patent Court, Local Division Munich, against Pfizer and BioNTech and certain of their subsidiaries alleging that Comirnaty infringes a European patent that is in force only in France, Germany and Sweden, and seeking unspecified monetary damages in connection with the manufacture and sale of Comirnaty in France, Germany and Sweden.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paxlovid</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2022, Enanta Pharmaceuticals, Inc. (Enanta) filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes a U.S.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> patent issued in June 2022, and seeking unspecified monetary damages. In December</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2024, the District Court issued an order granting Pfizer’s motion for summary judgment, finding Enanta’s patent invalid.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Abrysvo</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2023, GSK Group filed a complaint in the U.S. District Court for the District of Delaware against Pfizer alleging that the active ingredient in Abrysvo infringes four U.S. patents. In November 2023, GSK Group amended its complaint to assert infringement of two additional patents. In November 2024, the GSK Group filed a second amended complaint, adding a seventh patent to the lawsuit. The second amended complaint seeks unspecified monetary damages and a permanent injunction against sales of Abrysvo for use in adults in age ranges for which GSK Group’s Arexvy product is also indicated. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, we have challenged certain of GSK’s RSV vaccine patents in certain ex-U.S. jurisdictions, including the U.K., the Netherlands, Belgium and the Unified Patent Court, and GSK has asserted that Abrysvo infringes these patents. </span><span style="color:#0d0d0d;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2024, the U.K. Court held that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">two</span><span style="color:#0d0d0d;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of GSK’s U.K. patents were invalid and not infringed.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Matters Involving Pfizer and its Collaboration/Licensing Partners</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comirnaty (tozinameran)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In July 2022, Pfizer, BioNTech and BioNTech Manufacturing GmbH filed a declaratory judgment complaint against CureVac in the U.S. District Court for the District of Massachusetts seeking a judgment of non-infringement for three U.S. patents relating to Comirnaty. In May 2023, the case was transferred to the U.S. District Court for the Eastern District of Virginia. Also in May 2023, CureVac asserted that Comirnaty infringes the three patents that were the subject of our declaratory judgment complaint, and in May and July 2023, CureVac asserted that Comirnaty infringes a number of additional U.S. patents. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the U.K., Pfizer and BioNTech have sued CureVac seeking a judgment of invalidity of several patents and CureVac has made certain infringement counterclaims. In September 2024, the U.K. Court held that both of the CureVac patents in suit are invalid.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings––Product Litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asbestos</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lipitor</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy Laboratories Limited, among others, that asserted claims and sought relief on behalf of the State of West Virginia and residents of that state alleging delay in the launch of generic Lipitor, in violation of state antitrust, consumer protection and various other laws. In December 2024, we reached an agreement to settle this matter on terms not material to Pfizer. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. Hospira is a wholly-owned subsidiary that we acquired in September 2015. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Zantac</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to Johnson &amp; Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson &amp; Johnson in connection with the sale. Plaintiffs in these cases seek compensatory and punitive damages.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Southern District of Florida (the Federal MDL Court). Plaintiffs in the MDL filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In December 2022, </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the Federal MDL Court granted defendants’ Daubert motions to exclude plaintiffs’ expert testimony and motion for summary judgment on general causation, which has resulted in the dismissal of all complaints in the litigation. Plaintiffs have appealed the Federal MDL Court’s rulings.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants’ sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts. The large majority of the state court cases have been filed in the Superior Court of Delaware in New Castle County.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Many of these Zantac-related cases have been outstanding for a number of years and could take many more years to resolve. From time to time, Pfizer has explored and will continue to explore opportunistic settlements of these matters. As of January 2025, Pfizer had settled, or entered into definitive agreements or agreements-in-principle to settle, subject to certain conditions, a substantial majority of the cases filed in state courts in which the plaintiff alleges use of a Pfizer product. The remaining unresolved state court cases continue in various state courts.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Chantix</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer’s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. In December 2022, the federal actions were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Southern District of New York. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix. The class action in Israel has been dismissed.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Depo-Provera</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer and certain subsidiaries in various federal and state courts alleging that plaintiffs who used the injectable version of Depo-Provera (active ingredient medroxyprogesterone acetate, or MPA) for contraception developed meningioma. The cases also name other defendants, including the manufacturers of generic versions of injectable MPA for contraception. Plaintiffs assert claims against Pfizer relating to both Depo-Provera and generic MPA products, and seek compensatory and punitive damages. In February 2025, the federal cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Northern District of Florida.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings––Commercial and Other Matters</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation. In 2018, Bayer AG acquired Monsanto Company (New Monsanto), which is now a subsidiary of Bayer AG. Since the acquisition, New Monsanto has continued to defend and indemnify Pharmacia for these liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as Wyeth Holdings Corporation and American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of administrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency, the New Jersey Department of Environmental Protection and/or federal and state natural resource trustees to perform remedial design, removal and remedial actions, and related environmental remediation activities, and to resolve alleged damages to natural resources, at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are also party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health and seeks monetary relief. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of plaintiffs’ claims. In January 2022, the Court of Appeals reversed the District Court’s decision. In June 2024, the U.S. Supreme Court issued an order granting certiorari, vacating the Court of Appeals’ decision, and remanding the case to the Court of Appeals.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer’s acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Breach of Contract – Comirnaty</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2023, Pfizer and BioNTech Manufacturing GmbH initiated separate formal proceedings against the Republic of Poland, the Republic of Romania and Hungary in Belgium’s Court of First Instance of Brussels. Pfizer and BioNTech are seeking an order from the Court holding those countries to their commitments for COVID-19 vaccine orders, which were placed as part of their contracts signed in 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings––Government Investigations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Like other multi-national pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Greenstone Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019 and 2020, Attorneys General of more than 50 states and territories filed two complaints in the U.S. District Court for the District of Connecticut against a number of pharmaceutical companies, including Pfizer and Greenstone—a former Pfizer subsidiary that sold generic drugs. As to Greenstone and Pfizer, the complaints allege anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. The State Attorney General complaints were initially transferred to an MDL in the U.S. District Court for the Eastern District of Pennsylvania for coordinated pre-trial proceedings but were transferred back to the District of Connecticut in April 2024. The Greenstone antitrust litigation also includes civil complaints filed in federal and state court by private and governmental plaintiffs against Pfizer, Greenstone, and a number of other defendants. These related civil lawsuits assert allegations that generally overlap with those asserted by the State Attorneys General. All of the related federal lawsuits are part of the MDL pending in Pennsylvania.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Subpoena relating to Tris Pharma/Quillivant XR</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have produced records in response to this request</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2019, we received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office for the SDNY. The CID seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at Pfizer’s former Meridian site. In August 2019, we received a HIPAA subpoena issued by the U.S. Attorney’s Office for the Eastern District of Missouri, in coordination with the Department of Justice’s Consumer Protection Branch, seeking similar records and information. We have produced records in response to these and subsequent requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice’s Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney’s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We have produced records pursuant to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Zantac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">State of New Mexico and Mayor and City Council of Baltimore Civil Actions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings––Product Litigation––Zantac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government Inquiries relating to Biohaven</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2022, the U.S. Department of Justice’s Commercial Litigation Branch and the U.S. Attorney’s Office for the Western District of New York issued a CID to Biohaven. The CID seeks records and information related to, among other things, Biohaven’s engagements with healthcare professionals and co-pay coupons cards prior to Pfizer’s acquisition of Biohaven. In March 2023, the California Department of Insurance issued a subpoena seeking records similar to those requested by the CID. Biohaven is a wholly-owned subsidiary that we acquired in October 2022. We have produced records in response to these requests. In January 2025, Biohaven entered into civil settlement agreements with the U.S., numerous states, and the California Department of Insurance to resolve these matters. Pursuant to these settlement agreements, $59.7 million, plus interest, was paid to the U.S. and participating states, and $3.3 million was paid to the California Department of Insurance. The settlement agreements relate to alleged conduct at Biohaven before Pfizer’s acquisition of the company and do not include an admission of liability by Biohaven.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government Inquiries relating to Xeljanz</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In April 2023, we received a HIPAA subpoena issued by the U.S. Attorney’s Office for the Western District of Virginia, in coordination with the Department of Justice’s Commercial Litigation Branch, seeking records and information related to programs Pfizer sponsored in retail pharmacies relating to Xeljanz. We have produced records pursuant to this request.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2024, the estimated fair value of these indemnification obligations is not material to Pfizer. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_223" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7D</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information on Pfizer Inc.’s guarantee of the debt issued by PIE in May 2023. We have also guaranteed the long-term debt of certain subsidiaries of Pfizer and certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_223" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7D</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Certain Commitments</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2024, we had commitments totaling $4.1 billion that are legally binding and enforceable. These commitments include purchase obligations for goods and services and payments relating to potential milestone payments deemed reasonably likely to occur.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_208" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5A</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for information on the TCJA repatriation tax liability.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Contingent Consideration for Acquisitions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_178" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1D</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The estimated fair value of contingent consideration as of December 31, 2024 is $517 million, of which $39 million is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and $477 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and as of December 31, 2023 was $692 million, of which $179 million was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and $512 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The decrease in the contingent consideration balance from December 31, 2023 is primarily due to payments made upon the achievement of certain sales-based milestones.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Insurance</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability.</span><span style="color:#1f497d;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued.</span></div> 1000000 2 2 2 6 1 2 3 4 3 2 3 2 2 1 1 5 5 3 4 2 7 2 3 3 2 59700000 3300000 4100000000 517000000 39000000 477000000 692000000 179000000 512000000 <span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Segment, Geographic and Other Revenue Information</span><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Segment Information</span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We manage our commercial operations through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Pfizer Ignite is an offering that provides strategic guidance and end-to-end R&amp;D services to select innovative biotech companies that align with Pfizer’s R&amp;D focus areas. Prior to June 2024, PC1 and Pfizer Ignite were managed together by a single manager as part of the former Business Innovation operating segment. Biopharma is the only reportable segment. Pfizer’s CODM is the Chairman and Chief Executive Officer. Our CODM uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. The CODM uses segment revenues and earnings in the annual budgeting process when setting strategic goals for the company and considers periodic budget-to-actual variances in segment revenues and earnings when assessing performance of the segments and making decisions about allocating resources to the operating segments. By analyzing segment financial results, the CODM can discern trends, which can inform decisions that align with the company’s goals and objectives, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">help ensure r</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">isks are managed appropriately. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly review our operating segments and the approach used by management to evaluate performance and allocate resources.</span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our commercial divisions market, sell and distribute our products, and global operating functions are responsible for the research, development, manufacturing and supply of our products. Each operating segment is supported by our global corporate enabling functions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At the beginning of 2024, we made changes in our commercial organization to incorporate Seagen and improve focus, speed and execution. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The commercial structure within our Biopharma reportable segment in 2024 was comprised of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Pfizer Oncology Division combined the U.S. Oncology commercial organizations, global Oncology marketing organizations and global and U.S. Oncology medical affairs from both Pfizer and Seagen.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Pfizer U.S. Commercial Division included the U.S. Primary Care and U.S. Specialty Care customer groups, the Chief Marketing Office, the Global Chief Medical Affairs Office and Global Access &amp; Value.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Pfizer International Commercial Division included the ex-U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio in all international markets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning January 1, 2024, Biopharma’s earnings include costs related to manufacturing and supply, sales and marketing activities, R&amp;D, and medical and safety activities that are associated with products in our Biopharma segment. Prior to 2024, overhead costs associated with our manufacturing operations and costs associated with R&amp;D and medical and safety activities managed by our global ORD and PRD organizations in 2024 were presented as part of Other business activities. We have reclassified our prior period segment information to conform to the current period presentation.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">ORD was responsible in 2024 for discovery to late-phase clinical development for oncology research projects for our global portfolio along with facilitating regulatory submissions and interactions with regulatory agencies for these projects. R&amp;D spending may include upfront and milestone payments for intellectual property rights for oncology projects.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">PRD was responsible in 2024 for discovery to late-phase clinical development research projects for all therapeutic areas other than oncology for our global portfolio, along with facilitating regulatory submissions and interactions with regulatory agencies for these projects. R&amp;D spending may include upfront and milestone payments for intellectual property rights related to non-oncology projects. PRD also had responsibility for certain science-based and other services organizations, which provide end-to-end technical expertise and other services to both ORD and PRD projects, as well as the Worldwide Medical and Safety group, which helps ensure that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payors and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other Business Activities––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other business activities include the operating results of PC1 and Pfizer Ignite as well as certain pre-tax costs not allocated to our operating segment results, such as costs associated with:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement, among others) and other corporate costs, including, but not limited to, all strategy, business development and portfolio management capabilities and certain compensation, as well as interest income and expense, and gains and losses on investments; and </span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">our share of earnings from Haleon/the Consumer Healthcare JV (see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_187" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reconciling Items––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reconciling items include the following items, transactions and events that are not allocated to our operating segments: (i) all amortization of intangible assets; (ii) acquisition-related items, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company, and which may also include purchase accounting impacts, such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such certain significant items can include, but are not limited to, pension and postretirement actuarial remeasurement gains and losses, non-acquisition-related restructuring costs, net gains and losses on investments in equity securities, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Segment Assets––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $213 billion as of December 31, 2024 and $227 billion as of December 31, 2023.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Selected Statement of Operations Information</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table provides selected information by reportable segment:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Total Revenues</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biopharma</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">58,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">99,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">28,139</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">15,923 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">47,939 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">1,360</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,107 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other business activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">1,228</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,316 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(7,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(4,342)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(5,162)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">323 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">332 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(5,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(4,733)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,609)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">5,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3,609 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(1,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,874)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain significant items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(5,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,917)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,608)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">63,627</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">59,553 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">101,175 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">8,023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,058 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">34,729 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">7,013</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">6,290 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">5,064 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&amp;D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $331 million and $294 million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Biopharma’s revenues and earnings in 2024 reflect a non-cash favorable product return adjustment of $771 million recorded in the first quarter of 2024 and in 2023 reflected a non-cash revenue reversal of $3.5 billion (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i8531e747ebb543f3bf818166f157d26a_280" style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Note 17C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). In 2023, Biopharma earnings included approximately $6.2 billion of inventory write-offs and related charges to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> mainly due to lower-than-expected demand for our COVID-19 products. In 2022, Biopharma earnings included COVID-19-related charges of approximately $1.7 billion to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, composed of (i) inventory write-offs of approximately $1.2 billion related to COVID-19 </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for Paxlovid. Biopharma’s earnings also include dividend income from our investment in ViiV of $272 million in 2024, $265 million in 2023 and $314 million in 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in 2024 include, among other items: (i) intangible asset impairment charges of $3.3 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion (primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">sts), (iii) actuarial valuation and other postretirement plan losses of $579 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2966">Other (income)/deductions––net</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (iv) charges for certain legal matters of $567 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (v) a charge in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program, partially offset by (vi) net gains on equity securities of $1.0 billion and (vii) net gains of $825 million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945 million less (b) $120 million in the fourth quarter (included in Other business activities) representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Earnings in 2023 included, among other items: (i) intangible asset impairment charges of $3.0 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion ($290 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">sts), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Earnings in 2022 included, among other items: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.4 billion ($562 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">) and (ii) net losses on equity securities of $1.3 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_199" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Notes 3</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"><tr><td style="width:1.0%"></td><td style="width:61.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.731%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides Biopharma reportable segment information regularly provided to the CODM:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biopharma reportable segment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biopharma total revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">58,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">99,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">14,997</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">22,666 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">32,859 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">10,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10,235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">9,207 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">9,532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">9,763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10,324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">108</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">194 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">181 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(543)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(685)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biopharma earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">28,139</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">15,923 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">47,939 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Revenues - Comirnaty</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">5,353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">11,220 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">37,809 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Revenues - Paxlovid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">5,716</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,279 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">18,933 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Revenues - excluding Comirnaty and Paxlovid</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">51,331</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">45,738 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">43,084 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>Geographic Information<div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">38,691</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,145 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">43,317 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed Markets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16,057</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,910 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40,534 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,879</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,498 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">63,627</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59,553 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101,175 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues exceeded $500 million in each of 11, 14 and 24 countries outside the U.S. in 2024, 2023 and 2022, respectively. The U.S. is the only country to contribute more than 10% of total revenue in 2024, 2023 and 2022. As a percentage of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, China was our largest market outside the U.S. (representing 4% of total revenues) in 2024, and Japan was our largest market outside the U.S. in 2023 and 2022 (representing 6% and 8% of total revenues, respectively).</span></div>Other Revenue Information<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of Comirnaty with multiple developed and emerging nations around the world and are continuing to deliver doses of Comirnaty under such agreements. This includes supply agreements entered into in November 2020 and February and May 2021 with the EC for Comirnaty on behalf of the different EU member states and certain other countries. Each EU member state submits its own Comirnaty vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC. In May 2023, we and BioNTech amended our contract with the EC to deliver COVID-19 vaccines to the EU. The amended agreement includes rephasing of delivery of doses annually through 2026 and an aggregate volume reduction, providing additional flexibility for those EU member states who agreed to the amended agreement. The EC will maintain access to future adapted COVID-19 vaccines and the ability to donate doses, in alignment with the original agreement.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2022 and 2023, we had entered into agreements to supply pre-specified treatment courses of Paxlovid with government and government sponsored customers in multiple developed and emerging nations around the world, which represented most Paxlovid revenues in 2022 and 2023, while commercialization began in some markets in 2023. In October 2023, we announced an amended agreement with the U.S. government, which facilitated the transition of Paxlovid to traditional commercial markets in the U.S. starting in November 2023, with prices negotiated with commercial payors and a copay assistance program for eligible privately insured patients, as the U.S. government began to discontinue the distribution of EUA-labeled Paxlovid. We ensured commercial readiness by providing NDA-labeled commercial supply by the end of 2023. However, EUA-labeled Paxlovid remained available free-of-charge to all eligible patients until the end of 2023, and therefore, there was only minimal uptake of NDA-labeled commercial product before January 1, 2024. In connection with this agreement, we recorded a non-cash revenue reversal of $3.5 billion in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory. In the first quarter of 2024, we recorded a non-cash favorable final adjustment of $771 million to reflect 5.1 million EUA-labeled treatment courses returned through February 29, 2024, which were converted to a volume-based credit that supports continued access to Paxlovid through a U.S. government patient assistance program operated by Pfizer. In the third quarter of 2024, in connection with this amended agreement, we also supplied at no cost to the U.S. government or taxpayers a U.S. SNS of 1.0 million treatment courses to enable future pandemic preparedness through 2028, and recorded revenue of $442 million. While we are recognizing revenue as these treatment courses are delivered, there is no cash consideration for these treatment courses.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes revenue, as a percentage of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, for our three largest U.S. wholesaler customers and the U.S. government, which was concentrated in our Biopharma operating segment:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">McKesson, Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cencora, Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cardinal Health, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The decrease in revenues from the U.S. government as a percentage of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> for 2024 and 2023 compared to 2022 was primarily due to the transition of Comirnaty and Paxlovid to commercial market sales in the second half of 2023 as well as the revenue reversal for Paxlovid in the fourth quarter of 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collectively, our three largest U.S. wholesaler customers represented 34% and 42% of total trade accounts receivable as of December 31, 2024 and December 31, 2023, respectively. Accounts receivable from the U.S. government as of December 31, 2024 and December 31, 2023 were not material to our consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Significant Revenues by Product</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:20.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TOTAL REVENUES</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">63,627</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">59,553 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">101,175 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">58,237 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">99,826 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Primary Care</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">30,135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">30,799 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">73,181 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Eliquis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">7,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6,747 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6,480 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Prevnar family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent pneumonia, invasive disease and otitis media caused by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Streptococcus pneumoniae</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,411</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6,501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6,342 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Paxlovid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">COVID-19 in certain </span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">high-risk patients</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">5,716</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,279 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">18,933 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Comirnaty</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent COVID-19</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">5,353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">11,220 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">37,809 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Nurtec ODT/Vydura</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Acute treatment of migraine and prevention of episodic migraine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">928 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Abrysvo</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent RSV infection</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">890 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Premarin family</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">380</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">397 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">BMP2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bone graft for spinal fusion</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">352</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">338 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">268 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">200 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">All other Primary Care</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,259</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,233 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,473 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Specialty Care</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">16,652</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">14,988 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">13,851 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Vyndaqel family</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">ATTR-CM and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">5,451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">3,321 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,447 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Xeljanz</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,703 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,796 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">830 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Sulperazon</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">637</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">786 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">586</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">412 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Octagam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">245 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">186 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Inflectra</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">490 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">406 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:20.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Genotropin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">470</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">539 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">360 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">424 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">425 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cibinqo</span></div></td><td colspan="3" style="padding:0 1pt 0 10pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Atopic dermatitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Oxbryta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Sickle cell disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">201</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">328 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">All other Hospital</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">4,448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4,514 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4,730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">All other Specialty Care</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">907</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">792 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">743 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">15,612</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">12,450 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">12,794 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">4,367</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4,753 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,120 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Xtandi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">mCRPC, nmCRPC, mCSPC, nmCSPC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,659 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Padcev</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Locally advanced or metastatic urothelial cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">53 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Adcetris</span></div></td><td colspan="3" style="padding:0 1pt 0 10pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Hodgkin lymphoma and certain T-cell lymphomas</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,089</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Oncology biosimilars</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,037</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,407 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,753 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Inlyta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,036 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">731</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">539 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">343 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bosulif</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Philadelphia chromosome–positive chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">645</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">645 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">575 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Braftovi/Mektovi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux (cetuximab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> (after prior therapy) or cetuximab and mFOLFOX6 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">607</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">456 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Tukysa</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Elrexfio</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Relapsed or refractory multiple myeloma</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Tivdak</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Recurrent or mCC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Talzenna</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">In combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC; treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,272 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,342 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PFIZER IGNITE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">44 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">7 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">BIOPHARMA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">58,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">99,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">PFIZER U.S. COMMERCIAL DIVISION (U.S. Primary Care and U.S. Specialty Care)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">26,765</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">19,299 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">34,337 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">PFIZER ONCOLOGY DIVISION</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,567</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">8,450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">8,583 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">PFIZER INTERNATIONAL COMMERCIAL DIVISION</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">24,068</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">30,488 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">56,905 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Alliance revenues included above</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8,388</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">7,582 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">8,537 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Royalty revenues included above</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,423</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,058 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">845 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects Alliance revenues and product revenues.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2024 includes (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2024 includes $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.45pt">In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of expanded access programs worldwide, based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Primarily reflects Alliance revenues and royalty revenues.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Erbitux is a registered trademark of ImClone LLC.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt">PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty and Paxlovid to our customers totaled approximately $4 billion and $1 billion, respectively, as of December 31, 2024, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of these amounts, current contract terms provide for expected delivery of product with contracted revenue from 2025 through 2028, the timing of which may be renegotiated. Remaining performance obligations are based on foreign exchange rates as of the end of our fiscal fourth quarter of 2024 and exclude arrangements with an original expected contract duration of less than one year. Remaining performance obligations associated with contracts for other products and services were not significant as of December 31, 2024 or 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenues–– </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers for supply of Paxlovid and Comirnaty. The deferred revenues related to Paxlovid and Comirnaty totaled $2.2 billion as of December 31, 2024, with $1.4 billion and $785 million recorded in current liabilities and noncurrent liabilities, respectively. The deferred revenues related to Paxlovid and Comirnaty totaled $5.1 billion as of December 31, 2023, with $2.6 billion and $2.5 billion recorded in current liabilities and noncurrent liabilities, respectively. The decrease in Paxlovid and Comirnaty deferred revenues during full-year 2024 was primarily driven by amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as we delivered the products to our customers (including $442 million associated with the U.S. SNS for Paxlovid) as well as the aforementioned $771 million favorable final adjustment recorded in the first quarter of 2024 for Paxlovid, partially offset by additional advance payments received in 2024 as we entered into amended contracts. During 2024, we recognized revenue of approximately $2.9 billion that was included in the balance of Paxlovid and Comirnaty deferred revenues as of December 31, 2023. The Paxlovid and Comirnaty deferred revenues as of December 31, 2024 will be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> proportionately as we transfer control of the products to our customers and satisfy our performance obligations under the contracts, with the amounts included in current liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> from December 2025 (which falls in our international first quarter of 2026) through 2028. Deferred revenues associated with contracts for other products were not significant as of December 31, 2024 or December 31, 2023.</span></div> 3 213000000000 227000000000 <div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table provides selected information by reportable segment:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Total Revenues</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biopharma</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">58,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">99,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">28,139</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">15,923 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">47,939 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">1,360</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,107 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other business activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">1,228</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,316 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(7,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(4,342)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(5,162)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">323 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">332 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(5,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(4,733)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,609)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">5,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3,609 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(1,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,874)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain significant items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(5,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,917)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,608)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">63,627</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">59,553 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">101,175 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">8,023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,058 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">34,729 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">7,013</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">6,290 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">5,064 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&amp;D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $331 million and $294 million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Biopharma’s revenues and earnings in 2024 reflect a non-cash favorable product return adjustment of $771 million recorded in the first quarter of 2024 and in 2023 reflected a non-cash revenue reversal of $3.5 billion (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i8531e747ebb543f3bf818166f157d26a_280" style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Note 17C</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). In 2023, Biopharma earnings included approximately $6.2 billion of inventory write-offs and related charges to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> mainly due to lower-than-expected demand for our COVID-19 products. In 2022, Biopharma earnings included COVID-19-related charges of approximately $1.7 billion to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, composed of (i) inventory write-offs of approximately $1.2 billion related to COVID-19 </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for Paxlovid. Biopharma’s earnings also include dividend income from our investment in ViiV of $272 million in 2024, $265 million in 2023 and $314 million in 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in 2024 include, among other items: (i) intangible asset impairment charges of $3.3 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion (primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">sts), (iii) actuarial valuation and other postretirement plan losses of $579 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2966">Other (income)/deductions––net</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (iv) charges for certain legal matters of $567 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (v) a charge in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program, partially offset by (vi) net gains on equity securities of $1.0 billion and (vii) net gains of $825 million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945 million less (b) $120 million in the fourth quarter (included in Other business activities) representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Earnings in 2023 included, among other items: (i) intangible asset impairment charges of $3.0 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion ($290 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">sts), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Earnings in 2022 included, among other items: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.4 billion ($562 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">) and (ii) net losses on equity securities of $1.3 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_199" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Notes 3</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8531e747ebb543f3bf818166f157d26a_202" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"><tr><td style="width:1.0%"></td><td style="width:61.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.731%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides Biopharma reportable segment information regularly provided to the CODM:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biopharma reportable segment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biopharma total revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">58,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">99,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">14,997</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">22,666 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">32,859 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">10,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10,235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">9,207 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">9,532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">9,763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10,324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">108</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">194 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">181 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(543)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(685)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biopharma earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">28,139</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">15,923 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">47,939 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Revenues - Comirnaty</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">5,353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">11,220 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">37,809 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Revenues - Paxlovid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">5,716</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,279 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">18,933 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Revenues - excluding Comirnaty and Paxlovid</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">51,331</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">45,738 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">43,084 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 62400000000 58237000000 99826000000 28139000000 15923000000 47939000000 1360000000 1213000000 1107000000 1228000000 1316000000 1349000000 -7382000000 -4342000000 -5162000000 340000000 323000000 332000000 -5286000000 -4733000000 -3609000000 5286000000 4733000000 3609000000 -1938000000 -1874000000 -832000000 12000000 -11000000 -20000000 -5510000000 -3917000000 -3608000000 14000000 32000000 36000000 63627000000 59553000000 101175000000 8023000000 1058000000 34729000000 7013000000 6290000000 5064000000 14700000000 9200000000 331000000 294000000 771000000 771000000 3500000000 6200000000 1700000000 1200000000 500000000 272000000 265000000 314000000 3300000000 2200000000 -579000000 -567000000 -420000000 1 1000000000.0 825000000 945000000 120000000 3000000000.0 2200000000 290000000 1600000000 1400000000 562000000 -1300000000 62400000000 58237000000 99826000000 14997000000 22666000000 32859000000 10040000000 10235000000 9207000000 9532000000 9763000000 10324000000 108000000 194000000 181000000 416000000 543000000 685000000 28139000000 15923000000 47939000000 5353000000 11220000000 37809000000 5716000000 1279000000 18933000000 51331000000 45738000000 43084000000 <div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">38,691</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,145 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">43,317 </span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">International:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed Markets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16,057</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,910 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40,534 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,879</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,498 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">63,627</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59,553 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101,175 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 38691000000 28145000000 43317000000 16057000000 20910000000 40534000000 8879000000 10498000000 17324000000 63627000000 59553000000 101175000000 11 14 24 0.10 0.10 0.10 0.04 0.06 0.08 3500000000 6500000 771000000 5100000 1000000 442000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes revenue, as a percentage of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, for our three largest U.S. wholesaler customers and the U.S. government, which was concentrated in our Biopharma operating segment:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">McKesson, Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cencora, Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cardinal Health, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 0.23 0.16 0.08 0.17 0.12 0.05 0.14 0.10 0.04 0.06 0 0.23 0.34 0.42 <div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:20.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TOTAL REVENUES</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">63,627</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">59,553 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">101,175 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">58,237 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">99,826 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Primary Care</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">30,135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">30,799 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">73,181 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Eliquis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">7,366</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6,747 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6,480 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Prevnar family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent pneumonia, invasive disease and otitis media caused by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Streptococcus pneumoniae</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">6,411</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6,501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">6,342 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Paxlovid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">COVID-19 in certain </span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">high-risk patients</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">5,716</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,279 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">18,933 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Comirnaty</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent COVID-19</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">5,353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">11,220 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">37,809 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Nurtec ODT/Vydura</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Acute treatment of migraine and prevention of episodic migraine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">928 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Abrysvo</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent RSV infection</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">890 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Premarin family</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">380</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">397 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">BMP2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bone graft for spinal fusion</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">352</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">338 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">268 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">200 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">All other Primary Care</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,259</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,233 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,473 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Specialty Care</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">16,652</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">14,988 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">13,851 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Vyndaqel family</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">ATTR-CM and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">5,451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">3,321 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">2,447 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Xeljanz</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,703 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,796 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">830 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Sulperazon</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">637</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">757 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">786 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">586</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">412 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Octagam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">245 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">186 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Inflectra</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">490 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">406 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:20.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Genotropin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">470</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">539 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">360 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">424 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">425 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cibinqo</span></div></td><td colspan="3" style="padding:0 1pt 0 10pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Atopic dermatitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Oxbryta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Sickle cell disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">201</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">328 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">All other Hospital</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">4,448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4,514 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4,730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">All other Specialty Care</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">907</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">792 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">743 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">15,612</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">12,450 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">12,794 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">4,367</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4,753 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">5,120 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Xtandi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">mCRPC, nmCRPC, mCSPC, nmCSPC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">2,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,659 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Padcev</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Locally advanced or metastatic urothelial cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">53 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Adcetris</span></div></td><td colspan="3" style="padding:0 1pt 0 10pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Hodgkin lymphoma and certain T-cell lymphomas</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,089</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Oncology biosimilars</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,037</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,407 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,753 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Inlyta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,036 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">731</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">539 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">343 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Bosulif</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Philadelphia chromosome–positive chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">645</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">645 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">575 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Braftovi/Mektovi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux (cetuximab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> (after prior therapy) or cetuximab and mFOLFOX6 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">607</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">456 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Tukysa</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Elrexfio</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Relapsed or refractory multiple myeloma</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Tivdak</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Recurrent or mCC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Talzenna</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">In combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC; treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,272 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,342 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PFIZER IGNITE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">44 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">7 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">BIOPHARMA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">58,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">99,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">PFIZER U.S. COMMERCIAL DIVISION (U.S. Primary Care and U.S. Specialty Care)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">26,765</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">19,299 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">34,337 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">PFIZER ONCOLOGY DIVISION</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">11,567</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">8,450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">8,583 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">PFIZER INTERNATIONAL COMMERCIAL DIVISION</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">24,068</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">30,488 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">56,905 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Alliance revenues included above</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">8,388</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">7,582 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">8,537 </span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Royalty revenues included above</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">1,423</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1,058 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">845 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects Alliance revenues and product revenues.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2024 includes (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2024 includes $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.45pt">In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of expanded access programs worldwide, based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Primarily reflects Alliance revenues and royalty revenues.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Erbitux is a registered trademark of ImClone LLC.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt">PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.</span></div> 63627000000 59553000000 101175000000 62400000000 58237000000 99826000000 30135000000 30799000000 73181000000 7366000000 6747000000 6480000000 6411000000 6501000000 6342000000 5716000000 1279000000 18933000000 5353000000 11220000000 37809000000 1263000000 928000000 213000000 755000000 890000000 0 380000000 397000000 455000000 352000000 338000000 277000000 280000000 268000000 200000000 2259000000 2233000000 2473000000 16652000000 14988000000 13851000000 5451000000 3321000000 2447000000 1168000000 1703000000 1796000000 690000000 830000000 1003000000 637000000 757000000 786000000 586000000 511000000 412000000 509000000 245000000 186000000 509000000 490000000 532000000 480000000 406000000 331000000 470000000 539000000 360000000 381000000 424000000 425000000 215000000 128000000 27000000 201000000 328000000 73000000 4448000000 4514000000 4730000000 907000000 792000000 743000000 15612000000 12450000000 12794000000 4367000000 4753000000 5120000000 2039000000 1659000000 1650000000 1588000000 53000000 0 1089000000 56000000 0 1037000000 1407000000 1753000000 978000000 1036000000 1003000000 731000000 539000000 343000000 645000000 645000000 575000000 607000000 477000000 456000000 480000000 18000000 0 133000000 10000000 0 131000000 4000000 0 117000000 64000000 48000000 1670000000 1729000000 1846000000 1146000000 1272000000 1342000000 82000000 44000000 7000000 62400000000 58237000000 99826000000 26765000000 19299000000 34337000000 11567000000 8450000000 8583000000 24068000000 30488000000 56905000000 8388000000 7582000000 8537000000 1423000000 1058000000 845000000 771000000 771000000 3500000000 5100000 6500000 442000000 3500000000 6500000 129000000 4000000000 1000000000 2200000000 1400000000 785000000 5100000000 2600000000 2500000000 442000000 771000000 771000000 2900000000 false false false false true KPMG LLP New York, NY 185 See Note 1A. Exclusive of amortization of intangible assets. See Note 17A. Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E. Reclassified into Other (income)/deductions—net. See Note 17A. See Note 17C. See Note 2C. The changes in the estimated fair values are to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities. As adjusted, comprised of $1.1 billion current inventories and $2.1 billion noncurrent inventories. As adjusted, comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years. As adjusted, included primarily in Noncurrent deferred tax liabilities. The measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments. See Note 6. Included in Other (income)/deductions––net. Adjustments in 2024 include (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities. In 2024, includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements. The 2024 activity primarily represent foreign currency translation balances in Accumulated other comprehensive income related to the equity-method investment in Haleon that were reclassified into Equity-method investments upon our loss of significant influence over Haleon and our discontinuance of the equity method for the Haleon investment. The final carrying value of our equity-method investment in Haleon was reclassified to Short-term investments and is being accounted for as an equity investment with a readily determinable fair value. Represents sales to our partners of products manufactured by us. Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2024 was primarily driven by an increase in Alliance revenues from Eliquis and Xtandi, partially offset by a decrease in Alliance revenues from Bavencio. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis. Primarily relates to royalties from our collaboration partners. Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decreases in 2024 and in 2023 primarily relate to Comirnaty. Represents net reimbursements to our partners for selling, informational and administrative expenses incurred. Represents net reimbursements from our partners for research and development expenses incurred. Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners. Relates to exit costs associated with terminating a collaboration with SMPS. Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.8 billion for 2024 (including charges of $1.2 billion for our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program), $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed) and $796 million for 2022 (including charges of $601 million for our Transforming to a More Focused Company program). Represents external costs for banking, legal, accounting and other similar services. Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2023 costs mostly relate to our acquisition of Seagen, including $476 million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of 2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our acquisitions of Arena and GBT, including $138 million in payments to Arena employees in the first quarter of 2022 and $136 million in payments to GBT employees in the fourth quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See Note 2A. Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements. Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million). Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million). Capitalized interest totaled $182 million in 2024, $160 million in 2023 and $124 million in 2022. The increase in net interest expense in 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $8 billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen. (c)2024 net gains primarily include, among other things, an unrealized gain of $1.0 billion related to our investment in Haleon, which is now carried at fair value (see Note 2C). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of $986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas. 2024 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer. The amount for 2024 represents intangible asset impairment charges, and includes $2.9 billion recorded in the fourth quarter associated with our Biopharma segment, due to changes in development plans and updated long-range commercial forecasts, composed of: (i) $1.0 billion for B7H4V (felmetatug vedotin), a Phase 1 IPR&D asset, (ii) $475 million for Medrol, a finite-lived brand, (iii) $435 million for Zavzpret nasal spray developed technology rights, (iv) $400 million and $200 million for Tukysa and disitamab vedotin, respectively, IPR&D assets reflecting emerging competition, as well as (v) other developed technology rights, IPR&D impairments and a finite-lived licensing agreement totaling $436 million which also includes de-prioritization of certain assets. 2024 also includes a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The amount for 2023 primarily represented intangible asset impairment charges of $3.0 billion, of which $2.9 billion was associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: (i) $1.4 billion for etrasimod (Velsipity) IPR&D, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 developed technology rights due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) $486 million for various other IPR&D assets and developed technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also included $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset impairment charges associated with our Biopharma segment of $200 million for an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics. See Note 2C. The amount for 2024 primarily includes, among other things, (i) gains of $945 million on the partial sales of our investment in Haleon in March and October 2024, (ii) dividend income of $272 million from our investment in ViiV and (iii) a charge of $420 million recorded in the third quarter related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. 2023 included, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included, among other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the fair value of contingent consideration. The fair value amounts are presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E. Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows. 2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges. 2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022. The higher rate percentages for the 2023 reconciling items are significantly impacted by the lower domestic and international Income from continuing operations before provision/(benefit) for taxes on income (see Note 5A). For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income. In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We have Puerto Rican tax incentives pursuant to a grant that expires during 2053. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we have incentive tax rates effective through 2048 on income from manufacturing and other operations. See Note 5A. The higher rate benefit from the Foreign-Derived Intangible Income deduction in 2022 is mainly the result of the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021. Includes the impact of U.S. state and local taxes and changes in the state valuation allowances including those related to the acquisition of Seagen. Includes changes in interest related to our uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. All other, net is primarily due to routine business operations. The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See Note 1Q. The increase in net deferred tax assets in 2024 is primarily related to temporary differences associated with the timing of accruals recorded in the ordinary course of business. The increase in net deferred tax assets in 2024 is primarily due to measurement period adjustments of inventories related to Seagen. See Note 2A. The decrease in net deferred tax liabilities in 2024 is primarily due to amortization of intangible assets and certain impairment charges, as well as the measurement period adjustments of intangible assets related to Seagen. The decrease in net deferred tax assets in 2024 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See Note 11. The increase in deferred tax assets in 2024 is primarily related to the TCJA requirement to capitalize R&D costs for tax years beginning after December 31, 2021. The amounts in 2024 and 2023 are reduced for unrecognized tax benefits of $575 million and $1.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. In 2024, Noncurrent deferred tax assets and other noncurrent tax assets ($6.6 billion), and Noncurrent deferred tax liabilities ($2.1 billion). In 2023, Noncurrent deferred tax assets and other noncurrent tax assets ($1.8 billion), and Noncurrent deferred tax liabilities ($640 million). Excludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.3 billion and $11.1 billion for 2024 and 2023 respectively, given that management has determined based on applicable accounting rules that it is remote that these tax attributes will be utilized. Primarily included in Provision/(benefit) for taxes on income. In 2024, the amount includes a gross unrecognized tax benefit associated with the expected filing of an amended income tax return related to the Transition Tax liability under the TCJA. Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See Note 5A. Primarily related to cash payments and reductions of tax attributes. Primarily related to decreases as a result of a lapse of applicable statutes of limitations. In 2024, included in Income taxes payable ($103 million), Other current assets ($0.4 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.5 billion), Noncurrent deferred tax liabilities ($3 million) and Other taxes payable ($2.9 billion). In 2023, included in Income taxes payable ($94 million), Other current assets ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.3 billion), Noncurrent deferred tax liabilities ($4 million) and Other taxes payable ($3.4 billion). Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely. Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program and gains/(losses) related to our investment in Haleon (see Note 2C). Includes money market funds. As of December 31, 2024, short-term equity securities include our investment in Haleon of $6.5 billion. See Note 2C. Long-term equity securities of $133 million as of December 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans. Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4). As of December 31, 2024, our investment in Haleon is reported in Short-term investments and as of December 31, 2023 was reported in Equity-method investments. See Note 2C. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt. Represent investments in the life sciences sector. Reported in Other (income)/deductions––net. See Note 4. Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $360 million and upward adjustments of $222 million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022 Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see Note 2A). The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94% as of December 31, 2024 and 5.37% as of December 31, 2023. Primarily includes cash collateral. See Note 7F. Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest. Reclassified to the current portion of long-term debt. The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2024 and $4.9 billion as of December 31, 2023. OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss). The amounts reclassified from OCI into COS were a net gain of $119 million in 2024 and a net gain of $253 million in 2023. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $330 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 18 years and relates to foreign currency debt. The amounts reclassified from OCI were reclassified into OID. Long-term debt includes foreign currency borrowings which are used in net investment hedges; the related carrying values as of December 31, 2024 and December 31, 2023 were $777 million and $824 million, respectively. Carrying amounts exclude the cumulative amount of fair value hedging adjustments. The increase from December 31, 2023 reflects higher inventory levels for certain products mainly due to changes in net market demand, network strategy and new product launches. Included in Other noncurrent assets. The decrease from December 31, 2023 is primarily driven by a reduction in acquired Seagen inventory, inclusive of the acquisition accounting fair value step up. See Note 2A. Based on our current estimates and assumptions, there are no recoverability issues for these amounts. The increase in the gross carrying amount includes $740 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by impairments of $943 million (see Note 4). The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Medrol, partially offset by impairments of $475 million in finite-lived brands (see Note 4). The decrease in the gross carrying amount reflects impairments of $1.9 billion (see Note 4), $1.7 billion of measurement period adjustments related to our acquisition of Seagen (see Note 2A), and the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna). The decrease is primarily due to amortization expense of $5.3 billion, impairments of $3.3 billion (see Note 4) and measurement period adjustments related to our acquisition of Seagen of $950 million (see Note 2A). As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 17A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed the re-allocation during the fourth quarter of 2024 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment. Additions primarily represent our acquisition of Seagen in 2023 and measurement period adjustments related to our acquisition of Seagen in 2024 (see Note 2A). Reflects: (i) actuarial remeasurement net losses in 2024, primarily due to unfavorable asset performance for the U.S. pension plans and decreases in discount rates for the international pension plans, partially offset by increases in discount rates for the U.S. pension plans and favorable asset performance for the international pension plans and postretirement plans, (ii) actuarial remeasurement net gains in 2023, primarily due to favorable asset performance in the U.S. and increases in discount rates for the international plans, partially offset by unfavorable asset performance for certain international plans, and (iii) actuarial remeasurement net gains in 2022, primarily due to increases in discount rates, partially offset by unfavorable asset performance. The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen. For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.1 billion in 2024 and $7.0 billion in 2023. For the postretirement plans, the benefit obligation is the ABO. For 2024, primarily includes actuarial losses resulting from decreases in discount rates for the international pension plans, and other assumption changes for the postretirement plans, largely offset by actuarial gains resulting from increases in discount rates for the U.S. pension plans. For 2023, primarily included actuarial gains resulting from increases in discount rates for the international pension plans. Our U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2024. Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets. Government and agency obligations are inclusive of repurchase agreements. Mainly includes investments in private equity, private debt and real estate. Mostly includes investments in hedge funds and real estate. Reflects postretirement plan assets, which support our U.S. retiree medical plans. Weighted-average GDFV per TSRUs and stock options. Vested and non-vested shares outstanding, but not paid as of December 31, 2024 were 33.9 million. In 2024, we settled 2,419,674 TSRUs with a weighted-average grant price of $27.76 per unit. In 2024, 1,150,382 TSRUs with a weighted-average grant price of $31.54 per unit were converted into 100,307 PTUs. Market price of our underlying common stock less grant price plus dividend equivalents to date. The number of TSRUs expected to vest takes into account an estimate of expected forfeitures Market price of our underlying common stock less exercise price. The number of options expected to vest takes into account an estimate of expected forfeitures. These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect. Reflects lease payments due within 12 months subsequent to the balance sheet date. Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, overhead costs associated with our manufacturing operations and costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations as they operated in 2024 are included in Biopharma’s earnings. We have reclassified $14.7 billion and $9.2 billion of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation. Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. As described above, in connection with the organizational changes effective in the first quarter of 2024, we have reclassified $331 million and $294 million of net costs in 2023 and 2022, respectively, from Other business activities to Biopharma to conform to the current period presentation. Biopharma’s revenues and earnings in 2024 reflect a non-cash favorable product return adjustment of $771 million recorded in the first quarter of 2024 and in 2023 reflected a non-cash revenue reversal of $3.5 billion (see Note 17C). In 2023, Biopharma earnings included approximately $6.2 billion of inventory write-offs and related charges to Cost of sales mainly due to lower-than-expected demand for our COVID-19 products. In 2022, Biopharma earnings included COVID-19-related charges of approximately $1.7 billion to Cost of sales, composed of (i) inventory write-offs of approximately $1.2 billion related to COVID-19 products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for Paxlovid. Biopharma’s earnings also include dividend income from our investment in ViiV of $272 million in 2024, $265 million in 2023 and $314 million in 2022. Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above. Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in 2024 include, among other items: (i) intangible asset impairment charges of $3.3 billion recorded in Other (income)/deductions––net, (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs), (iii) actuarial valuation and other postretirement plan losses of $579 million recorded in Other (income)/deductions––net, (iv) charges for certain legal matters of $567 million recorded in Other (income)/deductions––net, and (v) a charge in Other (income)/deductions––net of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program, partially offset by (vi) net gains on equity securities of $1.0 billion and (vii) net gains of $825 million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945 million less (b) $120 million in the fourth quarter (included in Other business activities) representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares. Earnings in 2023 included, among other items: (i) intangible asset impairment charges of $3.0 billion recorded in Other (income)/deductions––net and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $2.2 billion ($290 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in Other (income)/deductions––net. Earnings in 2022 included, among other items: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.4 billion ($562 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs) and (ii) net losses on equity securities of $1.3 billion recorded in Other (income)/deductions––net. See Notes 3 and 4 Reflects Alliance revenues and product revenues. 2024 includes (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory. 2024 includes $129 million related to a one-time sales true-up settlement agreement with our commercialization partner. In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of expanded access programs worldwide, based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing. Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio. Primarily reflects Alliance revenues and royalty revenues. Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym. (h)Erbitux is a registered trademark of ImClone LLC. PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.

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

  •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end XML 170 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 171 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 173 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 1034 839 1 true 288 0 false 20 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.pfizer.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.pfizer.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 9952151 - Statement - Consolidated Statements of Operations Sheet http://www.pfizer.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 3 false false R4.htm 9952152 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 4 false false R5.htm 9952153 - Statement - Consolidated Balance Sheets Sheet http://www.pfizer.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 5 false false R6.htm 9952154 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 9952155 - Statement - Consolidated Statements of Equity Sheet http://www.pfizer.com/role/ConsolidatedStatementsofEquity Consolidated Statements of Equity Statements 7 false false R8.htm 9952156 - Statement - Consolidated Statements of Equity (Parenthetical) Sheet http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical Consolidated Statements of Equity (Parenthetical) Statements 8 false false R9.htm 9952157 - Statement - Consolidated Statements of Cash Flows Sheet http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 9952158 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 10 false false R11.htm 9952159 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangement Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement Notes 11 false false R12.htm 9952160 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Sheet http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Notes 12 false false R13.htm 9952161 - Disclosure - Other (Income)/Deductions???Net Sheet http://www.pfizer.com/role/OtherIncomeDeductionsNet Other (Income)/Deductions???Net Notes 13 false false R14.htm 9952162 - Disclosure - Tax Matters Sheet http://www.pfizer.com/role/TaxMatters Tax Matters Notes 14 false false R15.htm 9952163 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Sheet http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Notes 15 false false R16.htm 9952164 - Disclosure - Financial Instruments Sheet http://www.pfizer.com/role/FinancialInstruments Financial Instruments Notes 16 false false R17.htm 9952165 - Disclosure - Other Financial Information Sheet http://www.pfizer.com/role/OtherFinancialInformation Other Financial Information Notes 17 false false R18.htm 9952166 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.pfizer.com/role/PropertyPlantandEquipmentNet Property, Plant and Equipment, Net Notes 18 false false R19.htm 9952167 - Disclosure - Identifiable Intangible Assets, Net and Goodwill Sheet http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwill Identifiable Intangible Assets, Net and Goodwill Notes 19 false false R20.htm 9952168 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans Pension and Postretirement Benefit Plans and Defined Contribution Plans Notes 20 false false R21.htm 9952169 - Disclosure - Equity Sheet http://www.pfizer.com/role/Equity Equity Notes 21 false false R22.htm 9952170 - Disclosure - Share-Based Payments Sheet http://www.pfizer.com/role/ShareBasedPayments Share-Based Payments Notes 22 false false R23.htm 9952171 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders Sheet http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders Notes 23 false false R24.htm 9952172 - Disclosure - Leases Sheet http://www.pfizer.com/role/Leases Leases Notes 24 false false R25.htm 9952173 - Disclosure - Contingencies and Certain Commitments Sheet http://www.pfizer.com/role/ContingenciesandCertainCommitments Contingencies and Certain Commitments Notes 25 false false R26.htm 9952174 - Disclosure - Segment, Geographic and Other Revenue Information Sheet http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation Segment, Geographic and Other Revenue Information Notes 26 false false R27.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 27 false false R28.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 28 false false R29.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 29 false false R30.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 30 false false R31.htm 9955511 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies 31 false false R32.htm 9955512 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies 32 false false R33.htm 9955513 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement (Tables) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement (Tables) Tables http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangement 33 false false R34.htm 9955514 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables) Sheet http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables) Tables http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives 34 false false R35.htm 9955515 - Disclosure - Other (Income)/Deductions???Net (Tables) Sheet http://www.pfizer.com/role/OtherIncomeDeductionsNetTables Other (Income)/Deductions???Net (Tables) Tables http://www.pfizer.com/role/OtherIncomeDeductionsNet 35 false false R36.htm 9955516 - Disclosure - Tax Matters (Tables) Sheet http://www.pfizer.com/role/TaxMattersTables Tax Matters (Tables) Tables http://www.pfizer.com/role/TaxMatters 36 false false R37.htm 9955517 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables) Sheet http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables) Tables http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests 37 false false R38.htm 9955518 - Disclosure - Financial Instruments (Tables) Sheet http://www.pfizer.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.pfizer.com/role/FinancialInstruments 38 false false R39.htm 9955519 - Disclosure - Other Financial Information (Tables) Sheet http://www.pfizer.com/role/OtherFinancialInformationTables Other Financial Information (Tables) Tables http://www.pfizer.com/role/OtherFinancialInformation 39 false false R40.htm 9955520 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.pfizer.com/role/PropertyPlantandEquipmentNetTables Property, Plant and Equipment, Net (Tables) Tables http://www.pfizer.com/role/PropertyPlantandEquipmentNet 40 false false R41.htm 9955521 - Disclosure - Identifiable Intangible Assets, Net and Goodwill (Tables) Sheet http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillTables Identifiable Intangible Assets, Net and Goodwill (Tables) Tables http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwill 41 false false R42.htm 9955522 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables) Tables http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans 42 false false R43.htm 9955523 - Disclosure - Share-Based Payments (Tables) Sheet http://www.pfizer.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.pfizer.com/role/ShareBasedPayments 43 false false R44.htm 9955524 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables) Sheet http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables) Tables http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders 44 false false R45.htm 9955525 - Disclosure - Leases (Tables) Sheet http://www.pfizer.com/role/LeasesTables Leases (Tables) Tables http://www.pfizer.com/role/Leases 45 false false R46.htm 9955526 - Disclosure - Segment, Geographic and Other Revenue Information (Tables) Sheet http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables Segment, Geographic and Other Revenue Information (Tables) Tables http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation 46 false false R47.htm 9955527 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details) Sheet http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and Significant Accounting Policies - Narrative (Details) Details http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables 47 false false R48.htm 9955528 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) Sheet http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) Details 48 false false R49.htm 9955529 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Acquisitions (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Acquisitions (Details) Details http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables 49 false false R50.htm 9955530 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation (Details) Details http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables 50 false false R51.htm 9955531 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation - Footnotes (Details) Notes http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation - Footnotes (Details) Details 51 false false R52.htm 9955532 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information (Details) Details http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables 52 false false R53.htm 9955533 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information - Footnotes (Details) Notes http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information - Footnotes (Details) Details 53 false false R54.htm 9955534 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Divestitures (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Divestitures (Details) Details http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables 54 false false R55.htm 9955535 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment (Details) Details 55 false false R56.htm 9955536 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment - Footnotes (Details) Notes http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment - Footnotes (Details) Details 56 false false R57.htm 9955537 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Summarized Financial Information of Equity Method Investee (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Summarized Financial Information of Equity Method Investee (Details) Details 57 false false R58.htm 9955538 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Equity Method Investments (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Equity Method Investments (Details) Details http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables 58 false false R59.htm 9955539 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Collaborative Arrangements (Detail) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Collaborative Arrangements (Detail) Details http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables 59 false false R60.htm 9955540 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) Details 60 false false R61.htm 9955541 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Research and Development Arrangement (Details) Sheet http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Research and Development Arrangement (Details) Details 61 false false R62.htm 9955542 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) Sheet http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) Details http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables 62 false false R63.htm 9955543 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) Sheet http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) Details http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables 63 false false R64.htm 9955544 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) Notes http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) Details http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables 64 false false R65.htm 9955545 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) Sheet http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) Details http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables 65 false false R66.htm 9955546 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) Notes http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) Details 66 false false R67.htm 9955547 - Disclosure - Other (Income)/Deductions???Net - Schedule of Other Nonoperating Income (Expense) (Details) Sheet http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails Other (Income)/Deductions???Net - Schedule of Other Nonoperating Income (Expense) (Details) Details http://www.pfizer.com/role/OtherIncomeDeductionsNetTables 67 false false R68.htm 9955548 - Disclosure - Other (Income)/Deductions???Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details) Notes http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails Other (Income)/Deductions???Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details) Details http://www.pfizer.com/role/OtherIncomeDeductionsNetTables 68 false false R69.htm 9955549 - Disclosure - Other (Income)/Deductions???Net - Schedule of Additional Information About Intangible Assets Impaired (Details) Sheet http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails Other (Income)/Deductions???Net - Schedule of Additional Information About Intangible Assets Impaired (Details) Details http://www.pfizer.com/role/OtherIncomeDeductionsNetTables 69 false false R70.htm 9955550 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details) Sheet http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details) Details 70 false false R71.htm 9955551 - Disclosure - Tax Matters - Provision for Taxes on Income (Details) Sheet http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails Tax Matters - Provision for Taxes on Income (Details) Details 71 false false R72.htm 9955552 - Disclosure - Tax Matters - Narrative (Details) Sheet http://www.pfizer.com/role/TaxMattersNarrativeDetails Tax Matters - Narrative (Details) Details 72 false false R73.htm 9955553 - Disclosure - Tax Matters - Schedule of Cash Paid for Income Taxes, Net of Refunds (Details) Sheet http://www.pfizer.com/role/TaxMattersScheduleofCashPaidforIncomeTaxesNetofRefundsDetails Tax Matters - Schedule of Cash Paid for Income Taxes, Net of Refunds (Details) Details 73 false false R74.htm 9955554 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details) Sheet http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails Tax Matters - Tax Rate Reconciliation (Details) Details 74 false false R75.htm 9955555 - Disclosure - Tax Matters - Deferred Taxes (Details) Sheet http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails Tax Matters - Deferred Taxes (Details) Details 75 false false R76.htm 9955556 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details) Notes http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails Tax Matters - Deferred Taxes - Footnotes (Details) Details 76 false false R77.htm 9955557 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details) Sheet http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details) Details 77 false false R78.htm 9955558 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details) Notes http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details) Details 78 false false R79.htm 9955559 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details) Sheet http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details) Details 79 false false R80.htm 9955560 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details) Sheet http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details) Details http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables 80 false false R81.htm 9955561 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 81 false false R82.htm 9955562 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details) Notes http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details) Details 82 false false R83.htm 9955563 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) Details 83 false false R84.htm 9955564 - Disclosure - Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details) Details 84 false false R85.htm 9955565 - Disclosure - Financial Instruments - Investments - Debt Securities (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails Financial Instruments - Investments - Debt Securities (Details) Details 85 false false R86.htm 9955566 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) Details 86 false false R87.htm 9955567 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details) Notes http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details) Details 87 false false R88.htm 9955568 - Disclosure - Financial Instruments - Short-Term Borrowings (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails Financial Instruments - Short-Term Borrowings (Details) Details 88 false false R89.htm 9955569 - Disclosure - Financial Instruments - Short-Term Borrowings - Footnotes (Details) Notes http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsFootnotesDetails Financial Instruments - Short-Term Borrowings - Footnotes (Details) Details 89 false false R90.htm 9955570 - Disclosure - Financial Instruments - Long-Term Debt (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails Financial Instruments - Long-Term Debt (Details) Details 90 false false R91.htm 9955571 - Disclosure - Financial Instruments - Long-Term Debt, Issuances (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails Financial Instruments - Long-Term Debt, Issuances (Details) Details 91 false false R92.htm 9955572 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details) Details 92 false false R93.htm 9955573 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) Details 93 false false R94.htm 9955574 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) Details 94 false false R95.htm 9955575 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) Notes http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) Details 95 false false R96.htm 9955576 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) Details 96 false false R97.htm 9955577 - Disclosure - Financial Instruments - Credit Risk (Details) Sheet http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails Financial Instruments - Credit Risk (Details) Details 97 false false R98.htm 9955578 - Disclosure - Other Financial Information - Inventories (Details) Sheet http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails Other Financial Information - Inventories (Details) Details 98 false false R99.htm 9955579 - Disclosure - Other Financial Information - Other Current Liabilities (Details) Sheet http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails Other Financial Information - Other Current Liabilities (Details) Details 99 false false R100.htm 9955580 - Disclosure - Other Financial Information - Supplier Finance Program Obligation (Details) Sheet http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails Other Financial Information - Supplier Finance Program Obligation (Details) Details 100 false false R101.htm 9955581 - Disclosure - Property, Plant and Equipment - Components of Property, Plant and Equipment, Net (Details) Sheet http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails Property, Plant and Equipment - Components of Property, Plant and Equipment, Net (Details) Details 101 false false R102.htm 9955582 - Disclosure - Property, Plant and Equipment - Long-lived Assets by Geographic Areas, Net (Details) Sheet http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails Property, Plant and Equipment - Long-lived Assets by Geographic Areas, Net (Details) Details 102 false false R103.htm 9955583 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) Sheet http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) Details 103 false false R104.htm 9955584 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) Notes http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) Details 104 false false R105.htm 9955585 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Narrative (Details) Sheet http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillNarrativeDetails Identifiable Intangible Assets, Net and Goodwill - Narrative (Details) Details http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillTables 105 false false R106.htm 9955586 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Expected Annual Amortization Expense (Details) Sheet http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillExpectedAnnualAmortizationExpenseDetails Identifiable Intangible Assets, Net and Goodwill - Expected Annual Amortization Expense (Details) Details 106 false false R107.htm 9955587 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Goodwill (Details) Sheet http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillGoodwillDetails Identifiable Intangible Assets, Net and Goodwill - Goodwill (Details) Details http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillTables 107 false false R108.htm 9955588 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details) Details 108 false false R109.htm 9955589 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details) Details 109 false false R110.htm 9955590 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details) Details 110 false false R111.htm 9955591 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details) Details 111 false false R112.htm 9955592 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details) Details http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables 112 false false R113.htm 9955593 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail) Details 113 false false R114.htm 9955594 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details) Details 114 false false R115.htm 9955595 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details) Details 115 false false R116.htm 9955596 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details) Sheet http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details) Details http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables 116 false false R117.htm 9955597 - Disclosure - Equity (Details) Sheet http://www.pfizer.com/role/EquityDetails Equity (Details) Details http://www.pfizer.com/role/Equity 117 false false R118.htm 9955598 - Disclosure - Share-Based Payments - Narrative (Detail) Sheet http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail Share-Based Payments - Narrative (Detail) Details 118 false false R119.htm 9955599 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details) Sheet http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details) Details 119 false false R120.htm 9955600 - Disclosure - Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details) Sheet http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details) Details 120 false false R121.htm 9955601 - Disclosure - Share-Based Payments - Schedule of Valuation Assumptions (Detail) Sheet http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail Share-Based Payments - Schedule of Valuation Assumptions (Detail) Details 121 false false R122.htm 9955602 - Disclosure - Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail) Sheet http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail) Details 122 false false R123.htm 9955603 - Disclosure - Share-Based Payments - Summary of TSRU and PTU Activity (Details) Sheet http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails Share-Based Payments - Summary of TSRU and PTU Activity (Details) Details 123 false false R124.htm 9955604 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail) Sheet http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail) Details 124 false false R125.htm 9955605 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) Sheet http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) Details http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables 125 false false R126.htm 9955606 - Disclosure - Leases - Narrative (Details) Sheet http://www.pfizer.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 126 false false R127.htm 9955607 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details) Sheet http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails Leases - Schedule of Lease Assets and Liabilities (Details) Details 127 false false R128.htm 9955608 - Disclosure - Leases - Schedule of Lease Costs and Other Supplemental Information (Details) Sheet http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails Leases - Schedule of Lease Costs and Other Supplemental Information (Details) Details 128 false false R129.htm 9955609 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) Sheet http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) Details 129 false false R130.htm 9955610 - Disclosure - Contingencies and Certain Commitments - Patent Litigation (Details) Sheet http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails Contingencies and Certain Commitments - Patent Litigation (Details) Details 130 false false R131.htm 9955611 - Disclosure - Contingencies and Certain Commitments - Legal Proceedings-Government Investigations (Details) Sheet http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails Contingencies and Certain Commitments - Legal Proceedings-Government Investigations (Details) Details 131 false false R132.htm 9955612 - Disclosure - Contingencies and Certain Commitments - Certain Commitments and Contingent Consideration for Acquisitions (Details) Sheet http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails Contingencies and Certain Commitments - Certain Commitments and Contingent Consideration for Acquisitions (Details) Details 132 false false R133.htm 9955613 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail) Sheet http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail Segment, Geographic and Other Revenue Information - Narrative (Detail) Details http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables 133 false false R134.htm 9955614 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) Sheet http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) Details 134 false false R135.htm 9955615 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) Sheet http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) Details 135 false false R136.htm 9955616 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Geographic Area (Detail) Sheet http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail Segment, Geographic and Other Revenue Information - Revenues by Geographic Area (Detail) Details 136 false false R137.htm 9955617 - Disclosure - Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details) Sheet http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details) Details 137 false false R138.htm 9955618 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Product (Detail) Sheet http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail Segment, Geographic and Other Revenue Information - Revenues by Product (Detail) Details 138 false false R139.htm 9955619 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Product - Footnotes (Details) Notes http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails Segment, Geographic and Other Revenue Information - Revenues by Product - Footnotes (Details) Details 139 false false All Reports Book All Reports pfe-20241231.htm pfe-20241231.xsd pfe-20241231_cal.xml pfe-20241231_def.xml pfe-20241231_lab.xml pfe-20241231_pre.xml pfe-20241231_g1.jpg pfe-20241231_g10.jpg pfe-20241231_g11.jpg pfe-20241231_g12.jpg pfe-20241231_g2.jpg pfe-20241231_g3.jpg pfe-20241231_g4.jpg pfe-20241231_g5.jpg pfe-20241231_g6.jpg pfe-20241231_g7.jpg pfe-20241231_g8.jpg pfe-20241231_g9.jpg http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 176 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pfe-20241231.htm": { "nsprefix": "pfe", "nsuri": "http://www.pfizer.com/20241231", "dts": { "inline": { "local": [ "pfe-20241231.htm" ] }, "schema": { "local": [ "pfe-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "pfe-20241231_cal.xml" ] }, "definitionLink": { "local": [ "pfe-20241231_def.xml" ] }, "labelLink": { "local": [ "pfe-20241231_lab.xml" ] }, "presentationLink": { "local": [ "pfe-20241231_pre.xml" ] } }, "keyStandard": 673, "keyCustom": 166, "axisStandard": 57, "axisCustom": 4, "memberStandard": 97, "memberCustom": 176, "hidden": { "total": 66, "http://www.pfizer.com/20241231": 7, "http://fasb.org/us-gaap/2024": 55, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 1034, "entityCount": 1, "segmentCount": 288, "elementCount": 1485, "unitCount": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 2804, "http://xbrl.sec.gov/dei/2024": 41, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 5, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.pfizer.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.pfizer.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "longName": "9952151 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R4": { "role": "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome", "longName": "9952152 - Statement - Consolidated Statements of Comprehensive Income", "shortName": "Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R5": { "role": "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "longName": "9952153 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "9952154 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.pfizer.com/role/ConsolidatedStatementsofEquity", "longName": "9952155 - Statement - Consolidated Statements of Equity", "shortName": "Consolidated Statements of Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical", "longName": "9952156 - Statement - Consolidated Statements of Equity (Parenthetical)", "shortName": "Consolidated Statements of Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows", "longName": "9952157 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:AssetWriteOffsAndAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R10": { "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies", "longName": "9952158 - Disclosure - Basis of Presentation and Significant Accounting Policies", "shortName": "Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangement", "longName": "9952159 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives", "longName": "9952160 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNet", "longName": "9952161 - Disclosure - Other (Income)/Deductions\u2014Net", "shortName": "Other (Income)/Deductions\u2014Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.pfizer.com/role/TaxMatters", "longName": "9952162 - Disclosure - Tax Matters", "shortName": "Tax Matters", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests", "longName": "9952163 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests", "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.pfizer.com/role/FinancialInstruments", "longName": "9952164 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.pfizer.com/role/OtherFinancialInformation", "longName": "9952165 - Disclosure - Other Financial Information", "shortName": "Other Financial Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.pfizer.com/role/PropertyPlantandEquipmentNet", "longName": "9952166 - Disclosure - Property, Plant and Equipment, Net", "shortName": "Property, Plant and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwill", "longName": "9952167 - Disclosure - Identifiable Intangible Assets, Net and Goodwill", "shortName": "Identifiable Intangible Assets, Net and Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans", "longName": "9952168 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.pfizer.com/role/Equity", "longName": "9952169 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.pfizer.com/role/ShareBasedPayments", "longName": "9952170 - Disclosure - Share-Based Payments", "shortName": "Share-Based Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders", "longName": "9952171 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders", "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.pfizer.com/role/Leases", "longName": "9952172 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitments", "longName": "9952173 - Disclosure - Contingencies and Certain Commitments", "shortName": "Contingencies and Certain Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation", "longName": "9952174 - Disclosure - Segment, Geographic and Other Revenue Information", "shortName": "Segment, Geographic and Other Revenue Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1034", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1034", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R30": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies", "longName": "9955511 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables", "longName": "9955512 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables", "longName": "9955513 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement (Tables)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables", "longName": "9955514 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables", "longName": "9955515 - Disclosure - Other (Income)/Deductions\u2014Net (Tables)", "shortName": "Other (Income)/Deductions\u2014Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.pfizer.com/role/TaxMattersTables", "longName": "9955516 - Disclosure - Tax Matters (Tables)", "shortName": "Tax Matters (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables", "longName": "9955517 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)", "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.pfizer.com/role/FinancialInstrumentsTables", "longName": "9955518 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.pfizer.com/role/OtherFinancialInformationTables", "longName": "9955519 - Disclosure - Other Financial Information (Tables)", "shortName": "Other Financial Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.pfizer.com/role/PropertyPlantandEquipmentNetTables", "longName": "9955520 - Disclosure - Property, Plant and Equipment, Net (Tables)", "shortName": "Property, Plant and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillTables", "longName": "9955521 - Disclosure - Identifiable Intangible Assets, Net and Goodwill (Tables)", "shortName": "Identifiable Intangible Assets, Net and Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables", "longName": "9955522 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.pfizer.com/role/ShareBasedPaymentsTables", "longName": "9955523 - Disclosure - Share-Based Payments (Tables)", "shortName": "Share-Based Payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables", "longName": "9955524 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)", "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.pfizer.com/role/LeasesTables", "longName": "9955525 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables", "longName": "9955526 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)", "shortName": "Segment, Geographic and Other Revenue Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "longName": "9955527 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:SegmentReportingPolicyPolicyTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R48": { "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails", "longName": "9955528 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-14", "name": "pfe:RebatesAndOtherSalesRelatedAccruals", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "pfe:RebatesAndOtherSalesRelatedAccruals", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "longName": "9955529 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Acquisitions (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-121", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R50": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "longName": "9955530 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-80", "name": "pfe:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapitalExcludingInventories", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R51": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails", "longName": "9955531 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation - Footnotes (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-76", "name": "pfe:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "pfe:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails", "longName": "9955532 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails", "longName": "9955533 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information - Footnotes (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-90", "name": "us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R54": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "longName": "9955534 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Divestitures (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Divestitures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-122", "name": "pfe:ProceedsAndMilestonePaymentsExpectedToBeReceivedFromDivestitureOfBusinessMaximum", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-9", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "pfe:ProceedsAndMilestonePaymentsExpectedToBeReceivedFromDivestitureOfBusinessMaximum", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-9", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails", "longName": "9955535 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciEquityMethodInvestmentBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R56": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails", "longName": "9955536 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment - Footnotes (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Change in the Carrying Value of Equity Method Investment - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-141", "name": "pfe:EquityMethodInvestmentIncreaseDecreaseInvesteeCapitalTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "longName": "9955537 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Summarized Financial Information of Equity Method Investee (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Summarized Financial Information of Equity Method Investee (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R58": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "longName": "9955538 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Equity Method Investments (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Equity Method Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromSaleOfEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-153", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "gbp", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R59": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "longName": "9955539 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Collaborative Arrangements (Detail)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Collaborative Arrangements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-166", "name": "pfe:PrepaymentsAndPaymentsToCollaboratorsCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R60": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "longName": "9955540 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-171", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R61": { "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails", "longName": "9955541 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Research and Development Arrangement (Details)", "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement - Research and Development Arrangement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-177", "name": "pfe:ResearchAndDevelopmentArrangementMaximumFundingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "pfe:ResearchAndDevelopmentArrangementMaximumFundingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail", "longName": "9955542 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail", "longName": "9955543 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "longName": "9955544 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R65": { "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail", "longName": "9955545 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R66": { "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail", "longName": "9955546 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-72", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R67": { "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails", "longName": "9955547 - Disclosure - Other (Income)/Deductions\u2014Net - Schedule of Other Nonoperating Income (Expense) (Details)", "shortName": "Other (Income)/Deductions\u2014Net - Schedule of Other Nonoperating Income (Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "longName": "9955548 - Disclosure - Other (Income)/Deductions\u2014Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details)", "shortName": "Other (Income)/Deductions\u2014Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "longName": "9955549 - Disclosure - Other (Income)/Deductions\u2014Net - Schedule of Additional Information About Intangible Assets Impaired (Details)", "shortName": "Other (Income)/Deductions\u2014Net - Schedule of Additional Information About Intangible Assets Impaired (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-14", "name": "pfe:IntangibleAssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "pfe:IntangibleAssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails", "longName": "9955550 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)", "shortName": "Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails", "longName": "9955551 - Disclosure - Tax Matters - Provision for Taxes on Income (Details)", "shortName": "Tax Matters - Provision for Taxes on Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.pfizer.com/role/TaxMattersNarrativeDetails", "longName": "9955552 - Disclosure - Tax Matters - Narrative (Details)", "shortName": "Tax Matters - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-9", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R73": { "role": "http://www.pfizer.com/role/TaxMattersScheduleofCashPaidforIncomeTaxesNetofRefundsDetails", "longName": "9955553 - Disclosure - Tax Matters - Schedule of Cash Paid for Income Taxes, Net of Refunds (Details)", "shortName": "Tax Matters - Schedule of Cash Paid for Income Taxes, Net of Refunds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "pfe:ScheduleOfCashPaidForIncomeTaxesNetOfRefundsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "pfe:ScheduleOfCashPaidForIncomeTaxesNetOfRefundsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails", "longName": "9955554 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details)", "shortName": "Tax Matters - Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails", "longName": "9955555 - Disclosure - Tax Matters - Deferred Taxes (Details)", "shortName": "Tax Matters - Deferred Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails", "longName": "9955556 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details)", "shortName": "Tax Matters - Deferred Taxes - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails", "longName": "9955557 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)", "shortName": "Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R78": { "role": "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails", "longName": "9955558 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)", "shortName": "Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-279", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R79": { "role": "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails", "longName": "9955559 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)", "shortName": "Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails", "longName": "9955560 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)", "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-285", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R81": { "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "longName": "9955561 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-343", "name": "us-gaap:DerivativeAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R82": { "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "longName": "9955562 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R83": { "role": "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails", "longName": "9955563 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-373", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-9", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R84": { "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails", "longName": "9955564 - Disclosure - Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details)", "shortName": "Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R85": { "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails", "longName": "9955565 - Disclosure - Financial Instruments - Investments - Debt Securities (Details)", "shortName": "Financial Instruments - Investments - Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-14", "name": "pfe:DebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:HeldToMaturitySecuritiesTextBlock", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "pfe:DebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:HeldToMaturitySecuritiesTextBlock", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails", "longName": "9955566 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)", "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": null }, "R87": { "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails", "longName": "9955567 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)", "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-14", "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "link:footnote", "span", "div", "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "link:footnote", "span", "div", "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails", "longName": "9955568 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)", "shortName": "Financial Instruments - Short-Term Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CommercialPaper", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShortTermDebtTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShortTermDebtTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R89": { "role": "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsFootnotesDetails", "longName": "9955569 - Disclosure - Financial Instruments - Short-Term Borrowings - Footnotes (Details)", "shortName": "Financial Instruments - Short-Term Borrowings - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-413", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-383", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfShortTermDebtTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R90": { "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "longName": "9955570 - Disclosure - Financial Instruments - Long-Term Debt (Details)", "shortName": "Financial Instruments - Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-14", "name": "pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShortTermDebtTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-411", "name": "us-gaap:DebtWeightedAverageInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R91": { "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails", "longName": "9955571 - Disclosure - Financial Instruments - Long-Term Debt, Issuances (Details)", "shortName": "Financial Instruments - Long-Term Debt, Issuances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-413", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": null }, "R92": { "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails", "longName": "9955572 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)", "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-414", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-414", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails", "longName": "9955573 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)", "shortName": "Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "longName": "9955574 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)", "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "longName": "9955575 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)", "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-441", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R96": { "role": "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails", "longName": "9955576 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)", "shortName": "Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails", "longName": "9955577 - Disclosure - Financial Instruments - Credit Risk (Details)", "shortName": "Financial Instruments - Credit Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails", "longName": "9955578 - Disclosure - Other Financial Information - Inventories (Details)", "shortName": "Other Financial Information - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails", "longName": "9955579 - Disclosure - Other Financial Information - Other Current Liabilities (Details)", "shortName": "Other Financial Information - Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-443", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R100": { "role": "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails", "longName": "9955580 - Disclosure - Other Financial Information - Supplier Finance Program Obligation (Details)", "shortName": "Other Financial Information - Supplier Finance Program Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:SupplierFinanceProgramObligationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SupplierFinanceProgramTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:SupplierFinanceProgramObligationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SupplierFinanceProgramTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails", "longName": "9955581 - Disclosure - Property, Plant and Equipment - Components of Property, Plant and Equipment, Net (Details)", "shortName": "Property, Plant and Equipment - Components of Property, Plant and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails", "longName": "9955582 - Disclosure - Property, Plant and Equipment - Long-lived Assets by Geographic Areas, Net (Details)", "shortName": "Property, Plant and Equipment - Long-lived Assets by Geographic Areas, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-463", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R103": { "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "longName": "9955583 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)", "shortName": "Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "longName": "9955584 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)", "shortName": "Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "link:footnote", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R105": { "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillNarrativeDetails", "longName": "9955585 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Narrative (Details)", "shortName": "Identifiable Intangible Assets, Net and Goodwill - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillExpectedAnnualAmortizationExpenseDetails", "longName": "9955586 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Expected Annual Amortization Expense (Details)", "shortName": "Identifiable Intangible Assets, Net and Goodwill - Expected Annual Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R107": { "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillGoodwillDetails", "longName": "9955587 - Disclosure - Identifiable Intangible Assets, Net and Goodwill - Goodwill (Details)", "shortName": "Identifiable Intangible Assets, Net and Goodwill - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R108": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "longName": "9955588 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-488", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-488", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R109": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails", "longName": "9955589 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-488", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-488", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R110": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails", "longName": "9955590 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-497", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-497", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R111": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "longName": "9955591 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-488", "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R112": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "longName": "9955592 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-497", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-584", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R113": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "longName": "9955593 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-583", "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": null }, "R114": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "longName": "9955594 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-495", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-706", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R115": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "longName": "9955595 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-497", "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-497", "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R116": { "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails", "longName": "9955596 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)", "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R117": { "role": "http://www.pfizer.com/role/EquityDetails", "longName": "9955597 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-728", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-728", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R118": { "role": "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "longName": "9955598 - Disclosure - Share-Based Payments - Narrative (Detail)", "shortName": "Share-Based Payments - Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R119": { "role": "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "longName": "9955599 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)", "shortName": "Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-753", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R120": { "role": "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails", "longName": "9955600 - Disclosure - Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details)", "shortName": "Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-744", "name": "pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R121": { "role": "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail", "longName": "9955601 - Disclosure - Share-Based Payments - Schedule of Valuation Assumptions (Detail)", "shortName": "Share-Based Payments - Schedule of Valuation Assumptions (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-744", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "pfe:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-744", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "pfe:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R122": { "role": "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "longName": "9955602 - Disclosure - Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail)", "shortName": "Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "c-767", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-744", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R123": { "role": "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails", "longName": "9955603 - Disclosure - Share-Based Payments - Summary of TSRU and PTU Activity (Details)", "shortName": "Share-Based Payments - Summary of TSRU and PTU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "c-766", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-766", "name": "pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R124": { "role": "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail", "longName": "9955604 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)", "shortName": "Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R125": { "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails", "longName": "9955605 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)", "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "c-1", "name": "pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R126": { "role": "http://www.pfizer.com/role/LeasesNarrativeDetails", "longName": "9955606 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-445", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R127": { "role": "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails", "longName": "9955607 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details)", "shortName": "Leases - Schedule of Lease Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R128": { "role": "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails", "longName": "9955608 - Disclosure - Leases - Schedule of Lease Costs and Other Supplemental Information (Details)", "shortName": "Leases - Schedule of Lease Costs and Other Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R129": { "role": "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail", "longName": "9955609 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail)", "shortName": "Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R130": { "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails", "longName": "9955610 - Disclosure - Contingencies and Certain Commitments - Patent Litigation (Details)", "shortName": "Contingencies and Certain Commitments - Patent Litigation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "c-14", "name": "pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R131": { "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "longName": "9955611 - Disclosure - Contingencies and Certain Commitments - Legal Proceedings-Government Investigations (Details)", "shortName": "Contingencies and Certain Commitments - Legal Proceedings-Government Investigations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef": "c-817", "name": "pfe:NumberOfComplaints", "unitRef": "complaint", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-817", "name": "pfe:NumberOfComplaints", "unitRef": "complaint", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R132": { "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails", "longName": "9955612 - Disclosure - Contingencies and Certain Commitments - Certain Commitments and Contingent Consideration for Acquisitions (Details)", "shortName": "Contingencies and Certain Commitments - Certain Commitments and Contingent Consideration for Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R133": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "longName": "9955613 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)", "shortName": "Segment, Geographic and Other Revenue Information - Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:SegmentReportingPolicyPolicyTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-875", "name": "pfe:SupplyCommitmentRemainingMinimumAmountCommittedNumberOfTreatmentCourses", "unitRef": "treatmentcourse", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R134": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "longName": "9955614 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)", "shortName": "Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "link:footnote", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R135": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails", "longName": "9955615 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details)", "shortName": "Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-199", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R136": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail", "longName": "9955616 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Geographic Area (Detail)", "shortName": "Segment, Geographic and Other Revenue Information - Revenues by Geographic Area (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-854", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R137": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails", "longName": "9955617 - Disclosure - Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details)", "shortName": "Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "c-877", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-877", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true, "unique": true } }, "R138": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "longName": "9955618 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Product (Detail)", "shortName": "Segment, Geographic and Other Revenue Information - Revenues by Product (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "138", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1014", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } }, "R139": { "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "longName": "9955619 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues by Product - Footnotes (Details)", "shortName": "Segment, Geographic and Other Revenue Information - Revenues by Product - Footnotes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1027", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "link:footnote", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20241231.htm", "unique": true } } }, "tag": { "pfe_A1365ConsumerHealthcareJVLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "A1365ConsumerHealthcareJVLoanMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.365% Consumer Healthcare JV Loan [Member]", "label": "1.365% Consumer Healthcare JV Loan [Member]", "documentation": "1.365% Consumer Healthcare JV Loan" } } }, "auth_ref": [] }, "pfe_A2019StockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "A2019StockPlanMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Stock Plan [Member]", "label": "2019 Stock Plan [Member]", "documentation": "2019 Stock Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "pfe_AbrysvoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AbrysvoMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Abrysvo [Member]", "label": "Abrysvo [Member]", "documentation": "Abrysvo" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r157", "r1393" ] }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nontrade payables", "label": "Accounts Payable, Other", "documentation": "Amount of obligations incurred and payable classified as other." } } }, "auth_ref": [ "r252" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts [Member]", "verboseLabel": "Accounts Receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r1295" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, net of allowance for doubtful accounts: 2024\u2014$438; 2023\u2014$470", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1605" ] }, "pfe_AccruedRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AccruedRebates", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued rebates", "label": "Accrued Rebates", "documentation": "Accrued Rebates" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Service (Costs)/Credits and Other [Member]", "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r6", "r27", "r48", "r387", "r388", "r1571" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r72", "r350", "r1117" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Financial Instruments [Member]", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r377", "r387", "r388", "r904", "r1323", "r1571" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-For-Sale Securities [Member]", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r372", "r373", "r374", "r377", "r387", "r388", "r1571" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r386", "r387", "r971", "r973", "r974", "r975", "r976", "r978" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r47", "r48", "r184", "r362", "r1112", "r1165", "r1169" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r386", "r387", "r971", "r973", "r974", "r975", "r976", "r978" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accum. Other Comp. Loss [Member]", "verboseLabel": "Accumulated Other Comprehensive Income/(Loss) [Member]", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r27", "r48", "r927", "r930", "r1014", "r1160", "r1161", "r1571", "r1572", "r1573", "r1591", "r1592", "r1593", "r1594" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustments [Member]", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r5", "r27", "r48", "r181", "r182", "r387", "r388", "r973", "r974", "r975", "r976", "r978", "r1571" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intangible assets, useful life", "verboseLabel": "Acquired intangible assets, estimated weighted-average useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r588", "r1309" ] }, "pfe_AcquiredInventorySellingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AcquiredInventorySellingPeriod", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired inventory, selling period", "label": "Acquired Inventory, Selling Period", "documentation": "Acquired Inventory, Selling Period" } } }, "auth_ref": [] }, "pfe_AdcetrisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AdcetrisMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Adcetris [Member]", "label": "Adcetris [Member]", "documentation": "Adcetris" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1478" ] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Information", "label": "Additional Financial Information Disclosure [Text Block]", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r172", "r1393", "r1825" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Add\u2019l Paid-In Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r1186", "r1591", "r1592", "r1593", "r1594", "r1749", "r1826" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1491" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1491" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1491" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1491" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r822", "r1373" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1536" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1449", "r1460", "r1470", "r1503" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1452", "r1463", "r1473", "r1506" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1537" ] }, "pfe_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AgreementAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement [Axis]", "label": "Agreement [Axis]", "documentation": "Agreement" } } }, "auth_ref": [] }, "pfe_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AgreementDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement [Domain]", "label": "Agreement [Domain]", "documentation": "Agreement" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1491" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1498" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1453", "r1464", "r1474", "r1498", "r1507", "r1511", "r1519" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1517" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost recognized/(reduced), pre-tax", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r811", "r820" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r363", "r503", "r557" ] }, "pfe_AlnylamPatentInfringementCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AlnylamPatentInfringementCaseMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alnylam Patent Infringement Case [Member]", "label": "Alnylam Patent Infringement Case [Member]", "documentation": "Alnylam Patent Infringement Case" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "pfe_AmortizationExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AmortizationExpenseMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization Expense [Member]", "label": "Amortization Expense [Member]", "documentation": "Amortization Expense" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense for finite-lived intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r15", "r585", "r593", "r1344" ] }, "pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization Of Intangible Assets Not Associated With Single Function", "documentation": "The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses." } } }, "auth_ref": [] }, "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cost/(credit) recognized in Comprehensive income", "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax", "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss." } } }, "auth_ref": [ "r1362" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive common stock equivalents (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r446" ] }, "pfe_ArbutusAndGenevantUSPatentInfringementCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ArbutusAndGenevantUSPatentInfringementCaseMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arbutus and Genevant U.S. Patent Infringement Case [Member]", "label": "Arbutus and Genevant U.S. Patent Infringement Case [Member]", "documentation": "Arbutus and Genevant U.S. Patent Infringement Case" } } }, "auth_ref": [] }, "pfe_ArenaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ArenaMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Arena [Member]", "label": "Arena [Member]", "documentation": "Arena" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r898" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r586", "r587", "r588", "r589", "r591", "r1741" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, consideration transferred", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r1376", "r1742", "r1743", "r1744" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, contingent consideration", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1742", "r1743", "r1744" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r586", "r587", "r588", "r589", "r591", "r1741" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certain asset impairments", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r15", "r71" ] }, "pfe_AssetImpairmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AssetImpairmentsMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Impairment Charges [Member]", "label": "Asset Impairments [Member]", "documentation": "Asset impairments [Member]" } } }, "auth_ref": [] }, "pfe_AssetWriteOffsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AssetWriteOffsAndAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Asset write-offs and impairments", "label": "Asset Write-Offs And Asset Impairment Charges", "documentation": "Asset Write-Offs And Asset Impairment Charges" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r248", "r266", "r354", "r405", "r450", "r458", "r484", "r488", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r900", "r906", "r964", "r1108", "r1232", "r1335", "r1336", "r1393", "r1427", "r1680", "r1681", "r1775" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "terseLabel": "Current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r344", "r367", "r405", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r900", "r906", "r964", "r1393", "r1680", "r1681", "r1775" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r405", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r900", "r906", "r964", "r1680", "r1681", "r1775" ] }, "pfe_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.pfizer.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1432", "r1433", "r1456" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.pfizer.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor location", "label": "Auditor Location" } } }, "auth_ref": [ "r1432", "r1433", "r1456" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.pfizer.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor name", "label": "Auditor Name" } } }, "auth_ref": [ "r1432", "r1433", "r1456" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities, gross unrealized gain", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r510" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Available-for-sale debt securities, gross unrealized loss", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r511" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Available-for-sale debt securities, amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r507", "r563", "r1107" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale Securities, Debt Maturities [Abstract]", "label": "Available-for-Sale Securities, Debt Maturities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities, debt maturities, over 1 to 5 years, fair value", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r515", "r1102" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities, debt maturities, within 1 year, fair value", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r514", "r1101" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities", "weight": 1.0, "order": 2.0 }, "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities, debt securities", "verboseLabel": "Available-for-sale securities, debt maturities", "totalLabel": "Available-for-sale securities, debt maturities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r508", "r563", "r947", "r1093", "r1380", "r1384", "r1608", "r1753", "r1754", "r1755" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_OtherShortTermInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r505", "r563" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r348", "r505", "r563" ] }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]", "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities, debt maturities, over 5 years, fair value", "label": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value", "documentation": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value" } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1514" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1515" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1510" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1510" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1510" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1510" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1510" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1510" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r782", "r783", "r784", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r806", "r807", "r808", "r809", "r810" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1513" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1512" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1511" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1511" ] }, "pfe_B7H4VFelmetatugVedotinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "B7H4VFelmetatugVedotinMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B7H4V (felmetatug vedotin) [Member]", "label": "B7H4V (felmetatug vedotin) [Member]", "documentation": "B7H4V (felmetatug vedotin)" } } }, "auth_ref": [] }, "pfe_BMP2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BMP2Member", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "BMP2 [Member]", "label": "BMP2 [Member]", "documentation": "BMP2 [Member]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail", "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails", "http://www.pfizer.com/role/TaxMattersNarrativeDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r604", "r1791", "r1792" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail", "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails", "http://www.pfizer.com/role/TaxMattersNarrativeDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r121", "r124", "r604", "r1791", "r1792" ] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankTimeDepositsMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits and other [Member]", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": [ "r262" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r204" ] }, "pfe_BeneFIXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BeneFIXMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "BeneFIX [Member]", "label": "Bene F I X [Member]", "documentation": "Bene F I X [Member]" } } }, "auth_ref": [] }, "pfe_BioNTechAndCerevelTherapeuticsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BioNTechAndCerevelTherapeuticsLLCMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BioNTech and Cerevel Therapeutics, LLC [Member]", "label": "BioNTech and Cerevel Therapeutics, LLC [Member]", "documentation": "BioNTech and Cerevel Therapeutics, LLC" } } }, "auth_ref": [] }, "pfe_BioNTechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BioNTechMember", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BioNTech [Member]", "label": "BioNTech [Member]", "documentation": "BionTech [Member]" } } }, "auth_ref": [] }, "pfe_BiohavenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BiohavenMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biohaven [Member]", "label": "Biohaven [Member]", "documentation": "Biohaven" } } }, "auth_ref": [] }, "pfe_BiopharmaSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BiopharmaSegmentMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biopharma [Member]", "label": "Biopharma Segment [Member]", "documentation": "Biopharma Segment [Member]" } } }, "auth_ref": [] }, "pfe_BlackstoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BlackstoneMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Blackstone [Member]", "label": "Blackstone [Member]", "documentation": "Blackstone" } } }, "auth_ref": [] }, "pfe_BosulifMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BosulifMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Bosulif [Member]", "label": "Bosulif [Member]", "documentation": "Bosulif [Member]" } } }, "auth_ref": [] }, "pfe_BraftoviMektoviMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BraftoviMektoviMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Braftovi/Mektovi [Member]", "label": "Braftovi/Mektovi [Member]", "documentation": "Braftovi [Member]" } } }, "auth_ref": [] }, "pfe_BrandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BrandMember", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brand [Member]", "label": "Brand [Member]", "documentation": "Brand" } } }, "auth_ref": [] }, "pfe_BreakthroughPerformanceAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BreakthroughPerformanceAwardsMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Breakthrough Performance Awards (BPAs) [Member]", "label": "Breakthrough Performance Awards [Member]", "documentation": "Breakthrough Performance Awards" } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings [Member]", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r212" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r586", "r587", "r588", "r589", "r591", "r886", "r1364", "r1367" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r96", "r99", "r586", "r587", "r588", "r589", "r591", "r886", "r1364", "r1367" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r886" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r1550", "r1551" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pro Forma Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r1550", "r1551" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, per share in cash (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pro Forma net loss attributable to Pfizer Inc. common shareholders", "terseLabel": "Net income/(loss) attributable to Pfizer Inc. common shareholders", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r884", "r885" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r884", "r885" ] }, "us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquiredReceivablesGrossContractualAmount", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross contractual amount receivable", "label": "Business Combination, Acquired Receivables, Gross Contractual Amount", "documentation": "For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables." } } }, "auth_ref": [ "r101" ] }, "pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationAcquisitionRelatedCostsTransactionCosts", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Business Combination, Acquisition Related Costs, Transaction Costs", "documentation": "This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services." } } }, "auth_ref": [] }, "pfe_BusinessCombinationConsiderationTransferredDebtRepayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationConsiderationTransferredDebtRepayment", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of assumed debt", "label": "Business Combination, Consideration Transferred, Debt Repayment", "documentation": "Business Combination, Consideration Transferred, Debt Repayment" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, equity consideration", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r1", "r2" ] }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred, including equity interest held prior to business combination", "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held before Combination", "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r23", "r34" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of fair value contingent consideration liabilities", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r892", "r1582" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r106", "r239", "r891", "r949", "r950", "r951" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration liability, current", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r106", "r239" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration liability, noncurrent", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r106", "r239" ] }, "pfe_BusinessCombinationIdentifiableAssetAcquiredAndLiabilityAssumedDeferredTaxLiabilitiesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationIdentifiableAssetAcquiredAndLiabilityAssumedDeferredTaxLiabilitiesGross", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net deferred tax liabilities, gross", "label": "Business Combination, Identifiable Asset Acquired and Liability Assumed, Deferred Tax Liabilities, Gross", "documentation": "Business Combination, Identifiable Asset Acquired and Liability Assumed, Deferred Tax Liabilities, Gross" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationIntegrationRelatedCosts", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Integration costs and other", "label": "Business Combination, Integration Related Costs", "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to Pfizer Inc. common shareholders", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r98" ] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues subsequent to acquisition", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r98" ] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferredIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferredIncludingGoodwill", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired/total consideration transferred", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Including Goodwill", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Including Goodwill" } } }, "auth_ref": [] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferredNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferredNetOfAdjustments", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible assets, net of adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred, Net of Adjustments", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred, Net of Adjustments" } } }, "auth_ref": [] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInProcessResearchAndDevelopmentNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInProcessResearchAndDevelopmentNetOfAdjustments", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development, measurement period adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, In-Process Research and Development, Net of Adjustments", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, In-Process Research and Development, Net of Adjustments" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r103" ] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangiblesNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangiblesNetOfAdjustments", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles, measurement period adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles, Net of Adjustments", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles, Net of Adjustments" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r103" ] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferredIncludingGoodwill", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total identifiable net assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Assets Excluding Goodwill", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Assets Excluding Goodwill" } } }, "auth_ref": [] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetIncomeTaxAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetIncomeTaxAccounts", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income tax accounts", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Income Tax Accounts", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Income Tax Accounts" } } }, "auth_ref": [] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Assets", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Assets" } } }, "auth_ref": [] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other noncurrent liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Liabilities", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to property, plant, and equipment acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r103" ] }, "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentWorkingCapitalExcludingInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentWorkingCapitalExcludingInventories", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsExcludingGoodwill", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital, excluding inventories", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital, Excluding Inventories", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital, Excluding Inventories" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Period Adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible assets, excluding in-process research and development", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r100", "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "verboseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r100", "r102" ] }, "pfe_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryCurrent", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Current", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Current" } } }, "auth_ref": [] }, "pfe_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryNoncurrent", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Noncurrent", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total identifiable net assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r100", "r102" ] }, "pfe_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncomeTaxAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncomeTaxAccounts", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net income tax accounts", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Income Tax Accounts", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Income Tax Accounts" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed long-term debt, paid in full", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other noncurrent liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r100", "r102" ] }, "pfe_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapitalExcludingInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapitalExcludingInventories", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital, excluding inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital, Excluding Inventories", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital, Excluding Inventories" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired/total consideration transferred", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r102" ] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Post closing compensation expense", "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized", "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination." } } }, "auth_ref": [ "r97" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of previously held equity interest in acquiree", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r35" ] }, "pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]", "label": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]", "documentation": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]" } } }, "auth_ref": [] }, "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangement" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements and Research and Development Arrangement", "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]", "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]" } } }, "auth_ref": [] }, "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]", "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r233", "r234", "r235", "r236" ] }, "us-gaap_BusinessExitCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessExitCosts1", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exit costs", "label": "Business Exit Costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r15" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "China [Member]", "label": "CHINA" } } }, "auth_ref": [] }, "pfe_CaliforniaDepartmentOfInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CaliforniaDepartmentOfInsuranceMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California Department of Insurance [Member]", "label": "California Department of Insurance [Member]", "documentation": "California Department of Insurance" } } }, "auth_ref": [] }, "pfe_CardinalHealthInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CardinalHealthInc.Member", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardinal Health, Inc. [Member]", "label": "Cardinal Health, Inc. [Member]", "documentation": "Cardinal Health, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r54", "r347", "r1315" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r55" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period", "periodEndLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r54", "r201", "r403" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r201" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging [Member]", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r118" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash transaction:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "pfe_CencoraInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CencoraInc.Member", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cencora, Inc. [Member]", "label": "Cencora, Inc. [Member]", "documentation": "Cencora, Inc." } } }, "auth_ref": [] }, "pfe_CerevelTherapeuticsHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CerevelTherapeuticsHoldingsIncMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cerevel Therapeutics Holdings, Inc. [Member]", "label": "Cerevel Therapeutics Holdings, Inc. [Member]", "documentation": "Cerevel Therapeutics Holdings, Inc." } } }, "auth_ref": [] }, "pfe_CertainTSRUsGrantedIn2022And2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CertainTSRUsGrantedIn2022And2023Member", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certain TSRUs Granted in 2022 and 2023 [Member]", "label": "Certain TSRUs Granted in 2022 and 2023 [Member]", "documentation": "Certain TSRUs Granted in 2022 and 2023" } } }, "auth_ref": [] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Amount of Gains/(Losses) on interest rate contract Recognized in OID", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": [ "r245" ] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Amount of Gains/(Losses) on hedged item Recognized in OID", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": [ "r245" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1489" ] }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans." } } }, "auth_ref": [ "r41" ] }, "pfe_ChargesForExcessRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ChargesForExcessRawMaterials", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges to cost of sales related to raw materials", "label": "Charges For Excess Raw Materials", "documentation": "Charges For Excess Raw Materials" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1486" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1484" ] }, "pfe_CibinqoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CibinqoMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cibinqo [Member]", "label": "Cibinqo [Member]", "documentation": "Cibinqo" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r294", "r359", "r360", "r361", "r405", "r435", "r436", "r443", "r445", "r452", "r453", "r544", "r633", "r636", "r637", "r638", "r642", "r643", "r666", "r667", "r670", "r673", "r680", "r964", "r1178", "r1179", "r1180", "r1181", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1219", "r1241", "r1259", "r1287", "r1288", "r1289", "r1290", "r1291", "r1541", "r1585", "r1595" ] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Treasury Stock [Table]", "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r80", "r81", "r82", "r83" ] }, "pfe_ClinicalTrialAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ClinicalTrialAgreementTermsMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Trial Agreement Terms [Member]", "label": "Clinical Trial Agreement Terms [Member]", "documentation": "Clinical Trial Agreement Terms" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1490" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1490" ] }, "pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Committed investment from collaborator", "label": "Collaborative Arrangement, Committed Investment From Collaborator, Amount", "documentation": "Collaborative Arrangement, Committed Investment From Collaborator, Amount" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement [Member]", "label": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r898" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r898" ] }, "us-gaap_CollateralAlreadyPostedAggregateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollateralAlreadyPostedAggregateFairValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collateral posted", "label": "Collateral Already Posted, Aggregate Fair Value", "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features." } } }, "auth_ref": [ "r130" ] }, "pfe_ComirnatyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ComirnatyMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Comirnaty [Member]", "label": "Comirnaty [Member]", "documentation": "Comirnaty" } } }, "auth_ref": [] }, "us-gaap_CommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaper", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": { "parentTag": "pfe_ShorttermDebtGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper, principal amount", "label": "Commercial Paper", "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days." } } }, "auth_ref": [ "r155", "r249", "r1786" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r218", "r632", "r1421", "r1422", "r1423", "r1424" ] }, "pfe_CommercializationPartnerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CommercializationPartnerMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercialization Partner", "label": "Commercialization Partner [Member]", "documentation": "Commercialization Partner" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r166", "r254", "r1110", "r1218" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitments" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies and Certain Commitments", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r217", "r624", "r625", "r1296", "r1664", "r1671" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Legal and Environmental Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r76", "r1297" ] }, "pfe_CommonESOPPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CommonESOPPlanMember", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common ESOP Plan [Member]", "label": "Common ESOP Plan [Member]", "documentation": "Common ESOP Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared per share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r222" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity", "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1417", "r1418", "r1419", "r1421", "r1422", "r1423", "r1424", "r1591", "r1592", "r1594", "r1749", "r1823", "r1826" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r171" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r171", "r1219" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued (in shares)", "periodStartLabel": "Beginning balance, common (in shares)", "periodEndLabel": "Ending balance, common (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r171" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.05 par value; 12,000 shares authorized; issued: 2024\u20149,593; 2023\u20149,562", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r171", "r1111", "r1393" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1495" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1494" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1496" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1493" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets", "label": "Components of Deferred Tax Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities", "label": "Components of Deferred Tax Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income/(loss) attributable to Pfizer Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r49", "r382", "r384", "r393", "r1098", "r1127", "r1129" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Comprehensive income/(loss) attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r11", "r109", "r113", "r382", "r384", "r392", "r1097", "r1127", "r1128" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income/(loss) before allocation to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r113", "r240", "r382", "r384", "r391", "r1096", "r1127" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r180", "r390", "r1095", "r1125" ] }, "pfe_ConcentrationRiskAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ConcentrationRiskAmount", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, amount", "label": "Concentration Risk, Amount", "documentation": "Concentration Risk, Amount" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r59", "r61", "r136", "r137", "r496", "r1295" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r59", "r61", "r136", "r137", "r496", "r1171", "r1295" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r59", "r61", "r136", "r137", "r496", "r1295", "r1549" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1295" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Concentration risk, percentage", "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r59", "r61", "r136", "r137", "r496" ] }, "pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ConcentrationRiskRevenues500000000orMoreNumberofCountries", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of countries with revenue exceeding $500 million", "label": "Concentration Risk, Revenues, $500,000,000 or More, Number of Countries", "documentation": "Concentration Risk, Revenues, $500,000,000 or More, Number of Countries" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r58", "r59", "r61", "r62", "r136", "r246", "r1295" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r59", "r61", "r136", "r137", "r496", "r1295" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r264", "r295", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r412", "r450", "r460", "r482", "r483", "r484", "r485", "r486", "r488", "r489", "r490", "r633", "r634", "r635", "r636", "r638", "r639", "r640", "r641", "r642", "r1335", "r1336", "r1562", "r1563", "r1680", "r1681" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r264", "r295", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r412", "r450", "r460", "r482", "r483", "r484", "r485", "r486", "r488", "r489", "r490", "r633", "r634", "r635", "r636", "r638", "r639", "r640", "r641", "r642", "r1335", "r1336", "r1562", "r1563", "r1680", "r1681" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r110", "r1324" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress [Member]", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "pfe_ConsumerHealthcareJVHaleonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ConsumerHealthcareJVHaleonMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Haleon/Consumer Healthcare JV [Member]", "label": "Consumer Healthcare JV / Haleon [Member]", "documentation": "Consumer Healthcare JV / Haleon" } } }, "auth_ref": [] }, "pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ConsumerHealthcareJVSeniorNotesEURDenominatedMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes, EUR Denominated [Member]", "label": "Consumer Healthcare JV Senior Notes, EUR Denominated [Member]", "documentation": "Consumer Healthcare JV Senior Notes, EUR Denominated" } } }, "auth_ref": [] }, "pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ConsumerHealthcareJVSeniorNotesGBPDenominatedMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes, GBP Denominated [Member]", "label": "Consumer Healthcare JV Senior Notes, GBP Denominated [Member]", "documentation": "Consumer Healthcare JV Senior Notes, GBP Denominated" } } }, "auth_ref": [] }, "pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ConsumerHealthcareJVSeniorNotesUSDDenominatedMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes, USD Denominated [Member]", "label": "Consumer Healthcare JV Senior Notes, USD Denominated [Member]", "documentation": "Consumer Healthcare JV Senior Notes, USD Denominated" } } }, "auth_ref": [] }, "pfe_ContractWithCustomerFavorableAdjustmentForGovernmentEmergencyUseAuthorizationInventoryReturnedToTheCompanyDuringThePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ContractWithCustomerFavorableAdjustmentForGovernmentEmergencyUseAuthorizationInventoryReturnedToTheCompanyDuringThePeriod", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Favorable adjustment for government emergency use authorization inventory returned to the company during the period", "label": "Contract With Customer, Favorable Adjustment For Government Emergency Use Authorization Inventory Returned To The Company During The Period", "documentation": "Contract With Customer, Favorable Adjustment For Government Emergency Use Authorization Inventory Returned To The Company During The Period" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r682", "r683", "r694" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues", "verboseLabel": "Deferred revenues, current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r682", "r683", "r694" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues, noncurrent", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r682", "r683", "r694" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r695" ] }, "pfe_ContractWithCustomerRefundRecordedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ContractWithCustomerRefundRecordedDuringPeriod", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal of revenue", "label": "Contract With Customer, Refund Recorded During Period", "documentation": "Contract With Customer, Refund Recorded During Period" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Corporate and Other [Member]", "terseLabel": "Corporate debt [Member]", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r1360", "r1362", "r1380", "r1394", "r1415", "r1820" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Business Activities [Member]", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r39", "r483", "r484", "r485", "r486", "r489", "r1600" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 }, "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "negatedLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r190", "r191", "r1051" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r192", "r405", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r964", "r1335", "r1680" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales [Member]", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations." } } }, "auth_ref": [ "r43", "r214", "r215" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r330", "r331", "r409", "r410", "r647", "r668", "r1015", "r1033", "r1104", "r1320", "r1322" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r632", "r1678" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r632", "r1678", "r1679" ] }, "pfe_CreditFacilityMaturingOctober2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CreditFacilityMaturingOctober2025Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, Maturing October 2025 [Member]", "label": "Credit Facility, Maturing October 2025 [Member]", "documentation": "Credit Facility, Maturing October 2025" } } }, "auth_ref": [] }, "pfe_CreditFacilityMaturingOctober2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CreditFacilityMaturingOctober2029Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, Maturing October 2029 [Member]", "label": "Credit Facility, Maturing October 2029 [Member]", "documentation": "Credit Facility, Maturing October 2029" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1553", "r1588", "r1736" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current income taxes", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1553", "r1588" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current income taxes:", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State and local", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1553", "r1588", "r1736" ] }, "pfe_CurrentTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "CurrentTaxAssetsMember", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Tax Assets [Member]", "label": "Current Tax Assets [Member]", "documentation": "Current Tax Assets [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk [Member]", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r205", "r496" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1441", "r1530" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1441", "r1530" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1443", "r1532" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1443", "r1532" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1445", "r1534" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1443", "r1532" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1436", "r1525" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1437", "r1526" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1437", "r1526" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1435", "r1524" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1435", "r1524" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1435", "r1524" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1438", "r1527" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1440", "r1529" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1440", "r1529" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1441", "r1530" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1444", "r1533" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1442", "r1531" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1439", "r1528" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Short-term borrowings, including current portion of long-term debt: 2024\u2014$3,747; 2023\u2014$2,254", "totalLabel": "Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r357" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r44", "r159", "r160", "r250", "r253", "r412", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r1351", "r1352", "r1353", "r1354", "r1355", "r1391", "r1586", "r1665", "r1666", "r1667", "r1769", "r1770" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total long-term debt, principal amount", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r44", "r253", "r661" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r644", "r983", "r984", "r1352", "r1353", "r1391" ] }, "pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": { "parentTag": "us-gaap_DebtCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net fair value adjustments related to hedging and purchase accounting", "label": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting", "documentation": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r162", "r664", "r983", "r984", "r1391" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r162", "r645" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r412", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r1351", "r1352", "r1353", "r1354", "r1355", "r1391", "r1586", "r1769", "r1770" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r44", "r412", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r1351", "r1352", "r1353", "r1354", "r1355", "r1391", "r1586", "r1665", "r1666", "r1667", "r1769", "r1770" ] }, "us-gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchased debt", "label": "Debt Instrument, Repurchase Amount", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r44", "r78", "r79", "r138", "r220", "r221", "r412", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r1351", "r1352", "r1353", "r1354", "r1355", "r1391", "r1586", "r1769", "r1770" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": { "parentTag": "us-gaap_DebtCurrent", "weight": -1.0, "order": 2.0 }, "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net unamortized discounts, premiums and debt issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r650", "r662", "r982", "r983", "r984", "r1352", "r1353", "r1391" ] }, "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DebtSecuritiesAccumulatedGrossUnrealizedGain", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, gross unrealized gains", "label": "Debt Securities, Accumulated Gross Unrealized Gain", "documentation": "Debt Securities, Accumulated Gross Unrealized Gain" } } }, "auth_ref": [] }, "pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DebtSecuritiesAccumulatedGrossUnrealizedLoss", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt securities, gross unrealized losses", "label": "Debt Securities, Accumulated Gross Unrealized Loss", "documentation": "Debt Securities, Accumulated Gross Unrealized Loss" } } }, "auth_ref": [] }, "pfe_DebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt securities, amortized cost", "label": "Debt Securities, Amortized Cost Basis", "documentation": "Debt Securities, Amortized Cost Basis" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturity", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, fair value", "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1093", "r1607" ] }, "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DebtSecuritiesMaturitiesAfterYearFiveFairValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities maturities, over 5 years, fair value", "label": "Debt Securities Maturities, After Year Five, Fair Value", "documentation": "Debt Securities Maturities, After Year Five, Fair Value" } } }, "auth_ref": [] }, "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DebtSecuritiesMaturitiesNextTwelveMonthsFairValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities maturities, within 1 year, fair value", "label": "Debt Securities Maturities, Next Twelve Months, Fair Value", "documentation": "Debt Securities Maturities, Next Twelve Months, Fair Value" } } }, "auth_ref": [] }, "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities maturities, over 1 to 5 years, fair value", "label": "Debt Securities Maturities, Year Two Through Five, Fair Value", "documentation": "Debt Securities Maturities, Year Two Through Five, Fair Value" } } }, "auth_ref": [] }, "pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gains and Losses on Investment Securities", "label": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]", "documentation": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate, percentage", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r273" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1588", "r1735", "r1736" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income taxes", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1588", "r1735" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r15", "r291", "r1588" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes:", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Deferred tax liabilities, gross", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r167", "r168", "r251", "r852" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r830", "r831", "r1109" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State and local", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1588", "r1735", "r1736" ] }, "pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets associated with unrecognized tax benefits", "label": "Deferred Tax Assets Associated With Unrecognized Tax Benefits", "documentation": "Deferred Tax Assets Associated With Unrecognized Tax Benefits" } } }, "auth_ref": [] }, "pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction for unrecognized tax benefit", "label": "Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward", "documentation": "Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsDeferredIncome", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues - Deferred tax assets", "label": "Deferred Tax Assets, Deferred Income", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxAssetsEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsEquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments - Deferred tax assets", "label": "Deferred Tax Assets, Equity Method Investments", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets - Deferred tax assets", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Subtotal - Deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r853" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development - Deferred tax assets", "label": "Deferred Tax Asset, In-Process Research and Development", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both." } } }, "auth_ref": [ "r1733" ] }, "pfe_DeferredTaxAssetsIndefiniteLivedAndDefiniteLived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxAssetsIndefiniteLivedAndDefiniteLived", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived and definite-lived", "label": "Deferred Tax Assets, Indefinite-Lived and Definite-Lived", "documentation": "Deferred Tax Assets, Indefinite-Lived and Definite-Lived" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories - Deferred tax assets", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails", "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax asset", "terseLabel": "Net deferred tax asset", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1732" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred taxes - Deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1732" ] }, "pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent deferred tax assets and other noncurrent tax assets", "label": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent", "documentation": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent" } } }, "auth_ref": [] }, "pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss/tax credit carryforwards - Deferred tax assets", "label": "Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards", "documentation": "Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All other - Deferred tax assets", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment - Deferred tax assets", "label": "Deferred Tax Assets, Property, Plant and Equipment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1733" ] }, "pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxAssetsStateandLocalTaxesAdjustments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State and local tax adjustments - Deferred tax assets", "label": "Deferred Tax Assets, State and Local Taxes Adjustments", "documentation": "Deferred Tax Assets, State and Local Taxes Adjustments" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpense", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid/deferred items - Deferred tax assets", "label": "Deferred Tax Assets, Tax Deferred Expense", "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits - Deferred tax assets", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other." } } }, "auth_ref": [ "r1733" ] }, "pfe_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedRoyalties", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued/deferred royalties - Deferred tax assets", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Royalties", "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Royalties" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructurings and other charges - Deferred tax assets", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve." } } }, "auth_ref": [ "r1733" ] }, "pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal and product liability reserves - Deferred tax assets", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves", "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowances", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r854" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred tax liability", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1732" ] }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories - Deferred tax liabilities", "label": "Deferred Tax Liabilities, Inventory", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Intangible assets - Deferred tax liabilities", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investments - Deferred tax liabilities", "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "All other - Deferred tax liabilities", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid/deferred items - Deferred tax liabilities", "label": "Deferred Tax Liabilities, Prepaid Expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Property, plant and equipment - Deferred tax liabilities", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1733" ] }, "pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee benefits - Deferred tax liabilities", "label": "Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "documentation": "Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unremitted earnings - Deferred tax liabilities", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences." } } }, "auth_ref": [ "r1733" ] }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plan, accumulated benefit obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth_ref": [ "r731" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prior service (costs)/credits", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r48", "r743" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r713", "r1362" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsAbstract", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets:", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets sold during the period", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold", "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold." } } }, "auth_ref": [ "r727", "r1362" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held, ending", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held", "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held." } } }, "auth_ref": [ "r727", "r1362" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in actuarial assumptions and other", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r706" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit, actuarial valuation and other pension and postretirement plan, gain (loss)", "label": "Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit", "documentation": "Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of 10 percent of greater of fair value of plan assets or benefit obligation." } } }, "auth_ref": [ "r700", "r738", "r764" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Actuarial (gains)/losses", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r700", "r738", "r764", "r1362", "r1363" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of prior service cost/(credit)", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r700", "r739", "r765", "r1362", "r1363" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Funded status", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r84", "r85" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts recorded in our consolidated balance sheet:", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Other comprehensive income (loss), benefit plans, prior service (costs)/credits, before tax, total", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r6", "r184", "r223" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract]" } } }, "auth_ref": [] }, "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefit plans: prior service (costs)/credits and other, net", "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax", "documentation": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r247", "r697", "r698", "r721", "r1231", "r1362", "r1785" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r745" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r746" ] }, "pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate: Interest cost", "label": "Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate", "documentation": "Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate: Pension plans/postretirement plans", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r745" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r747", "r769" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r746" ] }, "pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate: Service cost", "label": "Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate", "documentation": "Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Benefit obligation, beginning", "periodEndLabel": "Benefit obligation, ending", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r701" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefits paid", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r708", "r772" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee contributions", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation." } } }, "auth_ref": [ "r705" ] }, "pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Curtailments and special termination benefits", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits", "documentation": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits" } } }, "auth_ref": [] }, "pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions/divestitures, net", "label": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation", "documentation": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation" } } }, "auth_ref": [] }, "pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions/divestitures, net", "label": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets", "documentation": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r750", "r1360", "r1361", "r1362" ] }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents [Member]", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1360" ] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in benefit obligation", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in plan assets", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Special termination benefits", "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits", "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan." } } }, "auth_ref": [ "r753" ] }, "us-gaap_DefinedBenefitPlanDebtSecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDebtSecurityMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed income securities [Member]", "label": "Defined Benefit Plan, Debt Security [Member]", "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution; in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1686" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity commingled funds [Member]", "label": "Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]", "documentation": "Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]" } } }, "auth_ref": [] }, "pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global equity securities [Member]", "label": "Defined Benefit Plan, Equity Securities, Global Equity Securities [Member]", "documentation": "Defined Benefit Plan, Equity Securities, Global Equity Securities" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities [Member]", "label": "Defined Benefit Plan, Equity Securities [Member]", "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": [ "r1360", "r1362" ] }, "us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected benefit payments:", "label": "Defined Benefit Plan, Expected Future Employer Contributions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030\u20132034", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r732" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r732" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2029", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r732" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r732" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r732" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r732" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected contributions in 2025", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r733", "r1363" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r700", "r737", "r763", "r1362", "r1363" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value of plan assets, beginning", "periodEndLabel": "Fair value of plan assets, ending", "verboseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r712", "r723", "r725", "r726", "r1360", "r1361", "r1362" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange impact", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r707" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funded status", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": [ "r697", "r721", "r1362" ] }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Healthcare cost trend rate assumed for next year", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status." } } }, "auth_ref": [ "r749" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r700", "r704", "r736", "r762", "r1362", "r1363" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit costs/(credits) recorded in Other (income)/deductions\u2013\u2013net", "totalLabel": "Net periodic benefit cost/(credit) reported in income", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r734", "r760", "r1362", "r1363" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditImmediateRecognitionOfActuarialGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditImmediateRecognitionOfActuarialGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Immediate Recognition of Actuarial Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Immediate Recognition of Actuarial Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes actuarial gain (loss) recognized immediately as component of net periodic benefit (cost) credit for defined benefit plan." } } }, "auth_ref": [ "r734", "r760" ] }, "pfe_DefinedBenefitPlanOtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanOtherInvestmentsMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments [Member]", "label": "Defined Benefit Plan, Other Investments [Member]", "documentation": "Defined Benefit Plan, Other Investments" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r757", "r1362" ] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PBO", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r757", "r1362" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Information related to the funded status of pension plans with an ABO in excess of plan assets(c):", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ABO", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r757", "r758", "r1362" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r757", "r758", "r1362" ] }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAmendments", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan amendments", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan." } } }, "auth_ref": [ "r709" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefits paid", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r717", "r1691" ] }, "pfe_DefinedBenefitPlanPlanAssetsContributionsByEmployerNetOfReimbursements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DefinedBenefitPlanPlanAssetsContributionsByEmployerNetOfReimbursements", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer, Net of Reimbursements", "documentation": "Defined Benefit Plan, Plan Assets, Contributions by Employer, Net of Reimbursements" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets." } } }, "auth_ref": [ "r716" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign exchange impact", "terseLabel": "Exchange rate changes", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r714" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity and debt securities, target allocation percentage", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r722", "r1362" ] }, "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Information related to the funded status of pension plans with a PBO in excess of plan assets(c):", "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases, sales, and settlements, net", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement", "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment." } } }, "auth_ref": [ "r728", "r1362" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Curtailments", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees." } } }, "auth_ref": [ "r699", "r741", "r767" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r702", "r735", "r761", "r1362", "r1363" ] }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement." } } }, "auth_ref": [ "r703" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r720" ] }, "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer into/(out\u00a0of) Level 3", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3", "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs." } } }, "auth_ref": [ "r729", "r1362" ] }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate to which the cost trend rate is assumed to decline", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan." } } }, "auth_ref": [ "r749" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average assumptions used to determine benefit obligations at fiscal year-end:", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average assumptions used to determine net periodic benefit cost:", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, cost recognized", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r773" ] }, "pfe_DepoMedrolMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DepoMedrolMember", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depo-Medrol [Member]", "label": "Depo-Medrol [Member]", "documentation": "Depo-Medrol" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r15", "r450", "r463", "r488", "r1335", "r1336" ] }, "pfe_DepreciationExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DepreciationExpenseMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation Expense [Member]", "label": "Depreciation Expense [Member]", "documentation": "Depreciation Expense" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset, statement of financial position", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r908" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative asset", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r368", "r369", "r947", "r948", "r955", "r963", "r1198", "r1199", "r1200", "r1202", "r1203", "r1205", "r1206", "r1207", "r1208", "r1209", "r1225", "r1226", "r1274", "r1277", "r1278", "r1279", "r1280", "r1281", "r1322", "r1380", "r1384", "r1419", "r1753", "r1754", "r1755", "r1824" ] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current derivative assets", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r368" ] }, "us-gaap_DerivativeAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent derivative assets", "label": "Derivative Asset, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r368" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r1207", "r1209", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1233", "r1234", "r1235", "r1236", "r1247", "r1248", "r1249", "r1250", "r1253", "r1254", "r1255", "r1256", "r1274", "r1275", "r1278", "r1280", "r1417", "r1419", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1763", "r1764" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Gains/(Losses) Recognized in OID", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1748" ] }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative." } } }, "auth_ref": [ "r1748" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r122", "r125", "r128", "r243", "r1207", "r1209", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1233", "r1234", "r1235", "r1236", "r1247", "r1248", "r1249", "r1250", "r1253", "r1254", "r1255", "r1256", "r1274", "r1275", "r1278", "r1280", "r1322", "r1417", "r1419", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1763", "r1764" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r29", "r122", "r125" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Amount of Gains/(Losses) Recognized in OID", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r127", "r1552" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "verboseLabel": "Derivative liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r368", "r369", "r947", "r948", "r955", "r963", "r1198", "r1199", "r1200", "r1202", "r1205", "r1206", "r1207", "r1208", "r1209", "r1233", "r1235", "r1236", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1322", "r1753", "r1754", "r1755", "r1824" ] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current derivative liabilities", "label": "Derivative Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r368" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent derivative liabilities", "label": "Derivative Liability, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r368" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, statement of financial position", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r908" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r933" ] }, "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNetLiabilityPositionAggregateFairValue", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives in a net liability position", "label": "Derivative, Net Liability Position, Aggregate Fair Value", "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument." } } }, "auth_ref": [ "r129" ] }, "pfe_DerivativeNetReceivablePositionAggregateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DerivativeNetReceivablePositionAggregateFairValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives in a net receivable position", "label": "Derivative, Net Receivable Position, Aggregate Fair Value", "documentation": "Derivative, Net Receivable Position, Aggregate Fair Value" } } }, "auth_ref": [] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1746", "r1747" ] }, "us-gaap_DerivativeRemainingMaturity1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeRemainingMaturity1", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining period of hedging exposure", "label": "Derivative, Remaining Maturity", "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r29", "r114", "r115", "r116", "r120", "r123", "r125", "r131", "r133", "r134", "r933" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative term of contract", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Financial Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r29", "r114", "r115", "r120", "r132", "r411", "r429" ] }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesReportingOfDerivativeActivity", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows", "label": "Derivatives, Reporting of Derivative Activity [Policy Text Block]", "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations." } } }, "auth_ref": [ "r114" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument [Member]", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r29" ] }, "pfe_DevelopedMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DevelopedMarketsMember", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Markets [Member]", "label": "Developed Markets [Member]", "documentation": "Developed Rest Of World [Member]" } } }, "auth_ref": [] }, "pfe_DevelopedTechnologyRightsAndOtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DevelopedTechnologyRightsAndOtherIntangibleAssetsMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology Rights and Other Intangible Assets [Member]", "label": "Developed Technology Rights and Other Intangible Assets [Member]", "documentation": "Developed Technology Rights and Other Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillNarrativeDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology Rights [Member]", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r238", "r1649", "r1650", "r1651", "r1652", "r1654", "r1656", "r1659", "r1660" ] }, "us-gaap_DilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecuritiesAbstract", "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EPS Numerator\u2013\u2013Diluted", "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.pfizer.com/role/ShareBasedPayments" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Payments", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r778", "r781", "r812", "r813", "r815", "r1371" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Awards and Valuation Details", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r18", "r91" ] }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of continuing involvement after disposal", "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r148" ] }, "pfe_DisitamabVedotinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DisitamabVedotinMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "disitamab vedotin [Member]", "label": "disitamab vedotin [Member]", "documentation": "disitamab vedotin" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r342" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposed of by Sale, Not Discontinued Operations [Member]", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r16", "r38" ] }, "pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal": { "xbrltype": "percentItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proposed percent of ownership disposal", "label": "Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal", "documentation": "Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r1364", "r1367" ] }, "us-gaap_DividendsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared:", "label": "Dividends [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Common stock", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r222" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r160" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1432", "r1433", "r1456" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1432", "r1433", "r1456", "r1499" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1477" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1430" ] }, "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DomesticIncomeTaxExpenseBenefitContinuedOperations", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total U.S. tax provision/(benefit)", "label": "Domestic Income Tax Expense (Benefit), Continued Operations", "documentation": "Domestic Income Tax Expense (Benefit), Continued Operations" } } }, "auth_ref": [] }, "pfe_DomesticIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "DomesticIncomeTaxesAbstract", "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "Domestic Income Taxes [Abstract]", "documentation": "Domestic Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticPlanMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan [Member]", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1692", "r1693", "r1694" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r1488" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r394", "r421", "r422", "r423", "r424", "r425", "r426", "r432", "r435", "r443", "r444", "r445", "r449", "r882", "r897", "r944", "r945", "r1099", "r1130", "r1327" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share\u2013\u2013basic:", "verboseLabel": "EPS Numerator", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r394", "r421", "r422", "r423", "r424", "r425", "r426", "r435", "r443", "r444", "r445", "r449", "r882", "r897", "r944", "r945", "r1099", "r1130", "r1327" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share\u2013\u2013diluted:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r431", "r446", "r447", "r448" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r969" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective tax rate for income from continuing operations", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r835", "r1375" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. statutory income tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r408", "r835", "r865", "r1375" ] }, "pfe_EffectiveIncomeTaxRateReconciliationCharitableContributionsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationCharitableContributionsPercent", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Charitable contributions", "label": "Effective Income Tax Rate Reconciliation, Charitable Contributions, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Charitable Contributions, Percent" } } }, "auth_ref": [] }, "pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationDeductionInterestPercent", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Effective Income Tax Rate Reconciliation, Deduction, Interest, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Interest, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign-Derived Intangible Income deduction", "label": "Effective Income Tax Rate Reconciliation, FDII, Percent", "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": [ "r1375", "r1727", "r1729" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxation of non-U.S. operations", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r836", "r839", "r1375", "r1589", "r1727" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All other, net", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1375", "r1589", "r1727", "r1728" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State & local taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r838", "r1375", "r1589", "r1727" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "U.S. R&D tax credit", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r840", "r841", "r1589", "r1727" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax settlements and resolution of certain tax positions", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements." } } }, "auth_ref": [ "r1589", "r1727", "r1728" ] }, "pfe_EffectiveIncomeTaxRateReconciliationTaxTransitionLiabilityPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationTaxTransitionLiabilityPercent", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transition Tax liability", "label": "Effective Income Tax Rate Reconciliation, Tax Transition Liability, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Tax Transition Liability, Percent" } } }, "auth_ref": [] }, "pfe_EliquisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EliquisMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Eliquis [Member]", "label": "Eliquis [Member]", "documentation": "Eliquis" } } }, "auth_ref": [] }, "pfe_ElrexfioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ElrexfioMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Elrexfio [Member]", "label": "Elrexfio [Member]", "documentation": "Elrexfio" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and related items", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r160" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total compensation cost related to nonvested awards not yet recognized, pre-tax", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r814" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period over which cost is expected to be recognized (years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r814" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total compensation cost related to nonvested awards not yet recognized, pre-tax", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1721" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit for share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r811" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefits realized from exercise", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r287" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Termination Costs [Member]", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options [Member]", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ESOP compensation expense", "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense", "documentation": "The amount of plan compensation cost recognized during the period." } } }, "auth_ref": [ "r95" ] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Axis]", "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]", "documentation": "Information by name of employee stock ownership plan." } } }, "auth_ref": [ "r93" ] }, "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPPlanDomain", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Ownership Plan (ESOP), Plan [Domain]", "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]", "documentation": "Entities identify multiple employee stock ownership plans by unique name." } } }, "auth_ref": [ "r94" ] }, "pfe_EnbrelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EnbrelMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Enbrel (Outside the U.S. and Canada) [Member]", "label": "Enbrel [Member]", "documentation": "Enbrel [Member]" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1429" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1429" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1429" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1539" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1429" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1429" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1429" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1429" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1540" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1482" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1535" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1535" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1535" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Class of Treasury Stock [Line Items]", "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r28", "r337", "r386", "r387", "r388", "r413", "r414", "r415", "r418", "r425", "r427", "r429", "r451", "r550", "r556", "r601", "r681", "r860", "r861", "r878", "r879", "r880", "r883", "r896", "r897", "r925", "r927", "r928", "r929", "r930", "r932", "r943", "r971", "r973", "r974", "r975", "r976", "r978", "r986", "r989", "r1014", "r1125", "r1160", "r1161", "r1162", "r1186", "r1259" ] }, "pfe_EquityMethodInvesteeAdjustedIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquityMethodInvesteeAdjustedIncome", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method, adjusted income", "label": "Equity Method Investee, Adjusted Income", "documentation": "Equity Method Investee, Adjusted Income" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r541", "r542", "r543", "r874", "r1542", "r1543", "r1544", "r1737", "r1738", "r1739", "r1740" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r12", "r15", "r187", "r1119" ] }, "pfe_EquityMethodInvestmentIncreaseDecreaseBasisDifferenceAdjustmentsAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquityMethodInvestmentIncreaseDecreaseBasisDifferenceAdjustmentsAndAmortization", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis difference adjustments and amortization", "label": "Equity Method Investment, Increase (Decrease), Basis Difference Adjustments and Amortization", "documentation": "Equity Method Investment, Increase (Decrease), Basis Difference Adjustments and Amortization" } } }, "auth_ref": [] }, "pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustments and other", "label": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation", "documentation": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation" } } }, "auth_ref": [] }, "pfe_EquityMethodInvestmentIncreaseDecreaseInvesteeCapitalTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquityMethodInvestmentIncreaseDecreaseInvesteeCapitalTransaction", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pfizer share of Haleon investee capital transaction", "label": "Equity Method Investment, Increase (Decrease), Investee Capital Transaction", "documentation": "Equity Method Investment, Increase (Decrease), Investee Capital Transaction" } } }, "auth_ref": [] }, "pfe_EquityMethodInvestmentIncreaseDecreaseTransferToInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquityMethodInvestmentIncreaseDecreaseTransferToInvestments", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of carrying value to Short-term investments", "label": "Equity Method Investment, Increase (Decrease), Transfer To Investments", "documentation": "Equity Method Investment, Increase (Decrease), Transfer To Investments" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r343", "r405", "r544", "r964", "r1057", "r1058", "r1063", "r1070", "r1077", "r1078", "r1089", "r1091", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r343", "r405", "r544", "r964", "r1057", "r1058", "r1063", "r1070", "r1077", "r1078", "r1089", "r1091", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r541" ] }, "pfe_EquityMethodInvestmentPercentageOfHoldingsSold": { "xbrltype": "percentItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquityMethodInvestmentPercentageOfHoldingsSold", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, ownership percentage sold", "label": "Equity Method Investment, Percentage Of Holdings Sold", "documentation": "Equity Method Investment, Percentage Of Holdings Sold" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentSoldCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentSoldCarryingAmount", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Carrying value of shares sold", "label": "Equity Method Investment, Amount Sold", "documentation": "Amount of the entity's equity method investment which has been sold." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentSummarizedFinancialInformationAbstract", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Summarized Financial Information [Abstract]", "label": "Equity Method Investment, Summarized Financial Information [Abstract]" } } }, "auth_ref": [] }, "pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]", "label": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]", "documentation": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_LongTermInvestments", "weight": 1.0, "order": 2.0 }, "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-method investments", "periodStartLabel": "Beginning carrying value reported in Equity-method investments", "periodEndLabel": "Ending carrying value", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r450", "r469", "r488", "r539", "r1566", "r1633" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summarized Financial Information of Equity Method Investments", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r540" ] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities with readily determinable fair values", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": [ "r961" ] }, "pfe_EquitySecuritiesFVNIRestrictedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquitySecuritiesFVNIRestrictedNoncurrent", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term equity securities held in trust", "label": "Equity Securities, FV-NI, Restricted, Noncurrent", "documentation": "Equity Securities, FV-NI, Restricted, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments", "weight": 1.0, "order": 2.0 }, "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_OtherShortTermInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity securities", "terseLabel": "Equity securities with readily determinable fair values", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r355", "r961", "r1317" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net (gains)/losses recognized during the period on equity securities", "negatedTotalLabel": "Net (gains)/losses recognized during the period on equity securities", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r1134", "r1632" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gain", "negatedTerseLabel": "Less: Net (gains)/losses recognized during the period on equity securities sold during the period", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r1132", "r1632" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r1133", "r1632" ] }, "pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative impairment losses and downward price adjustments on equity securities", "label": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount", "documentation": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative upward price adjustments on equity securities", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r537" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1492" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1449", "r1460", "r1470", "r1503" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1446", "r1457", "r1467", "r1500" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value [Member]", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r652", "r963", "r1352", "r1353" ] }, "pfe_EtrasimodVelsipityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "EtrasimodVelsipityMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Etrasimod (Velsipity) [Member]", "label": "Etrasimod (Velsipity) [Member]", "documentation": "Etrasimod (Velsipity)" } } }, "auth_ref": [] }, "pfe_ExcludingComirnatyAndPaxlovidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ExcludingComirnatyAndPaxlovidMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excluding Comirnaty and Paxlovid [Member]", "label": "Excluding Comirnaty and Paxlovid [Member]", "documentation": "Excluding Comirnaty and Paxlovid" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1498" ] }, "pfe_ExpirationPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ExpirationPeriodAxis", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Period [Axis]", "label": "Expiration Period [Axis]", "documentation": "Expiration Period" } } }, "auth_ref": [] }, "pfe_ExpirationPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ExpirationPeriodDomain", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Period [Domain]", "label": "Expiration Period [Domain]", "documentation": "Expiration Period [Domain]" } } }, "auth_ref": [] }, "pfe_Expiring2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "Expiring2030Member", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiring 2030 [Member]", "label": "Expiring 2030 [Member]", "documentation": "Expiring 2030" } } }, "auth_ref": [] }, "pfe_Expiring2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "Expiring2033Member", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiring 2033 [Member]", "label": "Expiring 2033 [Member]", "documentation": "Expiring 2033" } } }, "auth_ref": [] }, "pfe_FSMEIMMUNTicoVacMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "FSMEIMMUNTicoVacMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "FSME-IMMUN/TicoVac [Member]", "label": "FSME/IMMUN-TicoVac [Member]", "documentation": "FSME/IMMUN-TicoVac [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentToInventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentToInventoryMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Adjustment to Inventory [Member]", "label": "Fair Value Adjustment to Inventory [Member]", "documentation": "Fair value adjustment to acquisition-date inventory allocated (included) to (in) reported pro forma earnings (supplemental pro forma information)." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r947", "r948", "r955", "r1380" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r947", "r948", "r955", "r1380" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "verboseLabel": "Defined Benefit Plan, Fair Value of Plan Assets by Measurement [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r652", "r725", "r726", "r727", "r728", "r729", "r730", "r946", "r948", "r949", "r950", "r951", "r954", "r955", "r957", "r1020", "r1021", "r1022", "r1352", "r1353", "r1360", "r1361", "r1362", "r1380", "r1384" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r652", "r1352", "r1353" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r947", "r948", "r949", "r951", "r1380", "r1754", "r1765" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r652", "r1352", "r1353" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging [Member]", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r117" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r652", "r725", "r730", "r948", "r955", "r1020", "r1360", "r1361", "r1362", "r1380" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r652", "r725", "r730", "r948", "r949", "r955", "r1021", "r1352", "r1353", "r1360", "r1361", "r1362", "r1380" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r652", "r725", "r726", "r727", "r728", "r729", "r730", "r948", "r949", "r950", "r951", "r955", "r1022", "r1352", "r1353", "r1360", "r1361", "r1362", "r1380", "r1384" ] }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Measured at NAV [Member]", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r725", "r946", "r957", "r1380" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r947", "r948", "r949", "r951", "r1380", "r1754", "r1765" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "verboseLabel": "Fair Value Plan Asset Measurement [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r652", "r725", "r726", "r727", "r728", "r729", "r730", "r946", "r948", "r949", "r950", "r951", "r954", "r955", "r957", "r1020", "r1021", "r1022", "r1352", "r1353", "r1360", "r1361", "r1362", "r1380", "r1384" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring [Member]", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1380", "r1751", "r1752", "r1753", "r1754", "r1755", "r1765" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r558", "r559", "r560", "r561", "r562", "r564", "r565", "r566", "r660", "r678", "r933", "r958", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1126", "r1342", "r1380", "r1382", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1394", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1628", "r1629", "r1630", "r1631", "r1750", "r1753", "r1754", "r1755", "r1762", "r1765" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible asset, useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finite-lived intangible assets, accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r352", "r571", "r592", "r1344" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillExpectedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594", "r1309", "r1344" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillExpectedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594", "r1309", "r1344" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillExpectedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594", "r1309", "r1344" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillExpectedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594", "r1309", "r1344" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillExpectedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594", "r1309", "r1344" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillNarrativeDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r584", "r586", "r587", "r588", "r591", "r592", "r596", "r597", "r1052", "r1056", "r1309" ] }, "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails": { "parentTag": "pfe_IntangibleAssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived", "label": "Finite-Lived Intangible Assets, Fair Value Disclosure", "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [ "r1751", "r1752", "r1762" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets, gross carrying amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r571", "r592", "r1056", "r1344" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r584", "r592", "r596", "r597", "r599", "r1052", "r1309", "r1344" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillNarrativeDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r584", "r586", "r587", "r588", "r591", "r592", "r596", "r597", "r1309" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finite-lived intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r1052", "r1656" ] }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets period increase (decrease)", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FixedIncomeSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixedIncomeSecuritiesMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed income commingled funds [Member]", "label": "Fixed Income Securities [Member]", "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity." } } }, "auth_ref": [ "r1362", "r1417", "r1418", "r1686" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax gain expected to be reclassified within the next 12 months", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r135" ] }, "pfe_ForeignCurrencyDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ForeignCurrencyDebtMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Long-Term Debt [Member]", "label": "Foreign Currency Debt [Member]", "documentation": "Foreign currency long - term debt [Member]" } } }, "auth_ref": [] }, "pfe_ForeignCurrencyShortTermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ForeignCurrencyShortTermBorrowingsMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Short-Term Borrowings [Member]", "label": "Foreign Currency Short Term Borrowings [Member]", "documentation": "Foreign currency short - term borrowings [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r965" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign exchange contracts [Member]", "terseLabel": "Foreign Exchange Contract [Member]", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r1322", "r1360", "r1379", "r1380" ] }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government and agency debt - non-U.S. [Member]", "label": "Debt Security, Government, Non-US [Member]", "documentation": "Debt security issued by government not domiciled in United States of America (US)." } } }, "auth_ref": [ "r1394", "r1686", "r1820" ] }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total international tax provision/(benefit)", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations." } } }, "auth_ref": [ "r406", "r834" ] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignPlanMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International [Member]", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1692", "r1693", "r1694" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1453", "r1464", "r1474", "r1507" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1453", "r1464", "r1474", "r1507" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1453", "r1464", "r1474", "r1507" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1453", "r1464", "r1474", "r1507" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1453", "r1464", "r1474", "r1507" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1487" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and other [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "pfe_GBTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GBTMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "GBT [Member]", "label": "GBT [Member]", "documentation": "GBT" } } }, "auth_ref": [] }, "pfe_GSKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GSKMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GSK [Member]", "label": "GSK [Member]", "documentation": "GSK [Member]" } } }, "auth_ref": [] }, "us-gaap_GainContingenciesByNatureAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingenciesByNatureAxis", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain Contingencies, Nature [Axis]", "label": "Gain Contingencies, Nature [Axis]", "documentation": "Information by nature of gain contingency." } } }, "auth_ref": [ "r1677" ] }, "us-gaap_GainContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingenciesLineItems", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain Contingencies [Line Items]", "label": "Gain Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1677" ] }, "us-gaap_GainContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingenciesTable", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain Contingencies [Table]", "label": "Gain Contingencies [Table]", "documentation": "Disclosure of information about existing condition, situation, or set of circumstances involving uncertainty as to possible gain that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r1677" ] }, "us-gaap_GainContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingencyNatureDomain", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain Contingency, Nature [Domain]", "label": "Gain Contingency, Nature [Domain]", "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization." } } }, "auth_ref": [ "r1677" ] }, "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents allegedly infringed upon", "label": "Gain Contingency, Patents Allegedly Infringed upon, Number", "documentation": "Number of entity's patents that another entity has allegedly infringed." } } }, "auth_ref": [ "r1677" ] }, "pfe_GainLossOnDispositionOfStockInSubsidiaryOrEquityMethodInvesteeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GainLossOnDispositionOfStockInSubsidiaryOrEquityMethodInvesteeNet", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain on sale of equity method investment", "label": "Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee, Net", "documentation": "Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee, Net" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax gain on divestiture", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r905", "r1583" ] }, "us-gaap_GainLossOnSaleOfProperties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfProperties", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Charge related to expected sale of facilities", "label": "Gain (Loss) on Sale of Properties", "documentation": "The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method." } } }, "auth_ref": [ "r1583", "r1662", "r1663" ] }, "us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of equity method investment", "label": "Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee", "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r1094", "r1575", "r1576", "r1583", "r1789" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Certain legal matters, net", "label": "Gain (Loss) from Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r1335", "r1672" ] }, "pfe_GenericSterileInjectableProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GenericSterileInjectableProductMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Generic Sterile Injectable Product [Member]", "label": "Generic Sterile Injectable Product [Member]", "documentation": "Generic Sterile Injectable Product [Member]" } } }, "auth_ref": [] }, "pfe_GenotropinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GenotropinMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Genotropin [Member]", "label": "Genotropin [Member]", "documentation": "Genotropin [Member]" } } }, "auth_ref": [] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk [Member]", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r60", "r1295" ] }, "pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member]", "label": "GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC US Patent Infringement Case [Member]", "documentation": "GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC US Patent Infringement Case" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r351", "r572", "r1092", "r1336", "r1343", "r1381", "r1393", "r1638", "r1645" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r575", "r1343" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwill" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable Intangible Assets, Net and Goodwill", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1636", "r1648" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets and Goodwill", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r1636", "r1648" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of foreign exchange and other", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r579" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails": { "parentTag": "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferredIncludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r1644" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "pfe_GovernmentAndGovernmentSponsoredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GovernmentAndGovernmentSponsoredMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Government and Government Sponsored [Member]", "label": "Government and Government Sponsored [Member]", "documentation": "Government and Government Sponsored" } } }, "auth_ref": [] }, "pfe_GovernmentEmergencyUseAuthorizationInventoryReturnedToTheCompanyDuringThePeriodNumberOfTreatmentCourses": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GovernmentEmergencyUseAuthorizationInventoryReturnedToTheCompanyDuringThePeriodNumberOfTreatmentCourses", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government emergency use authorization inventory returned to the company during the period, number of treatment courses", "label": "Government Emergency Use Authorization Inventory Returned To The Company During The Period, Number Of Treatment Courses", "documentation": "Government Emergency Use Authorization Inventory Returned To The Company During The Period, Number Of Treatment Courses" } } }, "auth_ref": [] }, "pfe_GovernmentEmergencyUseAuthorizationInventoryToBeReturnedToCompanyNumberOfTreatmentCourses": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GovernmentEmergencyUseAuthorizationInventoryToBeReturnedToCompanyNumberOfTreatmentCourses", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated government emergency use authorization inventory to be returned to company, number of treatment courses", "label": "Government Emergency Use Authorization Inventory To Be Returned To Company, Number Of Treatment Courses", "documentation": "Government Emergency Use Authorization Inventory To Be Returned To Company, Number Of Treatment Courses" } } }, "auth_ref": [] }, "pfe_GovernmentInquiresRelatingToBiohavenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GovernmentInquiresRelatingToBiohavenMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Inquires Relating to Biohaven [Member]", "label": "Government Inquires Relating to Biohaven [Member]", "documentation": "Government Inquires Relating to Biohaven" } } }, "auth_ref": [] }, "pfe_GreenstoneAntitrustLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "GreenstoneAntitrustLitigationMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Greenstone Antitrust Litigation [Member]", "label": "Greenstone Antitrust Litigation [Member]", "documentation": "Greenstone Antitrust Litigation" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r185", "r192", "r265", "r405", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r964", "r1329", "r1335", "r1597", "r1599", "r1601", "r1602", "r1603", "r1680" ] }, "pfe_HaleonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "HaleonMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Haleon [Member]", "label": "Haleon [Member]", "documentation": "Haleon" } } }, "auth_ref": [] }, "pfe_HedgedItemAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "HedgedItemAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedged Item [Axis]", "label": "Hedged Item [Axis]", "documentation": "Hedged Item [Axis]" } } }, "auth_ref": [] }, "pfe_HedgedItemDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "HedgedItemDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedged Item [Domain]", "label": "Hedged Item [Domain]", "documentation": "[Domain] for Hedged Item [Axis]" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability", "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge." } } }, "auth_ref": [ "r920" ] }, "us-gaap_HedgedLiabilityFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedge", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount of Hedged Assets/Liabilities", "label": "Hedged Liability, Fair Value Hedge", "documentation": "Amount of liability hedged in fair value hedging relationship." } } }, "auth_ref": [ "r917" ] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r918" ] }, "us-gaap_HedgedLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedged Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Hedged Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes hedged liability." } } }, "auth_ref": [ "r919" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r29", "r916" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r29" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r29" ] }, "pfe_HeldToMaturityCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "HeldToMaturityCashEquivalents", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity cash equivalents", "label": "Held-To-Maturity Cash Equivalents", "documentation": "Held-To-Maturity Cash Equivalents" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecurities", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Held-to-maturity securities, amortized cost", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r267", "r519", "r560", "r1635" ] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity securities, gross unrealized gains", "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain", "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r269", "r529" ] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Held-to-maturity securities, gross unrealized losses", "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r270", "r530" ] }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_OtherShortTermInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity debt securities", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current." } } }, "auth_ref": [ "r505", "r1611", "r1635" ] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesAbstract", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Held-to-maturity, Maturity [Abstract]", "label": "Debt Securities, Held-to-Maturity, Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value", "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r272", "r276", "r533", "r1102" ] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]", "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity securities, debt maturities, within 1 year, fair value", "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r271", "r275", "r532", "r1101" ] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity securities, fair value", "label": "Debt Securities, Held-to-Maturity, Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r268", "r528", "r948", "r954", "r1093", "r1107" ] }, "us-gaap_HeldToMaturitySecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity debt securities", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent." } } }, "auth_ref": [ "r505", "r1611", "r1635" ] }, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity Securities", "label": "Debt Securities, Held-to-Maturity [Table Text Block]", "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r1610", "r1611", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627" ] }, "pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": { "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity securities, debt maturities, over 5 years, fair value", "label": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value", "documentation": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value" } } }, "auth_ref": [] }, "pfe_HospiraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "HospiraMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hospira [Member]", "label": "Hospira [Member]", "documentation": "Hospira [Member]" } } }, "auth_ref": [] }, "pfe_IbranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IbranceMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Ibrance [Member]", "label": "Ibrance [Member]", "documentation": "Ibrance [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1432", "r1433", "r1456" ] }, "pfe_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag", "label": "Impairment, Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag", "documentation": "Impairment, Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairments", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r15", "r585", "r598" ] }, "pfe_ImplementationCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ImplementationCostAbstract", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Implementation costs recorded in our consolidated statements of income as follows:", "label": "Implementation Cost [Abstract]", "documentation": "Implementation Cost [Abstract]" } } }, "auth_ref": [] }, "pfe_ImplementationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ImplementationCosts", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Implementation costs", "label": "Implementation Costs", "documentation": "Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D [Member]", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1656", "r1658", "r1659", "r1660" ] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired In-Process Research and Development Expenses", "label": "In Process Research and Development, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income from collaborations, out-licensing arrangements and sales of compound/product rights", "label": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights", "documentation": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights" } } }, "auth_ref": [] }, "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders", "label": "Income Loss From Continuing Operations Available To Common Stockholders Basic", "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any." } } }, "auth_ref": [] }, "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions", "label": "Income Loss From Continuing Operations Available To Common Stockholders diluted", "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r407", "r833" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails", "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income from continuing operations before provision/(benefit) for taxes on income", "verboseLabel": "Earnings", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r186", "r259", "r265", "r1100", "r1120", "r1329", "r1335", "r1597", "r1599", "r1601", "r1602", "r1603" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r407", "r833" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Income from continuing operations", "verboseLabel": "Net income from continuing operations before allocation to noncontrolling interests", "terseLabel": "Income from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r240", "r265", "r405", "r417", "r425", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r882", "r897", "r945", "r964", "r1120", "r1329", "r1597", "r1599", "r1601", "r1602", "r1603", "r1680" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r188", "r260", "r394", "r417", "r421", "r422", "r423", "r424", "r425", "r435", "r443", "r444", "r882", "r897", "r945", "r1099", "r1788" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r188", "r394", "r417", "r421", "r422", "r423", "r424", "r425", "r435", "r443", "r444", "r445", "r897", "r945", "r1099", "r1788" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations\u2013\u2013net of tax", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r140", "r141", "r142", "r143", "r144", "r152", "r343", "r871", "r1121" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r189", "r394", "r436", "r443", "r444", "r1783", "r1788" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r242", "r436", "r443", "r444" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Pfizer share of Haleon earnings", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r15", "r187", "r258", "r450", "r465", "r488", "r539", "r1119" ] }, "pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Haleon equity method (income)/loss", "label": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization", "documentation": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r1364", "r1367" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r38", "r45", "r139", "r145", "r146", "r147", "r149", "r150", "r151", "r153", "r154", "r213" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r602", "r604", "r616", "r952", "r953", "r956", "r1155", "r1157", "r1244", "r1309", "r1383", "r1793" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r604", "r616", "r952", "r953", "r956", "r1155", "r1157", "r1244", "r1309", "r1383", "r1793" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1730" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/TaxMatters" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matters", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r408", "r825", "r835", "r842", "r843", "r844", "r850", "r856", "r866", "r868", "r872", "r873", "r1183", "r1375" ] }, "us-gaap_IncomeTaxExaminationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationLineItems", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Examination [Line Items]", "label": "Income Tax Examination [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r845" ] }, "us-gaap_IncomeTaxExaminationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationTable", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Tax Examination [Table]", "label": "Income Tax, Examination [Table]", "documentation": "Disclosure of information about income tax examination currently in progress or completed during current period by tax authority. Includes, but is not limited to, description of examination, jurisdiction conducting examination, tax year under examination, likelihood of unfavorable settlement, range of possible loss, liability recorded, increase (decrease) of liability from prior period, and penalty and interest incurred or accrued." } } }, "auth_ref": [ "r1731" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 }, "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/TaxMattersNarrativeDetails", "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision/(benefit) for taxes on income", "totalLabel": "Provision/(benefit) for taxes on income", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r278", "r292", "r428", "r429", "r450", "r466", "r488", "r832", "r835", "r867", "r1135", "r1375" ] }, "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPaidFederalAfterRefundReceived", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersScheduleofCashPaidforIncomeTaxesNetofRefundsDetails": { "parentTag": "us-gaap_IncomeTaxesPaidNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersScheduleofCashPaidforIncomeTaxesNetofRefundsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "Income Tax Paid, Federal, after Refund Received", "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income." } } }, "auth_ref": [ "r402", "r857" ] }, "us-gaap_IncomeTaxPaidForeignAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPaidForeignAfterRefundReceived", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersScheduleofCashPaidforIncomeTaxesNetofRefundsDetails": { "parentTag": "us-gaap_IncomeTaxesPaidNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersScheduleofCashPaidforIncomeTaxesNetofRefundsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Income Tax Paid, Foreign, after Refund Received", "documentation": "Amount, after income tax refund received, of cash paid to foreign tax jurisdiction for tax on income." } } }, "auth_ref": [ "r402", "r857" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Assets and Liabilities and Income Tax Contingencies", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r385", "r828", "r829", "r850", "r851", "r855", "r859", "r1177" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersScheduleofCashPaidforIncomeTaxesNetofRefundsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows", "http://www.pfizer.com/role/TaxMattersScheduleofCashPaidforIncomeTaxesNetofRefundsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "totalLabel": "Total", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r56", "r402", "r857", "r858" ] }, "pfe_IncomeTaxesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IncomeTaxesPayableMember", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes Payable [Member]", "label": "Income Taxes Payable [Member]", "documentation": "Income Taxes Payable [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedTaxesPayable", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other tax accounts, net", "label": "Increase (Decrease) in Accrued Taxes Payable", "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes." } } }, "auth_ref": [ "r1582" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other changes in assets and liabilities, net of acquisitions and divestitures:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "pfe_IndefiniteLivedIntangibleAssetsAndFiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IndefiniteLivedIntangibleAssetsAndFiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class" } } }, "auth_ref": [] }, "pfe_IndefiniteLivedIntangibleAssetsAndFiniteLivedIntangibleAssetsByMajorClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IndefiniteLivedIntangibleAssetsAndFiniteLivedIntangibleAssetsByMajorClassDomain", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Domain]", "label": "Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Domain]", "documentation": "Indefinite-Lived Intangible Assets and Finite-Lived Intangible Assets by Major Class [Domain]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r584", "r589", "r595", "r1344" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r584", "r595", "r599", "r1344" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r571", "r595", "r1344" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails": { "parentTag": "pfe_IntangibleAssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure", "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit." } } }, "auth_ref": [ "r1751", "r1752", "r1762" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r584", "r589", "r595", "r1344" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets, period increase (decrease)", "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r1658" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1453", "r1464", "r1474", "r1498", "r1507", "r1511", "r1519" ] }, "pfe_InflectraRemsimaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InflectraRemsimaMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inflectra [Member]", "label": "Inflectra/Remsima [Member]", "documentation": "Inflectra/Remsima [Member]" } } }, "auth_ref": [] }, "pfe_InlytaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InlytaMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inlyta [Member]", "label": "Inlyta [Member]", "documentation": "Inlyta [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1517" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1434", "r1523" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1434", "r1523" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1434", "r1523" ] }, "pfe_InsuranceContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InsuranceContractsMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance contracts [Member]", "label": "Insurance Contracts [Member]", "documentation": "Insurance Contracts [Member]" } } }, "auth_ref": [] }, "pfe_IntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset, Statement Of Income Or Comprehensive Income Extensible Enumeration, Not Disclosed Flag", "label": "Intangible Asset, Statement Of Income Or Comprehensive Income Extensible Enumeration, Not Disclosed Flag", "documentation": "Intangible Asset, Statement Of Income Or Comprehensive Income Extensible Enumeration, Not Disclosed Flag" } } }, "auth_ref": [] }, "pfe_IntangibleAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "IntangibleAssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, fair value", "label": "Intangible Assets, Fair Value Disclosure", "documentation": "Intangible Assets, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, gross carrying amount", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r351" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Identifiable intangible assets, net", "totalLabel": "Identifiable Intangible Assets, Net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r584", "r1656", "r1658" ] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest costs capitalized", "label": "Interest Costs Capitalized", "documentation": "Amount of interest capitalized during the period." } } }, "auth_ref": [ "r981" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_InterestRevenueExpenseNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r450", "r458", "r462", "r468", "r488", "r980", "r1335", "r1336" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense [Member]", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r40" ] }, "us-gaap_InterestIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income [Member]", "label": "Interest Income [Member]", "documentation": "Primary financial statement caption in which reported facts about interest income have been included." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r396", "r400", "r401" ] }, "pfe_InterestPaidReceivedInterestRateHedges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InterestPaidReceivedInterestRateHedges", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate hedges", "label": "Interest Paid (Received), Interest Rate Hedges", "documentation": "Interest Paid (Received), Interest Rate Hedges" } } }, "auth_ref": [] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateContractMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate contracts [Member]", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r1311", "r1322", "r1360", "r1380" ] }, "us-gaap_InterestRevenueExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRevenueExpenseNet", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net interest expense", "label": "Interest Income (Expense), Operating and Nonoperating", "documentation": "Amount of interest income (expense) classified as operating and nonoperating." } } }, "auth_ref": [ "r450", "r458", "r488" ] }, "pfe_InternationalCommercialDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InternationalCommercialDivisionMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "International Commercial Division", "label": "International Commercial Division [Member]", "documentation": "International Commercial Division" } } }, "auth_ref": [] }, "pfe_InternationalDevelopedMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InternationalDevelopedMarketsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Markets [Member]", "label": "International Developed Markets [Member]", "documentation": "International Developed Markets" } } }, "auth_ref": [] }, "pfe_InternationalEmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InternationalEmergingMarketsMember", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Markets [Member]", "label": "International Emerging Markets [Member]", "documentation": "Emerging Markets [Member]" } } }, "auth_ref": [] }, "pfe_InternationalIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InternationalIncomeTaxesAbstract", "presentation": [ "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International Income Taxes [Abstract]", "documentation": "International Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r210", "r1318" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r365", "r1316", "r1393" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent inventories not included above", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r1568" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales and Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r280", "r346", "r364", "r567", "r568", "r570", "r1050", "r1325" ] }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and supplies", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments." } } }, "auth_ref": [ "r210", "r1569" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r210", "r1319" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory write-offs and related charges associated with COVID-19 products", "terseLabel": "Write-offs", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r569" ] }, "pfe_InventoryWriteDownAndOtherCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "InventoryWriteDownAndOtherCharges", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to cost of sales", "label": "Inventory Write-Down and Other Charges", "documentation": "Inventory Write-Down and Other Charges" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeDividend", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividend income", "terseLabel": "Dividend income", "label": "Investment Income, Dividend", "documentation": "Amount of dividend income on nonoperating securities." } } }, "auth_ref": [ "r195" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_InterestRevenueExpenseNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r450", "r461", "r488", "r1335", "r1574" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r1131", "r1173", "r1174", "r1175", "r1176", "r1266", "r1267" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Maturities of Available-for-sale and Held-to-maturity Securities", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "JP", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Japan [Member]", "label": "JAPAN" } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land [Member]", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r1685" ] }, "pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LeaseAssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.pfizer.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Assets and Liabilities", "label": "Lease, Assets and Liabilities, Lessee [Table Text Block]", "documentation": "Lease, Assets and Liabilities, Lessee" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r996", "r1392" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.pfizer.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Costs and Other Supplemental Information", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1772" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.pfizer.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r995", "r1007" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.pfizer.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r995", "r1007" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r994" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.pfizer.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1773" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r1005" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1773" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "4-5 years", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1773" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "3-4 years", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1773" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2-3 years", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1773" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "1-2 years", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1773" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Next one year", "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1773" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r1005" ] }, "pfe_LesseeOperatingLeaseOptionToExtendTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LesseeOperatingLeaseOptionToExtendTerm", "presentation": [ "http://www.pfizer.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease term, option to extend", "label": "Lessee, Operating Lease, Option To Extend, Term", "documentation": "Lessee, Operating Lease, Option To Extend, Term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.pfizer.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1771" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.pfizer.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r988" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r44", "r159", "r160", "r161", "r164", "r165", "r166", "r169", "r405", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r901", "r906", "r907", "r964", "r1217", "r1328", "r1427", "r1680", "r1775", "r1776" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r176", "r256", "r1115", "r1393", "r1587", "r1634", "r1766" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "terseLabel": "Current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r161", "r345", "r405", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r901", "r906", "r907", "r964", "r1393", "r1680", "r1775", "r1776" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r44", "r164", "r165", "r166", "r169", "r405", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r901", "r906", "r907", "r964", "r1680", "r1775", "r1776" ] }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other taxes payable", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent." } } }, "auth_ref": [ "r165" ] }, "pfe_LicensingAgreementsAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LicensingAgreementsAndOtherMember", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofAdditionalInformationAboutIntangibleAssetsImpairedDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements and Other [Member]", "label": "Licensing Agreements And Other [Member]", "documentation": "Licensing Agreements And Other [Member]" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements [Member]", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r105", "r824", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1656", "r1658", "r1659", "r1660", "r1725" ] }, "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LifeSettlementContractsFairValueMethodCarryingAmount", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance contracts", "label": "Life Settlement Contracts, Fair Value", "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method." } } }, "auth_ref": [ "r545", "r546" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r158", "r163" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit [Member]", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, due to expire within one year", "label": "Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year", "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1665", "r1666", "r1667", "r1672" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1665", "r1666", "r1667", "r1672" ] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Payable [Member]", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment, Net by Geographic Area", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": [ "r208" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt, carrying value", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r44", "r253", "r651", "r663", "r1352", "r1353", "r1391", "r1787" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "verboseLabel": "Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2024 and 2023))", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r356" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt, excluding the current portion", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r1751", "r1753", "r1754", "r1755" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 }, "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "totalLabel": "Total long-term debt, carried at historical proceeds, as adjusted", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r358" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term investments and equity-method investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r348" ] }, "us-gaap_LongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestmentsAbstract", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Long-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term purchase commitment, amount", "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": { "parentTag": "pfe_ShorttermDebtGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of long-term debt, principal amount", "label": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting", "documentation": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r44", "r1665", "r1666", "r1667" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r44", "r77", "r1665", "r1666", "r1667" ] }, "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term investments", "label": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments", "documentation": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments" } } }, "auth_ref": [] }, "pfe_LongtermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LongtermInvestmentsMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Investments [Member]", "label": "Long-term Investments [Member]", "documentation": "Long-term Investments [Member]" } } }, "auth_ref": [] }, "pfe_LorbrenaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LorbrenaMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Lorbrena [Member]", "label": "Lorbrena [Member]", "documentation": "Lorbrena" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r626", "r627", "r628", "r631", "r821", "r1350", "r1673", "r1674" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r626", "r627", "r628", "r631", "r821", "r1350", "r1673", "r1674" ] }, "pfe_LossContingencyPatentsAllegedlyInfringedAndSubsequentlyRevokedNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LossContingencyPatentsAllegedlyInfringedAndSubsequentlyRevokedNumber", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, patents allegedly infringed and subsequently revoked", "label": "Loss Contingency, Patents Allegedly Infringed And Subsequently Revoked, Number", "documentation": "Loss Contingency, Patents Allegedly Infringed And Subsequently Revoked, Number" } } }, "auth_ref": [] }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents allegedly infringed", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "documentation": "Number of another entity's patents that the entity has allegedly infringed." } } }, "auth_ref": [ "r1673", "r1674" ] }, "us-gaap_LossContingencyPatentsFoundInfringedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPatentsFoundInfringedNumber", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents found infringed", "label": "Loss Contingency, Patents Found Infringed, Number", "documentation": "Number of another entity's patents that the entity was found to have infringed." } } }, "auth_ref": [ "r1673", "r1674" ] }, "us-gaap_LossContingencyPatentsFoundNotInfringedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPatentsFoundNotInfringedNumber", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents found not infringed", "label": "Loss Contingency, Patents Found Not Infringed, Number", "documentation": "Number of another entity's patents that the entity was found not to have infringed." } } }, "auth_ref": [ "r1673", "r1674" ] }, "pfe_LossContingencyPatentsRuledInvalidAndSubsequentlyRevokedNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LossContingencyPatentsRuledInvalidAndSubsequentlyRevokedNumber", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, patents ruled invalid and subsequently revoked", "label": "Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number", "documentation": "Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number" } } }, "auth_ref": [] }, "pfe_LossContingencyPatentsUnderReview": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "LossContingencyPatentsUnderReview", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents under review", "label": "Loss Contingency, Patents Under Review", "documentation": "Loss Contingency, Patents Under Review" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment [Member]", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r496", "r1359", "r1408", "r1413", "r1684", "r1790", "r1794", "r1795", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1821", "r1822" ] }, "srt_ManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ManagementMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management [Member]", "label": "Management [Member]", "documentation": "Person or persons designated as part of management." } } }, "auth_ref": [ "r1604", "r1774" ] }, "pfe_ManufacturingAndSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ManufacturingAndSupplyAgreementMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing and Supply Agreement [Member]", "label": "Manufacturing and Supply Agreement [Member]", "documentation": "Manufacturing and Supply Agreement" } } }, "auth_ref": [] }, "pfe_ManufacturingOptimizationProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ManufacturingOptimizationProgramMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing Optimization Program [Member]", "label": "Manufacturing Optimization Program [Member]", "documentation": "Manufacturing Optimization Program" } } }, "auth_ref": [] }, "pfe_ManufacturingOptimizationProgramPhaseOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ManufacturingOptimizationProgramPhaseOneMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing Optimization Program - Phase One [Member]", "label": "Manufacturing Optimization Program - Phase One [Member]", "documentation": "Manufacturing Optimization Program - Phase One" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Investments", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciling Items [Member]", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r483", "r486", "r489", "r1335", "r1336" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/LeasesNarrativeDetails", "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r296", "r298", "r300", "r301", "r303", "r333", "r334", "r627", "r628", "r629", "r630", "r776", "r821", "r951", "r1049", "r1154", "r1156", "r1170", "r1208", "r1209", "r1264", "r1268", "r1270", "r1271", "r1282", "r1307", "r1308", "r1341", "r1356", "r1370", "r1384", "r1385", "r1389", "r1390", "r1409", "r1682", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782" ] }, "pfe_McKessonInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "McKessonInc.Member", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "McKesson, Inc. [Member]", "label": "McKesson, Inc. [Member]", "documentation": "McKesson, Inc. [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1490" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1490" ] }, "pfe_MedrolMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "MedrolMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medrol [Member]", "label": "Medrol [Member]", "documentation": "Medrol [Member]" } } }, "auth_ref": [] }, "pfe_MektoviMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "MektoviMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mektovi [Member]", "label": "Mektovi [Member]", "documentation": "Mektovi [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/LeasesNarrativeDetails", "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r296", "r298", "r300", "r301", "r303", "r333", "r334", "r627", "r628", "r629", "r630", "r776", "r821", "r951", "r1049", "r1154", "r1156", "r1170", "r1208", "r1209", "r1264", "r1268", "r1270", "r1271", "r1282", "r1307", "r1308", "r1341", "r1356", "r1370", "r1384", "r1385", "r1389", "r1409", "r1682", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Equity attributable to noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r175", "r255", "r405", "r544", "r633", "r636", "r637", "r638", "r642", "r643", "r964", "r1114", "r1221" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r222" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1510" ] }, "pfe_ModernaTXEuropeanPatentInfringementCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ModernaTXEuropeanPatentInfringementCaseMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ModernaTX European Patent Infringement Case [Member]", "label": "ModernaTX European Patent Infringement Case [Member]", "documentation": "ModernaTX European Patent Infringement Case" } } }, "auth_ref": [] }, "pfe_ModernaTXUSPatentInfringementCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ModernaTXUSPatentInfringementCaseMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ModernaTX U.S. Patent Infringement Case [Member]", "label": "ModernaTX U.S. Patent Infringement Case [Member]", "documentation": "ModernaTX U.S. Patent Infringement Case" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1518" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r496", "r1359", "r1408", "r1413", "r1684", "r1790", "r1794", "r1795", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1821", "r1822" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1491" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by/(used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r399" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by/(used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r399" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by/(used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r201", "r202", "r203" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Pfizer Inc. common shareholders", "terseLabel": "Income attributable to shareholders", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r193", "r203", "r261", "r343", "r380", "r383", "r388", "r405", "r417", "r421", "r422", "r423", "r424", "r425", "r428", "r429", "r441", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r882", "r897", "r945", "r964", "r1124", "r1240", "r1257", "r1258", "r1425", "r1680" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r112", "r241", "r380", "r383", "r425", "r428", "r429", "r1123", "r1573" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Pfizer Inc. common shareholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r395", "r421", "r422", "r423", "r424", "r432", "r433", "r442", "r445", "r897" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Pfizer Inc. common shareholders and assumed conversions", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r395", "r434", "r437", "r438", "r439", "r440", "r442", "r445" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging [Member]", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r119" ] }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit costs/(credits) other than service costs", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits." } } }, "auth_ref": [ "r700" ] }, "pfe_NetSalesAndRoyaltyAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NetSalesAndRoyaltyAgreementTermsMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Sales and Royalty Agreement Terms [Member]", "label": "Net Sales and Royalty Agreement Terms [Member]", "documentation": "Net Sales and Royalty Agreement Terms" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r335", "r336", "r337", "r338", "r339", "r340", "r416", "r417", "r418", "r419", "r420", "r423", "r430", "r449", "r497", "r498", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r600", "r601", "r611", "r860", "r861", "r862", "r863", "r864", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r887", "r888", "r889", "r893", "r894", "r895", "r896", "r897", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r959", "r960", "r985", "r986", "r987", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1053", "r1054", "r1055", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1172" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r57", "r335", "r336", "r337", "r338", "r339", "r340", "r416", "r417", "r418", "r419", "r420", "r423", "r430", "r449", "r497", "r498", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r600", "r601", "r611", "r860", "r861", "r862", "r863", "r864", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r887", "r888", "r889", "r893", "r894", "r895", "r896", "r897", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r959", "r960", "r985", "r986", "r987", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1053", "r1054", "r1055", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1172" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Standard Adopted in 2024", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "pfe_NimbusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NimbusMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nimbus [Member]", "label": "Nimbus [Member]", "documentation": "Nimbus" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1490" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1453", "r1464", "r1474", "r1498", "r1507" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1481" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1480" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1498" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1518" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1518" ] }, "pfe_NonUnitedStatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NonUnitedStatesMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Outside United States [Member]", "label": "Non-United States [Member]", "documentation": "Non-United States [Member]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests [Member]", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r107", "r681", "r1591", "r1592", "r1593", "r1594", "r1826" ] }, "pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails", "http://www.pfizer.com/role/TaxMattersNarrativeDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent Deferred Tax Assets and Other Noncurrent Tax Assets [Member]", "label": "Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]", "documentation": "Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]" } } }, "auth_ref": [] }, "pfe_NoncurrentDeferredTaxLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NoncurrentDeferredTaxLiabilitiesMember", "presentation": [ "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent Deferred Tax Liabilities [Member]", "label": "Noncurrent Deferred Tax Liabilities [Member]", "documentation": "Noncurrent Deferred Tax Liabilities [Member]" } } }, "auth_ref": [] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument [Member]", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r29" ] }, "us-gaap_NonrecurringAdjustmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrecurringAdjustmentAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrecurring Adjustment [Axis]", "label": "Nonrecurring Adjustment [Axis]", "documentation": "Information by nonrecurring adjustment directly attributable to business combination included in pro forma revenue and earnings." } } }, "auth_ref": [ "r36" ] }, "us-gaap_NonrecurringAdjustmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrecurringAdjustmentDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrecurring Adjustment [Domain]", "label": "Nonrecurring Adjustment [Domain]", "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": [ "r36" ] }, "pfe_NotesDue20271.000Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NotesDue20271.000Member", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Due 2027, 1.000% [Member]", "label": "Notes Due 2027, 1.000% [Member]", "documentation": "Notes Due 2027, 1.000% [Member]" } } }, "auth_ref": [] }, "pfe_NumberOfApprovedMedicines": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NumberOfApprovedMedicines", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of approved medicines", "label": "Number of Approved Medicines", "documentation": "Number of Approved Medicines" } } }, "auth_ref": [] }, "pfe_NumberOfCompaniesInLitigationCase": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NumberOfCompaniesInLitigationCase", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of companies in litigation case", "label": "Number of Companies in Litigation Case", "documentation": "Number of Companies in Litigation Case" } } }, "auth_ref": [] }, "pfe_NumberOfComplaints": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NumberOfComplaints", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of complaints", "label": "Number of Complaints", "documentation": "Number of Complaints" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1336", "r1598" ] }, "pfe_NumberOfRealEstatePropertiesHeldForSale": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NumberOfRealEstatePropertiesHeldForSale", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities for sale", "label": "Number of Real Estate Properties, Held-for-Sale", "documentation": "Number of Real Estate Properties, Held-for-Sale" } } }, "auth_ref": [] }, "pfe_NumberofEmployeeStockOwnershipPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NumberofEmployeeStockOwnershipPlans", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employee stock ownership plans", "label": "Number of Employee Stock Ownership Plans", "documentation": "Number of Employee Stock Ownership Plans" } } }, "auth_ref": [] }, "pfe_NurtecODTVyduraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "NurtecODTVyduraMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Nurtec ODT/Vydura [Member]", "label": "Nurtec ODT/Vydura [Member]", "documentation": "Nurtec ODT/Vydura" } } }, "auth_ref": [] }, "us-gaap_OciEquityMethodInvestmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciEquityMethodInvestmentBeforeTax", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of accumulated other comprehensive income balances in Equity-method investments", "label": "OCI, Equity Method Investment, before Tax", "documentation": "Amount, before tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI." } } }, "auth_ref": [ "r538" ] }, "pfe_OctagamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OctagamMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Octagam [Member]", "label": "Octagam [Member]", "documentation": "Octagam" } } }, "auth_ref": [] }, "pfe_OncologyBiosimilarsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OncologyBiosimilarsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Oncology Biosimilars [Member]", "label": "Oncology Biosimilars [Member]", "documentation": "Oncology Biosimilars" } } }, "auth_ref": [] }, "pfe_OncologyDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OncologyDivisionMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Oncology Division", "label": "Oncology Division [Member]", "documentation": "Oncology Division" } } }, "auth_ref": [] }, "pfe_OncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OncologyMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Oncology [Member]", "label": "Oncology [Member]", "documentation": "Oncology [Member]" } } }, "auth_ref": [] }, "us-gaap_OneTimeTerminationBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OneTimeTerminationBenefitsMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "One-time Termination Benefits", "label": "One-time Termination Benefits [Member]", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities." } } }, "auth_ref": [ "r1346", "r1347", "r1348", "r1349" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r997", "r1392" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of minimum lease payments", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r991" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail", "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities (short-term)", "verboseLabel": "Less: Current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r991" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities (short-term), statement of financial position", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r992" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail", "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities (long-term)", "verboseLabel": "Noncurrent portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r991" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities (long-term), statement of financial position", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r992" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r993", "r1001" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r990" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets, statement of financial position", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r992" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Discount Rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r1004", "r1392" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Lease Term (Years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1003", "r1392" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments [Member]", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r482", "r483", "r484", "r485", "r486", "r489", "r1335", "r1336" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "pfe_OtherAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherAccruals", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accruals", "label": "Other Accruals", "documentation": "Other Accruals" } } }, "auth_ref": [] }, "us-gaap_OtherAggregatedInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAggregatedInvestmentsMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other [Member]", "label": "Other Security Investments [Member]", "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests." } } }, "auth_ref": [ "r1201", "r1202", "r1272" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r366", "r1393" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other noncurrent assets", "totalLabel": "Total other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r353" ] }, "pfe_OtherCommingledFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherCommingledFundsMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other commingled funds [Member]", "label": "Other Commingled Funds [Member]", "documentation": "Other Commingled Funds [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefit plans: prior service (costs)/credits and other, net", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r6", "r184", "r742" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, net", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax", "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r184", "r966", "r967", "r970" ] }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r10", "r184", "r379", "r742" ] }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax", "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r8" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax", "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r372", "r373", "r375", "r1125" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), available-for-sale securities, tax, total", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r372", "r373", "r376" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income/(loss), before tax", "label": "Other Comprehensive Income (Loss), before Tax", "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r390", "r971", "r972", "r978", "r1095", "r1125", "r1571", "r1572" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax", "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r370", "r375", "r1125" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, tax, total", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r376" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net", "verboseLabel": "Derivative, Amount of Gains/(Losses) Recognized in OCI", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r370", "r375", "r909", "r910", "r921" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r376" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reclassification adjustments for (gains)/losses included in net income", "terseLabel": "Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r288", "r375", "r378" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reclassification adjustments for (gains)/losses included in net income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r376" ] }, "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification adjustments related to curtailments of prior service costs and other, net", "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax", "documentation": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax" } } }, "auth_ref": [] }, "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification adjustments related to curtailments of prior service costs and other, net", "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax", "documentation": "Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r371", "r375", "r378", "r912" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r371", "r375", "r911", "r915", "r921" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, net", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r8", "r968", "r977" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Amount of Gains/(Losses) Recognized in OCI", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r913" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r914" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income/(loss) before allocation to noncontrolling interests", "terseLabel": "Other\u00a0comprehensive income/(loss), net of tax", "verboseLabel": "Other comprehensive income/(loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r28", "r42", "r381", "r384", "r390", "r425", "r971", "r972", "r978", "r1095", "r1125", "r1571", "r1572" ] }, "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS", "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax", "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax" } } }, "auth_ref": [] }, "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Derivative, Amount of Gains/(Losses) Recognized in OCI", "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "auth_ref": [] }, "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS", "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax", "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax" } } }, "auth_ref": [] }, "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Gains/(Losses) Recognized in OCI", "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax", "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost/(credit) reported in Other comprehensive income/(loss)", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r6", "r7", "r183", "r184", "r1125", "r1362", "r1688" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax", "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r8", "r240" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r10", "r184", "r379", "r536" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 1.0 }, "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax provision/(benefit) on other comprehensive income/(loss)", "totalLabel": "Tax provision/(benefit) on other comprehensive income/(loss)", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r386", "r390", "r832", "r869", "r870", "r971", "r975", "r978", "r1095", "r1125" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxAbstract", "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)", "label": "Other Comprehensive Income (Loss), Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r372", "r375", "r536" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r8", "r373" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities [Member]", "verboseLabel": "Other Current Liabilities [Member]", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "pfe_OtherDevelopedTechnologyRightsInProcessResearchAndDevelopmentAndFiniteLivedLicensingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherDevelopedTechnologyRightsInProcessResearchAndDevelopmentAndFiniteLivedLicensingAgreementMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Developed Technology Rights, In-Process Research and Development and Finite-Lived Licensing Agreement [Member]", "label": "Other Developed Technology Rights, In-Process Research and Development and Finite-Lived Licensing Agreement [Member]", "documentation": "Other Developed Technology Rights, In-Process Research and Development and Finite-Lived Licensing Agreement" } } }, "auth_ref": [] }, "pfe_OtherFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherFinancialInformationAbstract", "lang": { "en-us": { "role": { "label": "Other Financial Information [Abstract]", "documentation": "Other Financial Information" } } }, "auth_ref": [] }, "pfe_OtherHospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherHospitalMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "All other Hospital [Member]", "label": "Other Hospital [Member]", "documentation": "Other Hospital" } } }, "auth_ref": [] }, "pfe_OtherInProcessResearchAndDevelopmentAndDevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherInProcessResearchAndDevelopmentAndDevelopedTechnologyRightsMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other In Process Research and Development and Developed Technology Rights [Member]", "label": "Other In Process Research and Development and Developed Technology Rights [Member]", "documentation": "Other In Process Research and Development and Developed Technology Rights" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNet" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income)/Deductions\u2014Net", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r1554", "r1722" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "verboseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r160", "r1393" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r165" ] }, "us-gaap_OtherLongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_LongTermInvestments", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "totalLabel": "Long-term investments", "label": "Other Long-Term Investments", "documentation": "Amount of long-term investments classified as other." } } }, "auth_ref": [ "r1104", "r1105", "r1567" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other adjustments, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r203" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Other noncurrent liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 }, "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 6.0 }, "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income)/deductions\u2013\u2013net", "terseLabel": "Other income/(deductions)\u2014net", "negatedTotalLabel": "Other (income)/deductions\u2013\u2013net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r196" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Other (Income)/Deductions--net [Member]", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "pfe_OtherNonoperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherNonoperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense), Net", "documentation": "Other Nonoperating Income (Expense), Net" } } }, "auth_ref": [] }, "pfe_OtherOncologyProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherOncologyProductsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "All other Oncology [Member]", "label": "Other Oncology Products [Member]", "documentation": "Other Oncology Products [Member]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1490" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Postretirement Plans [Member]", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r697", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r747", "r748", "r750", "r753", "r756", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r773", "r774", "r775", "r1362", "r1363", "r1364", "r1365", "r1366" ] }, "pfe_OtherPrimaryCareProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherPrimaryCareProductsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "All other Primary Care [Member]", "label": "Other Primary Care Products [Member]", "documentation": "Other Primary Care Products" } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exit Costs [Member]", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r1346", "r1347", "r1348", "r1349" ] }, "us-gaap_OtherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": { "parentTag": "pfe_ShorttermDebtGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other short-term borrowings", "verboseLabel": "Other short-term borrowings, principal amount", "label": "Other Short-Term Borrowings", "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r156", "r1216" ] }, "us-gaap_OtherShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherShortTermInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "totalLabel": "Total Short-term investments", "label": "Other Short-Term Investments", "documentation": "Amount of short-term investments classified as other." } } }, "auth_ref": [ "r257", "r1104", "r1106", "r1570" ] }, "pfe_OtherSpecialtyCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherSpecialtyCareMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "All other Specialty Care [Member]", "label": "Other Specialty Care [Member]", "documentation": "Other Specialty Care" } } }, "auth_ref": [] }, "pfe_OtherTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current tax assets", "label": "Other Tax Assets, Current", "documentation": "Other Tax Assets, Current" } } }, "auth_ref": [] }, "pfe_OtherTaxesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OtherTaxesPayableMember", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Taxes Payable [Member]", "label": "Other Taxes Payable [Member]", "documentation": "Other Taxes Payable [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1451", "r1462", "r1472", "r1505" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1454", "r1465", "r1475", "r1508" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1454", "r1465", "r1475", "r1508" ] }, "pfe_OxbrytaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "OxbrytaMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Oxbryta [Member]", "label": "Oxbryta [Member]", "documentation": "Oxbryta" } } }, "auth_ref": [] }, "pfe_PSAsGrantedIn2022And2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PSAsGrantedIn2022And2023Member", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PSAs Granted in 2022 and 2023 [Member]", "label": "PSAs Granted in 2022 and 2023 [Member]", "documentation": "PSAs Granted in 2022 and 2023" } } }, "auth_ref": [] }, "pfe_PadcevMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PadcevMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Padcev [Member]", "label": "Padcev [Member]", "documentation": "Padcev" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 Equity [Member]", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "srt_PartnershipInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "PartnershipInterestMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Partnership Interest [Member]", "label": "Partnership Interest [Member]", "documentation": "A general or limited ownership interest in a partnership or unincorporated joint venture." } } }, "auth_ref": [ "r1419" ] }, "pfe_PatentInfringementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PatentInfringementMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patent Infringement [Member]", "label": "Patent Infringement [Member]", "documentation": "Patent Infringement [Member]" } } }, "auth_ref": [] }, "pfe_PatentInvalidityAndNonInfringementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PatentInvalidityAndNonInfringementMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patent Invalidity And Non Infringement [Member]", "label": "Patent Invalidity And Non Infringement [Member]", "documentation": "Patent Invalidity And Non Infringement" } } }, "auth_ref": [] }, "pfe_PaxlovidAndComirnatyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PaxlovidAndComirnatyMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Paxlovid and Comirnaty [Member]", "label": "Paxlovid and Comirnaty [Member]", "documentation": "Paxlovid and Comirnaty" } } }, "auth_ref": [] }, "pfe_PaxlovidEUALabeledMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PaxlovidEUALabeledMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paxlovid, EUA-Labeled [Member]", "label": "Paxlovid, EUA-Labeled [Member]", "documentation": "Paxlovid, EUA-Labeled" } } }, "auth_ref": [] }, "pfe_PaxlovidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PaxlovidMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paxlovid [Member]", "label": "Paxlovid [Member]", "documentation": "Paxlovid" } } }, "auth_ref": [] }, "pfe_PaxlovidNDALabeledUSStrategicNationalStockpileMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PaxlovidNDALabeledUSStrategicNationalStockpileMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member]", "label": "Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member]", "documentation": "Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1479" ] }, "pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for asset acquisition, base payment", "label": "Payments for Asset Acquisitions, Before Working Capital Adjustments", "documentation": "Payments for Asset Acquisitions, Before Working Capital Adjustments" } } }, "auth_ref": [] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts paid in settlement agreement", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other investing activities, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1545", "r1578" ] }, "pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less", "label": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less", "documentation": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r199" ] }, "us-gaap_PaymentsOfOrdinaryDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfOrdinaryDividends", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends paid", "label": "Payments of Ordinary Dividends", "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings." } } }, "auth_ref": [ "r199" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Business acquisition, cash payment, gross", "terseLabel": "Business acquisition, cash payment", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r52", "r890" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of businesses, net of cash acquired", "terseLabel": "Business acquisition, cash payment, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r52" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of long-term investments", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r1609" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire asset", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r277", "r1742", "r1743", "r1744" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r198" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r197" ] }, "pfe_PaymentsToCollaboratorsUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PaymentsToCollaboratorsUpfrontPayment", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment to collaborators", "label": "Payments to Collaborators, Upfront Payment", "documentation": "Payments to Collaborators, Upfront Payment" } } }, "auth_ref": [] }, "pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Utilization and other", "label": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment", "documentation": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1489" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1489" ] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PendingLitigationMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation [Member]", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": [ "r1672" ] }, "pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefit plan contributions in excess of expense/income", "label": "Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)", "documentation": "The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments)." } } }, "auth_ref": [] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Postretirement Benefit Plans and Defined Contribution Plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r696", "r722", "r724", "r730", "r749", "r751", "r752", "r753", "r754", "r755", "r770", "r771", "r773", "r1362" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current liabilities", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r160", "r697", "r698", "r721", "r1362" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 2.0 }, "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and postretirement benefit obligations", "negatedLabel": "Noncurrent liabilities", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r165", "r697", "r698", "r721", "r1362" ] }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementPlansPolicy", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Postretirement Benefit Plans", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } } }, "auth_ref": [ "r20", "r21", "r22", "r30", "r90" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Plans [Member]", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r697", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r747", "r748", "r750", "r753", "r756", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r773", "r774", "r777", "r1362", "r1363", "r1367", "r1368", "r1369" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1481" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1498" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1491" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1480" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Awards [Member]", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "pfe_PfizerAndVersusSeveralGenericManufacturersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PfizerAndVersusSeveralGenericManufacturersMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pfizer Versus Several Generic Manufacturers [Member]", "label": "Pfizer and Versus Several Generic Manufacturers [Member]", "documentation": "Pfizer and Versus Several Generic Manufacturers" } } }, "auth_ref": [] }, "pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment of Non-Infringement [Member]", "label": "Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member]", "documentation": "Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement" } } }, "auth_ref": [] }, "pfe_PfizerCentreOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PfizerCentreOneMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pfizer CentreOne [Member]", "label": "Pfizer CentreOne [Member]", "documentation": "Pfizer CentreOne" } } }, "auth_ref": [] }, "pfe_PfizerIgniteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PfizerIgniteMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pfizer Ignite [Member]", "label": "Pfizer Ignite [Member]", "documentation": "Pfizer Ignite" } } }, "auth_ref": [] }, "pfe_PfizerVersusTevaPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PfizerVersusTevaPharmaceuticalsIncMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pfizer Versus Teva Pharmaceuticals, Inc. [Member]", "label": "Pfizer Versus Teva Pharmaceuticals, Inc. [Member]", "documentation": "Pfizer Versus Teva Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r750", "r1360", "r1361", "r1362" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r1482" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1538" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1481" ] }, "pfe_PortfolioPerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PortfolioPerformanceSharesMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portfolio Performance Shares [Member]", "label": "Portfolio Performance Shares [Member]", "documentation": "Portfolio Performance Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement [Member]", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r962" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r170", "r1219" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r170", "r666" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r170", "r1219", "r1238", "r1826", "r1827" ] }, "pfe_PremarinFamilyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PremarinFamilyMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Premarin Family [Member]", "label": "Premarin Family [Member]", "documentation": "Premarin family [Member]" } } }, "auth_ref": [] }, "pfe_PrepaymentsAndPaymentsToCollaboratorsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PrepaymentsAndPaymentsToCollaboratorsCash", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash payment to collaborators", "label": "Prepayments and Payments to Collaborators, Cash", "documentation": "Prepayments and Payments to Collaborators, Cash" } } }, "auth_ref": [] }, "pfe_Prevnar13Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "Prevnar13Member", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prevnar 13 [Member]", "label": "Prevnar 13 [Member]", "documentation": "Prevnar 13" } } }, "auth_ref": [] }, "pfe_PrevnarPrevenarFamilyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PrevnarPrevenarFamilyMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Prevnar Family [Member]", "label": "Prevnar Prevenar Family [Member]", "documentation": "Prevnar/Prevenar Family 13 [Member]" } } }, "auth_ref": [] }, "pfe_PrimaryCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PrimaryCareMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Primary Care [Member]", "label": "Primary Care [Member]", "documentation": "Primary Care" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Adjustments", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1565" ] }, "pfe_PrivateEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "PrivateEquityInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": { "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private equity securities at cost", "label": "Private Equity Investments", "documentation": "Private Equity Investments" } } }, "auth_ref": [] }, "pfe_ProceedsAndMilestonePaymentsExpectedToBeReceivedFromDivestitureOfBusinessMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ProceedsAndMilestonePaymentsExpectedToBeReceivedFromDivestitureOfBusinessMaximum", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum consideration to be received from divestiture", "label": "Proceeds And Milestone Payments Expected to Be Received From Divestiture of Business, Maximum", "documentation": "Proceeds And Milestone Payments Expected to Be Received From Divestiture of Business, Maximum" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds from disposal", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r51" ] }, "pfe_ProceedsFromEquityMethodInvestmentDistributionTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ProceedsFromEquityMethodInvestmentDistributionTotal", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends received, total", "label": "Proceeds from Equity Method Investment, Distribution, Total", "documentation": "Proceeds from Equity Method Investment, Distribution, Total" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend received from the Consumer Healthcare JV", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } } }, "auth_ref": [ "r398", "r1577" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r53", "r1178" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1546", "r1579" ] }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less", "label": "Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less", "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months." } } }, "auth_ref": [ "r1580", "r1581", "r1584" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from redemptions/sales of long-term investments", "label": "Proceeds from Sale, Maturity and Collection of Long-Term Investments", "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle." } } }, "auth_ref": [ "r1545" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from redemptions/sales of short-term investments", "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments", "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r50" ] }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from partial sales of investment in Haleon", "label": "Proceeds from Sale of Equity Method Investments", "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from short-term borrowings", "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received upon exercise", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r9", "r37" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk [Member]", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r206" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product [Member]", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r1357" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r332", "r492", "r1051", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1312", "r1357", "r1407", "r1409", "r1410", "r1414", "r1416", "r1564", "r1675", "r1676", "r1684", "r1790", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1821", "r1822" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r332", "r492", "r1051", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1312", "r1357", "r1407", "r1409", "r1410", "r1414", "r1416", "r1564", "r1675", "r1676", "r1684", "r1790", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1821", "r1822" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows", "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.pfizer.com/role/ConsolidatedStatementsofEquity", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income before allocation to noncontrolling interests", "terseLabel": "Net income before allocation to noncontrolling interests", "verboseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r343", "r380", "r383", "r397", "r405", "r417", "r425", "r428", "r429", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r882", "r897", "r899", "r902", "r903", "r945", "r964", "r1100", "r1122", "r1185", "r1240", "r1257", "r1258", "r1377", "r1378", "r1426", "r1573", "r1680" ] }, "pfe_ProfitUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ProfitUnitsMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profit Units [Member]", "label": "Profit Units [Member]", "documentation": "Profit Units [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment by Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r17", "r1006" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentNet" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r211", "r283", "r289", "r290" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property, plant and equipment before accumulated depreciation", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r212", "r349", "r1118" ] }, "us-gaap_PropertyPlantAndEquipmentImpairment": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentImpairment", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Impairment", "label": "Property, Plant and Equipment, Impairment [Policy Text Block]", "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment." } } }, "auth_ref": [ "r73" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails", "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1006" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails", "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r17", "r1006", "r1103", "r1118", "r1393" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r17", "r283", "r289", "r1116" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r212", "r1006" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful lives (years)", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1479" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1479" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/LeasesNarrativeDetails", "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r296", "r298", "r300", "r301", "r303", "r333", "r334", "r627", "r628", "r629", "r630", "r722", "r776", "r807", "r808", "r809", "r821", "r951", "r1023", "r1032", "r1049", "r1154", "r1156", "r1170", "r1208", "r1209", "r1264", "r1268", "r1270", "r1271", "r1282", "r1307", "r1308", "r1341", "r1356", "r1370", "r1384", "r1385", "r1389", "r1390", "r1409", "r1419", "r1669", "r1682", "r1754", "r1778", "r1779", "r1780", "r1781", "r1782" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/LeasesNarrativeDetails", "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r296", "r298", "r300", "r301", "r303", "r333", "r334", "r627", "r628", "r629", "r630", "r722", "r776", "r807", "r808", "r809", "r821", "r951", "r1023", "r1032", "r1049", "r1154", "r1156", "r1170", "r1208", "r1209", "r1264", "r1268", "r1270", "r1271", "r1282", "r1307", "r1308", "r1341", "r1356", "r1370", "r1384", "r1385", "r1389", "r1390", "r1409", "r1419", "r1669", "r1682", "r1754", "r1778", "r1779", "r1780", "r1781", "r1782" ] }, "pfe_ReViralAssetAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ReViralAssetAcquisitionMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ReViral [Member]", "label": "ReViral Asset Acquisition [Member]", "documentation": "ReViral Asset Acquisition" } } }, "auth_ref": [] }, "pfe_RealigningOurCostBaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RealigningOurCostBaseProgramMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Realigning Our Cost Base Program [Member]", "label": "Realigning Our Cost Base Program [Member]", "documentation": "Realigning Our Cost Base Program" } } }, "auth_ref": [] }, "pfe_RebatesAndOtherSalesRelatedAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RebatesAndOtherSalesRelatedAccruals", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total accrued rebates and other sales-related accruals", "label": "Rebates And Other Sales-Related Accruals", "documentation": "Certain accrued rebates and accrued sales returns" } } }, "auth_ref": [] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Trade Accounts Receivable", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r500", "r501", "r502", "r504", "r1606" ] }, "us-gaap_ReclassificationOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOtherMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification, Other", "label": "Reclassification, Other [Member]", "documentation": "Reclassification affecting comparability of financial statement, classified as other. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1565" ] }, "us-gaap_ReclassificationTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationTypeAxis", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification, Type [Axis]", "label": "Reclassification, Type [Axis]", "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1565" ] }, "us-gaap_ReclassificationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationTypeDomain", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification, Type [Domain]", "label": "Reclassification, Type [Domain]", "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1565" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "label": "Unrecognized Tax Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "pfe_ReconcilingItemsAcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ReconcilingItemsAcquisitionRelatedCostsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-Related Items [Member]", "label": "Reconciling Items, Acquisition Related Costs [Member]", "documentation": "Reconciling Items, Acquisition Related Costs" } } }, "auth_ref": [] }, "pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ReconcilingItemsAmortizationOfIntangibleAssetsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of Intangible Assets [Member]", "label": "Reconciling Items, Amortization of Intangible Assets [Member]", "documentation": "Reconciling Items, Amortization of Intangible Assets" } } }, "auth_ref": [] }, "pfe_ReconcilingItemsOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ReconcilingItemsOtherMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certain Significant Items [Member]", "label": "Reconciling Items, Other [Member]", "documentation": "Reconciling Items, Other" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1446", "r1457", "r1467", "r1500" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r200", "r1181" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on short-term borrowings", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r200" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r582", "r583", "r1343" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r582", "r583", "r1343" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r330", "r331", "r409", "r410", "r647", "r668", "r1015", "r1033", "r1104", "r1321", "r1322" ] }, "pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum potential consideration", "label": "Research And Development Arrangement, Contingent Payments, Maximum Exposure1", "documentation": "Research And Development Arrangement, Contingent Payments, Maximum Exposure1" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r824", "r1725" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r824", "r1725" ] }, "pfe_ResearchAndDevelopmentArrangementFundingToOffsetCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ResearchAndDevelopmentArrangementFundingToOffsetCostsIncurred", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development arrangement, funding to offset costs incurred", "label": "Research and Development Arrangement, Funding to Offset Costs Incurred", "documentation": "Research and Development Arrangement, Funding to Offset Costs Incurred" } } }, "auth_ref": [] }, "pfe_ResearchAndDevelopmentArrangementMaximumFundingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ResearchAndDevelopmentArrangementMaximumFundingAmount", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development arrangement, maximum funding amount", "label": "Research And Development Arrangement, Maximum Funding Amount", "documentation": "Research And Development Arrangement, Maximum Funding Amount" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 }, "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development expenses", "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff", "documentation": "Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": [ "r590", "r1309", "r1724" ] }, "pfe_ResearchAndDevelopmentExpenseAcquiredInProcessCostReimbursementWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ResearchAndDevelopmentExpenseAcquiredInProcessCostReimbursementWriteOff", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development expenses", "label": "Research and Development Expense, Acquired in Process Cost, Reimbursement (Write-off)", "documentation": "Research and Development Expense, Acquired in Process Cost, Reimbursement (Write-off)" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 }, "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "terseLabel": "Research and development expenses", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r1724" ] }, "pfe_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostNetOfReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostNetOfReimbursement", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research and development expenses", "label": "Research and Development Expense (Excluding Acquired in Process Cost), Net of Reimbursement", "documentation": "Research and Development Expense (Excluding Acquired in Process Cost), Net of Reimbursement" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r823" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1447", "r1458", "r1468", "r1501" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1448", "r1459", "r1469", "r1502" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1455", "r1466", "r1476", "r1509" ] }, "pfe_RestrictedStockUnitsGrantedBefore2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RestrictedStockUnitsGrantedBefore2022Member", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units Granted Before 2022 [Member]", "label": "Restricted Stock Units Granted Before 2022 [Member]", "documentation": "Restricted Stock Units Granted Before 2022" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Restricted Stock Units [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r612", "r613", "r615", "r618", "r623" ] }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs incurred to date", "label": "Restructuring and Related Cost, Cost Incurred to Date", "documentation": "Amount of costs incurred to date for the specified restructuring cost." } } }, "auth_ref": [ "r614", "r617", "r620", "r622" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected cost", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r614", "r617", "r620", "r622" ] }, "pfe_RestructuringAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RestructuringAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairments", "label": "Restructuring, Asset Impairment Charges", "documentation": "Restructuring, Asset Impairment Charges" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charge (credit)", "totalLabel": "Total restructuring charges/(credits)", "verboseLabel": "Provision", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r15", "r619", "r620", "r1670" ] }, "us-gaap_RestructuringChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesAbstract", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges:", "label": "Restructuring Charges [Abstract]" } } }, "auth_ref": [] }, "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RestructuringChargesAcquisitionRelatedCostsandImplementationCosts", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs associated with acquisitions and cost-reduction/productivity initiatives", "label": "Restructuring Charges, Acquisition Related Costs and Implementation Costs", "documentation": "Restructuring Charges, Acquisition Related Costs and Implementation Costs" } } }, "auth_ref": [] }, "pfe_RestructuringChargesAndAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RestructuringChargesAndAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges and certain acquisition-related costs", "totalLabel": "Restructuring charges and certain acquisition-related costs", "label": "Restructuring Charges And Acquisition Related Costs", "documentation": "This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities." } } }, "auth_ref": [] }, "pfe_RestructuringChargesAndAcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RestructuringChargesAndAcquisitionRelatedCostsMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges and Acquisition-Related Costs [Member]", "label": "Restructuring Charges And Acquisition-Related Costs [Member]", "documentation": "Restructuring Charges And Acquisition-Related Costs [Member]" } } }, "auth_ref": [] }, "pfe_RestructuringChargesAndCertainAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RestructuringChargesAndCertainAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges and certain acquisition-related costs", "label": "Restructuring Charges and Certain Acquisition-Related Costs", "documentation": "Restructuring Charges and Certain Acquisition-Related Costs" } } }, "auth_ref": [] }, "pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring", "label": "Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring", "documentation": "Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r614", "r615", "r620", "r621" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r614", "r615", "r616", "r617", "r620", "r621", "r622" ] }, "pfe_RestructuringIntegrationAndAcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "RestructuringIntegrationAndAcquisitionRelatedCostsMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring, integration and acquisition-related costs [Member]", "label": "Restructuring, integration and acquisition-related costs [Member]", "documentation": "Restructuring, integration and acquisition-related costs" } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Restructuring reserve", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r615", "r621" ] }, "us-gaap_RestructuringReserveAcceleratedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAcceleratedDepreciation", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Additional depreciation\u2013\u2013asset restructuring\u00a0recorded in our consolidated statements of income as follows", "label": "Restructuring and Related Cost, Accelerated Depreciation", "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r173", "r222", "r1113", "r1164", "r1169", "r1182", "r1220", "r1393" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r337", "r413", "r414", "r415", "r418", "r425", "r427", "r429", "r550", "r556", "r601", "r860", "r861", "r878", "r879", "r880", "r883", "r896", "r897", "r925", "r928", "r929", "r932", "r943", "r986", "r989", "r1160", "r1162", "r1186", "r1826" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r746", "r747", "r748", "r750", "r753", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r1692", "r1693", "r1694" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r746", "r747", "r748", "r750", "r753", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r1692", "r1693", "r1694" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r697", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r747", "r748", "r750", "r753", "r756", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r773", "r774", "r775", "r777", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r697", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r747", "r748", "r750", "r753", "r756", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r773", "r774", "r775", "r777", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Alliance revenues", "terseLabel": "Revenues\u2014Alliance revenues", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r279", "r1745" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Revenues\u2014Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r263", "r264", "r450", "r459", "r460", "r482", "r488", "r492", "r494", "r496", "r692", "r693", "r1051" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue [Member]", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r496", "r1547" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues and Collaborative Arrangements", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r293", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r1310" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r207" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligation", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r286" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 }, "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 6.0 }, "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "verboseLabel": "Revenues:", "terseLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r263", "r264", "r389", "r405", "r450", "r459", "r460", "r482", "r488", "r492", "r494", "r496", "r544", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r964", "r1100", "r1335", "r1680" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility [Member]", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use assets obtained in exchange for lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r1002", "r1392" ] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty [Member]", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r1685" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1518" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1518" ] }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleAndLeasebackTransactionGainLossNet", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Gains)/losses on sale and leaseback transactions, net", "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale." } } }, "auth_ref": [ "r1000", "r1008", "r1392" ] }, "pfe_SaleOfEquityMethodInvestmentInPrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SaleOfEquityMethodInvestmentInPrivatePlacementMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Equity-Method Investment in Private Placement", "label": "Sale of Equity-Method Investment in Private Placement [Member]", "documentation": "Sale of Equity-Method Investment in Private Placement" } } }, "auth_ref": [] }, "pfe_SaleOfEquityMethodInvestmentInPublicStockOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SaleOfEquityMethodInvestmentInPublicStockOfferingMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Equity-Method Investment in Public Stock Offering", "label": "Sale of Equity-Method Investment in Public Stock Offering [Member]", "documentation": "Sale of Equity-Method Investment in Public Stock Offering" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares sold in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales [Member]", "label": "Sales [Member]", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue [Member]", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r496", "r1547" ] }, "us-gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueProductLineMember", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue [Member]", "label": "Revenue, Product and Service Benchmark [Member]", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r1548" ] }, "pfe_ScheduleOfAccruedLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ScheduleOfAccruedLiabilitiesLineItems", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities [Line Items]", "label": "Schedule Of Accrued Liabilities [Line Items]", "documentation": "[Line Items] for Schedule Of Accrued Liabilities [Table]" } } }, "auth_ref": [] }, "pfe_ScheduleOfAccruedLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ScheduleOfAccruedLiabilitiesTable", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities [Table]", "label": "Schedule Of Accrued Liabilities [Table]", "documentation": "Schedule Of Accrued Liabilities [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Information About Balance Sheet Classification of Accruals", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1362", "r1689", "r1690" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r48", "r1767", "r1768" ] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allocation of Plan Assets", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": [ "r224" ] }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recognized in Balance Sheet", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized." } } }, "auth_ref": [ "r85" ] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions Used", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r744" ] }, "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]", "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]", "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]" } } }, "auth_ref": [] }, "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available for sale Securities and Held to maturity Securities [Table]", "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]", "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities Reconciliation", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1362", "r1689" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r96", "r99", "r886" ] }, "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges", "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r244" ] }, "pfe_ScheduleOfCashPaidForIncomeTaxesNetOfRefundsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ScheduleOfCashPaidForIncomeTaxesNetOfRefundsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/TaxMattersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Paid for Income Taxes, Net of Refunds", "label": "Schedule of Cash Paid for Income Taxes, Net of Refunds [Table Text Block]", "documentation": "Schedule of Cash Paid for Income Taxes, Net of Refunds" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementResearchandDevelopmentArrangementDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r898" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r1745" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.pfizer.com/role/TaxMattersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for Taxes on Income", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1734" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r44", "r78", "r79", "r138", "r220", "r221", "r1352", "r1354", "r1590", "r1769" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.pfizer.com/role/TaxMattersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1732" ] }, "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Periodic Benefit Costs", "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r20", "r86", "r87", "r88", "r89" ] }, "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Assets at Fair Value", "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of derivative assets at fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r122", "r125", "r916" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Financial Instruments", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r29", "r114", "r115", "r116", "r120", "r123", "r125", "r131", "r133" ] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Liabilities at Fair Value", "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Earning Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1596" ] }, "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets", "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period." } } }, "auth_ref": [ "r1687" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.pfizer.com/role/TaxMattersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r837", "r1375", "r1727" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Significant Product Revenues", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r69" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r541", "r542", "r543", "r874", "r1542", "r1543", "r1544", "r1737", "r1738", "r1739", "r1740" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r405", "r541", "r542", "r543", "r544", "r964" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementChangeintheCarryingValueofEquityMethodInvestmentFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": [ "r343", "r405", "r541", "r542", "r543", "r544", "r964" ] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Future Cash Flow Information", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r225" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1751", "r1752" ] }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r126" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r584", "r592", "r596", "r597", "r599", "r1052", "r1309", "r1344" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r1344", "r1655" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1343", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643", "r1644", "r1645", "r1646", "r1647" ] }, "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Health Care Cost Trend Rates", "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]", "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved." } } }, "auth_ref": [ "r227" ] }, "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Additional Information About Intangible Assets Impaired", "label": "Schedule of Impaired Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported." } } }, "auth_ref": [ "r1661" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.pfizer.com/role/TaxMattersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1588" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r584", "r595", "r599", "r1344" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r1344", "r1658" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Inventories, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r46", "r177", "r178", "r179" ] }, "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryNoncurrentTableTextBlock", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Inventories, Noncurrent", "label": "Schedule of Inventory, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]", "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation." } } }, "auth_ref": [ "r226" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Nonoperating Income (Expense)", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentNetDetails", "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r17", "r1006" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r237" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r614", "r615", "r616", "r617", "r620", "r621", "r622" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r74", "r214", "r215" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Reserve by Type of Cost", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r75", "r216" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r70", "r185" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r66", "r67", "r68" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r66", "r67", "r68" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Payment Arrangement Activity", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r32", "r33", "r231" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r779", "r780", "r782", "r783", "r784", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r806", "r807", "r808", "r809", "r810" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r32", "r33", "r228" ] }, "pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Valuation Assumptions", "label": "Schedule of Share-based Payment Award, Valuation Assumptions [Table Text Block]", "documentation": "Schedule of Share-based Payment Award, Valuation Assumptions" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-term Debt [Table]", "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r159" ] }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTextBlock", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-term Borrowings", "label": "Schedule of Short-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r159" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.pfizer.com/role/TaxMattersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r846", "r1374" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r1344", "r1657" ] }, "pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.pfizer.com/role/TaxMattersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)", "label": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedules of Concentration of Risk", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r58", "r59", "r61", "r62", "r136", "r246" ] }, "pfe_SeagenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeagenMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementProFormaInformationFootnotesDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementPurchasePriceAllocationFootnotesDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Seagen [Member]", "label": "Seagen [Member]", "documentation": "Seagen" } } }, "auth_ref": [] }, "us-gaap_SecuritiesReceivedAsCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesReceivedAsCollateral", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash collateral received", "label": "Securities Received as Collateral", "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability." } } }, "auth_ref": [ "r26" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1428" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1431" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r450", "r455", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r472", "r473", "r474", "r482", "r483", "r484", "r485", "r486", "r488", "r489", "r490", "r496", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r599", "r617", "r622", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1332", "r1335", "r1336", "r1343", "r1412", "r1790", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1821", "r1822" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r297", "r299", "r302", "r304", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r494", "r495", "r1057", "r1059", "r1060", "r1061", "r1062", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1200", "r1204", "r1206", "r1265", "r1269", "r1273", "r1283", "r1294", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1313", "r1358", "r1396", "r1397", "r1398", "r1399", "r1401", "r1403", "r1404", "r1405", "r1411", "r1419", "r1684", "r1790", "r1794", "r1795", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1821", "r1822" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment, Geographic and Other Revenue Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r266", "r450", "r454", "r455", "r456", "r457", "r458", "r471", "r473", "r474", "r486", "r487", "r488", "r489", "r490", "r492", "r493", "r496", "r1330", "r1333", "r1334", "r1335", "r1337", "r1339", "r1340" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r491", "r494", "r1331", "r1332", "r1338" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 }, "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, informational and administrative expenses", "negatedLabel": "Selling, informational and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r194" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Selling, Informational and Administrative Expenses [Member]", "terseLabel": "Selling, informational and administrative expenses [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, Informational and Administrative Expenses", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r1723" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes [Member]", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue2025Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2025 [Member]", "label": "Senior Unsecured Debt, Due 2025 [Member]", "documentation": "Senior Unsecured Debt, Due 2025" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue2026Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2026 [Member]", "label": "Senior Unsecured Debt, Due 2026 [Member]", "documentation": "Senior Unsecured Debt, Due 2026" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue2027Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2027 [Member]", "label": "Senior Unsecured Debt, Due 2027 [Member]", "documentation": "Senior Unsecured Debt, Due 2027" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue2028Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2028 [Member]", "label": "Senior Unsecured Debt, Due 2028 [Member]", "documentation": "Senior Unsecured Debt, Due 2028" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue2029Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2029 [Member]", "label": "Senior Unsecured Debt, Due 2029 [Member]", "documentation": "Senior Unsecured Debt, Due 2029" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue2030Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2030 [Member]", "label": "Senior Unsecured Debt, Due 2030 [Member]", "documentation": "Senior Unsecured Debt, Due 2030" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue20312035Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue20312035Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2031-2035 [Member]", "label": "Senior Unsecured Debt, Due 2031-2035 [Member]", "documentation": "Senior Unsecured Debt, Due 2031-2035" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue20362040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue20362040Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2036-2040 [Member]", "label": "Senior Unsecured Debt, Due 2036-2040 [Member]", "documentation": "Senior Unsecured Debt, Due 2036-2040" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue20412045Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue20412045Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2041-2045 [Member]", "label": "Senior Unsecured Debt, Due 2041-2045 [Member]", "documentation": "Senior Unsecured Debt, Due 2041-2045" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue20462050Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue20462050Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2046-2050 [Member]", "label": "Senior Unsecured Debt, Due 2046-2050 [Member]", "documentation": "Senior Unsecured Debt, Due 2046-2050" } } }, "auth_ref": [] }, "pfe_SeniorUnsecuredDebtDue20512063Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SeniorUnsecuredDebtDue20512063Member", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Debt, Due 2051-2063 [Member]", "label": "Senior Unsecured Debt, Due 2051-2063 [Member]", "documentation": "Senior Unsecured Debt, Due 2051-2063" } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation [Member]", "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r1672" ] }, "pfe_SettledLitigationNumberOfCompanies": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SettledLitigationNumberOfCompanies", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled litigation, number of companies", "label": "Settled Litigation, Number of Companies", "documentation": "Settled Litigation, Number of Companies" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee terminations", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award requisite service period", "verboseLabel": "Award requisite service period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1371" ] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardSettlementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardSettlementPeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award settlement period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Settlement Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Settlement Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1371" ] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units exercised and converted, aggregate intrinsic value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted" } } }, "auth_ref": [] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units converted and exercised, shares", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number" } } }, "auth_ref": [] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units exercised and converted, weighted average remaining contractual term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r799" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, weighted-average intrinsic value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share", "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r799" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, weighted-average grant date fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r799" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares granted in period (in shares)", "verboseLabel": "Granted, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r797" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, weighted-average intrinsic value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share", "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r797" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, weighted-average grant-date fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r797" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share)", "periodEndLabel": "Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value", "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r794", "r795" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested, beginning of period, shares", "periodEndLabel": "Nonvested, end of period, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r794", "r795" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)", "periodEndLabel": "Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r794", "r795" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Avg. GDFV per share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Grant Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Roll Forward]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units outstanding, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r232" ] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of options exercised or share units converted", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value" } } }, "auth_ref": [] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, end of period, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Expected to Vest, Outstanding, Number", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Expected to Vest, Outstanding, Number" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r798" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested, weighted-average intrinsic value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share", "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r798" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of shares vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r801" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested, weighted-average grant-date fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r798" ] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Avg. Intrinsic Value per share", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value [Roll Forward]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r808" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r807" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r809" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r779", "r780", "r782", "r783", "r784", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r806", "r807", "r808", "r809", "r810" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units exercised, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares outstanding (in shares)", "terseLabel": "Units outstanding, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r229", "r230" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for award", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of options exercised or share units converted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r801" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r793" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r792" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r790" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, end of period, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period, shares", "periodEndLabel": "Outstanding, end of period, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r786", "r787" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares (Thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)", "periodEndLabel": "Outstanding, end of period, weighted-average exercise price per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r786", "r787" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price Per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, end of period, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r803" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, end of period, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r803" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, end of period, weighted-average exercise price per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r803" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, end of period, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r802" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, end of period, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r802" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r802" ] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share payout measures, adjusted net income, period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period" } } }, "auth_ref": [] }, "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares counted toward maximum", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r782", "r783", "r784", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r806", "r807", "r808", "r809", "r810" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, weighted-average exercise price per share (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r791" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, weighted-average exercise price per share (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r793" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, weighted-average exercise price per share (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r792" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, weighted-average exercise price per share (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r790" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche One [Member]", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Three [Member]", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Two [Member]", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payments", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r778", "r785", "r804", "r805", "r806", "r807", "r810", "r816", "r817", "r818", "r819" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1695" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units outstanding, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units vested, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual term/expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r806" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, end of period, weighted-average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r232" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, end of period, weighted-average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r803" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, end of period, weighted-average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r802" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, weighted-average grant-date fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units settled, weighted average grant price (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units vested, weighted average grant price (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units expected to vest, aggregate intrinsic value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units exercised, weighted average grant price (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units expected to vest, shares", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units expected to vest, weighted average grant price (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units expected to vest, weighted average remaining contractual term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested, beginning of period, grant price (in dollars per share)", "periodEndLabel": "Nonvested, end of period, grant price (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward": { "xbrltype": "percentItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares earned as a percentage of initial award", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units outstanding, weighted average grant price (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Reinvested dividend equivalents, shares", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units settled, shares", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units vested, shares", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units vested, weighted average remaining contractual term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units granted upon conversion, shares", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of measures used to determine share payout", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trading day average", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share payout measures, adjusted net income, number of periods", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, grant price (in dollars per share)", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, grant price (in dollars per share)", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price" } } }, "auth_ref": [] }, "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested, grant price (in dollars per share)", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price", "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt [Line Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r159", "r1665", "r1666", "r1667" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r157", "r1665", "r1666", "r1667" ] }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsAbstract", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments [Member]", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r1284", "r1285", "r1286", "r1314" ] }, "pfe_ShorttermDebtGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShorttermDebtGross", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": { "parentTag": "us-gaap_DebtCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total short-term borrowings, principal amount", "label": "Short-term Debt, Gross", "documentation": "Short-term Debt, Gross" } } }, "auth_ref": [] }, "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ShorttermInvestmentsExcludingHeldToMaturitySecurities", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total short-term investments", "label": "Short-term Investments Excluding Held-To-Maturity Securities", "documentation": "Short-term Investments Excluding Held-To-Maturity Securities" } } }, "auth_ref": [] }, "pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SiteContingencyRegulatoryProceedingsDisclosureThreshold", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold for disclosure of proceedings under environmental laws", "label": "Site Contingency, Regulatory Proceedings, Disclosure Threshold", "documentation": "Site Contingency, Regulatory Proceedings, Disclosure Threshold" } } }, "auth_ref": [] }, "pfe_SpecialtyCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SpecialtyCareMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty Care [Member]", "label": "Specialty Care [Member]", "documentation": "Specialty Care" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSignificantBiopharmaSegmentExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r341", "r450", "r455", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r472", "r473", "r474", "r482", "r483", "r484", "r485", "r486", "r488", "r489", "r490", "r496", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r599", "r603", "r617", "r622", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1332", "r1335", "r1336", "r1343", "r1412", "r1790", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1821", "r1822" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r294", "r359", "r360", "r361", "r405", "r435", "r436", "r443", "r445", "r452", "r453", "r544", "r633", "r636", "r637", "r638", "r642", "r643", "r666", "r667", "r670", "r673", "r680", "r964", "r1178", "r1179", "r1180", "r1181", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1219", "r1241", "r1259", "r1287", "r1288", "r1289", "r1290", "r1291", "r1541", "r1585", "r1595" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails", "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r28", "r171", "r174", "r175", "r337", "r386", "r387", "r388", "r413", "r414", "r415", "r418", "r425", "r427", "r429", "r451", "r550", "r556", "r601", "r681", "r860", "r861", "r878", "r879", "r880", "r883", "r896", "r897", "r925", "r927", "r928", "r929", "r930", "r932", "r943", "r971", "r973", "r974", "r975", "r976", "r978", "r986", "r989", "r1014", "r1125", "r1160", "r1161", "r1162", "r1186", "r1259" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r297", "r299", "r302", "r304", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r494", "r495", "r1057", "r1059", "r1060", "r1061", "r1062", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1200", "r1204", "r1206", "r1265", "r1269", "r1273", "r1283", "r1294", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1313", "r1358", "r1396", "r1397", "r1398", "r1399", "r1401", "r1403", "r1404", "r1405", "r1411", "r1419", "r1684", "r1790", "r1794", "r1795", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1821", "r1822" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r413", "r414", "r415", "r451", "r989", "r1051", "r1173", "r1197", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1219", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1233", "r1234", "r1235", "r1236", "r1237", "r1239", "r1242", "r1243", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1259", "r1420" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity", "http://www.pfizer.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r413", "r414", "r415", "r451", "r499", "r989", "r1051", "r1173", "r1197", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1219", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1233", "r1234", "r1235", "r1236", "r1237", "r1239", "r1242", "r1243", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1259", "r1420" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1450", "r1461", "r1471", "r1504" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in acquisition (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r170", "r171", "r222" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment transactions (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r28", "r170", "r171", "r222" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r28", "r170", "r171", "r222", "r791" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment transactions", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r92", "r170", "r171", "r222" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of shares authorized in stock purchase plan, value", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1683" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of remaining shares authorized in stock purchase plan, value", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Pfizer Inc. shareholders\u2019 equity", "terseLabel": "Equity attributable to shareholders", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r171", "r174", "r175", "r209", "r1221", "r1238", "r1260", "r1261", "r1393", "r1427", "r1587", "r1634", "r1766", "r1826" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/ConsolidatedBalanceSheets", "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r107", "r108", "r111", "r337", "r338", "r387", "r413", "r414", "r415", "r418", "r425", "r427", "r550", "r556", "r601", "r681", "r860", "r861", "r878", "r879", "r880", "r883", "r896", "r897", "r925", "r927", "r928", "r929", "r930", "r932", "r943", "r971", "r973", "r978", "r987", "r1014", "r1161", "r1162", "r1184", "r1221", "r1238", "r1260", "r1261", "r1292", "r1426", "r1587", "r1634", "r1766", "r1826" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.pfizer.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r219", "r404", "r665", "r667", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r679", "r681", "r934", "r1262", "r1263", "r1293" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r999", "r1392" ] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsConsolidationItemsAxis", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments Consolidation Items [Axis]", "label": "Subsegments Consolidation Items [Axis]", "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsConsolidationItemsDomain", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments Consolidation Items [Domain]", "label": "Subsegments Consolidation Items [Domain]", "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r979", "r1016" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r979", "r1016" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails", "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r979", "r1016" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "pfe_SulperazonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SulperazonMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sulperazon [Member]", "label": "Sulperazon [Member]", "documentation": "Sulperazon [Member]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid/(received) during the period for:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramLineItems", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program [Line Items]", "label": "Supplier Finance Program [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r605", "r606", "r607" ] }, "us-gaap_SupplierFinanceProgramObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationCurrent", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Confirmed obligations outstanding, December 31, 2023", "periodEndLabel": "Confirmed obligations outstanding, December 31, 2024", "label": "Supplier Finance Program, Obligation, Current", "documentation": "Amount of obligation for supplier finance program, classified as current." } } }, "auth_ref": [ "r606", "r607", "r610" ] }, "us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current." } } }, "auth_ref": [ "r607" ] }, "us-gaap_SupplierFinanceProgramObligationDecreaseSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationDecreaseSettlement", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Confirmed invoices paid during the year", "label": "Supplier Finance Program, Obligation, Settlement", "documentation": "Amount of decrease in obligation for supplier finance program from settlement." } } }, "auth_ref": [ "r609", "r1345" ] }, "us-gaap_SupplierFinanceProgramObligationIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationIncrease", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invoices confirmed during the year", "label": "Supplier Finance Program, Obligation, Addition", "documentation": "Amount of increase in obligation for supplier finance program." } } }, "auth_ref": [ "r608", "r1345" ] }, "us-gaap_SupplierFinanceProgramObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationRollForward", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program, Obligation [Roll Forward]", "label": "Supplier Finance Program, Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramPaymentTimingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramPaymentTimingPeriod", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier finance program, payment timing, period", "label": "Supplier Finance Program, Payment Timing, Period", "documentation": "Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r605" ] }, "us-gaap_SupplierFinanceProgramTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramTable", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationSupplierFinanceProgramObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program [Table]", "label": "Supplier Finance Program [Table]", "documentation": "Disclosure of information about supplier finance program." } } }, "auth_ref": [ "r605", "r606", "r607" ] }, "us-gaap_SupplierFinanceProgramTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramTableTextBlock", "presentation": [ "http://www.pfizer.com/role/OtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Outstanding Trade Payables", "label": "Supplier Finance Program [Table Text Block]", "documentation": "Tabular disclosure of supplier finance program." } } }, "auth_ref": [ "r1345", "r1668" ] }, "pfe_SupplyCommitmentRemainingMinimumAmountCommittedNumberOfTreatmentCourses": { "xbrltype": "integerItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "SupplyCommitmentRemainingMinimumAmountCommittedNumberOfTreatmentCourses", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Supply commitment, minimum amount committed, number of treatment courses", "label": "Supply Commitment, Remaining Minimum Amount Committed, Number Of Treatment Courses", "documentation": "Supply Commitment, Remaining Minimum Amount Committed, Number Of Treatment Courses" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1497" ] }, "pfe_TalazoparibTalzennaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TalazoparibTalzennaMember", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "talazoparib (Talzenna) [Member]", "label": "talazoparib (Talzenna) [Member]", "documentation": "talazoparib (Talzenna)" } } }, "auth_ref": [] }, "pfe_TalzennaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TalzennaMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Talzenna [Member]", "label": "Talzenna [Member]", "documentation": "Talzenna" } } }, "auth_ref": [] }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repatriation tax liability", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability", "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act." } } }, "auth_ref": [ "r1726" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r159", "r160" ] }, "pfe_TelavantHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TelavantHoldingsIncMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Telavant Holdings, Inc. [Member]", "label": "Telavant Holdings, Inc. [Member]", "documentation": "Telavant Holdings, Inc." } } }, "auth_ref": [] }, "pfe_TevaPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TevaPharmaceuticalsIncMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Teva Pharmaceuticals, Inc. [Member]", "label": "Teva Pharmaceuticals, Inc. [Member]", "documentation": "Teva Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "pfe_ThreeLargestUSWholesaleCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ThreeLargestUSWholesaleCustomersMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Three Largest U.S. Wholesaler Customers [Member]", "label": "Three Largest US Wholesale Customers [Member]", "documentation": "Three Largest US Wholesale Customers [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r1604", "r1774" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "pfe_TivdakMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TivdakMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tivdak [Member]", "label": "Tivdak [Member]", "documentation": "Tivdak" } } }, "auth_ref": [] }, "pfe_TopElevenProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TopElevenProductsMember", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top Eleven Products", "label": "Top Eleven Products [Member]", "documentation": "Top Eleven Products" } } }, "auth_ref": [] }, "pfe_TopNineProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TopNineProductsMember", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top Nine Products [Member]", "label": "Top Nine Products [Member]", "documentation": "Top Nine Products" } } }, "auth_ref": [] }, "pfe_TopTenProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TopTenProductsMember", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top Ten Products [Member]", "label": "Top Ten Products [Member]", "documentation": "Top Ten Products" } } }, "auth_ref": [] }, "pfe_TotalAllianceBiopharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TotalAllianceBiopharmaceuticalsMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total Alliance revenues [Member]", "label": "Total Alliance Biopharmaceuticals [Member]", "documentation": "Total Alliance Biopharmaceuticals [Member]" } } }, "auth_ref": [] }, "pfe_TotalShareholderReturnUnitsTSRUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TotalShareholderReturnUnitsTSRUsMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail", "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails", "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Units (TSRUs) [Member]", "label": "Total Shareholder Return Units (TSRUs) [Member]", "documentation": "Total Shareholder Return Units (TSRUs) [Member]" } } }, "auth_ref": [] }, "pfe_TotalShareholderReturnUnitsVestingPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TotalShareholderReturnUnitsVestingPeriodOneMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Units, Vesting Period One", "label": "Total Shareholder Return Units, Vesting Period One [Member]", "documentation": "Total Shareholder Return Units, Vesting Period One" } } }, "auth_ref": [] }, "pfe_TotalShareholderReturnUnitsVestingPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TotalShareholderReturnUnitsVestingPeriodTwoMember", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Units, Vesting Period Two", "label": "Total Shareholder Return Units, Vesting Period Two [Member]", "documentation": "Total Shareholder Return Units, Vesting Period Two" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1489" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1496" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails", "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNetandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsFootnotesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Brands [Member]", "terseLabel": "Trade Names [Member]", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r104", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1656", "r1658", "r1659", "r1660" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1517" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1519" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails", "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r660", "r678", "r933", "r958", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1126", "r1380", "r1382", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1394", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1628", "r1629", "r1630", "r1631", "r1750", "r1753", "r1754", "r1755", "r1762", "r1765" ] }, "pfe_TransformingToAMoreFocusedCompanyPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TransformingToAMoreFocusedCompanyPlanMember", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transforming to a More Focused Company Plan [Member]", "label": "Transforming to a More Focused Company Plan [Member]", "documentation": "Transforming to a More Focused Company Plan" } } }, "auth_ref": [] }, "pfe_TransitionServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TransitionServiceAgreementMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition Service Agreement [Member]", "label": "Transition Service Agreement [Member]", "documentation": "Transition Service Agreement" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1520" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1521" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1521" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1519" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1519" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1522" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1520" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock [Member]", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r80" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.pfizer.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "negatedTerseLabel": "Beginning balance, treasury (in shares)", "negatedPeriodEndLabel": "Ending balance, treasury (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r80" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, shares at cost: 2024\u20143,926; 2023\u20143,916", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r80", "r83", "r174" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity", "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of common stock (in shares)", "terseLabel": "Shares repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r28", "r171", "r222" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofEquity", "http://www.pfizer.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of common stock", "verboseLabel": "Shares repurchased, cost", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r28", "r80", "r222" ] }, "pfe_TukysaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "TukysaMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tukysa [Member]", "label": "Tukysa [Member]", "documentation": "Tukysa" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementCollaborativeArrangementsDetail", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails", "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r898" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail", "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r614", "r615", "r620", "r621" ] }, "pfe_U.S.AndParticipatingStatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "U.S.AndParticipatingStatesMember", "presentation": [ "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsLegalProceedingsGovernmentInvestigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. and Participating States [Member]", "label": "U.S. and Participating States [Member]", "documentation": "U.S. and Participating States" } } }, "auth_ref": [] }, "pfe_U.S.CommercialDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "U.S.CommercialDivisionMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Commercial Division", "label": "U.S. Commercial Division [Member]", "documentation": "U.S. Commercial Division" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansLongtermTargetAssetAllocationsRangesandthePercentageoftheFairValueofPlanAssetsDetail", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails", "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails", "http://www.pfizer.com/role/PropertyPlantandEquipmentLonglivedAssetsbyGeographicAreasNetDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyGeographicAreaDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "United States [Member]", "terseLabel": "U.S. [Member]", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government and agency - U.S. [Member]", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r1326", "r1360", "r1784" ] }, "pfe_USGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "USGovernmentMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "US Government [Member]", "label": "US Government [Member]", "documentation": "US Government" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government and agency obligations [Member]", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r1326", "r1360", "r1362", "r1380", "r1784" ] }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsOfForeignSubsidiaries", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unremitted earnings of international subsidiaries", "label": "Undistributed Earnings of Foreign Subsidiaries", "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile." } } }, "auth_ref": [ "r24", "r25", "r274", "r826" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1516" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementAcquisitionsDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails", "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax positions", "negatedPeriodStartLabel": "Balance, beginning", "negatedPeriodEndLabel": "Balance, ending", "verboseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r827", "r846", "r1374" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decreases based on tax positions taken during a prior period", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r847", "r1374" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decreases based on settlements for a prior period", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r849", "r1374" ] }, "pfe_UnrecognizedTaxBenefitsExcludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "UnrecognizedTaxBenefitsExcludingInterest", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits excluding associated interest", "label": "Unrecognized Tax Benefits, Excluding Interest", "documentation": "Unrecognized Tax Benefits, Excluding Interest" } } }, "auth_ref": [] }, "pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions", "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition", "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition" } } }, "auth_ref": [] }, "pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impact of foreign exchange", "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation", "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Increases based on tax positions taken during the current period", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r848", "r1374" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Increases based on tax positions taken during a prior period", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r847", "r1374" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": [ "r1730" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense", "crdr": "debit", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) of interest on income taxes expense", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense", "documentation": "Amount of interest expense for an underpayment of income taxes." } } }, "auth_ref": [ "r1730" ] }, "pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrecognized accrued interest decrease as a result of cash payments", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual", "documentation": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual" } } }, "auth_ref": [] }, "pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther", "crdr": "credit", "presentation": [ "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Unrecognized Tax Benefits, Period Increase (Decrease), Other", "documentation": "Unrecognized Tax Benefits, Period Increase (Decrease), Other" } } }, "auth_ref": [] }, "us-gaap_UnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnsecuredDebtMember", "presentation": [ "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails", "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtIssuancesDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Debt [Member]", "label": "Unsecured Debt [Member]", "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Estimates and Assumptions", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r63", "r64", "r65", "r281", "r282", "r284", "r285" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/LeasesNarrativeDetails", "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r998", "r1392" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720" ] }, "pfe_ViatrisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ViatrisMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Viatris [Member]", "label": "Viatris [Member]", "documentation": "Viatris" } } }, "auth_ref": [] }, "pfe_ViiVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ViiVMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ViiV [Member]", "label": "ViiV [Member]", "documentation": "ViiV [Member]" } } }, "auth_ref": [] }, "pfe_ViivHealthcareLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ViivHealthcareLimitedMember", "presentation": [ "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementEquityMethodInvestmentsDetails", "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsCollaborativeArrangementsandResearchandDevelopmentArrangementSummarizedFinancialInformationofEquityMethodInvesteeDetails", "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails", "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ViiV [Member]", "label": "ViiV Healthcare Limited [Member]", "documentation": "ViiV Healthcare Limited [Member]" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1485" ] }, "pfe_VyndaqelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "VyndaqelMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vyndaqel Family [Member]", "label": "Vyndaqel [Member]", "documentation": "Vyndaqel [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common-share equivalents (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1596" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares\u2013\u2013diluted (in shares)", "totalLabel": "Weighted-average common shares outstanding\u2013\u2013Diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r434", "r445" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EPS Denominator", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pfizer.com/role/ConsolidatedStatementsofOperations", "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares\u2013\u2013basic (in shares)", "terseLabel": "Weighted-average common shares outstanding\u2013\u2013Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r432", "r445" ] }, "pfe_XeljanzMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "XeljanzMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Xeljanz [Member]", "label": "Xeljanz [Member]", "documentation": "Xeljanz [Member]" } } }, "auth_ref": [] }, "pfe_XtandiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "XtandiMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Xtandi [Member]", "label": "Xtandi [Member]", "documentation": "Xtandi Alliance Revenues [Member]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1483" ] }, "pfe_ZaviceftaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ZaviceftaMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Zavicefta [Member]", "label": "Zavicefta [Member]", "documentation": "Zavicefta" } } }, "auth_ref": [] }, "pfe_ZavzpretMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ZavzpretMember", "presentation": [ "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zavzpret [Member]", "label": "Zavzpret [Member]", "documentation": "Zavzpret" } } }, "auth_ref": [] }, "pfe_ZithromaxZmaxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20241231", "localname": "ZithromaxZmaxMember", "presentation": [ "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesbyProductDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Zithromax [Member]", "label": "Zithromax Zmax [Member]", "documentation": "Zithromax / Zmax [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481097/715-30-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "60", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)", "SubTopic": "30", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)(b)(c)", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "SubTopic": "10", "Topic": "420", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4H", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(j)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(l)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r228": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r234": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r235": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r236": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r237": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r238": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r239": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r240": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r241": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r242": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479836/810-10-S99-5" }, "r243": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r244": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r245": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r246": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r247": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r248": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r249": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r250": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r251": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r252": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r253": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r254": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r255": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r256": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r257": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r258": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r259": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r260": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r261": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r262": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1" }, "r263": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r264": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r265": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r266": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r267": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r268": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r269": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r271": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r272": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r273": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r274": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r275": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r276": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481725/323-10-35-18" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "325", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481493/325-30-45-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "325", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481463/325-30-50-8" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482620/740-10-25-3" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-15" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r1064": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r1065": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r1066": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r1067": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r1068": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r1069": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r1070": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r1071": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r1072": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r1073": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r1074": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r1075": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r1076": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r1077": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-33" }, "r1078": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A" }, "r1079": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r1080": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r1081": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r1082": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r1083": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r1084": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r1085": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r1086": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r1087": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r1088": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r1089": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r1090": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r1091": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r1092": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1093": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1094": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1095": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1096": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1097": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1098": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1099": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r1101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r1102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r1103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r1104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r1154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r1158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r1171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r1173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r1183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r1184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r1185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r1186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r1188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r1189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r1198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r1204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r1205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r1241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r1242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r1267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r1268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r1278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r1288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r1293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r1294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r1297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r1298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1310": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1311": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1312": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1313": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1314": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1315": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1316": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1317": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1318": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1319": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1320": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1321": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1322": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1323": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r1324": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1325": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1326": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1327": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1328": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1329": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1330": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1331": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1332": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1333": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1334": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1335": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1336": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1337": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1338": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1339": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1340": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1341": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1342": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1343": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1344": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1345": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5" }, "r1346": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1347": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1348": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1349": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1350": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r1351": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1352": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1353": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1354": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1355": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1356": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1357": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1358": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1359": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1360": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1361": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1362": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1363": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1364": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1365": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1366": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1367": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1368": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1369": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1370": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1371": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1372": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1373": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r1374": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1375": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r1377": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1378": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1379": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1380": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1381": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1382": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1383": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1384": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1385": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1386": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1387": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1388": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1389": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1390": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1391": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1392": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1393": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1394": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1395": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-12" }, "r1396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1398": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1399": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34" }, "r1401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-3" }, "r1403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7" }, "r1407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r1416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1426": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1427": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1541": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1542": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1543": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1544": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9" }, "r1585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r1621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r1622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r1623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r1636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r1664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r1669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1" }, "r1678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r1692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r1693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r1695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r1724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r1727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r1746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 177 0000078003-25-000054-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000078003-25-000054-xbrl.zip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�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